diff --git "a/drug.jsonl" "b/drug.jsonl"
new file mode 100644--- /dev/null
+++ "b/drug.jsonl"
@@ -0,0 +1,1000 @@
+{"drug_id":"143fa0bca0fb462cb2fa5b58ba574903","docid":1700200,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-07-17T06:04:42.000Z","updated_ts":"2025-07-17T06:48:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"IR-101","source_info":[{"code":"NCT07067346","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07067346"}],"status":"ACTIVE"}],"dev_code":[{"name":"IR-101","source_info":[{"code":"NCT07067346","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07067346"}],"status":"ACTIVE"}],"drug_type":["ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["128a1357d8181f62dff79c9d39f0181d"],"disease_id":["8fc66d310bb14d8da20692ca3671704e"],"active_org_master_entity_id":["128a1357d8181f62dff79c9d39f0181d"],"research_disease":["8fc66d310bb14d8da20692ca3671704e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1752796800000}}],"disease_phase":[{"disease_id":"8fc66d310bb14d8da20692ca3671704e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0395b8f3a84e41318fbf84b6a42c6468","docid":1731866,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":7,"target_extend_id":"a2e475ddbfd632cba402ba73225e6e4e","created_ts":"2025-10-22T08:38:24.000Z","updated_ts":"2026-03-07T21:12:59.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"SYH2072","status":"ACTIVE"}],"dev_code":[{"name":"SYH2072","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["f0610e2ad2e2642af5baee924892cd42"],"mechanism_action_id":["b2363ec75523e342a77d314188d7be6f"],"target_id":["8d6d5a4342ec41c1a2f8f0059fc2c18a"],"disease_id":["281fcf1b07ee4c13b0297e4ad1a9c106","f8a32519882d4e1580e0f67f5b33d4e8","6f56c02a7a68425aac8f52db375e0e5b"],"active_org_master_entity_id":["f0610e2ad2e2642af5baee924892cd42","5cf5fedddb15b3ca0a531d9b789f0286"],"research_disease":["281fcf1b07ee4c13b0297e4ad1a9c106","f8a32519882d4e1580e0f67f5b33d4e8","6f56c02a7a68425aac8f52db375e0e5b"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1768435200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1768262400000}}],"disease_phase":[{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6f56c02a7a68425aac8f52db375e0e5b","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"f8a32519882d4e1580e0f67f5b33d4e8","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"if_speculate":0,"data_source":10}
+{"drug_id":"055fb586f02343e0abbe84df3e5b1a06","docid":1611891,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":3,"target_extend_id":"a3f04c56ef913e79b9609135efbd9c8e","created_ts":"2025-10-09T06:34:53.000Z","updated_ts":"2026-03-18T06:28:57.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"CD123+CLL-1 CAR-T(Hematology Hospital of Chinese Academy of Medical Sciences)","source_info":[{"code":"NCT07201727","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07201727"}],"status":"ACTIVE"}],"dev_code":[{"name":"JY-017","source_info":[{"code":"NCT07201727","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07201727"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"mechanism_action_id":["f4ef09c58b08d412a680b1896217ed01","a74b02a128c0eb3e12d419eee54d4dd0"],"target_id":["ac9c4b7c0e1f4e449ab889817ae92ec7","d4431161069e45498064f04ce31df0c9"],"disease_id":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"research_disease":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02f799dc8b074a908e34b4e725123e49","docid":920374,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-02-26T08:44:12.000Z","updated_ts":"2026-03-03T23:42:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"MDX-2301","source_info":[{"attachment_path":"data/phs_source_info/7ce6/46cb/e771/05e4/1e40ad0f-aeb2-31ad-b318-0102c135c800.png","attachment_type":"image/png","code":"ModeX-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/750f/35d8/80e5/5e71/4f905c9b-4b27-3f35-ba13-78ebb035bbe2.png","source":"Company pipeline","source_url":"https://www.modextherapeutics.com/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"MDX 2301","source_info":[{"attachment_path":"data/phs_source_info/7ce6/46cb/e771/05e4/1e40ad0f-aeb2-31ad-b318-0102c135c800.png","attachment_type":"image/png","code":"ModeX-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/750f/35d8/80e5/5e71/4f905c9b-4b27-3f35-ba13-78ebb035bbe2.png","source":"Company pipeline","source_url":"https://www.modextherapeutics.com/pipeline/"}],"status":"ACTIVE"},{"name":"MDX2301","source_info":[{"attachment_path":"data/phs_source_info/7ce6/46cb/e771/05e4/1e40ad0f-aeb2-31ad-b318-0102c135c800.png","attachment_type":"image/png","code":"ModeX-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/750f/35d8/80e5/5e71/4f905c9b-4b27-3f35-ba13-78ebb035bbe2.png","source":"Company pipeline","source_url":"https://www.modextherapeutics.com/pipeline/"}],"status":"ACTIVE"}],"drug_type":["a9b7ab828c0f45c4b045e539ca16e737"],"originator_org_master_entity_id":["5b587ed14a2f339c9bcb748559733620"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["5b587ed14a2f339c9bcb748559733620"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1772323200000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"349ec99e46104a228cd6aeec7554d5e5","docid":1643780,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":41,"target_extend_id":"d81bdf4ce27c31b7bce00da6d4c2408c","created_ts":"2026-01-16T05:30:49.000Z","updated_ts":"2026-03-14T21:15:13.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous CD19+CD20 dual CAR-T cells(Hebei Senlang Biotechnology)","source_info":[{"code":"NCT07344818","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07344818"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["dab8ea4d57a17ffc0b8c1ec42261ce8f"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","16b5dca2ef00478ba4719851807e1c05"],"target_id":["5eb1fc5283d34305934a031af530f448","8b4260187fa64823b593f35188526e50"],"disease_id":["1b969bf36fe146598279d284e09e1d42"],"active_org_master_entity_id":["dab8ea4d57a17ffc0b8c1ec42261ce8f"],"research_disease":["1b969bf36fe146598279d284e09e1d42"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1767744000000}}],"disease_phase":[{"disease_id":"1b969bf36fe146598279d284e09e1d42","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"010d2453de5c42fdb01c62609cc37a99","docid":16412,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-07-28T07:52:44.000Z","updated_ts":"2026-03-02T14:44:09.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"limingna","drug_name":[{"lang":"CN","name":"重组结核杆菌融合蛋白（EEC）（成都可恩生物科技）","source_info":[{"code":"CXSL2200343","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"CXSL2200345","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"CXSL2200344","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant Mycobacterium Tuberculosis Fusion Protein(EEC)(Chengdu Coen Biotechnology)","source_info":[{"code":"CXSL2200343","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"CXSL2200345","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"CXSL2200344","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["56cd71d7b8c54b0fba69bbb8c7e10e9b","bbbb2e86da504b9d95a00c703880d9fb"],"originator_org_master_entity_id":["df90b0828a0119023d98dde903ed1b54"],"mechanism_action_id":["8c1db4c7a89c491c80b37d36ce733f2d"],"disease_id":["754fa682ba97464c8ce926b3c411c54d","764eee63555942f1bb171f1b8c1e71ea"],"active_org_master_entity_id":["df90b0828a0119023d98dde903ed1b54"],"research_disease":["754fa682ba97464c8ce926b3c411c54d","764eee63555942f1bb171f1b8c1e71ea"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1754524800000}}],"disease_phase":[{"disease_id":"764eee63555942f1bb171f1b8c1e71ea","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"754fa682ba97464c8ce926b3c411c54d","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"061f3c743a654321a9c262f0effedc78","docid":29941,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":3,"target_extend_id":"460dc64ea3eb30578404af63689e33be","has_leading_org_involved":1,"created_ts":"2022-03-03T02:06:37.000Z","updated_ts":"2026-04-19T21:18:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"Plosaracetam","source_info":[{"code":"list 130","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf?sfvrsn=ef74744a_5&download=true"}],"status":"ACTIVE"}],"dev_code":[{"name":"ABBV552","source_info":[{"normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","source":"Corporate Publications","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/abbv-20230630.htm"}],"status":"ACTIVE"},{"name":"SDI 118","status":"ACTIVE"},{"name":"SDI-118","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a7a3d8c4ca8f1ee9d82829cf8ccc3007"],"mechanism_action_id":["d37c09f4a5a25e06c69f99006b3b546d"],"target_id":["f40964255e094ec19f9f9572c0861490"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","71a4271b98874e96b16000266c8d79cc","c9d3c55f01d24f11a6035f989330c65f","2dbed7595ff04b8fae04724f91081116"],"active_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"non_research_disease":["71a4271b98874e96b16000266c8d79cc","c9d3c55f01d24f11a6035f989330c65f","2dbed7595ff04b8fae04724f91081116"],"inactive_org_master_entity_id":["bcc24c026e051d9eed5b01ddef337a77","b89d176703471e988b4857476d632013"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1646956800000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c9d3c55f01d24f11a6035f989330c65f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"71a4271b98874e96b16000266c8d79cc","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["b89d176703471e988b4857476d632013","d88590e686ad5608bbbfeb811b14d188"],"if_speculate":0,"data_source":10}
+{"drug_id":"503408275dd244e5ab8a341162d23e77","docid":34400,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:33.000Z","updated_ts":"2024-11-11T16:55:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"MSB-2179","status":"ACTIVE"}],"dev_code":[{"name":"MSB-2179","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["758fe6b1101af1705c8d5903fcb84357"],"disease_id":["cd2ca4b269af45feb8a68f1ecb3d6ba2"],"active_org_master_entity_id":["758fe6b1101af1705c8d5903fcb84357"],"research_disease":["cd2ca4b269af45feb8a68f1ecb3d6ba2"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1649203200000}}],"disease_phase":[{"disease_id":"cd2ca4b269af45feb8a68f1ecb3d6ba2","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"024f38b90e7548bb8e353d6f5c3c37c9","docid":440092,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"a5053334bca53f11a32f283b5476f2d0","created_ts":"2024-10-15T07:33:45.000Z","updated_ts":"2026-02-24T12:13:27.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CT-3001","source_info":[{"code":"NCT06598007","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06598007"}],"status":"ACTIVE"}],"dev_code":[{"name":"CT-3001","source_info":[{"code":"NCT06598007","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06598007"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["1dca85ea56babae6a80517dc60958112"],"mechanism_action_id":["c1397b6d3687426fa26de0954e885f35"],"target_id":["be789806b04a40d7b659183486fc40fa"],"disease_id":["275ecda875e0460f84aa768ca9b2e5d6","15cb523e0fbd4617a6a129ad2336eb9a","78cb173a4de34f07befac28de907e7bf"],"active_org_master_entity_id":["1dca85ea56babae6a80517dc60958112"],"research_disease":["275ecda875e0460f84aa768ca9b2e5d6","15cb523e0fbd4617a6a129ad2336eb9a","78cb173a4de34f07befac28de907e7bf"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1726790400000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"00edfc5c72194f109501109090cf418f","docid":59828,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1395273600000,"created_ts":"2022-09-06T07:59:22.000Z","updated_ts":"2024-10-30T10:22:00.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"yanglili","first_approved_date_cn":1395273600000,"drug_name":[{"lang":"CN","name":"正元胶囊","status":"ACTIVE"},{"lang":"EN","name":"Zhengyuan Capsule","source_info":[{"code":"CTR20220743","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=df884e66b9cb4310b1dbc415f94ae6cd"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["fb312356d35aedb4b0753ae079f20278"],"disease_id":["0dfc10e5c81e42869cd8f7479a1b5021"],"active_org_master_entity_id":["fb312356d35aedb4b0753ae079f20278"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["0dfc10e5c81e42869cd8f7479a1b5021"],"research_disease":["0dfc10e5c81e42869cd8f7479a1b5021"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1395273600000}}],"disease_phase":[{"disease_id":"0dfc10e5c81e42869cd8f7479a1b5021","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"2e5045c45f1b481784493ce724894af9","docid":50213,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"ac14778662b7448588663c26ce84cd9e","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":9,"target_extend_id":"6b8ac8f9502b31a6b8d1b591abe4a174","created_ts":"2021-10-08T14:37:56.000Z","updated_ts":"2026-02-14T21:09:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"司库奇尤单抗生物类似药（百奥泰）","status":"ACTIVE"},{"lang":"EN","name":"Secukinumab biosimilar (Bio-Thera Solutions)","status":"ACTIVE"}],"dev_code":[{"name":"BAT 2306","status":"ACTIVE"},{"name":"BAT-2306","status":"ACTIVE"}],"generic_name":[{"name":"secukinumab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["4b1d029e568db22f1e0aa5ff2efa80cd"],"mechanism_action_id":["529b9d60826a4c1a5765e42277efc255"],"target_id":["9b99b0dfb49c480fae5688010b373f83"],"disease_id":["d281a3b362a740d8aeb63e2a10102671"],"active_org_master_entity_id":["4b1d029e568db22f1e0aa5ff2efa80cd"],"research_disease":["d281a3b362a740d8aeb63e2a10102671"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1738972800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1665619200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1665619200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1665619200000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["a9dce7ab19e8436aacb08bab9f4dde07"],"deal_related_org":["0d854e9b4bc4ec17b3eeb3c991800bf1","0f947863554b0358175e7aa58d15d2fb","123d6094d3cb84c3c685f5acc3154437","4b1d029e568db22f1e0aa5ff2efa80cd","5d8b878bd293591689ab8c1c08117efe"],"data_source":10}
+{"drug_id":"02766d7c4abe45bfa47399fc9f9cbd66","docid":12735,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Trapidil","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":353030400000,"rnk":4,"target_extend_id":"cf8a7a2886d835699f86f504e0e5f2eb","created_ts":"2021-10-08T14:42:45.000Z","updated_ts":"2025-05-15T20:52:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":883612800000,"drug_name":[{"lang":"CN","name":"曲匹地尔","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Trapidil","source_info":[{"code":"21900AMX00751000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"トラピジル","source_info":[{"code":"21900AMX00751000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Trapidil (JP17/INN)","source_info":[{"code":"D01220","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Trapidril","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"dev_code":[{"name":"AR-12008","status":"ACTIVE"}],"trade_name":[{"name":"Rocornal","source_info":[{"code":"D01220","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"21900AMX00751000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/790005_2171012C1037_1_05"}],"status":"ACTIVE"},{"name":"Travisco R","status":"ACTIVE"},{"name":"ロコルナール","source_info":[{"code":"21900AMX00751000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/790005_2171012C1037_1_05"}],"status":"ACTIVE"}],"generic_name":[{"name":"Trapidil","source_info":[{"code":"D01220","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB09283"],"kegg_id":["D01220"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["23f15cac189382d1f9aad7de9a0fc685"],"mechanism_action_id":["13955edabde67af00dbd8465e91d8ac0"],"target_id":["1eb9e5552eda48c8beb755ca295fe1d2"],"atc_code":["267e2a4a8b5143a789c8bc825f0dd843"],"disease_id":["bf821ba3fb194a38a5b2f804bcf68c44","22d4d689fe8b43b88ec66a65d7575106","8cec41d5bdc544fd806b1578bb7ba435","893783e694b04965a704ad25001f247e","f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["23f15cac189382d1f9aad7de9a0fc685","a191238a1c78f6e9d78e1b039a9f069a"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["8cec41d5bdc544fd806b1578bb7ba435"],"research_disease":["bf821ba3fb194a38a5b2f804bcf68c44","22d4d689fe8b43b88ec66a65d7575106","8cec41d5bdc544fd806b1578bb7ba435"],"non_research_disease":["893783e694b04965a704ad25001f247e","f1ad50b3010e4721a3ce9b148c940a5a"],"inactive_org_master_entity_id":["831ff89692c29475342362fabc1c0f9f"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":883612800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":353030400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"8cec41d5bdc544fd806b1578bb7ba435","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"22d4d689fe8b43b88ec66a65d7575106","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"893783e694b04965a704ad25001f247e","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"0205a22ab9b84669ae8db4a1703f55dd","docid":1643063,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2025-11-24T09:24:57.000Z","updated_ts":"2025-11-24T09:26:15.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CVP-NASVAC","source_info":[{"normalized_source_id":"fe264ce6f4db4b6484ecc6e245bd7aa4","source":"AASLD","source_url":"https://www.aasld.org/the-liver-meeting/long-term-hbsag-reduction-nasal-administrative-therapeutic-vaccine-containing"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["d83d657e844f901cb99b565656df8aba"],"disease_id":["d91a2772ca874c83a45083c441668cc7"],"active_org_master_entity_id":["d83d657e844f901cb99b565656df8aba"],"research_disease":["d91a2772ca874c83a45083c441668cc7"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"d91a2772ca874c83a45083c441668cc7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04f325e898ad42829641dd89e6f9ddef","docid":1760551,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2025-08-14T08:57:48.000Z","updated_ts":"2025-12-04T21:32:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"GSK-6479720A","source_info":[{"code":"NCT07121192","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07121192"}],"status":"ACTIVE"}],"dev_code":[{"name":"GSK-6479720A","source_info":[{"code":"NCT07121192","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07121192"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"research_disease":["2a8a3f6ab7ec4061858144283e7ce0ca"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1756080000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1759795200000}}],"disease_phase":[{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0fc55598a4de49bab2d986b1cda295aa","docid":1611814,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-09-30T02:21:58.000Z","updated_ts":"2025-09-30T03:18:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"nL-MAPK8-001","source_info":[{"code":"NCT07197294","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07197294"}],"status":"ACTIVE"}],"dev_code":[{"name":"nL-MAPK8-001","source_info":[{"code":"NCT07197294","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07197294"}],"status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["b494f0d4b31d685eb6079c2f1a06405e"],"disease_id":["9eaac562ffab49fcbd7f71cc26a61ee3","f2f1ac32abe645039fa04b65f0d8bf96"],"active_org_master_entity_id":["b494f0d4b31d685eb6079c2f1a06405e"],"research_disease":["9eaac562ffab49fcbd7f71cc26a61ee3","f2f1ac32abe645039fa04b65f0d8bf96"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1740355200000}}],"disease_phase":[{"disease_id":"9eaac562ffab49fcbd7f71cc26a61ee3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f2f1ac32abe645039fa04b65f0d8bf96","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1117afc5451f48cf882b1acc102de6a6","docid":13860,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-02-17T02:44:01.000Z","updated_ts":"2025-03-31T07:00:09.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BM-219","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.weibo.com/ttarticle/p/show?id=2309404823698384486433"}],"status":"ACTIVE"}],"dev_code":[{"name":"BM 219","status":"ACTIVE"},{"name":"BM-219","status":"ACTIVE"},{"name":"BM219","status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["dc922c3d767b0c720aea9496b5607dba"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["dc922c3d767b0c720aea9496b5607dba"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1685923200000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"02d05425742a4f748a7cf47b6286ad1e","docid":35822,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","antibody_drug_id":"fcaf760bd0d54f5ca79c92ca47466fe7","antibody_type":"6cc2f1725abc4c479b30ba000ee17b35","linker_id":"73625cd368bf48fab7cf8f13a0d0e9eb","payload_id":"ed8aadc9cfe643079b9cc84ec3b59e7b","specific_site":0,"site_id":"8f7aa1139735405fa5346941a0693837","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":21,"target_extend_id":"4f2c22baf88e313e889f4359834c592a","created_ts":"2023-02-24T08:35:27.000Z","updated_ts":"2026-03-11T00:45:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SHR-A1201","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"恩美曲妥珠单抗类似药（江苏恒瑞）","status":"ACTIVE"}],"dev_code":[{"name":"SHR A1201","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151","138f7edea9d70a30233e854b342a1eca","569d7324d3bdd73cc1b9e225fdfc8d5f"],"target_id":["a3c3158483984ff9922b1b0ba939a068","d9461748c4c54a0b84cbad2ae3fce7d5"],"dar":{"lower_value":3.0,"upper_value":4.0,"value_type":"RANGE"},"adc_reference":[{"code":"PMID: 36730296","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/36730296/"}],"disease_id":["f8ade5ce0e364264af82a379ab65f6a2"],"active_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"research_disease":["f8ade5ce0e364264af82a379ab65f6a2"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1558483200000}}],"disease_phase":[{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"target_moiety_type":["c38eb408d6b842f487d6a27484156633"],"moiety_target_extend_id":"7b338f40fb243fc79806ffa4e81c4c5a","payload_target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","moiety_mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151","569d7324d3bdd73cc1b9e225fdfc8d5f"],"moiety_target_id":["a3c3158483984ff9922b1b0ba939a068"],"payload_target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"payload_mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"]}
+{"drug_id":"00b38ddd738e489cbafb5f361b216cc9","docid":65055,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":4,"target_extend_id":"707cad0bc9803e32a7f843bf847a55e8","created_ts":"2021-10-08T14:47:55.000Z","updated_ts":"2025-05-28T11:16:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Suvecaltamide","source_info":[{"code":"NCT05642442","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05642442"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Suvecaltamide Hydrochloride","source_info":[{"code":"jk-44","normalized_source_id":"47c8048a73f94d3b9c626eb4f8a6d7e4","source":"USAN","source_url":"https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fsuvecaltamide-HCl.pdf"}],"status":"ACTIVE"}],"dev_code":[{"name":"CX-8998","source_info":[{"code":"NCT05642442","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05642442"}],"status":"ACTIVE"},{"name":"JZP-385","status":"ACTIVE"},{"name":"MK-8998","source_info":[{"code":"NCT05642442","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05642442"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020"],"mechanism_action_id":["4a764d0774507b62e8af9c78ba7ebf93"],"target_id":["0ecf35ee0b74411fbe97844427deed27"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a","654c49b821d54123a586a41e6ad65011","8bf09741a34a4191acd3b235599089c7","1a24b57011454a0983db795c309c77fb","93fd28e08a544a8caba28019cba13e37","5e9f733582a346898f6610db4c13529a","3a32773ea89244019d2f11170e0f18ad","ec4d59ce792b465d8e55e7e52840c626","e29116bd4104436da4275b936996075f"],"active_org_master_entity_id":["e5cf7dd5ba7e6baf5948264251cebc7c"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a","654c49b821d54123a586a41e6ad65011","8bf09741a34a4191acd3b235599089c7"],"non_research_disease":["1a24b57011454a0983db795c309c77fb","93fd28e08a544a8caba28019cba13e37","5e9f733582a346898f6610db4c13529a","3a32773ea89244019d2f11170e0f18ad","ec4d59ce792b465d8e55e7e52840c626","e29116bd4104436da4275b936996075f"],"inactive_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1669852800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1503964800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1669852800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1638748800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1669852800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1638748800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1669852800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1638748800000}}],"disease_phase":[{"disease_id":"8bf09741a34a4191acd3b235599089c7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e29116bd4104436da4275b936996075f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"3a32773ea89244019d2f11170e0f18ad","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"5e9f733582a346898f6610db4c13529a","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"654c49b821d54123a586a41e6ad65011","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"93fd28e08a544a8caba28019cba13e37","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1a24b57011454a0983db795c309c77fb","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0599d52fe1cd4f5e8715f2a31f7eca21","docid":21143,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":78,"target_extend_id":"450cd6ab529c38d4b0ad05aaff0d5fd7","created_ts":"2021-11-30T08:55:27.000Z","updated_ts":"2026-02-24T22:24:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"波米泰酶α","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzIxNzgzMjYyMQ==&mid=2247489769&idx=1&sn=32f9a9b512d1155995648bd0ac9116b0"}],"status":"ACTIVE"},{"lang":"EN","name":"Bemiltenase alfa","source_info":[{"code":"WHOINN List 129","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_5&download=true"},{"code":"WO2023246680A1","normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Factor X activator injection STSP-0601","status":"ACTIVE"},{"lang":"CN","name":"凝血因子X激活剂(舒泰神生物)","source_info":[{"code":"CXSL0500082","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"STSP 0601","status":"ACTIVE"},{"name":"STSP-0601","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.staidson.com/article/36.html"},{"code":"36796484","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/36796484/"}],"status":"ACTIVE"}],"drug_type":["ff9477ffcb8346d59008ad9f2027fd57"],"originator_org_master_entity_id":["834fab3812b42014b670ddc9294820e3"],"mechanism_action_id":["979b395f8c612b269b4c98663691de9d"],"target_id":["3f888f3938b34a4ca124145b3fa1e229"],"special_review":["23d3523b7ece48ddacaddac53a66949d","c3c948340a7d40f3b7437081f5e8cb4e","043a131d85994801b3617e822e7f87b3"],"disease_id":["07d4cf59dafc4a35840dbf53e136394a","e30a25b1033043c4adf00e944889533c","2f7d97069f6945428cf65dd333b4e13d","71d86eb1f39c4e509b8da8fe4343bdd3"],"active_org_master_entity_id":["6208eccb22b44bd090552a579c1d4684","834fab3812b42014b670ddc9294820e3"],"research_disease":["07d4cf59dafc4a35840dbf53e136394a","e30a25b1033043c4adf00e944889533c","2f7d97069f6945428cf65dd333b4e13d","71d86eb1f39c4e509b8da8fe4343bdd3"],"inactive_org_master_entity_id":["f7617f2f9f7f67ba5669c236401990f9"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1748649600000}}],"disease_phase":[{"disease_id":"71d86eb1f39c4e509b8da8fe4343bdd3","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e30a25b1033043c4adf00e944889533c","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"2f7d97069f6945428cf65dd333b4e13d","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"07d4cf59dafc4a35840dbf53e136394a","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"0f9fd00750c54f3bbff7ec32e0983dc5","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"15e46ce6738e4d509b4fd7ee88ddc238","docid":35515,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-02-24T08:36:08.000Z","updated_ts":"2026-02-03T21:46:30.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"CRIS-100","source_info":[{"code":"NCT05739734","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05739734"}],"status":"ACTIVE"}],"dev_code":[{"name":"CRIS 100","status":"ACTIVE"},{"name":"CRIS100","status":"ACTIVE"}],"drug_type":["58846334b4a6496b83493429578a4faa"],"originator_org_master_entity_id":["e1dfd508d181404274dae50ad9bcac06"],"disease_id":["9baa2baa481b46639e29890e2abc0b91","ba4679e72d194ecea4833ef21d34d1e8"],"active_org_master_entity_id":["e1dfd508d181404274dae50ad9bcac06"],"research_disease":["9baa2baa481b46639e29890e2abc0b91","ba4679e72d194ecea4833ef21d34d1e8"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"ba4679e72d194ecea4833ef21d34d1e8","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"9baa2baa481b46639e29890e2abc0b91","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0a371e1dadd7415a851198c312dd982b","docid":5937,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":92,"target_extend_id":"23e78dc5bc9e3c569f29398d0a761044","created_ts":"2021-10-08T14:50:02.000Z","updated_ts":"2026-04-11T21:07:02.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"COR-101","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://corat-therapeutics.com/clinical-trails/"}],"status":"ACTIVE"}],"dev_code":[{"name":"COR 101","status":"ACTIVE"},{"name":"COR101","status":"ACTIVE"},{"name":"STE90-C11","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["5def637ee9d88ba39f7e28135f150ffe"],"mechanism_action_id":["80f3a83094c71a87cd8768d22cd277fd"],"target_id":["f2c8821a6e5845f1b698c8a5a00029e5"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["5def637ee9d88ba39f7e28135f150ffe"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1618963200000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"5a28b8f30510419c9a320b6e4f0b1b5b","docid":29836,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":1,"target_extend_id":"bdbaea34cce038d3a7a2b84cdbbbf54d","created_ts":"2021-10-08T14:39:14.000Z","updated_ts":"2025-11-25T09:06:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"UB-612","source_info":[{"code":"10.3390/vaccines12010040","normalized_source_id":"683aee17-c284-4747-81a6-7de7e61752de","source":"Vaccines (Basel)","source_url":"http://dx.doi.org/10.3390/vaccines12010040"},{"code":"38250853","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/38250853/"}],"status":"ACTIVE"}],"dev_code":[{"name":"UB 612","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e1aca0be003744f0afbfb1a90c7bc8ac"],"originator_org_master_entity_id":["ffe667e8786c4df15bc8549a5ea5afb8"],"mechanism_action_id":["51a0fff0e1824326b23c4a8ae913a9df","01f265de3d5d43a29455e38adc704859","80f3a83094c71a87cd8768d22cd277fd"],"target_id":["ecb364c934b94f0c887758f66a06838c","e7959427c0a54f70a3bad0adcac59487","f2c8821a6e5845f1b698c8a5a00029e5"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["ed96f902ccfbbcc444f7624ef3bb2cfc"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"inactive_org_master_entity_id":["195bd9adafc40802201692c664919444"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1662940800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1666569600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"528590fc-7857-3275-8e6f-09a951a7544b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["de4469c9c5cb0a7252f30459577e283b","ffe667e8786c4df15bc8549a5ea5afb8"],"if_speculate":0,"data_source":10}
+{"drug_id":"0f1719d564dac1cdafc2a617bfda6bdf","docid":261107,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":125,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2024-05-16T06:29:20.000Z","updated_ts":"2026-04-18T21:08:33.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"CD19 CAR-T (Tongji Hospital Tongji Medical College of HUST)","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["38716acfc0018167235bc86c0f96ddb2"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["1d78cca79eae4632bc4464c90a574f83"],"active_org_master_entity_id":["38716acfc0018167235bc86c0f96ddb2"],"research_disease":["1d78cca79eae4632bc4464c90a574f83"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"2898ac146ac54132997d19e1b96c1f10","docid":409963,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":7,"target_extend_id":"40553142a39c366eb7ee3e740fafa937","created_ts":"2024-09-26T02:28:21.000Z","updated_ts":"2026-02-06T00:41:06.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-CD33/CLL1 CAR-NK(Hangzhou Yingbairui Biomedical )","source_info":[{"code":"NCT05215015","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05215015"}],"status":"ACTIVE"}],"drug_type":["8554bd286df144c39af9350c62a5b309"],"originator_org_master_entity_id":["f997c2b15292aac06bed58a39e259487"],"mechanism_action_id":["455d24836320ebb7814fe0cc0de53638","a74b02a128c0eb3e12d419eee54d4dd0"],"target_id":["1240ab5a0e694537a813d074fab12cc0","d4431161069e45498064f04ce31df0c9"],"disease_id":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"research_disease":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1606694400000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"10012c773bbd4e05bac7589de8f42274","docid":74526,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"f7e6fc87258832fb97bc9db88a355e38","created_ts":"2023-01-04T02:22:17.000Z","updated_ts":"2025-11-08T00:25:37.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MHB018A","source_info":[{"code":"CXSL2300002","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"MHB018A","status":"ACTIVE"},{"name":"ZG166","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.zgbiotech.com/news/zgxw/555.html"}],"status":"ACTIVE"}],"drug_type":["3dc96d9272ad41a3833fc1e67887cd5b"],"originator_org_master_entity_id":["ef04c4c6c863d4ac50ad38da5a81f6bd"],"mechanism_action_id":["f349da250289129e84c09ced67a480f1","93c002d0bf04ad734b5da5d92245e235"],"target_id":["72152c447a264a44b1abf2ffdd1a8b4f","b66627f5b9cf42d0bafca85dec359274"],"disease_id":["200cadf5855b4a1e962c82fc373a49d5"],"active_org_master_entity_id":["ef04c4c6c863d4ac50ad38da5a81f6bd"],"research_disease":["200cadf5855b4a1e962c82fc373a49d5"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1750032000000}}],"disease_phase":[{"disease_id":"200cadf5855b4a1e962c82fc373a49d5","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"374592badbce4af8ad7eb8f36279b9d8","docid":203236,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":4,"target_extend_id":"def0fdaca5bc38a4977042479e36a088","created_ts":"2024-08-15T10:06:54.000Z","updated_ts":"2025-08-23T21:10:15.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Foslevodopa/Foscarbidopa","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Levodopa Phosphate/Carbidopa Phosphate","source_info":[{"code":"NCT04380142","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04380142"}],"status":"ACTIVE"}],"dev_code":[{"name":"ABBV-951","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://news.abbvie.com/2024-06-25-AbbVie-Provides-U-S-Regulatory-Update-on-ABBV-951-Foscarbidopa-Foslevodopa"}],"status":"ACTIVE"}],"related_component":["3defc03e5c51498fa051a25a1b1e30a4","50b0d412ec6344a08d8df2260f64101b"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"mechanism_action_id":["64c98d9178391c8c874837eaf2294d21","1f3788f2a405b9eacebf8e943509af03"],"target_id":["af7f43fe15e340f5871239caaa09cc01","d9393d7f2af3423395ae523eb98c0277"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1719273600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1556496000000}}],"disease_phase":[{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01e78450467a448b9970b38f2efd4126","docid":27207,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":206,"target_extend_id":"c2ae5bf143df357dbed72cf460d1cc2e","created_ts":"2021-10-08T14:47:49.000Z","updated_ts":"2026-04-04T21:04:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"ZZ-06","status":"ACTIVE"}],"dev_code":[{"name":"ZZ 06","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-monoclonal-antibody-zz06"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["22c2e30e6409be2416cdeb55a109251b"],"mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4"],"target_id":["c18d6f96c23b4d1e880daafa1b00472b"],"disease_id":["be7faf65fb5d4aa2a7fc1f1ac40cf3c4","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["22c2e30e6409be2416cdeb55a109251b"],"research_disease":["be7faf65fb5d4aa2a7fc1f1ac40cf3c4","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1598918400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1633737600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1598918400000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"be7faf65fb5d4aa2a7fc1f1ac40cf3c4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"04d7917306d64513aa1479424befc169","docid":1311191,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":9,"target_extend_id":"01ae38098c263fb9a0694ee7976a915f","created_ts":"2025-05-16T08:41:32.000Z","updated_ts":"2025-12-05T00:30:45.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"EphA2-targeted CAR-T Cell(Second Affiliated Hospital, School of Medicine, Zhejiang University)","source_info":[{"code":"NCT06972576","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06972576"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["c348d998be49bc119f185f57c3ecc713"],"mechanism_action_id":["9aa0195d5c70b5604fb8b30c417f3876"],"target_id":["2691f9d6452a4846a0dacafd95caccc6"],"disease_id":["2bb755a3f43f49dea60661c5f99712a3"],"active_org_master_entity_id":["c348d998be49bc119f185f57c3ecc713"],"research_disease":["2bb755a3f43f49dea60661c5f99712a3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1746748800000}}],"disease_phase":[{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"031b0739d638480ea51f46f875679b49","docid":231327,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-06-06T01:46:18.000Z","updated_ts":"2025-09-13T00:15:33.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Neoantigen Reactive T Cells(First Affiliated Hospital of Wenzhou Medical University)","source_info":[{"code":"NCT06432075","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06432075"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"NRTs(First Affiliated Hospital of Wenzhou Medical University)","source_info":[{"code":"NCT06432075","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06432075"}],"status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["8005740ad31c536283fc25fd3e96d42e"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["4c092510a2af42f387426e408f5c7694"],"active_org_master_entity_id":["8005740ad31c536283fc25fd3e96d42e"],"research_disease":["4c092510a2af42f387426e408f5c7694"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"disease_phase":[{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0fbdbd0b31cb4f71a3608896a039b78d","docid":9333,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:22.000Z","updated_ts":"2025-04-08T09:24:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ST14 (Signia Therapeutics)","source_info":[{"normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/32835306/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["66295c23b49409747bdd005814e5abc2"],"disease_id":["717a9bf79e584830859595b8dbe9d433","2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["66295c23b49409747bdd005814e5abc2"],"research_disease":["717a9bf79e584830859595b8dbe9d433","2a8a3f6ab7ec4061858144283e7ce0ca"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1648339200000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01012643b3ac4d3d9b548b65cfd264a8","docid":22477,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":19,"target_extend_id":"038d0a188a3b3b48b8fa33466a3379da","created_ts":"2021-10-08T14:45:55.000Z","updated_ts":"2026-04-04T21:09:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BPI-23314","status":"ACTIVE"}],"dev_code":[{"name":"BPI 23314","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["379be598ecf5beae8bbddfb658b003bb"],"mechanism_action_id":["1a969cf6bf3f72868c0acf5dc757c7d8","3ba9f3f7abb04eb3a2a91c20d34e8abe"],"target_id":["55183dc363e64dcdb12c3ea7c7b9596c"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","7cd0fcf1c5c243b9b3944405ec4855b5","1a95630392584c7892bec2dc9888cbfc","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["379be598ecf5beae8bbddfb658b003bb"],"research_disease":["7cb6983b4169498e89b08fd725a22b46"],"non_research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5","1a95630392584c7892bec2dc9888cbfc","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1586908800000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_before_ter_cn":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_before_ter_global":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_before_ter_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_before_ter_global":"e6438687ed214800bb98742ebbeb70a1","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"0c0fc2ddee8043e99db923481af9426c","docid":27862,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"7dbfe7a7fdd93b4b8c332b46344e8508","created_ts":"2022-02-28T05:06:05.000Z","updated_ts":"2024-10-30T10:19:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"AAV-LK03.hOTC","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AAV-LK03-OTC gene therapy (UCL)","status":"ACTIVE"},{"lang":"EN","name":"BGT-OTCD","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://pipelinereview.com/index.php/2023110784688/DNA-RNA-and-Cells/Bloomsbury-Genetic-Therapies-Announces-First-Patient-Enrolled-in-Phase-1/2-HORACE-Clinical-Trial-of-Investigational-Gene-Therapy-BGT-OTCD-for-the-Treatment-of-Ornithine.html"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["1061aac1a9dfed079f119ddc9f0db17c","199b3200555e5622ad5d763e5c4e88f9"],"mechanism_action_id":["58254fa71439ad055dc2694ae159415f"],"target_id":["65dd1dec13664c51851593301d8ed3e6"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["2d90092364ff4889ab8cd68e092194bb"],"active_org_master_entity_id":["199b3200555e5622ad5d763e5c4e88f9","1061aac1a9dfed079f119ddc9f0db17c"],"research_disease":["2d90092364ff4889ab8cd68e092194bb"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1698796800000}}],"disease_phase":[{"disease_id":"2d90092364ff4889ab8cd68e092194bb","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"07a4737deae24ca08b3902ff9fe49f52","docid":15788,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":33,"target_extend_id":"83a11804314a3dc292f4df65674d1860","created_ts":"2021-10-08T14:42:00.000Z","updated_ts":"2026-03-19T00:55:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"精氨酸布洛芬/盐酸曲马多","status":"ACTIVE"},{"lang":"EN","name":"Ibuprofen Arginine/Tramadol Hydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ibuprofen arginine/tramadol","status":"ACTIVE"},{"lang":"EN","name":"Tramadol/ibuprofen arginine","status":"ACTIVE"}],"related_component":["875e5dcc52c948258fbc9d05e332683d"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["300ee9b1b954229050757fde32e64369"],"mechanism_action_id":["bc1ca4f073073bb3a11e18d88a6e20af"],"target_id":["6e8a07393c9c4b019d1a6103e152ffcb"],"disease_id":["e05d3f1bc6e8430e8a7dc7171ae02206","876b6966a810410a8fe64de4064a2f26"],"active_org_master_entity_id":["300ee9b1b954229050757fde32e64369"],"research_disease":["e05d3f1bc6e8430e8a7dc7171ae02206","876b6966a810410a8fe64de4064a2f26"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","20f1c6915ff140519285386c54883aae","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"876b6966a810410a8fe64de4064a2f26","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e05d3f1bc6e8430e8a7dc7171ae02206","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0839b1d44b604810b82408fd3d40bcec","docid":10614,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-10-08T14:47:34.000Z","updated_ts":"2025-07-22T02:40:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"PGG-Glucan (Alpha-Beta Technology, Inc.)","status":"ACTIVE"}],"trade_name":[{"name":"Betafectin","status":"ACTIVE"},{"name":"PGGBetafectin","status":"ACTIVE"}],"drug_type":["1fe8fa7ef6724eb990397a56efe94d7b"],"originator_org_master_entity_id":["81aa37b15630b48cf5046a90f524654b"],"mechanism_action_id":["a30504b84e062940a9ec00f77c5f47be"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2"],"active_org_master_entity_id":["81aa37b15630b48cf5046a90f524654b"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"disease_phase":[{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"23802d8a7af44c9094e4fb65fc64367f","docid":38034,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":135,"target_extend_id":"c2ae5bf143df357dbed72cf460d1cc2e","created_ts":"2021-10-08T14:40:24.000Z","updated_ts":"2026-04-18T21:07:32.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"Panitumumab-IRDye800CW(Stanford University)","status":"ACTIVE"}],"drug_type":["e0da23d3aafb40028ef9ad5d6fabb4ef"],"originator_org_master_entity_id":["734b6d223a9d633b8419a74d2fd215ae"],"mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4"],"target_id":["c18d6f96c23b4d1e880daafa1b00472b"],"disease_id":["7c78dd7ca12d4eadbd772cf774c82efe","323717f7753b4ce6a5561d105a7531cf","28e796b39ead4f0da5b2edc34054a65e","913534b87d4543e28eeb8a7215bb8ef4","200844d5d73740deb3c3c825469da915","f7ce648d7eb448ada7d11726e0768ff8","6fe05469e09f4305b7615b2c277382cd"],"active_org_master_entity_id":["b4e7ddb00fae9ae39b6c068f75db66c8","734b6d223a9d633b8419a74d2fd215ae"],"research_disease":["7c78dd7ca12d4eadbd772cf774c82efe","323717f7753b4ce6a5561d105a7531cf","28e796b39ead4f0da5b2edc34054a65e","913534b87d4543e28eeb8a7215bb8ef4","200844d5d73740deb3c3c825469da915","f7ce648d7eb448ada7d11726e0768ff8","6fe05469e09f4305b7615b2c277382cd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","c8df5dce70fd4e0cb3320058ddb95461","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1775001600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1531958400000}}],"disease_phase":[{"disease_id":"f7ce648d7eb448ada7d11726e0768ff8","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"200844d5d73740deb3c3c825469da915","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"28e796b39ead4f0da5b2edc34054a65e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"323717f7753b4ce6a5561d105a7531cf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7c78dd7ca12d4eadbd772cf774c82efe","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"c2ae5bf143df357dbed72cf460d1cc2e","moiety_mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4"],"moiety_target_id":["c18d6f96c23b4d1e880daafa1b00472b"]}
+{"drug_id":"5f889aa52b474927a6829bd7d61fcfdb","docid":60016,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/SCYX-7158","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-10-08T14:49:25.000Z","updated_ts":"2026-04-14T21:14:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Acoziborole","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Acoziborole Winthrop","source_info":[{"normalized_source_id":"d69160e8845242f2b24e913dcb1e8b85","source":"FiercePharma","source_url":"https://www.fiercepharma.com/pharma/after-chmp-nod-moderna-ceo-applauds-eus-rigorous-scientific-review"},{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://dndi.org/press-releases/2026/acoziborole-winthrop-developed-dndi-sanofi-receives-european-medicines-agency-positive-opinion-sleeping-sickness/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AN-5568","status":"ACTIVE"},{"name":"OXABOROLE SCYX-7158","status":"ACTIVE"},{"name":"OXABOROLE-SCYX-7158","status":"ACTIVE"},{"name":"SCYX-7158","status":"ACTIVE"}],"drugbank_id":["DB13086"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f1f47b0a520f63f82bbe16cd62059f61"],"mechanism_action_id":["5f1807f09e3b9a2e5f68fd7562065c23"],"disease_id":["3ebaa12e1d5d4922b16391d7ea7cf441","cfa12918aa614e0ead0afcd140fa42f1","2f2341e9187145d3b515b91a58327479"],"active_org_master_entity_id":["a076500f0c92e84902ff3adc554db949","bf85af687373969355a25d2aacd31bfb","255b8090d2009294d5f7bca1a92225b3","f1f47b0a520f63f82bbe16cd62059f61"],"research_disease":["3ebaa12e1d5d4922b16391d7ea7cf441","cfa12918aa614e0ead0afcd140fa42f1","2f2341e9187145d3b515b91a58327479"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1772150400000}},{"country":"2d3ac388-90c2-3dee-a631-48cdf6b332b6","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1657324800000}},{"country":"2d3ac388-90c2-3dee-a631-48cdf6b332b6","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1476144000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"27e667db-e085-3d7b-a23d-e17e32233010","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1640822400000}},{"country":"27e667db-e085-3d7b-a23d-e17e32233010","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1476144000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1488240000000}},{"country":"24d95abf-ef9f-3b56-9871-e44b798d794b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754092800000}}],"disease_phase":[{"disease_id":"3ebaa12e1d5d4922b16391d7ea7cf441","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"cfa12918aa614e0ead0afcd140fa42f1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2f2341e9187145d3b515b91a58327479","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"}],"data_source":10}
+{"drug_id":"02601ee9b67c8c6626fcab3ca09387a2","docid":36280,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":510364800000,"created_ts":"2023-05-08T07:14:29.000Z","updated_ts":"2025-07-15T12:18:45.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"sunying","drug_name":[{"lang":"CN","name":"五虎汤","status":"ACTIVE"},{"lang":"EN","name":"Wuhu Decoction","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"五虎湯","status":"ACTIVE"}],"trade_name":[{"name":"オースギ五虎湯エキス錠","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["139a5a0760d49c49700c6fb2344bf709"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","564a2451296345689d8f778eb1beea86"],"active_org_master_entity_id":["4b6970d176e3e6b721ff835042c3c124","139a5a0760d49c49700c6fb2344bf709"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["15fe4881cb88431eb9d44b018619d7b0","564a2451296345689d8f778eb1beea86"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","564a2451296345689d8f778eb1beea86"],"inactive_org_master_entity_id":["6bd12e1a2a6dbe2c659e46be03d7f551"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":525052800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":510364800000}}],"disease_phase":[{"disease_id":"564a2451296345689d8f778eb1beea86","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02c3e65fa99a4cc6bc6a0a67f475e88e","docid":8020,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","created_ts":"2022-02-28T05:05:56.000Z","updated_ts":"2024-10-30T10:22:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"肺力咳","status":"ACTIVE"},{"lang":"EN","name":"FeiLiKe","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["df3f2af04dd146e28a3f1de0556b8a65"],"research_disease":["df3f2af04dd146e28a3f1de0556b8a65"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"df3f2af04dd146e28a3f1de0556b8a65","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"00dba845514d4e5b920603053a457f3a","docid":27205,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Crofelemer","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1356912000000,"rnk":1,"target_extend_id":"7815cb63dbe332408087357434eb57a9","created_ts":"2021-10-08T14:46:17.000Z","updated_ts":"2026-04-14T21:14:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Crofelemer","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CRO-HIV","status":"ACTIVE"},{"lang":"EN","name":"CRO-IBS","status":"ACTIVE"},{"lang":"EN","name":"CRO-ID","status":"ACTIVE"},{"lang":"EN","name":"CRO-PED","status":"ACTIVE"},{"lang":"EN","name":"Crofelemer (USAN)","source_info":[{"code":"D03605","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Provir","status":"ACTIVE"},{"lang":"EN","name":"Virend","status":"ACTIVE"}],"dev_code":[{"name":"NP-303","status":"ACTIVE"},{"name":"SP 303","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/crofelemer"}],"status":"ACTIVE"},{"name":"SP-303","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/crofelemer"}],"status":"ACTIVE"},{"name":"SP-303T","source_info":[{"code":"NCT00002310","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT00002310"}],"status":"ACTIVE"},{"name":"TRN-002","status":"ACTIVE"}],"trade_name":[{"name":"Fulyzaq","source_info":[{"code":"D03605","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Mytesi","source_info":[{"code":"D03605","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB04941"],"kegg_id":["D03605"],"drug_type":["1fe8fa7ef6724eb990397a56efe94d7b"],"originator_org_master_entity_id":["9130c12bf8ce48f787afe88452c74002"],"mechanism_action_id":["e45c18616587475fba5352a8cb5ea184","e271613087e6e7504f1f426b28f6306f"],"target_id":["a30e4f307f2447c3ae9e8b2f6cec0354","5035217e3d264d34b475ebcbc6086466"],"atc_code":["174bd68e2f3a41719918bc272138a00e"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["825dbe90c7ce441c88c525ed8c68678a","e24c1e7ae441435988fa53cdb8adf4d9","e48772acd33b494f96c05a8609e4189b","5a2141391e434c5d9de7bb22adf2d6a6","fa6ca7a9819a4329b980afa284203385","ae8e6f653866483981475b969413b581","831bdcf3826741cb9f7caf409a436914","53587f521e604cdda5fc7179ef4fa329"],"active_org_master_entity_id":["d6e3625262f3e83928253b7e9525a748","2a17f23757c29b6a70e2c5394efbdc56","55317f856f0d78124a6845222345ba8e","9130c12bf8ce48f787afe88452c74002"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["825dbe90c7ce441c88c525ed8c68678a"],"research_disease":["825dbe90c7ce441c88c525ed8c68678a","e24c1e7ae441435988fa53cdb8adf4d9","e48772acd33b494f96c05a8609e4189b","5a2141391e434c5d9de7bb22adf2d6a6","fa6ca7a9819a4329b980afa284203385"],"non_research_disease":["ae8e6f653866483981475b969413b581","831bdcf3826741cb9f7caf409a436914","53587f521e604cdda5fc7179ef4fa329"],"inactive_org_master_entity_id":["f0d6ab7e98b2b3b6175953b28fc55a57","d23991caa6dc65d75ef66ec6c1a67e77"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","bb1d5b11-d9f8-31c4-872c-65a9fad8d193","5360ca18-7876-3a66-8c52-412cbadf2ee0","7d55ca3b-505f-3288-affc-1819c964d53d","0d32466d-4eca-375c-ae57-5aab761cede6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1356912000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1508371200000}},{"country":"5360ca18-7876-3a66-8c52-412cbadf2ee0","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1505779200000}},{"country":"7d55ca3b-505f-3288-affc-1819c964d53d","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1504656000000}},{"country":"0d32466d-4eca-375c-ae57-5aab761cede6","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1505347200000}},{"country":"7e67ab67-b973-3c61-8850-3ba387e2b3fe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1746057600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1748476800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1748476800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1746057600000}},{"country":"a8dbb56e-1021-3ca2-8720-a5c1ca5a6aab","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1182643200000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1761696000000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1761696000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1761696000000}}],"disease_phase":[{"disease_id":"5a2141391e434c5d9de7bb22adf2d6a6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"825dbe90c7ce441c88c525ed8c68678a","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ae8e6f653866483981475b969413b581","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"e24c1e7ae441435988fa53cdb8adf4d9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e48772acd33b494f96c05a8609e4189b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"fa6ca7a9819a4329b980afa284203385","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"831bdcf3826741cb9f7caf409a436914","highest_phase_before_ter_global":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"53587f521e604cdda5fc7179ef4fa329","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["306166e944c24ccbd04579da7bd28ebc","5463d874b9d14dba7b645940ff8cb822","5e0bffd59916d6b4bd831664ffd36292","679c231f63880f46a53ef59ea2614524","7d5767118afffbd718c574f34299be54","9130c12bf8ce48f787afe88452c74002","d07ecb70042d9a0fd143070073ed1b3e","d6e3625262f3e83928253b7e9525a748","e98a9568d28f97e6459db75c8efb34e7"],"data_source":10}
+{"drug_id":"0c3459ce4a674c749e6ac58be2d380bd","docid":4656,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Methyldopa","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":-221961600000,"rnk":18,"target_extend_id":"e3964719eb1e38e991124f7c3fbac726","created_ts":"2021-10-08T14:50:16.000Z","updated_ts":"2026-02-25T01:03:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":504921600000,"drug_name":[{"lang":"CN","name":"甲基多巴","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Methyldopa","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"メチルドパ水和物","source_info":[{"code":"15700AMY00147000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"},{"code":"15700AMY00148000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(S)-(-)-alpha-Methyldopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"3-Hydroxy-alpha-methyl-L-tyrosine","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"AMD","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Alpha medopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Alphamethyldopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Anhydrous methyldopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"L-Methyl Dopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"L-alpha-Methyldopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Methyl dopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Methyldopa (USP)","source_info":[{"code":"D00405","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Methyldopa Hydrate","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Methyldopa anhydrous","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Methyldopa hydrate (JP17)","source_info":[{"code":"D00405","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Methytdopa","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"alpha-Methyl dopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"alpha-methyl-L-dopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"α-Methyl dopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"α-methyl-L-dopa","source_info":[{"code":"DB00968","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"dev_code":[{"name":"FLQ-101","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.feliqs.com/"}],"status":"ACTIVE"},{"name":"FLQ101","status":"ACTIVE"},{"name":"IMT-001","status":"ACTIVE"},{"name":"MK-351","source_info":[{"code":"15700AMY00147000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/750315_2145001F1027_3_03"},{"code":"15700AMY00148000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/750315_2145001F1027_3_03"}],"status":"ACTIVE"},{"name":"NSC-760080","source_info":[{"code":"56LH93261Y","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/d6e863ce-0de0-44c4-b769-dbed9d53bc7f"}],"status":"ACTIVE"}],"trade_name":[{"name":"Aldomet","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D00405","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"15700AMY00147000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/750315_2145001F1027_3_03"},{"code":"15700AMY00148000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/750315_2145001F1027_3_03"}],"status":"ACTIVE"},{"name":"Dopegyt","status":"ACTIVE"},{"name":"アルドメット","source_info":[{"code":"15700AMY00147000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/750315_2145001F1027_3_03"},{"code":"15700AMY00148000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/750315_2145001F1027_3_03"}],"status":"ACTIVE"}],"drugbank_id":["DB00968"],"kegg_id":["D00405"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020"],"mechanism_action_id":["9b9b9b39e1ec925fa9c9c16fbabf5364"],"target_id":["e95b58dd889c4f46ab31d1a5bae2f290"],"atc_code":["d5888caa9e384fc28f6124219dfa015b"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["281fcf1b07ee4c13b0297e4ad1a9c106","bd1c3a9add41425bb2a3015afa87335b"],"active_org_master_entity_id":["6159056de4d897f8d2d0ffbbee03ae2d","5204b2627ddd4e27d324d7f4cd0e67a5","03a9e14b749af6f0f705837d39c1e906"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["281fcf1b07ee4c13b0297e4ad1a9c106"],"research_disease":["281fcf1b07ee4c13b0297e4ad1a9c106","bd1c3a9add41425bb2a3015afa87335b"],"inactive_org_master_entity_id":["968717e6daebf9075caa7f0ef74c073a","6a8c172f1efc649035845f94c31a9c1e","17337b2c2e50e6f4a8db45429aaa6144"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":504921600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":399686400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7"}],"disease_phase":[{"disease_id":"bd1c3a9add41425bb2a3015afa87335b","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"22794ee22e0845889e315dd656dc568b","docid":8531,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:21.000Z","updated_ts":"2024-11-07T21:14:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ATB226","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.altibio.bio/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ATB226","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.altibio.bio/pipeline/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["feeffab0d61e20a25cfc8b441e66bdd7"],"disease_id":["3926dfb9b93246cda1a724441d3d0032"],"active_org_master_entity_id":["feeffab0d61e20a25cfc8b441e66bdd7"],"research_disease":["3926dfb9b93246cda1a724441d3d0032"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1643414400000}}],"disease_phase":[{"disease_id":"3926dfb9b93246cda1a724441d3d0032","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0e79de28948744d69f1a688d0032bd55","docid":1761152,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-09-17T05:52:54.000Z","updated_ts":"2026-03-03T00:38:50.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Umbilical Cord Blood Mononuclear Cells(Zhejiang Cancer Hospital)","source_info":[{"code":"NCT07175207","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07175207"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"UCB-MNCs(Zhejiang Cancer Hospital)","source_info":[{"code":"NCT07175207","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07175207"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["33340606ba062a7af59aa8a9d57cc3b1"],"disease_id":["68fd19fa7cd24439a6f5d31f72d02675","77a98a23365d4e769885da25e2bd6eca"],"active_org_master_entity_id":["33340606ba062a7af59aa8a9d57cc3b1"],"research_disease":["68fd19fa7cd24439a6f5d31f72d02675","77a98a23365d4e769885da25e2bd6eca"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1759276800000}}],"disease_phase":[{"disease_id":"77a98a23365d4e769885da25e2bd6eca","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"68fd19fa7cd24439a6f5d31f72d02675","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0415588dc4cf4749b785aac4f45e487b","docid":201454,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":107,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2024-05-17T08:55:32.000Z","updated_ts":"2026-04-11T21:05:34.000Z","data_status":"ACTIVE","created_by":"fanangle@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"TRX-319","source_info":[{"attachment_path":"data/phs_source_info/5ee9/8217/68c8/f751/5c93ec91-e981-338c-ba5c-6ff2a91bd181.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5031/5cf8/4e84/4194/ed7648d1-dc52-385a-bec7-d9de2f7470e7.png","source":"Company pipeline","source_url":"https://www.tr1x.bio/our-programs"}],"status":"ACTIVE"}],"dev_code":[{"name":"TRX 319","source_info":[{"attachment_path":"data/phs_source_info/5ee9/8217/68c8/f751/5c93ec91-e981-338c-ba5c-6ff2a91bd181.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5031/5cf8/4e84/4194/ed7648d1-dc52-385a-bec7-d9de2f7470e7.png","source":"Company pipeline","source_url":"https://www.tr1x.bio/our-programs"}],"status":"ACTIVE"},{"name":"TRX319","source_info":[{"attachment_path":"data/phs_source_info/5ee9/8217/68c8/f751/5c93ec91-e981-338c-ba5c-6ff2a91bd181.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5031/5cf8/4e84/4194/ed7648d1-dc52-385a-bec7-d9de2f7470e7.png","source":"Company pipeline","source_url":"https://www.tr1x.bio/our-programs"}],"status":"ACTIVE"}],"drug_type":["30a33ee5550b42739e86e1b84361deaa"],"originator_org_master_entity_id":["233e2700b7bb6f94aa81206afebb2c58"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["e437a345ba44462b930187c312f380d5","b6d26728646940ed97a62cf24af18ca2","112037e91e8844e3bc9a7aaef0304803"],"active_org_master_entity_id":["233e2700b7bb6f94aa81206afebb2c58"],"research_disease":["e437a345ba44462b930187c312f380d5","b6d26728646940ed97a62cf24af18ca2","112037e91e8844e3bc9a7aaef0304803"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1772323200000}}],"disease_phase":[{"disease_id":"e437a345ba44462b930187c312f380d5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b6d26728646940ed97a62cf24af18ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"112037e91e8844e3bc9a7aaef0304803","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1197c3809caa4cbf8af4f9043e15cf91","docid":115945,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-10-29T08:19:09.000Z","updated_ts":"2024-12-26T00:21:32.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NK cells(German Cancer Research Center)","source_info":[{"code":"NCT05319249","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05319249"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["bfb00f16ed4994b2b3b71b6f81263611"],"mechanism_action_id":["a3426fcb9c77fd99d0461848fe75fb8f"],"disease_id":["7cb6983b4169498e89b08fd725a22b46"],"active_org_master_entity_id":["bfb00f16ed4994b2b3b71b6f81263611"],"research_disease":["7cb6983b4169498e89b08fd725a22b46"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"4ac18dadde584c90a527043ede2d9743","docid":201643,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-05-24T06:56:46.000Z","updated_ts":"2025-03-25T10:56:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"[68Ga]Ga-Sa-DABI-4","source_info":[{"code":"NCT06419361","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06419361"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["3c03aad0bf356ab7b81b43412a681f88"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["3c03aad0bf356ab7b81b43412a681f88"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1717027200000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"3c26ef2d26514ea7802379a357feec7d","docid":1250003,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2025-03-25T08:32:59.000Z","updated_ts":"2025-03-25T08:40:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Inactivated Monovalent Influenza virus A/Vietnam/1194/2004 NIBRG 14 vaccine(Sanofi pasteur)","source_info":[{"code":"EMEA/H/C/000859","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/emerflu"}],"status":"ACTIVE"}],"trade_name":[{"name":"Emerflu","source_info":[{"code":"EMEA/H/C/000859","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/emerflu"}],"status":"ACTIVE"}],"drug_type":["00458ff770344a2b962324da6b29d16f","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["eb4060e58f37d389f81cb5ed23029213"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["192cc69543a04d57bc38da03cf89eff8"],"active_org_master_entity_id":["eb4060e58f37d389f81cb5ed23029213"],"research_disease":["192cc69543a04d57bc38da03cf89eff8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1177632000000}}],"disease_phase":[{"disease_id":"192cc69543a04d57bc38da03cf89eff8","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04c5c7593cfe4f5596cf0fdbf51e9066","docid":25178,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-09-02T10:34:58.000Z","updated_ts":"2026-02-24T13:35:42.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"CN","name":"怡導速","source_info":[{"attachment_path":"data/phs_source_info/ba98/b3d5/f035/042c/ba98b3d5f035042c.png","attachment_type":"image/png","code":"Gwo Xi Stem Cell-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/8944/78cf/c7d7/5493/894478cfc7d75493.png","source":"Company pipeline","source_url":"https://www.gwoxi.com.tw/product1.html"}],"status":"ACTIVE"},{"lang":"EN","name":"GXIPC-1","status":"ACTIVE"}],"dev_code":[{"name":"GXIPC-1","status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["41c69a37de4fc4fc3e0c05012a584f78"],"disease_id":["0d05187284b446c5803cce38a3e53ebf","1dec6017bd924aff8aeae6e7d4a3f874"],"active_org_master_entity_id":["f583bae77b1a3bf919d57ac784c0d9c0","41c69a37de4fc4fc3e0c05012a584f78"],"research_disease":["0d05187284b446c5803cce38a3e53ebf","1dec6017bd924aff8aeae6e7d4a3f874"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1620086400000}}],"disease_phase":[{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"5dbe831c662a47f0970ecd4c181798e7","docid":44772,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":68,"target_extend_id":"363b76b5c0743630b2bc2f68b86a2531","created_ts":"2021-10-08T14:42:12.000Z","updated_ts":"2026-04-02T12:14:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"CN","name":"阿达木单抗生物类似药(Outlook Therapeutics, Inc.)","status":"ACTIVE"},{"lang":"EN","name":"Adalimumab biosimilar(Outlook Therapeutics, Inc.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Adalimumab Biosimilar (Outlook Therapeutics, Inc.)","status":"ACTIVE"},{"lang":"CN","name":"阿达木单抗生物类似药（Outlook Therapeutics, Inc.）","status":"ACTIVE"}],"dev_code":[{"name":"HOT-3010","status":"ACTIVE"},{"name":"ONS-3010","status":"ACTIVE"}],"trade_name":[{"name":"闲康乐","source_info":[{"normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","source":"Corporate Publications","source_url":"https://www.sse.com.cn/disclosure/listedinfo/announcement/c/new/2024-12-14/600521_20241214_GLE1.pdf"}],"status":"ACTIVE"}],"generic_name":[{"name":"adalimumab","status":"ACTIVE"}],"drugbank_id":["DB00051"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["645996268b96e6ba48c156701c0be45a"],"mechanism_action_id":["7f0c948979d8c147468f6eec9980420d"],"target_id":["1cf1d1f419714af18f463bac42a732d5"],"atc_code":["d36187ae53514b3f8dd648c321954231"],"disease_id":["8da973b225c24afbba255413635fb240","05ae12d567784b85a5c1ca54b2063ee2","d281a3b362a740d8aeb63e2a10102671","fba2e886a6984bf0a99687816b58b064","6be96778ed424f8d91de00ab82364114","36071ab94003462ea2a7121bde6f2209"],"active_org_master_entity_id":["d56a382f300edb3b70255774754249cd"],"research_disease":["8da973b225c24afbba255413635fb240","05ae12d567784b85a5c1ca54b2063ee2","d281a3b362a740d8aeb63e2a10102671","fba2e886a6984bf0a99687816b58b064","6be96778ed424f8d91de00ab82364114","36071ab94003462ea2a7121bde6f2209"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","fce2b462d4fa493eb9d82513b9007011","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1760572800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1734134400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1464480000000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"36071ab94003462ea2a7121bde6f2209","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"fba2e886a6984bf0a99687816b58b064","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["68431d4745744d9e9e17a3073edd3920"],"deal_related_org":["645996268b96e6ba48c156701c0be45a","bdcc6c2f8bb253813c5ab20596dd395c"],"data_source":10}
+{"drug_id":"07bdc1e1c3f74753bed0c9fd0b3dd1fb","docid":62196,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","antibody_type":"52998785b9a04f81b0cc96f0262a4a53","linker_id":"8d974cafe4b74ad7a8187e81a5702466","payload_id":"e8556f9c1e6747b4ab22f04a9b6797f6","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":7,"target_extend_id":"b2c6fb7e717f388e88349de4e1b73cd7","has_leading_org_involved":1,"created_ts":"2022-06-07T06:10:01.000Z","updated_ts":"2026-02-25T01:27:00.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"DB-1305","source_info":[{"code":"CXSL2200248","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"BNT 325","status":"ACTIVE"},{"name":"BNT-325","source_info":[{"attachment_path":"data/phs_source_info/60c9/8380/0ccb/7d3a/5b3efc60-c5b9-315d-a29e-c5dc909dfb1f.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/69aa/2daf/b3b9/c179/7d9b7396-7c92-35b9-a1ab-db361a0c0f74.png","source":"Company pipeline","source_url":"https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#gen-1046-(bnt311)11"}],"status":"ACTIVE"},{"name":"BNT325","status":"ACTIVE"},{"name":"DB 1305","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-trop-2-antibody-drug-conjugate-db-1305"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["2119199eeb0543f5af1b5d1a4ebb9d12"],"mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99","9f012a6b83d88bf152ee30b3d01fa3df"],"target_id":["6acffb63799b4ba3bc85a4c59fcb05d7","d8cdb9ce63174077a9ef868b39bf3421"],"dar":{"avg_value":4.0,"value_type":"AVERAGE"},"adc_reference":[{"code":"10.1158/1538-7445.AM2023-CT248","normalized_source_id":"071bfb0a-a707-4060-9676-fe3efcad9b1b","source":"Cancer Res","source_url":"https://doi.org/10.1158/1538-7445.AM2023-CT248"},{"code":"2023_CT248","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/83/8_Supplement/CT248/725347/Abstract-CT248-First-in-human-trial-of-DB1305-in"}],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","c297238c41b2488abe3de6546b105a4e","11cacc262bfc41adbd6259325efbcfec","c3b9ec7eb2e2402fae4916a1d3f6504a","27538fe67e9b4648b06de8efdc9ab891","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","ae092fa59f4d44edaf59ffe23d0a44c3","f92e4ba771d04f27a1f4daae363b676a","b42488c9ce3245988e4e93caf2b95590","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["c1f9e73709ec2c2f7c39ac8765ae6bcc","2119199eeb0543f5af1b5d1a4ebb9d12","6fb11d60133b90213c35c47a10700173"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","c297238c41b2488abe3de6546b105a4e","11cacc262bfc41adbd6259325efbcfec","c3b9ec7eb2e2402fae4916a1d3f6504a","27538fe67e9b4648b06de8efdc9ab891","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","ae092fa59f4d44edaf59ffe23d0a44c3","f92e4ba771d04f27a1f4daae363b676a","b42488c9ce3245988e4e93caf2b95590","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1752796800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1752796800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1752796800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1752796800000}}],"disease_phase":[{"disease_id":"c3b9ec7eb2e2402fae4916a1d3f6504a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"11cacc262bfc41adbd6259325efbcfec","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["6fb11d60133b90213c35c47a10700173","2119199eeb0543f5af1b5d1a4ebb9d12"],"data_source":10,"moiety_target_extend_id":"ff10f99a311c31f39503da07f9503192","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["9f012a6b83d88bf152ee30b3d01fa3df"],"moiety_target_id":["d8cdb9ce63174077a9ef868b39bf3421"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"00d0db709b97402cbb268af306096b28","docid":71556,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-08-03T08:55:44.000Z","updated_ts":"2025-09-01T00:25:04.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"温胃阿亚然及片","status":"ACTIVE"},{"lang":"EN","name":"Wenwei Ayaranji Tablets","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["dec856798d67ab09434c9de59ffc244c"],"disease_id":["05c80b67cd714e42895b8e1867b171fa","a23a25678fc845a39228fd29b9e89b05"],"active_org_master_entity_id":["dec856798d67ab09434c9de59ffc244c"],"research_disease":["05c80b67cd714e42895b8e1867b171fa","a23a25678fc845a39228fd29b9e89b05"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1684195200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621987200000}}],"disease_phase":[{"disease_id":"a23a25678fc845a39228fd29b9e89b05","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"05c80b67cd714e42895b8e1867b171fa","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"06fae732cf604e4099035c8b9142c2e7","docid":140230,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":40,"target_extend_id":"6f8d59518aff331fbc53561fd8e94d09","created_ts":"2024-04-02T09:01:33.000Z","updated_ts":"2026-03-28T21:08:28.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"沙库巴曲/阿利沙坦酯/苯磺酸氨氯地平","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2024/2024-3/2024-03-26/9897104.PDF"}],"status":"ACTIVE"},{"lang":"EN","name":"Sacubitril/Allisartan Isoproxil/Amlodipine Besylate","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2024/2024-3/2024-03-26/9897104.PDF"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"S086/苯磺酸氨氯地平","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2024/2024-3/2024-03-26/9897104.PDF"}],"status":"ACTIVE"}],"dev_code":[{"name":"SAL 0130","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2024/2024-3/2024-03-26/9897104.PDF"}],"status":"ACTIVE"},{"name":"SAL-0130","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2024/2024-3/2024-03-26/9897104.PDF"}],"status":"ACTIVE"},{"name":"SAL0130","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2024/2024-3/2024-03-26/9897104.PDF"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["41c37d4aa2bccb5479b9cdb911e8126e"],"mechanism_action_id":["3692b3cead55ad47ec3e7823c5195f0e","85d9697959204d9ab650b58c6dbc3843"],"target_id":["0a24ceb721de4dfe8b853c81e5a7f2ef","827d6e2915094fe9a4ab64a7af09c6f2"],"disease_id":["281fcf1b07ee4c13b0297e4ad1a9c106","f8f9347202e043bab0e0d627ce10e767"],"active_org_master_entity_id":["41c37d4aa2bccb5479b9cdb911e8126e"],"research_disease":["281fcf1b07ee4c13b0297e4ad1a9c106","f8f9347202e043bab0e0d627ce10e767"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1757894400000}}],"disease_phase":[{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"4784c17bae374065ba1c8a7a15a40daa","docid":1341563,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-06-05T05:32:40.000Z","updated_ts":"2025-06-05T05:34:12.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"HS-03","source_info":[{"code":"ChiCTR2400079885","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://www.chictr.org.cn/showproj.html?proj=215056"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f91521dc90db021ebecba5078596d59c"],"disease_id":["738546bac89e4895b89af01545f1b054"],"active_org_master_entity_id":["f91521dc90db021ebecba5078596d59c"],"research_disease":["738546bac89e4895b89af01545f1b054"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1705276800000}}],"disease_phase":[{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"48fc1830906e4d62a710c16752065530","docid":202381,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":47,"target_extend_id":"f248208975d53d2da02467f40933af4d","created_ts":"2024-06-24T07:11:10.000Z","updated_ts":"2026-03-28T21:04:50.000Z","data_status":"ACTIVE","created_by":"yangjinhua@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"[68Ga]3BP-3775","source_info":[{"attachment_path":"data/phs_source_info/8982/949a/49b4/bac1/8982949a49b4bac1.png","attachment_type":"image/png","code":"3B Pharmaceuticals-202506","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/0652/dc97/5cf5/8314/0652dc975cf58314.png","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"}],"dev_code":[{"name":"3BP 3775","source_info":[{"attachment_path":"data/phs_source_info/7217/c491/5e35/bfd0/747e2568-2998-3f0b-b997-d65a06d8d486.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/94f7/e09d/fe99/d816/87b6b864-7ba2-3c76-9b77-dc2a71fd1fc7.jpeg","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"},{"name":"3BP-3775","source_info":[{"attachment_path":"data/phs_source_info/4adf/00bf/ef35/7d3d/bc041761-7963-3685-9829-83dad93a8d8a.png","attachment_type":"image/png","code":"3B Pharmaceuticals-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/314e/855a/865b/355a/41cf5c3c-9adf-3b2a-8423-90aee2ee6f7a.png","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"},{"name":"3BP3775","source_info":[{"attachment_path":"data/phs_source_info/7217/c491/5e35/bfd0/747e2568-2998-3f0b-b997-d65a06d8d486.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/94f7/e09d/fe99/d816/87b6b864-7ba2-3c76-9b77-dc2a71fd1fc7.jpeg","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["e1b49c6db6775df734af8e4abbf19f23"],"mechanism_action_id":["5815f2f432884c06b92eb8dd10a46df1"],"target_id":["a87e2f1913564a9aa418d6a6a8e1a799"],"disease_id":["480d2da166064cf1a89e809f7cac1a77"],"active_org_master_entity_id":["e1b49c6db6775df734af8e4abbf19f23"],"research_disease":["480d2da166064cf1a89e809f7cac1a77"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1718928000000}}],"disease_phase":[{"disease_id":"480d2da166064cf1a89e809f7cac1a77","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"09fabdbbc1f64ec292b7c478c2018252","docid":201332,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2024-05-15T06:27:59.000Z","updated_ts":"2024-10-30T10:20:48.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"VA-2","source_info":[{"attachment_path":"data/phs_source_info/6a6f/0a37/5219/6794/fdd50858-2c0c-3cbc-a5fc-dcbaf47ffb5a.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/87cb/02b1/b3ee/748f/0771f4ba-79f1-3a6d-b3e4-bc22573fdad3.png","source":"Company pipeline","source_url":"https://www.valorum.bio/pipeline"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["d081c8ba5677e004ea69d0ee9301ae63"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["d081c8ba5677e004ea69d0ee9301ae63"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"4ca1e580ae464fe4b6d054098ffd4e0e","docid":1731884,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":23,"target_extend_id":"67847d8d029e35478c321399664c1180","created_ts":"2025-10-23T09:53:13.000Z","updated_ts":"2026-04-11T21:08:47.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"地舒单抗生物类似药（JAMP Pharma Corp.）","status":"ACTIVE"},{"lang":"EN","name":"Denosumab Biosimilar (JAMP Pharma Corp.)","status":"ACTIVE"}],"generic_name":[{"name":"denosumab","source_info":[{"code":"EMEA/H/C/001120","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia"},{"code":"EMEA/H/C/002173","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["a067e9bb86d7a57c9d1450e73510cb97"],"mechanism_action_id":["70b3724f9c024338ed116b3bfb828496"],"target_id":["2a9a8ce9bb804bfd95a46d8e4f8bcb1f"],"atc_code":["988359d935c44b11aed8e231d74a483d"],"disease_id":["1713121f9e9b412d9495f3a785ec61c4"],"active_org_master_entity_id":["a067e9bb86d7a57c9d1450e73510cb97"],"research_disease":["1713121f9e9b412d9495f3a785ec61c4"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1756684800000}}],"disease_phase":[{"disease_id":"1713121f9e9b412d9495f3a785ec61c4","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["2dde5d0ddf4d49a2b0df4c4050b91d95"],"if_speculate":0,"data_source":10}
+{"drug_id":"0bea6ce8b7e047148dfa4307260ea8e7","docid":37088,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":2,"target_extend_id":"21e5c299e68f30aab7893b604607d97c","created_ts":"2022-01-06T12:18:58.000Z","updated_ts":"2026-03-14T00:42:27.000Z","data_status":"ACTIVE","created_by":"wanghuimin@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"瑞西奇拜单抗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/B1or0ZUUHO4KBTSXK3W7iA"}],"status":"ACTIVE"},{"lang":"EN","name":"Recibokibart","source_info":[{"code":"pl131","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl131.pdf?sfvrsn=ba04dc1b_5&download=true"},{"code":"WO2022127842A1","normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent","source_url":"https://synapse.zhihuiya.com/patent/319d2c55-8033-43b7-bbbc-690062310c33"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Recombinant humanized anti-interleukin 36R monoclonal antibody(Huaota Biopharma)","status":"ACTIVE"}],"dev_code":[{"name":"HB 0034","status":"ACTIVE"},{"name":"HB0034","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["1184509c6caf5289c06d345f6b0125f5"],"mechanism_action_id":["a3d71f57b6e2c6ac000f0808688ee844"],"target_id":["5ce34ba505f249688a63b7bb84b7109c"],"special_review":["23d3523b7ece48ddacaddac53a66949d","043a131d85994801b3617e822e7f87b3"],"disease_id":["383c36a83a0b4aa0a4603c3af3d89354","509a094ddb78441eaeeeae867832dfad","c5e1987e283c495aaab2a8d309c6085e"],"active_org_master_entity_id":["d56a382f300edb3b70255774754249cd","1184509c6caf5289c06d345f6b0125f5","4b5343e0cf7d4fb190086931bde323cd"],"research_disease":["383c36a83a0b4aa0a4603c3af3d89354","509a094ddb78441eaeeeae867832dfad","c5e1987e283c495aaab2a8d309c6085e"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1759276800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1765065600000}}],"disease_phase":[{"disease_id":"383c36a83a0b4aa0a4603c3af3d89354","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"509a094ddb78441eaeeeae867832dfad","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"07235c9967f14a1caa3e71a5b676899d","docid":43614,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"68d3b9569c9a3fe28aacd620fb3cd431","created_ts":"2021-10-08T14:37:26.000Z","updated_ts":"2026-03-11T00:45:46.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"重组人nsIL12溶瘤腺病毒(VacV Biotheraputics)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ad-TD-nsIL12","source_info":[{"code":"CTR20233830","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR"}],"status":"ACTIVE"}],"dev_code":[{"name":"BioTTT001","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://biottt.com/default.aspx?pageid=2&pageType=detail&id=156"}],"status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["3c76046389fcd41113c9eadfd68015ec"],"mechanism_action_id":["f330b98ebd35bd790da5e678b66069e8"],"target_id":["dcc03681fce14426884bb7a2fa9e203f"],"disease_id":["5f56d0189e534ecc99f8614a687ba171","7e5c317ff13b4214b0c012c41f245b6d","a980d01871674935848fdc3c1885834d","3beea980d93a4cc0abc864e27514601c","4c38270255bc4052a1a6d17475bdc51d","8f43e38cdd4e4794945b3ede3d6eaa4a","e2366e7c7d6a48689251d7fff7a1e239","e35ce4e9b7a846d49e600ce7ac4a7fd6","7665e5683a1a443a8f3d3b946d4c9ca2","11cacc262bfc41adbd6259325efbcfec","c50c74488b3b427b9a7b4260d76fa188","b42488c9ce3245988e4e93caf2b95590","0464f5493b0444e9875a0584df17cbf0","c1cc2528f29940fc95fd6bc37eb982d4","8ffd22aee8f241a3beaf13359e39ebe1"],"active_org_master_entity_id":["a7774a78f6e88244e69e0f7ce0aa59b5","b108ea800675fc335499a08ded68d2d0"],"research_disease":["5f56d0189e534ecc99f8614a687ba171","7e5c317ff13b4214b0c012c41f245b6d","a980d01871674935848fdc3c1885834d","3beea980d93a4cc0abc864e27514601c","4c38270255bc4052a1a6d17475bdc51d","8f43e38cdd4e4794945b3ede3d6eaa4a","e2366e7c7d6a48689251d7fff7a1e239","e35ce4e9b7a846d49e600ce7ac4a7fd6","7665e5683a1a443a8f3d3b946d4c9ca2","11cacc262bfc41adbd6259325efbcfec","c50c74488b3b427b9a7b4260d76fa188","b42488c9ce3245988e4e93caf2b95590","0464f5493b0444e9875a0584df17cbf0","c1cc2528f29940fc95fd6bc37eb982d4"],"non_research_disease":["8ffd22aee8f241a3beaf13359e39ebe1"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1750809600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1732579200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8ffd22aee8f241a3beaf13359e39ebe1","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"11cacc262bfc41adbd6259325efbcfec","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8f43e38cdd4e4794945b3ede3d6eaa4a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"5f56d0189e534ecc99f8614a687ba171","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a980d01871674935848fdc3c1885834d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"e2366e7c7d6a48689251d7fff7a1e239","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c50c74488b3b427b9a7b4260d76fa188","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7e5c317ff13b4214b0c012c41f245b6d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"087e6f98a10940e7ba9ba47d6d144e32","docid":42371,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":73,"target_extend_id":"76621b48f5493838b1dcd91c35dea28d","created_ts":"2021-12-10T12:55:02.000Z","updated_ts":"2025-05-31T21:08:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"Arformoterol/Glycopyrronium (Glenmark Pharmaceuticals)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Glycopyrronium/Formoterol","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["991e75b2224e9ce71bdd4970726fc61d"],"mechanism_action_id":["d5c558daba719aadf8062b1bdbac2bd8"],"target_id":["32ac24079a8f47b18069eb35a1f9120d"],"disease_id":["486c4f5995ae4425a9c98a48d22c84c8"],"active_org_master_entity_id":["991e75b2224e9ce71bdd4970726fc61d"],"research_disease":["486c4f5995ae4425a9c98a48d22c84c8"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"01da1d85d3dc4c66be74b32f4f62b623","docid":68005,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"a0e51a5307563413912520258c3f72b7","created_ts":"2021-10-08T14:50:35.000Z","updated_ts":"2026-04-02T12:53:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Galvokimig","source_info":[{"attachment_path":"data/phs_source_info/2565/7a53/8370/957d/25657a538370957d.png","attachment_type":"image/png","code":"UCB-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3a35/45fc/d075/a15a/3a3545fcd075a15a.png","source":"Company pipeline","source_url":"https://www.ucb.com/innovation/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"UCB 9741","source_info":[{"attachment_path":"data/phs_source_info/2565/7a53/8370/957d/25657a538370957d.png","attachment_type":"image/png","code":"UCB-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3a35/45fc/d075/a15a/3a3545fcd075a15a.png","source":"Company pipeline","source_url":"https://www.ucb.com/innovation/pipeline"}],"status":"ACTIVE"},{"name":"UCB-9741","source_info":[{"attachment_path":"data/phs_source_info/2565/7a53/8370/957d/25657a538370957d.png","attachment_type":"image/png","code":"UCB-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3a35/45fc/d075/a15a/3a3545fcd075a15a.png","source":"Company pipeline","source_url":"https://www.ucb.com/innovation/pipeline"}],"status":"ACTIVE"},{"name":"UCB9741","source_info":[{"attachment_path":"data/phs_source_info/2565/7a53/8370/957d/25657a538370957d.png","attachment_type":"image/png","code":"UCB-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3a35/45fc/d075/a15a/3a3545fcd075a15a.png","source":"Company pipeline","source_url":"https://www.ucb.com/innovation/pipeline"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["a7a3d8c4ca8f1ee9d82829cf8ccc3007"],"mechanism_action_id":["e02a7703a68d4f39d2ee3ffc929eb0a2","529b9d60826a4c1a5765e42277efc255","f6df0275c5d6afb5ea5c48412d47219f"],"target_id":["d8714f87ee3f4ba6a4b21a58500ea620","9b99b0dfb49c480fae5688010b373f83","11d6bafba3e3497e89e7bd73bf8b176c"],"disease_id":["b5068ce40bb1403ab9a02fa97954ebb1","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547"],"active_org_master_entity_id":["a7a3d8c4ca8f1ee9d82829cf8ccc3007"],"research_disease":["b5068ce40bb1403ab9a02fa97954ebb1","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1766966400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1766966400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1766966400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1606435200000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1606435200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1606435200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1606435200000}}],"disease_phase":[{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b5068ce40bb1403ab9a02fa97954ebb1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"07519de80fa9425684f590affb166595","docid":530047,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":48,"target_extend_id":"e2b2160581553002818ef8c2ab06de2c","created_ts":"2024-10-12T08:37:09.000Z","updated_ts":"2026-04-11T21:08:19.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"177Lu-JH04","source_info":[{"code":"NCT06636617","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06636617"},{"code":"2025_4599","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/1550"}],"status":"ACTIVE"}],"drug_type":["4f6af72be17b47249d6de8c3febef8ab","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["cb5cdd75f5584091aaa06a33cc336bbc"],"mechanism_action_id":["21242fc8cd06f56f023f937b9fadb3e9"],"target_id":["b7c5c1575f6d4048978a5b5da2159878"],"disease_id":["e1631f6e80784219932c2f5ec245f1be","6570754a6f0b43b78a9926c7bfd00519","d2ee0aa5e8a2440585e9a218d193b710","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["cb5cdd75f5584091aaa06a33cc336bbc","57e43e05338fe89fedfb0d408362ec79"],"research_disease":["e1631f6e80784219932c2f5ec245f1be","6570754a6f0b43b78a9926c7bfd00519","d2ee0aa5e8a2440585e9a218d193b710","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1724198400000}}],"disease_phase":[{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"e1631f6e80784219932c2f5ec245f1be","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"e2b2160581553002818ef8c2ab06de2c","moiety_mechanism_action_id":["21242fc8cd06f56f023f937b9fadb3e9"],"moiety_target_id":["b7c5c1575f6d4048978a5b5da2159878"]}
+{"drug_id":"04492efebfa34c53bde833b0af65bcdb","docid":36615,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Geron_Corporation#Cancer_therapies","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1717632000000,"rnk":1,"target_extend_id":"8bd0ef9673613a5b8d0b60229c7cc44d","has_leading_org_involved":1,"created_ts":"2021-10-08T14:48:32.000Z","updated_ts":"2026-04-02T16:43:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"伊美司他","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.ghitai.com/product/rytelo-imetelstat"}],"status":"ACTIVE"},{"lang":"EN","name":"Imetelstat","source_info":[{"code":"NDA217779","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217779"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Imetelstat (USAN/INN)","source_info":[{"code":"D09629","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Imetelstat sodium","status":"ACTIVE"}],"dev_code":[{"name":"GRN 140719","status":"ACTIVE"},{"name":"GRN 163","status":"ACTIVE"},{"name":"GRN 163-L","status":"ACTIVE"},{"name":"GRN 719","status":"ACTIVE"},{"name":"GRN-140719","status":"ACTIVE"},{"name":"GRN-163","status":"ACTIVE"},{"name":"GRN-163-L","status":"ACTIVE"},{"name":"GRN-719","status":"ACTIVE"},{"name":"GRN163L peptide","status":"ACTIVE"},{"name":"GRN163L, sodium salt","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imetelstat-sodium"}],"status":"ACTIVE"},{"name":"JNJ-63935937","status":"ACTIVE"}],"trade_name":[{"name":"RYTELO","source_info":[{"code":"NDA217779","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217779"}],"status":"ACTIVE"}],"generic_name":[{"name":"Imetelstat","source_info":[{"code":"D09629","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB14909"],"kegg_id":["D09629"],"drug_type":["df95cafb4597419caca9c7805bf43cac"],"originator_org_master_entity_id":["197b2737b5c9707a0acf225e9fbd56cc"],"mechanism_action_id":["308d890e86ba33006e50d9f1bf7fe8b1"],"target_id":["641a75d39f464fb3984fc4e1fed0095e"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["5b69fd3140ad47bd9848f20f1787f7ed","fb636caf56b44fbba86b702ad4f4b280","1a95630392584c7892bec2dc9888cbfc","fd6b927bd92044d7b240e09317dac79c","bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","7cb6983b4169498e89b08fd725a22b46","5e8defce0a8e4f8bbdf853ea20a56197","d90ca119ac4e4e65b9955e485f607f0d","d375036a43f64928be38e27410c1a835","a4afc28011454f2ca2f48f95f242a04f","989b2261ff864f4cbaa7b0c374c1c770","a0304a462da04e7cb03e3f2c5625544e","021560f52fba4898bcbbfb1aa78c29dd","8df1ce96a8fd4a66ba6dc13760c20282","d7a26da8f1ff43559e34fe72da812c56","f8ade5ce0e364264af82a379ab65f6a2","26535c6f16de4adfb19f0154be738535","8c3f0d7ea2ec444994ed286f45042dcb","7257365c831446dcbcf28024a2b70398","f98fd32baa8447119bb87f84093b925c","2bb755a3f43f49dea60661c5f99712a3","7cd0fcf1c5c243b9b3944405ec4855b5","1a2e903f6dab4bc9b4410b14e342ae5d","a425e59e374549b7bd0f75605eba80c8","7102c119439e42c5835802ab323b3c66","18595e2fb8ec4e41bafa9b28a01b3c2b","1c62320dcc394fea8c8ac97b04ccf868","847a0ea7462c4293b185766079ef37a2","8fc66d310bb14d8da20692ca3671704e","e10523d5d50e41f6841de149d8b794b7","e1bd7636e0d5406fbf8059da86b3c5fb","cec1504cb1d141d68776457c4b88b30f","6d78cbbeaff44aef8b0e80e346b4c48d","9b95ea508c2d43f7928ec1f2120b87b6","e61a6d319d7a402f8435c866c9e8584e"],"active_org_master_entity_id":["197b2737b5c9707a0acf225e9fbd56cc","6ab78ab8d0d9acc402130bf413913375"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["fb636caf56b44fbba86b702ad4f4b280"],"research_disease":["5b69fd3140ad47bd9848f20f1787f7ed","fb636caf56b44fbba86b702ad4f4b280","1a95630392584c7892bec2dc9888cbfc","fd6b927bd92044d7b240e09317dac79c","bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","7cb6983b4169498e89b08fd725a22b46","5e8defce0a8e4f8bbdf853ea20a56197","d90ca119ac4e4e65b9955e485f607f0d","d375036a43f64928be38e27410c1a835","a4afc28011454f2ca2f48f95f242a04f","989b2261ff864f4cbaa7b0c374c1c770"],"non_research_disease":["a0304a462da04e7cb03e3f2c5625544e","021560f52fba4898bcbbfb1aa78c29dd","8df1ce96a8fd4a66ba6dc13760c20282","d7a26da8f1ff43559e34fe72da812c56","f8ade5ce0e364264af82a379ab65f6a2","26535c6f16de4adfb19f0154be738535","8c3f0d7ea2ec444994ed286f45042dcb","7257365c831446dcbcf28024a2b70398","f98fd32baa8447119bb87f84093b925c","2bb755a3f43f49dea60661c5f99712a3","7cd0fcf1c5c243b9b3944405ec4855b5","1a2e903f6dab4bc9b4410b14e342ae5d","a425e59e374549b7bd0f75605eba80c8","7102c119439e42c5835802ab323b3c66","18595e2fb8ec4e41bafa9b28a01b3c2b","1c62320dcc394fea8c8ac97b04ccf868","847a0ea7462c4293b185766079ef37a2","8fc66d310bb14d8da20692ca3671704e","e10523d5d50e41f6841de149d8b794b7","e1bd7636e0d5406fbf8059da86b3c5fb","cec1504cb1d141d68776457c4b88b30f","6d78cbbeaff44aef8b0e80e346b4c48d","9b95ea508c2d43f7928ec1f2120b87b6","e61a6d319d7a402f8435c866c9e8584e"],"inactive_org_master_entity_id":["60852b5f635d4adae889386d4e07356e"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1717632000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618185600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1452556800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1452556800000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1452556800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1452556800000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1452556800000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"18595e2fb8ec4e41bafa9b28a01b3c2b","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"bb2d2cb31a9b4c9687a2fc8194b7ddbb","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"021560f52fba4898bcbbfb1aa78c29dd","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"5b69fd3140ad47bd9848f20f1787f7ed","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1a2e903f6dab4bc9b4410b14e342ae5d","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d90ca119ac4e4e65b9955e485f607f0d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8df1ce96a8fd4a66ba6dc13760c20282","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7102c119439e42c5835802ab323b3c66","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8fc66d310bb14d8da20692ca3671704e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f9411c5705084810ac5fffbb524c86c9","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e61a6d319d7a402f8435c866c9e8584e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"cec1504cb1d141d68776457c4b88b30f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e1bd7636e0d5406fbf8059da86b3c5fb","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d375036a43f64928be38e27410c1a835","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1c62320dcc394fea8c8ac97b04ccf868","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8c3f0d7ea2ec444994ed286f45042dcb","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9b95ea508c2d43f7928ec1f2120b87b6","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6d78cbbeaff44aef8b0e80e346b4c48d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"847a0ea7462c4293b185766079ef37a2","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7257365c831446dcbcf28024a2b70398","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fd6b927bd92044d7b240e09317dac79c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"989b2261ff864f4cbaa7b0c374c1c770","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a425e59e374549b7bd0f75605eba80c8","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"fb636caf56b44fbba86b702ad4f4b280","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["197b2737b5c9707a0acf225e9fbd56cc","ee3f62ab873c539d75e06f49cc09d7fc"],"genetic_material":"4da1e22a311e417a9906371a9a5eb744","if_speculate":0,"data_source":10,"source_info_xna":[{"code":"PMID: 39162963","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source_url":"https://pubmed.ncbi.nlm.nih.gov/39162963/"}],"regulation_type":["84514566470348b191dba9bdb664fb93"],"targeted_tissue":["5d8be432fdeb4e31a647f288e71124e2"],"paired_region":["d8b17183e35841a3b1c4577c246f3425"]}
+{"drug_id":"081e94fdcde8440e804ac57da0c01d57","docid":17244,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-02-24T02:10:19.000Z","updated_ts":"2024-12-21T00:22:49.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MRx-0005","status":"ACTIVE"}],"dev_code":[{"name":"CJRB 301","source_info":[{"attachment_path":"data/phs_source_info/4c09/91a6/2f0f/a1f9/499a9a52-b0e7-32b1-85d7-36100919db27.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/379d/aa15/e961/8e06/cbf19b92-6100-3261-8b2a-aeb1edee4aa4.jpeg","source":"Company pipeline","source_url":"https://www.cjbioscience.com/pipeline"}],"status":"ACTIVE"},{"name":"CJRB301","source_info":[{"attachment_path":"data/phs_source_info/4c09/91a6/2f0f/a1f9/499a9a52-b0e7-32b1-85d7-36100919db27.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/379d/aa15/e961/8e06/cbf19b92-6100-3261-8b2a-aeb1edee4aa4.jpeg","source":"Company pipeline","source_url":"https://www.cjbioscience.com/pipeline"}],"status":"ACTIVE"},{"name":"MRX 0005","status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["53388c1f1255e190c278a9815702f0c7"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","1a41a587feb28542b3050eb67b912259"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["53388c1f1255e190c278a9815702f0c7","aa143bdaa4930a8d5f99935b874b9b11"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1646611200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e6438687ed214800bb98742ebbeb70a1"},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"3da2ce3ce8b0443fb0b2d335be3e591a","dev_status_time":{"time_trust_code":7,"time_ts":1645488000000}}],"disease_phase":[{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"3320d2b574fe40d19ecd2cd4f450ce02","docid":68850,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","payload_id":"74120b09a0744d23b87f8955ef2111d2","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-05-10T05:38:48.000Z","updated_ts":"2025-02-24T12:03:43.000Z","data_status":"ACTIVE","created_by":"zhongxia","drug_name":[{"lang":"EN","name":"Hyperpolarized Bicarbonate (13C)","source_info":[{"code":"NCT05851365","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05851365"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HP C13","source_info":[{"code":"NCT05851365","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05851365"}],"status":"ACTIVE"},{"lang":"EN","name":"Hyperpolarized (HP) bicarbonate 13 (13C)","source_info":[{"code":"NCT05851365","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05851365"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["5a3440fb46fe93ce88c47950896dc1c6"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["976f9f8cf61f4a77a1866cb146de181e"],"active_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"research_disease":["976f9f8cf61f4a77a1866cb146de181e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1688601600000}}],"disease_phase":[{"disease_id":"976f9f8cf61f4a77a1866cb146de181e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01b4d5a4562b49619a3cb5f38f98e0be","docid":45525,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":20,"target_extend_id":"c8ba33d656bc38dd96d8e20e1373a45d","created_ts":"2023-02-22T09:31:26.000Z","updated_ts":"2026-03-07T21:11:48.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"ISM-3312","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NzY2MDQwMg==&mid=2650303204&idx=3&sn=9a63d937d9c6cfd6b13db6ce8148162b"}],"status":"ACTIVE"}],"dev_code":[{"name":"ISM3312","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f122e54add8b334c3245ff22d0d78115"],"mechanism_action_id":["7ad9ba0b58b5315e14168eeeb9684891"],"target_id":["43e7a86fd47941f992552fe35d1c5af7"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["f122e54add8b334c3245ff22d0d78115"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1676937600000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0825300a54994e8888e9be8a0f9b2ac2","docid":45028,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":34,"target_extend_id":"674a5e6e2f5137068c2bea8936b7de89","created_ts":"2022-04-14T05:24:02.000Z","updated_ts":"2026-03-14T21:10:31.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"GRC-54276","status":"ACTIVE"}],"dev_code":[{"name":"GRC 54276","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/hpk1-inhibitor-grc-54276"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["45acdac728ca8c28f6727e5f32d56ca6"],"mechanism_action_id":["15361c70aabb7a297fffba48611a2600"],"target_id":["5a34b1dfc07d416a8e43cc0d5520fe63"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","26535c6f16de4adfb19f0154be738535","524236920ce94d7d831f0ac59bcacae8","275ecda875e0460f84aa768ca9b2e5d6"],"active_org_master_entity_id":["45acdac728ca8c28f6727e5f32d56ca6","991e75b2224e9ce71bdd4970726fc61d","6af6efb451883d28cd74944bb4ad48b9"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","26535c6f16de4adfb19f0154be738535","524236920ce94d7d831f0ac59bcacae8","275ecda875e0460f84aa768ca9b2e5d6"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686182400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1649635200000}}],"disease_phase":[{"disease_id":"524236920ce94d7d831f0ac59bcacae8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["991e75b2224e9ce71bdd4970726fc61d","f11e7e6fa72ab434407f9fbd870f27cc"],"data_source":10}
+{"drug_id":"08df2463fe6d4f9d8968c56f4eed8cc6","docid":110485,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":55,"target_extend_id":"c3564a2e384d34ef94516d844f563ba3","created_ts":"2024-02-19T10:05:13.000Z","updated_ts":"2026-04-18T21:07:27.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"[177Lu]-LNC1011","source_info":[{"code":"NCT06250244","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06250244"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"177Lu-DansyI-PSMA","source_info":[{"code":"NCT06377683","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06377683"}],"status":"ACTIVE"}],"dev_code":[{"name":"177Lu-LNC1011","source_info":[{"code":"NCT06250244","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06250244"}],"status":"ACTIVE"},{"name":"[177Lu]Lu-LNC1011","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://link.springer.com/article/10.1007/s00259-025-07245-8"}],"status":"ACTIVE"}],"drug_type":["926e8e25a2b04d29864ed28dca6c57b7","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["b77972c0fe921e711edc4c80084f3e81"],"mechanism_action_id":["fee01edcb873f72bc42e7f48a29ed464"],"target_id":["1764007a7c384a4ab49bb3710bab5052"],"adc_reference":[{"code":"40113222","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/40113222/"}],"disease_id":["bc9afd054cea47d4afb0f41c676adbaa","27538fe67e9b4648b06de8efdc9ab891","961a29cd37ec471da3e70916138845bb","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["faa9ea08d792dc82af6444fa1fd8362a","b77972c0fe921e711edc4c80084f3e81","dd333034c2ac8edc49f387d7e5e2ed8f"],"research_disease":["bc9afd054cea47d4afb0f41c676adbaa","27538fe67e9b4648b06de8efdc9ab891","961a29cd37ec471da3e70916138845bb","07994e875a7f44dc9af7f9bf3f6989e5"],"inactive_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1737417600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"4cc6684d-f7b4-392b-9dec-6fce3264fac8","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1711324800000}}],"disease_phase":[{"disease_id":"bc9afd054cea47d4afb0f41c676adbaa","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"961a29cd37ec471da3e70916138845bb","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","moiety_mechanism_action_id":["fee01edcb873f72bc42e7f48a29ed464"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"]}
+{"drug_id":"0203a8aa9ffc49c0979fad0075cf4a79","docid":1642668,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":10,"target_extend_id":"6a290b3d82e9357a833ae58789d3b3ee","created_ts":"2025-10-30T08:52:41.000Z","updated_ts":"2026-02-07T21:11:42.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"[14C]MT1013","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA4NDM5OTk0Ng==&mid=2247488321&idx=1&sn=c137c512598c5314e3f45e8740554c7c"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","999a31860dd242028856d023b5e23d05"],"originator_org_master_entity_id":["e23be32cf93f7150c2edc76913103e22"],"mechanism_action_id":["356348f17627fd1dfe170a8d642c8caf"],"target_id":["5730c26c8efa45b49713e427e0334909"],"disease_id":["3199fba93d86456aa9e8223ba2b77f84"],"active_org_master_entity_id":["e23be32cf93f7150c2edc76913103e22"],"research_disease":["3199fba93d86456aa9e8223ba2b77f84"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1764460800000}}],"disease_phase":[{"disease_id":"3199fba93d86456aa9e8223ba2b77f84","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"08584e7057a14ebeaa302fee2802df0b","docid":6279,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Raltitrexed","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":837388800000,"rnk":11,"target_extend_id":"ba78232c3999336ebf7f96faed4b5afb","created_ts":"2021-10-08T14:46:50.000Z","updated_ts":"2026-02-25T02:17:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1251849600000,"drug_name":[{"lang":"CN","name":"雷替曲塞","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Raltitrexed","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Raltitrexed (JAN/USAN/INN)","source_info":[{"code":"D01064","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"D-1694","status":"ACTIVE"},{"name":"ICI-D-1694","status":"ACTIVE"},{"name":"ICI-D1694","status":"ACTIVE"},{"name":"NSC-639186","status":"ACTIVE"},{"name":"ZD 1694","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/raltitrexed"}],"status":"ACTIVE"},{"name":"ZD-1694","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/raltitrexed"}],"status":"ACTIVE"},{"name":"ZN-D1694","status":"ACTIVE"}],"trade_name":[{"name":"Tomudex","source_info":[{"code":"D01064","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"generic_name":[{"name":"Raltitrexed","source_info":[{"code":"D01064","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00293"],"kegg_id":["D01064"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506"],"mechanism_action_id":["c2b0909d5ec4f04f4d218553536d81a7"],"target_id":["7794e53ee5cb4daeb3d692d42bfb9566"],"atc_code":["90776cb2910946fa8f2f4488e1d9d35d"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","15839db0de0947ddb9e4c280884a3895","7aa64df8ca2c4b428c9132a6e3e60bc0","e2366e7c7d6a48689251d7fff7a1e239","f048bf0822254413a3ea354eced08eec","e35ce4e9b7a846d49e600ce7ac4a7fd6","1714ace3a2f941d8921c9dbc77a8ba1d"],"active_org_master_entity_id":["4b95858109395c09579d681fd3f8d72b","f957ab42bd2f8f2b529d85eb815faa5c","662d46871bd6f6dc727ddefab40c2a06","d1d9aec8810de093aaf76b6e93cedf57","adfeb589d77c607ceba32736bc8546bc"],"first_approved_country":["ecc919b1-c2b7-3740-bfa7-7cda77176d07"],"first_approved_indication":["7665e5683a1a443a8f3d3b946d4c9ca2"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","15839db0de0947ddb9e4c280884a3895","7aa64df8ca2c4b428c9132a6e3e60bc0"],"non_research_disease":["e2366e7c7d6a48689251d7fff7a1e239","f048bf0822254413a3ea354eced08eec","e35ce4e9b7a846d49e600ce7ac4a7fd6","1714ace3a2f941d8921c9dbc77a8ba1d"],"inactive_org_master_entity_id":["4723981e27cc91d2d0bfefe7cb94d12f","6e7a2de70d46daa0cef8586ca22ae506"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07","666d5a51-60da-3482-b804-e6df04651a1e"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1251849600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":848275200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":837388800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":896313600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1212192000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1587081600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1264291200000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1714ace3a2f941d8921c9dbc77a8ba1d","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e2366e7c7d6a48689251d7fff7a1e239","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7aa64df8ca2c4b428c9132a6e3e60bc0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"2d025285ed7343d5a34126aba9bc1fc6","docid":6305,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2022-06-15T06:22:29.000Z","updated_ts":"2024-11-08T13:20:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"AZ-06","status":"ACTIVE"}],"dev_code":[{"name":"AZ 06","status":"ACTIVE"},{"name":"AZ06","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f676009a073687839de530461feab64d"],"disease_id":["f24f4f7b902c4723a40c33559688a7c9"],"active_org_master_entity_id":["f676009a073687839de530461feab64d"],"research_disease":["f24f4f7b902c4723a40c33559688a7c9"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"f24f4f7b902c4723a40c33559688a7c9","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"03f6bf9356b0491f87aeb0b287424231","docid":6274,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","wiki_link":"https://en.wikipedia.org/wiki/Desidustat","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1646611200000,"rnk":3,"target_extend_id":"8d97cc2aff603b619e3dd8be0450305b","created_ts":"2021-10-08T14:48:29.000Z","updated_ts":"2026-04-02T02:27:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":1773100800000,"drug_name":[{"lang":"CN","name":"德昔度司他","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzA5MzE2MTQ5Mg==&mid=2247526370&idx=3&sn=805de0fc29da455d43a8350427bc9f0b"}],"status":"ACTIVE"},{"lang":"EN","name":"Desidustat","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"德度司他","status":"ACTIVE"}],"dev_code":[{"name":"ZYAN 1","status":"ACTIVE"},{"name":"ZYAN-1","status":"ACTIVE"},{"name":"ZYAN1","source_info":[{"code":"10.1055/s-0035-1554630","normalized_source_id":"222db58e-dc7d-41a8-ac31-a3577fddd7f3","source":"Drug Res (Stuttg)","source_url":"http://dx.doi.org/10.1055/s-0035-1554630"}],"status":"ACTIVE"},{"name":"ZYAN1-1001","status":"ACTIVE"}],"trade_name":[{"name":"Oxemia","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MTMyMDg0Ng==&mid=2650683580&idx=4&sn=feb5db9150ee05ef1ae7247653e8221e"}],"status":"ACTIVE"}],"drugbank_id":["DB16135"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dbb79f18e1bdad5d28c1a8e8c4b93eb8"],"mechanism_action_id":["fbb0ac377db50615c7d179db83f3260b"],"target_id":["6dfb83eb44a240ae9d826009b5089d5b"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["db18618b9731459d8d79eaf8fd719165","406bb889128347abb22b03906567527b","d44acd639f404e588b9a9afbf532318c","717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["8880b94c103115459f3f8bb32dbddc3e","ed78a146298421b81ecc1ef5003a29b9"],"first_approved_country":["2f753928-f426-3cc1-9ea6-8c25f6a4d330"],"first_approved_indication":["406bb889128347abb22b03906567527b"],"research_disease":["db18618b9731459d8d79eaf8fd719165","406bb889128347abb22b03906567527b","d44acd639f404e588b9a9afbf532318c"],"non_research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d","b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","2f753928-f426-3cc1-9ea6-8c25f6a4d330"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1773100800000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1646611200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1650844800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1680220800000}}],"disease_phase":[{"disease_id":"d44acd639f404e588b9a9afbf532318c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"406bb889128347abb22b03906567527b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"db18618b9731459d8d79eaf8fd719165","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["02dec8b991829dc7531a620e9ae00502","8880b94c103115459f3f8bb32dbddc3e","9ff89edb83df56ea8306bbba7bf0c374"],"if_speculate":0,"data_source":10}
+{"drug_id":"07bf6b38be634718897783feeabef441","docid":35669,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":11,"target_extend_id":"05791baccbd839049da0b6b489aa82f0","created_ts":"2021-11-30T08:55:57.000Z","updated_ts":"2025-12-20T21:11:13.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"VRON-0200","status":"ACTIVE"}],"dev_code":[{"name":"VRON 0200","status":"ACTIVE"},{"name":"VRON-0200","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["d06b8c2cb9022fa27b34c37ddb0f56f8"],"mechanism_action_id":["876db916c3e9aeeca520202b8ae911ac","d14c2ee8f93b7874768556f06ceeb8cf"],"target_id":["186a80f7c83d462fbb8ce3cec56d5f6b"],"disease_id":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"active_org_master_entity_id":["d06b8c2cb9022fa27b34c37ddb0f56f8","05710db69f6b9987a4a57186ef1b8a0d"],"research_disease":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677024000000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1695686400000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1695686400000}}],"disease_phase":[{"disease_id":"f196ef1a4d9c4cb3aede0ea60aac4a52","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["3322e9d6aba994dd1a4a3753b623e142","d06b8c2cb9022fa27b34c37ddb0f56f8"],"data_source":10}
+{"drug_id":"08ec1e54f6f24d018f8b7a119b45a9d0","docid":42218,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-08-30T05:10:26.000Z","updated_ts":"2025-12-09T03:14:09.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"sunying","drug_name":[{"lang":"CN","name":"人用狂犬病疫苗（人二倍体细胞）(江苏中慧元通生物科技)","source_info":[{"code":"CXSL2200401","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Rabies Vaccine (Human Diploid Cell)(Ab&b Bio-Tech)","source_info":[{"code":"CXSL2200401","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Rabies Vaccine(Human Diploid Cell) for Human Use,Freeze-dried(Ab&b Bio-Tech)","source_info":[{"code":"NCT06133478","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["3a3d1676eec6ba57855c693aea9cf080"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["26bdc387cad64dc985f00855d64a3d2d"],"active_org_master_entity_id":["3a3d1676eec6ba57855c693aea9cf080"],"research_disease":["26bdc387cad64dc985f00855d64a3d2d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765152000000}}],"disease_phase":[{"disease_id":"26bdc387cad64dc985f00855d64a3d2d","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"05836ae131cc48d5a147e86d15c8442d","docid":3074,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"130787d66d9530b6b04956fe96348a7a","created_ts":"2021-10-08T14:49:12.000Z","updated_ts":"2026-01-31T21:18:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"HRS-9950","status":"ACTIVE"}],"dev_code":[{"name":"HRS 9950","status":"ACTIVE"},{"name":"HRS9950","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"mechanism_action_id":["54ca34745a293f102954fce61ac1c97d"],"target_id":["bfd9ae9131904838b0a638f3917632f2"],"disease_id":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"active_org_master_entity_id":["eb149680ffd8f3718c18baa347a76721","918e581389bc3b2317988d5b46fafa34"],"research_disease":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690502400000}}],"disease_phase":[{"disease_id":"f196ef1a4d9c4cb3aede0ea60aac4a52","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"043559972d1b4d44b3ec19c5dd3f9c2f","docid":1731536,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-09-22T09:01:05.000Z","updated_ts":"2026-02-27T07:42:09.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"OPT101(Opterion Health)","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/402210611"}],"status":"ACTIVE"}],"dev_code":[{"name":"OPT-101(Opterion Health)","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/402210611"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["7c93bdeab83265ae59911c3837ea6d45"],"disease_id":["bb895a9780a94318973390e3df4eb213"],"active_org_master_entity_id":["7c93bdeab83265ae59911c3837ea6d45"],"research_disease":["bb895a9780a94318973390e3df4eb213"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"3da2ce3ce8b0443fb0b2d335be3e591a","dev_status_time":{"time_trust_code":7,"time_ts":1758067200000}}],"disease_phase":[{"disease_id":"bb895a9780a94318973390e3df4eb213","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02678f76981847e5b0062e1eee7142e1","docid":20544,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:41:31.000Z","updated_ts":"2025-12-06T04:28:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"PZH-2108","status":"ACTIVE"}],"dev_code":[{"name":"PZH2108","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["1bdec2fea516aa0a1e3d5dafd833d3dd"],"disease_id":["99e0da7f19d241408a5fe39ac6f18456"],"active_org_master_entity_id":["1bdec2fea516aa0a1e3d5dafd833d3dd"],"research_disease":["99e0da7f19d241408a5fe39ac6f18456"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1762128000000}}],"disease_phase":[{"disease_id":"99e0da7f19d241408a5fe39ac6f18456","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"04bf0988186844928f48327627f860bd","docid":18749,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"8217d13668323c4787f1e288f9470aab","created_ts":"2021-10-08T14:46:50.000Z","updated_ts":"2025-05-26T10:46:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"OB-318","status":"ACTIVE"}],"dev_code":[{"name":"OB 318","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["26b911d5d00d83caf03456dc07048847"],"mechanism_action_id":["62ea20c4d71266d0c5d6e91d9d056e2b","eaee1c5527b3a91b4ee1e520963463f7","17b969cc4957367108ebcd53fc87f22c"],"target_id":["ab6344feeead4ae1a30ab8bbf433d86e","fe5b12ba299a474b979d6ab1ddca7b4b","3ad943efb7d74b069791c954795aaff5"],"disease_id":["15839db0de0947ddb9e4c280884a3895","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["a0475a81d6ef2f5cf97876fb130df987","69262a4f1ee5175e409ad6e2c8933055"],"research_disease":["15839db0de0947ddb9e4c280884a3895"],"non_research_disease":["0464f5493b0444e9875a0584df17cbf0"],"inactive_org_master_entity_id":["26b911d5d00d83caf03456dc07048847"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"00c4ee452da842ffad4e2ba21fd04dda","docid":69958,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"178be3322a61357f92616114dd812bb2","created_ts":"2023-02-08T01:59:27.000Z","updated_ts":"2026-04-17T20:14:09.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wangya","drug_name":[{"lang":"EN","name":"SYS-6010","source_info":[{"code":"CXSL2300094","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"CPO-301","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247559388&idx=1&sn=c285029d2a4c5da9aaafb0dfcfda893b"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-antibody-drug-conjugate-cpo301"}],"status":"ACTIVE"},{"name":"SYS 6010","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-antibody-drug-conjugate-cpo301"}],"status":"ACTIVE"},{"name":"SYS-6010","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-antibody-drug-conjugate-cpo301"}],"status":"ACTIVE"},{"name":"SYS6010","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-antibody-drug-conjugate-cpo301"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"mechanism_action_id":["aa4209d45e544876a19ad690d486abc8","cb04012f4d160bc18f7f8337f3cb44ab","522321673e9345e3a6669052526fb06d"],"target_id":["bb95b2e9047a49f2934f5d0afa43dc28","56ba60c7c35144e8b7b0a6c708c04ab3","acf33065e2f34e3ab4e551ec8416738e"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["f98fd32baa8447119bb87f84093b925c","74ba301586ab419b9c9accd39cd20782","b186eb772eec487d8f3914b24c946af6","949c20c9e52549008773244a4230da7d","b382bc2a56644776b45dc6084224df3b","4d4cee82fa5c46f19de528f4a8423f62","b98763c97526476fb442d16344cb5e59","1954d1a9e4c04e7fb608cb3b89462ca2","b0f27ade93a54b5ab2a29a6a67bef00f","11c9483b13174c4686fd04f48dc66b92","47e03afcbd9b49e1a5d0407506e176c3","3bf6031206e848cd94f767cd1db43ea0","a0304a462da04e7cb03e3f2c5625544e","0464f5493b0444e9875a0584df17cbf0","7532c5e08c9d481ba9a25f3fbbb912bb","3beea980d93a4cc0abc864e27514601c","07994e875a7f44dc9af7f9bf3f6989e5","fe2cabaf9f024e9399d52e83d07f5883","436a0911d9e64afb97a74ef212e9fae5","6b397adaec4b4b73b4b9fccb1480ac7b"],"active_org_master_entity_id":["f6f07c9a95f0a155cbcc38f7fab146c2","3ac675fea3e4dfd3dbb1c1dfe219f2a7","5cf5fedddb15b3ca0a531d9b789f0286","631186c0133014d74840dcf97dbd94be"],"research_disease":["f98fd32baa8447119bb87f84093b925c","74ba301586ab419b9c9accd39cd20782","b186eb772eec487d8f3914b24c946af6","949c20c9e52549008773244a4230da7d","b382bc2a56644776b45dc6084224df3b","4d4cee82fa5c46f19de528f4a8423f62","b98763c97526476fb442d16344cb5e59","1954d1a9e4c04e7fb608cb3b89462ca2","b0f27ade93a54b5ab2a29a6a67bef00f","11c9483b13174c4686fd04f48dc66b92","47e03afcbd9b49e1a5d0407506e176c3","3bf6031206e848cd94f767cd1db43ea0","a0304a462da04e7cb03e3f2c5625544e","0464f5493b0444e9875a0584df17cbf0","7532c5e08c9d481ba9a25f3fbbb912bb","3beea980d93a4cc0abc864e27514601c","07994e875a7f44dc9af7f9bf3f6989e5","fe2cabaf9f024e9399d52e83d07f5883","436a0911d9e64afb97a74ef212e9fae5","6b397adaec4b4b73b4b9fccb1480ac7b"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1774224000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771977600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724630400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686009600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686009600000}}],"disease_phase":[{"disease_id":"b186eb772eec487d8f3914b24c946af6","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"11c9483b13174c4686fd04f48dc66b92","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"436a0911d9e64afb97a74ef212e9fae5","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"47e03afcbd9b49e1a5d0407506e176c3","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"74ba301586ab419b9c9accd39cd20782","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"fe2cabaf9f024e9399d52e83d07f5883","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"4d4cee82fa5c46f19de528f4a8423f62","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"b0f27ade93a54b5ab2a29a6a67bef00f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1954d1a9e4c04e7fb608cb3b89462ca2","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b98763c97526476fb442d16344cb5e59","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6b397adaec4b4b73b4b9fccb1480ac7b","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"b382bc2a56644776b45dc6084224df3b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7532c5e08c9d481ba9a25f3fbbb912bb","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["5cf5fedddb15b3ca0a531d9b789f0286"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"178be3322a61357f92616114dd812bb2","moiety_mechanism_action_id":["aa4209d45e544876a19ad690d486abc8","cb04012f4d160bc18f7f8337f3cb44ab","522321673e9345e3a6669052526fb06d"],"moiety_target_id":["bb95b2e9047a49f2934f5d0afa43dc28","56ba60c7c35144e8b7b0a6c708c04ab3","acf33065e2f34e3ab4e551ec8416738e"]}
+{"drug_id":"0eb01cdd15c64b6fa7550aa4167e4e83","docid":13211,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:24.000Z","updated_ts":"2024-11-06T13:44:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NTX-354","status":"ACTIVE"}],"dev_code":[{"name":"NTX-354","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["4b9abddefa9b29eabd2a81a36978f048"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["4b9abddefa9b29eabd2a81a36978f048"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1646092800000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"30a53995cc00411483859c15597e018a","docid":61864,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:46.000Z","updated_ts":"2024-10-30T10:25:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CAR adjuvant","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["3fc7613b512a531f6281d2fc4a9a54a2"],"disease_id":["717a9bf79e584830859595b8dbe9d433","1623a269e26647fda7ecbee5c6923076","7cf66a4af7ac4b51b888c59d7e30a2c4"],"active_org_master_entity_id":["3fc7613b512a531f6281d2fc4a9a54a2"],"research_disease":["717a9bf79e584830859595b8dbe9d433","1623a269e26647fda7ecbee5c6923076","7cf66a4af7ac4b51b888c59d7e30a2c4"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641945600000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1623a269e26647fda7ecbee5c6923076","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cf66a4af7ac4b51b888c59d7e30a2c4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"48751124cf194c95b743328892da403e","docid":530394,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-11-08T02:40:12.000Z","updated_ts":"2024-12-26T00:21:29.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"iNK cells(Shanghai Sixth People's Hospital)","source_info":[{"code":"ChiCTR2400086069","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://www.chictr.org.cn/showproj.html?proj=230842"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["38c794d8a9a4602fb67dd99e2ddf61be"],"mechanism_action_id":["a3426fcb9c77fd99d0461848fe75fb8f"],"disease_id":["9ef06130652e43d6867bbff12fe14493"],"active_org_master_entity_id":["38c794d8a9a4602fb67dd99e2ddf61be"],"research_disease":["9ef06130652e43d6867bbff12fe14493"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}}],"disease_phase":[{"disease_id":"9ef06130652e43d6867bbff12fe14493","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"037c24867f2446dc8e8764d3245b92ec","docid":77980,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Acetyldihydrocodeine","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","rnk":53,"target_extend_id":"8f132192766d35139935e71d3d728565","created_ts":"2021-10-08T14:46:25.000Z","updated_ts":"2026-02-28T21:13:52.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"盐酸醋氢可待因","status":"ACTIVE"},{"lang":"EN","name":"Acetyldihydrocodeine Hydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"O-Acetyldihydrocodeine hydrochloride","source_info":[{"code":"D07557","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"trade_name":[{"name":"Acetylcodone","source_info":[{"code":"D07557","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB01538"],"kegg_id":["D07557"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["9c181c06c7580eb6a2bc3a0b567cd6f3"],"target_id":["fca6387ae1b643c9a38a449652865f77"],"atc_code":["a4045cf7299b4482a3d32fca1ceb32bc"],"disease_id":["564a2451296345689d8f778eb1beea86"],"research_disease":["564a2451296345689d8f778eb1beea86"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"564a2451296345689d8f778eb1beea86","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"01d7696e1b20449f86f0d11b042af856","docid":27695,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2022-08-03T08:55:36.000Z","updated_ts":"2026-02-24T07:32:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"普通小麦提取物","status":"ACTIVE"},{"lang":"EN","name":"Common wheat Extract","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Triticum vulgare Extract","status":"ACTIVE"}],"trade_name":[{"name":"Fitostimoline","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["e5a7925d6af9d746f2b19be5be26d43a"],"disease_id":["7925449988aa4724bf9f75280531860f","6904072bd4ab4c67b4d0ca8d4728f5be","1b6b7c00e94848078344426facf6fd94"],"active_org_master_entity_id":["e5a7925d6af9d746f2b19be5be26d43a"],"research_disease":["7925449988aa4724bf9f75280531860f","6904072bd4ab4c67b4d0ca8d4728f5be"],"non_research_disease":["1b6b7c00e94848078344426facf6fd94"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"approval_country":["1b05c4d2-8156-3854-9898-c71e0077e3c6"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"7925449988aa4724bf9f75280531860f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6904072bd4ab4c67b4d0ca8d4728f5be","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1b6b7c00e94848078344426facf6fd94","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"02ade8eff948416382266857585fb7cb","docid":10304,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"16d0812df59f3ad5822f70795a20c786","created_ts":"2022-09-14T13:21:31.000Z","updated_ts":"2025-07-24T00:44:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MV-s-NAP","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"MV-S-NAP","status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["ce1783471a7add837e1062d85249c974"],"mechanism_action_id":["14a94a9bebc64c59994f6cc0bc4e5808"],"target_id":["0949c7ded5c547cfa5aaec93d7f4daeb"],"disease_id":["50c397f334694253be0d0ef704e23dc0","ff9aa0c7e2c947afb9749d2ce115c0da","f98fd32baa8447119bb87f84093b925c"],"active_org_master_entity_id":["ce1783471a7add837e1062d85249c974"],"research_disease":["50c397f334694253be0d0ef704e23dc0","ff9aa0c7e2c947afb9749d2ce115c0da","f98fd32baa8447119bb87f84093b925c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1600819200000}}],"disease_phase":[{"disease_id":"50c397f334694253be0d0ef704e23dc0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ff9aa0c7e2c947afb9749d2ce115c0da","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"05a9489c51396a0955b7cd15959227b3","docid":261953,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":20,"target_extend_id":"82093e9d24c0302396e62f8107daaec9","created_ts":"2024-06-04T07:49:20.000Z","updated_ts":"2026-04-04T21:04:49.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Anti-CD33 CAR-T (Beijing Gaobo Boren Hospital )","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"FL-33 CAR T","source_info":[{"code":"NCT06326021","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06326021"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["0aac761ab40417eecdbbc3df8d8594dc"],"mechanism_action_id":["fbb123f802658857ea6a4eeed3ec73b2"],"target_id":["1240ab5a0e694537a813d074fab12cc0"],"disease_id":["a4afc28011454f2ca2f48f95f242a04f"],"active_org_master_entity_id":["0aac761ab40417eecdbbc3df8d8594dc"],"research_disease":["a4afc28011454f2ca2f48f95f242a04f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1712016000000}}],"disease_phase":[{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"065523c06fd444d08260e91a12faca40","docid":1702791,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":7,"target_extend_id":"e8b9e811f6ca305a9f47b5233888ed2e","created_ts":"2026-02-28T07:43:46.000Z","updated_ts":"2026-03-21T21:09:10.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Lm-GUCY2C Vaccines(Thomas Jefferson University)","source_info":[{"code":"NCT07417488","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07417488"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["474b067a74ff8ab6aa3ff391a561d8ac"],"mechanism_action_id":["60e5eefa47f54d898329b1e847ecb0d9"],"target_id":["87503cf8232749b1a054d4acf4bb908b"],"disease_id":["a13397e0956848ae9ff5e5e5a4f5eebf","b902fe3512424802ac7659fc83b38222"],"active_org_master_entity_id":["474b067a74ff8ab6aa3ff391a561d8ac"],"research_disease":["a13397e0956848ae9ff5e5e5a4f5eebf","b902fe3512424802ac7659fc83b38222"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a13397e0956848ae9ff5e5e5a4f5eebf","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"083e7e2655b44949a4f73b3311bb1716","docid":1731761,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-10-09T10:11:28.000Z","updated_ts":"2026-02-11T22:06:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Allogenic Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells(iCamuno Biotherapeutics)","source_info":[{"code":"NCT07212088","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07212088"}],"status":"ACTIVE"}],"dev_code":[{"name":"ALC-01","source_info":[{"code":"NCT07212088","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07212088"}],"status":"ACTIVE"}],"drug_type":["b6c764e33db1468bb5c605488cfe00ca"],"originator_org_master_entity_id":["7ade18d1a557a9e8eada0c8cfeefdbfd"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["7ade18d1a557a9e8eada0c8cfeefdbfd"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1772236800000}}],"disease_phase":[{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0138189bcc1e4330a5be4cad33b34053","docid":113760,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"3faad3a9685140259a3b782e9ca1f3a3","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":55,"target_extend_id":"c3564a2e384d34ef94516d844f563ba3","created_ts":"2024-06-13T09:30:32.000Z","updated_ts":"2026-04-18T21:06:56.000Z","data_status":"ACTIVE","created_by":"wangshuqing@pstsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"99mTc-PSMA-GCK01","source_info":[{"code":"36759199","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/36759199"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"RHN001-Dx","source_info":[{"attachment_path":"data/phs_source_info/b29f/692c/a46d/d4ba/e3243f40-1e9f-3c81-9008-e14bf2fd001a.jpg","attachment_type":"image/jpeg","code":"Rhine-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/33dd/01dd/3109/8235/209cfedb-fe69-3087-9e3e-85db79351fbb.jpg","source":"Company pipeline","source_url":"https://rhine-pharma.com/#pipeline"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","f14cfb7f58c94058be35780bf372123f"],"originator_org_master_entity_id":["e81ed89f148782a69cd932700f4253db"],"mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"target_id":["1764007a7c384a4ab49bb3710bab5052"],"disease_id":["e50aad3dea474cf487e53bd91d5d7c45"],"active_org_master_entity_id":["f12bc1f871fac4e49081ce672d4b56bc"],"research_disease":["e50aad3dea474cf487e53bd91d5d7c45"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"192e487c57e24234b7562b7eafaeb8b7"},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1706745600000}}],"disease_phase":[{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10,"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","moiety_mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"]}
+{"drug_id":"0b66d11686dd4056b8d4dc7b297aa7dc","docid":3716,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"92025455667d3241acd967db0537858d","created_ts":"2021-10-08T14:45:59.000Z","updated_ts":"2024-12-26T00:21:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"孟鲁司特/苯磺贝他斯汀","status":"ACTIVE"},{"lang":"EN","name":"Montelukast/Bepotastine besilate","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bepotastine besilate/montelukast","status":"ACTIVE"},{"lang":"EN","name":"Bepotastine besilate/montelukast sodium","status":"ACTIVE"},{"lang":"EN","name":"Montelukast sodium/Bepotastine besilate","status":"ACTIVE"}],"related_component":["0d41e74aaaeb4e89810c429e6e73ce04","4c3d66b34eb842789a720aa9c198e438"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3f9b0c35fdaa8b0ecdbbdf657595b9e5"],"mechanism_action_id":["0c6a2321a314a817d6afda7d4da2aebf","d0c8106bb4622df47351b10c7473b784"],"target_id":["e02a61929c144189b60bfa1735e6e6c5","638ee1b240b74160b4456cc7857d6fa1"],"disease_id":["00894c5beba2467fa4489e0fa39ddffa"],"active_org_master_entity_id":["3f9b0c35fdaa8b0ecdbbdf657595b9e5"],"research_disease":["00894c5beba2467fa4489e0fa39ddffa"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0058ba0be36b4b3586f8ca82512b79f4","docid":38994,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Nedaplatin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":804470400000,"rnk":13,"target_extend_id":"f90bc6d4a6e23af09db788a5c7fe351a","created_ts":"2021-10-08T14:47:30.000Z","updated_ts":"2026-02-24T21:41:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1062547200000,"drug_name":[{"lang":"CN","name":"奈达铂","status":"ACTIVE"},{"lang":"EN","name":"Nedaplatin","source_info":[{"code":"20700AMZ00529000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ネダプラチン","source_info":[{"code":"20700AMZ00529000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(glycolato-O,O')diammineplatinum(II)","source_info":[{"code":"DB13145","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"CDGP","source_info":[{"code":"DB13145","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Nedaplatin (JAN/INN)","source_info":[{"code":"D01416","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"cis-Diammine (glycolato)platinum","source_info":[{"code":"DB13145","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"cis-Diammine(glycolato)platinum(II)","source_info":[{"code":"DB13145","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"cis-diammine(glycolato)platinum","source_info":[{"code":"DB13145","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"CN","name":"尼达铂","status":"ACTIVE"},{"lang":"CN","name":"捷佰舒","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NzQ4MTg2MQ==&mid=2650420903&idx=2&sn=965aff97964dc4064877dda395a69831"}],"status":"ACTIVE"}],"dev_code":[{"name":"254 S","status":"ACTIVE"},{"name":"254-S","source_info":[{"code":"20700AMZ00529000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4291405F1025_2_03"}],"status":"ACTIVE"},{"name":"NSC 375101D","status":"ACTIVE"},{"name":"NSC-375101D","source_info":[{"code":"20700AMZ00529000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4291405F1025_2_03"}],"status":"ACTIVE"}],"trade_name":[{"name":"Aqupla","source_info":[{"code":"D01416","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"20700AMZ00529000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4291405F1025_2_03"}],"status":"ACTIVE"},{"name":"アクプラ","source_info":[{"code":"20700AMZ00529000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4291405F1025_2_03"}],"status":"ACTIVE"}],"generic_name":[{"name":"Nedaplatin","source_info":[{"code":"D01416","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB13145"],"kegg_id":["D01416"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["28302ed119579570781ac5944dcb2b14"],"mechanism_action_id":["2ad7fc3f29a427c2cc290ea260e25186"],"target_id":["427d26c780ff4fe6afab11ca1c9fb297"],"atc_code":["a8d820bc4b9843bb9901e101c74cd532"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","d9c985ab1f04428493c029df6dca650d","f7ea24f0370d421480503e720310bf86","11cacc262bfc41adbd6259325efbcfec","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","8d29f554f371431c9b5b80f5befdf965","f3a2f9a205c642509ad4ae370c6e6085","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["c9e550e276ad57203c92e8f3147900da","28302ed119579570781ac5944dcb2b14","b588626ee937c8f2cd4408a977e9fc26"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["d9c985ab1f04428493c029df6dca650d","f7ea24f0370d421480503e720310bf86","11cacc262bfc41adbd6259325efbcfec","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","8d29f554f371431c9b5b80f5befdf965","f3a2f9a205c642509ad4ae370c6e6085","b42488c9ce3245988e4e93caf2b95590"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9","d9c985ab1f04428493c029df6dca650d","f7ea24f0370d421480503e720310bf86","11cacc262bfc41adbd6259325efbcfec","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","8d29f554f371431c9b5b80f5befdf965","f3a2f9a205c642509ad4ae370c6e6085","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1062547200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":810259200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":804470400000}}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f3a2f9a205c642509ad4ae370c6e6085","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"11cacc262bfc41adbd6259325efbcfec","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"086e40d4d94647cc8e982e8841d37aad","docid":14527,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-12-10T12:54:38.000Z","updated_ts":"2026-03-19T22:02:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Mesenchymal stem cells (Therapeutic Solutions International)","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/therapeutic-solutions-international-spin-off-campbell-neurosciences-announces-novel-mechanistic-data-on-campbellcell-stem-cell-therapy-for-schizophrenia"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"JadiCells","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.businesswire.com/news/home/20220419005646/en/Therapeutic-Solutions-International-Identifies-Novel-Biological-Pathway-Utilized-by-its-Phase-III-Adult-Stem-Cell-Product-JadiCell-to-Stimulate-Healing-of-Injured-Lung-Tissue"}],"status":"ACTIVE"}],"trade_name":[{"name":"JadiCell","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.businesswire.com/news/home/20220419005646/en/Therapeutic-Solutions-International-Identifies-Novel-Biological-Pathway-Utilized-by-its-Phase-III-Adult-Stem-Cell-Product-JadiCell-to-Stimulate-Healing-of-Injured-Lung-Tissue"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["ecdbe9a620bd9bc4c99271bac045f2d5"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["88cfc77d4a4d4c6b9bce6542b20f75ca","717a9bf79e584830859595b8dbe9d433","cf9a6321e8854968b3305a3e11ddadec","486c4f5995ae4425a9c98a48d22c84c8","ec4d59ce792b465d8e55e7e52840c626","5a66b9249fae4d97afa13193f05749b9","e9b27c71d3024fd6ab7dc1dfc304f54d"],"active_org_master_entity_id":["ecdbe9a620bd9bc4c99271bac045f2d5","6f2b1fcabc0b839d3018cd9a1832d1b2"],"research_disease":["88cfc77d4a4d4c6b9bce6542b20f75ca","717a9bf79e584830859595b8dbe9d433","cf9a6321e8854968b3305a3e11ddadec","486c4f5995ae4425a9c98a48d22c84c8","ec4d59ce792b465d8e55e7e52840c626","5a66b9249fae4d97afa13193f05749b9","e9b27c71d3024fd6ab7dc1dfc304f54d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"cf9a6321e8854968b3305a3e11ddadec","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e9b27c71d3024fd6ab7dc1dfc304f54d","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"5a66b9249fae4d97afa13193f05749b9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"88cfc77d4a4d4c6b9bce6542b20f75ca","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["ecdbe9a620bd9bc4c99271bac045f2d5","ac2de083e555b239c6419eb307f3c64f"],"if_speculate":0,"data_source":10}
+{"drug_id":"03dd8dc37b814a408f658f5374c4e632","docid":75161,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-01-14T12:43:46.000Z","updated_ts":"2024-11-01T05:46:42.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"痢疾杆菌结合疫苗（重庆智飞）","status":"ACTIVE"},{"lang":"EN","name":"Dysentery conjugate vaccine(Chongqing Zhifei Biological Products)","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","eb728b38dfb842778019260a7dd09801"],"originator_org_master_entity_id":["2d5cac8af9a8ac221e5ea9fa3ed85902"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["aa274a7144984376a7e57b5889e8a980"],"active_org_master_entity_id":["2d5cac8af9a8ac221e5ea9fa3ed85902"],"research_disease":["aa274a7144984376a7e57b5889e8a980"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"aa274a7144984376a7e57b5889e8a980","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0b8915f621a34be1849b3e642f71a8ab","docid":17395,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"fe483964866a3df288f893409b6f2aba","created_ts":"2021-10-08T14:44:21.000Z","updated_ts":"2024-11-06T13:21:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene(The University of Manchester)","status":"ACTIVE"}],"dev_code":[{"name":"OTL 201","status":"ACTIVE"},{"name":"OTL-201","status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72","cceb301a25ec4f3cbc1aff3ae1169416"],"originator_org_master_entity_id":["d2a3b2e84a10db068a32fd3815048893"],"mechanism_action_id":["4524e6075c5d9aca84063d339e6cb2b0"],"target_id":["cc253fd3c47947349233694aac235f76"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["8e2dcf0de37a4562ba3858e6767d2f7a"],"active_org_master_entity_id":["034b1882d36a16a425d68856a8db170c"],"research_disease":["8e2dcf0de37a4562ba3858e6767d2f7a"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1578355200000}}],"disease_phase":[{"disease_id":"8e2dcf0de37a4562ba3858e6767d2f7a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"3c8f5271c19949cbb3a46546b425ef57","docid":56932,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":39,"target_extend_id":"2f6a948bbd6933739725f14f91ec7042","created_ts":"2021-12-10T12:55:15.000Z","updated_ts":"2026-04-04T21:10:19.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-CD38 CAR-T cell therapy  (Yake Biotechnology)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD38 CART cell therapy Yake Biotechnology","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["5612c49c18a73767bc698ad1115e8315","d9627d77b8d00d879e22e88877e54736","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["db5b79c0f23347d087abd649364d7329"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","3badf78c2208463e96d2f1aa57f4813f","7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d","90163e2d1d85519e993176af80281cd8"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","3badf78c2208463e96d2f1aa57f4813f","7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1646006400000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"3badf78c2208463e96d2f1aa57f4813f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"03f480aa907e40468ee9d524e704e642","docid":52426,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Norelgestromin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","rnk":33,"target_extend_id":"e34419db37703998b0f9dd33fcf89c13","created_ts":"2021-10-08T14:43:41.000Z","updated_ts":"2026-01-17T21:22:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"CN","name":"去甲艾孕明","status":"ACTIVE"},{"lang":"EN","name":"Norelgestromin","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"17-Deacetylnorgestimate","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"17-Deacylnorgestimate","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"18-Methylnorethindrone oxime","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"D-Norgestrel 3-oxime","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Deacetylnorgestimate","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Levonorgestrel 3-oxime","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Levonorgestrel oxime","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Norelgestromin (USP/INN)","source_info":[{"code":"D05205","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Norplant 3-oxime","source_info":[{"code":"DB06713","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Transdermal system containing progestin","source_info":[{"code":"NCT06672016","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06672016"}],"status":"ACTIVE"}],"dev_code":[{"name":"MR-130A-01","source_info":[{"code":"NCT06048536","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06048536"}],"status":"ACTIVE"},{"name":"RWJ-10553","status":"ACTIVE"}],"generic_name":[{"name":"Norelgestromin","source_info":[{"code":"D05205","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB06713"],"kegg_id":["D05205"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["21c7ce2893fe266ba7af8c431ae820c2"],"target_id":["e020f841764d47a4a0b95803dc8a3652"],"atc_code":["dd362891c03e4899a569d3472c4e8d32"],"disease_id":["19f6ec868260488bb687479965ec73fb"],"active_org_master_entity_id":["072effd78fbddbc4991130a13be0da1a"],"research_disease":["19f6ec868260488bb687479965ec73fb"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1736726400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1768608000000}}],"disease_phase":[{"disease_id":"19f6ec868260488bb687479965ec73fb","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"05961bc4b6644eac8cd096fe03d36390","docid":74217,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-04-26T06:02:08.000Z","updated_ts":"2024-10-30T10:20:50.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"NovRF","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.novmeta.com/pipeline_NovDB2.php"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["021f81d2382519d9e6946ae7025c4e65"],"disease_id":["0b9c64bc6e66458dbe48748934f10467"],"active_org_master_entity_id":["021f81d2382519d9e6946ae7025c4e65"],"research_disease":["0b9c64bc6e66458dbe48748934f10467"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1682467200000}}],"disease_phase":[{"disease_id":"0b9c64bc6e66458dbe48748934f10467","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"0c26a483d2594ef4841ace215c58e404","docid":57849,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-11-30T08:58:05.000Z","updated_ts":"2024-11-06T13:25:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ZKGZ-001","status":"ACTIVE"}],"dev_code":[{"name":"ZKGZ 001","status":"ACTIVE"},{"name":"ZKGZ-001","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["5806922764071ed82a9c6e6283111271"],"disease_id":["54e2cf3dc3294445b4a27b990b0ba274"],"active_org_master_entity_id":["9a998e8040d286c07ca6bec440f12fc8"],"research_disease":["54e2cf3dc3294445b4a27b990b0ba274"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"disease_phase":[{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"50f64382a9f0436a9acb12acee78ace8","docid":1250126,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-04-01T03:26:58.000Z","updated_ts":"2025-04-01T05:24:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"LE-051","source_info":[{"code":"NCT06900049","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06900049"}],"status":"ACTIVE"}],"dev_code":[{"name":"LE-051","source_info":[{"code":"NCT06900049","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06900049"}],"status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["6e9a74ed63b386f51d6061d7b27d27c2"],"disease_id":["3edeea348eb24d8d8fbf0cccd058f464"],"active_org_master_entity_id":["6e9a74ed63b386f51d6061d7b27d27c2"],"research_disease":["3edeea348eb24d8d8fbf0cccd058f464"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1729728000000}}],"disease_phase":[{"disease_id":"3edeea348eb24d8d8fbf0cccd058f464","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00f149e3c1d944a998e0175305030bfe","docid":54995,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Dimenhydrinate","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":-577756800000,"rnk":14,"target_extend_id":"792c5cdcd4f13e459b9efe25bf4f4791","created_ts":"2021-10-08T14:46:08.000Z","updated_ts":"2026-02-24T22:51:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","drug_name":[{"lang":"CN","name":"茶苯海明","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Dimenhydrinate","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"ジメンヒドリナート","source_info":[{"code":"22100AMX01260","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/830001_1331001F1044_1_03"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Dimenhydrinate (JP17/USP/INN)","source_info":[{"code":"D00520","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Dimenhydrinate Buccal","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Diphenhydramine theoclate","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"diphenhydramine 8-chlorotheophyllinate","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"diphenhydramine 8-chlorotheophylline","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine","source_info":[{"code":"DB00985","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"trade_name":[{"name":"Dramamine","source_info":[{"code":"D00520","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"22100AMX01260","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/830001_1331001F1044_1_04"}],"status":"ACTIVE"},{"name":"Gravol","status":"ACTIVE"},{"name":"ドラマミン","source_info":[{"code":"22100AMX01260","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/830001_1331001F1044_1_04"}],"status":"ACTIVE"},{"name":"贻晗柠","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Dimenhydrinate","source_info":[{"code":"D00520","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00985"],"kegg_id":["D00520"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a51d08dbdd73878a9bdf9db618735f62"],"mechanism_action_id":["d0c8106bb4622df47351b10c7473b784"],"target_id":["638ee1b240b74160b4456cc7857d6fa1"],"atc_code":["81c1fd7991764326bf340fb6d7a8fc63"],"disease_id":["3d7125e980214ce9a9f40a9a736023c3","cb9d0a6f564f4263a05443ec6c6dba8e","97ba1612b7ed40fead843ac6e6e8b1e7","02b9f9b0f3464ccbb37429d10f9aea36","0dd2aae866da4aa8815bd690fe502724","e10e6a48f3ea4ee2b2eee51942ed4ef0","d613cc8191104d3190a445b327b9b950","3d8f88d61ed04c6193ddccaeda079237"],"active_org_master_entity_id":["a5915fe82211dbb5f237e7de25e02890","b1e36fddb78b46df74fc66398cedec63","3638989e51db382655e0f4762e275e8a"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["02b9f9b0f3464ccbb37429d10f9aea36","0dd2aae866da4aa8815bd690fe502724","e10e6a48f3ea4ee2b2eee51942ed4ef0","d613cc8191104d3190a445b327b9b950"],"research_disease":["3d7125e980214ce9a9f40a9a736023c3","cb9d0a6f564f4263a05443ec6c6dba8e","97ba1612b7ed40fead843ac6e6e8b1e7","02b9f9b0f3464ccbb37429d10f9aea36","0dd2aae866da4aa8815bd690fe502724","e10e6a48f3ea4ee2b2eee51942ed4ef0","d613cc8191104d3190a445b327b9b950","3d8f88d61ed04c6193ddccaeda079237"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-568080000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-577756800000}}],"disease_phase":[{"disease_id":"02b9f9b0f3464ccbb37429d10f9aea36","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3d8f88d61ed04c6193ddccaeda079237","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e10e6a48f3ea4ee2b2eee51942ed4ef0","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3d7125e980214ce9a9f40a9a736023c3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"cb9d0a6f564f4263a05443ec6c6dba8e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"0dd2aae866da4aa8815bd690fe502724","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"97ba1612b7ed40fead843ac6e6e8b1e7","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d613cc8191104d3190a445b327b9b950","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"067a8e93b55343ad8b3df79ec69dae0c","docid":15022,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"38dece364cd836fb9b1d20173578604b","created_ts":"2023-06-26T08:08:01.000Z","updated_ts":"2026-01-24T21:10:59.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"MG-D-1609","source_info":[{"attachment_path":"data/phs_source_info/d121/5386/20ba/b0bd/3c85334d-7b32-3124-b67e-6e6e79579205.jpg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/9e46/b065/1950/cec5/45248844-c838-3621-adef-8512709c9ad2.jpg","source":"Company pipeline","source_url":"https://www.metagone.com.tw/eng/p2_product.php"},{"attachment_path":"/data/DRUG_PIPELINE/screen_shot/20251223/513c54aecc0d9f346630ffd09c9fbac1_screen_shot.png","attachment_type":"image/png","code":"Metagone-202512","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"/data/DRUG_PIPELINE/screen_shot/20251223/513c54aecc0d9f346630ffd09c9fbac1_screen_shot.png","source":"Company pipeline","source_url":"https://www.metagone.com.tw/eng/p2_product.php"}],"status":"ACTIVE"}],"dev_code":[{"name":"MG-D-1609","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.metagone.com.tw/eng/p2_product.php"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["362322bdc991f7e4b4b48facf92e7328"],"mechanism_action_id":["2b8be7ad52664977ac1336c97af8be72"],"target_id":["679ccf1337704fb3ab245b7627b77232"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["362322bdc991f7e4b4b48facf92e7328"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0060cd2c493b4767bf2793a57868c278","docid":18745,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"78b9fc3eea443a10a7e0a52191b5e9d2","created_ts":"2022-09-21T01:47:57.000Z","updated_ts":"2025-11-28T00:28:08.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"JYB-1907","status":"ACTIVE"}],"dev_code":[{"name":"JYB 1907","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-garp-monoclonal-antibody-jyb1907"}],"status":"ACTIVE"},{"name":"JYB-1907","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-garp-monoclonal-antibody-jyb1907"}],"status":"ACTIVE"},{"name":"JYB1907","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-garp-monoclonal-antibody-jyb1907"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["da38a0196b9c470b09ba68c74f0e6d64"],"mechanism_action_id":["4cba4319b53a4efb8b4868584a82d7d2"],"target_id":["531d10c27e7f4b6c9f9322e72096e15c"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["489012493c55a1987b38ac8b9a9cc0ec"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","07994e875a7f44dc9af7f9bf3f6989e5"],"inactive_org_master_entity_id":["34c9fef683bda30d5f4ebc0be5973f67"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1672790400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01e11b5f37174b0e80633d6955fa2e98","docid":1109,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":4,"target_extend_id":"170f41778bc83673bd84d16589d29d9a","created_ts":"2022-02-28T05:05:55.000Z","updated_ts":"2026-02-07T21:10:14.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"柠檬苦素","status":"ACTIVE"},{"lang":"EN","name":"Limonin","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"limonin","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["f1cbb44702317424ceba133a0ab69d37"],"mechanism_action_id":["8d70b5e8da7c4004aad3095abf64b958"],"target_id":["9e207dc5d3824a6abcdff4037c96f183"],"disease_id":["d3db209bbef140c6be60ed9730fbec5b","df58db15a9224417aa10cc9e38ad6938"],"active_org_master_entity_id":["f1cbb44702317424ceba133a0ab69d37","f08d928093509788b5ebc9499ae9f2eb"],"research_disease":["d3db209bbef140c6be60ed9730fbec5b","df58db15a9224417aa10cc9e38ad6938"],"inactive_org_master_entity_id":["f51fd591b2d473e1815794ecdcf96127"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"d3db209bbef140c6be60ed9730fbec5b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"df58db15a9224417aa10cc9e38ad6938","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1b1494446f094300961d724dd1aae8ec","docid":33406,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":92,"target_extend_id":"23e78dc5bc9e3c569f29398d0a761044","created_ts":"2021-12-10T12:54:52.000Z","updated_ts":"2026-04-11T21:06:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Covigenix VAX 002","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Covigenix VAX002","status":"ACTIVE"},{"lang":"EN","name":"DNA SARSCoV2 vaccine Entos Pharmaceuticals/Epivax","status":"ACTIVE"},{"lang":"EN","name":"SARSCoV2 DNA Vaccine Entos Pharmaceuticals/Epivax","status":"ACTIVE"}],"dev_code":[{"name":"ENTVAX 002","source_info":[{"attachment_path":"data/phs_source_info/b910/c4cd/a726/6165/b910c4cda7266165.jpg","attachment_type":"image/jpeg","code":"Entos-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/789f/169b/fa32/02f3/789f169bfa3202f3.jpg","source":"Company pipeline","source_url":"https://entospharma.com/pipeline-%26-partners"}],"status":"ACTIVE"},{"name":"ENTVAX-002","source_info":[{"attachment_path":"data/phs_source_info/b910/c4cd/a726/6165/b910c4cda7266165.jpg","attachment_type":"image/jpeg","code":"Entos-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/789f/169b/fa32/02f3/789f169bfa3202f3.jpg","source":"Company pipeline","source_url":"https://entospharma.com/pipeline-%26-partners"}],"status":"ACTIVE"},{"name":"VAX-002","source_info":[{"attachment_path":"data/phs_source_info/b910/c4cd/a726/6165/b910c4cda7266165.jpg","attachment_type":"image/jpeg","code":"Entos-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/789f/169b/fa32/02f3/789f169bfa3202f3.jpg","source":"Company pipeline","source_url":"https://entospharma.com/pipeline-%26-partners"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["24a77eafd5af1c80eae59974ed0f6c08","85d311df0be669d4414d5e5398c89274"],"mechanism_action_id":["80f3a83094c71a87cd8768d22cd277fd"],"target_id":["f2c8821a6e5845f1b698c8a5a00029e5"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["24a77eafd5af1c80eae59974ed0f6c08","85d311df0be669d4414d5e5398c89274"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1721606400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0aaeb39e930740fcbc00f19e41c7786d","docid":170317,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"802e33eb91ff43d288423199c93c19fe","global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2024-04-12T09:08:00.000Z","updated_ts":"2026-03-26T06:44:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"CN","name":"重组呼吸道合胞病毒疫苗（CHO细胞）(迈科康生物)","source_info":[{"code":"CTR20243803","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=8ad9459dfc9c4b18bd46e671b87c88c1"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Maxvax Biotechnology)","source_info":[{"code":"NCT06642558","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06642558"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e1aca0be003744f0afbfb1a90c7bc8ac"],"originator_org_master_entity_id":["538913bc1025473dad1b499df932bae9"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["538913bc1025473dad1b499df932bae9"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761091200000}}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"067bfa412ade4a1fbc5702612f1d0bdd","docid":58006,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-11-30T08:58:05.000Z","updated_ts":"2024-11-06T12:49:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"ZKHF-002","status":"ACTIVE"}],"dev_code":[{"name":"ZKHF 002","status":"ACTIVE"},{"name":"ZKHF-002","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["54c300302ef99930090ae6cd2ea35cec"],"disease_id":["54e2cf3dc3294445b4a27b990b0ba274"],"active_org_master_entity_id":["54c300302ef99930090ae6cd2ea35cec"],"research_disease":["54e2cf3dc3294445b4a27b990b0ba274"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"disease_phase":[{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0665d5a306414b0a8a0c928142352592","docid":2000183,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2026-04-02T06:20:34.000Z","updated_ts":"2026-04-02T07:04:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"MOTS-c(Hudson Biotech)","source_info":[{"code":"NCT07505745","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07505745"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Mitochondrial-derived peptides(Hudson Biotech)","source_info":[{"code":"NCT07505745","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07505745"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["62e5ad9fa2e11e4e899ba11cf1d5ef44"],"disease_id":["68d3a2c921624debbeaa7898174cd2bf","05ee0bc5347a4677a95179fcdcc2b814","54ac9c3be9cb418d90b94dc50fadf38e"],"active_org_master_entity_id":["62e5ad9fa2e11e4e899ba11cf1d5ef44"],"research_disease":["68d3a2c921624debbeaa7898174cd2bf","05ee0bc5347a4677a95179fcdcc2b814","54ac9c3be9cb418d90b94dc50fadf38e"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1769990400000}}],"disease_phase":[{"disease_id":"68d3a2c921624debbeaa7898174cd2bf","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"54ac9c3be9cb418d90b94dc50fadf38e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"022c71d357394a6a8609aaac6546c895","docid":5933,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":119,"target_extend_id":"18b251c0f2f43800b245c1561bb9880f","created_ts":"2022-11-07T06:23:33.000Z","updated_ts":"2026-04-04T21:11:53.000Z","data_status":"ACTIVE","created_by":"sunying","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"BD311","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://bdgenetherapeutics.com/project.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"BD311","status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72","8f6519eee8d84b398bd3199efae8aa49"],"originator_org_master_entity_id":["01169e39f51162a6dd629072f19ada7b"],"mechanism_action_id":["e52fc84e22d5339919dc3242e3bba5ef"],"target_id":["1c2067e5ab054a8995f73efcfcf56207"],"disease_id":["b3613eb77a5d4795ac1a12db34d284ba","7bb5556c886343f4a9ec230aacf8706e","08ceae895e4c4d929d71bb1f60574f29"],"active_org_master_entity_id":["01169e39f51162a6dd629072f19ada7b"],"research_disease":["b3613eb77a5d4795ac1a12db34d284ba","7bb5556c886343f4a9ec230aacf8706e","08ceae895e4c4d929d71bb1f60574f29"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1660176000000}}],"disease_phase":[{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"08ceae895e4c4d929d71bb1f60574f29","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0b4892cb48be4ce89f808f5116a86da8","docid":1610236,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"774cc1c284f431f5afff153de27852f9","created_ts":"2025-07-16T06:29:40.000Z","updated_ts":"2025-07-31T00:31:11.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CD146-Targeted and HER2-Targeted CAR T Cells(Essen Biotech)","source_info":[{"code":"NCT07066982","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07066982"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD146/HER2 CAR-T cells(Essen Biotech)","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["0f6e40ce6852d07c2000c657cc03ef4f"],"mechanism_action_id":["e271a383eb7ff34bab00e3a8c174fe3c","687f7f9487fb4f32812fb85ceb4c5d70"],"target_id":["6b3b1160a6f448ba9133e5b4325946f9","a3c3158483984ff9922b1b0ba939a068"],"disease_id":["a4f7254e36da425087293790eb964551","db53733df6b441fe9ed25041a14839c8","26535c6f16de4adfb19f0154be738535","73fd82d969b1457a85183ca272200cb7","1d6d6b0086ff422ca00418c0e8b0e940","7032985f6c0b414f9993b7072c105fb4"],"active_org_master_entity_id":["0f6e40ce6852d07c2000c657cc03ef4f"],"research_disease":["a4f7254e36da425087293790eb964551","db53733df6b441fe9ed25041a14839c8","26535c6f16de4adfb19f0154be738535","73fd82d969b1457a85183ca272200cb7","1d6d6b0086ff422ca00418c0e8b0e940","7032985f6c0b414f9993b7072c105fb4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1748476800000}}],"disease_phase":[{"disease_id":"db53733df6b441fe9ed25041a14839c8","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"73fd82d969b1457a85183ca272200cb7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7032985f6c0b414f9993b7072c105fb4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1a4747c8236e42c0b1c8ce495545e84a","docid":58715,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1560816000000,"rnk":1,"target_extend_id":"9e6f4c2339ba3349aea78459ceadd2ac","created_ts":"2021-10-08T14:46:42.000Z","updated_ts":"2026-04-02T13:55:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1576627200000,"drug_name":[{"lang":"CN","name":"布地格福","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Budesonide/Formoterol fumarate/Glycopyrronium Bromide","source_info":[{"code":"30100AMX00002","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ブデソニド/グリコピロニウム臭化物/ホルモテロールフマル酸塩水和物","source_info":[{"code":"30100AMX00002","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BGF MDI","status":"ACTIVE"},{"lang":"EN","name":"Breztri Aerosphere","status":"ACTIVE"},{"lang":"EN","name":"Budesonide/Glycopyrronium Bromide/Formoterol Fumarate","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Hydrate","source_info":[{"code":"30100AMX00002","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Budesonide/PT 003","status":"ACTIVE"},{"lang":"EN","name":"Budesonide/formoterol fumarate/glycopyrronium","status":"ACTIVE"},{"lang":"EN","name":"Budesonide/formoterol/glycopyrrolate","status":"ACTIVE"},{"lang":"EN","name":"Budesonide/glycopyrrolate/formoterol","status":"ACTIVE"},{"lang":"EN","name":"Budesonide/glycopyrronium/formoterol fumarate","status":"ACTIVE"},{"lang":"EN","name":"Formoterol/budesonide/glycopyrrolate","status":"ACTIVE"},{"lang":"EN","name":"Formoterol/glycopyrrolate/budesonide","status":"ACTIVE"},{"lang":"CN","name":"布地奈德+格隆溴铵+福莫特罗","source_info":[{"normalized_source_id":"4313dbdea4844940816740b801d08999","source":"DBPC"}],"status":"ACTIVE"},{"lang":"CN","name":"布地奈德/富马酸福莫特/格隆溴铵","status":"ACTIVE"}],"dev_code":[{"name":"PT-010","status":"ACTIVE"},{"name":"PT010","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"trade_name":[{"name":"Breztri","source_info":[{"code":"30100AMX00002","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_2290805G1027_1_09"}],"status":"ACTIVE"},{"name":"Riltrava Aerosphere","source_info":[{"code":"EMEA/H/C/005311","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/riltrava-aerosphere"}],"status":"ACTIVE"},{"name":"Trixeo Aerosphere","status":"ACTIVE"},{"name":"ビレーズトリ","source_info":[{"code":"30100AMX00002","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_2290805G1027_1_09"}],"status":"ACTIVE"},{"name":"令畅","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/hOnX0n11o6hMyujQsSxlVg"}],"status":"ACTIVE"},{"name":"倍择瑞","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzk0NzI5MjYwNQ==&mid=2247680703&idx=1&sn=afbb77d0dfaed81f7acda887c86bbf98"}],"status":"ACTIVE"}],"related_component":["501bf017cbf640808020f6570c988ceb","b4360865262a443a8412e7213eee3713","cfa4dda722d049958b1e36006b7e5795"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506"],"mechanism_action_id":["b3b0790f82c48637c8ccae2fb7b59a32","931504f23ea44715a9ea324a47e0238d","d5c558daba719aadf8062b1bdbac2bd8"],"target_id":["6fe53f67a27241fcac53227526791322","449193bba3cd46bcad89d76a54d13d06","32ac24079a8f47b18069eb35a1f9120d"],"atc_code":["04e8554fab7f4334bca303571a8188e5"],"disease_id":["df3f2af04dd146e28a3f1de0556b8a65","486c4f5995ae4425a9c98a48d22c84c8","3f72c66155dd4bc6bb183f7147e9a04f","15fe4881cb88431eb9d44b018619d7b0","4862d0cd1ac7418a85678a36a407b1fb","9e67eb173c8a43cfb134c3c291decec6","040a8a8644d04004a185e801bd4870d1"],"active_org_master_entity_id":["d784b38f8630b0a18bfc94a5c6202d24","8e9b1775c5e4a058382c5c560e2c1fd5","6e7a2de70d46daa0cef8586ca22ae506","1d24fdf146af9f32dab7333bf67fc411","7d68f721fabda3ab647321e4a8668093","8656d37d668a52bf73421c7b34d2e105","445ea4164b30c123f74a0cc39c1a41af"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["df3f2af04dd146e28a3f1de0556b8a65","486c4f5995ae4425a9c98a48d22c84c8","3f72c66155dd4bc6bb183f7147e9a04f"],"research_disease":["df3f2af04dd146e28a3f1de0556b8a65","486c4f5995ae4425a9c98a48d22c84c8","3f72c66155dd4bc6bb183f7147e9a04f","15fe4881cb88431eb9d44b018619d7b0","4862d0cd1ac7418a85678a36a407b1fb","9e67eb173c8a43cfb134c3c291decec6","040a8a8644d04004a185e801bd4870d1"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","76732dd51f2842799e6843eef80820ea"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","672807de-6d33-3706-a350-c97e6ed7735e","cf11da47-6a9f-3948-9d29-8a824f805638","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1595462400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1576627200000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1607472000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1560816000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1747008000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1626307200000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1607472000000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1607472000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1607472000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1479945600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704931200000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1664236800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1479945600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1614556800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1614556800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704931200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1664236800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704931200000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1479945600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704931200000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1614556800000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704931200000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1664236800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1614556800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708473600000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704931200000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1322697600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1695945600000}},{"country":"528590fc-7857-3275-8e6f-09a951a7544b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1522540800000}}],"disease_phase":[{"disease_id":"040a8a8644d04004a185e801bd4870d1","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"4862d0cd1ac7418a85678a36a407b1fb","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9e67eb173c8a43cfb134c3c291decec6","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3f72c66155dd4bc6bb183f7147e9a04f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"df3f2af04dd146e28a3f1de0556b8a65","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04a05ec9f9a04ee1b1691a7dfa76e7aa","docid":41753,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-06-01T02:21:03.000Z","updated_ts":"2026-04-02T14:54:42.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Rabies vaccine(AstriVax)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://astrivax.com/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AVX70481","source_info":[{"normalized_source_id":"42d89394e1d7470596de758366ae816a","source":"PipelineReview","source_url":"https://pipelinereview.com/astrivax-enters-clinical-phase-with-its-novel-vaccine-platform-technology/"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["6314b30cd5970fe49029e12efc4389f8"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["26bdc387cad64dc985f00855d64a3d2d"],"active_org_master_entity_id":["6314b30cd5970fe49029e12efc4389f8"],"research_disease":["26bdc387cad64dc985f00855d64a3d2d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1718496000000}}],"disease_phase":[{"disease_id":"26bdc387cad64dc985f00855d64a3d2d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0751a26a70594b7ebe439011266c205f","docid":41594,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-12-15T05:21:27.000Z","updated_ts":"2026-03-16T07:50:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"JYP-0061","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"JYP 0061","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"JYP-0061","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"JYP0061","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9568a527321e8dab80b9c8b571ecb5f0"],"disease_id":["061a5c6c24164fadb7fa15fc1d303e75","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","60a67018512a44caafa8f5d6dcb5339f","6be96778ed424f8d91de00ab82364114","d40ef3cdfee64183a874ca8cc15bd469","c8d0737fa2ac4421bf1538bc54b22ce1","4712857948a346d3afcae1e72a543e4c"],"active_org_master_entity_id":["9568a527321e8dab80b9c8b571ecb5f0"],"research_disease":["061a5c6c24164fadb7fa15fc1d303e75","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","60a67018512a44caafa8f5d6dcb5339f","6be96778ed424f8d91de00ab82364114","d40ef3cdfee64183a874ca8cc15bd469","c8d0737fa2ac4421bf1538bc54b22ce1","4712857948a346d3afcae1e72a543e4c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1759190400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1703030400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1684281600000}}],"disease_phase":[{"disease_id":"061a5c6c24164fadb7fa15fc1d303e75","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d40ef3cdfee64183a874ca8cc15bd469","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"60a67018512a44caafa8f5d6dcb5339f","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4712857948a346d3afcae1e72a543e4c","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"c8d0737fa2ac4421bf1538bc54b22ce1","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"data_source":10}
+{"drug_id":"00964382857a4d7c8abb77eb8ee2fe13","docid":68820,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-02-03T09:25:53.000Z","updated_ts":"2026-02-02T00:48:24.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"68Ga-NY105","source_info":[{"code":"NCT05691881","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05691881"}],"status":"ACTIVE"}],"dev_code":[{"name":"68Ga NY105","status":"ACTIVE"},{"name":"68Ga-NY-105","status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["5e2938dc85dae2c1cd9d974ea6a6a601"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","0a885de5b4054c2b98d478f91f3e3418"],"active_org_master_entity_id":["faa9ea08d792dc82af6444fa1fd8362a"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"non_research_disease":["0a885de5b4054c2b98d478f91f3e3418"],"inactive_org_master_entity_id":["5e2938dc85dae2c1cd9d974ea6a6a601"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1664323200000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_before_ter_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10,"moiety_mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"]}
+{"drug_id":"01bf44cba8224d8995b2499f79495b81","docid":43150,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Omarigliptin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1443398400000,"rnk":6,"target_extend_id":"57613d84c3543895ba666c5eac08fa52","has_leading_org_involved":1,"created_ts":"2021-10-08T14:50:41.000Z","updated_ts":"2026-04-02T10:59:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"奥玛格列汀","status":"ACTIVE"},{"lang":"EN","name":"Omarigliptin","source_info":[{"code":"22700AMX01014000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/170050_3969025F1022_1_10"}],"status":"ACTIVE"},{"lang":"JP","name":"オマリグリプチン","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Omarigliptin (JAN/USAN/INN)","source_info":[{"code":"D10317","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"CN","name":"奥格列汀","status":"ACTIVE"}],"dev_code":[{"name":"MK-3102","status":"ACTIVE"}],"trade_name":[{"name":"MARIZEV","source_info":[{"code":"22700AMX01014000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/170050_3969025F1022_1_10"}],"status":"ACTIVE"},{"name":"マリゼブ","source_info":[{"code":"22700AMX01014000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/170050_3969025F1022_1_10"}],"status":"ACTIVE"}],"generic_name":[{"name":"Omarigliptin","source_info":[{"code":"D10317","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB11992"],"kegg_id":["D10317"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6a8c172f1efc649035845f94c31a9c1e"],"mechanism_action_id":["74936a607528a70f96b7bb43ed793a98"],"target_id":["54927504b1144faca0b7c66abedf1a78"],"atc_code":["9450f4e744f14d30962ca309f97ee07c"],"disease_id":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["002fcacd5d5f3b0dfa961f9cdcfc1850","6632a5800bfb389a90c6b15df46d2020"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["74d974da49ba407195b38595a0aff704"],"research_disease":["74d974da49ba407195b38595a0aff704"],"non_research_disease":["05ee0bc5347a4677a95179fcdcc2b814"],"inactive_org_master_entity_id":["462096edf3de7b2de5a70c8fa9b70fa3"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1443398400000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["f542e37eb5968e9ca06a58c67bb7a4ef","002fcacd5d5f3b0dfa961f9cdcfc1850"],"data_source":10}
+{"drug_id":"066b275eba824304b91dceaa0e850786","docid":4341,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"7612d82cad933e3ca680bce4afcae60d","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:42.000Z","updated_ts":"2025-11-08T21:08:07.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"QR-1123","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ISIS-GSK5RX","status":"ACTIVE"}],"dev_code":[{"name":"ION-357","status":"ACTIVE"},{"name":"IONIS-RHO-2.5RX","status":"ACTIVE"},{"name":"ISIS-GSK5-2.5Rx","status":"ACTIVE"},{"name":"ISIS-RHO-2.5RX","status":"ACTIVE"},{"name":"QR 1123","status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["26fccb4d7b5089cb0283d61fe43aa242"],"mechanism_action_id":["32433c48fa4742da98be6bd044327b35"],"target_id":["a7eb8c9ebd6b4198b894ff91ccc4e30a"],"disease_id":["2ef2f7065d1e476d839aaa6ce50d522d"],"active_org_master_entity_id":["8dacdda1778625ac155f767d2259b82e"],"research_disease":["2ef2f7065d1e476d839aaa6ce50d522d"],"inactive_org_master_entity_id":["26fccb4d7b5089cb0283d61fe43aa242"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1570406400000}}],"disease_phase":[{"disease_id":"2ef2f7065d1e476d839aaa6ce50d522d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["26fccb4d7b5089cb0283d61fe43aa242","8dacdda1778625ac155f767d2259b82e","9b027bb089fcaa2c937327ac652321dd"],"data_source":10,"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://www.proqr.com/press-releases/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant"}],"regulation_type":["f1cc657d8fe04d37918af804bd477fb5"],"targeted_tissue":["f0fa923d9e164faa8c498f724f9e1371"],"delivery_system":["42e15f5307df48c0b79434dc95ae3720"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"18a3326ca50149dd835f761cac3557d0","docid":48329,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":10,"target_extend_id":"a98f078c8fa73a39872fed67fe2556c4","created_ts":"2021-10-08T14:43:04.000Z","updated_ts":"2026-04-02T09:18:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"仑博替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://m.163.com/dy/article/KA769NQS0532CO9S.html"}],"status":"ACTIVE"},{"lang":"EN","name":"Lunbotinib","source_info":[{"code":"list 130","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf?sfvrsn=ef74744a_5&download=true"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"富马酸仑博替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://m.163.com/dy/article/KA769NQS0532CO9S.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"A400","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.163.com/dy/article/I7O72BOE0552MD9C.html"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ret-inhibitor-ep0031"}],"status":"ACTIVE"},{"name":"EP-0031","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ret-inhibitor-ep0031"}],"status":"ACTIVE"},{"name":"EP0031","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ret-inhibitor-ep0031"}],"status":"ACTIVE"},{"name":"EP0031/A400","source_info":[{"normalized_source_id":"e5b08f52d06d4e56a516b482a5fecb0f","source":"BusinessWire","source_url":"https://www.businesswire.com/news/home/20241222005554/en"}],"status":"ACTIVE"},{"name":"KL-590586","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ret-inhibitor-kl590586"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5025234e8bb97bf04295812da138e4bd"],"mechanism_action_id":["18962dd9294a402adf0ab56634ca84ea"],"target_id":["593ba65127444c25b4497209b82b90bd"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["4cd8c0679a6f4f64afe0896351402a27","3beea980d93a4cc0abc864e27514601c","0464f5493b0444e9875a0584df17cbf0","9b9d22a9617f4c77ba9cc4072807bf7e"],"active_org_master_entity_id":["52f71b8ce22867e90fd9081ce8a03e86","5025234e8bb97bf04295812da138e4bd"],"research_disease":["4cd8c0679a6f4f64afe0896351402a27","3beea980d93a4cc0abc864e27514601c","0464f5493b0444e9875a0584df17cbf0","9b9d22a9617f4c77ba9cc4072807bf7e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1758585600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}},{"country":"7e67ab67-b973-3c61-8850-3ba387e2b3fe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1664496000000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4cd8c0679a6f4f64afe0896351402a27","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"9b9d22a9617f4c77ba9cc4072807bf7e","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"deal_related_org":["5025234e8bb97bf04295812da138e4bd","52f71b8ce22867e90fd9081ce8a03e86"],"if_speculate":0,"data_source":10}
+{"drug_id":"0cb3ea8626514a4b94cdd8f7bc01b171","docid":1310053,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2025-03-26T07:51:25.000Z","updated_ts":"2025-03-26T07:58:12.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"VCC-001","source_info":[{"attachment_path":"data/phs_source_info/3db4/1190/02b1/c5b4/3db4119002b1c5b4.jpg","attachment_type":"image/jpeg","code":"Vaccentis-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd97/6f2e/3cfc/dd34/dd976f2e3cfcdd34.jpg","source":"Company pipeline","source_url":"https://vaccentis.com/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"VCC 001","source_info":[{"attachment_path":"data/phs_source_info/3db4/1190/02b1/c5b4/3db4119002b1c5b4.jpg","attachment_type":"image/jpeg","code":"Vaccentis-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd97/6f2e/3cfc/dd34/dd976f2e3cfcdd34.jpg","source":"Company pipeline","source_url":"https://vaccentis.com/pipeline"}],"status":"ACTIVE"},{"name":"VCC001","source_info":[{"attachment_path":"data/phs_source_info/3db4/1190/02b1/c5b4/3db4119002b1c5b4.jpg","attachment_type":"image/jpeg","code":"Vaccentis-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd97/6f2e/3cfc/dd34/dd976f2e3cfcdd34.jpg","source":"Company pipeline","source_url":"https://vaccentis.com/pipeline"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["2fc51c0a809fa6ac566685badb2f2cb0"],"disease_id":["c7fe8aa844d24e85ba32a990ea28ded3"],"active_org_master_entity_id":["2fc51c0a809fa6ac566685badb2f2cb0"],"research_disease":["c7fe8aa844d24e85ba32a990ea28ded3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"3c8845e10f5175ab64a91c30c771750e","docid":84388,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-03-07T08:56:20.000Z","updated_ts":"2025-08-02T00:29:57.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BMD-006","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"mRNA Tumor-associated Antigen Dry Powder Vaccine(Biorchestra)","source_info":[{"code":"NCT06928922","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06928922"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["fad77fee67d0c59de233cd979ab252f5"],"disease_id":["323717f7753b4ce6a5561d105a7531cf","4c0044bbaeba47258cf85131c2412421"],"active_org_master_entity_id":["51551d363d893be0041c70abd164075a"],"research_disease":["323717f7753b4ce6a5561d105a7531cf"],"non_research_disease":["4c0044bbaeba47258cf85131c2412421"],"inactive_org_master_entity_id":["fad77fee67d0c59de233cd979ab252f5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1740355200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1718150400000}}],"disease_phase":[{"disease_id":"323717f7753b4ce6a5561d105a7531cf","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"4c0044bbaeba47258cf85131c2412421","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"if_speculate":0,"data_source":10}
+{"drug_id":"017a3959239445b1addbaa8e299b4401","docid":68821,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","wiki_link":"https://en.wikipedia.org/wiki/Fentiazac","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:45:12.000Z","updated_ts":"2024-12-09T02:34:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"芬替酸","status":"ACTIVE"},{"lang":"EN","name":"Fentiazac","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"4-(4-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid","source_info":[{"code":"DB13217","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"4-(p-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid","source_info":[{"code":"DB13217","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Fentiazac (JAN/USAN/INN)","source_info":[{"code":"D01975","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"BR-700","status":"ACTIVE"},{"name":"NSC-282191","source_info":[{"code":"YHF6E6NLS","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2859f4e9-1fa6-4da9-a606-b37d1ff50c77"}],"status":"ACTIVE"},{"name":"WY-21,894","source_info":[{"code":"YHF6E6NLS","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2859f4e9-1fa6-4da9-a606-b37d1ff50c77"}],"status":"ACTIVE"},{"name":"WY-21894","source_info":[{"code":"YHF6E6NLS","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2859f4e9-1fa6-4da9-a606-b37d1ff50c77"}],"status":"ACTIVE"}],"generic_name":[{"name":"Fentiazac","source_info":[{"code":"D01975","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB13217"],"kegg_id":["D01975"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"atc_code":["16ff7504f6b94ab297f28ac0fed9fddd","5dcc78a8990448478540264befd3a31d"],"disease_id":["452558707a32402e80a9431bf4652814","25aa9dbd25714b36b8bcb9347d1b91d1"],"research_disease":["452558707a32402e80a9431bf4652814","25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"452558707a32402e80a9431bf4652814","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"05c0df2dcb3140e5a0531598d3d68efc","docid":205458,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":18,"target_extend_id":"780cd554a1653e7098b5815e8264f2dc","created_ts":"2025-01-13T06:15:53.000Z","updated_ts":"2026-04-18T21:07:46.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"KHN702","status":"ACTIVE"}],"dev_code":[{"name":"KHN702","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["1893ff197d3aa1ef15b596a625345e69"],"mechanism_action_id":["d403a18439764bb9227e7ed7ad637845"],"target_id":["a0efcac506604a2a9172e9d35e70c934"],"disease_id":["e05d3f1bc6e8430e8a7dc7171ae02206","f09b7cfbc8314c54a5a207e8f88a2b4c"],"active_org_master_entity_id":["1893ff197d3aa1ef15b596a625345e69"],"research_disease":["e05d3f1bc6e8430e8a7dc7171ae02206","f09b7cfbc8314c54a5a207e8f88a2b4c"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1764115200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1750118400000}}],"disease_phase":[{"disease_id":"f09b7cfbc8314c54a5a207e8f88a2b4c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e05d3f1bc6e8430e8a7dc7171ae02206","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"08195e8b77fe47f182269fd91bfa525f","docid":1670768,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-08-15T05:47:57.000Z","updated_ts":"2026-03-17T02:48:03.000Z","data_status":"ACTIVE","created_by":"jiaxingyu@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Pandemic Influenza (H5N1), CpG 1018 adjuvanted (Dynavax)","source_info":[{"attachment_path":"data/phs_source_info/f54a/1a33/d018/ede6/f54a1a33d018ede6.png","attachment_type":"image/png","code":"Dynavax-202603","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/bc72/8afd/1398/ccb8/bc728afd1398ccb8.png","source":"Company pipeline","source_url":"https://www.dynavax.com/pipeline/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"H5N1 influenza vaccine (Dynavax)","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investors.dynavax.com/news-releases/news-release-details/dynavax-reports-first-quarter-2025-financial-results-and"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["32b2744aaa6aaaa154105535c242eabb"],"disease_id":["192cc69543a04d57bc38da03cf89eff8"],"active_org_master_entity_id":["32b2744aaa6aaaa154105535c242eabb"],"research_disease":["192cc69543a04d57bc38da03cf89eff8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1754524800000}}],"disease_phase":[{"disease_id":"192cc69543a04d57bc38da03cf89eff8","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"50566063a7664c05a34b17ce5112b592","docid":115421,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"67d8eb770e674d37af57f0823968f7b7","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":10,"target_extend_id":"84b2f5c6acf63fde95a1e609a386330e","created_ts":"2024-09-20T10:25:43.000Z","updated_ts":"2025-08-12T07:32:48.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"重组天冬酰胺酶生物类似药（Porton Biopharma Ltd.）","status":"ACTIVE"},{"lang":"EN","name":"Asparaginase Biosimilar (Porton Biopharma Ltd.)","status":"ACTIVE"}],"generic_name":[{"name":"asparaginase","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c6f7aa5028654d4d8ac6153f9b53e8a2"],"originator_org_master_entity_id":["da9909c9fffa63d98ddcf471d052fb91"],"mechanism_action_id":["83f97101f6a115bc76a55063c79908bc"],"target_id":["85def8833c424a9f929ed7b2d533688c"],"atc_code":["85f1a484557b49bc8b29c2459dc1732b"],"disease_id":["1d78cca79eae4632bc4464c90a574f83"],"active_org_master_entity_id":["da9909c9fffa63d98ddcf471d052fb91"],"research_disease":["1d78cca79eae4632bc4464c90a574f83"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1688169600000}}],"disease_phase":[{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["15b6efac507a4cc3af5370140b84923a"],"data_source":10}
+{"drug_id":"01ff9533ce82417f86210e4f818f0327","docid":68478,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"130787d66d9530b6b04956fe96348a7a","created_ts":"2021-10-08T14:49:22.000Z","updated_ts":"2025-07-19T21:14:04.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"DN-1508052","status":"ACTIVE"}],"dev_code":[{"name":"DN 1508052","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr8-agonist-dn1508052"}],"status":"ACTIVE"},{"name":"DN A1","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr8-agonist-dn1508052"}],"status":"ACTIVE"},{"name":"DN-A1","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr8-agonist-dn1508052"}],"status":"ACTIVE"},{"name":"DN1508052-01","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr8-agonist-dn1508052"}],"status":"ACTIVE"},{"name":"DNA1","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr8-agonist-dn1508052"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4690f3eeeffe5586d11f02b41024dff0"],"mechanism_action_id":["54ca34745a293f102954fce61ac1c97d"],"target_id":["bfd9ae9131904838b0a638f3917632f2"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["4690f3eeeffe5586d11f02b41024dff0"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1666137600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1730160000000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"01ac8809318545d79da5dcd155cc59b8","docid":4179,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","wiki_link":"https://en.wikipedia.org/wiki/Octotiamine","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:45:51.000Z","updated_ts":"2024-12-09T02:34:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"辛硫胺","status":"ACTIVE"},{"lang":"EN","name":"Octotiamine","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"オクトチアミン","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Octotiamine (JAN/INN)","source_info":[{"code":"D01184","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"TATD","status":"ACTIVE"}],"trade_name":[{"name":"Neuvita","source_info":[{"code":"D01184","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Puroffit","source_info":[{"code":"D01184","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"generic_name":[{"name":"Octotiamine","source_info":[{"code":"D01184","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"kegg_id":["D01184"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"atc_code":["14ef3761e9b945d99cd9257cd4306b17"],"disease_id":["ca41fadbabbd459392b8d6047715da10"],"research_disease":["ca41fadbabbd459392b8d6047715da10"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"ca41fadbabbd459392b8d6047715da10","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"05400998d349496eac0ac7c9402c7509","docid":31689,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":10,"target_extend_id":"19f522e852573f0a9b8d7b6501ecd8c5","created_ts":"2022-02-28T05:06:06.000Z","updated_ts":"2026-02-21T21:10:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"QLS31904","status":"ACTIVE"}],"dev_code":[{"name":"QLS31904","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll3-cd3-bispecific-antibody-qls31904"}],"status":"ACTIVE"}],"drug_type":["6e43c7fb400c4fda8d8693f12241cc09"],"originator_org_master_entity_id":["0bb6804a2738b17bb305b0d80ce08460"],"mechanism_action_id":["59e827e69bbc5091c37f33d9798f8c02","d06a654603e9d808808297a8d81fafc1"],"target_id":["fe50c9b7f38746beb4bfd1ae9fa6fd1b","2207f013c4204775b1b1c7974c275747"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","8d29f554f371431c9b5b80f5befdf965"],"active_org_master_entity_id":["0bb6804a2738b17bb305b0d80ce08460"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","8d29f554f371431c9b5b80f5befdf965"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1660780800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"0d0132e1199e49108d0237d40e22c496","docid":14531,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":6,"target_extend_id":"2669b231cb8d3310a15a18a5a8a90daa","created_ts":"2022-09-27T12:39:24.000Z","updated_ts":"2025-07-07T10:40:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"SRW101","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://prizmtx.com/srw101/"}],"status":"ACTIVE"}],"dev_code":[{"name":"SRW101","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://prizmtx.com/srw101/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["94003d1280ee3e0fd34c237aa5d7ee9b"],"mechanism_action_id":["4b988d4ba69236c0c3cabe58f0e4a002"],"target_id":["5584abc65f5d41478273b9ea25722ee5"],"disease_id":["e42aba50d72445baac6688c7f49d06ba"],"active_org_master_entity_id":["94003d1280ee3e0fd34c237aa5d7ee9b"],"research_disease":["e42aba50d72445baac6688c7f49d06ba"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1647043200000}}],"disease_phase":[{"disease_id":"e42aba50d72445baac6688c7f49d06ba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0200035d532b4025b28e4deccb8f65aa","docid":39476,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"1a9ea1307f82439f86318fa381543664","null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":818985600000,"created_ts":"2021-10-08T14:45:20.000Z","updated_ts":"2024-11-29T07:15:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"CN","name":"重组乙型肝炎疫苗(Biogen, Inc.)","status":"ACTIVE"},{"lang":"EN","name":"Hepatitis B vaccine recombinant(Biogen, Inc.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HBY","status":"ACTIVE"},{"lang":"EN","name":"Hebsulin","status":"ACTIVE"},{"lang":"EN","name":"Hepatitis B vaccine recombinant","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e1aca0be003744f0afbfb1a90c7bc8ac"],"originator_org_master_entity_id":["6eff248679b18ba8153422b44298c49b"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["3e1836fb9ef3445f8a1e47494b203a3a"],"disease_id":["8b107203951e4ae9bfe9667fccbe8df9"],"active_org_master_entity_id":["6eff248679b18ba8153422b44298c49b"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["8b107203951e4ae9bfe9667fccbe8df9"],"research_disease":["8b107203951e4ae9bfe9667fccbe8df9"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":818985600000}}],"disease_phase":[{"disease_id":"8b107203951e4ae9bfe9667fccbe8df9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"193011f3076d5869a549f99f6ea46cfa","docid":202633,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-07-09T03:23:05.000Z","updated_ts":"2026-01-27T20:56:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Cytokine-induced killer cells (Institute of Biophysics and Cell Engineering)","status":"ACTIVE"}],"drug_type":["c1096e0b778945a4921de71ac1a7a730"],"originator_org_master_entity_id":["e911b0bf3aed8e0808168685b6571e31"],"mechanism_action_id":["0ea2609ac1574d0b26b4d1a1f7b40cc1"],"disease_id":["d9c985ab1f04428493c029df6dca650d","114966a80e4d4ce5a6885c9e09dc08d5","d2ee0aa5e8a2440585e9a218d193b710"],"active_org_master_entity_id":["e911b0bf3aed8e0808168685b6571e31"],"research_disease":["d9c985ab1f04428493c029df6dca650d","114966a80e4d4ce5a6885c9e09dc08d5","d2ee0aa5e8a2440585e9a218d193b710"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"e92cf5a5-43e5-3d54-a14b-272415437a2d","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1646092800000}}],"disease_phase":[{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"114966a80e4d4ce5a6885c9e09dc08d5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"0a9410aec3c54297bb38b96791e41e24","docid":75655,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2023-03-02T05:31:00.000Z","updated_ts":"2024-11-01T05:45:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"ACYW135群脑膜炎球菌结合疫苗(深圳康泰生物制品股份有限公司)","status":"ACTIVE"},{"lang":"EN","name":"Meningococcal Polysaccharide Conjugate Vaccine(Group A/C/Y/W135)(Shenzhen Kangtai Biological Products Co., Ltd.)","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","eb728b38dfb842778019260a7dd09801"],"originator_org_master_entity_id":["c07eb244da5082a671fd4397254bb14e"],"disease_id":["e3fc23ccb7c246a28010505f27ede647"],"active_org_master_entity_id":["c07eb244da5082a671fd4397254bb14e"],"research_disease":["e3fc23ccb7c246a28010505f27ede647"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}}],"disease_phase":[{"disease_id":"e3fc23ccb7c246a28010505f27ede647","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"1734fa04e48a42568a80c4ad7e92126b","docid":1760434,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-08-05T06:05:34.000Z","updated_ts":"2025-08-05T06:08:12.000Z","data_status":"ACTIVE","created_by":"zhuli@patnsap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"DT-101(Xiangya Hospital Central South University)","source_info":[{"code":"ChiCTR2500100503","normalized_source_id":"2a39e1fb59c446568df2b08f80e3f6f0","source":"ChiCTR","source_url":"https://www.chictr.org.cn/showproj.html?proj=267290"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["c0f2ba0062195d60acc965ded059da83"],"disease_id":["454bc58683914be1b6d97fbabf6bda5b"],"active_org_master_entity_id":["c0f2ba0062195d60acc965ded059da83"],"research_disease":["454bc58683914be1b6d97fbabf6bda5b"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1744243200000}}],"disease_phase":[{"disease_id":"454bc58683914be1b6d97fbabf6bda5b","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0edeeb9951e44de18eb6b1ad851e18a6","docid":709976,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":89,"target_extend_id":"1f675eaf039d37b5837b104f9aeea73f","created_ts":"2025-01-27T03:00:59.000Z","updated_ts":"2026-04-04T21:11:59.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"RF-16001","source_info":[{"code":"CXHL2101621","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"罗哌卡因（宜昌人福药业）","source_info":[{"code":"CTR20250293","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=4dae510ad7804208808e2c223ef57bf2"}],"status":"ACTIVE"}],"dev_code":[{"name":"RF 16001","status":"ACTIVE"},{"name":"RF-16001","status":"ACTIVE"},{"name":"RF16001","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["cb91b76f59da7f5f08bc8951d5a424f0"],"mechanism_action_id":["e6c08a0e9446621c3ff9d23a82a086f6"],"target_id":["51f1f4aed2c448da9431bb6a54aac45d"],"disease_id":["e05d3f1bc6e8430e8a7dc7171ae02206"],"active_org_master_entity_id":["3a1d21207f3a2bb7312ac3dbabafd638","cb91b76f59da7f5f08bc8951d5a424f0"],"research_disease":["e05d3f1bc6e8430e8a7dc7171ae02206"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1752537600000}}],"disease_phase":[{"disease_id":"e05d3f1bc6e8430e8a7dc7171ae02206","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"24411337e2214af993c267b5d96b9397","docid":232669,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-08-12T09:30:47.000Z","updated_ts":"2025-06-17T10:22:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"[177Lu]Lu-PSMA-137","source_info":[{"code":"NCT06546527","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06546527"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["646fef6e499e26997d2509d27b7c86dd"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["27538fe67e9b4648b06de8efdc9ab891"],"active_org_master_entity_id":["646fef6e499e26997d2509d27b7c86dd"],"research_disease":["27538fe67e9b4648b06de8efdc9ab891"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"moiety_mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"]}
+{"drug_id":"3da60e17564b4d2fa2018ccb3494ce91","docid":3109,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":166,"target_extend_id":"18b251c0f2f43800b245c1561bb9880f","created_ts":"2022-05-30T12:14:10.000Z","updated_ts":"2026-04-04T21:09:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"HM-2002","status":"ACTIVE"}],"dev_code":[{"name":"HM 2002","status":"ACTIVE"},{"name":"HM2002","status":"ACTIVE"}],"drug_type":["13552b2d4608459fa1addc238d10318a"],"originator_org_master_entity_id":["9498da652a0780fb72d3acfd0873a402"],"mechanism_action_id":["72d64a51cd6740671091da84743fa32c"],"target_id":["1c2067e5ab054a8995f73efcfcf56207"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["07d3b2bb68e645768b890e7a70d6fc90","c8e43d2b48ec49dba16418bc190a3eec","6b0f81a02c5045ba84b09e501be93180","f5593b7bc5994cea9d2f2d8466866587"],"active_org_master_entity_id":["9498da652a0780fb72d3acfd0873a402"],"research_disease":["07d3b2bb68e645768b890e7a70d6fc90","c8e43d2b48ec49dba16418bc190a3eec","6b0f81a02c5045ba84b09e501be93180","f5593b7bc5994cea9d2f2d8466866587"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1763510400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1748563200000}}],"disease_phase":[{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f5593b7bc5994cea9d2f2d8466866587","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"6b0f81a02c5045ba84b09e501be93180","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"07d3b2bb68e645768b890e7a70d6fc90","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"genetic_material":"f8894c8c9e424a27a25ebcd8ad178b38","if_speculate":0,"data_source":10}
+{"drug_id":"08c59035ae4b476d82655515d24e4729","docid":53565,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-12-19T12:30:09.000Z","updated_ts":"2024-11-07T20:20:00.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LF-0376","source_info":[{"code":"CXHL2101713","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"LF 0376","source_info":[{"code":"CXHL2101713","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"LF-0376","source_info":[{"code":"CXHL2101713","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"LF0376","source_info":[{"code":"CXHL2101713","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["13aad846b6d3e1b10b48f15ea0a18d6d"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","7665e5683a1a443a8f3d3b946d4c9ca2","1e6992f1403346acad1273d778686ca7","26535c6f16de4adfb19f0154be738535","ae092fa59f4d44edaf59ffe23d0a44c3","0e0dca4dd7f1499a8f65f4fdfcf09954"],"active_org_master_entity_id":["13aad846b6d3e1b10b48f15ea0a18d6d"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","7665e5683a1a443a8f3d3b946d4c9ca2","1e6992f1403346acad1273d778686ca7","26535c6f16de4adfb19f0154be738535","ae092fa59f4d44edaf59ffe23d0a44c3","0e0dca4dd7f1499a8f65f4fdfcf09954"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1655683200000}}],"disease_phase":[{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"40fa3041cf354bc3bf38fd1668e60da0","docid":1674323,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-04-09T06:42:06.000Z","updated_ts":"2026-04-09T06:44:15.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Sacituzumab vedotin","source_info":[{"normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","source":"Corporate Publications","source_url":"https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Oncology%2023.09.2025.pdf"}],"status":"ACTIVE"}],"dev_code":[{"name":"ZRC-3328","source_info":[{"normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","source":"Corporate Publications","source_url":"https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Oncology%2023.09.2025.pdf"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["8880b94c103115459f3f8bb32dbddc3e"],"disease_id":["52b616e66f38449a8f5000a2ed0d9585"],"active_org_master_entity_id":["8880b94c103115459f3f8bb32dbddc3e"],"research_disease":["52b616e66f38449a8f5000a2ed0d9585"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"91ac63db1def4da58e890aec574fe7f4"}],"disease_phase":[{"disease_id":"52b616e66f38449a8f5000a2ed0d9585","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"333cca2d444646de8a4039b99002da0e","docid":13705,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"ac14778662b7448588663c26ce84cd9e","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":1,"target_extend_id":"d6e849bd8aa5385aa83f37564e0ab0e8","created_ts":"2021-10-08T14:42:45.000Z","updated_ts":"2025-11-03T00:27:52.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"伊立芙普α","source_info":[{"code":"CXSS2500103","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Eflimrufusp alfa","status":"ACTIVE"}],"dev_code":[{"name":"RC-28","status":"ACTIVE"},{"name":"RC-28-E","status":"ACTIVE"},{"name":"RC28-E","status":"ACTIVE"}],"drug_type":["3dc96d9272ad41a3833fc1e67887cd5b"],"originator_org_master_entity_id":["9518a01d10c146a15014b98bd938334c"],"mechanism_action_id":["72d64a51cd6740671091da84743fa32c","46c5a108c9be2b6e0662565f6d8ce600"],"target_id":["1c2067e5ab054a8995f73efcfcf56207","582d0d76c80c446f80ee3b9118f1bbfd"],"special_review":["9eb8777c62af4712932b360e6ef3e454"],"disease_id":["7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba","f880f61785b940cd9ed1bb3212b5c1ce"],"active_org_master_entity_id":["9518a01d10c146a15014b98bd938334c"],"research_disease":["7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"non_research_disease":["f880f61785b940cd9ed1bb3212b5c1ce"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1759190400000}}],"disease_phase":[{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"f880f61785b940cd9ed1bb3212b5c1ce","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["2efaca42b4d940eaf0e502464dd9c184","56da48d98c7ed6dcab4605950662b41c","9518a01d10c146a15014b98bd938334c","cb239bf995f03ef21fd0d2cde37e9790"],"if_speculate":0,"data_source":10}
+{"drug_id":"0313a1a9eb7c49d3bdd0fa29feda1049","docid":26273,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:42:46.000Z","updated_ts":"2024-12-04T08:40:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Aluminoparaaminosalicylate Calcium Hydrate","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"アルミノパラアミノサリチル酸カルシウム水和物","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Aluminoparaaminosalicylate calcium","source_info":[{"code":"D01643","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Aluminoparaaminosalicylate calcium hydrate (JAN)","source_info":[{"code":"D01643","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Aluminoparaaminosalicylate calcium pentahydrate","source_info":[{"code":"D01643","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"trade_name":[{"name":"Alumino nippas calcium","source_info":[{"code":"D01643","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"kegg_id":["D01643"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8d17cd4d0627c440f278dbcfd8449bb3"],"atc_code":["17615faf039145a3a53790361203bda5"],"disease_id":["764eee63555942f1bb171f1b8c1e71ea","83a63550dcab42b6a7eaacba8afdf3d9"],"active_org_master_entity_id":["8d17cd4d0627c440f278dbcfd8449bb3"],"research_disease":["764eee63555942f1bb171f1b8c1e71ea","83a63550dcab42b6a7eaacba8afdf3d9"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"83a63550dcab42b6a7eaacba8afdf3d9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"764eee63555942f1bb171f1b8c1e71ea","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"11ca0e90200c4c8e9a4d72dcf297672d","docid":116806,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"e2fbbc433aa239eb96558fa73e29ba75","created_ts":"2025-01-13T09:30:39.000Z","updated_ts":"2025-08-27T21:05:06.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"BFB-101","source_info":[{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"https://www.prnewswire.com/news-releases/blackfinbio-ltd-announces-the-acquisition-of-parkinsons-ip-patent-portfolio-from-oxb-302344565.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"BFB 101","source_info":[{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"https://www.prnewswire.com/news-releases/blackfinbio-ltd-announces-the-acquisition-of-parkinsons-ip-patent-portfolio-from-oxb-302344565.html"}],"status":"ACTIVE"},{"name":"BFB101","source_info":[{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"https://www.prnewswire.com/news-releases/blackfinbio-ltd-announces-the-acquisition-of-parkinsons-ip-patent-portfolio-from-oxb-302344565.html"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["44bdd57efe23118162b38cf0b548e050"],"mechanism_action_id":["4aa356e0947c4de397805a41beb74fbf"],"target_id":["b3e8fc451f18436e8eed2818147835b9"],"disease_id":["1a41aab338154a0782d174543699b03a","fcae62a57dfe4f0ea751f2057abd850e","65b803a2d85148ffba84a0a83c46f9f5","2380572644b44359a8d516308d68b687","dd828aff89d54a6986dc62f422a0ca81"],"active_org_master_entity_id":["44bdd57efe23118162b38cf0b548e050"],"research_disease":["1a41aab338154a0782d174543699b03a","fcae62a57dfe4f0ea751f2057abd850e","65b803a2d85148ffba84a0a83c46f9f5","2380572644b44359a8d516308d68b687","dd828aff89d54a6986dc62f422a0ca81"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1754006400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"3da2ce3ce8b0443fb0b2d335be3e591a"}],"disease_phase":[{"disease_id":"65b803a2d85148ffba84a0a83c46f9f5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"dd828aff89d54a6986dc62f422a0ca81","highest_phase_global":"3da2ce3ce8b0443fb0b2d335be3e591a"},{"disease_id":"fcae62a57dfe4f0ea751f2057abd850e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2380572644b44359a8d516308d68b687","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a41aab338154a0782d174543699b03a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["44bdd57efe23118162b38cf0b548e050","a2383409bb34fa0928dd0d3d2f37cfaa"],"if_speculate":0,"data_source":10}
+{"drug_id":"18e52d0155454bbf92735ad0211fd2e8","docid":9813,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":36,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2021-10-08T14:48:45.000Z","updated_ts":"2026-04-04T21:06:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"CN","name":"CBM.BCMA嵌合抗原受体T细胞(AbelZeta Pharma)","source_info":[{"code":"CXSL2000060","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"C-CAR088","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti BCMA CAR T Cell Therapy","status":"ACTIVE"},{"lang":"EN","name":"BCMA-directed CAR-T Cells","status":"ACTIVE"},{"lang":"EN","name":"CBM.BCMA Chimeric Antigen Receptor T cell","status":"ACTIVE"},{"lang":"EN","name":"Trovocabtagene Autoleucel","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://ashpublications.org/blood/article/142/Supplement%201/6864/505652/Promising-Safety-and-Efficacy-of-Trovocabtagene"}],"status":"ACTIVE"}],"dev_code":[{"name":"C CAR 088","status":"ACTIVE"},{"name":"C-CAR 088","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-4-1bb-cd3zeta-expressing-t-cells-c-car088"}],"status":"ACTIVE"},{"name":"C-CAR-088","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-4-1bb-cd3zeta-expressing-t-cells-c-car088"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["ec71f92de4c0f0b557150c986c16b7f3"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["2e0c67080317c457ca2c5efecbd92cb8","82745163de1f1746d81ad30d6fbfe699"],"research_disease":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","7cd0fcf1c5c243b9b3944405ec4855b5"],"inactive_org_master_entity_id":["ec71f92de4c0f0b557150c986c16b7f3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1668124800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1657756800000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"0078c223594b4b27b20e5faecf5dc9bc","docid":81542,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":89,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2023-10-30T01:41:48.000Z","updated_ts":"2026-04-11T21:06:34.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous CD19-directed CAR-T cells(University of Sao Paulo)","source_info":[{"code":"NCT06101381","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["c631b506a9ac18076d071505f1780823"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["62bca3c4e2794be5a901cf7c004f0d12","0e0dca4dd7f1499a8f65f4fdfcf09954","e89afc6a432744b1a88281329dc46d91","a622cec9c1e34e88a3c46c3b7fa00884","321c439bbe614dc2afd13cb803a48cec"],"active_org_master_entity_id":["c631b506a9ac18076d071505f1780823"],"research_disease":["62bca3c4e2794be5a901cf7c004f0d12","0e0dca4dd7f1499a8f65f4fdfcf09954","e89afc6a432744b1a88281329dc46d91","a622cec9c1e34e88a3c46c3b7fa00884","321c439bbe614dc2afd13cb803a48cec"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1710979200000}}],"disease_phase":[{"disease_id":"a622cec9c1e34e88a3c46c3b7fa00884","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e89afc6a432744b1a88281329dc46d91","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"321c439bbe614dc2afd13cb803a48cec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"62bca3c4e2794be5a901cf7c004f0d12","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"13d9b99db41247b08512dfc4f1a64134","docid":14864,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_dev_status_before_termination_cn":"e6438687ed214800bb98742ebbeb70a1","rnk":4,"target_extend_id":"c9f4e17f174a3b0abc907089fe318c94","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:32.000Z","updated_ts":"2026-02-25T01:54:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"Camonsertib","source_info":[{"code":"10.21203/rs.3.rs-3854682/v1","normalized_source_id":"166c2bd5-da92-4e1f-94af-5fcbdb8f0140","source":"Res Sq","source_url":"http://dx.doi.org/10.21203/rs.3.rs-3854682/v1"},{"code":"38410486","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/38410486/"}],"status":"ACTIVE"}],"dev_code":[{"name":"RG6526","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/repare-therapeutics-announces-plenary-oral-presentation-at-the-2023-aacr-annual-meeting-on-camonsertib-and-additional-data-presentations-on-rp-6306/"},{"code":"10.21203/rs.3.rs-3854682/v1","normalized_source_id":"166c2bd5-da92-4e1f-94af-5fcbdb8f0140","source":"Res Sq","source_url":"http://dx.doi.org/10.21203/rs.3.rs-3854682/v1"},{"code":"38410486","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/38410486/"}],"status":"ACTIVE"},{"name":"RP 3500","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/camonsertib"}],"status":"ACTIVE"},{"name":"RP-3500","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/camonsertib"},{"code":"10.21203/rs.3.rs-3854682/v1","normalized_source_id":"166c2bd5-da92-4e1f-94af-5fcbdb8f0140","source":"Res Sq","source_url":"http://dx.doi.org/10.21203/rs.3.rs-3854682/v1"},{"code":"38410486","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/38410486/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2e92b9b24dbd78cca04db48db3f0eb7e"],"mechanism_action_id":["2768d83656f87c81b5a3fcda75e7f214"],"target_id":["f72552f8ce11468982eeb6a7db205f42"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["3beea980d93a4cc0abc864e27514601c","f048bf0822254413a3ea354eced08eec","6c9c5be211cb4d72a28205c49a16d653","0464f5493b0444e9875a0584df17cbf0","2bb755a3f43f49dea60661c5f99712a3","87a9454771a64f2191224b6b7684254a","c297238c41b2488abe3de6546b105a4e","8ae64343c39b4b09865ed0177000236b"],"active_org_master_entity_id":["d7dc381f4bf0f28f14bb88ed2f3535d9","2e92b9b24dbd78cca04db48db3f0eb7e","3bdcd22f6e2d3273ac9eac8e8ab7a0b0"],"research_disease":["3beea980d93a4cc0abc864e27514601c","f048bf0822254413a3ea354eced08eec","6c9c5be211cb4d72a28205c49a16d653","0464f5493b0444e9875a0584df17cbf0","2bb755a3f43f49dea60661c5f99712a3","87a9454771a64f2191224b6b7684254a","c297238c41b2488abe3de6546b105a4e"],"non_research_disease":["8ae64343c39b4b09865ed0177000236b"],"inactive_org_master_entity_id":["9734c5210944b06b27c42554d893798f","09136807963a30acf5c8b4eaca73519b","8a3c41b6b3536abfff46a5b43b7662b0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1595376000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1514332800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1595376000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1514332800000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1595376000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1514332800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1514332800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1514332800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1514332800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1707782400000}}],"disease_phase":[{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_before_ter_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8ae64343c39b4b09865ed0177000236b","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["2e92b9b24dbd78cca04db48db3f0eb7e","62728be9078d4f1b000c8df58dc3b134","87bfaf037f8e60c9e25595cd98bb27e4"],"data_source":10}
+{"drug_id":"27a3afab85df4c06ba2347c6538e0eb5","docid":7242,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":10,"target_extend_id":"1a054e6699b4367f8131a42e1e5d72fe","created_ts":"2021-10-08T14:49:13.000Z","updated_ts":"2026-03-08T21:16:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"CN","name":"托珠单抗生物类似药 (永昕生物)","status":"ACTIVE"},{"lang":"EN","name":"Tocilizumab biosimilar (Mycenax Biotech)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"LusiNEX","status":"ACTIVE"},{"lang":"EN","name":"Tocilizumab Biosimilar (Mycenax Biotech, Inc.)","status":"ACTIVE"},{"lang":"CN","name":"托珠单抗生物类似药（Mycenax Biotech, Inc.）","status":"ACTIVE"}],"dev_code":[{"name":"RGB 19","source_info":[{"attachment_path":"data/phs_source_info/9c8c/77db/ed3f/6662/9c8c77dbed3f6662.jpg","attachment_type":"image/jpeg","code":"Mochida-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2f2a/a0cf/86f3/783f/2f2aa0cf86f3783f.jpg","source":"Company pipeline","source_url":"https://www.mochida.co.jp/english/company/domain/rd.html"}],"status":"ACTIVE"},{"name":"RGB-19","source_info":[{"attachment_path":"data/phs_source_info/9c8c/77db/ed3f/6662/9c8c77dbed3f6662.jpg","attachment_type":"image/jpeg","code":"Mochida-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2f2a/a0cf/86f3/783f/2f2aa0cf86f3783f.jpg","source":"Company pipeline","source_url":"https://www.mochida.co.jp/english/company/domain/rd.html"}],"status":"ACTIVE"},{"name":"RGB19","source_info":[{"attachment_path":"data/phs_source_info/9c8c/77db/ed3f/6662/9c8c77dbed3f6662.jpg","attachment_type":"image/jpeg","code":"Mochida-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2f2a/a0cf/86f3/783f/2f2aa0cf86f3783f.jpg","source":"Company pipeline","source_url":"https://www.mochida.co.jp/english/company/domain/rd.html"}],"status":"ACTIVE"}],"trade_name":[{"name":"Tuyory","source_info":[{"code":"EMEA/H/C/006416","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tuyory#product-details"}],"status":"ACTIVE"}],"generic_name":[{"name":"Tocilizumab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["c6f7b3e95202717161fa4729eee86159"],"mechanism_action_id":["b30a0bdb2e0bd9c03a908a84588c4217"],"target_id":["8556307199154d34b1f9bc9685f2ec47"],"atc_code":["677f15ff98f54c5a9dbeeb9217830b53"],"disease_id":["717a9bf79e584830859595b8dbe9d433","4877fdea8af24861ac4d9dd0d5baab7f","8a404857a8634e818a9f5829a25a1156","fba2e886a6984bf0a99687816b58b064","67dcd3aede4b483288408dea43a816fb","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["c6f7b3e95202717161fa4729eee86159","32607017dfec8b815a7c5b050aa22b46","23f15cac189382d1f9aad7de9a0fc685"],"research_disease":["717a9bf79e584830859595b8dbe9d433","4877fdea8af24861ac4d9dd0d5baab7f","8a404857a8634e818a9f5829a25a1156","fba2e886a6984bf0a99687816b58b064","67dcd3aede4b483288408dea43a816fb","6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1772064000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1743033600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1742947200000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"67dcd3aede4b483288408dea43a816fb","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"8a404857a8634e818a9f5829a25a1156","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"fba2e886a6984bf0a99687816b58b064","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"4877fdea8af24861ac4d9dd0d5baab7f","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["15e9b335b94146f68051d261972d79a8"],"deal_related_org":["23f15cac189382d1f9aad7de9a0fc685","32607017dfec8b815a7c5b050aa22b46","c6f7b3e95202717161fa4729eee86159"],"if_speculate":0,"data_source":10}
+{"drug_id":"0037c553178641dc89bf4a61262f2cc3","docid":111024,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"f289afe1fa8d3feaba106fb838e64e7b","created_ts":"2024-03-29T08:35:57.000Z","updated_ts":"2026-03-14T21:10:55.000Z","data_status":"ACTIVE","created_by":"outxiaqi@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"ARO-INHBE","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-fiscal-2024-first-quarter"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"INHBE RNAi (Arrowhead Pharmaceuticals)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247523596&idx=3&sn=243d32960adfe95068a89390591e818c"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["f01c40a6380a0660b4ca7ff6b6f695a4"],"mechanism_action_id":["0fd393b236cc1d27070922cc4863dc31"],"target_id":["92d2d7b574bd4c17ad33de8868c5b21f"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["f01c40a6380a0660b4ca7ff6b6f695a4"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1733270400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1707177600000}}],"disease_phase":[{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","data_source":10,"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://arrowheadpharma.com/pipeline/"}],"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"targeted_tissue":["a63a02bf5b3f433aa7da4ea6edd802bf"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"0c489cd40c1e4ce984ba45a70c22de3a","docid":47845,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":21,"target_extend_id":"00eda393181b3e5f9f4c99036da316fb","created_ts":"2023-05-29T05:08:47.000Z","updated_ts":"2026-03-28T21:10:25.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Fimasartan Potassium Trihydrate/Indapamide","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Fimasartan/Indapamide","status":"ACTIVE"}],"dev_code":[{"name":"BR 1015","status":"ACTIVE"},{"name":"BR-1015","status":"ACTIVE"},{"name":"BR1015","source_info":[{"code":"NCT05878561","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05878561"}],"status":"ACTIVE"}],"related_component":["0dbb755262404713a58c4ef5780e0815","3d33d03b9be942898aacb22d055b2c61"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8749b8a1dde02c1e5f8706ce6346a28a"],"mechanism_action_id":["a56208e0f7c40aa5e367dd1131768136","136a0795ad589b4678b96ce66db3de39"],"target_id":["6d5027eeb15440ed9b14919e51dad4bd","9a2b9a4b9e51483dbe26d92a1e05c11f"],"disease_id":["f8f9347202e043bab0e0d627ce10e767"],"active_org_master_entity_id":["8749b8a1dde02c1e5f8706ce6346a28a"],"research_disease":["f8f9347202e043bab0e0d627ce10e767"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1667952000000}}],"disease_phase":[{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"374be0a898364758b6005a1cf515d315","docid":74247,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:51.000Z","updated_ts":"2025-05-15T19:33:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"氘代睾酮","status":"ACTIVE"},{"lang":"EN","name":"d-Testosterone","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["a005cad52b95a663039873bed1cf5564"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","89ea46c3c51a4312a8eed6148d563ca1","3d4d67a3dc9248f8b4fea96e338cdab7"],"active_org_master_entity_id":["a005cad52b95a663039873bed1cf5564"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","89ea46c3c51a4312a8eed6148d563ca1","3d4d67a3dc9248f8b4fea96e338cdab7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1643328000000}}],"disease_phase":[{"disease_id":"89ea46c3c51a4312a8eed6148d563ca1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"3d4d67a3dc9248f8b4fea96e338cdab7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"02648a9faaca4abba3c3ae238f5ea8bc","docid":36449,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Nafcillin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":625795200000,"rnk":85,"target_extend_id":"30ed854af12137b3869be714792ad19d","created_ts":"2021-10-08T14:44:35.000Z","updated_ts":"2026-02-14T00:43:35.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":820454400000,"drug_name":[{"lang":"CN","name":"萘夫西林钠","status":"ACTIVE"},{"lang":"EN","name":"Nafcillin Sodium","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(2-ethoxy-1-naphthalenyl)penicillin","source_info":[{"code":"DB00607","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"(2-ethoxy-1-naphthyl)penicillin","source_info":[{"code":"DB00607","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"6-(2-ethoxy-1-naphthamido)penicillanic acid","source_info":[{"code":"DB00607","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Nafcillin","source_info":[{"code":"DB00607","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Nafcillin Sodium(for oral)","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Nafcillin sodium (USP)","source_info":[{"code":"D00928","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Nafcillin sodium monohydrate","source_info":[{"code":"D00928","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Naphcillin","source_info":[{"code":"DB00607","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"CN","name":"萘夫西林钠(供)","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-757108","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1be2261b-825f-48db-9ac4-fffefcb7b317"}],"status":"ACTIVE"},{"name":"WY-3277","status":"ACTIVE"}],"trade_name":[{"name":"Nafcil","status":"ACTIVE"},{"name":"Nallpen","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"Unipen","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D00928","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"generic_name":[{"name":"Nafcillin","source_info":[{"code":"4CNZ27M7RV","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/7d66b998-0dcc-4613-aa8c-9921e1b776b2"}],"status":"ACTIVE"}],"drugbank_id":["DB00607"],"kegg_id":["D00928"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["eda0951333ad0320cb6033172427868f"],"mechanism_action_id":["96af81a44ae49944712b75894f39682f"],"target_id":["20c015d11407415a83ad7902f6d712a5"],"atc_code":["0b760c4ea41f4cb895f030797d5b745d"],"disease_id":["5c0aa3b2d4854732b862c7c2ae234fdb"],"active_org_master_entity_id":["bbc7a797b22ba36cdd9cd75817000fbe","eda0951333ad0320cb6033172427868f"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["5c0aa3b2d4854732b862c7c2ae234fdb"],"research_disease":["5c0aa3b2d4854732b862c7c2ae234fdb"],"inactive_org_master_entity_id":["d7e0c1d549090b41322198c0deb21305"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":625795200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":820454400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"}],"disease_phase":[{"disease_id":"5c0aa3b2d4854732b862c7c2ae234fdb","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"057c74eed5e04d0dbe0d899e318aa35a","docid":1762739,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-12-17T07:14:08.000Z","updated_ts":"2026-02-14T00:43:35.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ONC-PluReceptor NK Cells(The University of Texas MD Anderson Cancer Center)","source_info":[{"code":"NCT07283679","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07283679"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["9b887e67e08f4f520a3eae177d6ee451"],"disease_id":["06fb65d06e024491946f34384f1bae67","4c9d46b2b7794d128b14d8689f4c357d"],"active_org_master_entity_id":["9b887e67e08f4f520a3eae177d6ee451"],"research_disease":["06fb65d06e024491946f34384f1bae67","4c9d46b2b7794d128b14d8689f4c357d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1780272000000}}],"disease_phase":[{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"06fb65d06e024491946f34384f1bae67","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"081c79fbe96342ac9e53b9c459cf4d0a","docid":77365,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"72968bc010da3537aadae562c20b1081","created_ts":"2021-10-08T14:40:27.000Z","updated_ts":"2026-02-25T03:17:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CB-03-10","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cortexolone 17α-valerate-21-propionate","status":"ACTIVE"}],"dev_code":[{"name":"CB 03 10","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/androgen-receptor-glucocorticoid-receptor-antagonist-cb-03-10"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["abaafedd82f0b856d00ee263fdadb4d9"],"mechanism_action_id":["3aafbb6a6d1ae910afbd6c72c4c6e876","9a4d9c078cd0f7623c29d637aa10edfd"],"target_id":["713ab8cc6d3d41e0bce7ea2c7b0e64e5","6fe53f67a27241fcac53227526791322"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","ae092fa59f4d44edaf59ffe23d0a44c3","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["abaafedd82f0b856d00ee263fdadb4d9","400793319e516a0856f0b66bf695c6b6"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","ae092fa59f4d44edaf59ffe23d0a44c3","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"1d0018e19d2e48548624bd3cd501d9a5","docid":46040,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-06-17T09:30:41.000Z","updated_ts":"2025-02-24T12:03:40.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"maliman","drug_name":[{"lang":"EN","name":"RP-115","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Fluorine-18 labeled RP-115","status":"ACTIVE"}],"dev_code":[{"name":"F-18-RP-115","status":"ACTIVE"},{"name":"RP 115","status":"ACTIVE"},{"name":"[18F]-RP-115","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["a949415c7e94a849bd589463de45dffb"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","c2e755f2cdc34621ac8e4ad193f523b1"],"active_org_master_entity_id":["5a3440fb46fe93ce88c47950896dc1c6"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","c2e755f2cdc34621ac8e4ad193f523b1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c2e755f2cdc34621ac8e4ad193f523b1","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"490835db13d249e58eb53bd86ca01190","docid":12006,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:23.000Z","updated_ts":"2025-04-08T09:24:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ICE3 (Iceni Pharmaceuticals)","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["c600f6759e088561e4be27dc41e92ac3"],"disease_id":["f319fa27684c4cdeb6ce59d897217718"],"active_org_master_entity_id":["c600f6759e088561e4be27dc41e92ac3"],"research_disease":["f319fa27684c4cdeb6ce59d897217718"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1649203200000}}],"disease_phase":[{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"5d01a7602a634306b38cbba747703c3b","docid":226,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":1,"target_extend_id":"38f08924709e3854af6f5474823e4f5b","created_ts":"2021-10-08T14:46:32.000Z","updated_ts":"2026-04-02T03:20:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Ribitol","source_info":[{"attachment_path":"data/phs_source_info/ASGCT/22b0/d251/d471/08e4/ce90c35b-22b0-3251-9471-08e47bdf06a1.pdf","attachment_type":"PDF","code":"2023_1622","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","preview_attachment_path":"data/phs_source_info/ASGCT/22b0/d251/d471/08e4/ce90c35b-22b0-3251-9471-08e47bdf06a1.pdf","source":"ASGCT","source_url":"https://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(23)00248-4.pdf"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(2R,3s,4S)-pentane-1,2,3,4,5-pentol","source_info":[{"code":"DB14704","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Adonitol","source_info":[{"code":"DB14704","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"D-Adonitol","source_info":[{"code":"DB14704","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"D-Ribitol","source_info":[{"code":"DB14704","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"L-ribitol","source_info":[{"code":"DB14704","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"dev_code":[{"name":"BBP-418","status":"ACTIVE"}],"drugbank_id":["DB14704"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3c84b2fbf68f5509d80f022c6eb5dda8"],"mechanism_action_id":["9e94ca5bd9914a9798d65fe8396bef44"],"target_id":["d3ff6e00bacb4e1a8d45757374d39017"],"special_review":["425d71b560a7499087c4f5a36692741c","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["9841fc5ddad94256bb2cc815e1927a39"],"active_org_master_entity_id":["3c84b2fbf68f5509d80f022c6eb5dda8","c6ab7975aba7e4d263b992cc527dac08"],"research_disease":["9841fc5ddad94256bb2cc815e1927a39"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1774828800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}}],"disease_phase":[{"disease_id":"9841fc5ddad94256bb2cc815e1927a39","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["3c84b2fbf68f5509d80f022c6eb5dda8","60f284db62a156c6930f662a70a727c8"],"data_source":10}
+{"drug_id":"0494a835ec3a45269c6858c13977b880","docid":114673,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":12,"target_extend_id":"1947dae4e89531608c7c4bd7d552aae8","created_ts":"2024-08-12T09:29:56.000Z","updated_ts":"2026-01-17T21:11:39.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"RE001(Henan Cancer Hospital)","source_info":[{"code":"NCT06545201","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06545201"}],"status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["b108ea800675fc335499a08ded68d2d0"],"mechanism_action_id":["6eccf86be8344b478402a457c425b57e"],"target_id":["a73b6b29ca214a3abb51387380e5f1cb"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["b108ea800675fc335499a08ded68d2d0"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1722470400000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"2527d9d263c346d4a0091a20f536900b","docid":1642214,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":365,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2025-10-10T02:17:26.000Z","updated_ts":"2026-04-11T21:06:32.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Autologous CD19 CAR-T(Hematology Hospital of Chinese Academy of Medical Sciences)","source_info":[{"code":"NCT06680388","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06680388"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["dba0a7e65b51408ca401deb8364bce94","ef1925515e7b4062a6cfe8c5e1db1b95","51236dbf55d24268aa6d31d9be131f6f","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e","8bcea8336f70405faa8e20524166da68"],"active_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"research_disease":["dba0a7e65b51408ca401deb8364bce94","ef1925515e7b4062a6cfe8c5e1db1b95","51236dbf55d24268aa6d31d9be131f6f","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e","8bcea8336f70405faa8e20524166da68"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","fce2b462d4fa493eb9d82513b9007011","20f1c6915ff140519285386c54883aae","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1731628800000}}],"disease_phase":[{"disease_id":"dba0a7e65b51408ca401deb8364bce94","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"52573fcc151b4d9b9fc29e8ed015efb1","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ef1925515e7b4062a6cfe8c5e1db1b95","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8bcea8336f70405faa8e20524166da68","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"096f6451983b78ba62e0277dc7cb533f","docid":112712,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":248,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2024-05-10T09:06:03.000Z","updated_ts":"2026-04-11T21:09:24.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"CD19t T-antigen presenting cells","status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["f2fa40e032d63cac7235d6e5db7f262b"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["62bca3c4e2794be5a901cf7c004f0d12","2ef210ce6ef84836aa012ae7fb1a3a7f"],"active_org_master_entity_id":["f2fa40e032d63cac7235d6e5db7f262b"],"research_disease":["62bca3c4e2794be5a901cf7c004f0d12","2ef210ce6ef84836aa012ae7fb1a3a7f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1501804800000}}],"disease_phase":[{"disease_id":"2ef210ce6ef84836aa012ae7fb1a3a7f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62bca3c4e2794be5a901cf7c004f0d12","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"02daeb470cf24759a405828592b2c8a2","docid":14523,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Collagenase","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":820454400000,"rnk":2,"target_extend_id":"f538de9398f33a749f5cc5d85bc09ca9","created_ts":"2021-10-08T14:46:50.000Z","updated_ts":"2025-09-24T10:38:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","first_approved_date_cn":820454400000,"drug_name":[{"lang":"CN","name":"胶原酶 (辽宁味邦)","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Collagenase clostridium histolyticum (LiaoNing Weibang)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Collagenase","status":"ACTIVE"},{"lang":"EN","name":"Collagenase clostridium（USAN）","source_info":[{"code":"WW-54","normalized_source_id":"47c8048a73f94d3b9c626eb4f8a6d7e4","source":"USAN","source_url":"https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fcollagenase-clostridium-histolyticum.pdf"}],"status":"ACTIVE"},{"lang":"CN","name":"胶原酶","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"drugbank_id":["DB00048"],"drug_type":["c6f7aa5028654d4d8ac6153f9b53e8a2"],"originator_org_master_entity_id":["aeab518d109f25096e89884fdfaf9672"],"mechanism_action_id":["a9c6ee7eae648c0f4a008eb1b9bcde54"],"target_id":["46dc4b4f069c4df0ab12b14bd8f0b208"],"atc_code":["0f6c973c2c3341b8826e9e766dfbcf9d"],"disease_id":["b400a3f70d6842788e6a5b6901a4ef11","c5a9c2f01d9448f4b611fec2d4f6117e","3ee06b057874408ba4de18a4e7cac7c3"],"active_org_master_entity_id":["aeab518d109f25096e89884fdfaf9672"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["b400a3f70d6842788e6a5b6901a4ef11"],"research_disease":["b400a3f70d6842788e6a5b6901a4ef11","c5a9c2f01d9448f4b611fec2d4f6117e","3ee06b057874408ba4de18a4e7cac7c3"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":820454400000}}],"disease_phase":[{"disease_id":"c5a9c2f01d9448f4b611fec2d4f6117e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b400a3f70d6842788e6a5b6901a4ef11","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3ee06b057874408ba4de18a4e7cac7c3","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"data_source":10}
+{"drug_id":"0eac721bd7f94179929d4f0873077781","docid":72315,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"8666aad5477e4272b56b94ca1183781d","rnk":39,"target_extend_id":"a11d0d44f5ab35da969ce6e43ace48ee","created_ts":"2021-10-08T14:50:36.000Z","updated_ts":"2026-04-18T21:06:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"VXM-01","source_info":[{"attachment_path":"data/phs_source_info/1c4b/15d7/ebac/618b/1c4b15d7ebac618b.png","attachment_type":"image/png","code":"Vaximm-202506","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/708f/c1b3/4abb/a7ba/708fc1b34abba7ba.png","source":"Company pipeline","source_url":"https://vaximm.com/research-development/#PipelineChart"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"VEGFR2 peptide vaccine","status":"ACTIVE"},{"lang":"EN","name":"VEGFR2 peptide vaccine(Merck Serono SA)","status":"ACTIVE"},{"lang":"EN","name":"VEGFR2 specific T cell vaccine","status":"ACTIVE"}],"dev_code":[{"name":"VXM 01","status":"ACTIVE"},{"name":"VXM-01","status":"ACTIVE"}],"drug_type":["55e93be6816d43ea9c9751c190f30efd","6a644a1ca8704901b13a48d3c47b7952"],"originator_org_master_entity_id":["a567517814c52c69e671bcb377aee335"],"mechanism_action_id":["c7014f9be8d97569e126bb97fe00d979"],"target_id":["506cbb4b41184cda887dabf5fafb35db"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4","bfa13cf3c40f41e095e802d02238d33a","e35ce4e9b7a846d49e600ce7ac4a7fd6","e67c7fcd3d3a494ab70e1efe0b82ecdc","fc0780b4f42b41d0a3dbbc522d0724dd"],"active_org_master_entity_id":["a567517814c52c69e671bcb377aee335"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4"],"non_research_disease":["bfa13cf3c40f41e095e802d02238d33a","e35ce4e9b7a846d49e600ce7ac4a7fd6","e67c7fcd3d3a494ab70e1efe0b82ecdc","fc0780b4f42b41d0a3dbbc522d0724dd"],"inactive_org_master_entity_id":["6c5a07a4d05ca49c5ee94192e72193f0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7"},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"e8213325-7b0e-391e-9636-bb602375aa5d","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e67c7fcd3d3a494ab70e1efe0b82ecdc","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_before_ter_cn":"8666aad5477e4272b56b94ca1183781d","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"bfa13cf3c40f41e095e802d02238d33a","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fc0780b4f42b41d0a3dbbc522d0724dd","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["02dec8b991829dc7531a620e9ae00502","2eacc63f5bb9be253e34e698e3c617b2","7dfb6670e650936b50db90377046575f","a567517814c52c69e671bcb377aee335"],"if_speculate":0,"data_source":10}
+{"drug_id":"03b7924c20ac4ccabea70c3a74fb509f","docid":201637,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"568410474a233ae292ffbfd2db1cd452","created_ts":"2024-05-24T06:06:56.000Z","updated_ts":"2025-09-02T00:23:33.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HS-20124","status":"ACTIVE"}],"dev_code":[{"name":"HS-20124","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["743b10cd618393c5f5d99c32b172bb99"],"mechanism_action_id":["6b767c987b3e4823a2c1640b1299e388"],"target_id":["141c6da9d7dd46d9ab20ea8d03b3665b"],"disease_id":["15cb523e0fbd4617a6a129ad2336eb9a","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["946fa8d72705e08da771676fc3640eb6","743b10cd618393c5f5d99c32b172bb99"],"research_disease":["15cb523e0fbd4617a6a129ad2336eb9a","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1730246400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1729123200000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"568410474a233ae292ffbfd2db1cd452","moiety_mechanism_action_id":["6b767c987b3e4823a2c1640b1299e388"],"moiety_target_id":["141c6da9d7dd46d9ab20ea8d03b3665b"]}
+{"drug_id":"06108dbbbbdb44c583a4cef837be6365","docid":61052,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","has_leading_org_involved":1,"created_ts":"2021-10-08T14:46:42.000Z","updated_ts":"2025-11-11T05:10:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ATP-128","status":"ACTIVE"}],"dev_code":[{"name":"ATP 128","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/therapeutic-cancer-vaccine-atp128"}],"status":"ACTIVE"},{"name":"ATP128","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/therapeutic-cancer-vaccine-atp128"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","e1aca0be003744f0afbfb1a90c7bc8ac"],"originator_org_master_entity_id":["bde5e694ee4af251774175e883ac2776"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["5dc15a3bfff7405197a9e12963b07d1f","e35ce4e9b7a846d49e600ce7ac4a7fd6","1714ace3a2f941d8921c9dbc77a8ba1d"],"active_org_master_entity_id":["bde5e694ee4af251774175e883ac2776"],"research_disease":["5dc15a3bfff7405197a9e12963b07d1f","e35ce4e9b7a846d49e600ce7ac4a7fd6","1714ace3a2f941d8921c9dbc77a8ba1d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1563753600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1563753600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1563753600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1563753600000}}],"disease_phase":[{"disease_id":"1714ace3a2f941d8921c9dbc77a8ba1d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"5dc15a3bfff7405197a9e12963b07d1f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["cba83887463f7d8f8a1eec75c16e2c5d","bde5e694ee4af251774175e883ac2776"],"data_source":10}
+{"drug_id":"081d37ee4777477182b2304411deacfe","docid":66926,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":228,"target_extend_id":"c2ae5bf143df357dbed72cf460d1cc2e","created_ts":"2021-10-08T14:42:52.000Z","updated_ts":"2026-04-04T21:06:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CNX-2006","source_info":[{"code":"2013_2101A","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/73/8_Supplement/2101A/587699/Abstract-2101A-CNX-2006-a-novel-irreversible"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8eca2b1e039c19dfb9a0bf168b2f667c"],"mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4"],"target_id":["c18d6f96c23b4d1e880daafa1b00472b"],"disease_id":["7532c5e08c9d481ba9a25f3fbbb912bb"],"active_org_master_entity_id":["9c7a0f5f97eee9ae3cbd0fd1b9ab120e","8d15e128009d09f0bddb58890dc83739","8e9c8761f219206bdab6fb986adee6f0"],"research_disease":["7532c5e08c9d481ba9a25f3fbbb912bb"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1365984000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1365984000000}}],"disease_phase":[{"disease_id":"7532c5e08c9d481ba9a25f3fbbb912bb","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0874610765f541da9922c823db520e4c","docid":470122,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"289179a8d934337f96052b6db7e362d6","created_ts":"2024-10-25T05:54:37.000Z","updated_ts":"2026-03-28T03:10:21.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"CGT-6297","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/6544718"}],"status":"ACTIVE"}],"dev_code":[{"name":"CGT6297","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/6544718"},{"code":"2025_3004","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/5342"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7c63226fdfdc23259b4f1c24b29e3906"],"mechanism_action_id":["93d7412cdd2f4a729134994f0ec02bde"],"target_id":["6f155e1b63854d0e9dea707327f91aa7"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","87a9454771a64f2191224b6b7684254a","a8582981cb8d4184a13cdf6ae05ae380","6f7797132868456290dac6532b7aefa6","9fb98f774af94201abe6fed33eb3002a","4035a94ea2d240d7a52aa75633974381"],"active_org_master_entity_id":["7c63226fdfdc23259b4f1c24b29e3906"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","87a9454771a64f2191224b6b7684254a","a8582981cb8d4184a13cdf6ae05ae380","6f7797132868456290dac6532b7aefa6","9fb98f774af94201abe6fed33eb3002a","4035a94ea2d240d7a52aa75633974381"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1769904000000}}],"disease_phase":[{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a8582981cb8d4184a13cdf6ae05ae380","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4035a94ea2d240d7a52aa75633974381","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"9fb98f774af94201abe6fed33eb3002a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6f7797132868456290dac6532b7aefa6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"143fa29b4d9248788801c8de8455ad7a","docid":23261,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"204042d041de3db49cdfd468e13b0e15","created_ts":"2021-10-08T14:46:17.000Z","updated_ts":"2025-11-11T07:42:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"AXO-AAV-OPMD","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AXO AAV OPMD","status":"ACTIVE"},{"lang":"EN","name":"Pabparna","status":"ACTIVE"}],"dev_code":[{"name":"BB-301","status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["3a7979123c57009ac7124e6a10359ec5"],"mechanism_action_id":["36196a5dad584399aef7048009490c0b","e77dece162a0133e50d5b2357c40719f"],"target_id":["ac65458c6799417394d70e5921672812"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["ce9060b309894c658f184ffd1583be26"],"active_org_master_entity_id":["3a7979123c57009ac7124e6a10359ec5"],"research_disease":["ce9060b309894c658f184ffd1583be26"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701129600000}}],"disease_phase":[{"disease_id":"ce9060b309894c658f184ffd1583be26","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["1172e17bae4eb2cac8d06e7b2ff007c1","738ac47f9b5d28376dffd94c43662f0c"],"data_source":10,"tech_platform":["d9aef8b6eb084236b1d121caef380607"],"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://benitec.com/our-science/gene-silencing/"}],"delivery_system":["6b3769de1b454ab78499d5f6e97577a9"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"43ff9a6bb599485b85c0925cb46a3605","docid":62232,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":3,"target_extend_id":"f92880722754344eb2b03b59a13ddcde","created_ts":"2021-11-30T08:58:30.000Z","updated_ts":"2026-02-24T21:39:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"CS-6253","source_info":[{"code":"26207756","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/26207756"}],"status":"ACTIVE"}],"dev_code":[{"name":"CS 6253","source_info":[{"code":"26207756","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/26207756/"}],"status":"ACTIVE"},{"name":"CS6253","source_info":[{"code":"26207756","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/26207756/"}],"status":"ACTIVE"}],"trade_name":[{"name":"Cogpep","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["1fec7a8f9261d1079a075d2f1dadc476"],"mechanism_action_id":["3787d00544ec3da15a9803349980552e"],"target_id":["7a805684da4743778b32b11224c7e2cc"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","b11d1922c4744b7fa4440edba7f01bdf","74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["9b23e7ec662854af744c1675c1cac10a","52dd9ddb9ceb2dc900a07588b44adc15","f1e46cfc21494238668ecc019e45b8cf","1fec7a8f9261d1079a075d2f1dadc476"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","b11d1922c4744b7fa4440edba7f01bdf","74d974da49ba407195b38595a0aff704"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1698019200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"b11d1922c4744b7fa4440edba7f01bdf","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"02b1fc73b9cc41958134eac0b9ba03b9","docid":41904,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Potassium_citrate","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":494208000000,"created_ts":"2021-10-08T14:50:41.000Z","updated_ts":"2025-05-15T19:09:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":757382400000,"drug_name":[{"lang":"CN","name":"枸橼酸钾","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Potassium Citrate","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"K-Citra","source_info":[{"attachment_path":"data/phs_source_info/a1d9/6132/3462/ce16/48a9f536-56aa-356a-b345-0285e81d0744.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/c53e/2027/d529/668a/5d984f9b-6401-3159-90c0-4b6a48217c93.png","source":"Company pipeline","source_url":"https://lacunapharma.com/products/"}],"status":"ACTIVE"},{"lang":"EN","name":"Potassium Citrate Granules","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Potassium citrate anhydrous","source_info":[{"code":"DB09125","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Tripotassium citrate","source_info":[{"code":"DB09125","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"CN","name":"枸缘酸钾","status":"ACTIVE"}],"dev_code":[{"name":"E-332","status":"ACTIVE"}],"trade_name":[{"name":"K-Citra 10","source_info":[{"normalized_source_id":"d960dac41dfe49609b6b380987cae0d9","source":"TGA","source_url":"https://www.tga.gov.au/resources/artg/405527"}],"status":"ACTIVE"},{"name":"UROCIT-K","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"可维加","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Citric acid","source_info":[{"code":"GQH5A01T0W","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/c3aed2f2-385b-4ef6-a748-e551bb8b880e"}],"status":"ACTIVE"}],"drugbank_id":["DB09125"],"kegg_id":["D05578"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["1edb5ee4a452d6a6d9beaa6f1db91b2e"],"atc_code":["16e9ead8c6ac4ac2b8ca97a0acc0248a"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["f4764fb89a41426d80490d4255dc9039","3ded9aca2b714573a990eb9428aabd37","dcb5f4e9e183449f9d3dee5439d5403d","9ee5c6eccf204b0dacbda17218a212e2","b3fbcd71f916470d88c3c590793fe4f3"],"active_org_master_entity_id":["1edb5ee4a452d6a6d9beaa6f1db91b2e","6d01faf3ca59a0a1d341074038dadf85","451eb1cfca5ba95655a6783a753b7333"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["3ded9aca2b714573a990eb9428aabd37","dcb5f4e9e183449f9d3dee5439d5403d","9ee5c6eccf204b0dacbda17218a212e2"],"research_disease":["f4764fb89a41426d80490d4255dc9039","3ded9aca2b714573a990eb9428aabd37","dcb5f4e9e183449f9d3dee5439d5403d","9ee5c6eccf204b0dacbda17218a212e2","b3fbcd71f916470d88c3c590793fe4f3"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","ecc919b1-c2b7-3740-bfa7-7cda77176d07"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":494208000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":757382400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"9ee5c6eccf204b0dacbda17218a212e2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3ded9aca2b714573a990eb9428aabd37","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f4764fb89a41426d80490d4255dc9039","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b3fbcd71f916470d88c3c590793fe4f3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"dcb5f4e9e183449f9d3dee5439d5403d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"021c32f967db4d2ebfee81e1a9bb0965","docid":36937,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-04-28T12:55:35.000Z","updated_ts":"2025-05-07T11:34:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CD45RA depleted leukocytes(University of Pittsburgh)","status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["cbb4723f06bdfd28421177008078de55"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["3ab477dc108548a0a2b692fb304d5bb0","d5f09690c5fc4a1d9943fda459e8be26","42e70d35b3054821a8a726271abda051","5b69fd3140ad47bd9848f20f1787f7ed"],"active_org_master_entity_id":["cbb4723f06bdfd28421177008078de55"],"research_disease":["3ab477dc108548a0a2b692fb304d5bb0","d5f09690c5fc4a1d9943fda459e8be26","42e70d35b3054821a8a726271abda051","5b69fd3140ad47bd9848f20f1787f7ed"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1533168000000}}],"disease_phase":[{"disease_id":"42e70d35b3054821a8a726271abda051","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d5f09690c5fc4a1d9943fda459e8be26","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3ab477dc108548a0a2b692fb304d5bb0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"5b69fd3140ad47bd9848f20f1787f7ed","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"052657feef08453bb89669ff906e48df","docid":82098,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2023-11-20T08:37:10.000Z","updated_ts":"2026-02-24T16:22:57.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Fluorothiazinone","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["c1ea86b689a399a2d656d593a0b2ebea"],"disease_id":["a8d44ba9703e4808bcb1f01611bba864","d0e5ac689c6b4686aa7b97eb3d860a97","3188e0a3528c403d870500f8870081c0","8cc17f1bc04746db91dadfcd74f379aa","c75e9b907df74c03b98220a794b61b9d","5d50ac043c0441e1a7cbbc7d3efcf418","d07357cbeacd4ae388ddcb7d8af1036e","fc39368e3de54e2ab5c2d567074a6a4b"],"active_org_master_entity_id":["c1ea86b689a399a2d656d593a0b2ebea"],"research_disease":["a8d44ba9703e4808bcb1f01611bba864","d0e5ac689c6b4686aa7b97eb3d860a97","3188e0a3528c403d870500f8870081c0","8cc17f1bc04746db91dadfcd74f379aa","c75e9b907df74c03b98220a794b61b9d","5d50ac043c0441e1a7cbbc7d3efcf418","d07357cbeacd4ae388ddcb7d8af1036e","fc39368e3de54e2ab5c2d567074a6a4b"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1699228800000}}],"disease_phase":[{"disease_id":"c75e9b907df74c03b98220a794b61b9d","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a8d44ba9703e4808bcb1f01611bba864","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"fc39368e3de54e2ab5c2d567074a6a4b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5d50ac043c0441e1a7cbbc7d3efcf418","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3188e0a3528c403d870500f8870081c0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"8cc17f1bc04746db91dadfcd74f379aa","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"d07357cbeacd4ae388ddcb7d8af1036e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d0e5ac689c6b4686aa7b97eb3d860a97","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0576b5dff318416cadab99e0417328aa","docid":38499,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"9692dee240223ce68bcc127c03e040af","has_leading_org_involved":1,"created_ts":"2021-10-08T14:46:09.000Z","updated_ts":"2026-04-08T22:52:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"利替非利单抗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=Mzg2NzUyODkzMw==&mid=2247610551&idx=2&sn=c0813b13430eceef5cb58efa985e1072"}],"status":"ACTIVE"},{"lang":"EN","name":"Litifilimab","source_info":[{"code":"proposed 126","normalized_source_id":"eb78363bdddc460da5535c860c7a1811","source":"INN"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"利替非单抗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUyNTgyNjUzMw==&mid=2247891251&idx=5&sn=d661016456910ebc274946b23bc1c267"}],"status":"ACTIVE"}],"dev_code":[{"name":"BIIB 059","status":"ACTIVE"},{"name":"BIIB-059","status":"ACTIVE"},{"name":"BIIB059","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["6eff248679b18ba8153422b44298c49b"],"mechanism_action_id":["d8a42cc87b6b4f91b14431dc735ec18c"],"target_id":["79f877da859a403b91de90f249dc481d"],"special_review":["c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["310dc3b138284382bfbb6ffc7eceaf41","c5e1987e283c495aaab2a8d309c6085e","2e56f872bd7d4bf88c992d4812264883"],"active_org_master_entity_id":["6eff248679b18ba8153422b44298c49b","40bd16cdec33bb0b01bda568a32ffd79","c58d387f87e94df48517f01cce425862"],"research_disease":["310dc3b138284382bfbb6ffc7eceaf41","c5e1987e283c495aaab2a8d309c6085e"],"non_research_disease":["2e56f872bd7d4bf88c992d4812264883"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"a8dbb56e-1021-3ca2-8720-a5c1ca5a6aab","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"a8dbb56e-1021-3ca2-8720-a5c1ca5a6aab","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696291200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621900800000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1637107200000}}],"disease_phase":[{"disease_id":"310dc3b138284382bfbb6ffc7eceaf41","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2e56f872bd7d4bf88c992d4812264883","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["630a7bdc55eda246524b56b74039e06e","6eff248679b18ba8153422b44298c49b"],"if_speculate":0,"data_source":10}
+{"drug_id":"2c2b3273a2c24941a140b25cfb340c37","docid":114871,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"188c0617a96c38fa8ad04110a56b9e14","created_ts":"2024-08-23T07:32:20.000Z","updated_ts":"2024-12-27T00:24:31.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"nL-FLVC-001","source_info":[{"code":"NCT06565572","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06565572"}],"status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["513d794e8b86a640251ec9f09141e847"],"mechanism_action_id":["3892516505af4b678737d38d69facc48"],"target_id":["ff4f24db42c84f0bb204796fc2b642b1"],"disease_id":["ecea6fdf56f54436a8217e2de7744f8e"],"active_org_master_entity_id":["513d794e8b86a640251ec9f09141e847"],"research_disease":["ecea6fdf56f54436a8217e2de7744f8e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1692748800000}}],"disease_phase":[{"disease_id":"ecea6fdf56f54436a8217e2de7744f8e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"03bd373faff54f5f8f0dd5eecc539057","docid":261036,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-05-14T08:59:01.000Z","updated_ts":"2025-12-16T03:06:09.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"ALY-601","source_info":[{"attachment_path":"data/phs_source_info/a925/1e51/76be/fc00/6fe2ea4e-efa7-3936-8525-5cdbbbd7306b.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7bf/1689/08c0/27dc/47a0a00f-c6e6-3f32-b6be-3727d685c077.jpeg","source":"Company pipeline","source_url":"https://alyspharma.com/pipeline/#top"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Vitiligo(Alys)","source_info":[{"attachment_path":"data/phs_source_info/a925/1e51/76be/fc00/6fe2ea4e-efa7-3936-8525-5cdbbbd7306b.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7bf/1689/08c0/27dc/47a0a00f-c6e6-3f32-b6be-3727d685c077.jpeg","source":"Company pipeline","source_url":"https://alyspharma.com/pipeline/#top"}],"status":"ACTIVE"}],"dev_code":[{"name":"ALY 601","source_info":[{"attachment_path":"data/phs_source_info/a925/1e51/76be/fc00/6fe2ea4e-efa7-3936-8525-5cdbbbd7306b.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7bf/1689/08c0/27dc/47a0a00f-c6e6-3f32-b6be-3727d685c077.jpeg","source":"Company pipeline","source_url":"https://alyspharma.com/pipeline/#top"}],"status":"ACTIVE"},{"name":"ALY601","source_info":[{"attachment_path":"data/phs_source_info/a925/1e51/76be/fc00/6fe2ea4e-efa7-3936-8525-5cdbbbd7306b.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7bf/1689/08c0/27dc/47a0a00f-c6e6-3f32-b6be-3727d685c077.jpeg","source":"Company pipeline","source_url":"https://alyspharma.com/pipeline/#top"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["de2c9835de0d9e7102e55adfa17b3b4f"],"disease_id":["a995ea676cb44956a51af415a8bd2b14"],"active_org_master_entity_id":["de2c9835de0d9e7102e55adfa17b3b4f"],"research_disease":["a995ea676cb44956a51af415a8bd2b14"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"a995ea676cb44956a51af415a8bd2b14","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0b601f5963da4559bf58fc56c4fda720","docid":53567,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"bb65b6ab80f93e0ab769b00357835dbd","created_ts":"2023-03-29T08:29:10.000Z","updated_ts":"2026-03-11T00:45:35.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TU-2218","source_info":[{"code":"NCT05784688","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05784688"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Tosposertib","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.vbdata.cn/intelDetail/843047"},{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"https://www.prnewswire.com/news-releases/tiumbio-to-present-first-clinical-data-for-dual-tgf-vegf-inhibitor-tosposertib-tu2218-at-sitc-2025-robust-response-rate-302609990.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"TU 2218","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tgfbeta-inhibitor-tu2218"}],"status":"ACTIVE"},{"name":"TU2218","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tgfbeta-inhibitor-tu2218"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3a34570e469ec5a25f5e6b9920d749bf"],"mechanism_action_id":["0494262fbc7dfbd5f363b2d2c1ef93fc","467f02cff5553cb2736e3629597d8f27","c7014f9be8d97569e126bb97fe00d979"],"target_id":["506cbb4b41184cda887dabf5fafb35db","79793f656936406e933a08790dc6b343","9acee810ccd14fbda00d73f903bc70b1"],"disease_id":["0b6fc9357c10436293f430d95423c7ea","7665e5683a1a443a8f3d3b946d4c9ca2","6fe05469e09f4305b7615b2c277382cd","03bd23316cb54eecbbc4f53311087042","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["3a34570e469ec5a25f5e6b9920d749bf"],"research_disease":["0b6fc9357c10436293f430d95423c7ea","7665e5683a1a443a8f3d3b946d4c9ca2","6fe05469e09f4305b7615b2c277382cd","03bd23316cb54eecbbc4f53311087042","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1728000000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1728000000000}}],"disease_phase":[{"disease_id":"03bd23316cb54eecbbc4f53311087042","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0b6fc9357c10436293f430d95423c7ea","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"03aa0b392a6542d6bde1e1876bddcaae","docid":6915,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":21,"target_extend_id":"cabc5d29db0d3aa0b6c0b85f913e4eb6","created_ts":"2021-10-08T14:42:52.000Z","updated_ts":"2026-04-04T21:07:53.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"异甜菊醇","status":"ACTIVE"},{"lang":"EN","name":"Isosteviol","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ISV","status":"ACTIVE"}],"dev_code":[{"name":"STX-03","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["41593e59be8f787334ce5695f3949ca9"],"mechanism_action_id":["541959c9dead78ad1e01ff77cfc56766"],"target_id":["e9c1a8e4304044ef944d94e3118c266d"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["41d74078b4937b449f97a67109d769d5"],"research_disease":["74d974da49ba407195b38595a0aff704"],"inactive_org_master_entity_id":["41593e59be8f787334ce5695f3949ca9"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0165471fe4274b15aae6405f6bb04c51","docid":37085,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":12,"target_extend_id":"cc7f969adf953f0da10a3b622a7c113f","created_ts":"2021-10-08T14:47:37.000Z","updated_ts":"2026-04-04T21:06:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Necuparanib Sodium","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"M-402 free acid","source_info":[{"code":"DB16251","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Necuparanib","status":"ACTIVE"},{"lang":"EN","name":"Necuparanib sodium (USAN)","source_info":[{"code":"D11765","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"M-402","status":"ACTIVE"},{"name":"M-ONC 402","status":"ACTIVE"},{"name":"M-ONC-402","status":"ACTIVE"},{"name":"M402 heparan sulfate","status":"ACTIVE"},{"name":"MOM-M402-103","status":"ACTIVE"},{"name":"MONC-402","status":"ACTIVE"}],"drugbank_id":["DB16251"],"kegg_id":["D11765"],"drug_type":["1fe8fa7ef6724eb990397a56efe94d7b"],"originator_org_master_entity_id":["c25a08132331ac7d30b7f2640cb30e83"],"mechanism_action_id":["cd2862a3ee8d46dc9f81d9f3bec4d2d5","0e6dd837ac200d6d4b69e55395b22762"],"target_id":["6c8135910c2e4223aa54b790b9f8a7fc"],"disease_id":["78cb173a4de34f07befac28de907e7bf","e67c7fcd3d3a494ab70e1efe0b82ecdc"],"active_org_master_entity_id":["c25a08132331ac7d30b7f2640cb30e83"],"research_disease":["78cb173a4de34f07befac28de907e7bf"],"non_research_disease":["e67c7fcd3d3a494ab70e1efe0b82ecdc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1535500800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1535500800000}}],"disease_phase":[{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e67c7fcd3d3a494ab70e1efe0b82ecdc","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"07481c177e4246dfba88c5d6ac183da4","docid":82236,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"8b0403a66bcd358797187c0e244ed16b","created_ts":"2023-11-24T10:41:40.000Z","updated_ts":"2025-05-24T00:19:47.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"非奈利酮/恩格列净/氯沙坦钾","status":"ACTIVE"},{"lang":"EN","name":"Finerenone/Empagliflozin/Losartan Potassium","status":"ACTIVE"}],"related_component":["3c0e6640d94144b483cab713c9a9afd7","9ace184129024a3fad9a925e4b60fc67","adedc00314514d818b40fee5f95cb046"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["154f94cb5845ba16681bee73cd4b336f"],"mechanism_action_id":["a56208e0f7c40aa5e367dd1131768136","a9c0b013607f76ee7c55075edaac991b","b33a5535c71348d2824dea81333c6197"],"target_id":["6d5027eeb15440ed9b14919e51dad4bd","1b7a123e0848463e95066446483e09d6","a995e993b483437ab03a1b4f5da488a8"],"disease_id":["6bd0e3b161844f3197bfe9f2596dce89","74d974da49ba407195b38595a0aff704","c8e43d2b48ec49dba16418bc190a3eec","281fcf1b07ee4c13b0297e4ad1a9c106"],"active_org_master_entity_id":["154f94cb5845ba16681bee73cd4b336f"],"research_disease":["6bd0e3b161844f3197bfe9f2596dce89","74d974da49ba407195b38595a0aff704","c8e43d2b48ec49dba16418bc190a3eec","281fcf1b07ee4c13b0297e4ad1a9c106"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1710115200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6bd0e3b161844f3197bfe9f2596dce89","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"191146481ab94006ab7183d38e749645","docid":69803,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":7,"target_extend_id":"0e8c070b1927365bab8db36962be902a","created_ts":"2022-09-27T12:39:49.000Z","updated_ts":"2026-03-14T21:08:56.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"TI-168","status":"ACTIVE"}],"dev_code":[{"name":"TI 168","status":"ACTIVE"},{"name":"TI168","status":"ACTIVE"}],"drug_type":["b72760cce8f7461193c7b3362f9a2e3a"],"originator_org_master_entity_id":["f7c8e76c1f79c720d0b277bc17f2c6a9"],"mechanism_action_id":["6ae143ef22e98d53d86bb30af0196035"],"target_id":["a5ce1e0cfc1b48ac8bcff32762c3c446"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["07d4cf59dafc4a35840dbf53e136394a"],"active_org_master_entity_id":["f7c8e76c1f79c720d0b277bc17f2c6a9"],"research_disease":["07d4cf59dafc4a35840dbf53e136394a"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1644451200000}}],"disease_phase":[{"disease_id":"07d4cf59dafc4a35840dbf53e136394a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"039cad6696984af99caa512883d55b81","docid":15494,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":12,"target_extend_id":"1a054e6699b4367f8131a42e1e5d72fe","created_ts":"2021-10-08T14:48:58.000Z","updated_ts":"2025-11-08T21:12:07.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"托珠单抗生物类似药 (Aryogen)","status":"ACTIVE"},{"lang":"EN","name":"Tocilizumab biosimilar (Aryogen)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"TEMZIVA","status":"ACTIVE"},{"lang":"EN","name":"Tocilizumab biosimilar","status":"ACTIVE"}],"generic_name":[{"name":"Tocilizumab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["1bfa7196a20037ccbe62990bd1751aef"],"mechanism_action_id":["b30a0bdb2e0bd9c03a908a84588c4217"],"target_id":["8556307199154d34b1f9bc9685f2ec47"],"atc_code":["677f15ff98f54c5a9dbeeb9217830b53"],"disease_id":["6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["1bfa7196a20037ccbe62990bd1751aef"],"research_disease":["6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["15e9b335b94146f68051d261972d79a8"],"data_source":10}
+{"drug_id":"41612836d3f24d508798c7f9cd42ec4a","docid":1373280,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-05-07T10:08:25.000Z","updated_ts":"2025-05-07T10:10:15.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"EA0010","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://app.academiclabs.com/profile/3tzMMPPBi1FI?fullName=Ying%20Chen&clinical_trial=wH5XutiCh1U7&hr=the-safety-tolerability-and-efficacy-of-ea0010-in-the-treatment-of-otof-deficiency-hearing-loss"},{"code":"ChiCTR2400091517","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2400091517"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["59467db2d001adec6a0e514cf1b6940c"],"disease_id":["b24bd01bfd10404b99cad748d4e5e515"],"active_org_master_entity_id":["59467db2d001adec6a0e514cf1b6940c"],"research_disease":["b24bd01bfd10404b99cad748d4e5e515"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1730246400000}}],"disease_phase":[{"disease_id":"b24bd01bfd10404b99cad748d4e5e515","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0815218a4dae462dacb7482e5376f9da","docid":61200,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"47e6789c397f3cefa6025c61900f7dfc","created_ts":"2021-10-08T14:37:37.000Z","updated_ts":"2025-08-02T21:08:59.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AAV1-gamma-sarcoglycan vector(Viromed, Inc.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AAV1-gamma-sarcoglycan gene therapy - Genethon","status":"ACTIVE"},{"lang":"EN","name":"AAV1-gamma-sarcoglycan vector injection - Genethon","status":"ACTIVE"},{"lang":"EN","name":"Adeno-associated viral 1 vector-mediated gamma-sarcoglycan gene therapy","status":"ACTIVE"},{"lang":"EN","name":"Adeno-associated viral vector containing the human gamma-sarcoglycan gene","status":"ACTIVE"}],"dev_code":[{"name":"AAV1-GSG","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["26c5d90fc831d6e57b771c45a25766f9"],"mechanism_action_id":["33ca4e2f31d268144265babce1078e90"],"target_id":["eebc3b451f9d4458928f3cdd45e5d171"],"disease_id":["1fc673dc3608445ca028bbb2fa15d8f7","b8d5ee5db5b8448783ab0d23b1f41468"],"active_org_master_entity_id":["26c5d90fc831d6e57b771c45a25766f9"],"research_disease":["1fc673dc3608445ca028bbb2fa15d8f7"],"non_research_disease":["b8d5ee5db5b8448783ab0d23b1f41468"],"inactive_org_master_entity_id":["8618dfafa8e0e434f4dcb9a9cb4d258b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1338422400000}}],"disease_phase":[{"disease_id":"1fc673dc3608445ca028bbb2fa15d8f7","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b8d5ee5db5b8448783ab0d23b1f41468","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"0b0469f02502458da9d80867f12a2cf0","docid":36796,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1756080000000,"rnk":1,"target_extend_id":"4c22b1ac30db397dbc719b5a9b648c57","created_ts":"2021-10-08T14:47:17.000Z","updated_ts":"2026-03-18T23:08:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"多罗库比利","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.vbdata.cn/intelDetail/905725"}],"status":"ACTIVE"},{"lang":"EN","name":"Stem cell therapeutics (ExCellThera)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Dorocubicel","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://excellthera.com/news/excellthera-announces-emas-acceptance-under-accelerated-assessment-of-market-authorisation-application-maa-for-um171-cell-therapy-for-patients-with-hematological-malignancies-who-lack-a-rea/"}],"status":"ACTIVE"},{"lang":"EN","name":"ECT-001 cell therapy","status":"ACTIVE"},{"lang":"EN","name":"Stem cell therapeutics","status":"ACTIVE"},{"lang":"EN","name":"UM171-Expanded Cord Blood Transplantation","status":"ACTIVE"},{"lang":"CN","name":"UM171细胞疗法","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://medfind.link/info/22650#:~:text=Zemcelpro%EF%BC%88UM171%E7%BB%86%E8%83%9E%E7%96%97%E6%B3%95%EF%BC%89%E6%98%AF%E4%B8%80%E7%A7%8D%E5%88%9B%E6%96%B0%E7%9A%84%E5%86%B7%E5%86%BB%E4%BF%9D%E5%AD%98%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E4%BA%A7%E5%93%81%EF%BC%8C%E7%94%B1UM171%E6%89%A9%E5%A2%9E%E7%9A%84CD34%E9%98%B3%E6%80%A7%E7%BB%86%E8%83%9E%EF%BC%88dorocubicel%EF%BC%89%E5%92%8C%E6%9C%AA%E6%89%A9%E5%A2%9E%E7%9A%84CD34%E9%98%B4%E6%80%A7%E7%BB%86%E8%83%9E%E7%BB%84%E6%88%90%EF%BC%8C%E4%B8%A4%E8%80%85%E5%9D%87%E6%9D%A5%E6%BA%90%E4%BA%8E%E5%90%8C%E4%B8%80%E4%BB%BD%E8%84%90%E5%B8%A6%E8%A1%80%E3%80%82,%E5%A6%82%E6%9E%9C%E8%8E%B7%E5%BE%97%E6%AC%A7%E7%9B%9F%E5%A7%94%E5%91%98%E4%BC%9A%E7%9A%84%E6%9C%80%E7%BB%88%E6%89%B9%E5%87%86%EF%BC%8CZemcelpro%E5%B0%86%E6%88%90%E4%B8%BA%E6%AC%A7%E7%9B%9F%E9%A6%96%E4%B8%AA%E4%B8%94%E5%94%AF%E4%B8%80%E8%8E%B7%E6%89%B9%E7%94%A8%E4%BA%8E%E6%AD%A4%E7%B1%BB%E6%82%A3%E8%80%85%E7%BE%A4%E4%BD%93%E7%9A%84%E7%96%97%E6%B3%95%EF%BC%8C%E5%A1%AB%E8%A1%A5%E4%BA%86%E9%95%BF%E6%9C%9F%E5%AD%98%E5%9C%A8%E7%9A%84%20%E6%9C%AA%E6%BB%A1%E8%B6%B3%E5%8C%BB%E7%96%97%E9%9C%80%E6%B1%82%E3%80%82"}],"status":"ACTIVE"}],"dev_code":[{"name":"ECT 001","status":"ACTIVE"},{"name":"ECT 002","status":"ACTIVE"},{"name":"ECT 003","status":"ACTIVE"},{"name":"ECT 005","status":"ACTIVE"},{"name":"ECT-001-CB","status":"ACTIVE"},{"name":"ECT-002","status":"ACTIVE"},{"name":"ECT-003","status":"ACTIVE"},{"name":"ECT-005","status":"ACTIVE"},{"name":"ECT-100","status":"ACTIVE"},{"name":"UM 171","status":"ACTIVE"},{"name":"UM171 + UM092","status":"ACTIVE"},{"name":"UM171 + UM390","status":"ACTIVE"},{"name":"UM171-Expanded CB","status":"ACTIVE"}],"trade_name":[{"name":"Zemcelpro","source_info":[{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"https://www.prnewswire.com/news-releases/zemcelpro-um171-cell-therapy-receives-positive-chmp-opinion-for-treatment-of-blood-cancer-patients-without-access-to-suitable-donor-cells-302486395.html"}],"status":"ACTIVE"}],"drug_type":["cceb301a25ec4f3cbc1aff3ae1169416"],"originator_org_master_entity_id":["3f24314b664254903383dd403e56a2f3"],"mechanism_action_id":["a2048a13be8ab4f974c8a7a980477252","4624f368908ce756d43781c506659b01"],"target_id":["d7089f9709424d7da4dd677b86151c5a"],"special_review":["ed88b5b02898448483d0dd3ce010cfba","6501abeba2b6400ca8c822d8b2bff598","b7d7a459842543b7913979bf604084e4","f5c599472af046a5b482ffb1ea1a9d3c","043a131d85994801b3617e822e7f87b3","00f78c24c3644ef790d03e522ee1ea4c"],"disease_id":["131c3f4dfc0c4a958e9f91166e73c913","62bca3c4e2794be5a901cf7c004f0d12","1a95630392584c7892bec2dc9888cbfc","42487eb0fc9b4a488cf6e57bda7433dd","1a2e903f6dab4bc9b4410b14e342ae5d","7cd0fcf1c5c243b9b3944405ec4855b5","d6d30dfb1c604b55a56b0f79fa245d23","3ab477dc108548a0a2b692fb304d5bb0","4b7fa328f7b144c69cdf0c4ed38ee527","ae1104e7f11d4b7ca4a48e00672b82b6","cd524b773fc6463a9a080ec578bf9c0d"],"active_org_master_entity_id":["3f24314b664254903383dd403e56a2f3","c25ede116e11f0927d7965cde2b0fa16"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["131c3f4dfc0c4a958e9f91166e73c913"],"research_disease":["131c3f4dfc0c4a958e9f91166e73c913","62bca3c4e2794be5a901cf7c004f0d12","1a95630392584c7892bec2dc9888cbfc","42487eb0fc9b4a488cf6e57bda7433dd","1a2e903f6dab4bc9b4410b14e342ae5d","7cd0fcf1c5c243b9b3944405ec4855b5","d6d30dfb1c604b55a56b0f79fa245d23"],"non_research_disease":["3ab477dc108548a0a2b692fb304d5bb0","4b7fa328f7b144c69cdf0c4ed38ee527","ae1104e7f11d4b7ca4a48e00672b82b6","cd524b773fc6463a9a080ec578bf9c0d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","76732dd51f2842799e6843eef80820ea","67034410be134e2bbb5b0930595b5e75"],"approval_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1756080000000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1756080000000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1756080000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1756080000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1605225600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1554076800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1605225600000}}],"disease_phase":[{"disease_id":"1a2e903f6dab4bc9b4410b14e342ae5d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"cd524b773fc6463a9a080ec578bf9c0d","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d6d30dfb1c604b55a56b0f79fa245d23","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3ab477dc108548a0a2b692fb304d5bb0","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"42487eb0fc9b4a488cf6e57bda7433dd","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"62bca3c4e2794be5a901cf7c004f0d12","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4b7fa328f7b144c69cdf0c4ed38ee527","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"ae1104e7f11d4b7ca4a48e00672b82b6","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["3f24314b664254903383dd403e56a2f3","9f87642aa1a2cb1c639885b6cee29c32"],"if_speculate":0,"data_source":10}
+{"drug_id":"37178139184945d6b85794f7db1fb35a","docid":1673999,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-13T06:14:38.000Z","updated_ts":"2026-04-18T01:18:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"68Ga-FC516","source_info":[{"code":"NCT07468708","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07468708"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["1e87b04fa01f1b2f6b7d48e241247755"],"disease_id":["e50aad3dea474cf487e53bd91d5d7c45"],"active_org_master_entity_id":["1e87b04fa01f1b2f6b7d48e241247755"],"research_disease":["e50aad3dea474cf487e53bd91d5d7c45"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1773014400000}}],"disease_phase":[{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"008470b12c5e4ed0a0217be2b23de2e3","docid":36446,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"e38051deb85a4212a27ed27924e34449","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"f835774c48404593b64ef05369eb8eba","first_approved_date":970531200000,"has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:42.000Z","updated_ts":"2026-04-02T11:29:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Boostrix","status":"ACTIVE"},{"lang":"EN","name":"Refortrix","status":"ACTIVE"},{"lang":"EN","name":"dTpa vaccine","source_info":[{"code":"NCT05169905","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05169905"}],"status":"ACTIVE"}],"drug_type":["00458ff770344a2b962324da6b29d16f","5f5b59262b674cb0a560ddb6aa68bb4f","8f91996d778a4b93aebea69ade081b9f","9e9bb5756eb24c20b5c07cb4432990ce"],"originator_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["2e610a46bd4f456eac6aeb03b038e7b7"],"disease_id":["90a4f0aa8f4745188895e0cf401c3cac","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"active_org_master_entity_id":["ae566fb2495a1e13098ddaa465380a7e","eadc10deede4b8846c6aff09307f3ed1","9b027bb089fcaa2c937327ac652321dd"],"first_approved_country":["6efc9b0c-3cae-3f31-997d-ad35651f6e74","61238041-bc83-3404-a7b4-d7d38443f6b5","a7cb930b-9b67-3639-97cd-dab2ce82da83","a6141259-8d80-3db1-be8f-e435a49f1ae4","bf2107a8-40c7-303a-b4d5-7c28d3903f02","0e7802a9-bad3-33a3-98ae-ff755c717809","f90b616d-f10d-35fb-b13d-b2f114ecf4c2","30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dc266be9-66b5-3c85-af35-ef210568f738","e56545a6-17ff-3d65-812b-7485498ba644","d75944da-2a69-3c58-82a0-c8138ec47d50","a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","6d64b019-4f80-31e9-b248-297aa588c950","184959bf-87b7-3479-827e-d53d6c70ebd4","b7fd90b0-e7ac-3861-bfdb-762da5fc20be","3d57c904-23bf-3ee0-9924-83496c75b8ee","1b05c4d2-8156-3854-9898-c71e0077e3c6","b0e1cb77-7cf7-3c20-a846-3e377b838cfa","acd16cc5-b737-343f-9ffb-3966b2a3fd41","15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","4d8255f9-e0c6-3c24-b6d3-49e62f0c446b","bf460c70-eac8-3426-baa3-7e6c72bc0889","665d1d12-3d14-3e05-8459-014864489671","15d3c741-f4c4-35d8-9273-339b5972916e","deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","c2da2aca-0b0b-3198-aaf9-d35fe9c83766","b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","2db206be-90da-3fc0-8a37-72d9a2fc2b03"],"first_approved_indication":["90a4f0aa8f4745188895e0cf401c3cac","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"research_disease":["90a4f0aa8f4745188895e0cf401c3cac","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","ecc919b1-c2b7-3740-bfa7-7cda77176d07","6efc9b0c-3cae-3f31-997d-ad35651f6e74","61238041-bc83-3404-a7b4-d7d38443f6b5","a7cb930b-9b67-3639-97cd-dab2ce82da83","a6141259-8d80-3db1-be8f-e435a49f1ae4","bf2107a8-40c7-303a-b4d5-7c28d3903f02","0e7802a9-bad3-33a3-98ae-ff755c717809","f90b616d-f10d-35fb-b13d-b2f114ecf4c2","30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dc266be9-66b5-3c85-af35-ef210568f738","e56545a6-17ff-3d65-812b-7485498ba644","d75944da-2a69-3c58-82a0-c8138ec47d50","a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","6d64b019-4f80-31e9-b248-297aa588c950","184959bf-87b7-3479-827e-d53d6c70ebd4","b7fd90b0-e7ac-3861-bfdb-762da5fc20be","3d57c904-23bf-3ee0-9924-83496c75b8ee","1b05c4d2-8156-3854-9898-c71e0077e3c6","b0e1cb77-7cf7-3c20-a846-3e377b838cfa","acd16cc5-b737-343f-9ffb-3966b2a3fd41","15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","4d8255f9-e0c6-3c24-b6d3-49e62f0c446b","bf460c70-eac8-3426-baa3-7e6c72bc0889","665d1d12-3d14-3e05-8459-014864489671","15d3c741-f4c4-35d8-9273-339b5972916e","deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","c2da2aca-0b0b-3198-aaf9-d35fe9c83766","b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","2db206be-90da-3fc0-8a37-72d9a2fc2b03"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1115078400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1240185600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"a6141259-8d80-3db1-be8f-e435a49f1ae4","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"6d64b019-4f80-31e9-b248-297aa588c950","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"b0e1cb77-7cf7-3c20-a846-3e377b838cfa","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"acd16cc5-b737-343f-9ffb-3966b2a3fd41","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"4d8255f9-e0c6-3c24-b6d3-49e62f0c446b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":970531200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1241049600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1598745600000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1462752000000}}],"disease_phase":[{"disease_id":"90a4f0aa8f4745188895e0cf401c3cac","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8f73c0a533f24a49aeae602d1ca70eb7","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e255185bd59e4c2cbef67fd98444d16f","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["9b027bb089fcaa2c937327ac652321dd","48e0e206792826a7f51c514354fe6fdb"],"if_speculate":0,"data_source":10}
+{"drug_id":"00be2e08dd2b47c2be1f8adbcd358d4d","docid":79753,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":329443200000,"created_ts":"2023-08-30T10:09:28.000Z","updated_ts":"2024-11-19T01:50:39.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Dried Live Attenuated Mumps Vaccine(Daiichi Sankyo)","source_info":[{"code":"15500EZZ00958","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/430574_631340AD1075_1_05"}],"status":"ACTIVE"}],"trade_name":[{"name":"おたふくかぜ生ワクチン「第一三共」","source_info":[{"code":"15500EZZ00958","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/430574_631340AD1075_1_07"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["7867fd8c5c8fb5b43b912d4a03a9b148"],"disease_id":["f92a8fc8343f4e81bbd7d7fac49d483d"],"active_org_master_entity_id":["7867fd8c5c8fb5b43b912d4a03a9b148"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["f92a8fc8343f4e81bbd7d7fac49d483d"],"research_disease":["f92a8fc8343f4e81bbd7d7fac49d483d"],"therapeutic_area":["20f1c6915ff140519285386c54883aae"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":329443200000}}],"disease_phase":[{"disease_id":"f92a8fc8343f4e81bbd7d7fac49d483d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02c418929e6a496392fdcf1edd722df4","docid":31537,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Prednisolone","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":-284688000000,"rnk":8,"target_extend_id":"b93dbe262f233b8080ed88876821bd64","created_ts":"2021-10-08T14:45:38.000Z","updated_ts":"2026-02-24T21:22:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"氢化泼尼松琥珀酸钠","status":"ACTIVE"},{"lang":"EN","name":"Prednisolone Sodium Succinate","source_info":[{"code":"13527KUZ11297001","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"プレドニゾロンコハク酸エステルナトリウム","source_info":[{"code":"13527KUZ11297001","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(+)-prednisolone hemisuccinate","source_info":[{"code":"DB14633","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Prednisolone 21-hemisuccinate","source_info":[{"code":"DB14633","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Prednisolone 21-succinate","source_info":[{"code":"DB14633","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Prednisolone bisuccinate","source_info":[{"code":"DB14633","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Prednisolone hydrogen succinate","source_info":[{"code":"DB14633","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Prednisolone sodium succinate (JP17/USP)","source_info":[{"code":"D01239","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Prednisolone succinate","source_info":[{"code":"DB14633","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-9120","source_info":[{"code":"9PHQ9Y1OLM","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9646220b-4066-4271-9435-e166e3075d55"}],"status":"ACTIVE"},{"name":"NSC-9900","source_info":[{"code":"9PHQ9Y1OLM","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9646220b-4066-4271-9435-e166e3075d55"}],"status":"ACTIVE"}],"trade_name":[{"name":"Kohakusanin","source_info":[{"code":"D01239","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"PREDONINE","source_info":[{"code":"13527KUZ11297001","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"プレドニン","source_info":[{"code":"13527KUZ11297001","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Prednisolone","source_info":[{"code":"G7080T74ON","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/56d21026-7530-4db0-a725-94199fa8cc8b"}],"status":"ACTIVE"}],"drugbank_id":["DB14633"],"kegg_id":["D01239"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["b68c8095fd24aaea6a32494a24954a2d"],"mechanism_action_id":["b3b0790f82c48637c8ccae2fb7b59a32"],"target_id":["6fe53f67a27241fcac53227526791322"],"atc_code":["16dd5bc5e3af49c79af1f6037d473722","45ebd99c8e5f47e6894846891628db77","54184b77999b4ac0a8c63b5d454b0380","8a71ff895d2643388639261041f71bf1","90916cda1975475b98ea3bccd109b920","b88c539df66d46abaf1230e5f2563c2b","baec8d2b4782449eb505a2d9cfd5d70c","bd35c760e8d94862b8f2834497977cf3","c96b49b44fb74ef3b2f7a8837581fe30","d2f4b844af674ac19d8437bad7bd6770"],"disease_id":["8a319631aa1142e3a7a2831c2defe117","2a16e3a0761544b2990712356942352f","8da973b225c24afbba255413635fb240","15fe4881cb88431eb9d44b018619d7b0","161ad18de68b43cf9952144f8c66bb2f","d3d13f8097da422898673983d18f597e","85a5f5e742ad45b9ac62afaf9709249a","c8e43d2b48ec49dba16418bc190a3eec","86a692ed17664c8484a305f068064433","94deb71c1ce54fdf8923bfcb7c88d054","ef1925515e7b4062a6cfe8c5e1db1b95","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","761c45fec16a4fd6837446a672b0bb05","09529518c8164578ac870e810c3c677b","5c08b7fc6f404d769c9ec4993fd1baad","6be96778ed424f8d91de00ab82364114","c5e1987e283c495aaab2a8d309c6085e","6ea1d9ace3754dafaec5a24ae801a51f","181082be0ebb4fdfb5950ee1cc83a46c","1cac1949513c49a0b2af4b2f0a3d1455","7aa375fd31da4415978160ee1e782435"],"active_org_master_entity_id":["b68c8095fd24aaea6a32494a24954a2d"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["2a16e3a0761544b2990712356942352f","8da973b225c24afbba255413635fb240","15fe4881cb88431eb9d44b018619d7b0","161ad18de68b43cf9952144f8c66bb2f","d3d13f8097da422898673983d18f597e","85a5f5e742ad45b9ac62afaf9709249a","c8e43d2b48ec49dba16418bc190a3eec","86a692ed17664c8484a305f068064433","94deb71c1ce54fdf8923bfcb7c88d054","ef1925515e7b4062a6cfe8c5e1db1b95","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","761c45fec16a4fd6837446a672b0bb05","7aa375fd31da4415978160ee1e782435","09529518c8164578ac870e810c3c677b","5c08b7fc6f404d769c9ec4993fd1baad","6be96778ed424f8d91de00ab82364114","c5e1987e283c495aaab2a8d309c6085e","6ea1d9ace3754dafaec5a24ae801a51f","181082be0ebb4fdfb5950ee1cc83a46c","1cac1949513c49a0b2af4b2f0a3d1455"],"research_disease":["8a319631aa1142e3a7a2831c2defe117","2a16e3a0761544b2990712356942352f","8da973b225c24afbba255413635fb240","15fe4881cb88431eb9d44b018619d7b0","161ad18de68b43cf9952144f8c66bb2f","d3d13f8097da422898673983d18f597e","85a5f5e742ad45b9ac62afaf9709249a","c8e43d2b48ec49dba16418bc190a3eec","86a692ed17664c8484a305f068064433","94deb71c1ce54fdf8923bfcb7c88d054","ef1925515e7b4062a6cfe8c5e1db1b95","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","761c45fec16a4fd6837446a672b0bb05","09529518c8164578ac870e810c3c677b","5c08b7fc6f404d769c9ec4993fd1baad","6be96778ed424f8d91de00ab82364114","c5e1987e283c495aaab2a8d309c6085e","6ea1d9ace3754dafaec5a24ae801a51f","181082be0ebb4fdfb5950ee1cc83a46c","1cac1949513c49a0b2af4b2f0a3d1455"],"non_research_disease":["7aa375fd31da4415978160ee1e782435"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1379030400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-284688000000}}],"disease_phase":[{"disease_id":"6ea1d9ace3754dafaec5a24ae801a51f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"85a5f5e742ad45b9ac62afaf9709249a","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7aa375fd31da4415978160ee1e782435","highest_phase_global":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"disease_id":"181082be0ebb4fdfb5950ee1cc83a46c","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ef1925515e7b4062a6cfe8c5e1db1b95","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"161ad18de68b43cf9952144f8c66bb2f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"761c45fec16a4fd6837446a672b0bb05","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1cac1949513c49a0b2af4b2f0a3d1455","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d3d13f8097da422898673983d18f597e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5c08b7fc6f404d769c9ec4993fd1baad","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"94deb71c1ce54fdf8923bfcb7c88d054","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"86a692ed17664c8484a305f068064433","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2a16e3a0761544b2990712356942352f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"09529518c8164578ac870e810c3c677b","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8a319631aa1142e3a7a2831c2defe117","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0327aa3b59f94157a8ce0c27e4fa5e82","docid":64325,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-02-22T05:31:55.000Z","updated_ts":"2026-02-25T01:15:48.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"GVAX vaccine(The Sidney Kimmel Comprehensive Cancer Center)","source_info":[{"code":"NCT00024466","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT00024466"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogeneic Myeloma Vaccine","source_info":[{"code":"NCT01045460","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT01045460"}],"status":"ACTIVE"},{"lang":"EN","name":"Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine","source_info":[{"code":"NCT01045460","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT01045460"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["5a3bef9be7157c8c61731090e78376d7"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["024deb39dbdb42eea0863db300b15242","275ecda875e0460f84aa768ca9b2e5d6","e35ce4e9b7a846d49e600ce7ac4a7fd6","a75eb84c45444938809d1088852efb20","af6dd435a672467486576d577e5b7730","7cd0fcf1c5c243b9b3944405ec4855b5","d2ee0aa5e8a2440585e9a218d193b710"],"active_org_master_entity_id":["5a3bef9be7157c8c61731090e78376d7"],"research_disease":["024deb39dbdb42eea0863db300b15242"],"non_research_disease":["275ecda875e0460f84aa768ca9b2e5d6","e35ce4e9b7a846d49e600ce7ac4a7fd6","a75eb84c45444938809d1088852efb20","af6dd435a672467486576d577e5b7730","7cd0fcf1c5c243b9b3944405ec4855b5","d2ee0aa5e8a2440585e9a218d193b710"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1009843200000}}],"disease_phase":[{"disease_id":"024deb39dbdb42eea0863db300b15242","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a75eb84c45444938809d1088852efb20","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"af6dd435a672467486576d577e5b7730","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0d13264728e842fda9a3f923f6511fc0","docid":60440,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":20,"target_extend_id":"ba78232c3999336ebf7f96faed4b5afb","created_ts":"2022-06-24T07:41:19.000Z","updated_ts":"2026-04-04T21:08:22.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"LEAF-1703","source_info":[{"attachment_path":"data/phs_source_info/b101/be53/ddf0/d9e6/33542060-d502-3d35-b725-b2c84bbe4082.png","attachment_type":"image/png","code":"L.E.A.F.-202411","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/267c/ca27/3169/a68c/61bf30d6-b9db-388e-a461-874f3e5fe946.png","source":"Company pipeline","source_url":"https://www.leafpharmaceuticals.com/leaf-pharmaceuticals-pipeline"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Liposomal formulation of alpha-D pentaglutamated pemetrexed-D(L.E.A.F. Pharmaceuticals)","source_info":[{"attachment_path":"data/phs_source_info/b101/be53/ddf0/d9e6/33542060-d502-3d35-b725-b2c84bbe4082.png","attachment_type":"image/png","code":"L.E.A.F.-202411","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/267c/ca27/3169/a68c/61bf30d6-b9db-388e-a461-874f3e5fe946.png","source":"Company pipeline","source_url":"https://www.leafpharmaceuticals.com/leaf-pharmaceuticals-pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"LEAF 1703","source_info":[{"attachment_path":"data/phs_source_info/b101/be53/ddf0/d9e6/33542060-d502-3d35-b725-b2c84bbe4082.png","attachment_type":"image/png","code":"L.E.A.F.-202411","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/267c/ca27/3169/a68c/61bf30d6-b9db-388e-a461-874f3e5fe946.png","source":"Company pipeline","source_url":"https://www.leafpharmaceuticals.com/leaf-pharmaceuticals-pipeline"}],"status":"ACTIVE"},{"name":"LEAF1703","source_info":[{"attachment_path":"data/phs_source_info/b101/be53/ddf0/d9e6/33542060-d502-3d35-b725-b2c84bbe4082.png","attachment_type":"image/png","code":"L.E.A.F.-202411","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/267c/ca27/3169/a68c/61bf30d6-b9db-388e-a461-874f3e5fe946.png","source":"Company pipeline","source_url":"https://www.leafpharmaceuticals.com/leaf-pharmaceuticals-pipeline"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","f9b1093fafc547caabf90e26cef22a1f"],"originator_org_master_entity_id":["a9e66174a03b862dec479db1ed593a9a"],"mechanism_action_id":["c2b0909d5ec4f04f4d218553536d81a7"],"target_id":["7794e53ee5cb4daeb3d692d42bfb9566"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e"],"active_org_master_entity_id":["a9e66174a03b862dec479db1ed593a9a"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1730419200000}}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"048fa045f62340758c763403bdd25be4","docid":78993,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":3,"target_extend_id":"13593256e5cb3639af3e5a9e72f36aae","created_ts":"2022-05-27T06:38:08.000Z","updated_ts":"2026-03-23T13:40:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"B1962","status":"ACTIVE"}],"dev_code":[{"name":"AP-505","status":"ACTIVE"},{"name":"B 1962","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-l1-anti-vegf-bispecific-antibody-fusion-protein-b1962"}],"status":"ACTIVE"},{"name":"B-1962","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-l1-anti-vegf-bispecific-antibody-fusion-protein-b1962"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["371ec3f2eae29419fe58a691ce41e589"],"mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2","72d64a51cd6740671091da84743fa32c"],"target_id":["06c7ab146b884a3aa890cfd1a4a0e168","1c2067e5ab054a8995f73efcfcf56207"],"disease_id":["b902fe3512424802ac7659fc83b38222","0464f5493b0444e9875a0584df17cbf0","15839db0de0947ddb9e4c280884a3895","949c20c9e52549008773244a4230da7d","828fb9fef58643deaeb03ba65a7d3953","8d29f554f371431c9b5b80f5befdf965","f92e4ba771d04f27a1f4daae363b676a","b42488c9ce3245988e4e93caf2b95590","7665e5683a1a443a8f3d3b946d4c9ca2"],"active_org_master_entity_id":["371ec3f2eae29419fe58a691ce41e589","dacb8a0ccff7826abd4edaed4ce0bc2f"],"research_disease":["b902fe3512424802ac7659fc83b38222","0464f5493b0444e9875a0584df17cbf0","15839db0de0947ddb9e4c280884a3895","949c20c9e52549008773244a4230da7d","828fb9fef58643deaeb03ba65a7d3953","8d29f554f371431c9b5b80f5befdf965","f92e4ba771d04f27a1f4daae363b676a","b42488c9ce3245988e4e93caf2b95590","7665e5683a1a443a8f3d3b946d4c9ca2"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1740355200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1680134400000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"828fb9fef58643deaeb03ba65a7d3953","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["1303e7e203d6cccc8f5b09664d4eafe2","dacb8a0ccff7826abd4edaed4ce0bc2f"],"data_source":10}
+{"drug_id":"24c59e8373104e1d8ca0b34433dae675","docid":201134,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2024-04-22T05:13:17.000Z","updated_ts":"2025-09-28T00:21:30.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AFYX-003","source_info":[{"attachment_path":"data/phs_source_info/dbfe/c014/0c12/df79/74624628-f162-386b-8021-e49b15718a12.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/e3a1/e95a/c025/3f30/88a60221-2463-38cd-b98e-9eaec1895c49.png","source":"Company pipeline","source_url":"https://afyxtx.com/research-development/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AFYX 003","status":"ACTIVE"},{"name":"AFYX003","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5b11b455583094beb22f9b6bf8e1cad1"],"disease_id":["938a26fa6bd842639c7d669a3f4feb62"],"active_org_master_entity_id":["5b11b455583094beb22f9b6bf8e1cad1"],"research_disease":["938a26fa6bd842639c7d669a3f4feb62"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59"},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"938a26fa6bd842639c7d669a3f4feb62","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"073b222fea4b49e1ba4fd1130bca01bd","docid":22791,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-10-08T14:46:41.000Z","updated_ts":"2026-03-17T06:34:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Veverimer","status":"ACTIVE"}],"dev_code":[{"name":"TRC 101","status":"ACTIVE"},{"name":"TRC-101","status":"ACTIVE"}],"trade_name":[{"name":"Alezuris","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/renibus-therapeutics-announces-presentation-at-oppenheimer-34th-annual-healthcare-conference-302055962.html"}],"status":"ACTIVE"}],"drug_type":["1fe8fa7ef6724eb990397a56efe94d7b"],"originator_org_master_entity_id":["cd4d2ce506c2173b36e16d76052f9371"],"mechanism_action_id":["6009a97b27f19ba0558e414436171f27"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["1cbcb32c6c68407cb34f79814cd2e26c","bb895a9780a94318973390e3df4eb213","7dc9953293cc4182b59961ed5353a519"],"active_org_master_entity_id":["127010a5023d35e4c906db834fbaa504","f43ef83f7fd79722bca7eecba8e4d663"],"research_disease":["1cbcb32c6c68407cb34f79814cd2e26c","bb895a9780a94318973390e3df4eb213","7dc9953293cc4182b59961ed5353a519"],"inactive_org_master_entity_id":["cd4d2ce506c2173b36e16d76052f9371"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1768262400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"7370a42d-171f-32f5-b2f0-913c4519c55f","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"7890eed6-df6d-3e76-a942-7736b7ac21b4","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"e92cf5a5-43e5-3d54-a14b-272415437a2d","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"0293809f-cf7e-3684-b4d2-1fffdaedbb52","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1665705600000}},{"country":"07e9c77a-e7a4-342a-80e7-697e32502186","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"6d64b019-4f80-31e9-b248-297aa588c950","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1589414400000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1613865600000}}],"disease_phase":[{"disease_id":"7dc9953293cc4182b59961ed5353a519","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1cbcb32c6c68407cb34f79814cd2e26c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bb895a9780a94318973390e3df4eb213","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["cd4d2ce506c2173b36e16d76052f9371","f43ef83f7fd79722bca7eecba8e4d663"],"if_speculate":0,"data_source":10}
+{"drug_id":"12950781729c411d88b2a7072aa68da4","docid":72657,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":3,"target_extend_id":"b5d2d97a86cb3b37a42247a59d71bdf3","created_ts":"2021-10-08T14:42:29.000Z","updated_ts":"2026-04-02T10:58:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Glepaglutide","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Glepaglutide (USAN)","source_info":[{"code":"D11337","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"ZP 1848","status":"ACTIVE"},{"name":"ZP-1848","status":"ACTIVE"}],"drugbank_id":["DB14794"],"kegg_id":["D11337"],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["d9f8980203384a2c32b16d03c99e936c"],"mechanism_action_id":["eb3726bbf3ac0d077cb7e53233af094d"],"target_id":["71bf0c0de3d94a018548c9e8c8ff3ded"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["e24c1e7ae441435988fa53cdb8adf4d9","05ae12d567784b85a5c1ca54b2063ee2"],"active_org_master_entity_id":["d9f8980203384a2c32b16d03c99e936c","679f275cb5a37da90ec7880ba302168e"],"research_disease":["e24c1e7ae441435988fa53cdb8adf4d9"],"non_research_disease":["05ae12d567784b85a5c1ca54b2063ee2"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1748822400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1538611200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770768000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1657756800000}}],"disease_phase":[{"disease_id":"e24c1e7ae441435988fa53cdb8adf4d9","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"14ff49f1211c47789f794b877ba274bb","docid":269045,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":2,"target_extend_id":"6be98b00e90d386fa87548f18d60b644","created_ts":"2025-01-23T07:07:51.000Z","updated_ts":"2025-12-05T00:30:45.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"RD-IIT-001","source_info":[{"code":"NCT06786299","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06786299"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy","source_info":[{"code":"NCT06786299","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06786299"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["82ad43598d0815d35c26d0d7a5e4565a"],"mechanism_action_id":["76ad0d815a074cf2a75561adfbc75ede"],"target_id":["92ce53a3192b480eb2fdb8702e5607c9"],"disease_id":["0ade2c6f9dec476595d303c91c8babc9","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["82ad43598d0815d35c26d0d7a5e4565a"],"research_disease":["0ade2c6f9dec476595d303c91c8babc9","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1739145600000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0ade2c6f9dec476595d303c91c8babc9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00a184adec684c479f780dacec83eeb5","docid":10452,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":28,"target_extend_id":"5dda89db055132f9b4718ad9d5af409b","created_ts":"2021-10-08T14:47:55.000Z","updated_ts":"2026-04-04T21:05:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LX-086","status":"ACTIVE"}],"dev_code":[{"name":"LX 086","status":"ACTIVE"},{"name":"LX086","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f4c743047d2d8020deb8298a859cd19a"],"mechanism_action_id":["eaee1c5527b3a91b4ee1e520963463f7"],"target_id":["fe5b12ba299a474b979d6ab1ddca7b4b"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["f4c743047d2d8020deb8298a859cd19a"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1616457600000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"06bcdc402a8b4e63ab390294f76dc022","docid":47556,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"af0f4593fa0b406da9157f451913adb3","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"f7b04664ea723d09b4fcac20b7c27c8c","created_ts":"2021-10-08T14:50:15.000Z","updated_ts":"2026-03-03T23:02:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"[11C]ER-176","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"11C-ER176","source_info":[{"code":"NCT04762719","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04762719"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["4db5219801808e5c44453ae6ca99ff66"],"mechanism_action_id":["cc14c6d9474776356e5d09d9c60dd3ee"],"target_id":["140d3f5c2e0441c082d52004c0346aa8"],"disease_id":["99bd009aa0e84d9599e2428d73786197","4f326ddd20e4476b93d077e5ee1f24d0","54a77f56d72c4ac6a0eb840f4518e3a0","738546bac89e4895b89af01545f1b054","9a83ff35f9c94f31b6d88c0f5aa0da2c","666f464c54244d64874869e12d150659","c2e755f2cdc34621ac8e4ad193f523b1","d29b21fcdc2847ba87f5d34d519eb4d9","4c0044bbaeba47258cf85131c2412421","749c254a1db5427ab33373874013ea96","3c95f7a28d124daea2a8ed354ce98583"],"active_org_master_entity_id":["ce1783471a7add837e1062d85249c974","97df527e5625cec303309efe38fb586a"],"research_disease":["99bd009aa0e84d9599e2428d73786197","4f326ddd20e4476b93d077e5ee1f24d0","54a77f56d72c4ac6a0eb840f4518e3a0"],"non_research_disease":["738546bac89e4895b89af01545f1b054","9a83ff35f9c94f31b6d88c0f5aa0da2c","666f464c54244d64874869e12d150659","c2e755f2cdc34621ac8e4ad193f523b1","d29b21fcdc2847ba87f5d34d519eb4d9","4c0044bbaeba47258cf85131c2412421","749c254a1db5427ab33373874013ea96","3c95f7a28d124daea2a8ed354ce98583"],"inactive_org_master_entity_id":["689fd5301b12dfe62031c7944329d3b5"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1617062400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1605571200000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"749c254a1db5427ab33373874013ea96","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c2e755f2cdc34621ac8e4ad193f523b1","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"4f326ddd20e4476b93d077e5ee1f24d0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3c95f7a28d124daea2a8ed354ce98583","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"666f464c54244d64874869e12d150659","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4c0044bbaeba47258cf85131c2412421","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"99bd009aa0e84d9599e2428d73786197","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d29b21fcdc2847ba87f5d34d519eb4d9","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"9a83ff35f9c94f31b6d88c0f5aa0da2c","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10,"moiety_target_extend_id":"f7b04664ea723d09b4fcac20b7c27c8c","moiety_mechanism_action_id":["cc14c6d9474776356e5d09d9c60dd3ee"],"moiety_target_id":["140d3f5c2e0441c082d52004c0346aa8"]}
+{"drug_id":"03e988a76d0f430ba17fe0f0e8a9b2fb","docid":82040,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"165ce47c985e3e60ada002232755c9a0","created_ts":"2023-11-16T10:32:06.000Z","updated_ts":"2026-04-01T10:04:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"wangya","drug_name":[{"lang":"EN","name":"AZD-3470","source_info":[{"code":"NCT06130553","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"dev_code":[{"name":"AZD 3470","source_info":[{"code":"NCT06130553","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06130553"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt5-inhibitor-azd3470"}],"status":"ACTIVE"},{"name":"AZD-3470","source_info":[{"code":"NCT06130553","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06130553"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt5-inhibitor-azd3470"}],"status":"ACTIVE"},{"name":"AZD3470","source_info":[{"code":"NCT06130553","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06130553"},{"code":"2024_TPS3179","normalized_source_id":"c47a5730bf5e40b3aa76c26820ec6d4e","source":"ASCO","source_url":"https://meetings.asco.org/abstracts-presentations/238345"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt5-inhibitor-azd3470"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506"],"mechanism_action_id":["e6a4767a5dd3493eb7bc349b98a471d1"],"target_id":["7a68e99130134dbc9048af6318b6a4c9"],"disease_id":["131c3f4dfc0c4a958e9f91166e73c913","ee780474e5f94aecb33643a8f39a0f77","af389ead8cc04bac8a77f028c34a5e84","0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","38165dea7b4840888d2d9fe98ca81a94","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506","8656d37d668a52bf73421c7b34d2e105"],"research_disease":["131c3f4dfc0c4a958e9f91166e73c913","ee780474e5f94aecb33643a8f39a0f77","af389ead8cc04bac8a77f028c34a5e84","0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","38165dea7b4840888d2d9fe98ca81a94","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}}],"disease_phase":[{"disease_id":"af389ead8cc04bac8a77f028c34a5e84","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ee780474e5f94aecb33643a8f39a0f77","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"38165dea7b4840888d2d9fe98ca81a94","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0bd62b6a4f874574bf9bac7f03edd18c","docid":84152,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-02-28T08:10:19.000Z","updated_ts":"2026-02-24T23:36:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"GM-103","source_info":[{"code":"NCT06265025","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06265025"}],"status":"ACTIVE"}],"dev_code":[{"name":"GM-103","source_info":[{"code":"NCT06265025","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06265025"}],"status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["40a511099dd43c1ad064206fd1e8c964"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","7665e5683a1a443a8f3d3b946d4c9ca2","11cacc262bfc41adbd6259325efbcfec","15cb523e0fbd4617a6a129ad2336eb9a","c1cc2528f29940fc95fd6bc37eb982d4","c7fe8aa844d24e85ba32a990ea28ded3","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["40a511099dd43c1ad064206fd1e8c964"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","7665e5683a1a443a8f3d3b946d4c9ca2","11cacc262bfc41adbd6259325efbcfec","15cb523e0fbd4617a6a129ad2336eb9a","c1cc2528f29940fc95fd6bc37eb982d4","c7fe8aa844d24e85ba32a990ea28ded3","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708387200000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"11cacc262bfc41adbd6259325efbcfec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"0072ccb871e04c489eb1ebf732e3b118","docid":35167,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","created_ts":"2022-02-28T05:06:12.000Z","updated_ts":"2024-10-30T10:22:38.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"益母草","status":"ACTIVE"},{"lang":"EN","name":"YiMuCao","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["e1af740820d94abda0022b5aace3a177","098c1c4e05f04c0e8e422e284d7439d7"],"research_disease":["e1af740820d94abda0022b5aace3a177","098c1c4e05f04c0e8e422e284d7439d7"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"e1af740820d94abda0022b5aace3a177","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"098c1c4e05f04c0e8e422e284d7439d7","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02e0f3fb79904edb93be1de93775219b","docid":54042,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","rnk":25,"target_extend_id":"dc7de6393dbb399aa0d8e2f8236159c3","created_ts":"2021-10-08T14:47:55.000Z","updated_ts":"2025-12-06T21:11:08.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"培非格司亭生物类似药(Aryatinagene Biopharmaceuticals)","status":"ACTIVE"},{"lang":"EN","name":"Pegfilgrastim biosimilar(Aryatinagene Biopharmaceuticals)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Pegfilgrastim biosimilar","status":"ACTIVE"},{"lang":"EN","name":"Tinapeg","status":"ACTIVE"}],"generic_name":[{"name":"pegfilgrastim","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["5c0ca37b409bc837169e2733eb212c82"],"mechanism_action_id":["358e5f0ba725062ad8f0c56973cc3e35"],"target_id":["532763442f00416fa392a55be34bad5a"],"atc_code":["dff83be6b0c146ceaf0e213dc51d78ca"],"disease_id":["e1aa9957d02046eab953a43b285f521f"],"active_org_master_entity_id":["5c0ca37b409bc837169e2733eb212c82"],"research_disease":["e1aa9957d02046eab953a43b285f521f"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"approval_country":["ab1a98cb-d362-3a11-9e63-99cb01cc9474"],"research_country":[{"country":"ab1a98cb-d362-3a11-9e63-99cb01cc9474","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"e1aa9957d02046eab953a43b285f521f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["c8ae82ce74fc4776a63b3a7ad409566f"],"data_source":10}
+{"drug_id":"051a653dbc0543698c0b113c487ebd00","docid":38498,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-04-28T12:55:35.000Z","updated_ts":"2024-12-31T05:16:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BK Specific Cytotoxic T-cells(New York Medical College)","status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["a07fa29de0abe7080db6ccd025d662f9"],"mechanism_action_id":["0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["3d537b3f7d1c4c17bfafa100654c5235","03eb5d3e15c14dca9bf67d355a8d20be"],"active_org_master_entity_id":["a07fa29de0abe7080db6ccd025d662f9"],"research_disease":["3d537b3f7d1c4c17bfafa100654c5235","03eb5d3e15c14dca9bf67d355a8d20be"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1593561600000}}],"disease_phase":[{"disease_id":"3d537b3f7d1c4c17bfafa100654c5235","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"03eb5d3e15c14dca9bf67d355a8d20be","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"04b7fca1f2174dd185e3afd53d159050","docid":440051,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-10-08T10:03:27.000Z","updated_ts":"2026-04-01T08:56:09.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CRG-002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.chinaventure.com.cn/news/111-20240919-383070.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"CRG 002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.chinaventure.com.cn/news/111-20240919-383070.html"}],"status":"ACTIVE"},{"name":"CRG002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.chinaventure.com.cn/news/111-20240919-383070.html"}],"status":"ACTIVE"}],"drug_type":["b6c764e33db1468bb5c605488cfe00ca"],"originator_org_master_entity_id":["90ca90cc8be9db7d7dc6ee33b7a37a7f"],"disease_id":["1dec6017bd924aff8aeae6e7d4a3f874","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["90ca90cc8be9db7d7dc6ee33b7a37a7f"],"research_disease":["1dec6017bd924aff8aeae6e7d4a3f874","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1760659200000}}],"disease_phase":[{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"0ce71e9c270b498f85f6f84b4e31e0cb","docid":28654,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":9,"target_extend_id":"16c251e8a8703eb682a7cf3f1a404095","created_ts":"2022-07-15T09:37:15.000Z","updated_ts":"2026-02-24T14:59:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"APR-TD011","status":"ACTIVE"}],"dev_code":[{"name":"APR-1206","status":"ACTIVE"},{"name":"APR-TD011","status":"ACTIVE"},{"name":"RLF-TD011","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/relief-therapeutics-announces-enrollment-of-first-three-patients-in-proof-of-concept-clinical-trial-of-rlf-td011-for-the-treatment-of-epidermolysis-bullosa/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e574ce9ae6ba6a21297df7fe6c891cb4"],"mechanism_action_id":["eca0582c2a39448c8b6bb075bcf38e9f"],"target_id":["c3de2c3e3f454e4697d691d37335073f"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["2477ea95d1294f8987313ebabd749252","4e59dff5f54e40d4b7ededa7eb9e54b4","5ca3461ddccf4ed9a777c112936766ea","454bc58683914be1b6d97fbabf6bda5b"],"active_org_master_entity_id":["7937647b33459a3502fa187d9cd3e551","30d8c010d54e4c8feffc57abc8c24fed"],"research_disease":["2477ea95d1294f8987313ebabd749252","4e59dff5f54e40d4b7ededa7eb9e54b4","5ca3461ddccf4ed9a777c112936766ea","454bc58683914be1b6d97fbabf6bda5b"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1684454400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1676332800000}}],"disease_phase":[{"disease_id":"454bc58683914be1b6d97fbabf6bda5b","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"4e59dff5f54e40d4b7ededa7eb9e54b4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5ca3461ddccf4ed9a777c112936766ea","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2477ea95d1294f8987313ebabd749252","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"11d208e0c26a4345946d95f92d9fcaf0","docid":48641,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","first_approved_date":1713916800000,"rnk":7,"target_extend_id":"348d5b3776a235efb2944d1b7949b5c8","created_ts":"2021-10-08T14:50:36.000Z","updated_ts":"2026-04-09T08:44:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Zastaprazan citrate","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/onconic-therapeutics-receives-mfds-approval-for-jaqbo-a-new-treatment-for-gastroesophageal-reflux-disease-gerd-302127461.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"JP 1366","status":"ACTIVE"},{"name":"JP-1366","status":"ACTIVE"},{"name":"OCN-101","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://onconic.co.kr/ourscience/pipeline.php"}],"status":"ACTIVE"}],"trade_name":[{"name":"JAQBO","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/onconic-therapeutics-receives-mfds-approval-for-jaqbo-a-new-treatment-for-gastroesophageal-reflux-disease-gerd-302127461.html"}],"status":"ACTIVE"},{"name":"자큐보구강붕해정","source_info":[{"code":"202502813","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202502813aupdateTs2026-01-08%2008:10:18.500906b"}],"status":"ACTIVE"}],"generic_name":[{"name":"Zastaprazan","source_info":[{"normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl125.pdf?sfvrsn=af269747_5&download=true"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["29d78bf117f572da2103a2fc22869bbe"],"mechanism_action_id":["d0cc3c29eb148fe07feccce6ea7cafec"],"target_id":["d154ffe1ed2847e6a1dc649f8a570a5b"],"disease_id":["3d3b4d85d52b4602a56b144086f40148","b932eb420c6e42139e3402651804c66e","53b0789eac574b90a2d1ebe94d10a166","e82286d695724d3da10f96c4942ed824","c624831e82eb4e149289223f037d38bf","4d5ee75f79514e3dbbba26473ea2d9b6","f74b528e83974263b57f02008fd0e3d0"],"active_org_master_entity_id":["920c7580f076bd97751dec82d2de7e16","400319587967e3c1a470a3efb6a1e53d"],"first_approved_country":["52d1b118-b540-37ba-9cb2-f5aff686bb10"],"first_approved_indication":["b932eb420c6e42139e3402651804c66e"],"research_disease":["3d3b4d85d52b4602a56b144086f40148","b932eb420c6e42139e3402651804c66e","53b0789eac574b90a2d1ebe94d10a166","e82286d695724d3da10f96c4942ed824","c624831e82eb4e149289223f037d38bf"],"non_research_disease":["4d5ee75f79514e3dbbba26473ea2d9b6","f74b528e83974263b57f02008fd0e3d0"],"inactive_org_master_entity_id":["29d78bf117f572da2103a2fc22869bbe"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8"],"approval_country":["52d1b118-b540-37ba-9cb2-f5aff686bb10"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1760918400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1713916800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1756080000000}}],"disease_phase":[{"disease_id":"53b0789eac574b90a2d1ebe94d10a166","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"e82286d695724d3da10f96c4942ed824","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"3d3b4d85d52b4602a56b144086f40148","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6904072bd4ab4c67b4d0ca8d4728f5be","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4d5ee75f79514e3dbbba26473ea2d9b6","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f74b528e83974263b57f02008fd0e3d0","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b932eb420c6e42139e3402651804c66e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c624831e82eb4e149289223f037d38bf","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"deal_related_org":["29d78bf117f572da2103a2fc22869bbe","400319587967e3c1a470a3efb6a1e53d","920c7580f076bd97751dec82d2de7e16","c005a71a67b996032468c8265b02ac54","ffb7c44a2d5b634dc4a46e1d5ff204fd"],"if_speculate":0,"data_source":10}
+{"drug_id":"4465fadec58f47ad818a86bf762f5e37","docid":33581,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1725926400000,"rnk":2,"target_extend_id":"eabec2d88b5d3878b8148ff0e852fe3f","created_ts":"2021-10-08T14:39:33.000Z","updated_ts":"2026-04-03T03:24:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","first_approved_date_cn":1725926400000,"drug_name":[{"lang":"CN","name":"司普奇拜单抗","source_info":[{"code":"CXSS2300090","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Stapokibart","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-IL-4Rα recombinant fully humanized antibody","status":"ACTIVE"},{"lang":"CN","name":"CM310重组人源化单克隆抗体(康诺亚)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant humannized monoclonal antibody (Keymed Biosciences, Inc.)","status":"ACTIVE"},{"lang":"EN","name":"Scipibaimab","source_info":[{"code":"NCT07388758","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07388758"}],"status":"ACTIVE"}],"dev_code":[{"name":"CM 310","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/stapokibart"}],"status":"ACTIVE"},{"name":"CM-310","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/stapokibart"}],"status":"ACTIVE"},{"name":"CM310","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/stapokibart"}],"status":"ACTIVE"}],"trade_name":[{"name":"康悦达","source_info":[{"normalized_source_id":"09a9e2414846487c9e66f4bfca02cea9","source":"NMPA_NEWS","source_url":"https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240912171529122.html"}],"status":"ACTIVE"}],"generic_name":[{"name":"Stapokibart","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["77a58f3c97e31f0428f36e670965e2a4"],"mechanism_action_id":["8e46e6d7cb5ef25ed25572cd326c56ec"],"target_id":["9055fd3b7cd6459f9dbb0f84bab4c9aa"],"special_review":["23d3523b7ece48ddacaddac53a66949d","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["07ca4cbd5bbe460590b9f3982fa38ec1","323fd3aac06145689cb8e1b4fd0a3bc2","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","d40ef3cdfee64183a874ca8cc15bd469","16c3709f543e463bb78c9941505657bb","b5068ce40bb1403ab9a02fa97954ebb1","df3f2af04dd146e28a3f1de0556b8a65","666ca45028ad4ccc9383172f2715c649","15fe4881cb88431eb9d44b018619d7b0","486c4f5995ae4425a9c98a48d22c84c8","00894c5beba2467fa4489e0fa39ddffa","e10e6a48f3ea4ee2b2eee51942ed4ef0","9a9a7e18cf5748b3be14097aa560a3ab","cb7217deff414b12aa26916c246295de","5fa2d6f6369c4823bd2e3caebab7256b"],"active_org_master_entity_id":["e2b3cdee9212bbf405abb4aa4f7ff8f1","3206c84d3bae4ea547213024defc6653","77a58f3c97e31f0428f36e670965e2a4","5cf5fedddb15b3ca0a531d9b789f0286"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547"],"research_disease":["07ca4cbd5bbe460590b9f3982fa38ec1","323fd3aac06145689cb8e1b4fd0a3bc2","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","d40ef3cdfee64183a874ca8cc15bd469","16c3709f543e463bb78c9941505657bb","b5068ce40bb1403ab9a02fa97954ebb1","df3f2af04dd146e28a3f1de0556b8a65","666ca45028ad4ccc9383172f2715c649","15fe4881cb88431eb9d44b018619d7b0","486c4f5995ae4425a9c98a48d22c84c8","00894c5beba2467fa4489e0fa39ddffa","e10e6a48f3ea4ee2b2eee51942ed4ef0","9a9a7e18cf5748b3be14097aa560a3ab"],"non_research_disease":["cb7217deff414b12aa26916c246295de","5fa2d6f6369c4823bd2e3caebab7256b"],"inactive_org_master_entity_id":["1ee2ef06f7a588e42142080b4c971338"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1737676800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1734393600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1725926400000}}],"disease_phase":[{"disease_id":"d40ef3cdfee64183a874ca8cc15bd469","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"07ca4cbd5bbe460590b9f3982fa38ec1","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"e10e6a48f3ea4ee2b2eee51942ed4ef0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"323fd3aac06145689cb8e1b4fd0a3bc2","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"9a9a7e18cf5748b3be14097aa560a3ab","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"df3f2af04dd146e28a3f1de0556b8a65","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"b5068ce40bb1403ab9a02fa97954ebb1","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"cb7217deff414b12aa26916c246295de","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5fa2d6f6369c4823bd2e3caebab7256b","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"666ca45028ad4ccc9383172f2715c649","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"16c3709f543e463bb78c9941505657bb","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["90dde2cce6d4a0eb17abb8eb7b47be9d","77a58f3c97e31f0428f36e670965e2a4"],"if_speculate":0,"data_source":10}
+{"drug_id":"01b411d2d0684091b871af48b22957b1","docid":42983,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-06-17T09:29:49.000Z","updated_ts":"2024-11-07T14:56:48.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"FNP 150","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.ferrer.com/en/our-activities/r-d-strategy"}],"status":"ACTIVE"}],"dev_code":[{"name":"FNP 150","status":"ACTIVE"},{"name":"FNP-150","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5a1e4ad2ed2ec24cc6dff59becf73071"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["5a1e4ad2ed2ec24cc6dff59becf73071"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1653177600000}}],"disease_phase":[{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"09931681edf6486da922b84d952c44de","docid":13380,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":21,"target_extend_id":"8c52d6e0b566342a9409a0f4d0068bf3","has_leading_org_involved":1,"created_ts":"2021-11-30T08:55:12.000Z","updated_ts":"2026-04-04T21:06:16.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"BI-3720931","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cystic fibrosis gene therapy - Boehringer Ingelheim/Oxford BioMedica/the UK Cystic Fibrosis Gene Therapy Consortium","status":"ACTIVE"}],"dev_code":[{"name":"BI 3720931","status":"ACTIVE"},{"name":"BI-3720931","status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["2dc84fe879ac162b68ea5359510a6aac"],"mechanism_action_id":["f94b15147938429e91f5b625b5bb9e1c"],"target_id":["5035217e3d264d34b475ebcbc6086466"],"disease_id":["7f8657c4a15148219c75eeb330d92c42"],"active_org_master_entity_id":["269f1e358ef7f1e4191094971edd4222","2dc84fe879ac162b68ea5359510a6aac","2ef20b1fcc046618e3d13c9af1cd70b1"],"research_disease":["7f8657c4a15148219c75eeb330d92c42"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1730678400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1730678400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1730678400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1730678400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1730678400000}}],"disease_phase":[{"disease_id":"7f8657c4a15148219c75eeb330d92c42","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["269f1e358ef7f1e4191094971edd4222","2ef20b1fcc046618e3d13c9af1cd70b1"],"data_source":10}
+{"drug_id":"0e0e59a6b7b04d1f992ca328caa28221","docid":262139,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2024-06-20T01:50:02.000Z","updated_ts":"2026-01-27T13:12:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"AD-227A","source_info":[{"code":"NCT06441630","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06441630"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4d1d5a2734be8dcabc02ecbfbf780ad7"],"disease_id":["f8f9347202e043bab0e0d627ce10e767"],"active_org_master_entity_id":["4d1d5a2734be8dcabc02ecbfbf780ad7"],"research_disease":["f8f9347202e043bab0e0d627ce10e767"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}}],"disease_phase":[{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"02652b8269c0469ba1fd3ab0c2c3e324","docid":75499,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1662422400000,"rnk":2,"target_extend_id":"23e78dc5bc9e3c569f29398d0a761044","created_ts":"2021-10-08T14:46:10.000Z","updated_ts":"2025-12-12T07:34:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"iNCOVACC","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://medicine.wustl.edu/news/worlds-first-nasal-covid-19-vaccine-approved-in-india-based-on-washington-university-technology/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ChAd-SARS-CoV-2-S","status":"ACTIVE"}],"dev_code":[{"name":"BBV 154","status":"ACTIVE"},{"name":"BBV-154","status":"ACTIVE"},{"name":"BBV154","status":"ACTIVE"}],"trade_name":[{"name":"iNCOVACC","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NzExNDQ4Nw==&mid=2650789586&idx=1&sn=94770ed4f855f00ae1ab5d2fc6f4fdf6"}],"status":"ACTIVE"}],"drug_type":["49e3fb94500546eb916faaee1707fabe","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["fd2ce172a6293f7c061772bb002a6278"],"mechanism_action_id":["5897c51cbf11540c8a156081a111c0be"],"target_id":["f2c8821a6e5845f1b698c8a5a00029e5"],"special_review":["74efa92412694fcfaab6151e88ce57c2"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["fd2ce172a6293f7c061772bb002a6278"],"first_approved_country":["2f753928-f426-3cc1-9ea6-8c25f6a4d330"],"first_approved_indication":["717a9bf79e584830859595b8dbe9d433"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"inactive_org_master_entity_id":["c247f0fb72b5c027c69606995996a9d1"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["2f753928-f426-3cc1-9ea6-8c25f6a4d330"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1662422400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["78c21581b706bf84a2ea8da0ba1c7348","bc725c8c328f32d4e2027d8ac40932b1","c247f0fb72b5c027c69606995996a9d1","fd2ce172a6293f7c061772bb002a6278"],"data_source":10}
+{"drug_id":"047c9e7943f941e3b2fc84a8fb1d9982","docid":9322,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"955e16120dc9345aa41b67b33a96f591","created_ts":"2021-10-08T14:43:35.000Z","updated_ts":"2026-02-24T12:59:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"盐酸氯苯哌酮","source_info":[{"normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR"}],"status":"ACTIVE"},{"lang":"EN","name":"Chlorobenzopiperidone Hydrochloride","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a9e1036b86828a41b027860c5e54f89d"],"mechanism_action_id":["1da1a766036d2f25a81936e61b123c54"],"target_id":["a9f0a6290ac54b089d41862599db01ca"],"disease_id":["e05d3f1bc6e8430e8a7dc7171ae02206","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["a9e1036b86828a41b027860c5e54f89d","7d2ce3422e13151f3260bfc6815fd2ec"],"research_disease":["e05d3f1bc6e8430e8a7dc7171ae02206","6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1558569600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e05d3f1bc6e8430e8a7dc7171ae02206","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0769d921cbd343ceb972d2dce27d81aa","docid":920129,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":14,"target_extend_id":"3caffb2312c53eddbe10f333da24165f","created_ts":"2025-02-18T11:24:04.000Z","updated_ts":"2025-02-18T21:08:06.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"DSP-0039","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NTI3MDE0NQ==&mid=2653768319&idx=1&sn=1286141493f6fbab72e7e52aff4c47bf"}],"status":"ACTIVE"}],"dev_code":[{"name":"DSP 0039","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NTI3MDE0NQ==&mid=2653768319&idx=1&sn=1286141493f6fbab72e7e52aff4c47bf"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ca66d2661dafdf2735d06ae038123df4"],"mechanism_action_id":["86ef0b1b55f6a3bd00eb3885dab2ed73","dc041ecead785c19109eaaab3c8625b8"],"target_id":["97c2026e3e384d5db0742de7b9573db3","4f0c095b670045188332b89979106a8e"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0"],"active_org_master_entity_id":["9cab9e052438d023cc22333dfd8142ab"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0975f124db734e2aa0feb655606617cf","docid":270015,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-01-24T05:51:05.000Z","updated_ts":"2026-04-13T21:24:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta)","source_info":[{"code":"NCT06789081","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06789081"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"GCAR1(AHS Cancer Control Alberta)","source_info":[{"code":"NCT06789081","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06789081"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["aceb29188cd7f8c22d45ceb8d59576ff"],"disease_id":["c15f11921f7042bea3fe717df04bcd2d","c7fe8aa844d24e85ba32a990ea28ded3","f92e4ba771d04f27a1f4daae363b676a"],"active_org_master_entity_id":["aceb29188cd7f8c22d45ceb8d59576ff","e9a28ca8902f4082e53926fd0c4362ea"],"research_disease":["c15f11921f7042bea3fe717df04bcd2d","c7fe8aa844d24e85ba32a990ea28ded3","f92e4ba771d04f27a1f4daae363b676a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1777593600000}}],"disease_phase":[{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c15f11921f7042bea3fe717df04bcd2d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01c118cf8dab4d359452cf9d81e95512","docid":55518,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:41:24.000Z","updated_ts":"2025-12-08T07:24:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"VRC-MARADC087-00-VP","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"cAd3-Marburg vaccine","status":"ACTIVE"}],"dev_code":[{"name":"CHAD3-MARV","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://medcitynews.com/2023/02/nih-marburg-vaccine-posts-encouraging-results-in-first-in-human-study/"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["e0af6e08f6be40d98e106935ce57da5e"],"active_org_master_entity_id":["6d6259569cec4e396e4c9b87b29716ea"],"research_disease":["e0af6e08f6be40d98e106935ce57da5e"],"inactive_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1744588800000}},{"country":"7b8fd1bd-c7fb-3ebd-b9e4-5372d8f85711","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1697673600000}},{"country":"3ec31c64-1669-3c69-9f1c-cf9f277fb45b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1697673600000}}],"disease_phase":[{"disease_id":"e0af6e08f6be40d98e106935ce57da5e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"1825a7a114bc4376a4fcc7afc04d5c95","docid":1731815,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":17,"target_extend_id":"46631cde0308360d97b73e60682d1b3c","created_ts":"2025-10-13T10:04:53.000Z","updated_ts":"2026-04-11T21:06:27.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Pan-T booster co-expressing MSLN CAR T cell(UTC Therapeutics)","source_info":[{"code":"NCT05693844","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05693844"}],"status":"ACTIVE"}],"dev_code":[{"name":"UCLM-805F","source_info":[{"attachment_path":"data/phs_source_info/6ad8/ec29/56e8/df54/6ad8ec2956e8df54.png","attachment_type":"image/png","code":"UTC Therapeutics-202512","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/852d/e131/545b/14ba/852de131545b14ba.png","source":"Company pipeline","source_url":"https://www.utctherapeutics.com/Pipeline/list.aspx?lcid=2"}],"status":"ACTIVE"},{"name":"UCLM805F","source_info":[{"attachment_path":"data/phs_source_info/6ad8/ec29/56e8/df54/6ad8ec2956e8df54.png","attachment_type":"image/png","code":"UTC Therapeutics-202512","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/852d/e131/545b/14ba/852de131545b14ba.png","source":"Company pipeline","source_url":"https://www.utctherapeutics.com/Pipeline/list.aspx?lcid=2"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["0e1efb8e969ab2c074a1e0d3ed3e43b0"],"mechanism_action_id":["b7720880ecd836503bbe1d9f15cae31e"],"target_id":["3305619b6ea741a19aa4a690d083582b"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["0e1efb8e969ab2c074a1e0d3ed3e43b0"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1674172800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0545bb4f70f14a07aa1d85a730ee6ac3","docid":69483,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":8,"target_extend_id":"5dda89db055132f9b4718ad9d5af409b","created_ts":"2022-06-24T07:41:37.000Z","updated_ts":"2026-02-24T22:43:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ART-001","status":"ACTIVE"}],"dev_code":[{"name":"ART 001","status":"ACTIVE"},{"name":"ART001","status":"ACTIVE"},{"name":"KP-001","status":"ACTIVE"},{"name":"KP001","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["77ba317c47fab874872a1c5025cf54f8"],"mechanism_action_id":["eaee1c5527b3a91b4ee1e520963463f7"],"target_id":["fe5b12ba299a474b979d6ab1ddca7b4b"],"disease_id":["578f253529a842508cdd7b609ba0ed3f","fff0e3afaabc44d3a5c4beef2174ddf2","6b51c03922ad43709c98a4826c063c87","abd9da29d16c4e31a4a94546a4b9c7e1","1cd4f48ea9d64099a5b2fe74f277bcf5","ae52ac6bb63b4ec3a994ab0e20b7f3ad"],"active_org_master_entity_id":["e207b806161c4848076fdc3c1891e3dd","77ba317c47fab874872a1c5025cf54f8","c5d275e3e4b9be67d2ad5ab700dd01b8"],"research_disease":["578f253529a842508cdd7b609ba0ed3f","fff0e3afaabc44d3a5c4beef2174ddf2","6b51c03922ad43709c98a4826c063c87","abd9da29d16c4e31a4a94546a4b9c7e1","1cd4f48ea9d64099a5b2fe74f277bcf5","ae52ac6bb63b4ec3a994ab0e20b7f3ad"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1729728000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1702598400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1746748800000}}],"disease_phase":[{"disease_id":"fff0e3afaabc44d3a5c4beef2174ddf2","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"ae52ac6bb63b4ec3a994ab0e20b7f3ad","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6b51c03922ad43709c98a4826c063c87","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"1cd4f48ea9d64099a5b2fe74f277bcf5","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"abd9da29d16c4e31a4a94546a4b9c7e1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"578f253529a842508cdd7b609ba0ed3f","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"27f66531dde6495f989d4eba6fab4bdc","docid":111085,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":75,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2024-04-03T06:56:10.000Z","updated_ts":"2026-04-04T21:10:50.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"靶向BCMA的嵌合抗原受体T细胞（石药集团中奇制药）","source_info":[{"code":"CTR20244175","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=d52eb720a3f94c49b5afe27a31f34207"}],"status":"ACTIVE"},{"lang":"EN","name":"SYS-6020","status":"ACTIVE"}],"dev_code":[{"name":"SYS6020","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["aa80dd945e334b322c9deaac3810291a"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["f3433922efe24dfaada77415e3e66ea0","c5e1987e283c495aaab2a8d309c6085e","7cd0fcf1c5c243b9b3944405ec4855b5","56842bd5a0fb4199bc0d99ae22798bdc"],"active_org_master_entity_id":["aa80dd945e334b322c9deaac3810291a","5cf5fedddb15b3ca0a531d9b789f0286","aacba1cf511d2713ac418425f8edcb67"],"research_disease":["f3433922efe24dfaada77415e3e66ea0","c5e1987e283c495aaab2a8d309c6085e","7cd0fcf1c5c243b9b3944405ec4855b5","56842bd5a0fb4199bc0d99ae22798bdc"],"inactive_org_master_entity_id":["1ee2ef06f7a588e42142080b4c971338"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1740096000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"56842bd5a0fb4199bc0d99ae22798bdc","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"063fc30e8a294b3c829ca896c5cecafa","docid":202695,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":28,"target_extend_id":"70cb31797d953b2fa31f93b5e2303de0","created_ts":"2024-07-11T08:18:03.000Z","updated_ts":"2026-03-07T21:12:54.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"JNJ-1459","source_info":[{"attachment_path":"data/phs_source_info/31ab/2254/b28b/dad7/31ab2254b28bdad7.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/025e/1462/e520/4067/025e1462e5204067.png","source":"Company pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"JNJ 1459","source_info":[{"attachment_path":"data/phs_source_info/31ab/2254/b28b/dad7/31ab2254b28bdad7.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/025e/1462/e520/4067/025e1462e5204067.png","source":"Company pipeline"}],"status":"ACTIVE"},{"name":"JNJ 81241459","source_info":[{"code":"CTIS2023-508992-35-00","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-508992-35-00"}],"status":"ACTIVE"},{"name":"JNJ-81241459","source_info":[{"code":"CTIS2023-508992-35-00","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-508992-35-00"}],"status":"ACTIVE"},{"name":"JNJ1459","source_info":[{"attachment_path":"data/phs_source_info/31ab/2254/b28b/dad7/31ab2254b28bdad7.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/025e/1462/e520/4067/025e1462e5204067.png","source":"Company pipeline"}],"status":"ACTIVE"},{"name":"JNJ81241459","source_info":[{"code":"CTIS2023-508992-35-00","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-508992-35-00"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["fa85404e9b2f62d55e5167ed2213eca7"],"mechanism_action_id":["6a657d2071af4318ce868bfc377025d9"],"target_id":["fe57a898c13b496a9ba39094b9fe219a"],"disease_id":["d281a3b362a740d8aeb63e2a10102671"],"research_disease":["d281a3b362a740d8aeb63e2a10102671"],"inactive_org_master_entity_id":["fa85404e9b2f62d55e5167ed2213eca7"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716940800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1710720000000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00817323abb347e1b5ae745b1dec0f51","docid":20853,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"6707b05fb34839d69f24ffe686798967","created_ts":"2021-10-08T14:48:46.000Z","updated_ts":"2026-04-04T21:09:47.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"KD-025(Nanjing Kaedi Biotechnology Co Ltd)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"NKG2D chimeric antigen receptor-T cells","status":"ACTIVE"}],"dev_code":[{"name":"KD 025","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-nkg2d-car-t-cells-kd-025"}],"status":"ACTIVE"},{"name":"KD-025","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-nkg2d-car-t-cells-kd-025"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["a84b262969eb7660cfb4cf260909cf17"],"mechanism_action_id":["3c1893f52f3c1c581412e3a9fe652490"],"target_id":["16e5861f40ba402fb71bf4d404a5f3c2"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4","0464f5493b0444e9875a0584df17cbf0","7ebeb7b6d9ff470f830cb83aba8fe6e2"],"active_org_master_entity_id":["a84b262969eb7660cfb4cf260909cf17"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4","0464f5493b0444e9875a0584df17cbf0","7ebeb7b6d9ff470f830cb83aba8fe6e2"],"inactive_org_master_entity_id":["9a1b16fd178b55e41ab14b30e6352097"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7"}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7ebeb7b6d9ff470f830cb83aba8fe6e2","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"deal_related_org":["1a9edc57ee6e83434512a8c412208bbf","ed0e6e076d5ee9bb60d7b88acb5eca95"],"data_source":10}
+{"drug_id":"20127015c5114b269c690b841df3972d","docid":110202,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2024-01-25T08:14:18.000Z","updated_ts":"2026-03-24T03:20:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"Oxylanthanum Carbonate","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"OLC","source_info":[{"attachment_path":"data/phs_source_info/c3aa/7311/2059/bbcf/e3f22f5f-ec96-3062-95a6-6f4cd5c115a2.png","attachment_type":"image/png","code":"Unicycive-20240925","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5635/9f5b/a4c6/9b2c/275c0a21-2fa6-3cd1-a902-426766efecf8.png","source":"Company pipeline","source_url":"https://unicycive.com/pipeline/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e9745f947255f31153bc31964780fbb4"],"disease_id":["834fbd398de443f59c480fc3b82971ac","bb895a9780a94318973390e3df4eb213"],"active_org_master_entity_id":["e9745f947255f31153bc31964780fbb4"],"research_disease":["834fbd398de443f59c480fc3b82971ac","bb895a9780a94318973390e3df4eb213"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1769644800000}}],"disease_phase":[{"disease_id":"834fbd398de443f59c480fc3b82971ac","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"bb895a9780a94318973390e3df4eb213","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"2c3fe2a76c6743469534c079aa831f79","docid":45053,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2022-09-27T12:39:38.000Z","updated_ts":"2024-12-26T00:21:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"WAV-102","status":"ACTIVE"}],"dev_code":[{"name":"WAV-102","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0db04d5810e1499a71151458ebe9225d"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["0db04d5810e1499a71151458ebe9225d"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1647302400000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1647302400000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0ff3311f585942da95a1694eca4f0c39","docid":1309966,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-03-24T02:47:42.000Z","updated_ts":"2025-03-24T02:58:15.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"METR-NK Cells(Anhui Provincial Cancer Hospital)","source_info":[{"code":"NCT06884345","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06884345"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["4375d12245ea22ad5028c783104670f5"],"disease_id":["3aecb71c582e487c962fa840ee3ef8f5"],"active_org_master_entity_id":["4375d12245ea22ad5028c783104670f5"],"research_disease":["3aecb71c582e487c962fa840ee3ef8f5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741824000000}}],"disease_phase":[{"disease_id":"3aecb71c582e487c962fa840ee3ef8f5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1c6edee39b0340eea58c5f8464fbf0aa","docid":45541,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"1b7366a3b6133129b67c4e2664ec69db","created_ts":"2023-01-10T12:29:40.000Z","updated_ts":"2026-04-02T12:01:45.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"ENTR-601-45","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2023/01/09/2585042/0/en/Entrada-Therapeutics-Announces-Clinical-Candidate-ENTR-601-45-for-the-Potential-Treatment-of-People-Living-with-Duchenne-Muscular-Dystrophy-who-are-Exon-45-Skipping-Amenable.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Exon 45 Skipping Oligonucleotide","source_info":[{"attachment_path":"data/phs_source_info/e534/aa55/aa55/4dd4/e534aa55aa554dd4.png","attachment_type":"image/png","code":"entradatx202509","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/14c4/9890/911f/bebe/14c49890911fbebe.png","source":"Company pipeline","source_url":"https://www.entradatx.com/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"ENTR 601-45","status":"ACTIVE"},{"name":"ENTR-601-45","status":"ACTIVE"},{"name":"ENTR601-45","status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["63ace6c0fa3d4c4ef3aa8c2432933984"],"mechanism_action_id":["72064e43ea03440db10fa411c978d769"],"target_id":["f20214cc16fd47ca9f7f8cb079c90fcf"],"disease_id":["3edeea348eb24d8d8fbf0cccd058f464"],"active_org_master_entity_id":["63ace6c0fa3d4c4ef3aa8c2432933984"],"research_disease":["3edeea348eb24d8d8fbf0cccd058f464"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756512000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756512000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756512000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756512000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756512000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1748390400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"3edeea348eb24d8d8fbf0cccd058f464","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10,"tech_platform":["062f226a86d644bd8d499c1dc59daae2"],"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://www.entradatx.com/platform"}],"regulation_type":["95a1412d87af492498bb97fd5112028f"],"targeted_tissue":["810e3182f7544de495abcbe49ec6ce56"],"delivery_system":["7385ba5ca4fc4732a0f90ebe74533884"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"007d4a659fd147f6b57e9c1ba03115fa","docid":77361,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":96,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2021-10-08T14:49:32.000Z","updated_ts":"2026-03-21T21:08:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"门冬胰岛素 (北京双鹭药业)","status":"ACTIVE"},{"lang":"EN","name":"Insulin Aspart(Beijing SL Pharmaceutical Co., Ltd.)","status":"ACTIVE"}],"generic_name":[{"name":"insulin aspart","status":"ACTIVE"}],"kegg_id":["D04475"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["86c08d7bb7973b982ea3c499d4d2fbcd"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["86c08d7bb7973b982ea3c499d4d2fbcd"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576627200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["24369259a5664ab38bc28c350f16fa04"],"data_source":10}
+{"drug_id":"239dd62cb00346e6b99cad698ef8350a","docid":1674070,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":30,"target_extend_id":"f925d5d339cc3170b7e1448f50b4f1d7","created_ts":"2026-03-18T06:28:51.000Z","updated_ts":"2026-04-11T21:08:38.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Autologous CD7 CAR-T cell(Hematology Hospital of Chinese Academy of Medical Sciences)","source_info":[{"code":"NCT07476027","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07476027"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"mechanism_action_id":["bc3ae3d2a63347f8a25d3186b2a852f0"],"target_id":["b893e5b66e334131a95a3d8e69a969e3"],"disease_id":["33a9d37dd10f424289324134d84d0bbb","321ac17172fe4cf591c294f981cdba78"],"active_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"research_disease":["33a9d37dd10f424289324134d84d0bbb","321ac17172fe4cf591c294f981cdba78"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"321ac17172fe4cf591c294f981cdba78","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"33a9d37dd10f424289324134d84d0bbb","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"484b096b83d3460696e1f50470b7d8f8","docid":15384,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2023-05-30T08:21:30.000Z","updated_ts":"2024-12-24T08:28:09.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"fangdongbing","drug_name":[{"lang":"EN","name":"M6050C","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.maruho.co.jp/english/about/activities/pipeline/"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["38ca3349192e11aaf265cd1bb7805976"],"disease_id":["10ed4cbd447e4fe6a9dc80e700982ce0"],"active_org_master_entity_id":["38ca3349192e11aaf265cd1bb7805976"],"research_disease":["10ed4cbd447e4fe6a9dc80e700982ce0"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"78c45f1d523646808032edcff807ca59"}],"disease_phase":[{"disease_id":"10ed4cbd447e4fe6a9dc80e700982ce0","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"02d859ba39fd47cf8f0c2e253e8db7e5","docid":28163,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":402,"target_extend_id":"f17bf7a3464437f3b800048cb8c15a7a","created_ts":"2021-10-08T14:45:43.000Z","updated_ts":"2026-04-04T21:12:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SHP-680","status":"ACTIVE"}],"dev_code":[{"name":"SHP 680","status":"ACTIVE"},{"name":"TAK 680","status":"ACTIVE"},{"name":"TAK-680","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["30bf50d0b0414c75aed1c1c9c3aa006c"],"mechanism_action_id":["55d83b3ae8d808b42bf730f916d31651","66e78181b6de902f374fab8ebe00d1f0"],"target_id":["3331837a8ec8485bb6128789110ead41"],"disease_id":["71a4271b98874e96b16000266c8d79cc"],"active_org_master_entity_id":["cb481a02e52acaad359340eda31e12e4"],"research_disease":["71a4271b98874e96b16000266c8d79cc"],"inactive_org_master_entity_id":["3213232cf3774bc734def2420b679bb6"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1526083200000}}],"disease_phase":[{"disease_id":"71a4271b98874e96b16000266c8d79cc","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"044efc425cc8404291064a29abaa69f3","docid":75809,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-07-11T03:18:38.000Z","updated_ts":"2026-04-20T00:08:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Fusion-VAC-XS15","source_info":[{"code":"NCT05937295","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05937295"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DNAJB1-PRKACA Fusion Transcript-based Peptide(University Hospital Tuebingen)","source_info":[{"code":"NCT06789198","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06789198"}],"status":"ACTIVE"},{"lang":"EN","name":"Fusion Transcript-based Peptide Vaccine(University Hospital Tuebingen)","source_info":[{"code":"NCT06789198","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06789198"}],"status":"ACTIVE"},{"lang":"EN","name":"FusionVAC-XS15","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["a263415770402d507a727c8238f18b7b"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["c42587486de443e1ab9795a933526013"],"active_org_master_entity_id":["a263415770402d507a727c8238f18b7b"],"research_disease":["c42587486de443e1ab9795a933526013"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1695686400000}}],"disease_phase":[{"disease_id":"c42587486de443e1ab9795a933526013","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0210358949724fe4b1bfe04f65a07599","docid":1700055,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"d5a1aa9c7d424afa8fd8ffbf5f21a0db","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-07-07T07:48:02.000Z","updated_ts":"2026-02-02T00:48:23.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"89Zr-NY009","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.ks-vpeptide.com.cn/news_detail/64.html"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["5e2938dc85dae2c1cd9d974ea6a6a601"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","ae092fa59f4d44edaf59ffe23d0a44c3"],"active_org_master_entity_id":["faa9ea08d792dc82af6444fa1fd8362a","5e2938dc85dae2c1cd9d974ea6a6a601"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9","ae092fa59f4d44edaf59ffe23d0a44c3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10}
+{"drug_id":"237b5a1242df4ce0b50f12f1fb8c505c","docid":203690,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2024-09-12T07:09:11.000Z","updated_ts":"2025-08-23T00:21:38.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"甲苯磺酸钠烟酰胺腙聚乙二醇双环RGD肽","status":"ACTIVE"},{"lang":"EN","name":"HYNIC-3PRGD2(Foshan Rui Diao)","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["89b78ab5a8ded2513db675e44db3a18a"],"special_review":["23d3523b7ece48ddacaddac53a66949d"],"disease_id":["5deff26087df4390bd5ab807fca3556b"],"active_org_master_entity_id":["89b78ab5a8ded2513db675e44db3a18a","63d83cc5cb5aa7fc7cfc9444094aaa5c"],"research_disease":["5deff26087df4390bd5ab807fca3556b"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1749686400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1724889600000}}],"disease_phase":[{"disease_id":"5deff26087df4390bd5ab807fca3556b","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"10298cbbaa3c43ffb464767ac1c01b77","docid":1671463,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-09-22T03:21:12.000Z","updated_ts":"2025-10-30T10:48:42.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"MSC Exosome Therapy(Universitas Padjadjaran)","source_info":[{"code":"NCT07183384","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07183384"}],"status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["15efe9879ca321c02c1228a18350c6f5"],"disease_id":["74fcbe67c99f4263b6713bc197e2ea17","c4c887181b4947de99e242d24dd3e176"],"active_org_master_entity_id":["15efe9879ca321c02c1228a18350c6f5"],"research_disease":["74fcbe67c99f4263b6713bc197e2ea17","c4c887181b4947de99e242d24dd3e176"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ba5f77a3-321f-3e45-91fc-4ff21b4edad7","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}}],"disease_phase":[{"disease_id":"74fcbe67c99f4263b6713bc197e2ea17","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c4c887181b4947de99e242d24dd3e176","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"09286d07aa4741d98003083bed359cbc","docid":22792,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-05-26T07:56:04.000Z","updated_ts":"2024-11-07T20:20:48.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"OPL-026","source_info":[{"attachment_path":"data/phs_source_info/b659/3307/7f38/2a35/8b83990c-47a6-3e59-bec0-27450b623154.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/32a4/3e1d/0742/24af/b6a1c7be-8be6-34e8-a42e-208c8d704ef6.png","source":"Company pipeline","source_url":"http://www.overseaspharm.com/page/289656.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"OPL-026","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://cn.overseaspharm.com/domain/"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["3642174ed7ee65096c0a17bb9615f0c3"],"disease_id":["5a66b9249fae4d97afa13193f05749b9"],"active_org_master_entity_id":["3642174ed7ee65096c0a17bb9615f0c3"],"research_disease":["5a66b9249fae4d97afa13193f05749b9"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686614400000}}],"disease_phase":[{"disease_id":"5a66b9249fae4d97afa13193f05749b9","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"3db45a9a4f9243589d9ad3e275cba58c","docid":980066,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":35,"target_extend_id":"75fdcf5bf499369580c308e613a6a161","created_ts":"2025-02-17T05:22:46.000Z","updated_ts":"2026-04-11T21:06:21.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Allogeneic CAR-T targeting CD70(Nanjing Calmhome Cell & Gene Engineering Institute)","source_info":[{"code":"NCT06828341","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06828341"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["44efcf43953fdb55fab6f7977a320fc5"],"mechanism_action_id":["e0a0b70f83bc40c2b45d872d0fe4b7d4"],"target_id":["79d24e30a7ff40bb806ff36962c750e8"],"disease_id":["0a885de5b4054c2b98d478f91f3e3418"],"active_org_master_entity_id":["44efcf43953fdb55fab6f7977a320fc5"],"research_disease":["0a885de5b4054c2b98d478f91f3e3418"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1718236800000}}],"disease_phase":[{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0012c8629fa64f41a1a30bd7d3f0ccca","docid":33388,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:50:21.000Z","updated_ts":"2024-11-06T12:09:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"乌拉扎胺","status":"ACTIVE"},{"lang":"EN","name":"Urazamide","status":"ACTIVE"}],"trade_name":[{"name":"Recover","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"atc_code":["34dd847de24740458d8da34a2bf4d5b8"],"disease_id":["31a7df44282a442997e650a215ce8159"],"research_disease":["31a7df44282a442997e650a215ce8159"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"disease_phase":[{"disease_id":"31a7df44282a442997e650a215ce8159","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0177c0e880f940a29b0acbdcf3bbdad7","docid":76734,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1009843200000,"created_ts":"2021-10-08T14:49:48.000Z","updated_ts":"2026-02-14T00:43:37.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1009843200000,"drug_name":[{"lang":"CN","name":"卡介菌多糖核酸 (湖南斯奇生物制药)","status":"ACTIVE"},{"lang":"EN","name":"BCG Polysaccharide and Nucleic Acid(Hunan Jiuzhitang Siqi Biological Pharmaceutical Co. Ltd.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BCG Polysaccharide and Nucleic Acid","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"卡介菌多糖核酸注射剂","status":"ACTIVE"}],"trade_name":[{"name":"斯奇康","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["ebf1612d3f61cda5a19c30e1b796e6e5"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["8b65d40c1a554ef1bcdeb9613ec4e683"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","41d613c1ab7e41c3ae5a87b2e44da37b","02b9f9b0f3464ccbb37429d10f9aea36","be685463e8e640119dff51e5125e6d0f","d613cc8191104d3190a445b327b9b950"],"active_org_master_entity_id":["ebf1612d3f61cda5a19c30e1b796e6e5"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["15fe4881cb88431eb9d44b018619d7b0","41d613c1ab7e41c3ae5a87b2e44da37b","02b9f9b0f3464ccbb37429d10f9aea36","be685463e8e640119dff51e5125e6d0f","d613cc8191104d3190a445b327b9b950"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","41d613c1ab7e41c3ae5a87b2e44da37b","02b9f9b0f3464ccbb37429d10f9aea36","be685463e8e640119dff51e5125e6d0f","d613cc8191104d3190a445b327b9b950"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1009843200000}}],"disease_phase":[{"disease_id":"02b9f9b0f3464ccbb37429d10f9aea36","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"41d613c1ab7e41c3ae5a87b2e44da37b","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d613cc8191104d3190a445b327b9b950","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0c56401b88244faca8560521b69af0ec","docid":1282007,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-06-24T00:59:22.000Z","updated_ts":"2025-06-24T01:22:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"I-01/23","source_info":[{"code":"NCT07032142","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07032142"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["26f39238b88fd3c0192a8a0edfebde72"],"disease_id":["444f00446e864db8a813b7303adffdeb"],"active_org_master_entity_id":["26f39238b88fd3c0192a8a0edfebde72"],"research_disease":["444f00446e864db8a813b7303adffdeb"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1751328000000}}],"disease_phase":[{"disease_id":"444f00446e864db8a813b7303adffdeb","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"166a1d13285f4f688ed2556823c06ce9","docid":74368,"is_nme":0,"is_compound_medicine":0,"payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-12-04T07:34:53.000Z","updated_ts":"2025-02-24T12:03:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"18F-FMT","status":"ACTIVE"}],"dev_code":[{"name":"18F-FMT","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["8549346543da718fd83a7d03b7e5db4f"],"disease_id":["7c78dd7ca12d4eadbd772cf774c82efe"],"active_org_master_entity_id":["8549346543da718fd83a7d03b7e5db4f"],"research_disease":["7c78dd7ca12d4eadbd772cf774c82efe"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}}],"disease_phase":[{"disease_id":"7c78dd7ca12d4eadbd772cf774c82efe","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4fccb56720a446d28b37ffe28ab3f9f0","docid":24608,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:29.000Z","updated_ts":"2024-11-11T16:15:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ZL015","status":"ACTIVE"}],"dev_code":[{"name":"ZL015","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["524565d5c1398d539b0d677d9fdc0ef0"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["524565d5c1398d539b0d677d9fdc0ef0"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1643155200000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"06aef7b3bc6244b4812baa6a83f173ab","docid":73278,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"7ab9265bfb193060826eb61fc62e9e43","created_ts":"2021-10-08T14:50:28.000Z","updated_ts":"2025-08-30T21:16:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AAV2 smCBA based G11778A ND4 gene therapy(University of Miami)","status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["be821640d7370091974e4a6997f1d187"],"mechanism_action_id":["76cf169cbc390e3b67b76316bc410ed6"],"target_id":["d4b3dbc494204d0cafbe5fa4cc7e547f"],"disease_id":["cc70a0353d064657951df0c1bfad3f35"],"active_org_master_entity_id":["be821640d7370091974e4a6997f1d187"],"research_disease":["cc70a0353d064657951df0c1bfad3f35"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"cc70a0353d064657951df0c1bfad3f35","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"089921fdebaf4d469c0f6547acc60813","docid":31056,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-03-13T02:18:04.000Z","updated_ts":"2026-03-20T20:54:12.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"钇90炭微球","source_info":[{"code":"CTR20240312","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=8a5731806c6a4b69ac3cb537731c2399"}],"status":"ACTIVE"},{"lang":"EN","name":"NRT6008","source_info":[{"code":"CXHL2300295","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"NRT 6008","status":"ACTIVE"},{"name":"NRT-6008","status":"ACTIVE"},{"name":"NRT6008","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3645c85ed81891d086ea88c5ce0972e4"],"disease_id":["e67c7fcd3d3a494ab70e1efe0b82ecdc","e47ba0c33e85473e9171b4125ae2216b","8bea5bec08e44c1ea7a90c7a1e3daeb8"],"active_org_master_entity_id":["6d5a11e07500682b0fdecbeb19090d95","3645c85ed81891d086ea88c5ce0972e4"],"research_disease":["e67c7fcd3d3a494ab70e1efe0b82ecdc","e47ba0c33e85473e9171b4125ae2216b","8bea5bec08e44c1ea7a90c7a1e3daeb8"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1727308800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1704758400000}}],"disease_phase":[{"disease_id":"e67c7fcd3d3a494ab70e1efe0b82ecdc","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8bea5bec08e44c1ea7a90c7a1e3daeb8","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e47ba0c33e85473e9171b4125ae2216b","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"063b0c0ab5154ec080cea6263a897586","docid":5605,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-05-29T03:37:25.000Z","updated_ts":"2024-11-07T15:19:48.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"zhongxia","drug_name":[{"lang":"EN","name":"AER-002","source_info":[{"code":"NCT05877508","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05877508"}],"status":"ACTIVE"}],"dev_code":[{"name":"AER 002","status":"ACTIVE"},{"name":"AER002","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["9537645aae73642d74a73c78beed0823"],"disease_id":["f21b246b05574261844954d981c3ba89"],"active_org_master_entity_id":["5a3440fb46fe93ce88c47950896dc1c6"],"research_disease":["f21b246b05574261844954d981c3ba89"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}}],"disease_phase":[{"disease_id":"f21b246b05574261844954d981c3ba89","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"008d9726a5744bc7951070eb60375bf7","docid":1312078,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-06-17T09:48:06.000Z","updated_ts":"2025-06-17T10:14:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"SHED-CM(U Factor)","source_info":[{"code":"NCT06889857","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06889857"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["002a8404b1468b4aa8f063bba10c6bd2"],"disease_id":["738546bac89e4895b89af01545f1b054"],"active_org_master_entity_id":["002a8404b1468b4aa8f063bba10c6bd2"],"research_disease":["738546bac89e4895b89af01545f1b054"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1712275200000}}],"disease_phase":[{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0b1ba442cbe94493870a1215cf5a397a","docid":113830,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-06-15T12:50:06.000Z","updated_ts":"2026-02-13T02:52:42.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CBG-131","source_info":[{"attachment_path":"data/phs_source_info/9796/4ee1/fe2e/b1ea/554e8e75-7873-3235-b736-f18c0a3a32f4.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5ad7/cd80/d524/bf67/10498a61-be5d-36de-9466-db778978b302.png","source":"Company pipeline","source_url":"https://www.compvss.com/en/proline.php"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["ea2d340dfc9ef8f4afb729e9649d2936"],"disease_id":["03f11bbd7f914af3ae6730b911c4a29a","7c3e7b3d0d8a4e13bfe0a3a26af27368"],"active_org_master_entity_id":["ea2d340dfc9ef8f4afb729e9649d2936"],"research_disease":["03f11bbd7f914af3ae6730b911c4a29a","7c3e7b3d0d8a4e13bfe0a3a26af27368"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1790726400000}}],"disease_phase":[{"disease_id":"03f11bbd7f914af3ae6730b911c4a29a","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7c3e7b3d0d8a4e13bfe0a3a26af27368","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0dbf597898f64919a3e3473a9aacaf49","docid":83381,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-01-10T07:37:00.000Z","updated_ts":"2025-01-16T10:12:09.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"NV01-E01","source_info":[{"attachment_path":"data/phs_source_info/8aec/9655/80bb/b3e7/4743fbb3-78fe-35b2-8da4-32acb4ae3f4c.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f61d/8d92/7d52/7d7c/fe64fca2-9cd6-37f1-9808-4d90b086b4b4.png","source":"Company pipeline","source_url":"http://www.neuroventi.com/theme/theme06/en/sub/pipeline.php"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["d4e2d2fd0fcf4adce0d5a2f8f46c9308"],"disease_id":["94f13bf88b344e3d9da1438266fa7d58"],"active_org_master_entity_id":["b4adff15e50e4a633a5a7dddf2592965","d4e2d2fd0fcf4adce0d5a2f8f46c9308"],"research_disease":["94f13bf88b344e3d9da1438266fa7d58"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"91ac63db1def4da58e890aec574fe7f4"}],"disease_phase":[{"disease_id":"94f13bf88b344e3d9da1438266fa7d58","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4ae1a6a8cdc7486dbc91295785708b3a","docid":74096,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-02-28T01:56:33.000Z","updated_ts":"2026-01-27T17:25:12.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Allogenic NK cells(Xuzhou Medical University)","source_info":[{"code":"NCT05744440","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05744440"}],"status":"ACTIVE"}],"dev_code":[{"name":"JD-002","source_info":[{"code":"NCT05744440","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05744440"}],"status":"ACTIVE"}],"drug_type":["191ae7835fbd4549bf30d04910df4acc"],"originator_org_master_entity_id":["b161e6c6633d5aa4df0b1fc133bf3a4c"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","a3426fcb9c77fd99d0461848fe75fb8f"],"disease_id":["5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["b161e6c6633d5aa4df0b1fc133bf3a4c"],"research_disease":["5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1677628800000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0411047f85344e49a429321367267798","docid":1701838,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-11-11T07:41:29.000Z","updated_ts":"2025-12-09T06:30:25.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"J8-K4S2/p*17-K4S2","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzIxNzIyNTIyMA==&mid=2650564099&idx=1&sn=1f8e4741aac2234bc3cd988e757744c3"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["6e75c949d71f55bb52bfc44d0cb48044","a274fe1952a4e759fda4feba6f41b6b2"],"disease_id":["95e626c5fd0249029927a9bceb12bb35"],"active_org_master_entity_id":["6e75c949d71f55bb52bfc44d0cb48044"],"research_disease":["95e626c5fd0249029927a9bceb12bb35"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1667779200000}}],"disease_phase":[{"disease_id":"95e626c5fd0249029927a9bceb12bb35","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1ac6120b66f44431aa26d2b2e95c8658","docid":8186,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-09-27T12:39:21.000Z","updated_ts":"2024-10-30T10:19:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NB127","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["533657a5dc32d5746ea06fc9327915a7"],"disease_id":["25aa9dbd25714b36b8bcb9347d1b91d1","54a77f56d72c4ac6a0eb840f4518e3a0","a3fae44a4406426ea9f6d2b151bedbbd"],"active_org_master_entity_id":["533657a5dc32d5746ea06fc9327915a7"],"research_disease":["25aa9dbd25714b36b8bcb9347d1b91d1","54a77f56d72c4ac6a0eb840f4518e3a0","a3fae44a4406426ea9f6d2b151bedbbd"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1647388800000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a3fae44a4406426ea9f6d2b151bedbbd","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01deee6fbd6844688dc6fd468b9090bd","docid":21302,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"178a28dce5dd307cac15b2dc5758641e","created_ts":"2021-11-30T08:55:27.000Z","updated_ts":"2025-12-05T00:30:44.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"KD-496","status":"ACTIVE"}],"dev_code":[{"name":"KD 496","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-nkg2dl-anti-cldn182-bispecific-car-t-cells-kd-496"}],"status":"ACTIVE"},{"name":"KD-496","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-nkg2dl-anti-cldn182-bispecific-car-t-cells-kd-496"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["a84b262969eb7660cfb4cf260909cf17"],"mechanism_action_id":["e5de4296d7d64eb68d12689d0ef4af53","17ed31c50231d53349a6bee9a4ef310a","c21cd55d21c3a009862003d8fac21b41","3c1893f52f3c1c581412e3a9fe652490","d9627d77b8d00d879e22e88877e54736","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["16e5861f40ba402fb71bf4d404a5f3c2","45f4868607f34cd5aa6d23ec518f90ac","4e562d9f915b46e9833e55ce382d7e4d","965671e4a869426b9417da511729661c"],"disease_id":["537a0fdac33b48fca37cab8f3450e8ed","7ebeb7b6d9ff470f830cb83aba8fe6e2","ae092fa59f4d44edaf59ffe23d0a44c3","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["a84b262969eb7660cfb4cf260909cf17"],"research_disease":["537a0fdac33b48fca37cab8f3450e8ed","7ebeb7b6d9ff470f830cb83aba8fe6e2","ae092fa59f4d44edaf59ffe23d0a44c3","ab7c198e47834770a36ab3282d331531"],"inactive_org_master_entity_id":["9a1b16fd178b55e41ab14b30e6352097"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1700092800000}}],"disease_phase":[{"disease_id":"537a0fdac33b48fca37cab8f3450e8ed","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7ebeb7b6d9ff470f830cb83aba8fe6e2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"020703709f944bb2aa7cdfe42a70bfde","docid":45024,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":24,"target_extend_id":"8c52d6e0b566342a9409a0f4d0068bf3","created_ts":"2021-10-08T14:44:06.000Z","updated_ts":"2026-04-04T21:10:16.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"KB-407","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2023/01/18/2590789/0/en/Krystal-Biotech-Receives-European-Commission-Orphan-Designation-for-KB407-for-the-Treatment-of-Cystic-Fibrosis.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"KB 407","status":"ACTIVE"},{"name":"KB407","status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["33c9dff1bfb9e1b7e5d3e57e39151a05"],"mechanism_action_id":["d85fc1197582e07b978e751b43dcfe9f"],"target_id":["5035217e3d264d34b475ebcbc6086466"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["7f8657c4a15148219c75eeb330d92c42"],"active_org_master_entity_id":["33c9dff1bfb9e1b7e5d3e57e39151a05"],"research_disease":["7f8657c4a15148219c75eeb330d92c42"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1688083200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1691971200000}}],"disease_phase":[{"disease_id":"7f8657c4a15148219c75eeb330d92c42","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0516b9ff58724cef8792040a3bed7ca2","docid":19087,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Trilaciclib","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1613088000000,"rnk":4,"target_extend_id":"20d9fb313a55301f8de038859eb247b2","has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:59.000Z","updated_ts":"2026-04-02T16:47:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","first_approved_date_cn":1657584000000,"drug_name":[{"lang":"CN","name":"盐酸曲拉西利","source_info":[{"code":"JXHS2101087","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Trilaciclib Dihydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Trilaciclib","source_info":[{"code":"U6072DO9XG","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/e5dd47ae-f848-412c-846d-8762dea6bdbb"}],"status":"ACTIVE"},{"lang":"EN","name":"Trilaciclib hydrochloride","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://en.simcere.com/kxcx/yfgx.aspx"}],"status":"ACTIVE"}],"dev_code":[{"name":"G1T 28","status":"ACTIVE"},{"name":"G1T28","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trilaciclib"}],"status":"ACTIVE"},{"name":"G1T28-1","status":"ACTIVE"}],"trade_name":[{"name":"Cosela","source_info":[{"code":"D11987","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"科赛拉","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzAxODA5MTU3NQ==&mid=2650280645&idx=1&sn=99676b52cc7fa143849c43a0c6d85346"}],"status":"ACTIVE"}],"generic_name":[{"name":"Trilaciclib","source_info":[{"code":"U6072DO9XG","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/e5dd47ae-f848-412c-846d-8762dea6bdbb"}],"status":"ACTIVE"}],"drugbank_id":["DB15442"],"kegg_id":["D11987"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bacd647239c276d02bd305754d33882b"],"mechanism_action_id":["35627e4eec1e3431be33b96b6f77dd56","24787486e57de6b1428a1229ed3a7840"],"target_id":["1c9a8e0192c1473cb0155b1d3196ee34","f29254fec6614d4d8396deec87a95f36"],"atc_code":["38b800a73be94e4c937b5e6ff3584198"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","ca2f2c7dacec450e8a45e2b7f4b74d05","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["2536e79ced34450fbb09de73061cf096","7a6d5e7eb7bf42a08da8144db4c931df","332d60a14b7b43278a24d0ac2961a361","f92e4ba771d04f27a1f4daae363b676a","58f692a66e03451d89d57770cd915d61","a0304a462da04e7cb03e3f2c5625544e","e938f07eba7148ecadbaa56ae7904072","7665e5683a1a443a8f3d3b946d4c9ca2","e35ce4e9b7a846d49e600ce7ac4a7fd6","29693bf775e54da5b22560ce69095d77","2bb755a3f43f49dea60661c5f99712a3","7af2742b1e824bb4bae223164df67757","c7879aa9883f473695aea6cc7470cb48","ca1336d953b4489d9378b4a6ccf0de6f"],"active_org_master_entity_id":["69b6547a2c75cdb0fe756f29c3c105a7","84ad28fb8a0b6eef403ba652e15c62be","bacd647239c276d02bd305754d33882b","8281c545ce2645eecfee0875b87a65ef","8713f0d895479accdeb49b4b47336ef0","edb235817e025cff944e34b60f3ee5c1"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["7a6d5e7eb7bf42a08da8144db4c931df"],"research_disease":["2536e79ced34450fbb09de73061cf096","7a6d5e7eb7bf42a08da8144db4c931df","332d60a14b7b43278a24d0ac2961a361","f92e4ba771d04f27a1f4daae363b676a","58f692a66e03451d89d57770cd915d61","a0304a462da04e7cb03e3f2c5625544e","e938f07eba7148ecadbaa56ae7904072"],"non_research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","e35ce4e9b7a846d49e600ce7ac4a7fd6","29693bf775e54da5b22560ce69095d77","2bb755a3f43f49dea60661c5f99712a3","7af2742b1e824bb4bae223164df67757","c7879aa9883f473695aea6cc7470cb48","ca1336d953b4489d9378b4a6ccf0de6f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1613088000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1657584000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1769904000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"2112a05f-55a8-36a9-b77e-ce71a16c4e24","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1620950400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1732579200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1757289600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1732579200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1732579200000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1676246400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1513468800000}}],"disease_phase":[{"disease_id":"e938f07eba7148ecadbaa56ae7904072","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"332d60a14b7b43278a24d0ac2961a361","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c7879aa9883f473695aea6cc7470cb48","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"29693bf775e54da5b22560ce69095d77","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"58f692a66e03451d89d57770cd915d61","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"ca1336d953b4489d9378b4a6ccf0de6f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"72bf9cc7b919488db49ec3583950ea17","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7a6d5e7eb7bf42a08da8144db4c931df","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7af2742b1e824bb4bae223164df67757","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["117a5f32ce1c8be38af11fd43fffaa48","ac792512de89164a6c583bd33a64f472","b997b175516cc653e4ad088e4808b395","bacd647239c276d02bd305754d33882b","cba83887463f7d8f8a1eec75c16e2c5d"],"data_source":10}
+{"drug_id":"05ec2519261f4df5974980cca523c825","docid":81783,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-11-07T05:10:53.000Z","updated_ts":"2024-12-26T00:21:34.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CAR-TG(Jiangsu Pacific Meinuoke Bio Pharmaceutical)","source_info":[{"attachment_path":"data/phs_source_info/cc88/5c69/5868/8692/f8a8130c-6d3f-3164-9ef9-52473b09ab16.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/33db/9596/2b74/6ab7/c7859b79-e28f-35da-8c4a-be3dafe6f3b7.png","source":"Company pipeline","source_url":"http://www.pacificmeinuoke.com/single_ty/209.html#"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["50249f662ebfb61901492f7bb9e2721d"],"disease_id":["0a885de5b4054c2b98d478f91f3e3418"],"active_org_master_entity_id":["50249f662ebfb61901492f7bb9e2721d"],"research_disease":["0a885de5b4054c2b98d478f91f3e3418"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"disease_phase":[{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"180437db409f46ef9e0eb231fda0971f","docid":234340,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-11-25T07:57:04.000Z","updated_ts":"2024-11-29T07:07:24.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Corneal Stromal Stem Cells(Zhongshan Ophthalmic Center)","source_info":[{"code":"NCT06700655","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06700655"}],"status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"originator_org_master_entity_id":["c696637611eea1d390bb3a3920af714c"],"disease_id":["9d9f920c6c734bc3a9bf08c07a74d78c","d412643248ca442a852a276b18806908"],"active_org_master_entity_id":["c696637611eea1d390bb3a3920af714c"],"research_disease":["9d9f920c6c734bc3a9bf08c07a74d78c","d412643248ca442a852a276b18806908"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"9d9f920c6c734bc3a9bf08c07a74d78c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d412643248ca442a852a276b18806908","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"047b3a63648a4b65b6f66033343746b5","docid":14011,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"0dd1683f4d093becb02134970d0415a1","created_ts":"2021-10-08T14:49:34.000Z","updated_ts":"2026-04-04T21:06:07.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BMS-986258","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-TIM3 Monoclonal antibody","status":"ACTIVE"}],"dev_code":[{"name":"BMS 986258","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-tim-3-antibody-bms-986258"}],"status":"ACTIVE"},{"name":"ONO 7807","status":"ACTIVE"},{"name":"ONO-7807","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["2af053afbb447dcc4f739df730bec8d1","dea970434c1183ebd6632e77bd1e19c0"],"mechanism_action_id":["de58f400c11de83497e4b30d1c361dcb"],"target_id":["876f2d06b8634b6ba8c67fcdb9bb7a6b"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5","62eaee6d9ee44410b8aca59dfc7408e9","6570754a6f0b43b78a9926c7bfd00519","7665e5683a1a443a8f3d3b946d4c9ca2","3beea980d93a4cc0abc864e27514601c","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a"],"active_org_master_entity_id":["cf5928311166e2592a973c3aff34c309","2af053afbb447dcc4f739df730bec8d1","813e795cea04e65c6dba9796e2ed6dc4"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5","62eaee6d9ee44410b8aca59dfc7408e9"],"non_research_disease":["6570754a6f0b43b78a9926c7bfd00519","7665e5683a1a443a8f3d3b946d4c9ca2","3beea980d93a4cc0abc864e27514601c","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a"],"inactive_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1758153600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1758153600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1758153600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1758153600000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"1556ddb9c72d449ca7f47569f7b4111e","docid":44556,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-09-27T12:39:38.000Z","updated_ts":"2024-11-06T14:52:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"AB-207","status":"ACTIVE"}],"dev_code":[{"name":"AB-207","status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["fef604b651b882e557b83cf3c93bb1ae"],"disease_id":["451e702b7d3f404aa42a6c4e3602a9b2"],"active_org_master_entity_id":["fef604b651b882e557b83cf3c93bb1ae"],"research_disease":["451e702b7d3f404aa42a6c4e3602a9b2"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1649030400000}}],"disease_phase":[{"disease_id":"451e702b7d3f404aa42a6c4e3602a9b2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"2492371f833a487ca6133fd8cdd88b28","docid":110643,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"fdb24f319a8b31aea7f14f8d405a0ab5","created_ts":"2024-02-29T09:33:55.000Z","updated_ts":"2025-12-05T00:30:52.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CD19-BAFF Targeted CAR T-cells(Yake Biotechnology)","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["19b0594400b60adf148aaaeb2c7b4bf1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["8c65244b2086472ca0fd2b31c6cd9911","5eb1fc5283d34305934a031af530f448"],"disease_id":["0e0dca4dd7f1499a8f65f4fdfcf09954","6ebabd61cd034b86a332ac32a201ce63","60a67018512a44caafa8f5d6dcb5339f","51236dbf55d24268aa6d31d9be131f6f","c5e1987e283c495aaab2a8d309c6085e"],"active_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"research_disease":["0e0dca4dd7f1499a8f65f4fdfcf09954","6ebabd61cd034b86a332ac32a201ce63","60a67018512a44caafa8f5d6dcb5339f","51236dbf55d24268aa6d31d9be131f6f","c5e1987e283c495aaab2a8d309c6085e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1717027200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1713139200000}}],"disease_phase":[{"disease_id":"60a67018512a44caafa8f5d6dcb5339f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"6ebabd61cd034b86a332ac32a201ce63","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01b5485126534586bb2fffc028976cff","docid":3232,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1695945600000,"created_ts":"2021-10-08T14:45:04.000Z","updated_ts":"2025-09-18T01:47:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"EN","name":"Technetium Tc-99m  Labeled Carbon","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Technetium Tc 99M carbon","source_info":[{"code":"NDA022335","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022335"}],"status":"ACTIVE"}],"trade_name":[{"name":"TECHNEGAS","source_info":[{"code":"NDA022335","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022335"}],"status":"ACTIVE"}],"drugbank_id":["DB14227"],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["179dbe93e506d961970a341891c2a4e8"],"mechanism_action_id":["d2f92a17bcb7e88f4e3ae266790aa7c0"],"disease_id":["f6f21ed0a2bc4df5a7fe4e6982bc8e53"],"active_org_master_entity_id":["179dbe93e506d961970a341891c2a4e8"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["f6f21ed0a2bc4df5a7fe4e6982bc8e53"],"research_disease":["f6f21ed0a2bc4df5a7fe4e6982bc8e53"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1695945600000}}],"disease_phase":[{"disease_id":"f6f21ed0a2bc4df5a7fe4e6982bc8e53","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"14d8670c78854875b1c564fc91a49ef3","docid":232185,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-07-11T06:53:40.000Z","updated_ts":"2025-07-02T21:26:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"ChAdOx1.HIVconsv62","source_info":[{"code":"NCT05604209","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05604209"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["c8684477d3638a7fca4b33c9d4d3da35"],"mechanism_action_id":["a30504b84e062940a9ec00f77c5f47be"],"disease_id":["acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd"],"research_disease":["acfaaa0373944ffd89b0a2ace0d8c564"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1711929600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1711929600000}}],"disease_phase":[{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1028237be2e24156b7ce0b9fd186962f","docid":19419,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":15,"target_extend_id":"b1391bc834803f0faabbb5cc05fb37d9","has_leading_org_involved":1,"created_ts":"2021-10-08T14:41:16.000Z","updated_ts":"2026-02-25T01:39:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Flutafuranol F-18","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Flutafuranol F 18","status":"ACTIVE"}],"dev_code":[{"name":"AZD-4694","status":"ACTIVE"},{"name":"NAV-4694","status":"ACTIVE"},{"name":"[18F]-AZD4694","status":"ACTIVE"},{"name":"[18F]-NAV4694","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["df50a750217b01244a8814ee8d79bcfd"],"mechanism_action_id":["2432cfaebe36932280ce47078d97672c"],"target_id":["5ff9d5388b7c4c0a9abf556c9d8659d6"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","c9d3c55f01d24f11a6035f989330c65f","3da3a0b18fb5409d8827611b09254298"],"active_org_master_entity_id":["1f6cebdd9e66c9c5e4a3dd54042c969a","df50a750217b01244a8814ee8d79bcfd","92fb9da5ddb94ce40dbbde50d925102a","cbb4723f06bdfd28421177008078de55"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","c9d3c55f01d24f11a6035f989330c65f"],"non_research_disease":["3da3a0b18fb5409d8827611b09254298"],"inactive_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506","7ee0bce1b4449fad8b5bbf1e323d7732"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1646179200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1646179200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1646179200000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1764547200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1317427200000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c9d3c55f01d24f11a6035f989330c65f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3da3a0b18fb5409d8827611b09254298","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["26fc9670676d8ca2301a65d14b0de8f8","2bee6c6ef7c3c6168147f53a8a4cf7f6","6e7a2de70d46daa0cef8586ca22ae506","7ee0bce1b4449fad8b5bbf1e323d7732","92fb9da5ddb94ce40dbbde50d925102a","a2919336b940133dcb0b9fcdb16900b6"],"if_speculate":0,"data_source":10}
+{"drug_id":"070d6750ba7f48a592c96762fe51b7b4","docid":50939,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-05-26T07:56:06.000Z","updated_ts":"2024-11-07T20:16:36.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"OPL-025B","source_info":[{"attachment_path":"data/phs_source_info/8564/3807/a5a8/4b35/0af64782-3f70-3011-8c17-32146567e4e0.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/e674/0c51/32d0/5167/bbed8d0d-99c6-3ccc-b5ad-b912fe39898e.png","source":"Company pipeline","source_url":"http://cn.overseaspharm.com/domain/"}],"status":"ACTIVE"}],"dev_code":[{"name":"OPL 025B","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://cn.overseaspharm.com/domain/"}],"status":"ACTIVE"},{"name":"OPL025B","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["3642174ed7ee65096c0a17bb9615f0c3"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["3642174ed7ee65096c0a17bb9615f0c3"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686614400000}}],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"08eaad107710479dbbb478a23bcd7ac1","docid":42676,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-08-02T02:21:00.000Z","updated_ts":"2026-02-25T01:17:27.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"B7-H3CART(Stanford University)","source_info":[{"code":"NCT05474378","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05474378"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["734b6d223a9d633b8419a74d2fd215ae"],"mechanism_action_id":["0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["828fb9fef58643deaeb03ba65a7d3953","a4f7254e36da425087293790eb964551","83c00fea95ab443a997c1e3818bea37e","c349d56721634602bd73c8f36c3b496a","f7a28558e1f244a8846ce00c6bf6ab25","1d6d6b0086ff422ca00418c0e8b0e940","b0800e21f0184056bee214fdae05ed8b","05554578204541148a5482ad5df4a600","5244e19b1be4440894371237bc81bc89"],"active_org_master_entity_id":["734b6d223a9d633b8419a74d2fd215ae"],"research_disease":["828fb9fef58643deaeb03ba65a7d3953","a4f7254e36da425087293790eb964551","83c00fea95ab443a997c1e3818bea37e","c349d56721634602bd73c8f36c3b496a","f7a28558e1f244a8846ce00c6bf6ab25","1d6d6b0086ff422ca00418c0e8b0e940","b0800e21f0184056bee214fdae05ed8b","05554578204541148a5482ad5df4a600","5244e19b1be4440894371237bc81bc89"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1731283200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1657584000000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5244e19b1be4440894371237bc81bc89","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f7a28558e1f244a8846ce00c6bf6ab25","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b0800e21f0184056bee214fdae05ed8b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"83c00fea95ab443a997c1e3818bea37e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c349d56721634602bd73c8f36c3b496a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"828fb9fef58643deaeb03ba65a7d3953","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"3d39d014e36a429a83d74dfb77d758aa","docid":2000075,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-17T05:36:41.000Z","updated_ts":"2026-03-17T06:34:15.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Targeted Activated Dendritic Cells(Frontiergate Biopharm)","source_info":[{"code":"NCT07475182","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07475182"}],"status":"ACTIVE"}],"drug_type":["86adaf0bdaf94d2b8f3be02d66efb264"],"originator_org_master_entity_id":["5b4b20a63d413c8bc2707f908abffedb"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["5b4b20a63d413c8bc2707f908abffedb"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1764979200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"3a72c403c4d44376a6bd205014b73211","docid":7422,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"945d2886bdc043a687db986dcd8f84d3","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":34,"target_extend_id":"462f4be0a7f630efa6b9cb3dbb9ab9ef","created_ts":"2021-10-08T14:42:36.000Z","updated_ts":"2026-04-16T07:34:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"利妥昔单抗生物类似药(华兰基因工程有限公司)","status":"ACTIVE"},{"lang":"EN","name":"Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)","status":"ACTIVE"}],"dev_code":[{"name":"WBP-263","status":"ACTIVE"}],"generic_name":[{"name":"rituximab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["dda67de7533a07335298800498455b32"],"mechanism_action_id":["fefd9086773834160eb2d0371e3248c4","569d7324d3bdd73cc1b9e225fdfc8d5f","751eea86950f47e10eb1a4476d03a2df","00b6059ee988f0c3de9917c24ad94912"],"target_id":["8b4260187fa64823b593f35188526e50"],"atc_code":["ad4dc94bf7794217ba2d62c80402e0b7"],"disease_id":["0e0dca4dd7f1499a8f65f4fdfcf09954","4354d84143954a64b2f7acffe5962ddc"],"active_org_master_entity_id":["dda67de7533a07335298800498455b32"],"research_disease":["0e0dca4dd7f1499a8f65f4fdfcf09954"],"non_research_disease":["4354d84143954a64b2f7acffe5962ddc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1732346552690}}],"disease_phase":[{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"4354d84143954a64b2f7acffe5962ddc","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"original_drug_id":["031779b3c9dd452dace83c8d0eebf144"],"data_source":10}
+{"drug_id":"055d2eb0a4df4cbfa104269875e9411c","docid":113620,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"35177ca819c63734b05a81f81525776b","created_ts":"2024-06-06T01:46:20.000Z","updated_ts":"2025-05-26T18:04:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Recombinant Mutant HumanTumor Necrosis Factor(Sun Yat-Sen University)","source_info":[{"code":"NCT06433869","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06433869"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"rmhTNF-NC(Sun Yat-Sen University)","source_info":[{"code":"NCT06433869","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06433869"}],"status":"ACTIVE"}],"drug_type":["c9752cfc9bb0478c907d7379d45af318"],"originator_org_master_entity_id":["eb66e6877cb6ec7fa9e1fc6da678d52d"],"mechanism_action_id":["247b5c65b8cee67822b51f6de88e59c8"],"target_id":["3f1342ed7c824f0f9a87dfdda3343a61"],"disease_id":["f048bf0822254413a3ea354eced08eec","2f517e87830847afa442f78fcc9cb1db","d2b2ebae3fec44428fc52f354966b222","7e5c317ff13b4214b0c012c41f245b6d"],"active_org_master_entity_id":["eb66e6877cb6ec7fa9e1fc6da678d52d"],"research_disease":["f048bf0822254413a3ea354eced08eec","2f517e87830847afa442f78fcc9cb1db","d2b2ebae3fec44428fc52f354966b222","7e5c317ff13b4214b0c012c41f245b6d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1702512000000}}],"disease_phase":[{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2f517e87830847afa442f78fcc9cb1db","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7e5c317ff13b4214b0c012c41f245b6d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d2b2ebae3fec44428fc52f354966b222","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"29381bee94ae4f60a70d017b19e71ce8","docid":70448,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"1a9ea1307f82439f86318fa381543664","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":86,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2022-11-29T11:17:55.000Z","updated_ts":"2026-03-07T21:11:40.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"CN","name":"德谷胰岛素生物类似药(东阳光生物)","source_info":[{"code":"CXSL2100024","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Insulin Degludec biosimilar(HEC Biopharmaceutical)","source_info":[{"code":"CXSL2100024","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"RD15003","source_info":[{"code":"CTR20211914","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=09b706933fb5458bbf36972daf411c85"}],"status":"ACTIVE"}],"generic_name":[{"name":"Insulin degludec","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["2362f0fcecd66dc013b51953fc94f4de"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["06180663afa4cec49644c6bbf2f272b3"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1739059200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["3ad819db7da542789a9feab5a092c60d"],"data_source":10}
+{"drug_id":"03f2118246b247cea7a7078bfd35ff7e","docid":56763,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"f925d5d339cc3170b7e1448f50b4f1d7","created_ts":"2021-12-10T12:55:15.000Z","updated_ts":"2026-03-11T14:40:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"PA3-17","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.persongen.com.cn/cell-therapy-pipeline.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-CD7 CAR-T- cell therapy (PersonGen Biomedicine)","status":"ACTIVE"},{"lang":"EN","name":"Autologous CD7CART cells PersonGen Biotherapeutics","status":"ACTIVE"}],"dev_code":[{"name":"PA3 17","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-cd7-car-t-cells-pa3-17"}],"status":"ACTIVE"},{"name":"PA317","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-cd7-car-t-cells-pa3-17"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["59025c915be3ec87ec8b222d0630510e"],"mechanism_action_id":["c2e183e32319bd3def62c3ba9a4f0d58","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["b893e5b66e334131a95a3d8e69a969e3"],"special_review":["043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["abe040ddcd3543a3b95e05af39749b07","74d74e0d5a5c4a59b5576bc3c40a05e1","570b3cb9d08246788a5c1ccfc4ab5b09","4357b6a3bf3c45b0af2e45ef157848c0","9048c8fe6ee3407296e74e292128dcc0","27c81d33df044a648187f81864221799","51236dbf55d24268aa6d31d9be131f6f","284482edfde044728c186616b8ddad41","18cc841e918e42d282711ebbc083001e","dc8f6e5c031f4dd484b705ca8b52e334","fce059e037f04689ac1042e597647501","54585b410d874858889ad1037d99b675","e2251a2774ee4eff8723a33fc035d809","1cfde61efce54a8c9b92dd7b60c30995","321ac17172fe4cf591c294f981cdba78"],"active_org_master_entity_id":["59025c915be3ec87ec8b222d0630510e","034a13302a34c7e462f5f2182019f338"],"research_disease":["abe040ddcd3543a3b95e05af39749b07","74d74e0d5a5c4a59b5576bc3c40a05e1","570b3cb9d08246788a5c1ccfc4ab5b09","4357b6a3bf3c45b0af2e45ef157848c0","9048c8fe6ee3407296e74e292128dcc0","27c81d33df044a648187f81864221799","51236dbf55d24268aa6d31d9be131f6f"],"non_research_disease":["284482edfde044728c186616b8ddad41","18cc841e918e42d282711ebbc083001e","dc8f6e5c031f4dd484b705ca8b52e334","fce059e037f04689ac1042e597647501","54585b410d874858889ad1037d99b675","e2251a2774ee4eff8723a33fc035d809","1cfde61efce54a8c9b92dd7b60c30995","321ac17172fe4cf591c294f981cdba78"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1760140800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758758400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1628121600000}}],"disease_phase":[{"disease_id":"abe040ddcd3543a3b95e05af39749b07","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4357b6a3bf3c45b0af2e45ef157848c0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"fce059e037f04689ac1042e597647501","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"570b3cb9d08246788a5c1ccfc4ab5b09","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"27c81d33df044a648187f81864221799","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"18cc841e918e42d282711ebbc083001e","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"284482edfde044728c186616b8ddad41","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"74d74e0d5a5c4a59b5576bc3c40a05e1","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9048c8fe6ee3407296e74e292128dcc0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"dc8f6e5c031f4dd484b705ca8b52e334","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"321ac17172fe4cf591c294f981cdba78","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1cfde61efce54a8c9b92dd7b60c30995","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e2251a2774ee4eff8723a33fc035d809","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"54585b410d874858889ad1037d99b675","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["59025c915be3ec87ec8b222d0630510e","8c249a31652224aa8e52b8f18876111e"],"if_speculate":0,"data_source":10}
+{"drug_id":"043f775bc27a40449dde2b35fd7fc666","docid":12131,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"618ae0f198fa3243a58c2c7c6ff3c991","created_ts":"2021-10-08T14:49:09.000Z","updated_ts":"2026-03-24T21:16:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"DSP-107","status":"ACTIVE"}],"dev_code":[{"name":"DSP 107","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sirpa-4-1bbl-fusion-protein-dsp107"}],"status":"ACTIVE"},{"name":"DSP107","source_info":[{"normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerimmunolres/article/7/2_Supplement/A076/469183/Abstract-A076-DSP107-a-novel-SIRP-4-1BBL-dual"}],"status":"ACTIVE"},{"name":"KAHR-107","status":"ACTIVE"}],"drug_type":["bbbb2e86da504b9d95a00c703880d9fb"],"originator_org_master_entity_id":["d5a2d85dab4a1d0ff28ca3470a8e3027"],"mechanism_action_id":["9d3fe67727026f98efc484ed71bd4fe2","ecdecb96df0822b461bb552a478b68de"],"target_id":["08d84b9625394e2a9b3aa5dfccd85ffb","05f29b7c333d434ea82671eb708dd19f"],"disease_id":["8222bb15bc7049a1b4426b9f00d701a6","7665e5683a1a443a8f3d3b946d4c9ca2","3beea980d93a4cc0abc864e27514601c","0464f5493b0444e9875a0584df17cbf0","131c3f4dfc0c4a958e9f91166e73c913","ee423e7465a441f9b91198eb4a53bd6d","0e0dca4dd7f1499a8f65f4fdfcf09954","1a95630392584c7892bec2dc9888cbfc","a4afc28011454f2ca2f48f95f242a04f"],"active_org_master_entity_id":["d5a2d85dab4a1d0ff28ca3470a8e3027","8a3c41b6b3536abfff46a5b43b7662b0","f6f714e41fadc368e1a50681f931a5a2"],"research_disease":["8222bb15bc7049a1b4426b9f00d701a6","7665e5683a1a443a8f3d3b946d4c9ca2","3beea980d93a4cc0abc864e27514601c","0464f5493b0444e9875a0584df17cbf0","131c3f4dfc0c4a958e9f91166e73c913"],"non_research_disease":["ee423e7465a441f9b91198eb4a53bd6d","0e0dca4dd7f1499a8f65f4fdfcf09954","1a95630392584c7892bec2dc9888cbfc","a4afc28011454f2ca2f48f95f242a04f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1768521600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1602028800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1768521600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"8222bb15bc7049a1b4426b9f00d701a6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ee423e7465a441f9b91198eb4a53bd6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"0119e7b9874c4aef9fcc258f0659816a","docid":16413,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"e07fddf922fe3be4a925bab96d3c9103","created_ts":"2021-11-30T08:55:20.000Z","updated_ts":"2026-01-28T00:40:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"BVAC-C","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BVAC C","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["c86f741ce8bd2a2bd7fecb7f23e9fe67"],"mechanism_action_id":["c8f8aeb87d1a2b1e7003140916cc454b","3e7ce35c1c154abfabc07d01fa79f750"],"target_id":["5e0ca6fb6ffe46769106283f8e595a29","0ad1b511e21e412daf77317217b8e4f1"],"disease_id":["b42488c9ce3245988e4e93caf2b95590","e3f17d28780743359417798ae8ef34b3","4c218caf0fc743fda0f4029881b59c29"],"active_org_master_entity_id":["c86f741ce8bd2a2bd7fecb7f23e9fe67"],"research_disease":["b42488c9ce3245988e4e93caf2b95590","e3f17d28780743359417798ae8ef34b3","4c218caf0fc743fda0f4029881b59c29"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"4c218caf0fc743fda0f4029881b59c29","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e3f17d28780743359417798ae8ef34b3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"1a75f0f6d5674c209fa4bcaf77c4d193","docid":45883,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"d9dd8c689ab33fed9c86a03e6a6b5387","has_leading_org_involved":1,"created_ts":"2021-10-08T14:46:51.000Z","updated_ts":"2026-03-19T05:26:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ATSN-101","status":"ACTIVE"}],"dev_code":[{"name":"ATSN 101","status":"ACTIVE"},{"name":"ATSN101","status":"ACTIVE"},{"name":"SAR 439483","status":"ACTIVE"},{"name":"SAR-439483","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb"],"mechanism_action_id":["b02214f03ff94ee5af21770890525ad5"],"target_id":["6dd02a2f55d5402b8f827246b97c4881"],"special_review":["ed88b5b02898448483d0dd3ce010cfba","425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["a7eeb00c771c4d20ad958c2a694f3ba0"],"active_org_master_entity_id":["ddc45e31afef58807f811fc274fc88a5"],"research_disease":["a7eeb00c771c4d20ad958c2a694f3ba0"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1568246400000}}],"disease_phase":[{"disease_id":"a7eeb00c771c4d20ad958c2a694f3ba0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["bf85af687373969355a25d2aacd31bfb","c347cc34487a9a8d1724955d514fe6b4","ddc45e31afef58807f811fc274fc88a5","f8040168ec94f738980c97a698fdec63"],"if_speculate":0,"data_source":10}
+{"drug_id":"01bc70960e1f442da40a8c2fe8cd1165","docid":78478,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"a9bfe2997ade49a08dca89e1d46be584","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":1,"target_extend_id":"12a368477a123732bfb555bab57fb31f","created_ts":"2021-10-08T14:42:46.000Z","updated_ts":"2026-04-20T06:58:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Vusolimogene oderparepvec","source_info":[{"code":"10.1136/jitc-2025-013692","normalized_source_id":"336664ad-8e54-49db-a451-4d51c9e53e01","source":"J Immunother Cancer","source_url":"https://doi.org/10.1136/jitc-2025-013692"},{"code":"41775431","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/41775431"}],"status":"ACTIVE"}],"dev_code":[{"name":"RP 1","status":"ACTIVE"},{"name":"RP-1","status":"ACTIVE"},{"name":"RP1","source_info":[{"code":"10.1136/jitc-2025-013692","normalized_source_id":"336664ad-8e54-49db-a451-4d51c9e53e01","source":"J Immunother Cancer","source_url":"https://doi.org/10.1136/jitc-2025-013692"},{"code":"41775431","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/41775431"}],"status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["f3241188313b237ca459a83d9ad7c260"],"mechanism_action_id":["b2e50fe32f8a683b25a12971ad8f6e37","5eed58790fb843b7bc4d1a82d58d9bb1","4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["6203f5698c2b49329193437643b04fb5","9786d32e3d244a688ec6a60d2fe1b10b","9b8ccf5d227140adbc50afe4b369bf71"],"special_review":["23d3523b7ece48ddacaddac53a66949d","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["c1cc2528f29940fc95fd6bc37eb982d4","2477c68e093d4b818b11333ee1a5ee02","56e4dcc14b9345298b4715f74c691a18","12036d6e668a44a09b1eecd1ae793b69","690c4587b27e4f1a83aba2314fc0903d","8da4804a5bd24352b7d568a7da54c6dc","11157b7e0d784fca9cf6506e1dce15e7","3ca2a71b70254c31be407272753883c3","3beea980d93a4cc0abc864e27514601c","e3bb40386c3840a7841213b5d02fd358","7219506c944a427c8f84ce7f4faf6741","80d8fbba6a93442a8f2baffeb3be4388","8bdcc15b3ac9414e9e937fdcf3849d8c","8e6f6909e2944b7fa8f3593ee96562c1","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["00a0e0cd2677e9b007fbd6e0aae86bb4","9bc8283776c014a7a458730c9b8ab287","60a7d56edfaf9f0f66025e000f7370c3","f3241188313b237ca459a83d9ad7c260"],"research_disease":["c1cc2528f29940fc95fd6bc37eb982d4","2477c68e093d4b818b11333ee1a5ee02","56e4dcc14b9345298b4715f74c691a18","12036d6e668a44a09b1eecd1ae793b69","690c4587b27e4f1a83aba2314fc0903d","8da4804a5bd24352b7d568a7da54c6dc","11157b7e0d784fca9cf6506e1dce15e7","3ca2a71b70254c31be407272753883c3","3beea980d93a4cc0abc864e27514601c","e3bb40386c3840a7841213b5d02fd358","7219506c944a427c8f84ce7f4faf6741","80d8fbba6a93442a8f2baffeb3be4388","8bdcc15b3ac9414e9e937fdcf3849d8c","8e6f6909e2944b7fa8f3593ee96562c1","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1732147200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1570492800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1570492800000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1570492800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1570492800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1570492800000}}],"disease_phase":[{"disease_id":"8e6f6909e2944b7fa8f3593ee96562c1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"11157b7e0d784fca9cf6506e1dce15e7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7219506c944a427c8f84ce7f4faf6741","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"56e4dcc14b9345298b4715f74c691a18","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"80d8fbba6a93442a8f2baffeb3be4388","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"690c4587b27e4f1a83aba2314fc0903d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"12036d6e668a44a09b1eecd1ae793b69","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3ca2a71b70254c31be407272753883c3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8bdcc15b3ac9414e9e937fdcf3849d8c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"e3bb40386c3840a7841213b5d02fd358","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01ef6cefc135461984ba2640bf2776fc","docid":48787,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":5,"target_extend_id":"472eaa77e4ac3d3dbf2763666cd808c8","created_ts":"2021-10-08T14:49:34.000Z","updated_ts":"2026-01-31T21:11:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AVI-4015","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ad0dcaebef9ff80bdae0a46a90a5bb1a"],"mechanism_action_id":["c08559c30f7eff7458be28df0fc12fc3"],"target_id":["2a68b28b17cf42c6a54de704c690138d"],"disease_id":["87a544b4d9354d1487fdd70ed48a779b"],"active_org_master_entity_id":["ad0dcaebef9ff80bdae0a46a90a5bb1a"],"research_disease":["87a544b4d9354d1487fdd70ed48a779b"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"disease_phase":[{"disease_id":"87a544b4d9354d1487fdd70ed48a779b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"183ecb5f6fb94b8eae1f689043b9623f","docid":982270,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"b5c2b8432bf634f29b085db05e7565d5","created_ts":"2025-03-18T10:50:44.000Z","updated_ts":"2025-03-22T21:13:30.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"RS1 AAV Vector(VegaVect)","source_info":[{"code":"NCT02317887","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT02317887"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AAV8-scRS/IRBPhRS(VegaVect)","source_info":[{"code":"NCT02317887","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT02317887"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["5778e8987931fb5832c623268da162a6"],"mechanism_action_id":["39188acb537ca52a876d9720d3e82e07"],"target_id":["eed8233526564d06b2ec5c7968c8834c"],"disease_id":["87fe22d3ab8049b3896715faee6d6699"],"active_org_master_entity_id":["5778e8987931fb5832c623268da162a6"],"research_disease":["87fe22d3ab8049b3896715faee6d6699"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1423612800000}}],"disease_phase":[{"disease_id":"87fe22d3ab8049b3896715faee6d6699","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"08ae5312514042fd80ffd07878b23894","docid":65673,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"c261ef171ab1384ebc0697068eccaeb9","created_ts":"2021-10-08T14:43:42.000Z","updated_ts":"2026-03-11T00:45:40.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"EP-2101","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Tedopi","status":"ACTIVE"}],"dev_code":[{"name":"IDM 2101","status":"ACTIVE"},{"name":"IDM-2101","status":"ACTIVE"},{"name":"OSE 2101","status":"ACTIVE"},{"name":"OSE-2101","status":"ACTIVE"}],"drug_type":["55e93be6816d43ea9c9751c190f30efd"],"originator_org_master_entity_id":["30cd447320f91bedde1d5426eeb248e7"],"mechanism_action_id":["a47d54c34fc871c07f08a1fd90b47e4f","31fadb5b59dc513706fe7b9bf39b9151","14eb0078f63b42c08062a97745980f71","3a30b3b704354b11a5e25923448089f0","21d0b58d78f44149f0be8eae94a5cacb"],"target_id":["2863c310f66740fcbf9b33f2adc47e8a","5fcb61b03dfb4c76a0b4bdfac2dc26da","798ae7a761fa4473996df70bfa1ac297","a3c3158483984ff9922b1b0ba939a068","c91c4e44444e4d918ff8033c464aaf7c"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["061e43dfb5a94fda98f5adf1de2a22a1","2bb755a3f43f49dea60661c5f99712a3","3beea980d93a4cc0abc864e27514601c","e9d6fc1f21704dba80bc8465bbe87d96","218de7027c39474b884ca5d174846630","30b1787d28ea4a65aee18822a1279bfb","7e87f9c6dcd841edb4d0f250b6bee3d9","d2ee0aa5e8a2440585e9a218d193b710","a0304a462da04e7cb03e3f2c5625544e","f319fa27684c4cdeb6ce59d897217718","7665e5683a1a443a8f3d3b946d4c9ca2","9eeccc4caf594a5abedc0559fd9e0424","e50aad3dea474cf487e53bd91d5d7c45","52168d859c5c4211b0cf99b6a3e34221","e56fe20f456b47acb241e61348a613be"],"active_org_master_entity_id":["09f6ae7613f008fab5280eedaa5e27cd","6632a5800bfb389a90c6b15df46d2020"],"research_disease":["061e43dfb5a94fda98f5adf1de2a22a1","2bb755a3f43f49dea60661c5f99712a3","3beea980d93a4cc0abc864e27514601c","e9d6fc1f21704dba80bc8465bbe87d96","218de7027c39474b884ca5d174846630","30b1787d28ea4a65aee18822a1279bfb","7e87f9c6dcd841edb4d0f250b6bee3d9","d2ee0aa5e8a2440585e9a218d193b710"],"non_research_disease":["a0304a462da04e7cb03e3f2c5625544e","f319fa27684c4cdeb6ce59d897217718","7665e5683a1a443a8f3d3b946d4c9ca2","9eeccc4caf594a5abedc0559fd9e0424","e50aad3dea474cf487e53bd91d5d7c45","52168d859c5c4211b0cf99b6a3e34221","e56fe20f456b47acb241e61348a613be"],"inactive_org_master_entity_id":["230e18c41a0f51b64089895eb49bc5e0","ca28f37b82155ad0f26ac1807aa8c0eb","30cd447320f91bedde1d5426eeb248e7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1706832000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1706832000000}}],"disease_phase":[{"disease_id":"061e43dfb5a94fda98f5adf1de2a22a1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9eeccc4caf594a5abedc0559fd9e0424","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e9d6fc1f21704dba80bc8465bbe87d96","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"30b1787d28ea4a65aee18822a1279bfb","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e56fe20f456b47acb241e61348a613be","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"52168d859c5c4211b0cf99b6a3e34221","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["09f6ae7613f008fab5280eedaa5e27cd","9357d1e703c119ca75f7958625b4efda","ca28f37b82155ad0f26ac1807aa8c0eb"],"if_speculate":0,"data_source":10}
+{"drug_id":"4e9666b52d194b5995b91aebd3b34a2f","docid":204959,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":144,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2024-12-13T07:38:28.000Z","updated_ts":"2026-04-04T21:05:19.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ESO-T01(EsoBiotec)","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/6629573"}],"status":"ACTIVE"}],"drug_type":["cc10afbd78954c8db6d1d3fee0684a77"],"originator_org_master_entity_id":["2370d09177c8bbd215a4701531eca6d4"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5","bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","1f54367dda3b44f590bf2e196f85ff93"],"active_org_master_entity_id":["bd97aefcf0351f56624075645bb3261a","2370d09177c8bbd215a4701531eca6d4"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5","bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","1f54367dda3b44f590bf2e196f85ff93"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1733875200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1731888000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"8666aad5477e4272b56b94ca1183781d","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1f54367dda3b44f590bf2e196f85ff93","highest_phase_global":"8666aad5477e4272b56b94ca1183781d"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"deal_related_org":["2370d09177c8bbd215a4701531eca6d4","34ca7cbc1e06dd0be7cfa98456828c9a"],"data_source":10}
+{"drug_id":"0265d820df9f4ec2a58bcab1bb795c26","docid":1641140,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":69,"target_extend_id":"363b76b5c0743630b2bc2f68b86a2531","created_ts":"2025-08-04T05:53:32.000Z","updated_ts":"2025-12-06T21:11:47.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"戈利木单抗生物类似药","status":"ACTIVE"},{"lang":"EN","name":"Golimumab Biosimilar (JAMP Pharma Corp.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Golimumab Biosimilar (JAMP Pharma Corp.)","status":"ACTIVE"},{"lang":"CN","name":"戈利木单抗生物类似药（JAMP Pharma Corp.）","status":"ACTIVE"}],"generic_name":[{"name":"Golimumab","source_info":[{"code":"D04358"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["a067e9bb86d7a57c9d1450e73510cb97"],"mechanism_action_id":["7f0c948979d8c147468f6eec9980420d"],"target_id":["1cf1d1f419714af18f463bac42a732d5"],"atc_code":["47eb987d26ac435d9427bec766cdeb6f"],"disease_id":["42cdcbb9aab84d888f2aa90462019c78"],"active_org_master_entity_id":["a067e9bb86d7a57c9d1450e73510cb97"],"research_disease":["42cdcbb9aab84d888f2aa90462019c78"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1748736000000}}],"disease_phase":[{"disease_id":"42cdcbb9aab84d888f2aa90462019c78","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["e989e44766b34cedb2a0c8a9ce6d112e"],"if_speculate":0,"data_source":10}
+{"drug_id":"44d4ca60d75641d4826fba61b72c0bc6","docid":57089,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":63,"target_extend_id":"146bb3f428153314a68f4fd49a2b7e98","created_ts":"2021-10-08T14:49:58.000Z","updated_ts":"2026-04-15T21:12:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"贝伐珠单抗生物类似药 (上海三生国健)","status":"ACTIVE"},{"lang":"EN","name":"Bevacizumab biosimilar (Sunshine Guojian)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-VEGF monoclonal antibody (Sunshine Guojian)","status":"ACTIVE"},{"lang":"EN","name":"Bevacizumab Biosimilar (Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"贝伐珠单抗生物类似药（三生国健药业（上海）股份有限公司）","status":"ACTIVE"},{"lang":"CN","name":"重组抗VEGF人源化单克隆抗��� (上海三生国健)","status":"ACTIVE"}],"dev_code":[{"name":"601","status":"ACTIVE"},{"name":"601 A","status":"ACTIVE"},{"name":"601-A","status":"ACTIVE"},{"name":"601A","status":"ACTIVE"},{"name":"SSGJ-601","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.fillseo.com/news/445.html"}],"status":"ACTIVE"}],"generic_name":[{"name":"bevacizumab","status":"ACTIVE"}],"drugbank_id":["DB00112"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["34a4a366a6f5ee72e58a893fcaad50bf"],"mechanism_action_id":["6b6c2b10657446ed45e401214272b244","0e6dd837ac200d6d4b69e55395b22762"],"target_id":["934f7ab958ca4daf85f5eb42393a0b28"],"atc_code":["e81b6f358235428196e6703ad4dac799"],"disease_id":["aa6b1f65d7d740498f2b487ea553c661","72326c716f944555a1bd8329cf94f358","1f54367dda3b44f590bf2e196f85ff93","7bb5556c886343f4a9ec230aacf8706e","75a55b0ac0564b41b0f4bb34d123e668","66a1b66e616749eda0c9c89651d60764","b3613eb77a5d4795ac1a12db34d284ba"],"active_org_master_entity_id":["34a4a366a6f5ee72e58a893fcaad50bf","81f178dc1bfb1b46341b049bee528f4f"],"research_disease":["aa6b1f65d7d740498f2b487ea553c661","72326c716f944555a1bd8329cf94f358","1f54367dda3b44f590bf2e196f85ff93"],"non_research_disease":["7bb5556c886343f4a9ec230aacf8706e","75a55b0ac0564b41b0f4bb34d123e668","66a1b66e616749eda0c9c89651d60764","b3613eb77a5d4795ac1a12db34d284ba"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75","76732dd51f2842799e6843eef80820ea"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}}],"disease_phase":[{"disease_id":"aa6b1f65d7d740498f2b487ea553c661","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1f54367dda3b44f590bf2e196f85ff93","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"72326c716f944555a1bd8329cf94f358","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"75a55b0ac0564b41b0f4bb34d123e668","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"cf139751c1fd4a5892c786230e6f6b6a","highest_phase_global":"cf139751c1fd4a5892c786230e6f6b6a"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"66a1b66e616749eda0c9c89651d60764","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"original_drug_id":["fcb8a931669b42458f3daad684b7c1b6"],"deal_related_org":["0558695b5fddaa7de3cc3edbddccae7b","34a4a366a6f5ee72e58a893fcaad50bf","e0002593f5549b5e1ed56b646f69227b"],"if_speculate":0,"data_source":10}
+{"drug_id":"07ff99f8722c4467aa39407eb7c7ca19","docid":39000,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"19ec51e55d8539b38cb0a0428320a93a","created_ts":"2023-03-01T02:19:35.000Z","updated_ts":"2025-02-07T00:19:41.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ADCLEC.syn1 CAR T cells(Takeda)","source_info":[{"code":"NCT05748197","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05748197"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["3213232cf3774bc734def2420b679bb6"],"mechanism_action_id":["6acb2690b4aa432aa10f6ae23ff7a168","f7ee5b73571d49138985ba4122fb9247","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["8bae67781aea4154b39bd5a58d577d67","d4431161069e45498064f04ce31df0c9"],"disease_id":["5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["3213232cf3774bc734def2420b679bb6"],"research_disease":["5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1713398400000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"10cc003f14964814808219341d8dc2d7","docid":1764022,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2026-04-01T10:16:29.000Z","updated_ts":"2026-04-01T10:24:15.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"RP-001-Taxane","source_info":[{"code":"NCT07504263","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07504263"}],"status":"ACTIVE"}],"dev_code":[{"name":"RP-001(Recurv Pharma)","source_info":[{"code":"NCT07504263","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07504263"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8d21d7786dad72448d65933f79a4f0c4"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","ae092fa59f4d44edaf59ffe23d0a44c3"],"active_org_master_entity_id":["8d21d7786dad72448d65933f79a4f0c4"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","ae092fa59f4d44edaf59ffe23d0a44c3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1b3b79400a704728b488e4aea110ab92","docid":83505,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":16,"target_extend_id":"f47db6e209e63a5993c5e0dcd2a988ce","created_ts":"2024-01-11T05:33:24.000Z","updated_ts":"2026-04-04T21:08:25.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"CGT-4859","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2024/01/09/2806211/0/en/Cogent-Biosciences-Announces-Planned-2024-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"CGT4859","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2024/01/09/2806211/0/en/Cogent-Biosciences-Announces-Planned-2024-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["7c63226fdfdc23259b4f1c24b29e3906"],"mechanism_action_id":["0af6d3922ed8115f31d7896c767937cb","7623ff3e23b0a47ea4e6495c2331ca1a"],"target_id":["b7154e7a8edb45649931d1e665f9d803","7ac086b876b34941a494ed991a5140f6"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","1161b9a8548f4f2c8ef48372ac8adaa8","cc85c4ed264a45278b84e0779013dbda","e5090e6e73c349b9a671c67b6e0ef6e3"],"active_org_master_entity_id":["7c63226fdfdc23259b4f1c24b29e3906"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","1161b9a8548f4f2c8ef48372ac8adaa8","cc85c4ed264a45278b84e0779013dbda","e5090e6e73c349b9a671c67b6e0ef6e3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1737504000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1737504000000}}],"disease_phase":[{"disease_id":"e5090e6e73c349b9a671c67b6e0ef6e3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1161b9a8548f4f2c8ef48372ac8adaa8","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"cc85c4ed264a45278b84e0779013dbda","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04aa57c948d34a92828ac22325ea42fa","docid":60742,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Mupirocin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":567907200000,"rnk":1,"target_extend_id":"ed88fa428054357480a119feb9d6f222","created_ts":"2021-10-08T14:48:20.000Z","updated_ts":"2026-04-02T17:21:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"chenghongyan@patsnap.com","first_approved_date_cn":725846400000,"drug_name":[{"lang":"CN","name":"莫匹罗星","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Mupirocin","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bactroban Nasal","status":"ACTIVE"},{"lang":"EN","name":"Mupirocin (USP/INN)","source_info":[{"code":"D01076","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Mupirocin cream","status":"ACTIVE"}],"dev_code":[{"name":"BRL-4910A","status":"ACTIVE"},{"name":"IDT-001","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"http://www.indetek-lab.com/News/show/id/7"}],"status":"ACTIVE"},{"name":"NSC-759182","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/fcad5f18-52b5-4478-a1b2-8bb9d2a8b1f6"}],"status":"ACTIVE"}],"trade_name":[{"name":"BACTROBAN","source_info":[{"code":"NDA050591","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050591"}],"status":"ACTIVE"},{"name":"Centany","source_info":[{"code":"D01076","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"百多邦","status":"ACTIVE"}],"generic_name":[{"name":"Mupirocin","source_info":[{"code":"D01076","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00410"],"kegg_id":["D01076"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"mechanism_action_id":["372cf00a809d4432b143e0e218cf9ef2"],"target_id":["45609b5480374b6a8240ad812d6c0442"],"atc_code":["8b9210ddc438404a8b5bbb3322056944","e6f08735156c42dfa59607a9c2b37ea3"],"disease_id":["9bbea742c3494416b5e85000e57a9dfd","c58593f4ebdd4a1f8d475ddb86da3f52","8a4339e3f2634ad9ba882a9688be65bd","c9291efa317041b1833d2574dd5aa528","fa1830aabb6b44e7aad798a19ee6fd07"],"active_org_master_entity_id":["1e19db66215581e3a35671c34290c420","595c955c398f8c26cfc2ffb458ace9c7","b0fd7a1bcd59b8cfe6123a3bd7cb3e00","a9c81536bb9938a30e48254bd93b7b8e","f4252f68e61a6fa81a30154e1c0ab056","41815c592bf91b36694c074b3fdba59d","461b205eb0e047cb49cda54c5f031fe0"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["9bbea742c3494416b5e85000e57a9dfd"],"research_disease":["9bbea742c3494416b5e85000e57a9dfd","c58593f4ebdd4a1f8d475ddb86da3f52","8a4339e3f2634ad9ba882a9688be65bd","c9291efa317041b1833d2574dd5aa528","fa1830aabb6b44e7aad798a19ee6fd07"],"inactive_org_master_entity_id":["b0efb316895c162569690e2ae4e39ab6","9b027bb089fcaa2c937327ac652321dd"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","ecc919b1-c2b7-3740-bfa7-7cda77176d07"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":725846400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":891561600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1756684800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1541030400000}}],"disease_phase":[{"disease_id":"c9291efa317041b1833d2574dd5aa528","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"fa1830aabb6b44e7aad798a19ee6fd07","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"8a4339e3f2634ad9ba882a9688be65bd","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c58593f4ebdd4a1f8d475ddb86da3f52","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"9bbea742c3494416b5e85000e57a9dfd","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02acb6577aa4453c98abecad69b1645b","docid":35343,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"bb21af7a45364d079259d1494512668b","wiki_link":"https://en.wikipedia.org/wiki/Meningococcal_vaccine","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1334880000000,"created_ts":"2021-10-08T14:47:37.000Z","updated_ts":"2026-04-02T17:16:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"MenACWY","status":"ACTIVE"},{"lang":"EN","name":"MenACWY conjugated vaccine","status":"ACTIVE"},{"lang":"EN","name":"MenACWY-TT","status":"ACTIVE"},{"lang":"EN","name":"Meningococcal group A, C, W 135 and Y conjugate vaccine (Pfizer)","status":"ACTIVE"},{"lang":"EN","name":"Meningococcal vaccine groups A C Y W-135 conjugate (GSK)","status":"ACTIVE"},{"lang":"EN","name":"Nimenrix","status":"ACTIVE"},{"lang":"EN","name":"meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"}],"dev_code":[{"name":"GSK 134612","status":"ACTIVE"}],"trade_name":[{"name":"Mencevax ACWY","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","9e9bb5756eb24c20b5c07cb4432990ce","eb728b38dfb842778019260a7dd09801"],"originator_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["935cbdab630c422f95e49f620d1c1b8b"],"disease_id":["a2d4410b4a8542478edef6ff82787600"],"active_org_master_entity_id":["70ce299eb7ad8b64924ba2dbb9f02c68"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["a2d4410b4a8542478edef6ff82787600"],"research_disease":["a2d4410b4a8542478edef6ff82787600"],"inactive_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd","9597e75ba30c9958d4331f586407d7cf"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"approval_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1334880000000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1334880000000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1334880000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1334880000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1488412800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1638576000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1374969600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1638576000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1524182400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1294272000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1638576000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1488412800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1463356800000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1272412800000}},{"country":"37066d39-f900-39d2-a96f-2411384260e5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1461801600000}},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1461801600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1725753600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1441843200000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1725753600000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1410307200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1463356800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1452902400000}},{"country":"f2cc1822-6aab-320f-9275-f317462fcbd9","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1508284800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1508284800000}},{"country":"528590fc-7857-3275-8e6f-09a951a7544b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1638576000000}},{"country":"528590fc-7857-3275-8e6f-09a951a7544b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1356739200000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1596153600000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1356739200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1725753600000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1294272000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1272412800000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1461801600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1638576000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1284076800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1638576000000}}],"disease_phase":[{"disease_id":"a2d4410b4a8542478edef6ff82787600","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e3fc23ccb7c246a28010505f27ede647","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"0013794bdea3428b94edfbca1c27e701","docid":68641,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"54ae7b4adb693fd3961dc49711fbd165","created_ts":"2022-08-31T05:30:04.000Z","updated_ts":"2025-06-28T21:10:55.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"TR128","source_info":[{"code":"CXHL2200640","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"TR 128","status":"ACTIVE"},{"name":"TR-128","status":"ACTIVE"},{"name":"TR128","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["b5493927692bbe299629e18cc1df34e8"],"mechanism_action_id":["7397d67c7e8b0c8f7076fec757ac38bc","a1568d0449df7a45c6fe901137c919b3"],"target_id":["4be608c5c3934e6892e10de8608b30d9","62ec8113d69346b0a2e2e8c6121073e6"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["b5493927692bbe299629e18cc1df34e8"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1707091200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"02c1480651e0406ca026bcc26ab9cf9e","docid":25629,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:49:07.000Z","updated_ts":"2024-12-30T08:02:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"EDE-1204","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["14c35c8aba96b5ec89aff1df2b9e802b"],"disease_id":["c16a2cd5fcb0481ea01c9431fac9d98d"],"active_org_master_entity_id":["3a06f4ef61892649276c79be051f7427"],"research_disease":["c16a2cd5fcb0481ea01c9431fac9d98d"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"c16a2cd5fcb0481ea01c9431fac9d98d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"02c3ed200a3a4c79b2620de1999361a3","docid":21639,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"linker_id":"b6b2199ed4544f5ea43c3c1dd1adbaf7","payload_id":"630bfd8c471c4dbf8f9df883d28afc07","specific_site":1,"site_id":"ecb212ef756c45c78ad87f77468daa87","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"63343aca63e73f60a24ce23707416a85","created_ts":"2021-10-08T14:50:36.000Z","updated_ts":"2026-02-24T19:38:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"chenghongyan@patsnap.com","drug_name":[{"lang":"EN","name":"DCLL-9718S","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DCLL9718S","source_info":[{"code":"33617672","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/33617672/"}],"status":"ACTIVE"}],"dev_code":[{"name":"DCLL 9718S","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cll1-pbd-adc-dcll9718s"}],"status":"ACTIVE"},{"name":"RG-6109","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cll1-pbd-adc-dcll9718s"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["8a3c41b6b3536abfff46a5b43b7662b0"],"mechanism_action_id":["a74b02a128c0eb3e12d419eee54d4dd0","2ad7fc3f29a427c2cc290ea260e25186"],"target_id":["d4431161069e45498064f04ce31df0c9","427d26c780ff4fe6afab11ca1c9fb297"],"dar":{"avg_value":2.0,"value_type":"AVERAGE"},"adc_reference":[{"code":"PMID: 33617672","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/33617672/"}],"disease_id":["7cb6983b4169498e89b08fd725a22b46","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["9b887e67e08f4f520a3eae177d6ee451"],"research_disease":["7cb6983b4169498e89b08fd725a22b46"],"non_research_disease":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"inactive_org_master_entity_id":["8e9a09c415413dc4cd1c139b8fcb6993"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1619827200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1626307200000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10,"moiety_target_extend_id":"34d5ca3ec32a3dab91476fa784301df0","payload_target_extend_id":"f90bc6d4a6e23af09db788a5c7fe351a","moiety_mechanism_action_id":["a74b02a128c0eb3e12d419eee54d4dd0"],"moiety_target_id":["d4431161069e45498064f04ce31df0c9"],"payload_target_id":["427d26c780ff4fe6afab11ca1c9fb297"],"payload_mechanism_action_id":["2ad7fc3f29a427c2cc290ea260e25186"]}
+{"drug_id":"10207a4649e4434f9fe45422c207724c","docid":23917,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1695859200000,"rnk":14,"target_extend_id":"67847d8d029e35478c321399664c1180","created_ts":"2021-10-08T14:47:34.000Z","updated_ts":"2026-01-21T08:58:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1695859200000,"drug_name":[{"lang":"CN","name":"地舒单抗生物类似药 (齐鲁制药)","status":"ACTIVE"},{"lang":"EN","name":"Denosumab biosimilar (Qilu Pharma)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Denosumab Biosimilar (Qilu Pharmaceutical Co., Ltd.)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant human anti-RANKL momoclonal antibody(Qilu Pharmaceutical Co., Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"地舒单抗生物类似药（Qilu Pharmaceutical Co., Ltd.）","status":"ACTIVE"},{"lang":"CN","name":"重组抗RANKL全人单抗 (齐鲁制药)","status":"ACTIVE"}],"dev_code":[{"name":"QL-1206","status":"ACTIVE"},{"name":"QL1206","status":"ACTIVE"}],"trade_name":[{"name":"鲁可欣","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NTA4Mzc2Mg==&mid=2653545955&idx=6&sn=914e67e6262a4c85fe092024d2d19252&poc_token=HDP_KGWjF_D4KCF5d3GkvoBHyJDGNgLiCH_8qogR"}],"status":"ACTIVE"},{"name":"鲁达欣","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NzY2MDQwMg==&mid=2650386729&idx=2&sn=b6edc390b18e7c7a562b2e4c8f24ca46"}],"status":"ACTIVE"}],"generic_name":[{"name":"denosumab","status":"ACTIVE"}],"drugbank_id":["DB06643"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["0bb6804a2738b17bb305b0d80ce08460"],"mechanism_action_id":["70b3724f9c024338ed116b3bfb828496"],"target_id":["2a9a8ce9bb804bfd95a46d8e4f8bcb1f"],"atc_code":["988359d935c44b11aed8e231d74a483d"],"disease_id":["5f1211c6977c4c9c89aecffecdfda68f","bdaf5f3afa6447d9889bd7e8311a162b","8e116582a7bf47a0ac481dcebd37d16c","892e0b3107fc47caba8107d91242697d"],"active_org_master_entity_id":["0bb6804a2738b17bb305b0d80ce08460","81dbfaf46748f6be2cb649aad48903e4"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["bdaf5f3afa6447d9889bd7e8311a162b"],"research_disease":["5f1211c6977c4c9c89aecffecdfda68f","bdaf5f3afa6447d9889bd7e8311a162b","8e116582a7bf47a0ac481dcebd37d16c"],"non_research_disease":["892e0b3107fc47caba8107d91242697d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","e623abcb-dee9-3ce1-a315-9f3f0e8b0362"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1714435200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1695859200000}},{"country":"e623abcb-dee9-3ce1-a315-9f3f0e8b0362","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1768435200000}}],"disease_phase":[{"disease_id":"8e116582a7bf47a0ac481dcebd37d16c","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bdaf5f3afa6447d9889bd7e8311a162b","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5f1211c6977c4c9c89aecffecdfda68f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"892e0b3107fc47caba8107d91242697d","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"original_drug_id":["2dde5d0ddf4d49a2b0df4c4050b91d95"],"data_source":10}
+{"drug_id":"0a1f5d32b97340d1ab225002e6c85b45","docid":57846,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":38,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2023-03-31T05:10:27.000Z","updated_ts":"2026-04-18T21:04:59.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"利拉鲁肽（重庆派金）","status":"ACTIVE"},{"lang":"EN","name":"Liraglutide (Chongqing Paijin)","source_info":[{"code":"CTR20210173","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=72f5f1bae899482fa3251849ea0c7ee8"}],"status":"ACTIVE"}],"generic_name":[{"name":"liraglutide","status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6"],"originator_org_master_entity_id":["5da3a006be55e49bf1a9e68e8e7d3cff","8bfd16ba46bc37d0ac5e561603605018"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["8bfd16ba46bc37d0ac5e561603605018"],"research_disease":["74d974da49ba407195b38595a0aff704"],"inactive_org_master_entity_id":["5da3a006be55e49bf1a9e68e8e7d3cff"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["2d5cac8af9a8ac221e5ea9fa3ed85902","8bfd16ba46bc37d0ac5e561603605018"],"data_source":10}
+{"drug_id":"0053131850ea454d91431dee891d783e","docid":62644,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:43:41.000Z","updated_ts":"2024-11-26T09:02:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Adsorbed Cell Culture-Derived Influenza Vaccine H5N1","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Cell-culture H5N1 flu vaccine (Daiichi Sankyo Biotech)","status":"ACTIVE"}],"dev_code":[{"name":"KIB-PCI","status":"ACTIVE"},{"name":"VN-101","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["d7eca03ae0053d44d0f7ae1d8c32e21b"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["a6a71a2205f943ae8db8b8f8c29c920d"],"disease_id":["2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["d7eca03ae0053d44d0f7ae1d8c32e21b"],"research_disease":["2a8a3f6ab7ec4061858144283e7ce0ca"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"015437d055a049509b02ab111d65f2f6","docid":980185,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"87f46c5815c238f39f5a185c49c162e3","created_ts":"2025-03-03T05:34:28.000Z","updated_ts":"2026-03-30T13:36:09.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"JSKN-027","source_info":[{"attachment_path":"data/phs_source_info/0374/7661/37b4/b897/0374766137b4b897.jpg","attachment_type":"image/jpeg","code":"Alphamab-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2b75/2e9a/9bcb/1b8c/2b752e9a9bcb1b8c.jpg","source":"Company pipeline","source_url":"https://www.alphamabonc.com/pipeline/overview.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"JSKN 027","source_info":[{"attachment_path":"data/phs_source_info/0374/7661/37b4/b897/0374766137b4b897.jpg","attachment_type":"image/jpeg","code":"Alphamab-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2b75/2e9a/9bcb/1b8c/2b752e9a9bcb1b8c.jpg","source":"Company pipeline","source_url":"https://www.alphamabonc.com/pipeline/overview.html"}],"status":"ACTIVE"},{"name":"JSKN027","source_info":[{"attachment_path":"data/phs_source_info/0374/7661/37b4/b897/0374766137b4b897.jpg","attachment_type":"image/jpeg","code":"Alphamab-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2b75/2e9a/9bcb/1b8c/2b752e9a9bcb1b8c.jpg","source":"Company pipeline","source_url":"https://www.alphamabonc.com/pipeline/overview.html"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["f8152416291fbf498d83406289c8b8fc"],"mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2","c7014f9be8d97569e126bb97fe00d979"],"target_id":["06c7ab146b884a3aa890cfd1a4a0e168","506cbb4b41184cda887dabf5fafb35db"],"adc_reference":[{"code":"Alphamab-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.alphamabonc.com/pipeline/overview.html"}],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["f8152416291fbf498d83406289c8b8fc"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1773014400000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10,"target_moiety_type":["9a847883d786485489d0ee1d75ae90ba"],"moiety_target_extend_id":"87f46c5815c238f39f5a185c49c162e3","moiety_mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2","c7014f9be8d97569e126bb97fe00d979"],"moiety_target_id":["06c7ab146b884a3aa890cfd1a4a0e168","506cbb4b41184cda887dabf5fafb35db"]}
+{"drug_id":"04e9123e4bdb4284a3885affedee1e70","docid":1373739,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":25,"target_extend_id":"eabec2d88b5d3878b8148ff0e852fe3f","created_ts":"2025-06-06T04:55:38.000Z","updated_ts":"2026-04-18T21:05:35.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"度普利尤单抗生物类似药(石药集团巨石生物制药)","source_info":[{"attachment_path":"data/phs_source_info/6170/5103/d25c/8914/61705103d25c8914.html","attachment_type":"text/html","code":"BiosanaPharma-202003","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/6170/5103/d25c/8914/61705103d25c8914.html","source":"Company pipeline"}],"status":"ACTIVE"},{"lang":"EN","name":"Dupilumab biosimilar(CSPC Megalith)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Dupilumab Biosimilar (CSPC Megalith Biopharmaceutial Co., Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"度普利尤单抗生物类似药（石药集团巨石生物制药有限公司）","status":"ACTIVE"}],"dev_code":[{"name":"SYS6033","source_info":[{"code":"CTR20254103","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=caedc0f052574817aa64ce756c708d2a"}],"status":"ACTIVE"}],"generic_name":[{"name":"dupilumab","source_info":[{"code":"EMEA/H/C/004390","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"mechanism_action_id":["8e46e6d7cb5ef25ed25572cd326c56ec"],"target_id":["9055fd3b7cd6459f9dbb0f84bab4c9aa"],"atc_code":["ed43bd40d7a74a5a85454a1846b86eb8"],"disease_id":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547"],"active_org_master_entity_id":["3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"research_disease":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1762128000000}}],"disease_phase":[{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"original_drug_id":["76ca1d6863064d0395644411eae0583d"],"if_speculate":0,"data_source":10}
+{"drug_id":"00a5491a5f3f4c3eb792b3e8f3e21c09","docid":115818,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2024-10-23T09:17:59.000Z","updated_ts":"2026-04-16T21:26:24.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"PfSPZ-LARC2 Vaccine(Sanaria)","source_info":[{"code":"NCT06652737","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06652737"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Sanaria PfSPZ-LARC2 Vaccine","source_info":[{"code":"NCT06652737","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06652737"}],"status":"ACTIVE"},{"lang":"EN","name":"The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream","source_info":[{"code":"NCT06652737","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06652737"}],"status":"ACTIVE"}],"drug_type":["6eddc904ae514d7eb769ec272586e3f3","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["ce5c9808ff04f2d77a61302bf7234e0d"],"disease_id":["bbfdf2c3bccb44b691539d7f89408111","a20fd10e00e8460ca8d5cb227360d09c"],"active_org_master_entity_id":["ce5c9808ff04f2d77a61302bf7234e0d"],"research_disease":["bbfdf2c3bccb44b691539d7f89408111","a20fd10e00e8460ca8d5cb227360d09c"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"7e557d37-ce70-3cb2-ba25-631fe607d1af","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1775001600000}}],"disease_phase":[{"disease_id":"bbfdf2c3bccb44b691539d7f89408111","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a20fd10e00e8460ca8d5cb227360d09c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["8df138b9015bff620418fb585237f2ba","ce5c9808ff04f2d77a61302bf7234e0d"],"data_source":10}
+{"drug_id":"009db2a9121c4565be722cf0dc0005a1","docid":27523,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:30.000Z","updated_ts":"2024-12-26T00:21:34.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TRPA1 Antagonist(Algomedix, Inc.)","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["03c7a1ddc2553edbe9e1dc97081744b8"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["03c7a1ddc2553edbe9e1dc97081744b8"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1642291200000}}],"disease_phase":[{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"00e205ff8d6248839a520d35365a2796","docid":54684,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","wiki_link":"https://en.wikipedia.org/wiki/Adalimumab","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1575590400000,"rnk":44,"target_extend_id":"363b76b5c0743630b2bc2f68b86a2531","created_ts":"2021-10-08T14:49:34.000Z","updated_ts":"2026-02-28T21:14:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":1575590400000,"drug_name":[{"lang":"CN","name":"阿达木单抗生物类似药 (海正药业)","status":"ACTIVE"},{"lang":"EN","name":"Adalimumab biosimilar(Hisun Pharmaceutical)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Adalimumab (Hisun Pharmaceutical)","status":"ACTIVE"},{"lang":"CN","name":"阿达木单抗（海正药业）","status":"ACTIVE"}],"dev_code":[{"name":"HS-016","status":"ACTIVE"},{"name":"HS016","status":"ACTIVE"}],"trade_name":[{"name":"安健宁","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.bioraypharm.com/index.php?m=list&a=index&classid=20"}],"status":"ACTIVE"}],"generic_name":[{"name":"adalimumab","status":"ACTIVE"}],"drugbank_id":["DB00051"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["2aa3e683bc620f41205c1b9a8a37d616"],"mechanism_action_id":["7f0c948979d8c147468f6eec9980420d"],"target_id":["1cf1d1f419714af18f463bac42a732d5"],"atc_code":["d36187ae53514b3f8dd648c321954231"],"disease_id":["8da973b225c24afbba255413635fb240","d281a3b362a740d8aeb63e2a10102671","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["2d8a5a893bafc98c77073bb1383602e8"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["8da973b225c24afbba255413635fb240","d281a3b362a740d8aeb63e2a10102671","6be96778ed424f8d91de00ab82364114"],"research_disease":["8da973b225c24afbba255413635fb240","d281a3b362a740d8aeb63e2a10102671","6be96778ed424f8d91de00ab82364114"],"inactive_org_master_entity_id":["2aa3e683bc620f41205c1b9a8a37d616","8b7268abb3df24047366ada5c000a713","4e19da5760f07ff8bbbb0e35a88c826f"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1575590400000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["68431d4745744d9e9e17a3073edd3920"],"data_source":10}
+{"drug_id":"204ed82d661a4835b30287a747817180","docid":2000375,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-04-14T08:59:50.000Z","updated_ts":"2026-04-14T09:24:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"GV-907","source_info":[{"code":"NCT07520214","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07520214"}],"status":"ACTIVE"}],"dev_code":[{"name":"GV-907","source_info":[{"code":"NCT07520214","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07520214"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["9f9b047ed50f661cf3cae0542bfd35c0"],"disease_id":["5244e19b1be4440894371237bc81bc89"],"active_org_master_entity_id":["9f9b047ed50f661cf3cae0542bfd35c0"],"research_disease":["5244e19b1be4440894371237bc81bc89"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1757462400000}}],"disease_phase":[{"disease_id":"5244e19b1be4440894371237bc81bc89","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0c8d08a340a14a308fbf194346bee3f2","docid":67538,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":2,"target_extend_id":"1dd4af5742ba38b6829c44b72745f232","created_ts":"2022-12-06T03:18:08.000Z","updated_ts":"2026-02-24T11:38:24.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"NoNO-42","source_info":[{"code":"NCT05636306","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05636306"}],"status":"ACTIVE"}],"dev_code":[{"name":"NONO-42","source_info":[{"code":"NCT05636306","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05636306"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["c0e81a719b3749f44af96d821699f8c9"],"mechanism_action_id":["1e197cf514d742b26ddf4abc72b3ffec"],"target_id":["0f6a0b695f53436f9ee2f5d3cad1a35a"],"disease_id":["e79cc331e912409da00bd00f9165c573","e2bf071405ab4c4787be311613287430"],"active_org_master_entity_id":["c0e81a719b3749f44af96d821699f8c9","4e672875600c0476bd5f7bd2f760b53d"],"research_disease":["e79cc331e912409da00bd00f9165c573","e2bf071405ab4c4787be311613287430"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1727308800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1727308800000}}],"disease_phase":[{"disease_id":"e79cc331e912409da00bd00f9165c573","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e2bf071405ab4c4787be311613287430","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"14a927dca83544829b6eb6f5a307185b","docid":16751,"is_nme":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-04-28T12:55:24.000Z","updated_ts":"2024-10-30T10:19:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Allogeneic stem cell therapy(NIAID)","status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"originator_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["bc8beecd9ffe43188afdde6bbdc3dae1"],"active_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd"],"research_disease":["bc8beecd9ffe43188afdde6bbdc3dae1"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1572220800000}}],"disease_phase":[{"disease_id":"bc8beecd9ffe43188afdde6bbdc3dae1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0cd50b37514a4ca99f966b43d952d125","docid":74681,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":2,"target_extend_id":"ca8bf3037d7c3917b04003031f44b2f5","created_ts":"2021-10-08T14:45:02.000Z","updated_ts":"2026-04-18T21:12:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"莱康奇塔单抗","source_info":[{"code":"CXSS2500144","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Lecankitug","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU3Nzg4NzQyNg==&mid=2247694642&idx=1&sn=b5109e2921a7db0c3a822a084d4192c6"}],"status":"ACTIVE"},{"lang":"CN","name":"重组抗人IL-17A/F人源化单克隆抗体 (丽珠医药集团)","status":"ACTIVE"}],"dev_code":[{"name":"LZM-012","status":"ACTIVE"},{"name":"LZM012","status":"ACTIVE"},{"name":"XKH004","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.kanovabiopharma.com/news/44.html"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["920c7580f076bd97751dec82d2de7e16"],"mechanism_action_id":["529b9d60826a4c1a5765e42277efc255","f6df0275c5d6afb5ea5c48412d47219f"],"target_id":["9b99b0dfb49c480fae5688010b373f83","11d6bafba3e3497e89e7bd73bf8b176c"],"special_review":["23d3523b7ece48ddacaddac53a66949d"],"disease_id":["d281a3b362a740d8aeb63e2a10102671","8da973b225c24afbba255413635fb240"],"active_org_master_entity_id":["436959dcd0ff0c90d9a9b2d1d291e822","e4436ba4f762c95be678c4427ef352a8","9a38494c4608a6c11d2e470888265fbc"],"research_disease":["d281a3b362a740d8aeb63e2a10102671","8da973b225c24afbba255413635fb240"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1766534400000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02abfc8b837e4cf5b57bc6f3dd0fbdc1","docid":75015,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":140,"target_extend_id":"b0ea200ef98133288a18281a674f862d","created_ts":"2022-06-27T05:36:33.000Z","updated_ts":"2026-04-11T21:09:14.000Z","data_status":"ACTIVE","created_by":"sunying","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"HC-009","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzU4MDk0MDE0Mw==&mid=2247509983&idx=2&sn=ce70f7214e1d53ecf538134e81319fac"}],"status":"ACTIVE"}],"dev_code":[{"name":"HC 009","status":"ACTIVE"},{"name":"HC009","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["0476607373af902236eb25a575c95718"],"mechanism_action_id":["d8cf80828c564c6889168e2249b034fa"],"target_id":["d4ed73bcacc74cf9a7066f422194f1a3"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["0476607373af902236eb25a575c95718"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1666742400000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"tech_platform":["43c8b2b1dca646959f332cab227eced7"],"delivery_system":["0e885fc6bdf54e0eb91f89fbd562d1f6"]}
+{"drug_id":"052db8acb8ae41ed8ef320517f24ffb4","docid":1670088,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-07-02T06:56:12.000Z","updated_ts":"2025-07-02T11:34:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"LY-066708","source_info":[{"code":"NCT07046559","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07046559"}],"status":"ACTIVE"}],"dev_code":[{"name":"LY-4066708","source_info":[{"code":"NCT07046559","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07046559"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1747094400000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0baa5dd966574f80b7b48ea7d8ea1c3d","docid":1250838,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":37,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2025-05-19T07:14:11.000Z","updated_ts":"2026-03-28T21:08:46.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"RN1101","source_info":[{"code":"NCT06976437","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06976437"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogeneic CD19/​BCMA CAR-T Cells(Rui Therapeutics)","source_info":[{"code":"NCT06976437","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06976437"}],"status":"ACTIVE"}],"dev_code":[{"name":"RN-1101","source_info":[{"code":"NCT06976437","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06976437"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["4a3a14c8cb1640d069e55b819c5cb0c4"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["4a3a14c8cb1640d069e55b819c5cb0c4"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1746489600000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"12cfe24bddef468e83d2bb92d39c7e8f","docid":63155,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":114,"target_extend_id":"dc7de6393dbb399aa0d8e2f8236159c3","created_ts":"2021-10-08T14:47:50.000Z","updated_ts":"2026-03-21T00:42:46.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"培非格司亭生���类似药 (Reliance Life Sciences Pvt Ltd.)","status":"ACTIVE"},{"lang":"EN","name":"Pegfilgrastim biosimilar(Reliance Life Sciences Pvt Ltd.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Pegfilgrastim biosimilar","status":"ACTIVE"}],"dev_code":[{"name":"R-TPR-029","status":"ACTIVE"}],"generic_name":[{"name":"pegfilgrastim","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["1dbb4c71c03a0c267366fbcb8d1be10c"],"mechanism_action_id":["358e5f0ba725062ad8f0c56973cc3e35"],"target_id":["532763442f00416fa392a55be34bad5a"],"atc_code":["dff83be6b0c146ceaf0e213dc51d78ca"],"disease_id":["c7879aa9883f473695aea6cc7470cb48"],"active_org_master_entity_id":["1dbb4c71c03a0c267366fbcb8d1be10c"],"research_disease":["c7879aa9883f473695aea6cc7470cb48"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"c7879aa9883f473695aea6cc7470cb48","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["c8ae82ce74fc4776a63b3a7ad409566f"],"data_source":10}
+{"drug_id":"2a83ec5bc45a4668aa097f023bfd081a","docid":1372524,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":13,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2025-04-10T05:35:01.000Z","updated_ts":"2026-03-07T21:09:54.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-CD19/BCMA CAR T-cells(Shanghai Xiniao Biotechnology)","source_info":[{"code":"NCT06920446","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06920446"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"UCAR T-cell(Shanghai Xiniao Biotechnology)","source_info":[{"code":"NCT06920446","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06920446"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["dfffb46d7a41b0f54d10064fda77719f"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448","aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["db2b9c3a18e4430e88c68eaa712fb77e","0841c039729d4b458d60a39e4808ddbf","85a5f5e742ad45b9ac62afaf9709249a","0c8a0603507542faac6b5ef3e27c6728","ef1925515e7b4062a6cfe8c5e1db1b95","d3a8e491a4c84426a7d31d10c8e166f3","df0bf87aba2e4525b23457955cf2e727","cdfb06abaeaf48fd92abe6a96b73de57","60a67018512a44caafa8f5d6dcb5339f","8b0644971f31409283cac32a7d08fd52","ba69b7404da845268f223ea747921cb3","f3433922efe24dfaada77415e3e66ea0"],"active_org_master_entity_id":["dfffb46d7a41b0f54d10064fda77719f"],"research_disease":["db2b9c3a18e4430e88c68eaa712fb77e","0841c039729d4b458d60a39e4808ddbf","85a5f5e742ad45b9ac62afaf9709249a","0c8a0603507542faac6b5ef3e27c6728","ef1925515e7b4062a6cfe8c5e1db1b95","d3a8e491a4c84426a7d31d10c8e166f3","df0bf87aba2e4525b23457955cf2e727","cdfb06abaeaf48fd92abe6a96b73de57","60a67018512a44caafa8f5d6dcb5339f","8b0644971f31409283cac32a7d08fd52","ba69b7404da845268f223ea747921cb3","f3433922efe24dfaada77415e3e66ea0"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1739232000000}}],"disease_phase":[{"disease_id":"ba69b7404da845268f223ea747921cb3","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"85a5f5e742ad45b9ac62afaf9709249a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"db2b9c3a18e4430e88c68eaa712fb77e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d3a8e491a4c84426a7d31d10c8e166f3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"60a67018512a44caafa8f5d6dcb5339f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8b0644971f31409283cac32a7d08fd52","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0841c039729d4b458d60a39e4808ddbf","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ef1925515e7b4062a6cfe8c5e1db1b95","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"df0bf87aba2e4525b23457955cf2e727","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0193b28c4b3640f3ae6491ed5d9d4c52","docid":78817,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Oxybuprocaine","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":-112665600000,"rnk":18,"target_extend_id":"1f675eaf039d37b5837b104f9aeea73f","created_ts":"2021-10-08T14:47:50.000Z","updated_ts":"2026-02-24T20:43:42.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":820454400000,"drug_name":[{"lang":"CN","name":"盐酸奥布卡因","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Benoxinate Hydrochloride","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"オキシブプロカイン塩酸塩","source_info":[{"code":"21900AMX01721000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530304_1313700Q2089_1_06"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"BNX","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Benoxinate","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Benoxinate hydrochloride (USP)","source_info":[{"code":"D01768","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Butoxyaminobenzoyldiethylaminoethanol","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxybucaine","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxybuprocaine","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxybuprocaine HydrochIoride Gel","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxybuprocaine Hydrochloride","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxybuprocaine Hydrochloride Gel","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxybuprocaine hydrochloride (JP17)","source_info":[{"code":"D01768","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Oxyriprocaine","source_info":[{"code":"DB00892","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"JP","name":"塩酸オキシブプロカイン","source_info":[{"code":"21900AMX01721000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530304_1313700Q2089_1_06"}],"status":"ACTIVE"},{"lang":"JP","name":"塩酸ベノキシネート","source_info":[{"code":"21900AMX01721000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530304_1313700Q2089_1_06"}],"status":"ACTIVE"}],"trade_name":[{"name":"Benoxil","source_info":[{"code":"D01768","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Lacrimin","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"Neovenol","source_info":[{"code":"21900AMX01721000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530304_1313700Q2089_1_06"}],"status":"ACTIVE"},{"name":"Novesin","status":"ACTIVE"},{"name":"Novesine","status":"ACTIVE"},{"name":"ネオベノール","source_info":[{"code":"21900AMX01721000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530304_1313700Q2089_1_06"}],"status":"ACTIVE"},{"name":"ベノキシール","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"ラクリミン","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"倍诺喜","status":"ACTIVE"}],"generic_name":[{"name":"benoxinate","source_info":[{"code":"AXQ0JYM303","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/b288c093-9d20-40a2-ac51-0b2f1be189a5"}],"status":"ACTIVE"}],"drugbank_id":["DB00892"],"kegg_id":["D01768"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2efaca42b4d940eaf0e502464dd9c184"],"mechanism_action_id":["e6c08a0e9446621c3ff9d23a82a086f6"],"target_id":["51f1f4aed2c448da9431bb6a54aac45d"],"atc_code":["4c23da77d6df49a4b4a70ca5d0362036","56b3dccb7adf47a09da710969bdad436"],"disease_id":["eaa28055a38044c98921d6f84c7f8b7a","6ce0ad7b690f47158f3f2ce2756f2193"],"active_org_master_entity_id":["2efaca42b4d940eaf0e502464dd9c184","adfb45450c438a10347dfc41c35882f0","5f16b2bce3ac72404d910f177b5b57d4"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["6ce0ad7b690f47158f3f2ce2756f2193"],"research_disease":["eaa28055a38044c98921d6f84c7f8b7a","6ce0ad7b690f47158f3f2ce2756f2193"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe"},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":820454400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":379814400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":94176000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-112665600000}}],"disease_phase":[{"disease_id":"6ce0ad7b690f47158f3f2ce2756f2193","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"eaa28055a38044c98921d6f84c7f8b7a","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"03e7e1a92df04b5cbf733507f22064ee","docid":37396,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1510099200000,"created_ts":"2022-08-03T08:55:37.000Z","updated_ts":"2024-10-30T10:22:25.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1510099200000,"drug_name":[{"lang":"CN","name":"利脑心片","status":"ACTIVE"},{"lang":"EN","name":"Linaoxin Tablets","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["b79efec6d958cca790d0f82d05d7d8ea"],"disease_id":["6cf8ff4207bd4f75a9c7ce66676516a0","bf821ba3fb194a38a5b2f804bcf68c44"],"active_org_master_entity_id":["b79efec6d958cca790d0f82d05d7d8ea"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["6cf8ff4207bd4f75a9c7ce66676516a0","bf821ba3fb194a38a5b2f804bcf68c44"],"research_disease":["6cf8ff4207bd4f75a9c7ce66676516a0","bf821ba3fb194a38a5b2f804bcf68c44"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1510099200000}}],"disease_phase":[{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6cf8ff4207bd4f75a9c7ce66676516a0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02f4172a1f674d9298b7cc1d29349781","docid":205453,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-01-09T10:56:04.000Z","updated_ts":"2025-06-13T18:48:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"SHR-9803","status":"ACTIVE"}],"dev_code":[{"name":"SHR-9803","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["a5d655dcc4615f2ef28eddf0e501befd","8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1744848000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1743465600000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0110717eed2c40409cfd556462a478d6","docid":3073,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1685059200000,"rnk":2,"target_extend_id":"ea74f54bf3d73d11a65d04d654f511ac","created_ts":"2022-07-14T10:36:40.000Z","updated_ts":"2026-01-28T05:25:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"达格列净/西格列汀","status":"ACTIVE"},{"lang":"EN","name":"Dapagliflozin/Sitagliptin","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Dapagliflozin propanediol monohydrate/Sitagliptin phosphate monohydrate","source_info":[{"code":"405540","normalized_source_id":"d960dac41dfe49609b6b380987cae0d9","source":"TGA","source_url":"https://www.tga.gov.au/resources/artg/405540"}],"status":"ACTIVE"},{"lang":"EN","name":"Dapagliflozin/Sitagliptin Phosphate","status":"ACTIVE"}],"dev_code":[{"name":"DW6012","status":"ACTIVE"},{"name":"SID1903","source_info":[{"code":"NCT05236998","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05236998"}],"status":"ACTIVE"}],"trade_name":[{"name":"SIDAPVIA","source_info":[{"code":"405540","normalized_source_id":"d960dac41dfe49609b6b380987cae0d9","source":"TGA","source_url":"https://www.tga.gov.au/resources/artg/405540"}],"status":"ACTIVE"}],"related_component":["19148bf0a1cc465d852814aa47d373a6","e33cf86cdd544ad2be421bdc463c5867"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["68924fde6a441f470de87ddd627116f2"],"mechanism_action_id":["74936a607528a70f96b7bb43ed793a98","b33a5535c71348d2824dea81333c6197"],"target_id":["54927504b1144faca0b7c66abedf1a78","a995e993b483437ab03a1b4f5da488a8"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["f7ceef270cda82dc4ef6ca07c8421e54","68924fde6a441f470de87ddd627116f2"],"first_approved_country":["52d1b118-b540-37ba-9cb2-f5aff686bb10"],"first_approved_indication":["74d974da49ba407195b38595a0aff704"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["ecc919b1-c2b7-3740-bfa7-7cda77176d07","52d1b118-b540-37ba-9cb2-f5aff686bb10"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1717718400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1685059200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0e2d790268a04c21bbe979487884561b","docid":33238,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":7,"target_extend_id":"89b78fe520143e468a3acf989023b183","created_ts":"2022-04-28T12:55:34.000Z","updated_ts":"2026-04-20T00:08:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"4SCAR30(Shenzhen Geno-Immune Medical Institute)","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["26ed2ba5c537881390984f7bc0aefa34"],"mechanism_action_id":["74caffd2c6248a7a537bf95222b59ee9","dcffdad6c05d58f9ce2c12d757a27686","d9627d77b8d00d879e22e88877e54736"],"target_id":["cb6691e57fe94b2b834e78f94a4d9eb9"],"disease_id":["30cbd74bbed440aca099ef6222d388bc","d7a26da8f1ff43559e34fe72da812c56"],"active_org_master_entity_id":["26ed2ba5c537881390984f7bc0aefa34"],"research_disease":["30cbd74bbed440aca099ef6222d388bc","d7a26da8f1ff43559e34fe72da812c56"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1754006400000}}],"disease_phase":[{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"30cbd74bbed440aca099ef6222d388bc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"121fc03b7f5a4d3a9c0c59bf91ee2169","docid":46487,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-06-14T07:14:40.000Z","updated_ts":"2025-08-14T13:46:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TCIC-001","source_info":[{"code":"CXHL2200382","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"TCIC 001","status":"ACTIVE"},{"name":"TCIC001","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["8fd1e48028e980d40afb8f971ca59762"],"disease_id":["5c12b70c702b485c8cace37825439a52","ac5ea2be7bb745458261c3bbb740ee4c"],"active_org_master_entity_id":["8fd1e48028e980d40afb8f971ca59762"],"research_disease":["5c12b70c702b485c8cace37825439a52","ac5ea2be7bb745458261c3bbb740ee4c"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1752537600000}}],"disease_phase":[{"disease_id":"5c12b70c702b485c8cace37825439a52","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"ac5ea2be7bb745458261c3bbb740ee4c","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"data_source":10}
+{"drug_id":"1496405d2d8a49b78e3a8947bbbd98a2","docid":1733055,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2026-01-13T03:02:07.000Z","updated_ts":"2026-03-30T22:06:09.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"UKK-0018","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/ukko-provides-2026-strategic-outlook-and-highlights-recent-milestones"}],"status":"ACTIVE"}],"dev_code":[{"name":"UKK 0018","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/ukko-provides-2026-strategic-outlook-and-highlights-recent-milestones"}],"status":"ACTIVE"},{"name":"UKK0018","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/ukko-provides-2026-strategic-outlook-and-highlights-recent-milestones"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["d3d8cd255ae40d3bd2f7143e00818e3f"],"disease_id":["dbf67c6dedd9446c9ffd8a9904e8d4ea"],"active_org_master_entity_id":["d3d8cd255ae40d3bd2f7143e00818e3f"],"research_disease":["dbf67c6dedd9446c9ffd8a9904e8d4ea"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1771372800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1771372800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1767830400000}}],"disease_phase":[{"disease_id":"dbf67c6dedd9446c9ffd8a9904e8d4ea","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"179be72167454803862cb9917d856801","docid":69500,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"79274e78db3632ce9ff071f79764c13d","created_ts":"2021-11-30T08:59:01.000Z","updated_ts":"2026-03-11T00:45:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ABL-104","source_info":[{"attachment_path":"data/phs_source_info/73f3/de39/63b8/8db5/c8f5ca62-fe42-3537-bd1c-f2f9906fdbc9.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/c569/7a27/b16b/d5db/c8327355-7817-316f-bdd6-07fd2cc535dd.png","source":"Company pipeline","source_url":"https://www.ablbio.com/en/company/pipeline01"}],"status":"ACTIVE"}],"dev_code":[{"name":"ABL 104","status":"ACTIVE"},{"name":"ABL-104","status":"ACTIVE"},{"name":"ABL104","source_info":[{"code":"2025_6084","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/7951"}],"status":"ACTIVE"},{"name":"YH-32364","status":"ACTIVE"},{"name":"YH32364","source_info":[{"attachment_path":"data/phs_source_info/178b/4384/b0cb/770a/dd8dd4b6-2f92-31c4-b18a-15bc9519097e.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/60c4/d2aa/f0b0/3bbe/afe6f1b9-9c35-326e-8c96-815d1b7986eb.png","source":"Company pipeline","source_url":"https://www.ablbio.com/en/company/pipeline01"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["f57bfbbcdf2372e91619c8860a073648"],"mechanism_action_id":["9d3fe67727026f98efc484ed71bd4fe2","6189e018b719e5a53aa23d75d8b0e8c4"],"target_id":["08d84b9625394e2a9b3aa5dfccd85ffb","c18d6f96c23b4d1e880daafa1b00472b"],"disease_id":["15cb523e0fbd4617a6a129ad2336eb9a","6c9c5be211cb4d72a28205c49a16d653","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["4d2bb307a7e84f386eeed64251299f20","f57bfbbcdf2372e91619c8860a073648"],"research_disease":["15cb523e0fbd4617a6a129ad2336eb9a","6c9c5be211cb4d72a28205c49a16d653","ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1749686400000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"deal_related_org":["4d2bb307a7e84f386eeed64251299f20","f57bfbbcdf2372e91619c8860a073648"],"if_speculate":0,"data_source":10}
+{"drug_id":"03331db1f1164d44bedfa8facb6dfacc","docid":62798,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1655424000000,"rnk":14,"target_extend_id":"52de1860ec3c31fd8ebd7f330333dfb5","created_ts":"2023-05-11T10:33:53.000Z","updated_ts":"2025-12-06T21:14:50.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"特立帕肽(Sawai Pharmaceutical)","status":"ACTIVE"},{"lang":"EN","name":"Teriparatide Acetata(Sawai Pharmaceutical)","source_info":[{"code":"30400AMX00150000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/300119_2439401D2032_1_04"}],"status":"ACTIVE"},{"lang":"JP","name":"テリパラチド酢酸塩（沢井製薬株式会社）","source_info":[{"code":"30400AMX00150000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/300119_2439401D2032_1_04"}],"status":"ACTIVE"}],"generic_name":[{"name":"Teriparatide","source_info":[{"code":"30400AMX00150000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/300119_2439401D2032_1_04"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["01f9100d4ce73da92f4aa361d7562c9a"],"mechanism_action_id":["c5bac46141038db61c739ec6b9090533"],"target_id":["55294d17d84447b980194910fb6548d8"],"disease_id":["1713121f9e9b412d9495f3a785ec61c4"],"active_org_master_entity_id":["01f9100d4ce73da92f4aa361d7562c9a"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["1713121f9e9b412d9495f3a785ec61c4"],"research_disease":["1713121f9e9b412d9495f3a785ec61c4"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1655424000000}}],"disease_phase":[{"disease_id":"1713121f9e9b412d9495f3a785ec61c4","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0654c0b344ea413093977f0364acd3d7","docid":82245,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"0443835a293b31648f35e70413b98b85","created_ts":"2023-11-24T11:43:36.000Z","updated_ts":"2026-03-28T21:09:29.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"ARO-DM1","source_info":[{"code":"NCT06138743","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"},{"code":"2024_T310","normalized_source_id":"907b68184ed84f5dba063477e77f5425","source":"MDA","source_url":"https://www.mdaconference.org/abstract-library/silencing-dmpk-gene-by-aro-dm1-an-sirna-therapeutic-for-type-1-myotonic-dystrophy/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ARO-DM1","source_info":[{"code":"NCT06138743","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06138743"}],"status":"ACTIVE"},{"name":"SRP 1003","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024"}],"status":"ACTIVE"},{"name":"SRP-1003","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024"}],"status":"ACTIVE"},{"name":"SRP1003","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["f01c40a6380a0660b4ca7ff6b6f695a4"],"mechanism_action_id":["36a140e21a1a4700b72382963c5da37f"],"target_id":["992e17d9147e4feb859f608ec6ca78f7"],"disease_id":["cfd4ddb7ee3c4be88e215741088dab5b"],"active_org_master_entity_id":["f01c40a6380a0660b4ca7ff6b6f695a4"],"research_disease":["cfd4ddb7ee3c4be88e215741088dab5b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1709510400000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1709510400000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1709510400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1709510400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1709424000000}}],"disease_phase":[{"disease_id":"cfd4ddb7ee3c4be88e215741088dab5b","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["4a5b23bd563d5214742ab9f17ea7a12a","f01c40a6380a0660b4ca7ff6b6f695a4"],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","if_speculate":0,"data_source":10,"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://arrowheadpharma.com/pipeline/"}],"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"targeted_tissue":["a63a02bf5b3f433aa7da4ea6edd802bf"],"delivery_system":["cebfbf5158294267badc32e9c9619992"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"2c9e009b820e4df3b49a4650700e0f4c","docid":1643806,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-01-19T07:28:55.000Z","updated_ts":"2026-01-19T08:48:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"[18F]MK-0947","source_info":[{"code":"NCT07348250","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07348250"}],"status":"ACTIVE"}],"dev_code":[{"name":"[18F]MK-0947","source_info":[{"code":"NCT07348250","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07348250"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["462096edf3de7b2de5a70c8fa9b70fa3"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["462096edf3de7b2de5a70c8fa9b70fa3"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1765152000000}}],"disease_phase":[{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"09038846e71d44e3b9c616a125874251","docid":82171,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-11-22T08:07:25.000Z","updated_ts":"2025-02-18T11:26:12.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"RV-001","source_info":[{"attachment_path":"data/phs_source_info/b9c1/5dc7/5d9a/b0e1/3c3ddf53-e0e6-3b08-a715-8433c8520735.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/d69e/8320/f0d3/8e3a/cc8ccb9f-80f0-3df5-a5f3-1f810a73aaaf.png","source":"Company pipeline","source_url":"https://restore-vis.com/en/sciences/"}],"status":"ACTIVE"}],"dev_code":[{"name":"RV 001","status":"ACTIVE"},{"name":"RV001","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["d641ed3e4cca3d3e4acf45d07d6f3911"],"disease_id":["2ef2f7065d1e476d839aaa6ce50d522d"],"active_org_master_entity_id":["d641ed3e4cca3d3e4acf45d07d6f3911"],"research_disease":["2ef2f7065d1e476d839aaa6ce50d522d"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1739404800000}}],"disease_phase":[{"disease_id":"2ef2f7065d1e476d839aaa6ce50d522d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"168b85cc78e245fd8425554bf60ddaa2","docid":233840,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"71ec68f930e83151b03bfb490dd00c86","has_leading_org_involved":1,"created_ts":"2024-10-12T09:44:23.000Z","updated_ts":"2026-03-14T21:13:50.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"HS-20110","status":"ACTIVE"}],"dev_code":[{"name":"HS-20110","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["946fa8d72705e08da771676fc3640eb6"],"mechanism_action_id":["891cf53127bc45c8a4b5cbaa4f5a55a0"],"target_id":["2de9abedbec545e29d6cd6e57b7dc9a8"],"disease_id":["03bd23316cb54eecbbc4f53311087042","b902fe3512424802ac7659fc83b38222","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["946fa8d72705e08da771676fc3640eb6","743b10cd618393c5f5d99c32b172bb99"],"research_disease":["03bd23316cb54eecbbc4f53311087042","b902fe3512424802ac7659fc83b38222","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1766361600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1739836800000}}],"disease_phase":[{"disease_id":"03bd23316cb54eecbbc4f53311087042","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["87bfaf037f8e60c9e25595cd98bb27e4","d1f8ba0a5ebca96f53f09eff814a78e7"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"71ec68f930e83151b03bfb490dd00c86","moiety_mechanism_action_id":["891cf53127bc45c8a4b5cbaa4f5a55a0"],"moiety_target_id":["2de9abedbec545e29d6cd6e57b7dc9a8"]}
+{"drug_id":"0818703d170e47ed909764ffd5b763e7","docid":58878,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-12-10T12:55:16.000Z","updated_ts":"2024-11-01T10:52:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Recombinant Hepatitis B vaccine (PT Bio Farma)","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["8233e2c351e2c603c36055c831372289"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["8b107203951e4ae9bfe9667fccbe8df9"],"active_org_master_entity_id":["8233e2c351e2c603c36055c831372289"],"research_disease":["8b107203951e4ae9bfe9667fccbe8df9"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"ba5f77a3-321f-3e45-91fc-4ff21b4edad7","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1702684800000}}],"disease_phase":[{"disease_id":"8b107203951e4ae9bfe9667fccbe8df9","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"3c947fbeef1f46ff8671b162cb122a78","docid":17278,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2023-03-02T05:30:43.000Z","updated_ts":"2024-10-30T10:24:50.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"GLH1SM","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["b7192b4f4f71ef78d05b19906985a040"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["b7192b4f4f71ef78d05b19906985a040"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"004953db01ac4571be308d20616e1752","docid":31684,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:43:07.000Z","updated_ts":"2024-12-06T09:36:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"苯明青霉素","status":"ACTIVE"},{"lang":"EN","name":"Benethamine Penicillin","status":"ACTIVE"}],"generic_name":[{"name":"penicillin","source_info":[{"code":"Q42T66VG0C","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/17f4c6e4-d578-4f58-87ce-572324ec1838"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"atc_code":["1a8796d8604448eeac6780e9da87f261"],"disease_id":["fa1830aabb6b44e7aad798a19ee6fd07"],"research_disease":["fa1830aabb6b44e7aad798a19ee6fd07"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"disease_phase":[{"disease_id":"fa1830aabb6b44e7aad798a19ee6fd07","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0441ba1bec25474f91caaa94f04f62cb","docid":1610860,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2025-08-08T02:39:00.000Z","updated_ts":"2025-08-08T03:06:12.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"天癸苁盈颗粒","source_info":[{"code":"CXZL2300022","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Tiangui Congying Granules","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["dc67cf804d52d3bed80f8dfd363139e0"],"disease_id":["5f0514d1714a4b6db8cc59183e7c6812"],"active_org_master_entity_id":["dc67cf804d52d3bed80f8dfd363139e0"],"research_disease":["5f0514d1714a4b6db8cc59183e7c6812"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1754524800000}}],"disease_phase":[{"disease_id":"5f0514d1714a4b6db8cc59183e7c6812","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0627fd9b9a294af58866770cb91a08f6","docid":14678,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"135bd71859ab3fa3adfb0476c15784a1","created_ts":"2021-11-30T08:55:13.000Z","updated_ts":"2026-02-25T00:53:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"IMT-009","source_info":[{"code":"2023_2815","normalized_source_id":"ca88304bde6747888c1de53f13aa16fb","source":"ASH","source_url":"https://ash.confex.com/ash/2023/webprogram/Paper190957.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Rezorstobart","source_info":[{"code":"Q3SE2QPZ2H","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/fce46ed7-07f7-4a1b-ab24-0c6598458f68"}],"status":"ACTIVE"}],"dev_code":[{"name":"IMT 009","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rezorstobart"}],"status":"ACTIVE"},{"name":"IMT-009","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rezorstobart"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["ec77e0122f783aabb7e1e906b688be04"],"mechanism_action_id":["54dcf6145eba489fa16da2bba3c93ac1"],"target_id":["81d5c7f3315f4afaa2088a94996319d7"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","e78f809b697b4becaa8d265389638562","690c4587b27e4f1a83aba2314fc0903d","0e0dca4dd7f1499a8f65f4fdfcf09954","f7ea24f0370d421480503e720310bf86","e89afc6a432744b1a88281329dc46d91","524236920ce94d7d831f0ac59bcacae8","924d33e560a143a69a2756799f1cd546","a75eb84c45444938809d1088852efb20","8222bb15bc7049a1b4426b9f00d701a6","3beea980d93a4cc0abc864e27514601c","e1bd7636e0d5406fbf8059da86b3c5fb","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a","131c3f4dfc0c4a958e9f91166e73c913","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["60922a420be0b6830048eb498f8422e9","ec77e0122f783aabb7e1e906b688be04","b75676ea15c0a2d8e2f63c5207027e73","be80e7229effa227d80551bda7bbc59d"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","e78f809b697b4becaa8d265389638562","690c4587b27e4f1a83aba2314fc0903d","0e0dca4dd7f1499a8f65f4fdfcf09954","f7ea24f0370d421480503e720310bf86","e89afc6a432744b1a88281329dc46d91","524236920ce94d7d831f0ac59bcacae8","924d33e560a143a69a2756799f1cd546","a75eb84c45444938809d1088852efb20","8222bb15bc7049a1b4426b9f00d701a6","3beea980d93a4cc0abc864e27514601c","e1bd7636e0d5406fbf8059da86b3c5fb","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a","131c3f4dfc0c4a958e9f91166e73c913","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1669593600000}}],"disease_phase":[{"disease_id":"524236920ce94d7d831f0ac59bcacae8","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a75eb84c45444938809d1088852efb20","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8222bb15bc7049a1b4426b9f00d701a6","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e78f809b697b4becaa8d265389638562","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"690c4587b27e4f1a83aba2314fc0903d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e89afc6a432744b1a88281329dc46d91","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"924d33e560a143a69a2756799f1cd546","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e1bd7636e0d5406fbf8059da86b3c5fb","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["be80e7229effa227d80551bda7bbc59d","ec77e0122f783aabb7e1e906b688be04"],"data_source":10}
+{"drug_id":"181e2ce569a34945905e9ed0cd55eb81","docid":264685,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-10-30T08:07:05.000Z","updated_ts":"2026-01-31T21:18:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Donor NK cells(Chinese People's Liberation Army Air Force General Hospital)","source_info":[{"code":"ChiCTR2000039892","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"http://www.chictr.org.cn/showproj.aspx?proj=64187"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["3b1ad68e270cfb0ad6b7b04c5d7a2d5f"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158"],"disease_id":["94deb71c1ce54fdf8923bfcb7c88d054"],"active_org_master_entity_id":["3b1ad68e270cfb0ad6b7b04c5d7a2d5f"],"research_disease":["94deb71c1ce54fdf8923bfcb7c88d054"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1604188800000}}],"disease_phase":[{"disease_id":"94deb71c1ce54fdf8923bfcb7c88d054","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"11d3637215c8490b9491990c0c1e4174","docid":28656,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":3,"target_extend_id":"b446177d017f378e8a21bd38942748ce","created_ts":"2021-10-08T14:42:45.000Z","updated_ts":"2025-05-31T21:12:31.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"左旋氨氯地平/比索洛尔","status":"ACTIVE"},{"lang":"EN","name":"Levamlodipine/Bisoprolol","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"左氨氯地平比索洛尔","source_info":[{"code":"CTR20240049","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=84482fe331de4559a37a3eba90f93b6f"}],"status":"ACTIVE"}],"related_component":["a69678576b41428bbcd93dc26fd915da","c3451ef78a72418f99494963df39a4d5"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3e98b5730ce92f3d632f1c1458d876fc"],"mechanism_action_id":["36ae41fe0ed469cafadad2fbfe2cd220","d598b397735eed3368862c100009222e"],"target_id":["cbfe96a08cbd4821bd2043ccb66bf7d8","dc3e36bb0e204db6b9a558e2710cbae0"],"disease_id":["f8f9347202e043bab0e0d627ce10e767"],"active_org_master_entity_id":["3e98b5730ce92f3d632f1c1458d876fc","869b6e3f5ab75f1a47655f7b16469e05"],"research_disease":["f8f9347202e043bab0e0d627ce10e767"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1745798400000}}],"disease_phase":[{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"06f733a0ab78427cb0373a5419ca7fb4","docid":82221,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":5,"target_extend_id":"11b611ac4f2e37f494dd92c16d500f0d","has_leading_org_involved":1,"created_ts":"2023-11-24T09:38:23.000Z","updated_ts":"2025-12-27T21:10:10.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"GUB-014295","source_info":[{"code":"NCT06144684","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"GUBamy","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.gubra.dk/mfn_news/gubra-announces-first-subject-dosed-in-phase-1-clinical-trial-of-amylin-agonist-gubamy-for-the-treatment-of-obesity/"}],"status":"ACTIVE"},{"lang":"EN","name":"long-acting amylin analogue(Gubra ApS)","source_info":[{"code":"NCT06144684","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"dev_code":[{"name":"ABBV 295","source_info":[{"attachment_path":"data/phs_source_info/5386/3e3d/f025/8911/53863e3df0258911.png","attachment_type":"image/png","code":"AbbVie-202509","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1fbb/e2a9/053d/0042/1fbbe2a9053d0042.png","source":"Company pipeline","source_url":"https://www.abbvie.com/science/pipeline.html"}],"status":"ACTIVE"},{"name":"ABBV-295","source_info":[{"attachment_path":"data/phs_source_info/5386/3e3d/f025/8911/53863e3df0258911.png","attachment_type":"image/png","code":"AbbVie-202509","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1fbb/e2a9/053d/0042/1fbbe2a9053d0042.png","source":"Company pipeline","source_url":"https://www.abbvie.com/science/pipeline.html"}],"status":"ACTIVE"},{"name":"ABBV295","source_info":[{"attachment_path":"data/phs_source_info/5386/3e3d/f025/8911/53863e3df0258911.png","attachment_type":"image/png","code":"AbbVie-202509","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1fbb/e2a9/053d/0042/1fbbe2a9053d0042.png","source":"Company pipeline","source_url":"https://www.abbvie.com/science/pipeline.html"}],"status":"ACTIVE"},{"name":"GUB 014295","status":"ACTIVE"},{"name":"GUB014295","source_info":[{"code":"NCT06144684","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06144684"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["1dd55c66a799c47e0d6b67e77bd1f0b7"],"mechanism_action_id":["aa9b3ed765a044faa6c6be0fa1ad2f9e","6c9449d0ae3a6d91869a0f2e04398c7e"],"target_id":["38911cf4a43943138afaedc955488d91","707205a8d14844dfaa226b0906ff1c51"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1763510400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1701216000000}}],"disease_phase":[{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["1dd55c66a799c47e0d6b67e77bd1f0b7","d88590e686ad5608bbbfeb811b14d188"],"if_speculate":0,"data_source":10}
+{"drug_id":"035ffdda69fb47b9863234ed91c88a50","docid":22135,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":1,"target_extend_id":"9f4c1b9be51a338baac2cbef9e08066e","created_ts":"2021-10-08T14:42:52.000Z","updated_ts":"2026-03-11T00:45:50.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Darleukin/fibromun","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bifikafusp alfa + onfekafusp alfa","status":"ACTIVE"},{"lang":"EN","name":"Darleukin + Fibromun","status":"ACTIVE"},{"lang":"EN","name":"Daromun","status":"ACTIVE"},{"lang":"EN","name":"Nidlegy","status":"ACTIVE"}],"dev_code":[{"name":"L19-IL-2/ L19-TNF-α","status":"ACTIVE"},{"name":"L19-IL2 + L19-TNF","status":"ACTIVE"},{"name":"L19IL2-L19TNF","status":"ACTIVE"},{"name":"L19IL2/L19TNF","status":"ACTIVE"}],"related_component":["bfec8be7df094afeaf77f06f5f92f887"],"drug_type":["2f320ad742e54195b29c6737eeaa86af"],"originator_org_master_entity_id":["6192223526d3157ca6a8b013c78a8272"],"mechanism_action_id":["61795bf2c755921730b4edbbe3bc1cbc","247b5c65b8cee67822b51f6de88e59c8"],"target_id":["6ec0f112e7f24e8eb09ee10490362648","3f1342ed7c824f0f9a87dfdda3343a61"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["c1cc2528f29940fc95fd6bc37eb982d4","83d4a7a4b99e4c9fa8e6c012527381b5","8adbfdede70b4f0f94b27dd79b4e439f","690c4587b27e4f1a83aba2314fc0903d","667a1fe76dde4a62a66acf6afc798a6f","2477c68e093d4b818b11333ee1a5ee02","7219506c944a427c8f84ce7f4faf6741","db53733df6b441fe9ed25041a14839c8","65b9b17ec6704daa877caac721796061","8bdcc15b3ac9414e9e937fdcf3849d8c","5ca3461ddccf4ed9a777c112936766ea","7a9d924cdedd446a90214febad20f3ae","598372309fac44dfa9afd74266b0d581","8da4804a5bd24352b7d568a7da54c6dc","a311ae2187914c2bbad45810b91f9414","90a3a12984ce4382a2b43e44e67fd301"],"active_org_master_entity_id":["6192223526d3157ca6a8b013c78a8272","af158b4c0c1147af049717bbc1b44d4c"],"research_disease":["c1cc2528f29940fc95fd6bc37eb982d4","83d4a7a4b99e4c9fa8e6c012527381b5","8adbfdede70b4f0f94b27dd79b4e439f","690c4587b27e4f1a83aba2314fc0903d","667a1fe76dde4a62a66acf6afc798a6f","2477c68e093d4b818b11333ee1a5ee02","7219506c944a427c8f84ce7f4faf6741","db53733df6b441fe9ed25041a14839c8","65b9b17ec6704daa877caac721796061","8bdcc15b3ac9414e9e937fdcf3849d8c","5ca3461ddccf4ed9a777c112936766ea","7a9d924cdedd446a90214febad20f3ae"],"non_research_disease":["598372309fac44dfa9afd74266b0d581","8da4804a5bd24352b7d568a7da54c6dc","a311ae2187914c2bbad45810b91f9414","90a3a12984ce4382a2b43e44e67fd301"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","20f1c6915ff140519285386c54883aae","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1717459200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1537401600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1537401600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1467331200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1537401600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1467331200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1467331200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1467331200000}}],"disease_phase":[{"disease_id":"8adbfdede70b4f0f94b27dd79b4e439f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7219506c944a427c8f84ce7f4faf6741","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5ca3461ddccf4ed9a777c112936766ea","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"65b9b17ec6704daa877caac721796061","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"690c4587b27e4f1a83aba2314fc0903d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"90a3a12984ce4382a2b43e44e67fd301","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"598372309fac44dfa9afd74266b0d581","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"db53733df6b441fe9ed25041a14839c8","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8bdcc15b3ac9414e9e937fdcf3849d8c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"83d4a7a4b99e4c9fa8e6c012527381b5","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"667a1fe76dde4a62a66acf6afc798a6f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7a9d924cdedd446a90214febad20f3ae","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["9ff89edb83df56ea8306bbba7bf0c374","6192223526d3157ca6a8b013c78a8272"],"data_source":10}
+{"drug_id":"072ed0edad6d4cb58df31ee3b115d35c","docid":55976,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"4e696a675a7d390f880bdc30eb0a7307","has_leading_org_involved":1,"created_ts":"2021-10-08T14:48:27.000Z","updated_ts":"2025-07-31T00:31:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"WVE-003","status":"ACTIVE"}],"dev_code":[{"name":"WVE 003","status":"ACTIVE"},{"name":"WVE003","status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["26c3dd9fab0cd4fde4732fd3426c685a"],"mechanism_action_id":["b479cac45a475d083322bd0c29160903"],"target_id":["b7aaeb0a717240cc893a6debab66d7f3"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["4c0044bbaeba47258cf85131c2412421"],"active_org_master_entity_id":["26c3dd9fab0cd4fde4732fd3426c685a"],"research_disease":["4c0044bbaeba47258cf85131c2412421"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}}],"disease_phase":[{"disease_id":"4c0044bbaeba47258cf85131c2412421","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["26c3dd9fab0cd4fde4732fd3426c685a","3213232cf3774bc734def2420b679bb6"],"genetic_material":"98d361a2fe78458182e3b68f30d261d5","data_source":10,"tech_platform":["0764fd11b990484c8b1891a9f234f3bd"],"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://wavelifesciences.com/pipeline/research-and-development/"}],"regulation_type":["f1cc657d8fe04d37918af804bd477fb5"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"0938e1d3e7824f5eb2a193753a6758ac","docid":114671,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"43ee4f8e816e33bea4cb9b961d821b2c","created_ts":"2024-08-12T07:12:31.000Z","updated_ts":"2026-01-03T21:08:39.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Duvalgagene otiparvovec","source_info":[{"code":"list 130","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf?sfvrsn=ef74744a_5&download=true"}],"status":"ACTIVE"}],"dev_code":[{"name":"4D 310","status":"ACTIVE"},{"name":"4D-310","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/6414660"}],"status":"ACTIVE"},{"name":"4D310","source_info":[{"attachment_path":"data/phs_source_info/ASGCT/fb80/a97d/8a6d/f4a9/72e243d9-fb80-397d-8a6d-f4a9aa3c1162.pdf","attachment_type":"PDF","code":"2021_220","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","preview_attachment_path":"data/phs_source_info/ASGCT/fb80/a97d/8a6d/f4a9/72e243d9-fb80-397d-8a6d-f4a9aa3c1162.pdf","source":"ASGCT","source_url":"https://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(21)00206-9.pdf"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["799f462ff4f684bc41e1e57bf922167b"],"mechanism_action_id":["d9637106c9d09d63e00a279cad60040a"],"target_id":["06587a6f0b5842d4a597dd69f783e61f"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["c030b4369d7b41c2953386b363b99f6e"],"active_org_master_entity_id":["799f462ff4f684bc41e1e57bf922167b"],"research_disease":["c030b4369d7b41c2953386b363b99f6e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1598918400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1665878400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1665878400000}}],"disease_phase":[{"disease_id":"c030b4369d7b41c2953386b363b99f6e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1c8a3ab8b44f47e3be94b7701855ed7c","docid":3887,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":24,"target_extend_id":"72f0756e968137c593f0a814fe9c30b6","created_ts":"2023-07-18T07:35:29.000Z","updated_ts":"2026-04-17T07:30:09.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"SHR-1826","source_info":[{"code":"CXSL2300466","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"SHR 1826","source_info":[{"code":"CXSL2300466","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"SHR1826","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1ODM0NjI2MA==&mid=2247504329&idx=1&sn=46acdc7c824998e3dcc7a117f210e165"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["1d449fbb74a814f5f257e7ad1fd5b7e1"],"mechanism_action_id":["42a08387c5467c334017c9831c2ed7bd"],"target_id":["72bcad51964147ffb8208403eb9c1243"],"special_review":["c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["6c9886cb25eb45faba70292cee1f5518","949c20c9e52549008773244a4230da7d","7fb8ceff333b48e8adea2c0803494a48","a0304a462da04e7cb03e3f2c5625544e","0464f5493b0444e9875a0584df17cbf0","800d2cfb899f4e6983a759d03734503d"],"active_org_master_entity_id":["1d449fbb74a814f5f257e7ad1fd5b7e1"],"research_disease":["6c9886cb25eb45faba70292cee1f5518","949c20c9e52549008773244a4230da7d","7fb8ceff333b48e8adea2c0803494a48","a0304a462da04e7cb03e3f2c5625544e","0464f5493b0444e9875a0584df17cbf0","800d2cfb899f4e6983a759d03734503d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1775001600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1773878400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1746057600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"800d2cfb899f4e6983a759d03734503d","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6c9886cb25eb45faba70292cee1f5518","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"72f0756e968137c593f0a814fe9c30b6","moiety_mechanism_action_id":["42a08387c5467c334017c9831c2ed7bd"],"moiety_target_id":["72bcad51964147ffb8208403eb9c1243"]}
+{"drug_id":"06e693feaec94f1396e6c1100a2c0b4a","docid":49890,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":19,"target_extend_id":"9580b8de3efb30d6972cdcbb088dc3d4","created_ts":"2022-03-11T06:53:16.000Z","updated_ts":"2026-04-04T21:10:31.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"SCG-142","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.scgcell.com/science.html?pointId=pipeline"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HPV TCR-TB T cells(SCG Cell Therapy)","source_info":[{"code":"2024_416","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","source":"ASGCT","source_url":"https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=59294"}],"status":"ACTIVE"}],"dev_code":[{"name":"SCG 142","status":"ACTIVE"},{"name":"SCG142","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.scgcell.com/science.html?pointId=pipeline"}],"status":"ACTIVE"}],"drug_type":["b72760cce8f7461193c7b3362f9a2e3a"],"originator_org_master_entity_id":["0b56b861edfb75767df405d0509686a5"],"mechanism_action_id":["c8f8aeb87d1a2b1e7003140916cc454b","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["0ad1b511e21e412daf77317217b8e4f1"],"disease_id":["fd889e1dd1744ffa9be7bb0584ff3110","52aeb8aacb5a46129f031a7e534d383d","d0c606fd02d94c04a2576cfac4550766","36cdcc4c6d9b434396effac4dc48f4ff","aba598f8e3ff4777979b733ef5262210","96e3b0b060974ad9bd27070571ebae64","86c9dec6885345009f177cb20378fa62","bb5baa14bc3e4e11be812216ce0faed4","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["0b56b861edfb75767df405d0509686a5","5b67067112d5f9c0199879f0746d524b","988d990e329fffe8bf8528cd0b628b14"],"research_disease":["fd889e1dd1744ffa9be7bb0584ff3110","52aeb8aacb5a46129f031a7e534d383d","d0c606fd02d94c04a2576cfac4550766","36cdcc4c6d9b434396effac4dc48f4ff","aba598f8e3ff4777979b733ef5262210","96e3b0b060974ad9bd27070571ebae64","86c9dec6885345009f177cb20378fa62","bb5baa14bc3e4e11be812216ce0faed4","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1744243200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1719705600000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"3da2ce3ce8b0443fb0b2d335be3e591a","dev_status_time":{"time_trust_code":7,"time_ts":1686009600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1715040000000}}],"disease_phase":[{"disease_id":"aba598f8e3ff4777979b733ef5262210","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"bb5baa14bc3e4e11be812216ce0faed4","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"86c9dec6885345009f177cb20378fa62","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"36cdcc4c6d9b434396effac4dc48f4ff","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d0c606fd02d94c04a2576cfac4550766","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"3da2ce3ce8b0443fb0b2d335be3e591a"},{"disease_id":"96e3b0b060974ad9bd27070571ebae64","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"52aeb8aacb5a46129f031a7e534d383d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"fd889e1dd1744ffa9be7bb0584ff3110","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1929df13d6634552abab3051b70b946d","docid":42992,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-10-08T14:47:02.000Z","updated_ts":"2026-04-02T11:58:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"MaaT-013","status":"ACTIVE"}],"dev_code":[{"name":"MAAT 013","status":"ACTIVE"},{"name":"MAAT013","status":"ACTIVE"}],"trade_name":[{"name":"Xervyteg","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.maatpharma.com/june-2-2025-maat-pharma-advances-toward-commercialization-and-submits-marketing-authorization-application-to-the-european-medicines-agency-ema-for-xervyteg-maat013-in-acute-graft-versus-ho/"},{"normalized_source_id":"e5b08f52d06d4e56a516b482a5fecb0f","source":"BusinessWire","source_url":"https://www.businesswire.com/news/home/20251103879768/en/MaaT-Pharma-Reports-Financial-Results-for-the-Third-Quarter-2025-and-Provides-Financing-Update"}],"status":"ACTIVE"}],"drug_type":["c6c79e0153624f09a88202767aae3926"],"originator_org_master_entity_id":["0750133e9d873e5fe4a2e14a0750418d"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","e11d32d254aba0e2defc5d6c4cd64b1a"],"special_review":["6486b22c3562461aaf94ee4623b29b1e","043a131d85994801b3617e822e7f87b3"],"disease_id":["116fbe2167a648e6b4ca70ccdfb4af57","170144d041c9427a8cfe5e542c2014c7","c1cc2528f29940fc95fd6bc37eb982d4","a311ae2187914c2bbad45810b91f9414","2477c68e093d4b818b11333ee1a5ee02"],"active_org_master_entity_id":["0750133e9d873e5fe4a2e14a0750418d","9bf7b39c74786b4c3afbe80bea229bbf"],"research_disease":["116fbe2167a648e6b4ca70ccdfb4af57","170144d041c9427a8cfe5e542c2014c7","c1cc2528f29940fc95fd6bc37eb982d4","a311ae2187914c2bbad45810b91f9414","2477c68e093d4b818b11333ee1a5ee02"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1748822400000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648166400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648166400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648166400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648166400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648166400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648166400000}}],"disease_phase":[{"disease_id":"116fbe2167a648e6b4ca70ccdfb4af57","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"170144d041c9427a8cfe5e542c2014c7","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["0750133e9d873e5fe4a2e14a0750418d","5f024ba17dd6d239b6a2fe3416ca5e9d"],"if_speculate":0,"data_source":10}
+{"drug_id":"08158ba0c8b248b6b5c78c6faf780a47","docid":113648,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-06-07T05:50:07.000Z","updated_ts":"2024-11-29T09:05:36.000Z","data_status":"ACTIVE","created_by":"yangjinhua@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"TEV-'192","source_info":[{"attachment_path":"data/phs_source_info/8967/bb1c/c808/d0f4/2ad49ede-8b85-391d-a910-177f64463e32.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5d96/7fc6/c043/95f9/5433505f-772a-3e44-a59a-2a6d930d12ac.jpeg","source":"Company pipeline","source_url":"https://www.tevapharm.com/product-focus/research/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"TEV '192","source_info":[{"attachment_path":"data/phs_source_info/8967/bb1c/c808/d0f4/2ad49ede-8b85-391d-a910-177f64463e32.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5d96/7fc6/c043/95f9/5433505f-772a-3e44-a59a-2a6d930d12ac.jpeg","source":"Company pipeline","source_url":"https://www.tevapharm.com/product-focus/research/pipeline/"}],"status":"ACTIVE"},{"name":"TEV'192","source_info":[{"attachment_path":"data/phs_source_info/8967/bb1c/c808/d0f4/2ad49ede-8b85-391d-a910-177f64463e32.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5d96/7fc6/c043/95f9/5433505f-772a-3e44-a59a-2a6d930d12ac.jpeg","source":"Company pipeline","source_url":"https://www.tevapharm.com/product-focus/research/pipeline/"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["1a53f7c62b9cb7bd69ffb74b97c35ed1"],"disease_id":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6"],"active_org_master_entity_id":["1a53f7c62b9cb7bd69ffb74b97c35ed1"],"research_disease":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6"],"disease_phase":[{"disease_id":"042cbe45c973477b957717ded29ef7b6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"76732dd51f2842799e6843eef80820ea","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"09245db029ef40ecb80286d0290e7553","docid":5777,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"linker_id":"764fec4db9e849058bb8aab63aab92b6","payload_id":"0a0ff46435274129adeaa8162129990b","specific_site":1,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"ce16157302a53fce92b62d9e0ac88bd8","has_leading_org_involved":1,"created_ts":"2023-02-24T08:35:27.000Z","updated_ts":"2026-02-17T21:32:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"ARX-517","status":"ACTIVE"}],"dev_code":[{"name":"ARX 517","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-psma-antibody-drug-conjugate-arx517"}],"status":"ACTIVE"},{"name":"ARX517","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-psma-antibody-drug-conjugate-arx517"}],"status":"ACTIVE"},{"name":"JNJ-8177","status":"ACTIVE"},{"name":"JNJ-95298177","source_info":[{"code":"NCT07082920","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07082920"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["47c71c5daf0ec3f1a8a8e82957dbf0fd"],"mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33","138f7edea9d70a30233e854b342a1eca"],"target_id":["1764007a7c384a4ab49bb3710bab5052","d9461748c4c54a0b84cbad2ae3fce7d5"],"dar":{"avg_value":2.0,"value_type":"AVERAGE"},"adc_reference":[{"code":"2023_3997","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"http://dx.doi.org/10.1158/1538-7445.am2023-3997"}],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["31a4a651f7744562b44cedbe4a0f942f","27538fe67e9b4648b06de8efdc9ab891","e50aad3dea474cf487e53bd91d5d7c45"],"active_org_master_entity_id":["631c6f07e79059fa97daf4f14a2c925d","fa85404e9b2f62d55e5167ed2213eca7"],"research_disease":["31a4a651f7744562b44cedbe4a0f942f","27538fe67e9b4648b06de8efdc9ab891","e50aad3dea474cf487e53bd91d5d7c45"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1751846400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1620000000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1751846400000}}],"disease_phase":[{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"31a4a651f7744562b44cedbe4a0f942f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["214cb75c44723d188591c0a5e610a180","47c71c5daf0ec3f1a8a8e82957dbf0fd","5549b8d686b8ba5aaf2a8fb0051d463c","a665df629734198e70a16b3fe9644458"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","payload_target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","moiety_mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"],"payload_target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"payload_mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"]}
+{"drug_id":"02c6c2c0430141849906a3b41df3e81f","docid":1761651,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":14,"target_extend_id":"73fd722415e83c2eac0a43a495b860bf","created_ts":"2025-10-23T05:57:16.000Z","updated_ts":"2026-03-14T21:13:47.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"CD19-CD22 CAR-T cells(Shanghai Ultra-T Immune Therapeutics)","source_info":[{"code":"NCT04714593","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04714593"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["4ecbddb54a21f0af0263827791587890"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","5010304c2ff249d5dbf674367642de9b"],"target_id":["5eb1fc5283d34305934a031af530f448","d02b07e15b354447b8f22cb9e5c1d369"],"disease_id":["19c82ee54b5345c4989d527af9e06caa","4c9d46b2b7794d128b14d8689f4c357d"],"active_org_master_entity_id":["4ecbddb54a21f0af0263827791587890"],"research_disease":["19c82ee54b5345c4989d527af9e06caa"],"non_research_disease":["4c9d46b2b7794d128b14d8689f4c357d"],"inactive_org_master_entity_id":["9eeb3489bf01cd2463a4039eb5f53c4c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1610668800000}}],"disease_phase":[{"disease_id":"19c82ee54b5345c4989d527af9e06caa","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1af8c982a8ef4e40b85feb66f68aa345","docid":3729,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":91,"target_extend_id":"27484dc2d43338fd8ff008f88abc23e7","created_ts":"2023-03-02T05:30:40.000Z","updated_ts":"2026-04-18T21:07:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"XZB-0002","status":"ACTIVE"}],"dev_code":[{"name":"XZB-0002","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["03660fd087fbbeed5359f7c5ce90109e"],"mechanism_action_id":["8a2d5573390441d7b6b583b122baa289"],"target_id":["eb553b25d950464798e93c7e998425d2"],"disease_id":["f319fa27684c4cdeb6ce59d897217718"],"active_org_master_entity_id":["03660fd087fbbeed5359f7c5ce90109e"],"research_disease":["f319fa27684c4cdeb6ce59d897217718"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}}],"disease_phase":[{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"385ce830df434bc5af15140c932009a9","docid":61081,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","wiki_link":"https://en.wikipedia.org/wiki/Ziresovir","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":6,"target_extend_id":"103207366d6e3996b6fce2e606cc3996","has_leading_org_involved":1,"created_ts":"2021-10-08T14:50:15.000Z","updated_ts":"2025-09-23T01:14:22.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"齐瑞索韦","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/QlXr0H4bj7laRYDy3S95oA"}],"status":"ACTIVE"},{"lang":"EN","name":"Ziresovir","status":"ACTIVE"}],"dev_code":[{"name":"AK-0529","status":"ACTIVE"},{"name":"AK0529","status":"ACTIVE"},{"name":"RO-0529","status":"ACTIVE"}],"trade_name":[{"name":"爱司韦","source_info":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2022/04/07/2418164/0/zh-hans/%E7%88%B1%E7%A7%91%E7%99%BE%E5%8F%91%E5%AE%A3%E5%B8%83%E7%88%B1%E5%8F%B8%E9%9F%A6-%E5%9C%A8%E6%B2%BB%E7%96%97%E5%91%BC%E5%90%B8%E9%81%93%E5%90%88%E8%83%9E%E7%97%85%E6%AF%92-RSV-%E6%84%9F%E6%9F%93%E7%9A%84%E4%BD%8F%E9%99%A2%E5%A9%B4%E5%B9%BC%E5%84%BF%E4%B8%AD%E7%9A%84%E4%B8%B4%E5%BA%8A%E4%B8%89%E6%9C%9F%E8%AF%95%E9%AA%8C%E8%BE%BE%E5%88%B0%E4%B8%BB%E8%A6%81%E7%BB%88%E7%82%B9.html"}],"status":"ACTIVE"}],"drugbank_id":["DB15145"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8a3c41b6b3536abfff46a5b43b7662b0"],"mechanism_action_id":["0ebcf1d3c900942ea26ee8d79dfabac7"],"target_id":["77f82229727143e383387cbf39f934fe"],"special_review":["23d3523b7ece48ddacaddac53a66949d","c3c948340a7d40f3b7437081f5e8cb4e","9eb8777c62af4712932b360e6ef3e454"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["9dce7af33237d28e237a05254a7c2405"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1670457600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1689984000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1598659200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1617840000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1617840000000}}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["87bfaf037f8e60c9e25595cd98bb27e4","9dce7af33237d28e237a05254a7c2405","db2daa90b8cc1f650bb9672ee74cde8c"],"data_source":10}
+{"drug_id":"5c627819f53041c0bff93a8e3697da48","docid":55883,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2021-10-08T14:50:27.000Z","updated_ts":"2024-11-12T11:37:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SSS-32","status":"ACTIVE"}],"dev_code":[{"name":"SSS 32","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0558695b5fddaa7de3cc3edbddccae7b"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["1f54367dda3b44f590bf2e196f85ff93"],"active_org_master_entity_id":["81f178dc1bfb1b46341b049bee528f4f"],"research_disease":["1f54367dda3b44f590bf2e196f85ff93"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"1f54367dda3b44f590bf2e196f85ff93","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0655ea9cd10346d3aec198ac6f1102c9","docid":65826,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":15,"target_extend_id":"a98f078c8fa73a39872fed67fe2556c4","created_ts":"2021-12-15T05:21:27.000Z","updated_ts":"2025-11-22T21:08:14.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BYS-10","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"BYS 10","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"BYS-10","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"BYS10","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["b84e3bb9eea3d40bb097fdd8b9524bf6"],"mechanism_action_id":["18962dd9294a402adf0ab56634ca84ea"],"target_id":["593ba65127444c25b4497209b82b90bd"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["b84e3bb9eea3d40bb097fdd8b9524bf6"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1658707200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"2789a6c9295c466bb17c7f760c7a65e7","docid":3255,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"b2ca28b01c34419db0365bad2f8dd09e","created_ts":"2022-09-27T13:38:04.000Z","updated_ts":"2026-01-27T22:50:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"WTX-221","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.westlaketpx.com/project.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"WTX 221","status":"ACTIVE"},{"name":"WTX221","status":"ACTIVE"}],"drug_type":["71bc3ec61acf4095b17a748da29068ef"],"originator_org_master_entity_id":["e811be1b9d290decc025e86d2c59e179"],"disease_id":["d0579fcbe06046b4b44990d910e1dc73"],"active_org_master_entity_id":["e811be1b9d290decc025e86d2c59e179"],"research_disease":["d0579fcbe06046b4b44990d910e1dc73"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"d0579fcbe06046b4b44990d910e1dc73","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"03fb2f146e6247b7b4a9fc66e4c390e1","docid":64164,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":67,"target_extend_id":"f86bcaded78a3034aade60daa2129306","created_ts":"2021-10-08T14:43:41.000Z","updated_ts":"2026-04-11T21:08:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Nevadistinel","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://zellbio.eu/product/nevadistinel/"},{"code":"WHOINN List 129","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_5&download=true"}],"status":"ACTIVE"}],"dev_code":[{"name":"NYX 458","status":"ACTIVE"},{"name":"NYX-3054","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://zellbio.eu/product/nevadistinel/"}],"status":"ACTIVE"},{"name":"NYX-458","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["c3a9e64a3aad8a7f59f0f71f91818ff4"],"mechanism_action_id":["7983a1aebe4741d66ac7fe44b278a2b2"],"target_id":["d1dec8037c6e4e8f9d0b120992be88c8"],"disease_id":["99bd009aa0e84d9599e2428d73786197","3da3a0b18fb5409d8827611b09254298","afeda617379d4ba48867bd5f076c9517","f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["c3a9e64a3aad8a7f59f0f71f91818ff4"],"research_disease":["99bd009aa0e84d9599e2428d73786197","3da3a0b18fb5409d8827611b09254298","afeda617379d4ba48867bd5f076c9517","f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1573689600000}}],"disease_phase":[{"disease_id":"afeda617379d4ba48867bd5f076c9517","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3da3a0b18fb5409d8827611b09254298","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"99bd009aa0e84d9599e2428d73786197","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0e2f433bc7f9424b8541d9a38520e48b","docid":1733795,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"bba80a9a386f3ac1bb0f2e0f3d82878a","created_ts":"2026-03-31T05:46:56.000Z","updated_ts":"2026-04-04T21:04:18.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"EB-G3B7-NK","source_info":[{"code":"NCT07500220","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07500220"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3(Beijing Biotech)","source_info":[{"code":"NCT07500220","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07500220"}],"status":"ACTIVE"}],"dev_code":[{"name":"EB-G3B7-NK","source_info":[{"code":"NCT07500220","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07500220"}],"status":"ACTIVE"}],"drug_type":["8554bd286df144c39af9350c62a5b309"],"originator_org_master_entity_id":["0c616c6570685503fcfa3c4fbb63a7cf"],"mechanism_action_id":["1253d086644f4034a91c30422bb266f2","a9206be3e7e72d447899465b4a04ef9a"],"target_id":["1728e61d30a543eda454c47f2bf1a73a","bdff4cbcdf8c43469571c3d82306d6e6"],"disease_id":["7fb8ceff333b48e8adea2c0803494a48","f048bf0822254413a3ea354eced08eec"],"active_org_master_entity_id":["0c616c6570685503fcfa3c4fbb63a7cf"],"research_disease":["7fb8ceff333b48e8adea2c0803494a48","f048bf0822254413a3ea354eced08eec"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1772409600000}}],"disease_phase":[{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"096213ae9e6842daad36dd62df8a0fce","docid":72970,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-03-02T05:30:59.000Z","updated_ts":"2025-04-08T09:19:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"lbogaine HCI(Dermex Pharmaceuticals)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.demerx.com/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0017903b2e17ee0d6a880ff6b4404764"],"mechanism_action_id":["17b6821afc544cdca2d96c01cbeb1d73"],"disease_id":["27dbebece4ff4babbc6faa1162d8f26c"],"active_org_master_entity_id":["0017903b2e17ee0d6a880ff6b4404764"],"research_disease":["27dbebece4ff4babbc6faa1162d8f26c"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}}],"disease_phase":[{"disease_id":"27dbebece4ff4babbc6faa1162d8f26c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"024613b135014755a0e89fe9c4494beb","docid":1010264,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"f5c11f42de5c34f1bcd23b24d81f9bf9","created_ts":"2025-03-10T06:57:09.000Z","updated_ts":"2026-01-09T07:34:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Etoricoxib/Betamethasone","source_info":[{"code":"NCT06863701","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06863701"}],"status":"ACTIVE"}],"related_component":["38c685bdde4245a585564b7a6b26ff14","ab9aec1adbd94c98a5cbf073e5573130"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ab3b33b7721de70e9914b6bf3e9e3f10"],"mechanism_action_id":["6ea83f15b431cf57d758448596d2b0d6","b3b0790f82c48637c8ccae2fb7b59a32"],"target_id":["271815d56d4440f3b425e4bd5f1dff38","6fe53f67a27241fcac53227526791322"],"disease_id":["bffe318c5217474cb27af710d14d04a9","93fde4ccd0a24a70801f5c8178104933","1c30fc074bb1449f9b36994e8b3084d7","35df228d7cc5461dab659878686fba07"],"active_org_master_entity_id":["ab3b33b7721de70e9914b6bf3e9e3f10"],"research_disease":["bffe318c5217474cb27af710d14d04a9","93fde4ccd0a24a70801f5c8178104933","1c30fc074bb1449f9b36994e8b3084d7","35df228d7cc5461dab659878686fba07"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1747180800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1737936000000}}],"disease_phase":[{"disease_id":"bffe318c5217474cb27af710d14d04a9","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"93fde4ccd0a24a70801f5c8178104933","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"35df228d7cc5461dab659878686fba07","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"1c30fc074bb1449f9b36994e8b3084d7","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"105104a7c9da4f26987e75f197badfe9","docid":68492,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"3e35c1bd3b923794bea49f93e3475266","created_ts":"2022-12-04T07:34:53.000Z","updated_ts":"2025-05-09T00:19:49.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CimetrA","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ArtemiC","source_info":[{"code":"NCT04802382","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04802382"}],"status":"ACTIVE"},{"lang":"EN","name":"Artemisinin, Curcumin, and Boswellia, and Vitamin C in a nanoparticular formulation","source_info":[{"code":"NCT04802382","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04802382"}],"status":"ACTIVE"}],"dev_code":[{"name":"MGC-006","source_info":[{"code":"NCT04802382","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04802382"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["0275ab2d54ffb8e087927298c1007501"],"mechanism_action_id":["6e5db8ae3d0249424037f47c84b47580","942a2d27fb81e1dcb73b5a1d39f2a92d","873de82656f76829d80921542c2d2d8a"],"target_id":["0f2ec9159728426ea835dc28a3e9d1e8","df25e9fee06e4c74b935f6c3a8486810","1cf1d1f419714af18f463bac42a732d5"],"disease_id":["4877fdea8af24861ac4d9dd0d5baab7f"],"active_org_master_entity_id":["0275ab2d54ffb8e087927298c1007501"],"research_disease":["4877fdea8af24861ac4d9dd0d5baab7f"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1660694400000}}],"disease_phase":[{"disease_id":"4877fdea8af24861ac4d9dd0d5baab7f","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4d264d7848b74f9da0f0cfa8b4e2dfbc","docid":47277,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":116,"target_extend_id":"c3564a2e384d34ef94516d844f563ba3","created_ts":"2022-11-03T06:10:48.000Z","updated_ts":"2026-04-18T21:04:26.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"177Lu-P17-087","source_info":[{"code":"NCT05603559","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05603559"}],"status":"ACTIVE"}],"drug_type":["ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a"],"mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"target_id":["1764007a7c384a4ab49bb3710bab5052"],"disease_id":["27538fe67e9b4648b06de8efdc9ab891"],"active_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a"],"research_disease":["27538fe67e9b4648b06de8efdc9ab891"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1672531200000}}],"disease_phase":[{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","moiety_mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"]}
+{"drug_id":"03226dd5ea8d41ae8698f4998b96926e","docid":201207,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":29,"target_extend_id":"748fb1b16e9b3afcbd8928205ee73cdd","created_ts":"2024-04-30T05:29:24.000Z","updated_ts":"2026-03-28T21:09:44.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"α-PD-L1/4-1BB DLL3 CAR-T(Brilliant Pharmaceutical)","source_info":[{"code":"NCT06348797","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06348797"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DLL3 Targeted α-PD-L1/4-1BB Modifying Chimeric Antigen Receptor T-cells","source_info":[{"code":"NCT06348797","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06348797"}],"status":"ACTIVE"}],"dev_code":[{"name":"BHP-01","source_info":[{"code":"NCT06348797","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06348797"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["b9b43b1dbf3c547724cddbac81b65a1c"],"mechanism_action_id":["a59e6c478b6565d0dee823b116867677"],"target_id":["2207f013c4204775b1b1c7974c275747"],"disease_id":["2536e79ced34450fbb09de73061cf096"],"active_org_master_entity_id":["b9b43b1dbf3c547724cddbac81b65a1c"],"research_disease":["2536e79ced34450fbb09de73061cf096"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1743638400000}}],"disease_phase":[{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"03d99ac7fca440dbada6ecec12e2db54","docid":27208,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:35.000Z","updated_ts":"2026-01-01T00:16:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"正宫胶囊","status":"ACTIVE"},{"lang":"EN","name":"Zhenggong Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["817d89cd565d397512e37a2c726a7293","d342973db4d0e95b911aef9c21a98019"],"disease_id":["deb0d6f9914746da8552c24fbd87b730"],"active_org_master_entity_id":["817d89cd565d397512e37a2c726a7293","d342973db4d0e95b911aef9c21a98019"],"research_disease":["deb0d6f9914746da8552c24fbd87b730"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1396224000000}}],"disease_phase":[{"disease_id":"deb0d6f9914746da8552c24fbd87b730","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"2538a5e231a840e7ba984e7bfead9c64","docid":1702041,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-12-01T03:19:13.000Z","updated_ts":"2025-12-01T05:44:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"[68Ga]-NOTA-RF","source_info":[{"code":"NCT07254104","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07254104"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a"],"disease_id":["f7ce648d7eb448ada7d11726e0768ff8"],"active_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a"],"research_disease":["f7ce648d7eb448ada7d11726e0768ff8"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1763337600000}}],"disease_phase":[{"disease_id":"f7ce648d7eb448ada7d11726e0768ff8","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1b2bf07dd76541c5b55da0b0a4958cb9","docid":234584,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":52,"target_extend_id":"23e78dc5bc9e3c569f29398d0a761044","created_ts":"2024-12-25T10:02:06.000Z","updated_ts":"2025-11-08T21:09:41.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"Bamlanivimab/Etesevimab","status":"ACTIVE"}],"related_component":["1308547a92754718bd13f785fa3345e5","c53988902a6646d8bc10ccdf819c28ae"],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"mechanism_action_id":["80f3a83094c71a87cd8768d22cd277fd"],"target_id":["f2c8821a6e5845f1b698c8a5a00029e5"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["49e2a14a99f82a1ccbb315edf2910349"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"inactive_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1632096000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1684540800000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0053fe2be2be4165a1be0e1cd773f077","docid":44046,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":155,"target_extend_id":"30ed854af12137b3869be714792ad19d","created_ts":"2021-10-08T14:40:57.000Z","updated_ts":"2026-02-07T21:08:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LCB10-0200","status":"ACTIVE"}],"dev_code":[{"name":"GT-1","status":"ACTIVE"},{"name":"LCB10 0200","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dad86a0ee8a66146b673658585283ca5"],"mechanism_action_id":["96af81a44ae49944712b75894f39682f"],"target_id":["20c015d11407415a83ad7902f6d712a5"],"disease_id":["fc39368e3de54e2ab5c2d567074a6a4b"],"active_org_master_entity_id":["dad86a0ee8a66146b673658585283ca5"],"research_disease":["fc39368e3de54e2ab5c2d567074a6a4b"],"inactive_org_master_entity_id":["24ab7b0947a7b4dd19ea0735271972a3"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"cf139751c1fd4a5892c786230e6f6b6a"}],"disease_phase":[{"disease_id":"fc39368e3de54e2ab5c2d567074a6a4b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"01acbdf91a594e279ad3a55cf8c153d8","docid":115111,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":33,"target_extend_id":"f7778933748c360dbd94f61f8041eb87","created_ts":"2024-09-10T11:00:26.000Z","updated_ts":"2026-03-19T00:55:28.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Tirzepatide(Anya Biopharma)","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.centerlab.com.tw/news/detail/147"}],"status":"ACTIVE"}],"dev_code":[{"name":"ANY004","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.centerlab.com.tw/news/detail/147"}],"status":"ACTIVE"}],"generic_name":[{"name":"tirzepatide","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["67d0cd7274aed1b1e0ca619bd22b8145"],"mechanism_action_id":["47b4c1651fa2bfb01b1d26d0a0d27a6f","888b99dda6a62ef2551937c34e253e9c"],"target_id":["a87e2f1913564a9aa418d6a6a8e1a799","c385dcba5fea4e97bf02bc256757613a"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["67d0cd7274aed1b1e0ca619bd22b8145"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0734e8bc845246a7b10ba632fe1af967","docid":61199,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"38ca15ae4ccd3aafbcec18509f6a93d3","created_ts":"2021-10-08T14:38:04.000Z","updated_ts":"2026-04-03T09:01:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"TT-4","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PORT-7","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.portagebiotech.com/our-portfolio/adenosine-portfolio/"}],"status":"ACTIVE"}],"dev_code":[{"name":"TT 4","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenosine-a2b-receptor-antagonist-tt-4"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f9079d6d564cb86c83498cbb9dfe27b4"],"mechanism_action_id":["2f06a7c75ab06442b66705184969985f"],"target_id":["97fe9fc41b5d4e8e94c3a5ca8facb6cf"],"disease_id":["5cedd9732f5b45f1b6e9b226b32a0314","7665e5683a1a443a8f3d3b946d4c9ca2","87a9454771a64f2191224b6b7684254a","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","3df822c8c6984e33bf17c1e2861c9ba3","4c092510a2af42f387426e408f5c7694","7fb8ceff333b48e8adea2c0803494a48","0464f5493b0444e9875a0584df17cbf0","8bea5bec08e44c1ea7a90c7a1e3daeb8"],"active_org_master_entity_id":["39ef9abc3e9c91a1c111e3787c536cba","e965f09149a97a8905bbe8e63f7e2d5c"],"research_disease":["5cedd9732f5b45f1b6e9b226b32a0314","7665e5683a1a443a8f3d3b946d4c9ca2","87a9454771a64f2191224b6b7684254a","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","3df822c8c6984e33bf17c1e2861c9ba3"],"non_research_disease":["4c092510a2af42f387426e408f5c7694","7fb8ceff333b48e8adea2c0803494a48","0464f5493b0444e9875a0584df17cbf0","8bea5bec08e44c1ea7a90c7a1e3daeb8"],"inactive_org_master_entity_id":["f9079d6d564cb86c83498cbb9dfe27b4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1687478400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1745798400000}}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"8bea5bec08e44c1ea7a90c7a1e3daeb8","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"3df822c8c6984e33bf17c1e2861c9ba3","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"5cedd9732f5b45f1b6e9b226b32a0314","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["39ef9abc3e9c91a1c111e3787c536cba","f9079d6d564cb86c83498cbb9dfe27b4"],"data_source":10}
+{"drug_id":"1bbdb92084e346358328d50d43fc4c1c","docid":8825,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","wiki_link":"https://en.wikipedia.org/wiki/Siplizumab","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"f391ceed411b3195ac99e05bdfa8f07d","created_ts":"2021-10-08T14:42:19.000Z","updated_ts":"2026-04-03T05:06:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"希普利珠单抗","status":"ACTIVE"},{"lang":"EN","name":"Siplizumab","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Siplizumab (USAN/INN)","source_info":[{"code":"D05847","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"MEDI-507","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/siplizumab"}],"status":"ACTIVE"},{"name":"TCD 601","status":"ACTIVE"},{"name":"TCD-601","source_info":[{"code":"NCT06025110","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06025110"}],"status":"ACTIVE"},{"name":"TCD601","status":"ACTIVE"}],"generic_name":[{"name":"Siplizumab","source_info":[{"code":"D05847","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB06371"],"kegg_id":["D05847"],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["de6416bb9618e858641161f827f1d1c5"],"mechanism_action_id":["665831b22fc7cb2bf3cc56330a28568b"],"target_id":["6f3fb6c7f91547949757c37fc2669eee"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["309decc979cd4802a346ae247a6fede2","11941a13580a48b28a5d20fe7e42552f","932fa466d6784a9d82cc42387ae729b1","b810ecec69eb481aba45547dcf413537","54585b410d874858889ad1037d99b675","156a874d70524bf699be1cb57a469e2a","006e8974946846f58e296dd19113668c","738546bac89e4895b89af01545f1b054","3a61bb332f264038b1612091521eaae7","7a92f69cdbd343dea8043ec3c078dbc0","116fbe2167a648e6b4ca70ccdfb4af57","ec1a5f9ee5194b44ab4829e737cb053a","a66f414abeda43d7876a58c350cb1777","7b1b0e62e13945b0bd5a4eff6aa47038","4e59dff5f54e40d4b7ededa7eb9e54b4","1dec6017bd924aff8aeae6e7d4a3f874","11fe8a3c7f04470fb887aa9ff8bc53e3","99533cae1a3540648595200a452bd93c","5208de309a5142549e39bdb0d247d3e6","94deb71c1ce54fdf8923bfcb7c88d054","1cfde61efce54a8c9b92dd7b60c30995","d281a3b362a740d8aeb63e2a10102671","6be96778ed424f8d91de00ab82364114","170144d041c9427a8cfe5e542c2014c7"],"active_org_master_entity_id":["0a9ae83bd1b3902c18259e27f05818be","38161d506415cc1653331cc552f0e6db","6200c909915b1ced05552aa075719bf3"],"research_disease":["309decc979cd4802a346ae247a6fede2","11941a13580a48b28a5d20fe7e42552f","932fa466d6784a9d82cc42387ae729b1","b810ecec69eb481aba45547dcf413537","54585b410d874858889ad1037d99b675","156a874d70524bf699be1cb57a469e2a","006e8974946846f58e296dd19113668c","738546bac89e4895b89af01545f1b054","3a61bb332f264038b1612091521eaae7","7a92f69cdbd343dea8043ec3c078dbc0"],"non_research_disease":["116fbe2167a648e6b4ca70ccdfb4af57","ec1a5f9ee5194b44ab4829e737cb053a","a66f414abeda43d7876a58c350cb1777","7b1b0e62e13945b0bd5a4eff6aa47038","4e59dff5f54e40d4b7ededa7eb9e54b4","1dec6017bd924aff8aeae6e7d4a3f874","11fe8a3c7f04470fb887aa9ff8bc53e3","99533cae1a3540648595200a452bd93c","5208de309a5142549e39bdb0d247d3e6","94deb71c1ce54fdf8923bfcb7c88d054","1cfde61efce54a8c9b92dd7b60c30995","d281a3b362a740d8aeb63e2a10102671","6be96778ed424f8d91de00ab82364114","170144d041c9427a8cfe5e542c2014c7"],"inactive_org_master_entity_id":["b91320e8a844a0d3ef7a9ce2a5d1fe85","de6416bb9618e858641161f827f1d1c5"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1703721600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1622937600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1773273600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1773273600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1120089600000}}],"disease_phase":[{"disease_id":"3a61bb332f264038b1612091521eaae7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"5208de309a5142549e39bdb0d247d3e6","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"156a874d70524bf699be1cb57a469e2a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a66f414abeda43d7876a58c350cb1777","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"116fbe2167a648e6b4ca70ccdfb4af57","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4e59dff5f54e40d4b7ededa7eb9e54b4","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"570b3cb9d08246788a5c1ccfc4ab5b09","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"11941a13580a48b28a5d20fe7e42552f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7b1b0e62e13945b0bd5a4eff6aa47038","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"ec1a5f9ee5194b44ab4829e737cb053a","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"309decc979cd4802a346ae247a6fede2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"006e8974946846f58e296dd19113668c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"ae1104e7f11d4b7ca4a48e00672b82b6","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7a92f69cdbd343dea8043ec3c078dbc0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"99533cae1a3540648595200a452bd93c","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"932fa466d6784a9d82cc42387ae729b1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"1cfde61efce54a8c9b92dd7b60c30995","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"b810ecec69eb481aba45547dcf413537","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"170144d041c9427a8cfe5e542c2014c7","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"94deb71c1ce54fdf8923bfcb7c88d054","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"11fe8a3c7f04470fb887aa9ff8bc53e3","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"54585b410d874858889ad1037d99b675","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"38ec8524a2fe441d8b9368b0998cf8ee","docid":262142,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":65,"target_extend_id":"cb08ad70f6053dde8ff74674e5530e98","created_ts":"2024-06-20T01:50:14.000Z","updated_ts":"2026-04-18T21:07:45.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"[68Ga] B7H3 Affibody-BCH","source_info":[{"code":"NCT06454955","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06454955"}],"status":"ACTIVE"}],"drug_type":["05957e8371da41fd825986282a4acce0","78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["7597a5f65e482a0af413c1f07baef875"],"mechanism_action_id":["1253d086644f4034a91c30422bb266f2"],"target_id":["1728e61d30a543eda454c47f2bf1a73a"],"disease_id":["b5b563bbb9c1499ba35cc30018dc437f","f048bf0822254413a3ea354eced08eec","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["4d1496dc73fd4e2bcc6fb95fa2cb15b4"],"research_disease":["b5b563bbb9c1499ba35cc30018dc437f","f048bf0822254413a3ea354eced08eec","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1704067200000}}],"disease_phase":[{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b5b563bbb9c1499ba35cc30018dc437f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"moiety_target_extend_id":"cb08ad70f6053dde8ff74674e5530e98","moiety_mechanism_action_id":["1253d086644f4034a91c30422bb266f2"],"moiety_target_id":["1728e61d30a543eda454c47f2bf1a73a"]}
+{"drug_id":"00a92630eeea4071aeb0aa0057dccbed","docid":30700,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":915148800000,"created_ts":"2021-10-08T14:45:23.000Z","updated_ts":"2024-11-01T03:59:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","first_approved_date_cn":915148800000,"drug_name":[{"lang":"CN","name":"吸附无细胞百白破联合疫苗 (兰州生物制品研究所)","status":"ACTIVE"},{"lang":"EN","name":"Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed(Lanzhou Institute of Biological Products)","status":"ACTIVE"}],"drug_type":["5f5b59262b674cb0a560ddb6aa68bb4f","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["15aba8d18c91dfdc4f7d3f461f8f2838"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["260708e60ed540aa8eb5e240c3fb2932"],"disease_id":["90a4f0aa8f4745188895e0cf401c3cac","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"active_org_master_entity_id":["15aba8d18c91dfdc4f7d3f461f8f2838"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["90a4f0aa8f4745188895e0cf401c3cac","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"research_disease":["90a4f0aa8f4745188895e0cf401c3cac","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":915148800000}}],"disease_phase":[{"disease_id":"90a4f0aa8f4745188895e0cf401c3cac","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8f73c0a533f24a49aeae602d1ca70eb7","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e255185bd59e4c2cbef67fd98444d16f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"019f0a95386444f19945c4bdd2a232cb","docid":110774,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":42,"target_extend_id":"879072cd8a783a57b906b2c251864bb4","created_ts":"2024-03-07T06:38:17.000Z","updated_ts":"2026-03-14T21:10:21.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"DA-5221-T","source_info":[{"code":"NCT06290349","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06290349"}],"status":"ACTIVE"}],"dev_code":[{"name":"DA-5221-T","source_info":[{"code":"NCT06290349","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06290349"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ffb7c44a2d5b634dc4a46e1d5ff204fd"],"mechanism_action_id":["b33a5535c71348d2824dea81333c6197"],"target_id":["a995e993b483437ab03a1b4f5da488a8"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["ffb7c44a2d5b634dc4a46e1d5ff204fd"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1711929600000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0880ec0ad2294cedb5ac95b46b1ef097","docid":110164,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-01-23T10:27:13.000Z","updated_ts":"2026-01-27T12:38:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"EuRSV(EuBiologics)","source_info":[{"code":"NCT06216093","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06216093"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"RSV (POP Biotechnologies)","source_info":[{"attachment_path":"data/phs_source_info/df96/c958/5202/0d5c/017e5d7d-17be-3247-a727-b1a4f43c8701.jpg","attachment_type":"image/jpeg","code":"POP-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/8ed7/3796/109b/c07b/8dcbd350-c66d-3057-a8ac-bd74ce242586.jpg","source":"Company pipeline","source_url":"https://www.pop.bio/clinical-pipeline"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["a63daa83bde499a893b64f129437865d"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["a63daa83bde499a893b64f129437865d","99da64b8e867c7dec88719b65cf526bf","7a1ad269cd2f477ac6c967eb826749e0"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1715126400000}}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0424888c369648e1a692616a4f3c4e87","docid":980126,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-02-21T06:21:32.000Z","updated_ts":"2025-02-24T09:07:13.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Osteoarthritis (Yooyoung)","source_info":[{"attachment_path":"data/phs_source_info/1367/7eb3/6623/37d4/4a867138-4c5e-36eb-a898-d2bc4d195366.jpg","attachment_type":"image/jpeg","code":"Yooyoung-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/40cd/4671/8b53/2912/8213bd1d-968f-398f-b0e1-7ae2a4e94675.jpg","source":"Company pipeline","source_url":"https://eng.yypharm.co.kr/product/pipeline"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["f8408a10b0cfd7df709428a92dd0a1b1"],"disease_id":["d124992d44c44ac4801806e7a62943a9"],"active_org_master_entity_id":["f8408a10b0cfd7df709428a92dd0a1b1"],"research_disease":["d124992d44c44ac4801806e7a62943a9"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"d124992d44c44ac4801806e7a62943a9","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"062a9cc3b975410b88a3837cdc7b22b7","docid":1310261,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-04-07T07:56:48.000Z","updated_ts":"2025-04-07T09:36:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Adenovirus Specific T- Lymphocytes(Stanford University)","source_info":[{"code":"NCT06909110","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06909110"}],"status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["734b6d223a9d633b8419a74d2fd215ae"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158"],"disease_id":["488c95523ea94a2985edc1144cadf1aa"],"active_org_master_entity_id":["734b6d223a9d633b8419a74d2fd215ae"],"research_disease":["488c95523ea94a2985edc1144cadf1aa"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1747008000000}}],"disease_phase":[{"disease_id":"488c95523ea94a2985edc1144cadf1aa","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0fc630ac2e704250a2d01e8748457693","docid":16119,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-01-22T07:31:40.000Z","updated_ts":"2026-03-25T13:40:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"XY-03-EA","status":"ACTIVE"}],"dev_code":[{"name":"XY-03-EA","status":"ACTIVE"},{"name":"XY03-EA","status":"ACTIVE"},{"name":"ZONK-1103","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["eae04b2967cff19af9458fe968add5e5"],"disease_id":["e2bf071405ab4c4787be311613287430"],"active_org_master_entity_id":["0b3914ea0ddfc8794c214970054e8f6b"],"research_disease":["e2bf071405ab4c4787be311613287430"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1774396800000}}],"disease_phase":[{"disease_id":"e2bf071405ab4c4787be311613287430","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"4edc29f70916481c88d8198770b530c2","docid":234335,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-11-25T07:16:17.000Z","updated_ts":"2025-05-29T13:46:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"INK Cell Therapy(Guangzhou Ruixin Biotechnology)","source_info":[{"code":"NCT06702098","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06702098"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Induced Pluripotent Stem Cells Derived Natural Killer Cells(Guangzhou Ruixin Biotechnology)","source_info":[{"code":"NCT06702098","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06702098"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["68b5bf4ac3572722a0326abf9b9a5fab"],"disease_id":["8d29f554f371431c9b5b80f5befdf965","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["68b5bf4ac3572722a0326abf9b9a5fab"],"research_disease":["8d29f554f371431c9b5b80f5befdf965","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1734220800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1732492800000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"00863ab218554848b4ccb196845f6156","docid":19410,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:50:26.000Z","updated_ts":"2024-10-30T10:22:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"H-5C","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["c3395ee048553a86ebe82acc36cbddb9"],"disease_id":["5f0765227409473d803995e585313374"],"active_org_master_entity_id":["c3395ee048553a86ebe82acc36cbddb9"],"research_disease":["5f0765227409473d803995e585313374"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"disease_phase":[{"disease_id":"5f0765227409473d803995e585313374","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"03531fde75a8445fa180ed1d9df7c44b","docid":34486,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-12-04T06:31:44.000Z","updated_ts":"2024-11-07T20:07:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"CU-106","source_info":[{"normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent","source_url":"https://worldwide.espacenet.com/publicationDetails/inpadoc?CC=WO&NR=2021225233#"}],"status":"ACTIVE"}],"dev_code":[{"name":"CU106","source_info":[{"normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent","source_url":"https://worldwide.espacenet.com/publicationDetails/inpadoc?CC=WO&NR=2021225233#"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["b61c23fbc0a94e2383b51ad075e7004c"],"mechanism_action_id":["ab1d5b334eef877dd52cf10faec6df78"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["b61c23fbc0a94e2383b51ad075e7004c"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0cba4af89a744df2b021c2cec1e7dd08","docid":60115,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":189,"target_extend_id":"b0ea200ef98133288a18281a674f862d","created_ts":"2022-04-28T12:55:48.000Z","updated_ts":"2026-04-11T21:07:56.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)","status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["9b887e67e08f4f520a3eae177d6ee451"],"mechanism_action_id":["d8cf80828c564c6889168e2249b034fa"],"target_id":["d4ed73bcacc74cf9a7066f422194f1a3"],"disease_id":["717a9bf79e584830859595b8dbe9d433","131c3f4dfc0c4a958e9f91166e73c913","83c00fea95ab443a997c1e3818bea37e"],"active_org_master_entity_id":["9b887e67e08f4f520a3eae177d6ee451"],"research_disease":["717a9bf79e584830859595b8dbe9d433","131c3f4dfc0c4a958e9f91166e73c913","83c00fea95ab443a997c1e3818bea37e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1608249600000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"83c00fea95ab443a997c1e3818bea37e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0e59a34f6d19418a8cc164a78671c835","docid":8348,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":18,"target_extend_id":"4eac07f164903163a066639e35adca2b","created_ts":"2022-03-29T06:29:31.000Z","updated_ts":"2026-02-24T20:41:06.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"头孢吡肟/阿维巴坦","status":"ACTIVE"},{"lang":"EN","name":"Cefepime/Avibactam","source_info":[{"code":"CTR20213157","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=edd71535308f42a497a66c0d60ea4333"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"头孢吡肟阿维巴坦钠","source_info":[{"code":"CTR20250851","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ec83685f0e08457bbd56d2e2eb625143"}],"status":"ACTIVE"}],"dev_code":[{"name":"YK-1169","source_info":[{"code":"CTR20213157","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=edd71535308f42a497a66c0d60ea4333"}],"status":"ACTIVE"}],"related_component":["001ab4d02229445bb129a717442d1097","66f519947524478fa131ffcadd6cd3af"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["96af81a44ae49944712b75894f39682f","86854a788448f094e8d3851fa5c3c552","b16637447f22f84eac33286792fb9770"],"target_id":["20c015d11407415a83ad7902f6d712a5","41a6c5ad0dfc4553918f4048827137d6"],"disease_id":["406bbc4c9f2643fe8b1a1acd637a0534","6bd047d43d104e9d94047664163a0f8b","350d3db9893e4498b2e396c24aa6a029","7cf66a4af7ac4b51b888c59d7e30a2c4","4194f6eb346e4e06872a2383ae20afe7","478a3554509441e7936078bddfbca593"],"active_org_master_entity_id":["90eca8a82b9cfb27c624214a3f2f75e0","c82a34334b897271d15fb8944a03ee01"],"research_disease":["406bbc4c9f2643fe8b1a1acd637a0534","6bd047d43d104e9d94047664163a0f8b","350d3db9893e4498b2e396c24aa6a029","7cf66a4af7ac4b51b888c59d7e30a2c4"],"non_research_disease":["4194f6eb346e4e06872a2383ae20afe7","478a3554509441e7936078bddfbca593"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1769126400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1743379200000}}],"disease_phase":[{"disease_id":"350d3db9893e4498b2e396c24aa6a029","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"406bbc4c9f2643fe8b1a1acd637a0534","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7cf66a4af7ac4b51b888c59d7e30a2c4","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"478a3554509441e7936078bddfbca593","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6bd047d43d104e9d94047664163a0f8b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"4194f6eb346e4e06872a2383ae20afe7","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"3c1736facc4b453bb953a31f9b87f9ae","docid":1340529,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"4803ab793c5044aba32b1786640938d3","global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-04-18T10:15:46.000Z","updated_ts":"2025-07-31T17:10:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"18F-JSS20-183A","source_info":[{"code":"NCT06932809","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06932809"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["3bdcd22f6e2d3273ac9eac8e8ab7a0b0"],"disease_id":["c2e755f2cdc34621ac8e4ad193f523b1","e750d2827d3b4217b8c1561c11aa8eab","06800c58775143058fa08c139594ed4a"],"active_org_master_entity_id":["3bdcd22f6e2d3273ac9eac8e8ab7a0b0"],"research_disease":["c2e755f2cdc34621ac8e4ad193f523b1","e750d2827d3b4217b8c1561c11aa8eab","06800c58775143058fa08c139594ed4a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1746748800000}}],"disease_phase":[{"disease_id":"c2e755f2cdc34621ac8e4ad193f523b1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"06800c58775143058fa08c139594ed4a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e750d2827d3b4217b8c1561c11aa8eab","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03ffd9e0b947401fa16b672d2eba2edb","docid":25631,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1600646400000,"created_ts":"2022-08-03T08:55:35.000Z","updated_ts":"2024-10-30T10:22:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1600646400000,"drug_name":[{"lang":"CN","name":"华蟾素口服液","status":"ACTIVE"},{"lang":"EN","name":"Cinobufagin Oral Liquid","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["63037f413c5fee51a36347f4e66483ca"],"disease_id":["f196ef1a4d9c4cb3aede0ea60aac4a52","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["63037f413c5fee51a36347f4e66483ca"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["f196ef1a4d9c4cb3aede0ea60aac4a52","62eaee6d9ee44410b8aca59dfc7408e9"],"research_disease":["f196ef1a4d9c4cb3aede0ea60aac4a52","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1600646400000}}],"disease_phase":[{"disease_id":"f196ef1a4d9c4cb3aede0ea60aac4a52","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"008400466e53474686b01d1ca26346c8","docid":61834,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Clomifene","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":102,"target_extend_id":"27484dc2d43338fd8ff008f88abc23e7","created_ts":"2021-10-08T14:46:57.000Z","updated_ts":"2026-04-04T21:05:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"珠氯米芬","status":"ACTIVE"},{"lang":"EN","name":"Zuclomifene(Veru Healthcare, Inc.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine","source_info":[{"code":"DB00882","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine","source_info":[{"code":"DB00882","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"2-(p-(β-chloro-α-phenylstyryl)phenoxy)triethylamine","source_info":[{"code":"DB00882","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Clomifene","source_info":[{"code":"DB00882","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Clomiphene","source_info":[{"code":"DB00882","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Zuclomifene","status":"ACTIVE"},{"lang":"EN","name":"Zuclomiphene citrate","status":"ACTIVE"},{"lang":"EN","name":"cis-clomifene","status":"ACTIVE"},{"lang":"EN","name":"cis-clomiphene citrate","status":"ACTIVE"}],"dev_code":[{"name":"APP 944","status":"ACTIVE"},{"name":"APP-944","status":"ACTIVE"},{"name":"RMI-16312","status":"ACTIVE"},{"name":"VERU-944","status":"ACTIVE"}],"generic_name":[{"name":"Zuclomifene","source_info":[{"code":"1HRS458QU2","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/ee3158f4-8e67-45aa-bd13-75d84370946b"}],"status":"ACTIVE"}],"drugbank_id":["DB00882"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dad184ef170c2cacd07a0c7ee2b82d48"],"mechanism_action_id":["621511aeeb15010ccb35c449a27b3718"],"target_id":["eb553b25d950464798e93c7e998425d2"],"disease_id":["bfe0bfce976b470ca960901d4ea8f6f1","fd7ba28668d8489eb8c951444259baf4","c429db71d4a441d9823a909208d8f08e","26535c6f16de4adfb19f0154be738535","c349d56721634602bd73c8f36c3b496a","14458e6e0593405983a2a4c2ca1571bf"],"active_org_master_entity_id":["dad184ef170c2cacd07a0c7ee2b82d48"],"research_disease":["bfe0bfce976b470ca960901d4ea8f6f1"],"non_research_disease":["fd7ba28668d8489eb8c951444259baf4","c429db71d4a441d9823a909208d8f08e","26535c6f16de4adfb19f0154be738535","c349d56721634602bd73c8f36c3b496a","14458e6e0593405983a2a4c2ca1571bf"],"inactive_org_master_entity_id":["00da7b62acc8e17594bafc9b89d8e8ec","ed4709abe5514910df90ac28b93205fc"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1665792000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"bfe0bfce976b470ca960901d4ea8f6f1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"14458e6e0593405983a2a4c2ca1571bf","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c429db71d4a441d9823a909208d8f08e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c349d56721634602bd73c8f36c3b496a","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fd7ba28668d8489eb8c951444259baf4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"1544bc78eb7f8c6f0e50d13ecc543ea3","docid":46646,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":49,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2023-05-19T07:33:23.000Z","updated_ts":"2026-04-04T21:07:47.000Z","data_status":"ACTIVE","created_by":"sunying","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"GLPG-5301","status":"ACTIVE"}],"dev_code":[{"name":"GLPG 5301","status":"ACTIVE"},{"name":"GLPG5301","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["ae31c06285a854eabb4512f8c13648ef"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["ae31c06285a854eabb4512f8c13648ef"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"912d59cd-f1d3-3551-bae2-1f6f0062258f","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1681171200000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"178dc9c590fa4a0298359917fcaf1bac","docid":1286,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-12-10T12:54:28.000Z","updated_ts":"2026-01-27T16:13:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Peripheral arterial disease cell therapy (MultiGene Vascular Systems)","status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["ea0bd47943a43401e834c237b21e44b3"],"disease_id":["10e1eb8695754228ad20da0a78c90631","58fd49f71a3f4a3483307fbc643c9725","c5dbda12237b45cca74d49f7bb1e6808"],"active_org_master_entity_id":["ea0bd47943a43401e834c237b21e44b3"],"research_disease":["10e1eb8695754228ad20da0a78c90631","58fd49f71a3f4a3483307fbc643c9725","c5dbda12237b45cca74d49f7bb1e6808"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1159660800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1264982400000}}],"disease_phase":[{"disease_id":"10e1eb8695754228ad20da0a78c90631","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"58fd49f71a3f4a3483307fbc643c9725","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c5dbda12237b45cca74d49f7bb1e6808","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"19b4cff5b71f4405b7162359092ae317","docid":15032,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-12-05T02:37:32.000Z","updated_ts":"2025-08-13T21:26:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"TGFβi expanded NK cells(Nationwide Children's Hospital)","source_info":[{"code":"NCT05634369","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05634369"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"UD TGFβi NK cell","source_info":[{"code":"NCT05887882","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05887882"}],"status":"ACTIVE"},{"lang":"EN","name":"Universal Donor (UD) TGFβi NK Cells(Nationwide Children's Hospital)","source_info":[{"code":"NCT06450041","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06450041"}],"status":"ACTIVE"}],"drug_type":["191ae7835fbd4549bf30d04910df4acc"],"originator_org_master_entity_id":["438610c1eb38a017224349e54414e69f"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","a3426fcb9c77fd99d0461848fe75fb8f"],"disease_id":["e691b28345414c698c8f91946d82cff8","85d6e660829049bb9157d5744491c109","b32b5bfc7a364519a7e8c78370be7d99","a4f7254e36da425087293790eb964551","1cdaf052705b4ed4a67fa2c2033c0b8a"],"active_org_master_entity_id":["438610c1eb38a017224349e54414e69f","abb412529f75561501d791059796ef36"],"research_disease":["e691b28345414c698c8f91946d82cff8","85d6e660829049bb9157d5744491c109","b32b5bfc7a364519a7e8c78370be7d99","a4f7254e36da425087293790eb964551","1cdaf052705b4ed4a67fa2c2033c0b8a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","67034410be134e2bbb5b0930595b5e75","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1734307200000}}],"disease_phase":[{"disease_id":"b32b5bfc7a364519a7e8c78370be7d99","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1cdaf052705b4ed4a67fa2c2033c0b8a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"85d6e660829049bb9157d5744491c109","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e691b28345414c698c8f91946d82cff8","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"052eefcd9d9d4410b86e26058d707fde","docid":260434,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"fa50b1c919f03f0a9e7b1a16b989fc63","created_ts":"2024-04-22T02:32:07.000Z","updated_ts":"2024-11-07T15:13:09.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"OKG-0303","source_info":[{"attachment_path":"data/phs_source_info/a39c/3071/8da8/2dbf/8bc76402-a6f5-34c6-b836-4b1e276c71b3.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a33e/a749/9302/4135/421c2878-ba73-33bc-814b-95f051ebc012.png","source":"Company pipeline","source_url":"https://okogen.com/research-development/"}],"status":"ACTIVE"}],"dev_code":[{"name":"OKG 0303","status":"ACTIVE"},{"name":"OKG0303","status":"ACTIVE"}],"drug_type":["c6f7aa5028654d4d8ac6153f9b53e8a2"],"originator_org_master_entity_id":["030b8cd10bd400dac6f7347b15270dc6"],"mechanism_action_id":["e46da11fc7524ab7baef1170c590ed20"],"target_id":["55e82a1abe604b3ca2d36b78e1010897"],"disease_id":["cc20c475957245898eefe4faa3d3ff6c"],"active_org_master_entity_id":["030b8cd10bd400dac6f7347b15270dc6"],"research_disease":["cc20c475957245898eefe4faa3d3ff6c"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"cc20c475957245898eefe4faa3d3ff6c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"331bfe85c4b2419db245a2580c39adbc","docid":43009,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"0992f38502793ce6a77f7986f4ca60a2","created_ts":"2021-11-05T01:37:45.000Z","updated_ts":"2026-02-24T21:05:33.000Z","data_status":"ACTIVE","created_by":"fangdongbing@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TP-0390","status":"ACTIVE"}],"dev_code":[{"name":"DSP-0390","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ca66d2661dafdf2735d06ae038123df4"],"mechanism_action_id":["7d931f93c6b340ab93ee49ae13fc14f7"],"target_id":["705a5e8ff39442eda4c9f7ba68cdcdf9"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["4c38270255bc4052a1a6d17475bdc51d","2b6f9261326d44d28aa75feaba10e977","05554578204541148a5482ad5df4a600","8f43e38cdd4e4794945b3ede3d6eaa4a"],"active_org_master_entity_id":["19b9fdd4002c2afb541793e96164355b","acf08db27512ef1915aef61ea07655f9"],"research_disease":["4c38270255bc4052a1a6d17475bdc51d","2b6f9261326d44d28aa75feaba10e977","05554578204541148a5482ad5df4a600","8f43e38cdd4e4794945b3ede3d6eaa4a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1631059200000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2b6f9261326d44d28aa75feaba10e977","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8f43e38cdd4e4794945b3ede3d6eaa4a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"1f93bf3c17b6494da31668d27949d7f5","docid":68837,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":1,"target_extend_id":"2603346b735835bca6a26da92e1608ec","created_ts":"2021-10-08T14:48:33.000Z","updated_ts":"2026-04-02T11:21:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Tinlarebant","source_info":[{"code":"CXHL2200417","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/7196358"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one","source_info":[{"normalized_source_id":"df564163e18b49cfb6dbe49169e22f2d","source":"FDA","source_url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=601217"}],"status":"ACTIVE"}],"dev_code":[{"name":"BPN-14967","status":"ACTIVE"},{"name":"LBS-008","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["27691575a0fe5b3219a34943d30d8c5d"],"mechanism_action_id":["5516a910a038218caae4f0dbd0c1984d"],"target_id":["22f634e1687c421f908f9650719f5f62"],"special_review":["23d3523b7ece48ddacaddac53a66949d","d9cc8d2513734e49817e7d059dede238","425d71b560a7499087c4f5a36692741c","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["e08c193dbbb34a59b29bfc570a516de7","de73670e475f43288d92726966cc5962","94437cab300944a58b3ea8134dea1482","164ba9b819474bcd9c0f89bbf21a934c"],"active_org_master_entity_id":["6882f67673fd67d8dcd7820abcd62388","b72c72de71079abbb7dd3e201188234d","27691575a0fe5b3219a34943d30d8c5d"],"research_disease":["e08c193dbbb34a59b29bfc570a516de7","de73670e475f43288d92726966cc5962","94437cab300944a58b3ea8134dea1482"],"non_research_disease":["164ba9b819474bcd9c0f89bbf21a934c"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1762041600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1690416000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1690416000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1690416000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1690416000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1690416000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1690416000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}}],"disease_phase":[{"disease_id":"e08c193dbbb34a59b29bfc570a516de7","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"164ba9b819474bcd9c0f89bbf21a934c","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"94437cab300944a58b3ea8134dea1482","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"de73670e475f43288d92726966cc5962","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["cc60d1a603686dad6819490f3dd6f5fb","27691575a0fe5b3219a34943d30d8c5d"],"if_speculate":0,"data_source":10}
+{"drug_id":"236fc7745be44759a56c795977669f40","docid":58518,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-09-27T12:39:44.000Z","updated_ts":"2024-12-29T00:22:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"IOLs (AffaMed Therapeutics)","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["55ef0d10286a598915a7b38e52b12a36"],"disease_id":["47a3fda86a154e7ea49f2f4a50390871"],"active_org_master_entity_id":["55ef0d10286a598915a7b38e52b12a36"],"research_disease":["47a3fda86a154e7ea49f2f4a50390871"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1644192000000}}],"disease_phase":[{"disease_id":"47a3fda86a154e7ea49f2f4a50390871","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"12207fa5d8c746cd8a80e5ae777b395b","docid":54504,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"6e5ad586bf7644cc8dc40f0c33efb033","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":114,"target_extend_id":"dc7de6393dbb399aa0d8e2f8236159c3","created_ts":"2022-10-18T02:47:02.000Z","updated_ts":"2026-03-21T00:42:48.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"培非格司亭（科兴生物制药）","status":"ACTIVE"},{"lang":"EN","name":"Pegylated human granulocyte colony stimulating factor(Shandong Kexing Bioproducts)","source_info":[{"code":"CXSL2200346","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Pegfilgrastim (Shandong Kexing Bioproducts)","source_info":[{"code":"CTR20230867","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a4de677384b240848b2c7c56e5eed090"}],"status":"ACTIVE"},{"lang":"CN","name":"升白针","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzI2NjY1NjA5Mw==&mid=2247571359&idx=4&sn=9cd1d2eb80e8447eeff33cd0bab26a84"}],"status":"ACTIVE"},{"lang":"CN","name":"聚乙二醇化人粒细胞刺激因子（科兴生物制药）","status":"ACTIVE"}],"dev_code":[{"name":"PEG-RHG-CSF","status":"ACTIVE"}],"generic_name":[{"name":"pegfilgrastim","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["5982ff1462d2654030cd09812cca0e84"],"mechanism_action_id":["358e5f0ba725062ad8f0c56973cc3e35"],"target_id":["532763442f00416fa392a55be34bad5a"],"disease_id":["0df94b4cbdda4b139e247afcb9a94760"],"active_org_master_entity_id":["5982ff1462d2654030cd09812cca0e84"],"research_disease":["0df94b4cbdda4b139e247afcb9a94760"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1735776000000}}],"disease_phase":[{"disease_id":"0df94b4cbdda4b139e247afcb9a94760","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["c8ae82ce74fc4776a63b3a7ad409566f"],"data_source":10}
+{"drug_id":"01973eb16ddc4247bfb0562e9b7858b7","docid":2781,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Suvorexant","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1407888000000,"rnk":1,"target_extend_id":"fec0110b4eec3511a3357542a6908a3a","created_ts":"2021-10-08T14:38:24.000Z","updated_ts":"2026-04-02T16:11:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"舒沃雷生","status":"ACTIVE"},{"lang":"EN","name":"Suvorexant","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"スボレキサント","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Suvorexant (JAN/USAN)","source_info":[{"code":"D10082","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"CN","name":"苏沃雷生","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://zh.wikipedia.org/wiki/%E8%8B%8F%E6%B2%83%E9%9B%B7%E7%94%9F"}],"status":"ACTIVE"}],"dev_code":[{"name":"L-001958419","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"MK-4305","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/suvorexant"}],"status":"ACTIVE"}],"trade_name":[{"name":"Belsomra","source_info":[{"code":"D10082","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"ベルソムラ","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"drugbank_id":["DB09034"],"kegg_id":["D10082"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020"],"mechanism_action_id":["a9d7c7316fe7038bcfa745e0ee202d9b","1732a29aa2c88db120b327e5dc061d0f"],"target_id":["d8a21dab92a44f1689c01197f9e7eaad","2f6f2a1619a14ea4b2701297caf45751"],"atc_code":["5e52efac34b048829fe4f1bdbf248c44"],"disease_id":["dca26135a3174a70b3094a4751d59f5f","f8fc6402302b4781984600e69e35d4de","54a77f56d72c4ac6a0eb840f4518e3a0","486c4f5995ae4425a9c98a48d22c84c8","8ae7b8895639407b906410d1b46cf4d7"],"active_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020","462096edf3de7b2de5a70c8fa9b70fa3","e8303a647e64a1ffae10cf58b15fddf0","cf4762a441de84a5af459b58c1ef4e00"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["dca26135a3174a70b3094a4751d59f5f"],"research_disease":["dca26135a3174a70b3094a4751d59f5f","f8fc6402302b4781984600e69e35d4de","54a77f56d72c4ac6a0eb840f4518e3a0"],"non_research_disease":["486c4f5995ae4425a9c98a48d22c84c8","8ae7b8895639407b906410d1b46cf4d7"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","676de5ba-893a-36bb-8683-c93306aaf769","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1407888000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1411689600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1543449600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1479254400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1383177600000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"dca26135a3174a70b3094a4751d59f5f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8ae7b8895639407b906410d1b46cf4d7","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f8fc6402302b4781984600e69e35d4de","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"02de3e82a0a342bc98b9b6484de94995","docid":34485,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","rnk":25,"target_extend_id":"dc7de6393dbb399aa0d8e2f8236159c3","created_ts":"2021-10-08T14:49:33.000Z","updated_ts":"2025-12-06T21:11:37.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"非格司亭生物类似药(Landsteiner Scientific SA de CV)","status":"ACTIVE"},{"lang":"EN","name":"Filgrastim biosimilar(Landsteiner Scientific SA de CV)","status":"ACTIVE"}],"trade_name":[{"name":"Biofilgran","status":"ACTIVE"}],"generic_name":[{"name":"filgrastim","status":"ACTIVE"}],"drugbank_id":["DB00099"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["8e3a70daf76eb9284cf36095d3d4fc29"],"mechanism_action_id":["358e5f0ba725062ad8f0c56973cc3e35"],"target_id":["532763442f00416fa392a55be34bad5a"],"atc_code":["307fdeda10a24dcb96ea118b213e2c34"],"disease_id":["c7879aa9883f473695aea6cc7470cb48"],"active_org_master_entity_id":["8e3a70daf76eb9284cf36095d3d4fc29"],"research_disease":["c7879aa9883f473695aea6cc7470cb48"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"c7879aa9883f473695aea6cc7470cb48","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["1e46ea873c084b08b8d5566812fdffd3"],"data_source":10}
+{"drug_id":"006afa92c2f54a65b3a3310110ae968f","docid":72027,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"0c7759e2b8c53152a68d41d84124b1b9","created_ts":"2023-06-12T02:20:16.000Z","updated_ts":"2026-04-10T20:36:09.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"ISM-4808","source_info":[{"code":"CXHL2300629","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"CXHL2300630","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"ISM 4808","status":"ACTIVE"},{"name":"ISM-4808","status":"ACTIVE"},{"name":"ISM4808","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f122e54add8b334c3245ff22d0d78115"],"mechanism_action_id":["70d99af12d07a899d8627d0bc84ca588","a262861dabfa422db11fa4e54d1f06f5"],"target_id":["16cdcf1166bc485c8eac63263e835635","19711d00ce864c259eb1a3b665a67b2c"],"disease_id":["8bc211a920054103a6ddba6992edff8a"],"active_org_master_entity_id":["f122e54add8b334c3245ff22d0d78115","5e73de25112db1c51cecb3d65860644a"],"research_disease":["8bc211a920054103a6ddba6992edff8a"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1772236800000}}],"disease_phase":[{"disease_id":"8bc211a920054103a6ddba6992edff8a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["2f8a36b6f270354b062d847af86a573d","5e73de25112db1c51cecb3d65860644a","6879420b440a9e2a7bcdd15c48ee85cc"],"data_source":10}
+{"drug_id":"030882fa74004bc99f0461d2c5fdfa15","docid":29137,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"70c9e4acb3f839a89bb3f7ef0f9435b2","created_ts":"2022-09-27T12:39:31.000Z","updated_ts":"2025-07-31T00:31:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"JN-210","status":"ACTIVE"}],"dev_code":[{"name":"JN-210","status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["c3f6292235f3eef1dadef8a343899d8a"],"mechanism_action_id":["9b44343d127047c3bea0bdde905848c2","3ba9f3f7abb04eb3a2a91c20d34e8abe"],"target_id":["4b7c852ccd5f4f9aa75175d342633c7a"],"disease_id":["1ac27567eb754e7ab46a71e0feef53bd"],"active_org_master_entity_id":["c3f6292235f3eef1dadef8a343899d8a"],"research_disease":["1ac27567eb754e7ab46a71e0feef53bd"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641427200000}}],"disease_phase":[{"disease_id":"1ac27567eb754e7ab46a71e0feef53bd","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"tech_platform":["c412f5dbc9dc42bfa0568833f7ea77d8"],"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"http://jaanbio.com/science-and-technology/"}],"delivery_system":["6b3769de1b454ab78499d5f6e97577a9"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"061f9cb8f8c2450a839ef6deb2d4252b","docid":45336,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","express_system":"ac14778662b7448588663c26ce84cd9e","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1728432000000,"rnk":4,"target_extend_id":"36b06938fcaa3b2c9a1fab9a8dbfcd8d","created_ts":"2021-10-08T14:45:50.000Z","updated_ts":"2026-02-25T00:25:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":1728432000000,"drug_name":[{"lang":"CN","name":"昂戈瑞西单抗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.163.com/dy/article/GKBNTD7L05349C3I.html"}],"status":"ACTIVE"},{"lang":"EN","name":"Ongericimab","source_info":[{"code":"X126G5DZ36","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/b2b29492-60b8-4f93-aa54-bd4adfecd46c"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"重组人源化抗PCSK9单克隆抗体（上海君实）","status":"ACTIVE"},{"lang":"CN","name":"重组人源化抗PCSK9单抗 (上海君实)","status":"ACTIVE"}],"dev_code":[{"name":"JS 002","status":"ACTIVE"},{"name":"JS-002","status":"ACTIVE"},{"name":"JS002","status":"ACTIVE"},{"name":"LAMA 001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg4ODU1NDA1Ng==&mid=2247742412&idx=7&sn=bb62cd483d78d74de26312dd723cdbc4"}],"status":"ACTIVE"},{"name":"LAMA-001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg4ODU1NDA1Ng==&mid=2247742412&idx=7&sn=bb62cd483d78d74de26312dd723cdbc4"}],"status":"ACTIVE"},{"name":"LAMA001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg4ODU1NDA1Ng==&mid=2247742412&idx=7&sn=bb62cd483d78d74de26312dd723cdbc4"}],"status":"ACTIVE"}],"trade_name":[{"name":"君适达","source_info":[{"normalized_source_id":"09a9e2414846487c9e66f4bfca02cea9","source":"NMPA_NEWS","source_url":"https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20241011164701182.html"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["6d8c77d8ef57c426b969ecf3691f96f1"],"mechanism_action_id":["1692f76ca75bca6d508a8797c3193788"],"target_id":["e776b20ae1484692a5d5cd254d5dd788"],"disease_id":["e08e1291a7f24698b8aea6bb8497584d","8c291b3a751c472e82021883f4ba1c6f","98d9beffe4d14bb6a7ee599146b8beb2","85e9e48e7a1e4c768ddfb1f1cb446690","cf50e81f29e3458aa47f76a7555a8e32","b902fe3512424802ac7659fc83b38222","6570754a6f0b43b78a9926c7bfd00519","27013926797d4bc4bf088e4104530e7d","7cabe6f4f4ec48d9bd5b6e7225315f93"],"active_org_master_entity_id":["6d8c77d8ef57c426b969ecf3691f96f1"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["8c291b3a751c472e82021883f4ba1c6f","98d9beffe4d14bb6a7ee599146b8beb2"],"research_disease":["e08e1291a7f24698b8aea6bb8497584d","8c291b3a751c472e82021883f4ba1c6f","98d9beffe4d14bb6a7ee599146b8beb2","85e9e48e7a1e4c768ddfb1f1cb446690","cf50e81f29e3458aa47f76a7555a8e32","b902fe3512424802ac7659fc83b38222"],"non_research_disease":["6570754a6f0b43b78a9926c7bfd00519","27013926797d4bc4bf088e4104530e7d","7cabe6f4f4ec48d9bd5b6e7225315f93"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75","c354b2ea74d349da99bef8388390c7d8","62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1747699200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1728432000000}}],"disease_phase":[{"disease_id":"85e9e48e7a1e4c768ddfb1f1cb446690","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8c291b3a751c472e82021883f4ba1c6f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e08e1291a7f24698b8aea6bb8497584d","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"98d9beffe4d14bb6a7ee599146b8beb2","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7cabe6f4f4ec48d9bd5b6e7225315f93","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f94b64e76dd54a7dbda4acdadfc050d9","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"cf50e81f29e3458aa47f76a7555a8e32","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["1420ed5430d3f49a1c2366d9c7b8e2e1","6d8c77d8ef57c426b969ecf3691f96f1"],"data_source":10}
+{"drug_id":"08accf28274e4135a2a2dde94bdbb50f","docid":82575,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-12-08T05:45:12.000Z","updated_ts":"2026-03-04T20:20:09.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"BGY-1601","source_info":[{"attachment_path":"data/phs_source_info/f53c/03a7/7400/948c/c0e0db45-6e94-3152-a4b8-6816a4a471f0.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/41bd/8b3e/9299/1ef4/26e822e0-f6a4-38d2-ad9b-02db7a2c6045.png","source":"Company pipeline","source_url":"https://www.nexbiome.com/#pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"BGY 1601","status":"ACTIVE"},{"name":"BGY1601","status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["4e2957900916a72f717559b53446033f"],"disease_id":["34360e2b3a6d498cbfb3a844ff6635cd","34a4665d7a5c4c6eba92ec840f130d64","66d05da4e216448ba435feab59dea650","38c70a1563844246811d755cbcfeb8ed"],"active_org_master_entity_id":["4e2957900916a72f717559b53446033f"],"research_disease":["34360e2b3a6d498cbfb3a844ff6635cd","34a4665d7a5c4c6eba92ec840f130d64","66d05da4e216448ba435feab59dea650","38c70a1563844246811d755cbcfeb8ed"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3","9a802adb6e94433f8f4eb9be678991b8"],"disease_phase":[{"disease_id":"66d05da4e216448ba435feab59dea650","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"38c70a1563844246811d755cbcfeb8ed","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"34360e2b3a6d498cbfb3a844ff6635cd","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"34a4665d7a5c4c6eba92ec840f130d64","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"4b31fe6ad72f4f7a85244910895efff2","docid":19297,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":4,"target_extend_id":"24a87b7ffdfc3cfc932f7845b3132077","created_ts":"2022-02-28T09:04:38.000Z","updated_ts":"2025-11-25T09:21:12.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"LY-M003","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://lingyimed.com/jyzl"}],"status":"ACTIVE"}],"dev_code":[{"name":"LY M003","status":"ACTIVE"},{"name":"LYM003","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["9def3ba8152afb93b4c3678ab82b0cae"],"mechanism_action_id":["af0dc7ffaf044fc59b9dad9fd7b8390d"],"target_id":["bd381765fc3c411fbd4acbb2be76ba68"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["898bae0512be420ca7720a91c9a7dc44"],"active_org_master_entity_id":["9def3ba8152afb93b4c3678ab82b0cae","d8b99ec70d63858f17916c0e7d91f3f2"],"research_disease":["898bae0512be420ca7720a91c9a7dc44"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1727136000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1763424000000}}],"disease_phase":[{"disease_id":"898bae0512be420ca7720a91c9a7dc44","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"16d7efe736144069a620d0eb7b2cff0d","docid":44869,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:38.000Z","updated_ts":"2024-11-06T15:16:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"T3D-970","status":"ACTIVE"}],"dev_code":[{"name":"T3D-970","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bc35c512454cf667631647bfa91902fd"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","5419cadb33a542f29c555cc9c588709b"],"active_org_master_entity_id":["bc35c512454cf667631647bfa91902fd"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","5419cadb33a542f29c555cc9c588709b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641340800000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"5419cadb33a542f29c555cc9c588709b","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"37a0a8a940d84eb08d3d1828f52956e0","docid":49278,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:40.000Z","updated_ts":"2025-08-21T00:21:28.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BioC (Xinnate)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://xinnate.com/concept/"}],"status":"ACTIVE"}],"drug_type":["ff9477ffcb8346d59008ad9f2027fd57"],"originator_org_master_entity_id":["d23911da2dd36ed298d76fd18531e4bf"],"disease_id":["e475471e5ba546a595deede0d50616fa"],"active_org_master_entity_id":["d23911da2dd36ed298d76fd18531e4bf"],"research_disease":["e475471e5ba546a595deede0d50616fa"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1644969600000}}],"disease_phase":[{"disease_id":"e475471e5ba546a595deede0d50616fa","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0202175c96054af8a37f3bc403fefc92","docid":54495,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":23,"target_extend_id":"6231d8d05d42336785bf5e69af5d0080","created_ts":"2022-08-05T07:03:30.000Z","updated_ts":"2026-04-04T21:05:21.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"IM-101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://pipelinereview.com/index.php/2022080481361/Antibodies/ImmunAbs-Inc.-Announces-US-FDA-Approval-for-a-Phase-1-Clinical-Trial.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"IAB-101","status":"ACTIVE"},{"name":"IM 101","status":"ACTIVE"},{"name":"IM101","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["fd9853ce6d733a7431f3f1e133962ccd"],"mechanism_action_id":["5d834367756b66c3ad0d0fb07c81e534"],"target_id":["bb8a8480e1c0426392dbfd8f98176fa4"],"disease_id":["2c59629b90b64daea6ace2ed163e7ff6"],"active_org_master_entity_id":["fd9853ce6d733a7431f3f1e133962ccd"],"research_disease":["2c59629b90b64daea6ace2ed163e7ff6"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}}],"disease_phase":[{"disease_id":"2c59629b90b64daea6ace2ed163e7ff6","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"03c2b538b24543658a92f3b8d48800e3","docid":56595,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2023-03-02T05:30:55.000Z","updated_ts":"2024-12-31T00:19:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"DKB-17002","status":"ACTIVE"}],"dev_code":[{"name":"DKB 17002","status":"ACTIVE"},{"name":"DKB17002","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e8d24d58a5317834afcc7190459156c6"],"disease_id":["4c5dfa106108492c90e2389719eb1d08"],"active_org_master_entity_id":["e8d24d58a5317834afcc7190459156c6"],"research_disease":["4c5dfa106108492c90e2389719eb1d08"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1665532800000}}],"disease_phase":[{"disease_id":"4c5dfa106108492c90e2389719eb1d08","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"31cd1883d14e45839f98f4273cda1a2e","docid":48958,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"1c638a20aa7643b7a261c7bacb40d30a","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"68478a8f7d263022902e654ec4288f4a","created_ts":"2021-10-08T14:37:23.000Z","updated_ts":"2026-04-02T10:50:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"INA-03","status":"ACTIVE"}],"dev_code":[{"name":"INA 03","status":"ACTIVE"},{"name":"INA03","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["19eabb6b8faea8295c8581ec2160f5d5"],"mechanism_action_id":["cebc59c40a9ea8360b1cbca9a298b2ef","138f7edea9d70a30233e854b342a1eca"],"target_id":["88d74bd72e784f7e9e33a99abf86c4aa","d9461748c4c54a0b84cbad2ae3fce7d5"],"adc_reference":[{"code":"10.1158/1535-7163.MCT-23-0548","normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"http://dx.doi.org/10.1158/1535-7163.mct-23-0548"}],"disease_id":["1d78cca79eae4632bc4464c90a574f83","7cb6983b4169498e89b08fd725a22b46","656409aff7e24ff1b5f87526a2b6a70b","e2251a2774ee4eff8723a33fc035d809","42487eb0fc9b4a488cf6e57bda7433dd","5e8defce0a8e4f8bbdf853ea20a56197","4dfdd8ad3a924d7b9e9b33b1ec53c5fc","26175067ed3a4e6890063548f6c1b2fa"],"active_org_master_entity_id":["2fd6bbe4bcf3c93f9439a1486e2dbb2c","19eabb6b8faea8295c8581ec2160f5d5"],"research_disease":["1d78cca79eae4632bc4464c90a574f83","7cb6983b4169498e89b08fd725a22b46","656409aff7e24ff1b5f87526a2b6a70b","e2251a2774ee4eff8723a33fc035d809","42487eb0fc9b4a488cf6e57bda7433dd","5e8defce0a8e4f8bbdf853ea20a56197","4dfdd8ad3a924d7b9e9b33b1ec53c5fc"],"non_research_disease":["26175067ed3a4e6890063548f6c1b2fa"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1590710400000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"656409aff7e24ff1b5f87526a2b6a70b","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4dfdd8ad3a924d7b9e9b33b1ec53c5fc","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"26175067ed3a4e6890063548f6c1b2fa","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"42487eb0fc9b4a488cf6e57bda7433dd","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e2251a2774ee4eff8723a33fc035d809","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"moiety_target_extend_id":"6c43b462baaf3f2e8571eb2898b63ce7","payload_target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","moiety_mechanism_action_id":["cebc59c40a9ea8360b1cbca9a298b2ef"],"moiety_target_id":["88d74bd72e784f7e9e33a99abf86c4aa"],"payload_target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"payload_mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"]}
+{"drug_id":"023a28c900f141bbac05e6cf120f8f06","docid":33082,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1763337600000,"rnk":4,"target_extend_id":"67847d8d029e35478c321399664c1180","created_ts":"2021-10-08T14:47:17.000Z","updated_ts":"2026-04-13T01:50:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"CN","name":"地舒单抗生物类似药 (Teva Pharma)","status":"ACTIVE"},{"lang":"EN","name":"Denosumab biosimilar(Teva Pharma)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DENOSUMAB-ADET","source_info":[{"code":"BLA761385","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761385"}],"status":"ACTIVE"},{"lang":"EN","name":"Denosumab Biosimilar (Teva Pharmaceutical Industries Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"地舒单抗生物类似药（Teva Pharmaceutical Industries Ltd.）","status":"ACTIVE"}],"dev_code":[{"name":"TVB-009","status":"ACTIVE"},{"name":"TVB-009P","status":"ACTIVE"}],"trade_name":[{"name":"Degevma","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/degevma"}],"status":"ACTIVE"},{"name":"Ponlimsi","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ponlimsi"}],"status":"ACTIVE"}],"generic_name":[{"name":"denosumab","source_info":[{"code":"EMEA/H/C/001120","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/prolia"},{"code":"EMEA/H/C/002173","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["1a53f7c62b9cb7bd69ffb74b97c35ed1"],"mechanism_action_id":["70b3724f9c024338ed116b3bfb828496"],"target_id":["2a9a8ce9bb804bfd95a46d8e4f8bcb1f"],"atc_code":["988359d935c44b11aed8e231d74a483d"],"disease_id":["892e0b3107fc47caba8107d91242697d","d332d0d1849846c29ed8b3edb7703d6a","7cd0fcf1c5c243b9b3944405ec4855b5","8b46f5a2ac544e30ab179a9fa444f884","1713121f9e9b412d9495f3a785ec61c4","8e116582a7bf47a0ac481dcebd37d16c","0026b7df2f9649b3849fefcbd25a5fcf","5f1211c6977c4c9c89aecffecdfda68f","45b3c25e67114f7e9c9f23304f479c61","bdaf5f3afa6447d9889bd7e8311a162b","7b3f8886fced413baab25d3072c53d07"],"active_org_master_entity_id":["c9153775038b25a2105455271cf11607","878450d42fcafa9f172d662c0b7fb225","1a53f7c62b9cb7bd69ffb74b97c35ed1"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["0026b7df2f9649b3849fefcbd25a5fcf","5f1211c6977c4c9c89aecffecdfda68f","45b3c25e67114f7e9c9f23304f479c61","bdaf5f3afa6447d9889bd7e8311a162b","7b3f8886fced413baab25d3072c53d07"],"research_disease":["892e0b3107fc47caba8107d91242697d","d332d0d1849846c29ed8b3edb7703d6a","7cd0fcf1c5c243b9b3944405ec4855b5","8b46f5a2ac544e30ab179a9fa444f884","1713121f9e9b412d9495f3a785ec61c4","8e116582a7bf47a0ac481dcebd37d16c","0026b7df2f9649b3849fefcbd25a5fcf","5f1211c6977c4c9c89aecffecdfda68f","45b3c25e67114f7e9c9f23304f479c61","bdaf5f3afa6447d9889bd7e8311a162b","7b3f8886fced413baab25d3072c53d07"],"inactive_org_master_entity_id":["6b350368a8e6b23b9fb49b9d7ac27f82"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1774828800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1774569600000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1763337600000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1763337600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1763337600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1763337600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1750204800000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1750204800000}}],"disease_phase":[{"disease_id":"8b46f5a2ac544e30ab179a9fa444f884","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"0026b7df2f9649b3849fefcbd25a5fcf","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d332d0d1849846c29ed8b3edb7703d6a","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8e116582a7bf47a0ac481dcebd37d16c","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5f1211c6977c4c9c89aecffecdfda68f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1713121f9e9b412d9495f3a785ec61c4","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"bdaf5f3afa6447d9889bd7e8311a162b","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7b3f8886fced413baab25d3072c53d07","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"892e0b3107fc47caba8107d91242697d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"45b3c25e67114f7e9c9f23304f479c61","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["2dde5d0ddf4d49a2b0df4c4050b91d95"],"if_speculate":0,"data_source":10}
+{"drug_id":"04f49097bd60423eb02b0c62257af1d6","docid":1250689,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":72,"target_extend_id":"b20ddfb673453ad0bf757446f68cd696","created_ts":"2025-05-06T08:49:03.000Z","updated_ts":"2026-04-18T21:06:37.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"AMG 410","source_info":[{"code":"2025_ND01","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/7352"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["11ef8a9e8bf5ca80213a1183511cded3"],"mechanism_action_id":["6ee694e99ae16a6cb17f1232df9c7dcd"],"target_id":["d9ded8f23b4140a5828314a55d2d66b4"],"disease_id":["dce45f5ca24a433bafa10c53d0fe46fe","800d2cfb899f4e6983a759d03734503d"],"active_org_master_entity_id":["11ef8a9e8bf5ca80213a1183511cded3"],"research_disease":["dce45f5ca24a433bafa10c53d0fe46fe","800d2cfb899f4e6983a759d03734503d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1775088000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1775088000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}}],"disease_phase":[{"disease_id":"800d2cfb899f4e6983a759d03734503d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"dce45f5ca24a433bafa10c53d0fe46fe","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1a82d0beaca44cfb9877ef665c324f55","docid":67083,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":36,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2021-10-08T14:49:23.000Z","updated_ts":"2026-04-04T21:04:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"BCMA CAR-T cell therapy(Chongqing Precision Biotechnology Co., Ltd.)","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["375e648955cf6a3875191052ad791963"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["d6d30dfb1c604b55a56b0f79fa245d23","bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["375e648955cf6a3875191052ad791963"],"research_disease":["d6d30dfb1c604b55a56b0f79fa245d23","bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1554076800000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d6d30dfb1c604b55a56b0f79fa245d23","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"10d2753da1c64488b615058923e55226","docid":31223,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":15,"target_extend_id":"b1391bc834803f0faabbb5cc05fb37d9","has_leading_org_involved":1,"created_ts":"2021-10-08T14:46:33.000Z","updated_ts":"2026-04-13T07:25:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Valiltramiprosate","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/jcpkrHCnxuzySma7Z580AQ"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Tramiprosate prodrug","status":"ACTIVE"},{"lang":"EN","name":"Valitramiprosate","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/alzheon-advances-industry-leading-portfolio-of-oral-anti-amyloid-aggregation-inhibitors-with-first-subject-dosed-in-phase-1-of-alz-507-highlighting-potential-for-once-daily-administration-improved-safety-and-efficacy-and-apoe4-corrector-mechanism"}],"status":"ACTIVE"}],"dev_code":[{"name":"ALZ 801","status":"ACTIVE"},{"name":"ALZ-801","source_info":[{"normalized_source_id":"259fa6c9b7b44a83842da82f9bec5ee6","source":"DBAD","source_url":"https://adisinsight.springer.com/drugs/800040203"}],"status":"ACTIVE"},{"name":"BLU-8499","status":"ACTIVE"},{"name":"NRM-8499","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7dfef6d40907b8d5b7de1918ee51afd1"],"mechanism_action_id":["d4e1560de4a5234590d7e480973bc215"],"target_id":["5ff9d5388b7c4c0a9abf556c9d8659d6"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","9f79d5ae3d834e988572482a902e1d7f"],"active_org_master_entity_id":["7dfef6d40907b8d5b7de1918ee51afd1"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","9f79d5ae3d834e988572482a902e1d7f"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1621382400000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9f79d5ae3d834e988572482a902e1d7f","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"deal_related_org":["a3af1c8d63c89af9d0d3a0f7f6081859","7dfef6d40907b8d5b7de1918ee51afd1"],"data_source":10}
+{"drug_id":"49439481681045e390242c20c314520f","docid":12172,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-06-09T06:55:16.000Z","updated_ts":"2026-01-27T15:47:06.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous tumour infiltrating lymphocyte therapy( Hebei Senlangbio Biotechnology)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Autologous tumour infiltrating lymphocyte therapy - Hebei Senlang Biotechnology","status":"ACTIVE"}],"drug_type":["f6fc8ab5ba6e4b48bcaf7d8dc8d76305"],"originator_org_master_entity_id":["dab8ea4d57a17ffc0b8c1ec42261ce8f"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["05554578204541148a5482ad5df4a600"],"active_org_master_entity_id":["dab8ea4d57a17ffc0b8c1ec42261ce8f"],"research_disease":["05554578204541148a5482ad5df4a600"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1644883200000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"04b346fa271a43fa9b67a4f92f6b4b0e","docid":1731195,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-09-08T08:26:11.000Z","updated_ts":"2025-09-08T09:08:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"B10-FC","source_info":[{"code":"NCT07156864","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07156864"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["c1ea86b689a399a2d656d593a0b2ebea"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["c1ea86b689a399a2d656d593a0b2ebea"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"05c1a258dabe4a40b8ffda0e22b96820","docid":6764,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":102,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2022-08-22T08:35:29.000Z","updated_ts":"2026-04-11T21:07:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"BRL-302","status":"ACTIVE"}],"dev_code":[{"name":"BRL302","status":"ACTIVE"}],"drug_type":["8cda7e9356a7439ea27ce1a899143e5c"],"originator_org_master_entity_id":["82ad43598d0815d35c26d0d7a5e4565a"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["1d9cb4fabfc74fc49d342c14c9ff3b1a","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","60a67018512a44caafa8f5d6dcb5339f","8b0644971f31409283cac32a7d08fd52","0c8a0603507542faac6b5ef3e27c6728"],"active_org_master_entity_id":["82ad43598d0815d35c26d0d7a5e4565a"],"research_disease":["1d9cb4fabfc74fc49d342c14c9ff3b1a","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","60a67018512a44caafa8f5d6dcb5339f","8b0644971f31409283cac32a7d08fd52","0c8a0603507542faac6b5ef3e27c6728"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1740700800000}}],"disease_phase":[{"disease_id":"60a67018512a44caafa8f5d6dcb5339f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8b0644971f31409283cac32a7d08fd52","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1d9cb4fabfc74fc49d342c14c9ff3b1a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"02bedc5c88f2405692edeeb22740482b","docid":17997,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"708b47a521863294828909df20e4cc13","created_ts":"2021-10-08T14:47:26.000Z","updated_ts":"2026-02-28T21:18:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Strontium Malonate","status":"ACTIVE"}],"dev_code":[{"name":"NB S101","status":"ACTIVE"},{"name":"NBS-101","status":"ACTIVE"},{"name":"NSB-101","status":"ACTIVE"}],"generic_name":[{"name":"Malonic acid","source_info":[{"code":"9KX7ZMG0MK","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/e315cdf5-ffb0-4817-b225-c78f00b579fc"}],"status":"ACTIVE"}],"drugbank_id":["DB05732"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e332e0e54a3aae5afff215f3057bfe54"],"mechanism_action_id":["872e73d5964f0f595a5fa9b618688821","6d611d2a175b2494c695b7cbc4adbbee"],"target_id":["fb93cab9be314303b9bbf744a2a73522"],"disease_id":["bdaf5f3afa6447d9889bd7e8311a162b"],"active_org_master_entity_id":["942bd681ad69067d4f44b1ff404acc6b"],"research_disease":["bdaf5f3afa6447d9889bd7e8311a162b"],"inactive_org_master_entity_id":["e332e0e54a3aae5afff215f3057bfe54"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"bdaf5f3afa6447d9889bd7e8311a162b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["942bd681ad69067d4f44b1ff404acc6b","e332e0e54a3aae5afff215f3057bfe54"],"data_source":10}
+{"drug_id":"078d4593ef0c464d9846a11bf4e965cc","docid":65672,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-08-03T08:55:43.000Z","updated_ts":"2026-03-06T20:44:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"小儿麻龙止咳平喘颗粒","status":"ACTIVE"},{"lang":"EN","name":"Xiaoer Malong Zhike Pingchuan Granules","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["e60d7d7582158b6cbe0d72eee28f96c3"],"disease_id":["e9017aa6409240f98565d693cc6a82ce"],"active_org_master_entity_id":["e60d7d7582158b6cbe0d72eee28f96c3"],"research_disease":["e9017aa6409240f98565d693cc6a82ce"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772236800000}}],"disease_phase":[{"disease_id":"e9017aa6409240f98565d693cc6a82ce","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0ff6453785974eb0801ee3c630c0b5e1","docid":39658,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":12,"target_extend_id":"36b06938fcaa3b2c9a1fab9a8dbfcd8d","created_ts":"2021-11-30T08:56:02.000Z","updated_ts":"2026-04-04T21:10:53.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"葵酸恩利西肽","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA4NjA0NzUyNg==&mid=2247485353&idx=1&sn=b15ad3ec2def481606df10d22c088843"}],"status":"ACTIVE"},{"lang":"EN","name":"Enlicitide chloride","source_info":[{"code":"list 128","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf?sfvrsn=889fe54b_3&download=true"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Enlicitide Decanoate","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.msdclinicaltrials.com/trial/nct06492291/"}],"status":"ACTIVE"}],"dev_code":[{"name":"MK 0616","status":"ACTIVE"},{"name":"MK-0616","status":"ACTIVE"},{"name":"MK0616","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de","b3f3ecbc5fe645d79060e009b17b6e76"],"originator_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020"],"mechanism_action_id":["1692f76ca75bca6d508a8797c3193788"],"target_id":["e776b20ae1484692a5d5cd254d5dd788"],"special_review":["c321d428b7134ee39263221fcb315935"],"disease_id":["27013926797d4bc4bf088e4104530e7d","bf821ba3fb194a38a5b2f804bcf68c44","f94b64e76dd54a7dbda4acdadfc050d9","724b860f21c04049a543505e27335391","e08e1291a7f24698b8aea6bb8497584d"],"active_org_master_entity_id":["462096edf3de7b2de5a70c8fa9b70fa3","ed2726cd02738de869e61ad610dd6df6"],"research_disease":["27013926797d4bc4bf088e4104530e7d","bf821ba3fb194a38a5b2f804bcf68c44","f94b64e76dd54a7dbda4acdadfc050d9","724b860f21c04049a543505e27335391","e08e1291a7f24698b8aea6bb8497584d"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704240000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1699488000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722816000000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704240000000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722816000000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704240000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1699488000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691452800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696809600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691625600000}}],"disease_phase":[{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e08e1291a7f24698b8aea6bb8497584d","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f94b64e76dd54a7dbda4acdadfc050d9","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"724b860f21c04049a543505e27335391","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"5bf23faa94ee46bdba4926fe13b86301","docid":28209,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":89,"target_extend_id":"27484dc2d43338fd8ff008f88abc23e7","has_leading_org_involved":1,"created_ts":"2021-10-08T14:46:01.000Z","updated_ts":"2026-04-18T21:07:19.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"吉雷司群","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.weikeqi-biotech.com/product-WKQ-0018833"}],"status":"ACTIVE"},{"lang":"EN","name":"Giredestrant","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Giredestrant (USAN/INN)","source_info":[{"code":"D11961","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"CN","name":"吉瑞司群","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA4MDM4MzExMA==&mid=2663326966&idx=4&sn=823d4ab8438f21500ee1f2c63d7e56a9"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://medfind.link/info/41354"}],"status":"ACTIVE"}],"dev_code":[{"name":"GDC-49545","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/giredestrant"}],"status":"ACTIVE"},{"name":"GDC-9545","status":"ACTIVE"},{"name":"RG-6171","status":"ACTIVE"},{"name":"RO7197597","status":"ACTIVE"}],"generic_name":[{"name":"Giredestrant","source_info":[{"code":"D11961","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"kegg_id":["D11961"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8e9a09c415413dc4cd1c139b8fcb6993"],"mechanism_action_id":["434e724318d671764a62810b56700546"],"target_id":["eb553b25d950464798e93c7e998425d2"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","b785b1cc5ead4eb3b241d380750d496d","de23eb7576d244d4bd3d2263c15d4b85","b382bc2a56644776b45dc6084224df3b","8ffd22aee8f241a3beaf13359e39ebe1","ba02154031ca48aba76cd279bdca8ade","fbdd6976d5cb413fb0733ae761138853","a9f502452b4a484fb5ee531d3aa4e1b7","4035a94ea2d240d7a52aa75633974381","87a9454771a64f2191224b6b7684254a","c8af1f6afc6445e49fc47f4f0837f134","7a4a14243a4b49e3b5b691978e9e3087"],"active_org_master_entity_id":["87bfaf037f8e60c9e25595cd98bb27e4","d7dc381f4bf0f28f14bb88ed2f3535d9","8a3c41b6b3536abfff46a5b43b7662b0","8e9a09c415413dc4cd1c139b8fcb6993","9734c5210944b06b27c42554d893798f","5207a557397fde17efe0a622deab5c80","455d00bdaddccfdcd197acdc480c7670"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","b785b1cc5ead4eb3b241d380750d496d","de23eb7576d244d4bd3d2263c15d4b85","b382bc2a56644776b45dc6084224df3b","8ffd22aee8f241a3beaf13359e39ebe1","ba02154031ca48aba76cd279bdca8ade","fbdd6976d5cb413fb0733ae761138853","a9f502452b4a484fb5ee531d3aa4e1b7","4035a94ea2d240d7a52aa75633974381","87a9454771a64f2191224b6b7684254a","c8af1f6afc6445e49fc47f4f0837f134","7a4a14243a4b49e3b5b691978e9e3087"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1772236800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1776297600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1601942400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1601942400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"7e67ab67-b973-3c61-8850-3ba387e2b3fe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"e40dcd8d-d285-3fbd-b349-41b55c0fac2b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"59bfe400-ff5a-3a39-a86c-df18b6320f05","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"59bfe400-ff5a-3a39-a86c-df18b6320f05","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1601942400000}},{"country":"9c6ae9d7-5179-3787-9a19-a8a795c52fdf","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"9c6ae9d7-5179-3787-9a19-a8a795c52fdf","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"8050a7c3-e4ca-32bf-9f3f-e1598c447eb3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"8050a7c3-e4ca-32bf-9f3f-e1598c447eb3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"6d64b019-4f80-31e9-b248-297aa588c950","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"3529ccb3-1a90-3cf6-a0cc-3cea1d2f0220","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"7b8fd1bd-c7fb-3ebd-b9e4-5372d8f85711","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"7b8fd1bd-c7fb-3ebd-b9e4-5372d8f85711","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"7b8fd1bd-c7fb-3ebd-b9e4-5372d8f85711","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"7b90ce53-6d1f-333b-bd37-e60357531565","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"f2cc1822-6aab-320f-9275-f317462fcbd9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"0293809f-cf7e-3684-b4d2-1fffdaedbb52","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"15b75194-9ab6-36f1-897e-065754073aa9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1601942400000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1666051200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1601942400000}},{"country":"3ec31c64-1669-3c69-9f1c-cf9f277fb45b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"3ec31c64-1669-3c69-9f1c-cf9f277fb45b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1702252800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659484800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1658102400000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1630022400000}}],"disease_phase":[{"disease_id":"b785b1cc5ead4eb3b241d380750d496d","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"fbdd6976d5cb413fb0733ae761138853","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c8af1f6afc6445e49fc47f4f0837f134","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4035a94ea2d240d7a52aa75633974381","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"8ffd22aee8f241a3beaf13359e39ebe1","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"ba02154031ca48aba76cd279bdca8ade","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"b382bc2a56644776b45dc6084224df3b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"de23eb7576d244d4bd3d2263c15d4b85","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a9f502452b4a484fb5ee531d3aa4e1b7","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7a4a14243a4b49e3b5b691978e9e3087","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["516d904705294108267562766530c18b","87bfaf037f8e60c9e25595cd98bb27e4"],"data_source":10}
+{"drug_id":"1f9acc6928684d54bc135393ff5bb5e1","docid":440511,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-11-28T08:43:23.000Z","updated_ts":"2025-02-21T08:02:54.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous Blood Monocyte Vesicles(Sun Yat-Sen Memorial Hospital)","source_info":[{"code":"NCT06707389","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06707389"}],"status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["71d71b05e3a71f2758dc77d60eb70f38"],"disease_id":["6c02ef1aa6b54801b17a1caa411b0f25","c4dcf207ce7c41a7ae564fe97fc845f3"],"active_org_master_entity_id":["71d71b05e3a71f2758dc77d60eb70f38"],"research_disease":["6c02ef1aa6b54801b17a1caa411b0f25","c4dcf207ce7c41a7ae564fe97fc845f3"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","4e8519876cfb47e1a3b07957e869ef32"],"disease_phase":[{"disease_id":"c4dcf207ce7c41a7ae564fe97fc845f3","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"6c02ef1aa6b54801b17a1caa411b0f25","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2fa5519a55714c8e9045b9903d6310cc","docid":47586,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":11,"target_extend_id":"0972478724bb348e830660cd9f6aec20","created_ts":"2021-12-10T12:55:07.000Z","updated_ts":"2026-03-14T21:09:53.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Anti CD5 CAR-T cell therapy  ( Shanghai Yake Biotechnology)","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["375075448007c5f1309b7919ebaf9fed","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["4cf0d4e5f0da4d1db85d2ce79445fc7a"],"disease_id":["27c81d33df044a648187f81864221799","a58b22cd20644f2fa3517ac8010b29ad"],"active_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"research_disease":["27c81d33df044a648187f81864221799","a58b22cd20644f2fa3517ac8010b29ad"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1729382400000}}],"disease_phase":[{"disease_id":"27c81d33df044a648187f81864221799","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a58b22cd20644f2fa3517ac8010b29ad","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0e6788ca12164a43b6fd9c5e0fc324a5","docid":45716,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-07-11T12:46:23.000Z","updated_ts":"2024-12-27T00:25:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"FNP-402","status":"ACTIVE"}],"dev_code":[{"name":"FNP402","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["a73e8596dd0520effbceb6fe5cd1c3d9"],"disease_id":["7633b4a0785544138d5bb73a74100f7b"],"active_org_master_entity_id":["a73e8596dd0520effbceb6fe5cd1c3d9"],"research_disease":["7633b4a0785544138d5bb73a74100f7b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1651708800000}}],"disease_phase":[{"disease_id":"7633b4a0785544138d5bb73a74100f7b","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0ed3680fd78244dca6667d68688ac248","docid":230793,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-05-15T03:21:37.000Z","updated_ts":"2025-06-14T00:15:51.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Vγ9Vδ2 T cell(Beijing Tiantan Hospital)","status":"ACTIVE"}],"drug_type":["82d9b474ba434d6ca4e0a6740a55ac23"],"originator_org_master_entity_id":["609040193bd5081e3925e0453055af79"],"disease_id":["c429db71d4a441d9823a909208d8f08e","05554578204541148a5482ad5df4a600","ff2bfb165bee41d6a0d28f32755d0c5e","5851e12cf1324f78ba0e32c6a6e16f31"],"active_org_master_entity_id":["609040193bd5081e3925e0453055af79"],"research_disease":["c429db71d4a441d9823a909208d8f08e","05554578204541148a5482ad5df4a600","ff2bfb165bee41d6a0d28f32755d0c5e","5851e12cf1324f78ba0e32c6a6e16f31"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1714435200000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c429db71d4a441d9823a909208d8f08e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ff2bfb165bee41d6a0d28f32755d0c5e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"5851e12cf1324f78ba0e32c6a6e16f31","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"486a0e8a0ecd46a9816a0748c8ac85dd","docid":169967,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-03-06T03:13:10.000Z","updated_ts":"2026-03-16T08:27:42.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"yuanjing","drug_name":[{"lang":"EN","name":"GA-002","source_info":[{"attachment_path":"data/phs_source_info/36d1/7986/ef05/38fe/7f98f54b-d342-3d6c-8cde-fd9005726a7b.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/48cb/2c4a/1194/074e/7987218a-b8e7-36ff-bcb4-24e19d23314d.png","source":"Company pipeline","source_url":"http://www.genansco.com/col.jsp?id=190"}],"status":"ACTIVE"}],"dev_code":[{"name":"GA 002","source_info":[{"attachment_path":"data/phs_source_info/36d1/7986/ef05/38fe/7f98f54b-d342-3d6c-8cde-fd9005726a7b.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/48cb/2c4a/1194/074e/7987218a-b8e7-36ff-bcb4-24e19d23314d.png","source":"Company pipeline","source_url":"http://www.genansco.com/col.jsp?id=190"}],"status":"ACTIVE"},{"name":"GA002","source_info":[{"attachment_path":"data/phs_source_info/36d1/7986/ef05/38fe/7f98f54b-d342-3d6c-8cde-fd9005726a7b.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/48cb/2c4a/1194/074e/7987218a-b8e7-36ff-bcb4-24e19d23314d.png","source":"Company pipeline","source_url":"http://www.genansco.com/col.jsp?id=190"}],"status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["90dbf3ef56c30b11cc297419ee75f445"],"disease_id":["5a66b9249fae4d97afa13193f05749b9"],"active_org_master_entity_id":["90dbf3ef56c30b11cc297419ee75f445"],"research_disease":["5a66b9249fae4d97afa13193f05749b9"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1709683200000}}],"disease_phase":[{"disease_id":"5a66b9249fae4d97afa13193f05749b9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4138723eeba84e0794d8992f456d2f5a","docid":76913,"is_nme":1,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2022-08-12T04:22:42.000Z","updated_ts":"2024-11-09T05:09:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ALM-004","status":"ACTIVE"}],"dev_code":[{"name":"ALM004","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["67a1d85f26f327b07e38ab99a8776538"],"disease_id":["379002cf898b4d6bb650379ba93f525a"],"active_org_master_entity_id":["67a1d85f26f327b07e38ab99a8776538"],"research_disease":["379002cf898b4d6bb650379ba93f525a"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"379002cf898b4d6bb650379ba93f525a","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"090266c7b24f455db0c8b786d7e4794f","docid":34666,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Riluzole","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":818726400000,"rnk":36,"target_extend_id":"1f675eaf039d37b5837b104f9aeea73f","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:21.000Z","updated_ts":"2026-04-12T01:54:10.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1653955200000,"drug_name":[{"lang":"CN","name":"利鲁唑","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Riluzole","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"リルゾール","source_info":[{"code":"21000AMY00286","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_1190011F1021_1_15"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"IT-Riluzole","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/brain-trust-bio-receives-approval-for-patient-trials-targeting-als-and-other-cns-diseases-with-continuous-intrathecal-drug-delivery-method-302098374.html"}],"status":"ACTIVE"},{"lang":"EN","name":"Riluzole (JAN/USP/INN)","source_info":[{"code":"D00775","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"BF-37","status":"ACTIVE"},{"name":"BHV-0223","status":"ACTIVE"},{"name":"NSC-753433","source_info":[{"code":"7LJ87RS6F","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/f3a5e1ef-140d-479e-9397-597e2a9c30b0"}],"status":"ACTIVE"},{"name":"NSC-759823","source_info":[{"code":"7LJ87RS6F","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/f3a5e1ef-140d-479e-9397-597e2a9c30b0"}],"status":"ACTIVE"},{"name":"PK-26124","status":"ACTIVE"},{"name":"RP-54274","source_info":[{"code":"21000AMY00286","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_1190011F1021_1_16"}],"status":"ACTIVE"}],"trade_name":[{"name":"Exservan","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"Rilutek","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D00775","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"21000AMY00286","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_1190011F1021_1_16"}],"status":"ACTIVE"},{"name":"Riluzole Zentiva","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"},{"name":"Teglutik","status":"ACTIVE"},{"name":"リルテック","source_info":[{"code":"21000AMY00286","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_1190011F1021_1_16"}],"status":"ACTIVE"},{"name":"万全力太","status":"ACTIVE"},{"name":"力如太","status":"ACTIVE"},{"name":"协一力","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Riluzole","source_info":[{"code":"D00775","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00740"],"kegg_id":["D00775"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb"],"mechanism_action_id":["e6c08a0e9446621c3ff9d23a82a086f6","bfdd1f0d036801eb21cbbeb5110fd403"],"target_id":["51f1f4aed2c448da9431bb6a54aac45d"],"atc_code":["f8291697bf5a4244a3be3ac568826114"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["738546bac89e4895b89af01545f1b054","0464f5493b0444e9875a0584df17cbf0","83d4a7a4b99e4c9fa8e6c012527381b5","8da4804a5bd24352b7d568a7da54c6dc","847a0ea7462c4293b185766079ef37a2","d0ff88a816794907a59ee3b387696769","2dbed7595ff04b8fae04724f91081116","f1c3e5bf53414ba481ce6c6876b7b6f2","4c0044bbaeba47258cf85131c2412421","e750d2827d3b4217b8c1561c11aa8eab","06800c58775143058fa08c139594ed4a"],"active_org_master_entity_id":["8a4752a4e5e1fab8ab074b148eba6558","6f1e5d4aa0db05022496f52dcdf60034","baf20922dd4caf5552a7f82c0affa8a0","cbbf76a88531a784ba707dcae4df57ac","bdb31a0ef372c1dafce734bc1c79601f","47b91850d88874b5d182f353db71027a","e4900b0cde886fbf2d21410ae438d8d0","74699ecc3ef1abe16be74c0b2e3370f0","dc180c752e2e318177fc5db76c4e0933"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["738546bac89e4895b89af01545f1b054"],"research_disease":["738546bac89e4895b89af01545f1b054","0464f5493b0444e9875a0584df17cbf0","83d4a7a4b99e4c9fa8e6c012527381b5","8da4804a5bd24352b7d568a7da54c6dc","847a0ea7462c4293b185766079ef37a2"],"non_research_disease":["d0ff88a816794907a59ee3b387696769","2dbed7595ff04b8fae04724f91081116","f1c3e5bf53414ba481ce6c6876b7b6f2","4c0044bbaeba47258cf85131c2412421","e750d2827d3b4217b8c1561c11aa8eab","06800c58775143058fa08c139594ed4a"],"inactive_org_master_entity_id":["689fd5301b12dfe62031c7944329d3b5","dfecdeefdba01191fed7c1fec2562766","7676e6322bf280c3f4cc91f6e5cebc31","f676009a073687839de530461feab64d","bf85af687373969355a25d2aacd31bfb","8f46f5e8079952061a9370b4bad964cf"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1536105600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1653955200000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1336348800000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":834364800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":914544000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1021248000000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1336348800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":834364800000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1336348800000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":834364800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1336348800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":834364800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1134604800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1678752000000}}],"disease_phase":[{"disease_id":"847a0ea7462c4293b185766079ef37a2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d0ff88a816794907a59ee3b387696769","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f1c3e5bf53414ba481ce6c6876b7b6f2","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"06800c58775143058fa08c139594ed4a","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"e750d2827d3b4217b8c1561c11aa8eab","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"83d4a7a4b99e4c9fa8e6c012527381b5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4c0044bbaeba47258cf85131c2412421","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["0dfe45a790454601a647a533ad613fd4","11ccb2bb1c4821c6f219409beb181b69","40da745f9922a753b29ec1eebc26e9b2","47b91850d88874b5d182f353db71027a","54a5f90ed2e95b2035b38ac7bacadf57","8a4752a4e5e1fab8ab074b148eba6558","a8cab6d82b391450f0e844a94cfe0cae","bf85af687373969355a25d2aacd31bfb"],"data_source":10}
+{"drug_id":"016c4301b8a44a7885528e5e645155a0","docid":47554,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":4,"target_extend_id":"07c72e1766623e639f2594dacb32a815","created_ts":"2022-07-14T10:16:35.000Z","updated_ts":"2026-03-11T00:45:32.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Ontunisertib","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/money-on-the-move-truebinding-agomab-raise-funds-teva-abbvie-settle-opioid-claims/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AGMB 129","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/money-on-the-move-truebinding-agomab-raise-funds-teva-abbvie-settle-opioid-claims/"}],"status":"ACTIVE"},{"name":"AGMB129","status":"ACTIVE"},{"name":"ORG-129","status":"ACTIVE"},{"name":"ORG129","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5d2c0aa1fdb782a4b3754933e810f48e"],"mechanism_action_id":["0494262fbc7dfbd5f363b2d2c1ef93fc"],"target_id":["9acee810ccd14fbda00d73f903bc70b1"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["05ae12d567784b85a5c1ca54b2063ee2"],"active_org_master_entity_id":["5d2c0aa1fdb782a4b3754933e810f48e"],"research_disease":["05ae12d567784b85a5c1ca54b2063ee2"],"inactive_org_master_entity_id":["150ac4ab9e46078870c07c5530e97f6e"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}}],"disease_phase":[{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"067b0af5686f461f9dc921fdbb8dd524","docid":140175,"is_nme":0,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"a2efa4fe09c537359f5d0c05319480e2","created_ts":"2024-03-25T09:17:31.000Z","updated_ts":"2026-03-30T21:14:09.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"AK-139","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.hangyan.co/reports/3328413417101853939"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NTA4Mzc2Mg==&mid=2653573213&idx=5&sn=f02bca26677a362b0eca48733d608e14"}],"status":"ACTIVE"}],"dev_code":[{"name":"AK 139","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.hangyan.co/reports/3328413417101853939"}],"status":"ACTIVE"},{"name":"AK139","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NTA4Mzc2Mg==&mid=2653573213&idx=5&sn=f02bca26677a362b0eca48733d608e14"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["560adf58b078ca78ce54967cd5386274"],"mechanism_action_id":["dc7223fedee410ff78d6c74d7c6229f1","8e46e6d7cb5ef25ed25572cd326c56ec"],"target_id":["101e6c98f4d448379e01f960edb985d9","9055fd3b7cd6459f9dbb0f84bab4c9aa"],"disease_id":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","07ca4cbd5bbe460590b9f3982fa38ec1","15fe4881cb88431eb9d44b018619d7b0","486c4f5995ae4425a9c98a48d22c84c8","286ea42cd2f94d18b9f0876bf2c531ac","323fd3aac06145689cb8e1b4fd0a3bc2","795f46b5277f489d863dea8cb3d74960"],"active_org_master_entity_id":["391046f8744a1cde275e09de08b483f3"],"research_disease":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","07ca4cbd5bbe460590b9f3982fa38ec1","15fe4881cb88431eb9d44b018619d7b0","486c4f5995ae4425a9c98a48d22c84c8","286ea42cd2f94d18b9f0876bf2c531ac","323fd3aac06145689cb8e1b4fd0a3bc2","795f46b5277f489d863dea8cb3d74960"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1774396800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1770940800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}}],"disease_phase":[{"disease_id":"07ca4cbd5bbe460590b9f3982fa38ec1","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"286ea42cd2f94d18b9f0876bf2c531ac","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"795f46b5277f489d863dea8cb3d74960","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"323fd3aac06145689cb8e1b4fd0a3bc2","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0b778fa296d94dcdb7722943dcfe23c1","docid":1760535,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"4c763cf9f735372bb347b847f8b5466a","created_ts":"2025-08-13T09:01:23.000Z","updated_ts":"2025-11-08T21:11:56.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"mRNA-2808","source_info":[{"code":"NCT07116616","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07116616"},{"attachment_path":"data/phs_source_info/65ea/a53d/90b6/62c0/65eaa53d90b662c0.png","attachment_type":"image/png","code":"Moderna-202510","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f2bd/a1aa/0b90/ca13/f2bda1aa0b90ca13.png","source":"Company pipeline","source_url":"https://www.modernatx.com/research/product-pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"mRNA-2808","source_info":[{"code":"NCT07116616","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07116616"},{"attachment_path":"data/phs_source_info/65ea/a53d/90b6/62c0/65eaa53d90b662c0.png","attachment_type":"image/png","code":"Moderna-202510","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f2bd/a1aa/0b90/ca13/f2bda1aa0b90ca13.png","source":"Company pipeline","source_url":"https://www.modernatx.com/research/product-pipeline"}],"status":"ACTIVE"}],"drug_type":["07c615d6d6644a87ba74fb48dd7eefe8"],"originator_org_master_entity_id":["74275107d346b274949eee8477168cac"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9","d626b459c76e2f32af15c100b2abf073","c381a43c49f980eec09bb793304abf8c"],"target_id":["014baa5413234b40aaa2da18adb5413e","aea9fa6f45bb4e48859be4110f70547b","c934ca9fe8e242af9c7d4ed33a45c27f"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["74275107d346b274949eee8477168cac"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1759190400000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0bd2738a68b446ada9b5f6d242b13bdf","docid":205273,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"7f6258929cfe3a34894d43ee40a52dc9","created_ts":"2024-12-23T10:46:30.000Z","updated_ts":"2026-03-04T21:40:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"MUNC-CD34","source_info":[{"code":"NCT06736080","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06736080"}],"status":"ACTIVE"}],"drug_type":["cceb301a25ec4f3cbc1aff3ae1169416"],"originator_org_master_entity_id":["9bf7b39c74786b4c3afbe80bea229bbf"],"mechanism_action_id":["ce6c7a15fefb48088c56211c14991282"],"target_id":["bfeefa9676b643b69776e9cba33d1549"],"disease_id":["3ab477dc108548a0a2b692fb304d5bb0","8384e4fc3d274ad6a75edbd3af8a5cd3"],"active_org_master_entity_id":["9bf7b39c74786b4c3afbe80bea229bbf"],"research_disease":["3ab477dc108548a0a2b692fb304d5bb0","8384e4fc3d274ad6a75edbd3af8a5cd3"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1771977600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1735689600000}}],"disease_phase":[{"disease_id":"8384e4fc3d274ad6a75edbd3af8a5cd3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3ab477dc108548a0a2b692fb304d5bb0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"105c83e7dd4f4ac09a03d79225649875","docid":19257,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"f76c938b9c3038a6b861573982f91626","created_ts":"2021-10-08T14:50:18.000Z","updated_ts":"2026-04-02T15:26:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"EP-0042","status":"ACTIVE"}],"dev_code":[{"name":"EP 0042","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aurora-kinase-flt3-inhibitor-ep0042"}],"status":"ACTIVE"},{"name":"EP-0042","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aurora-kinase-flt3-inhibitor-ep0042"}],"status":"ACTIVE"},{"name":"EP0042","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aurora-kinase-flt3-inhibitor-ep0042"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["52f71b8ce22867e90fd9081ce8a03e86"],"mechanism_action_id":["42bff6897e7b912141d2d30072d93d8f","b16f90ad4311e3d343c0b0d51fbea5b8"],"target_id":["35bbbda181884cceb47599f39c18d964","2ec11e5c292848d5b07cf6e132871a11"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","ee423e7465a441f9b91198eb4a53bd6d","1a95630392584c7892bec2dc9888cbfc"],"active_org_master_entity_id":["52f71b8ce22867e90fd9081ce8a03e86"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","ee423e7465a441f9b91198eb4a53bd6d","1a95630392584c7892bec2dc9888cbfc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1604275200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1604275200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1604275200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1675209600000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ee423e7465a441f9b91198eb4a53bd6d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"02f90de430c34c109bbd6fbcf47be5db","docid":30702,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","created_ts":"2022-02-28T05:06:05.000Z","updated_ts":"2024-10-30T10:20:37.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"中华跌打","status":"ACTIVE"},{"lang":"EN","name":"ZhongHuaDieDa","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["e475471e5ba546a595deede0d50616fa"],"research_disease":["e475471e5ba546a595deede0d50616fa"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"e475471e5ba546a595deede0d50616fa","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"000171fa75d8467f9520cefeb674b850","docid":2303,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"478270e5648733d0b1fb1b28303e544d","created_ts":"2022-06-24T07:36:36.000Z","updated_ts":"2025-11-15T21:08:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"VVZ-2471","status":"ACTIVE"}],"dev_code":[{"name":"VVZ 2471","status":"ACTIVE"},{"name":"VVZ2471","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0a93840262b6ad50cc02cb7c6795490c"],"mechanism_action_id":["dc041ecead785c19109eaaab3c8625b8","dbc84e3d9d51060f10a42f7cd69952f3"],"target_id":["4f0c095b670045188332b89979106a8e","99cb6deb4560417ea72e83b8736a4234"],"disease_id":["25aa9dbd25714b36b8bcb9347d1b91d1","b52bf7b51e7b4af5a003b6e001565468","00a4007368f84f52a23effea76883bbf","2dbed7595ff04b8fae04724f91081116","18fb73cdc2c742268dcbc90771fcd786","d2c09fe7775c4bc580490e5ff4fca509"],"active_org_master_entity_id":["0a93840262b6ad50cc02cb7c6795490c"],"research_disease":["25aa9dbd25714b36b8bcb9347d1b91d1","b52bf7b51e7b4af5a003b6e001565468","00a4007368f84f52a23effea76883bbf","2dbed7595ff04b8fae04724f91081116","18fb73cdc2c742268dcbc90771fcd786","d2c09fe7775c4bc580490e5ff4fca509"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1762732800000}}],"disease_phase":[{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b52bf7b51e7b4af5a003b6e001565468","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d2c09fe7775c4bc580490e5ff4fca509","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"00a4007368f84f52a23effea76883bbf","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"18fb73cdc2c742268dcbc90771fcd786","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"17a6d595c73641d6955b6b1c0388bbef","docid":1310256,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":77,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2025-04-07T07:56:47.000Z","updated_ts":"2026-04-11T21:07:23.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"CD19 CAR-T Cells(Hebei Taihe Chunyu Biotechnology)","source_info":[{"code":"NCT06911710","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06911710"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["49e7b893d0d72dac631f99b43429298a"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","1b969bf36fe146598279d284e09e1d42","27c81d33df044a648187f81864221799","2e7d2d244b984bcb9206d68231d6001f","321c439bbe614dc2afd13cb803a48cec","e10523d5d50e41f6841de149d8b794b7","570b3cb9d08246788a5c1ccfc4ab5b09"],"active_org_master_entity_id":["49e7b893d0d72dac631f99b43429298a"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","1b969bf36fe146598279d284e09e1d42","27c81d33df044a648187f81864221799","2e7d2d244b984bcb9206d68231d6001f","321c439bbe614dc2afd13cb803a48cec","e10523d5d50e41f6841de149d8b794b7","570b3cb9d08246788a5c1ccfc4ab5b09"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1731110400000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"570b3cb9d08246788a5c1ccfc4ab5b09","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"27c81d33df044a648187f81864221799","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2e7d2d244b984bcb9206d68231d6001f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"321c439bbe614dc2afd13cb803a48cec","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1b969bf36fe146598279d284e09e1d42","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"40b8bc06a50d4cdb9c6b738ec12e7b92","docid":77238,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-10-08T14:45:55.000Z","updated_ts":"2026-01-08T07:34:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"Coacillium","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/legacy-healthcare-announces-positive-top-line-results-from-phase-2-3-trial-of-coacillium-cutaneous-solution-the-first-drug-for-children-and-adolescents-with-moderate-and-severe-alopecia-areata/"}],"status":"ACTIVE"}],"dev_code":[{"name":"LH 8","status":"ACTIVE"},{"name":"LH-8","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/legacy-healthcare-announces-positive-top-line-results-from-phase-2-3-trial-of-coacillium-cutaneous-solution-the-first-drug-for-children-and-adolescents-with-moderate-and-severe-alopecia-areata/"}],"status":"ACTIVE"},{"name":"LH8","status":"ACTIVE"}],"trade_name":[{"name":"Cinainu","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/cinainu"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["66d4ac47d64caaad86e888064ca0c8c2"],"disease_id":["061a5c6c24164fadb7fa15fc1d303e75","0dfc10e5c81e42869cd8f7479a1b5021","452558707a32402e80a9431bf4652814","a995ea676cb44956a51af415a8bd2b14"],"active_org_master_entity_id":["66d4ac47d64caaad86e888064ca0c8c2","c45160fbd3a2a0809edcc5f8d3d581c9","add99032c489f8527445429e4e5a8c72"],"research_disease":["061a5c6c24164fadb7fa15fc1d303e75","0dfc10e5c81e42869cd8f7479a1b5021","452558707a32402e80a9431bf4652814","a995ea676cb44956a51af415a8bd2b14"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1687132800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1767657600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1726185600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1726185600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1726185600000}}],"disease_phase":[{"disease_id":"061a5c6c24164fadb7fa15fc1d303e75","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"0dfc10e5c81e42869cd8f7479a1b5021","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"452558707a32402e80a9431bf4652814","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"a995ea676cb44956a51af415a8bd2b14","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02dd2a1a2492445286066dcd0c71f1cf","docid":1967,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Fluocinonide","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":47088000000,"rnk":17,"target_extend_id":"b93dbe262f233b8080ed88876821bd64","created_ts":"2021-10-08T14:45:38.000Z","updated_ts":"2026-02-25T01:29:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":347155200000,"drug_name":[{"lang":"CN","name":"醋酸氟轻松","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Fluocinonide","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"フルオシノニド","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Fluocinonide (JP17/USP/INN)","source_info":[{"code":"D00325","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Fluocinonide Cream","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Fluocinonide Gream","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Fluocinonide Liniment","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"氟轻松","status":"ACTIVE"}],"dev_code":[{"name":"NSC-101791","status":"ACTIVE"},{"name":"OT-703","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.ocumension.com/cn/product"}],"status":"ACTIVE"}],"trade_name":[{"name":"LIDEX-E","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"Lidex","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D00325","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"TOPSYM","source_info":[{"code":"22000AMX00368000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"Topsyn","status":"ACTIVE"},{"name":"Vanos","source_info":[{"code":"D00325","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"トプシム","source_info":[{"code":"22000AMX00368000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Fluocinonide","source_info":[{"code":"D00325","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB01047"],"kegg_id":["D00325"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9d86175bbf3ef65fdf880fe1e4163252"],"mechanism_action_id":["b3b0790f82c48637c8ccae2fb7b59a32"],"target_id":["6fe53f67a27241fcac53227526791322"],"atc_code":["6bfc0562116e43fe816cf9edebb82033","a874e3618c4d405db472ff712c370946"],"disease_id":["061a5c6c24164fadb7fa15fc1d303e75","e315db2e757046cd96274cf631d79546","9bbea742c3494416b5e85000e57a9dfd","627d5ec46d1d4cc6ba766c7a6e61aba4","a995ea676cb44956a51af415a8bd2b14","2e52db813eb94143a5488cb1b73f87b5","d281a3b362a740d8aeb63e2a10102671","b5068ce40bb1403ab9a02fa97954ebb1","3b1efd66997741189935bf20cfe9774f","b5c9fb6553a943fab9520c9a00b19fd7","02b9f9b0f3464ccbb37429d10f9aea36","26397353803f4f738d6f361d21adea4b","e10e6a48f3ea4ee2b2eee51942ed4ef0","be685463e8e640119dff51e5125e6d0f","7bb5556c886343f4a9ec230aacf8706e","452558707a32402e80a9431bf4652814"],"active_org_master_entity_id":["5c1bb5bbf9f8ba3a5ac452b91613798c","6a9233ee904e52b8f4000a6929c63346","359b0a6a7a24399984b83a1ced87678e","5b4f787d2e3948f14ab8daffe46f7a93","aca10265f636fabb0df416d60f7ab024"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["452558707a32402e80a9431bf4652814","e10e6a48f3ea4ee2b2eee51942ed4ef0"],"research_disease":["061a5c6c24164fadb7fa15fc1d303e75","e315db2e757046cd96274cf631d79546","9bbea742c3494416b5e85000e57a9dfd","627d5ec46d1d4cc6ba766c7a6e61aba4","a995ea676cb44956a51af415a8bd2b14","2e52db813eb94143a5488cb1b73f87b5","d281a3b362a740d8aeb63e2a10102671","b5068ce40bb1403ab9a02fa97954ebb1","3b1efd66997741189935bf20cfe9774f","b5c9fb6553a943fab9520c9a00b19fd7","02b9f9b0f3464ccbb37429d10f9aea36","26397353803f4f738d6f361d21adea4b","e10e6a48f3ea4ee2b2eee51942ed4ef0","be685463e8e640119dff51e5125e6d0f","7bb5556c886343f4a9ec230aacf8706e"],"non_research_disease":["452558707a32402e80a9431bf4652814"],"inactive_org_master_entity_id":["2d1042828d45bfb5be0effa4c61e16d8","514af3e8519258f36ce6d173a07c1b69"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1141257600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1108080000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":347155200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1588291200000}}],"disease_phase":[{"disease_id":"02b9f9b0f3464ccbb37429d10f9aea36","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"061a5c6c24164fadb7fa15fc1d303e75","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e10e6a48f3ea4ee2b2eee51942ed4ef0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"26397353803f4f738d6f361d21adea4b","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9bbea742c3494416b5e85000e57a9dfd","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"452558707a32402e80a9431bf4652814","highest_phase_global":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"disease_id":"b5068ce40bb1403ab9a02fa97954ebb1","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2e52db813eb94143a5488cb1b73f87b5","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"a995ea676cb44956a51af415a8bd2b14","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b5c9fb6553a943fab9520c9a00b19fd7","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"627d5ec46d1d4cc6ba766c7a6e61aba4","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e315db2e757046cd96274cf631d79546","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3b1efd66997741189935bf20cfe9774f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"060392a4c9d34ae7a363591ef0166204","docid":1764161,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2026-04-16T06:09:03.000Z","updated_ts":"2026-04-16T08:54:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CKD-215","source_info":[{"code":"NCT07532148","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07532148"}],"status":"ACTIVE"}],"dev_code":[{"name":"CKD-215","source_info":[{"code":"NCT07532148","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07532148"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["ca28f37b82155ad0f26ac1807aa8c0eb"],"disease_id":["2727f13d200e4493b2f6db709193035b","3615202fb9fb468391a53ee84733ca53","60058a4fc91f474688db03e7a12edf67"],"active_org_master_entity_id":["ca28f37b82155ad0f26ac1807aa8c0eb"],"research_disease":["2727f13d200e4493b2f6db709193035b","3615202fb9fb468391a53ee84733ca53","60058a4fc91f474688db03e7a12edf67"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"2727f13d200e4493b2f6db709193035b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3615202fb9fb468391a53ee84733ca53","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"60058a4fc91f474688db03e7a12edf67","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"172e6f4c8f284aae95c0c04ce7815a5b","docid":75027,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:51.000Z","updated_ts":"2025-03-06T07:40:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CAR liposomes","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de","f9b1093fafc547caabf90e26cef22a1f"],"originator_org_master_entity_id":["3fc7613b512a531f6281d2fc4a9a54a2"],"disease_id":["717a9bf79e584830859595b8dbe9d433","1623a269e26647fda7ecbee5c6923076","7cf66a4af7ac4b51b888c59d7e30a2c4"],"active_org_master_entity_id":["3fc7613b512a531f6281d2fc4a9a54a2"],"research_disease":["717a9bf79e584830859595b8dbe9d433","1623a269e26647fda7ecbee5c6923076","7cf66a4af7ac4b51b888c59d7e30a2c4"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641945600000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1623a269e26647fda7ecbee5c6923076","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cf66a4af7ac4b51b888c59d7e30a2c4","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"4c3340be729e45858c2c055bcc2af2fc","docid":470817,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":10,"target_extend_id":"6ddf1e83f20b3dd2b6d09f56a521bd9a","created_ts":"2024-11-15T10:18:28.000Z","updated_ts":"2024-11-30T21:10:54.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Lanthanum oxycarbonate","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.echemi.com/cms/2120120.html"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0c3ca8b5ac9a7af1ab21cbd7d5376ccd"],"mechanism_action_id":["c0bc14089fbff88bae8290996799f0fb"],"target_id":["99ac176c91fc45c5bf0ae0f1c78a851e"],"disease_id":["834fbd398de443f59c480fc3b82971ac"],"active_org_master_entity_id":["0c3ca8b5ac9a7af1ab21cbd7d5376ccd"],"research_disease":["834fbd398de443f59c480fc3b82971ac"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1731456000000}}],"disease_phase":[{"disease_id":"834fbd398de443f59c480fc3b82971ac","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0439da333187492d9098076e039b9451","docid":1251465,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1755129600000,"rnk":10,"target_extend_id":"8571ed277f0034fe90555c0079329340","created_ts":"2025-06-23T09:59:00.000Z","updated_ts":"2026-01-28T00:42:00.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"阿柏西普生物类似药","status":"ACTIVE"},{"lang":"EN","name":"Aflibercept Biosimilar(Zakłady Farmaceutyczne Polpharma SA)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Aflibercept Biosimilar (Polpharma SA)","status":"ACTIVE"},{"lang":"CN","name":"阿柏西普生物类似药（Polpharma SA）","status":"ACTIVE"}],"trade_name":[{"name":"Eiyzey","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/eiyzey"}],"status":"ACTIVE"},{"name":"Vgenfli","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/vgenfli"}],"status":"ACTIVE"}],"generic_name":[{"name":"Aflibercept","source_info":[{"code":"D09574"}],"status":"ACTIVE"}],"drug_type":["3dc96d9272ad41a3833fc1e67887cd5b","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["d07e9c17311b98ede46212c93b904d7f"],"mechanism_action_id":["0a279e6aea1bbea67b61e7b1d5d68777","6b6c2b10657446ed45e401214272b244"],"target_id":["184e4922d87143aa9340b5e2ee525f92","934f7ab958ca4daf85f5eb42393a0b28"],"atc_code":["c195e470df8347b6a7a6e4585be0e48d","f8109ba43287429d91eed61edddab75f"],"disease_id":["7bb5556c886343f4a9ec230aacf8706e","75a55b0ac0564b41b0f4bb34d123e668","aa6b1f65d7d740498f2b487ea553c661","b3613eb77a5d4795ac1a12db34d284ba"],"active_org_master_entity_id":["d07e9c17311b98ede46212c93b904d7f"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["7bb5556c886343f4a9ec230aacf8706e","75a55b0ac0564b41b0f4bb34d123e668","aa6b1f65d7d740498f2b487ea553c661","b3613eb77a5d4795ac1a12db34d284ba"],"research_disease":["7bb5556c886343f4a9ec230aacf8706e","75a55b0ac0564b41b0f4bb34d123e668","aa6b1f65d7d740498f2b487ea553c661","b3613eb77a5d4795ac1a12db34d284ba"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"approval_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}}],"disease_phase":[{"disease_id":"aa6b1f65d7d740498f2b487ea553c661","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"75a55b0ac0564b41b0f4bb34d123e668","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["207a2b37840543c0a1e4321d731b526a"],"if_speculate":0,"data_source":10}
+{"drug_id":"03a18ece86954b6397166f680bfcf07e","docid":4650,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":6,"target_extend_id":"cd8a609f80f0385ea50dada4177c9e9d","created_ts":"2021-11-30T08:54:51.000Z","updated_ts":"2026-01-10T21:08:32.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"AJ-302","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.ajpharm.com/aj302-page/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AJ 302","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.ajpharm.com/aj302-page/"}],"status":"ACTIVE"},{"name":"AJ-302","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.ajpharm.com/aj302-page/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3c43c01ba0f9955161344105592f8757"],"mechanism_action_id":["47b40a883c695af72a03f4c4f6e7a9f9","3ba9f3f7abb04eb3a2a91c20d34e8abe"],"target_id":["b9996b727424409c9faca6d4160a5a2f"],"disease_id":["dfa0bf953a094901a32012e6ce76aa27"],"active_org_master_entity_id":["3c43c01ba0f9955161344105592f8757"],"research_disease":["dfa0bf953a094901a32012e6ce76aa27"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719187200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"dfa0bf953a094901a32012e6ce76aa27","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"04df44ae18d74dc8b00f4759e9c5d9e4","docid":61838,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":6,"target_extend_id":"13c7bb0ae61531d9a4a5559da2b5cffc","created_ts":"2021-10-08T14:46:00.000Z","updated_ts":"2026-02-28T21:11:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"GFH-312","status":"ACTIVE"}],"dev_code":[{"name":"GFH 312","status":"ACTIVE"},{"name":"GFH312","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["40bf01d212e70db17bb7757f99a2a68f"],"mechanism_action_id":["cf7f3bd52ee04d5e1f2e3ed43e170897"],"target_id":["ed306a3eb03040869060843c0a92755c"],"disease_id":["d1412e90153c488995027186619d33f4","c5dbda12237b45cca74d49f7bb1e6808","418cb344fa844c8f8e494fc3ac177a12","58fd49f71a3f4a3483307fbc643c9725","b4049948f4d04c33acfc66b6449e00fd","6be96778ed424f8d91de00ab82364114","9c5d1631749345ef990a8ed5d14e6caf"],"active_org_master_entity_id":["40bf01d212e70db17bb7757f99a2a68f"],"research_disease":["d1412e90153c488995027186619d33f4","c5dbda12237b45cca74d49f7bb1e6808","418cb344fa844c8f8e494fc3ac177a12"],"non_research_disease":["58fd49f71a3f4a3483307fbc643c9725","b4049948f4d04c33acfc66b6449e00fd","6be96778ed424f8d91de00ab82364114","9c5d1631749345ef990a8ed5d14e6caf"],"inactive_org_master_entity_id":["f665b985cf1833e7f5861da6a7fea2c0","94333ed12a4f2268501134e85e46aa46"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1730246400000}}],"disease_phase":[{"disease_id":"d1412e90153c488995027186619d33f4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"9c5d1631749345ef990a8ed5d14e6caf","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b4049948f4d04c33acfc66b6449e00fd","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"58fd49f71a3f4a3483307fbc643c9725","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"418cb344fa844c8f8e494fc3ac177a12","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"c5dbda12237b45cca74d49f7bb1e6808","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0bdd12e87e3e43318301901708a61dc2","docid":47844,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:39.000Z","updated_ts":"2025-07-31T00:31:17.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"RNAliv","status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["874929922bdf686689ed8f8ac5640d9b"],"disease_id":["1e6992f1403346acad1273d778686ca7"],"active_org_master_entity_id":["874929922bdf686689ed8f8ac5640d9b"],"research_disease":["1e6992f1403346acad1273d778686ca7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1649289600000}}],"disease_phase":[{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","if_speculate":0,"data_source":10,"tech_platform":["e4b677e587e040b497f11ba8360b7cb4"],"source_info_xna":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source_url":"https://www.biospace.com/exonanorna-and-mdimune-enter-service-agreement-to-advance-targeted-drug-delivery-for-cancer"}],"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"delivery_system":["a34ad79a04ca46e5ae65e09ccc559be5"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"28070f7196fc47079add6b5ee2e4123e","docid":46348,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":2,"target_extend_id":"4f59e1f5cdcc37fe8c844d24609ae3b3","created_ts":"2021-10-08T14:46:22.000Z","updated_ts":"2026-02-24T16:20:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Anti BCMA CART cell therapy(Shanghai YaKe Biotechnology Co Ltd)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti BCMA CART cell therapy","status":"ACTIVE"},{"lang":"EN","name":"BCMA-CART therapy","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["9d3fe67727026f98efc484ed71bd4fe2","05c361c13a65003a2be6fed62b2276a1","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["08d84b9625394e2a9b3aa5dfccd85ffb","aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d","90163e2d1d85519e993176af80281cd8"],"research_disease":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1609459200000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"06990a56cf3643d9bfa81930ad702507","docid":16906,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-11-30T08:55:21.000Z","updated_ts":"2025-10-21T21:30:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"NG-101m","status":"ACTIVE"}],"dev_code":[{"name":"NG 101M","status":"ACTIVE"},{"name":"NG101M","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["00257e1dd3e05a805f098cca54022be7"],"disease_id":["05554578204541148a5482ad5df4a600"],"active_org_master_entity_id":["00257e1dd3e05a805f098cca54022be7"],"research_disease":["05554578204541148a5482ad5df4a600"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1798761600000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"16357b01fbcb44eaab3ae5312c47e993","docid":1611890,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":357,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2025-10-09T06:29:48.000Z","updated_ts":"2026-04-11T21:07:59.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"GT801","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzkxMDI2NzkwOA==&mid=2247511947&idx=8&sn=3c04d3b020199cd1b58ea67c49198771&poc_token=HMWd5GijAeuke9vrGZQtp07Qh9BABV4UnyRhdChU"}],"status":"ACTIVE"}],"dev_code":[{"name":"GT801","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzkxMDI2NzkwOA==&mid=2247511947&idx=8&sn=3c04d3b020199cd1b58ea67c49198771&poc_token=HMWd5GijAeuke9vrGZQtp07Qh9BABV4UnyRhdChU"}],"status":"ACTIVE"}],"drug_type":["cc10afbd78954c8db6d1d3fee0684a77"],"originator_org_master_entity_id":["b09d9a8bddb4ba5dbc648795b65649c0"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["db2b9c3a18e4430e88c68eaa712fb77e","85a5f5e742ad45b9ac62afaf9709249a","dba0a7e65b51408ca401deb8364bce94","ef1925515e7b4062a6cfe8c5e1db1b95","9524995c426b4d93a80908af4a018bba","51236dbf55d24268aa6d31d9be131f6f","c5e1987e283c495aaab2a8d309c6085e","068f9838b3cc44c0b85968479230fa7b","e78f809b697b4becaa8d265389638562","d7a26da8f1ff43559e34fe72da812c56"],"active_org_master_entity_id":["b09d9a8bddb4ba5dbc648795b65649c0"],"research_disease":["db2b9c3a18e4430e88c68eaa712fb77e","85a5f5e742ad45b9ac62afaf9709249a","dba0a7e65b51408ca401deb8364bce94","ef1925515e7b4062a6cfe8c5e1db1b95","9524995c426b4d93a80908af4a018bba","51236dbf55d24268aa6d31d9be131f6f","c5e1987e283c495aaab2a8d309c6085e","068f9838b3cc44c0b85968479230fa7b","e78f809b697b4becaa8d265389638562","d7a26da8f1ff43559e34fe72da812c56"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","fce2b462d4fa493eb9d82513b9007011","5b1dfc2ca8564662860187aef864467d","20f1c6915ff140519285386c54883aae","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1762473600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1758844800000}}],"disease_phase":[{"disease_id":"dba0a7e65b51408ca401deb8364bce94","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"db2b9c3a18e4430e88c68eaa712fb77e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"85a5f5e742ad45b9ac62afaf9709249a","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ef1925515e7b4062a6cfe8c5e1db1b95","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e78f809b697b4becaa8d265389638562","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"9524995c426b4d93a80908af4a018bba","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"068f9838b3cc44c0b85968479230fa7b","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"198f68f1f282402d9faac893df1f889b","docid":204859,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-11-20T09:08:00.000Z","updated_ts":"2025-05-31T18:24:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"LM-303","source_info":[{"code":"NCT06695689","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06695689"}],"status":"ACTIVE"}],"dev_code":[{"name":"LM-303","source_info":[{"code":"NCT06695689","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06695689"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["ce72e9b0077cdd71f7e3979a71f761c0"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","3beea980d93a4cc0abc864e27514601c","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["ce72e9b0077cdd71f7e3979a71f761c0"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","3beea980d93a4cc0abc864e27514601c","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1729123200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4151464ddda449a3a3c7160e35da231f","docid":1641476,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-08-28T09:54:26.000Z","updated_ts":"2025-10-24T23:58:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"TGF-beta Imprinted Natural Killer Cells(Ohio State University Comprehensive Cancer Center)","source_info":[{"code":"NCT07144384","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07144384"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["842e808d920ca6b35ef75e80eb2cc210"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["7219506c944a427c8f84ce7f4faf6741","690c4587b27e4f1a83aba2314fc0903d"],"active_org_master_entity_id":["842e808d920ca6b35ef75e80eb2cc210"],"research_disease":["7219506c944a427c8f84ce7f4faf6741","690c4587b27e4f1a83aba2314fc0903d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1760572800000}}],"disease_phase":[{"disease_id":"7219506c944a427c8f84ce7f4faf6741","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"690c4587b27e4f1a83aba2314fc0903d","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"001cbd537d224832ae9495124782f637","docid":3072,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Huperzine_A","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":757382400000,"rnk":1,"target_extend_id":"8a7ad82774923c7f98abfcd3d04344dd","created_ts":"2021-10-08T14:49:14.000Z","updated_ts":"2026-04-02T13:03:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":757382400000,"drug_name":[{"lang":"CN","name":"石杉碱甲","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Huperzine A","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HupA oral","status":"ACTIVE"},{"lang":"EN","name":"Qian-ceng-ta","status":"ACTIVE"}],"dev_code":[{"name":"BIS-001","status":"ACTIVE"},{"name":"BIS-001ER","status":"ACTIVE"},{"name":"FN12","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.zyzhan.com/news/detail/97855.html"}],"status":"ACTIVE"},{"name":"INS-001","status":"ACTIVE"},{"name":"SPN 817","status":"ACTIVE"},{"name":"WP-107","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=Mzk0ODIxMzU4Mw==&mid=2247534309&idx=5&sn=a411eb53f5ca97cd3939da12e0e0fc48"}],"status":"ACTIVE"},{"name":"WP103","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.toutiao.com/article/7589205487430746634/"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/gcPBI3yVrto4dqsn8sLHgw"}],"status":"ACTIVE"}],"trade_name":[{"name":"凡坦","source_info":[{"code":"CTR20255231","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=f7f8b8db3f984a548f71d9377b356cde"}],"status":"ACTIVE"},{"name":"双益平","status":"ACTIVE"},{"name":"哈伯因","status":"ACTIVE"},{"name":"忆诺","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"drugbank_id":["DB04864"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ce1783471a7add837e1062d85249c974"],"mechanism_action_id":["7b7fdc4654689c0fa4c2df36e76ff29d","622496254802129a678fe473b6492b41"],"target_id":["1d48042ba16f41e0b7f9071da5ce8a80","d1dec8037c6e4e8f9d0b120992be88c8"],"atc_code":["e7d96c25898c40d4a9413514f8ba4446"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","600bab8787a04a1fa21e9645e646197d","032a1cf373954a02bee6272aac6b5fa0","e29116bd4104436da4275b936996075f","7eb982f99f634f52aeb5567ec003ea0a","f3433922efe24dfaada77415e3e66ea0","5a66b9249fae4d97afa13193f05749b9","f0a16ccc962f4850b4072727b9f11738","27adc36a99f94ccaaf980ba8f57f0b4a","8ae7b8895639407b906410d1b46cf4d7","7633b4a0785544138d5bb73a74100f7b","066ceaf0fae84f83912000fa80a5319b","c9d3c55f01d24f11a6035f989330c65f","04448940c97b4fb1947cc4f60f3bb9cc"],"active_org_master_entity_id":["9ec40f66a22f730d6499e825bf360ce5","48937ad71cda72dcf7d4cba6aa600be6","3257f141f7bc83b63ffcdb26ed3ddcf9","3ada4d64312f59310d8efed5a65959b6","11ce80532a7f20a9af71463b3d88fc3b","2d6e1a470c632e39944941fbc8145811","77402be232d8101fd06a1ee7655b182f","fa1c317cedcce0bbfbb17ef4031f6730","bf66ddadca93d5bf88a5d4ab0173bacf","c6da6ecb305242493c48bac3419b9d7d","a4153319369bc776c9b69eb043189a3c"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["54a77f56d72c4ac6a0eb840f4518e3a0"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","600bab8787a04a1fa21e9645e646197d","032a1cf373954a02bee6272aac6b5fa0","e29116bd4104436da4275b936996075f","7eb982f99f634f52aeb5567ec003ea0a","f3433922efe24dfaada77415e3e66ea0","5a66b9249fae4d97afa13193f05749b9","f0a16ccc962f4850b4072727b9f11738","27adc36a99f94ccaaf980ba8f57f0b4a","8ae7b8895639407b906410d1b46cf4d7","7633b4a0785544138d5bb73a74100f7b"],"non_research_disease":["066ceaf0fae84f83912000fa80a5319b","c9d3c55f01d24f11a6035f989330c65f","04448940c97b4fb1947cc4f60f3bb9cc"],"inactive_org_master_entity_id":["f6b9e736afd984e2526dcddae480e1a6"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":757382400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1735516800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1151712000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1675728000000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f0a16ccc962f4850b4072727b9f11738","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"27adc36a99f94ccaaf980ba8f57f0b4a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5a66b9249fae4d97afa13193f05749b9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"04448940c97b4fb1947cc4f60f3bb9cc","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7633b4a0785544138d5bb73a74100f7b","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"600bab8787a04a1fa21e9645e646197d","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"032a1cf373954a02bee6272aac6b5fa0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7eb982f99f634f52aeb5567ec003ea0a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e29116bd4104436da4275b936996075f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c9d3c55f01d24f11a6035f989330c65f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"8ae7b8895639407b906410d1b46cf4d7","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"066ceaf0fae84f83912000fa80a5319b","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["11ce80532a7f20a9af71463b3d88fc3b","604ca75fc8e663ab6ea98697182c435f"],"if_speculate":0,"data_source":10}
+{"drug_id":"005e96fb747948d991390676628eb208","docid":204884,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-11-28T09:06:54.000Z","updated_ts":"2025-05-23T07:36:30.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous Regulatory T Cells(Nanjing Drum Tower Hospital)","source_info":[{"code":"NCT06708780","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06708780"}],"status":"ACTIVE"}],"drug_type":["f4b90b82ef0d408a8d668ea670bb9020"],"originator_org_master_entity_id":["9626e2643f0c8888fb1ccc488696c75a"],"disease_id":["1dec6017bd924aff8aeae6e7d4a3f874"],"research_disease":["1dec6017bd924aff8aeae6e7d4a3f874"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1681257600000}}],"disease_phase":[{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"003f4f8605894906a1db19b31719faa4","docid":234813,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"71ec68f930e83151b03bfb490dd00c86","created_ts":"2025-01-13T06:15:51.000Z","updated_ts":"2026-03-14T21:10:36.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CM518D1","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/keymed-biosciences-announces-approval-of-ind-for-cm518d1-by-the-national-medical-products-administration-of-china-for-the-treatment-of-solid-tumors"}],"status":"ACTIVE"}],"dev_code":[{"name":"CM518D1","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/keymed-biosciences-announces-approval-of-ind-for-cm518d1-by-the-national-medical-products-administration-of-china-for-the-treatment-of-solid-tumors"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["77a58f3c97e31f0428f36e670965e2a4"],"mechanism_action_id":["891cf53127bc45c8a4b5cbaa4f5a55a0"],"target_id":["2de9abedbec545e29d6cd6e57b7dc9a8"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["77a58f3c97e31f0428f36e670965e2a4","3206c84d3bae4ea547213024defc6653"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1750982400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1749772800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"71ec68f930e83151b03bfb490dd00c86","moiety_mechanism_action_id":["891cf53127bc45c8a4b5cbaa4f5a55a0"],"moiety_target_id":["2de9abedbec545e29d6cd6e57b7dc9a8"]}
+{"drug_id":"4a4ba61c981e444284c65422420a2bda","docid":58553,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":20,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2021-10-08T14:50:35.000Z","updated_ts":"2026-04-04T21:08:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"抗人BCMA T细胞 (上海恒润达生生物)","status":"ACTIVE"},{"lang":"EN","name":"HR-003","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://pdf.dfcfw.com/pdf/H2_AN202210181579253310_1.pdf?1666113612000.pdf"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti BCMA CAR T cell therapy (Hrain Biotechnology)","status":"ACTIVE"},{"lang":"EN","name":"BCMA-CART","status":"ACTIVE"},{"lang":"EN","name":"Human BCMA Targeted T Cells (Hrain Biotechnology)","source_info":[{"code":"CTR20221684","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=76bb59ccb67d4626a383f53a9c026ed8"}],"status":"ACTIVE"}],"dev_code":[{"name":"HR 003","status":"ACTIVE"},{"name":"HR003","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["b4c624212749f84e83429c5a8673c692"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"special_review":["c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5","56842bd5a0fb4199bc0d99ae22798bdc","e10523d5d50e41f6841de149d8b794b7","bf27abf8e60a4af4a578cedc875e80b9"],"active_org_master_entity_id":["b4c624212749f84e83429c5a8673c692"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5","56842bd5a0fb4199bc0d99ae22798bdc","e10523d5d50e41f6841de149d8b794b7"],"non_research_disease":["bf27abf8e60a4af4a578cedc875e80b9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1657584000000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"56842bd5a0fb4199bc0d99ae22798bdc","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_before_ter_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"02783dd9c3a4461d9c1d68c70dd7b83a","docid":69623,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"945d2886bdc043a687db986dcd8f84d3","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1483228800000,"rnk":28,"target_extend_id":"c2ae5bf143df357dbed72cf460d1cc2e","created_ts":"2021-10-08T14:46:25.000Z","updated_ts":"2026-03-11T00:45:50.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"西妥昔单抗生物类似药(Cinnagen)","status":"ACTIVE"},{"lang":"EN","name":"Cetuximab biosimilar(Cinnagen)","status":"ACTIVE"}],"generic_name":[{"name":"Cetuximab","status":"ACTIVE"}],"drugbank_id":["DB00002"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["4035ceacbf136fd59f6e9090d4fa803c"],"mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4"],"target_id":["c18d6f96c23b4d1e880daafa1b00472b"],"atc_code":["2df1e225410f4b22aadb7b9d73dd178d"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2"],"active_org_master_entity_id":["4035ceacbf136fd59f6e9090d4fa803c"],"first_approved_country":["ab1a98cb-d362-3a11-9e63-99cb01cc9474"],"first_approved_indication":["7665e5683a1a443a8f3d3b946d4c9ca2"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"approval_country":["ab1a98cb-d362-3a11-9e63-99cb01cc9474"],"research_country":[{"country":"ab1a98cb-d362-3a11-9e63-99cb01cc9474","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1483228800000}}],"disease_phase":[{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["1d39e67389f946ada4e45bdf4d930055"],"data_source":10}
+{"drug_id":"076c698a489243bab132ab5e4be34e85","docid":19577,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-03-01T09:29:16.000Z","updated_ts":"2026-03-09T23:30:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"ZOC2017217","source_info":[{"code":"CTR20213389","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE"}],"status":"ACTIVE"}],"dev_code":[{"name":"ZOC 2017217","status":"ACTIVE"},{"name":"ZOC-2017217","status":"ACTIVE"},{"name":"ZOC2017217","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["c696637611eea1d390bb3a3920af714c"],"disease_id":["6f1c3cddc3ff43a381b2310efe73f756"],"active_org_master_entity_id":["297d47cf2257a529f8447b120396f219","c696637611eea1d390bb3a3920af714c"],"research_disease":["6f1c3cddc3ff43a381b2310efe73f756"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1770681600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1718755200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1634688000000}}],"disease_phase":[{"disease_id":"6f1c3cddc3ff43a381b2310efe73f756","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"00e7f55f83af499fba71495c3771c40c","docid":20688,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-07-31T05:21:55.000Z","updated_ts":"2026-01-27T19:14:36.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"BR-3006","source_info":[{"code":"NCT05951946","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05951946"}],"status":"ACTIVE"}],"dev_code":[{"name":"BR 3006","status":"ACTIVE"},{"name":"BR3006","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8749b8a1dde02c1e5f8706ce6346a28a"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["8749b8a1dde02c1e5f8706ce6346a28a"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"023af667170c4fa9a6cc6098f2412306","docid":49248,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Berzosertib","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_dev_status_before_termination_cn":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"c9f4e17f174a3b0abc907089fe318c94","created_ts":"2021-10-08T14:47:14.000Z","updated_ts":"2026-04-02T16:58:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Berzosertib","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Berzosertib (USAN/INN)","source_info":[{"code":"D11148","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"M-6620","status":"ACTIVE"},{"name":"M6620","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/berzosertib"}],"status":"ACTIVE"},{"name":"VE-822","status":"ACTIVE"},{"name":"VX-970","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/berzosertib"}],"status":"ACTIVE"}],"generic_name":[{"name":"Berzosertib","source_info":[{"code":"D11148","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB11794"],"kegg_id":["D11148"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f71f2e67633d6da9b028b8d0c1ca7d09"],"mechanism_action_id":["2768d83656f87c81b5a3fcda75e7f214"],"target_id":["f72552f8ce11468982eeb6a7db205f42"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["598372309fac44dfa9afd74266b0d581","1d6d6b0086ff422ca00418c0e8b0e940","62eaee6d9ee44410b8aca59dfc7408e9","7a8157d6b6dd4e8689858979aeb3bacb","a6cd07ecf38e48b584e8da2adfbe5f42","f58920e650344564b5dc93712863af81","978b2e0e83614e3f80e9003905b63c98","2536e79ced34450fbb09de73061cf096","dd9e2929f98244cbb86c5a7265e60882","7f8dba6cc5c24bff9bfffb5d5a9352bc","39662ec303a440d8984a18e973f87c9d","332d60a14b7b43278a24d0ac2961a361","27538fe67e9b4648b06de8efdc9ab891","6d98a1f6be594b0ba2e1ee55c3738006","6a6753c1c1d74648aa399e9f3bc22350","218de7027c39474b884ca5d174846630","1d3b5642bc8740639e8972872688855a","f0e77325ab1e46a899ce62a7c13214cc","c297238c41b2488abe3de6546b105a4e","90ffc68d955c4ddaac828195a04fd5a4","0464f5493b0444e9875a0584df17cbf0","dfc147da1e8e41da84a60159f84903ef","800b7119dfb34d4dad4c0528b2a0305c","b2fa14a75a53403881be137eba040dbf","e9d6fc1f21704dba80bc8465bbe87d96","b42488c9ce3245988e4e93caf2b95590","50c397f334694253be0d0ef704e23dc0","b382bc2a56644776b45dc6084224df3b","f92e4ba771d04f27a1f4daae363b676a","1eb8457f22e94e3b8280ae1989fbfdca","2bb755a3f43f49dea60661c5f99712a3","863f609690954f78ab2e9d54013597ee","e951cb2d1af6487e8fe25702c6744fcb","dc3ac98bdc5a4f9298fc030de877c4b6","2ec5825d4b1844538f076141667aa5b0","3aecb71c582e487c962fa840ee3ef8f5","9e654bca42a342cfb3611ff78869eac6","94ac5bd14d964124acacc3de59b307b3","43a01c3d180b45438f911c6502567931","5b88f0a220d2415a809c04479eba469e","6d2370224f2c4964a6ea2c11e0c93038","e66bd159ca524a14af868bead50619f2","1b823cb0a9a34447b285f109b1745dd9","f7ff421129ab40b19648cd3b1fc08f0f","e35ce4e9b7a846d49e600ce7ac4a7fd6","a636be1e48e347ac9018a1f1223532b0","6c9c5be211cb4d72a28205c49a16d653","6a962a4341364bbe9959b413849567de","8bea5bec08e44c1ea7a90c7a1e3daeb8","1dd4be2a22d04ef39e07fb5cdbc2c2d5","847a0ea7462c4293b185766079ef37a2","572d2b5e179a4c8b9c5b3397bf70fecb","d8ba7ca3e2324ae981eedd136acedb30","6628f20517954c2686891bd9adf29a97","9b0e971ed74b497bb9f52350fb4da13f","74ba301586ab419b9c9accd39cd20782","95aea6610cf849e0950a0771c6b25c69","73fd82d969b1457a85183ca272200cb7","7af2742b1e824bb4bae223164df67757","f4e1eb84e0a74f6aa7273836a35f0ba9"],"active_org_master_entity_id":["6f1e5d4aa0db05022496f52dcdf60034","a30b6631747b5c051c883cec3959771f","f71f2e67633d6da9b028b8d0c1ca7d09","105226e3d0f5d62025615a46608adc78"],"research_disease":["598372309fac44dfa9afd74266b0d581","1d6d6b0086ff422ca00418c0e8b0e940","62eaee6d9ee44410b8aca59dfc7408e9","7a8157d6b6dd4e8689858979aeb3bacb","a6cd07ecf38e48b584e8da2adfbe5f42","f58920e650344564b5dc93712863af81","978b2e0e83614e3f80e9003905b63c98","2536e79ced34450fbb09de73061cf096","dd9e2929f98244cbb86c5a7265e60882","7f8dba6cc5c24bff9bfffb5d5a9352bc","39662ec303a440d8984a18e973f87c9d","332d60a14b7b43278a24d0ac2961a361","27538fe67e9b4648b06de8efdc9ab891","6d98a1f6be594b0ba2e1ee55c3738006","6a6753c1c1d74648aa399e9f3bc22350","218de7027c39474b884ca5d174846630","1d3b5642bc8740639e8972872688855a","f0e77325ab1e46a899ce62a7c13214cc","c297238c41b2488abe3de6546b105a4e","90ffc68d955c4ddaac828195a04fd5a4","0464f5493b0444e9875a0584df17cbf0","dfc147da1e8e41da84a60159f84903ef","800b7119dfb34d4dad4c0528b2a0305c","b2fa14a75a53403881be137eba040dbf","e9d6fc1f21704dba80bc8465bbe87d96","b42488c9ce3245988e4e93caf2b95590","50c397f334694253be0d0ef704e23dc0","b382bc2a56644776b45dc6084224df3b","f92e4ba771d04f27a1f4daae363b676a","1eb8457f22e94e3b8280ae1989fbfdca","2bb755a3f43f49dea60661c5f99712a3","863f609690954f78ab2e9d54013597ee","e951cb2d1af6487e8fe25702c6744fcb","dc3ac98bdc5a4f9298fc030de877c4b6","2ec5825d4b1844538f076141667aa5b0","3aecb71c582e487c962fa840ee3ef8f5","9e654bca42a342cfb3611ff78869eac6","94ac5bd14d964124acacc3de59b307b3","43a01c3d180b45438f911c6502567931","5b88f0a220d2415a809c04479eba469e","6d2370224f2c4964a6ea2c11e0c93038","e66bd159ca524a14af868bead50619f2","1b823cb0a9a34447b285f109b1745dd9","f7ff421129ab40b19648cd3b1fc08f0f","e35ce4e9b7a846d49e600ce7ac4a7fd6","a636be1e48e347ac9018a1f1223532b0","6c9c5be211cb4d72a28205c49a16d653","6a962a4341364bbe9959b413849567de","8bea5bec08e44c1ea7a90c7a1e3daeb8","1dd4be2a22d04ef39e07fb5cdbc2c2d5","847a0ea7462c4293b185766079ef37a2","572d2b5e179a4c8b9c5b3397bf70fecb","d8ba7ca3e2324ae981eedd136acedb30","6628f20517954c2686891bd9adf29a97"],"non_research_disease":["9b0e971ed74b497bb9f52350fb4da13f","74ba301586ab419b9c9accd39cd20782","95aea6610cf849e0950a0771c6b25c69","73fd82d969b1457a85183ca272200cb7","7af2742b1e824bb4bae223164df67757","f4e1eb84e0a74f6aa7273836a35f0ba9"],"inactive_org_master_entity_id":["66c020b31471c1ac34a8e51bdce20217","8aeac6f0301fbd217e0369e8bfc666ba"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1605484800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1577664000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1559088000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1472083200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1644364800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1681776000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1752969600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1769299200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1712102400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1636070400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1752969600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1636070400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1752969600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1750982400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1752969600000}}],"disease_phase":[{"disease_id":"7f8dba6cc5c24bff9bfffb5d5a9352bc","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f7ff421129ab40b19648cd3b1fc08f0f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5b1807d6c7fe4f069816bbb27a23d507","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8bea5bec08e44c1ea7a90c7a1e3daeb8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"95aea6610cf849e0950a0771c6b25c69","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e9d6fc1f21704dba80bc8465bbe87d96","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"73fd82d969b1457a85183ca272200cb7","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d8ba7ca3e2324ae981eedd136acedb30","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f4e1eb84e0a74f6aa7273836a35f0ba9","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6a962a4341364bbe9959b413849567de","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6a6753c1c1d74648aa399e9f3bc22350","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"dd9e2929f98244cbb86c5a7265e60882","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e951cb2d1af6487e8fe25702c6744fcb","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6628f20517954c2686891bd9adf29a97","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f0e77325ab1e46a899ce62a7c13214cc","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"572d2b5e179a4c8b9c5b3397bf70fecb","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"74ba301586ab419b9c9accd39cd20782","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7a8157d6b6dd4e8689858979aeb3bacb","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"598372309fac44dfa9afd74266b0d581","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"978b2e0e83614e3f80e9003905b63c98","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"dfc147da1e8e41da84a60159f84903ef","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3aecb71c582e487c962fa840ee3ef8f5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"43a01c3d180b45438f911c6502567931","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2ec5825d4b1844538f076141667aa5b0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b2fa14a75a53403881be137eba040dbf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"5b88f0a220d2415a809c04479eba469e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"332d60a14b7b43278a24d0ac2961a361","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a636be1e48e347ac9018a1f1223532b0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"39662ec303a440d8984a18e973f87c9d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a6cd07ecf38e48b584e8da2adfbe5f42","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"50c397f334694253be0d0ef704e23dc0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1b823cb0a9a34447b285f109b1745dd9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"800b7119dfb34d4dad4c0528b2a0305c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"dc3ac98bdc5a4f9298fc030de877c4b6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f58920e650344564b5dc93712863af81","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7af2742b1e824bb4bae223164df67757","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"90ffc68d955c4ddaac828195a04fd5a4","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1d3b5642bc8740639e8972872688855a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1dd4be2a22d04ef39e07fb5cdbc2c2d5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6d2370224f2c4964a6ea2c11e0c93038","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1eb8457f22e94e3b8280ae1989fbfdca","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"94ac5bd14d964124acacc3de59b307b3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e66bd159ca524a14af868bead50619f2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"847a0ea7462c4293b185766079ef37a2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"9e654bca42a342cfb3611ff78869eac6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9b0e971ed74b497bb9f52350fb4da13f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b382bc2a56644776b45dc6084224df3b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"863f609690954f78ab2e9d54013597ee","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6d98a1f6be594b0ba2e1ee55c3738006","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["105226e3d0f5d62025615a46608adc78","f71f2e67633d6da9b028b8d0c1ca7d09"],"data_source":10}
+{"drug_id":"032fc0689b5c4cff92f7c09a906f2250","docid":38830,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:38.000Z","updated_ts":"2025-07-15T12:12:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","drug_name":[{"lang":"CN","name":"净固片","status":"ACTIVE"},{"lang":"EN","name":"Jinggu Tablets","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["d4439160ba58470886c8e89f7c0bef2b","46be978b4ca44389bb07aa8fcb8f8b3c"],"active_org_master_entity_id":["d9cee89741e4e8a605a05eab856e9cbf"],"research_disease":["d4439160ba58470886c8e89f7c0bef2b","46be978b4ca44389bb07aa8fcb8f8b3c"],"inactive_org_master_entity_id":["a48522f21735b7a7c14631bffd960dd6"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1437955200000}}],"disease_phase":[{"disease_id":"46be978b4ca44389bb07aa8fcb8f8b3c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d4439160ba58470886c8e89f7c0bef2b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0406627a470945289f96677ad7e806d0","docid":31053,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":17,"target_extend_id":"1a054e6699b4367f8131a42e1e5d72fe","created_ts":"2021-10-08T14:50:10.000Z","updated_ts":"2026-02-25T00:14:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Atexakin alfa","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Recombinant IL-6","status":"ACTIVE"},{"lang":"EN","name":"Recombinant Interleukin-6","status":"ACTIVE"},{"lang":"EN","name":"recombinant human Interleukin-6","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/sonnet-biotherapeutics-to-present-preclinical-data-on-son-080-for-chemotherapy-induced-peripheral-neuropathy-cipn-at-the-aacr-2024-annual-meeting/"}],"status":"ACTIVE"},{"lang":"EN","name":"rhIL-6","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/sonnet-biotherapeutics-to-present-preclinical-data-on-son-080-for-chemotherapy-induced-peripheral-neuropathy-cipn-at-the-aacr-2024-annual-meeting/"}],"status":"ACTIVE"}],"dev_code":[{"name":"R-IL-6","status":"ACTIVE"},{"name":"SON 080","status":"ACTIVE"},{"name":"SON-080","status":"ACTIVE"},{"name":"SON-081","status":"ACTIVE"}],"drug_type":["2f320ad742e54195b29c6737eeaa86af"],"originator_org_master_entity_id":["b7f591d867942e5982158588272d34c2"],"mechanism_action_id":["64e4204a6d2417be40ae340c1aa71dbf"],"target_id":["8556307199154d34b1f9bc9685f2ec47"],"disease_id":["dfa0bf953a094901a32012e6ce76aa27","6559fc2117eb4da5bfb0e421044902b8"],"active_org_master_entity_id":["b7f591d867942e5982158588272d34c2","5853e45546897809e9696568301a1e37","120c4d174ea4123278bccaf5613f17e4","20f91efba2f70447218ad626c7432fe3","7c8f72096c1d64ce9f17ebe6c0e47268","34f04062d7ffc60c3ba023b768e122b5","7937647b33459a3502fa187d9cd3e551"],"research_disease":["dfa0bf953a094901a32012e6ce76aa27","6559fc2117eb4da5bfb0e421044902b8"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1727740800000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1727740800000}}],"disease_phase":[{"disease_id":"dfa0bf953a094901a32012e6ce76aa27","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6559fc2117eb4da5bfb0e421044902b8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["120c4d174ea4123278bccaf5613f17e4","20f91efba2f70447218ad626c7432fe3","34f04062d7ffc60c3ba023b768e122b5","5a3a7bdd1192c4f8044272a2f7e7d5c1","607de62bed0f0173a74762d7431fe180"],"data_source":10}
+{"drug_id":"1ea64e38220f4e7ab68688b506590d87","docid":1702634,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-02-11T05:43:37.000Z","updated_ts":"2026-04-19T00:30:08.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LVIVO-TaVec400","source_info":[{"code":"NCT07399444","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07399444"}],"status":"ACTIVE"}],"dev_code":[{"name":"LVIVO-TaVec400","source_info":[{"code":"NCT07399444","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07399444"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["a22fd154855c015ed283545df379f0de"],"disease_id":["e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["a22fd154855c015ed283545df379f0de"],"research_disease":["e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1768003200000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2044e69fc3e742cda6382462d14688a1","docid":231713,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"196af3c7f8093273929f668f7d8d61c1","created_ts":"2024-06-20T01:50:17.000Z","updated_ts":"2025-12-05T00:30:41.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BZE-2204","source_info":[{"code":"NCT06446128","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06446128"},{"attachment_path":"data/phs_source_info/5d0c/9ce4/f7f4/2ec7/f13a0694-a7d2-32c8-936e-4ab2d372d3b7.pdf","attachment_type":"application/pdf","normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","preview_attachment_path":"data/phs_source_info/af25/6a9e/53b3/b77c/3c537cdd-548d-31b5-b469-73192349e2eb.png","source":"Corporate Publications"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD19/​CD22/​BCMA CAR-T(Shanghai Cell Therapy Group)","source_info":[{"code":"NCT06446128","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06446128"}],"status":"ACTIVE"}],"dev_code":[{"name":"BZE 2204","status":"ACTIVE"},{"name":"BZE2204","source_info":[{"code":"2025_3173","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/2005"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["d05a562f73143f0b10963b04cb44abf4"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9","2ac451946966904ac6da0d54008cdd9a","5010304c2ff249d5dbf674367642de9b"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448","d02b07e15b354447b8f22cb9e5c1d369"],"disease_id":["dba0a7e65b51408ca401deb8364bce94","0c8a0603507542faac6b5ef3e27c6728","b9790aa2ed5c48eda26f2224870a8e52","e10523d5d50e41f6841de149d8b794b7","4c9d46b2b7794d128b14d8689f4c357d","a425e59e374549b7bd0f75605eba80c8"],"active_org_master_entity_id":["d05a562f73143f0b10963b04cb44abf4","998397e059b4993c6bb3a95e1374e45e"],"research_disease":["dba0a7e65b51408ca401deb8364bce94","0c8a0603507542faac6b5ef3e27c6728","b9790aa2ed5c48eda26f2224870a8e52","e10523d5d50e41f6841de149d8b794b7","4c9d46b2b7794d128b14d8689f4c357d","a425e59e374549b7bd0f75605eba80c8"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1756684800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1733961600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1715040000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1745798400000}}],"disease_phase":[{"disease_id":"dba0a7e65b51408ca401deb8364bce94","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b9790aa2ed5c48eda26f2224870a8e52","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a425e59e374549b7bd0f75605eba80c8","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10}
+{"drug_id":"26cc146131714883adb0e64bbfcd9638","docid":42848,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:36.000Z","updated_ts":"2024-11-29T07:04:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"LCTG-002","status":"ACTIVE"}],"dev_code":[{"name":"LCTG-002","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["5e50032bbaaa3a231da5d1123facc184"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["5e50032bbaaa3a231da5d1123facc184"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1645488000000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01fffb0dd13a4cab865d3187fe8593d1","docid":22478,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"a983b07f08ae372691ebb766402b51f7","created_ts":"2022-07-15T09:37:05.000Z","updated_ts":"2026-03-04T22:50:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ANG-003","source_info":[{"attachment_path":"data/phs_source_info/84c7/5136/e941/e4b2/41f2215a-0915-3bd9-8f85-fb8eddcfed6e.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/121c/b4b2/6da2/2a7a/d9a1c9d0-b056-327f-9d32-de72ebb029c2.png","source":"Company pipeline","source_url":"https://anagramtx.com/index.html#pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"ANG003","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://anagramtx.com/press/Anagram-Launch-Release-FINAL-040423.pdf"}],"status":"ACTIVE"},{"name":"SNSP-003","status":"ACTIVE"}],"drug_type":["c6f7aa5028654d4d8ac6153f9b53e8a2"],"originator_org_master_entity_id":["2cae2c3bd1e3ab0d03dd216cb9a849c4"],"mechanism_action_id":["22d905122c264476add18ae2c3b307e9","0a9585f769a94ddf895e2e674ea1580c","a0480525aa89400a957acaac7c23e2a1"],"target_id":["24f31be8952f4ac3af1c9f312a6f3ecc","d7fe8d9c262641468c25faf999c72c9b","0a123538c81f49e28c86ac4bf7231a4f"],"disease_id":["7f8657c4a15148219c75eeb330d92c42","7746e33a3d614585a8a77c4b02d45009","85cb2ebc8e4441bc802553c6215a3e68"],"active_org_master_entity_id":["2cae2c3bd1e3ab0d03dd216cb9a849c4"],"research_disease":["7f8657c4a15148219c75eeb330d92c42","7746e33a3d614585a8a77c4b02d45009","85cb2ebc8e4441bc802553c6215a3e68"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1692921600000}}],"disease_phase":[{"disease_id":"7746e33a3d614585a8a77c4b02d45009","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7f8657c4a15148219c75eeb330d92c42","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"85cb2ebc8e4441bc802553c6215a3e68","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"056017b3915145ca83e1b487fe84db46","docid":72961,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-10-08T14:38:25.000Z","updated_ts":"2025-03-11T07:39:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"RPESC-RPE-4W","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"RPESC-RPE-4W","status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"special_review":["ed88b5b02898448483d0dd3ce010cfba"],"disease_id":["164ba9b819474bcd9c0f89bbf21a934c"],"active_org_master_entity_id":["2e0d31ddf2e00e493c184d0132590ed3"],"research_disease":["164ba9b819474bcd9c0f89bbf21a934c"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1649116800000}}],"disease_phase":[{"disease_id":"164ba9b819474bcd9c0f89bbf21a934c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0f7ee26ed9561e61a9ae6abd6cc4824f","docid":231196,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"71445c6af41138eebb0675d8f43f0d22","created_ts":"2024-06-04T07:48:16.000Z","updated_ts":"2025-05-24T00:19:55.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-PSCA CAR-T (Hebei People's Hospital)","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["73542fc47abe3ae4adf0e4c06ade9780"],"mechanism_action_id":["8e4fb982bcf2b036d5d72beff7b956cc"],"target_id":["a3e90d1c5e7749fb9143749b97b484b8"],"disease_id":["5cedd9732f5b45f1b6e9b226b32a0314"],"active_org_master_entity_id":["73542fc47abe3ae4adf0e4c06ade9780"],"research_disease":["5cedd9732f5b45f1b6e9b226b32a0314"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"5cedd9732f5b45f1b6e9b226b32a0314","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"02524fc353ee405eace63d08e749f207","docid":1340522,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-04-18T09:41:01.000Z","updated_ts":"2026-01-27T11:40:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"PA-111A","source_info":[{"code":"NCT06932705","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06932705"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4d1d5a2734be8dcabc02ecbfbf780ad7"],"disease_id":["ca12d2d355454d82b19068ad96acf14e"],"active_org_master_entity_id":["4d1d5a2734be8dcabc02ecbfbf780ad7"],"research_disease":["ca12d2d355454d82b19068ad96acf14e"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1743465600000}}],"disease_phase":[{"disease_id":"ca12d2d355454d82b19068ad96acf14e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"042babbfe1a8409fa1e8759579097a1b","docid":48317,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-09-27T12:39:40.000Z","updated_ts":"2024-10-30T10:20:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Insightec","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3ea93a3479c8e6895cbd069d2dacc523"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4"],"active_org_master_entity_id":["3ea93a3479c8e6895cbd069d2dacc523"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1642291200000}}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"106c1dc8329c4c7bba4df9cef53cb2f9","docid":14863,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-10-08T14:37:52.000Z","updated_ts":"2024-10-30T10:20:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Grass allergen immunotherapy(Karolinska Institutet)","status":"ACTIVE"}],"drug_type":["de1ecb4751c24f4e9f0fd82235204c60"],"originator_org_master_entity_id":["7d6ad649cc5003ec4ddafc87552d0930"],"disease_id":["00894c5beba2467fa4489e0fa39ddffa"],"active_org_master_entity_id":["7d6ad649cc5003ec4ddafc87552d0930"],"research_disease":["00894c5beba2467fa4489e0fa39ddffa"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"06e2b6d9fea1471c93b73c47f5a8a890","docid":27370,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-04-26T02:03:57.000Z","updated_ts":"2026-01-27T17:27:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","drug_name":[{"lang":"EN","name":"[18F]SF-DEVD-2","source_info":[{"code":"NCT05828238","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05828238"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["faa9ea08d792dc82af6444fa1fd8362a"],"disease_id":["f319fa27684c4cdeb6ce59d897217718"],"active_org_master_entity_id":["faa9ea08d792dc82af6444fa1fd8362a"],"research_disease":["f319fa27684c4cdeb6ce59d897217718"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1672531200000}}],"disease_phase":[{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"00512e0c113845f48f17dc7e5384812a","docid":74834,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":10,"target_extend_id":"3928103bdb3c3c0387c3d0caaa5965c1","created_ts":"2022-11-03T02:04:58.000Z","updated_ts":"2026-04-04T21:05:40.000Z","data_status":"ACTIVE","created_by":"liuqianru","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ADU-1805","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.sairopa.com/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ADU 1805","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-sirpa-monoclonal-antibody-adu-1805"}],"status":"ACTIVE"},{"name":"ADU1805","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-sirpa-monoclonal-antibody-adu-1805"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["b44b9fb06709d85f9b51dc32597f7fc6"],"mechanism_action_id":["5c4245a94c59f64f733f58bc3c4a5ece"],"target_id":["b94ae28f2cd44386b20b30a85e997db3"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","7665e5683a1a443a8f3d3b946d4c9ca2","87a9454771a64f2191224b6b7684254a","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","3ac5604c4dde49c29b561648d0c0543c","c7fe8aa844d24e85ba32a990ea28ded3","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["b44b9fb06709d85f9b51dc32597f7fc6","40fed18b544f74fe8be4d803b3bc4454"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","7665e5683a1a443a8f3d3b946d4c9ca2","87a9454771a64f2191224b6b7684254a","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","3ac5604c4dde49c29b561648d0c0543c","c7fe8aa844d24e85ba32a990ea28ded3","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1680480000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1680480000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1680480000000}}],"disease_phase":[{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3ac5604c4dde49c29b561648d0c0543c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["b44b9fb06709d85f9b51dc32597f7fc6","40fed18b544f74fe8be4d803b3bc4454"],"data_source":10}
+{"drug_id":"048da4a99c0f43788328c7b754a29703","docid":116408,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-12-25T07:08:36.000Z","updated_ts":"2025-04-08T09:20:57.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"STPX (Stalicla)","source_info":[{"attachment_path":"data/phs_source_info/5e90/dd4b/95c6/a41b/50e3bae7-27aa-3b80-89ab-abe3eb32e5bc.png","attachment_type":"image/png","code":"Stalicla-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/56dc/4f72/bed1/2027/7bbe6ba4-d0c5-35a5-9dc9-9c1a2c47fd42.png","source":"Company pipeline","source_url":"https://stalicla.com/pipeline"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["b1c7d028d80f069b0d00679301d87efa"],"disease_id":["94f13bf88b344e3d9da1438266fa7d58"],"active_org_master_entity_id":["b1c7d028d80f069b0d00679301d87efa"],"research_disease":["94f13bf88b344e3d9da1438266fa7d58"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"94f13bf88b344e3d9da1438266fa7d58","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"065ea3026dc0407b9a9556785bd0a9aa","docid":201116,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2024-04-17T06:44:13.000Z","updated_ts":"2026-01-20T21:16:18.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"BCM-894","status":"ACTIVE"}],"dev_code":[{"name":"BCM894","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["f858055eb803224ea4fe5f88d587a3bf"],"disease_id":["04d4209bd6bc4901ab59848d96c0623b","53b0789eac574b90a2d1ebe94d10a166","c624831e82eb4e149289223f037d38bf","3d3b4d85d52b4602a56b144086f40148"],"active_org_master_entity_id":["f858055eb803224ea4fe5f88d587a3bf","173a84c79db14ad55d35a8a8e1aeb321","44a8dbf167635622adc686a644ec6b28"],"research_disease":["04d4209bd6bc4901ab59848d96c0623b","53b0789eac574b90a2d1ebe94d10a166","c624831e82eb4e149289223f037d38bf","3d3b4d85d52b4602a56b144086f40148"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1766534400000}}],"disease_phase":[{"disease_id":"53b0789eac574b90a2d1ebe94d10a166","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3d3b4d85d52b4602a56b144086f40148","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c624831e82eb4e149289223f037d38bf","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"04d4209bd6bc4901ab59848d96c0623b","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0065888b50544e5992603d190e5c0599","docid":26585,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-01-05T02:37:48.000Z","updated_ts":"2025-04-07T00:18:53.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"黄葵颗粒","status":"ACTIVE"},{"lang":"EN","name":"Huangkui Granules","source_info":[{"code":"CTR20230013","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=2c67046e7e5d49228574276228b86f58"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["1e77d6c3717c5edb60015b1a99883eac"],"disease_id":["0bd2c46082c54564b7124da78bb3ff2a"],"active_org_master_entity_id":["1e77d6c3717c5edb60015b1a99883eac"],"research_disease":["0bd2c46082c54564b7124da78bb3ff2a"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1678406400000}}],"disease_phase":[{"disease_id":"0bd2c46082c54564b7124da78bb3ff2a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"017b97574fe943b0901094aa492cb785","docid":56305,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":11,"target_extend_id":"1a054e6699b4367f8131a42e1e5d72fe","created_ts":"2021-10-08T14:48:28.000Z","updated_ts":"2026-02-02T13:42:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"VDJ-001","source_info":[{"code":"NCT05957107","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05957107"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Recombinant humanized anti-IL-6R monoclonal antibody(VDJBio)","status":"ACTIVE"},{"lang":"CN","name":"重组人源化抗白介素-6受体单克隆抗体 (北京伟德杰生物)","status":"ACTIVE"}],"dev_code":[{"name":"VDJ-001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247542151&idx=3&sn=53b8a18a40b1ac5273c4ff31b8131cd7"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["b02f96369c9ff1f6d4dc9bab0b16ffd0"],"mechanism_action_id":["b30a0bdb2e0bd9c03a908a84588c4217"],"target_id":["8556307199154d34b1f9bc9685f2ec47"],"disease_id":["48531872c61f41a2a9a68e65062e4659","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["b02f96369c9ff1f6d4dc9bab0b16ffd0"],"research_disease":["48531872c61f41a2a9a68e65062e4659","6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1767916800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742947200000}}],"disease_phase":[{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"48531872c61f41a2a9a68e65062e4659","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"53433015ee4940a5b4b1b405d72e23ff","docid":1731191,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2025-09-08T07:16:30.000Z","updated_ts":"2025-09-08T07:18:15.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"wangya","drug_name":[{"lang":"EN","name":"CR999C2110L1","source_info":[{"normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","source":"Corporate Publications","source_url":"https://www.999.com.cn/quarterlyReport/2024-11-04/0a12f7bf-6d18-4eb5-8a85-0b57eb41aa36.PDF"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["3dad53a4219d41289076aa2343c14004"],"disease_id":["420e1c14acd74b36ad192201d3d8a44b"],"active_org_master_entity_id":["3dad53a4219d41289076aa2343c14004"],"research_disease":["420e1c14acd74b36ad192201d3d8a44b"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"420e1c14acd74b36ad192201d3d8a44b","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04b1a764377b4e88b6f2becc6033dd81","docid":53245,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-09-27T12:39:42.000Z","updated_ts":"2024-10-30T10:22:32.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Yutiq 50","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["16d5042cba0c222ac72b266404ca6c2b"],"disease_id":["1a355241b75e44ae85c0d04033353974"],"active_org_master_entity_id":["16d5042cba0c222ac72b266404ca6c2b"],"research_disease":["1a355241b75e44ae85c0d04033353974"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1650067200000}}],"disease_phase":[{"disease_id":"1a355241b75e44ae85c0d04033353974","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"108135aa59604e8e9063d150abe5dc0f","docid":79745,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":10,"target_extend_id":"d4102fb7c0f53673a27a5abc5a60447e","created_ts":"2023-08-30T03:22:42.000Z","updated_ts":"2026-03-19T08:16:12.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"wangya","drug_name":[{"lang":"EN","name":"DC cells(Shanghai Cell Therapy Group)","source_info":[{"code":"NCT06015269","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06015269"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Super DC Vaccine","status":"ACTIVE"}],"dev_code":[{"name":"JL-104","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","da28889c6a9146fa9d13e524d58bd0b2"],"originator_org_master_entity_id":["d05a562f73143f0b10963b04cb44abf4"],"mechanism_action_id":["739208b853cce48c909828f26049cb6c","4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["664d9478c81b4059b32f286b5047416c","9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["941ef5bdf9fa49b3b8054dd755019209","1e6992f1403346acad1273d778686ca7","7665e5683a1a443a8f3d3b946d4c9ca2","ae092fa59f4d44edaf59ffe23d0a44c3","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["d05a562f73143f0b10963b04cb44abf4"],"research_disease":["941ef5bdf9fa49b3b8054dd755019209","1e6992f1403346acad1273d778686ca7","7665e5683a1a443a8f3d3b946d4c9ca2","ae092fa59f4d44edaf59ffe23d0a44c3","ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1753920000000}}],"disease_phase":[{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"941ef5bdf9fa49b3b8054dd755019209","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"17d7d7d4dfbc4f9ab6e60c47fbcdd10b","docid":61371,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-12-10T12:55:17.000Z","updated_ts":"2026-04-02T11:19:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Ad26 Mos4 HIV tetravalent vaccine (Janssen Vaccines and Prevention B.V)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.GagPol + Ad26.Mos2.GagPol","status":"ACTIVE"},{"lang":"EN","name":"Ad26.Mos4.HIV","status":"ACTIVE"},{"lang":"EN","name":"Adenovirus serotype26 mosaic4 HIV vaccine","status":"ACTIVE"},{"lang":"EN","name":"Adenovirus serotype26 mosaic4 human immunodeficiency virus vaccine","status":"ACTIVE"}],"dev_code":[{"name":"HPX 3002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NzExNDQ4Nw==&mid=2650789875&idx=1&sn=0216bd7e2f04db5a7dcf4a31774cb3d9"}],"status":"ACTIVE"},{"name":"HPX-3002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NzExNDQ4Nw==&mid=2650789875&idx=1&sn=0216bd7e2f04db5a7dcf4a31774cb3d9"}],"status":"ACTIVE"},{"name":"HPX3002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NzExNDQ4Nw==&mid=2650789875&idx=1&sn=0216bd7e2f04db5a7dcf4a31774cb3d9"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","b24e8825fd1d42d1b8832824599ee903"],"originator_org_master_entity_id":["418690067cbd3e9837903964a49236f3"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["418690067cbd3e9837903964a49236f3","503d0e500d685aca4fc84acf2d2ce764"],"research_disease":["acfaaa0373944ffd89b0a2ace0d8c564"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"7b8fd1bd-c7fb-3ebd-b9e4-5372d8f85711","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"7b8fd1bd-c7fb-3ebd-b9e4-5372d8f85711","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1490918400000}},{"country":"a96b6ad6-fe3a-38f5-afc0-c34201a2b5c8","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"a96b6ad6-fe3a-38f5-afc0-c34201a2b5c8","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1490918400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1754697600000}}],"disease_phase":[{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"07a7c6d386304726b8b4f14d912fa9d5","docid":55977,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-07-04T10:54:23.000Z","updated_ts":"2026-01-27T15:30:24.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"AGT2","source_info":[{"code":"NCT05206578","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05206578"}],"status":"ACTIVE"}],"dev_code":[{"name":"AGT 2","source_info":[{"code":"NCT05206578","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05206578"}],"status":"ACTIVE"},{"name":"AGT-2","source_info":[{"code":"NCT05206578","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05206578"}],"status":"ACTIVE"},{"name":"AGT2","source_info":[{"code":"NCT05206578","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05206578"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3b00c6de31c67df723e4acfe7e94925e"],"disease_id":["98d9beffe4d14bb6a7ee599146b8beb2"],"active_org_master_entity_id":["3b00c6de31c67df723e4acfe7e94925e"],"research_disease":["98d9beffe4d14bb6a7ee599146b8beb2"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}}],"disease_phase":[{"disease_id":"98d9beffe4d14bb6a7ee599146b8beb2","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0181ed621cfa416c81da4291d06cadd9","docid":79515,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1139875200000,"created_ts":"2023-08-23T05:21:40.000Z","updated_ts":"2025-02-06T03:15:42.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"次氯酸钠","status":"ACTIVE"},{"lang":"EN","name":"Sodium Hypochlorite","source_info":[{"code":"22100AMX00666000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/800012_261170AQ2039_1_07"}],"status":"ACTIVE"},{"lang":"JP","name":"次亜塩素酸ナトリウム","source_info":[{"code":"22100AMX00666000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/800012_261170AQ2039_1_07"}],"status":"ACTIVE"}],"trade_name":[{"name":"Canal","source_info":[{"code":"22100AMX00928000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/650614_2730806Q1069_2_02"}],"status":"ACTIVE"},{"name":"TEXANT","source_info":[{"code":"21800AMX10327","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"Yakulax","source_info":[{"code":"22100AMX00666000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/800012_261170AQ2039_1_07"}],"status":"ACTIVE"},{"name":"キャナル","source_info":[{"code":"22100AMX00928000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/650614_2730806Q1069_2_02"}],"status":"ACTIVE"},{"name":"テキサント","source_info":[{"code":"21800AMX10327","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"ヤクラックス","source_info":[{"code":"22100AMX00666000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/800012_261170AQ2039_1_07"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a7c76b40847aa66f240b03417db36c60"],"disease_id":["0a6c6eaf0178467d9ab3e8015522901d"],"active_org_master_entity_id":["16e3677d6e9115997fc2b9a828b31f72","a7c76b40847aa66f240b03417db36c60","c18df29e5b9ff81a64444446ec4dc811"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["0a6c6eaf0178467d9ab3e8015522901d"],"research_disease":["0a6c6eaf0178467d9ab3e8015522901d"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1245369600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1208131200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1139875200000}}],"disease_phase":[{"disease_id":"0a6c6eaf0178467d9ab3e8015522901d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"01ab40c8360b449aae51c9e8e03bf9de","docid":42523,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":165,"target_extend_id":"c1ac453247713a2aad9d306341865992","has_leading_org_involved":1,"created_ts":"2021-11-30T08:56:06.000Z","updated_ts":"2026-04-04T21:04:10.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"TAK-940","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"19(T2)28z1xx CAR-T cell therapy","status":"ACTIVE"}],"dev_code":[{"name":"TAK 940","status":"ACTIVE"},{"name":"TAK-940","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["3213232cf3774bc734def2420b679bb6","9e69a16cb488720675288e77dd41cd84"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["f60141249781464bb54bf1700c83143c","a622cec9c1e34e88a3c46c3b7fa00884","ce09181e978a4a3f9932f35001b9fa13","e78f809b697b4becaa8d265389638562","d7a26da8f1ff43559e34fe72da812c56","e89afc6a432744b1a88281329dc46d91","6ab030f07c1e4ab4ba6d23fdee898e09","1a51c709099840a381471343fb21c3a9","c17d3b80f53e409c930fc2d37ed244ec","8b4ec11f2a504c4ead5f61981e9f3320","e61a6d319d7a402f8435c866c9e8584e"],"active_org_master_entity_id":["9e69a16cb488720675288e77dd41cd84"],"research_disease":["f60141249781464bb54bf1700c83143c","a622cec9c1e34e88a3c46c3b7fa00884","ce09181e978a4a3f9932f35001b9fa13","e78f809b697b4becaa8d265389638562","d7a26da8f1ff43559e34fe72da812c56","e89afc6a432744b1a88281329dc46d91","6ab030f07c1e4ab4ba6d23fdee898e09","1a51c709099840a381471343fb21c3a9","c17d3b80f53e409c930fc2d37ed244ec","8b4ec11f2a504c4ead5f61981e9f3320","e61a6d319d7a402f8435c866c9e8584e"],"inactive_org_master_entity_id":["3213232cf3774bc734def2420b679bb6"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677110400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}}],"disease_phase":[{"disease_id":"a622cec9c1e34e88a3c46c3b7fa00884","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e89afc6a432744b1a88281329dc46d91","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f60141249781464bb54bf1700c83143c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c17d3b80f53e409c930fc2d37ed244ec","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e78f809b697b4becaa8d265389638562","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e61a6d319d7a402f8435c866c9e8584e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"1a51c709099840a381471343fb21c3a9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8b4ec11f2a504c4ead5f61981e9f3320","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6ab030f07c1e4ab4ba6d23fdee898e09","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ce09181e978a4a3f9932f35001b9fa13","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["3213232cf3774bc734def2420b679bb6","9e69a16cb488720675288e77dd41cd84"],"data_source":10}
+{"drug_id":"0ca6befcd08744c7bbe91a71b621a807","docid":17567,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":11,"target_extend_id":"5dda89db055132f9b4718ad9d5af409b","created_ts":"2022-03-23T11:34:35.000Z","updated_ts":"2026-02-24T18:19:15.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"RP903","source_info":[{"code":"CXHL2200180 CXHL2200179","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE"}],"status":"ACTIVE"}],"dev_code":[{"name":"JS-105","source_info":[{"code":"CTR20233790","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bf63365270ea4ddba30b20629e7bb31f"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-alpha-inhibitor-js105"}],"status":"ACTIVE"},{"name":"JS105","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650013890&idx=2&sn=f4ab17c7f5a1900ff2914d6632f5d8aa"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-alpha-inhibitor-js105"}],"status":"ACTIVE"},{"name":"RP903","source_info":[{"code":"CXHL2200180 CXHL2200179","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["609086c24a0e6d724fdb349207b00424"],"mechanism_action_id":["eaee1c5527b3a91b4ee1e520963463f7"],"target_id":["fe5b12ba299a474b979d6ab1ddca7b4b"],"disease_id":["efcd50239bf745d7ae091c9542bde777","0464f5493b0444e9875a0584df17cbf0","e130bdf36b3d4432a317beddbd11d181","b42488c9ce3245988e4e93caf2b95590","6570754a6f0b43b78a9926c7bfd00519","07994e875a7f44dc9af7f9bf3f6989e5","f7b30eedfaa349cd9a79fdfb51de1ade"],"active_org_master_entity_id":["609086c24a0e6d724fdb349207b00424","626cdc4e9161b8ea7aa836f7aca998ad"],"research_disease":["efcd50239bf745d7ae091c9542bde777","0464f5493b0444e9875a0584df17cbf0","e130bdf36b3d4432a317beddbd11d181","b42488c9ce3245988e4e93caf2b95590","6570754a6f0b43b78a9926c7bfd00519","07994e875a7f44dc9af7f9bf3f6989e5","f7b30eedfaa349cd9a79fdfb51de1ade"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1762905600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"efcd50239bf745d7ae091c9542bde777","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f7b30eedfaa349cd9a79fdfb51de1ade","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e130bdf36b3d4432a317beddbd11d181","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["626cdc4e9161b8ea7aa836f7aca998ad","6d8c77d8ef57c426b969ecf3691f96f1"],"data_source":10}
+{"drug_id":"1722765b7e664bc1a3bb55e1830b5382","docid":80982,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-10-09T08:19:13.000Z","updated_ts":"2024-12-27T00:25:02.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ZM-01","source_info":[{"code":"NCT06066008","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06066008"}],"status":"ACTIVE"}],"dev_code":[{"name":"ZM 01","status":"ACTIVE"},{"name":"ZM01","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["e6de71731b1c152f689dc7299d11137c"],"disease_id":["87fe22d3ab8049b3896715faee6d6699"],"active_org_master_entity_id":["e6de71731b1c152f689dc7299d11137c"],"research_disease":["87fe22d3ab8049b3896715faee6d6699"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1664064000000}}],"disease_phase":[{"disease_id":"87fe22d3ab8049b3896715faee6d6699","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4ac3fcc55d8e4400a64beea3bdb5709f","docid":70623,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:49.000Z","updated_ts":"2024-11-09T18:45:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"NVK-006","status":"ACTIVE"}],"dev_code":[{"name":"NVK-006","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e6e4a27ded36c8bcacd33975d814fdb5"],"disease_id":["9a802adb6e94433f8f4eb9be678991b8"],"active_org_master_entity_id":["e6e4a27ded36c8bcacd33975d814fdb5"],"research_disease":["9a802adb6e94433f8f4eb9be678991b8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1645315200000}}],"disease_phase":[{"disease_id":"9a802adb6e94433f8f4eb9be678991b8","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"03d4727948954cde8edd101098f31eb1","docid":1670054,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-07-01T07:21:51.000Z","updated_ts":"2025-12-22T13:38:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"TP1001(Shengyuan Zetong)","status":"ACTIVE"}],"dev_code":[{"name":"TP1001","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["dab64f0eb30f5560cb3dc126613aa904"],"disease_id":["c978e6fcc5124517a590344200645b42"],"active_org_master_entity_id":["dab64f0eb30f5560cb3dc126613aa904"],"research_disease":["c978e6fcc5124517a590344200645b42"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1764288000000}}],"disease_phase":[{"disease_id":"c978e6fcc5124517a590344200645b42","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0409ea7c812a4e849346ca233e13ee51","docid":29940,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":14,"target_extend_id":"e7f39b5cc32e35e5aba4c17c76a04d6d","created_ts":"2021-10-08T14:37:10.000Z","updated_ts":"2025-07-17T03:28:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Tc99m-Heparin","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ace4268d1762b84fe0d91a2aaf15539b"],"mechanism_action_id":["c092988fbaca3d65d0890c2ec2ae15d5"],"target_id":["2a4c0ae5a65f4e5682f008e8f8336f2b"],"disease_id":["6523871da87f43e293400330b7514fb3"],"active_org_master_entity_id":["57d483f5d35bc5c1b455b990210068de"],"research_disease":["6523871da87f43e293400330b7514fb3"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1664582400000}}],"disease_phase":[{"disease_id":"6523871da87f43e293400330b7514fb3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"08c019e313a2426e928b034387a81a17","docid":72968,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1935,"target_extend_id":"e01cb77406723b4b8fbede4420511299","created_ts":"2021-10-08T14:41:16.000Z","updated_ts":"2026-04-18T21:04:14.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"GP-1681","status":"ACTIVE"}],"dev_code":[{"name":"CTO-1681","status":"ACTIVE"},{"name":"CTO1681","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://cytoagents.com/our-science/"}],"status":"ACTIVE"},{"name":"GP-1001","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["1f0988a46c49ca490625dc053df99a99"],"mechanism_action_id":["36fd9b6e773b6f6cb20db1d089b2f8e8"],"target_id":["123ae053565449148a273f4f77b6d400"],"disease_id":["4877fdea8af24861ac4d9dd0d5baab7f","84040e6e03744450831486ca2601402f","bc7466431f284849b17655ff5df80c26","2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["15ede34133096f7ddaa88c1dd1fb02e0"],"research_disease":["4877fdea8af24861ac4d9dd0d5baab7f","84040e6e03744450831486ca2601402f","bc7466431f284849b17655ff5df80c26"],"non_research_disease":["2a8a3f6ab7ec4061858144283e7ce0ca"],"inactive_org_master_entity_id":["1f0988a46c49ca490625dc053df99a99"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1703721600000}}],"disease_phase":[{"disease_id":"bc7466431f284849b17655ff5df80c26","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"84040e6e03744450831486ca2601402f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4877fdea8af24861ac4d9dd0d5baab7f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"07926ee2c6c948dd87b886fd513fd8a7","docid":1760524,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":35,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2025-08-13T07:39:59.000Z","updated_ts":"2026-03-28T21:05:27.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"BCMA/CD19 dual-target CAR","source_info":[{"code":"NCT07101705","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07101705"}],"status":"ACTIVE"}],"dev_code":[{"name":"OriV-508","source_info":[{"code":"NCT07101705","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07101705"}],"status":"ACTIVE"}],"drug_type":["cc10afbd78954c8db6d1d3fee0684a77"],"originator_org_master_entity_id":["9fc1cc4a46019d7182497925279073ad"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448"],"disease_id":["131c3f4dfc0c4a958e9f91166e73c913","7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["9fc1cc4a46019d7182497925279073ad"],"research_disease":["131c3f4dfc0c4a958e9f91166e73c913","7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1757289600000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"19bcbbfbe1d74f7fbeb816dee6943875","docid":25191,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-02-16T01:33:53.000Z","updated_ts":"2026-02-25T00:08:57.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"SONALA-001","source_info":[{"code":"NCT04559685","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04559685"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ALA","source_info":[{"code":"NCT04559685","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04559685"}],"status":"ACTIVE"}],"dev_code":[{"name":"SONALA 001","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aminolevulinic-acid-intravenous-formulation-sonala-001"}],"status":"ACTIVE"},{"name":"SONALA001","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aminolevulinic-acid-intravenous-formulation-sonala-001"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8d338bc52acf0167331ab99a884412b4"],"mechanism_action_id":["93ab4d349a2d23ee9edcd0fb4c8134bd"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["05554578204541148a5482ad5df4a600","fc0780b4f42b41d0a3dbbc522d0724dd","4c38270255bc4052a1a6d17475bdc51d","8f43e38cdd4e4794945b3ede3d6eaa4a","c429db71d4a441d9823a909208d8f08e","7f01022078fa4fba84854f1be2308064"],"active_org_master_entity_id":["8d338bc52acf0167331ab99a884412b4","ce1783471a7add837e1062d85249c974"],"research_disease":["05554578204541148a5482ad5df4a600","fc0780b4f42b41d0a3dbbc522d0724dd","4c38270255bc4052a1a6d17475bdc51d","8f43e38cdd4e4794945b3ede3d6eaa4a"],"non_research_disease":["c429db71d4a441d9823a909208d8f08e","7f01022078fa4fba84854f1be2308064"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1615766400000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7f01022078fa4fba84854f1be2308064","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"cf139751c1fd4a5892c786230e6f6b6a"},{"disease_id":"c429db71d4a441d9823a909208d8f08e","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"cf139751c1fd4a5892c786230e6f6b6a"},{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"fc0780b4f42b41d0a3dbbc522d0724dd","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8f43e38cdd4e4794945b3ede3d6eaa4a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"062cae168c6b45fbba6fb6c5c5c8eeb1","docid":262903,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"3d1673175263389181bb5e001f480d1f","created_ts":"2024-07-29T11:26:05.000Z","updated_ts":"2026-01-02T00:35:35.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SIR2501","source_info":[{"code":"CXHL2400758","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"attachment_path":"data/phs_source_info/519e/e2a9/87e6/8503/519ee2a987e68503.png","attachment_type":"image/png","code":"Sironax-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/55ab/2246/010b/c865/55ab2246010bc865.png","source":"Company pipeline","source_url":"https://www.sironax.com.cn/pipeline.php"}],"status":"ACTIVE"}],"dev_code":[{"name":"SIR2501","source_info":[{"attachment_path":"data/phs_source_info/519e/e2a9/87e6/8503/519ee2a987e68503.png","attachment_type":"image/png","code":"Sironax-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/55ab/2246/010b/c865/55ab2246010bc865.png","source":"Company pipeline","source_url":"https://www.sironax.com.cn/pipeline.php"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["32c8b1c6f0f6297454c25ae36f42bde2"],"mechanism_action_id":["4453951e14ca492eab813e504be9fb16"],"target_id":["893fbd15c99c4531969c22e0800f51c1"],"disease_id":["738546bac89e4895b89af01545f1b054","dfa0bf953a094901a32012e6ce76aa27","53f31b7756664bb9b3f7139f7aa9014e"],"active_org_master_entity_id":["32c8b1c6f0f6297454c25ae36f42bde2"],"research_disease":["738546bac89e4895b89af01545f1b054","dfa0bf953a094901a32012e6ce76aa27","53f31b7756664bb9b3f7139f7aa9014e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758672000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1717113600000}}],"disease_phase":[{"disease_id":"53f31b7756664bb9b3f7139f7aa9014e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"dfa0bf953a094901a32012e6ce76aa27","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"089bdea0828093c7b5fcf1b94dc85ba5","docid":111105,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","linker_id":"8d974cafe4b74ad7a8187e81a5702466","payload_id":"40d9551d08754d7a93296bd0fd2ff4ca","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"a0c97d36890831818aa8cab7f03b9517","created_ts":"2024-04-09T05:05:04.000Z","updated_ts":"2026-04-18T21:05:28.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"LY-4052031","source_info":[{"normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20272/presentation/8123"}],"status":"ACTIVE"}],"dev_code":[{"name":"LY 4052031","status":"ACTIVE"},{"name":"LY4052031","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99","e61bfdf805122a61eb614c340b3ec5db"],"target_id":["6acffb63799b4ba3bc85a4c59fcb05d7","b966ecd427644b59ac0ce2e1ff6e813a"],"adc_reference":[{"code":"10.1158/1538-7445.AM2024-1872","normalized_source_id":"071bfb0a-a707-4060-9676-fe3efcad9b1b","source":"Cancer Res","source_url":"https://doi.org/10.1158/1538-7445.AM2024-1872"},{"code":"2024_1872","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/84/6_Supplement/1872/739225/Abstract-1872-A-next-generation-treatment-for"}],"disease_id":["0464f5493b0444e9875a0584df17cbf0","d9c985ab1f04428493c029df6dca650d","8ef6c10e2dd54d2db65776a97e0bf2c2","f7ea24f0370d421480503e720310bf86","6c9c5be211cb4d72a28205c49a16d653","7af2742b1e824bb4bae223164df67757","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","f7a28558e1f244a8846ce00c6bf6ab25","6d17ae1fe17c4b6e99a17f6db3d7544e","6fe05469e09f4305b7615b2c277382cd","3428d019f74042c9b04557aaa3f597e2","f92e4ba771d04f27a1f4daae363b676a","4825a51fe5164f03aa7857ebe41392e8","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7","9d4592b3ad4fa5157a8ab5e38e6b0af4"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","d9c985ab1f04428493c029df6dca650d","8ef6c10e2dd54d2db65776a97e0bf2c2","f7ea24f0370d421480503e720310bf86","6c9c5be211cb4d72a28205c49a16d653","7af2742b1e824bb4bae223164df67757","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","f7a28558e1f244a8846ce00c6bf6ab25","6d17ae1fe17c4b6e99a17f6db3d7544e","6fe05469e09f4305b7615b2c277382cd","3428d019f74042c9b04557aaa3f597e2","f92e4ba771d04f27a1f4daae363b676a","4825a51fe5164f03aa7857ebe41392e8","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1773878400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}}],"disease_phase":[{"disease_id":"f7a28558e1f244a8846ce00c6bf6ab25","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4825a51fe5164f03aa7857ebe41392e8","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"8ef6c10e2dd54d2db65776a97e0bf2c2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6d17ae1fe17c4b6e99a17f6db3d7544e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7af2742b1e824bb4bae223164df67757","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3428d019f74042c9b04557aaa3f597e2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"42d7cc67ca153214ac94498a86c4559a","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["e61bfdf805122a61eb614c340b3ec5db"],"moiety_target_id":["b966ecd427644b59ac0ce2e1ff6e813a"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"19eb18f32ec74328a88570cdbaeb3d62","docid":21166,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-02-08T07:46:41.000Z","updated_ts":"2025-01-26T07:46:28.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"zhongxia","drug_name":[{"lang":"EN","name":"CARDIX-101","source_info":[{"code":"NCT05117346","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05117346"}],"status":"ACTIVE"}],"dev_code":[{"name":"CARDIX-101A","source_info":[{"code":"NCT05117346","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05117346"}],"status":"ACTIVE"},{"name":"CARDIX-101B","source_info":[{"code":"NCT05117346","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05117346"}],"status":"ACTIVE"},{"name":"CARDIX-101C","source_info":[{"code":"NCT05117346","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05117346"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"disease_id":["ccb8948209484dec970cd5fd993e7851"],"active_org_master_entity_id":["a7c59168996a791ef4e435ddade788e8"],"research_disease":["ccb8948209484dec970cd5fd993e7851"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1669852800000}}],"disease_phase":[{"disease_id":"ccb8948209484dec970cd5fd993e7851","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"100dec7d2f4446a39f937c7e1f0a7d2e","docid":51609,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":2,"target_extend_id":"8f8e0ac9f16b3e1996806ad97c5525c8","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:44.000Z","updated_ts":"2026-04-02T11:57:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Setrusumab","status":"ACTIVE"}],"dev_code":[{"name":"BPS-804","status":"ACTIVE"},{"name":"MOR-05813","status":"ACTIVE"},{"name":"NOV-3","status":"ACTIVE"},{"name":"UX143","status":"ACTIVE"}],"drugbank_id":["DB14778"],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["cc1ed7dd50c455ab17cfca37e3bc9ffc"],"mechanism_action_id":["0e4257ab8b7c65be32e5faf2504984d6"],"target_id":["f6b2e3ac052248a6865358ce963acdf3"],"special_review":["425d71b560a7499087c4f5a36692741c","b7d7a459842543b7913979bf604084e4","c3c948340a7d40f3b7437081f5e8cb4e","043a131d85994801b3617e822e7f87b3"],"disease_id":["38610ba1d93a47dc87ec12f9bb0dbfe7","d897a4ecfb274e60b8830f3bb0f18650","b18aaff5a4494dd0a0495922f5a3b30c","2b6e9bb0ecb54530bbe077417e1234f4","7b34c4c341a74b9984deff61be03c587","1713121f9e9b412d9495f3a785ec61c4"],"active_org_master_entity_id":["b38b0ee39b29016f1daa2341f90e049d","4cacd78a57b08d67fa9a42dd08dd53f0"],"research_disease":["38610ba1d93a47dc87ec12f9bb0dbfe7","d897a4ecfb274e60b8830f3bb0f18650","b18aaff5a4494dd0a0495922f5a3b30c"],"non_research_disease":["2b6e9bb0ecb54530bbe077417e1234f4","7b34c4c341a74b9984deff61be03c587","1713121f9e9b412d9495f3a785ec61c4"],"inactive_org_master_entity_id":["748edba0a3a4bbaee72b1c213a940053"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1729814400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba"},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1645401600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1645401600000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1668211200000}}],"disease_phase":[{"disease_id":"d897a4ecfb274e60b8830f3bb0f18650","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2b6e9bb0ecb54530bbe077417e1234f4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b18aaff5a4494dd0a0495922f5a3b30c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7b34c4c341a74b9984deff61be03c587","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"1713121f9e9b412d9495f3a785ec61c4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"38610ba1d93a47dc87ec12f9bb0dbfe7","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["748edba0a3a4bbaee72b1c213a940053","a9cbfed1923b3dee3eabcbeda726dc0e","b38b0ee39b29016f1daa2341f90e049d"],"if_speculate":0,"data_source":10}
+{"drug_id":"2fc3c6edd3594a00a58236a358e97fb4","docid":63683,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2023-03-02T05:30:57.000Z","updated_ts":"2024-11-08T16:44:42.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"GP-708","status":"ACTIVE"}],"dev_code":[{"name":"GP-708","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["cae2e780142dc38fe3a17046f739c048"],"disease_id":["25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["cae2e780142dc38fe3a17046f739c048"],"research_disease":["25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1665532800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1665532800000}}],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"001e20189d9a4ad9ba2df1367458a94b","docid":5431,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1364515200000,"rnk":28,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2021-10-08T14:49:43.000Z","updated_ts":"2025-05-24T00:19:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1364515200000,"drug_name":[{"lang":"CN","name":"精蛋白重组人胰岛素 (BIOTON)","status":"ACTIVE"},{"lang":"EN","name":"Isophane Protamine Recombinant Human Insulin (BIOTON)","status":"ACTIVE"}],"trade_name":[{"name":"Scilin N","source_info":[{"code":"国药准字SJ20171027","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MWJjYzlhMTU0YjRhNWU1YjczYzViYzUxOTQ4MzBhYzMmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4NjY1NzExODAw"}],"status":"ACTIVE"},{"name":"重和林N","source_info":[{"code":"国药准字SJ20171027","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MWJjYzlhMTU0YjRhNWU1YjczYzViYzUxOTQ4MzBhYzMmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4NjY1NzExODAw"}],"status":"ACTIVE"}],"drug_type":["aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["86545504451d90811d5f4f6266da5db9"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"atc_code":["09644f2bce324dd8931e37feac825793"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["86545504451d90811d5f4f6266da5db9"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["0d05187284b446c5803cce38a3e53ebf"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1364515200000}}],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"06a9d1c4c12140fcb9be23efbe246b79","docid":80824,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":21,"target_extend_id":"da2d843b2371377b9fd94bb66d24c2f1","created_ts":"2023-09-28T09:00:14.000Z","updated_ts":"2026-04-20T00:08:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ITM-55D","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/research-development/"}],"status":"ACTIVE"}],"dev_code":[{"name":"18F-ITM55D","status":"ACTIVE"},{"name":"ITM 55D","status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["73a71a4b938dfe77120f34aae93b1774"],"mechanism_action_id":["d481cf2933e4f2e1b5db036fe95dcef4"],"target_id":["e0dab97ac1614355be22b937bcecf781"],"disease_id":["3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e"],"active_org_master_entity_id":["73a71a4b938dfe77120f34aae93b1774"],"research_disease":["3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"089b7c907a4b48df93ee79efa9bb7e70","docid":39002,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":10,"target_extend_id":"cc29b75dfabf3b10859a70c5fa359385","created_ts":"2022-08-11T05:56:34.000Z","updated_ts":"2025-05-10T21:16:06.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wangya","drug_name":[{"lang":"EN","name":"VD-1219","source_info":[{"code":"CXHL2200565","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"VD 1219","status":"ACTIVE"},{"name":"VD1219","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a7da11f65a5308937fed470148488e74"],"mechanism_action_id":["80deb151684849fd9516dcdf0044a51e"],"target_id":["8f23e37df748406dbb6310b82cec77fc"],"disease_id":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"active_org_master_entity_id":["a7da11f65a5308937fed470148488e74"],"research_disease":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1695254400000}}],"disease_phase":[{"disease_id":"f196ef1a4d9c4cb3aede0ea60aac4a52","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0531a0df90854ec6897b2c5f807c2daf","docid":68822,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:44.000Z","updated_ts":"2024-10-30T10:20:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","drug_name":[{"lang":"CN","name":"滋肾壮骨片","status":"ACTIVE"},{"lang":"EN","name":"Zishen Zhuanggu Tablets","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["58c2c01af8f4402b9a2c1739eef40db5"],"active_org_master_entity_id":["58e0dfebbc1c7b4855d5a865e9f2c2a2","7e3da5e0883733850b50afe115371ee3"],"research_disease":["58c2c01af8f4402b9a2c1739eef40db5"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1422230400000}}],"disease_phase":[{"disease_id":"58c2c01af8f4402b9a2c1739eef40db5","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"02975957b05a41c1b5bbadfde86d8d16","docid":65823,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-06-29T02:49:57.000Z","updated_ts":"2026-01-07T03:40:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HiD-2102","source_info":[{"attachment_path":"data/phs_source_info/816c/f54d/5315/fa1a/1a0781f3-4308-3773-bc66-9ff908f7f3ec.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/ba30/1b95/ed32/c5b3/40a23c97-c689-3cb9-9308-bea8565ec504.png","source":"Company pipeline","source_url":"http://hidiamondbio.com/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"HiD 2102","status":"ACTIVE"},{"name":"HiD2102","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["17d1187803891ce11bce77f9e819a04b"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["17d1187803891ce11bce77f9e819a04b"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7"}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1cfa6504f0ab4328b550f57c88a7844b","docid":32686,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":8,"target_extend_id":"3928103bdb3c3c0387c3d0caaa5965c1","created_ts":"2022-05-09T02:48:14.000Z","updated_ts":"2026-02-07T21:10:24.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LM-101","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.lanovamedicines.com/"}],"status":"ACTIVE"}],"dev_code":[{"name":"LM 101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.lanovamedicines.com/"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-sirpa-monoclonal-antibody-lm-101"}],"status":"ACTIVE"},{"name":"LM-101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.lanovamedicines.com/"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-sirpa-monoclonal-antibody-lm-101"}],"status":"ACTIVE"},{"name":"LM101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.lanovamedicines.com/"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-sirpa-monoclonal-antibody-lm-101"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["0692f07ceae745d358cad53df0fb7a07"],"mechanism_action_id":["5c4245a94c59f64f733f58bc3c4a5ece"],"target_id":["b94ae28f2cd44386b20b30a85e997db3"],"disease_id":["6570754a6f0b43b78a9926c7bfd00519","131c3f4dfc0c4a958e9f91166e73c913","0464f5493b0444e9875a0584df17cbf0","7665e5683a1a443a8f3d3b946d4c9ca2","a425e59e374549b7bd0f75605eba80c8","c7fe8aa844d24e85ba32a990ea28ded3"],"active_org_master_entity_id":["0692f07ceae745d358cad53df0fb7a07"],"research_disease":["6570754a6f0b43b78a9926c7bfd00519","131c3f4dfc0c4a958e9f91166e73c913","0464f5493b0444e9875a0584df17cbf0","7665e5683a1a443a8f3d3b946d4c9ca2","a425e59e374549b7bd0f75605eba80c8","c7fe8aa844d24e85ba32a990ea28ded3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606","5b1dfc2ca8564662860187aef864467d","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1676505600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1673395200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1659312000000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a425e59e374549b7bd0f75605eba80c8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["0692f07ceae745d358cad53df0fb7a07","73250f6c999409db2de831bb536cf07c"],"data_source":10}
+{"drug_id":"0beaaefbbb9543b5b5304290331056a5","docid":11064,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:23.000Z","updated_ts":"2024-11-29T07:15:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"HPI-287","status":"ACTIVE"}],"dev_code":[{"name":"HPI-287","status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["9c8340f84a245fb4e424f1dc19593fcf"],"disease_id":["cccdb6765c4e49e3b0434bc18da695e7"],"active_org_master_entity_id":["9c8340f84a245fb4e424f1dc19593fcf"],"research_disease":["cccdb6765c4e49e3b0434bc18da695e7"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1645401600000}}],"disease_phase":[{"disease_id":"cccdb6765c4e49e3b0434bc18da695e7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"279107c49be344fdb89261b94d4793a5","docid":75678,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:51.000Z","updated_ts":"2024-10-30T10:21:31.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PIPE-LPA1","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["02cdcc42c4e1eeabdecee44ad93acd2c"],"disease_id":["4f326ddd20e4476b93d077e5ee1f24d0"],"active_org_master_entity_id":["02cdcc42c4e1eeabdecee44ad93acd2c"],"research_disease":["4f326ddd20e4476b93d077e5ee1f24d0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1648944000000}}],"disease_phase":[{"disease_id":"4f326ddd20e4476b93d077e5ee1f24d0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"009172180b8e4d3286945301b095a7b8","docid":234896,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":20,"target_extend_id":"10831210edeb3ebe8236508fef67ab9d","created_ts":"2025-01-16T08:23:33.000Z","updated_ts":"2026-02-14T21:10:23.000Z","data_status":"ACTIVE","created_by":"zhoumeng@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"AT-101 (A28 Therapeutics)","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://a28therapeutics.com/technology/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AT-101","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://a28therapeutics.com/technology/"}],"status":"ACTIVE"}],"drug_type":["f14cfb7f58c94058be35780bf372123f"],"originator_org_master_entity_id":["c593a40de87e7f57b6902bca57da8e48"],"mechanism_action_id":["83d35a5eacdeabe7c77c44dfb601bc70"],"target_id":["6d2d46616ec9474397265de0ece27442"],"disease_id":["c297238c41b2488abe3de6546b105a4e","15839db0de0947ddb9e4c280884a3895"],"active_org_master_entity_id":["c593a40de87e7f57b6902bca57da8e48"],"research_disease":["c297238c41b2488abe3de6546b105a4e","15839db0de0947ddb9e4c280884a3895"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1735689600000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"10831210edeb3ebe8236508fef67ab9d","moiety_mechanism_action_id":["83d35a5eacdeabe7c77c44dfb601bc70"],"moiety_target_id":["6d2d46616ec9474397265de0ece27442"]}
+{"drug_id":"078d7cb3866c455e981d9b806686a058","docid":202698,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-07-11T09:41:57.000Z","updated_ts":"2024-12-27T00:25:16.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CBE-161","source_info":[{"attachment_path":"data/phs_source_info/ae70/9ade/555f/37fa/785e2b62-2287-3c89-9baf-b6db1440feb4.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7fe/cbff/798a/5e57/798f3cf1-bf9d-38df-a394-c0ec39909c12.png","source":"Company pipeline","source_url":"https://calibr.scripps.edu/our-pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"CBE 161","source_info":[{"attachment_path":"data/phs_source_info/ae70/9ade/555f/37fa/785e2b62-2287-3c89-9baf-b6db1440feb4.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7fe/cbff/798a/5e57/798f3cf1-bf9d-38df-a394-c0ec39909c12.png","source":"Company pipeline","source_url":"https://calibr.scripps.edu/our-pipeline/"}],"status":"ACTIVE"},{"name":"CBE161","source_info":[{"attachment_path":"data/phs_source_info/ae70/9ade/555f/37fa/785e2b62-2287-3c89-9baf-b6db1440feb4.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a7fe/cbff/798a/5e57/798f3cf1-bf9d-38df-a394-c0ec39909c12.png","source":"Company pipeline","source_url":"https://calibr.scripps.edu/our-pipeline/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3a6db0580ddb5a4c86850d7c2b8749d1"],"disease_id":["a20fd10e00e8460ca8d5cb227360d09c"],"active_org_master_entity_id":["3a6db0580ddb5a4c86850d7c2b8749d1"],"research_disease":["a20fd10e00e8460ca8d5cb227360d09c"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"disease_phase":[{"disease_id":"a20fd10e00e8460ca8d5cb227360d09c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"07de3539273b47adbda990e35cba623f","docid":73127,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":4,"target_extend_id":"f2ec6395820a3e79b7516b2c0460e135","created_ts":"2022-03-18T09:17:35.000Z","updated_ts":"2026-02-25T00:56:57.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"BN-104","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.bionovapharma.com/pipeline/pipeline.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"BN 104","status":"ACTIVE"},{"name":"BN104","status":"ACTIVE"},{"name":"BNM-1192","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.com/bn-104.html?srsltid=AfmBOopWVAyM0gZqdYXBawMyfSatMDPa8IepSSw1DJH-DTMeIchGUcKC"}],"status":"ACTIVE"},{"name":"BNM1192","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.com/bn-104.html?srsltid=AfmBOopWVAyM0gZqdYXBawMyfSatMDPa8IepSSw1DJH-DTMeIchGUcKC"}],"status":"ACTIVE"},{"name":"S-243249","source_info":[{"attachment_path":"data/phs_source_info/f2d0/cac0/c426/1336/f2d0cac0c4261336.png","attachment_type":"image/png","code":"Servier-202506","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/438f/d290/818d/c9d1/438fd290818dc9d1.png","source":"Company pipeline","source_url":"https://servier.com/en/research-innovation/our-development-pipeline/"}],"status":"ACTIVE"},{"name":"S243249","source_info":[{"attachment_path":"data/phs_source_info/f2d0/cac0/c426/1336/f2d0cac0c4261336.png","attachment_type":"image/png","code":"Servier-202506","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/438f/d290/818d/c9d1/438fd290818dc9d1.png","source":"Company pipeline","source_url":"https://servier.com/en/research-innovation/our-development-pipeline/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["510286335d2b7829aa997e40a3832148"],"mechanism_action_id":["fd92fd7d68e89a87aea4c4dab1b103e1"],"target_id":["a50fde4d700d44528bdd0daa3a6f2a61"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","c3c948340a7d40f3b7437081f5e8cb4e","043a131d85994801b3617e822e7f87b3"],"disease_id":["b5023063754040d7bd79ec921ed8889c","352be760a2d64383a83cb200d223e55e","a4afc28011454f2ca2f48f95f242a04f","1d78cca79eae4632bc4464c90a574f83","7cb6983b4169498e89b08fd725a22b46","774c47a9cc904667a74dabe8fa53fc40","e2251a2774ee4eff8723a33fc035d809","224620d4ffab40a0b52cd669ef7f7011","42487eb0fc9b4a488cf6e57bda7433dd"],"active_org_master_entity_id":["942bd681ad69067d4f44b1ff404acc6b","510286335d2b7829aa997e40a3832148","6184b7e07741a24b9e904bf49029128b","3eba591ce225f3a77d08c74dce995227"],"research_disease":["b5023063754040d7bd79ec921ed8889c","352be760a2d64383a83cb200d223e55e","a4afc28011454f2ca2f48f95f242a04f","1d78cca79eae4632bc4464c90a574f83","7cb6983b4169498e89b08fd725a22b46","774c47a9cc904667a74dabe8fa53fc40","e2251a2774ee4eff8723a33fc035d809","224620d4ffab40a0b52cd669ef7f7011","42487eb0fc9b4a488cf6e57bda7433dd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1754006400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1695254400000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"352be760a2d64383a83cb200d223e55e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"224620d4ffab40a0b52cd669ef7f7011","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b5023063754040d7bd79ec921ed8889c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"774c47a9cc904667a74dabe8fa53fc40","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"42487eb0fc9b4a488cf6e57bda7433dd","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e2251a2774ee4eff8723a33fc035d809","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["510286335d2b7829aa997e40a3832148","942bd681ad69067d4f44b1ff404acc6b"],"if_speculate":0,"data_source":10}
+{"drug_id":"0d0f50925d7d455cb8008beced1e7e39","docid":66455,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1530748800000,"rnk":2,"target_extend_id":"348d5b3776a235efb2944d1b7949b5c8","created_ts":"2021-10-08T14:49:49.000Z","updated_ts":"2026-04-02T23:26:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","first_approved_date_cn":1649376000000,"drug_name":[{"lang":"CN","name":"替戈拉生","status":"ACTIVE"},{"lang":"EN","name":"Tegoprazan","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"K-CAB","status":"ACTIVE"},{"lang":"CN","name":"特戈拉赞","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.cs.com.cn/ssgs/gsxw/202006/t20200630_6071852.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"446","source_info":[{"code":"CTR20260620","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=486b806c8bf04f9b9dd0d9a8f6e39c07"}],"status":"ACTIVE"},{"name":"BLI-5100","status":"ACTIVE"},{"name":"CJ-12420","status":"ACTIVE"},{"name":"IN-A001","status":"ACTIVE"},{"name":"IN-C004","source_info":[{"code":"NCT04654065","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04654065"}],"status":"ACTIVE"},{"name":"LXI-15028","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://money.finance.sina.com.cn/corp/view/vCB_AllBulletinDetail.php?stockid=002793&id=6155017"}],"status":"ACTIVE"},{"name":"RQ-00000004","status":"ACTIVE"},{"name":"RQ-4","status":"ACTIVE"}],"trade_name":[{"name":"PCAB","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/dr-reddys-launches-innovative-acid-blocker-tegoprazan-in-india/123932808?utm_source=top_news&utm_medium=sectionListing"}],"status":"ACTIVE"},{"name":"泰欣赞","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.cs.com.cn/ssgs/gsxw/202204/t20220414_6260084.html"}],"status":"ACTIVE"}],"drugbank_id":["DB16690"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"mechanism_action_id":["d0cc3c29eb148fe07feccce6ea7cafec"],"target_id":["d154ffe1ed2847e6a1dc649f8a570a5b"],"atc_code":["201195b6437a468d88ab277568bfa42c"],"disease_id":["b932eb420c6e42139e3402651804c66e","801770be2c414ae5a15289e29f2d3345","3d3b4d85d52b4602a56b144086f40148","04d4209bd6bc4901ab59848d96c0623b","53b0789eac574b90a2d1ebe94d10a166","204e0fe514054896af8d61ef1025b62d","c624831e82eb4e149289223f037d38bf","4d5ee75f79514e3dbbba26473ea2d9b6","e9a93e0e1460463f9b07c8be368f5f1f","4c29fbf49e3645d2a1a1fe38d637f27d","d626b37675454888aa36de00ba898cc8"],"active_org_master_entity_id":["f4c743047d2d8020deb8298a859cd19a","33b1ffe9d28870ff46a51b0fb9c62e5b","cbd775ebf63985aaf784615205f805fa","1cc9fb258019e64abc142368cb2b13d5","3cea3d47db3719e44a7b1c9075ace9d5","0d854e9b4bc4ec17b3eeb3c991800bf1"],"first_approved_country":["52d1b118-b540-37ba-9cb2-f5aff686bb10"],"first_approved_indication":["204e0fe514054896af8d61ef1025b62d","c624831e82eb4e149289223f037d38bf"],"research_disease":["b932eb420c6e42139e3402651804c66e","801770be2c414ae5a15289e29f2d3345","3d3b4d85d52b4602a56b144086f40148","04d4209bd6bc4901ab59848d96c0623b","53b0789eac574b90a2d1ebe94d10a166","204e0fe514054896af8d61ef1025b62d","c624831e82eb4e149289223f037d38bf","4d5ee75f79514e3dbbba26473ea2d9b6","e9a93e0e1460463f9b07c8be368f5f1f","4c29fbf49e3645d2a1a1fe38d637f27d","d626b37675454888aa36de00ba898cc8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","2f753928-f426-3cc1-9ea6-8c25f6a4d330","52d1b118-b540-37ba-9cb2-f5aff686bb10"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1729036800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1699920000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1649376000000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1758067200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1530748800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1767916800000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"78c45f1d523646808032edcff807ca59"},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"4c29fbf49e3645d2a1a1fe38d637f27d","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"53b0789eac574b90a2d1ebe94d10a166","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3d3b4d85d52b4602a56b144086f40148","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"4d5ee75f79514e3dbbba26473ea2d9b6","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"e9a93e0e1460463f9b07c8be368f5f1f","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"d626b37675454888aa36de00ba898cc8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b932eb420c6e42139e3402651804c66e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"801770be2c414ae5a15289e29f2d3345","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"204e0fe514054896af8d61ef1025b62d","highest_phase_before_ter_cn":"78c45f1d523646808032edcff807ca59","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c624831e82eb4e149289223f037d38bf","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"04d4209bd6bc4901ab59848d96c0623b","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["0d854e9b4bc4ec17b3eeb3c991800bf1","1cc9fb258019e64abc142368cb2b13d5","2573b4ede92666fe05b77015e5c4672e","3a39470908bd571733b7825ea6430e31","3cea3d47db3719e44a7b1c9075ace9d5","4b470c75f477bf35c13e51f8e187fe6c","923c351a9893f6636178ced466643234","af89c553826f123ae6ba3f39aa66c9c5","bc36332ac9d1f64fbcd466c296b172b3","bf3d8823b61ba24142aa13b47d67d537","cbd775ebf63985aaf784615205f805fa","d1aa55b657c88fda701265b4de3c9a96","f4c743047d2d8020deb8298a859cd19a"],"if_speculate":0,"data_source":10}
+{"drug_id":"318794216d874b9fa07cdd89b1c574b3","docid":72336,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"779ec95f43c939b7b7c45eb11a104a5c","created_ts":"2021-10-08T14:47:59.000Z","updated_ts":"2026-02-24T21:39:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"米拉贝隆/琥珀酸索利那新","status":"ACTIVE"},{"lang":"EN","name":"Mirabegron/Solifenacin Succinate","status":"ACTIVE"}],"dev_code":[{"name":"EB-178","status":"ACTIVE"},{"name":"YM178/YM905","status":"ACTIVE"}],"related_component":["81e5cd499e7547eb92d48ba6c49bc768","b5447ebae2d84c0e8013af58f346604f"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["80526e59ddbdf2ee3924ea0c2caf25c5"],"mechanism_action_id":["3d4fa5af694a1b4712e52b603e65edc5","70daddcdabb4f1bd96a8a3e62a22db3e"],"target_id":["c976f8a204a642e4b3a58682c55c5455","09f3cf69881e4348ab334c341eaa0dde"],"atc_code":["6817139f6bfd4e08a3112ef578ccbf8d"],"disease_id":["66ce65d2ad3e456bab0414cf8248f55b","807f280076314d958dd610d6e19d1692"],"active_org_master_entity_id":["cd347379d839ed6064e5ae19d48a0a8b","9dde29d407e2b1dbf241a58a497c0655","920b843fed733fbb1fb88647373c4c89"],"research_disease":["66ce65d2ad3e456bab0414cf8248f55b","807f280076314d958dd610d6e19d1692"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1769644800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1409011200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"ba5f77a3-321f-3e45-91fc-4ff21b4edad7","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"b0e1cb77-7cf7-3c20-a846-3e377b838cfa","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1386028800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1634774400000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"66ce65d2ad3e456bab0414cf8248f55b","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"807f280076314d958dd610d6e19d1692","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"09143186ce904e0f860c5821f385fbc7","docid":73128,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-03-02T05:30:59.000Z","updated_ts":"2024-11-06T13:09:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"VRP-I012","status":"ACTIVE"}],"dev_code":[{"name":"VRP-I012","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["bd6cb0744d3cab06b86a0bde035dd858"],"disease_id":["25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["bd6cb0744d3cab06b86a0bde035dd858"],"research_disease":["25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1661904000000}}],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0429bbaf80df47c0b41f7f6ad969f4ab","docid":35666,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"c15f8678ac1c3cdf8855119a177033ff","created_ts":"2023-05-09T06:53:16.000Z","updated_ts":"2025-01-26T07:46:16.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"dualCAR-NK19/70 cell(Shanghai Tongji Hospital)","source_info":[{"code":"NCT05842707","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05842707"}],"status":"ACTIVE"}],"drug_type":["8554bd286df144c39af9350c62a5b309"],"originator_org_master_entity_id":["e79a45af9e26adb1b3d4065e592060dc"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","e0a0b70f83bc40c2b45d872d0fe4b7d4","dfe37d566f9caa8f0037337e91887158","a3426fcb9c77fd99d0461848fe75fb8f"],"target_id":["5eb1fc5283d34305934a031af530f448","79d24e30a7ff40bb806ff36962c750e8"],"disease_id":["06fb65d06e024491946f34384f1bae67","4c9d46b2b7794d128b14d8689f4c357d"],"active_org_master_entity_id":["e79a45af9e26adb1b3d4065e592060dc"],"research_disease":["06fb65d06e024491946f34384f1bae67","4c9d46b2b7794d128b14d8689f4c357d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1674000000000}}],"disease_phase":[{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"06fb65d06e024491946f34384f1bae67","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"06db586fd3234016befdd3941eb3a3a8","docid":16907,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-07-07T06:19:00.000Z","updated_ts":"2025-03-04T08:24:18.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"sunying","drug_name":[{"lang":"CN","name":"净斯本草饮","source_info":[{"normalized_source_id":"e327c7fe232e4b3ba172121614cef0ba","source":"MANUAL"}],"status":"ACTIVE"},{"lang":"EN","name":"Jing Si herbal tea","source_info":[{"code":"NCT05436938","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05436938"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["1c77557dc135a06906a8ea3e6517b615"],"disease_id":["b52e20ecc260479ba434992b125c243c","486c4f5995ae4425a9c98a48d22c84c8"],"active_org_master_entity_id":["1c77557dc135a06906a8ea3e6517b615"],"research_disease":["b52e20ecc260479ba434992b125c243c","486c4f5995ae4425a9c98a48d22c84c8"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1640995200000}}],"disease_phase":[{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b52e20ecc260479ba434992b125c243c","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"062bea0bba344e7e9b4bf8a02e75cfa7","docid":75162,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1748304000000,"rnk":2,"target_extend_id":"6f40321346393d15829fedc73424efe8","created_ts":"2021-10-08T14:45:38.000Z","updated_ts":"2026-04-02T16:41:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1748304000000,"drug_name":[{"lang":"CN","name":"盐酸吉卡昔替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI5Njk2ODkwMg==&mid=2247486744&idx=1&sn=b0ccccc84029cbb2fa007977bc20be7d"}],"status":"ACTIVE"},{"lang":"EN","name":"Jaktinib Hydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Gecacitinib Hydrochloride","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI5Njk2ODkwMg==&mid=2247486744&idx=1&sn=b0ccccc84029cbb2fa007977bc20be7d"}],"status":"ACTIVE"},{"lang":"EN","name":"Jakotinib hydrochloride","status":"ACTIVE"},{"lang":"EN","name":"Jaktinib","status":"ACTIVE"},{"lang":"EN","name":"Jaktinib dihydrochloride monohydrate","status":"ACTIVE"},{"lang":"CN","name":"杰克替尼二盐酸盐一水合物","source_info":[{"code":"CXHL1600112","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"CN","name":"盐酸杰克替尼","status":"ACTIVE"}],"trade_name":[{"name":"泽普平","source_info":[{"normalized_source_id":"09a9e2414846487c9e66f4bfca02cea9","source":"NMPA_NEWS","source_url":"https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20250529152155157.html"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["789cd096fd3eb00450dccb1fe6b04f24"],"mechanism_action_id":["5f5e0563a81f2d5d04703799942dff44","5319d0b9180f0b12957d61cde7932a27","9b727283886bf27919754e9853eed999"],"target_id":["10fb9d32f0e44458a308538ca21be6a6","471b7ac440a64d3cbf2d5d01f274f7b5","75baf324563b4c8ab7eaac21da3a9fb8"],"special_review":["043a131d85994801b3617e822e7f87b3","9eb8777c62af4712932b360e6ef3e454"],"disease_id":["bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868","061a5c6c24164fadb7fa15fc1d303e75","8da973b225c24afbba255413635fb240","116fbe2167a648e6b4ca70ccdfb4af57","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","717a9bf79e584830859595b8dbe9d433","63333c316c3b493487303520d1e0c9d8","0464f5493b0444e9875a0584df17cbf0","a0304a462da04e7cb03e3f2c5625544e","26535c6f16de4adfb19f0154be738535","a496b17f52324c86838c2812c3066404","b01483d216fd4777973c6583bbd58d90","c8d0737fa2ac4421bf1538bc54b22ce1","c5e1987e283c495aaab2a8d309c6085e","41fd66016afd465a83e2aa4b01c7b657","a4553a07d41b47b3aa96442a0f718303","e9b27c71d3024fd6ab7dc1dfc304f54d","68fd19fa7cd24439a6f5d31f72d02675","5931830edf004694b27fec1d915b3784","1a95630392584c7892bec2dc9888cbfc","6be96778ed424f8d91de00ab82364114","170144d041c9427a8cfe5e542c2014c7"],"active_org_master_entity_id":["789cd096fd3eb00450dccb1fe6b04f24"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868"],"research_disease":["bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868","061a5c6c24164fadb7fa15fc1d303e75","8da973b225c24afbba255413635fb240","116fbe2167a648e6b4ca70ccdfb4af57","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","717a9bf79e584830859595b8dbe9d433","63333c316c3b493487303520d1e0c9d8","0464f5493b0444e9875a0584df17cbf0","a0304a462da04e7cb03e3f2c5625544e","26535c6f16de4adfb19f0154be738535","a496b17f52324c86838c2812c3066404","b01483d216fd4777973c6583bbd58d90","c8d0737fa2ac4421bf1538bc54b22ce1","c5e1987e283c495aaab2a8d309c6085e"],"non_research_disease":["41fd66016afd465a83e2aa4b01c7b657","a4553a07d41b47b3aa96442a0f718303","e9b27c71d3024fd6ab7dc1dfc304f54d","68fd19fa7cd24439a6f5d31f72d02675","5931830edf004694b27fec1d915b3784","1a95630392584c7892bec2dc9888cbfc","6be96778ed424f8d91de00ab82364114","170144d041c9427a8cfe5e542c2014c7"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","948c9548c2ed46b5865b8693f7f96604","62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1748304000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1662249600000}}],"disease_phase":[{"disease_id":"061a5c6c24164fadb7fa15fc1d303e75","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"bb2d2cb31a9b4c9687a2fc8194b7ddbb","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"68fd19fa7cd24439a6f5d31f72d02675","highest_phase_before_ter_cn":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_before_ter_global":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b01483d216fd4777973c6583bbd58d90","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"63333c316c3b493487303520d1e0c9d8","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f9411c5705084810ac5fffbb524c86c9","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"41fd66016afd465a83e2aa4b01c7b657","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"1c62320dcc394fea8c8ac97b04ccf868","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"116fbe2167a648e6b4ca70ccdfb4af57","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a496b17f52324c86838c2812c3066404","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"e9b27c71d3024fd6ab7dc1dfc304f54d","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"170144d041c9427a8cfe5e542c2014c7","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a4553a07d41b47b3aa96442a0f718303","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"5931830edf004694b27fec1d915b3784","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c8d0737fa2ac4421bf1538bc54b22ce1","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"if_speculate":0,"data_source":10}
+{"drug_id":"05174d1c6150471ca6ee94a0befd9f25","docid":349961,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-09-25T09:57:48.000Z","updated_ts":"2024-11-29T07:03:39.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"(Autologous Fecal Microbiota Transplantation(Rutgers State University of New Jersey)","source_info":[{"code":"NCT06609980","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06609980"}],"status":"ACTIVE"}],"drug_type":["c6c79e0153624f09a88202767aae3926"],"originator_org_master_entity_id":["dfecdeefdba01191fed7c1fec2562766"],"disease_id":["22b3750a031d4371925ef2561b93b291"],"active_org_master_entity_id":["dfecdeefdba01191fed7c1fec2562766"],"research_disease":["22b3750a031d4371925ef2561b93b291"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1722470400000}}],"disease_phase":[{"disease_id":"22b3750a031d4371925ef2561b93b291","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0d55407135a34a1fa61730e03124a59e","docid":202830,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"d81bdf4ce27c31b7bce00da6d4c2408c","created_ts":"2024-07-19T08:01:16.000Z","updated_ts":"2026-03-21T21:10:03.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"CD19&CD20 bispecific CAR-T cells(Hebei Taihe Chunyu Biotechnology)","source_info":[{"code":"NCT06503094","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06503094"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["49e7b893d0d72dac631f99b43429298a"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","16b5dca2ef00478ba4719851807e1c05"],"target_id":["5eb1fc5283d34305934a031af530f448","8b4260187fa64823b593f35188526e50"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","1b969bf36fe146598279d284e09e1d42","27c81d33df044a648187f81864221799","2e7d2d244b984bcb9206d68231d6001f","321c439bbe614dc2afd13cb803a48cec","e10523d5d50e41f6841de149d8b794b7","570b3cb9d08246788a5c1ccfc4ab5b09"],"active_org_master_entity_id":["49e7b893d0d72dac631f99b43429298a"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","1b969bf36fe146598279d284e09e1d42","27c81d33df044a648187f81864221799","2e7d2d244b984bcb9206d68231d6001f","321c439bbe614dc2afd13cb803a48cec","e10523d5d50e41f6841de149d8b794b7","570b3cb9d08246788a5c1ccfc4ab5b09"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1731110400000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"570b3cb9d08246788a5c1ccfc4ab5b09","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"27c81d33df044a648187f81864221799","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2e7d2d244b984bcb9206d68231d6001f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1b969bf36fe146598279d284e09e1d42","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"321c439bbe614dc2afd13cb803a48cec","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"17720e7e8e1f4798b8461f3bb74c52bb","docid":1763212,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":35,"target_extend_id":"00b356d9ee21395c999057465460d53b","created_ts":"2026-01-27T07:24:31.000Z","updated_ts":"2026-03-14T21:10:35.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"GPRC5D CAR-T Cell(Tianjin First Central Hospital)","source_info":[{"code":"NCT07365059","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07365059"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["e80fb0117a0081edbf47d89a524a9ea5"],"mechanism_action_id":["c429e8b4d6b147789c27bca748ca8222"],"target_id":["c934ca9fe8e242af9c7d4ed33a45c27f"],"disease_id":["2a202c1a9b6f497b93bb6d86300a298b","0b9d388261234c7caf24dd5466ed104f","d6d30dfb1c604b55a56b0f79fa245d23","9793c1d8a9c54cfd8c838580297fd540"],"active_org_master_entity_id":["e80fb0117a0081edbf47d89a524a9ea5"],"research_disease":["2a202c1a9b6f497b93bb6d86300a298b","0b9d388261234c7caf24dd5466ed104f","d6d30dfb1c604b55a56b0f79fa245d23","9793c1d8a9c54cfd8c838580297fd540"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"9793c1d8a9c54cfd8c838580297fd540","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2a202c1a9b6f497b93bb6d86300a298b","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"d6d30dfb1c604b55a56b0f79fa245d23","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0b9d388261234c7caf24dd5466ed104f","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4694d43a935245dc817282f23098453e","docid":60159,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"antibody_drug_id":"8a983d591b554e96b1cf5fdeba566d72","antibody_type":"1c5762a1bb1843618a8de39f4593a387","linker_id":"5422d40faf57446fb000081abcb0fa9e","payload_id":"d5a1aa9c7d424afa8fd8ffbf5f21a0db","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":34,"target_extend_id":"26013e9ee9c434979a0df5faedb76f17","created_ts":"2021-10-08T14:37:10.000Z","updated_ts":"2026-03-21T21:11:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"89Zr-DFO-REGN3767","status":"ACTIVE"}],"drug_type":["35708352e4e4487499a6964b5ddb2ceb","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["9e69a16cb488720675288e77dd41cd84"],"mechanism_action_id":["2a155ec9363ae514ad3190b5697b3af0","919c58b354c4c90138f8136723ec6c2d"],"target_id":["b6b70c7951c749e4a0420bad1ddc0808"],"disease_id":["0e0dca4dd7f1499a8f65f4fdfcf09954"],"active_org_master_entity_id":["9e69a16cb488720675288e77dd41cd84"],"research_disease":["0e0dca4dd7f1499a8f65f4fdfcf09954"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1599782400000}}],"disease_phase":[{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"target_moiety_type":["c38eb408d6b842f487d6a27484156633"],"moiety_target_extend_id":"26013e9ee9c434979a0df5faedb76f17","moiety_mechanism_action_id":["2a155ec9363ae514ad3190b5697b3af0","919c58b354c4c90138f8136723ec6c2d"],"moiety_target_id":["b6b70c7951c749e4a0420bad1ddc0808"]}
+{"drug_id":"00d3622eab8f4e1eb737d28becaa766c","docid":76580,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"1a9ea1307f82439f86318fa381543664","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1701129600000,"rnk":10,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2021-10-08T14:43:21.000Z","updated_ts":"2026-03-07T21:12:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":1701129600000,"drug_name":[{"lang":"CN","name":"利拉鲁肽生物类似药 (通化东宝)","status":"ACTIVE"},{"lang":"EN","name":"Liraglutide Biosimilar (Tonghua Dongbao)","status":"ACTIVE"}],"trade_name":[{"name":"统博力","source_info":[{"code":"国药准字S20230066","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9NWEyMDkyMGJlYmQ5MDkzMzY1MWE2YmVjMTBjODhmY2ImaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm"}],"status":"ACTIVE"}],"generic_name":[{"name":"liraglutide","status":"ACTIVE"}],"drugbank_id":["DB06655"],"kegg_id":["D06404"],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["ecf88873141c33f061a410af68a16318"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"atc_code":["cdb54335a12a40f9960034a4e9b218a5"],"disease_id":["0d05187284b446c5803cce38a3e53ebf","74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["ecf88873141c33f061a410af68a16318"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["74d974da49ba407195b38595a0aff704"],"research_disease":["0d05187284b446c5803cce38a3e53ebf","74d974da49ba407195b38595a0aff704"],"inactive_org_master_entity_id":["d62ef11e0e507f6225102dc2ff9e8a59"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9b340ca1-caed-3b00-9811-af8d46feb729"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1701129600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1764288000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["d158e2963dae4e1cb6038f1274a98c37"],"deal_related_org":["5982ff1462d2654030cd09812cca0e84","ecf88873141c33f061a410af68a16318"],"data_source":10}
+{"drug_id":"01bb61fbafb84b85a4d0c40974b00bee","docid":66141,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1293840000000,"rnk":36,"target_extend_id":"bf62bd8dffad3c5dab58859fa4ebb785","created_ts":"2021-10-08T14:46:51.000Z","updated_ts":"2025-07-19T21:09:29.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"干扰素α-2b生物类似药(Biosidus SA)","status":"ACTIVE"},{"lang":"EN","name":"Interferon alpha-2b biosimilar(Biosidus SA)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bioferon","status":"ACTIVE"},{"lang":"EN","name":"Biosidus interferon alpha 2b","status":"ACTIVE"},{"lang":"EN","name":"Citopheron","status":"ACTIVE"},{"lang":"EN","name":"Ganapar","status":"ACTIVE"},{"lang":"EN","name":"Interferon alpha-2b biosimilar","status":"ACTIVE"},{"lang":"EN","name":"Zavinex","status":"ACTIVE"}],"dev_code":[{"name":"INTER 2B","status":"ACTIVE"}],"generic_name":[{"name":"interferon alfa-2b","status":"ACTIVE"}],"drug_type":["57c42dc16879482eb4ac47835d127eca","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["6f9c20584645a73ddfadd56a83e2ac00"],"mechanism_action_id":["29dce79255d3796ed0748359d54c87bf","d14c2ee8f93b7874768556f06ceeb8cf","d05876caed645eadb8a2c315d512516f"],"target_id":["5d3fe45508034425ab92f769d3fafdb0"],"atc_code":["a6ee92aacdce4fafb5241d828d162256"],"disease_id":["8b107203951e4ae9bfe9667fccbe8df9","5f0765227409473d803995e585313374","db53733df6b441fe9ed25041a14839c8"],"active_org_master_entity_id":["6f9c20584645a73ddfadd56a83e2ac00"],"first_approved_indication":["8b107203951e4ae9bfe9667fccbe8df9","5f0765227409473d803995e585313374","db53733df6b441fe9ed25041a14839c8"],"research_disease":["8b107203951e4ae9bfe9667fccbe8df9","5f0765227409473d803995e585313374","db53733df6b441fe9ed25041a14839c8"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"8b107203951e4ae9bfe9667fccbe8df9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"db53733df6b441fe9ed25041a14839c8","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5f0765227409473d803995e585313374","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["b988ccaa9c1147bfbc6a254e423da2ce"],"data_source":10}
+{"drug_id":"02d0a8ed4dd04a9fb0abf6477cbe790c","docid":1310807,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-04-27T07:13:57.000Z","updated_ts":"2026-03-26T14:40:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"177Lu-HX02","status":"ACTIVE"}],"dev_code":[{"name":"177Lu-HX02","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["8d28d970ba0f5588f5c702ad45abdcc2"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["8d28d970ba0f5588f5c702ad45abdcc2"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1769126400000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03d0a7818be241b9a9e31334f97252a4","docid":270180,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2025-02-05T06:12:32.000Z","updated_ts":"2026-02-24T23:38:36.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"BCMA-CD19 CAR-T(Peking University People's Hospital)","source_info":[{"code":"NCT06794008","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06794008"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BCMA-CD19 CAR-T therapy(Peking University People's Hospital)","source_info":[{"code":"NCT06794008","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06794008"}],"status":"ACTIVE"},{"lang":"EN","name":"BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell(Peking University People's Hospital)","source_info":[{"code":"NCT06794008","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06794008"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["9455fb2ac7a72dedeb5d551ae453801e"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448","aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["21dbc39b953a493ea6e254a6b012156c","2369dfc38539466aa9ebe1e07eb05a4d","74c3f904663c46f996d88404cc1955e9","b494a906592f47b09ce303fb0963e3b8","deb581081bf244d38ffe2641c1312746","d3a8e491a4c84426a7d31d10c8e166f3","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e","2e2b1ec3d9ed4c4c9de85eb5464b254c"],"active_org_master_entity_id":["9455fb2ac7a72dedeb5d551ae453801e"],"research_disease":["21dbc39b953a493ea6e254a6b012156c","2369dfc38539466aa9ebe1e07eb05a4d","74c3f904663c46f996d88404cc1955e9","b494a906592f47b09ce303fb0963e3b8","deb581081bf244d38ffe2641c1312746","d3a8e491a4c84426a7d31d10c8e166f3","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e","2e2b1ec3d9ed4c4c9de85eb5464b254c"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","5b1dfc2ca8564662860187aef864467d","20f1c6915ff140519285386c54883aae","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1735171200000}}],"disease_phase":[{"disease_id":"deb581081bf244d38ffe2641c1312746","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"74c3f904663c46f996d88404cc1955e9","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"52573fcc151b4d9b9fc29e8ed015efb1","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d3a8e491a4c84426a7d31d10c8e166f3","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2e2b1ec3d9ed4c4c9de85eb5464b254c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2369dfc38539466aa9ebe1e07eb05a4d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b494a906592f47b09ce303fb0963e3b8","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"21dbc39b953a493ea6e254a6b012156c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0b80e1ed1de3425bbaf775532cc53b0b","docid":7847,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"85d8827b1e2b3287b5d91bd87bb5b475","created_ts":"2021-11-30T08:54:59.000Z","updated_ts":"2026-04-04T21:11:17.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"ARO-DUX4","status":"ACTIVE"}],"dev_code":[{"name":"ARO DUX4","status":"ACTIVE"},{"name":"ARODUX4","status":"ACTIVE"},{"name":"SRP 1001","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024"}],"status":"ACTIVE"},{"name":"SRP-1001","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024"}],"status":"ACTIVE"},{"name":"SRP1001","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["f01c40a6380a0660b4ca7ff6b6f695a4"],"mechanism_action_id":["9603636ffdac4835b3ea12728d60f038"],"target_id":["352b5d70ebe2469f8daf963280653cc3"],"disease_id":["64706e7b27f744eaa972e868561ded94"],"active_org_master_entity_id":["f01c40a6380a0660b4ca7ff6b6f695a4"],"research_disease":["64706e7b27f744eaa972e868561ded94"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}}],"disease_phase":[{"disease_id":"64706e7b27f744eaa972e868561ded94","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["4a5b23bd563d5214742ab9f17ea7a12a","f01c40a6380a0660b4ca7ff6b6f695a4"],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","if_speculate":0,"data_source":10,"tech_platform":["227171175e144c01b9acf6729132efd3"],"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://arrowheadpharma.com/pipeline/"}],"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"targeted_tissue":["810e3182f7544de495abcbe49ec6ce56"],"delivery_system":["42e15f5307df48c0b79434dc95ae3720"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"020b6c3c04a944a6ac0ed3586f8c0d40","docid":43301,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:47:42.000Z","updated_ts":"2026-02-25T01:30:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"Tuberculosis vaccine(Aeras Technologies LLC)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Tuberculosis vaccine","status":"ACTIVE"}],"dev_code":[{"name":"AERAS-402","source_info":[{"code":"22296955","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/22296955/"}],"status":"ACTIVE"},{"name":"AERAS-402/CRUCELL AD35","status":"ACTIVE"}],"drug_type":["49e3fb94500546eb916faaee1707fabe","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["89003c450057528123298ff44f4c1042"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["764eee63555942f1bb171f1b8c1e71ea","83a63550dcab42b6a7eaacba8afdf3d9"],"active_org_master_entity_id":["03a64e930c071553471c52e3974c6714","55317f856f0d78124a6845222345ba8e","5a9e0d71711b00798d13879ebe32dfac","89003c450057528123298ff44f4c1042"],"research_disease":["764eee63555942f1bb171f1b8c1e71ea","83a63550dcab42b6a7eaacba8afdf3d9"],"inactive_org_master_entity_id":["7d6b34521277b2d5c696e1ab6c6719bf"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1330560000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1330560000000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1351641600000}}],"disease_phase":[{"disease_id":"83a63550dcab42b6a7eaacba8afdf3d9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"764eee63555942f1bb171f1b8c1e71ea","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0195383ffb3e487dbdcf06cd1bb38567","docid":31534,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"8666aad5477e4272b56b94ca1183781d","rnk":1,"target_extend_id":"51c9115157433da0acefd8fce7ee46b3","created_ts":"2023-08-11T05:53:08.000Z","updated_ts":"2026-01-10T21:11:26.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"SOA-101","source_info":[{"attachment_path":"data/phs_source_info/e98e/060d/47d2/ac75/a43608bf-9548-3fb7-88cd-156fa5fac7af.jpg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/b7e7/0a28/5927/1a89/352764a7-bea0-35d3-bcf3-c0a131de5939.jpg","source":"Company pipeline","source_url":"https://www.shineon-bio.com/products2_detail/20"}],"status":"ACTIVE"}],"dev_code":[{"name":"SOA 101","status":"ACTIVE"},{"name":"SOA101","status":"ACTIVE"}],"drug_type":["6b2f8d357e8a428496018a029dc8e825"],"originator_org_master_entity_id":["cf7a7d9e70ac882f402abfc5d4004770"],"mechanism_action_id":["4cf7de0025dc9a224db39187cf2614cd","d13fa382fc394ba6955ecdff5589c9c9","5f2b5842256779f2516d3dc21cf298e2"],"target_id":["06c7ab146b884a3aa890cfd1a4a0e168","3daf27ced4f34085ab703b040116b77b","fe50c9b7f38746beb4bfd1ae9fa6fd1b"],"disease_id":["15cb523e0fbd4617a6a129ad2336eb9a","3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["cf7a7d9e70ac882f402abfc5d4004770"],"research_disease":["15cb523e0fbd4617a6a129ad2336eb9a","3beea980d93a4cc0abc864e27514601c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1753833600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"8666aad5477e4272b56b94ca1183781d","dev_status_time":{"time_trust_code":7,"time_ts":1691712000000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"8666aad5477e4272b56b94ca1183781d"}],"data_source":10}
+{"drug_id":"041e5ec47e3e49fea9f3992502ac746f","docid":72643,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"f835774c48404593b64ef05369eb8eba","rnk":74,"target_extend_id":"b0ea200ef98133288a18281a674f862d","created_ts":"2022-04-26T10:40:12.000Z","updated_ts":"2026-01-28T21:08:20.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"limingna","drug_name":[{"lang":"CN","name":"奥密克戎株新冠灭活疫苗(Beijing Bio-Institute Biological Products)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/4s0QJtzXVkgkqDgV4Z5yhA"}],"status":"ACTIVE"},{"lang":"EN","name":"Omicron COVID-19 Vaccine(Vero Cell),Inactivated(Beijing Bio-Institute Biological Products)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/4s0QJtzXVkgkqDgV4Z5yhA"}],"status":"ACTIVE"}],"drug_type":["00458ff770344a2b962324da6b29d16f","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["5628e31b2bc29e70b526f9994ce6e2f5"],"mechanism_action_id":["d8cf80828c564c6889168e2249b034fa"],"target_id":["d4ed73bcacc74cf9a7066f422194f1a3"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["5628e31b2bc29e70b526f9994ce6e2f5"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"inactive_org_master_entity_id":["a1da9f9b8f341888ee2c3b9cd27a1028"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653609600000}},{"country":"7e67ab67-b973-3c61-8850-3ba387e2b3fe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1651190400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1687046400000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"39c6fc915e2e4321b9dcbc9abf961dfc","docid":10951,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:23.000Z","updated_ts":"2024-10-30T10:24:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Ox-02","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3b28b6ee66bb7a400e9866e2a8e936ca"],"disease_id":["299e91fc2f234bbb9e0156c4f43ad970"],"active_org_master_entity_id":["3b28b6ee66bb7a400e9866e2a8e936ca"],"research_disease":["299e91fc2f234bbb9e0156c4f43ad970"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1646611200000}}],"disease_phase":[{"disease_id":"299e91fc2f234bbb9e0156c4f43ad970","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"00199692457c4721b88795b26b04129b","docid":49572,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1677542400000,"rnk":21,"target_extend_id":"7b338f40fb243fc79806ffa4e81c4c5a","created_ts":"2021-10-08T14:39:33.000Z","updated_ts":"2026-04-02T14:22:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","first_approved_date_cn":1677542400000,"drug_name":[{"lang":"CN","name":"曲妥珠单抗生物类似药 (海正药业)","status":"ACTIVE"},{"lang":"EN","name":"Trastuzumab biosimilar (Hisun Pharma)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Trastuzumab biosimilar","status":"ACTIVE"}],"dev_code":[{"name":"HS-022","status":"ACTIVE"}],"trade_name":[{"name":"安瑞泽","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.hisunpharm.com/main/news-content.thtml?id=13207"}],"status":"ACTIVE"}],"generic_name":[{"name":"Trastuzumab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["2aa3e683bc620f41205c1b9a8a37d616"],"mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151","569d7324d3bdd73cc1b9e225fdfc8d5f"],"target_id":["a3c3158483984ff9922b1b0ba939a068"],"atc_code":["4081257f66244b44bbf0914abc3ac0a7"],"disease_id":["f8ade5ce0e364264af82a379ab65f6a2","ab7c198e47834770a36ab3282d331531","ba02154031ca48aba76cd279bdca8ade"],"active_org_master_entity_id":["2d8a5a893bafc98c77073bb1383602e8"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["f8ade5ce0e364264af82a379ab65f6a2","ab7c198e47834770a36ab3282d331531"],"research_disease":["f8ade5ce0e364264af82a379ab65f6a2","ab7c198e47834770a36ab3282d331531"],"non_research_disease":["ba02154031ca48aba76cd279bdca8ade"],"inactive_org_master_entity_id":["2aa3e683bc620f41205c1b9a8a37d616"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1677542400000}}],"disease_phase":[{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ba02154031ca48aba76cd279bdca8ade","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["fcaf760bd0d54f5ca79c92ca47466fe7"],"deal_related_org":["379be598ecf5beae8bbddfb658b003bb","528b2f3a18ee46f78efc07d92439952e"],"data_source":10}
+{"drug_id":"3ede1b4ade4142a8ba6b09a8f5f16e08","docid":75988,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:52.000Z","updated_ts":"2025-04-08T09:20:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AP20 (Aprogen)","status":"ACTIVE"}],"dev_code":[{"name":"AP20 (Aprogen)","status":"ACTIVE"}],"drug_type":["58846334b4a6496b83493429578a4faa"],"originator_org_master_entity_id":["11a3636b4ae040fd012c5f5c4ffdd6f6"],"disease_id":["d124992d44c44ac4801806e7a62943a9"],"active_org_master_entity_id":["11a3636b4ae040fd012c5f5c4ffdd6f6"],"research_disease":["d124992d44c44ac4801806e7a62943a9"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1644451200000}}],"disease_phase":[{"disease_id":"d124992d44c44ac4801806e7a62943a9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4c0bdc2217e8497aa9ea452e193763ec","docid":74098,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-08-03T08:55:45.000Z","updated_ts":"2025-04-10T11:20:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"三贝苎鼾胶囊","status":"ACTIVE"},{"lang":"EN","name":"Sanbei Zhuhan Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["8c41581058ef831a92d17f92dfbea404"],"disease_id":["8ae7b8895639407b906410d1b46cf4d7"],"active_org_master_entity_id":["8337863cad77775baa3fc5349d230967","d31a9f8896d28402baf1117ba4e1655d","8c41581058ef831a92d17f92dfbea404"],"research_disease":["8ae7b8895639407b906410d1b46cf4d7"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1744156800000}}],"disease_phase":[{"disease_id":"8ae7b8895639407b906410d1b46cf4d7","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"016976b75d8b413bba866b6f1e292360","docid":81038,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-10-09T10:33:57.000Z","updated_ts":"2026-04-16T09:58:03.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"fangdongbing","drug_name":[{"lang":"EN","name":"BMS-986460","source_info":[{"code":"NCT06067841","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06067841"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Orevandrodeg","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C202988?sources=NCI"}],"status":"ACTIVE"}],"dev_code":[{"name":"BMS 986460","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ligand-directed-degrader-bms-986460"}],"status":"ACTIVE"},{"name":"BMS986460","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ligand-directed-degrader-bms-986460"}],"status":"ACTIVE"},{"name":"CC-2043137","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C202988?sources=NCI"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"disease_id":["27538fe67e9b4648b06de8efdc9ab891"],"active_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"research_disease":["27538fe67e9b4648b06de8efdc9ab891"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1742342400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1697587200000}}],"disease_phase":[{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"047bce3b7f524968a9a9954b3a784955","docid":1760534,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":9,"target_extend_id":"b83916203d873712ba25ab71a442c450","created_ts":"2025-08-13T09:01:22.000Z","updated_ts":"2026-04-18T00:38:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"LY-4257496","source_info":[{"code":"NCT07114601","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07114601"}],"status":"ACTIVE"}],"dev_code":[{"name":"LY-4257496","source_info":[{"code":"NCT07114601","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07114601"}],"status":"ACTIVE"}],"drug_type":["ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"mechanism_action_id":["417de2ffc1e2384d55330e9055e669d7"],"target_id":["7d5c31ca87224ebe91f29eb98cc4b99a"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","91ff17cb5761443794a7ba0fff45827e","4035a94ea2d240d7a52aa75633974381","fbdd6976d5cb413fb0733ae761138853","19679f907246424396afdb5999d191a5","27538fe67e9b4648b06de8efdc9ab891","d2ee0aa5e8a2440585e9a218d193b710"],"active_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","91ff17cb5761443794a7ba0fff45827e","4035a94ea2d240d7a52aa75633974381","fbdd6976d5cb413fb0733ae761138853","19679f907246424396afdb5999d191a5","27538fe67e9b4648b06de8efdc9ab891","d2ee0aa5e8a2440585e9a218d193b710"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}}],"disease_phase":[{"disease_id":"fbdd6976d5cb413fb0733ae761138853","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4035a94ea2d240d7a52aa75633974381","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"91ff17cb5761443794a7ba0fff45827e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"19679f907246424396afdb5999d191a5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0f1ee086c13745209e2572d803e49e92","docid":13530,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"29e9f450b6cc3117921ba477804db35a","created_ts":"2023-07-26T02:19:33.000Z","updated_ts":"2025-08-09T21:11:20.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"TQA-3038","source_info":[{"code":"CXHL2300820","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"TQA3038","status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["662d46871bd6f6dc727ddefab40c2a06"],"mechanism_action_id":["d46e90f57d7c43be90c787e610e8a0e2"],"target_id":["b4da9ce6d947474883fdffb5c1f5522f"],"disease_id":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"active_org_master_entity_id":["662d46871bd6f6dc727ddefab40c2a06"],"research_disease":["f196ef1a4d9c4cb3aede0ea60aac4a52"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1717200000000}}],"disease_phase":[{"disease_id":"f196ef1a4d9c4cb3aede0ea60aac4a52","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","data_source":10,"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1205/2023120502069.pdf"}],"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"targeted_tissue":["a63a02bf5b3f433aa7da4ea6edd802bf"],"delivery_system":["cebfbf5158294267badc32e9c9619992"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"5150de18ade8458b82f83d7d78b7b410","docid":1341522,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-06-04T06:16:53.000Z","updated_ts":"2025-06-04T06:18:15.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"L60c","source_info":[{"normalized_source_id":"2a39e1fb59c446568df2b08f80e3f6f0","source":"ChiCTR","source_url":"https://www.chictr.org.cn/showproj.html?proj=210200"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["619fe4cc4c7b221621bb6aa05930e20a"],"disease_id":["4c092510a2af42f387426e408f5c7694"],"active_org_master_entity_id":["619fe4cc4c7b221621bb6aa05930e20a"],"research_disease":["4c092510a2af42f387426e408f5c7694"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1690156800000}}],"disease_phase":[{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"21b4350dea2c4b739c8667c1a20a37c5","docid":82926,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"6e5ad586bf7644cc8dc40f0c33efb033","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1743120000000,"rnk":13,"target_extend_id":"dc7de6393dbb399aa0d8e2f8236159c3","created_ts":"2023-12-25T06:53:21.000Z","updated_ts":"2026-03-21T00:42:45.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"培非格司亭生物类似药（Curateq）","status":"ACTIVE"},{"lang":"EN","name":"Pegfilgrastim(CuraTeQ)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Pegfilgrastim  Biosimilar (Curateq Biologics Pvt Ltd.)","status":"ACTIVE"}],"dev_code":[{"name":"BP 14","source_info":[{"attachment_path":"data/phs_source_info/74d9/3426/0d24/39f9/74d934260d2439f9.jpg","attachment_type":"image/jpeg","code":"Curateq-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/ba89/285f/bee3/937d/ba89285fbee3937d.jpg","source":"Company pipeline","source_url":"https://curateqbio.com/biosimilar-products/"}],"status":"ACTIVE"},{"name":"BP-14","source_info":[{"attachment_path":"data/phs_source_info/74d9/3426/0d24/39f9/74d934260d2439f9.jpg","attachment_type":"image/jpeg","code":"Curateq-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/ba89/285f/bee3/937d/ba89285fbee3937d.jpg","source":"Company pipeline","source_url":"https://curateqbio.com/biosimilar-products/"}],"status":"ACTIVE"},{"name":"BP14","source_info":[{"attachment_path":"data/phs_source_info/74d9/3426/0d24/39f9/74d934260d2439f9.jpg","attachment_type":"image/jpeg","code":"Curateq-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/ba89/285f/bee3/937d/ba89285fbee3937d.jpg","source":"Company pipeline","source_url":"https://curateqbio.com/biosimilar-products/"}],"status":"ACTIVE"}],"trade_name":[{"name":"Dyrupeg","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/dyrupeg-0"}],"status":"ACTIVE"}],"generic_name":[{"name":"pegfilgrastim","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["2ee65e4fcdf1ac0abd6b7954011d75b4"],"mechanism_action_id":["358e5f0ba725062ad8f0c56973cc3e35"],"target_id":["532763442f00416fa392a55be34bad5a"],"disease_id":["e1aa9957d02046eab953a43b285f521f","c7879aa9883f473695aea6cc7470cb48","0df94b4cbdda4b139e247afcb9a94760"],"active_org_master_entity_id":["2ee65e4fcdf1ac0abd6b7954011d75b4"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["e1aa9957d02046eab953a43b285f521f","c7879aa9883f473695aea6cc7470cb48"],"research_disease":["e1aa9957d02046eab953a43b285f521f","c7879aa9883f473695aea6cc7470cb48","0df94b4cbdda4b139e247afcb9a94760"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"approval_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","cf11da47-6a9f-3948-9d29-8a824f805638","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1743120000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1767225600000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1743120000000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1743120000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1743120000000}}],"disease_phase":[{"disease_id":"0df94b4cbdda4b139e247afcb9a94760","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"c7879aa9883f473695aea6cc7470cb48","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e1aa9957d02046eab953a43b285f521f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["c8ae82ce74fc4776a63b3a7ad409566f"],"if_speculate":0,"data_source":10}
+{"drug_id":"061af696de884ccc825758e295a69718","docid":10766,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-03-02T05:30:42.000Z","updated_ts":"2024-11-06T12:47:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TGRM02","status":"ACTIVE"}],"dev_code":[{"name":"TGRM02","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["4c663f22e56ff2c37c012ee372e46bb7"],"disease_id":["d09a2813ca98448db981fb55bdeba55e"],"active_org_master_entity_id":["4c663f22e56ff2c37c012ee372e46bb7"],"research_disease":["d09a2813ca98448db981fb55bdeba55e"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}}],"disease_phase":[{"disease_id":"d09a2813ca98448db981fb55bdeba55e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0a2e4dd699e44b278328b451fd90e9fb","docid":44718,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-08-03T08:55:39.000Z","updated_ts":"2026-01-31T19:52:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"妇舒颗粒","status":"ACTIVE"},{"lang":"EN","name":"Fushu Granules","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["28b8491811997a9f1a07c18ca62a6e9b"],"disease_id":["797de48dbefc4bfdbfec47bf1d30327b"],"active_org_master_entity_id":["28b8491811997a9f1a07c18ca62a6e9b"],"research_disease":["797de48dbefc4bfdbfec47bf1d30327b"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1358380800000}}],"disease_phase":[{"disease_id":"797de48dbefc4bfdbfec47bf1d30327b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"3ca7b27d7601455dbd4b3bdb3e49c4c3","docid":57421,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:44.000Z","updated_ts":"2024-11-29T06:56:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"SHEP-003","status":"ACTIVE"}],"dev_code":[{"name":"SHEP-003","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["8797882f2959526e63f602297d801e8f"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["8797882f2959526e63f602297d801e8f"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641772800000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4ec02b76bcfa43f1ace75ad31be8c7bb","docid":54556,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-02-02T06:50:20.000Z","updated_ts":"2026-03-27T00:34:21.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HS-IT201","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=Mzg4MTAxOTM2Ng==&mid=2247522763&idx=1&sn=2a96459a6bbc2b1c6189957c50bea6da"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"NICE-TIL","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NjE1NzMxOQ==&mid=2652515490&idx=1&sn=fad8efc9707451ef98e6e75fd7287b40"}],"status":"ACTIVE"}],"dev_code":[{"name":"HS-IT201","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.sino-cellbiomed.com/immune-cell.html"}],"status":"ACTIVE"}],"drug_type":["11de7e83a6b24af5833eb63aca730750"],"originator_org_master_entity_id":["27a9c392504d12d13e944e208dd259cb"],"mechanism_action_id":["d7e303c0b4242026087378f5dd5006f0"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","65552aa23c0e405ea87623aa0de08dd8","3beea980d93a4cc0abc864e27514601c","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a","8519ced921e14933b779c41d4cd5fe67"],"active_org_master_entity_id":["27a9c392504d12d13e944e208dd259cb"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","65552aa23c0e405ea87623aa0de08dd8","3beea980d93a4cc0abc864e27514601c","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a","8519ced921e14933b779c41d4cd5fe67"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4"}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"65552aa23c0e405ea87623aa0de08dd8","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8519ced921e14933b779c41d4cd5fe67","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0d3e56849c3540b8bebed339b600deaf","docid":1974,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-12-10T12:54:28.000Z","updated_ts":"2024-11-06T13:32:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"ZKGZ-003","status":"ACTIVE"}],"dev_code":[{"name":"ZKGZ 003","status":"ACTIVE"},{"name":"ZKGZ003","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["5806922764071ed82a9c6e6283111271"],"disease_id":["2e52db813eb94143a5488cb1b73f87b5"],"active_org_master_entity_id":["9a998e8040d286c07ca6bec440f12fc8"],"research_disease":["2e52db813eb94143a5488cb1b73f87b5"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"2e52db813eb94143a5488cb1b73f87b5","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"02c5df427a344cb38a7a167497ad570b","docid":1627,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":999043200000,"rnk":4,"target_extend_id":"10831210edeb3ebe8236508fef67ab9d","created_ts":"2023-05-11T08:18:32.000Z","updated_ts":"2025-12-24T02:45:38.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"人绒毛膜促性腺激素(Fuji Pharma )","status":"ACTIVE"},{"lang":"EN","name":"Human Chorionic Gonadotrophin (Fuji Pharma)","source_info":[{"code":"21300AMZ00677","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ヒト絨毛性性腺刺激ホルモン(富士製薬工業株式会社)","source_info":[{"code":"21300AMZ00677","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"drug_type":["aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["246c2293a0c7590cbd4db22616798569"],"mechanism_action_id":["70a3cee5e03444bd7113b7ddc8eb1f32"],"target_id":["6d2d46616ec9474397265de0ece27442"],"disease_id":["a73312919bd340a38b26b06d28901369","485483fb560543dda023a909a3339716","dbd9752fae124ef7a4775e3e7af5509e","2e511ff0e28c4218b6f2d510b4ba8ea3","11f4ea6a8353449897b7e47ef55ae80f"],"active_org_master_entity_id":["246c2293a0c7590cbd4db22616798569"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["a73312919bd340a38b26b06d28901369","485483fb560543dda023a909a3339716","dbd9752fae124ef7a4775e3e7af5509e","11f4ea6a8353449897b7e47ef55ae80f","2e511ff0e28c4218b6f2d510b4ba8ea3"],"research_disease":["a73312919bd340a38b26b06d28901369","485483fb560543dda023a909a3339716","dbd9752fae124ef7a4775e3e7af5509e","2e511ff0e28c4218b6f2d510b4ba8ea3","11f4ea6a8353449897b7e47ef55ae80f"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":999043200000}}],"disease_phase":[{"disease_id":"a73312919bd340a38b26b06d28901369","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"dbd9752fae124ef7a4775e3e7af5509e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2e511ff0e28c4218b6f2d510b4ba8ea3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"11f4ea6a8353449897b7e47ef55ae80f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"485483fb560543dda023a909a3339716","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"075cabab250c43b0a584fb067767e0e0","docid":55354,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:41.000Z","updated_ts":"2024-11-10T00:22:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"金不换骨通胶囊","status":"ACTIVE"},{"lang":"EN","name":"Jinbuhuan Gutong Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["c6830c6e2336b45218e490de8991dada"],"disease_id":["eed2673e00254f389c696618b59cccea","fd0b1bf93fef45d49eeda147cf253e58"],"active_org_master_entity_id":["c6830c6e2336b45218e490de8991dada"],"research_disease":["eed2673e00254f389c696618b59cccea","fd0b1bf93fef45d49eeda147cf253e58"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1399420800000}}],"disease_phase":[{"disease_id":"eed2673e00254f389c696618b59cccea","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"fd0b1bf93fef45d49eeda147cf253e58","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"05c59e2a728e4708b3460c68fc94ac42","docid":19412,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1582675200000,"rnk":1,"target_extend_id":"4f049d9f6ea7353ba2de0ccc7f51f34c","has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:30.000Z","updated_ts":"2026-02-25T06:49:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"贝培多酸/依折麦布","status":"ACTIVE"},{"lang":"EN","name":"Bempedoic acid/Ezetimibe","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ETC-1002/ezetimibe","status":"ACTIVE"},{"lang":"EN","name":"Ezetimibe/ETC-1002","status":"ACTIVE"},{"lang":"EN","name":"Ezetimibe/bempedoic acid","status":"ACTIVE"},{"lang":"EN","name":"NEXLIZET","status":"ACTIVE"},{"lang":"EN","name":"Nustendi","status":"ACTIVE"}],"trade_name":[{"name":"Nustendl","source_info":[{"normalized_source_id":"4313dbdea4844940816740b801d08999","source":"DBPC"}],"status":"ACTIVE"}],"related_component":["576aeb65d3ee474685dce2b9e7e720f8","83242a07c74648b1a9ba8b5a737bca83"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["fa0127e622e58658fe1ff4efd060f2f4"],"mechanism_action_id":["966463593a16a554cd064a82da353496","a7a59d7ae073589b19a629590cb763a9","d580d40b55b85042a345ae2575bf97cd"],"target_id":["6bd19a0f566a405e88e3275d7b2327f1","82761700b56b48fd9fae161e239594f2"],"atc_code":["e7fce82220d647eabd0bb7a1d354915b"],"disease_id":["54e2cf3dc3294445b4a27b990b0ba274","22d4d689fe8b43b88ec66a65d7575106","eecf5f9d7d624dbb9913a9c6b86c87f3","ca12d2d355454d82b19068ad96acf14e","98d9beffe4d14bb6a7ee599146b8beb2","27013926797d4bc4bf088e4104530e7d","e08e1291a7f24698b8aea6bb8497584d","514492e8e5db4dd9afb5d32c5841b2ef","74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["fa0127e622e58658fe1ff4efd060f2f4","7e99e609750b07754c4c193f2f3dae4d","7867fd8c5c8fb5b43b912d4a03a9b148"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["27013926797d4bc4bf088e4104530e7d","e08e1291a7f24698b8aea6bb8497584d"],"research_disease":["54e2cf3dc3294445b4a27b990b0ba274","22d4d689fe8b43b88ec66a65d7575106","eecf5f9d7d624dbb9913a9c6b86c87f3","ca12d2d355454d82b19068ad96acf14e","98d9beffe4d14bb6a7ee599146b8beb2","27013926797d4bc4bf088e4104530e7d","e08e1291a7f24698b8aea6bb8497584d","514492e8e5db4dd9afb5d32c5841b2ef"],"non_research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","9a18968a-f130-3a00-80b6-8b9e2eec4838","666d5a51-60da-3482-b804-e6df04651a1e","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1711065600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1582675200000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1718841600000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1585267200000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1718841600000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1585267200000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1718841600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1585267200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1718841600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1585267200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1735689600000}}],"disease_phase":[{"disease_id":"514492e8e5db4dd9afb5d32c5841b2ef","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"eecf5f9d7d624dbb9913a9c6b86c87f3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"22d4d689fe8b43b88ec66a65d7575106","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ca12d2d355454d82b19068ad96acf14e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"98d9beffe4d14bb6a7ee599146b8beb2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5afbb03451e242f0a07d14c05b62d4eb","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e08e1291a7f24698b8aea6bb8497584d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["0d41954852813bba3f35d8381a71eaa4","21c8b7b468cb27ac62a155d570917028","7e99e609750b07754c4c193f2f3dae4d","9dfe87592c8430fd9d4efe99e8a779b5","c272ebb7a963a1b4526c20885c1ad4b4","e04fbf3cf0a0af2bc6856c70d527f8b7","fa0127e622e58658fe1ff4efd060f2f4"],"data_source":10}
+{"drug_id":"0125e400fbc04465b75db9ef8e5bad36","docid":9320,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","rnk":33,"target_extend_id":"e40c5128aae63792842c0a8d5ce256c9","created_ts":"2021-10-08T14:38:15.000Z","updated_ts":"2025-07-19T21:08:19.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"红霉素/醋酸锌二水合物","status":"ACTIVE"},{"lang":"EN","name":"Erythromycin/Zinc acetate dihydrate","status":"ACTIVE"}],"related_component":["5f04c2e051c643e3b04de6386436267d","83a37ab8a030467bb8eae2447741aa1b"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["69b18a384304bf44d2471f11d85d58ba"],"target_id":["32813993f70c47c396c8954cd5eab46c"],"disease_id":["10ed4cbd447e4fe6a9dc80e700982ce0"],"research_disease":["10ed4cbd447e4fe6a9dc80e700982ce0"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"10ed4cbd447e4fe6a9dc80e700982ce0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02407796f4e34ec7ac9ed422104fd67e","docid":15178,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"c6828d7097933a80bf6de3ffa798748a","has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:01.000Z","updated_ts":"2026-04-03T09:42:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Cenerimod","source_info":[{"code":"2023_POS1028 (2023)","normalized_source_id":"75c904150f154a17be0bd4db1a3866f9","source":"EULAR","source_url":"https://scientific.sparx-ip.net/archiveeular/?c=a&view=2&item=2023POS1028"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cenerimod (USAN/INN)","source_info":[{"code":"D11283","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"ACT-334441","status":"ACTIVE"}],"generic_name":[{"name":"Cenerimod","source_info":[{"code":"D11283","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB12705"],"kegg_id":["D11283"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6dfe153fdbe27f7a6bc92c4fb51e3e54"],"mechanism_action_id":["6f76253057cf23a51c5c7ab930dad06b"],"target_id":["28bb11044bf04cac8884b3e877938ba9"],"disease_id":["0c8a0603507542faac6b5ef3e27c6728","c5e1987e283c495aaab2a8d309c6085e","d626b37675454888aa36de00ba898cc8","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["61d1ed1d0b831ec375b9398d7fe78288","f65c4b82c5f78b64ebf6bea25dfc7b42","bf261c8ee81428f4dd4d1ec3f217209d","e3a3ef71de0475145995758747319017","6dfe153fdbe27f7a6bc92c4fb51e3e54"],"research_disease":["0c8a0603507542faac6b5ef3e27c6728","c5e1987e283c495aaab2a8d309c6085e","d626b37675454888aa36de00ba898cc8","6be96778ed424f8d91de00ab82364114"],"inactive_org_master_entity_id":["d22f8b40c817bd2b76eda3594a7b9902"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1670889600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1687737600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1765497600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1629849600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1472688000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1724457600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1724457600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1724457600000}}],"disease_phase":[{"disease_id":"d626b37675454888aa36de00ba898cc8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["03bf734996554b9569180f44544f0b5a","23ef6a098fe7d2a991895ae29b482a6a","61d1ed1d0b831ec375b9398d7fe78288","6dfe153fdbe27f7a6bc92c4fb51e3e54"],"data_source":10}
+{"drug_id":"079d0349d36f4b8882236e20683cdc42","docid":10308,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","linker_id":"5422d40faf57446fb000081abcb0fa9e","payload_id":"d5a1aa9c7d424afa8fd8ffbf5f21a0db","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"eb5c7b69d8623cb0ab9389b84971bac1","created_ts":"2021-10-08T14:48:32.000Z","updated_ts":"2026-02-24T23:23:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"89Zr-HuMab 5B1","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"89Zr-DFO-HuMab-5B1","status":"ACTIVE"},{"lang":"EN","name":"Zirconium anti-sialyl Lewisa imaging agent","status":"ACTIVE"}],"dev_code":[{"name":"MVT 2163","status":"ACTIVE"},{"name":"MVT-2163","status":"ACTIVE"}],"drug_type":["35708352e4e4487499a6964b5ddb2ceb","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["282b97435bf1884181343ae17f4d1115"],"mechanism_action_id":["ee54d5d405c140c2b99b7926f1a3053b"],"target_id":["58a8b5a66d2b4a0085067442fa42f3e2"],"disease_id":["7e87f9c6dcd841edb4d0f250b6bee3d9","78cb173a4de34f07befac28de907e7bf","a74f1881cefd4c2aa0ee86eedf5b49f7","ae092fa59f4d44edaf59ffe23d0a44c3","d9c985ab1f04428493c029df6dca650d","7665e5683a1a443a8f3d3b946d4c9ca2","8d29f554f371431c9b5b80f5befdf965"],"active_org_master_entity_id":["282b97435bf1884181343ae17f4d1115","6fb11d60133b90213c35c47a10700173"],"research_disease":["7e87f9c6dcd841edb4d0f250b6bee3d9","78cb173a4de34f07befac28de907e7bf","a74f1881cefd4c2aa0ee86eedf5b49f7","ae092fa59f4d44edaf59ffe23d0a44c3"],"non_research_disease":["d9c985ab1f04428493c029df6dca650d","7665e5683a1a443a8f3d3b946d4c9ca2","8d29f554f371431c9b5b80f5befdf965"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1620604800000}}],"disease_phase":[{"disease_id":"a74f1881cefd4c2aa0ee86eedf5b49f7","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"moiety_target_extend_id":"eb5c7b69d8623cb0ab9389b84971bac1","moiety_mechanism_action_id":["ee54d5d405c140c2b99b7926f1a3053b"],"moiety_target_id":["58a8b5a66d2b4a0085067442fa42f3e2"]}
+{"drug_id":"09243de3dd9a4b88a6beb629e993b864","docid":82900,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-12-22T03:18:51.000Z","updated_ts":"2024-11-07T15:32:45.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"YN-1203","source_info":[{"attachment_path":"data/phs_source_info/f094/77f3/9ef7/ea28/83993156-8c16-39b9-91f7-bd6bec26a5d4.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/70db/ef66/c67a/2fe6/a404c81d-dcca-342c-b29b-5a2aec7678af.png","source":"Company pipeline","source_url":"http://www.innobationbio.com/pipeline/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"YN 1203","status":"ACTIVE"},{"name":"YN1203","status":"ACTIVE"}],"drug_type":["56cd71d7b8c54b0fba69bbb8c7e10e9b"],"originator_org_master_entity_id":["c87d2edc1d4a226adf37f3e842bf4837"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["c87d2edc1d4a226adf37f3e842bf4837"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"1481792d349c44229e03a9d09340d1ae","docid":5785,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":5,"target_extend_id":"b133352ae7f63a40bcbd6441b4ebbfa1","created_ts":"2021-10-08T14:47:50.000Z","updated_ts":"2026-02-24T19:27:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"PGDM-1400","status":"ACTIVE"}],"dev_code":[{"name":"PGDM1400","source_info":[{"code":"10.1126/scitranslmed.aal1321","normalized_source_id":"ea68fe7b-5030-4ab7-b13c-f6246ad68e3e","source":"Sci Transl Med","source_url":"http://dx.doi.org/10.1126/scitranslmed.aal1321"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["503d0e500d685aca4fc84acf2d2ce764"],"mechanism_action_id":["58c5187d9e83e77cc612920f993e4e37"],"target_id":["f8d0738611e04dd2a3f538b363314075"],"disease_id":["acfaaa0373944ffd89b0a2ace0d8c564","ae8e6f653866483981475b969413b581"],"active_org_master_entity_id":["16ea44cdf8173cfd47847a73c3b3b3af","d4d92a03e5018a19f576119a9c25debd","503d0e500d685aca4fc84acf2d2ce764","55317f856f0d78124a6845222345ba8e"],"research_disease":["acfaaa0373944ffd89b0a2ace0d8c564","ae8e6f653866483981475b969413b581"],"inactive_org_master_entity_id":["8932132407f45bf637ea5c06f16b8569"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}}],"disease_phase":[{"disease_id":"ae8e6f653866483981475b969413b581","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"02bffd3aeeda457db1d5a9023139693b","docid":31051,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"b1a2f46b1d2f3427940903800022a333","created_ts":"2021-10-08T14:43:07.000Z","updated_ts":"2024-12-25T21:05:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"DPI-125","status":"ACTIVE"}],"dev_code":[{"name":"MCP 201","status":"ACTIVE"},{"name":"MCP-201","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e3073c0235187e90bd5b51e8aeee0300"],"mechanism_action_id":["13303bb39cbb9e432e1a55152b73b2ae","b140e0c0f4e3e3d0cfc35c8ed236cefc","bc1ca4f073073bb3a11e18d88a6e20af"],"target_id":["5f6487c6802f4be5b883a28a4efc3a7a","f90cd704355648eb9f42d7fbc9e032bf","6e8a07393c9c4b019d1a6103e152ffcb"],"disease_id":["c61ac982a2ab4897a9b426aa6b81ee78","25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["90b5727c72feb42dee27ce54a59c96ed","e3073c0235187e90bd5b51e8aeee0300","d29d555db2ee68bdab480639b54bce0d"],"research_disease":["c61ac982a2ab4897a9b426aa6b81ee78","25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"c61ac982a2ab4897a9b426aa6b81ee78","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["90b5727c72feb42dee27ce54a59c96ed","dae1cf5f494799495753cb0fbbdc55bd"],"data_source":10}
+{"drug_id":"039517ec9120474fb76f0f147d9a8b7c","docid":36614,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:37.000Z","updated_ts":"2024-10-30T10:22:22.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"益今生胶囊","status":"ACTIVE"},{"lang":"EN","name":"Yijinsheng Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["0dfc10e5c81e42869cd8f7479a1b5021","e2fd9bda4aeb4a7b9fa53a2560126d24","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["34e157a8bd05f443b2788ec29e4323cc"],"research_disease":["0dfc10e5c81e42869cd8f7479a1b5021","e2fd9bda4aeb4a7b9fa53a2560126d24"],"non_research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1583712000000}}],"disease_phase":[{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0dfc10e5c81e42869cd8f7479a1b5021","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"104a0bf5523b4adc9751cf062158036c","docid":920301,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-02-25T09:46:09.000Z","updated_ts":"2026-04-03T00:04:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"IB160-adjuvanted H5N8 cell culture-derived influenza vaccine(Butantan Institute)","source_info":[{"code":"NCT06842173","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06842173"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Avian Flu vaccine(Butantan Institute)","source_info":[{"code":"NCT06842173","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06842173"}],"status":"ACTIVE"},{"lang":"EN","name":"Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted)+IB160 adjuvant(Butantan Institute)","source_info":[{"code":"NCT06842173","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06842173"}],"status":"ACTIVE"}],"drug_type":["00458ff770344a2b962324da6b29d16f","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["73783d408b1b78ee65e25e50869cc203"],"disease_id":["867f8c2d4d71451083835ae4320a7ca3"],"active_org_master_entity_id":["73783d408b1b78ee65e25e50869cc203"],"research_disease":["867f8c2d4d71451083835ae4320a7ca3"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1757462400000}}],"disease_phase":[{"disease_id":"867f8c2d4d71451083835ae4320a7ca3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"10d1222291af4f6da855ebf62ae45068","docid":72972,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","linker_id":"5422d40faf57446fb000081abcb0fa9e","payload_id":"d5a1aa9c7d424afa8fd8ffbf5f21a0db","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":55,"target_extend_id":"c3564a2e384d34ef94516d844f563ba3","created_ts":"2021-10-08T14:50:36.000Z","updated_ts":"2026-04-18T21:08:25.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"89Zr-DFO-huJ591","status":"ACTIVE"}],"dev_code":[{"name":"89ZR-DFO-J591","status":"ACTIVE"},{"name":"ZR89-J591","status":"ACTIVE"}],"drug_type":["35708352e4e4487499a6964b5ddb2ceb","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["9e69a16cb488720675288e77dd41cd84"],"mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"target_id":["1764007a7c384a4ab49bb3710bab5052"],"disease_id":["1259d9c96614472ea03b5c8b51458a7b"],"active_org_master_entity_id":["9e69a16cb488720675288e77dd41cd84"],"research_disease":["1259d9c96614472ea03b5c8b51458a7b"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1329782400000}}],"disease_phase":[{"disease_id":"1259d9c96614472ea03b5c8b51458a7b","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10,"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","moiety_mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"]}
+{"drug_id":"16609a39c369454cb858feccd4634fe3","docid":36631,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"9b41a7945b47396caba66c4cd9795e0d","has_leading_org_involved":1,"created_ts":"2021-10-08T14:50:11.000Z","updated_ts":"2026-04-02T13:56:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BI-1910","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["a386cdb3b202d480ca4f6c125586164d"],"mechanism_action_id":["bcf2b894b2b53321fdcae5df1469410d","569d7324d3bdd73cc1b9e225fdfc8d5f","aec1d2051e5ae427cc9647b504af7266"],"target_id":["f4de7233a16a4575bba844af31645122"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","15839db0de0947ddb9e4c280884a3895","3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["a386cdb3b202d480ca4f6c125586164d"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","15839db0de0947ddb9e4c280884a3895","3beea980d93a4cc0abc864e27514601c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701648000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701648000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701648000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701648000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"cf139751c1fd4a5892c786230e6f6b6a","dev_status_time":{"time_trust_code":7,"time_ts":1772085899464}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"cf139751c1fd4a5892c786230e6f6b6a"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["6632a5800bfb389a90c6b15df46d2020","a386cdb3b202d480ca4f6c125586164d"],"data_source":10}
+{"drug_id":"4cab137e1da7440cafe440b1b41f30f8","docid":23293,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-05-27T03:45:38.000Z","updated_ts":"2024-10-30T10:27:46.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"人用狂犬病疫苗(MRC-5细胞)(安徽智飞龙科马生物)","source_info":[{"code":"CXSL1500073","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Rabies Vaccine(MRC-5 Cell)(Anhui Zhifei Longcom Biologic Pharmacy)","source_info":[{"code":"CXSL1500073","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["e5b09d1a4cf1e2f5d73fc73627513148"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["26bdc387cad64dc985f00855d64a3d2d"],"active_org_master_entity_id":["e5b09d1a4cf1e2f5d73fc73627513148"],"research_disease":["26bdc387cad64dc985f00855d64a3d2d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1729036800000}}],"disease_phase":[{"disease_id":"26bdc387cad64dc985f00855d64a3d2d","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"4d37da17e71e48b7b61dc4ff668b269e","docid":13720,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2023-03-02T05:30:43.000Z","updated_ts":"2024-11-09T19:47:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"UI040","status":"ACTIVE"}],"dev_code":[{"name":"UI040","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4db612721a1cfe7ad1848edd5d9b5aaa"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["4db612721a1cfe7ad1848edd5d9b5aaa"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1661990400000}}],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"5326e3b925ff4659b66f1db7d3fdac29","docid":35046,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2023-03-02T05:30:49.000Z","updated_ts":"2024-12-31T00:20:07.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"KY-1102","status":"ACTIVE"}],"dev_code":[{"name":"KY 1102","status":"ACTIVE"},{"name":"KY1102","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["34d05f489b24df9487fc7b1c823391a1"],"disease_id":["25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["34d05f489b24df9487fc7b1c823391a1"],"research_disease":["25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1667174400000}}],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"02777258392c45d9be57596ea891a70a","docid":71714,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-08-23T06:41:27.000Z","updated_ts":"2025-01-26T07:46:12.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AAV9/CLN7(University of Texas Southwestern Medical Center)","source_info":[{"code":"NCT04737460","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04737460"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["154f94cb5845ba16681bee73cd4b336f"],"mechanism_action_id":["d9627d77b8d00d879e22e88877e54736"],"disease_id":["9bafb928d6a5454fb7edfd5dfca9058b"],"active_org_master_entity_id":["154f94cb5845ba16681bee73cd4b336f"],"research_disease":["9bafb928d6a5454fb7edfd5dfca9058b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1620086400000}}],"disease_phase":[{"disease_id":"9bafb928d6a5454fb7edfd5dfca9058b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"08453de7190e433e9be9cb9ecdc72a1c","docid":81011,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"78b9fc3eea443a10a7e0a52191b5e9d2","created_ts":"2023-10-09T05:19:11.000Z","updated_ts":"2025-11-28T00:28:06.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PMB-107","source_info":[{"attachment_path":"data/phs_source_info/8a1e/48b4/ce4e/314b/074cfe73-f2b9-3937-afab-8824c683b5cd.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/6f57/dd79/9556/fe77/6542b8da-79f4-3052-abfa-f8202e898eda.png","source":"Company pipeline","source_url":"https://www.protheragen.com/available-projects.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"PMB 107","status":"ACTIVE"},{"name":"PMB107","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["1de9f3fba031e846aa7fb241b3b96955"],"mechanism_action_id":["4cba4319b53a4efb8b4868584a82d7d2"],"target_id":["531d10c27e7f4b6c9f9322e72096e15c"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["1de9f3fba031e846aa7fb241b3b96955"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0648f17d4360405789eda1c23824b877","docid":53729,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":6,"target_extend_id":"103643e0506138e7b29e3c36d470d0f9","created_ts":"2021-10-08T14:46:01.000Z","updated_ts":"2025-12-25T00:45:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Xininurad","source_info":[{"code":"WHOINN list 127","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_6&download=true"},{"normalized_source_id":"2f32e987116348eca5dea1a5aa2eb68e","source":"MedChemExpress","source_url":"https://www.medchemexpress.cn/xininurad.html?srsltid=AfmBOopWxP3BrJR0u21bVXaqXZf5rSfVsDGdyUyuXIeqqUprwyRggsSL"}],"status":"ACTIVE"}],"dev_code":[{"name":"XNW 3009","status":"ACTIVE"},{"name":"XNW-3009","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["120516bd7b1854b9b3b756ac843efb40"],"mechanism_action_id":["c7996bf2e78384d6909be1ac06e5a4e4"],"target_id":["290236e86d7242d6ad39426849da4b3e"],"disease_id":["79cc3bb048cb4837a36e22b1bcab50d3"],"active_org_master_entity_id":["120516bd7b1854b9b3b756ac843efb40"],"research_disease":["79cc3bb048cb4837a36e22b1bcab50d3"],"inactive_org_master_entity_id":["f97ef31587329638e901128a37c8971f"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba"},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1685404800000}}],"disease_phase":[{"disease_id":"79cc3bb048cb4837a36e22b1bcab50d3","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"d0579fcbe06046b4b44990d910e1dc73","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"110e99a1801a49a494be0f2671edd7b5","docid":48174,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-11-30T08:56:55.000Z","updated_ts":"2026-04-02T11:12:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Zimislecel","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-program-updates-type-1-diabetes-portfolio"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Stem cell-derived beta cells - Vertex Pharmaceuticals","status":"ACTIVE"}],"dev_code":[{"name":"STX-02","status":"ACTIVE"},{"name":"VX 880","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU1NTg4OTM3Mg==&mid=2247698919&idx=6&sn=46af713c7dd8d977f2f82821ea6b5c28"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-human-stem-cell-derived-pancreatic-islet-cells-vx-880"}],"status":"ACTIVE"},{"name":"VX-880","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU1NTg4OTM3Mg==&mid=2247698919&idx=6&sn=46af713c7dd8d977f2f82821ea6b5c28"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-human-stem-cell-derived-pancreatic-islet-cells-vx-880"}],"status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"originator_org_master_entity_id":["d3ed777a9963045de5c654e84157666d"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686","a617d77188fb2820388048fd5e4ad39c"],"special_review":["ed88b5b02898448483d0dd3ce010cfba","b7d7a459842543b7913979bf604084e4","ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["1dec6017bd924aff8aeae6e7d4a3f874"],"active_org_master_entity_id":["f71f2e67633d6da9b028b8d0c1ca7d09"],"research_disease":["1dec6017bd924aff8aeae6e7d4a3f874"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1616976000000}}],"disease_phase":[{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["165544b4f60acd151ec797c1e6c2bb9b","f71f2e67633d6da9b028b8d0c1ca7d09"],"if_speculate":0,"data_source":10}
+{"drug_id":"1dd88b35481b4412aa8df3c3833330e7","docid":1040344,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-03-10T06:44:41.000Z","updated_ts":"2025-10-30T10:48:39.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"ARC-001","source_info":[{"code":"NCT06864884","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06864884"}],"status":"ACTIVE"}],"dev_code":[{"name":"ARC-001","source_info":[{"code":"NCT06864884","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06864884"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["cb3af1899064bc77656a02a48878cae6"],"disease_id":["e05d3f1bc6e8430e8a7dc7171ae02206"],"active_org_master_entity_id":["cb3af1899064bc77656a02a48878cae6"],"research_disease":["e05d3f1bc6e8430e8a7dc7171ae02206"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1740528000000}}],"disease_phase":[{"disease_id":"e05d3f1bc6e8430e8a7dc7171ae02206","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"23f569a70dc348968ae5d4c3bf773174","docid":500111,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":377,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2024-10-30T02:30:38.000Z","updated_ts":"2026-04-18T21:06:39.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"CD19 ​CAR-NK Cells(The Second Hospital of Shandong University)","source_info":[{"code":"NCT06596057","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06596057"}],"status":"ACTIVE"}],"drug_type":["8554bd286df144c39af9350c62a5b309"],"originator_org_master_entity_id":["93f90723b997d97c715ce62063b0b86a"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a","dfe37d566f9caa8f0037337e91887158"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["1d78cca79eae4632bc4464c90a574f83","d06a737ae1d8400eb1a6b2d3034c0ebf"],"active_org_master_entity_id":["93f90723b997d97c715ce62063b0b86a"],"research_disease":["1d78cca79eae4632bc4464c90a574f83","d06a737ae1d8400eb1a6b2d3034c0ebf"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1707523200000}}],"disease_phase":[{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"d06a737ae1d8400eb1a6b2d3034c0ebf","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"3d2181bb26a146f099e4d3f633fe0c1c","docid":29816,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":60,"target_extend_id":"b27666c92ce230f08793c1d178a9d8aa","created_ts":"2023-08-14T02:22:16.000Z","updated_ts":"2026-04-18T21:08:35.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"maliman","drug_name":[{"lang":"EN","name":"RRG001","source_info":[{"code":"CXSL2300539","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"2024_656","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","source":"ASGCT","source_url":"https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=98323"}],"status":"ACTIVE"}],"dev_code":[{"name":"RRG001","source_info":[{"code":"CXSL2300539","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["9e96fb9ff6f5d53407d357b1adc76679"],"mechanism_action_id":["a7893aab3fbb5bfc849bf605888416c6"],"target_id":["e13323f0bfd343fba2f0c3a3be776873"],"disease_id":["b3613eb77a5d4795ac1a12db34d284ba","d173cfb1b42c4fd0a233da7408661091"],"active_org_master_entity_id":["9e96fb9ff6f5d53407d357b1adc76679"],"research_disease":["b3613eb77a5d4795ac1a12db34d284ba","d173cfb1b42c4fd0a233da7408661091"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701734400000}}],"disease_phase":[{"disease_id":"d173cfb1b42c4fd0a233da7408661091","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["275e6a2701a4f7195e4015058b189673","9e96fb9ff6f5d53407d357b1adc76679"],"data_source":10}
+{"drug_id":"00e61dec61534ff196d8aa6a443fe29f","docid":10762,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":28,"target_extend_id":"cb08ad70f6053dde8ff74674e5530e98","created_ts":"2023-05-04T06:12:37.000Z","updated_ts":"2026-04-18T21:08:53.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"B7-H3-CAR T cells(St. Jude Children's Research Hospital)","source_info":[{"code":"NCT05835687","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05835687"},{"attachment_path":"data/phs_source_info/SITC/1812/057c/570c/1944/c8de6dc8-1812-357c-970c-1944b5f7f34d.pdf","attachment_type":"PDF","code":"2024_471","normalized_source_id":"d6bf27e3495948d2a4d1ca87d5b5ba56","preview_attachment_path":"data/phs_source_info/SITC/1812/057c/570c/1944/c8de6dc8-1812-357c-970c-1944b5f7f34d.pdf","source":"SITC","source_url":"https://jitc.bmj.com/content/12/Suppl_2/A532"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["dc5fe49ea8e399d6cb27d389c3576b91"],"mechanism_action_id":["8026414f15c13cc907c313dc52581217","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["1728e61d30a543eda454c47f2bf1a73a"],"disease_id":["b32b5bfc7a364519a7e8c78370be7d99","0c0de9114cac42ed9e38e45b2d18475b","e63a036e6c6f41aea3ae65d2899be6af","913534b87d4543e28eeb8a7215bb8ef4","4c38270255bc4052a1a6d17475bdc51d","5851e12cf1324f78ba0e32c6a6e16f31","f7840d6af98848d28173d268c898e8ae","87d076248e754bd0b463c67df417896d","52b616e66f38449a8f5000a2ed0d9585","897d2e410ff849aeaeecc767e5907c2a","176f233747c540aca06ca7e150180765","a4f7254e36da425087293790eb964551","0da259698a9e460f91689ce99cefd42a","f71c11c225174b6781f30d98c5a022fa","c1cc2528f29940fc95fd6bc37eb982d4","c349d56721634602bd73c8f36c3b496a","5959e9df344348a984267a003b6097f7","1d6d6b0086ff422ca00418c0e8b0e940","b0800e21f0184056bee214fdae05ed8b"],"active_org_master_entity_id":["dc5fe49ea8e399d6cb27d389c3576b91"],"research_disease":["b32b5bfc7a364519a7e8c78370be7d99","0c0de9114cac42ed9e38e45b2d18475b","e63a036e6c6f41aea3ae65d2899be6af","913534b87d4543e28eeb8a7215bb8ef4","4c38270255bc4052a1a6d17475bdc51d","5851e12cf1324f78ba0e32c6a6e16f31","f7840d6af98848d28173d268c898e8ae","87d076248e754bd0b463c67df417896d","52b616e66f38449a8f5000a2ed0d9585","897d2e410ff849aeaeecc767e5907c2a","176f233747c540aca06ca7e150180765","a4f7254e36da425087293790eb964551","0da259698a9e460f91689ce99cefd42a","f71c11c225174b6781f30d98c5a022fa","c1cc2528f29940fc95fd6bc37eb982d4","c349d56721634602bd73c8f36c3b496a","5959e9df344348a984267a003b6097f7","1d6d6b0086ff422ca00418c0e8b0e940","b0800e21f0184056bee214fdae05ed8b"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1768953600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1682553600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1657065600000}}],"disease_phase":[{"disease_id":"0da259698a9e460f91689ce99cefd42a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e63a036e6c6f41aea3ae65d2899be6af","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b0800e21f0184056bee214fdae05ed8b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c349d56721634602bd73c8f36c3b496a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"176f233747c540aca06ca7e150180765","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5851e12cf1324f78ba0e32c6a6e16f31","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0c0de9114cac42ed9e38e45b2d18475b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b32b5bfc7a364519a7e8c78370be7d99","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f7840d6af98848d28173d268c898e8ae","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f71c11c225174b6781f30d98c5a022fa","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5959e9df344348a984267a003b6097f7","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"87d076248e754bd0b463c67df417896d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"52b616e66f38449a8f5000a2ed0d9585","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"897d2e410ff849aeaeecc767e5907c2a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01ed772f143c4817b8fe12bf8d5d20cf","docid":54998,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"6079fe787437342a80c24aba7d0f97d8","created_ts":"2021-10-08T14:45:52.000Z","updated_ts":"2025-08-02T02:10:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"APL-1301","status":"ACTIVE"}],"dev_code":[{"name":"APL 1501","status":"ACTIVE"},{"name":"APL-1501","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/extended-release-metap2-inhibitor-apl-1501"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["79f4d32ade58db8a44a5948e4ddc6ce7"],"mechanism_action_id":["1f717e426f8a80e298d0e05bc08b93ff","3f4c5327ac897ddad465a5792262a031"],"target_id":["30b1be6dc3a8422780502c4f42dd686e","e1b73a1cdd484ded85ad6748a0ec240e"],"disease_id":["8519ced921e14933b779c41d4cd5fe67","3a464b7a4d574586b14fc513bf6743ed","d9c985ab1f04428493c029df6dca650d"],"active_org_master_entity_id":["79f4d32ade58db8a44a5948e4ddc6ce7"],"research_disease":["8519ced921e14933b779c41d4cd5fe67","3a464b7a4d574586b14fc513bf6743ed"],"non_research_disease":["d9c985ab1f04428493c029df6dca650d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1660089600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1657065600000}}],"disease_phase":[{"disease_id":"3a464b7a4d574586b14fc513bf6743ed","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8519ced921e14933b779c41d4cd5fe67","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"00fe54a1024e4376a0d03f649418e257","docid":9132,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":7,"target_extend_id":"b4940d2a5ec733f58673cc8702f7445b","created_ts":"2021-10-08T14:48:52.000Z","updated_ts":"2026-02-24T22:17:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"NRP-2945","status":"ACTIVE"}],"dev_code":[{"name":"NNZ 4945","status":"ACTIVE"},{"name":"NNZ-4945","status":"ACTIVE"},{"name":"NRP 2945","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["6b7f6cb36d72821f7ebd428d041d2876"],"mechanism_action_id":["d2cd4756d3696a1e999497da1762f8bc"],"target_id":["3096492f215b4b89bff28010af7992b9"],"disease_id":["5a66b9249fae4d97afa13193f05749b9","82a40a56a2d7468f9375d0694366c785","5266f8596ee44b5ab9719b5882865251","738546bac89e4895b89af01545f1b054","f573ea66b81a4b799e7654e40f796a46","93fd28e08a544a8caba28019cba13e37","cdfb06abaeaf48fd92abe6a96b73de57","9921ede78a0946a5969bfbd06cac4f5e"],"active_org_master_entity_id":["6f10e82a1bb200dbf2026515f7124afc","6b7f6cb36d72821f7ebd428d041d2876"],"research_disease":["5a66b9249fae4d97afa13193f05749b9","82a40a56a2d7468f9375d0694366c785","5266f8596ee44b5ab9719b5882865251"],"non_research_disease":["738546bac89e4895b89af01545f1b054","f573ea66b81a4b799e7654e40f796a46","93fd28e08a544a8caba28019cba13e37","cdfb06abaeaf48fd92abe6a96b73de57","9921ede78a0946a5969bfbd06cac4f5e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1565654400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"82a40a56a2d7468f9375d0694366c785","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5a66b9249fae4d97afa13193f05749b9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"5266f8596ee44b5ab9719b5882865251","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9921ede78a0946a5969bfbd06cac4f5e","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"93fd28e08a544a8caba28019cba13e37","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f573ea66b81a4b799e7654e40f796a46","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"037db3a9d2eb497a84563e18dd4ce7d0","docid":234601,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":4,"target_extend_id":"e893fe268cc0320f8939f4682e5444c1","created_ts":"2024-12-26T06:45:56.000Z","updated_ts":"2026-04-18T21:06:06.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"GW906","status":"ACTIVE"}],"dev_code":[{"name":"GW906","status":"ACTIVE"},{"name":"SAL0132","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://news.futunn.com/en/post/60987144/sinopharm-002294-the-innovation-pipeline-continues-to-expand-with-the"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://xueqiu.com/7475643401/333524618"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["c903f9e20aebf776fbf98fe6d383bea7"],"mechanism_action_id":["33244514d4ae025296df2298d1b10914"],"target_id":["72aa1351fc0140d2a7f1a212003aabc1"],"disease_id":["f8f9347202e043bab0e0d627ce10e767"],"active_org_master_entity_id":["59ca7496cc95484985a6c698910796e3","c903f9e20aebf776fbf98fe6d383bea7"],"research_disease":["f8f9347202e043bab0e0d627ce10e767"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1764115200000}}],"disease_phase":[{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["41c37d4aa2bccb5479b9cdb911e8126e","c903f9e20aebf776fbf98fe6d383bea7"],"if_speculate":0,"data_source":10}
+{"drug_id":"085e9cd47e3c427980dca6b28761cf9a","docid":1671598,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"a043f919556730178e3396082671d66b","created_ts":"2025-10-10T03:28:16.000Z","updated_ts":"2026-04-02T16:38:36.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"IPN-60300","source_info":[{"code":"NCT07213817","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07213817"}],"status":"ACTIVE"}],"dev_code":[{"name":"IPN-60300","source_info":[{"code":"NCT07213817","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07213817"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["03eabe45b7364c78e49d61f2d01d4750"],"mechanism_action_id":["e4bf93a2184b47a3b5bf4dd5ee683d16"],"target_id":["75b0cad036fe40c899095671c3936b49"],"disease_id":["15cb523e0fbd4617a6a129ad2336eb9a","6c9c5be211cb4d72a28205c49a16d653"],"active_org_master_entity_id":["03eabe45b7364c78e49d61f2d01d4750"],"research_disease":["15cb523e0fbd4617a6a129ad2336eb9a","6c9c5be211cb4d72a28205c49a16d653"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1764892800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1764892800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1764892800000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"219c0db7b2f54a2eb42204073fa00dae","docid":1730397,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":39,"target_extend_id":"d81bdf4ce27c31b7bce00da6d4c2408c","created_ts":"2025-08-01T10:11:10.000Z","updated_ts":"2026-03-14T21:10:41.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"LUCAR-E9D","source_info":[{"code":"NCT07093411","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07093411"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["5a1e5cbb0de12fd41dff50a5d99f9508"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","16b5dca2ef00478ba4719851807e1c05"],"target_id":["5eb1fc5283d34305934a031af530f448","8b4260187fa64823b593f35188526e50"],"disease_id":["06fb65d06e024491946f34384f1bae67","4c9d46b2b7794d128b14d8689f4c357d"],"active_org_master_entity_id":["5a1e5cbb0de12fd41dff50a5d99f9508"],"research_disease":["06fb65d06e024491946f34384f1bae67","4c9d46b2b7794d128b14d8689f4c357d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1754352000000}}],"disease_phase":[{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"06fb65d06e024491946f34384f1bae67","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"32480643772e4405a6fee9f10b60fd7c","docid":22170,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":38,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2023-04-20T02:39:12.000Z","updated_ts":"2026-04-18T21:05:18.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"司美格鲁肽生物类似药（惠升生物）","status":"ACTIVE"},{"lang":"EN","name":"Semaglutide biosimilar (Jilin Huisheng)","source_info":[{"code":"CXSL2300274","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"generic_name":[{"name":"Semaglutide","status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["1b130caf2b241723ee507706dd2bae56"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"atc_code":["679079a6331a49aaa6b192c7455e8e0e"],"disease_id":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["1b130caf2b241723ee507706dd2bae56"],"research_disease":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1755302400000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["c7a2671dc0574f19bc42d557eca3906f"],"deal_related_org":["1b130caf2b241723ee507706dd2bae56","3bcf6950a75150fc675bf64405ce9d68"],"data_source":10}
+{"drug_id":"005c0f091e9f461aaf473c6e6386c688","docid":16411,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"a37b202721cb3e1db5965b3b255441e3","created_ts":"2021-10-08T14:44:06.000Z","updated_ts":"2026-04-02T11:28:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"AL-002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzU2MTQ2MDE0Ng==&mid=2247557025&idx=3&sn=0b706b90a38c83a0dd69b3ead6eea7b1"}],"status":"ACTIVE"}],"dev_code":[{"name":"AL 002","status":"ACTIVE"},{"name":"AL 002A","status":"ACTIVE"},{"name":"AL002","source_info":[{"code":"2022_P5-3.004","normalized_source_id":"d704ed770c474e2c9efb869e48ed7e7c","source":"AAN","source_url":"https://www.neurology.org/doi/full/10.1212/WNL.98.18_supplement.3133"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["5c9176a4b481f10fe7b2875ff66fad2a"],"mechanism_action_id":["a5bfd6908272ed378145da2636bc0143"],"target_id":["2acf8cdf088a44498363bdefd665f741"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0"],"active_org_master_entity_id":["5c9176a4b481f10fe7b2875ff66fad2a"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"inactive_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1611273600000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"07e42e780f144cb4a72f16de9f52c9df","docid":73281,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":55,"target_extend_id":"72f0756e968137c593f0a814fe9c30b6","created_ts":"2023-03-03T03:57:07.000Z","updated_ts":"2026-04-18T21:09:02.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"DO-2","source_info":[{"code":"NCT05752552","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05752552"}],"status":"ACTIVE"}],"dev_code":[{"name":"DO 2","status":"ACTIVE"},{"name":"DO2","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["81cc5202cbce52e20c918f229bd85d3f"],"mechanism_action_id":["42a08387c5467c334017c9831c2ed7bd"],"target_id":["72bcad51964147ffb8208403eb9c1243"],"disease_id":["e2fd9bda4aeb4a7b9fa53a2560126d24","0464f5493b0444e9875a0584df17cbf0","06547f1d0758469d863d6a799b8e2e6b","3beea980d93a4cc0abc864e27514601c","847a0ea7462c4293b185766079ef37a2"],"active_org_master_entity_id":["81cc5202cbce52e20c918f229bd85d3f"],"research_disease":["e2fd9bda4aeb4a7b9fa53a2560126d24","0464f5493b0444e9875a0584df17cbf0","06547f1d0758469d863d6a799b8e2e6b","3beea980d93a4cc0abc864e27514601c","847a0ea7462c4293b185766079ef37a2"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1671494400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1671494400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1733961600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1671494400000}}],"disease_phase":[{"disease_id":"847a0ea7462c4293b185766079ef37a2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"06547f1d0758469d863d6a799b8e2e6b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"00fabe9205414c498b33119113d2a9a7","docid":1611585,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2025-09-12T05:24:54.000Z","updated_ts":"2025-11-13T22:06:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"BL-1107","source_info":[{"code":"NCT07168902","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07168902"}],"status":"ACTIVE"}],"dev_code":[{"name":"BL-1107","source_info":[{"code":"NCT07168902","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07168902"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["2365f8d421364f2fb42fa11d478e8024"],"disease_id":["ea0f42e761174de5aeebef65a0a97f8f"],"active_org_master_entity_id":["2365f8d421364f2fb42fa11d478e8024"],"research_disease":["ea0f42e761174de5aeebef65a0a97f8f"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1761264000000}}],"disease_phase":[{"disease_id":"ea0f42e761174de5aeebef65a0a97f8f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"050af64b7c024cb496f86c96ad2f468d","docid":33234,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":277,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2022-08-22T08:35:30.000Z","updated_ts":"2026-04-11T21:09:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"靶向CD19基因修饰的异体嵌合抗原受体T细胞(邦耀)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5ODIxMjA1Mg==&mid=2655183124&idx=3&sn=c4be25bdac5bda339d5b166f3b34e7b4"}],"status":"ACTIVE"},{"lang":"EN","name":"BRL-303","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti CD19 universal chimeric antigen receptor T cell therapy(Bioray)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5ODIxMjA1Mg==&mid=2655183124&idx=3&sn=c4be25bdac5bda339d5b166f3b34e7b4"}],"status":"ACTIVE"}],"dev_code":[{"name":"BRL 303","status":"ACTIVE"},{"name":"BRL303","status":"ACTIVE"}],"drug_type":["8cda7e9356a7439ea27ce1a899143e5c"],"originator_org_master_entity_id":["82ad43598d0815d35c26d0d7a5e4565a"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["0c8a0603507542faac6b5ef3e27c6728","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","60a67018512a44caafa8f5d6dcb5339f","8b0644971f31409283cac32a7d08fd52","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["82ad43598d0815d35c26d0d7a5e4565a"],"research_disease":["0c8a0603507542faac6b5ef3e27c6728","cdfb06abaeaf48fd92abe6a96b73de57","f3433922efe24dfaada77415e3e66ea0","60a67018512a44caafa8f5d6dcb5339f","8b0644971f31409283cac32a7d08fd52"],"non_research_disease":["ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1773360000000}}],"disease_phase":[{"disease_id":"60a67018512a44caafa8f5d6dcb5339f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"8b0644971f31409283cac32a7d08fd52","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_before_ter_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"if_speculate":0,"data_source":10}
+{"drug_id":"215beee8ca444ffcafc78896b4da08e8","docid":1763366,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":145,"target_extend_id":"462f4be0a7f630efa6b9cb3dbb9ab9ef","created_ts":"2026-02-09T06:16:09.000Z","updated_ts":"2026-04-04T21:11:12.000Z","data_status":"ACTIVE","created_by":"yuanjing","updated_by":"yuanjing","drug_name":[{"lang":"EN","name":"In vivo CAR-T drug targeting CD20 based on mRNA-LNP (The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation)","source_info":[{"code":"NCT07362602","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07362602"}],"status":"ACTIVE"}],"drug_type":["07c615d6d6644a87ba74fb48dd7eefe8","cc10afbd78954c8db6d1d3fee0684a77"],"originator_org_master_entity_id":["237a0074c2b84e83cc74d8cc27887b18"],"mechanism_action_id":["16b5dca2ef00478ba4719851807e1c05"],"target_id":["8b4260187fa64823b593f35188526e50"],"disease_id":["03ed67c7a80847d5951b51a54f6290fe"],"research_disease":["03ed67c7a80847d5951b51a54f6290fe"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"03ed67c7a80847d5951b51a54f6290fe","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4cec1d2738294441a19d4aeb903cef3d","docid":231376,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2024-06-06T06:53:26.000Z","updated_ts":"2026-03-19T09:18:09.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"TRN-257","source_info":[{"attachment_path":"data/phs_source_info/279c/19b5/8db9/5e71/d599802f-b7bf-35ad-9c65-c4be9ad47e84.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/02c5/43ef/964c/97e9/2b59ea34-4f93-3607-a74d-f7b50403d1f2.png","source":"Company pipeline","source_url":"https://www.trispharma.com/who-we-are/"}],"status":"ACTIVE"}],"dev_code":[{"name":"TRN 257","source_info":[{"attachment_path":"data/phs_source_info/279c/19b5/8db9/5e71/d599802f-b7bf-35ad-9c65-c4be9ad47e84.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/02c5/43ef/964c/97e9/2b59ea34-4f93-3607-a74d-f7b50403d1f2.png","source":"Company pipeline","source_url":"https://www.trispharma.com/who-we-are/"}],"status":"ACTIVE"},{"name":"TRN257","source_info":[{"attachment_path":"data/phs_source_info/279c/19b5/8db9/5e71/d599802f-b7bf-35ad-9c65-c4be9ad47e84.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/02c5/43ef/964c/97e9/2b59ea34-4f93-3607-a74d-f7b50403d1f2.png","source":"Company pipeline","source_url":"https://www.trispharma.com/who-we-are/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a3710263b921a1b57017fe05fd2c9e6d"],"disease_id":["5e3541677d4341319d1aa02cfca4968b","749138e144c24dc08d20e583727f3642","c8d129b624ea43e09138ee8385d23024"],"active_org_master_entity_id":["a3710263b921a1b57017fe05fd2c9e6d"],"research_disease":["5e3541677d4341319d1aa02cfca4968b","749138e144c24dc08d20e583727f3642","c8d129b624ea43e09138ee8385d23024"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1765238400000}}],"disease_phase":[{"disease_id":"c8d129b624ea43e09138ee8385d23024","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"749138e144c24dc08d20e583727f3642","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"5e3541677d4341319d1aa02cfca4968b","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"00628594f6154ed1b73621f01c5b5d66","docid":263556,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":14,"target_extend_id":"1db19bb876bd35df98951dedd37fdd81","created_ts":"2024-09-05T05:11:31.000Z","updated_ts":"2026-03-12T09:52:09.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"GB-7624","source_info":[{"attachment_path":"data/phs_source_info/dc54/a37f/4378/d523/df66aa76-d25e-3586-ae4c-ea40b025bd45.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f757/6f07/b79e/3cc6/a4445118-1d7b-3a6c-801a-03fd41f4513f.png","source":"Company pipeline","source_url":"https://generatebiomedicines.com/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"GB 7624","source_info":[{"attachment_path":"data/phs_source_info/dc54/a37f/4378/d523/df66aa76-d25e-3586-ae4c-ea40b025bd45.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f757/6f07/b79e/3cc6/a4445118-1d7b-3a6c-801a-03fd41f4513f.png","source":"Company pipeline","source_url":"https://generatebiomedicines.com/pipeline"}],"status":"ACTIVE"},{"name":"GB7624","source_info":[{"attachment_path":"data/phs_source_info/dc54/a37f/4378/d523/df66aa76-d25e-3586-ae4c-ea40b025bd45.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f757/6f07/b79e/3cc6/a4445118-1d7b-3a6c-801a-03fd41f4513f.png","source":"Company pipeline","source_url":"https://generatebiomedicines.com/pipeline"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["4078f43da5ac7d019eacedba42492661"],"mechanism_action_id":["e02a7703a68d4f39d2ee3ffc929eb0a2"],"target_id":["d8714f87ee3f4ba6a4b21a58500ea620"],"disease_id":["b5068ce40bb1403ab9a02fa97954ebb1"],"active_org_master_entity_id":["4078f43da5ac7d019eacedba42492661"],"research_disease":["b5068ce40bb1403ab9a02fa97954ebb1"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1743033600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1772323200000}}],"disease_phase":[{"disease_id":"b5068ce40bb1403ab9a02fa97954ebb1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"04a86076215f41eea8f21a1995da49be","docid":31539,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":6,"target_extend_id":"71445c6af41138eebb0675d8f43f0d22","created_ts":"2023-04-11T05:48:55.000Z","updated_ts":"2025-12-05T00:30:47.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing CAR-T(City of Hope Medical Center)","source_info":[{"code":"NCT03873805","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03873805"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"MB-105","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://ir.mustangbio.com/news-events/press-releases/detail/131/mustang-bio-announces-city-of-hope-mb-105-prostate-stem"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["cc168bd6b3777890022201b4f755e4ed"],"mechanism_action_id":["8e4fb982bcf2b036d5d72beff7b956cc","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["a3e90d1c5e7749fb9143749b97b484b8"],"disease_id":["27538fe67e9b4648b06de8efdc9ab891"],"active_org_master_entity_id":["cc168bd6b3777890022201b4f755e4ed"],"research_disease":["27538fe67e9b4648b06de8efdc9ab891"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1566259200000}}],"disease_phase":[{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["38d455ae46701de1355c85611b8d90d5","cc168bd6b3777890022201b4f755e4ed"],"if_speculate":0,"data_source":10}
+{"drug_id":"002ff1c130254b02983a9282528b4d1c","docid":62969,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"antibody_drug_id":"88c50334743b0e3d17bb3306c5d95092","payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":40,"target_extend_id":"c3564a2e384d34ef94516d844f563ba3","created_ts":"2021-10-08T14:37:56.000Z","updated_ts":"2026-04-18T21:07:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Gallium-68 P16-093","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HBED-CC-PHENOXY-PSMA","status":"ACTIVE"}],"dev_code":[{"name":"68GA-P16-093","source_info":[{"code":"NCT05569434","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05569434"}],"status":"ACTIVE"},{"name":"GA-68 P16-093","status":"ACTIVE"},{"name":"GALLIUM-68-P16 093","status":"ACTIVE"},{"name":"PSMA-093","status":"ACTIVE"},{"name":"PSMA-93","status":"ACTIVE"},{"name":"PSMA-93 Latest","status":"ACTIVE"},{"name":"[68GA]P16-093","status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["b779eaa164a02b79ba3de554cc2e490e"],"mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"target_id":["1764007a7c384a4ab49bb3710bab5052"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4","4c38270255bc4052a1a6d17475bdc51d","f3b6709f95d34c30ae5c97423c8e2450","31a4a651f7744562b44cedbe4a0f942f","1259d9c96614472ea03b5c8b51458a7b","9524995c426b4d93a80908af4a018bba","7a4b3645bc7c4b2aa1a4f50f1fc5a98e","c7fe8aa844d24e85ba32a990ea28ded3"],"active_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a","b779eaa164a02b79ba3de554cc2e490e"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4","4c38270255bc4052a1a6d17475bdc51d","f3b6709f95d34c30ae5c97423c8e2450"],"non_research_disease":["31a4a651f7744562b44cedbe4a0f942f","1259d9c96614472ea03b5c8b51458a7b","9524995c426b4d93a80908af4a018bba","7a4b3645bc7c4b2aa1a4f50f1fc5a98e","c7fe8aa844d24e85ba32a990ea28ded3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1525910400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1638057600000}}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7a4b3645bc7c4b2aa1a4f50f1fc5a98e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_before_ter_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"9524995c426b4d93a80908af4a018bba","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1259d9c96614472ea03b5c8b51458a7b","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f3b6709f95d34c30ae5c97423c8e2450","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"31a4a651f7744562b44cedbe4a0f942f","highest_phase_before_ter_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10,"target_moiety_type":["58f172e4a4794372b08b2dda980530de"],"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","moiety_mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"]}
+{"drug_id":"173895f4ca9c4114995b44d2b51792b7","docid":57215,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-08-03T08:55:41.000Z","updated_ts":"2026-01-27T15:47:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"通降颗粒","status":"ACTIVE"},{"lang":"EN","name":"Tongjiang granule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["a99cc48730694f2bd757169fc1e1661a"],"disease_id":["801770be2c414ae5a15289e29f2d3345","3d958eb7647f4866a9d9c7e6e59cbdd3","528fd47440a645e28862e7df87234ed2","e9a93e0e1460463f9b07c8be368f5f1f"],"active_org_master_entity_id":["a99cc48730694f2bd757169fc1e1661a","13def6a18229f5d18f5ec2278256933c"],"research_disease":["801770be2c414ae5a15289e29f2d3345","3d958eb7647f4866a9d9c7e6e59cbdd3","528fd47440a645e28862e7df87234ed2","e9a93e0e1460463f9b07c8be368f5f1f"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1730764800000}}],"disease_phase":[{"disease_id":"528fd47440a645e28862e7df87234ed2","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e9a93e0e1460463f9b07c8be368f5f1f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"801770be2c414ae5a15289e29f2d3345","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3d958eb7647f4866a9d9c7e6e59cbdd3","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"0349f4cfbf5544e09ad8c949176467cd","docid":52913,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":515808000000,"created_ts":"2022-05-30T12:15:21.000Z","updated_ts":"2025-02-06T10:49:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"柴苓湯","source_info":[{"code":"61AM3275","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Chai Ling Decoction","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Saireito","status":"ACTIVE"},{"lang":"EN","name":"Saireto","source_info":[{"code":"61AM3275","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"dev_code":[{"name":"TJ 114","source_info":[{"code":"61AM3275","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"trade_name":[{"name":"TSUMURA","source_info":[{"code":"61AM3275","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"ツムラ","source_info":[{"code":"61AM3275","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["139a5a0760d49c49700c6fb2344bf709"],"mechanism_action_id":["17b6821afc544cdca2d96c01cbeb1d73","d63148de4ef4473294926d731d4abe2d"],"disease_id":["9ae2cc5998864064b64b6921f689165d","c767942729234ca5bc68f8e5058670d9","3712475ac79145819001df5f635cf149"],"active_org_master_entity_id":["139a5a0760d49c49700c6fb2344bf709"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["9ae2cc5998864064b64b6921f689165d","c767942729234ca5bc68f8e5058670d9","3712475ac79145819001df5f635cf149"],"research_disease":["9ae2cc5998864064b64b6921f689165d","c767942729234ca5bc68f8e5058670d9","3712475ac79145819001df5f635cf149"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":515808000000}}],"disease_phase":[{"disease_id":"c767942729234ca5bc68f8e5058670d9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3712475ac79145819001df5f635cf149","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"9ae2cc5998864064b64b6921f689165d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0842f22ad142037e21a1f35a228c6f25","docid":231222,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":26,"target_extend_id":"75fdcf5bf499369580c308e613a6a161","created_ts":"2024-06-04T07:50:15.000Z","updated_ts":"2026-04-04T21:06:00.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-CD70 CAR-T (Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine)","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["59467db2d001adec6a0e514cf1b6940c"],"mechanism_action_id":["694da660ce878d08d75c79e8a4b7d807"],"target_id":["79d24e30a7ff40bb806ff36962c750e8"],"disease_id":["6fe05469e09f4305b7615b2c277382cd"],"active_org_master_entity_id":["59467db2d001adec6a0e514cf1b6940c"],"research_disease":["6fe05469e09f4305b7615b2c277382cd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"248936113cda4c6c87b5cfac85370346","docid":262290,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"3faad3a9685140259a3b782e9ca1f3a3","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":50,"target_extend_id":"e2b2160581553002818ef8c2ab06de2c","created_ts":"2024-06-24T07:10:50.000Z","updated_ts":"2026-04-11T21:04:00.000Z","data_status":"ACTIVE","created_by":"yangjinhua@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"3BP-4961","source_info":[{"attachment_path":"data/phs_source_info/7217/c491/5e35/bfd0/747e2568-2998-3f0b-b997-d65a06d8d486.jpeg","attachment_type":"image/jpeg","code":"3B Pharmaceuticals-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/94f7/e09d/fe99/d816/87b6b864-7ba2-3c76-9b77-dc2a71fd1fc7.jpeg","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"}],"dev_code":[{"name":"3BP 4961","source_info":[{"attachment_path":"data/phs_source_info/7217/c491/5e35/bfd0/747e2568-2998-3f0b-b997-d65a06d8d486.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/94f7/e09d/fe99/d816/87b6b864-7ba2-3c76-9b77-dc2a71fd1fc7.jpeg","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"},{"name":"3BP4961","source_info":[{"attachment_path":"data/phs_source_info/7217/c491/5e35/bfd0/747e2568-2998-3f0b-b997-d65a06d8d486.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/94f7/e09d/fe99/d816/87b6b864-7ba2-3c76-9b77-dc2a71fd1fc7.jpeg","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"},{"name":"99mTc-3BP-4961","status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["e1b49c6db6775df734af8e4abbf19f23"],"mechanism_action_id":["0389578921da93a1bb6dd14e83f31524"],"target_id":["b7c5c1575f6d4048978a5b5da2159878"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["e1b49c6db6775df734af8e4abbf19f23"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1718928000000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"028dbd255126421ca9a04a364ecf6806","docid":42819,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Olaparib","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1418688000000,"rnk":1,"target_extend_id":"47599b8594313e28b8225bf65f5488ca","has_leading_org_involved":1,"created_ts":"2021-10-08T14:38:32.000Z","updated_ts":"2026-04-16T22:15:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":1534896000000,"drug_name":[{"lang":"CN","name":"奥拉帕利","status":"ACTIVE"},{"lang":"EN","name":"Olaparib","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"オラパリブ","source_info":[{"code":"23000AMX00022","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one","source_info":[{"code":"DB09074","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Olaparib (JAN/USAN/INN)","source_info":[{"code":"D09730","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"CN","name":"奥拉帕尼","status":"ACTIVE"}],"dev_code":[{"name":"AZ-2281","source_info":[{"code":"WOH1JD9AR8","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/c4a89749-b5ae-4079-a28f-367c5907f63f"}],"status":"ACTIVE"},{"name":"AZ2281","source_info":[{"code":"WOH1JD9AR8","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/c4a89749-b5ae-4079-a28f-367c5907f63f"}],"status":"ACTIVE"},{"name":"AZD-2281","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/olaparib"}],"status":"ACTIVE"},{"name":"AZD2281","source_info":[{"code":"23000AMX00022","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_13"},{"code":"23000AMX00023","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_13"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/olaparib"}],"status":"ACTIVE"},{"name":"KEYLYNK-010 COMPONENT OLAPARIB","source_info":[{"code":"WOH1JD9AR8","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/c4a89749-b5ae-4079-a28f-367c5907f63f"}],"status":"ACTIVE"},{"name":"KU-0059436","source_info":[{"code":"23000AMX00022","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_13"},{"code":"23000AMX00023","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_13"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/olaparib"}],"status":"ACTIVE"},{"name":"KU-59436","status":"ACTIVE"},{"name":"MK-7339","status":"ACTIVE"},{"name":"NSC-747856","source_info":[{"code":"WOH1JD9AR8","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/c4a89749-b5ae-4079-a28f-367c5907f63f"}],"status":"ACTIVE"}],"trade_name":[{"name":"Lynparib ","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzYyNTUwMDUzMg==&mid=2247484083&idx=1&sn=9d4cb9a07b9ce2ab47fae5a2fd3946ba"}],"status":"ACTIVE"},{"name":"Lynparza","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D09730","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"23000AMX00022","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_12"},{"code":"23000AMX00023","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_12"}],"status":"ACTIVE"},{"name":"リムパーザ","source_info":[{"code":"23000AMX00022","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_12"},{"code":"23000AMX00023","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670227_4291052F1027_1_12"}],"status":"ACTIVE"},{"name":"利普卓","status":"ACTIVE"},{"name":"린파자정","source_info":[{"code":"201907537","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=201907537aupdateTs2024-05-26%2015:13:20.0b"}],"status":"ACTIVE"}],"generic_name":[{"name":"Olaparib","source_info":[{"code":"D09730","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB09074"],"kegg_id":["D09730"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506"],"mechanism_action_id":["628e980749144ca874b0b46fdcc15375","70407f867b0c27aadbdbf758edf61da8","efd5715e7a916d5d6a3b0afa9f3cf9c0"],"target_id":["509d1b32b6d54cf5859a50e36c5192d5","50eac89b0d3a4f15a5ca5fc079869188","1380fb47b4e24343917137b19dd75291"],"atc_code":["557b315ded7547e58d6d01f9958a8cb6"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","df5e83eb171a4eb095fcab2f1470348d","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e","9eb8777c62af4712932b360e6ef3e454"],"disease_id":["2b45ab274bbb47cbacf94b280d32d1d8","15efc91d373b41f08cea343f62d56420","5735ae177a59485fb92f09e758e4224b","78bce8f420c8482bbf1b2bafdf281357","a7b08795ca6c4e249dfdb6f9a990eccf","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","e9d6fc1f21704dba80bc8465bbe87d96","815e953f089a4510b397bd3f901ece20","6a962a4341364bbe9959b413849567de","f319fa27684c4cdeb6ce59d897217718","c297238c41b2488abe3de6546b105a4e","358a5369f3ed4952915e1713c998e477","2727f13d200e4493b2f6db709193035b","3615202fb9fb468391a53ee84733ca53","60058a4fc91f474688db03e7a12edf67","6d98a1f6be594b0ba2e1ee55c3738006","e9d90a15b30a4185b8f2e6091c125195","653c8e3e508441b6af17b525de5c6b3e","d61edc148e2f472ba1aef3c491ed9fd3","27538fe67e9b4648b06de8efdc9ab891","3aecb71c582e487c962fa840ee3ef8f5","024deb39dbdb42eea0863db300b15242","9e654bca42a342cfb3611ff78869eac6","94ac5bd14d964124acacc3de59b307b3","14ec9b8e33d44047806876c548688ba0","5b1807d6c7fe4f069816bbb27a23d507","5cedd9732f5b45f1b6e9b226b32a0314","0f21202737c54171b46b5fbb422cefe3","87a9454771a64f2191224b6b7684254a","e130bdf36b3d4432a317beddbd11d181","332d60a14b7b43278a24d0ac2961a361","2d94f94415454317a68f499ad53332db","9eeccc4caf594a5abedc0559fd9e0424","703dd75ecc8740df908141aa5252ff4c","dd16b20c0ed446fc8f3fa4791f8aca8a","8591258764a4428a9d9d641e74fc1591","90ffc68d955c4ddaac828195a04fd5a4","32b2a7f88bfd47f08d38b864034f7ee1","e951cb2d1af6487e8fe25702c6744fcb","eb1a3677476e4684bdf3a3e27121c768","9e50d44715e747bbbe1de4ec04b668b2","c8af1f6afc6445e49fc47f4f0837f134","6a6753c1c1d74648aa399e9f3bc22350","f0e77325ab1e46a899ce62a7c13214cc","3428d019f74042c9b04557aaa3f597e2","a4e38c779cd349c2a4f92189f6aba256","b382bc2a56644776b45dc6084224df3b","f98fd32baa8447119bb87f84093b925c","a9f502452b4a484fb5ee531d3aa4e1b7","e437e1bf7a0d4b309027a6d4bfead264","218de7027c39474b884ca5d174846630","f92e4ba771d04f27a1f4daae363b676a","2ec5825d4b1844538f076141667aa5b0","be26bd5a3626417eabc7fde7a7b8b3d9","2027b8d2fc1b4e42adbd1af5e32671e6","9566286e4bce400eb3e4e6c4baaef014","976f9f8cf61f4a77a1866cb146de181e","2536e79ced34450fbb09de73061cf096","a6cd07ecf38e48b584e8da2adfbe5f42","112de5f741ee49e296dc1b4e90c5d1be","fc0780b4f42b41d0a3dbbc522d0724dd","8e6f6909e2944b7fa8f3593ee96562c1","43a01c3d180b45438f911c6502567931","ba6b0ff4d7dd41759043537555abad4c","6f7797132868456290dac6532b7aefa6","5244e19b1be4440894371237bc81bc89","0a885de5b4054c2b98d478f91f3e3418","de54542063ce4e43b254c7605045d9ed","4c218caf0fc743fda0f4029881b59c29","1954d1a9e4c04e7fb608cb3b89462ca2","d00b4df2a8fb4a97960ede39bf58c0ef","ed204c2d1b6245098bb07da9c6b00eb5","c3b9ec7eb2e2402fae4916a1d3f6504a","7e87f9c6dcd841edb4d0f250b6bee3d9","715cf5754a784fa6bad846d43e0f95df","2830f7d877eb4edbb02322f5bfd5b20b","1d6d6b0086ff422ca00418c0e8b0e940","73fd82d969b1457a85183ca272200cb7","e8b97ed62c0841fea7bc994d9cee120d","ca0f986ae31842b7bddbb61e1b22d5c5","0280230944dd459981ccb201a4aa173d","1259d9c96614472ea03b5c8b51458a7b","3beea980d93a4cc0abc864e27514601c","172ae38eecf24baf9af4f00892b79268","3feede3e46cc4445a3f98e8c2347deb2","3c3e57982b6e4b9ca67763646d96def0","4538da8b1178468dba60afdf16a82030","e9011a11cfd94ac6bbf9980ff2b5c04f","b13c61f6e6624d9aac0b084bb8c7e302","36768453c23d4834a4e2025f9628fa27","7665e5683a1a443a8f3d3b946d4c9ca2","598372309fac44dfa9afd74266b0d581","07994e875a7f44dc9af7f9bf3f6989e5","15cb523e0fbd4617a6a129ad2336eb9a","f746f1cefd0045e8be690bb5d0cf367d","881cc9ec9e4f4b80afcb49a2e3cf2c98","6c9c5be211cb4d72a28205c49a16d653","31a4a651f7744562b44cedbe4a0f942f","771cf2b42f9c4d45821d2a1e47065a8a","7af2742b1e824bb4bae223164df67757","ff9aa0c7e2c947afb9749d2ce115c0da","da39057092a4433ca83732d7f5f368ea","d9c985ab1f04428493c029df6dca650d","3286f34c38e046d59dfb2217e31655a2","d54d312275024917bb28ca24dec027b1","5d354303e3c6403b81ad16f51d58a327","3bf6031206e848cd94f767cd1db43ea0","7a4a14243a4b49e3b5b691978e9e3087","1d3b5642bc8740639e8972872688855a","f3b6709f95d34c30ae5c97423c8e2450","1c98b7b762dc466c9cc4a32d4074a350","45b63f48721147a8be2c3291d20b19ac","d13184f8097c42b081e9eea0a29c69cf","0464f5493b0444e9875a0584df17cbf0","a636be1e48e347ac9018a1f1223532b0","2bb755a3f43f49dea60661c5f99712a3","58f692a66e03451d89d57770cd915d61","8c161437fb424389ab1fde27b93a895b","8bea5bec08e44c1ea7a90c7a1e3daeb8","78cb173a4de34f07befac28de907e7bf","d8ba7ca3e2324ae981eedd136acedb30","6570754a6f0b43b78a9926c7bfd00519","941ef5bdf9fa49b3b8054dd755019209","8d29f554f371431c9b5b80f5befdf965","8eaa9c59b7674ad692d8fbc5c68e845c","ab7c198e47834770a36ab3282d331531","7f8dba6cc5c24bff9bfffb5d5a9352bc","3df822c8c6984e33bf17c1e2861c9ba3","55dedf76dca5451aa305803789a02f30","ebd4baa37271451385bbae40b7d0f3e6","5851e12cf1324f78ba0e32c6a6e16f31","65552aa23c0e405ea87623aa0de08dd8","e2caed1e43604f0fb5eaea4351dbe5f7","e2fd9bda4aeb4a7b9fa53a2560126d24","09529518c8164578ac870e810c3c677b","63333c316c3b493487303520d1e0c9d8","4c092510a2af42f387426e408f5c7694","a0304a462da04e7cb03e3f2c5625544e","fd7ba28668d8489eb8c951444259baf4","23e532ec53174e7eb1b672cd0e343751","0d330b060a734207baf61dd85f8d77cd","50c397f334694253be0d0ef704e23dc0","f7ea24f0370d421480503e720310bf86","74ba301586ab419b9c9accd39cd20782","dc3ac98bdc5a4f9298fc030de877c4b6","951522b08c924c77a8023509e8e3fe93","536f59a6981645d88bbd7b1facea031f","62c9dd9ddf6c4960bfa4dd9f5bf57d08","1e6992f1403346acad1273d778686ca7","f6e482d871f14267892ce687d3eeea1a","6c9886cb25eb45faba70292cee1f5518","30b1787d28ea4a65aee18822a1279bfb","01773f22c03f4beda403b65654c1698d","83d4a7a4b99e4c9fa8e6c012527381b5","8da4804a5bd24352b7d568a7da54c6dc","e35ce4e9b7a846d49e600ce7ac4a7fd6","5f56d0189e534ecc99f8614a687ba171","ba02154031ca48aba76cd279bdca8ade","a311ae2187914c2bbad45810b91f9414","e67c7fcd3d3a494ab70e1efe0b82ecdc","f6678ca4757d4b46843d6dfd2739e2a1","8c0eafe0f91148099c2aaf56b71ad355","8af6a1a934a64113b19e8024a8037f87","ee2ede109de84cfda49bc999601085b4","e47ba0c33e85473e9171b4125ae2216b","9b60b7d38a4044b3b7f98c61c365e6b9","557f5ccfe746466cbdb9383a94178eef","ea61957e488b4ae3b60e7f73c8e297c6","c9591fe1148945969dd4acaf88747236","8ab4572efc344edbad36869731b2bc25","f3f1224c00c644b4bf32504e9c4ea175","33c23b2c292c49b8b941b169a698bf02","828fb9fef58643deaeb03ba65a7d3953","644d78b6fae343b98e118e64f2717be2","847a0ea7462c4293b185766079ef37a2","e66bd159ca524a14af868bead50619f2","f7ff421129ab40b19648cd3b1fc08f0f","2477c68e093d4b818b11333ee1a5ee02","ca1336d953b4489d9378b4a6ccf0de6f"],"active_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020","6e7a2de70d46daa0cef8586ca22ae506","c9d21951f235ac704a6c0b37d1556f0f","8656d37d668a52bf73421c7b34d2e105","462096edf3de7b2de5a70c8fa9b70fa3","07437ec41d6752fddbc9c36e0aa06860","d88590e686ad5608bbbfeb811b14d188","a14d392812c90845d3b3aa6c1924ea62","df50a750217b01244a8814ee8d79bcfd","d784b38f8630b0a18bfc94a5c6202d24","445ea4164b30c123f74a0cc39c1a41af","f7ceef270cda82dc4ef6ca07c8421e54","c875d08709c0a926cf0c5c8bd4248c9a","7d68f721fabda3ab647321e4a8668093","f542e37eb5968e9ca06a58c67bb7a4ef","751ff1f0326406ac8e2cdb6b0a9f5c9c","cb3446037d08a7f62c2d8ecc35059d2a"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["358a5369f3ed4952915e1713c998e477","2727f13d200e4493b2f6db709193035b","3615202fb9fb468391a53ee84733ca53","60058a4fc91f474688db03e7a12edf67","6d98a1f6be594b0ba2e1ee55c3738006","e9d90a15b30a4185b8f2e6091c125195","653c8e3e508441b6af17b525de5c6b3e","d61edc148e2f472ba1aef3c491ed9fd3","27538fe67e9b4648b06de8efdc9ab891","3aecb71c582e487c962fa840ee3ef8f5","024deb39dbdb42eea0863db300b15242","9e654bca42a342cfb3611ff78869eac6","94ac5bd14d964124acacc3de59b307b3","14ec9b8e33d44047806876c548688ba0","5b1807d6c7fe4f069816bbb27a23d507"],"research_disease":["2b45ab274bbb47cbacf94b280d32d1d8","15efc91d373b41f08cea343f62d56420","5735ae177a59485fb92f09e758e4224b","78bce8f420c8482bbf1b2bafdf281357","a7b08795ca6c4e249dfdb6f9a990eccf","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","e9d6fc1f21704dba80bc8465bbe87d96","815e953f089a4510b397bd3f901ece20","6a962a4341364bbe9959b413849567de","f319fa27684c4cdeb6ce59d897217718","c297238c41b2488abe3de6546b105a4e","358a5369f3ed4952915e1713c998e477","2727f13d200e4493b2f6db709193035b","3615202fb9fb468391a53ee84733ca53","60058a4fc91f474688db03e7a12edf67","6d98a1f6be594b0ba2e1ee55c3738006","e9d90a15b30a4185b8f2e6091c125195","653c8e3e508441b6af17b525de5c6b3e","d61edc148e2f472ba1aef3c491ed9fd3","27538fe67e9b4648b06de8efdc9ab891","3aecb71c582e487c962fa840ee3ef8f5","024deb39dbdb42eea0863db300b15242","9e654bca42a342cfb3611ff78869eac6","94ac5bd14d964124acacc3de59b307b3","14ec9b8e33d44047806876c548688ba0","5b1807d6c7fe4f069816bbb27a23d507","5cedd9732f5b45f1b6e9b226b32a0314","0f21202737c54171b46b5fbb422cefe3","87a9454771a64f2191224b6b7684254a","e130bdf36b3d4432a317beddbd11d181","332d60a14b7b43278a24d0ac2961a361","2d94f94415454317a68f499ad53332db","9eeccc4caf594a5abedc0559fd9e0424","703dd75ecc8740df908141aa5252ff4c","dd16b20c0ed446fc8f3fa4791f8aca8a","8591258764a4428a9d9d641e74fc1591","90ffc68d955c4ddaac828195a04fd5a4","32b2a7f88bfd47f08d38b864034f7ee1","e951cb2d1af6487e8fe25702c6744fcb","eb1a3677476e4684bdf3a3e27121c768","9e50d44715e747bbbe1de4ec04b668b2","c8af1f6afc6445e49fc47f4f0837f134","6a6753c1c1d74648aa399e9f3bc22350","f0e77325ab1e46a899ce62a7c13214cc","3428d019f74042c9b04557aaa3f597e2","a4e38c779cd349c2a4f92189f6aba256","b382bc2a56644776b45dc6084224df3b","f98fd32baa8447119bb87f84093b925c","a9f502452b4a484fb5ee531d3aa4e1b7","e437e1bf7a0d4b309027a6d4bfead264","218de7027c39474b884ca5d174846630","f92e4ba771d04f27a1f4daae363b676a","2ec5825d4b1844538f076141667aa5b0","be26bd5a3626417eabc7fde7a7b8b3d9","2027b8d2fc1b4e42adbd1af5e32671e6","9566286e4bce400eb3e4e6c4baaef014","976f9f8cf61f4a77a1866cb146de181e","2536e79ced34450fbb09de73061cf096","a6cd07ecf38e48b584e8da2adfbe5f42","112de5f741ee49e296dc1b4e90c5d1be","fc0780b4f42b41d0a3dbbc522d0724dd","8e6f6909e2944b7fa8f3593ee96562c1","43a01c3d180b45438f911c6502567931","ba6b0ff4d7dd41759043537555abad4c","6f7797132868456290dac6532b7aefa6","5244e19b1be4440894371237bc81bc89","0a885de5b4054c2b98d478f91f3e3418","de54542063ce4e43b254c7605045d9ed","4c218caf0fc743fda0f4029881b59c29","1954d1a9e4c04e7fb608cb3b89462ca2","d00b4df2a8fb4a97960ede39bf58c0ef","ed204c2d1b6245098bb07da9c6b00eb5","c3b9ec7eb2e2402fae4916a1d3f6504a","7e87f9c6dcd841edb4d0f250b6bee3d9","715cf5754a784fa6bad846d43e0f95df","2830f7d877eb4edbb02322f5bfd5b20b","1d6d6b0086ff422ca00418c0e8b0e940","73fd82d969b1457a85183ca272200cb7","e8b97ed62c0841fea7bc994d9cee120d","ca0f986ae31842b7bddbb61e1b22d5c5","0280230944dd459981ccb201a4aa173d","1259d9c96614472ea03b5c8b51458a7b","3beea980d93a4cc0abc864e27514601c","172ae38eecf24baf9af4f00892b79268","3feede3e46cc4445a3f98e8c2347deb2","3c3e57982b6e4b9ca67763646d96def0","4538da8b1178468dba60afdf16a82030","e9011a11cfd94ac6bbf9980ff2b5c04f","b13c61f6e6624d9aac0b084bb8c7e302","36768453c23d4834a4e2025f9628fa27","7665e5683a1a443a8f3d3b946d4c9ca2","598372309fac44dfa9afd74266b0d581","07994e875a7f44dc9af7f9bf3f6989e5","15cb523e0fbd4617a6a129ad2336eb9a","f746f1cefd0045e8be690bb5d0cf367d","881cc9ec9e4f4b80afcb49a2e3cf2c98","6c9c5be211cb4d72a28205c49a16d653","31a4a651f7744562b44cedbe4a0f942f","771cf2b42f9c4d45821d2a1e47065a8a","7af2742b1e824bb4bae223164df67757","ff9aa0c7e2c947afb9749d2ce115c0da","da39057092a4433ca83732d7f5f368ea","d9c985ab1f04428493c029df6dca650d","3286f34c38e046d59dfb2217e31655a2","d54d312275024917bb28ca24dec027b1","5d354303e3c6403b81ad16f51d58a327","3bf6031206e848cd94f767cd1db43ea0","7a4a14243a4b49e3b5b691978e9e3087","1d3b5642bc8740639e8972872688855a","f3b6709f95d34c30ae5c97423c8e2450","1c98b7b762dc466c9cc4a32d4074a350","45b63f48721147a8be2c3291d20b19ac","d13184f8097c42b081e9eea0a29c69cf","0464f5493b0444e9875a0584df17cbf0","a636be1e48e347ac9018a1f1223532b0","2bb755a3f43f49dea60661c5f99712a3","58f692a66e03451d89d57770cd915d61","8c161437fb424389ab1fde27b93a895b","8bea5bec08e44c1ea7a90c7a1e3daeb8","78cb173a4de34f07befac28de907e7bf","d8ba7ca3e2324ae981eedd136acedb30","6570754a6f0b43b78a9926c7bfd00519","941ef5bdf9fa49b3b8054dd755019209","8d29f554f371431c9b5b80f5befdf965","8eaa9c59b7674ad692d8fbc5c68e845c","ab7c198e47834770a36ab3282d331531","7f8dba6cc5c24bff9bfffb5d5a9352bc","3df822c8c6984e33bf17c1e2861c9ba3","55dedf76dca5451aa305803789a02f30","ebd4baa37271451385bbae40b7d0f3e6","5851e12cf1324f78ba0e32c6a6e16f31","65552aa23c0e405ea87623aa0de08dd8","e2caed1e43604f0fb5eaea4351dbe5f7","e2fd9bda4aeb4a7b9fa53a2560126d24","09529518c8164578ac870e810c3c677b"],"non_research_disease":["63333c316c3b493487303520d1e0c9d8","4c092510a2af42f387426e408f5c7694","a0304a462da04e7cb03e3f2c5625544e","fd7ba28668d8489eb8c951444259baf4","23e532ec53174e7eb1b672cd0e343751","0d330b060a734207baf61dd85f8d77cd","50c397f334694253be0d0ef704e23dc0","f7ea24f0370d421480503e720310bf86","74ba301586ab419b9c9accd39cd20782","dc3ac98bdc5a4f9298fc030de877c4b6","951522b08c924c77a8023509e8e3fe93","536f59a6981645d88bbd7b1facea031f","62c9dd9ddf6c4960bfa4dd9f5bf57d08","1e6992f1403346acad1273d778686ca7","f6e482d871f14267892ce687d3eeea1a","6c9886cb25eb45faba70292cee1f5518","30b1787d28ea4a65aee18822a1279bfb","01773f22c03f4beda403b65654c1698d","83d4a7a4b99e4c9fa8e6c012527381b5","8da4804a5bd24352b7d568a7da54c6dc","e35ce4e9b7a846d49e600ce7ac4a7fd6","5f56d0189e534ecc99f8614a687ba171","ba02154031ca48aba76cd279bdca8ade","a311ae2187914c2bbad45810b91f9414","e67c7fcd3d3a494ab70e1efe0b82ecdc","f6678ca4757d4b46843d6dfd2739e2a1","8c0eafe0f91148099c2aaf56b71ad355","8af6a1a934a64113b19e8024a8037f87","ee2ede109de84cfda49bc999601085b4","e47ba0c33e85473e9171b4125ae2216b","9b60b7d38a4044b3b7f98c61c365e6b9","557f5ccfe746466cbdb9383a94178eef","ea61957e488b4ae3b60e7f73c8e297c6","c9591fe1148945969dd4acaf88747236","8ab4572efc344edbad36869731b2bc25","f3f1224c00c644b4bf32504e9c4ea175","33c23b2c292c49b8b941b169a698bf02","828fb9fef58643deaeb03ba65a7d3953","644d78b6fae343b98e118e64f2717be2","847a0ea7462c4293b185766079ef37a2","e66bd159ca524a14af868bead50619f2","f7ff421129ab40b19648cd3b1fc08f0f","2477c68e093d4b818b11333ee1a5ee02","ca1336d953b4489d9378b4a6ccf0de6f"],"inactive_org_master_entity_id":["3421869a22a737b682f4b9cf8237eaa6","1905ba88bbda8eb8fb283aca995aa620","18a7fb3cba31735a4803b69a9297904d","748edba0a3a4bbaee72b1c213a940053"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","76732dd51f2842799e6843eef80820ea","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","5b1dfc2ca8564662860187aef864467d"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","672807de-6d33-3706-a350-c97e6ed7735e","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","52d1b118-b540-37ba-9cb2-f5aff686bb10","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1589846400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1577404800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1515715200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1502928000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1418947200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1735084800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1663113600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1575331200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1534896000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1723689672198}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1418688000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1661299200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1608854400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1560816000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1530489600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1679270400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1689206400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1660176000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1461888000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1527033600000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1723689672198}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1418688000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1572307200000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1723689672198}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1418688000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1723689672198}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1418688000000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1540944000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1540944000000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1540944000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1735516800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719360000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"b0e1cb77-7cf7-3c20-a846-3e377b838cfa","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"b0e1cb77-7cf7-3c20-a846-3e377b838cfa","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1527552000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1378166400000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1377475200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395792000000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1588636800000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1540944000000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1486339200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1421193600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1398124800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1395878400000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1561680000000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1607385600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"8050a7c3-e4ca-32bf-9f3f-e1598c447eb3","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1574035200000}},{"country":"8050a7c3-e4ca-32bf-9f3f-e1598c447eb3","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1544572800000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1544572800000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1520380800000}},{"country":"528590fc-7857-3275-8e6f-09a951a7544b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1265241600000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1462147200000}}],"disease_phase":[{"disease_id":"7f8dba6cc5c24bff9bfffb5d5a9352bc","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2027b8d2fc1b4e42adbd1af5e32671e6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"644d78b6fae343b98e118e64f2717be2","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8af6a1a934a64113b19e8024a8037f87","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f7ff421129ab40b19648cd3b1fc08f0f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8bea5bec08e44c1ea7a90c7a1e3daeb8","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"73fd82d969b1457a85183ca272200cb7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"58f692a66e03451d89d57770cd915d61","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"32b2a7f88bfd47f08d38b864034f7ee1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"55dedf76dca5451aa305803789a02f30","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"63333c316c3b493487303520d1e0c9d8","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"5f56d0189e534ecc99f8614a687ba171","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"3c3e57982b6e4b9ca67763646d96def0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d00b4df2a8fb4a97960ede39bf58c0ef","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ed204c2d1b6245098bb07da9c6b00eb5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"358a5369f3ed4952915e1713c998e477","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"e951cb2d1af6487e8fe25702c6744fcb","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"69931f8a98884cccb61242f482548020","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1c98b7b762dc466c9cc4a32d4074a350","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ea61957e488b4ae3b60e7f73c8e297c6","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f0e77325ab1e46a899ce62a7c13214cc","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"74ba301586ab419b9c9accd39cd20782","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f6e482d871f14267892ce687d3eeea1a","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"dd16b20c0ed446fc8f3fa4791f8aca8a","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2b45ab274bbb47cbacf94b280d32d1d8","highest_phase_before_ter_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ff9aa0c7e2c947afb9749d2ce115c0da","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f6678ca4757d4b46843d6dfd2739e2a1","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"598372309fac44dfa9afd74266b0d581","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"45b63f48721147a8be2c3291d20b19ac","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3aecb71c582e487c962fa840ee3ef8f5","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"941ef5bdf9fa49b3b8054dd755019209","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"14ec9b8e33d44047806876c548688ba0","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ba6b0ff4d7dd41759043537555abad4c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"332d60a14b7b43278a24d0ac2961a361","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3feede3e46cc4445a3f98e8c2347deb2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a636be1e48e347ac9018a1f1223532b0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"30b1787d28ea4a65aee18822a1279bfb","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a6cd07ecf38e48b584e8da2adfbe5f42","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e47ba0c33e85473e9171b4125ae2216b","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e9d90a15b30a4185b8f2e6091c125195","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f3f1224c00c644b4bf32504e9c4ea175","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"50c397f334694253be0d0ef704e23dc0","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"4c218caf0fc743fda0f4029881b59c29","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5244e19b1be4440894371237bc81bc89","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d54d312275024917bb28ca24dec027b1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8c161437fb424389ab1fde27b93a895b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e8b97ed62c0841fea7bc994d9cee120d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7a4a14243a4b49e3b5b691978e9e3087","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5d354303e3c6403b81ad16f51d58a327","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"112de5f741ee49e296dc1b4e90c5d1be","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"36768453c23d4834a4e2025f9628fa27","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"024deb39dbdb42eea0863db300b15242","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"be26bd5a3626417eabc7fde7a7b8b3d9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8e6f6909e2944b7fa8f3593ee96562c1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9eeccc4caf594a5abedc0559fd9e0424","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"60058a4fc91f474688db03e7a12edf67","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ca0f986ae31842b7bddbb61e1b22d5c5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"703dd75ecc8740df908141aa5252ff4c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"1259d9c96614472ea03b5c8b51458a7b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f3b6709f95d34c30ae5c97423c8e2450","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"94ac5bd14d964124acacc3de59b307b3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e66bd159ca524a14af868bead50619f2","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"31a4a651f7744562b44cedbe4a0f942f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"847a0ea7462c4293b185766079ef37a2","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"815e953f089a4510b397bd3f901ece20","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c8af1f6afc6445e49fc47f4f0837f134","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"ca1336d953b4489d9378b4a6ccf0de6f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b382bc2a56644776b45dc6084224df3b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"78bce8f420c8482bbf1b2bafdf281357","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"a9f502452b4a484fb5ee531d3aa4e1b7","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"23e532ec53174e7eb1b672cd0e343751","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6d98a1f6be594b0ba2e1ee55c3738006","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5735ae177a59485fb92f09e758e4224b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7a9d924cdedd446a90214febad20f3ae","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"828fb9fef58643deaeb03ba65a7d3953","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"2830f7d877eb4edbb02322f5bfd5b20b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5b1807d6c7fe4f069816bbb27a23d507","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8ab4572efc344edbad36869731b2bc25","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e9d6fc1f21704dba80bc8465bbe87d96","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3df822c8c6984e33bf17c1e2861c9ba3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d8ba7ca3e2324ae981eedd136acedb30","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3286f34c38e046d59dfb2217e31655a2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1954d1a9e4c04e7fb608cb3b89462ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"da39057092a4433ca83732d7f5f368ea","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e2caed1e43604f0fb5eaea4351dbe5f7","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c3b9ec7eb2e2402fae4916a1d3f6504a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6a962a4341364bbe9959b413849567de","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"6a6753c1c1d74648aa399e9f3bc22350","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ba02154031ca48aba76cd279bdca8ade","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"01773f22c03f4beda403b65654c1698d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"557f5ccfe746466cbdb9383a94178eef","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"0f21202737c54171b46b5fbb422cefe3","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"653c8e3e508441b6af17b525de5c6b3e","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"881cc9ec9e4f4b80afcb49a2e3cf2c98","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8591258764a4428a9d9d641e74fc1591","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a4e38c779cd349c2a4f92189f6aba256","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"62c9dd9ddf6c4960bfa4dd9f5bf57d08","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"9e50d44715e747bbbe1de4ec04b668b2","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"5851e12cf1324f78ba0e32c6a6e16f31","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ee2ede109de84cfda49bc999601085b4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f746f1cefd0045e8be690bb5d0cf367d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0d330b060a734207baf61dd85f8d77cd","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"a7b08795ca6c4e249dfdb6f9a990eccf","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c9591fe1148945969dd4acaf88747236","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"b13c61f6e6624d9aac0b084bb8c7e302","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4538da8b1178468dba60afdf16a82030","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ebd4baa37271451385bbae40b7d0f3e6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"43a01c3d180b45438f911c6502567931","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2ec5825d4b1844538f076141667aa5b0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6f7797132868456290dac6532b7aefa6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3615202fb9fb468391a53ee84733ca53","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"de54542063ce4e43b254c7605045d9ed","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8c0eafe0f91148099c2aaf56b71ad355","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"fd7ba28668d8489eb8c951444259baf4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6c9886cb25eb45faba70292cee1f5518","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"951522b08c924c77a8023509e8e3fe93","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"2727f13d200e4493b2f6db709193035b","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e9011a11cfd94ac6bbf9980ff2b5c04f","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9b60b7d38a4044b3b7f98c61c365e6b9","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e67c7fcd3d3a494ab70e1efe0b82ecdc","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e437e1bf7a0d4b309027a6d4bfead264","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"715cf5754a784fa6bad846d43e0f95df","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"dc3ac98bdc5a4f9298fc030de877c4b6","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"83d4a7a4b99e4c9fa8e6c012527381b5","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"27538fe67e9b4648b06de8efdc9ab891","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d13184f8097c42b081e9eea0a29c69cf","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"90ffc68d955c4ddaac828195a04fd5a4","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7af2742b1e824bb4bae223164df67757","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e130bdf36b3d4432a317beddbd11d181","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"536f59a6981645d88bbd7b1facea031f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"3428d019f74042c9b04557aaa3f597e2","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1d3b5642bc8740639e8972872688855a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"771cf2b42f9c4d45821d2a1e47065a8a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0280230944dd459981ccb201a4aa173d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8eaa9c59b7674ad692d8fbc5c68e845c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"65552aa23c0e405ea87623aa0de08dd8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5cedd9732f5b45f1b6e9b226b32a0314","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"15efc91d373b41f08cea343f62d56420","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"172ae38eecf24baf9af4f00892b79268","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9e654bca42a342cfb3611ff78869eac6","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d61edc148e2f472ba1aef3c491ed9fd3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"eb1a3677476e4684bdf3a3e27121c768","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2d94f94415454317a68f499ad53332db","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"33c23b2c292c49b8b941b169a698bf02","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fc0780b4f42b41d0a3dbbc522d0724dd","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"976f9f8cf61f4a77a1866cb146de181e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"09529518c8164578ac870e810c3c677b","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"9566286e4bce400eb3e4e6c4baaef014","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["6a8c172f1efc649035845f94c31a9c1e","6e7a2de70d46daa0cef8586ca22ae506","69c40b77a4f2e476966f9cae0422ee19","18926e4e58ef52c734e3320e40a1306b"],"if_speculate":0,"data_source":10}
+{"drug_id":"13a80885a41e471cb3e1a8daa7e4284e","docid":81905,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":5,"target_extend_id":"43ee4f8e816e33bea4cb9b961d821b2c","created_ts":"2023-11-13T03:23:40.000Z","updated_ts":"2026-03-25T13:38:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ZS-805","status":"ACTIVE"}],"dev_code":[{"name":"ZS 805","status":"ACTIVE"},{"name":"ZS805","source_info":[{"code":"2024_1099","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","source":"ASGCT","source_url":"https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=98043"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["f75840f48b4bc49d54fb2747a97d23f0"],"mechanism_action_id":["d9637106c9d09d63e00a279cad60040a"],"target_id":["06587a6f0b5842d4a597dd69f783e61f"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["c030b4369d7b41c2953386b363b99f6e"],"active_org_master_entity_id":["f75840f48b4bc49d54fb2747a97d23f0"],"research_disease":["c030b4369d7b41c2953386b363b99f6e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1735084800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1707955200000}}],"disease_phase":[{"disease_id":"c030b4369d7b41c2953386b363b99f6e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"445b9fcb41944813b96ef63a7730d42b","docid":1673394,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":224,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2026-01-19T07:15:17.000Z","updated_ts":"2026-04-18T21:06:16.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CR-059","source_info":[{"code":"NCT07347080","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07347080"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Exenatide Circular RNA-Lipid Nanoparticle Injection","source_info":[{"code":"NCT07347080","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07347080"}],"status":"ACTIVE"}],"dev_code":[{"name":"CR-059","source_info":[{"code":"NCT07347080","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07347080"}],"status":"ACTIVE"}],"drug_type":["13552b2d4608459fa1addc238d10318a","f9b1093fafc547caabf90e26cef22a1f"],"originator_org_master_entity_id":["fb5bb2240d3c60da9d116e3f6e9314cc"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["fb5bb2240d3c60da9d116e3f6e9314cc"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1768867200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1764547200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0480b837f0364b3ba2d91ddc567bedb1","docid":14187,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"055a60cf40bb4b4eb69c41b492c45a03","created_ts":"2022-08-24T02:15:56.000Z","updated_ts":"2025-03-12T06:08:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"KEX02","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650015711&idx=2&sn=839c37802cdff4c75de59250aa8eb51a"}],"status":"ACTIVE"}],"dev_code":[{"name":"KEX 02","status":"ACTIVE"},{"name":"KEX-02","status":"ACTIVE"}],"drug_type":["f37c4b8eae1d4091a14e8e9fab4e96c5"],"originator_org_master_entity_id":["c7d905d1d090e91dc4f0fda9e012d3c7"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","1a41a587feb28542b3050eb67b912259"],"disease_id":["3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["c7d905d1d090e91dc4f0fda9e012d3c7"],"research_disease":["3beea980d93a4cc0abc864e27514601c"],"inactive_org_master_entity_id":["d2fed53f43daa91074f81a1c683ff2eb"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1660262400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1635206400000}}],"disease_phase":[{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_before_ter_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0ef7d81aa8e949f49c94bb302013a475","docid":69797,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:49.000Z","updated_ts":"2024-12-27T00:24:25.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TMi-018","status":"ACTIVE"}],"dev_code":[{"name":"TMI-018","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4219cf2649116767539a2d812374af06"],"disease_id":["164ba9b819474bcd9c0f89bbf21a934c","69717f8699ec4d48984bf2ef6540f288"],"active_org_master_entity_id":["4219cf2649116767539a2d812374af06"],"research_disease":["164ba9b819474bcd9c0f89bbf21a934c","69717f8699ec4d48984bf2ef6540f288"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1646179200000}}],"disease_phase":[{"disease_id":"164ba9b819474bcd9c0f89bbf21a934c","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"69717f8699ec4d48984bf2ef6540f288","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"03b9b17ba3254e72bc5045f775030712","docid":48933,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-05-11T11:35:53.000Z","updated_ts":"2025-01-31T13:22:42.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"fangdongbing","drug_name":[{"lang":"EN","name":"MS-1901","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.medinno.kr/pipeline/overview.php"}],"status":"ACTIVE"}],"dev_code":[{"name":"HIEstem for HIE","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"http://www.medinno.kr/pipeline/hie.php"}],"status":"ACTIVE"},{"name":"MS 1901","status":"ACTIVE"},{"name":"MS1901","status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["df41b05a6cdc8cbcb02f85b992bcb55a"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["9486b7801657420aad2d1cfc41da6246"],"active_org_master_entity_id":["df41b05a6cdc8cbcb02f85b992bcb55a"],"research_disease":["9486b7801657420aad2d1cfc41da6246"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1683763200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1704326400000}}],"disease_phase":[{"disease_id":"9486b7801657420aad2d1cfc41da6246","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["446624d95e7afe66561a17119a7f02f7","df41b05a6cdc8cbcb02f85b992bcb55a"],"if_speculate":0,"data_source":10}
+{"drug_id":"0494b09f12604e338411727c4fec8bfe","docid":58002,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"1e1b73208b5d3a7d8b101f2ea54e05a4","created_ts":"2023-06-16T08:30:00.000Z","updated_ts":"2025-07-31T00:31:14.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"XB-628","source_info":[{"attachment_path":"data/phs_source_info/33ae/fe65/0de1/a897/fe9e9615-dd0e-34dd-a97b-6e8ba931ece7.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/c6e4/377a/5d4d/5ef6/c215ea8d-d097-31c1-b795-476cde4bb35f.png","source":"Company pipeline","source_url":"https://www.exelixis.com/our-pipeline-compounds/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"invenra#2","source_info":[{"attachment_path":"data/phs_source_info/78d0/a5d7/6ce3/f7e1/e0756665-112e-33b9-8521-ac35ed8f8e00.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/69ae/49eb/d339/8d63/a53ff7de-6240-3ba8-b278-8e2d2a251d79.png","source":"Company pipeline","source_url":"https://invenra.com/science/"}],"status":"ACTIVE"}],"dev_code":[{"name":"XB 628","status":"ACTIVE"},{"name":"XB628","source_info":[{"code":"2025_6067","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/7934"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["40fed18b544f74fe8be4d803b3bc4454"],"mechanism_action_id":["21a32a596707a37ddec2bdc7199ff28b","5f2b5842256779f2516d3dc21cf298e2"],"target_id":["b7a690c165204abdb7363ec5112a2bf3","06c7ab146b884a3aa890cfd1a4a0e168"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["40fed18b544f74fe8be4d803b3bc4454","dd1c3c03d6358ef1b1dc0dcda7e1c00a"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1746057600000}}],"disease_phase":[{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"05ef6ae704a8483b8b7b07bbbb0478c1","docid":62009,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":33,"target_extend_id":"46631cde0308360d97b73e60682d1b3c","created_ts":"2021-12-10T12:55:17.000Z","updated_ts":"2026-04-11T21:05:50.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"SynKIR-110","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://verismotherapeutics.com/pipeline/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-mesothelin killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapy(Verismo Therapeutics)","status":"ACTIVE"},{"lang":"EN","name":"KIRCARmeso Verismo Therapeutics","status":"ACTIVE"},{"lang":"EN","name":"SynKIRmeso","status":"ACTIVE"},{"lang":"EN","name":"SynKIRmeso CAR-T cells (Verismo Therapeutics)","status":"ACTIVE"},{"lang":"EN","name":"SynKIRmeso CART cells","status":"ACTIVE"}],"dev_code":[{"name":"SynKIR 110","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://verismotherapeutics.com/pipeline/"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-mesothelin-kir-car-transduced-t-cells-synkir-110"}],"status":"ACTIVE"},{"name":"SynKIR110","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://verismotherapeutics.com/pipeline/"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-mesothelin-kir-car-transduced-t-cells-synkir-110"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["28073587101676d18db076478b9b23a1"],"mechanism_action_id":["b7720880ecd836503bbe1d9f15cae31e","d9627d77b8d00d879e22e88877e54736","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["3305619b6ea741a19aa4a690d083582b"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["eb501dbf6aa449f7a75898e4096f3916","218de7027c39474b884ca5d174846630","9fa7237b86bc4bdba73c3b23e8d84e24","ae092fa59f4d44edaf59ffe23d0a44c3"],"active_org_master_entity_id":["28073587101676d18db076478b9b23a1"],"research_disease":["eb501dbf6aa449f7a75898e4096f3916","218de7027c39474b884ca5d174846630","9fa7237b86bc4bdba73c3b23e8d84e24"],"non_research_disease":["ae092fa59f4d44edaf59ffe23d0a44c3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1680134400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1671062400000}}],"disease_phase":[{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"9fa7237b86bc4bdba73c3b23e8d84e24","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"eb501dbf6aa449f7a75898e4096f3916","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["28073587101676d18db076478b9b23a1","3bdcd22f6e2d3273ac9eac8e8ab7a0b0"],"data_source":10}
+{"drug_id":"013787897fbf4ebf9e6f51911402551a","docid":1625,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"ae79fa5864e24d66ba5726c59aaa163c","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1265068800000,"rnk":1,"target_extend_id":"0af8a806695c3915aa8a183ba81eaf8e","has_leading_org_involved":1,"created_ts":"2021-10-08T14:46:01.000Z","updated_ts":"2026-04-02T17:24:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"溶组织梭菌胶原酶","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://www.wahjie.com/post/64.html"}],"status":"ACTIVE"},{"lang":"EN","name":"Collagenase Clostridium histolyticum(Biospecifics Technologies Corp)","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"コラゲナーゼ（クロストリジウム ヒストリチクム）","source_info":[{"code":"22700AMX00699000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://image.packageinsert.jp/pdf.php?mode=1&yjcode=2900401D1020"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CCH","status":"ACTIVE"},{"lang":"EN","name":"Clostridial collagenase","status":"ACTIVE"},{"lang":"EN","name":"Collagenase (Clostridium Histolyticum)","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Collagenase Clostridium histolyticum (Endo/SOBI/Asahi Kasei)","status":"ACTIVE"},{"lang":"EN","name":"Collagenase clostridium histolyticum-aaes","status":"ACTIVE"},{"lang":"EN","name":"Cordase","status":"ACTIVE"},{"lang":"EN","name":"Plaquase","status":"ACTIVE"},{"lang":"EN","name":"XIAFLEX","status":"ACTIVE"},{"lang":"EN","name":"Xiapex","status":"ACTIVE"},{"lang":"EN","name":"collagenase Clostridium histolyticum","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"}],"dev_code":[{"name":"AA-4500","status":"ACTIVE"},{"name":"AK-160","source_info":[{"code":"22700AMX00699000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://image.packageinsert.jp/pdf.php?mode=1&yjcode=2900401D1020"}],"status":"ACTIVE"},{"name":"EN-3835","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/collagenase-clostridium-histolyticum-en3835"}],"status":"ACTIVE"},{"name":"PF-5076985","status":"ACTIVE"}],"trade_name":[{"name":"Qwo","status":"ACTIVE"},{"name":"XIAFLEX","source_info":[{"code":"22700AMX00699000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://image.packageinsert.jp/pdf.php?mode=1&yjcode=2900401D1020"}],"status":"ACTIVE"},{"name":"ザイヤフレックス","source_info":[{"code":"22700AMX00699000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://image.packageinsert.jp/pdf.php?mode=1&yjcode=2900401D1020"}],"status":"ACTIVE"}],"drugbank_id":["DB00048"],"drug_type":["c6f7aa5028654d4d8ac6153f9b53e8a2"],"originator_org_master_entity_id":["9733571579679e243819029550d6a711"],"mechanism_action_id":["a694a897633cd49ad2c912f0485f77b3"],"target_id":["3113fa804db9475fb14f6ffd0eab4dd6"],"atc_code":["d2accfddd652440c914fcff080f26cea"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["6d04d3d944354e218c7e48c0cce85c90","b1eac1f977fe405b870ef73713c84d92","f3244fd4616c4044b6d701d0723ae8eb","a0bb922d2d8b46aba558835a075863ea","25aa9dbd25714b36b8bcb9347d1b91d1","49a57e0e80714545b097cc7a41cb3351","bffe318c5217474cb27af710d14d04a9","fc28b676e72f400b9900ae2d2bad7dd3","e50ec8ccb9b94d81b520b020eb704396","7f206c85b5f9410e8cf9718c559d83b7","0fcda6562626473991ace091a75db58f","97dcf3cdd0734e3d9988a88ba5665bcc","9447e4bcaf3b4a958ada630e99d89404","112a0930e2314733a0404ebad0e0309b"],"active_org_master_entity_id":["ddc72da5118b085f88645e5bed5c0023","9597e75ba30c9958d4331f586407d7cf","b38ed349943e23685cc13aa9175b70b1","d447bf2063780170d86f25e0badcc795","bb3e555264c41ee3c60ae6ffbe95795e","885fe791b255500329a7ec5892366ecb"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["f3244fd4616c4044b6d701d0723ae8eb"],"research_disease":["6d04d3d944354e218c7e48c0cce85c90","b1eac1f977fe405b870ef73713c84d92","f3244fd4616c4044b6d701d0723ae8eb","a0bb922d2d8b46aba558835a075863ea","25aa9dbd25714b36b8bcb9347d1b91d1","49a57e0e80714545b097cc7a41cb3351"],"non_research_disease":["bffe318c5217474cb27af710d14d04a9","fc28b676e72f400b9900ae2d2bad7dd3","e50ec8ccb9b94d81b520b020eb704396","7f206c85b5f9410e8cf9718c559d83b7","0fcda6562626473991ace091a75db58f","97dcf3cdd0734e3d9988a88ba5665bcc","9447e4bcaf3b4a958ada630e99d89404","112a0930e2314733a0404ebad0e0309b"],"inactive_org_master_entity_id":["bcc0a904e61bbf516cc0df1d34044b61","f9a1dfbc457c499af5b870b77f0955ef","91fc4f74049b60f48601163e836f2014"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1593993600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1386288000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1265068800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1435881600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1359244800000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1519862400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1480464000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1396310400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1391126400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1406851200000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1428537600000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1406851200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1406851200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1406851200000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1406851200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1406851200000}}],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6d04d3d944354e218c7e48c0cce85c90","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"49a57e0e80714545b097cc7a41cb3351","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9447e4bcaf3b4a958ada630e99d89404","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7f206c85b5f9410e8cf9718c559d83b7","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0fcda6562626473991ace091a75db58f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f3244fd4616c4044b6d701d0723ae8eb","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"112a0930e2314733a0404ebad0e0309b","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b1eac1f977fe405b870ef73713c84d92","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e50ec8ccb9b94d81b520b020eb704396","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a0bb922d2d8b46aba558835a075863ea","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bffe318c5217474cb27af710d14d04a9","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"97dcf3cdd0734e3d9988a88ba5665bcc","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"2e52db813eb94143a5488cb1b73f87b5","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fc28b676e72f400b9900ae2d2bad7dd3","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["b38ed349943e23685cc13aa9175b70b1","9597e75ba30c9958d4331f586407d7cf","bb3e555264c41ee3c60ae6ffbe95795e","ddc72da5118b085f88645e5bed5c0023","9733571579679e243819029550d6a711"],"if_speculate":0,"data_source":10}
+{"drug_id":"12b7384f427040928431675ae6821871","docid":61365,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":5,"target_extend_id":"5d1b1610fc4e3418957ecebef1c34a6c","has_leading_org_involved":1,"created_ts":"2021-10-08T14:38:22.000Z","updated_ts":"2026-04-03T21:04:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Lucerastat","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Lucerastat (JAN/USAN/INN)","source_info":[{"code":"D11439","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"ACT-434964","status":"ACTIVE"},{"name":"CDP-923","status":"ACTIVE"},{"name":"N-BU-DGJ","status":"ACTIVE"},{"name":"NB-DGJ","status":"ACTIVE"},{"name":"OGT-923","status":"ACTIVE"}],"generic_name":[{"name":"Lucerastat","source_info":[{"code":"D11439","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB14872"],"kegg_id":["D11439"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e3a3ef71de0475145995758747319017"],"mechanism_action_id":["b36d2ffe137dad688df718b7d9cb3c33"],"target_id":["db219c99890844a3b09d1e7406600d37"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["c030b4369d7b41c2953386b363b99f6e"],"active_org_master_entity_id":["e3a3ef71de0475145995758747319017"],"research_disease":["c030b4369d7b41c2953386b363b99f6e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1545091200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1529539200000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1693612800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1693612800000}}],"disease_phase":[{"disease_id":"c030b4369d7b41c2953386b363b99f6e","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["03bf734996554b9569180f44544f0b5a","6dfe153fdbe27f7a6bc92c4fb51e3e54"],"data_source":10}
+{"drug_id":"3be0bfe952c5434c918a394520ae29a2","docid":1641670,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":3,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2025-09-01T08:33:19.000Z","updated_ts":"2026-02-07T21:10:02.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Anti-BCMA-CD19 CAR-T cells(Chinese PLA General Hospital)","source_info":[{"code":"NCT07148791","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07148791"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["4e19da5760f07ff8bbbb0e35a88c826f"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448"],"disease_id":["b494a906592f47b09ce303fb0963e3b8","b333bb7c6f974ac8893e67082c824ea0","d6d30dfb1c604b55a56b0f79fa245d23"],"active_org_master_entity_id":["4e19da5760f07ff8bbbb0e35a88c826f"],"research_disease":["b494a906592f47b09ce303fb0963e3b8","b333bb7c6f974ac8893e67082c824ea0","d6d30dfb1c604b55a56b0f79fa245d23"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1757030400000}}],"disease_phase":[{"disease_id":"d6d30dfb1c604b55a56b0f79fa245d23","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b494a906592f47b09ce303fb0963e3b8","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b333bb7c6f974ac8893e67082c824ea0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0dbbae189b6e4afaaeb65f8c9ea28e4b","docid":37723,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1727395200000,"rnk":1,"target_extend_id":"330028818c82391288d78494761bc393","created_ts":"2021-10-08T14:45:56.000Z","updated_ts":"2026-04-02T12:59:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"chenghongyan@patsnap.com","drug_name":[{"lang":"EN","name":"Flurpiridaz F 18","source_info":[{"code":"NDA215168","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215168"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"18F-flurpiridaz","status":"ACTIVE"},{"lang":"EN","name":"Flurpiridaz","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.massdevice.com/ge-healthcare-lantheus-radiotracer-trial-endpoints/"}],"status":"ACTIVE"},{"lang":"EN","name":"Flurpiridaz F-18","status":"ACTIVE"}],"dev_code":[{"name":"BMS-747158","status":"ACTIVE"},{"name":"BMS-747158-02","status":"ACTIVE"}],"trade_name":[{"name":"Flyrcado","source_info":[{"code":"NDA215168","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215168"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["927999a76ffdbc67bf6703d6b4d9feae"],"mechanism_action_id":["021a8b62a47eb439ee84d4b0e9d37f24","09e50b55b8d2d450dcee28f3b3225e6a","0749288ce5e4be2dc4dcdf9173d8f6b3"],"target_id":["c5b84e6792764bc29f61c7a1e8f5d3eb","a6910fd403a04c60b03ea20766dea920"],"disease_id":["bf821ba3fb194a38a5b2f804bcf68c44","54e2cf3dc3294445b4a27b990b0ba274","22713e1eb6cb47209a13c9def522a6f7","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["2bee6c6ef7c3c6168147f53a8a4cf7f6","927999a76ffdbc67bf6703d6b4d9feae","75d36a500640abd4e9687f4541aa9a17","45ecdb1c087e8d2c2fd23c89a9fb662d"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["bf821ba3fb194a38a5b2f804bcf68c44"],"research_disease":["bf821ba3fb194a38a5b2f804bcf68c44","54e2cf3dc3294445b4a27b990b0ba274"],"non_research_disease":["22713e1eb6cb47209a13c9def522a6f7","62eaee6d9ee44410b8aca59dfc7408e9"],"inactive_org_master_entity_id":["588f8f208e06d6da5e850669770f9a60","3ea93a3479c8e6895cbd069d2dacc523","d94923980905512f8eac870e9ac6f983"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1727395200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1714780800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1441065600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1714780800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1714780800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1259625600000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1714780800000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1441065600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1714780800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1714780800000}}],"disease_phase":[{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"22713e1eb6cb47209a13c9def522a6f7","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["2bee6c6ef7c3c6168147f53a8a4cf7f6","4a85fa00954ee8ba443bf0bd89160dba","d732535a3ffb19f32920604a13a5cead"],"data_source":10}
+{"drug_id":"0141dfef323d4abaa1cd2f4e82cd424c","docid":7843,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Vindesine","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":482457600000,"rnk":5,"target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","created_ts":"2021-10-08T14:49:23.000Z","updated_ts":"2026-02-24T18:12:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":788918400000,"drug_name":[{"lang":"CN","name":"硫酸长春地辛","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Vindesine Sulfate","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ビンデシン硫酸塩","source_info":[{"code":"16000AMY00052000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine","source_info":[{"code":"DB00309","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine","source_info":[{"code":"DB00309","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Desacetylvinblastine amide","source_info":[{"code":"DB00309","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Vindesine","source_info":[{"code":"DB00309","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Vindesine sulfate (JAN/USAN)","source_info":[{"code":"D01769","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"VindesineSulfatefor","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"长春地辛","status":"ACTIVE"}],"dev_code":[{"name":"Compound-112531","status":"ACTIVE"},{"name":"LY-099094","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/b7a63b2d-6d3e-40d0-af92-e7b503904af3"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vindesine-sulfate"}],"status":"ACTIVE"},{"name":"LY099094","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/b7a63b2d-6d3e-40d0-af92-e7b503904af3"}],"status":"ACTIVE"},{"name":"NSC-245","source_info":[{"code":"16000AMY00052000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4240402D1021_2_02"}],"status":"ACTIVE"},{"name":"NSC-245467","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/b7a63b2d-6d3e-40d0-af92-e7b503904af3"}],"status":"ACTIVE"},{"name":"S-7820","source_info":[{"code":"16000AMY00052000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4240402D1021_2_02"}],"status":"ACTIVE"}],"trade_name":[{"name":"Eldisine","status":"ACTIVE"},{"name":"Fildesin","source_info":[{"code":"D01769","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"16000AMY00052000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4240402D1021_2_02"}],"status":"ACTIVE"},{"name":"フィルデシン","source_info":[{"code":"16000AMY00052000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530169_4240402D1021_2_02"}],"status":"ACTIVE"},{"name":"西艾克","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Vindesine","source_info":[{"code":"RSA8KO39WH","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/0dc39713-1d2f-4567-b6dc-4ec27e09d4b5"}],"status":"ACTIVE"}],"drugbank_id":["DB00309"],"kegg_id":["D01769"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"],"target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"atc_code":["df9557ebc1454041b698ea4ab5d8a733"],"disease_id":["94deb71c1ce54fdf8923bfcb7c88d054","f319fa27684c4cdeb6ce59d897217718","c1cc2528f29940fc95fd6bc37eb982d4","3beea980d93a4cc0abc864e27514601c","8d29f554f371431c9b5b80f5befdf965","f7ea24f0370d421480503e720310bf86","7cb6983b4169498e89b08fd725a22b46","e2fd9bda4aeb4a7b9fa53a2560126d24","26535c6f16de4adfb19f0154be738535","7102c119439e42c5835802ab323b3c66"],"active_org_master_entity_id":["6a9217a51db7f437c07efd185299c53c","28302ed119579570781ac5944dcb2b14","2f55b324e0e20f9411ed3667550d0ba7"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["7cb6983b4169498e89b08fd725a22b46","e2fd9bda4aeb4a7b9fa53a2560126d24","26535c6f16de4adfb19f0154be738535","7102c119439e42c5835802ab323b3c66"],"research_disease":["94deb71c1ce54fdf8923bfcb7c88d054","f319fa27684c4cdeb6ce59d897217718","c1cc2528f29940fc95fd6bc37eb982d4","3beea980d93a4cc0abc864e27514601c","8d29f554f371431c9b5b80f5befdf965","f7ea24f0370d421480503e720310bf86","7cb6983b4169498e89b08fd725a22b46","e2fd9bda4aeb4a7b9fa53a2560126d24","26535c6f16de4adfb19f0154be738535","7102c119439e42c5835802ab323b3c66"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769","672807de-6d33-3706-a350-c97e6ed7735e"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":788918400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":644457600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":482457600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1237272849411}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7102c119439e42c5835802ab323b3c66","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"94deb71c1ce54fdf8923bfcb7c88d054","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02647670b02a47f1bf8dfaa77cfa1152","docid":38996,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-06-24T07:40:03.000Z","updated_ts":"2024-12-31T00:20:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TRN-213","status":"ACTIVE"}],"dev_code":[{"name":"TRN-213","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a3710263b921a1b57017fe05fd2c9e6d"],"disease_id":["7b4e53db61474fedb169293723923caa","f24f4f7b902c4723a40c33559688a7c9"],"active_org_master_entity_id":["a3710263b921a1b57017fe05fd2c9e6d"],"research_disease":["7b4e53db61474fedb169293723923caa","f24f4f7b902c4723a40c33559688a7c9"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"055a60cf40bb4b4eb69c41b492c45a03","dev_status_time":{"time_trust_code":7,"time_ts":1643932800000}}],"disease_phase":[{"disease_id":"7b4e53db61474fedb169293723923caa","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f24f4f7b902c4723a40c33559688a7c9","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"data_source":10}
+{"drug_id":"026f4333bbdb451f9674620029398b77","docid":28318,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":76,"target_extend_id":"e87ff0d2c5223cb0b10f60b549c22441","has_leading_org_involved":1,"created_ts":"2021-10-08T14:45:02.000Z","updated_ts":"2026-04-02T11:01:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Inupadenant","source_info":[{"code":"NCT05403385","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05403385"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Inupadenant hydrochloride","status":"ACTIVE"}],"dev_code":[{"name":"EOS-100850","source_info":[{"code":"NCT03873883","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03873883"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/inupadenant"}],"status":"ACTIVE"},{"name":"EOS-850","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["c2536a7f0ad09425136300221e0daa59"],"mechanism_action_id":["50c5bc150c0d69dfb682c96956000c3f"],"target_id":["08758366ffb64169a43e89145be7fd2b"],"disease_id":["6c9886cb25eb45faba70292cee1f5518","2bb755a3f43f49dea60661c5f99712a3","949c20c9e52549008773244a4230da7d","6570754a6f0b43b78a9926c7bfd00519","0464f5493b0444e9875a0584df17cbf0","c1cc2528f29940fc95fd6bc37eb982d4","1954d1a9e4c04e7fb608cb3b89462ca2","dd16b20c0ed446fc8f3fa4791f8aca8a","5cedd9732f5b45f1b6e9b226b32a0314","3beea980d93a4cc0abc864e27514601c","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a"],"active_org_master_entity_id":["201e15b723a32a51d6c648034824c8f0","00cc33265fae8405c9b05fc4c1925bc8"],"research_disease":["6c9886cb25eb45faba70292cee1f5518","2bb755a3f43f49dea60661c5f99712a3","949c20c9e52549008773244a4230da7d","6570754a6f0b43b78a9926c7bfd00519","0464f5493b0444e9875a0584df17cbf0","c1cc2528f29940fc95fd6bc37eb982d4","1954d1a9e4c04e7fb608cb3b89462ca2","dd16b20c0ed446fc8f3fa4791f8aca8a","5cedd9732f5b45f1b6e9b226b32a0314","3beea980d93a4cc0abc864e27514601c","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1549324800000}}],"disease_phase":[{"disease_id":"1954d1a9e4c04e7fb608cb3b89462ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5cedd9732f5b45f1b6e9b226b32a0314","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"dd16b20c0ed446fc8f3fa4791f8aca8a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9886cb25eb45faba70292cee1f5518","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["4fdf026b21d8754bb4c603c8878d7257","6a8c172f1efc649035845f94c31a9c1e"],"data_source":10}
+{"drug_id":"03b194ea30ad4ef391a8ff2275897110","docid":41592,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"ec44682070a13c7990413283fd45db5a","created_ts":"2021-10-08T14:44:46.000Z","updated_ts":"2026-04-01T03:06:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhanghuaizheng@patsnap.com","drug_name":[{"lang":"EN","name":"Certepetide","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ac-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-NH2 (Cys:Cys disulfide linkage)","source_info":[{"normalized_source_id":"df564163e18b49cfb6dbe49169e22f2d","source":"FDA","source_url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=952423"}],"status":"ACTIVE"},{"lang":"EN","name":"iRGD","status":"ACTIVE"}],"dev_code":[{"name":"CEND 1","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/internalized-arginylglycylaspartic-acid-cyclic-peptide"}],"status":"ACTIVE"},{"name":"CEND-1","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/internalized-arginylglycylaspartic-acid-cyclic-peptide"}],"status":"ACTIVE"},{"name":"LSTA 1","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/internalized-arginylglycylaspartic-acid-cyclic-peptide"}],"status":"ACTIVE"},{"name":"LSTA-1","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-reports-third-quarter-2022-financial-results"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/internalized-arginylglycylaspartic-acid-cyclic-peptide"}],"status":"ACTIVE"},{"name":"LSTA1","source_info":[{"code":"NCT05712356","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05712356"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/internalized-arginylglycylaspartic-acid-cyclic-peptide"}],"status":"ACTIVE"},{"name":"QLC-12102","status":"ACTIVE"},{"name":"QLC12102","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247524416&idx=1&sn=ebe6c518c2221c825f3cbc43be331893"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de","b3f3ecbc5fe645d79060e009b17b6e76"],"originator_org_master_entity_id":["f0869eed0bea7e07f7db85e2480894b8"],"mechanism_action_id":["d064734df8a87ac58a0f53e6c737a7e4","870a81acab4a798914d6df838d184010"],"target_id":["2330b1333252461189d0dace8b533d60","9c9a99315d364d2fb6a4ab8361f20484"],"special_review":["425d71b560a7499087c4f5a36692741c","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["78cb173a4de34f07befac28de907e7bf","05554578204541148a5482ad5df4a600","7e87f9c6dcd841edb4d0f250b6bee3d9","ae092fa59f4d44edaf59ffe23d0a44c3","d2c026d4e24242879b1a9410e9b9ecfc","275ecda875e0460f84aa768ca9b2e5d6","7665e5683a1a443a8f3d3b946d4c9ca2","f35bef6975af4a90b570b81ad3217832","28935c60ded04150bbdd16876cc0082e","90ffc68d955c4ddaac828195a04fd5a4","ff2bfb165bee41d6a0d28f32755d0c5e","e67c7fcd3d3a494ab70e1efe0b82ecdc","e47ba0c33e85473e9171b4125ae2216b","8bea5bec08e44c1ea7a90c7a1e3daeb8"],"active_org_master_entity_id":["d1e884f3d1682313ec4260219670bf96","a78c1ed734d8441efe8f8a6660ce7ac6","0bb6804a2738b17bb305b0d80ce08460","f0869eed0bea7e07f7db85e2480894b8","98328766dce472776fdac32337485e31"],"research_disease":["78cb173a4de34f07befac28de907e7bf","05554578204541148a5482ad5df4a600","7e87f9c6dcd841edb4d0f250b6bee3d9","ae092fa59f4d44edaf59ffe23d0a44c3","d2c026d4e24242879b1a9410e9b9ecfc","275ecda875e0460f84aa768ca9b2e5d6","7665e5683a1a443a8f3d3b946d4c9ca2","f35bef6975af4a90b570b81ad3217832","28935c60ded04150bbdd16876cc0082e","90ffc68d955c4ddaac828195a04fd5a4","ff2bfb165bee41d6a0d28f32755d0c5e"],"non_research_disease":["e67c7fcd3d3a494ab70e1efe0b82ecdc","e47ba0c33e85473e9171b4125ae2216b","8bea5bec08e44c1ea7a90c7a1e3daeb8"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710288000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1705449600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1718236800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1634688000000}}],"disease_phase":[{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8bea5bec08e44c1ea7a90c7a1e3daeb8","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"d2c026d4e24242879b1a9410e9b9ecfc","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e47ba0c33e85473e9171b4125ae2216b","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"ff2bfb165bee41d6a0d28f32755d0c5e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e67c7fcd3d3a494ab70e1efe0b82ecdc","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f35bef6975af4a90b570b81ad3217832","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"90ffc68d955c4ddaac828195a04fd5a4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"28935c60ded04150bbdd16876cc0082e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["0bb6804a2738b17bb305b0d80ce08460","68f05f73c48bfaab38078f041f763ab0","9f4ef9df4bfd60de05a24bd0ba86c186","a78c1ed734d8441efe8f8a6660ce7ac6","d175c6de0d73df2a3d727ff1e3776e2b","f0869eed0bea7e07f7db85e2480894b8"],"data_source":10}
+{"drug_id":"0744be72a300421cbea7d3c53fe9a629","docid":230643,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":13,"target_extend_id":"2e71afad7729373fb5dad2ac1eccdc65","created_ts":"2024-05-09T09:03:10.000Z","updated_ts":"2026-03-27T07:56:12.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"HP-001","source_info":[{"code":"2025_LB235","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/10059"}],"status":"ACTIVE"}],"dev_code":[{"name":"CY-001","source_info":[{"attachment_path":"data/phs_source_info/a83b/54d8/918c/7b83/f522eb6a-3f33-38df-b104-5673bc89b7a7.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dc5e/41fa/09ff/815b/83afeffc-81ed-3ed9-b303-9aa700c682c4.png","source":"Company pipeline","source_url":"http://www.shcyyy.com/Info_research.shtml#place2"}],"status":"ACTIVE"},{"name":"HP-001","status":"ACTIVE"}],"drug_type":["1e415c1056f546dcbfde712726f6d58f"],"originator_org_master_entity_id":["025bb55086293827d1ffeef38289ef34"],"mechanism_action_id":["149d5e9cb7394465bb3ee8c5af370d8f","e0e0a0a673504ddfbff05f9477de253d"],"target_id":["1a59fde6bea148ed84d3103e126a7bda","73bac385975743ee8a97dff3fb4f2507"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5","131c3f4dfc0c4a958e9f91166e73c913"],"active_org_master_entity_id":["025bb55086293827d1ffeef38289ef34"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5","131c3f4dfc0c4a958e9f91166e73c913"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1766361600000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"if_speculate":0,"data_source":10}
+{"drug_id":"06326c0f97f74bb998ad4ba53ba827f5","docid":117855,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2025-02-10T08:15:21.000Z","updated_ts":"2025-02-10T08:30:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Measles and Rubella Vaccine (Live)(Zydus Lifesciences)","source_info":[{"code":"NCT06815835","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06815835"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Measles-Rubella vaccine (Live) I.P. (Freeze Dried)(Zydus Lifesciences)","source_info":[{"code":"NCT06815835","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06815835"}],"status":"ACTIVE"}],"drug_type":["6eddc904ae514d7eb769ec272586e3f3","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["8880b94c103115459f3f8bb32dbddc3e"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["9caefdc94002408ea7d794c6960e8695","c81d389040894d6db4a0cda96e2f0d2f","960abf4e113d4f1ab13b4e693cbca8a3"],"active_org_master_entity_id":["8880b94c103115459f3f8bb32dbddc3e"],"research_disease":["9caefdc94002408ea7d794c6960e8695","c81d389040894d6db4a0cda96e2f0d2f","960abf4e113d4f1ab13b4e693cbca8a3"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"6752c34a-10a0-396a-ab3f-d5371204f7a8","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1743465600000}}],"disease_phase":[{"disease_id":"960abf4e113d4f1ab13b4e693cbca8a3","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c81d389040894d6db4a0cda96e2f0d2f","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9caefdc94002408ea7d794c6960e8695","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01786a6b997a460f9771aaaec35d511b","docid":28952,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"638468b7bd1e4713b73229bf971e121b","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":793411200000,"has_leading_org_involved":1,"created_ts":"2021-10-08T14:45:51.000Z","updated_ts":"2026-04-02T14:10:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"贺福立适","status":"ACTIVE"},{"lang":"EN","name":"Hepatitis A vaccine, inactivated(GlaxoSmithKline Plc)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Havrix Junior","status":"ACTIVE"},{"lang":"EN","name":"Havrix Monodose","status":"ACTIVE"},{"lang":"EN","name":"Hepatitis A vaccine inactivated","status":"ACTIVE"}],"trade_name":[{"name":"Havrix","source_info":[{"code":"BLA103475","normalized_source_id":"f3bd4fd130ec4588971e9008b5010e32","source":"FDA_CBER"}],"status":"ACTIVE"}],"drug_type":["00458ff770344a2b962324da6b29d16f","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["36c1b5c4511747e5a1a8c3efd9c65ad4"],"disease_id":["0205cc64eadd4ad7bf93dc03795e3c70"],"active_org_master_entity_id":["eadc10deede4b8846c6aff09307f3ed1"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["0205cc64eadd4ad7bf93dc03795e3c70"],"research_disease":["0205cc64eadd4ad7bf93dc03795e3c70"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":793411200000}}],"disease_phase":[{"disease_id":"0205cc64eadd4ad7bf93dc03795e3c70","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["48e0e206792826a7f51c514354fe6fdb","9b027bb089fcaa2c937327ac652321dd"],"data_source":10}
+{"drug_id":"01b040c204c94962b7240a08758164ad","docid":13847,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"a7bfab54abb63556a19101f72aa87c63","created_ts":"2021-10-08T14:46:01.000Z","updated_ts":"2026-04-02T11:22:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Apazunersen","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/news-release/2025/06/27/3106516/0/en/Ultragenyx-Receives-Breakthrough-Therapy-Designation-for-GTX-102-in-Angelman-Syndrome.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"GTX 102","status":"ACTIVE"},{"name":"GTX-102","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/news-release/2025/06/27/3106516/0/en/Ultragenyx-Receives-Breakthrough-Therapy-Designation-for-GTX-102-in-Angelman-Syndrome.html"}],"status":"ACTIVE"},{"name":"GTX102","status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["61d3fc4fc0ddd227d5cd105bb6771df3"],"mechanism_action_id":["45452f9ce7364da29da5ae5a75c912fd"],"target_id":["cb4ec0d203894deb9689e2e4b576610a"],"special_review":["425d71b560a7499087c4f5a36692741c","b7d7a459842543b7913979bf604084e4","ca2f2c7dacec450e8a45e2b7f4b74d05","c3c948340a7d40f3b7437081f5e8cb4e","043a131d85994801b3617e822e7f87b3"],"disease_id":["f573ea66b81a4b799e7654e40f796a46"],"active_org_master_entity_id":["b38b0ee39b29016f1daa2341f90e049d"],"research_disease":["f573ea66b81a4b799e7654e40f796a46"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733184000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1760313600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1760313600000}}],"disease_phase":[{"disease_id":"f573ea66b81a4b799e7654e40f796a46","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["7e6eaf5976f4c56790800ce6e880e6a2","b38b0ee39b29016f1daa2341f90e049d"],"genetic_material":"98d361a2fe78458182e3b68f30d261d5","if_speculate":0,"data_source":10,"source_info_xna":[{"code":"PMID: 33888895","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source_url":"https://pubmed.ncbi.nlm.nih.gov/33888895/"}],"regulation_type":["f1cc657d8fe04d37918af804bd477fb5"],"delivery_system":["caa0bfbf4bb34602a3d7723ecec5fd14"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"07603d37d12d4bc1b2e1a1a7aac67c2b","docid":57209,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-01-07T10:25:07.000Z","updated_ts":"2026-02-24T23:28:57.000Z","data_status":"ACTIVE","created_by":"sunying@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"MG-01","status":"ACTIVE"}],"dev_code":[{"name":"MG-01","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["d98483c65ab7b174be12d6ed9a53f635"],"disease_id":["d514ca46147040b3b74bdb2977860449","00894c5beba2467fa4489e0fa39ddffa","79bf13d1f4fa469287d07607c89d17d9","375bfada33084974b98821c192ec10b8","c0a151b4650248f1893a3d9d0c295de1","07ca4cbd5bbe460590b9f3982fa38ec1"],"active_org_master_entity_id":["d98483c65ab7b174be12d6ed9a53f635"],"research_disease":["d514ca46147040b3b74bdb2977860449","00894c5beba2467fa4489e0fa39ddffa","79bf13d1f4fa469287d07607c89d17d9"],"non_research_disease":["375bfada33084974b98821c192ec10b8","c0a151b4650248f1893a3d9d0c295de1","07ca4cbd5bbe460590b9f3982fa38ec1"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1622419200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1619740800000}}],"disease_phase":[{"disease_id":"79bf13d1f4fa469287d07607c89d17d9","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"07ca4cbd5bbe460590b9f3982fa38ec1","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c0a151b4650248f1893a3d9d0c295de1","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"d514ca46147040b3b74bdb2977860449","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"375bfada33084974b98821c192ec10b8","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"262edbc27cb24a5d83332fe5ef509c9a","docid":30548,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:31.000Z","updated_ts":"2024-12-31T00:19:55.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LAUR-004","status":"ACTIVE"}],"dev_code":[{"name":"LAUR-004","status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6"],"originator_org_master_entity_id":["7af8ca3eb47deeb543a7e399931c544e"],"disease_id":["25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["7af8ca3eb47deeb543a7e399931c544e"],"research_disease":["25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1650240000000}}],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"34bfe5a60854431bade3c30bbd5b4a99","docid":63858,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:47.000Z","updated_ts":"2024-11-09T00:18:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MDR-301","status":"ACTIVE"}],"dev_code":[{"name":"MDR-301","status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["b42c1fb237df7983caa4c09059e195f3"],"disease_id":["4b7fa328f7b144c69cdf0c4ed38ee527"],"active_org_master_entity_id":["b42c1fb237df7983caa4c09059e195f3"],"research_disease":["4b7fa328f7b144c69cdf0c4ed38ee527"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1642809600000}}],"disease_phase":[{"disease_id":"4b7fa328f7b144c69cdf0c4ed38ee527","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0068d1a4732949bbaf3f51ee52c9a74f","docid":32336,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-03-03T02:25:16.000Z","updated_ts":"2025-12-09T03:47:30.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ALXN-1920","source_info":[{"code":"NCT05751642","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05751642"}],"status":"ACTIVE"}],"dev_code":[{"name":"ALXN 1920","status":"ACTIVE"},{"name":"ALXN1920","status":"ACTIVE"}],"drug_type":["ff9477ffcb8346d59008ad9f2027fd57"],"originator_org_master_entity_id":["0f6b1f5704b311d37dcff81b4b3b4fe3"],"disease_id":["ed353b32505e482fb23bcce4d444e9b4","99533cae1a3540648595200a452bd93c"],"active_org_master_entity_id":["0f6b1f5704b311d37dcff81b4b3b4fe3"],"research_disease":["ed353b32505e482fb23bcce4d444e9b4","99533cae1a3540648595200a452bd93c"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1764720000000}}],"disease_phase":[{"disease_id":"99533cae1a3540648595200a452bd93c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ed353b32505e482fb23bcce4d444e9b4","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00d70b5d30d94ca78131d470c7dfea8d","docid":16267,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-03-02T05:30:43.000Z","updated_ts":"2024-11-01T10:55:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Hepatitis B vaccine( ConserV)","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["664c3bcf97bc9d8055013daafaaaa0a2"],"disease_id":["8b107203951e4ae9bfe9667fccbe8df9"],"active_org_master_entity_id":["664c3bcf97bc9d8055013daafaaaa0a2"],"research_disease":["8b107203951e4ae9bfe9667fccbe8df9"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}}],"disease_phase":[{"disease_id":"8b107203951e4ae9bfe9667fccbe8df9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0764b016fe0b442d87542ccd6b32cd25","docid":23249,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"9afcdcd07b5b38b19153b1170802ca80","created_ts":"2022-09-27T12:39:28.000Z","updated_ts":"2025-05-24T21:17:23.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"BVAC-P","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BVAC P","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["c86f741ce8bd2a2bd7fecb7f23e9fe67"],"mechanism_action_id":["28044b32b6894064ae022f10d0af852e","85fbecaa7d0f51f9901e300e6b3eae33"],"target_id":["0a50e696e9914178899f0df25b96bcab","1764007a7c384a4ab49bb3710bab5052"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4","e50aad3dea474cf487e53bd91d5d7c45","c7fe8aa844d24e85ba32a990ea28ded3"],"active_org_master_entity_id":["c86f741ce8bd2a2bd7fecb7f23e9fe67"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4","e50aad3dea474cf487e53bd91d5d7c45","c7fe8aa844d24e85ba32a990ea28ded3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1640217600000}}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"00b6befc136143df8c1afb1012001771","docid":43149,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":3,"target_extend_id":"42792ef2a9cd3336b4b20fde448cfa56","created_ts":"2021-10-08T14:45:13.000Z","updated_ts":"2026-03-22T00:35:31.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Relicpixant","source_info":[{"attachment_path":"data/phs_source_info/80b0/4880/da99/09a7/9be4701f-a5ee-3b75-aafd-49f0943efecc.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/2e55/2c9a/b99c/a7bf/0aec3131-f287-3146-a94f-a60d6172ff5e.png","source":"Company pipeline","source_url":"https://www.createrna.com/research-and-development/pipeline"},{"code":"WO2020135771A1","normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent","source_url":"https://synapse.zhihuiya.com/patent/5dbdf417-743f-4034-8344-12df55cfd43c"},{"code":"pl131","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl131.pdf?sfvrsn=ba04dc1b_5&download=true"}],"status":"ACTIVE"}],"dev_code":[{"name":"QR 052107B","status":"ACTIVE"},{"name":"QR-052","status":"ACTIVE"},{"name":"QR052","status":"ACTIVE"},{"name":"QR052107B","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["017a77ba457fbd0a0a70c3d83cf9bfd5"],"mechanism_action_id":["a7eff0034e2d647bfe036967c35144aa"],"target_id":["f00d8eda6cd3416cbfd479c493904fca"],"disease_id":["39036cbf338945a485bff2217e29eaaf","713953d4cc504e0e8137369a208ed64b","00a4007368f84f52a23effea76883bbf","bb149749c6994f6cbce61ff2e18dc6e4"],"active_org_master_entity_id":["017a77ba457fbd0a0a70c3d83cf9bfd5"],"research_disease":["39036cbf338945a485bff2217e29eaaf","713953d4cc504e0e8137369a208ed64b","00a4007368f84f52a23effea76883bbf"],"non_research_disease":["bb149749c6994f6cbce61ff2e18dc6e4"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1698796800000}}],"disease_phase":[{"disease_id":"713953d4cc504e0e8137369a208ed64b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"bb149749c6994f6cbce61ff2e18dc6e4","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"00a4007368f84f52a23effea76883bbf","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"39036cbf338945a485bff2217e29eaaf","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"09fb7539e0b24781b99f826af839d053","docid":26108,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Valoctocogene_roxaparvovec","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"b2ca28b01c34419db0365bad2f8dd09e","first_approved_date":1661299200000,"rnk":3,"target_extend_id":"0e8c070b1927365bab8db36962be902a","created_ts":"2021-10-08T14:47:50.000Z","updated_ts":"2026-02-28T21:09:10.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"Valoctocogene roxaparvovec","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AAV5-HFVIII-SQ","status":"ACTIVE"},{"lang":"EN","name":"DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)","source_info":[{"code":"DB15561","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Factor-VIII-gene-therapy-BioMarin","status":"ACTIVE"},{"lang":"EN","name":"Valoctocogene roxaparvovec-rvox","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/biomarin-announces-agreement-with-german-health-insurance-fund-on-reimbursement-amount-for-roctavian-valoctocogene-roxaparvovec-rvox-for-severe-hemophilia-a-in-germany/"}],"status":"ACTIVE"},{"lang":"EN","name":"Valrox","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://med.sina.com/article_detail_103_2_117657.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"BMN-270","source_info":[{"code":"2024_1085","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","source":"ASGCT","source_url":"https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=59498"}],"status":"ACTIVE"}],"trade_name":[{"name":"Roctavian","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU1NTg4OTM3Mg==&mid=2247736651&idx=4&sn=e3387a655fcaaea36aa0807c930eb9cc"}],"status":"ACTIVE"}],"generic_name":[{"name":"Valoctocogene roxaparvovec","source_info":[{"code":"EMEA/H/C/005830","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian"}],"status":"ACTIVE"}],"drugbank_id":["DB15561"],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["945a78962ce6ae24be3fc455ea813669"],"mechanism_action_id":["faaaf6a0473a2f69476e176ab746aa59"],"target_id":["a5ce1e0cfc1b48ac8bcff32762c3c446"],"special_review":["23d3523b7ece48ddacaddac53a66949d","ed88b5b02898448483d0dd3ce010cfba","6501abeba2b6400ca8c822d8b2bff598","b7d7a459842543b7913979bf604084e4","f5c599472af046a5b482ffb1ea1a9d3c","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["07d4cf59dafc4a35840dbf53e136394a"],"active_org_master_entity_id":["945a78962ce6ae24be3fc455ea813669","af4429dd673d612c5963f08f96133637"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["07d4cf59dafc4a35840dbf53e136394a"],"research_disease":["07d4cf59dafc4a35840dbf53e136394a"],"inactive_org_master_entity_id":["805e09366bd80e9963dc0c3b18b66514"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1703462400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1513641600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1715040000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}}],"disease_phase":[{"disease_id":"07d4cf59dafc4a35840dbf53e136394a","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2e761dca048842f08cee27e5c23b5772","docid":7097,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:21.000Z","updated_ts":"2024-11-08T14:02:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"4P-202","status":"ACTIVE"}],"dev_code":[{"name":"4P-202","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3b3fa6b3be1eb6713c3099ac53c074b4"],"disease_id":["164ba9b819474bcd9c0f89bbf21a934c","e08c193dbbb34a59b29bfc570a516de7"],"active_org_master_entity_id":["3b3fa6b3be1eb6713c3099ac53c074b4"],"research_disease":["164ba9b819474bcd9c0f89bbf21a934c","e08c193dbbb34a59b29bfc570a516de7"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1647993600000}}],"disease_phase":[{"disease_id":"e08c193dbbb34a59b29bfc570a516de7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"164ba9b819474bcd9c0f89bbf21a934c","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"24e4dc60fb0d41038febc54ad52f677e","docid":37887,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"945d2886bdc043a687db986dcd8f84d3","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1737676800000,"rnk":28,"target_extend_id":"c2ae5bf143df357dbed72cf460d1cc2e","created_ts":"2021-10-08T14:49:21.000Z","updated_ts":"2026-04-04T21:16:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":1737676800000,"drug_name":[{"lang":"CN","name":"西妥昔单抗生物类似药 (科伦博泰)","status":"ACTIVE"},{"lang":"EN","name":"Cetuximab biosimilar (Kelun Botai)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cetuximab Biosimilar (Sichuan Kelun Botai Biomedicine Co., Ltd.)","status":"ACTIVE"},{"lang":"EN","name":"Cetuximab N01","source_info":[{"code":"国药准字S20250006","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MTZjZjViYWZjMDI3NWYxNzY5MTk5NTBlZDdiMWI4YmImaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm"}],"status":"ACTIVE"},{"lang":"CN","name":"西妥昔单抗N01","source_info":[{"code":"国药准字S20250006","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MTZjZjViYWZjMDI3NWYxNzY5MTk5NTBlZDdiMWI4YmImaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm"}],"status":"ACTIVE"},{"lang":"CN","name":"西妥昔单抗生物类似药（四川科伦博泰生物医药股份有限公司）","status":"ACTIVE"},{"lang":"CN","name":"重组抗表皮生长因子受体 (EGFR)人鼠嵌合单抗 (四川科伦药业)","status":"ACTIVE"}],"dev_code":[{"name":"A140","source_info":[{"code":"CTR20202451","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=96689a65fb434c119fd9f58199ce349c"}],"status":"ACTIVE"},{"name":"KL-140","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://med.sina.com/article_detail_103_2_76265.html"}],"status":"ACTIVE"},{"name":"KL-A140","status":"ACTIVE"},{"name":"KLA140","status":"ACTIVE"}],"trade_name":[{"name":"达泰莱","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247548870&idx=3&sn=fce3e4c3dc641025e6cf7ace9667d0a6"}],"status":"ACTIVE"}],"generic_name":[{"name":"Cetuximab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["5025234e8bb97bf04295812da138e4bd"],"mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4"],"target_id":["c18d6f96c23b4d1e880daafa1b00472b"],"atc_code":["2df1e225410f4b22aadb7b9d73dd178d"],"disease_id":["cca43cc5a383493fa28d1d7766f15b6f","6fe05469e09f4305b7615b2c277382cd","e35ce4e9b7a846d49e600ce7ac4a7fd6","c4046d407c134e3f93c5c9a09226c6a7","b3d498b086894c13bf5ac981a350af82"],"active_org_master_entity_id":["5025234e8bb97bf04295812da138e4bd","ebe648fc543d2d0e15821e82dcb806e9"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["cca43cc5a383493fa28d1d7766f15b6f"],"research_disease":["cca43cc5a383493fa28d1d7766f15b6f","6fe05469e09f4305b7615b2c277382cd","e35ce4e9b7a846d49e600ce7ac4a7fd6","c4046d407c134e3f93c5c9a09226c6a7","b3d498b086894c13bf5ac981a350af82"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1737676800000}}],"disease_phase":[{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"b3d498b086894c13bf5ac981a350af82","highest_phase_cn":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_global":"3da2ce3ce8b0443fb0b2d335be3e591a"},{"disease_id":"c4046d407c134e3f93c5c9a09226c6a7","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"cca43cc5a383493fa28d1d7766f15b6f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["1d39e67389f946ada4e45bdf4d930055"],"if_speculate":0,"data_source":10}
+{"drug_id":"04339681f2cd449190598fa3728320c7","docid":15021,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-07-11T12:46:22.000Z","updated_ts":"2026-04-03T09:20:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"VE-818","status":"ACTIVE"}],"dev_code":[{"name":"VE818","status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["438d329f621bf84158ababa196caa78f"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","e11d32d254aba0e2defc5d6c4cd64b1a"],"disease_id":["db9c3b6ae9604cdb83a5909cfba5ef80","ac5ea2be7bb745458261c3bbb740ee4c"],"active_org_master_entity_id":["8ade18cb809ded305b8d4a7273fd66f9","438d329f621bf84158ababa196caa78f","e55b493e5f8bcfecab639b0cfc684ab7"],"research_disease":["db9c3b6ae9604cdb83a5909cfba5ef80","ac5ea2be7bb745458261c3bbb740ee4c"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"6752c34a-10a0-396a-ab3f-d5371204f7a8","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1745107200000}},{"country":"7e557d37-ce70-3cb2-ba25-631fe607d1af","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1753833600000}},{"country":"e623abcb-dee9-3ce1-a315-9f3f0e8b0362","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1756512000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1653350400000}}],"disease_phase":[{"disease_id":"db9c3b6ae9604cdb83a5909cfba5ef80","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ac5ea2be7bb745458261c3bbb740ee4c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0ffb3bd944bf4409b2250ccede0b28fd","docid":74844,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":8,"target_extend_id":"6a7742adb33c3a6da2c632af2a03be2e","created_ts":"2021-11-30T08:59:04.000Z","updated_ts":"2026-04-17T18:38:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CM 355","status":"ACTIVE"}],"dev_code":[{"name":"CM-355","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd20-anti-cd3-bispecific-antibody-cm355"}],"status":"ACTIVE"},{"name":"CM355","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.keymedbio.com/list-12-1.html#catid150"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd20-anti-cd3-bispecific-antibody-cm355"}],"status":"ACTIVE"},{"name":"ICP-B02","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.innocarepharma.com/cn/pipeline/our-pipeline/"}],"status":"ACTIVE"},{"name":"PRO 203","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://m.sohu.com/a/992878775_121613636?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334"}],"status":"ACTIVE"},{"name":"PRO-203","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://m.sohu.com/a/992878775_121613636?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334"}],"status":"ACTIVE"},{"name":"PRO203","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://m.sohu.com/a/992878775_121613636?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334"}],"status":"ACTIVE"}],"drug_type":["6e43c7fb400c4fda8d8693f12241cc09"],"originator_org_master_entity_id":["77a58f3c97e31f0428f36e670965e2a4","99d6d34142f9e104d617f0182d941654"],"mechanism_action_id":["16b5dca2ef00478ba4719851807e1c05","59e827e69bbc5091c37f33d9798f8c02"],"target_id":["8b4260187fa64823b593f35188526e50","fe50c9b7f38746beb4bfd1ae9fa6fd1b"],"disease_id":["d06a737ae1d8400eb1a6b2d3034c0ebf","4c9d46b2b7794d128b14d8689f4c357d","3f3d760a29f843cf979a432676c54603","51236dbf55d24268aa6d31d9be131f6f","023eff079db647e0bc390cf84b8de199","c5e1987e283c495aaab2a8d309c6085e","26535c6f16de4adfb19f0154be738535"],"active_org_master_entity_id":["e2b3cdee9212bbf405abb4aa4f7ff8f1","99d6d34142f9e104d617f0182d941654","77a58f3c97e31f0428f36e670965e2a4","18f1bbcfd242608c86071c1794caa201","b948db12d5219661c85e8d12d93d592f","9e828c85ae680155fcbeb4221a275ceb"],"research_disease":["d06a737ae1d8400eb1a6b2d3034c0ebf","4c9d46b2b7794d128b14d8689f4c357d","3f3d760a29f843cf979a432676c54603","51236dbf55d24268aa6d31d9be131f6f","023eff079db647e0bc390cf84b8de199","c5e1987e283c495aaab2a8d309c6085e","26535c6f16de4adfb19f0154be738535"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1640563200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1637020800000}}],"disease_phase":[{"disease_id":"3f3d760a29f843cf979a432676c54603","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"023eff079db647e0bc390cf84b8de199","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d06a737ae1d8400eb1a6b2d3034c0ebf","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"deal_related_org":["18f1bbcfd242608c86071c1794caa201","3206c84d3bae4ea547213024defc6653","3b7aebf8694074eb834092b8ca784e60","77a58f3c97e31f0428f36e670965e2a4","99d6d34142f9e104d617f0182d941654"],"data_source":10}
+{"drug_id":"19f0e2ac8604433487c60e371e1d019d","docid":470797,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":19,"target_extend_id":"a86d25fb4edb3b0880b9170ded39c5e0","created_ts":"2024-11-14T09:38:59.000Z","updated_ts":"2026-04-02T10:59:36.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"CRN-09682","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/6578480"}],"status":"ACTIVE"}],"dev_code":[{"name":"CRN09682","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/6578480"}],"status":"ACTIVE"}],"drug_type":["d44cc4ee34c4454d9d91c94b2d902cab"],"originator_org_master_entity_id":["9eb2ecdd656deeeadbf85c04d24d7202"],"mechanism_action_id":["a26baa4991a1e39365bb8230dd855709"],"target_id":["5c1416e0066c4ae0a306f931bffb3890"],"disease_id":["480d2da166064cf1a89e809f7cac1a77","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["9eb2ecdd656deeeadbf85c04d24d7202"],"research_disease":["480d2da166064cf1a89e809f7cac1a77","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1764115200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1764115200000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"480d2da166064cf1a89e809f7cac1a77","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10,"moiety_target_extend_id":"a86d25fb4edb3b0880b9170ded39c5e0","moiety_mechanism_action_id":["a26baa4991a1e39365bb8230dd855709"],"moiety_target_id":["5c1416e0066c4ae0a306f931bffb3890"]}
+{"drug_id":"005adfba0e574c7da168efb9879ae51e","docid":11358,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":2,"target_extend_id":"292337a53dd73e199696678d11bb364d","created_ts":"2021-10-08T14:37:10.000Z","updated_ts":"2026-04-02T11:15:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Deucrictibant","source_info":[{"code":"NCT04618211","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04618211"}],"status":"ACTIVE"}],"dev_code":[{"name":"PHA 121","status":"ACTIVE"},{"name":"PHA-022121","status":"ACTIVE"},{"name":"PHVS-416","status":"ACTIVE"},{"name":"PHVS-719","status":"ACTIVE"},{"name":"PHVS416","status":"ACTIVE"},{"name":"PHVS719","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2f7b64a95d1aa34414062e627ede29f7"],"mechanism_action_id":["c5921c0b0319eef821fdf53df0adea7c"],"target_id":["db82bef178d9417daf5958b1be71703c"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["375c9c363e10470c9c5d09ec1a3e1996","6e0b19fb626347a18144a6f986035dfc","3792471fca3c40d08c8f5e3c571676cb","a9209de5d36c4de6a98a475011e56b7b"],"active_org_master_entity_id":["2f7b64a95d1aa34414062e627ede29f7","222f918796ed5f5b5c4c505fc5585071"],"research_disease":["375c9c363e10470c9c5d09ec1a3e1996","6e0b19fb626347a18144a6f986035dfc","3792471fca3c40d08c8f5e3c571676cb","a9209de5d36c4de6a98a475011e56b7b"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760572800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760572800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760572800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"0293809f-cf7e-3684-b4d2-1fffdaedbb52","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"a8dbb56e-1021-3ca2-8720-a5c1ca5a6aab","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"ba636edd-8de8-3672-8835-04a9db0d8a59","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708905600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1672185600000}}],"disease_phase":[{"disease_id":"375c9c363e10470c9c5d09ec1a3e1996","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a9209de5d36c4de6a98a475011e56b7b","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6e0b19fb626347a18144a6f986035dfc","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3792471fca3c40d08c8f5e3c571676cb","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4a3e8c8d6a7d4866b7d2cdda993973a5","docid":1763593,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-10T02:52:55.000Z","updated_ts":"2026-03-10T03:12:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CAR-M(Cancer Hospital Chinese Academy of Medical Sciences)","source_info":[{"code":"NCT07409766","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07409766"}],"status":"ACTIVE"}],"drug_type":["7258a19d175943708ffd90a34f8e68d1"],"originator_org_master_entity_id":["51551d363d893be0041c70abd164075a"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","f048bf0822254413a3ea354eced08eec"],"active_org_master_entity_id":["51551d363d893be0041c70abd164075a"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","f048bf0822254413a3ea354eced08eec"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1769817600000}}],"disease_phase":[{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00d3d56d17ea49769381b568afd2ad7e","docid":30701,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":997401600000,"rnk":8,"target_extend_id":"3f4e4a8ef2b33d658c455cc792d3676e","created_ts":"2021-10-08T14:48:21.000Z","updated_ts":"2025-12-01T00:29:31.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1135900800000,"drug_name":[{"lang":"CN","name":"西替伪麻","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"盐酸西替利嗪/盐酸伪麻黄碱","status":"ACTIVE"}],"trade_name":[{"name":"Zyrtec-D","status":"ACTIVE"},{"name":"斯特蒙","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"related_component":["54e24cae31ad42aca9c0eb081c98679f","6c5fd178e37e4cfa9f1003fb58477ccf"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["cce07f69ef93d4fc1fb183b996c66f70"],"mechanism_action_id":["d0c8106bb4622df47351b10c7473b784","20bb43d7c96cef20879d53636dd7014c"],"target_id":["638ee1b240b74160b4456cc7857d6fa1","8ea3a4cd3b5c4243b1255ed6996045c0"],"atc_code":["b4a0d6a4b53e45aabfec00a1f246884a"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","1b66be3b29424f4fa2e1a7aee3e77749"],"active_org_master_entity_id":["289a14bcc0be240a69e5bb38e79b79aa","b5a6d96cdebc86a31f1d574fbcf60b2e"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["1b66be3b29424f4fa2e1a7aee3e77749"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","1b66be3b29424f4fa2e1a7aee3e77749"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":997401600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1135900800000}}],"disease_phase":[{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1b66be3b29424f4fa2e1a7aee3e77749","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"03f61208e2c446d287f052d4ccd82cee","docid":38497,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1619740800000,"rnk":25,"target_extend_id":"dc7de6393dbb399aa0d8e2f8236159c3","created_ts":"2021-10-08T14:40:51.000Z","updated_ts":"2026-03-21T00:42:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1619740800000,"drug_name":[{"lang":"CN","name":"培非格司亭生物类似药 (鲁南制药)","status":"ACTIVE"},{"lang":"EN","name":"Pegfilgrastim biosimilar(Lunan Pharma)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Pegfilgrastim  Biosimilar (Lunan Pharmaceutical Group Co., Ltd.)","status":"ACTIVE"},{"lang":"EN","name":"Pegylated Human Granulocyte Colony-stimulating Factor (Lunan Pharma)","status":"ACTIVE"},{"lang":"CN","name":"培非司亭生物类似药 (鲁南制药)","status":"ACTIVE"},{"lang":"CN","name":"培非格司亭生物类似药（Lunan Pharmaceutical Group Co., Ltd.）","status":"ACTIVE"},{"lang":"CN","name":"聚乙二醇化人粒细胞刺激因子(鲁南制药)","source_info":[{"code":"国药准字S20210011","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"聚乙二醇化重组人粒细胞集落刺激因子（重庆富进生物医药）","source_info":[{"code":"CTR20182117","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=43d68254d7f444d8b16cdd1fdf487b8e_p"}],"status":"ACTIVE"}],"trade_name":[{"name":"申力达","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://zhuanlan.zhihu.com/p/685308981"}],"status":"ACTIVE"}],"generic_name":[{"name":"pegfilgrastim","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["814fe916bb2ce730306c0e09dd74a64c"],"mechanism_action_id":["358e5f0ba725062ad8f0c56973cc3e35"],"target_id":["532763442f00416fa392a55be34bad5a"],"atc_code":["dff83be6b0c146ceaf0e213dc51d78ca"],"disease_id":["c7879aa9883f473695aea6cc7470cb48"],"active_org_master_entity_id":["4626b1641ed3af8ed82891f4a73301fe"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["c7879aa9883f473695aea6cc7470cb48"],"research_disease":["c7879aa9883f473695aea6cc7470cb48"],"inactive_org_master_entity_id":["1709ccb4d413baa29729a4617cc8f468"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1619740800000}}],"disease_phase":[{"disease_id":"c7879aa9883f473695aea6cc7470cb48","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["c8ae82ce74fc4776a63b3a7ad409566f"],"data_source":10}
+{"drug_id":"01dd21d4df6e46fbba157d212bb6bfeb","docid":73564,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":17,"target_extend_id":"12a88b2880f03d4590d2f05debee11d1","created_ts":"2023-05-04T02:50:27.000Z","updated_ts":"2026-04-04T21:05:45.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"CN","name":"重组人血清白蛋白（山东健通）","status":"ACTIVE"},{"lang":"EN","name":"Recombinant human albumin (Shandong Kingtone)","source_info":[{"code":"CTR20231314","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=51114ca74cb9406b9153e1669ebaa065"}],"status":"ACTIVE"}],"drug_type":["543364a7f55e4f1ca88a741b4a863fc6"],"originator_org_master_entity_id":["7bb03c22e0dc979d6d8246b116e0435f"],"mechanism_action_id":["6f137cf9fe3248f220892f1343923b29"],"target_id":["2ed6e6a73d214020a5107c48797bbcd4"],"disease_id":["0c167d450cb14df0b7da57263b05f562"],"active_org_master_entity_id":["7bb03c22e0dc979d6d8246b116e0435f"],"research_disease":["0c167d450cb14df0b7da57263b05f562"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1709251200000}}],"disease_phase":[{"disease_id":"0c167d450cb14df0b7da57263b05f562","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"05ae0577b351416cae50ec5b5a2025eb","docid":170064,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2024-03-19T05:24:27.000Z","updated_ts":"2025-02-24T21:48:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"4-Methylumbelliferyl Trimebutine Sulfate","source_info":[{"code":"NCT06315387","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06315387"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"4-MUST","source_info":[{"code":"NCT06315387","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06315387"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["35a338b43d8439a6b6ef567370e76b3b"],"disease_id":["299db6c29e6b4b2c93da4e7deda34e9d","f56ba35badce4bb69653ae65c70c8a86"],"active_org_master_entity_id":["35a338b43d8439a6b6ef567370e76b3b"],"research_disease":["299db6c29e6b4b2c93da4e7deda34e9d","f56ba35badce4bb69653ae65c70c8a86"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1729123200000}}],"disease_phase":[{"disease_id":"f56ba35badce4bb69653ae65c70c8a86","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"299db6c29e6b4b2c93da4e7deda34e9d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0e03672414c74fb28f6459c8f6e847f3","docid":15502,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"0665d96c3efd3f5bb000988d11ad8911","has_leading_org_involved":1,"created_ts":"2023-01-03T08:10:48.000Z","updated_ts":"2026-03-12T09:44:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"GV20-0251","source_info":[{"normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/ct2/show/NCT05669430"},{"code":"2023_3O","normalized_source_id":"67fd8cea1a49410ebdd966dda2755bf6","source":"ESMO","source_url":"https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/lis"}],"status":"ACTIVE"}],"dev_code":[{"name":"GV20 0251","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-igsf8-monoclonal-antibody-gv20-0251"}],"status":"ACTIVE"},{"name":"XBH25","source_info":[{"attachment_path":"data/phs_source_info/f5f4/078a/3916/2cda/5159300a-e5a7-3fd9-9336-c89f5f918001.jpg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/457a/146f/6c80/d973/5e82fdd2-0424-3a53-bf24-b66f32fecfb0.jpg","source":"Company pipeline","source_url":"https://gv20oncotherapy.com/pipeline"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-igsf8-monoclonal-antibody-gv20-0251"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"mechanism_action_id":["730fc293907e4578830e34d5ea43aa31"],"target_id":["95ddd681098849ada1b26a99d484401a"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","9fa7237b86bc4bdba73c3b23e8d84e24","f319fa27684c4cdeb6ce59d897217718","956a06d7545e413d81e5a2eeb642c357","a6cd07ecf38e48b584e8da2adfbe5f42","0a885de5b4054c2b98d478f91f3e3418","15839db0de0947ddb9e4c280884a3895","c1cc2528f29940fc95fd6bc37eb982d4","8222bb15bc7049a1b4426b9f00d701a6","78cb173a4de34f07befac28de907e7bf","e50aad3dea474cf487e53bd91d5d7c45","1714ace3a2f941d8921c9dbc77a8ba1d","c7fe8aa844d24e85ba32a990ea28ded3","8d29f554f371431c9b5b80f5befdf965","f3a2f9a205c642509ad4ae370c6e6085","8e6f6909e2944b7fa8f3593ee96562c1","87a9454771a64f2191224b6b7684254a","8da4804a5bd24352b7d568a7da54c6dc","3beea980d93a4cc0abc864e27514601c","b066b599013c44fc8f97812941d0f5aa","3ac5604c4dde49c29b561648d0c0543c","6fe05469e09f4305b7615b2c277382cd","6c9c5be211cb4d72a28205c49a16d653"],"active_org_master_entity_id":["cc0cd8924e332e13a208035d3d98a2db","60922a420be0b6830048eb498f8422e9"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","9fa7237b86bc4bdba73c3b23e8d84e24","f319fa27684c4cdeb6ce59d897217718","956a06d7545e413d81e5a2eeb642c357","a6cd07ecf38e48b584e8da2adfbe5f42","0a885de5b4054c2b98d478f91f3e3418","15839db0de0947ddb9e4c280884a3895","c1cc2528f29940fc95fd6bc37eb982d4","8222bb15bc7049a1b4426b9f00d701a6","78cb173a4de34f07befac28de907e7bf","e50aad3dea474cf487e53bd91d5d7c45","1714ace3a2f941d8921c9dbc77a8ba1d","c7fe8aa844d24e85ba32a990ea28ded3","8d29f554f371431c9b5b80f5befdf965","f3a2f9a205c642509ad4ae370c6e6085","8e6f6909e2944b7fa8f3593ee96562c1","87a9454771a64f2191224b6b7684254a","8da4804a5bd24352b7d568a7da54c6dc","3beea980d93a4cc0abc864e27514601c","b066b599013c44fc8f97812941d0f5aa","3ac5604c4dde49c29b561648d0c0543c","6fe05469e09f4305b7615b2c277382cd","6c9c5be211cb4d72a28205c49a16d653"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1679529600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1752192000000}}],"disease_phase":[{"disease_id":"8e6f6909e2944b7fa8f3593ee96562c1","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8222bb15bc7049a1b4426b9f00d701a6","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b066b599013c44fc8f97812941d0f5aa","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f3a2f9a205c642509ad4ae370c6e6085","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a6cd07ecf38e48b584e8da2adfbe5f42","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"956a06d7545e413d81e5a2eeb642c357","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3ac5604c4dde49c29b561648d0c0543c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1714ace3a2f941d8921c9dbc77a8ba1d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"9fa7237b86bc4bdba73c3b23e8d84e24","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["60922a420be0b6830048eb498f8422e9","6632a5800bfb389a90c6b15df46d2020"],"data_source":10}
+{"drug_id":"2d01829484ac4ad59ccfeeec1dbf69ce","docid":980121,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":33,"target_extend_id":"75fdcf5bf499369580c308e613a6a161","created_ts":"2025-02-21T05:36:32.000Z","updated_ts":"2026-04-11T21:05:53.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Universal NK cell(Jiangsu Provincial People's Hospital)","source_info":[{"code":"NCT06837389","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06837389"}],"status":"ACTIVE"}],"dev_code":[{"name":"JY-306","source_info":[{"code":"NCT06837389","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06837389"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["d613cfe2e2f119683e8ab75a930a978e"],"mechanism_action_id":["e0a0b70f83bc40c2b45d872d0fe4b7d4"],"target_id":["79d24e30a7ff40bb806ff36962c750e8"],"disease_id":["2e7d2d244b984bcb9206d68231d6001f","ea990be4ecf6403a83b60159d2ed9b29"],"active_org_master_entity_id":["370534d34dc091ee1a1fcd4d1f1d0d54"],"research_disease":["2e7d2d244b984bcb9206d68231d6001f","ea990be4ecf6403a83b60159d2ed9b29"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"disease_phase":[{"disease_id":"2e7d2d244b984bcb9206d68231d6001f","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ea990be4ecf6403a83b60159d2ed9b29","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4685bdbc3074481795fee87b2b6cc436","docid":17111,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:25.000Z","updated_ts":"2025-04-08T09:22:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ERRa (Lead Pharma)","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7b25ac8fe5fa7a7ec1c1f4b7f459206c"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["7b25ac8fe5fa7a7ec1c1f4b7f459206c"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1649203200000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"00c9a3cd44f142f29f8f30eb0bef4e7f","docid":55352,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":910828800000,"created_ts":"2021-11-29T10:50:05.000Z","updated_ts":"2024-11-07T09:43:33.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Rabies Vaccine Adsorbed","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"trade_name":[{"name":"Biorab","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["5f965544d69ba88c5f6828760466a5af"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["26bdc387cad64dc985f00855d64a3d2d"],"active_org_master_entity_id":["5f965544d69ba88c5f6828760466a5af"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["26bdc387cad64dc985f00855d64a3d2d"],"research_disease":["26bdc387cad64dc985f00855d64a3d2d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":910828800000}}],"disease_phase":[{"disease_id":"26bdc387cad64dc985f00855d64a3d2d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"05f4a580ccd94ded87c1b65b93b4d528","docid":64329,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":10,"target_extend_id":"208920a825ee333ebd4fa835bd4755c5","created_ts":"2022-08-02T09:16:00.000Z","updated_ts":"2026-04-04T21:04:52.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"BI-1703880","status":"ACTIVE"}],"dev_code":[{"name":"BI 1703880","source_info":[{"code":"NCT05471856","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05471856"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-bi-1703880"},{"code":"39817655","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/39817655/"}],"status":"ACTIVE"},{"name":"BI-1703880","source_info":[{"code":"NCT05471856","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05471856"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-bi-1703880"}],"status":"ACTIVE"},{"name":"BI1703880","source_info":[{"code":"NCT05471856","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05471856"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-bi-1703880"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["269f1e358ef7f1e4191094971edd4222"],"mechanism_action_id":["83ea729baff14cb9a29f637d8a98dc8d"],"target_id":["3a796e4938384c68a5afc62701c5b97b"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["269f1e358ef7f1e4191094971edd4222"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677196800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677196800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677196800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677196800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"1ce2667319da4eeda7edb0eb1a00d083","docid":46944,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"e122004049e63b98a1fed21ce28a2151","created_ts":"2021-10-08T14:49:15.000Z","updated_ts":"2026-02-25T01:15:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Pexmetinib","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Pexmetinib hydrochloride","status":"ACTIVE"}],"dev_code":[{"name":"ARRY 614","status":"ACTIVE"},{"name":"ARRY-614","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pexmetinib"}],"status":"ACTIVE"}],"drugbank_id":["DB16294"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["97ed8d68d96f6125b02545a9b465aa21"],"mechanism_action_id":["3666432eaf26ac5e4a6a771a26d89852","578075b713025c334db7562d4c8bc511"],"target_id":["3609a1991e5d471db35e9a53f46431e7","130077135b834ef4b375a52efbbc2a56"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","c1cc2528f29940fc95fd6bc37eb982d4","3beea980d93a4cc0abc864e27514601c","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","1a95630392584c7892bec2dc9888cbfc"],"active_org_master_entity_id":["97ed8d68d96f6125b02545a9b465aa21"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","c1cc2528f29940fc95fd6bc37eb982d4","3beea980d93a4cc0abc864e27514601c","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd"],"non_research_disease":["1a95630392584c7892bec2dc9888cbfc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1591833600000}}],"disease_phase":[{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"1893870392d84fbc8d33aac9d13ffe85","docid":1702497,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-01-19T05:44:10.000Z","updated_ts":"2026-01-19T10:00:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"[18F]ABBV-964i","source_info":[{"code":"NCT07348276","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07348276"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["5a60d392b817c5382c3c4b9e708bf857"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["06800c58775143058fa08c139594ed4a"],"active_org_master_entity_id":["5a60d392b817c5382c3c4b9e708bf857"],"research_disease":["06800c58775143058fa08c139594ed4a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1763337600000}}],"disease_phase":[{"disease_id":"06800c58775143058fa08c139594ed4a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"3c7e572ada3c4cbc915a1f8133a39b17","docid":110244,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"0fc42bbba2283ce2a43e956c6fd824ab","created_ts":"2024-01-29T06:57:58.000Z","updated_ts":"2026-02-24T22:50:24.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"IVB-107","source_info":[{"attachment_path":"data/phs_source_info/a929/a673/406a/6e0f/f56a231e-a88b-3823-9054-97ba5c244d4d.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/91ba/a3d2/89e3/dee9/5f002b99-14e2-344d-96f7-94c832d716f6.png","source":"Company pipeline","source_url":"http://www.innovecbio.com/about1.html#w_grid-1699600607156"}],"status":"ACTIVE"}],"dev_code":[{"name":"IVB 107","source_info":[{"attachment_path":"data/phs_source_info/a929/a673/406a/6e0f/f56a231e-a88b-3823-9054-97ba5c244d4d.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/91ba/a3d2/89e3/dee9/5f002b99-14e2-344d-96f7-94c832d716f6.png","source":"Company pipeline","source_url":"http://www.innovecbio.com/about1.html#w_grid-1699600607156"}],"status":"ACTIVE"},{"name":"IVB107","source_info":[{"attachment_path":"data/phs_source_info/a929/a673/406a/6e0f/f56a231e-a88b-3823-9054-97ba5c244d4d.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/91ba/a3d2/89e3/dee9/5f002b99-14e2-344d-96f7-94c832d716f6.png","source":"Company pipeline","source_url":"http://www.innovecbio.com/about1.html#w_grid-1699600607156"}],"status":"ACTIVE"},{"name":"PUMCH-E101","source_info":[{"attachment_path":"data/phs_source_info/923f/e0e7/3c1b/6893/923fe0e73c1b6893.png","attachment_type":"image/png","code":"Innovec-2020505","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a773/cbe0/f831/7653/a773cbe0f8317653.png","source":"Company pipeline","source_url":"https://www.innovecbio.com/h-col-103.html#anchor=module_1102_tab_4"}],"status":"ACTIVE"},{"name":"PUMCHE101","source_info":[{"attachment_path":"data/phs_source_info/923f/e0e7/3c1b/6893/923fe0e73c1b6893.png","attachment_type":"image/png","code":"Innovec-2020505","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a773/cbe0/f831/7653/a773cbe0f8317653.png","source":"Company pipeline","source_url":"https://www.innovecbio.com/h-col-103.html#anchor=module_1102_tab_4"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["a907012f401e0bfca06564b611f7ccad"],"mechanism_action_id":["e39cfff1745c4e21b33eed3619ce5095"],"target_id":["20116297f2d245359deaea296f64e8f6"],"disease_id":["69717f8699ec4d48984bf2ef6540f288","2ef2f7065d1e476d839aaa6ce50d522d"],"active_org_master_entity_id":["13ef679bd3f5964d80448c355e09226a","a907012f401e0bfca06564b611f7ccad","beebc6ce37eea9564f579aaded805044"],"research_disease":["69717f8699ec4d48984bf2ef6540f288","2ef2f7065d1e476d839aaa6ce50d522d"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1726790400000}}],"disease_phase":[{"disease_id":"69717f8699ec4d48984bf2ef6540f288","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2ef2f7065d1e476d839aaa6ce50d522d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"deal_related_org":["13ef679bd3f5964d80448c355e09226a","a907012f401e0bfca06564b611f7ccad"],"if_speculate":0,"data_source":10}
+{"drug_id":"0325cbabe38449708f362bb7c26847c0","docid":61656,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Minoxidil","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":309052800000,"rnk":1,"target_extend_id":"fcb0d833789530b388186906e35a1543","created_ts":"2021-10-08T14:48:39.000Z","updated_ts":"2026-04-20T06:19:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":1704844800000,"drug_name":[{"lang":"CN","name":"米诺地尔","status":"ACTIVE"},{"lang":"EN","name":"Minoxidil","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"2,4-Diamino-6-piperidinopyrimidine 3-oxide","source_info":[{"code":"DB00350","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide","source_info":[{"code":"DB00350","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Minoxidil (JAN/USP/INN)","source_info":[{"code":"D00418","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Minoxidil Liniment","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Minoxidil Tincture","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Mixnoxidil Tincture","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Solution of Minoxidil","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"米诺地尔酊","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"dev_code":[{"name":"AN01","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.aneirapharma.com/science"}],"status":"ACTIVE"},{"name":"ANR-001","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.aneirapharma.com/science"}],"status":"ACTIVE"},{"name":"CU-40103","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg4MTAxOTM2Ng==&mid=2247533941&idx=1&sn=608f6d885b69c28552a26e9a29234d10"}],"status":"ACTIVE"},{"name":"MN 709","status":"ACTIVE"},{"name":"MN-709","status":"ACTIVE"},{"name":"N-1087","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzk3NTA3Nzc2Ng==&mid=2247634336&idx=1&sn=8463404ed6bcd40a98f389a5fdbc7401"},{"code":"NCT07303322","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07303322"}],"status":"ACTIVE"},{"name":"NSC-757106","source_info":[{"code":"596512SH1","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/b446f099-52f6-4ef4-b3e9-ac83fbe1006a"}],"status":"ACTIVE"},{"name":"TM-160","status":"ACTIVE"},{"name":"U-10858","status":"ACTIVE"},{"name":"VDPHL","status":"ACTIVE"},{"name":"VDPHL01","source_info":[{"code":"NCT06527365","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06527365"}],"status":"ACTIVE"}],"trade_name":[{"name":"Loniten","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D00418","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Minodyl","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"Minoximen","status":"ACTIVE"},{"name":"Neoxidil","status":"ACTIVE"},{"name":"Nupelo","source_info":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2023/03/16/2628597/0/en/ViaDerma-Announces-FDA-Registration-Application-Update-Brand-Name-for-New-Hair-Regrowth-Product.html"}],"status":"ACTIVE"},{"name":"Regaine","status":"ACTIVE"},{"name":"RiUP","source_info":[{"code":"D00418","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Rogaine","source_info":[{"code":"D00418","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Theroxidil","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"保法生","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzkzNTIxNTY1MQ==&mid=2247493603&idx=1&sn=156be66ce0fe620676a9d6b3a7ec4387&poc_token=HNZWNmmjQt-ds-Ps6abQGr4uW6YxoNVz6NmvRfGs"}],"status":"ACTIVE"},{"name":"学瑞","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"蔓迪","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"达霏欣","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"영일미녹시딜정","source_info":[{"code":"202401974","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202401974aupdateTs2024-08-13%2017:14:26.945157b"}],"status":"ACTIVE"},{"name":"현대미녹시딜정","source_info":[{"code":"198501401","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=198501401aupdateTs2025-11-04%2018:16:45.478737b"}],"status":"ACTIVE"}],"generic_name":[{"name":"Minoxidil","source_info":[{"code":"D00418","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00350"],"kegg_id":["D00418"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"mechanism_action_id":["3a9042bf2e504564a488a6d4a1b12ad3","324fdecb3d324d3bb51046772d4934ce"],"target_id":["8af54b4ac3014b138b058aa86a536e9e","5f6d7bbeafc9494385e9bb2c4fd6e69e"],"atc_code":["62650de963d14f86b7e160116e781ab3","a47b004dcb044f4999f306bfd771c81d"],"disease_id":["061a5c6c24164fadb7fa15fc1d303e75","4ebc5aba09f54c31a1f2abc8dca4231d","281fcf1b07ee4c13b0297e4ad1a9c106","2e52db813eb94143a5488cb1b73f87b5","4d00afb477764294aa314a5d5ddefaba","0709f63863134bd19c51d5d3fba39fe9","ccd172a9b1a6497aa7a8b3eb35e09819"],"active_org_master_entity_id":["f08e2829377c1e9cbced9cd29481ba81","afa397f1c41300195a0e9d70817859bb","92931735194c3639a58adfec1bde6cc3","1b9aa55954acbb778bc84e2c82da328b","81f178dc1bfb1b46341b049bee528f4f","4e1761ef87fbfde570f8e843a5d1e125","f716b7fbd14932c77a6657a2e50c7c0b"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["281fcf1b07ee4c13b0297e4ad1a9c106"],"research_disease":["061a5c6c24164fadb7fa15fc1d303e75","4ebc5aba09f54c31a1f2abc8dca4231d","281fcf1b07ee4c13b0297e4ad1a9c106","2e52db813eb94143a5488cb1b73f87b5","4d00afb477764294aa314a5d5ddefaba","0709f63863134bd19c51d5d3fba39fe9","ccd172a9b1a6497aa7a8b3eb35e09819"],"inactive_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","52d1b118-b540-37ba-9cb2-f5aff686bb10"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":587779200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1704844800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":489888000000}}],"disease_phase":[{"disease_id":"061a5c6c24164fadb7fa15fc1d303e75","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"4d00afb477764294aa314a5d5ddefaba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"0709f63863134bd19c51d5d3fba39fe9","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"4ebc5aba09f54c31a1f2abc8dca4231d","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ccd172a9b1a6497aa7a8b3eb35e09819","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2e52db813eb94143a5488cb1b73f87b5","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"005da392705b45c69a01d73db26bf3a2","docid":15962,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-03-30T02:13:10.000Z","updated_ts":"2026-01-27T19:33:48.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"AutoSTEM-OA(StemMedical )","source_info":[{"code":"NCT05789719","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05789719"}],"status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"originator_org_master_entity_id":["ff107878806478b27043e9979ac51d0d"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["fd0b1bf93fef45d49eeda147cf253e58"],"active_org_master_entity_id":["ff107878806478b27043e9979ac51d0d"],"research_disease":["fd0b1bf93fef45d49eeda147cf253e58"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1698796800000}}],"disease_phase":[{"disease_id":"fd0b1bf93fef45d49eeda147cf253e58","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"01d3257caf1d4d8499bb4c32c4e8809d","docid":81105,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-10-10T07:43:33.000Z","updated_ts":"2024-11-07T14:57:03.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"YIV-111","source_info":[{"attachment_path":"data/phs_source_info/f761/1647/85e2/ed5f/d9d931d8-bb74-354f-bfc7-bb608c2641dc.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/ac00/838c/4ee6/d896/0de70c3a-19c2-3d1d-b1d9-1318e6778db8.png","source":"Company pipeline","source_url":"https://yiviva.com/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"YIV 111","status":"ACTIVE"},{"name":"YIV111","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["c2a1ceaf58744b5795ebadbd0b06ebd5"],"disease_id":["e2fd9bda4aeb4a7b9fa53a2560126d24","09529518c8164578ac870e810c3c677b"],"active_org_master_entity_id":["c2a1ceaf58744b5795ebadbd0b06ebd5"],"research_disease":["e2fd9bda4aeb4a7b9fa53a2560126d24","09529518c8164578ac870e810c3c677b"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"09529518c8164578ac870e810c3c677b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"06336ffb425a490fa29b4db7cdc88e8e","docid":202935,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"5d1b1610fc4e3418957ecebef1c34a6c","created_ts":"2024-07-22T08:09:30.000Z","updated_ts":"2026-04-20T09:24:54.000Z","data_status":"ACTIVE","created_by":"wangxianda@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"YH-35995","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://kormedi.com/1701733/yuhan-gets-phase-1-trial-nod-for-gaucher-disease-treatment/"}],"status":"ACTIVE"}],"dev_code":[{"name":"YH35995","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://kormedi.com/1701733/yuhan-gets-phase-1-trial-nod-for-gaucher-disease-treatment/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4d2bb307a7e84f386eeed64251299f20"],"mechanism_action_id":["b36d2ffe137dad688df718b7d9cb3c33"],"target_id":["db219c99890844a3b09d1e7406600d37"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["cf0119fdbf9445088f591e2fce4782a8"],"active_org_master_entity_id":["4d2bb307a7e84f386eeed64251299f20"],"research_disease":["cf0119fdbf9445088f591e2fce4782a8"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1722211200000}}],"disease_phase":[{"disease_id":"cf0119fdbf9445088f591e2fce4782a8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00023bcab2274722b9c6cfde9f264576","docid":50047,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Indinavir","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":826675200000,"rnk":1,"target_extend_id":"39034765a69f3979987edc9b6eb1afcb","created_ts":"2021-10-08T14:42:29.000Z","updated_ts":"2026-04-12T21:14:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","first_approved_date_cn":1015286400000,"drug_name":[{"lang":"CN","name":"硫酸茚地那韦","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Indinavir Sulfate","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Indinavir anhydrous","source_info":[{"code":"DB00224","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Indinavir sulfate (USP)","source_info":[{"code":"D00897","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"indinavir","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"},{"code":"DB00224","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"indinavir sulfate ethanolate","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"}],"dev_code":[{"name":"L 735524","status":"ACTIVE"},{"name":"L-735524","status":"ACTIVE"},{"name":"MK 639","status":"ACTIVE"},{"name":"MK-0639","source_info":[{"code":"NCT00001443","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT00001443"}],"status":"ACTIVE"},{"name":"MK-639","status":"ACTIVE"},{"name":"NSC-697197","source_info":[{"code":"771H53976Q","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ef410e5b-2992-4904-af31-c7cfb7909ad9"}],"status":"ACTIVE"}],"trade_name":[{"name":"Crixivan","source_info":[{"code":"D00897","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"佳息患","status":"ACTIVE"},{"name":"欧直","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"indinavir","source_info":[{"code":"9MG78X43ZT","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/ced0adc1-cbb6-4007-a90a-6fc0b7909e1f"}],"status":"ACTIVE"}],"drugbank_id":["DB00224"],"kegg_id":["D00897"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6632a5800bfb389a90c6b15df46d2020"],"mechanism_action_id":["b7db6c15208e582de8bd61f6e359426d"],"target_id":["251788fc69b449e58596a8bf8b3c9e54"],"atc_code":["2b26d14138d5404c8b3db53507b96970"],"special_review":["df5e83eb171a4eb095fcab2f1470348d","043a131d85994801b3617e822e7f87b3"],"disease_id":["acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["6a8c172f1efc649035845f94c31a9c1e","6632a5800bfb389a90c6b15df46d2020"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["acfaaa0373944ffd89b0a2ace0d8c564"],"research_disease":["acfaaa0373944ffd89b0a2ace0d8c564"],"inactive_org_master_entity_id":["cf4762a441de84a5af459b58c1ef4e00","37644001d015f20c92d6232713bd09eb"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1015286400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":859507200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3","dev_status_time":{"time_trust_code":7,"time_ts":1477958400000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"}],"disease_phase":[{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"051a87b33cb2445ca71e8a1c86faa44c","docid":64781,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-06-15T06:22:31.000Z","updated_ts":"2024-11-07T20:13:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"EA-3571","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://jrct.niph.go.jp/en-latest-detail/jRCT2051220036"}],"status":"ACTIVE"}],"dev_code":[{"name":"EA 3571","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://jrct.niph.go.jp/en-latest-detail/jRCT2051220036"}],"status":"ACTIVE"},{"name":"EA3571","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://jrct.niph.go.jp/en-latest-detail/jRCT2051220036"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2fe19bf4dda1c9461cfefd542226e17b"],"disease_id":["9922422b86804d79a88005958e17ec8e"],"active_org_master_entity_id":["2fe19bf4dda1c9461cfefd542226e17b"],"research_disease":["9922422b86804d79a88005958e17ec8e"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1653004800000}}],"disease_phase":[{"disease_id":"9922422b86804d79a88005958e17ec8e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"03b71166c5074c3a94c301bf2142a493","docid":18912,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":103,"target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","created_ts":"2021-10-08T14:50:03.000Z","updated_ts":"2026-04-11T21:04:32.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"AB-8939","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"1-{4-[2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl]-phenyl}-imidazolidin-2-one","source_info":[{"normalized_source_id":"df564163e18b49cfb6dbe49169e22f2d","source":"FDA","source_url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=695919"}],"status":"ACTIVE"}],"dev_code":[{"name":"AB 8939","status":"ACTIVE"},{"name":"AB8939","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e5169cbb837297fa0804837b42b99396"],"mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"],"target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["7eb7ab92311b474d85e02269b2edc269","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"active_org_master_entity_id":["e5169cbb837297fa0804837b42b99396"],"research_disease":["7eb7ab92311b474d85e02269b2edc269","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7eb7ab92311b474d85e02269b2edc269","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0baa4f4335964b02b5ab46cc8957a5ef","docid":16419,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-09-02T10:34:47.000Z","updated_ts":"2024-11-06T13:22:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SVT-6A4710","status":"ACTIVE"}],"dev_code":[{"name":"SVT6A4710","status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["fdd2473031866beff45d39685de555e4"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","1a41a587feb28542b3050eb67b912259"],"disease_id":["6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["fdd2473031866beff45d39685de555e4"],"research_disease":["6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1668988800000}}],"disease_phase":[{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"137ae90a6c8546e6b278f256ef97620a","docid":20866,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":7,"target_extend_id":"17ee4e74ef5a360489fb9b792df5686e","created_ts":"2022-06-24T07:38:01.000Z","updated_ts":"2026-04-04T21:11:32.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"RZ-001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/cevec-s-license-partner-rznomics-inc-receives-approval-to-initiate-clinical-development-of-cap-r-ad-technology-produced-gene-therapy-vector-in-liver-cancer-patients/"}],"status":"ACTIVE"}],"dev_code":[{"name":"RZ 001","status":"ACTIVE"},{"name":"RZ-001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/cevec-s-license-partner-rznomics-inc-receives-approval-to-initiate-clinical-development-of-cap-r-ad-technology-produced-gene-therapy-vector-in-liver-cancer-patients/"}],"status":"ACTIVE"},{"name":"RZ001","status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["0402a99e67036fb1876b34c64936c48b"],"mechanism_action_id":["47017ad75453dbe601b7fd480e482e01"],"target_id":["6973124cc96544bca5ed646766b27d72"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["05554578204541148a5482ad5df4a600","15839db0de0947ddb9e4c280884a3895"],"active_org_master_entity_id":["0402a99e67036fb1876b34c64936c48b"],"research_disease":["05554578204541148a5482ad5df4a600","15839db0de0947ddb9e4c280884a3895"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1666656000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1657670400000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0d749d02babb48cb861e8b544171c526","docid":1643097,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-11-24T09:32:14.000Z","updated_ts":"2025-12-09T06:30:18.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"ZZSW-01","source_info":[{"code":"NCT07240974","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07240974"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CAR-EVs(Wuhan Xiehe Hospital Tower)","source_info":[{"code":"NCT07240974","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07240974"}],"status":"ACTIVE"},{"lang":"EN","name":"Extracellular vesicle vector that carries CD19 CAR mRNA(Wuhan Xiehe Hospital Tower)","source_info":[{"code":"NCT07240974","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07240974"}],"status":"ACTIVE"}],"dev_code":[{"name":"ZZSW-01","source_info":[{"code":"NCT07240974","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07240974"}],"status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["aacba1cf511d2713ac418425f8edcb67"],"disease_id":["ce09181e978a4a3f9932f35001b9fa13"],"active_org_master_entity_id":["aacba1cf511d2713ac418425f8edcb67"],"research_disease":["ce09181e978a4a3f9932f35001b9fa13"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1761609600000}}],"disease_phase":[{"disease_id":"ce09181e978a4a3f9932f35001b9fa13","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1c1c8ad8c4954a75a36d295fffc2fddf","docid":7086,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":22,"target_extend_id":"5a5f0715a80d3980915d6429b7c85819","created_ts":"2021-10-08T14:49:59.000Z","updated_ts":"2026-04-04T21:07:20.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Lasme-cel","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://marketchameleon.com/articles/b/2025/10/16/cellectis-showcases-pivotal-phase-2-strategy-lasme-cel-b-all-rd-day"}],"status":"ACTIVE"}],"dev_code":[{"name":"BALLI-01","status":"ACTIVE"},{"name":"UCART 22","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-cd22-specific-universal-car-expressing-t-lymphocytes-ucart22"}],"status":"ACTIVE"},{"name":"UCART-22","status":"ACTIVE"},{"name":"UCART22","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-cd22-specific-universal-car-expressing-t-lymphocytes-ucart22"}],"status":"ACTIVE"}],"drug_type":["8cda7e9356a7439ea27ce1a899143e5c"],"originator_org_master_entity_id":["feb4a0055163e8a0f45cc763e76efacd"],"mechanism_action_id":["4c9c02bbdfaac0c794d51e268155fc51"],"target_id":["d02b07e15b354447b8f22cb9e5c1d369"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["294846f579d440bda034235d757bcd53"],"active_org_master_entity_id":["feb4a0055163e8a0f45cc763e76efacd"],"research_disease":["294846f579d440bda034235d757bcd53"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1571011200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1571011200000}}],"disease_phase":[{"disease_id":"294846f579d440bda034235d757bcd53","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"05eb89bb15fd438ebab974b4006d8e3e","docid":7066,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"6605fd2000fd34878e28c4bb8f4ba8b6","created_ts":"2021-10-08T14:49:43.000Z","updated_ts":"2026-02-25T00:55:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"kongfengfeng","drug_name":[{"lang":"EN","name":"[F-18]Flornaptitril","source_info":[{"attachment_path":"data/phs_source_info/1b51/04de/5071/7729/aa95a4f9-e179-3c70-8916-b1394dac6809.png","attachment_type":"image/png","code":"202501","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/7802/8daa/93e3/d20e/db185fe5-f37d-3972-a4cc-38ba386efc71.png","source":"Company pipeline","source_url":"https://ceremarkpharma.com/f-18-flornaptitril/"}],"status":"ACTIVE"}],"dev_code":[{"name":"18F-FDDNP","source_info":[{"attachment_path":"data/phs_source_info/1b51/04de/5071/7729/aa95a4f9-e179-3c70-8916-b1394dac6809.png","attachment_type":"image/png","code":"202501","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/7802/8daa/93e3/d20e/db185fe5-f37d-3972-a4cc-38ba386efc71.png","source":"Company pipeline","source_url":"https://ceremarkpharma.com/f-18-flornaptitril/"}],"status":"ACTIVE"},{"name":"F-18 FNT","source_info":[{"attachment_path":"data/phs_source_info/1b51/04de/5071/7729/aa95a4f9-e179-3c70-8916-b1394dac6809.png","attachment_type":"image/png","code":"202501","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/7802/8daa/93e3/d20e/db185fe5-f37d-3972-a4cc-38ba386efc71.png","source":"Company pipeline","source_url":"https://ceremarkpharma.com/f-18-flornaptitril/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["42bff280341902d53ae6b66bfd915945","e7bbf260d7c2f34aefd5331f6af03cbc"],"mechanism_action_id":["d4e1560de4a5234590d7e480973bc215","c7684e9a997583fcba171bd5dc2952e1","0749288ce5e4be2dc4dcdf9173d8f6b3"],"target_id":["5ff9d5388b7c4c0a9abf556c9d8659d6","47175928e7fb46619920e090090bf410"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0","cf9a6321e8854968b3305a3e11ddadec","59eead7c77c14824bfa8c76df5b252c5","e750d2827d3b4217b8c1561c11aa8eab","4db8920b7585412c8876a2c31a020835","06800c58775143058fa08c139594ed4a"],"active_org_master_entity_id":["42bff280341902d53ae6b66bfd915945"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0","cf9a6321e8854968b3305a3e11ddadec"],"non_research_disease":["59eead7c77c14824bfa8c76df5b252c5","e750d2827d3b4217b8c1561c11aa8eab","4db8920b7585412c8876a2c31a020835","06800c58775143058fa08c139594ed4a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751328000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1517356800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1417392000000}}],"disease_phase":[{"disease_id":"cf9a6321e8854968b3305a3e11ddadec","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"06800c58775143058fa08c139594ed4a","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e750d2827d3b4217b8c1561c11aa8eab","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"59eead7c77c14824bfa8c76df5b252c5","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4db8920b7585412c8876a2c31a020835","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"09d724c45be247bb96bfa805f48c8333","docid":72311,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":96,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2022-11-06T07:14:40.000Z","updated_ts":"2026-03-21T21:11:04.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"lnsulin Aspart 30(Sunshine Lake Pharma Co. Ltd.)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://pharm.hec.cn/proyf.aspx?AboutCateId=65"}],"status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6"],"originator_org_master_entity_id":["eb98b8e94cfb5db5afd777edd77b44fa"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["eb98b8e94cfb5db5afd777edd77b44fa"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0ae5a0fb33f8439f9d0e1984c7258702","docid":33236,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"6eb7064ec02a3ac681437af0dbc77a1a","created_ts":"2021-10-08T14:37:10.000Z","updated_ts":"2024-12-26T00:21:29.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"安多司特","status":"ACTIVE"},{"lang":"EN","name":"Andolast","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Diazolast","status":"ACTIVE"}],"dev_code":[{"name":"CR 2039","status":"ACTIVE"},{"name":"CR-2039","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["497d552818a0f5b78903e1b19321fb1d"],"mechanism_action_id":["3aa544ab7d7b4d31a3974270aa37292d"],"target_id":["d0c291eeccfa4fd58031d0cfb12cc1d0"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","486c4f5995ae4425a9c98a48d22c84c8","00894c5beba2467fa4489e0fa39ddffa"],"active_org_master_entity_id":["497d552818a0f5b78903e1b19321fb1d"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","486c4f5995ae4425a9c98a48d22c84c8","00894c5beba2467fa4489e0fa39ddffa"],"inactive_org_master_entity_id":["001bd57c40b5ff68f59db2c213522dac"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"2b6d20adfcc048548ed30829274d5cbf","docid":46047,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-08-03T08:55:39.000Z","updated_ts":"2026-03-23T02:56:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"安神滴丸","status":"ACTIVE"},{"lang":"EN","name":"Anshen Dropping Pills","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"枣仁宁心滴丸","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://paper.cnstock.com/html/2026-03/20/content_2190349.htm"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["1303e7e203d6cccc8f5b09664d4eafe2"],"disease_id":["dca26135a3174a70b3094a4751d59f5f"],"active_org_master_entity_id":["1303e7e203d6cccc8f5b09664d4eafe2"],"research_disease":["dca26135a3174a70b3094a4751d59f5f"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1737590400000}}],"disease_phase":[{"disease_id":"dca26135a3174a70b3094a4751d59f5f","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0043bcbe33b44414ba5213bc7c71371f","docid":37549,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:49:13.000Z","updated_ts":"2024-10-30T10:22:37.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Oncolytic viruses(EpicentRx, Inc.)","status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["8937d9f701a09f2cf1839faaecd721d2"],"mechanism_action_id":["3f1fbab708a0063b7d8cda18f4a25f6f"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["8937d9f701a09f2cf1839faaecd721d2"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"00fc1dbd6d4c4d7e9c46ed6b77ddfd69","docid":789,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":7,"target_extend_id":"0d34a0ce767a34eaa77fad7cef2ac553","created_ts":"2021-10-08T14:49:53.000Z","updated_ts":"2026-04-02T17:06:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Guadecitabine Sodium","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DNMT-inhibitor-SGI-110","status":"ACTIVE"},{"lang":"EN","name":"Decitabine deoxyguanosine","status":"ACTIVE"},{"lang":"EN","name":"Decitabine deoxyguanosine dinucleotide","status":"ACTIVE"},{"lang":"EN","name":"Guadecitabine","source_info":[{"code":"2023_1877","normalized_source_id":"ca88304bde6747888c1de53f13aa16fb","source":"ASH","source_url":"https://ash.confex.com/ash/2023/webprogram/Paper184690.html"},{"code":"2018_https://ashpublications.org/blood/article/132/Supplement 1/1811/272922/Phase-I-Results-of-a-Multicenter-Clinical-Trial","normalized_source_id":"ca88304bde6747888c1de53f13aa16fb","source":"ASH","source_url":"https://ashpublications.org/blood/article/132/Supplement 1/1811/272922/Phase-I-Results-of-a-Multicenter-Clinical-Trial"},{"code":"2018_TPS2608","normalized_source_id":"c47a5730bf5e40b3aa76c26820ec6d4e","source":"ASCO","source_url":"https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS2608"}],"status":"ACTIVE"},{"lang":"EN","name":"Guadecitabine sodium (JAN/USAN)","source_info":[{"code":"D10809","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Guadecitabine-sodium","status":"ACTIVE"}],"dev_code":[{"name":"0RB89YH367 (UNII code)","status":"ACTIVE"},{"name":"S-110","status":"ACTIVE"},{"name":"SGI-110","source_info":[{"code":"2016_TPS9595","normalized_source_id":"c47a5730bf5e40b3aa76c26820ec6d4e","source":"ASCO","source_url":"https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS9595"},{"code":"2014_https://ashpublications.org/blood/article/124/21/2303/89877/Immunomodulatory-Effect-of-SGI-110-a-Novel","normalized_source_id":"ca88304bde6747888c1de53f13aa16fb","source":"ASH","source_url":"https://ashpublications.org/blood/article/124/21/2303/89877/Immunomodulatory-Effect-of-SGI-110-a-Novel"},{"code":"2013_4623","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/73/8_Supplement/4623/590516/Abstract-4623-The-novel-small-molecule-DNA"},{"code":"2015_2943","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/75/15_Supplement/2943/601987/Abstract-2943-Novel-combination-therapy-of-DNMT"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/guadecitabine"}],"status":"ACTIVE"}],"generic_name":[{"name":"Guadecitabine","source_info":[{"code":"2KT4YN1DP7","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/802cf734-3646-4c04-8eb6-82228ca9e404"}],"status":"ACTIVE"}],"drugbank_id":["DB11918"],"kegg_id":["D10809"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["59dcf87af139ff1f4e8750087efb03d9"],"mechanism_action_id":["c0b5aa095cfaaa35e9588836726b6e57","ecc5faed66fa622972fbe6f2cb95b244","3ba9f3f7abb04eb3a2a91c20d34e8abe"],"target_id":["a5f3a7f1a0094b7b938119a4fd1cf5da"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","4b0f73d4edfb4a4096712e37c25212b4","fd398ddf7d0843fa85c144cdceca8251","0f1db06de3604121b621a1bc492b473d","79fc76ece05345348f5d7662c9e30b2e","941ef5bdf9fa49b3b8054dd755019209","fd918c0ed89c405abc5d8625ab570aa5","a311ae2187914c2bbad45810b91f9414","3beea980d93a4cc0abc864e27514601c","2477c68e093d4b818b11333ee1a5ee02","ee423e7465a441f9b91198eb4a53bd6d","224620d4ffab40a0b52cd669ef7f7011","d375036a43f64928be38e27410c1a835","55308ce01ccf489fa6a811cc0896f0cb","d9c985ab1f04428493c029df6dca650d","7665e5683a1a443a8f3d3b946d4c9ca2","95aea6610cf849e0950a0771c6b25c69","c297238c41b2488abe3de6546b105a4e","c7fe8aa844d24e85ba32a990ea28ded3","570b3cb9d08246788a5c1ccfc4ab5b09","114966a80e4d4ce5a6885c9e09dc08d5","7eb7ab92311b474d85e02269b2edc269","1a95630392584c7892bec2dc9888cbfc","c1cc2528f29940fc95fd6bc37eb982d4","7fb8ceff333b48e8adea2c0803494a48","119867ee537140d7ae1ab89e541d98f9","9eeccc4caf594a5abedc0559fd9e0424","6a962a4341364bbe9959b413849567de","8bea5bec08e44c1ea7a90c7a1e3daeb8","b0ac866f2b8d4d17b5deeb130ab17543","07994e875a7f44dc9af7f9bf3f6989e5","62eaee6d9ee44410b8aca59dfc7408e9","05554578204541148a5482ad5df4a600","da37b8c0153d4a6bbbf3c424c4f0b3fc","03bd23316cb54eecbbc4f53311087042","0ade2c6f9dec476595d303c91c8babc9","d39b64a7a7714a9f9227c3607e801e41","2536e79ced34450fbb09de73061cf096","30e04459131b46f58318f1e84b63135a","5dc15a3bfff7405197a9e12963b07d1f","e35ce4e9b7a846d49e600ce7ac4a7fd6","58fbfbf692184307a72a2a4f72a657f2","c0603b4a25234f2bb1615f64d7d6fc63","8bd6e60a4549486a8d690e66701eb676","9b60b7d38a4044b3b7f98c61c365e6b9","557f5ccfe746466cbdb9383a94178eef","32b2a7f88bfd47f08d38b864034f7ee1","218de7027c39474b884ca5d174846630","828fb9fef58643deaeb03ba65a7d3953","f0e77325ab1e46a899ce62a7c13214cc","a4afc28011454f2ca2f48f95f242a04f","1dd4be2a22d04ef39e07fb5cdbc2c2d5"],"active_org_master_entity_id":["bc6241e8a42dd6dff1fe2a92249cdb9d","0f7542cae32633211f7f5f335794b136","6f7aa0d5b978b4e70d9a1f0c04384139","9b887e67e08f4f520a3eae177d6ee451","db7e411ffa7538a2824ed8c5e14dfe44","c6da6ecb305242493c48bac3419b9d7d","a4aef0b72fe4ca4a2c31a89b698bd3d0","6f1e5d4aa0db05022496f52dcdf60034","f022114dff43c313369eb2cd471e8fea","c347cc34487a9a8d1724955d514fe6b4","dea970434c1183ebd6632e77bd1e19c0","5272b6373700c3d58d2cf942792a6307","98e9327c55abf6c8432ac3710796aebb","80c5f3debb9e7e4eece55117196ac687"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","4b0f73d4edfb4a4096712e37c25212b4","fd398ddf7d0843fa85c144cdceca8251","0f1db06de3604121b621a1bc492b473d","79fc76ece05345348f5d7662c9e30b2e","941ef5bdf9fa49b3b8054dd755019209","fd918c0ed89c405abc5d8625ab570aa5","a311ae2187914c2bbad45810b91f9414","3beea980d93a4cc0abc864e27514601c","2477c68e093d4b818b11333ee1a5ee02","ee423e7465a441f9b91198eb4a53bd6d","224620d4ffab40a0b52cd669ef7f7011","d375036a43f64928be38e27410c1a835","55308ce01ccf489fa6a811cc0896f0cb","d9c985ab1f04428493c029df6dca650d","7665e5683a1a443a8f3d3b946d4c9ca2","95aea6610cf849e0950a0771c6b25c69","c297238c41b2488abe3de6546b105a4e","c7fe8aa844d24e85ba32a990ea28ded3","570b3cb9d08246788a5c1ccfc4ab5b09","114966a80e4d4ce5a6885c9e09dc08d5","7eb7ab92311b474d85e02269b2edc269","1a95630392584c7892bec2dc9888cbfc","c1cc2528f29940fc95fd6bc37eb982d4","7fb8ceff333b48e8adea2c0803494a48","119867ee537140d7ae1ab89e541d98f9","9eeccc4caf594a5abedc0559fd9e0424","6a962a4341364bbe9959b413849567de","8bea5bec08e44c1ea7a90c7a1e3daeb8","b0ac866f2b8d4d17b5deeb130ab17543","07994e875a7f44dc9af7f9bf3f6989e5","62eaee6d9ee44410b8aca59dfc7408e9","05554578204541148a5482ad5df4a600"],"non_research_disease":["da37b8c0153d4a6bbbf3c424c4f0b3fc","03bd23316cb54eecbbc4f53311087042","0ade2c6f9dec476595d303c91c8babc9","d39b64a7a7714a9f9227c3607e801e41","2536e79ced34450fbb09de73061cf096","30e04459131b46f58318f1e84b63135a","5dc15a3bfff7405197a9e12963b07d1f","e35ce4e9b7a846d49e600ce7ac4a7fd6","58fbfbf692184307a72a2a4f72a657f2","c0603b4a25234f2bb1615f64d7d6fc63","8bd6e60a4549486a8d690e66701eb676","9b60b7d38a4044b3b7f98c61c365e6b9","557f5ccfe746466cbdb9383a94178eef","32b2a7f88bfd47f08d38b864034f7ee1","218de7027c39474b884ca5d174846630","828fb9fef58643deaeb03ba65a7d3953","f0e77325ab1e46a899ce62a7c13214cc","a4afc28011454f2ca2f48f95f242a04f","1dd4be2a22d04ef39e07fb5cdbc2c2d5"],"inactive_org_master_entity_id":["97df527e5625cec303309efe38fb586a","d3c335d8fd9df5c00236ee3bd071f6c9","e04fbf3cf0a0af2bc6856c70d527f8b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1573603200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1583020800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1601337600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1622332800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1533081600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1532217600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1504137600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1587513600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1669766400000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623801600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}}],"disease_phase":[{"disease_id":"95aea6610cf849e0950a0771c6b25c69","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8bea5bec08e44c1ea7a90c7a1e3daeb8","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"5dc15a3bfff7405197a9e12963b07d1f","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"8bd6e60a4549486a8d690e66701eb676","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"79fc76ece05345348f5d7662c9e30b2e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"32b2a7f88bfd47f08d38b864034f7ee1","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6a962a4341364bbe9959b413849567de","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"557f5ccfe746466cbdb9383a94178eef","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fd918c0ed89c405abc5d8625ab570aa5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"b0ac866f2b8d4d17b5deeb130ab17543","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f0e77325ab1e46a899ce62a7c13214cc","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ee423e7465a441f9b91198eb4a53bd6d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"114966a80e4d4ce5a6885c9e09dc08d5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d39b64a7a7714a9f9227c3607e801e41","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"8666aad5477e4272b56b94ca1183781d"},{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"30e04459131b46f58318f1e84b63135a","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"941ef5bdf9fa49b3b8054dd755019209","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"03bd23316cb54eecbbc4f53311087042","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"224620d4ffab40a0b52cd669ef7f7011","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0ade2c6f9dec476595d303c91c8babc9","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d9c985ab1f04428493c029df6dca650d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"58fbfbf692184307a72a2a4f72a657f2","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4b0f73d4edfb4a4096712e37c25212b4","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"fd398ddf7d0843fa85c144cdceca8251","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9b60b7d38a4044b3b7f98c61c365e6b9","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"55308ce01ccf489fa6a811cc0896f0cb","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"119867ee537140d7ae1ab89e541d98f9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d375036a43f64928be38e27410c1a835","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"9eeccc4caf594a5abedc0559fd9e0424","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1dd4be2a22d04ef39e07fb5cdbc2c2d5","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"570b3cb9d08246788a5c1ccfc4ab5b09","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0f1db06de3604121b621a1bc492b473d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7eb7ab92311b474d85e02269b2edc269","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"da37b8c0153d4a6bbbf3c424c4f0b3fc","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c0603b4a25234f2bb1615f64d7d6fc63","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"828fb9fef58643deaeb03ba65a7d3953","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"056068f3e8944ed48f840693a3f5c835","docid":56454,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"specific_site":1,"site_id":"8f7aa1139735405fa5346941a0693837","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"d90247cb6f703ad88b7d4bcd9ef09322","created_ts":"2021-12-10T12:55:15.000Z","updated_ts":"2025-10-23T00:32:16.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BPT-567","source_info":[{"attachment_path":"data/phs_source_info/0d5f/451b/e92a/38dc/0d5f451be92a38dc.png","attachment_type":"image/png","code":"Bright Peak Therapeutics-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/0cdf/6e80/8563/b443/0cdf6e808563b443.png","source":"Company pipeline","source_url":"https://brightpeaktx.com/pipeline/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"modified IL18 therapeutic Bright Peak Therapeutics","status":"ACTIVE"}],"dev_code":[{"name":"BPT 567","status":"ACTIVE"},{"name":"BPT-567","status":"ACTIVE"},{"name":"BPT567","source_info":[{"attachment_path":"data/phs_source_info/0d5f/451b/e92a/38dc/0d5f451be92a38dc.png","attachment_type":"image/png","code":"Bright Peak Therapeutics-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/0cdf/6e80/8563/b443/0cdf6e808563b443.png","source":"Company pipeline","source_url":"https://brightpeaktx.com/pipeline/"}],"status":"ACTIVE"}],"drug_type":["b024633d09c6439d901898557075c8af"],"originator_org_master_entity_id":["740b9d4914109244aaaa940158a2405c"],"mechanism_action_id":["e8223b77607d463c812317bf54497460","4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["915da22015954d89ab8c53b8b3f85f6b","9786d32e3d244a688ec6a60d2fe1b10b"],"adc_reference":[{"code":"2023_1850","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/83/7_Supplement/1850/721374/Abstract-1850-A-first-in-class-PD1-IL18"},{"code":"10.1158/1538-7445.AM2023-1850","normalized_source_id":"071bfb0a-a707-4060-9676-fe3efcad9b1b","source":"Cancer Res","source_url":"https://doi.org/10.1158/1538-7445.AM2023-1850"}],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5","0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["740b9d4914109244aaaa940158a2405c","0cd40d8b7f8d25d5a0440ddb64b0ccf5"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5","0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1729123200000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1681689600000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"d90247cb6f703ad88b7d4bcd9ef09322","moiety_mechanism_action_id":["e8223b77607d463c812317bf54497460","4dd338b149b3ecd0ee860e1fb379b44f"],"moiety_target_id":["915da22015954d89ab8c53b8b3f85f6b","9786d32e3d244a688ec6a60d2fe1b10b"]}
+{"drug_id":"513614f8bf4642c7a71cad52c1d29859","docid":17615,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"df8080198ee73e7daa0023566bc5d2f9","created_ts":"2021-10-08T14:47:12.000Z","updated_ts":"2024-10-30T10:27:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CSR02-Fab-TF","status":"ACTIVE"}],"drug_type":["669d0e356708447ebc322ddf47633731"],"originator_org_master_entity_id":["b26e83ce0ae73fb199f5fa57d0b6dd63"],"mechanism_action_id":["4fdc29ce060944dc8929b52d31b163fc"],"target_id":["44414ff5fe1d4ebabed0759aacb27532"],"disease_id":["15839db0de0947ddb9e4c280884a3895"],"active_org_master_entity_id":["b26e83ce0ae73fb199f5fa57d0b6dd63"],"research_disease":["15839db0de0947ddb9e4c280884a3895"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1611619200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"5794338bfb7d42f991acac51a60a5612","docid":70634,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":86,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2022-07-14T07:50:01.000Z","updated_ts":"2026-03-07T21:11:26.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"德谷胰岛素生物类似药 (杭州中美华东)","status":"ACTIVE"},{"lang":"EN","name":"Insulin Degludec biosimilar (Hangzhou Zhongmeihuadong)","source_info":[{"code":"CXSL2200317","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"HJY 36","status":"ACTIVE"},{"name":"HJY-36","source_info":[{"code":"CTR20232366","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a82679f7819247a99d24d60197bb037c"}],"status":"ACTIVE"},{"name":"HJY36","status":"ACTIVE"}],"generic_name":[{"name":"Insulin degludec","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["4151879e2be683699c95135e4af229c4"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["4151879e2be683699c95135e4af229c4"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1740009600000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["3ad819db7da542789a9feab5a092c60d"],"data_source":10}
+{"drug_id":"1c433ffea7d344d288888cfacf81ad82","docid":1310307,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-04-11T06:54:41.000Z","updated_ts":"2026-01-04T07:14:12.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"JWK-010","source_info":[{"attachment_path":"data/phs_source_info/b19f/8e97/7ba8/8c43/b19f8e977ba88c43.jpg","attachment_type":"image/jpeg","code":"Genevector-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a3c2/984b/2e16/1927/a3c2984b2e161927.jpg","source":"Company pipeline","source_url":"https://www.jwksw.com/yfgx"}],"status":"ACTIVE"}],"dev_code":[{"name":"JWK 010","source_info":[{"attachment_path":"data/phs_source_info/b19f/8e97/7ba8/8c43/b19f8e977ba88c43.jpg","attachment_type":"image/jpeg","code":"Genevector-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a3c2/984b/2e16/1927/a3c2984b2e161927.jpg","source":"Company pipeline","source_url":"https://www.jwksw.com/yfgx"}],"status":"ACTIVE"},{"name":"JWK010","source_info":[{"attachment_path":"data/phs_source_info/b19f/8e97/7ba8/8c43/b19f8e977ba88c43.jpg","attachment_type":"image/jpeg","code":"Genevector-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/a3c2/984b/2e16/1927/a3c2984b2e161927.jpg","source":"Company pipeline","source_url":"https://www.jwksw.com/yfgx"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["8d5f45d256f0c7ff92eedfcbd26d0c5f"],"disease_id":["6e7e2c8313674795b548e129727ad543","fce2b462d4fa493eb9d82513b9007011"],"active_org_master_entity_id":["8d5f45d256f0c7ff92eedfcbd26d0c5f","249e66edbf668a19ede75cfe48e520bf"],"research_disease":["6e7e2c8313674795b548e129727ad543","fce2b462d4fa493eb9d82513b9007011"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1766361600000}}],"disease_phase":[{"disease_id":"6e7e2c8313674795b548e129727ad543","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"fce2b462d4fa493eb9d82513b9007011","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"if_speculate":0,"data_source":10}
+{"drug_id":"47e11f58769744348a7231dcf2aaf3ba","docid":205067,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"cdf0d83658d340b29450503ad59ff362","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":59,"target_extend_id":"97a618b0fec83a4189c7d85ee1bdad16","created_ts":"2024-12-16T07:52:02.000Z","updated_ts":"2026-04-18T21:04:33.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ITM-63","source_info":[{"attachment_path":"data/phs_source_info/c393/6a0b/0dae/b0f9/042d48c4-db99-38b2-8561-514ff276c645.jpg","attachment_type":"image/jpeg","code":"Itm Isotope-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd20/5755/91cb/1963/489e7840-f668-3fae-ba3f-7fc637bccd23.jpg","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/pipeline/pipeline-overview/"}],"status":"ACTIVE"}],"dev_code":[{"name":"161Tb-ITM63","status":"ACTIVE"},{"name":"ITM 63","source_info":[{"attachment_path":"data/phs_source_info/c393/6a0b/0dae/b0f9/042d48c4-db99-38b2-8561-514ff276c645.jpg","attachment_type":"image/jpeg","code":"Itm Isotope-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd20/5755/91cb/1963/489e7840-f668-3fae-ba3f-7fc637bccd23.jpg","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/pipeline/pipeline-overview/"}],"status":"ACTIVE"},{"name":"ITM63","source_info":[{"attachment_path":"data/phs_source_info/c393/6a0b/0dae/b0f9/042d48c4-db99-38b2-8561-514ff276c645.jpg","attachment_type":"image/jpeg","code":"Itm Isotope-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd20/5755/91cb/1963/489e7840-f668-3fae-ba3f-7fc637bccd23.jpg","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/pipeline/pipeline-overview/"}],"status":"ACTIVE"},{"name":"Tb161-ITM 63","source_info":[{"attachment_path":"data/phs_source_info/c393/6a0b/0dae/b0f9/042d48c4-db99-38b2-8561-514ff276c645.jpg","attachment_type":"image/jpeg","code":"Itm Isotope-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd20/5755/91cb/1963/489e7840-f668-3fae-ba3f-7fc637bccd23.jpg","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/pipeline/pipeline-overview/"}],"status":"ACTIVE"},{"name":"Tb161-ITM-63","source_info":[{"attachment_path":"data/phs_source_info/c393/6a0b/0dae/b0f9/042d48c4-db99-38b2-8561-514ff276c645.jpg","attachment_type":"image/jpeg","code":"Itm Isotope-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd20/5755/91cb/1963/489e7840-f668-3fae-ba3f-7fc637bccd23.jpg","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/pipeline/pipeline-overview/"}],"status":"ACTIVE"},{"name":"Tb161-ITM63","source_info":[{"attachment_path":"data/phs_source_info/c393/6a0b/0dae/b0f9/042d48c4-db99-38b2-8561-514ff276c645.jpg","attachment_type":"image/jpeg","code":"Itm Isotope-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/dd20/5755/91cb/1963/489e7840-f668-3fae-ba3f-7fc637bccd23.jpg","source":"Company pipeline","source_url":"https://www.itm-radiopharma.com/pipeline/pipeline-overview/"}],"status":"ACTIVE"}],"drug_type":["ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["73a71a4b938dfe77120f34aae93b1774"],"mechanism_action_id":["6b2a99a26ccdb77eb7c90aa8f8afd876"],"target_id":["0ace2287368a44be86497dafac655acb"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["73a71a4b938dfe77120f34aae93b1774"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"098fe8f0f4f741819d14f78fb01d7339","docid":231854,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":150,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2024-06-23T06:07:38.000Z","updated_ts":"2026-04-18T21:06:42.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"GS-4571","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://diabetesjournals.org/diabetes/article/73/Supplement_1/1625-P/155028/1625-P-GS-4571-an-Oral-Small-Molecule-GLP-1R"}],"status":"ACTIVE"}],"dev_code":[{"name":"GS 4571","source_info":[{"code":"10.2337/db24-1625-p","normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://diabetesjournals.org/diabetes/article/73/Supplement_1/1625-P/155028/1625-P-GS-4571-an-Oral-Small-Molecule-GLP-1R"}],"status":"ACTIVE"},{"name":"GS4571","source_info":[{"code":"10.2337/db24-1625-p","normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://diabetesjournals.org/diabetes/article/73/Supplement_1/1625-P/155028/1625-P-GS-4571-an-Oral-Small-Molecule-GLP-1R"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["52aee12631589b24dca3ae62de8a0886"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"disease_id":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["52aee12631589b24dca3ae62de8a0886"],"research_disease":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"32c4738fd171430fab6cdfbd86339730","docid":3102,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-08-16T03:29:36.000Z","updated_ts":"2025-02-24T12:03:44.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"zhongxia","drug_name":[{"lang":"EN","name":"[Lu-177]-Catalase","source_info":[{"code":"NCT05985278","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05985278"}],"status":"ACTIVE"}],"drug_type":["c6f7aa5028654d4d8ac6153f9b53e8a2","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["7597a5f65e482a0af413c1f07baef875"],"disease_id":["6570754a6f0b43b78a9926c7bfd00519"],"active_org_master_entity_id":["7597a5f65e482a0af413c1f07baef875"],"research_disease":["6570754a6f0b43b78a9926c7bfd00519"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1688601600000}}],"disease_phase":[{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"002598e421544cb3a2f88d300bb2c39a","docid":21635,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:41:08.000Z","updated_ts":"2025-04-14T00:18:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ZHB-111","status":"ACTIVE"}],"dev_code":[{"name":"QHRD211","source_info":[{"code":"CTR20220824","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=cd9a0c83a04c4c31a652656e1e20484a"}],"status":"ACTIVE"},{"name":"ZHB111","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["813b70dd02b28ff732e1c1ef181ed180"],"disease_id":["93aa6c2c00ce4f8d9fb9aaddc8f12178"],"active_org_master_entity_id":["813b70dd02b28ff732e1c1ef181ed180","62db1a81106e2f40f4d55d5e99807ec6"],"research_disease":["93aa6c2c00ce4f8d9fb9aaddc8f12178"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1730505600000}}],"disease_phase":[{"disease_id":"93aa6c2c00ce4f8d9fb9aaddc8f12178","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"01b4ec69dc5042a88e01710d87053c7e","docid":68643,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1703808000000,"rnk":3,"target_extend_id":"4d016fb1cab33f229a1ef722b3460062","created_ts":"2021-12-15T05:21:27.000Z","updated_ts":"2025-02-26T00:16:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1703808000000,"drug_name":[{"lang":"CN","name":"恒格列净/二甲双胍","status":"ACTIVE"},{"lang":"EN","name":"Henagliflozein Proline/Metformin Hydrochloride","status":"ACTIVE"}],"dev_code":[{"name":"HR 20033","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"HR-20033","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"HR20033","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"trade_name":[{"name":"瑞沁达","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.hengrui.com//media/detail-480.html"}],"status":"ACTIVE"}],"related_component":["1c81cefd6b55426b9169f44f398f8241","71e9432e85be417ab48f0143786486fb","9657cbcc9f4042d5a8f324024c32b7e7"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6b1d50252b2e2ea1d72ca591aeb6bca3"],"mechanism_action_id":["2f8d928921b506e350c09eb3f2f8ed6d","b33a5535c71348d2824dea81333c6197"],"target_id":["7c6744915bcf435497c2b2e6ae24ae6d","a995e993b483437ab03a1b4f5da488a8"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["6b1d50252b2e2ea1d72ca591aeb6bca3"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["74d974da49ba407195b38595a0aff704"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1703808000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"032c9ca5bf6143bfbe6ce59824737c3c","docid":1880401,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-12-23T07:12:06.000Z","updated_ts":"2025-12-23T07:14:12.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Human umbilical cord mesenchymal stromal cell derivatives (The University of Jordan)","source_info":[{"code":"41287013","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/41287013/"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["d457c741ac7784987db15742b92ea2bd"],"disease_id":["c5a9c2f01d9448f4b611fec2d4f6117e"],"active_org_master_entity_id":["d457c741ac7784987db15742b92ea2bd"],"research_disease":["c5a9c2f01d9448f4b611fec2d4f6117e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"3529ccb3-1a90-3cf6-a0cc-3cea1d2f0220","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1733011200000}}],"disease_phase":[{"disease_id":"c5a9c2f01d9448f4b611fec2d4f6117e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"062cabd13c9e427da7ce4ebd25ff628c","docid":114004,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":53,"target_extend_id":"fa372710198a3a49aea63858663dfc4f","created_ts":"2024-06-24T10:20:40.000Z","updated_ts":"2026-04-15T21:04:15.000Z","data_status":"ACTIVE","created_by":"zhoumeng@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"NDI-5001","source_info":[{"normalized_source_id":"d329a8da45ca4ecf9eaedcceef60f224","source":"GlobeNewswire","source_url":"http://www.globenewswire.com/news-release/2024/06/20/2901562/0/en/NephroDI-Therapeutics-Announces-Investment-by-Sound-Bioventures-to-Accelerate-Development-of-NDI-5001-as-a-Potential-First-in-Class-Therapy-for-Pediatric-Orphan-Kidney-Disease.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"NDI-5001","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.globenewswire.com/news-release/2024/06/20/2901562/0/en/NephroDI-Therapeutics-Announces-Investment-by-Sound-Bioventures-to-Accelerate-Development-of-NDI-5001-as-a-Potential-First-in-Class-Therapy-for-Pediatric-Orphan-Kidney-Disease.html"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["72762dbe476352df2c8eabce9e781935"],"mechanism_action_id":["b8829b4410814d7d82292f29f8bfceac"],"target_id":["4288e8d0198d4a5697df609cd647280c"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["c504515f6e8b4442a5802e36440e1e26"],"active_org_master_entity_id":["72762dbe476352df2c8eabce9e781935","ce21863d311464c759e1882ee9acdd37"],"research_disease":["c504515f6e8b4442a5802e36440e1e26"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1718841600000}}],"disease_phase":[{"disease_id":"c504515f6e8b4442a5802e36440e1e26","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["72762dbe476352df2c8eabce9e781935","eb19183a6d609c5684ddce93c69e6882"],"data_source":10}
+{"drug_id":"104580e3b6a44e1b8845fa08501c4662","docid":23255,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":4,"target_extend_id":"359e8578555f3754add7c14baa4d18ec","created_ts":"2022-01-06T07:37:45.000Z","updated_ts":"2026-02-25T01:33:21.000Z","data_status":"ACTIVE","created_by":"wanghuimin@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HB-0036","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"anti-TIGIT/anti-PD-L1 bispecific antibody","status":"ACTIVE"}],"dev_code":[{"name":"HB-0036","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-tigit-anti-pd-l1-bispecific-antibody-hb0036"}],"status":"ACTIVE"},{"name":"HB0036","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-tigit-anti-pd-l1-bispecific-antibody-hb0036"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["1184509c6caf5289c06d345f6b0125f5"],"mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2","054e8d3f5e89d1ba5bc975d4614a6141"],"target_id":["06c7ab146b884a3aa890cfd1a4a0e168","369b0d8bda6c4e7e9bfa08bbabd60f0d"],"disease_id":["a0304a462da04e7cb03e3f2c5625544e","15cb523e0fbd4617a6a129ad2336eb9a","74ba301586ab419b9c9accd39cd20782","28935c60ded04150bbdd16876cc0082e","15839db0de0947ddb9e4c280884a3895","c1cc2528f29940fc95fd6bc37eb982d4","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","8eaa9c59b7674ad692d8fbc5c68e845c","b42488c9ce3245988e4e93caf2b95590","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["4b5343e0cf7d4fb190086931bde323cd","1184509c6caf5289c06d345f6b0125f5"],"research_disease":["a0304a462da04e7cb03e3f2c5625544e","15cb523e0fbd4617a6a129ad2336eb9a","74ba301586ab419b9c9accd39cd20782","28935c60ded04150bbdd16876cc0082e","15839db0de0947ddb9e4c280884a3895","c1cc2528f29940fc95fd6bc37eb982d4","c7fe8aa844d24e85ba32a990ea28ded3","6fe05469e09f4305b7615b2c277382cd","8eaa9c59b7674ad692d8fbc5c68e845c","b42488c9ce3245988e4e93caf2b95590","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1661385600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1661385600000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8eaa9c59b7674ad692d8fbc5c68e845c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"74ba301586ab419b9c9accd39cd20782","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"28935c60ded04150bbdd16876cc0082e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0efa4e3802a34344a25436c80fc6089c","docid":57536,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"3faad3a9685140259a3b782e9ca1f3a3","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":28,"target_extend_id":"c3564a2e384d34ef94516d844f563ba3","created_ts":"2021-10-08T14:41:08.000Z","updated_ts":"2026-02-28T21:10:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"99m-TC-PSMA-I&S","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"\t [99cmTc]Tc-PSMA-I&S","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkzNjQzOTk4Mg==&mid=2247527086&idx=1&sn=34695be092a9b9ab5bebdcedab41fdf8"},{"code":"32382945","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/32382945/"},{"code":"10.1007/s00259-025-07623-2","normalized_source_id":"f6d00e98-bb28-4539-a4cf-bcc446683e5c","source":"Eur J Nucl Med Mol Imaging","source_url":"https://link.springer.com/article/10.1007/s00259-025-07623-2"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","4f6af72be17b47249d6de8c3febef8ab","78e77521ce074022b4e14bc242b86549","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["47223ed99eec83cf84be30a11fa1d610"],"mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"target_id":["1764007a7c384a4ab49bb3710bab5052"],"disease_id":["e50aad3dea474cf487e53bd91d5d7c45","1c2dcdeb3c4b499691d79928ae9d1285"],"active_org_master_entity_id":["47223ed99eec83cf84be30a11fa1d610","17c995fdb2adeebcbea92786cfbe52de","3e5d3d661e7739cc53a4204c3f25243a"],"research_disease":["e50aad3dea474cf487e53bd91d5d7c45","1c2dcdeb3c4b499691d79928ae9d1285"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1621036800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1619481600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"055a60cf40bb4b4eb69c41b492c45a03","dev_status_time":{"time_trust_code":7,"time_ts":1588809600000}}],"disease_phase":[{"disease_id":"1c2dcdeb3c4b499691d79928ae9d1285","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10,"target_moiety_type":["58f172e4a4794372b08b2dda980530de"],"moiety_target_extend_id":"c3564a2e384d34ef94516d844f563ba3","moiety_mechanism_action_id":["85fbecaa7d0f51f9901e300e6b3eae33"],"moiety_target_id":["1764007a7c384a4ab49bb3710bab5052"]}
+{"drug_id":"0fb9fef33c20473792c1ae95da022149","docid":75966,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:52.000Z","updated_ts":"2024-12-06T00:21:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MTD211","status":"ACTIVE"}],"dev_code":[{"name":"MTD211","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["45a7bedf4746bbfbe01a5e1f275d341d"],"disease_id":["2dbed7595ff04b8fae04724f91081116","ec4d59ce792b465d8e55e7e52840c626"],"active_org_master_entity_id":["45a7bedf4746bbfbe01a5e1f275d341d"],"research_disease":["2dbed7595ff04b8fae04724f91081116","ec4d59ce792b465d8e55e7e52840c626"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1642809600000}}],"disease_phase":[{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"3dd88b3467f04cd4ac7634da919e06fd","docid":78348,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":10,"target_extend_id":"dffadf8d904e3c71b5accfc2964d9853","created_ts":"2022-06-23T03:31:35.000Z","updated_ts":"2025-12-20T21:13:08.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"wangya","drug_name":[{"lang":"CN","name":"唯康度塔单抗","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://web.cms.net.cn/zh/2025/09/%e5%ba%b7%e5%93%b2%e8%8d%af%e4%b8%9a%e5%b0%b11%e7%b1%bb%e5%88%9b%e6%96%b0%e7%94%9f%e7%89%a9%e5%88%b6%e5%89%82%e5%94%af%e5%ba%b7%e5%ba%a6%e5%a1%94%e5%8d%95%e6%8a%97%e6%b3%a8%e5%b0%84%e6%b6%b2%ef%bc%88/"}],"status":"ACTIVE"},{"lang":"EN","name":"Vecantoxatug","source_info":[{"attachment_path":"data/phs_source_info/041e/cc72/891a/d65a/262d072e-1c18-3f75-ab56-6a32d7d16770.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5da3/9337/4c0f/3634/a318d8db-76b5-3a79-9ffa-57e0916bb79d.png","source":"Company pipeline","source_url":"http://www.genrixbio.com/#/science?classId=class1"}],"status":"ACTIVE"}],"dev_code":[{"name":"GR 2001","status":"ACTIVE"},{"name":"GR-2001","status":"ACTIVE"},{"name":"GR2001","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["b616983e88821e3a0d8c202958457443"],"mechanism_action_id":["6fcd60fba38c4707f9200828939d1772"],"target_id":["2e69f4481c804798b6383d93d00134fc"],"special_review":["c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["e255185bd59e4c2cbef67fd98444d16f"],"active_org_master_entity_id":["b616983e88821e3a0d8c202958457443"],"research_disease":["e255185bd59e4c2cbef67fd98444d16f"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1747872000000}}],"disease_phase":[{"disease_id":"e255185bd59e4c2cbef67fd98444d16f","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["6c5a07a4d05ca49c5ee94192e72193f0","b616983e88821e3a0d8c202958457443"],"if_speculate":0,"data_source":10}
+{"drug_id":"503f053f416a4ae6a3a39ce435f6ddf0","docid":31883,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":86,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2022-08-05T03:16:46.000Z","updated_ts":"2026-03-07T21:08:26.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"maliman","drug_name":[{"lang":"CN","name":"德谷胰岛素生物类似药(重庆宸安生物)","status":"ACTIVE"},{"lang":"EN","name":"Insulin degludec biosimilar (Chongqing Chenan Biopharmaceutical)","source_info":[{"code":"CTR20221898","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=26486919b92844d6ba71a9c14b3edb44"}],"status":"ACTIVE"}],"dev_code":[{"name":"CA501","source_info":[{"code":"CTR20221898","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=cedb71f8f9c64055a7f219e618e1f37d"}],"status":"ACTIVE"}],"generic_name":[{"name":"Insulin degludec","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["8bfd16ba46bc37d0ac5e561603605018"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["8bfd16ba46bc37d0ac5e561603605018"],"research_disease":["74d974da49ba407195b38595a0aff704"],"inactive_org_master_entity_id":["f33a229f67141375405c1a3888df5961"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["3ad819db7da542789a9feab5a092c60d"],"deal_related_org":["2d5cac8af9a8ac221e5ea9fa3ed85902","8bfd16ba46bc37d0ac5e561603605018"],"data_source":10}
+{"drug_id":"04f2bed1e9a446ce876a3313fc9b3308","docid":1250424,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-04-22T03:31:57.000Z","updated_ts":"2025-10-27T07:06:12.000Z","data_status":"ACTIVE","created_by":"lixuejun@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Allogeneic adipose derived mesenchymal stem cells(Mayo Clinic)","source_info":[{"code":"NCT04388761","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04388761"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["ce1783471a7add837e1062d85249c974"],"disease_id":["34d7e5800df242afac55742a44542de2","fc0780b4f42b41d0a3dbbc522d0724dd","73051f3a9caa409aa98b779362de1c6e","c5a9c2f01d9448f4b611fec2d4f6117e","1a951a454f2f489bafeddedea85edbce","9b344530ac6c4a109108474a64182933"],"active_org_master_entity_id":["ce1783471a7add837e1062d85249c974"],"research_disease":["34d7e5800df242afac55742a44542de2","fc0780b4f42b41d0a3dbbc522d0724dd","73051f3a9caa409aa98b779362de1c6e","c5a9c2f01d9448f4b611fec2d4f6117e","1a951a454f2f489bafeddedea85edbce"],"non_research_disease":["9b344530ac6c4a109108474a64182933"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686873600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1675036800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1435708800000}}],"disease_phase":[{"disease_id":"c5a9c2f01d9448f4b611fec2d4f6117e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"73051f3a9caa409aa98b779362de1c6e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1a951a454f2f489bafeddedea85edbce","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"fc0780b4f42b41d0a3dbbc522d0724dd","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"34d7e5800df242afac55742a44542de2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"9b344530ac6c4a109108474a64182933","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"if_speculate":0,"data_source":10}
+{"drug_id":"049983d7d59c45b49b6dfa4e8ca37a9c","docid":68327,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-02-28T05:06:26.000Z","updated_ts":"2026-01-27T23:52:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"天麻苄醇酯苷","status":"ACTIVE"},{"lang":"EN","name":"Tianmabianchunzhigan","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["ddba7a86574f1bce44baa9fcd1bf458b"],"disease_id":["5419cadb33a542f29c555cc9c588709b"],"active_org_master_entity_id":["ce977137c1a723ffc2f137db7e036f30","ddba7a86574f1bce44baa9fcd1bf458b"],"research_disease":["5419cadb33a542f29c555cc9c588709b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1653436800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"5419cadb33a542f29c555cc9c588709b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"01e2e368160e4af2839145e9b666d9a2","docid":8509,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":15,"target_extend_id":"915fe5ae4db43b61ab5dcbac4b920b20","created_ts":"2021-10-08T14:49:57.000Z","updated_ts":"2026-03-28T21:10:04.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"HR-17020","status":"ACTIVE"}],"dev_code":[{"name":"HR17020","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e8c89d3a4ba662c536e1df1292da580f"],"mechanism_action_id":["64460088fe6053256042898cc73e7a9a"],"target_id":["94c0e1d4b05d4dc4ae4c7666c9534635"],"disease_id":["72fa7aaf89cf4ec4b5e6217c198aafff","9652fabe2b9843ea95eb71b72d57be38"],"active_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"research_disease":["72fa7aaf89cf4ec4b5e6217c198aafff","9652fabe2b9843ea95eb71b72d57be38"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1603238400000}}],"disease_phase":[{"disease_id":"72fa7aaf89cf4ec4b5e6217c198aafff","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"9652fabe2b9843ea95eb71b72d57be38","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"07645ffe74d7445b99fd71b26994e464","docid":33873,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:46:22.000Z","updated_ts":"2025-08-02T00:29:55.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TriMix MEL","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"TriMix immunotherapies","status":"ACTIVE"}],"dev_code":[{"name":"ECI-001","status":"ACTIVE"},{"name":"ECI-003","status":"ACTIVE"},{"name":"ECI-006","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mrna-based-trimix-melanoma-vaccine-eci-006"}],"status":"ACTIVE"},{"name":"ECI-007","status":"ACTIVE"}],"drug_type":["07c615d6d6644a87ba74fb48dd7eefe8"],"originator_org_master_entity_id":["aaf16bc7ff6dcada63656652c7810f38"],"mechanism_action_id":["87597f6bafaba02d3c1fa6828685929a","70323be40b71376cd158cee2b5ddc093"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","acfaaa0373944ffd89b0a2ace0d8c564","1e6992f1403346acad1273d778686ca7","a311ae2187914c2bbad45810b91f9414"],"active_org_master_entity_id":["aaf16bc7ff6dcada63656652c7810f38"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","acfaaa0373944ffd89b0a2ace0d8c564","1e6992f1403346acad1273d778686ca7"],"non_research_disease":["a311ae2187914c2bbad45810b91f9414"],"inactive_org_master_entity_id":["49f824ce7cecc33a87b470fa66c592a3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1624233600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1624233600000}}],"disease_phase":[{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["49f824ce7cecc33a87b470fa66c592a3","4e04b1d4a4b7622c376807ced6d922ca"],"data_source":10}
+{"drug_id":"1510a7236ca340f7b7f1ab91e07ab428","docid":50365,"is_nme":0,"is_first_in_class":0,"is_qidp":1,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:44:50.000Z","updated_ts":"2026-01-27T16:56:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"枸橼酸镓","status":"ACTIVE"},{"lang":"EN","name":"Gallium citrate","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"GA-CIT","status":"ACTIVE"},{"lang":"EN","name":"Panaecin","status":"ACTIVE"},{"lang":"EN","name":"gallium(III) citrate","status":"ACTIVE"}],"dev_code":[{"name":"AR 501","status":"ACTIVE"},{"name":"AR-501","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["4e6a0ab2e4140cdd7287fa53874a858f"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","2b4f6fb42f1545ccb6a748dc42f4b88c","043a131d85994801b3617e822e7f87b3"],"disease_id":["40031216f1bb4af6af94cfff0439f9b6","7f8657c4a15148219c75eeb330d92c42"],"active_org_master_entity_id":["4e6a0ab2e4140cdd7287fa53874a858f"],"research_disease":["40031216f1bb4af6af94cfff0439f9b6","7f8657c4a15148219c75eeb330d92c42"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1544140800000}}],"disease_phase":[{"disease_id":"7f8657c4a15148219c75eeb330d92c42","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"40031216f1bb4af6af94cfff0439f9b6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4c5ed5c6e6bf4655a6609f63cdb3e818","docid":49297,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2023-03-02T05:30:53.000Z","updated_ts":"2026-01-09T00:35:43.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PT-004","status":"ACTIVE"}],"dev_code":[{"name":"PT-004","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8ab39dbfd931e81102f55c46d10e6118"],"disease_id":["6b5817fcfc0a4e4cba98f692202b8821"],"active_org_master_entity_id":["8ab39dbfd931e81102f55c46d10e6118"],"research_disease":["6b5817fcfc0a4e4cba98f692202b8821"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1665532800000}}],"disease_phase":[{"disease_id":"6b5817fcfc0a4e4cba98f692202b8821","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"125b1bbda17e4f869dc6a9850f987418","docid":41759,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"d19c4e5198b83314b8954fa445579837","has_leading_org_involved":1,"created_ts":"2021-10-08T14:42:13.000Z","updated_ts":"2026-04-15T21:44:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Avutometinib","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Avutometinib Potassium","source_info":[{"code":"lm-56","normalized_source_id":"47c8048a73f94d3b9c626eb4f8a6d7e4","source":"USAN","source_url":"https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Favutometinib-potassium.pdf"}],"status":"ACTIVE"}],"dev_code":[{"name":"CH 5127566","status":"ACTIVE"},{"name":"CH-5126766","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"},{"name":"CKI-27","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"},{"name":"R-7304","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"},{"name":"RG 7304","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"},{"name":"RG-7304","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"},{"name":"RO-5126766","status":"ACTIVE"},{"name":"VS 6766","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"},{"name":"VS-6766","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avutometinib"}],"status":"ACTIVE"}],"trade_name":[{"name":"AVMAPKI","source_info":[{"normalized_source_id":"42d89394e1d7470596de758366ae816a","source":"PipelineReview","source_url":"https://pipelinereview.com/fda-approves-the-avmapki-fakzynja-combination-therapy-as-the-first-ever-treatment-for-adult-patients-with-kras-mutated-recurrent-low-grade-serous-ovarian-cancer/"}],"status":"ACTIVE"}],"drugbank_id":["DB15254"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8a3c41b6b3536abfff46a5b43b7662b0"],"mechanism_action_id":["48be7a1eddadbeee6fc8d86c9ef8ef6c","f076fda4aff702d138451c3fdf50a776","d07e1ae6f2e5c6d049ba7ebf5a9bee28"],"target_id":["499024bfdbff4188ae87b76242949084","74f8b6f41026421e87f07daf2af81ae3","80ffe24b0c984446a8a0e1e1c0c1dc98"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["a1ddbb69fd3e46b6980bd4e1f1e64a45","024deb39dbdb42eea0863db300b15242","6a6753c1c1d74648aa399e9f3bc22350","d61edc148e2f472ba1aef3c491ed9fd3","6f7797132868456290dac6532b7aefa6","6a962a4341364bbe9959b413849567de","03bd23316cb54eecbbc4f53311087042","b902fe3512424802ac7659fc83b38222","83272e90cc5d43fd845c91e01b379ac4","e35ce4e9b7a846d49e600ce7ac4a7fd6","6570754a6f0b43b78a9926c7bfd00519","d2ee0aa5e8a2440585e9a218d193b710","b3d498b086894c13bf5ac981a350af82","87a9454771a64f2191224b6b7684254a","e4507aef6c7e4537b5989c6f323cc518","08ab6b627e43472398a63d1b25efb133","c349d56721634602bd73c8f36c3b496a","97b558396a8043fc92f5b15e2855d8b6","6446c9ad5ac0494a9364bc23ea6e1999","c77ff9f9a3d54eb5be3e6b41ae7dba0e","3ac5604c4dde49c29b561648d0c0543c","7eb5750613044044bb5d6c8a12598bfa","a0304a462da04e7cb03e3f2c5625544e","5653d5f4ddd64666970104ebb522a937","7cd0fcf1c5c243b9b3944405ec4855b5","c297238c41b2488abe3de6546b105a4e","de23eb7576d244d4bd3d2263c15d4b85","0464f5493b0444e9875a0584df17cbf0","83353b81ca564c9ca90cde45a16a9a37"],"active_org_master_entity_id":["9e69a16cb488720675288e77dd41cd84","0c98a39a5836871554972d719528b613","7054f8b05d488feed2d423fb5b8f4cb4","3e885b5c62bef6b8debb50cca392ee47"],"research_disease":["a1ddbb69fd3e46b6980bd4e1f1e64a45","024deb39dbdb42eea0863db300b15242","6a6753c1c1d74648aa399e9f3bc22350","d61edc148e2f472ba1aef3c491ed9fd3","6f7797132868456290dac6532b7aefa6","6a962a4341364bbe9959b413849567de","03bd23316cb54eecbbc4f53311087042","b902fe3512424802ac7659fc83b38222","83272e90cc5d43fd845c91e01b379ac4","e35ce4e9b7a846d49e600ce7ac4a7fd6","6570754a6f0b43b78a9926c7bfd00519","d2ee0aa5e8a2440585e9a218d193b710","b3d498b086894c13bf5ac981a350af82","87a9454771a64f2191224b6b7684254a","e4507aef6c7e4537b5989c6f323cc518","08ab6b627e43472398a63d1b25efb133","c349d56721634602bd73c8f36c3b496a","97b558396a8043fc92f5b15e2855d8b6","6446c9ad5ac0494a9364bc23ea6e1999","c77ff9f9a3d54eb5be3e6b41ae7dba0e","3ac5604c4dde49c29b561648d0c0543c","7eb5750613044044bb5d6c8a12598bfa","a0304a462da04e7cb03e3f2c5625544e","5653d5f4ddd64666970104ebb522a937","7cd0fcf1c5c243b9b3944405ec4855b5","c297238c41b2488abe3de6546b105a4e","de23eb7576d244d4bd3d2263c15d4b85"],"non_research_disease":["0464f5493b0444e9875a0584df17cbf0","83353b81ca564c9ca90cde45a16a9a37"],"inactive_org_master_entity_id":["d7dc381f4bf0f28f14bb88ed2f3535d9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","fce2b462d4fa493eb9d82513b9007011","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1775779200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1608508800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1649721600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1765411200000}}],"disease_phase":[{"disease_id":"03bd23316cb54eecbbc4f53311087042","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c349d56721634602bd73c8f36c3b496a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"de23eb7576d244d4bd3d2263c15d4b85","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"08ab6b627e43472398a63d1b25efb133","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6a962a4341364bbe9959b413849567de","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6a6753c1c1d74648aa399e9f3bc22350","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c77ff9f9a3d54eb5be3e6b41ae7dba0e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6446c9ad5ac0494a9364bc23ea6e1999","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"83272e90cc5d43fd845c91e01b379ac4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"024deb39dbdb42eea0863db300b15242","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a1ddbb69fd3e46b6980bd4e1f1e64a45","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3ac5604c4dde49c29b561648d0c0543c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7eb5750613044044bb5d6c8a12598bfa","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"5653d5f4ddd64666970104ebb522a937","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d61edc148e2f472ba1aef3c491ed9fd3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b3d498b086894c13bf5ac981a350af82","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e4507aef6c7e4537b5989c6f323cc518","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"97b558396a8043fc92f5b15e2855d8b6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"83353b81ca564c9ca90cde45a16a9a37","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6f7797132868456290dac6532b7aefa6","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["0c98a39a5836871554972d719528b613","11ef8a9e8bf5ca80213a1183511cded3","3e885b5c62bef6b8debb50cca392ee47"],"if_speculate":0,"data_source":10}
+{"drug_id":"0102b3b4cd174935bdfff5de532973ef","docid":44544,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","rnk":7,"target_extend_id":"d4f50079e0cf332fbc918f874ccab352","created_ts":"2021-10-08T14:42:52.000Z","updated_ts":"2026-01-28T00:42:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"依那西普生物类似药 (海正生物)","status":"ACTIVE"},{"lang":"EN","name":"Etanercept biosimilar (Hisun Bio)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://med.sina.com/article_detail_100_2_41825.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Etanercept Biosimilar (Hisun Bio Pharmaceutical Co., Ltd.)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant Human Tumor Necrosis Factor-α Receptor II(Hisun Bio Pharmaceutical)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.bioraypharm.com/index.php?m=list&a=index&classid=20"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant Human Tumor Necrosis Factor-α Receptor II:IgG Fc Fusion Protein(Hisun Bio Pharmaceutical)","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9NzU3MTYmaXRlbUlkPWZmODA4MDgxN2M4MzEyYzQwMTdjOWJiZmM4ZGUwMzYw"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Bio Pharmaceutical Co., Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"依那西普生物类似药（杭州博之锐生物制药有限公司）","status":"ACTIVE"},{"lang":"CN","name":"注射用重组人II型肿瘤坏死因子受体-抗体融合蛋白(海正生物制药)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.bioraypharm.com/index.php?m=list&a=index&classid=20"}],"status":"ACTIVE"},{"lang":"CN","name":"重组人II型肿瘤坏死因子受体-抗体融合蛋白 (海正生物制药)","status":"ACTIVE"}],"trade_name":[{"name":"安佰诺","source_info":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://med.sina.com/article_detail_100_2_41825.html"},{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.bioraypharm.com/index.php?m=list&a=index&classid=20"}],"status":"ACTIVE"}],"generic_name":[{"name":"etanercept","status":"ACTIVE"}],"drug_type":["3dc96d9272ad41a3833fc1e67887cd5b","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["2d8a5a893bafc98c77073bb1383602e8"],"mechanism_action_id":["9cce011ba8c098b73f8b35df0b92d787","7f0c948979d8c147468f6eec9980420d"],"target_id":["1cf1d1f419714af18f463bac42a732d5","1567554f9c24416081bc92052784db95"],"disease_id":["8da973b225c24afbba255413635fb240","be685463e8e640119dff51e5125e6d0f","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["2d8a5a893bafc98c77073bb1383602e8","528b2f3a18ee46f78efc07d92439952e"],"research_disease":["8da973b225c24afbba255413635fb240","be685463e8e640119dff51e5125e6d0f","6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["5c4cc9c1c83b40fc8cd6d00a3405c397"],"if_speculate":0,"data_source":10}
+{"drug_id":"13540fd3b4854a25a48bd167b2e43d69","docid":17717,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:49:45.000Z","updated_ts":"2026-02-28T01:08:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"18F-αvβ6-Binding-Peptide","status":"ACTIVE"}],"dev_code":[{"name":"18F-αVβ6-BP","status":"ACTIVE"}],"drug_type":["4f6af72be17b47249d6de8c3febef8ab","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["6f1e5d4aa0db05022496f52dcdf60034"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["941ef5bdf9fa49b3b8054dd755019209","2bb755a3f43f49dea60661c5f99712a3","62eaee6d9ee44410b8aca59dfc7408e9","717a9bf79e584830859595b8dbe9d433","f319fa27684c4cdeb6ce59d897217718","275ecda875e0460f84aa768ca9b2e5d6","ae092fa59f4d44edaf59ffe23d0a44c3","1714ace3a2f941d8921c9dbc77a8ba1d","323717f7753b4ce6a5561d105a7531cf"],"active_org_master_entity_id":["fbb1347c2e94a52259dbfea77fe93484","55317f856f0d78124a6845222345ba8e"],"research_disease":["941ef5bdf9fa49b3b8054dd755019209","2bb755a3f43f49dea60661c5f99712a3","62eaee6d9ee44410b8aca59dfc7408e9","717a9bf79e584830859595b8dbe9d433","f319fa27684c4cdeb6ce59d897217718","275ecda875e0460f84aa768ca9b2e5d6","ae092fa59f4d44edaf59ffe23d0a44c3","1714ace3a2f941d8921c9dbc77a8ba1d","323717f7753b4ce6a5561d105a7531cf"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1663027200000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1714ace3a2f941d8921c9dbc77a8ba1d","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"323717f7753b4ce6a5561d105a7531cf","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"941ef5bdf9fa49b3b8054dd755019209","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"moiety_mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"]}
+{"drug_id":"1dcee0d757154df08e4d0d7e8d6e1785","docid":75514,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:51.000Z","updated_ts":"2024-11-29T07:04:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"Oncoquest-Ovarian","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["510490d31ee9769974cc347d39a4f425"],"disease_id":["c297238c41b2488abe3de6546b105a4e"],"active_org_master_entity_id":["510490d31ee9769974cc347d39a4f425"],"research_disease":["c297238c41b2488abe3de6546b105a4e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641686400000}}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"12c8942d480b4b1988f26917c82e576c","docid":81505,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":12,"target_extend_id":"76c8d0f49ab83021a4c21f8915ff4437","created_ts":"2023-10-27T06:57:19.000Z","updated_ts":"2026-03-12T21:07:47.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CS-01","source_info":[{"attachment_path":"data/phs_source_info/90a3/d744/9333/3ba0/9b84bf09-528e-3f27-8846-b00dced2b120.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/cac2/d69a/c034/d234/833d4f0a-ce6f-3fd5-b9d0-e6b8b2fbe7c2.png","source":"Company pipeline","source_url":"https://www.constimulus.com/"}],"status":"ACTIVE"}],"dev_code":[{"name":"CS 01","source_info":[{"attachment_path":"data/phs_source_info/90a3/d744/9333/3ba0/9b84bf09-528e-3f27-8846-b00dced2b120.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/cac2/d69a/c034/d234/833d4f0a-ce6f-3fd5-b9d0-e6b8b2fbe7c2.png","source":"Company pipeline","source_url":"https://www.constimulus.com/"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["b2a8d8fea03269c8f48179e4587bba1f"],"mechanism_action_id":["2b89a4c8c1000c14d6a39e28fd4b0683"],"target_id":["f1ca3bdcdc594d548bbfe35fc4dd381b"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["b2a8d8fea03269c8f48179e4587bba1f"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1735516800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"03e81e7a87cf4171926a2412bdbd4ad4","docid":27365,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Caramiphen","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":13,"target_extend_id":"7a63f331ee4539efb40850e23ff6e778","created_ts":"2022-05-07T05:32:07.000Z","updated_ts":"2025-12-20T21:10:26.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Caramiphen edisylate","source_info":[{"code":"DBSALT001670","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Caramiphen","source_info":[{"code":"DB11504","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Caramiphen hydrochloride","source_info":[{"code":"DBSALT002875","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"generic_name":[{"name":"caramiphen","source_info":[{"code":"97J7NP0XJY","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/849433cb-ed81-4843-9fe8-17f0cf1bbb98"}],"status":"ACTIVE"}],"drugbank_id":["DB11504"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["dc31a446cac566b51afc01dd84e8a64e"],"target_id":["9e0dd433312142b29f99ce1710ddf6cb"],"disease_id":["41d613c1ab7e41c3ae5a87b2e44da37b","564a2451296345689d8f778eb1beea86","f1ad50b3010e4721a3ce9b148c940a5a"],"research_disease":["41d613c1ab7e41c3ae5a87b2e44da37b","564a2451296345689d8f778eb1beea86"],"non_research_disease":["f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"564a2451296345689d8f778eb1beea86","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"41d613c1ab7e41c3ae5a87b2e44da37b","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"c9e8fce7eb6b4bbd9cc66dc356017aab"}],"data_source":10}
+{"drug_id":"20501f3cf86a692ba1660e50b3237059","docid":84285,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"8666aad5477e4272b56b94ca1183781d","rnk":2,"target_extend_id":"87fe2f1d181436c4a554ac7d23c5956d","created_ts":"2024-03-07T08:53:19.000Z","updated_ts":"2025-07-31T00:31:15.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"RAG-21","status":"ACTIVE"}],"dev_code":[{"name":"RAG 21","status":"ACTIVE"},{"name":"RAG21","status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["b7eca62b60c7f8df5b7a47d1c78b6600"],"mechanism_action_id":["f3bb3b636f4540469c838bdce943b6d0"],"target_id":["ff6cc8e6c47a476b8eb8a94f86659942"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["738546bac89e4895b89af01545f1b054"],"active_org_master_entity_id":["609040193bd5081e3925e0453055af79","b7eca62b60c7f8df5b7a47d1c78b6600"],"research_disease":["738546bac89e4895b89af01545f1b054"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"8666aad5477e4272b56b94ca1183781d","dev_status_time":{"time_trust_code":7,"time_ts":1683417600000}}],"disease_phase":[{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_cn":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","data_source":10,"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"1cd7108748374f1d8b43a78edcf3485e","docid":60448,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-12-10T12:55:16.000Z","updated_ts":"2024-12-27T00:24:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ZKHF-010","status":"ACTIVE"}],"dev_code":[{"name":"ZKHF 010","status":"ACTIVE"},{"name":"ZKHF010","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["5806922764071ed82a9c6e6283111271"],"disease_id":["14b07fec521b49a78ad2ded5b61d3eec"],"active_org_master_entity_id":["9a998e8040d286c07ca6bec440f12fc8"],"research_disease":["14b07fec521b49a78ad2ded5b61d3eec"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"14b07fec521b49a78ad2ded5b61d3eec","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"00f5a739b4ab4fc791d7ee4337861511","docid":21637,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":6,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2021-12-10T12:54:46.000Z","updated_ts":"2026-04-11T00:28:56.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BCMA-CD19 cCAR-T cell therapy (iCell Gene Therapeutics)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BCMA-CD19 cCAR (iCell Gene Therapeutics)","status":"ACTIVE"},{"lang":"EN","name":"Compound BCMACD19 CAR T cells iCell Gene Therapeutics","status":"ACTIVE"}],"dev_code":[{"name":"BCMA-CD19 cCAR","status":"ACTIVE"},{"name":"ICG-318","source_info":[{"code":"NCT07328581","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07328581"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["712444a261794096619505c12048506b"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9","2ac451946966904ac6da0d54008cdd9a","d9627d77b8d00d879e22e88877e54736","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448"],"disease_id":["0c8a0603507542faac6b5ef3e27c6728","c5e1987e283c495aaab2a8d309c6085e","eb29c48a2bd94462ab25c50a461c4d61","b9790aa2ed5c48eda26f2224870a8e52","4e4ac0d6ca624cab8864c506fac16014","e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["af946049642a44c8016045cf62a7c976","6c52fb3409a529474d7766a609ed4e5a","712444a261794096619505c12048506b"],"research_disease":["0c8a0603507542faac6b5ef3e27c6728","c5e1987e283c495aaab2a8d309c6085e","eb29c48a2bd94462ab25c50a461c4d61","b9790aa2ed5c48eda26f2224870a8e52","4e4ac0d6ca624cab8864c506fac16014","e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1745193600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1"}],"disease_phase":[{"disease_id":"4e4ac0d6ca624cab8864c506fac16014","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b9790aa2ed5c48eda26f2224870a8e52","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"eb29c48a2bd94462ab25c50a461c4d61","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02f40a5594d745f7962f969702693f31","docid":31217,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"1d9d23f486fa342ba21682dc9cf26c63","created_ts":"2021-10-08T14:47:26.000Z","updated_ts":"2026-04-15T21:12:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"kongfengfeng","drug_name":[{"lang":"EN","name":"Nefextinib","source_info":[{"code":"list 130","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf?sfvrsn=ef74744a_5&download=true"},{"attachment_path":"data/phs_source_info/1d59/6b36/c6fb/9086/d9182b4f-f645-34ab-92f5-ab86a5e39513.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/851a/1961/56f3/0288/3e4e33f9-337e-3785-9a3d-a7788e053bd5.png","source":"Company pipeline","source_url":"https://www.maxinovel.com/pipeline.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"MA Max 4","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flt3-fgfr-dual-kinase-inhibitor-max-40279"}],"status":"ACTIVE"},{"name":"MAX 4","status":"ACTIVE"},{"name":"MAX 40279","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flt3-fgfr-dual-kinase-inhibitor-max-40279"}],"status":"ACTIVE"},{"name":"MAX-4","status":"ACTIVE"},{"name":"MAX-40279","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flt3-fgfr-dual-kinase-inhibitor-max-40279"}],"status":"ACTIVE"},{"name":"MAX-40279-001","status":"ACTIVE"},{"name":"MAX-40279-01","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flt3-fgfr-dual-kinase-inhibitor-max-40279"}],"status":"ACTIVE"},{"name":"MAX-5","status":"ACTIVE"},{"name":"MAX-6","status":"ACTIVE"},{"name":"Max 4","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flt3-fgfr-dual-kinase-inhibitor-max-40279"}],"status":"ACTIVE"}],"drugbank_id":["DB15191"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4a129b400963371c8c4abfc6d67d526e"],"mechanism_action_id":["5ef926581867ae53e0b3fc4fdca66211","42bff6897e7b912141d2d30072d93d8f","15361c70aabb7a297fffba48611a2600"],"target_id":["2ec11e5c292848d5b07cf6e132871a11","5a34b1dfc07d416a8e43cc0d5520fe63","9b673462043e40e0afda4ead7cc855b2"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","4c092510a2af42f387426e408f5c7694","a6cd07ecf38e48b584e8da2adfbe5f42","1a95630392584c7892bec2dc9888cbfc","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197","0464f5493b0444e9875a0584df17cbf0","e9b27c71d3024fd6ab7dc1dfc304f54d","b902fe3512424802ac7659fc83b38222","7665e5683a1a443a8f3d3b946d4c9ca2","2536e79ced34450fbb09de73061cf096","1e6992f1403346acad1273d778686ca7","15cb523e0fbd4617a6a129ad2336eb9a","e35ce4e9b7a846d49e600ce7ac4a7fd6"],"active_org_master_entity_id":["4a129b400963371c8c4abfc6d67d526e","444d310c1c9db64020364ecd98bff83e"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","4c092510a2af42f387426e408f5c7694","a6cd07ecf38e48b584e8da2adfbe5f42","1a95630392584c7892bec2dc9888cbfc","a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197","0464f5493b0444e9875a0584df17cbf0","e9b27c71d3024fd6ab7dc1dfc304f54d"],"non_research_disease":["b902fe3512424802ac7659fc83b38222","7665e5683a1a443a8f3d3b946d4c9ca2","2536e79ced34450fbb09de73061cf096","1e6992f1403346acad1273d778686ca7","15cb523e0fbd4617a6a129ad2336eb9a","e35ce4e9b7a846d49e600ce7ac4a7fd6"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1756771200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1642550400000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e9b27c71d3024fd6ab7dc1dfc304f54d","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a6cd07ecf38e48b584e8da2adfbe5f42","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"03143929ced94e56aa1a6d25fcdc3a68","docid":1643252,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-12-03T09:40:12.000Z","updated_ts":"2026-01-27T10:28:15.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Autologous Immune Cell Therapy(Liaoning Medical Diagnosis and Treatment Technology)","source_info":[{"code":"NCT07260058","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07260058"}],"status":"ACTIVE"}],"drug_type":["ba6d649a46b94099864b1173223c2737"],"originator_org_master_entity_id":["16865bf0bc8e4da8ce9bbd1953e4d97e"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","f048bf0822254413a3ea354eced08eec","15cb523e0fbd4617a6a129ad2336eb9a","f98fd32baa8447119bb87f84093b925c","323717f7753b4ce6a5561d105a7531cf"],"active_org_master_entity_id":["16865bf0bc8e4da8ce9bbd1953e4d97e"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","f048bf0822254413a3ea354eced08eec","15cb523e0fbd4617a6a129ad2336eb9a","f98fd32baa8447119bb87f84093b925c","323717f7753b4ce6a5561d105a7531cf"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"323717f7753b4ce6a5561d105a7531cf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02d657b943634173a7bc0de8cb336379","docid":1281714,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-05-30T03:17:40.000Z","updated_ts":"2025-05-30T03:18:15.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"AHC-01","source_info":[{"normalized_source_id":"e08f476d093148eebbb20af2d7aee723","source":"Globaldata","source_url":"https://www.globaldata.com/store/report/ahc-01-in-metrorrhagia-abnormal-uterine-bleeding-loa-innovation-and-trend-analysis/"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["c64cb6e2426066a198eec9496b45bf43"],"disease_id":["3e130ac319ba498b81805ee9dd853980"],"active_org_master_entity_id":["c64cb6e2426066a198eec9496b45bf43"],"research_disease":["3e130ac319ba498b81805ee9dd853980"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1737590400000}}],"disease_phase":[{"disease_id":"3e130ac319ba498b81805ee9dd853980","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"040783b496d5405fb99806dc6dc483e9","docid":72816,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e6438687ed214800bb98742ebbeb70a1","rnk":113,"target_extend_id":"77acfd901795357eb2f2e048b1ee0ca6","created_ts":"2022-01-22T07:31:57.000Z","updated_ts":"2026-04-18T21:04:56.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ASC-61","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PD-L1 checkpoint inhibitor  Ascletis","status":"ACTIVE"}],"dev_code":[{"name":"ASC 61","status":"ACTIVE"},{"name":"ASC-61","status":"ACTIVE"},{"name":"ASC61","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["c23d590d6e5b1949655db64e015461dc"],"mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2"],"target_id":["06c7ab146b884a3aa890cfd1a4a0e168"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["f30efe1f2104035f0e967b8d25432e03","c23d590d6e5b1949655db64e015461dc","f0fc8e3ef1952e161f547ceb82237212"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1659398400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1644192000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1668470400000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"09773121624e42b5bde1225cf76087d4","docid":18001,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"antibody_drug_id":"fcaf760bd0d54f5ca79c92ca47466fe7","antibody_type":"6cc2f1725abc4c479b30ba000ee17b35","payload_id":"5974ead3ae534928b5e88f36bedaa4d7","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":194,"target_extend_id":"7b338f40fb243fc79806ffa4e81c4c5a","created_ts":"2021-11-30T08:55:22.000Z","updated_ts":"2026-04-18T21:05:14.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"227Th-Trastuzumab corixetan","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.bayer.com/en/pharma/development-pipeline"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HER2-targetted thorium conjugate- Bayer","status":"ACTIVE"}],"dev_code":[{"name":"BAY 2701439","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/thorium-th-227-trastuzumab-corixetan"}],"status":"ACTIVE"},{"name":"BAY-2701439","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/thorium-th-227-trastuzumab-corixetan"}],"status":"ACTIVE"},{"name":"BAY2701439","status":"ACTIVE"}],"drug_type":["35708352e4e4487499a6964b5ddb2ceb","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["d94923980905512f8eac870e9ac6f983"],"mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151","569d7324d3bdd73cc1b9e225fdfc8d5f"],"target_id":["a3c3158483984ff9922b1b0ba939a068"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","db56b9ce013742c384e6c11298ae84d4","9f1a3ea9c03c447da49de7ed1ee72da3","8715a156105c4300bc31443cb22de044"],"active_org_master_entity_id":["d94923980905512f8eac870e9ac6f983"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"non_research_disease":["db56b9ce013742c384e6c11298ae84d4","9f1a3ea9c03c447da49de7ed1ee72da3","8715a156105c4300bc31443cb22de044"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1662422400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1758758400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1758758400000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"db56b9ce013742c384e6c11298ae84d4","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8715a156105c4300bc31443cb22de044","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"9f1a3ea9c03c447da49de7ed1ee72da3","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10,"target_moiety_type":["c38eb408d6b842f487d6a27484156633"],"moiety_target_extend_id":"7b338f40fb243fc79806ffa4e81c4c5a","moiety_mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151","569d7324d3bdd73cc1b9e225fdfc8d5f"],"moiety_target_id":["a3c3158483984ff9922b1b0ba939a068"]}
+{"drug_id":"0080dea480ae4ed69d263ccd72f1dc80","docid":27042,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:46:00.000Z","updated_ts":"2024-12-30T02:57:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Magnesium L-lactate dihydrate","source_info":[{"code":"NCT03567824","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03567824"}],"status":"ACTIVE"}],"dev_code":[{"name":"MLD-10","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9eecc04caf7e53ae7609dc1620fe0678"],"disease_id":["74d974da49ba407195b38595a0aff704","996f4be170ad4bda9d1d8575bb8eaa09","011e34c7364441b2b18b56375242b918"],"active_org_master_entity_id":["9eecc04caf7e53ae7609dc1620fe0678"],"research_disease":["74d974da49ba407195b38595a0aff704","996f4be170ad4bda9d1d8575bb8eaa09"],"non_research_disease":["011e34c7364441b2b18b56375242b918"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1559347200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"011e34c7364441b2b18b56375242b918","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"996f4be170ad4bda9d1d8575bb8eaa09","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0215c7a18a3e49af87fdf96a40790f5e","docid":204728,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":49,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2024-10-29T09:32:28.000Z","updated_ts":"2026-04-04T21:04:34.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Anti-BCMA CAR-NK(Payesh company)","source_info":[{"code":"IRCT20200413047063N4","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://irct.behdasht.gov.ir/trial/74932"}],"status":"ACTIVE"}],"drug_type":["8554bd286df144c39af9350c62a5b309"],"originator_org_master_entity_id":["30692d4811a1e13aa75d9877e7d21c49"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["30692d4811a1e13aa75d9877e7d21c49"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"ab1a98cb-d362-3a11-9e63-99cb01cc9474","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1705708800000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"3bf6092e308a4f79b588c0cf65375901","docid":8201,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:21.000Z","updated_ts":"2024-11-09T02:16:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"GENA-004","status":"ACTIVE"}],"dev_code":[{"name":"GENA-004","status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["c01b4fc87dd368ac5ceb4cea9493dabc"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","1a41a587feb28542b3050eb67b912259"],"disease_id":["2e511ff0e28c4218b6f2d510b4ba8ea3"],"active_org_master_entity_id":["c01b4fc87dd368ac5ceb4cea9493dabc"],"research_disease":["2e511ff0e28c4218b6f2d510b4ba8ea3"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1645488000000}}],"disease_phase":[{"disease_id":"2e511ff0e28c4218b6f2d510b4ba8ea3","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01c7bd83c2324cc585cab4dcb9c11485","docid":72173,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"1a9ea1307f82439f86318fa381543664","wiki_link":"https://en.wikipedia.org/wiki/Insulin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1259107200000,"rnk":28,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2021-10-08T14:45:23.000Z","updated_ts":"2025-03-21T00:19:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1259107200000,"drug_name":[{"lang":"CN","name":"重组人胰岛素 (珠海联邦制药)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant human insulin(Zhuhai United Laboratories Co. Ltd.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Insulin human  Biosimilar (Zhuhai United Pharmaceutical Co.,Ltd.)","status":"ACTIVE"},{"lang":"EN","name":"Isophane Protamine Recombinant Human Insulin","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Premixed Protamine Recombinant Human Insulin (30/70)","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Premixed Protamine Recombinant Human Insulin(50/50)","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant Human Insulin","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"人胰岛素生物类似药（珠海联邦制药股份有限公司）","status":"ACTIVE"}],"trade_name":[{"name":"Uslin","status":"ACTIVE"},{"name":"优思灵","status":"ACTIVE"},{"name":"优思灵USLIN 30R","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"优思灵USLIN 50R","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"优思灵USLIN N","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"优思灵USLIN R","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["0c472fef8935504cad3e1cbb31ea4927"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"atc_code":["28015fca57a447dcac34b9b0af394ac3","7129a7650f0440aba56be1da495672f0","8354992ea2b3479a84701ad47bba4ef5","c4948bc83ed44adc8bcc3bc417e0a790","c4a25ad1934a4c3b8e129f4b1ca8ba7a"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["0c472fef8935504cad3e1cbb31ea4927"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["0d05187284b446c5803cce38a3e53ebf"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1259107200000}}],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["3069e8984dc64c25ad8c3eb51404e3b0","cf536e85609049b89093775c799cb1e3"],"if_speculate":0,"data_source":10}
+{"drug_id":"02b4f2d10377412d9d33592bbb89277e","docid":27854,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":6,"target_extend_id":"9d82ffeca6e13c90ad0bf5cf61d9ab5d","created_ts":"2021-11-30T08:55:40.000Z","updated_ts":"2026-04-15T21:16:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"NT-0796","source_info":[{"code":"10.1021/acs.jmedchem.3c01398","normalized_source_id":"c76133d1-b056-4907-9edc-930de76e679d","source":"J Med Chem","source_url":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01398"}],"status":"ACTIVE"}],"dev_code":[{"name":"NT 0796","source_info":[{"code":"10.1021/acs.jmedchem.3c01398","normalized_source_id":"c76133d1-b056-4907-9edc-930de76e679d","source":"J Med Chem","source_url":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01398"}],"status":"ACTIVE"},{"name":"NT-0796","source_info":[{"code":"10.1021/acs.jmedchem.3c01398","normalized_source_id":"c76133d1-b056-4907-9edc-930de76e679d","source":"J Med Chem","source_url":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01398"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["064544303384345830b6ba32a4529de7"],"mechanism_action_id":["4950c0668e7b338b93c6c70258f10ed1"],"target_id":["e0e707b9e9cd4c0982e8b81aa83fa185"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814","df338ea527f34aee80af9380345600ee","54e2cf3dc3294445b4a27b990b0ba274","f1ad50b3010e4721a3ce9b148c940a5a","452558707a32402e80a9431bf4652814","27013926797d4bc4bf088e4104530e7d","281fcf1b07ee4c13b0297e4ad1a9c106"],"active_org_master_entity_id":["0f7e455a624fb5de13f12a147837176f"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814","df338ea527f34aee80af9380345600ee","54e2cf3dc3294445b4a27b990b0ba274","f1ad50b3010e4721a3ce9b148c940a5a","452558707a32402e80a9431bf4652814"],"non_research_disease":["27013926797d4bc4bf088e4104530e7d","281fcf1b07ee4c13b0297e4ad1a9c106"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","54e2cf3dc3294445b4a27b990b0ba274","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1746662400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1652140800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1765929600000}}],"disease_phase":[{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"452558707a32402e80a9431bf4652814","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"df338ea527f34aee80af9380345600ee","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"077fdcc7eb8d478b9f6ea4afa227fe25","docid":43754,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":8,"target_extend_id":"fd8ca3cee3b33a2aa3231a107bc8615c","created_ts":"2021-10-08T14:45:30.000Z","updated_ts":"2025-12-20T21:10:20.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"EN","name":"JJH201501","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5454ec71a29359a7e1b2f1d2868cab78"],"mechanism_action_id":["17700fad92d1f578ae3cd9980037200d","5ccf3ad1ee5854a9b707ef691d8c1983","16c550da4591abf23ba1a0d4cbc4e000"],"target_id":["12d15ecd35384571aa3a6aa592fae0c7","d50c8f7431e24c2ebcc8ea493633780e","fdf428be3b244734a67e05e23a0ac809"],"disease_id":["2dbed7595ff04b8fae04724f91081116","f1c3e5bf53414ba481ce6c6876b7b6f2","4ba63c2d43e9449c8e0feca5779faca0"],"active_org_master_entity_id":["5454ec71a29359a7e1b2f1d2868cab78"],"research_disease":["2dbed7595ff04b8fae04724f91081116"],"non_research_disease":["f1c3e5bf53414ba481ce6c6876b7b6f2","4ba63c2d43e9449c8e0feca5779faca0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1716249600000}}],"disease_phase":[{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f1c3e5bf53414ba481ce6c6876b7b6f2","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"4ba63c2d43e9449c8e0feca5779faca0","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"180b00084dee4245b509d7d7176732f0","docid":62988,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2022-08-22T08:35:32.000Z","updated_ts":"2026-02-24T21:04:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","drug_name":[{"lang":"EN","name":"Orca-T (Orca Bio)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Orca T (Orca Bio)","status":"ACTIVE"},{"lang":"EN","name":"Orca-T (Orca Bio)","status":"ACTIVE"},{"lang":"EN","name":"Treg CD34+HSPC (Orca Bio)","status":"ACTIVE"},{"lang":"EN","name":"TregGraft","status":"ACTIVE"}],"dev_code":[{"name":"TRGFT-201","source_info":[{"code":"NCT06195891","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06195891"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/partially-engineered-t-regulatory-cell-donor-graft-trgft-201"}],"status":"ACTIVE"}],"drug_type":["f4b90b82ef0d408a8d668ea670bb9020"],"originator_org_master_entity_id":["59560d2728dfa722de63dc6310ef8e02","734b6d223a9d633b8419a74d2fd215ae"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"special_review":["23d3523b7ece48ddacaddac53a66949d","ed88b5b02898448483d0dd3ce010cfba","043a131d85994801b3617e822e7f87b3"],"disease_id":["1d78cca79eae4632bc4464c90a574f83","7cb6983b4169498e89b08fd725a22b46","1a95630392584c7892bec2dc9888cbfc","e2251a2774ee4eff8723a33fc035d809","43f12a7fc0be498fab8c1102e4b75ff0","55308ce01ccf489fa6a811cc0896f0cb","fd6b927bd92044d7b240e09317dac79c","c45e529e87834fd582bfd557c409028d","0281becfa98a40be9feae38fbead920f","793c4159dfa04ceb90acae7a76502ac9","dbc797f54e094da7a74c3b222ca47671"],"active_org_master_entity_id":["59560d2728dfa722de63dc6310ef8e02","734b6d223a9d633b8419a74d2fd215ae"],"research_disease":["1d78cca79eae4632bc4464c90a574f83","7cb6983b4169498e89b08fd725a22b46","1a95630392584c7892bec2dc9888cbfc","e2251a2774ee4eff8723a33fc035d809","43f12a7fc0be498fab8c1102e4b75ff0","55308ce01ccf489fa6a811cc0896f0cb","fd6b927bd92044d7b240e09317dac79c","c45e529e87834fd582bfd557c409028d","0281becfa98a40be9feae38fbead920f","793c4159dfa04ceb90acae7a76502ac9","dbc797f54e094da7a74c3b222ca47671"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1759708800000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"dbc797f54e094da7a74c3b222ca47671","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"43f12a7fc0be498fab8c1102e4b75ff0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"55308ce01ccf489fa6a811cc0896f0cb","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c45e529e87834fd582bfd557c409028d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"fd6b927bd92044d7b240e09317dac79c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e2251a2774ee4eff8723a33fc035d809","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"0281becfa98a40be9feae38fbead920f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"793c4159dfa04ceb90acae7a76502ac9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00e5fad66be848dbada0f128104c703f","docid":10453,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","wiki_link":"https://en.wikipedia.org/wiki/Aminobenzoic_acid","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:44:06.000Z","updated_ts":"2024-11-07T09:44:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili@patsnap.com","drug_name":[{"lang":"CN","name":"氨基苯甲酸","status":"ACTIVE"},{"lang":"EN","name":"Aminobenzoic acid","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"1-Amino-4-carboxybenzene","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"4-Carboxyaniline","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"4-aminobenzoic acid","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Aminobenzoic acid (USP)","source_info":[{"code":"D02456","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"PAB","status":"ACTIVE"},{"lang":"EN","name":"PABA","status":"ACTIVE"},{"lang":"EN","name":"p-Aminobenzoic acid","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"},{"code":"D02456","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"p-Carboxyaniline","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"p-Carboxyphenylamine","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"para-Aminobenzoic acid","source_info":[{"code":"DB02362","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"trade_name":[{"name":"Pabasun","status":"ACTIVE"},{"name":"RVPaba lipstick","source_info":[{"code":"D02456","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB02362"],"kegg_id":["D02456"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"atc_code":["43394b1803b7483c9f2bf23ff31766ac"],"disease_id":["f732d28665e344edbe686e8166f96dc4","6435ba48ca29483e936419178d317ed8"],"research_disease":["f732d28665e344edbe686e8166f96dc4"],"non_research_disease":["6435ba48ca29483e936419178d317ed8"],"inactive_org_master_entity_id":["48016f816bb3556361b7e54975e35057"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":800409600000}}],"disease_phase":[{"disease_id":"f732d28665e344edbe686e8166f96dc4","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6435ba48ca29483e936419178d317ed8","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"091381b5b19049dc989f9bc7e1e7ccc4","docid":69001,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"12114d8c85913e52bed23361aae49bb7","created_ts":"2022-02-28T05:06:26.000Z","updated_ts":"2025-07-07T10:06:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"SPVN-20","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Adeno-associated virus based gene therapy (SparingVision)","status":"ACTIVE"}],"dev_code":[{"name":"SPVN-20","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["82227132e74db6a95927e5ea91a4d845"],"mechanism_action_id":["ce968e5cd08d4f81b2bbb5ed2f6f2bfa"],"target_id":["d816e431aa8a4ec2b5b6dd0eb27472b2"],"disease_id":["2ef2f7065d1e476d839aaa6ce50d522d"],"active_org_master_entity_id":["82227132e74db6a95927e5ea91a4d845"],"research_disease":["2ef2f7065d1e476d839aaa6ce50d522d"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"2ef2f7065d1e476d839aaa6ce50d522d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"16c55cc8b61d4da1a2208129a587b21f","docid":58713,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1767052800000,"rnk":2,"target_extend_id":"47077a6735ee341b9b1d2c76acf3ff35","has_leading_org_involved":1,"created_ts":"2021-10-08T14:50:11.000Z","updated_ts":"2026-04-20T13:40:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":1767052800000,"drug_name":[{"lang":"CN","name":"索托克拉","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=Mzk0ODIxMzU4Mw==&mid=2247534010&idx=2&sn=03dc7321bd6fa7d90ec275be4bbd3b09"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA3OTIxOTkyMw==&mid=2257532392&idx=1&sn=19a79ad94c56cb7f31f4cc2875ee5af3"}],"status":"ACTIVE"},{"lang":"EN","name":"Sonrotoclax","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.cn/sonrotoclax.html#:~:text=Sonrotoclax%20%28Synonyms%3A%20BGB%2011417%29%20Cat.%20No.%3A%20HY-148026%20Handling,a%20variety%20of%20lymphoma%20and%20leukemia%20cell%20lines."}],"status":"ACTIVE"}],"dev_code":[{"name":"BG-71332","source_info":[{"code":"NCT07141511","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07141511"}],"status":"ACTIVE"},{"name":"BGB 11417","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sonrotoclax"}],"status":"ACTIVE"},{"name":"BGB-11417","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.cn/sonrotoclax.html#:~:text=Sonrotoclax%20%28Synonyms%3A%20BGB%2011417%29%20Cat.%20No.%3A%20HY-148026%20Handling,a%20variety%20of%20lymphoma%20and%20leukemia%20cell%20lines."},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sonrotoclax"}],"status":"ACTIVE"}],"trade_name":[{"name":"百悦达","source_info":[{"normalized_source_id":"09a9e2414846487c9e66f4bfca02cea9","source":"NMPA_NEWS","source_url":"https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20260106180458186.html"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4d16a460eb330b401d69b3103739c2fd"],"mechanism_action_id":["ea5c58873d8582884db7996287ed6df1"],"target_id":["fd23fd900514452d8978eac02dc46649"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["d7a26da8f1ff43559e34fe72da812c56","7257365c831446dcbcf28024a2b70398","cec1504cb1d141d68776457c4b88b30f","0307c7ee71334e818fd4f78fca65c658","8ae64343c39b4b09865ed0177000236b","d06a737ae1d8400eb1a6b2d3034c0ebf","a793080f1c0d4f9cbe3fe4230a21b8f5","04ca93f7db32411eabd05798d78a045b","6f8590260b18439e85db9d737db2ea3b","08f6a4fc104140038d3de489697182f2","e61a6d319d7a402f8435c866c9e8584e","967c51dd399a44a19f81b015781fbc7a","7cd0fcf1c5c243b9b3944405ec4855b5","7cb6983b4169498e89b08fd725a22b46","1a95630392584c7892bec2dc9888cbfc","1779aedf6a9744f2a29ddc1feb89f231","f231f8a36a0049ac9b404b06b8d478b2","ce09181e978a4a3f9932f35001b9fa13","5b1d61d8a13c4967a3457de72c3413c3","3ac5604c4dde49c29b561648d0c0543c","bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","da37b8c0153d4a6bbbf3c424c4f0b3fc","9c825d66bf4d45ea8a94364b28d87bb3","1a2e903f6dab4bc9b4410b14e342ae5d","0e0dca4dd7f1499a8f65f4fdfcf09954","e89afc6a432744b1a88281329dc46d91","255129f3eedb44a8a25eb50be897186c","1a51c709099840a381471343fb21c3a9","841d404eb6434d36b3f0d593f2c26dfe","d55adbca6aa34fd18d1a5f4050b83bd6","43657a072d3c4704974584884ef19df7"],"active_org_master_entity_id":["4d16a460eb330b401d69b3103739c2fd","c10cafd779028e2e53d06cc3c34ff5f7","0ac85e4bda88375520577a9a31f4fe01"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["d7a26da8f1ff43559e34fe72da812c56","7257365c831446dcbcf28024a2b70398","cec1504cb1d141d68776457c4b88b30f"],"research_disease":["d7a26da8f1ff43559e34fe72da812c56","7257365c831446dcbcf28024a2b70398","cec1504cb1d141d68776457c4b88b30f","0307c7ee71334e818fd4f78fca65c658","8ae64343c39b4b09865ed0177000236b","d06a737ae1d8400eb1a6b2d3034c0ebf","a793080f1c0d4f9cbe3fe4230a21b8f5","04ca93f7db32411eabd05798d78a045b","6f8590260b18439e85db9d737db2ea3b","08f6a4fc104140038d3de489697182f2","e61a6d319d7a402f8435c866c9e8584e","967c51dd399a44a19f81b015781fbc7a","7cd0fcf1c5c243b9b3944405ec4855b5","7cb6983b4169498e89b08fd725a22b46","1a95630392584c7892bec2dc9888cbfc","1779aedf6a9744f2a29ddc1feb89f231","f231f8a36a0049ac9b404b06b8d478b2","ce09181e978a4a3f9932f35001b9fa13","5b1d61d8a13c4967a3457de72c3413c3","3ac5604c4dde49c29b561648d0c0543c","bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","da37b8c0153d4a6bbbf3c424c4f0b3fc","9c825d66bf4d45ea8a94364b28d87bb3","1a2e903f6dab4bc9b4410b14e342ae5d","0e0dca4dd7f1499a8f65f4fdfcf09954","e89afc6a432744b1a88281329dc46d91","255129f3eedb44a8a25eb50be897186c","1a51c709099840a381471343fb21c3a9","841d404eb6434d36b3f0d593f2c26dfe","d55adbca6aa34fd18d1a5f4050b83bd6","43657a072d3c4704974584884ef19df7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","54e2cf3dc3294445b4a27b990b0ba274","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1767052800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1764115200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1699660800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1699660800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1769040000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1749600000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741132800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1740614400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1699660800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1698019200000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1695859200000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1631750400000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d06a737ae1d8400eb1a6b2d3034c0ebf","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9c825d66bf4d45ea8a94364b28d87bb3","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"43657a072d3c4704974584884ef19df7","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"f231f8a36a0049ac9b404b06b8d478b2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ce09181e978a4a3f9932f35001b9fa13","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a2e903f6dab4bc9b4410b14e342ae5d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"04ca93f7db32411eabd05798d78a045b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e61a6d319d7a402f8435c866c9e8584e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"cec1504cb1d141d68776457c4b88b30f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d55adbca6aa34fd18d1a5f4050b83bd6","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"967c51dd399a44a19f81b015781fbc7a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1779aedf6a9744f2a29ddc1feb89f231","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"08f6a4fc104140038d3de489697182f2","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3ac5604c4dde49c29b561648d0c0543c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a793080f1c0d4f9cbe3fe4230a21b8f5","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"0307c7ee71334e818fd4f78fca65c658","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"da37b8c0153d4a6bbbf3c424c4f0b3fc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7257365c831446dcbcf28024a2b70398","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e89afc6a432744b1a88281329dc46d91","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"255129f3eedb44a8a25eb50be897186c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8ae64343c39b4b09865ed0177000236b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"841d404eb6434d36b3f0d593f2c26dfe","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6f8590260b18439e85db9d737db2ea3b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1a51c709099840a381471343fb21c3a9","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5b1d61d8a13c4967a3457de72c3413c3","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["11ef8a9e8bf5ca80213a1183511cded3","4d16a460eb330b401d69b3103739c2fd"],"if_speculate":0,"data_source":10}
+{"drug_id":"07ff02a93cf04392b356c9efefdfa3c9","docid":203165,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-08-08T06:30:30.000Z","updated_ts":"2025-08-02T00:29:56.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"EVM-16","source_info":[{"code":"NCT06541639","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06541639"}],"status":"ACTIVE"}],"dev_code":[{"name":"EVM16","source_info":[{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"https://www.prnewswire.com/news-releases/everest-medicines-announces-the-initiation-of-an-investigator-initiated-clinical-trial-iit-for-personalized-mrna-cancer-vaccine-program-evm16-302227489.html"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["3ec5f8ff6a565d586af277772b5ea93e"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["f7a28558e1f244a8846ce00c6bf6ab25","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["7bc7e93586918f2bd0048cbca85bf6c5","3ec5f8ff6a565d586af277772b5ea93e"],"research_disease":["f7a28558e1f244a8846ce00c6bf6ab25","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1741219200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f7a28558e1f244a8846ce00c6bf6ab25","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"074079be4b1742818333dba85529711b","docid":1760523,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2025-08-13T07:26:44.000Z","updated_ts":"2025-11-04T09:42:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Umbilical cord Mesenchymal stem cell( Institute of Liver & Biliary Sciences)","source_info":[{"code":"NCT07075315","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07075315"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["994c218c8ee7ae878629498b0a38e70a"],"disease_id":["a4b7fd85fb8a41448493daf73128e7d2"],"active_org_master_entity_id":["994c218c8ee7ae878629498b0a38e70a"],"research_disease":["a4b7fd85fb8a41448493daf73128e7d2"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1830297600000}}],"disease_phase":[{"disease_id":"a4b7fd85fb8a41448493daf73128e7d2","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00638da590c9494b9368f4d069f4ed62","docid":70114,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1455494400000,"created_ts":"2022-06-16T10:22:23.000Z","updated_ts":"2026-04-02T13:01:39.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"yuanjing","drug_name":[{"lang":"EN","name":"Human fibrinogen concentrate(LFB Biomedicaments)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Clottafact","status":"ACTIVE"},{"lang":"EN","name":"FGTW","status":"ACTIVE"},{"lang":"EN","name":"Fibrinogen(LFB Biomedicaments)","status":"ACTIVE"}],"trade_name":[{"name":"FibCLOT","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.groupe-lfb.com/en/news/registration-of-fibclot-lfbs-human-fibrinogen-in-europe/"}],"status":"ACTIVE"}],"drug_type":["4d2dcd3fc8b644db955f8cccefca280b"],"originator_org_master_entity_id":["2b7af270b4639c92324123cb23c1e0a9"],"mechanism_action_id":["7cf5c18627d31ec12c70eee14bce4b71"],"disease_id":["a878e836d10f4f3092ac081350b250c6"],"active_org_master_entity_id":["2b7af270b4639c92324123cb23c1e0a9"],"first_approved_country":["0e7802a9-bad3-33a3-98ae-ff755c717809"],"first_approved_indication":["a878e836d10f4f3092ac081350b250c6"],"research_disease":["a878e836d10f4f3092ac081350b250c6"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0e7802a9-bad3-33a3-98ae-ff755c717809"],"research_country":[{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1455494400000}}],"disease_phase":[{"disease_id":"a878e836d10f4f3092ac081350b250c6","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0058a0cccd3a48779cbf0263d230c4f9","docid":77195,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":11,"target_extend_id":"f50b580b88c33fa39f82e23bb249f297","created_ts":"2021-11-30T08:59:07.000Z","updated_ts":"2026-04-18T00:29:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Nucresiran","source_info":[{"normalized_source_id":"e5b08f52d06d4e56a516b482a5fecb0f","source":"BusinessWire","source_url":"https://www.businesswire.com/news/home/20241117936734/en"}],"status":"ACTIVE"}],"dev_code":[{"name":"ALN TTRSC04","status":"ACTIVE"},{"name":"ALN-TTRSC04","source_info":[{"normalized_source_id":"e5b08f52d06d4e56a516b482a5fecb0f","source":"BusinessWire","source_url":"https://www.businesswire.com/news/home/20241117936734/en"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["64b868824be13f21c65806ae1672608a"],"mechanism_action_id":["e6ed73403ff4681ca3cc3c30d25b5dbe","e77dece162a0133e50d5b2357c40719f"],"target_id":["fdae7562a29a4cfdad96579480d87d5c"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["4b824ca9b7524dd9a154f71de8d02e45","5c44fa0ab6f44ebf9c65552d36cfdd60"],"active_org_master_entity_id":["5e7b5ef1bb8d82575e7d68cd838dade0","64b868824be13f21c65806ae1672608a"],"research_disease":["4b824ca9b7524dd9a154f71de8d02e45","5c44fa0ab6f44ebf9c65552d36cfdd60"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"cd3e6701-4441-33f8-b1eb-6b09e843c964","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}}],"disease_phase":[{"disease_id":"5c44fa0ab6f44ebf9c65552d36cfdd60","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4b824ca9b7524dd9a154f71de8d02e45","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","if_speculate":0,"data_source":10,"source_info_xna":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source_url":"https://www.oligotherapeutics.org/ikaria-an-innovative-platform-that-yields-long-acting-sirna/"}],"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"targeted_tissue":["a63a02bf5b3f433aa7da4ea6edd802bf"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"1a106a8098d24cfab8f4a25c21750f15","docid":71885,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"express_system":"ac14778662b7448588663c26ce84cd9e","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1656374400000,"rnk":1,"target_extend_id":"d4102fb7c0f53673a27a5abc5a60447e","has_leading_org_involved":1,"created_ts":"2021-10-08T14:43:53.000Z","updated_ts":"2026-04-15T07:32:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","first_approved_date_cn":1656374400000,"drug_name":[{"lang":"CN","name":"卡度尼利单抗","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Cadonilimab","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PD-1/CTLA-4 Bispecific Antibody","source_info":[{"code":"NCT06532591","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06532591"}],"status":"ACTIVE"},{"lang":"CN","name":"凯得宁单抗","status":"ACTIVE"},{"lang":"CN","name":"卡度尼利","status":"ACTIVE"},{"lang":"CN","name":"卡杜尼利单抗","source_info":[{"normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"AK 104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cadonilimab"}],"status":"ACTIVE"},{"name":"AK-104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cadonilimab"}],"status":"ACTIVE"},{"name":"AK104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cadonilimab"}],"status":"ACTIVE"}],"trade_name":[{"name":"开坦尼","status":"ACTIVE"}],"generic_name":[{"name":"Cadonilimab","status":"ACTIVE"}],"kegg_id":["D12190"],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["391046f8744a1cde275e09de08b483f3"],"mechanism_action_id":["702fa47e9a71b31550c38470d2204ce9","4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["664d9478c81b4059b32f286b5047416c","9786d32e3d244a688ec6a60d2fe1b10b"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["4c092510a2af42f387426e408f5c7694","08a4e8d8a1ed476fa456191e4b5fdefc","bcd25eb2059e443cb7bf20445cbf413c","f3ab7c215d5e4904a6c9859f3e15259d","28935c60ded04150bbdd16876cc0082e","a75eb84c45444938809d1088852efb20","02450a108c4c4bf0adc12f67b0f50e0e","2d94f94415454317a68f499ad53332db","2bb755a3f43f49dea60661c5f99712a3","dd16b20c0ed446fc8f3fa4791f8aca8a","6b80eb2530e64952b99d1b50407fab55","15839db0de0947ddb9e4c280884a3895","a12064e327a946618fc52338c4dffa03","a4256d84f83747e89045f0133c1133f1","6a582c5fe4754be8a043249152504710","513741b459a8450fabc9616c87599e5f","f58920e650344564b5dc93712863af81","978b2e0e83614e3f80e9003905b63c98","8eaa9c59b7674ad692d8fbc5c68e845c","f04e110974bf45b58dd4d2eabcd2c6c1","41311a72b91b4e2290ffc61d00ad1f5b","e5090e6e73c349b9a671c67b6e0ef6e3","ae092fa59f4d44edaf59ffe23d0a44c3","43a01c3d180b45438f911c6502567931","ed204c2d1b6245098bb07da9c6b00eb5","63333c316c3b493487303520d1e0c9d8","218de7027c39474b884ca5d174846630","342b1d03069b47ce8075d9930a4b24af","885a88527cdd45989941da6165ccd00a","703dd75ecc8740df908141aa5252ff4c","881cc9ec9e4f4b80afcb49a2e3cf2c98","be26bd5a3626417eabc7fde7a7b8b3d9","14143fc9923b41d9950a59ed79f7731a","7e87f9c6dcd841edb4d0f250b6bee3d9","78cb173a4de34f07befac28de907e7bf","b5906197018e47b1a34e2fcf9ea60c3a","f92e4ba771d04f27a1f4daae363b676a","49deb7ff8f2e4803b51f1145e4de982c","e3a912febc6543bbad7ce969c809b488","b98763c97526476fb442d16344cb5e59","6ca2db7d9e044c74a20da7017fa416e6","80517ada10994b33a79d98e7dddd945f","a0304a462da04e7cb03e3f2c5625544e","7fb8ceff333b48e8adea2c0803494a48","2536e79ced34450fbb09de73061cf096","6570754a6f0b43b78a9926c7bfd00519","9eeccc4caf594a5abedc0559fd9e0424","52168d859c5c4211b0cf99b6a3e34221","1cfde61efce54a8c9b92dd7b60c30995","2830f7d877eb4edbb02322f5bfd5b20b","0464f5493b0444e9875a0584df17cbf0","07994e875a7f44dc9af7f9bf3f6989e5","a6cd07ecf38e48b584e8da2adfbe5f42","ab7c198e47834770a36ab3282d331531","33679852d82540b6b4fa86d88a52dd68","6c9886cb25eb45faba70292cee1f5518","01773f22c03f4beda403b65654c1698d","5c266194199442338a3aa84590758ad8","a311ae2187914c2bbad45810b91f9414","e3bb40386c3840a7841213b5d02fd358","9076279a331c4d3b8a3cdf6ea2360fd6","45de0082f65f48c3b2c9a654543c879f","3428d019f74042c9b04557aaa3f597e2"],"active_org_master_entity_id":["620b11f9e3b99c64efa8c7ca677c675f","f8909923771a8fb556c2708a8762c0a8","391046f8744a1cde275e09de08b483f3","249e66edbf668a19ede75cfe48e520bf","560adf58b078ca78ce54967cd5386274","7a1651c53842307381146217c3025e2c"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["bcd25eb2059e443cb7bf20445cbf413c","f3ab7c215d5e4904a6c9859f3e15259d"],"research_disease":["4c092510a2af42f387426e408f5c7694","08a4e8d8a1ed476fa456191e4b5fdefc","bcd25eb2059e443cb7bf20445cbf413c","f3ab7c215d5e4904a6c9859f3e15259d","28935c60ded04150bbdd16876cc0082e","a75eb84c45444938809d1088852efb20","02450a108c4c4bf0adc12f67b0f50e0e","2d94f94415454317a68f499ad53332db","2bb755a3f43f49dea60661c5f99712a3","dd16b20c0ed446fc8f3fa4791f8aca8a","6b80eb2530e64952b99d1b50407fab55","15839db0de0947ddb9e4c280884a3895","a12064e327a946618fc52338c4dffa03","a4256d84f83747e89045f0133c1133f1","6a582c5fe4754be8a043249152504710","513741b459a8450fabc9616c87599e5f","f58920e650344564b5dc93712863af81","978b2e0e83614e3f80e9003905b63c98","8eaa9c59b7674ad692d8fbc5c68e845c","f04e110974bf45b58dd4d2eabcd2c6c1","41311a72b91b4e2290ffc61d00ad1f5b","e5090e6e73c349b9a671c67b6e0ef6e3","ae092fa59f4d44edaf59ffe23d0a44c3","43a01c3d180b45438f911c6502567931","ed204c2d1b6245098bb07da9c6b00eb5","63333c316c3b493487303520d1e0c9d8","218de7027c39474b884ca5d174846630","342b1d03069b47ce8075d9930a4b24af","885a88527cdd45989941da6165ccd00a","703dd75ecc8740df908141aa5252ff4c","881cc9ec9e4f4b80afcb49a2e3cf2c98","be26bd5a3626417eabc7fde7a7b8b3d9","14143fc9923b41d9950a59ed79f7731a","7e87f9c6dcd841edb4d0f250b6bee3d9","78cb173a4de34f07befac28de907e7bf","b5906197018e47b1a34e2fcf9ea60c3a","f92e4ba771d04f27a1f4daae363b676a","49deb7ff8f2e4803b51f1145e4de982c","e3a912febc6543bbad7ce969c809b488","b98763c97526476fb442d16344cb5e59","6ca2db7d9e044c74a20da7017fa416e6","80517ada10994b33a79d98e7dddd945f","a0304a462da04e7cb03e3f2c5625544e","7fb8ceff333b48e8adea2c0803494a48","2536e79ced34450fbb09de73061cf096","6570754a6f0b43b78a9926c7bfd00519","9eeccc4caf594a5abedc0559fd9e0424","52168d859c5c4211b0cf99b6a3e34221","1cfde61efce54a8c9b92dd7b60c30995","2830f7d877eb4edbb02322f5bfd5b20b","0464f5493b0444e9875a0584df17cbf0","07994e875a7f44dc9af7f9bf3f6989e5","a6cd07ecf38e48b584e8da2adfbe5f42","ab7c198e47834770a36ab3282d331531"],"non_research_disease":["33679852d82540b6b4fa86d88a52dd68","6c9886cb25eb45faba70292cee1f5518","01773f22c03f4beda403b65654c1698d","5c266194199442338a3aa84590758ad8","a311ae2187914c2bbad45810b91f9414","e3bb40386c3840a7841213b5d02fd358","9076279a331c4d3b8a3cdf6ea2360fd6","45de0082f65f48c3b2c9a654543c879f","3428d019f74042c9b04557aaa3f597e2"],"inactive_org_master_entity_id":["01292cc59a89d30c91774dbe1e058dbd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1727308800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1656374400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1739836800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1661472000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1738195200000}}],"disease_phase":[{"disease_id":"2830f7d877eb4edbb02322f5bfd5b20b","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b5906197018e47b1a34e2fcf9ea60c3a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"52168d859c5c4211b0cf99b6a3e34221","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"63333c316c3b493487303520d1e0c9d8","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ed204c2d1b6245098bb07da9c6b00eb5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"01773f22c03f4beda403b65654c1698d","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"881cc9ec9e4f4b80afcb49a2e3cf2c98","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a4256d84f83747e89045f0133c1133f1","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"342b1d03069b47ce8075d9930a4b24af","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"dd16b20c0ed446fc8f3fa4791f8aca8a","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"02450a108c4c4bf0adc12f67b0f50e0e","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e5090e6e73c349b9a671c67b6e0ef6e3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"49deb7ff8f2e4803b51f1145e4de982c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f04e110974bf45b58dd4d2eabcd2c6c1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"80517ada10994b33a79d98e7dddd945f","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6a582c5fe4754be8a043249152504710","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"978b2e0e83614e3f80e9003905b63c98","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"33679852d82540b6b4fa86d88a52dd68","highest_phase_cn":"c9e8fce7eb6b4bbd9cc66dc356017aab","highest_phase_global":"c9e8fce7eb6b4bbd9cc66dc356017aab"},{"disease_id":"e3bb40386c3840a7841213b5d02fd358","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"43a01c3d180b45438f911c6502567931","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a75eb84c45444938809d1088852efb20","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f3ab7c215d5e4904a6c9859f3e15259d","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"885a88527cdd45989941da6165ccd00a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a6cd07ecf38e48b584e8da2adfbe5f42","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6c9886cb25eb45faba70292cee1f5518","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e3a912febc6543bbad7ce969c809b488","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"14143fc9923b41d9950a59ed79f7731a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"45de0082f65f48c3b2c9a654543c879f","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6ca2db7d9e044c74a20da7017fa416e6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"08a4e8d8a1ed476fa456191e4b5fdefc","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f58920e650344564b5dc93712863af81","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3428d019f74042c9b04557aaa3f597e2","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"be26bd5a3626417eabc7fde7a7b8b3d9","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"9eeccc4caf594a5abedc0559fd9e0424","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"41311a72b91b4e2290ffc61d00ad1f5b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8eaa9c59b7674ad692d8fbc5c68e845c","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a12064e327a946618fc52338c4dffa03","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bcd25eb2059e443cb7bf20445cbf413c","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"703dd75ecc8740df908141aa5252ff4c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"b98763c97526476fb442d16344cb5e59","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1cfde61efce54a8c9b92dd7b60c30995","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"5c266194199442338a3aa84590758ad8","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"513741b459a8450fabc9616c87599e5f","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6b80eb2530e64952b99d1b50407fab55","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2d94f94415454317a68f499ad53332db","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9076279a331c4d3b8a3cdf6ea2360fd6","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"28935c60ded04150bbdd16876cc0082e","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["0aa9cefa0ae80a9392f54f89d10c4ed0","391046f8744a1cde275e09de08b483f3","620b11f9e3b99c64efa8c7ca677c675f","9597e75ba30c9958d4331f586407d7cf"],"if_speculate":0,"data_source":10}
+{"drug_id":"08182e66bc894c608b255dd6468804fd","docid":43615,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-04-30T00:31:15.000Z","updated_ts":"2024-11-07T20:18:24.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"K11(Jiangsu Kanghe Biopharmaceutical)","source_info":[{"code":"CXSL2200186","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"K11","source_info":[{"code":"CXSL2200186","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["77a3a0aaf12e68feb369ddc15af1bf70"],"disease_id":["fd0b1bf93fef45d49eeda147cf253e58"],"active_org_master_entity_id":["77a3a0aaf12e68feb369ddc15af1bf70"],"research_disease":["fd0b1bf93fef45d49eeda147cf253e58"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1666656000000}}],"disease_phase":[{"disease_id":"fd0b1bf93fef45d49eeda147cf253e58","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"073dfda3d38044b6ab08a94a9fe1b39c","docid":35503,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":33,"target_extend_id":"5bd5eff4d5e33dc89b4e0a04a74704a9","created_ts":"2021-10-08T14:47:37.000Z","updated_ts":"2025-08-07T10:27:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"chenghongyan@patsnap.com","drug_name":[{"lang":"CN","name":"氟诺哌齐","source_info":[{"normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR"}],"status":"ACTIVE"},{"lang":"EN","name":"Fluoropezil","status":"ACTIVE"}],"dev_code":[{"name":"Compound 12","source_info":[{"code":"10.1021/acs.jmedchem.0c01863","normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"http://dx.doi.org/10.1021/acs.jmedchem.0c01863"}],"status":"ACTIVE"},{"name":"DC-20","status":"ACTIVE"},{"name":"DC-511020","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d342973db4d0e95b911aef9c21a98019"],"mechanism_action_id":["7b7fdc4654689c0fa4c2df36e76ff29d"],"target_id":["1d48042ba16f41e0b7f9071da5ce8a80"],"special_review":["9eb8777c62af4712932b360e6ef3e454"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0"],"active_org_master_entity_id":["d342973db4d0e95b911aef9c21a98019","9ec40f66a22f730d6499e825bf360ce5"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1635206400000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"06f0e883b85e49d4956341e8ebf35cdd","docid":1701108,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-09-24T03:41:54.000Z","updated_ts":"2025-09-24T05:46:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"SPOT-mRNA03","source_info":[{"code":"NCT07188012","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07188012"}],"status":"ACTIVE"}],"dev_code":[{"name":"SPOT-mRNA03","source_info":[{"code":"NCT07188012","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07188012"}],"status":"ACTIVE"}],"drug_type":["07c615d6d6644a87ba74fb48dd7eefe8","72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["a9b14d6da57e74a18916fb3ad40126f2"],"disease_id":["3edeea348eb24d8d8fbf0cccd058f464"],"active_org_master_entity_id":["a9b14d6da57e74a18916fb3ad40126f2"],"research_disease":["3edeea348eb24d8d8fbf0cccd058f464"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1754438400000}}],"disease_phase":[{"disease_id":"3edeea348eb24d8d8fbf0cccd058f464","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0edec8cf7d2c4369b8d630f52aab6fe9","docid":73284,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":8,"target_extend_id":"1975335096ae324e8e2cea86260b643f","created_ts":"2023-03-09T08:20:56.000Z","updated_ts":"2025-08-02T21:08:29.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CS1-targeted CAR-T Cells Therapy(Yake Biotechnology)","source_info":[{"code":"NCT04541368","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04541368"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["0e2f3932c7faa5d3cd46093ca4ea466e"],"target_id":["42aba04926b84a9e8b992de07fa00083"],"disease_id":["e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["90163e2d1d85519e993176af80281cd8","65adf3c1dca5ffe3f67583f2a393cb1d"],"research_disease":["e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1609372800000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"139c9a11f6124e8fa49f2a26622b44d3","docid":78673,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":4,"target_extend_id":"f30c53256a0a34f88b71a32d50c7509c","created_ts":"2021-12-19T11:57:15.000Z","updated_ts":"2025-12-01T00:29:32.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Arpraziquantel","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["105226e3d0f5d62025615a46608adc78"],"mechanism_action_id":["78f7a6c71a027fe6a1a2817e7219bde1"],"target_id":["e0a56a8ef39843d0a60bbd73689df060"],"disease_id":["cb32e6eddeff4592a469c5f090041fc5"],"active_org_master_entity_id":["01bc55394f6057f5efc5052c4a504cae"],"research_disease":["cb32e6eddeff4592a469c5f090041fc5"],"inactive_org_master_entity_id":["105226e3d0f5d62025615a46608adc78"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1702512000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"cb32e6eddeff4592a469c5f090041fc5","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"22f92ec23c85449ab386384b7afbe102","docid":7862,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","express_system":"8ac6bc4127ad4b47aa436a9b497007dc","wiki_link":"https://en.wikipedia.org/wiki/Ixekizumab","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1458604800000,"rnk":1,"target_extend_id":"6b8ac8f9502b31a6b8d1b591abe4a174","has_leading_org_involved":1,"created_ts":"2021-10-08T14:50:37.000Z","updated_ts":"2026-04-02T17:09:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1567036800000,"drug_name":[{"lang":"CN","name":"依奇珠单抗","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Ixekizumab","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"イキセキズマブ（遺伝子組換え）","source_info":[{"code":"22800AMX00439","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ixekizumab (Genetical Recombination)","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Ixekizumab (USAN)","source_info":[{"code":"D10071","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Ixekizumab (genetical recombination) (JAN)","source_info":[{"code":"D10071","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"CN","name":"伊克珠单抗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzE5ODY3OTQ2NQ==&mid=2247484611&idx=1&sn=18e05d684ffab8b100770e5825bbdb04"}],"status":"ACTIVE"}],"dev_code":[{"name":"LY-2439821","status":"ACTIVE"},{"name":"LY2439821","source_info":[{"code":"22800AMX00439","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530471_3999442G1023_1_13"}],"status":"ACTIVE"}],"trade_name":[{"name":"Taltz","source_info":[{"code":"22800AMX00440","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530471_3999442G1023_1_13"},{"code":"D10071","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"トルツ","source_info":[{"code":"22800AMX00440","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530471_3999442G1023_1_13"}],"status":"ACTIVE"},{"name":"拓咨","status":"ACTIVE"}],"generic_name":[{"name":"ixekizumab","source_info":[{"code":"EMEA/H/C/003943","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/taltz"}],"status":"ACTIVE"}],"drugbank_id":["DB11569"],"kegg_id":["D10071"],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"mechanism_action_id":["529b9d60826a4c1a5765e42277efc255"],"target_id":["9b99b0dfb49c480fae5688010b373f83"],"atc_code":["d5ba0d6769834217b130031e562c4adf"],"special_review":["cf246d061d3f4483a6479f9df8faadda","23d3523b7ece48ddacaddac53a66949d"],"disease_id":["e0ed29cc1f4c498db05debcce66dff32","457dfa175b3149deb0e8a7867f3e8a7e","be685463e8e640119dff51e5125e6d0f","e97fd2618ec34b9b965b2ac71a0ee4b5","fdf7ffeee71b4fa0ac6cd310814f49de","8da973b225c24afbba255413635fb240","132a9473337744789e044d73da056bdc","4712857948a346d3afcae1e72a543e4c","973559487cc743bf8e735686bcabcd06","d281a3b362a740d8aeb63e2a10102671","e6ee5660ea1d44ad8edb142046da866f","86a692ed17664c8484a305f068064433","05ee0bc5347a4677a95179fcdcc2b814","a4553a07d41b47b3aa96442a0f718303","58990176df4a403dbb08cd95e75642bd","25aa9dbd25714b36b8bcb9347d1b91d1","16c3709f543e463bb78c9941505657bb","d8be5ce6db9e4d0ea6947af096ce7a0a","46637a05e293490f87d679075231c69f","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["92e48305f1ec7b1f99fedc3f27506002","2f55b324e0e20f9411ed3667550d0ba7","1e584c48b6d373978b680f4cb27480d8","49e2a14a99f82a1ccbb315edf2910349"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["d281a3b362a740d8aeb63e2a10102671"],"research_disease":["e0ed29cc1f4c498db05debcce66dff32","457dfa175b3149deb0e8a7867f3e8a7e","be685463e8e640119dff51e5125e6d0f","e97fd2618ec34b9b965b2ac71a0ee4b5","fdf7ffeee71b4fa0ac6cd310814f49de","8da973b225c24afbba255413635fb240","132a9473337744789e044d73da056bdc","4712857948a346d3afcae1e72a543e4c","973559487cc743bf8e735686bcabcd06","d281a3b362a740d8aeb63e2a10102671","e6ee5660ea1d44ad8edb142046da866f","86a692ed17664c8484a305f068064433","05ee0bc5347a4677a95179fcdcc2b814"],"non_research_disease":["a4553a07d41b47b3aa96442a0f718303","58990176df4a403dbb08cd95e75642bd","25aa9dbd25714b36b8bcb9347d1b91d1","16c3709f543e463bb78c9941505657bb","d8be5ce6db9e4d0ea6947af096ce7a0a","46637a05e293490f87d679075231c69f","6be96778ed424f8d91de00ab82364114"],"inactive_org_master_entity_id":["ebd6fc200cd45911508e5b48cbd91bbf"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07","666d5a51-60da-3482-b804-e6df04651a1e","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1590710400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1566518400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1512086400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1458604800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1658793600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1567036800000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1461542400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1600992000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1574380800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1467590400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1470873600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1464134400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1473120000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1481500800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1461542400000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1461542400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1461542400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1404172800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1404172800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1404172800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1618272000000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1410825600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1410825600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623888000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1582243200000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1626825600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1685145600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1620259200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1626825600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1626825600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1685145600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1619913600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1685145600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1620259200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1564790400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1626825600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623888000000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1569888000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1582243200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1685145600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1624579200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1564790400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1401580800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1603929600000}}],"disease_phase":[{"disease_id":"e6ee5660ea1d44ad8edb142046da866f","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"973559487cc743bf8e735686bcabcd06","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"46637a05e293490f87d679075231c69f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e97fd2618ec34b9b965b2ac71a0ee4b5","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"132a9473337744789e044d73da056bdc","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"a4553a07d41b47b3aa96442a0f718303","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"457dfa175b3149deb0e8a7867f3e8a7e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d8be5ce6db9e4d0ea6947af096ce7a0a","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4712857948a346d3afcae1e72a543e4c","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"86a692ed17664c8484a305f068064433","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"16c3709f543e463bb78c9941505657bb","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e0ed29cc1f4c498db05debcce66dff32","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"58990176df4a403dbb08cd95e75642bd","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"fdf7ffeee71b4fa0ac6cd310814f49de","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["2f55b324e0e20f9411ed3667550d0ba7","50ff7868c8c9eca3d4f65b181248342a"],"data_source":10}
+{"drug_id":"013dbb5f949247fb9afd746140fea22a","docid":19082,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1539648000000,"created_ts":"2022-08-03T08:55:34.000Z","updated_ts":"2024-11-11T06:26:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1539648000000,"drug_name":[{"lang":"CN","name":"通络祛痛膏","status":"ACTIVE"},{"lang":"EN","name":"Tongluo Qutong Plaster","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["050d0b9ff6396f0a49b09941daa16c63"],"disease_id":["42cdcbb9aab84d888f2aa90462019c78","9dd61ae9b03f45768b207cb7abd3865c","fd0b1bf93fef45d49eeda147cf253e58","b1decfa93b81467798db506de596f787"],"active_org_master_entity_id":["050d0b9ff6396f0a49b09941daa16c63"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["42cdcbb9aab84d888f2aa90462019c78"],"research_disease":["42cdcbb9aab84d888f2aa90462019c78","9dd61ae9b03f45768b207cb7abd3865c","fd0b1bf93fef45d49eeda147cf253e58","b1decfa93b81467798db506de596f787"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1539648000000}}],"disease_phase":[{"disease_id":"b1decfa93b81467798db506de596f787","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"42cdcbb9aab84d888f2aa90462019c78","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"fd0b1bf93fef45d49eeda147cf253e58","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9dd61ae9b03f45768b207cb7abd3865c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"19a7faf5fcfd4ef1839fc62245cbda03","docid":230510,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-05-07T06:55:13.000Z","updated_ts":"2025-07-08T07:18:15.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"HUFF-01","status":"ACTIVE"}],"dev_code":[{"name":"HUFF-01","status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["1111ddde4daa82188d4e624470474d51","1822f838ba95f7cfae8c72c117f771c9"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["07e16848760b4be0a3ef260a64786fb9"],"active_org_master_entity_id":["fc512b9e9809631d7464c0707583e636","1111ddde4daa82188d4e624470474d51"],"research_disease":["07e16848760b4be0a3ef260a64786fb9"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701388800000}}],"disease_phase":[{"disease_id":"07e16848760b4be0a3ef260a64786fb9","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"010a10cb06ee4017ad9f28ac3467e44a","docid":2144,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":4,"target_extend_id":"6f15477640fd3afeb2ccbbd9998d37d7","created_ts":"2023-04-06T01:35:15.000Z","updated_ts":"2026-02-26T00:17:18.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"CN","name":"C1酯酶抑制剂（华润博雅）","status":"ACTIVE"},{"lang":"EN","name":"C1 Esterase Inhibitor (China Resources Boya)","source_info":[{"code":"CXSL2300226","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drugbank_id":["DB09228"],"drug_type":["3ee397048adc48468d2786207424940a"],"originator_org_master_entity_id":["55ce2ec7321fa3c325832c067a877c5b"],"mechanism_action_id":["2bf8bd7a028145008dc38ba453d2367e"],"target_id":["0731da1ac37746da8f17653905a1d287"],"atc_code":["4ed1797f7ecc49f091073dd4b2d01d76"],"disease_id":["6e0b19fb626347a18144a6f986035dfc"],"active_org_master_entity_id":["55ce2ec7321fa3c325832c067a877c5b"],"research_disease":["6e0b19fb626347a18144a6f986035dfc"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708387200000}}],"disease_phase":[{"disease_id":"6e0b19fb626347a18144a6f986035dfc","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"11c3480ecffd4e5e9c209e55bba0adda","docid":20865,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:27.000Z","updated_ts":"2025-08-23T00:21:41.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CBR-T01","status":"ACTIVE"}],"dev_code":[{"name":"CBR-T01","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["095fbb6c80533c5daf4650461f0c133d"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["095fbb6c80533c5daf4650461f0c133d"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"06c7e4e71c3b4d668aff1cffa88045a8","docid":114120,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-07-05T05:35:56.000Z","updated_ts":"2024-12-27T00:25:12.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CIGB-470","source_info":[{"attachment_path":"data/phs_source_info/c3d6/09eb/7c72/b3e2/8cb636ba-08ae-3bc1-947f-c2c07fa4722b.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/97a4/4e37/cdd1/da1e/efbfe22e-0387-3739-a03f-f5f4112c1560.png","source":"Company pipeline","source_url":"https://www.cigb.edu.cu/en/project_category/bioph_project/"}],"status":"ACTIVE"}],"dev_code":[{"name":"CIGB 470","source_info":[{"attachment_path":"data/phs_source_info/c3d6/09eb/7c72/b3e2/8cb636ba-08ae-3bc1-947f-c2c07fa4722b.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/97a4/4e37/cdd1/da1e/efbfe22e-0387-3739-a03f-f5f4112c1560.png","source":"Company pipeline","source_url":"https://www.cigb.edu.cu/en/project_category/bioph_project/"}],"status":"ACTIVE"},{"name":"CIGB470","source_info":[{"attachment_path":"data/phs_source_info/c3d6/09eb/7c72/b3e2/8cb636ba-08ae-3bc1-947f-c2c07fa4722b.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/97a4/4e37/cdd1/da1e/efbfe22e-0387-3739-a03f-f5f4112c1560.png","source":"Company pipeline","source_url":"https://www.cigb.edu.cu/en/project_category/bioph_project/"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["53d8701ec1ea28ff82e9ca940f6a559f"],"disease_id":["94437cab300944a58b3ea8134dea1482"],"active_org_master_entity_id":["53d8701ec1ea28ff82e9ca940f6a559f"],"research_disease":["94437cab300944a58b3ea8134dea1482"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011"],"disease_phase":[{"disease_id":"94437cab300944a58b3ea8134dea1482","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"07f0b04f55ab3af803a65e330875aa2b","docid":231207,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":48,"target_extend_id":"674a5e6e2f5137068c2bea8936b7de89","created_ts":"2024-06-04T07:49:12.000Z","updated_ts":"2026-03-14T21:08:28.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"XYF-13","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["5f1ed0f78b0b109b3feb22ca36d80e02"],"mechanism_action_id":["15361c70aabb7a297fffba48611a2600"],"target_id":["5a34b1dfc07d416a8e43cc0d5520fe63"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4"],"active_org_master_entity_id":["5f1ed0f78b0b109b3feb22ca36d80e02"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1683158400000}}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0940f8068ef54d379df13d60bec1df5d","docid":204833,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-11-18T06:03:23.000Z","updated_ts":"2025-09-23T22:04:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Allogeneic Engineered Gingival Fibroblasts(Scarcell Therapeutics S.A.S)","source_info":[{"code":"NCT06690710","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06690710"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AeGF(Scarcell Therapeutics S.A.S)","source_info":[{"code":"NCT06690710","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06690710"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["0763e705167c0b2d5fcb1705b67d22e0"],"disease_id":["fd0b1bf93fef45d49eeda147cf253e58"],"active_org_master_entity_id":["0763e705167c0b2d5fcb1705b67d22e0"],"research_disease":["fd0b1bf93fef45d49eeda147cf253e58"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1755129600000}}],"disease_phase":[{"disease_id":"fd0b1bf93fef45d49eeda147cf253e58","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"5163ef2625804b1db1b7eb1157cca3cb","docid":230576,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":47,"target_extend_id":"f248208975d53d2da02467f40933af4d","created_ts":"2024-05-07T10:11:19.000Z","updated_ts":"2026-04-02T23:40:42.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"GIP[3-30]NH2(Gentofte Hospital)","status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6"],"originator_org_master_entity_id":["4c82484bbfc8d4ef52bb35ccdf88b09c"],"mechanism_action_id":["4d933c3e82f4628e2c584d9a0b3c28ed"],"target_id":["a87e2f1913564a9aa418d6a6a8e1a799"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["4c82484bbfc8d4ef52bb35ccdf88b09c"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1683158400000}}],"disease_phase":[{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0b7ff617dcbe46ceaf08036a332da872","docid":69795,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":107,"target_extend_id":"c1ac453247713a2aad9d306341865992","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:07.000Z","updated_ts":"2026-04-11T21:06:26.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"TBI-1501","source_info":[{"code":"NCT03155191","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03155191"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD19-CAR T cell therapy","status":"ACTIVE"},{"lang":"EN","name":"CD19-CAR gene therapy","status":"ACTIVE"},{"lang":"EN","name":"Cd19 Car Gene Transduced T Lymphocytes","status":"ACTIVE"},{"lang":"EN","name":"Cd19 Chimeric Antigen Receptor T Cell Therapy","status":"ACTIVE"}],"dev_code":[{"name":"TBI-1501","source_info":[{"code":"NCT03155191","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03155191"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-cd19-car-t-cells-tbi-1501"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["03331447b889f27b7f1e40752a1e591d"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["40837198f02e4e118f8abcccc1939d01","321c439bbe614dc2afd13cb803a48cec"],"active_org_master_entity_id":["03331447b889f27b7f1e40752a1e591d"],"research_disease":["40837198f02e4e118f8abcccc1939d01","321c439bbe614dc2afd13cb803a48cec"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1496275200000}}],"disease_phase":[{"disease_id":"40837198f02e4e118f8abcccc1939d01","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"321c439bbe614dc2afd13cb803a48cec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["03331447b889f27b7f1e40752a1e591d","e04fbf3cf0a0af2bc6856c70d527f8b7"],"if_speculate":0,"data_source":10}
+{"drug_id":"1a48afbf566b422f969be624a494d844","docid":1970515,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":17,"target_extend_id":"5dda89db055132f9b4718ad9d5af409b","created_ts":"2026-03-26T10:33:13.000Z","updated_ts":"2026-04-04T21:11:19.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"GDC-0325","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzE5MTUwNTMwNQ==&mid=2247485388&idx=1&sn=d3cae01e57d865920ac68d195f4592b1"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["87bfaf037f8e60c9e25595cd98bb27e4"],"mechanism_action_id":["c8b903a2d2144c45ad7bfe99e265ed53"],"target_id":["fe5b12ba299a474b979d6ab1ddca7b4b"],"disease_id":["f319fa27684c4cdeb6ce59d897217718"],"active_org_master_entity_id":["87bfaf037f8e60c9e25595cd98bb27e4"],"research_disease":["f319fa27684c4cdeb6ce59d897217718"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"07d7fe77cccd4301acb921f54f6309e5","docid":204417,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":99,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2024-10-10T07:30:14.000Z","updated_ts":"2026-04-11T21:09:44.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-CD19 CAR-NK Cell(Shahid Beheshti University of Medical Sciences)","source_info":[{"code":"NCT06631040","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06631040"}],"status":"ACTIVE"}],"drug_type":["8554bd286df144c39af9350c62a5b309"],"originator_org_master_entity_id":["34e2967910c7bd53dd4ec8cf793b8711"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["656409aff7e24ff1b5f87526a2b6a70b","40837198f02e4e118f8abcccc1939d01","c45e529e87834fd582bfd557c409028d"],"active_org_master_entity_id":["34e2967910c7bd53dd4ec8cf793b8711"],"research_disease":["656409aff7e24ff1b5f87526a2b6a70b","40837198f02e4e118f8abcccc1939d01","c45e529e87834fd582bfd557c409028d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"ab1a98cb-d362-3a11-9e63-99cb01cc9474","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1734566400000}}],"disease_phase":[{"disease_id":"656409aff7e24ff1b5f87526a2b6a70b","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c45e529e87834fd582bfd557c409028d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"40837198f02e4e118f8abcccc1939d01","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1a849997635c48cfb1bb9216baff8e16","docid":83835,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-02-06T05:24:57.000Z","updated_ts":"2024-12-27T00:24:20.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BM-MSC derived sEVs(Mahidol University)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bone Marrow Mesenchymal Stem Cell-derived Small Extracellular Vesicles","status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["a9df84aa2532149a1f2fa8cc983bcdf4"],"disease_id":["2ef2f7065d1e476d839aaa6ce50d522d"],"active_org_master_entity_id":["a9df84aa2532149a1f2fa8cc983bcdf4"],"research_disease":["2ef2f7065d1e476d839aaa6ce50d522d"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1716422400000}}],"disease_phase":[{"disease_id":"2ef2f7065d1e476d839aaa6ce50d522d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"5187be9b2e24495f97506b140d4fd8b4","docid":1762298,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":37,"target_extend_id":"73560325274c3e7598fc5e95df064372","created_ts":"2025-11-26T05:09:25.000Z","updated_ts":"2026-03-28T21:05:56.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"CAR19-BCMA dual-target CAR-T(Hebei Taihe Chunyu Biotechnology)","source_info":[{"code":"NCT07249073","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07249073"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["49e7b893d0d72dac631f99b43429298a"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1","a663e30a2dcb766c1583e40cad7adc51"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5"],"active_org_master_entity_id":["49e7b893d0d72dac631f99b43429298a"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1743120000000}}],"disease_phase":[{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0621ff4a11a04f059e1f4b2bd4601b9c","docid":20694,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"f4e07ec950ee3afa82871f6053a5b6d8","created_ts":"2022-03-08T02:33:02.000Z","updated_ts":"2026-02-25T00:30:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Dronabinol/Melatonin","source_info":[{"code":"NCT05543681","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05543681"}],"status":"ACTIVE"}],"dev_code":[{"name":"IGC-AD1","source_info":[{"code":"NCT05543681","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05543681"}],"status":"ACTIVE"}],"related_component":["9dad15a4d02947c7a8fce4cfe5c0f702","bd0f04bb2db94d3fa6c59b1c6420a2e7"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4831e3d22136181ccfa891f4809ae8d9"],"mechanism_action_id":["0af619b4abb8105104205c4f4a8903a2","05645323a9bf5bf9dd1ffc686a9174b6"],"target_id":["903c058b322b44e19a997d9a6f9d030e","a6f15dba58a14fe8bd5f36e7c19710f9"],"disease_id":["9186f148a8834786aa95cea9714a0485","1fb1007707194419aa148dc740093c43","54a77f56d72c4ac6a0eb840f4518e3a0","2318b1b1344f4b36bbaa13a182856894"],"active_org_master_entity_id":["4831e3d22136181ccfa891f4809ae8d9"],"research_disease":["9186f148a8834786aa95cea9714a0485","1fb1007707194419aa148dc740093c43","54a77f56d72c4ac6a0eb840f4518e3a0","2318b1b1344f4b36bbaa13a182856894"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1665446400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1665446400000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1665446400000}}],"disease_phase":[{"disease_id":"9186f148a8834786aa95cea9714a0485","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2318b1b1344f4b36bbaa13a182856894","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1fb1007707194419aa148dc740093c43","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0288e92c14a9410990f6152312bb4bcc","docid":6110,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":48,"target_extend_id":"3976064457533bbaa8b1f0900b5da8f2","created_ts":"2021-10-08T14:45:43.000Z","updated_ts":"2026-04-18T21:07:01.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"重组人血小板源生长因子（北京金赛狮）","source_info":[{"code":"CTR20132176","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=618bef753c2841df89d2af86d65aa504_p"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant human platelet-derived growth factor(Beijing Jinsaishi Biopharmaceutical Technology Development Co Ltd)","status":"ACTIVE"}],"drug_type":["c5ab6f92102a4f99a1f8fdc6e24a7f66"],"originator_org_master_entity_id":["2d44b6d67bad4dcf8de4c6c6083f71c1"],"mechanism_action_id":["be847c97b359b1fd38675267aade54fb"],"target_id":["d3bd755037c44527a3b94c7179cc69b3"],"disease_id":["0c824cd0c49b452c9a0186d3e58e4861"],"active_org_master_entity_id":["1303e7e203d6cccc8f5b09664d4eafe2"],"research_disease":["0c824cd0c49b452c9a0186d3e58e4861"],"inactive_org_master_entity_id":["2d44b6d67bad4dcf8de4c6c6083f71c1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1372291200000}}],"disease_phase":[{"disease_id":"0c824cd0c49b452c9a0186d3e58e4861","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"1954f5f878ef493497a6e3a7925ab7a3","docid":10928,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:23.000Z","updated_ts":"2024-11-01T10:57:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PolyPEPI 821","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["99e1d31aebf256ac9434c7ed7bbfccfc"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["e2fd9bda4aeb4a7b9fa53a2560126d24"],"active_org_master_entity_id":["99e1d31aebf256ac9434c7ed7bbfccfc"],"research_disease":["e2fd9bda4aeb4a7b9fa53a2560126d24"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1648252800000}}],"disease_phase":[{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0c5112a6a1684f9e9f7c11994ed161f2","docid":53249,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"bfcd2b99030a39f3af5677fd40d819b3","created_ts":"2021-10-08T14:49:14.000Z","updated_ts":"2026-04-02T13:07:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"厄贝沙坦/丙帕诺","status":"ACTIVE"},{"lang":"EN","name":"Repagermanium","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Irbesartan/Propagermanium","status":"ACTIVE"},{"lang":"EN","name":"Propagermanium/irbesartan","status":"ACTIVE"}],"dev_code":[{"name":"DMX-200","status":"ACTIVE"}],"related_component":["1b854ab3eaa24b219602e6910b682eb6","b91b54d834214133a97ee1c295ea7212"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f481122fa792f4c9cec8bda5806926a0"],"mechanism_action_id":["a56208e0f7c40aa5e367dd1131768136","035c264c5a880c9e0b651297c0a73329"],"target_id":["6d5027eeb15440ed9b14919e51dad4bd","8156cd8b42c3436daecea09a34a2b9ff"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["4b8d712e73b14a1783910b5ec395d820"],"active_org_master_entity_id":["f481122fa792f4c9cec8bda5806926a0"],"research_disease":["4b8d712e73b14a1783910b5ec395d820"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1653868800000}}],"disease_phase":[{"disease_id":"4b8d712e73b14a1783910b5ec395d820","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["0e9a644af010a5ddea4f6173cb9fa286","5d9b2a1dfeb768a9da42de0beabc37e3","61b144ee62b493adaa60a24d799ed4d3","ddc996956089a28d96f41656eda00cc4","f481122fa792f4c9cec8bda5806926a0","f6bde0ce3b71dc588cff8ea791654379"],"if_speculate":0,"data_source":10}
+{"drug_id":"083d55c731e74f35ab6e0dc8f2558682","docid":48170,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":37,"target_extend_id":"46631cde0308360d97b73e60682d1b3c","created_ts":"2022-03-01T09:29:08.000Z","updated_ts":"2026-04-19T00:30:10.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LB1902","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/1rK3UAZOYBfUzS-hz4F0jQ"}],"status":"ACTIVE"}],"dev_code":[{"name":"LB 1902","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/1rK3UAZOYBfUzS-hz4F0jQ"}],"status":"ACTIVE"},{"name":"LB-1902","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/1rK3UAZOYBfUzS-hz4F0jQ"}],"status":"ACTIVE"},{"name":"LB1902","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/1rK3UAZOYBfUzS-hz4F0jQ"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["a22fd154855c015ed283545df379f0de"],"mechanism_action_id":["09e6ad36914fc8a3c0175fa9576b9388"],"target_id":["3305619b6ea741a19aa4a690d083582b"],"disease_id":["c297238c41b2488abe3de6546b105a4e"],"active_org_master_entity_id":["a22fd154855c015ed283545df379f0de"],"research_disease":["c297238c41b2488abe3de6546b105a4e"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"1c48a73c5f9947b4a404ed7e300dd6f6","docid":46039,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Cycloserine","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":-173836800000,"rnk":1,"target_extend_id":"c1cc7e00fefd3764bb66d2547161fff6","has_leading_org_involved":1,"created_ts":"2021-10-08T14:45:13.000Z","updated_ts":"2026-03-10T22:27:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"环丝氨酸","source_info":[{"code":"国药准字H20130063","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Cycloserine","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"サイクロセリン","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"(+)-4-amino-3-isoxazolidinone","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"(+)-cycloserine","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Cycloserine (JP17/USP/INN)","source_info":[{"code":"D00877","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Cycloserine-D","status":"ACTIVE"},{"lang":"EN","name":"D-(+)-cycloserine","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"D-4-amino-3-isoxazolidinone","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"D-4-amino-3-isoxazolidone","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"D-Cycloserine","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"DCS","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Orientomycin","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"alpha-Cycloserine","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"cyclo-D-Serine","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"α-Cycloserine","source_info":[{"code":"DB00260","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-154851","status":"ACTIVE"},{"name":"NSC-76029","status":"ACTIVE"},{"name":"SC 49088","status":"ACTIVE"}],"trade_name":[{"name":"SEROMYCIN","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"D00877","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"赛来星","source_info":[{"code":"国药准字H20130063","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9OGFkYzdmMWJhN2UyZDQxZDZhYTJhODdmNDFjYTNjOGImaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm"}],"status":"ACTIVE"}],"generic_name":[{"name":"Cycloserine","source_info":[{"code":"D00877","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00260"],"kegg_id":["D00877"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"mechanism_action_id":["936dfde8bf42af7c5c7ad1aec616aba1","2d239b4742bca5fcb6b490be7ffec74f"],"target_id":["e454190783db4b57aa461fde7cc16f90"],"atc_code":["378904ff3ff64c71afaa099eec181765"],"special_review":["9eb8777c62af4712932b360e6ef3e454"],"disease_id":["764eee63555942f1bb171f1b8c1e71ea","4513c2cff88148daae974cc7b393027f","d0ff88a816794907a59ee3b387696769","ec4d59ce792b465d8e55e7e52840c626","754fa682ba97464c8ce926b3c411c54d","3a464b7a4d574586b14fc513bf6743ed"],"active_org_master_entity_id":["381406b1286c2d4c48882e2637da437d","1f02bc8c77b67e7707198b4af9892b92","2aa3e683bc620f41205c1b9a8a37d616","ffb7c44a2d5b634dc4a46e1d5ff204fd"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["764eee63555942f1bb171f1b8c1e71ea"],"research_disease":["764eee63555942f1bb171f1b8c1e71ea","4513c2cff88148daae974cc7b393027f"],"non_research_disease":["d0ff88a816794907a59ee3b387696769","ec4d59ce792b465d8e55e7e52840c626","754fa682ba97464c8ce926b3c411c54d","3a464b7a4d574586b14fc513bf6743ed"],"inactive_org_master_entity_id":["d199c82c9b6e23d165043f6e0f5b677c"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-173836800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"4513c2cff88148daae974cc7b393027f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3a464b7a4d574586b14fc513bf6743ed","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d0ff88a816794907a59ee3b387696769","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"764eee63555942f1bb171f1b8c1e71ea","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"754fa682ba97464c8ce926b3c411c54d","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["15b6b7fa12277397b00e1369eb2421df","2e9222845de4f74934817a6e7aa07f95","2f55b324e0e20f9411ed3667550d0ba7","517115ac14d9be809e791c8e4a46eeff","56b3eadd7541370097f8e4c85c8ce98c","5957d093ac3c34db424faf5cbc2dcada","7779c450ec6da0e414ef762e1011e1a2","d64d8074e24c5e0c0351e76b96622351","e66b5805e2d123b02346917c7b07685f"],"data_source":10}
+{"drug_id":"17acfee67e1f4f07a852cf08ccc8da15","docid":42224,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"ac14778662b7448588663c26ce84cd9e","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":15,"target_extend_id":"8571ed277f0034fe90555c0079329340","created_ts":"2021-10-08T14:44:23.000Z","updated_ts":"2025-10-26T00:22:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"阿柏西普生物类似药 (迈威生物)","status":"ACTIVE"},{"lang":"EN","name":"Aflibercept biosimilar (Mabwell Bioscience)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Aflibercept Biosimilar (Mabwell (Shanghai) Bioscience Co., Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"阿柏西普生物类似药（Mabwell (Shanghai) Bioscience Co., Ltd.）","status":"ACTIVE"}],"dev_code":[{"name":"9MW-0813","source_info":[{"code":"800068119","normalized_source_id":"259fa6c9b7b44a83842da82f9bec5ee6","source":"DBAD"}],"status":"ACTIVE"},{"name":"9MW0813","status":"ACTIVE"}],"generic_name":[{"name":"Aflibercept","status":"ACTIVE"}],"drug_type":["3dc96d9272ad41a3833fc1e67887cd5b","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["2c66d980fb566d3206c2c01a81b29cb0"],"mechanism_action_id":["0a279e6aea1bbea67b61e7b1d5d68777","6b6c2b10657446ed45e401214272b244"],"target_id":["184e4922d87143aa9340b5e2ee525f92","934f7ab958ca4daf85f5eb42393a0b28"],"atc_code":["c195e470df8347b6a7a6e4585be0e48d","f8109ba43287429d91eed61edddab75f"],"disease_id":["7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"active_org_master_entity_id":["2c66d980fb566d3206c2c01a81b29cb0"],"research_disease":["7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1758240000000}}],"disease_phase":[{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["207a2b37840543c0a1e4321d731b526a"],"deal_related_org":["2c66d980fb566d3206c2c01a81b29cb0"],"data_source":10}
+{"drug_id":"431c152b2f074c9b9825214dfbeda0b6","docid":41794,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-04-03T02:55:26.000Z","updated_ts":"2026-01-27T18:41:06.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Linggui Yangyuan Paste","source_info":[{"code":"NCT05792813","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05792813"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"LGYY","source_info":[{"code":"NCT05792813","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05792813"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["a99cc48730694f2bd757169fc1e1661a"],"disease_id":["c81cb122cf9342bb930e6ab2c47ad773","cfb3da86f8b44136a224af2b21bd8674"],"active_org_master_entity_id":["a99cc48730694f2bd757169fc1e1661a"],"research_disease":["c81cb122cf9342bb930e6ab2c47ad773","cfb3da86f8b44136a224af2b21bd8674"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"c81cb122cf9342bb930e6ab2c47ad773","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"cfb3da86f8b44136a224af2b21bd8674","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"015de55915154d1db66b812294071be2","docid":32662,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"ed0b6e883bed3c1f8e1a632faf0a9f76","created_ts":"2021-10-08T14:50:04.000Z","updated_ts":"2025-04-26T21:08:31.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HLX56","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.henlius.com/upload/202009/28/e101.pdf"}],"status":"ACTIVE"}],"dev_code":[{"name":"HLX 56","status":"ACTIVE"},{"name":"HLX-56","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["ceb797c0888f3c7be8a72493b1266244"],"mechanism_action_id":["d03a2abf0972eeccb0552947630ed5cd"],"target_id":["b837ef717a834ca7bfaca0dfe6e31cfc"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["157a035c0ee41f6aa4f2bc0cbdd1f2fb"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1651363200000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"098cb6f71f2446c194b8aa161b2dcfbc","docid":11971,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":24,"target_extend_id":"20d9fb313a55301f8de038859eb247b2","created_ts":"2022-08-22T08:35:29.000Z","updated_ts":"2026-04-04T21:07:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"PRT-3645","status":"ACTIVE"}],"dev_code":[{"name":"PRT3645","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk4-6-inhibitor-prt3645"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["629b8ef53f0be2a209feb7a6131194e0"],"mechanism_action_id":["35627e4eec1e3431be33b96b6f77dd56","24787486e57de6b1428a1229ed3a7840"],"target_id":["1c9a8e0192c1473cb0155b1d3196ee34","f29254fec6614d4d8396deec87a95f36"],"disease_id":["87a9454771a64f2191224b6b7684254a","05554578204541148a5482ad5df4a600","f8ade5ce0e364264af82a379ab65f6a2","c3b9ec7eb2e2402fae4916a1d3f6504a","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","755abeee587145398fee777a94c27445","6fe05469e09f4305b7615b2c277382cd"],"active_org_master_entity_id":["629b8ef53f0be2a209feb7a6131194e0"],"research_disease":["87a9454771a64f2191224b6b7684254a","05554578204541148a5482ad5df4a600","f8ade5ce0e364264af82a379ab65f6a2","c3b9ec7eb2e2402fae4916a1d3f6504a","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","755abeee587145398fee777a94c27445","6fe05469e09f4305b7615b2c277382cd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1672099200000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1672099200000}}],"disease_phase":[{"disease_id":"755abeee587145398fee777a94c27445","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c3b9ec7eb2e2402fae4916a1d3f6504a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"15eadc456c834d0fa54834b594975054","docid":38023,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":4,"target_extend_id":"57580b1a109d3227bb5d428c25a1ce24","created_ts":"2023-07-07T03:41:06.000Z","updated_ts":"2025-01-25T00:19:29.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NGGT-002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://xueqiu.com/5603603160/250329987"}],"status":"ACTIVE"}],"dev_code":[{"name":"NGGT 002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://xueqiu.com/5603603160/250329987"}],"status":"ACTIVE"},{"name":"NGGT002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://xueqiu.com/5603603160/250329987"},{"attachment_path":"data/phs_source_info/ASGCT/22b0/d251/d471/08e4/ce90c35b-22b0-3251-9471-08e47bdf06a1.pdf","attachment_type":"PDF","code":"2023_650","normalized_source_id":"8c8cf59f78594583bee6b58eea578116","preview_attachment_path":"data/phs_source_info/ASGCT/22b0/d251/d471/08e4/ce90c35b-22b0-3251-9471-08e47bdf06a1.pdf","source":"ASGCT","source_url":"https://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(23)00248-4.pdf"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["131b15f0621d353760d45e1f35c19f7f"],"mechanism_action_id":["65203af93677584539b8d58fb39a20b3"],"target_id":["b6a5fbd0106d476db64d4bb97f4a6a9a"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["1c54a976217a4312bdc9ee687e228899"],"active_org_master_entity_id":["131b15f0621d353760d45e1f35c19f7f"],"research_disease":["1c54a976217a4312bdc9ee687e228899"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1736467200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1720656000000}}],"disease_phase":[{"disease_id":"1c54a976217a4312bdc9ee687e228899","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"13cd0d8d9f3d43aba0a8ebdc82b63a8b","docid":1763587,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-09T10:40:39.000Z","updated_ts":"2026-03-10T01:52:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"PT-MSCs Exosome(Third Affiliated Hospital, Sun Yat-Sen University)","source_info":[{"code":"NCT07409259","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07409259"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PT-MSCs-EVS-2023-1","source_info":[{"code":"NCT07409259","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07409259"}],"status":"ACTIVE"}],"dev_code":[{"name":"PT-MSCs-EVS-2023-1","source_info":[{"code":"NCT07409259","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07409259"}],"status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["3cedb6c4730aa3153d276482ba90b5cc"],"disease_id":["a4b7fd85fb8a41448493daf73128e7d2"],"active_org_master_entity_id":["3cedb6c4730aa3153d276482ba90b5cc"],"research_disease":["a4b7fd85fb8a41448493daf73128e7d2"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1767225600000}}],"disease_phase":[{"disease_id":"a4b7fd85fb8a41448493daf73128e7d2","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2c952962be874e35a3bb63d8bfad21f4","docid":82266,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":34,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2023-11-28T05:47:26.000Z","updated_ts":"2026-04-04T21:06:36.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"司美格鲁肽生物类似药（成都倍特）","status":"ACTIVE"},{"lang":"EN","name":"Semaglutide biosimilar (Brilliant)","source_info":[{"code":"CXSL2300279","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"generic_name":[{"name":"Semaglutide","status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["bd01d7d3c6a5debe1c30acd61315b5ae"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"atc_code":["679079a6331a49aaa6b192c7455e8e0e"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814","74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["bd01d7d3c6a5debe1c30acd61315b5ae"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814","74d974da49ba407195b38595a0aff704"],"inactive_org_master_entity_id":["b9b43b1dbf3c547724cddbac81b65a1c"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1775001600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1756857600000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"original_drug_id":["c7a2671dc0574f19bc42d557eca3906f"],"data_source":10}
+{"drug_id":"00c818fb83f64a0f923b1b1c77faa9f2","docid":49573,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":466300800000,"created_ts":"2021-10-08T14:42:16.000Z","updated_ts":"2024-11-19T08:47:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"双吗啉胺","status":"ACTIVE"},{"lang":"EN","name":"Dimorpholamine","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ジモルホラミン","source_info":[{"code":"21900AMX00055000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/170033_2213400A2034_1_04"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Dimorpholamine (JP17)","source_info":[{"code":"D01607","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"trade_name":[{"name":"Theraptique","source_info":[{"code":"D01607","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"21900AMX00055000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/170033_2213400A2034_1_04"}],"status":"ACTIVE"},{"name":"テラプチク","source_info":[{"code":"21900AMX00055000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/170033_2213400A2034_1_04"}],"status":"ACTIVE"}],"kegg_id":["D01607"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d39a3469967633f68037950c33a4a268"],"atc_code":["1013992959414ed983aa5b090a8d9d58"],"disease_id":["49d65e47669e4213b279d4e3c812fe2d"],"active_org_master_entity_id":["d39a3469967633f68037950c33a4a268"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["49d65e47669e4213b279d4e3c812fe2d"],"research_disease":["49d65e47669e4213b279d4e3c812fe2d"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":466300800000}}],"disease_phase":[{"disease_id":"49d65e47669e4213b279d4e3c812fe2d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0945ad31eb834c4f9ca9a9e6d8128df7","docid":3400,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":22,"target_extend_id":"5717ba854b1c3b938ae226d11cdbf1dd","created_ts":"2021-10-08T14:46:51.000Z","updated_ts":"2026-04-18T21:07:47.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"CKD-702","source_info":[{"code":"2025_1708","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/2513"}],"status":"ACTIVE"}],"dev_code":[{"name":"CKD 702","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-c-met-bispecific-antibody-ckd-702"}],"status":"ACTIVE"},{"name":"CKD702","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-c-met-bispecific-antibody-ckd-702"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["ca28f37b82155ad0f26ac1807aa8c0eb"],"mechanism_action_id":["6189e018b719e5a53aa23d75d8b0e8c4","42a08387c5467c334017c9831c2ed7bd"],"target_id":["c18d6f96c23b4d1e880daafa1b00472b","72bcad51964147ffb8208403eb9c1243"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","28935c60ded04150bbdd16876cc0082e","2bb755a3f43f49dea60661c5f99712a3"],"active_org_master_entity_id":["ca28f37b82155ad0f26ac1807aa8c0eb"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"non_research_disease":["28935c60ded04150bbdd16876cc0082e","2bb755a3f43f49dea60661c5f99712a3"],"inactive_org_master_entity_id":["6ec91cd43a7439cb29a338c6693a35c0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"28935c60ded04150bbdd16876cc0082e","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"02137fdb1ddb401eba0122c6a5acd21f","docid":49574,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-03-08T02:33:10.000Z","updated_ts":"2026-04-20T00:08:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ATB1651","status":"ACTIVE"}],"dev_code":[{"name":"ATB-1651","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["863a4e21efd85fc7533d7ebe5a8f000a"],"mechanism_action_id":["b16637447f22f84eac33286792fb9770"],"disease_id":["5f454bf144f743089439dadde5ae0812"],"active_org_master_entity_id":["863a4e21efd85fc7533d7ebe5a8f000a"],"research_disease":["5f454bf144f743089439dadde5ae0812"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}}],"disease_phase":[{"disease_id":"5f454bf144f743089439dadde5ae0812","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"127e789627554676b17e694c2f98f5d6","docid":63154,"is_nme":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-12-10T12:55:23.000Z","updated_ts":"2026-02-14T00:43:34.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"缺血耐受人同种异体骨髓间充质干细胞(九芝堂美科)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzk0MjIwNzY5OQ==&mid=2247541280&idx=1&sn=47a52f9a63d15371ef6205e3dea4aa72"},{"code":"JXSL1900126","normalized_source_id":"7a5e47bec9d74c3794b46aeb214310c9","source":"CDE IND clearance","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Mesenchymal stem cell therapy (Jiuzhitang Maker Cell Technology)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ithMSC","status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["8671a8bb9e00c65ac1e97f1c403124a9"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["299e91fc2f234bbb9e0156c4f43ad970"],"active_org_master_entity_id":["1ec2969129790299e8c77e5ec4fee288","8671a8bb9e00c65ac1e97f1c403124a9"],"research_disease":["299e91fc2f234bbb9e0156c4f43ad970"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1617667200000}}],"disease_phase":[{"disease_id":"299e91fc2f234bbb9e0156c4f43ad970","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"44c76d23c46d4d3e9d4635b17d375e17","docid":1790157,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-12-02T03:27:29.000Z","updated_ts":"2025-12-05T00:30:41.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Allogeneic umbilical cord blood-derived CAR-T(Chengdu Ucello Therapeutics)","source_info":[{"code":"NCT07256353","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07256353"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["5ad15d6b889ed723624d67226d20757a"],"disease_id":["774c47a9cc904667a74dabe8fa53fc40","c45e529e87834fd582bfd557c409028d"],"active_org_master_entity_id":["5ad15d6b889ed723624d67226d20757a"],"research_disease":["774c47a9cc904667a74dabe8fa53fc40","c45e529e87834fd582bfd557c409028d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1764547200000}}],"disease_phase":[{"disease_id":"c45e529e87834fd582bfd557c409028d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"774c47a9cc904667a74dabe8fa53fc40","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"032886b6a860465c8f465b7bd702dc7a","docid":24717,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1062115200000,"rnk":28,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2021-10-08T14:50:36.000Z","updated_ts":"2024-11-18T07:55:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1062115200000,"drug_name":[{"lang":"CN","name":"重组人胰岛素 (江苏万邦生化医药集团)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant Human Insulin(Jiangsu Wanbang Biopharmaceuticals Co., Ltd.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Recombinant Human Insulin","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"重组人胰岛素（万邦生化）","status":"ACTIVE"}],"trade_name":[{"name":"万邦林R","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"drug_type":["aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["7f41872b6487857c388a8c7cdaf3b244"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"atc_code":["28015fca57a447dcac34b9b0af394ac3","7129a7650f0440aba56be1da495672f0","8354992ea2b3479a84701ad47bba4ef5","c4948bc83ed44adc8bcc3bc417e0a790","c4a25ad1934a4c3b8e129f4b1ca8ba7a"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["7f41872b6487857c388a8c7cdaf3b244"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["0d05187284b446c5803cce38a3e53ebf"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1062115200000}}],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02b14d80f57e47b8888547127168dca2","docid":26898,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","rnk":1,"target_extend_id":"2ad84ee1ff7c3e6b83e65330437ee061","created_ts":"2021-10-08T14:45:02.000Z","updated_ts":"2025-07-31T00:31:20.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"盐酸溴己新/盐酸氯丙那林/磺胺甲噁唑/甲氧苄啶","status":"ACTIVE"},{"lang":"EN","name":"Bromhexine Hydrochloride/Clorprenaline Hydrochloride/Sulfamethoxazole/Trimethoprim","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"磺啶新林","source_info":[{"code":"国药准字H44024379","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9YjI0NDk5ODA3OTk5ZWQ2MTc4Y2Y3NzU4MzQ0ZjI5NTYmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm"}],"status":"ACTIVE"}],"related_component":["3e8abadf294b471493fb3c8ca0dcea08","74bf48c742844128ba9033e8fcae588e","9ae497cb8df44579b101aa691ef22526","ef77522b8d1342d5ada2d77169a2e5f8"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["2e293277398c0886b8b694fdfcc4dc3c","1365bedbd641eb1ab7bb3f3e901c772f","d5c558daba719aadf8062b1bdbac2bd8"],"target_id":["e8adffb2b305438bb04a003813280125","9e740d2ddddc40848befab17d30616e7","32ac24079a8f47b18069eb35a1f9120d"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","8fd7f2b21bff4eacac47e40d6801aa39"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","8fd7f2b21bff4eacac47e40d6801aa39"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8fd7f2b21bff4eacac47e40d6801aa39","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0330f379f5504ea38f84f39bf0ecd659","docid":75648,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1504569600000,"created_ts":"2021-11-19T11:30:57.000Z","updated_ts":"2026-04-02T12:27:21.000Z","data_status":"ACTIVE","created_by":"fangdongbing@patsnap.com","updated_by":"yanglili","first_approved_date_cn":1703808000000,"drug_name":[{"lang":"CN","name":"四盐酸曲恩汀","status":"ACTIVE"},{"lang":"EN","name":"Trientine tetrahydrochloride","source_info":[{"code":"EMEA/H/C/004005","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"TETA 4HCl","status":"ACTIVE"},{"lang":"CN","name":"曲恩汀","source_info":[{"normalized_source_id":"4313dbdea4844940816740b801d08999","source":"DBPC"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-158271","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/215cb877-c3c1-4c38-800b-40236a1aa7a8"}],"status":"ACTIVE"}],"trade_name":[{"name":"Cuprior","source_info":[{"code":"EMEA/H/C/004005","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/cuprior"},{"code":"NDA215760","country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215760"}],"status":"ACTIVE"},{"name":"Cuvrior","source_info":[{"code":"NDA215760","country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215760"}],"status":"ACTIVE"}],"generic_name":[{"name":"trientine","source_info":[{"code":"EMEA/H/C/004005","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/cuprior"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ef0107b85076e19bb2037d6ca5074280"],"mechanism_action_id":["d416ea0194732289c41df12fa9eeb95b"],"atc_code":["8c985056997c4199bae118210b5700ab"],"special_review":["23d3523b7ece48ddacaddac53a66949d","043a131d85994801b3617e822e7f87b3"],"disease_id":["898bae0512be420ca7720a91c9a7dc44"],"active_org_master_entity_id":["ef0107b85076e19bb2037d6ca5074280","cfa377c4996386d907a871ce6d0675d6","4ca14a3b97385a62b9c0c01c84af1726"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["898bae0512be420ca7720a91c9a7dc44"],"research_disease":["898bae0512be420ca7720a91c9a7dc44"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1651104000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1703808000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1504569600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1632787200000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1504569600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1504569600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1504569600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1752537600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1705536000000}}],"disease_phase":[{"disease_id":"898bae0512be420ca7720a91c9a7dc44","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["e2ca1355eaa264a45f0a02378eb67af8","ef0107b85076e19bb2037d6ca5074280"],"data_source":10}
+{"drug_id":"1a603b52d41b4f55b7cefc5d31570a4b","docid":40014,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"4030989df680388dab8a8c247ed9e315","has_leading_org_involved":1,"created_ts":"2023-02-24T08:35:27.000Z","updated_ts":"2026-04-15T06:04:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Mocertatug Rezetecan","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247528023&idx=1&sn=3d53136b08566daf95ac2db1ac790d5c"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Mo-Rez","source_info":[{"normalized_source_id":"de7d6b1f0da64678b8639e596779bc23","source":"Firstwordpharma","source_url":"https://firstwordpharma.com/story/7178926"}],"status":"ACTIVE"}],"dev_code":[{"name":"GSK-5733584","status":"ACTIVE"},{"name":"GSK5733584","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.gsk.com/en-gb/innovation/pipeline/#our-pipeline"},{"code":"2026_4575","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/21436/presentation/8833"}],"status":"ACTIVE"},{"name":"HS 20089","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"HS-20089","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"HS20089","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"generic_name":[{"name":"Mocertatug rezetecan","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247528023&idx=1&sn=3d53136b08566daf95ac2db1ac790d5c"}],"status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["946fa8d72705e08da771676fc3640eb6"],"mechanism_action_id":["c01315be957c8c1777af535043d03f2c","cf1cf8ea0f9b80ee88876a3324ceac99"],"target_id":["68b3fb94145f42f5aa6ed0cf8577aee6","6acffb63799b4ba3bc85a4c59fcb05d7"],"dar":{"avg_value":6.0,"value_type":"AVERAGE"},"adc_reference":[{"code":"2023_381O","normalized_source_id":"67fd8cea1a49410ebdd966dda2755bf6","source":"ESMO","source_url":"https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/lis"}],"special_review":["c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["557f5ccfe746466cbdb9383a94178eef","15efc91d373b41f08cea343f62d56420","3df8dcc0a64942c9a1a193ed8f865ec8","9b60b7d38a4044b3b7f98c61c365e6b9","32b2a7f88bfd47f08d38b864034f7ee1","0280230944dd459981ccb201a4aa173d","e9d6fc1f21704dba80bc8465bbe87d96","0464f5493b0444e9875a0584df17cbf0","3bf6031206e848cd94f767cd1db43ea0","4c092510a2af42f387426e408f5c7694","fd7ba28668d8489eb8c951444259baf4","218de7027c39474b884ca5d174846630","f92e4ba771d04f27a1f4daae363b676a"],"active_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd","946fa8d72705e08da771676fc3640eb6","e940cb22d6d22be4dcb4cf31b7afd944","743b10cd618393c5f5d99c32b172bb99","430f53a5638749b16465abe113254b21"],"research_disease":["557f5ccfe746466cbdb9383a94178eef","15efc91d373b41f08cea343f62d56420","3df8dcc0a64942c9a1a193ed8f865ec8","9b60b7d38a4044b3b7f98c61c365e6b9","32b2a7f88bfd47f08d38b864034f7ee1","0280230944dd459981ccb201a4aa173d","e9d6fc1f21704dba80bc8465bbe87d96","0464f5493b0444e9875a0584df17cbf0","3bf6031206e848cd94f767cd1db43ea0","4c092510a2af42f387426e408f5c7694","fd7ba28668d8489eb8c951444259baf4","218de7027c39474b884ca5d174846630","f92e4ba771d04f27a1f4daae363b676a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1741824000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"528590fc-7857-3275-8e6f-09a951a7544b","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e9d6fc1f21704dba80bc8465bbe87d96","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0280230944dd459981ccb201a4aa173d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"32b2a7f88bfd47f08d38b864034f7ee1","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"fd7ba28668d8489eb8c951444259baf4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"15efc91d373b41f08cea343f62d56420","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3df8dcc0a64942c9a1a193ed8f865ec8","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9b60b7d38a4044b3b7f98c61c365e6b9","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"218de7027c39474b884ca5d174846630","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"4c092510a2af42f387426e408f5c7694","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"557f5ccfe746466cbdb9383a94178eef","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["9b027bb089fcaa2c937327ac652321dd","83f4bc9a8f2bf2eddfa43b2be738775d"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"3af7cb28451d3972b4d5c15d13bf3211","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["c01315be957c8c1777af535043d03f2c"],"moiety_target_id":["68b3fb94145f42f5aa6ed0cf8577aee6"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"18ebb9d77b114a1da5f2499cf1f57dab","docid":1311149,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":6,"target_extend_id":"8cf9ae2579c93aa58183d85c93e0b2fd","created_ts":"2025-05-15T07:48:11.000Z","updated_ts":"2025-11-18T21:08:18.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"UTAA-91","source_info":[{"code":"NCT06970951","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06970951"}],"status":"ACTIVE"}],"drug_type":["82d9b474ba434d6ca4e0a6740a55ac23"],"originator_org_master_entity_id":["59025c915be3ec87ec8b222d0630510e"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a","4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["5eb1fc5283d34305934a031af530f448","9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["dba0a7e65b51408ca401deb8364bce94","51236dbf55d24268aa6d31d9be131f6f","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e"],"active_org_master_entity_id":["59025c915be3ec87ec8b222d0630510e"],"research_disease":["dba0a7e65b51408ca401deb8364bce94","51236dbf55d24268aa6d31d9be131f6f","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","20f1c6915ff140519285386c54883aae","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1747526400000}}],"disease_phase":[{"disease_id":"dba0a7e65b51408ca401deb8364bce94","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"52573fcc151b4d9b9fc29e8ed015efb1","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00c7da476ed74b9d892eddad77f37e51","docid":76109,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:43:41.000Z","updated_ts":"2026-02-25T01:55:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ZEP-3","status":"ACTIVE"}],"dev_code":[{"name":"ZEP 3","status":"ACTIVE"},{"name":"ZEP-3Na","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["e69adafdc94c1bf8102485a3c2510ea1"],"mechanism_action_id":["2690217405168ea07cb08900d6c899f6"],"disease_id":["5931830edf004694b27fec1d915b3784","36e0c025abee4597a1af4c2a7cd79896","7925449988aa4724bf9f75280531860f","d6d2753e6cbb4d7e8d5a68864c145fa4","25aa9dbd25714b36b8bcb9347d1b91d1","0579305aecc7460dbf7d89b923dfef05","b910f946457644f28630580432a34e3f","ca7e2a243e6c415e9a29cce4adfa6f1a"],"active_org_master_entity_id":["e69adafdc94c1bf8102485a3c2510ea1"],"research_disease":["5931830edf004694b27fec1d915b3784","36e0c025abee4597a1af4c2a7cd79896","7925449988aa4724bf9f75280531860f","d6d2753e6cbb4d7e8d5a68864c145fa4","25aa9dbd25714b36b8bcb9347d1b91d1","0579305aecc7460dbf7d89b923dfef05","b910f946457644f28630580432a34e3f"],"non_research_disease":["ca7e2a243e6c415e9a29cce4adfa6f1a"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1577577600000}}],"disease_phase":[{"disease_id":"7925449988aa4724bf9f75280531860f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0579305aecc7460dbf7d89b923dfef05","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"d6d2753e6cbb4d7e8d5a68864c145fa4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b910f946457644f28630580432a34e3f","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"5931830edf004694b27fec1d915b3784","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ca7e2a243e6c415e9a29cce4adfa6f1a","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"0171eb48be5f44999cef6b8206ea4000","docid":24399,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1095206400000,"rnk":8,"target_extend_id":"681e30bccd383d9b81d763585640c2ce","created_ts":"2022-07-07T01:41:23.000Z","updated_ts":"2026-03-28T00:39:47.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"data@patsnap.com","first_approved_date_cn":1095206400000,"drug_name":[{"lang":"CN","name":"醋酸曲普瑞林","source_info":[{"code":"JYHB2200140","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Triptorelin acetate","source_info":[{"code":"JYHB2200140","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"GenSci006","status":"ACTIVE"},{"name":"ISR-048","status":"ACTIVE"},{"name":"NPD 004","status":"ACTIVE"},{"name":"NPD-004","status":"ACTIVE"},{"name":"NPD004","source_info":[{"code":"CTR20233144","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=327bc62813d0489cac3b790d969ed00c"}],"status":"ACTIVE"}],"trade_name":[{"name":"维宝宁","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkxMTM1MDMyMA==&mid=2247537620&idx=1&sn=70826dfed4967c6c7522cbec90c862e6"}],"status":"ACTIVE"},{"name":"达菲林","source_info":[{"code":"CTR20243425","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a747ef23fcb0432cae05e0866b2371c5"}],"status":"ACTIVE"}],"generic_name":[{"name":"Triptorelin","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["ea1e84520ff5ea7ad5a8c63c4a8eb332"],"mechanism_action_id":["ac250ede99d3ba1c7bb75f774cbeee23"],"target_id":["d6899f61d3a24d1fb690d949e08df635"],"disease_id":["deb0d6f9914746da8552c24fbd87b730","11eb845ea5b542f7bb365526e049106f","e50aad3dea474cf487e53bd91d5d7c45","acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["2aa04240f95b96d1acfa6b525ced2189","ea1e84520ff5ea7ad5a8c63c4a8eb332","26122e2667abc943c9540c9e6f16f20e","77402be232d8101fd06a1ee7655b182f","920c7580f076bd97751dec82d2de7e16","30a3245352f9c60eb683d12fe956b90d","eaa64f0153bb73989b72202390a0912c"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["e50aad3dea474cf487e53bd91d5d7c45"],"research_disease":["deb0d6f9914746da8552c24fbd87b730","11eb845ea5b542f7bb365526e049106f","e50aad3dea474cf487e53bd91d5d7c45"],"non_research_disease":["acfaaa0373944ffd89b0a2ace0d8c564"],"inactive_org_master_entity_id":["c485928621f880b5a4e8bbe3b40e79b1"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3","c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","ecc919b1-c2b7-3740-bfa7-7cda77176d07"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1727308800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1683331200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1095206400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1425427200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1610496000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1610496000000}}],"disease_phase":[{"disease_id":"deb0d6f9914746da8552c24fbd87b730","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"11eb845ea5b542f7bb365526e049106f","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["0077f4eda68bbb965699a278c80d8ed6","0915735b2bf289e5c4ffaa4b710ec02c","fa025c3c22a4940599b43079ed6583dc"],"if_speculate":0,"data_source":10}
+{"drug_id":"0413a5077285442aabbfa0efe743d7a6","docid":70273,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-08-11T01:35:18.000Z","updated_ts":"2025-01-23T05:56:00.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"GIM-122","source_info":[{"attachment_path":"data/phs_source_info/2421/37e2/2197/f3cd/4e9452a1-e4a0-3686-9342-f6f460b1c50d.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/21c7/02e7/7a93/e8e0/2e91f931-713f-3284-9509-b8ffbac891a4.png","source":"Company pipeline","source_url":"https://www.georgiamune.com/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"GIM 122","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/monoclonal-antibody-gim-122"}],"status":"ACTIVE"},{"name":"GIM122","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/monoclonal-antibody-gim-122"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["942ab067068a21946b044d21a15fb119"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["942ab067068a21946b044d21a15fb119"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1702339200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"13f20d3c35b34c08921e208b0e8d6a86","docid":51434,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":31,"target_extend_id":"2127d2d1ce6736a8be550cf37f0c1c63","created_ts":"2023-07-14T01:40:09.000Z","updated_ts":"2026-04-13T08:47:45.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"帕博利珠单抗生物类似药(齐鲁制药)","status":"ACTIVE"},{"lang":"EN","name":"Pembrolizumab biosimilar(Qilu Pharmaceutical)","source_info":[{"code":"CXSL2300477","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"QL 2107","status":"ACTIVE"},{"name":"QL-2107","status":"ACTIVE"},{"name":"QL2107","status":"ACTIVE"}],"generic_name":[{"name":"pembrolizumab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["0bb6804a2738b17bb305b0d80ce08460"],"mechanism_action_id":["4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["9786d32e3d244a688ec6a60d2fe1b10b"],"atc_code":["af9331971ca94f5b850fd4a86a5943a9"],"disease_id":["3beea980d93a4cc0abc864e27514601c","8c161437fb424389ab1fde27b93a895b","703dd75ecc8740df908141aa5252ff4c","921aa3f95ab346369296cd1a02422866","2aeafb89d32c44a7a1b107728d9aca3b","8eaa9c59b7674ad692d8fbc5c68e845c","800d2cfb899f4e6983a759d03734503d","0464f5493b0444e9875a0584df17cbf0","6ca2db7d9e044c74a20da7017fa416e6","0b6fc9357c10436293f430d95423c7ea","16518904f8184a42aa17b6220502dc33","9eb282db1d864199b1c03582a2cbd27c","6570754a6f0b43b78a9926c7bfd00519"],"active_org_master_entity_id":["0bb6804a2738b17bb305b0d80ce08460"],"research_disease":["3beea980d93a4cc0abc864e27514601c","8c161437fb424389ab1fde27b93a895b","703dd75ecc8740df908141aa5252ff4c","921aa3f95ab346369296cd1a02422866","2aeafb89d32c44a7a1b107728d9aca3b","8eaa9c59b7674ad692d8fbc5c68e845c","800d2cfb899f4e6983a759d03734503d","0464f5493b0444e9875a0584df17cbf0","6ca2db7d9e044c74a20da7017fa416e6","0b6fc9357c10436293f430d95423c7ea","16518904f8184a42aa17b6220502dc33","9eb282db1d864199b1c03582a2cbd27c","6570754a6f0b43b78a9926c7bfd00519"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1736899200000}},{"country":"e40dcd8d-d285-3fbd-b349-41b55c0fac2b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761523200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"800d2cfb899f4e6983a759d03734503d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"921aa3f95ab346369296cd1a02422866","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"16518904f8184a42aa17b6220502dc33","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"8eaa9c59b7674ad692d8fbc5c68e845c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"703dd75ecc8740df908141aa5252ff4c","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2aeafb89d32c44a7a1b107728d9aca3b","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6ca2db7d9e044c74a20da7017fa416e6","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"8c161437fb424389ab1fde27b93a895b","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"0b6fc9357c10436293f430d95423c7ea","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"9eb282db1d864199b1c03582a2cbd27c","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"original_drug_id":["945fa31ebe9e41ae912e493aa3324576"],"data_source":10}
+{"drug_id":"4448ac44f26946bf94e30dad6975f574","docid":289981,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":9,"target_extend_id":"b7438ad4734f3e249ed6a89098abb4a2","created_ts":"2024-09-25T05:37:36.000Z","updated_ts":"2026-04-04T21:11:00.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"EBV TCR-T Cell(Fudan University)","source_info":[{"code":"NCT05587543","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05587543"}],"status":"ACTIVE"}],"drug_type":["b72760cce8f7461193c7b3362f9a2e3a"],"originator_org_master_entity_id":["ccaafbee0171e5536440c00f317f3ce7"],"mechanism_action_id":["cedc49a6d9d043bab7484639a397a8c1"],"target_id":["ad585933e9a94e96ae5b6ee15e3387ab"],"disease_id":["1c6eb4a8c0534005b8e17c1129e01784"],"active_org_master_entity_id":["ccaafbee0171e5536440c00f317f3ce7"],"research_disease":["1c6eb4a8c0534005b8e17c1129e01784"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1672185600000}}],"disease_phase":[{"disease_id":"1c6eb4a8c0534005b8e17c1129e01784","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"08862f32091642ea804ec3342a8b643c","docid":82834,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-12-20T02:31:46.000Z","updated_ts":"2025-08-02T00:29:52.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"RV-1770","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/rnaimmune-receives-investigational-new-drug-application-clearance-from-us-fda-for-mrna-based-respiratory-syncytial-virus-vaccine-rv-1770-302017866.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"RV 1770","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/rnaimmune-receives-investigational-new-drug-application-clearance-from-us-fda-for-mrna-based-respiratory-syncytial-virus-vaccine-rv-1770-302017866.html"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["8fbdea03124e40a68a79403f5d8cd48c"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["8fbdea03124e40a68a79403f5d8cd48c","92ec6ebad5bafb29b8fe2699b734dbbd"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["92ec6ebad5bafb29b8fe2699b734dbbd","e65bc82792f22688dc2d90dc3de0942f"],"data_source":10}
+{"drug_id":"097d13345759411b8e96a3b1e17715ba","docid":73731,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:50:28.000Z","updated_ts":"2025-01-03T00:19:32.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"多功能凋亡受体激动剂 (成都地奥九泓制药厂)","status":"ACTIVE"},{"lang":"EN","name":"Multifunctional apoptotic receptor agonist(Chengdu Diao Jiuhong Pharmaceutical Factory)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DATR","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["d3ba9a2d6bf651b45e78537018e29046"],"special_review":["9eb8777c62af4712932b360e6ef3e454"],"disease_id":["6570754a6f0b43b78a9926c7bfd00519"],"active_org_master_entity_id":["d3ba9a2d6bf651b45e78537018e29046"],"research_disease":["6570754a6f0b43b78a9926c7bfd00519"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1430956800000}}],"disease_phase":[{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"00f68b71779e459ea1b89a69014b22fa","docid":41751,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Flunarizine","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","rnk":1,"target_extend_id":"6f5cf7b2cc413530acac8642d4b1bce3","has_leading_org_involved":1,"created_ts":"2021-10-08T14:45:12.000Z","updated_ts":"2025-05-15T19:42:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"氟桂利嗪","status":"ACTIVE"},{"lang":"EN","name":"Flunarizine","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine","source_info":[{"code":"DB04841","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Flunarizin Hydrochloride","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Flunarizine Hydrochloride","status":"ACTIVE"},{"lang":"EN","name":"Flunarizine Hydrochloride Cap","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Flunarizine hydrochloride (JAN/USAN)","source_info":[{"code":"D01303","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Flunarizini Hydrochloridum","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Flunmrizine Hydrochloride","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Yansuan Fuguiliqin Diwan","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"CN","name":"盐酸氟桂利嗪","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"dev_code":[{"name":"R-14950","status":"ACTIVE"},{"name":"XEN 007","status":"ACTIVE"}],"trade_name":[{"name":"Flugeral","status":"ACTIVE"},{"name":"Sibelium","status":"ACTIVE"},{"name":"奥力保克","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"孚瑞尔","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"弗瑞林","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"花欣","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"西比灵","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Flunarizine","source_info":[{"code":"R7PLA2DM0J","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/dd36888d-5392-4fc7-856f-9b6a0651d4c2"}],"status":"ACTIVE"}],"drugbank_id":["DB04841"],"kegg_id":["D01303"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["16ea44cdf8173cfd47847a73c3b3b3af"],"mechanism_action_id":["1f4c7a318c524c8190935ff2bf8d2bed","1e1ec2d78c0d4c208c094568e9a6cda1","1e3502b939fe4391a08350408c7688eb"],"target_id":["95f25ce0a06f42ee84dd49852659247a","43925c670cb84a7e84864d546572fa9a","cd3bc916dee343eb8df03157027ffb27"],"atc_code":["d369be6c20054a4291ba9bbb5e3b0209"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["011e34c7364441b2b18b56375242b918","b64322b4608041b280556167c6ee511e","3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["f42f82f9f421dcf8b786a19d3b5bf54d","9c9f959d86b82c3cdbf5a083b04a3635"],"research_disease":["011e34c7364441b2b18b56375242b918","b64322b4608041b280556167c6ee511e","3beea980d93a4cc0abc864e27514601c"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","4e8519876cfb47e1a3b07957e869ef32","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"b64322b4608041b280556167c6ee511e","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"011e34c7364441b2b18b56375242b918","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"8666aad5477e4272b56b94ca1183781d"}],"deal_related_org":["a81de79e17e4ce6597f25ba6fae81d8a","d7092af6bb2b22200b4cfd2f14840778"],"data_source":10}
+{"drug_id":"05d1ac84d4ee46b6b735788c657c4ac4","docid":17702,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":10,"target_extend_id":"103643e0506138e7b29e3c36d470d0f9","created_ts":"2021-10-08T14:43:21.000Z","updated_ts":"2026-01-31T21:08:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"SAP-001","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://shantonpharma.com/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"SAP 001","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f1bd6bc154fa31a88c595fa792494f76"],"mechanism_action_id":["c7996bf2e78384d6909be1ac06e5a4e4"],"target_id":["290236e86d7242d6ad39426849da4b3e"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["35df228d7cc5461dab659878686fba07","79cc3bb048cb4837a36e22b1bcab50d3"],"active_org_master_entity_id":["f1bd6bc154fa31a88c595fa792494f76"],"research_disease":["35df228d7cc5461dab659878686fba07","79cc3bb048cb4837a36e22b1bcab50d3"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1670803200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546300800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1768003200000}}],"disease_phase":[{"disease_id":"79cc3bb048cb4837a36e22b1bcab50d3","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"35df228d7cc5461dab659878686fba07","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2ab7b078384c40e5a410bb2e7928bc43","docid":289983,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-09-25T05:46:12.000Z","updated_ts":"2026-01-27T22:50:18.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"68Ga-HER2 Affibody","source_info":[{"code":"NCT05411432","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05411432"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"68Ga Labeled HER2 Affibody Analogues","source_info":[{"code":"NCT05411432","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05411432"}],"status":"ACTIVE"}],"drug_type":["05957e8371da41fd825986282a4acce0","78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["7f3864cf4fb5e2597e5b34c4f313ef79"],"disease_id":["f8ade5ce0e364264af82a379ab65f6a2","a3f62b479cfe4dec97f352c212a62db7"],"active_org_master_entity_id":["7f3864cf4fb5e2597e5b34c4f313ef79"],"research_disease":["f8ade5ce0e364264af82a379ab65f6a2","a3f62b479cfe4dec97f352c212a62db7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a3f62b479cfe4dec97f352c212a62db7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"3421b35b57f847d2a97caddbcf939523","docid":235057,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-01-23T06:25:31.000Z","updated_ts":"2025-03-28T16:18:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Allogeneic hematopoietic stem cell transplantation(Yake Biotechnology)","source_info":[{"code":"NCT06787560","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06787560"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allo-HSCT(Yake Biotechnology)","source_info":[{"code":"NCT06787560","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06787560"}],"status":"ACTIVE"}],"drug_type":["cceb301a25ec4f3cbc1aff3ae1169416"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"disease_id":["d5f09690c5fc4a1d9943fda459e8be26","e63492bef73d418cb1135980879d9d14","951522b08c924c77a8023509e8e3fe93","eac360ffffb64198a428890ec556f558"],"active_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"research_disease":["d5f09690c5fc4a1d9943fda459e8be26","e63492bef73d418cb1135980879d9d14","951522b08c924c77a8023509e8e3fe93","eac360ffffb64198a428890ec556f558"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1738281600000}}],"disease_phase":[{"disease_id":"eac360ffffb64198a428890ec556f558","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"d5f09690c5fc4a1d9943fda459e8be26","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e63492bef73d418cb1135980879d9d14","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"951522b08c924c77a8023509e8e3fe93","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"059c4f3581af4e89a812c2b2c3a6bd8e","docid":74218,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Rebamipide","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":654480000000,"rnk":1,"target_extend_id":"3208f5a1426f3120a494e7f1c099f231","has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:26.000Z","updated_ts":"2026-02-25T01:06:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhanghuaizheng@patsnap.com","first_approved_date_cn":953164800000,"drug_name":[{"lang":"CN","name":"雷巴米特","status":"ACTIVE"},{"lang":"EN","name":"Rebamipide","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"},{"code":"10.1021/acs.jmedchem.3c01763","normalized_source_id":"c76133d1-b056-4907-9edc-930de76e679d","source":"J Med Chem","source_url":"http://dx.doi.org/10.1021/acs.jmedchem.3c01763"},{"code":"2016_https://arvojournals.org/article.aspx?articleid=2559273&resultClick=1","normalized_source_id":"5345a266f4e04d28a3d63a34d54026ad","source":"ARVO","source_url":"https://arvojournals.org/article.aspx?articleid=2559273&resultClick=1"}],"status":"ACTIVE"},{"lang":"JP","name":"レバミピド","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"MCT-SR","status":"ACTIVE"},{"lang":"EN","name":"Pramipide","status":"ACTIVE"},{"lang":"EN","name":"Proamipide","status":"ACTIVE"},{"lang":"JP","name":"プロアミピド","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"CN","name":"瑞巴派特","status":"ACTIVE"}],"dev_code":[{"name":"KSR-001","source_info":[{"attachment_path":"data/phs_source_info/253c/1d7d/9f93/bbbe/db7bbef4-3ed0-3065-abba-0b731fdfdf63.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/8a80/4487/8eef/4e05/23e10810-3b47-33c3-8dcd-7a34c320f932.png","source":"Company pipeline","source_url":"https://www.samil-pharm.com/front/ourBusiness/rd/EN"}],"status":"ACTIVE"},{"name":"NSC-758955","source_info":[{"code":"LR583V32ZR","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1c5c10be-53f2-4032-b321-cb7f487b7f5a"}],"status":"ACTIVE"},{"name":"OPC-12759","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"OPC-12759E","status":"ACTIVE"},{"name":"OPC-759","status":"ACTIVE"},{"name":"OPC759","status":"ACTIVE"}],"trade_name":[{"name":"Mucosta","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"ムコスタ","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"膜固思达","status":"ACTIVE"}],"generic_name":[{"name":"Rebamipide","status":"ACTIVE"}],"drugbank_id":["DB11656"],"kegg_id":["D01121"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e04fbf3cf0a0af2bc6856c70d527f8b7"],"mechanism_action_id":["0fffa2dd3e8e4ac0a51ef97e91b3764c"],"target_id":["8db9498521694ea4a7b529fba06fca3f"],"atc_code":["b4cffd6332b348a885bf4e7fe6ff4aef"],"disease_id":["f1cdefb21eea49d584f9a91569adef88","3d3b4d85d52b4602a56b144086f40148","3271242b681840bcbd5ad0e4baee0770","f1ad50b3010e4721a3ce9b148c940a5a","c7808507b6cd41348c0e5e8f57e7e9d1","8da973b225c24afbba255413635fb240","b83b824cbcb542fcb6badb610ae8b9d2","509a094ddb78441eaeeeae867832dfad","8c233c0c2538469e9b72deb56b689d58","5577c2a48212423c8a3185fa02bdb045","11cacc262bfc41adbd6259325efbcfec","0508bd7f9f4f40feb5e1f38578f64d18","d124992d44c44ac4801806e7a62943a9","624a8b26544a45ee9559986a75bbe720","6be96778ed424f8d91de00ab82364114","52573fcc151b4d9b9fc29e8ed015efb1","9c5d1631749345ef990a8ed5d14e6caf"],"active_org_master_entity_id":["e04fbf3cf0a0af2bc6856c70d527f8b7","651e3e9318743ebb01e79ec95207a6ea","bc6241e8a42dd6dff1fe2a92249cdb9d","1822f838ba95f7cfae8c72c117f771c9","7e553e4a7e3fae41d07d80416391f0f5","8674250f7e0bb0fd3b487f54accd375d"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["3d3b4d85d52b4602a56b144086f40148"],"research_disease":["f1cdefb21eea49d584f9a91569adef88","3d3b4d85d52b4602a56b144086f40148","3271242b681840bcbd5ad0e4baee0770","f1ad50b3010e4721a3ce9b148c940a5a"],"non_research_disease":["c7808507b6cd41348c0e5e8f57e7e9d1","8da973b225c24afbba255413635fb240","b83b824cbcb542fcb6badb610ae8b9d2","509a094ddb78441eaeeeae867832dfad","8c233c0c2538469e9b72deb56b689d58","5577c2a48212423c8a3185fa02bdb045","11cacc262bfc41adbd6259325efbcfec","0508bd7f9f4f40feb5e1f38578f64d18","d124992d44c44ac4801806e7a62943a9","624a8b26544a45ee9559986a75bbe720","6be96778ed424f8d91de00ab82364114","52573fcc151b4d9b9fc29e8ed015efb1","9c5d1631749345ef990a8ed5d14e6caf"],"inactive_org_master_entity_id":["58739ab40b26a771f476d8ed2c673403","74fa1285cbf79384185afe468e63184d","ce21863d311464c759e1882ee9acdd37"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606","fce2b462d4fa493eb9d82513b9007011","042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":953164800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":770428800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":654480000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"78c45f1d523646808032edcff807ca59"},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"8666aad5477e4272b56b94ca1183781d","dev_status_time":{"time_trust_code":7,"time_ts":1705881600000}},{"country":"ba5f77a3-321f-3e45-91fc-4ff21b4edad7","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1388448000000}}],"disease_phase":[{"disease_id":"3271242b681840bcbd5ad0e4baee0770","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"3d3b4d85d52b4602a56b144086f40148","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"9c5d1631749345ef990a8ed5d14e6caf","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d124992d44c44ac4801806e7a62943a9","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"5577c2a48212423c8a3185fa02bdb045","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0508bd7f9f4f40feb5e1f38578f64d18","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"624a8b26544a45ee9559986a75bbe720","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8c233c0c2538469e9b72deb56b689d58","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"509a094ddb78441eaeeeae867832dfad","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"11cacc262bfc41adbd6259325efbcfec","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c7808507b6cd41348c0e5e8f57e7e9d1","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"52573fcc151b4d9b9fc29e8ed015efb1","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b83b824cbcb542fcb6badb610ae8b9d2","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f1cdefb21eea49d584f9a91569adef88","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"deal_related_org":["748edba0a3a4bbaee72b1c213a940053","e04fbf3cf0a0af2bc6856c70d527f8b7"],"data_source":10}
+{"drug_id":"1885da2f86c1493ab1a31db0b5765cfd","docid":33244,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":127,"target_extend_id":"7b338f40fb243fc79806ffa4e81c4c5a","created_ts":"2021-12-15T05:21:27.000Z","updated_ts":"2026-04-18T21:05:13.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"ST-1703","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"ST 1703","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"ST-1703","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"ST1703","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["39eeeb837ea299911d763ffb18815e45"],"mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151"],"target_id":["a3c3158483984ff9922b1b0ba939a068"],"disease_id":["3f57dd8d41ef4c68abb3228b7fdac7b6","f4c2a7e8389844259426e288d970bfb7","f8ade5ce0e364264af82a379ab65f6a2","547644c4131c43c78607a807f04cbabb","a3f62b479cfe4dec97f352c212a62db7"],"active_org_master_entity_id":["39eeeb837ea299911d763ffb18815e45"],"research_disease":["3f57dd8d41ef4c68abb3228b7fdac7b6"],"non_research_disease":["f4c2a7e8389844259426e288d970bfb7","f8ade5ce0e364264af82a379ab65f6a2","547644c4131c43c78607a807f04cbabb","a3f62b479cfe4dec97f352c212a62db7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1642032000000}}],"disease_phase":[{"disease_id":"3f57dd8d41ef4c68abb3228b7fdac7b6","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"547644c4131c43c78607a807f04cbabb","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a3f62b479cfe4dec97f352c212a62db7","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f4c2a7e8389844259426e288d970bfb7","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"056ba0fab02e4d3db1f7e1a5161ac82b","docid":53561,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":3,"target_extend_id":"5ee977263b2d363dba3c73f00f24f12a","created_ts":"2022-07-11T12:46:24.000Z","updated_ts":"2026-03-31T03:30:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"ABX-1100","status":"ACTIVE"}],"dev_code":[{"name":"ABX 1100","status":"ACTIVE"},{"name":"ABX1100","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.businesswire.com/news/home/20220810005057/en/Aro-Biotherapeutics-Receives-FDA-Orphan-Drug-Designation-for-ABX1100-for-the-Treatment-of-Pompe-Disease/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT"}],"status":"ACTIVE"}],"drug_type":["f14cfb7f58c94058be35780bf372123f"],"originator_org_master_entity_id":["631c6f07e79059fa97daf4f14a2c925d"],"mechanism_action_id":["4833e818b9d44226978d81283e5af01b","e77dece162a0133e50d5b2357c40719f"],"target_id":["9697a184d68a475e8f86357c622d2c8a"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["d3f9f37a9cb6414c86443ca3865fc954"],"active_org_master_entity_id":["6ddd1b4d295c1f3c7bdc95a62f675b5a"],"research_disease":["d3f9f37a9cb6414c86443ca3865fc954"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1697673600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1697673600000}}],"disease_phase":[{"disease_id":"d3f9f37a9cb6414c86443ca3865fc954","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"moiety_target_extend_id":"5ee977263b2d363dba3c73f00f24f12a","moiety_mechanism_action_id":["4833e818b9d44226978d81283e5af01b"],"moiety_target_id":["9697a184d68a475e8f86357c622d2c8a"]}
+{"drug_id":"00200d902c5d4549b9c9d1c977e33647","docid":8165,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":607305600000,"created_ts":"2022-03-23T08:35:04.000Z","updated_ts":"2025-06-18T03:31:39.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"Technetium(99mTc) Human Serum Albumin Diethylenetriamine Pentaacetic Acid","source_info":[{"code":"20100AMZ00204000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530359_4300419A1020_1_11"}],"status":"ACTIVE"},{"lang":"JP","name":"人血清アルブミンジエチレントリアミン五酢酸テクネチウム(99mTc)","source_info":[{"code":"20100AMZ00204000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530359_4300419A1020_1_11"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"99mTc-HSA-D","source_info":[{"code":"20100AMZ00204000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530359_4300419A1020_1_11"}],"status":"ACTIVE"}],"trade_name":[{"name":"Poolscinti","source_info":[{"code":"20100AMZ00204000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530359_4300419A1020_1_12"}],"status":"ACTIVE"},{"name":"プールシンチ","source_info":[{"code":"20100AMZ00204000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/530359_4300419A1020_1_12"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["387adc85419d86906a9b49d20ea1179a"],"mechanism_action_id":["d2f92a17bcb7e88f4e3ae266790aa7c0"],"disease_id":["37aac2c87e904ab3bdeda47ef4faf2a5"],"active_org_master_entity_id":["387adc85419d86906a9b49d20ea1179a"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["37aac2c87e904ab3bdeda47ef4faf2a5"],"research_disease":["37aac2c87e904ab3bdeda47ef4faf2a5"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":607305600000}}],"disease_phase":[{"disease_id":"37aac2c87e904ab3bdeda47ef4faf2a5","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00d860eecfad49f890defeb41fbbb548","docid":7842,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1607990400000,"rnk":4,"target_extend_id":"abef84752e54337ba5baa4f8ab837b78","created_ts":"2021-12-19T11:56:07.000Z","updated_ts":"2025-12-27T21:09:25.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"wangyufu@patsnap.com","first_approved_date_cn":1607990400000,"drug_name":[{"lang":"CN","name":"人凝血酶原复合物（成都蓉生）","status":"ACTIVE"},{"lang":"EN","name":"Human prothrombin complex (Chengdu Rongsheng)","status":"ACTIVE"}],"drug_type":["b2780aa4370b4e0382d43e53927be52a"],"originator_org_master_entity_id":["22babf2ceddb5c1347c0e86007a961d7"],"mechanism_action_id":["2427320c7f322e14df941a3852e9a12b","4af11fa7da5904a19ac5f1972c51655e","e2719c8308d5e88ca359cde11227ad94","266f91dadd5c992eed143c8a810306f9"],"target_id":["3f888f3938b34a4ca124145b3fa1e229","329835164c6047bd85ad8cdb26408cf2","0237102ff1fa4fb6adb004758180225d","b766e95e361446cebbaee74b1f9091b1"],"disease_id":["71d86eb1f39c4e509b8da8fe4343bdd3","e30a25b1033043c4adf00e944889533c"],"active_org_master_entity_id":["22babf2ceddb5c1347c0e86007a961d7"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["71d86eb1f39c4e509b8da8fe4343bdd3"],"research_disease":["71d86eb1f39c4e509b8da8fe4343bdd3"],"non_research_disease":["e30a25b1033043c4adf00e944889533c"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1607990400000}}],"disease_phase":[{"disease_id":"71d86eb1f39c4e509b8da8fe4343bdd3","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e30a25b1033043c4adf00e944889533c","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"01f55af83e614bea823c57a13d106441","docid":32503,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Proglumetacin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":754617600000,"rnk":89,"target_extend_id":"d0b5454663203883947bd65a6f6978f2","created_ts":"2021-10-08T14:50:23.000Z","updated_ts":"2026-01-10T21:09:29.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"马来酸丙谷美辛","status":"ACTIVE"},{"lang":"EN","name":"Proglumetacin Maleate","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"プログルメタシンマレイン酸塩","source_info":[{"code":"21800AMX10227000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400107_1145004F1034_1_06"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Proglumetacin","source_info":[{"code":"DB13527","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Proglumetacin maleate (JAN)","source_info":[{"code":"D01765","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Protacine","source_info":[{"code":"21800AMX10227000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400107_1145004F1034_1_06"}],"status":"ACTIVE"}],"dev_code":[{"name":"CR-604","source_info":[{"code":"21800AMX10227000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400107_1145004F1034_1_08"}],"status":"ACTIVE"}],"trade_name":[{"name":"Miridacin","source_info":[{"code":"21800AMX10227000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400107_1145004F1034_1_08"}],"status":"ACTIVE"},{"name":"Protaxo","status":"ACTIVE"},{"name":"Proxil","status":"ACTIVE"},{"name":"ミリダシン","source_info":[{"code":"21800AMX10227000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400107_1145004F1034_1_08"}],"status":"ACTIVE"}],"generic_name":[{"name":"Proglumetacin","source_info":[{"code":"FV919079LU","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/0a489507-d939-4126-a4d7-a9f784a3a3e4"}],"status":"ACTIVE"}],"drugbank_id":["DB13527"],"kegg_id":["D01765"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["eeda6486949c64d12bbdc6dcded66945"],"mechanism_action_id":["a6d441edec1fb3a71931094d6252e344"],"target_id":["bf9e4551379f4185b4f71d3a97678478"],"atc_code":["70a7ed5ea6ab4b90b6f10384e00cd5c2"],"disease_id":["452558707a32402e80a9431bf4652814","25aa9dbd25714b36b8bcb9347d1b91d1"],"active_org_master_entity_id":["eeda6486949c64d12bbdc6dcded66945"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["452558707a32402e80a9431bf4652814","25aa9dbd25714b36b8bcb9347d1b91d1"],"research_disease":["452558707a32402e80a9431bf4652814","25aa9dbd25714b36b8bcb9347d1b91d1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":754617600000}}],"disease_phase":[{"disease_id":"25aa9dbd25714b36b8bcb9347d1b91d1","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"452558707a32402e80a9431bf4652814","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0626548a56c848b3865af2308fe8ce79","docid":202043,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"399f0cc064523e9284c43ba7217ed434","created_ts":"2024-06-13T08:48:55.000Z","updated_ts":"2025-12-05T00:30:45.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Claudin18.2-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)","source_info":[{"code":"NCT03198052","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03198052"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["ec0955ba25411c26f2d56b8fccf6b12f"],"mechanism_action_id":["e5de4296d7d64eb68d12689d0ef4af53","15361c70aabb7a297fffba48611a2600","4dd338b149b3ecd0ee860e1fb379b44f","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["45f4868607f34cd5aa6d23ec518f90ac","5a34b1dfc07d416a8e43cc0d5520fe63","9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["6570754a6f0b43b78a9926c7bfd00519","e2fd9bda4aeb4a7b9fa53a2560126d24"],"active_org_master_entity_id":["ec0955ba25411c26f2d56b8fccf6b12f"],"research_disease":["6570754a6f0b43b78a9926c7bfd00519","e2fd9bda4aeb4a7b9fa53a2560126d24"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1498867200000}}],"disease_phase":[{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"08036d6da9094b78a68b809683ac4fa5","docid":81545,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-10-30T02:08:34.000Z","updated_ts":"2025-10-31T00:35:05.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (CanSino Biologics)","source_info":[{"code":"NCT06101173","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"VLP-Polio","status":"ACTIVE"}],"drug_type":["2012258ba2004d04a345b2bc0a1d99de","8f91996d778a4b93aebea69ade081b9f","b24e8825fd1d42d1b8832824599ee903"],"originator_org_master_entity_id":["e9879b9929b30556ea87baf86ad6c3d3"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["c4686870735748a0a7a1ded113b83f7f"],"active_org_master_entity_id":["e9879b9929b30556ea87baf86ad6c3d3","141a28d98ce8dd29ff644fbc8c071e42"],"research_disease":["c4686870735748a0a7a1ded113b83f7f"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ba5f77a3-321f-3e45-91fc-4ff21b4edad7","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1734566400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1705276800000}}],"disease_phase":[{"disease_id":"c4686870735748a0a7a1ded113b83f7f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"196eeef1d9a44502a409244cb5011fd7","docid":1221067,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-04-03T06:37:38.000Z","updated_ts":"2025-08-02T00:29:56.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Pandemic flu H5 HA mRNA SD2 vaccine(Sanofi)","source_info":[{"code":"NCT06907511","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06907511"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb"],"research_disease":["2a8a3f6ab7ec4061858144283e7ce0ca"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1744848000000}}],"disease_phase":[{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0046b18cf48143f79a803df213f0899b","docid":1798,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"1a9ea1307f82439f86318fa381543664","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":5,"target_extend_id":"d4fa58fe2a36394cb7742e900369cd94","created_ts":"2021-10-08T14:45:43.000Z","updated_ts":"2026-02-24T14:33:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"TT-173","source_info":[{"code":"28687347","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/28687347/"}],"status":"ACTIVE"}],"dev_code":[{"name":"TT 173","status":"ACTIVE"},{"name":"TT-103","status":"ACTIVE"},{"name":"TT-103MH","status":"ACTIVE"}],"drug_type":["4d2dcd3fc8b644db955f8cccefca280b"],"originator_org_master_entity_id":["64608c2c03beba76cd2e632b8b7b76f4"],"mechanism_action_id":["7c684f581640472b8b1b7ffaafc8ff82"],"target_id":["d540efb5ee6646a09936e6341b2d8fb5"],"disease_id":["d09a2813ca98448db981fb55bdeba55e","71d86eb1f39c4e509b8da8fe4343bdd3","e475471e5ba546a595deede0d50616fa","7925449988aa4724bf9f75280531860f","fd0b1bf93fef45d49eeda147cf253e58"],"active_org_master_entity_id":["1de9f3fba031e846aa7fb241b3b96955","64608c2c03beba76cd2e632b8b7b76f4"],"research_disease":["d09a2813ca98448db981fb55bdeba55e","71d86eb1f39c4e509b8da8fe4343bdd3","e475471e5ba546a595deede0d50616fa"],"non_research_disease":["7925449988aa4724bf9f75280531860f","fd0b1bf93fef45d49eeda147cf253e58"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"71d86eb1f39c4e509b8da8fe4343bdd3","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"7925449988aa4724bf9f75280531860f","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e475471e5ba546a595deede0d50616fa","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"fd0b1bf93fef45d49eeda147cf253e58","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d09a2813ca98448db981fb55bdeba55e","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"12955f9780624fb79ef0472c38bfc3a4","docid":203544,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"e4f9601f31f7350387278476e978a3d5","created_ts":"2024-09-05T07:37:53.000Z","updated_ts":"2025-07-31T00:31:13.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HNF4α srRNA","source_info":[{"code":"NCT06583993","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06583993"}],"status":"ACTIVE"}],"dev_code":[{"name":"CD-GA-102","source_info":[{"code":"NCT07050394","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07050394"}],"status":"ACTIVE"}],"drug_type":["ff150160e7294c6d910f944425be1c7f"],"originator_org_master_entity_id":["eeadb63b04897d9a470f0822a5d6b120"],"mechanism_action_id":["e7e1e4509a9540dda478410254b56ba8"],"target_id":["e2862e2c4a22404a8e04c3f2eae5006a"],"disease_id":["5dc51ff8d8224248a92774e018694180","e35ce4e9b7a846d49e600ce7ac4a7fd6","5f6e45c9955a433781d129df1791a975","e5090e6e73c349b9a671c67b6e0ef6e3"],"active_org_master_entity_id":["eeadb63b04897d9a470f0822a5d6b120"],"research_disease":["5dc51ff8d8224248a92774e018694180","e35ce4e9b7a846d49e600ce7ac4a7fd6","5f6e45c9955a433781d129df1791a975","e5090e6e73c349b9a671c67b6e0ef6e3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1749513600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1731369600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1730937600000}}],"disease_phase":[{"disease_id":"e5090e6e73c349b9a671c67b6e0ef6e3","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"5dc51ff8d8224248a92774e018694180","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"5f6e45c9955a433781d129df1791a975","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"098b6d2a307645169bd95046dc258ad4","docid":81625,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-10-31T05:05:57.000Z","updated_ts":"2024-12-31T00:20:04.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PDX-06","status":"ACTIVE"}],"dev_code":[{"name":"PDX-06","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["e32dfbf79944e259e351cff9a15316e5"],"disease_id":["4c5dfa106108492c90e2389719eb1d08","d124992d44c44ac4801806e7a62943a9","1090787014ac43fabc505ef56d5f7b0d"],"active_org_master_entity_id":["e32dfbf79944e259e351cff9a15316e5"],"research_disease":["4c5dfa106108492c90e2389719eb1d08","d124992d44c44ac4801806e7a62943a9","1090787014ac43fabc505ef56d5f7b0d"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1713225600000}}],"disease_phase":[{"disease_id":"4c5dfa106108492c90e2389719eb1d08","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"d124992d44c44ac4801806e7a62943a9","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1090787014ac43fabc505ef56d5f7b0d","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"199f002675c24757a89cce2f78cf1097","docid":111292,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"023db97f78c034598835321ccef095c2","created_ts":"2024-04-16T09:44:59.000Z","updated_ts":"2025-12-26T20:30:09.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"maliman","drug_name":[{"lang":"EN","name":"TYK-01054","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MjM5NjY5MTI4NA==&mid=2650936737&idx=1&sn=f4cb04551a67c3df3a1f32faa3cf34b8"}],"status":"ACTIVE"}],"dev_code":[{"name":"TYK 01054","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NjY5MTI4NA==&mid=2650936737&idx=1&sn=f4cb04551a67c3df3a1f32faa3cf34b8"}],"status":"ACTIVE"},{"name":"TYK01054","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NjY5MTI4NA==&mid=2650936737&idx=1&sn=f4cb04551a67c3df3a1f32faa3cf34b8"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d6fbee6146c7ddb5de8f813b15f1c990"],"mechanism_action_id":["bcd7394f546848ecb180560f042dd5ce","0c5041f369474d09912a051eff0ef026"],"target_id":["8a9fa4725bb4430bbeb3aa314c9576e0","17e6a93d9d8d4e0fa6785cf0703ac8a4"],"disease_id":["c3b9ec7eb2e2402fae4916a1d3f6504a","0464f5493b0444e9875a0584df17cbf0","6570754a6f0b43b78a9926c7bfd00519"],"active_org_master_entity_id":["d6fbee6146c7ddb5de8f813b15f1c990"],"research_disease":["c3b9ec7eb2e2402fae4916a1d3f6504a","0464f5493b0444e9875a0584df17cbf0","6570754a6f0b43b78a9926c7bfd00519"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1767225600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1766707200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1712793600000}}],"disease_phase":[{"disease_id":"c3b9ec7eb2e2402fae4916a1d3f6504a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"data_source":10}
+{"drug_id":"1b11e6fce4c74216aa1dd770f711aa20","docid":81746,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"721d14fd3408370f9e80195c9edc9009","created_ts":"2023-11-06T05:19:17.000Z","updated_ts":"2025-10-30T22:06:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"NT-101 (NexThera)","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.nexthera.org/en/html/pipelines/pipelines.php"}],"status":"ACTIVE"}],"dev_code":[{"name":"NT 101 (NexThera)","status":"ACTIVE"},{"name":"NT101 (NexThera)","status":"ACTIVE"}],"drug_type":["ff9477ffcb8346d59008ad9f2027fd57"],"originator_org_master_entity_id":["666c83ae76a1fe99e8ad953004dd585a"],"mechanism_action_id":["0f5e978657d9dd7b11fa45ade673c434"],"target_id":["8d5b6e5002694f42a5faf75261dee3a1"],"disease_id":["b3613eb77a5d4795ac1a12db34d284ba"],"active_org_master_entity_id":["666c83ae76a1fe99e8ad953004dd585a"],"research_disease":["b3613eb77a5d4795ac1a12db34d284ba"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741651200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1699228800000}}],"disease_phase":[{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1316e68d559c49d1aac15671bcd76bde","docid":1222365,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"a98156ae78c348ecbeed960cd54d5a99","global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-06-11T03:33:07.000Z","updated_ts":"2026-03-02T10:52:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"177Lu-CTR-FAPI","source_info":[{"code":"NCT07014254","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07014254"}],"status":"ACTIVE"}],"drug_type":["926e8e25a2b04d29864ed28dca6c57b7","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["7f3864cf4fb5e2597e5b34c4f313ef79"],"disease_id":["b58bf50923fc4a898d7a94495d2a6657","f8ade5ce0e364264af82a379ab65f6a2","1e6992f1403346acad1273d778686ca7","f98fd32baa8447119bb87f84093b925c","90a3a12984ce4382a2b43e44e67fd301","ae092fa59f4d44edaf59ffe23d0a44c3","e35ce4e9b7a846d49e600ce7ac4a7fd6","2d8998f199f7453ea90cf79a4f4b7c28","b2fa14a75a53403881be137eba040dbf","78cb173a4de34f07befac28de907e7bf","8eaa9c59b7674ad692d8fbc5c68e845c"],"active_org_master_entity_id":["7f3864cf4fb5e2597e5b34c4f313ef79","c4856da10e73bdc25680bb543c05936e","51551d363d893be0041c70abd164075a"],"research_disease":["b58bf50923fc4a898d7a94495d2a6657","f8ade5ce0e364264af82a379ab65f6a2","1e6992f1403346acad1273d778686ca7","f98fd32baa8447119bb87f84093b925c","90a3a12984ce4382a2b43e44e67fd301","ae092fa59f4d44edaf59ffe23d0a44c3","e35ce4e9b7a846d49e600ce7ac4a7fd6","2d8998f199f7453ea90cf79a4f4b7c28","b2fa14a75a53403881be137eba040dbf","78cb173a4de34f07befac28de907e7bf","8eaa9c59b7674ad692d8fbc5c68e845c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1767225600000}}],"disease_phase":[{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b58bf50923fc4a898d7a94495d2a6657","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"90a3a12984ce4382a2b43e44e67fd301","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2d8998f199f7453ea90cf79a4f4b7c28","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"8eaa9c59b7674ad692d8fbc5c68e845c","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"b2fa14a75a53403881be137eba040dbf","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0282d38f13f74ce4a3c2853a47bc9962","docid":67061,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":852076800000,"rnk":9,"target_extend_id":"cf8a7a2886d835699f86f504e0e5f2eb","created_ts":"2021-10-08T14:50:16.000Z","updated_ts":"2024-12-26T00:22:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":852076800000,"drug_name":[{"lang":"CN","name":"赖氨酸茶碱","status":"ACTIVE"},{"lang":"EN","name":"Lysine Theophyllinate","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0885f51dbbaafad2d2ee55449c3add6d"],"mechanism_action_id":["13955edabde67af00dbd8465e91d8ac0"],"target_id":["1eb9e5552eda48c8beb755ca295fe1d2"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","df3f2af04dd146e28a3f1de0556b8a65"],"active_org_master_entity_id":["0885f51dbbaafad2d2ee55449c3add6d"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["15fe4881cb88431eb9d44b018619d7b0","df3f2af04dd146e28a3f1de0556b8a65"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","df3f2af04dd146e28a3f1de0556b8a65"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":852076800000}}],"disease_phase":[{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"df3f2af04dd146e28a3f1de0556b8a65","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"05085c6e3f6d44bd9491047d1efefc24","docid":42215,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":18,"target_extend_id":"c6828d7097933a80bf6de3ffa798748a","created_ts":"2021-10-08T14:50:15.000Z","updated_ts":"2026-03-14T21:15:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BMS-520","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"mechanism_action_id":["cdf0345e1644aef4fb098d5dd7396829"],"target_id":["28bb11044bf04cac8884b3e877938ba9"],"disease_id":["cdfb06abaeaf48fd92abe6a96b73de57"],"active_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"research_disease":["cdfb06abaeaf48fd92abe6a96b73de57"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"019d3afd7b2d4caba81a789781a3d556","docid":500192,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-11-05T06:43:27.000Z","updated_ts":"2025-12-05T00:30:40.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PRG-2302","source_info":[{"code":"NCT06659653","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06659653"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD19/CD22 Chimeric Antigen Receptor T Cells(Shenzhen Puruijin Biological Pharmaceutical)","source_info":[{"code":"NCT06659653","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06659653"}],"status":"ACTIVE"}],"dev_code":[{"name":"PRG-2302","source_info":[{"code":"NCT06659653","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06659653"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["bd97aefcf0351f56624075645bb3261a"],"disease_id":["7593fb8265c54bdc9ccfb7bc788785dc","19c82ee54b5345c4989d527af9e06caa"],"active_org_master_entity_id":["bd97aefcf0351f56624075645bb3261a"],"research_disease":["7593fb8265c54bdc9ccfb7bc788785dc","19c82ee54b5345c4989d527af9e06caa"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1716508800000}}],"disease_phase":[{"disease_id":"19c82ee54b5345c4989d527af9e06caa","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7593fb8265c54bdc9ccfb7bc788785dc","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"3dc4aa68d4b64524935de8f9279f2eb4","docid":233836,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-10-12T06:08:50.000Z","updated_ts":"2025-08-02T00:29:56.000Z","data_status":"ACTIVE","created_by":"liuyiming@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"InnoPCV","source_info":[{"code":"NCT06497010","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06497010"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["4cc8caa009a439c9cf5db6704818cfe6"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["90c6469ad0a5b329cabc7e0feb3cdd13","4cc8caa009a439c9cf5db6704818cfe6"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1724889600000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0881687a06094c86b4f98242e3267ba9","docid":11221,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-08-03T08:55:33.000Z","updated_ts":"2024-10-30T10:20:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"柴黄利胆胶囊","status":"ACTIVE"},{"lang":"EN","name":"Chaihuang Lidan Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["0b3914ea0ddfc8794c214970054e8f6b"],"disease_id":["f56ba35badce4bb69653ae65c70c8a86"],"active_org_master_entity_id":["0b3914ea0ddfc8794c214970054e8f6b"],"research_disease":["f56ba35badce4bb69653ae65c70c8a86"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1718236800000}}],"disease_phase":[{"disease_id":"f56ba35badce4bb69653ae65c70c8a86","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"13ee7500e3d04eaa834fd36a4d9b1b09","docid":1674448,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2026-04-16T07:34:44.000Z","updated_ts":"2026-04-16T07:36:12.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"DKF-427","source_info":[{"attachment_path":"data/phs_source_info/4bcf/6913/887d/a64c/4bcf6913887da64c.png","attachment_type":"image/png","code":"DongKook-202604","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/07ed/0fdd/32fd/75d9/07ed0fdd32fd75d9.png","source":"Company pipeline","source_url":"https://www.dkpharm.co.kr/rnd/pipeline.php"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["7f22906dbbdc2cd736e0167a62b89675"],"disease_id":["979761c8b3bf4412b14714746617f31a"],"active_org_master_entity_id":["7f22906dbbdc2cd736e0167a62b89675"],"research_disease":["979761c8b3bf4412b14714746617f31a"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"78c45f1d523646808032edcff807ca59"}],"disease_phase":[{"disease_id":"979761c8b3bf4412b14714746617f31a","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"16819d3ba640484f9d056c5e36cb93b1","docid":76743,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":9,"target_extend_id":"28fa18b08f4d3df5a14597c9227a1923","has_leading_org_involved":1,"created_ts":"2022-05-11T12:41:10.000Z","updated_ts":"2026-02-28T21:12:15.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ALN-SOD","status":"ACTIVE"}],"dev_code":[{"name":"ALN SOD","status":"ACTIVE"},{"name":"ALN-SOD1","source_info":[{"attachment_path":"data/phs_source_info/9cbd/a894/ca6a/d2bb/3307f8e4-e546-3f0d-8baa-f4e0542cd9eb.pdf","attachment_type":"application/pdf","normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","preview_attachment_path":"data/phs_source_info/88ac/0326/8fe7/cf4c/7067fa7c-4882-353f-a6f0-4520f3639b2e.png","source":"Corporate Publications"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["64b868824be13f21c65806ae1672608a"],"mechanism_action_id":["a9eba25e5a68456f9c2c6dc6266cf9c5"],"target_id":["d1539f818236424389b4326aa64702d8"],"disease_id":["738546bac89e4895b89af01545f1b054"],"active_org_master_entity_id":["60a7d56edfaf9f0f66025e000f7370c3","64b868824be13f21c65806ae1672608a"],"research_disease":["738546bac89e4895b89af01545f1b054"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1724803200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1682899200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1652227200000}}],"disease_phase":[{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["64b868824be13f21c65806ae1672608a","60a7d56edfaf9f0f66025e000f7370c3"],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","if_speculate":0,"data_source":10,"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"delivery_system":["42e15f5307df48c0b79434dc95ae3720"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"019e9c96d65e4dcf825dd343f79c3b64","docid":52085,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":6,"target_extend_id":"e68f7364751e34ff9a2afb81c99497b9","created_ts":"2021-10-08T14:39:40.000Z","updated_ts":"2026-04-04T21:07:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ABBV-382","source_info":[{"normalized_source_id":"b0dcb0f2f0ba4c1cb2b777bfb5f1420a","source":"CROI","source_url":"https://www.croiconference.org/abstract/abbv-382-an-anti-%CE%B14%CE%B27-ab-that-enhances-hiv-1-antigen-presentation-for-immune-mediated-viral-control/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ABBV 382","source_info":[{"normalized_source_id":"b0dcb0f2f0ba4c1cb2b777bfb5f1420a","source":"CROI","source_url":"https://www.croiconference.org/abstract/abbv-382-an-anti-%CE%B14%CE%B27-ab-that-enhances-hiv-1-antigen-presentation-for-immune-mediated-viral-control/"}],"status":"ACTIVE"},{"name":"ABBV382","source_info":[{"normalized_source_id":"b0dcb0f2f0ba4c1cb2b777bfb5f1420a","source":"CROI","source_url":"https://www.croiconference.org/abstract/abbv-382-an-anti-%CE%B14%CE%B27-ab-that-enhances-hiv-1-antigen-presentation-for-immune-mediated-viral-control/"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"mechanism_action_id":["55cd976e4932ffb9507221d694e52894"],"target_id":["1e9f0774b5a9423faa6d5d38c0a050c9"],"disease_id":["05ae12d567784b85a5c1ca54b2063ee2","acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["d88590e686ad5608bbbfeb811b14d188"],"research_disease":["05ae12d567784b85a5c1ca54b2063ee2","acfaaa0373944ffd89b0a2ace0d8c564"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"30cd3ad1-e7d0-3604-b6c7-54eacd2d961c","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"6d64b019-4f80-31e9-b248-297aa588c950","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"b0e1cb77-7cf7-3c20-a846-3e377b838cfa","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"15ca9b6f-29d3-35c2-a4b0-096aee64f0d7","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"5ebd2bf1-83fc-3ed8-98f3-dc94d8c1c502","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1725408000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1761696000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1761696000000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1761696000000}}],"disease_phase":[{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"data_source":10}
+{"drug_id":"027865294b25410d946df2b8c50d3a13","docid":31373,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":9,"target_extend_id":"edfc716638c93860a1bef20b6dc68b2b","created_ts":"2022-09-02T10:35:05.000Z","updated_ts":"2026-04-04T21:06:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"[18F]-MC-225","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Fluorine -18-MC-225","status":"ACTIVE"},{"lang":"EN","name":"MC-225-[18F]","status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["ec5b6e3cdd3db43cb49a291ea5b940f8"],"mechanism_action_id":["692403e4af974666993e5c330c13051f"],"target_id":["13d14f580a704de485dda079bd4a4d0a"],"disease_id":["4b33f75f5c0f40b38f4797af8c0be566","54a77f56d72c4ac6a0eb840f4518e3a0","3da3a0b18fb5409d8827611b09254298","f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["c9052c5864c5c9132dd0dbad6e6b076a"],"research_disease":["4b33f75f5c0f40b38f4797af8c0be566","54a77f56d72c4ac6a0eb840f4518e3a0","3da3a0b18fb5409d8827611b09254298","f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1752451200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1643673600000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3da3a0b18fb5409d8827611b09254298","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4b33f75f5c0f40b38f4797af8c0be566","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10,"moiety_target_extend_id":"edfc716638c93860a1bef20b6dc68b2b","moiety_mechanism_action_id":["692403e4af974666993e5c330c13051f"],"moiety_target_id":["13d14f580a704de485dda079bd4a4d0a"]}
+{"drug_id":"055007242ae14cbd8bf7bcc5b4c7c0ca","docid":1730648,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-08-13T09:01:19.000Z","updated_ts":"2025-08-29T07:36:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Induced pluripotent stem cell-derived extracellular vesicles(Shanghai Sixth People's Hospital)","source_info":[{"code":"NCT07111325","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07111325"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"iEV","source_info":[{"code":"NCT07111325","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07111325"}],"status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["38c794d8a9a4602fb67dd99e2ddf61be"],"disease_id":["c9d3c55f01d24f11a6035f989330c65f","507403050bf0413ca295f4e6f644d329"],"active_org_master_entity_id":["38c794d8a9a4602fb67dd99e2ddf61be"],"research_disease":["c9d3c55f01d24f11a6035f989330c65f","507403050bf0413ca295f4e6f644d329"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1741305600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1688169600000}}],"disease_phase":[{"disease_id":"c9d3c55f01d24f11a6035f989330c65f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"507403050bf0413ca295f4e6f644d329","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"19e94330066143cd83dd5b0d38254bbb","docid":1643153,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"4d13078c60ca3d02a12f4f9490e1b15e","created_ts":"2025-11-28T03:14:04.000Z","updated_ts":"2025-11-29T21:13:14.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CircFAM53B mRNA vaccine(Sun Yat-Sen Memorial Hospital)","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["71d71b05e3a71f2758dc77d60eb70f38"],"mechanism_action_id":["ddb32fa87c2d420fbad3cd1f965a0e40"],"target_id":["1ff19bc4972b47069761d0c10a32e84c"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["71d71b05e3a71f2758dc77d60eb70f38"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"128e2bfabd014759a14f00d5a47d2257","docid":20071,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"c9e8fce7eb6b4bbd9cc66dc356017aab","rnk":4,"target_extend_id":"d4102fb7c0f53673a27a5abc5a60447e","created_ts":"2021-10-08T14:47:09.000Z","updated_ts":"2026-02-25T01:50:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Prolgolimab/nurulimab","status":"ACTIVE"}],"dev_code":[{"name":"BCD 217","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ctla-4-anti-pd-1-monoclonal-antibody-combination-bcd-217"}],"status":"ACTIVE"}],"related_component":["73ee1fd0b6de4b749b2bd14133cdebe7","a7e5e9cff51a4f5f96bb995964eb5372"],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["f8f87f812246777702da26e30acb69af"],"mechanism_action_id":["702fa47e9a71b31550c38470d2204ce9","4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["664d9478c81b4059b32f286b5047416c","9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["e00ee531c5d84449ab9f6c997b79b746","8da4804a5bd24352b7d568a7da54c6dc","2477c68e093d4b818b11333ee1a5ee02"],"active_org_master_entity_id":["f8f87f812246777702da26e30acb69af","d3a57466e6d758e197b357a64eb4df4f"],"research_disease":["e00ee531c5d84449ab9f6c997b79b746","8da4804a5bd24352b7d568a7da54c6dc","2477c68e093d4b818b11333ee1a5ee02"],"inactive_org_master_entity_id":["a8ac4fa1e85406305cba5e6cacb552f8"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659398400000}},{"country":"e92cf5a5-43e5-3d54-a14b-272415437a2d","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659398400000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1659398400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"c9e8fce7eb6b4bbd9cc66dc356017aab"}],"disease_phase":[{"disease_id":"e00ee531c5d84449ab9f6c997b79b746","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"c9e8fce7eb6b4bbd9cc66dc356017aab","highest_phase_global":"c9e8fce7eb6b4bbd9cc66dc356017aab"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"34d3ff4fc2d440ee99c15a95fa1416d9","docid":27395,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":47,"target_extend_id":"73fd722415e83c2eac0a43a495b860bf","created_ts":"2021-10-08T14:45:31.000Z","updated_ts":"2026-03-14T21:13:34.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"CN","name":"CTA101 UCAR T细胞(Nanjing Bioheng Biotech)","source_info":[{"code":"CXSL2101509","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"CTA-101","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"UCART therapy","status":"ACTIVE"},{"lang":"EN","name":"Universal Chimeric Antigen Receptor T-cell therapy","status":"ACTIVE"}],"dev_code":[{"name":"CTA 101","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-anti-cd19-universal-car-t-cells-cta101"}],"status":"ACTIVE"}],"drug_type":["8cda7e9356a7439ea27ce1a899143e5c"],"originator_org_master_entity_id":["f5feb4efa80605284ae3176397703cb6"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","4c9c02bbdfaac0c794d51e268155fc51"],"target_id":["5eb1fc5283d34305934a031af530f448","d02b07e15b354447b8f22cb9e5c1d369"],"disease_id":["7593fb8265c54bdc9ccfb7bc788785dc","bc7466431f284849b17655ff5df80c26","e89afc6a432744b1a88281329dc46d91","a622cec9c1e34e88a3c46c3b7fa00884","40837198f02e4e118f8abcccc1939d01","84040e6e03744450831486ca2601402f"],"active_org_master_entity_id":["f5feb4efa80605284ae3176397703cb6"],"research_disease":["7593fb8265c54bdc9ccfb7bc788785dc","bc7466431f284849b17655ff5df80c26","e89afc6a432744b1a88281329dc46d91","a622cec9c1e34e88a3c46c3b7fa00884"],"non_research_disease":["40837198f02e4e118f8abcccc1939d01","84040e6e03744450831486ca2601402f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1578441600000}}],"disease_phase":[{"disease_id":"7593fb8265c54bdc9ccfb7bc788785dc","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a622cec9c1e34e88a3c46c3b7fa00884","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e89afc6a432744b1a88281329dc46d91","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"bc7466431f284849b17655ff5df80c26","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"40837198f02e4e118f8abcccc1939d01","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"84040e6e03744450831486ca2601402f","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["f5feb4efa80605284ae3176397703cb6","34849105be8e3666092330e8ee20c2c0"],"data_source":10}
+{"drug_id":"39d5ec065b9a4f6e9efaf604b2cc01c0","docid":35533,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":248,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2023-05-22T09:30:57.000Z","updated_ts":"2026-04-11T21:08:02.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"UTAA09/17","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.persongen.com/cell-therapy-pipeline.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD19-CAR-Vδ1T","source_info":[{"attachment_path":"data/phs_source_info/aacr/360f/b1ec/7f8f/f8ac/1ba263be-360f-31ec-bf8f-f8aceff0a43c.html","attachment_type":"HTML","code":"2024_5254","normalized_source_id":"8806d6ca778544e497f77fce5165778f","preview_attachment_path":"data/phs_source_info/aacr/360f/b1ec/7f8f/f8ac/1ba263be-360f-31ec-bf8f-f8aceff0a43c.html","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/84/6_Supplement/5254/739457/Abstract-5254-The-off-the-shelf-CD19-CAR-V-1T"}],"status":"ACTIVE"}],"dev_code":[{"name":"CD19-UCAR-Vδ1T","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzA4MzQ1NTgyMw==&mid=2659005158&idx=1&sn=b399ed3085ff8a9e12b059eb4d30df8a"}],"status":"ACTIVE"},{"name":"UTAA 09","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-anti-cd19-gamma-delta-car-t-cells-utaa09"}],"status":"ACTIVE"},{"name":"UTAA-09","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-anti-cd19-gamma-delta-car-t-cells-utaa09"}],"status":"ACTIVE"},{"name":"UTAA09","source_info":[{"code":"NCT06092047","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06092047"},{"attachment_path":"data/phs_source_info/aacr/360f/b1ec/7f8f/f8ac/1ba263be-360f-31ec-bf8f-f8aceff0a43c.html","attachment_type":"HTML","code":"2024_5254","normalized_source_id":"8806d6ca778544e497f77fce5165778f","preview_attachment_path":"data/phs_source_info/aacr/360f/b1ec/7f8f/f8ac/1ba263be-360f-31ec-bf8f-f8aceff0a43c.html","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/84/6_Supplement/5254/739457/Abstract-5254-The-off-the-shelf-CD19-CAR-V-1T"}],"status":"ACTIVE"},{"name":"UTAA09/17","status":"ACTIVE"}],"drug_type":["82d9b474ba434d6ca4e0a6740a55ac23","8cda7e9356a7439ea27ce1a899143e5c"],"originator_org_master_entity_id":["59025c915be3ec87ec8b222d0630510e"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["4c9d46b2b7794d128b14d8689f4c357d","0e0dca4dd7f1499a8f65f4fdfcf09954","dba0a7e65b51408ca401deb8364bce94","418cb344fa844c8f8e494fc3ac177a12","b9790aa2ed5c48eda26f2224870a8e52","51236dbf55d24268aa6d31d9be131f6f","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e","f60141249781464bb54bf1700c83143c","131c3f4dfc0c4a958e9f91166e73c913","b494a906592f47b09ce303fb0963e3b8","9524995c426b4d93a80908af4a018bba","19c82ee54b5345c4989d527af9e06caa","321c439bbe614dc2afd13cb803a48cec","ce09181e978a4a3f9932f35001b9fa13"],"active_org_master_entity_id":["59025c915be3ec87ec8b222d0630510e","370534d34dc091ee1a1fcd4d1f1d0d54"],"research_disease":["4c9d46b2b7794d128b14d8689f4c357d","0e0dca4dd7f1499a8f65f4fdfcf09954","dba0a7e65b51408ca401deb8364bce94","418cb344fa844c8f8e494fc3ac177a12","b9790aa2ed5c48eda26f2224870a8e52","51236dbf55d24268aa6d31d9be131f6f","52573fcc151b4d9b9fc29e8ed015efb1","c5e1987e283c495aaab2a8d309c6085e","f60141249781464bb54bf1700c83143c","131c3f4dfc0c4a958e9f91166e73c913","b494a906592f47b09ce303fb0963e3b8","9524995c426b4d93a80908af4a018bba","19c82ee54b5345c4989d527af9e06caa","321c439bbe614dc2afd13cb803a48cec","ce09181e978a4a3f9932f35001b9fa13"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","fce2b462d4fa493eb9d82513b9007011","5b1dfc2ca8564662860187aef864467d","20f1c6915ff140519285386c54883aae","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1722384000000}}],"disease_phase":[{"disease_id":"b9790aa2ed5c48eda26f2224870a8e52","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"131c3f4dfc0c4a958e9f91166e73c913","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f60141249781464bb54bf1700c83143c","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"9524995c426b4d93a80908af4a018bba","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b494a906592f47b09ce303fb0963e3b8","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"ce09181e978a4a3f9932f35001b9fa13","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"19c82ee54b5345c4989d527af9e06caa","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"dba0a7e65b51408ca401deb8364bce94","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"52573fcc151b4d9b9fc29e8ed015efb1","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"321c439bbe614dc2afd13cb803a48cec","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"418cb344fa844c8f8e494fc3ac177a12","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03c379217acd4448bfefba66d7f749d5","docid":79513,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-08-23T03:33:17.000Z","updated_ts":"2026-01-04T13:38:09.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SYS-6011","source_info":[{"code":"CXSL2300563","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"SYS 6011","status":"ACTIVE"},{"name":"SYS6011","source_info":[{"code":"CXSL2300563","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1723507200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"06f2e0730b424f83ae568668f629ef50","docid":66449,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":117,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2022-03-03T07:27:56.000Z","updated_ts":"2026-04-18T21:05:18.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"GZR101","source_info":[{"code":"CXSL2200110","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"GZR-101","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["a85d65d874773e03409c51203f9e1b55"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["a85d65d874773e03409c51203f9e1b55"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1700524800000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"05dcc145518545fb84a551f69647d83f","docid":32666,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-08-03T08:55:36.000Z","updated_ts":"2025-03-08T00:20:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"香橘乳癖宁胶囊","status":"ACTIVE"},{"lang":"EN","name":"Xiangju Rupining Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["6a809ef304d5d57952fcab8517b3c1ab"],"disease_id":["932249028f5848a99dd794c45d9fbb97","df28502495a34ee6af38d44819fff039"],"active_org_master_entity_id":["1303e7e203d6cccc8f5b09664d4eafe2","6a809ef304d5d57952fcab8517b3c1ab"],"research_disease":["932249028f5848a99dd794c45d9fbb97","df28502495a34ee6af38d44819fff039"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728864000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1714089600000}}],"disease_phase":[{"disease_id":"932249028f5848a99dd794c45d9fbb97","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"df28502495a34ee6af38d44819fff039","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"08e582e580e443e39d1a5be595588761","docid":57063,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":5,"target_extend_id":"8ce597d2683f324d84a2d1a1953ab1ce","created_ts":"2022-07-04T07:51:30.000Z","updated_ts":"2026-04-04T21:05:49.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Meperizumab","source_info":[{"code":"NCT05353179","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05353179"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["662d46871bd6f6dc727ddefab40c2a06"],"mechanism_action_id":["016503c61af6221aca5a9d59d6248957"],"target_id":["ce6f84497b634971b16c567064024c83"],"disease_id":["85a5f5e742ad45b9ac62afaf9709249a","e918886725594b31980380b66df9b8e5"],"active_org_master_entity_id":["662d46871bd6f6dc727ddefab40c2a06"],"research_disease":["85a5f5e742ad45b9ac62afaf9709249a","e918886725594b31980380b66df9b8e5"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1654041600000}}],"disease_phase":[{"disease_id":"85a5f5e742ad45b9ac62afaf9709249a","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e918886725594b31980380b66df9b8e5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"4d046526a9c44f3cbb49fd79261e1a72","docid":1672825,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":3,"target_extend_id":"f9a38bc2f8893a9995655745e2e20b56","created_ts":"2025-12-15T05:34:45.000Z","updated_ts":"2026-03-19T00:55:26.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"阿瑞匹坦/帕洛诺司琼","status":"ACTIVE"},{"lang":"EN","name":"Aprepitant/Palonosetron","status":"ACTIVE"}],"dev_code":[{"name":"QLM2010","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkzNTY4NTk0Mw==&mid=2247534228&idx=2&sn=3d1cb4702317b39c25179eb38479face"}],"status":"ACTIVE"}],"related_component":["4f3b7da6285c444e9c0c4ed4b7410c6e","b7dfb347194c4d72810c5a6e6d2afe99"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["477ca31fa365d35f7dcd21ea98f3feb4"],"mechanism_action_id":["273e8b74e3925dbf59aaf6881e7e1f68","9fec9edffcaab20619f42be86d9ac40f"],"target_id":["bce1eaa0d5004eb6aa788d3b558dc4ec","ea89c615b1db4e87accb2963091b5d5b"],"disease_id":["5061483d9af141a79f3e2bac00002e7b"],"active_org_master_entity_id":["477ca31fa365d35f7dcd21ea98f3feb4"],"research_disease":["5061483d9af141a79f3e2bac00002e7b"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1765756800000}}],"disease_phase":[{"disease_id":"5061483d9af141a79f3e2bac00002e7b","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0346c58938854424b7a0657a4bac7d37","docid":13522,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":7,"target_extend_id":"11c1f0b63944324388a75a80d1508c88","created_ts":"2021-10-08T14:46:32.000Z","updated_ts":"2026-04-04T21:05:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Compstatin 40","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)","source_info":[{"code":"EU/3/14/1327","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://ec.europa.eu/health/documents/community-register/html/o1327.htm"}],"status":"ACTIVE"}],"dev_code":[{"name":"AMY 101","status":"ACTIVE"},{"name":"AMY-101","status":"ACTIVE"},{"name":"AMY101","status":"ACTIVE"}],"drugbank_id":["DB14803"],"drug_type":["58f172e4a4794372b08b2dda980530de","b3f3ecbc5fe645d79060e009b17b6e76"],"originator_org_master_entity_id":["3bdcd22f6e2d3273ac9eac8e8ab7a0b0"],"mechanism_action_id":["546d255d2d4f0ced90c836014f60b18b"],"target_id":["edbb3c1e117f46b3ba3b34881d8e588d"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["717a9bf79e584830859595b8dbe9d433","2e66d84237ff4cc783539c366380924d","24b2b6ec7af3414c810700a46331ad63","309decc979cd4802a346ae247a6fede2","123885573bcc4737bc690ae17b20c06d","83daa46595604af9ae9b42ff968e4f51","88cfc77d4a4d4c6b9bce6542b20f75ca","3a5e2515973f49fea6ca065e3864ede2"],"active_org_master_entity_id":["003ec4ebe45b4452c5d38b8fbbb181f8"],"research_disease":["717a9bf79e584830859595b8dbe9d433","2e66d84237ff4cc783539c366380924d","24b2b6ec7af3414c810700a46331ad63","309decc979cd4802a346ae247a6fede2"],"non_research_disease":["123885573bcc4737bc690ae17b20c06d","83daa46595604af9ae9b42ff968e4f51","88cfc77d4a4d4c6b9bce6542b20f75ca","3a5e2515973f49fea6ca065e3864ede2"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","20f1c6915ff140519285386c54883aae","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2"}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"24b2b6ec7af3414c810700a46331ad63","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"88cfc77d4a4d4c6b9bce6542b20f75ca","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"3a5e2515973f49fea6ca065e3864ede2","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"309decc979cd4802a346ae247a6fede2","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"83daa46595604af9ae9b42ff968e4f51","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"2e66d84237ff4cc783539c366380924d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"123885573bcc4737bc690ae17b20c06d","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"17b37d47915f4e49a48815a9963374b6","docid":140134,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"85ff601f223e3d6f852f989ca97cb7cb","created_ts":"2024-03-18T02:25:42.000Z","updated_ts":"2026-04-04T21:05:03.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"SHR-4849","status":"ACTIVE"}],"dev_code":[{"name":"IDE 849","source_info":[{"attachment_path":"data/phs_source_info/def7/f19b/172b/fe72/def7f19b172bfe72.jpg","attachment_type":"image/jpeg","code":"IDEAYA-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/bd78/3bd4/b660/cd24/bd783bd4b660cd24.jpg","source":"Company pipeline","source_url":"https://www.ideayabio.com/pipeline/"}],"status":"ACTIVE"},{"name":"IDE-849","source_info":[{"attachment_path":"data/phs_source_info/def7/f19b/172b/fe72/def7f19b172bfe72.jpg","attachment_type":"image/jpeg","code":"IDEAYA-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/bd78/3bd4/b660/cd24/bd783bd4b660cd24.jpg","source":"Company pipeline","source_url":"https://www.ideayabio.com/pipeline/"}],"status":"ACTIVE"},{"name":"IDE849","source_info":[{"attachment_path":"data/phs_source_info/def7/f19b/172b/fe72/def7f19b172bfe72.jpg","attachment_type":"image/jpeg","code":"IDEAYA-202504","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/bd78/3bd4/b660/cd24/bd783bd4b660cd24.jpg","source":"Company pipeline","source_url":"https://www.ideayabio.com/pipeline/"}],"status":"ACTIVE"},{"name":"SHR-4849","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["1d449fbb74a814f5f257e7ad1fd5b7e1"],"mechanism_action_id":["d06a654603e9d808808297a8d81fafc1","cf1cf8ea0f9b80ee88876a3324ceac99"],"target_id":["2207f013c4204775b1b1c7974c275747","6acffb63799b4ba3bc85a4c59fcb05d7"],"disease_id":["83c00fea95ab443a997c1e3818bea37e","2536e79ced34450fbb09de73061cf096","b2fa14a75a53403881be137eba040dbf","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["99cc9089486198363f22c55d3fbe3534","0457fb3299e6bbc28df4b65e38e5ef77","1d449fbb74a814f5f257e7ad1fd5b7e1"],"research_disease":["83c00fea95ab443a997c1e3818bea37e","2536e79ced34450fbb09de73061cf096","b2fa14a75a53403881be137eba040dbf","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1751932800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1760400000000}}],"disease_phase":[{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"83c00fea95ab443a997c1e3818bea37e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b2fa14a75a53403881be137eba040dbf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["8cf7f3af90ad45cdeb2a74b6e73b6ebf","99cc9089486198363f22c55d3fbe3534"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"748fb1b16e9b3afcbd8928205ee73cdd","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["d06a654603e9d808808297a8d81fafc1"],"moiety_target_id":["2207f013c4204775b1b1c7974c275747"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"181330cff554487d85c2091dce6bb92d","docid":35996,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"86494848e7d43b6287037e927e0f8651","created_ts":"2022-07-06T12:02:45.000Z","updated_ts":"2026-02-24T18:47:57.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"TGRX-814","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.tjrbiosciences.com/index.php?m=content&c=index&a=lists&catid=4"}],"status":"ACTIVE"}],"dev_code":[{"name":"TGRX 814","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-tgrx-814"}],"status":"ACTIVE"},{"name":"TGRX-814","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.tjrbiosciences.com/index.php?m=content&c=index&a=lists&catid=4"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-tgrx-814"}],"status":"ACTIVE"},{"name":"TGRX814","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-tgrx-814"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["419a294c0dcb3eb8e37c4c3e275885e4"],"mechanism_action_id":["ea5c58873d8582884db7996287ed6df1","fe7356095084581c347d1313322820ac"],"target_id":["fd23fd900514452d8978eac02dc46649","bb11c625a65042baa371f50d2804fd37"],"disease_id":["1d78cca79eae4632bc4464c90a574f83","d7a26da8f1ff43559e34fe72da812c56","1a51c709099840a381471343fb21c3a9","cec1504cb1d141d68776457c4b88b30f","e61a6d319d7a402f8435c866c9e8584e","7cb6983b4169498e89b08fd725a22b46","774c47a9cc904667a74dabe8fa53fc40","1a95630392584c7892bec2dc9888cbfc"],"active_org_master_entity_id":["419a294c0dcb3eb8e37c4c3e275885e4"],"research_disease":["1d78cca79eae4632bc4464c90a574f83","d7a26da8f1ff43559e34fe72da812c56","1a51c709099840a381471343fb21c3a9","cec1504cb1d141d68776457c4b88b30f","e61a6d319d7a402f8435c866c9e8584e","7cb6983b4169498e89b08fd725a22b46","774c47a9cc904667a74dabe8fa53fc40","1a95630392584c7892bec2dc9888cbfc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1715558400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1709683200000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"774c47a9cc904667a74dabe8fa53fc40","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e61a6d319d7a402f8435c866c9e8584e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a51c709099840a381471343fb21c3a9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"cec1504cb1d141d68776457c4b88b30f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"02f4a5e05a3e43969863ad3349fe0cbc","docid":19084,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-05-26T07:55:46.000Z","updated_ts":"2026-02-25T00:34:57.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"wangya","drug_name":[{"lang":"CN","name":"重组三价人乳头瘤病毒(16/18/58型)疫苗(大肠杆菌)(北京康乐卫士生物)","source_info":[{"code":"CXSL1500033","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)","source_info":[{"code":"CXSL1500033","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["f247261504c7c09e0abc9bb0dbb31353"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"special_review":["23d3523b7ece48ddacaddac53a66949d"],"disease_id":["bb5baa14bc3e4e11be812216ce0faed4","e2f4f35fe182404a93797bf69a1697f5","956a06d7545e413d81e5a2eeb642c357","094e8b34333546c08ac7065e12ef9d52","5c2d46f9e53a49b3bb369426445fc629","8e04d2b322b04e38848288e4877f3536","ab4b1e211d044fc2ae24c01ff59fe0e6","402f598324d54b7399130af6a3b31465","eb66daaa12c6416ea299a175f10a1937","14c7611e52214faa9f622b94ea111217","f9b845222b9b44a4b0b8807177b74961","05b221987ce94deeb422ab85e2956304"],"active_org_master_entity_id":["f247261504c7c09e0abc9bb0dbb31353","d750d6a26e06406876134be34048f568","820e36dcbdb2e74fa53ef111b7ad995b"],"research_disease":["bb5baa14bc3e4e11be812216ce0faed4","e2f4f35fe182404a93797bf69a1697f5","956a06d7545e413d81e5a2eeb642c357","094e8b34333546c08ac7065e12ef9d52","5c2d46f9e53a49b3bb369426445fc629","8e04d2b322b04e38848288e4877f3536","ab4b1e211d044fc2ae24c01ff59fe0e6","402f598324d54b7399130af6a3b31465","eb66daaa12c6416ea299a175f10a1937","14c7611e52214faa9f622b94ea111217"],"non_research_disease":["f9b845222b9b44a4b0b8807177b74961","05b221987ce94deeb422ab85e2956304"],"inactive_org_master_entity_id":["635a7d17d7c9b8285f4debd865514615"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1745366400000}}],"disease_phase":[{"disease_id":"8e04d2b322b04e38848288e4877f3536","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bb5baa14bc3e4e11be812216ce0faed4","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"5c2d46f9e53a49b3bb369426445fc629","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"eb66daaa12c6416ea299a175f10a1937","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"094e8b34333546c08ac7065e12ef9d52","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e2f4f35fe182404a93797bf69a1697f5","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"956a06d7545e413d81e5a2eeb642c357","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"ab4b1e211d044fc2ae24c01ff59fe0e6","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"14c7611e52214faa9f622b94ea111217","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"05b221987ce94deeb422ab85e2956304","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f9b845222b9b44a4b0b8807177b74961","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"402f598324d54b7399130af6a3b31465","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"610ae1022fe744d2a3cd5aedcd3da855","docid":51325,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-10-08T14:48:20.000Z","updated_ts":"2024-10-30T10:38:05.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HP-5070","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["de5a7db47d076953fd3eeb0dd6ad7a57"],"disease_id":["3a6bf58b81e44b47b2371f7ed2fc6b25"],"active_org_master_entity_id":["de5a7db47d076953fd3eeb0dd6ad7a57"],"research_disease":["3a6bf58b81e44b47b2371f7ed2fc6b25"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1662336000000}}],"disease_phase":[{"disease_id":"3a6bf58b81e44b47b2371f7ed2fc6b25","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"01f2eff34bbd44c3a2c717dcbba0a40b","docid":38828,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:43.000Z","updated_ts":"2025-01-16T21:05:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ABI-M201","status":"ACTIVE"}],"dev_code":[{"name":"ABI M201","status":"ACTIVE"},{"name":"LBP02","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.xbiome.com/pipeline"}],"status":"ACTIVE"},{"name":"M-201","status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["ba089da23fd6ddb69b2a3b4700dfdd8f"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","e11d32d254aba0e2defc5d6c4cd64b1a"],"disease_id":["509a094ddb78441eaeeeae867832dfad"],"active_org_master_entity_id":["6e8bb71b8dcf92da6d2c08e3b3df911f","d88590e686ad5608bbbfeb811b14d188"],"research_disease":["509a094ddb78441eaeeeae867832dfad"],"inactive_org_master_entity_id":["ba089da23fd6ddb69b2a3b4700dfdd8f"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1650931200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1616112000000}}],"disease_phase":[{"disease_id":"509a094ddb78441eaeeeae867832dfad","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["6e8bb71b8dcf92da6d2c08e3b3df911f","ba089da23fd6ddb69b2a3b4700dfdd8f","eae957b52952a1f465ab89cdd7e41904"],"data_source":10}
+{"drug_id":"1956a0c0760b4c4ca94a63de92466e13","docid":920077,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"f828ab3594613a83bca5f0b1f1bb87dc","created_ts":"2025-02-13T05:49:30.000Z","updated_ts":"2025-07-31T00:31:19.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"nL-LMNB1-001","source_info":[{"code":"NCT06816498","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov"}],"status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["b494f0d4b31d685eb6079c2f1a06405e"],"mechanism_action_id":["304cc5d4bd734d1bbf080281a68d0d53"],"target_id":["53b274b6a85d4c8988c804fe2c73e0b4"],"disease_id":["bfc8b1ea10834e0389df563a05f2b022"],"active_org_master_entity_id":["b494f0d4b31d685eb6079c2f1a06405e"],"research_disease":["bfc8b1ea10834e0389df563a05f2b022"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1742169600000}}],"disease_phase":[{"disease_id":"bfc8b1ea10834e0389df563a05f2b022","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"21dd27916130464eb271fb39ae1ebd61","docid":79019,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2021-10-08T14:49:33.000Z","updated_ts":"2026-04-13T07:15:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"吡康格雷","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/JCJ7FbWLQoUfNrktAZJ5Ug"}],"status":"ACTIVE"},{"lang":"EN","name":"Becondogrel","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzIxNzE0NzQxOA==&mid=2247487246&idx=1&sn=0dfb086af2fc1e3ca709ed5af38f6b1a"}],"status":"ACTIVE"}],"dev_code":[{"name":"SBK-002","status":"ACTIVE"},{"name":"sbk 002","status":"ACTIVE"},{"name":"sbk002","source_info":[{"code":"CXHS2300051","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bc4b96f474fe8fe931f4c0509fa004e0"],"disease_id":["2a102769860f4f30aeb464b8123e562c","299e91fc2f234bbb9e0156c4f43ad970","22d4d689fe8b43b88ec66a65d7575106","979761c8b3bf4412b14714746617f31a","bf821ba3fb194a38a5b2f804bcf68c44","27013926797d4bc4bf088e4104530e7d"],"active_org_master_entity_id":["bc4b96f474fe8fe931f4c0509fa004e0","240697e9689159977d0c390de9dc4034"],"research_disease":["2a102769860f4f30aeb464b8123e562c","299e91fc2f234bbb9e0156c4f43ad970","22d4d689fe8b43b88ec66a65d7575106","979761c8b3bf4412b14714746617f31a","bf821ba3fb194a38a5b2f804bcf68c44","27013926797d4bc4bf088e4104530e7d"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1765238400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1685404800000}}],"disease_phase":[{"disease_id":"979761c8b3bf4412b14714746617f31a","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2a102769860f4f30aeb464b8123e562c","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"22d4d689fe8b43b88ec66a65d7575106","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"299e91fc2f234bbb9e0156c4f43ad970","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"08ce2650d83545a6bfb2346ed84ba173","docid":1278,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"9f31233bceb94d9796d3f3556f17ab13","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":8,"target_extend_id":"886c0e8e02d03932baba22f8a1fa2773","created_ts":"2023-01-05T09:48:34.000Z","updated_ts":"2026-02-25T00:16:51.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wangya","drug_name":[{"lang":"EN","name":"TLL-041","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://highlightllpharma.com/service/#page0"}],"status":"ACTIVE"}],"dev_code":[{"name":"BHV-8000","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://ir.biohaven.com/news-releases/news-release-details/biohaven-acquires-exclusive-license-oral-brain-penetrant-dual"}],"status":"ACTIVE"},{"name":"TLL 041","status":"ACTIVE"},{"name":"TLL-041","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["66e21cc9b4af323294049ddef0c7f414"],"mechanism_action_id":["5f5e0563a81f2d5d04703799942dff44","11b70dcc83ff6e146c0a3f445d1c1b9e"],"target_id":["75baf324563b4c8ab7eaac21da3a9fb8","84f5b9e6a5e44eabbb2a79180b79489c"],"disease_id":["f1ad50b3010e4721a3ce9b148c940a5a","54a77f56d72c4ac6a0eb840f4518e3a0","cdfb06abaeaf48fd92abe6a96b73de57","efa00642a00748a1b6196fc9db7ff211","89c0baa6b7db4089aaad7be19fc0d4e8"],"active_org_master_entity_id":["66e21cc9b4af323294049ddef0c7f414","81c7c15c372ffd0c1d2a878a76d778ee","4d2f9401227d6a222a7b2b16f3420425"],"research_disease":["f1ad50b3010e4721a3ce9b148c940a5a","54a77f56d72c4ac6a0eb840f4518e3a0","cdfb06abaeaf48fd92abe6a96b73de57","efa00642a00748a1b6196fc9db7ff211","89c0baa6b7db4089aaad7be19fc0d4e8"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1748390400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1762992000000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"89c0baa6b7db4089aaad7be19fc0d4e8","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"efa00642a00748a1b6196fc9db7ff211","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"cdfb06abaeaf48fd92abe6a96b73de57","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"}],"deal_related_org":["66e21cc9b4af323294049ddef0c7f414","81c7c15c372ffd0c1d2a878a76d778ee"],"data_source":10}
+{"drug_id":"127ace3c18f04d92a32e6a23f9048d7b","docid":110621,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"bbfab30dd83436259980f0fec41b6ea5","created_ts":"2024-02-29T06:33:38.000Z","updated_ts":"2025-10-09T13:38:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"JMT202","status":"ACTIVE"}],"dev_code":[{"name":"JMT202","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["90dde2cce6d4a0eb17abb8eb7b47be9d"],"mechanism_action_id":["02eca384589a4574aaac505e9f2081df"],"target_id":["2b3acd3475244225a00f9cb00d05c76a"],"disease_id":["f00b9f74b45042caa6a9fe367400732a"],"active_org_master_entity_id":["90dde2cce6d4a0eb17abb8eb7b47be9d","5cf5fedddb15b3ca0a531d9b789f0286"],"research_disease":["f00b9f74b45042caa6a9fe367400732a"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756425600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1746144000000}}],"disease_phase":[{"disease_id":"f00b9f74b45042caa6a9fe367400732a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"185b6f10f5ea4612b289afd968a82092","docid":1733719,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":4,"target_extend_id":"01af232868bd374fa021bef720de877b","created_ts":"2026-03-24T08:59:22.000Z","updated_ts":"2026-03-28T21:08:47.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"TB-500 (Thymosin Beta 4 17-23 Fragment)","source_info":[{"code":"NCT07487363","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07487363"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["62e5ad9fa2e11e4e899ba11cf1d5ef44"],"mechanism_action_id":["eebac1c3468a42f68a31afad342804ab"],"target_id":["17a03ec8969f4d93b2d22251b069455e"],"disease_id":["27013926797d4bc4bf088e4104530e7d","74fcbe67c99f4263b6713bc197e2ea17"],"active_org_master_entity_id":["62e5ad9fa2e11e4e899ba11cf1d5ef44"],"research_disease":["27013926797d4bc4bf088e4104530e7d","74fcbe67c99f4263b6713bc197e2ea17"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1770249600000}}],"disease_phase":[{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"74fcbe67c99f4263b6713bc197e2ea17","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"032e67a99576467c9404642de84804a8","docid":26103,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":49,"target_extend_id":"8213c47538943d6abbd8a82878581fef","created_ts":"2021-10-08T14:46:41.000Z","updated_ts":"2026-04-11T21:06:16.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"CEB-01","source_info":[{"code":"2024_11566","normalized_source_id":"c47a5730bf5e40b3aa76c26820ec6d4e","source":"ASCO","source_url":"https://meetings.asco.org/abstracts-presentations/233344"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"7-ethyl-10-hydroxy Camptothecin","source_info":[{"code":"NCT06986811","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06986811"}],"status":"ACTIVE"},{"lang":"EN","name":"N-38 loaded biodegradable nanofiber","status":"ACTIVE"},{"lang":"EN","name":"SN 38 loaded biodegradable nanofiber","status":"ACTIVE"}],"dev_code":[{"name":"CEB 01","status":"ACTIVE"},{"name":"CEB01","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["cccab697d9c7b4d65887030f29ec5aeb"],"mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"],"target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["27e5bea6fbe341e7a2d375d36cf85606","78cb173a4de34f07befac28de907e7bf","c349d56721634602bd73c8f36c3b496a","b710ed37a11246c387b08efbe0196b55","a4f7254e36da425087293790eb964551"],"active_org_master_entity_id":["a27ae1160cbd5bd30045a45e99f2b617"],"research_disease":["27e5bea6fbe341e7a2d375d36cf85606","78cb173a4de34f07befac28de907e7bf","c349d56721634602bd73c8f36c3b496a","b710ed37a11246c387b08efbe0196b55"],"non_research_disease":["a4f7254e36da425087293790eb964551"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1746489600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1724112000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"b710ed37a11246c387b08efbe0196b55","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"27e5bea6fbe341e7a2d375d36cf85606","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c349d56721634602bd73c8f36c3b496a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"057ce8ce9f0447fd91da461db88487ab","docid":58701,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":139,"target_extend_id":"8fcd89bcdc5232438568e168ec9a4b11","created_ts":"2022-03-08T02:33:10.000Z","updated_ts":"2026-04-04T21:04:25.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"UI018","status":"ACTIVE"}],"dev_code":[{"name":"UI 018","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4db612721a1cfe7ad1848edd5d9b5aaa"],"mechanism_action_id":["8fe103cd6dd29ca91c56f37a4583b730"],"target_id":["d67566f9d19847b5b59425ab82876225"],"disease_id":["ca653a74565244b48ac6cc6ec1bf09a9"],"active_org_master_entity_id":["4db612721a1cfe7ad1848edd5d9b5aaa"],"research_disease":["ca653a74565244b48ac6cc6ec1bf09a9"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1630886400000}}],"disease_phase":[{"disease_id":"ca653a74565244b48ac6cc6ec1bf09a9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0929a9ba33584aaa84be569bca1f96cf","docid":71876,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-08-15T06:01:54.000Z","updated_ts":"2024-11-07T15:32:48.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"U16","source_info":[{"code":"CXSL2200375","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"U 16","status":"ACTIVE"},{"name":"U-16","status":"ACTIVE"},{"name":"U16","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["2c5356faa04bedc78ff955942b79fd5e"],"disease_id":["5822abc7ac09433bba89ca2349b2dec7","8af6d8786d5b4153a5e789972ad8b409"],"active_org_master_entity_id":["2c5356faa04bedc78ff955942b79fd5e"],"research_disease":["5822abc7ac09433bba89ca2349b2dec7","8af6d8786d5b4153a5e789972ad8b409"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1677196800000}}],"disease_phase":[{"disease_id":"5822abc7ac09433bba89ca2349b2dec7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8af6d8786d5b4153a5e789972ad8b409","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"21515772207c43ef90d0d344b087b944","docid":65843,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":16,"target_extend_id":"12da1094622c367d8409b3fb561d144a","created_ts":"2021-10-08T14:41:16.000Z","updated_ts":"2026-04-18T21:06:16.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"泽普昔替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/lmpeLVSn-ef5mp-XdQQULg"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUxOTgxNzg4NA==&mid=2247593911&idx=5&sn=6985267926857a05f03bc375d6841000"}],"status":"ACTIVE"},{"lang":"EN","name":"Zemprocitinib","source_info":[{"code":"list 130","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf?sfvrsn=ef74744a_5&download=true"}],"status":"ACTIVE"}],"dev_code":[{"name":"LNK 001","status":"ACTIVE"},{"name":"LNK 01001","status":"ACTIVE"},{"name":"LNK-001","status":"ACTIVE"},{"name":"LNK001","source_info":[{"code":"CTR20230840","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=7dbdb34400aa4ef3ac64fd7cdfa214a4"}],"status":"ACTIVE"},{"name":"LNK01001","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0f6f636f8656085a68d49c2327ac9947"],"mechanism_action_id":["5f5e0563a81f2d5d04703799942dff44"],"target_id":["75baf324563b4c8ab7eaac21da3a9fb8"],"disease_id":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","8da973b225c24afbba255413635fb240","6be96778ed424f8d91de00ab82364114","a995ea676cb44956a51af415a8bd2b14"],"active_org_master_entity_id":["0f6f636f8656085a68d49c2327ac9947","26a983ae088aa0be961bbf8205bd4eea","84ad28fb8a0b6eef403ba652e15c62be"],"research_disease":["36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","8da973b225c24afbba255413635fb240","6be96778ed424f8d91de00ab82364114","a995ea676cb44956a51af415a8bd2b14"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1775606400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1647820800000}}],"disease_phase":[{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a995ea676cb44956a51af415a8bd2b14","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["0f6f636f8656085a68d49c2327ac9947","84c5733aa1667bc99c644deddcc2eeab","b997b175516cc653e4ad088e4808b395"],"if_speculate":0,"data_source":10}
+{"drug_id":"0987c8e52c42455598061bb9caf3c216","docid":205223,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2024-12-19T11:28:37.000Z","updated_ts":"2026-04-02T11:27:03.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CRMA-1001","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://chromamedicine.com/2024/12/10/chroma-medicine-and-nvelop-therapeutics-unite-to-form-nchroma-bio-securing-75-million-to-accelerate-genetic-medicines/"}],"status":"ACTIVE"}],"drug_type":["b9d918351d7b46dd89ef202b2d33c38d"],"originator_org_master_entity_id":["1aa206d91e82be530f6c7ed6b0620664"],"disease_id":["f196ef1a4d9c4cb3aede0ea60aac4a52","e4deccc598a549d2a0dd06c0477691c2"],"active_org_master_entity_id":["c0e5675fbc8c18ebcb858d02feb28e5b"],"research_disease":["f196ef1a4d9c4cb3aede0ea60aac4a52","e4deccc598a549d2a0dd06c0477691c2"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1766361600000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1766361600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1769558400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1733875200000}}],"disease_phase":[{"disease_id":"f196ef1a4d9c4cb3aede0ea60aac4a52","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e4deccc598a549d2a0dd06c0477691c2","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"deal_related_org":["1aa206d91e82be530f6c7ed6b0620664","6ee069bb637994c236db3ce7f2fc1ec4","c0e5675fbc8c18ebcb858d02feb28e5b"],"data_source":10}
+{"drug_id":"050a6ba51d7947a9b0dd78fcc6485002","docid":59972,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:50:03.000Z","updated_ts":"2026-02-24T23:48:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MLC901","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://moleac.com/pipeline/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"NeuroAiD II","status":"ACTIVE"}],"dev_code":[{"name":"MLC601","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://moleac.com/pipeline/"}],"status":"ACTIVE"}],"trade_name":[{"name":"NeuroAiD","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["a11f6fe56692f6332bd2b41738ac0c2e"],"atc_code":["b14c961806e144cca468cf901ec93534"],"disease_id":["066ceaf0fae84f83912000fa80a5319b","c9d3c55f01d24f11a6035f989330c65f","58a3d7c5f89242739ab5ea83463d9b1b","54a77f56d72c4ac6a0eb840f4518e3a0","7c6adeed2c67494b9197876df5548508","6cf8ff4207bd4f75a9c7ce66676516a0"],"active_org_master_entity_id":["a11f6fe56692f6332bd2b41738ac0c2e","bff7b6822f826e66131d51d63770f348","9eadd6cd080ebdc2880741e6e8c7135e"],"research_disease":["066ceaf0fae84f83912000fa80a5319b","c9d3c55f01d24f11a6035f989330c65f","58a3d7c5f89242739ab5ea83463d9b1b","54a77f56d72c4ac6a0eb840f4518e3a0"],"non_research_disease":["7c6adeed2c67494b9197876df5548508","6cf8ff4207bd4f75a9c7ce66676516a0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764547200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1749168000000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1749168000000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1739404800000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c9d3c55f01d24f11a6035f989330c65f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"58a3d7c5f89242739ab5ea83463d9b1b","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6cf8ff4207bd4f75a9c7ce66676516a0","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"066ceaf0fae84f83912000fa80a5319b","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7c6adeed2c67494b9197876df5548508","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"020f81d7a59942cfb5eb2c71f3bb90a3","docid":35169,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":983750400000,"created_ts":"2021-12-10T12:54:53.000Z","updated_ts":"2025-07-15T12:16:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"NIM-76","source_info":[{"code":"PMID: 8968666","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed"}],"status":"ACTIVE"}],"dev_code":[{"name":"NIM 76","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["9077337fa0932e9ca82a565cbcd055da"],"mechanism_action_id":["1f2c350e633443391d80a07199baef9a"],"disease_id":["a8a1068dabd544968d8c7d956effaaaa"],"active_org_master_entity_id":["b04f17a821e857d43fca6ea2f6419cb6"],"first_approved_country":["2f753928-f426-3cc1-9ea6-8c25f6a4d330"],"first_approved_indication":["a8a1068dabd544968d8c7d956effaaaa"],"research_disease":["a8a1068dabd544968d8c7d956effaaaa"],"inactive_org_master_entity_id":["9077337fa0932e9ca82a565cbcd055da"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["2f753928-f426-3cc1-9ea6-8c25f6a4d330"],"research_country":[{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":983750400000}}],"disease_phase":[{"disease_id":"a8a1068dabd544968d8c7d956effaaaa","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"17e47718ede943988fdde7c99301a519","docid":13067,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:24.000Z","updated_ts":"2024-11-07T04:30:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"LC-100","status":"ACTIVE"}],"dev_code":[{"name":"LC-100","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["275dad6e516a181a74885c043ab0c6ae"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["275dad6e516a181a74885c043ab0c6ae"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1644364800000}}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"398f268ccfc94758813d8a87f0adc21a","docid":16300,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"4803ab793c5044aba32b1786640938d3","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2023-01-10T05:28:14.000Z","updated_ts":"2026-02-20T22:32:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"sunying","drug_name":[{"lang":"EN","name":"[F-18]MeFAMP","source_info":[{"code":"NCT05676489","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05676489"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["9f588615919b79714978d8adb24063c6"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["941ef5bdf9fa49b3b8054dd755019209","db0eb9ef2c3a46458ab1640232a6730f"],"active_org_master_entity_id":["9f588615919b79714978d8adb24063c6"],"research_disease":["941ef5bdf9fa49b3b8054dd755019209","db0eb9ef2c3a46458ab1640232a6730f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1775001600000}}],"disease_phase":[{"disease_id":"db0eb9ef2c3a46458ab1640232a6730f","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"941ef5bdf9fa49b3b8054dd755019209","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"02c2d1804a064c7c8b044d6138da70b7","docid":12286,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":946684800000,"rnk":33,"target_extend_id":"e40c5128aae63792842c0a8d5ce256c9","created_ts":"2021-10-08T14:45:41.000Z","updated_ts":"2025-07-19T21:15:01.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","first_approved_date_cn":946684800000,"drug_name":[{"lang":"CN","name":"门冬氨酸阿奇霉素","status":"ACTIVE"},{"lang":"EN","name":"Azithromycin Aspartate","status":"ACTIVE"}],"generic_name":[{"name":"Azithromycin","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ec7289b52f97b29caaffc7e81bac3433"],"mechanism_action_id":["69b18a384304bf44d2471f11d85d58ba"],"target_id":["32813993f70c47c396c8954cd5eab46c"],"atc_code":["2d3b351e0fb14c658bb300ba3632acae","fecee4a8f9914f568d65211ade93ba6e"],"disease_id":["9a802adb6e94433f8f4eb9be678991b8"],"active_org_master_entity_id":["ec7289b52f97b29caaffc7e81bac3433"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["9a802adb6e94433f8f4eb9be678991b8"],"research_disease":["9a802adb6e94433f8f4eb9be678991b8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":946684800000}}],"disease_phase":[{"disease_id":"9a802adb6e94433f8f4eb9be678991b8","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0390949a086442eaa626d678028e7c8a","docid":27855,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/P-Cymene","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","created_ts":"2021-10-08T14:49:02.000Z","updated_ts":"2024-11-10T00:22:10.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"伞花烃","status":"ACTIVE"},{"lang":"EN","name":"Cymene","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8bc7fed3e1cbcf01d4283667fc0c1b57"],"atc_code":["5e088b60a6e54766a1c2767a1122f291"],"disease_id":["d1a3be98c4f649c58815869901b27888"],"active_org_master_entity_id":["8bc7fed3e1cbcf01d4283667fc0c1b57"],"research_disease":["d1a3be98c4f649c58815869901b27888"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"d1a3be98c4f649c58815869901b27888","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"08bff6b61a2342bb8901829200617405","docid":39650,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-07-19T06:03:05.000Z","updated_ts":"2024-11-07T15:32:03.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"XYP-001","source_info":[{"code":"CXHL2200508","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"XYP 001","status":"ACTIVE"},{"name":"XYP001","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["384037642fad2eb1b085146aa601f666"],"disease_id":["e9b27c71d3024fd6ab7dc1dfc304f54d"],"active_org_master_entity_id":["384037642fad2eb1b085146aa601f666"],"research_disease":["e9b27c71d3024fd6ab7dc1dfc304f54d"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1669680000000}}],"disease_phase":[{"disease_id":"e9b27c71d3024fd6ab7dc1dfc304f54d","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"01656503f4624dfa8f47a23d059db200","docid":1610120,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-07-09T08:06:32.000Z","updated_ts":"2026-03-10T23:08:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"LX-111","source_info":[{"code":"NCT07053358","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07053358"}],"status":"ACTIVE"}],"dev_code":[{"name":"LX-111","source_info":[{"code":"NCT07053358","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07053358"}],"status":"ACTIVE"}],"drug_type":["5a4e5467a94447b4b721e4b74e2f3d72"],"originator_org_master_entity_id":["7c8ddab62a944367b3f804bf2e5ab1b2"],"disease_id":["7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"active_org_master_entity_id":["7c8ddab62a944367b3f804bf2e5ab1b2"],"research_disease":["7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1772323200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1751414400000}}],"disease_phase":[{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"056891c9d67ca7c5f857ec792c6db491","docid":11966,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-03-29T04:24:19.000Z","updated_ts":"2024-10-30T10:20:49.000Z","data_status":"ACTIVE","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Multiplex targeted chimeric antigen receptor CAR-T cell therapy(Cellevolve)","status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["12b8a50dfc8a9db25896e84e9cdbd106"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["8df1ce96a8fd4a66ba6dc13760c20282"],"active_org_master_entity_id":["12b8a50dfc8a9db25896e84e9cdbd106"],"research_disease":["8df1ce96a8fd4a66ba6dc13760c20282"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1670284800000}}],"disease_phase":[{"disease_id":"8df1ce96a8fd4a66ba6dc13760c20282","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"04b3e1b3b8bf4b81b06fb33cb7bf3eac","docid":24403,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1597968000000,"created_ts":"2022-08-03T08:55:35.000Z","updated_ts":"2025-04-25T20:52:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1597968000000,"drug_name":[{"lang":"CN","name":"复方一枝蒿颗粒","status":"ACTIVE"},{"lang":"EN","name":"Compound Yizhihao Granules","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["cef600e67ef9fa85039311631c94b7a3"],"disease_id":["8b891cd6e0eb46359c0ce5424a86c124","2eea73e5ecab4c75b7837aa75f5a6392"],"active_org_master_entity_id":["cef600e67ef9fa85039311631c94b7a3"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["8b891cd6e0eb46359c0ce5424a86c124"],"research_disease":["8b891cd6e0eb46359c0ce5424a86c124","2eea73e5ecab4c75b7837aa75f5a6392"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1597968000000}}],"disease_phase":[{"disease_id":"2eea73e5ecab4c75b7837aa75f5a6392","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8b891cd6e0eb46359c0ce5424a86c124","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"06f2df7bab6d4d92991ceb46af395538","docid":3236,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:31.000Z","updated_ts":"2025-03-23T16:22:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"CN","name":"止咳颗粒","status":"ACTIVE"},{"lang":"EN","name":"Zhike Granules","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["c8cb8f3625f9515a33ea108db8b5d07e"],"disease_id":["3ff780f1137a464ab0a977fd9228b405","564a2451296345689d8f778eb1beea86"],"active_org_master_entity_id":["c8cb8f3625f9515a33ea108db8b5d07e"],"research_disease":["3ff780f1137a464ab0a977fd9228b405","564a2451296345689d8f778eb1beea86"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1592784000000}}],"disease_phase":[{"disease_id":"3ff780f1137a464ab0a977fd9228b405","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"564a2451296345689d8f778eb1beea86","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"02f410529f844f04b28378d614cd6507","docid":43151,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"wiki_link":"https://en.wikipedia.org/wiki/Sofosbuvir/velpatasvir","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1467072000000,"rnk":1,"target_extend_id":"19f04bd19ca23a5b905bb2827fc95038","created_ts":"2021-10-08T14:49:58.000Z","updated_ts":"2026-02-24T22:11:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1527033600000,"drug_name":[{"lang":"CN","name":"索磷布韦维帕他韦","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Sofosbuvir/Velpatasvir","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"ソホスブビル/ベルパタスビル","source_info":[{"code":"23100AMX00001000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/230867_6250116F1025_1_06"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"GS 5816/sofosbuvir","status":"ACTIVE"},{"lang":"EN","name":"SOF/VEL","status":"ACTIVE"},{"lang":"EN","name":"Sofosbuvir and Velpatasvir","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Sofosbuvir/GS 5816","status":"ACTIVE"},{"lang":"EN","name":"Velpatasvir/sofosbuvir","status":"ACTIVE"},{"lang":"CN","name":"索磷布韦/维帕他韦","status":"ACTIVE"}],"dev_code":[{"name":"GS 7977/GS 5816","source_info":[{"code":"23100AMX00001000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/230867_6250116F1025_1_07"}],"status":"ACTIVE"}],"trade_name":[{"name":"Epclusa","source_info":[{"code":"23100AMX00001000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/230867_6250116F1025_1_07"}],"status":"ACTIVE"},{"name":"エプクルーサ","source_info":[{"code":"23100AMX00001000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/230867_6250116F1025_1_07"}],"status":"ACTIVE"},{"name":"丙通沙","status":"ACTIVE"},{"name":"엡클루사정","source_info":[{"code":"202200754","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202200754aupdateTs2024-05-20%2018:19:23.0b"}],"status":"ACTIVE"}],"related_component":["4b37e6ecd88241ffb6dcd49b2ef444d7","a3c746af8d894a50913fcda6eb574eaa"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["52aee12631589b24dca3ae62de8a0886"],"mechanism_action_id":["533d9cddbd73a9057895297da07d1121","04ea899678fd2d10cd11345443fe9a69"],"target_id":["301c9a2fac6a4431acfb969b043dc4b4","ef5e97c105e947c3859e4eb32572c989"],"atc_code":["d2e91714a673459c85c698d12465ee0d"],"special_review":["23d3523b7ece48ddacaddac53a66949d","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["594f20605b924a10aefe7d4cfd877737","216b0dcc86a34619bad44c996e80b7b8","d49375c49b104622bc287a4f78aadd62","5f0765227409473d803995e585313374","7b34c4c341a74b9984deff61be03c587","47385e430db349dba0005f75f623ba3e","752718d528cd4eb89005c3febf5815ab","d897133453e34ab8852daa25c197a011","12bb66d09ff34c86b3b06e4ab0e40c65","840f6357def44f5aba7f76e4511a14a8","acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["52aee12631589b24dca3ae62de8a0886","96c41a2c05ba90813a74817c49699727","1c4433dc406aa97f0f8ec70876a2e3ab"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["5f0765227409473d803995e585313374"],"research_disease":["594f20605b924a10aefe7d4cfd877737","216b0dcc86a34619bad44c996e80b7b8","d49375c49b104622bc287a4f78aadd62","5f0765227409473d803995e585313374","7b34c4c341a74b9984deff61be03c587","47385e430db349dba0005f75f623ba3e"],"non_research_disease":["752718d528cd4eb89005c3febf5815ab","d897133453e34ab8852daa25c197a011","12bb66d09ff34c86b3b06e4ab0e40c65","840f6357def44f5aba7f76e4511a14a8","acfaaa0373944ffd89b0a2ace0d8c564"],"inactive_org_master_entity_id":["2f66089358efafab988ad991c3b0ead4"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3","76732dd51f2842799e6843eef80820ea"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07","666d5a51-60da-3482-b804-e6df04651a1e","3d57c904-23bf-3ee0-9924-83496c75b8ee","52d1b118-b540-37ba-9cb2-f5aff686bb10","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1467072000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1527033600000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1467763200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1546905600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1470096000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1468195200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1482105600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1474502400000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1467763200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1645056000000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1467763200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1467763200000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1564790400000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1564790400000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1564790400000}},{"country":"5525dc87-4a1f-39c5-8b61-13e827fe3c5b","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1564790400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1604620800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1546387200000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1581033600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1686182400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1546387200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1604620800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1572134400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1546387200000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1529020800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1604620800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1512000000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1604620800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1547769600000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1546387200000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1523491200000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1568332800000}}],"disease_phase":[{"disease_id":"47385e430db349dba0005f75f623ba3e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"752718d528cd4eb89005c3febf5815ab","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d897133453e34ab8852daa25c197a011","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7b34c4c341a74b9984deff61be03c587","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"216b0dcc86a34619bad44c996e80b7b8","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5f0765227409473d803995e585313374","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d49375c49b104622bc287a4f78aadd62","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"840f6357def44f5aba7f76e4511a14a8","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"12bb66d09ff34c86b3b06e4ab0e40c65","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"594f20605b924a10aefe7d4cfd877737","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"1a4a32b3b70f43008333af86c940c17b","docid":29462,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"b2ca28b01c34419db0365bad2f8dd09e","created_ts":"2021-11-30T08:55:41.000Z","updated_ts":"2024-11-07T04:47:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ZKHF-007","status":"ACTIVE"}],"dev_code":[{"name":"ZKHF 007","status":"ACTIVE"},{"name":"ZKHF-007","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["5806922764071ed82a9c6e6283111271"],"disease_id":["99533cae1a3540648595200a452bd93c"],"active_org_master_entity_id":["54c300302ef99930090ae6cd2ea35cec"],"research_disease":["99533cae1a3540648595200a452bd93c"],"therapeutic_area":["b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"99533cae1a3540648595200a452bd93c","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"01a921e9988248bc8fc2d6cb32abcebd","docid":51419,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Benzbromarone","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":270786914248,"rnk":1,"target_extend_id":"103643e0506138e7b29e3c36d470d0f9","created_ts":"2021-10-08T14:38:37.000Z","updated_ts":"2025-10-10T02:38:10.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":915148800000,"drug_name":[{"lang":"CN","name":"苯溴马隆","source_info":[{"normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR"}],"status":"ACTIVE"},{"lang":"EN","name":"Benzbromarone","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ベンズブロマロン","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"2-ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran","source_info":[{"code":"DB12319","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone","source_info":[{"code":"DB12319","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Benzbromarone (JP17/USAN/INN)","source_info":[{"code":"D01056","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"L-2214","status":"ACTIVE"},{"name":"MJ-10061","status":"ACTIVE"},{"name":"NSC-85433","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3d57dac8-7572-4413-89d6-61c7a3ffa19c"}],"status":"ACTIVE"},{"name":"TO-082","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"trade_name":[{"name":"Desuric","status":"ACTIVE"},{"name":"Narcaricin","status":"ACTIVE"},{"name":"Urinorm","status":"ACTIVE"},{"name":"Uroleap","source_info":[{"code":"D01056","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"ユリノーム","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"尤诺","status":"ACTIVE"},{"name":"立加利仙","source_info":[{"code":"CTR20222979","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=16dfe2df5da74e0caa3742b456724eec"}],"status":"ACTIVE"}],"generic_name":[{"name":"Benzbromarone","source_info":[{"code":"D01056","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB12319"],"kegg_id":["D01056"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d68773a244cda7175989f501d436fc0a"],"mechanism_action_id":["c7996bf2e78384d6909be1ac06e5a4e4"],"target_id":["290236e86d7242d6ad39426849da4b3e"],"atc_code":["19986de438874bf38616a51340eac074"],"disease_id":["79cc3bb048cb4837a36e22b1bcab50d3","d0579fcbe06046b4b44990d910e1dc73","281fcf1b07ee4c13b0297e4ad1a9c106"],"active_org_master_entity_id":["d68773a244cda7175989f501d436fc0a","666dc7acee432ac83e1ebf2121fab5e3","cbc43f0e89d7093367a9f6e0feaae567"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["d0579fcbe06046b4b44990d910e1dc73","281fcf1b07ee4c13b0297e4ad1a9c106"],"research_disease":["79cc3bb048cb4837a36e22b1bcab50d3","d0579fcbe06046b4b44990d910e1dc73","281fcf1b07ee4c13b0297e4ad1a9c106"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":915148800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":531446400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":270786914248}}],"disease_phase":[{"disease_id":"d0579fcbe06046b4b44990d910e1dc73","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"79cc3bb048cb4837a36e22b1bcab50d3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"01ae4b6c961346a7b4daf738589ab59d","docid":34024,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":-511747200000,"rnk":1,"target_extend_id":"53adb6b2f24a345393db6d125ca1eda1","created_ts":"2022-04-07T07:52:09.000Z","updated_ts":"2024-12-31T00:19:53.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"苯妥英/苯巴比妥","status":"ACTIVE"},{"lang":"EN","name":"Phenytoin/Phenobarbital","source_info":[{"code":"22100AMX00802","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400093_1139100F1037_1_13"}],"status":"ACTIVE"},{"lang":"JP","name":"フェニトイン/フェノバルビタール","source_info":[{"code":"22100AMX00802","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400093_1139100F1037_1_13"}],"status":"ACTIVE"}],"trade_name":[{"name":"ALEVIATIN with PHENOBARBITAL","source_info":[{"code":"22100AMX00802","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400093_1139100F1037_1_14"}],"status":"ACTIVE"},{"name":"複合アレビアチン","source_info":[{"code":"22100AMX00802","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400093_1139100F1037_1_14"}],"status":"ACTIVE"}],"related_component":["7de52e02fd654470a36fb5368d95dc2e","91eaf47da02b4aa69dcaae6c0a0d88d7"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ca66d2661dafdf2735d06ae038123df4"],"mechanism_action_id":["c86fa16989b253f3b62115c4c3685062","c860c6916869151a3b9ff7e46a7987cc","21dc9cb853432e3ae52716b8f97ba807"],"target_id":["504f33d0958c4c128ee629fdca31a63d","aa63f46d01534a6ea6bc2a3b80c63ddc","8786d17f00f04d56828d039e28ec48aa"],"disease_id":["e29116bd4104436da4275b936996075f"],"active_org_master_entity_id":["ca66d2661dafdf2735d06ae038123df4"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["e29116bd4104436da4275b936996075f"],"research_disease":["e29116bd4104436da4275b936996075f"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-511747200000}}],"disease_phase":[{"disease_id":"e29116bd4104436da4275b936996075f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0182d190a6234fe19cd8dcc1511ac09d","docid":52249,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":7,"target_extend_id":"0cdfebd0c6e13631a8d651a94eb9fb7e","created_ts":"2023-01-09T08:43:59.000Z","updated_ts":"2026-03-11T00:45:44.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"BR-115","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247510088&idx=2&sn=e388f380adb6ac8187c10747fc8b8ba7"}],"status":"ACTIVE"}],"dev_code":[{"name":"BR 115","status":"ACTIVE"},{"name":"BR-115","status":"ACTIVE"},{"name":"BR115","status":"ACTIVE"},{"name":"CMG6A19","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzE2MTQ5Mg==&mid=2247520896&idx=2&sn=6cde3033f011de576d15af7cec363206"}],"status":"ACTIVE"}],"drug_type":["5301d9a2324b45f98ff3a2233f73464c"],"originator_org_master_entity_id":["9042493838ae405c2ba248b014772543"],"mechanism_action_id":["59e827e69bbc5091c37f33d9798f8c02","31fadb5b59dc513706fe7b9bf39b9151"],"target_id":["a3c3158483984ff9922b1b0ba939a068","fe50c9b7f38746beb4bfd1ae9fa6fd1b"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["528b2f3a18ee46f78efc07d92439952e","9042493838ae405c2ba248b014772543"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1713830400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1708300800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["528b2f3a18ee46f78efc07d92439952e","9042493838ae405c2ba248b014772543"],"if_speculate":0,"data_source":10}
+{"drug_id":"066791dec98a43fead507d7c1ae0a8ed","docid":28168,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"1efdecea61ba399f8032c803387c6a46","created_ts":"2021-11-30T08:55:41.000Z","updated_ts":"2026-03-24T00:46:28.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ASKG-712","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://ask-gene.com/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AM 712","status":"ACTIVE"},{"name":"ASKG 712","status":"ACTIVE"},{"name":"ASKG-712","status":"ACTIVE"},{"name":"VIS 101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg2NDY0NzkxNA==&mid=2247498959&idx=1&sn=970b9040c608bcab0bb1df7955314b5b"}],"status":"ACTIVE"},{"name":"VIS-101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg2NDY0NzkxNA==&mid=2247498959&idx=1&sn=970b9040c608bcab0bb1df7955314b5b"}],"status":"ACTIVE"},{"name":"VIS101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg2NDY0NzkxNA==&mid=2247498959&idx=1&sn=970b9040c608bcab0bb1df7955314b5b"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["d7a2a1eced39dc311d67f9ddb4e12291"],"mechanism_action_id":["4b07f17a0e5ec4d636e5b3d2362becdd","6b6c2b10657446ed45e401214272b244"],"target_id":["934f7ab958ca4daf85f5eb42393a0b28","f5b622f4d38840faacb16d2836d16322"],"disease_id":["94437cab300944a58b3ea8134dea1482","fce2b462d4fa493eb9d82513b9007011","7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"active_org_master_entity_id":["f6796d384ea04460ea166e369719f803","47e2d41629dc3312e13aa8e1fd0ab95d","773789404df264271babec930b97c6b4","d7a2a1eced39dc311d67f9ddb4e12291"],"research_disease":["94437cab300944a58b3ea8134dea1482","fce2b462d4fa493eb9d82513b9007011","7bb5556c886343f4a9ec230aacf8706e","b3613eb77a5d4795ac1a12db34d284ba"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1665187200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1651104000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1698019200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1685318400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1675987200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1675641600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1660176000000}}],"disease_phase":[{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"94437cab300944a58b3ea8134dea1482","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"fce2b462d4fa493eb9d82513b9007011","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["0edda0994aefd23b0658c1d560fdbdee","1f8a0e7cd754547acdf336987a67dc62","3ec5f8ff6a565d586af277772b5ea93e","47e2d41629dc3312e13aa8e1fd0ab95d","51ab5bf2c7bf6e19782cae8eaa5dea2e","84c53982ed918ca7b474480492455e58"],"if_speculate":0,"data_source":10}
+{"drug_id":"01c5dd4339714110a167c57fee6de47c","docid":13519,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-06-16T09:47:00.000Z","updated_ts":"2026-01-27T22:36:30.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"异体甲状旁腺细胞(The National Academy of Sciences of Belarus)","status":"ACTIVE"},{"lang":"EN","name":"Allogenic parathyroid cells(The National Academy of Sciences of Belarus)","source_info":[{"code":"NCT05186883","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05186883"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["e911b0bf3aed8e0808168685b6571e31"],"disease_id":["b92671ffb88c466d9d8603effe7eeb76"],"active_org_master_entity_id":["e911b0bf3aed8e0808168685b6571e31"],"research_disease":["b92671ffb88c466d9d8603effe7eeb76"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"b92671ffb88c466d9d8603effe7eeb76","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"5dc876b288a84cb187956b26a8d32ca6","docid":233431,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2024-09-20T10:23:47.000Z","updated_ts":"2025-08-12T07:29:15.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"MV140 mucosal bacterial vaccine; Inactivated Escherichia coli / Klebsiella pneumoniae / Enterococcus faecalis / Proteus vulgaris","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["0a63cb6e0c8494eb8a6f0324dca351bd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["c65b92358a5b43cd8d9bb9357854f240"],"active_org_master_entity_id":["0a63cb6e0c8494eb8a6f0324dca351bd"],"research_disease":["c65b92358a5b43cd8d9bb9357854f240"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1682899200000}}],"disease_phase":[{"disease_id":"c65b92358a5b43cd8d9bb9357854f240","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"089ea28d708b4f8c914b2e3d6668a65c","docid":64500,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2023-08-17T05:17:51.000Z","updated_ts":"2026-04-01T22:38:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"ALF-202","source_info":[{"attachment_path":"data/phs_source_info/ddfd/bd3c/648a/bea1/8918cb8f-abdc-301a-871c-2b59caa42484.jpg","attachment_type":"image/jpeg","code":"Allife-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5f1f/018c/b593/e6c4/9b7e9de7-1c35-32ba-b571-204f1171ea57.jpg","source":"Company pipeline","source_url":"http://www.allifetech.com/productline.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogeneic Endothelial Progenitor Cells(Allife Medical Science and Technology)","status":"ACTIVE"},{"lang":"EN","name":"iEPCs","status":"ACTIVE"}],"dev_code":[{"name":"ALF 202","source_info":[{"attachment_path":"data/phs_source_info/ddfd/bd3c/648a/bea1/8918cb8f-abdc-301a-871c-2b59caa42484.jpg","attachment_type":"image/jpeg","code":"Allife-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5f1f/018c/b593/e6c4/9b7e9de7-1c35-32ba-b571-204f1171ea57.jpg","source":"Company pipeline","source_url":"http://www.allifetech.com/productline.html"}],"status":"ACTIVE"},{"name":"ALF202","source_info":[{"attachment_path":"data/phs_source_info/ddfd/bd3c/648a/bea1/8918cb8f-abdc-301a-871c-2b59caa42484.jpg","attachment_type":"image/jpeg","code":"Allife-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5f1f/018c/b593/e6c4/9b7e9de7-1c35-32ba-b571-204f1171ea57.jpg","source":"Company pipeline","source_url":"http://www.allifetech.com/productline.html"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["c8482427690be0f26a7bc3dccee654c6"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["293d744af33241789aab61502cc9c8b8","e2bf071405ab4c4787be311613287430","d5375f2b4c214bf2b9ea0ee60347e988"],"active_org_master_entity_id":["c8482427690be0f26a7bc3dccee654c6"],"research_disease":["293d744af33241789aab61502cc9c8b8","e2bf071405ab4c4787be311613287430"],"non_research_disease":["d5375f2b4c214bf2b9ea0ee60347e988"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1711929600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1692835200000}}],"disease_phase":[{"disease_id":"293d744af33241789aab61502cc9c8b8","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"299e91fc2f234bbb9e0156c4f43ad970","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d5375f2b4c214bf2b9ea0ee60347e988","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e2bf071405ab4c4787be311613287430","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"17da6ee8330e470abca0ef39b51fc9f6","docid":40807,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"9f31233bceb94d9796d3f3556f17ab13","highest_dev_status_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_dev_status_before_termination_cn":"8666aad5477e4272b56b94ca1183781d","rnk":1,"target_extend_id":"494d7eed1ab433f19d03cf91ad9d643d","created_ts":"2021-10-08T14:47:19.000Z","updated_ts":"2026-02-25T02:01:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Prilukae","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkzNTY4NTk0Mw==&mid=2247536383&idx=1&sn=fcbe0bbed7d11403b0beefb394971cce"}],"status":"ACTIVE"}],"dev_code":[{"name":"NP G2 044","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fascin-inhibitor-np-g2-044"}],"status":"ACTIVE"},{"name":"NP-G2-044","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkzNTY4NTk0Mw==&mid=2247536383&idx=1&sn=fcbe0bbed7d11403b0beefb394971cce"}],"status":"ACTIVE"}],"drugbank_id":["DB14995"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2bd8ed4e45aa1d7f42851434eaa3ac2b","db51a6254f7202b8f5e3dd84416159b8"],"mechanism_action_id":["8d3831f85ab34ea4a282644d967e2eba"],"target_id":["ba4e2ee6d90a48249968d00c33d318f6"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["557f5ccfe746466cbdb9383a94178eef","0464f5493b0444e9875a0584df17cbf0","74ba301586ab419b9c9accd39cd20782","ee2ede109de84cfda49bc999601085b4","78cb173a4de34f07befac28de907e7bf","f7ff421129ab40b19648cd3b1fc08f0f","f92e4ba771d04f27a1f4daae363b676a","275ecda875e0460f84aa768ca9b2e5d6","38833c689e494b8195a9537b9641e4fb","1e6992f1403346acad1273d778686ca7","f048bf0822254413a3ea354eced08eec","e2fd9bda4aeb4a7b9fa53a2560126d24","26535c6f16de4adfb19f0154be738535","f98fd32baa8447119bb87f84093b925c","2bb755a3f43f49dea60661c5f99712a3","1259d9c96614472ea03b5c8b51458a7b","e50aad3dea474cf487e53bd91d5d7c45"],"active_org_master_entity_id":["db51a6254f7202b8f5e3dd84416159b8"],"research_disease":["557f5ccfe746466cbdb9383a94178eef","0464f5493b0444e9875a0584df17cbf0","74ba301586ab419b9c9accd39cd20782","ee2ede109de84cfda49bc999601085b4","78cb173a4de34f07befac28de907e7bf","f7ff421129ab40b19648cd3b1fc08f0f","f92e4ba771d04f27a1f4daae363b676a"],"non_research_disease":["275ecda875e0460f84aa768ca9b2e5d6","38833c689e494b8195a9537b9641e4fb","1e6992f1403346acad1273d778686ca7","f048bf0822254413a3ea354eced08eec","e2fd9bda4aeb4a7b9fa53a2560126d24","26535c6f16de4adfb19f0154be738535","f98fd32baa8447119bb87f84093b925c","2bb755a3f43f49dea60661c5f99712a3","1259d9c96614472ea03b5c8b51458a7b","e50aad3dea474cf487e53bd91d5d7c45"],"inactive_org_master_entity_id":["a8169781ca27224c42f5ff40972c78ad","66ce4e3fdc7ca1f28819298ae921d6c4","1719053d5e59cd209a7a248589bc5962"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1766966400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"e8213325-7b0e-391e-9636-bb602375aa5d","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"f7ff421129ab40b19648cd3b1fc08f0f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_before_ter_cn":"8666aad5477e4272b56b94ca1183781d","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"74ba301586ab419b9c9accd39cd20782","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"38833c689e494b8195a9537b9641e4fb","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1259d9c96614472ea03b5c8b51458a7b","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ee2ede109de84cfda49bc999601085b4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"26535c6f16de4adfb19f0154be738535","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"557f5ccfe746466cbdb9383a94178eef","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"}],"deal_related_org":["db51a6254f7202b8f5e3dd84416159b8","1719053d5e59cd209a7a248589bc5962"],"if_speculate":0,"data_source":10}
+{"drug_id":"04d4af9512b540bb87076a3e4c0bfa27","docid":980119,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-02-21T05:31:53.000Z","updated_ts":"2025-02-27T07:10:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CMTS-0929","source_info":[{"code":"NCT06836427","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06836427"}],"status":"ACTIVE"}],"dev_code":[{"name":"CMTS-0929","source_info":[{"code":"NCT06836427","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06836427"}],"status":"ACTIVE"}],"drug_type":["4d4d1bd0559b49c1bb9f22cf30480c8f"],"originator_org_master_entity_id":["5e02bf50ed1a777cd1f5201ce057f4b6"],"disease_id":["2cf3ae811a694aff83abfca8f92cafed","68fd19fa7cd24439a6f5d31f72d02675"],"active_org_master_entity_id":["5e02bf50ed1a777cd1f5201ce057f4b6"],"research_disease":["2cf3ae811a694aff83abfca8f92cafed","68fd19fa7cd24439a6f5d31f72d02675"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1740009600000}}],"disease_phase":[{"disease_id":"68fd19fa7cd24439a6f5d31f72d02675","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"2cf3ae811a694aff83abfca8f92cafed","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02acc8f6bc9742ad8ff3157fbc67baf1","docid":48166,"is_nme":0,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":1,"wiki_link":"https://en.wikipedia.org/wiki/Lumacaftor/ivacaftor","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1435795200000,"rnk":1,"target_extend_id":"2fe07a04b76733b1b36c71d1e05873bd","created_ts":"2021-10-08T14:49:41.000Z","updated_ts":"2026-03-15T21:16:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"依伐卡托/芦马卡托","status":"ACTIVE"},{"lang":"EN","name":"Ivacaftor/Lumacaftor","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ivacaftor/VX-809","status":"ACTIVE"},{"lang":"EN","name":"Lumacaftor/ivacaftor","source_info":[{"normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"},{"lang":"EN","name":"Orkambi","status":"ACTIVE"},{"lang":"EN","name":"VX-809/ivacaftor","status":"ACTIVE"}],"dev_code":[{"name":"VX-770/VX-809","status":"ACTIVE"},{"name":"VX-809/VX-770","status":"ACTIVE"}],"related_component":["0f12f753a6fd40c898287ed9259aaf0a","bf6ed07260f54c35bdaa3c391b5c9716"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f71f2e67633d6da9b028b8d0c1ca7d09"],"mechanism_action_id":["3ca125b547c8f75448ee6a0861219f84","c6d408c457c9fdb4e6bfc59dac01f6d0"],"target_id":["5035217e3d264d34b475ebcbc6086466","13d14f580a704de485dda079bd4a4d0a"],"atc_code":["947de3e1814e44869ec74a258493f37a"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["7f8657c4a15148219c75eeb330d92c42"],"active_org_master_entity_id":["c11460ab57353e5e5284a9547b07494a","f71f2e67633d6da9b028b8d0c1ca7d09","0d5e7e68856ac9ec52668a9f63719be4"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["7f8657c4a15148219c75eeb330d92c42"],"research_disease":["7f8657c4a15148219c75eeb330d92c42"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","9a18968a-f130-3a00-80b6-8b9e2eec4838","672807de-6d33-3706-a350-c97e6ed7735e","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1435795200000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1447891200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1609459200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1457395200000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1447891200000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1447891200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1447891200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1755734400000}}],"disease_phase":[{"disease_id":"7f8657c4a15148219c75eeb330d92c42","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"09606c3941814eaeb8b14da1566ad580","docid":260692,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-05-06T11:36:42.000Z","updated_ts":"2025-12-05T00:30:44.000Z","data_status":"ACTIVE","created_by":"yangjinhua@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"GP28zT2","source_info":[{"attachment_path":"data/phs_source_info/a47a/7aa7/fabe/9340/def2f3d2-eac2-308f-8291-3a558448a93d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/f75c/3df2/ef39/303d/27ec3686-e00a-3cf0-ba45-98ad2db2423c.jpeg","source":"Company pipeline","source_url":"https://www.wellingtonzhaotai.com/pipeline"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["a576adff30d4cc8a1659e1f5052b8428"],"disease_id":["1e6992f1403346acad1273d778686ca7"],"active_org_master_entity_id":["a576adff30d4cc8a1659e1f5052b8428"],"research_disease":["1e6992f1403346acad1273d778686ca7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"1e6992f1403346acad1273d778686ca7","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"06769b38d3524382b3de59c5949015e3","docid":20695,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-10-08T14:42:42.000Z","updated_ts":"2026-01-27T20:05:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Umbilical mesenchymal stem cells derived exosomes(Zhongshan Ophthalmic Center)","source_info":[{"code":"NCT04213248","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04213248"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"UC-MSC-Exos","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzk0MzcyMzM2MA==&mid=2247493682&idx=4&sn=bf3b0fa4b1d8b748d5b90e42b7ac177a"}],"status":"ACTIVE"},{"lang":"EN","name":"UMSCs Derived Exosomes","source_info":[{"code":"NCT04213248","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04213248"}],"status":"ACTIVE"}],"drug_type":["72c0d093a2154aaf94ac6c2f30cca15e"],"originator_org_master_entity_id":["c696637611eea1d390bb3a3920af714c"],"disease_id":["3271242b681840bcbd5ad0e4baee0770"],"active_org_master_entity_id":["c696637611eea1d390bb3a3920af714c"],"research_disease":["3271242b681840bcbd5ad0e4baee0770"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1582243200000}}],"disease_phase":[{"disease_id":"3271242b681840bcbd5ad0e4baee0770","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"16d0a53b8131464a83f77c95ab4229f0","docid":1673159,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-12-30T06:27:46.000Z","updated_ts":"2026-02-25T06:53:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CREPT-618","source_info":[{"code":"ChiCTR2500109564","normalized_source_id":"2a39e1fb59c446568df2b08f80e3f6f0","source":"ChiCTR","source_url":"https://www.chictr.org.cn/showproj.html?proj=288604"}],"status":"ACTIVE"}],"dev_code":[{"name":"CREPT-618","source_info":[{"code":"ChiCTR2500109564","normalized_source_id":"2a39e1fb59c446568df2b08f80e3f6f0","source":"ChiCTR","source_url":"https://www.chictr.org.cn/showproj.html?proj=288604"}],"status":"ACTIVE"}],"drug_type":["b2e34ca9d9c949a98ab7589635873cd7"],"originator_org_master_entity_id":["3563ea7b1838cc76618deafd778ebc11"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","3cbfa9bce97c4d18bfd5271c4c3f48d3","418cb344fa844c8f8e494fc3ac177a12"],"active_org_master_entity_id":["3563ea7b1838cc76618deafd778ebc11","51551d363d893be0041c70abd164075a"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","3cbfa9bce97c4d18bfd5271c4c3f48d3","418cb344fa844c8f8e494fc3ac177a12"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1757894400000}}],"disease_phase":[{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3cbfa9bce97c4d18bfd5271c4c3f48d3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"418cb344fa844c8f8e494fc3ac177a12","highest_phase_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0eca87a629b54424a19e51644ef97471","docid":46031,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-06-20T10:31:35.000Z","updated_ts":"2026-02-24T18:11:42.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"23价肺炎球菌多糖疫苗 (卫信生物)","source_info":[{"code":"CTR20213013","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=3e0a9c7f38a94b9598ca2564d727114b"}],"status":"ACTIVE"},{"lang":"EN","name":"Pneumococcal polysaccharide vaccine 23-valent (Vacin Biomedicine)","source_info":[{"code":"CTR20213013","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=3e0a9c7f38a94b9598ca2564d727114b"}],"status":"ACTIVE"}],"drug_type":["45caf4033ea6425bb41aa89c00143cfe","8f91996d778a4b93aebea69ade081b9f","b24e8825fd1d42d1b8832824599ee903"],"originator_org_master_entity_id":["e1fa95876bf826eb756c28d03e88aff2"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["862e74fcd5744d1a914d10fe1dd67b70","b910f946457644f28630580432a34e3f","b8cf44eaf5d54d56a602142b4553c285","f7d9acc73f894d759455d8d8996caeb3"],"active_org_master_entity_id":["e1fa95876bf826eb756c28d03e88aff2"],"research_disease":["862e74fcd5744d1a914d10fe1dd67b70","b910f946457644f28630580432a34e3f","b8cf44eaf5d54d56a602142b4553c285","f7d9acc73f894d759455d8d8996caeb3"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","042cbe45c973477b957717ded29ef7b6","4e8519876cfb47e1a3b07957e869ef32"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1694044800000}}],"disease_phase":[{"disease_id":"862e74fcd5744d1a914d10fe1dd67b70","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"b8cf44eaf5d54d56a602142b4553c285","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b910f946457644f28630580432a34e3f","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f7d9acc73f894d759455d8d8996caeb3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"021bd7730a1747a792fb1bf824e79382","docid":79720,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2023-08-29T09:52:20.000Z","updated_ts":"2024-10-30T10:22:52.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"氢氧化钾/甘油","status":"ACTIVE"},{"lang":"EN","name":"Potassium hydroxide/Glycerin","source_info":[{"code":"16000AMZ06500000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/800084_2662701X1206_1_03"}],"status":"ACTIVE"},{"lang":"JP","name":"水酸化カリウム/グリセリン","source_info":[{"code":"16000AMZ06500000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/800084_2662701X1206_1_03"}],"status":"ACTIVE"}],"related_component":["691ed0a2b23742efa6ab47848ec8bdf2","b31f955af07043d3958b993a65a6f685"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"disease_id":["e315db2e757046cd96274cf631d79546"],"research_disease":["e315db2e757046cd96274cf631d79546"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"e315db2e757046cd96274cf631d79546","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0395b9350c5c4201bc6cfe83cd031a96","docid":4339,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"f9e5f9bbe40e332fa5182d2932f9daf9","created_ts":"2023-06-07T06:26:21.000Z","updated_ts":"2025-10-30T00:37:43.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"[18F]BF3-BPA","source_info":[{"code":"CXHL2300616","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"BR-02","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkxMDI4ODA1OQ==&mid=2247532984&idx=1&sn=79eb46cc959bf5134405181b8bdedf8a"}],"status":"ACTIVE"},{"name":"[18F]BF3 BPA","status":"ACTIVE"},{"name":"[18F]BF3-BPA","status":"ACTIVE"},{"name":"[18F]BF3BPA","status":"ACTIVE"},{"name":"[¹⁸F]BF₃-BPA","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzkxMDI4ODA1OQ==&mid=2247532984&idx=1&sn=79eb46cc959bf5134405181b8bdedf8a"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["823adf6d095e171bea94a42f12ca36ff"],"mechanism_action_id":["2b49c6a7ba7b415ba29749ad2ebcafd1","0749288ce5e4be2dc4dcdf9173d8f6b3"],"target_id":["f675238983dc42c594c5df74e004f354"],"disease_id":["7c78dd7ca12d4eadbd772cf774c82efe"],"active_org_master_entity_id":["823adf6d095e171bea94a42f12ca36ff","f0b7b2d61d9df485bd03ede477494af4"],"research_disease":["7c78dd7ca12d4eadbd772cf774c82efe"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1713312000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1"}],"disease_phase":[{"disease_id":"7c78dd7ca12d4eadbd772cf774c82efe","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"08dc373789f9441e990a15b316d8d060","docid":63825,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"3d2eb481e4e6308c91f65fde3b04d000","created_ts":"2022-05-20T07:14:46.000Z","updated_ts":"2026-03-30T13:38:09.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"HRS-4642","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI1ODM0NjI2MA==&mid=2247504329&idx=1&sn=46acdc7c824998e3dcc7a117f210e165"}],"status":"ACTIVE"}],"dev_code":[{"name":"HRS 4642","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kras-g12d-inhibitor-hrs-4642"}],"status":"ACTIVE"},{"name":"HRS4642","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kras-g12d-inhibitor-hrs-4642"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","f9b1093fafc547caabf90e26cef22a1f"],"originator_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"mechanism_action_id":["1c890b03d7aa4e219970573f312cd998"],"target_id":["51a0d0165ef849378242597918b3755b"],"special_review":["c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["6a962a4341364bbe9959b413849567de","42b94f15c66847ff829231f863e32e89","78cb173a4de34f07befac28de907e7bf","e67c7fcd3d3a494ab70e1efe0b82ecdc","0464f5493b0444e9875a0584df17cbf0","800d2cfb899f4e6983a759d03734503d","7ed120cd1772462482e0f72e906c1bdc","7e87f9c6dcd841edb4d0f250b6bee3d9","7bbd3c81bd5940ffbfb5cfc424e5830b","6c9c5be211cb4d72a28205c49a16d653"],"active_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf","0457fb3299e6bbc28df4b65e38e5ef77"],"research_disease":["6a962a4341364bbe9959b413849567de","42b94f15c66847ff829231f863e32e89","78cb173a4de34f07befac28de907e7bf","e67c7fcd3d3a494ab70e1efe0b82ecdc","0464f5493b0444e9875a0584df17cbf0","800d2cfb899f4e6983a759d03734503d","7ed120cd1772462482e0f72e906c1bdc","7e87f9c6dcd841edb4d0f250b6bee3d9","7bbd3c81bd5940ffbfb5cfc424e5830b","6c9c5be211cb4d72a28205c49a16d653"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764547200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761264000000}}],"disease_phase":[{"disease_id":"42b94f15c66847ff829231f863e32e89","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6a962a4341364bbe9959b413849567de","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e67c7fcd3d3a494ab70e1efe0b82ecdc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"800d2cfb899f4e6983a759d03734503d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7ed120cd1772462482e0f72e906c1bdc","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7bbd3c81bd5940ffbfb5cfc424e5830b","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"041dab3a1a1c4cebbd18f44f88905cf9","docid":1880331,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-12-22T03:13:40.000Z","updated_ts":"2025-12-22T03:16:12.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"FY015A","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.163.com/dy/article/J59HCTVB053270YS.html"}],"status":"ACTIVE"}],"drug_type":["1f455eba74a44f2eb2c710eaede94571"],"originator_org_master_entity_id":["ff4fd8a6e1e44d0560b44270b7a40b38"],"disease_id":["21b8015a540845d5b2b4c2b185a76e1a"],"active_org_master_entity_id":["ff4fd8a6e1e44d0560b44270b7a40b38"],"research_disease":["21b8015a540845d5b2b4c2b185a76e1a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"21b8015a540845d5b2b4c2b185a76e1a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"0884fbe4e7db4f9fa1eab598ad6207d8","docid":47389,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:39.000Z","updated_ts":"2025-07-18T09:00:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"IBL-100s","status":"ACTIVE"}],"dev_code":[{"name":"IBL-100S","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["033f8812bc56f23a6b318e912861a1cb"],"disease_id":["94deb71c1ce54fdf8923bfcb7c88d054","07994e875a7f44dc9af7f9bf3f6989e5","68fd19fa7cd24439a6f5d31f72d02675","0c8a0603507542faac6b5ef3e27c6728","be685463e8e640119dff51e5125e6d0f","6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["033f8812bc56f23a6b318e912861a1cb"],"research_disease":["94deb71c1ce54fdf8923bfcb7c88d054","07994e875a7f44dc9af7f9bf3f6989e5"],"non_research_disease":["68fd19fa7cd24439a6f5d31f72d02675","0c8a0603507542faac6b5ef3e27c6728","be685463e8e640119dff51e5125e6d0f","6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1647388800000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"94deb71c1ce54fdf8923bfcb7c88d054","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"68fd19fa7cd24439a6f5d31f72d02675","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["033f8812bc56f23a6b318e912861a1cb","9bea033f0191c93888701d7d88bb79a4"],"data_source":10}
+{"drug_id":"024d582502874f5093785f808bbe30e0","docid":204908,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1457481600000,"rnk":2,"target_extend_id":"598bca12fdf93b13892e1811092d5b9c","created_ts":"2024-12-02T05:07:25.000Z","updated_ts":"2025-09-16T09:52:30.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"fangdongbing","drug_name":[{"lang":"EN","name":"Amlodipine/perindopril tert-butylamine","source_info":[{"normalized_source_id":"fb10b55318a44d7ba14405d26e3ac9c2","source":"HMA","source_url":"https://mri.cts-mrp.eu/portal/details?productnumber=PL%2FH%2F0378%2F001"}],"status":"ACTIVE"}],"trade_name":[{"name":"Prestozek Combi","status":"ACTIVE"}],"related_component":["6d45fa849caa4ed9831e6e5b09ec9c05","a954b7517d124815a70b7b47e7bbcd91"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9bd6dda1b9d302dd9b182cfd6dff0f24"],"mechanism_action_id":["5016a3f6676e68e4b0bee11875e2567e","36ae41fe0ed469cafadad2fbfe2cd220"],"target_id":["8e4f82bd158f46ec8d378681d919b812","cbfe96a08cbd4821bd2043ccb66bf7d8"],"disease_id":["f8f9347202e043bab0e0d627ce10e767"],"active_org_master_entity_id":["9bd6dda1b9d302dd9b182cfd6dff0f24"],"first_approved_country":["15d3c741-f4c4-35d8-9273-339b5972916e"],"first_approved_indication":["f8f9347202e043bab0e0d627ce10e767"],"research_disease":["f8f9347202e043bab0e0d627ce10e767"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"approval_country":["15d3c741-f4c4-35d8-9273-339b5972916e"],"research_country":[{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1457481600000}}],"disease_phase":[{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"050f23df40a74d07a22f346cc00e7c4d","docid":9633,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":127,"target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","created_ts":"2021-10-08T14:48:11.000Z","updated_ts":"2026-04-11T21:09:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"CN","name":"信立他赛","status":"ACTIVE"},{"lang":"EN","name":"Salutaxel","status":"ACTIVE"}],"dev_code":[{"name":"MDC-405+","source_info":[{"code":"CTR20211264","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=b4fba8e3cfdc4f50aa1ad4b181092758"}],"status":"ACTIVE"},{"name":"SAL-0101","source_info":[{"code":"CTR20211264","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=b4fba8e3cfdc4f50aa1ad4b181092758"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["41c37d4aa2bccb5479b9cdb911e8126e"],"mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"],"target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"disease_id":["3bf6031206e848cd94f767cd1db43ea0","7665e5683a1a443a8f3d3b946d4c9ca2","f7ea24f0370d421480503e720310bf86","c1cc2528f29940fc95fd6bc37eb982d4","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","6fe05469e09f4305b7615b2c277382cd","ab7c198e47834770a36ab3282d331531","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["41c37d4aa2bccb5479b9cdb911e8126e","53af744358379da09cf99b86b5506a7a"],"research_disease":["3bf6031206e848cd94f767cd1db43ea0","7665e5683a1a443a8f3d3b946d4c9ca2","f7ea24f0370d421480503e720310bf86","c1cc2528f29940fc95fd6bc37eb982d4","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","6fe05469e09f4305b7615b2c277382cd","ab7c198e47834770a36ab3282d331531","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1631836800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1583107200000}}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0217a02365784328b5fad698d9eb1643","docid":76412,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":2,"target_extend_id":"3b55102c30a83bd3ad804e10e9aa1b66","created_ts":"2022-01-04T07:01:35.000Z","updated_ts":"2026-04-11T21:04:00.000Z","data_status":"ACTIVE","created_by":"fangdongbing@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"JS-207","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/0v-NT7qv7AuksNFX79pH8w"}],"status":"ACTIVE"}],"dev_code":[{"name":"JS 207","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-anti-vegf-bispecific-antibody-js207"}],"status":"ACTIVE"},{"name":"JS207","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-anti-vegf-bispecific-antibody-js207"}],"status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["6d8c77d8ef57c426b969ecf3691f96f1"],"mechanism_action_id":["4dd338b149b3ecd0ee860e1fb379b44f","6b6c2b10657446ed45e401214272b244"],"target_id":["934f7ab958ca4daf85f5eb42393a0b28","9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["e35ce4e9b7a846d49e600ce7ac4a7fd6","7665e5683a1a443a8f3d3b946d4c9ca2","e2fd9bda4aeb4a7b9fa53a2560126d24","52168d859c5c4211b0cf99b6a3e34221","8d29f554f371431c9b5b80f5befdf965","f92e4ba771d04f27a1f4daae363b676a","58f692a66e03451d89d57770cd915d61","172ae38eecf24baf9af4f00892b79268","6c9886cb25eb45faba70292cee1f5518","7fb8ceff333b48e8adea2c0803494a48","8222bb15bc7049a1b4426b9f00d701a6","b902fe3512424802ac7659fc83b38222","2d94f94415454317a68f499ad53332db","8c161437fb424389ab1fde27b93a895b","3beea980d93a4cc0abc864e27514601c","a0304a462da04e7cb03e3f2c5625544e","949c20c9e52549008773244a4230da7d","6570754a6f0b43b78a9926c7bfd00519","83c00fea95ab443a997c1e3818bea37e","2536e79ced34450fbb09de73061cf096"],"active_org_master_entity_id":["6d8c77d8ef57c426b969ecf3691f96f1"],"research_disease":["e35ce4e9b7a846d49e600ce7ac4a7fd6","7665e5683a1a443a8f3d3b946d4c9ca2","e2fd9bda4aeb4a7b9fa53a2560126d24","52168d859c5c4211b0cf99b6a3e34221","8d29f554f371431c9b5b80f5befdf965","f92e4ba771d04f27a1f4daae363b676a","58f692a66e03451d89d57770cd915d61","172ae38eecf24baf9af4f00892b79268","6c9886cb25eb45faba70292cee1f5518","7fb8ceff333b48e8adea2c0803494a48","8222bb15bc7049a1b4426b9f00d701a6","b902fe3512424802ac7659fc83b38222","2d94f94415454317a68f499ad53332db","8c161437fb424389ab1fde27b93a895b","3beea980d93a4cc0abc864e27514601c","a0304a462da04e7cb03e3f2c5625544e","949c20c9e52549008773244a4230da7d","6570754a6f0b43b78a9926c7bfd00519","83c00fea95ab443a997c1e3818bea37e","2536e79ced34450fbb09de73061cf096"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1776211200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1774483200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1767052800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1758067200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1757894400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1750291200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1748476800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1745625600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1745366400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1745107200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1744588800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741996800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1760572800000}}],"disease_phase":[{"disease_id":"8222bb15bc7049a1b4426b9f00d701a6","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"b902fe3512424802ac7659fc83b38222","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"52168d859c5c4211b0cf99b6a3e34221","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"58f692a66e03451d89d57770cd915d61","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6c9886cb25eb45faba70292cee1f5518","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"172ae38eecf24baf9af4f00892b79268","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"83c00fea95ab443a997c1e3818bea37e","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8c161437fb424389ab1fde27b93a895b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2d94f94415454317a68f499ad53332db","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"044f03d1a19549c4aacfa985147a5788","docid":5604,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:20.000Z","updated_ts":"2024-12-18T21:10:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"EBX-002","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Potentiated Inhaled Amikacin","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.bing.com/search?q=EBX-002&qs=n&form=QBRE&sp=-1&lq=0&pq=ebx-002&sc=10-7&sk=&cvid=891C8FAC27554007B751D6F88C82F7AD&ghsh=0&ghacc=0&ghpl="}],"status":"ACTIVE"}],"dev_code":[{"name":"EBX-002","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.bing.com/search?q=EBX-002&qs=n&form=QBRE&sp=-1&lq=0&pq=ebx-002&sc=10-7&sk=&cvid=891C8FAC27554007B751D6F88C82F7AD&ghsh=0&ghacc=0&ghpl="}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["903f6755a19ae207073bf31c9a89c2aa"],"disease_id":["72424e2de5cb4965a08ec6c95d705997"],"active_org_master_entity_id":["903f6755a19ae207073bf31c9a89c2aa"],"research_disease":["72424e2de5cb4965a08ec6c95d705997"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1644105600000}}],"disease_phase":[{"disease_id":"72424e2de5cb4965a08ec6c95d705997","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"deal_related_org":["903f6755a19ae207073bf31c9a89c2aa","ce3ce83713b6c1b2a6e3c6b470667e16"],"data_source":10}
+{"drug_id":"4d9ef5106b9e45d9a675c3a4fc349ed6","docid":35556,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2022-06-24T07:39:40.000Z","updated_ts":"2025-07-31T00:31:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SVT-15652","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"SVT-15652(Laboratorios SALVAT)","status":"ACTIVE"}],"dev_code":[{"name":"SVT 15652","status":"ACTIVE"},{"name":"SVT15652","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7c014fc1a02a8a903c083f51b98dac36"],"disease_id":["3f3577b7d33a4971a2dfb713b6971567","c5d37db6a7054cf78bf3b3ea6651fd49"],"active_org_master_entity_id":["7c014fc1a02a8a903c083f51b98dac36"],"research_disease":["3f3577b7d33a4971a2dfb713b6971567"],"non_research_disease":["c5d37db6a7054cf78bf3b3ea6651fd49"],"inactive_org_master_entity_id":["0e8284ffd8d39d351ea4e12887eb961b"],"therapeutic_area":["4e8519876cfb47e1a3b07957e869ef32"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59"},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1697673600000}}],"disease_phase":[{"disease_id":"3f3577b7d33a4971a2dfb713b6971567","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"c5d37db6a7054cf78bf3b3ea6651fd49","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"09215b2b66734fbd8f864b048c399974","docid":2000327,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2026-04-14T07:42:24.000Z","updated_ts":"2026-04-14T09:20:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"JNJ-1761981","source_info":[{"code":"NCT07525141","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07525141"}],"status":"ACTIVE"}],"dev_code":[{"name":"JNJ-1761981","source_info":[{"code":"NCT07525141","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07525141"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["cc240fa8b2ef6a7b80914fcdb1e780ac"],"disease_id":["8df1ce96a8fd4a66ba6dc13760c20282","3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["cc240fa8b2ef6a7b80914fcdb1e780ac"],"research_disease":["8df1ce96a8fd4a66ba6dc13760c20282","3beea980d93a4cc0abc864e27514601c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"8df1ce96a8fd4a66ba6dc13760c20282","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03bac6ac7bf34f409e21624831ea3be3","docid":12893,"is_nme":1,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-05-30T12:14:22.000Z","updated_ts":"2024-11-06T12:32:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"ADPT-06","status":"ACTIVE"}],"dev_code":[{"name":"ADPT 06","status":"ACTIVE"},{"name":"ADPT06","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["748edba0a3a4bbaee72b1c213a940053"],"disease_id":["71a4271b98874e96b16000266c8d79cc"],"active_org_master_entity_id":["748edba0a3a4bbaee72b1c213a940053"],"research_disease":["71a4271b98874e96b16000266c8d79cc"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1644192000000}}],"disease_phase":[{"disease_id":"71a4271b98874e96b16000266c8d79cc","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"118dfa5682224124b236a412befbf223","docid":26594,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":14,"target_extend_id":"691fc762e2073b378921c51497cb44e7","created_ts":"2022-05-30T12:14:39.000Z","updated_ts":"2026-01-30T00:38:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"乌司奴单抗生物类似药（Generium）","status":"ACTIVE"},{"lang":"EN","name":"Ustekinumab Biosimilar (Generium)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ustekinumab Biosimilar","status":"ACTIVE"},{"lang":"CN","name":"乌司奴单抗生物类似药","status":"ACTIVE"}],"dev_code":[{"name":"GNR-068","status":"ACTIVE"},{"name":"GNR068","status":"ACTIVE"}],"generic_name":[{"name":"Ustekinumab","source_info":[{"code":"D09214"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["5f89461c275adaf4343e76688891b16a"],"mechanism_action_id":["8e50d690768a4da2833f4f3dac43056b"],"target_id":["36265960096d4e9fbc536c49f13cd690"],"atc_code":["c5c58dbd85bd402fa4ba7faa42ee4f7c"],"disease_id":["d281a3b362a740d8aeb63e2a10102671"],"active_org_master_entity_id":["5f89461c275adaf4343e76688891b16a"],"research_disease":["d281a3b362a740d8aeb63e2a10102671"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1679529600000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["79644a1860f84ad787850e4b40d4f71a"],"if_speculate":0,"data_source":10}
+{"drug_id":"0f9d8bd889e947939bc4683426625de1","docid":112805,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":8,"target_extend_id":"caa4b7f05c28305db29400ec2c77a0a6","created_ts":"2024-05-11T03:04:02.000Z","updated_ts":"2026-01-03T21:12:50.000Z","data_status":"ACTIVE","created_by":"sunying@patsnap.com","updated_by":"limingna","drug_name":[{"lang":"EN","name":"[18F]FPEB","source_info":[{"code":"15803497","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/15803497"}],"status":"ACTIVE"}],"dev_code":[{"name":"[18F]F-PEB","source_info":[{"code":"15803497","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/15803497/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["6a8c172f1efc649035845f94c31a9c1e"],"mechanism_action_id":["dbc84e3d9d51060f10a42f7cd69952f3"],"target_id":["99cb6deb4560417ea72e83b8736a4234"],"disease_id":["042cbe45c973477b957717ded29ef7b6"],"active_org_master_entity_id":["6a8c172f1efc649035845f94c31a9c1e","e3d1c7595267494e029dca1445dc5b58"],"research_disease":["042cbe45c973477b957717ded29ef7b6"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1537228800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1104537600000}}],"disease_phase":[{"disease_id":"042cbe45c973477b957717ded29ef7b6","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"50a51cf88ea748bd956b63fe50c26082","docid":50243,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":3,"target_extend_id":"103643e0506138e7b29e3c36d470d0f9","created_ts":"2021-10-08T14:46:49.000Z","updated_ts":"2025-06-23T08:48:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Ruzinurad","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"鲁兹诺雷钠","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzU4Njc2Njc0NA==&mid=2247532460&idx=2&sn=d715d4d293f52696894efb5ed914c3ef"}],"status":"ACTIVE"}],"dev_code":[{"name":"HR-011303","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://dmd.aspetjournals.org/content/dmd/early/2021/12/03/dmd.121.000581.full.pdf"}],"status":"ACTIVE"},{"name":"SHR 4640","status":"ACTIVE"},{"name":"SHR4640","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"mechanism_action_id":["c7996bf2e78384d6909be1ac06e5a4e4"],"target_id":["290236e86d7242d6ad39426849da4b3e"],"special_review":["9eb8777c62af4712932b360e6ef3e454"],"disease_id":["79cc3bb048cb4837a36e22b1bcab50d3","35df228d7cc5461dab659878686fba07"],"active_org_master_entity_id":["8cf7f3af90ad45cdeb2a74b6e73b6ebf"],"research_disease":["79cc3bb048cb4837a36e22b1bcab50d3","35df228d7cc5461dab659878686fba07"],"inactive_org_master_entity_id":["07bf37752956a04d79674662aad82a57"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1736380800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1581724800000}}],"disease_phase":[{"disease_id":"79cc3bb048cb4837a36e22b1bcab50d3","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"35df228d7cc5461dab659878686fba07","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04b06ce839e1493d92bc76cef5e43446","docid":1611597,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2025-09-12T06:08:42.000Z","updated_ts":"2025-09-12T07:02:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"DW-1807","source_info":[{"code":"NCT07168473","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07168473"}],"status":"ACTIVE"}],"dev_code":[{"name":"DW-1807","source_info":[{"code":"NCT07168473","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07168473"}],"status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["ad26505ccc27c02b2d8312b1c1b066a9"],"disease_id":["15fe4881cb88431eb9d44b018619d7b0","c0a151b4650248f1893a3d9d0c295de1"],"active_org_master_entity_id":["ad26505ccc27c02b2d8312b1c1b066a9"],"research_disease":["15fe4881cb88431eb9d44b018619d7b0","c0a151b4650248f1893a3d9d0c295de1"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1725840000000}}],"disease_phase":[{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c0a151b4650248f1893a3d9d0c295de1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1270c4c61f314eae8a77d6b557cc1864","docid":68337,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-09-27T12:39:48.000Z","updated_ts":"2024-12-31T00:19:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ACP SR","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["041206f6ed27af6c5c065b951b5270bd"],"disease_id":["80673a393a8e4168a4cb99a4e55249df","b95cd33a9c1345728eeaa0da3e1a53c9","94f13bf88b344e3d9da1438266fa7d58"],"active_org_master_entity_id":["041206f6ed27af6c5c065b951b5270bd"],"research_disease":["80673a393a8e4168a4cb99a4e55249df","b95cd33a9c1345728eeaa0da3e1a53c9","94f13bf88b344e3d9da1438266fa7d58"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1648425600000}}],"disease_phase":[{"disease_id":"94f13bf88b344e3d9da1438266fa7d58","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"80673a393a8e4168a4cb99a4e55249df","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b95cd33a9c1345728eeaa0da3e1a53c9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"57d5c263e6c8460fa190ec5ebb64e0d5","docid":44256,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":9,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","has_leading_org_involved":1,"created_ts":"2021-10-08T14:48:20.000Z","updated_ts":"2026-04-02T10:50:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"阿尼托卡布他基因自体淋巴细胞","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NjY5MTI4NA==&mid=2650964432&idx=2&sn=2b928d5fea2f42eb9d45742966023f12"}],"status":"ACTIVE"},{"lang":"EN","name":"Anitocabtagene autoleucel","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anito-cel","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://endpts.com/arcellx-kite-aim-to-keep-chipping-away-at-carvykti-advantage-with-new-multiple-myeloma-data-at-ash/"}],"status":"ACTIVE"},{"lang":"EN","name":"Anitocabtagene autoleucel","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzAwMDA5NTIxNQ==&mid=2650080757&idx=2&sn=c1a91d99bdc38a2e064a0b607dca08ad"}],"status":"ACTIVE"},{"lang":"EN","name":"Anti BCMA directed ARC T cell therapy","status":"ACTIVE"},{"lang":"EN","name":"BCMA-targeted cell therapy","status":"ACTIVE"},{"lang":"EN","name":"CART-ddBCMA","source_info":[{"code":"2022_8003","normalized_source_id":"c47a5730bf5e40b3aa76c26820ec6d4e","source":"ASCO","source_url":"https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8003"}],"status":"ACTIVE"},{"lang":"CN","name":"阿尼托塞尔","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NTI3MDE0NQ==&mid=2653781620&idx=1&sn=1b4a2390eefb6d7bdf2ee97047db8623"}],"status":"ACTIVE"}],"dev_code":[{"name":"Kite 772","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.evernorth.com/sites/default/files/2025-06/Evernorth_June-2025_Gene-Therapy-Pipeline.pdf"}],"status":"ACTIVE"},{"name":"Kite-772","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.evernorth.com/sites/default/files/2025-06/Evernorth_June-2025_Gene-Therapy-Pipeline.pdf"}],"status":"ACTIVE"},{"name":"Kite772","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.evernorth.com/sites/default/files/2025-06/Evernorth_June-2025_Gene-Therapy-Pipeline.pdf"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["d8de2d7265fe223451d3ec3851fc2f64"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"special_review":["ed88b5b02898448483d0dd3ce010cfba","6486b22c3562461aaf94ee4623b29b1e","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","7cd0fcf1c5c243b9b3944405ec4855b5","f3433922efe24dfaada77415e3e66ea0"],"active_org_master_entity_id":["d8de2d7265fe223451d3ec3851fc2f64","28d8cf85430f20eeb9b9e045a9772fb5","52aee12631589b24dca3ae62de8a0886"],"research_disease":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7","7cd0fcf1c5c243b9b3944405ec4855b5","f3433922efe24dfaada77415e3e66ea0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724371200000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"deal_related_org":["28d8cf85430f20eeb9b9e045a9772fb5","52aee12631589b24dca3ae62de8a0886","d8de2d7265fe223451d3ec3851fc2f64"],"if_speculate":0,"data_source":10}
+{"drug_id":"001ab4d02229445bb129a717442d1097","docid":2464,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Cefepime","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":807235200000,"rnk":5,"target_extend_id":"30ed854af12137b3869be714792ad19d","created_ts":"2021-10-08T14:46:16.000Z","updated_ts":"2026-02-25T01:46:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":1090540800000,"drug_name":[{"lang":"CN","name":"盐酸头孢吡肟","status":"ACTIVE"},{"lang":"EN","name":"Cefepime hydrochloride","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"セフェピム塩酸塩水和物","source_info":[{"code":"16200EMZ01861000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cefepime","source_info":[{"code":"DB01413","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Cefepime Dihydrochloride Hydrate","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Cefepime dihydrochloride hydrate (JP17)","source_info":[{"code":"D01157","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Cefepime hydrochloride (USP)","source_info":[{"code":"D01157","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Cefepime hydrochloride hydrate","source_info":[{"code":"07AMY0168","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"dev_code":[{"name":"BMY-28142","status":"ACTIVE"},{"name":"NSC-760051","source_info":[{"code":"I8X1O67P","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/0134c1b5-ec4e-4553-a29b-bd8e776f5311"}],"status":"ACTIVE"},{"name":"SP-1001","status":"ACTIVE"}],"trade_name":[{"name":"Axepim","status":"ACTIVE"},{"name":"Maxipime","source_info":[{"code":"07AMY0168","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670605_6132425D1024_3_21"}],"status":"ACTIVE"},{"name":"マキシ ピ","source_info":[{"code":"07AMY0168","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/670605_6132425D1024_3_21"}],"status":"ACTIVE"},{"name":"马斯平","source_info":[{"code":"H20040526","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"세라신캡슐","source_info":[{"code":"202401355","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202401355aupdateTs2024-05-31%2011:09:10.440507b"}],"status":"ACTIVE"}],"generic_name":[{"name":"Cefepime","source_info":[{"code":"807PW4VQE3","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/1ea37786-4d7b-4457-8d77-f0ff52eb8f5d"}],"status":"ACTIVE"}],"drugbank_id":["DB01413"],"kegg_id":["D01157"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0"],"mechanism_action_id":["96af81a44ae49944712b75894f39682f","b16637447f22f84eac33286792fb9770"],"target_id":["20c015d11407415a83ad7902f6d712a5"],"atc_code":["f4302a7c35074e73ae3ac093175728d1"],"disease_id":["b0749d24d444442fad131d6b50ae4a1e","d1412e90153c488995027186619d33f4","1bfd0bc875394dec892402de8b927ed9","6d912c173a5543418298c7e385fcba20","b2cd7510e8e24dcdae2be0fd88cdf925","c27b471cedb94556b19ba35534145483","fc39368e3de54e2ab5c2d567074a6a4b","f7d9acc73f894d759455d8d8996caeb3","00c01ace570f4aa6ae5bc937eb956e61","6ab9f3053f674f7aa4bc5c56ba2bb955","af8eee4f871f4e51abe0da09faa978cd","8fd7f2b21bff4eacac47e40d6801aa39","97acfad2c5a54440bf23bd4a13f7aa73","660f8309f52447a6bd49f692bbc735ac","6086c978b1e242ea9fdfa5a0c5debb3a","0df94b4cbdda4b139e247afcb9a94760","1ed882684b7d4537b4987049c5be4bc2","86dc7f528caa4b79bf7b8372bc516d87","b910f946457644f28630580432a34e3f","350d3db9893e4498b2e396c24aa6a029","478a3554509441e7936078bddfbca593","b00bb76f187a4c028a547c6f3470c1d8","c7879aa9883f473695aea6cc7470cb48","7cf66a4af7ac4b51b888c59d7e30a2c4","4ecfc9bb4a654958a3b6d117bba9c0d8","3a464b7a4d574586b14fc513bf6743ed","fa1830aabb6b44e7aad798a19ee6fd07","e1aa9957d02046eab953a43b285f521f","d04e1bca2b9842c9bcac11bd94f66640"],"active_org_master_entity_id":["a622b117e269c940ce611eacf4a7aa91","2ad5d567ba475ef515697f58c289ab6a","eda0951333ad0320cb6033172427868f","42572376f70a67b3394454dff6275256","6e18d2c7b796defcd2f7e1523180c5fd","39bca394dee6cf89479116c593591e02","dea970434c1183ebd6632e77bd1e19c0"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["fa1830aabb6b44e7aad798a19ee6fd07","e1aa9957d02046eab953a43b285f521f"],"research_disease":["b0749d24d444442fad131d6b50ae4a1e","d1412e90153c488995027186619d33f4","1bfd0bc875394dec892402de8b927ed9","6d912c173a5543418298c7e385fcba20","b2cd7510e8e24dcdae2be0fd88cdf925","c27b471cedb94556b19ba35534145483","fc39368e3de54e2ab5c2d567074a6a4b","f7d9acc73f894d759455d8d8996caeb3","00c01ace570f4aa6ae5bc937eb956e61","6ab9f3053f674f7aa4bc5c56ba2bb955","af8eee4f871f4e51abe0da09faa978cd","8fd7f2b21bff4eacac47e40d6801aa39","97acfad2c5a54440bf23bd4a13f7aa73","660f8309f52447a6bd49f692bbc735ac","6086c978b1e242ea9fdfa5a0c5debb3a","0df94b4cbdda4b139e247afcb9a94760","1ed882684b7d4537b4987049c5be4bc2","86dc7f528caa4b79bf7b8372bc516d87","b910f946457644f28630580432a34e3f","350d3db9893e4498b2e396c24aa6a029","478a3554509441e7936078bddfbca593","b00bb76f187a4c028a547c6f3470c1d8","c7879aa9883f473695aea6cc7470cb48","7cf66a4af7ac4b51b888c59d7e30a2c4","4ecfc9bb4a654958a3b6d117bba9c0d8","3a464b7a4d574586b14fc513bf6743ed","fa1830aabb6b44e7aad798a19ee6fd07","e1aa9957d02046eab953a43b285f521f","d04e1bca2b9842c9bcac11bd94f66640"],"inactive_org_master_entity_id":["4723981e27cc91d2d0bfefe7cb94d12f"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","5b1dfc2ca8564662860187aef864467d","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769","ecc919b1-c2b7-3740-bfa7-7cda77176d07","52d1b118-b540-37ba-9cb2-f5aff686bb10"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1273104000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1217894400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1090540800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":807235200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1282780800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1717113600000}}],"disease_phase":[{"disease_id":"fa1830aabb6b44e7aad798a19ee6fd07","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d1412e90153c488995027186619d33f4","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b0749d24d444442fad131d6b50ae4a1e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8a4339e3f2634ad9ba882a9688be65bd","highest_phase_global":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"disease_id":"6ab9f3053f674f7aa4bc5c56ba2bb955","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"660f8309f52447a6bd49f692bbc735ac","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b910f946457644f28630580432a34e3f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b2cd7510e8e24dcdae2be0fd88cdf925","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e1aa9957d02046eab953a43b285f521f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"4ecfc9bb4a654958a3b6d117bba9c0d8","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6086c978b1e242ea9fdfa5a0c5debb3a","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"af8eee4f871f4e51abe0da09faa978cd","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1ed882684b7d4537b4987049c5be4bc2","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"86dc7f528caa4b79bf7b8372bc516d87","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c27b471cedb94556b19ba35534145483","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b00bb76f187a4c028a547c6f3470c1d8","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"f7d9acc73f894d759455d8d8996caeb3","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"97acfad2c5a54440bf23bd4a13f7aa73","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c7879aa9883f473695aea6cc7470cb48","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"00c01ace570f4aa6ae5bc937eb956e61","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d04e1bca2b9842c9bcac11bd94f66640","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8fd7f2b21bff4eacac47e40d6801aa39","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"478a3554509441e7936078bddfbca593","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"0df94b4cbdda4b139e247afcb9a94760","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3a464b7a4d574586b14fc513bf6743ed","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"fc39368e3de54e2ab5c2d567074a6a4b","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"350d3db9893e4498b2e396c24aa6a029","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7cf66a4af7ac4b51b888c59d7e30a2c4","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6d912c173a5543418298c7e385fcba20","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"1bfd0bc875394dec892402de8b927ed9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"024c94c741b541659716b6e5ac2abc37","docid":25025,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":5,"target_extend_id":"8eff89f35a6837faad41af646b8e10f3","has_leading_org_involved":1,"created_ts":"2021-10-08T14:45:22.000Z","updated_ts":"2026-04-07T21:20:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhongxia","drug_name":[{"lang":"EN","name":"E-6742","status":"ACTIVE"}],"dev_code":[{"name":"E 6742","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d39a3469967633f68037950c33a4a268"],"mechanism_action_id":["57e7ff61ed6b4efa3cd8ccea9b34d9fa","28c86348cc365b60346ab04b15f3a2fa"],"target_id":["37de98db3ccb46a3ac8e4df8fd7ad124","bfd9ae9131904838b0a638f3917632f2"],"disease_id":["c5e1987e283c495aaab2a8d309c6085e"],"active_org_master_entity_id":["d39a3469967633f68037950c33a4a268"],"research_disease":["c5e1987e283c495aaab2a8d309c6085e"],"inactive_org_master_entity_id":["c7036efab235dbeab3af3b6e8a62da31"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1775174400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1774915200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1570752000000}}],"disease_phase":[{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["3a2e4e54ab898866967ec5fbafbe919b","d39a3469967633f68037950c33a4a268"],"data_source":10}
+{"drug_id":"01555e1f2f2e4a73b0ac5e6cc660e72c","docid":1732918,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2026-01-06T03:23:28.000Z","updated_ts":"2026-04-03T05:10:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"RN-1701","source_info":[{"code":"NCT07316920","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07316920"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bispecific CD19/CD20-targeted allogeneic CAR-T(Allorunning Therapeutics)","source_info":[{"code":"NCT07316920","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07316920"}],"status":"ACTIVE"}],"dev_code":[{"name":"RN-1701","source_info":[{"code":"NCT07316920","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07316920"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["052a07e40d2c6f949fa29968d05587e6"],"disease_id":["0e0dca4dd7f1499a8f65f4fdfcf09954"],"active_org_master_entity_id":["e677b53cd99d6c61ffce18eb63fd2f61","052a07e40d2c6f949fa29968d05587e6"],"research_disease":["0e0dca4dd7f1499a8f65f4fdfcf09954"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1766361600000}}],"disease_phase":[{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"198ef20937d247ae8a5bbb1d552ed0aa","docid":4190,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-02-12T06:44:17.000Z","updated_ts":"2026-04-02T12:20:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"MesoPher (Amphera)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogeneic tumour cell lysate pulsed autologous dendritic cells Amphera","status":"ACTIVE"},{"lang":"EN","name":"Autologous dendritic cell vaccine (Amphera)","status":"ACTIVE"},{"lang":"EN","name":"Autologous dendritic cells pulsed with allogeneic tumour cell lysate","source_info":[{"code":"EU/3/23/2790","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA"}],"status":"ACTIVE"},{"lang":"EN","name":"MesoCancerVac","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","da28889c6a9146fa9d13e524d58bd0b2"],"originator_org_master_entity_id":["cc326ef01c73d9a2d1955c888a78bce7"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["ed204c2d1b6245098bb07da9c6b00eb5","ae092fa59f4d44edaf59ffe23d0a44c3","d00b4df2a8fb4a97960ede39bf58c0ef"],"active_org_master_entity_id":["cc326ef01c73d9a2d1955c888a78bce7"],"research_disease":["ed204c2d1b6245098bb07da9c6b00eb5","ae092fa59f4d44edaf59ffe23d0a44c3","d00b4df2a8fb4a97960ede39bf58c0ef"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba"},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1719619200000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1719619200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1719619200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1719619200000}}],"disease_phase":[{"disease_id":"d00b4df2a8fb4a97960ede39bf58c0ef","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ed204c2d1b6245098bb07da9c6b00eb5","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3df822c8c6984e33bf17c1e2861c9ba3","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"1149e30840c74c7da686823606a6b461","docid":59213,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"f7fa4e293f1a3128a5b7e692c7eb2ad8","has_leading_org_involved":1,"created_ts":"2022-02-28T05:06:22.000Z","updated_ts":"2026-02-27T09:14:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"AAV-AIPL1","source_info":[{"attachment_path":"data/phs_source_info/c602/98d1/44d1/fbda/50cf96e5-acbf-3ee4-b4d2-0a7a01ce04ca.png","attachment_type":"image/png","code":"MeiraGTx-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3bd1/f449/0fd2/c8b4/e5215f40-d60b-3e49-abd2-62cc580d6e9d.png","source":"Company pipeline","source_url":"https://meiragtx.com/programs-pipeline/pipeline/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AAV8-AIPL1 gene therapy (MeiraGTx)","source_info":[{"normalized_source_id":"df564163e18b49cfb6dbe49169e22f2d","source":"FDA","source_url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=622217"}],"status":"ACTIVE"},{"lang":"EN","name":"rAAV8.hRKp.AIPL1","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzAwMDA5NTIxNQ==&mid=2650106874&idx=3&sn=845556969cde47e1222829cba03e7914"}],"status":"ACTIVE"}],"dev_code":[{"name":"AAV AIPL1","source_info":[{"attachment_path":"data/phs_source_info/c602/98d1/44d1/fbda/50cf96e5-acbf-3ee4-b4d2-0a7a01ce04ca.png","attachment_type":"image/png","code":"MeiraGTx-202502","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3bd1/f449/0fd2/c8b4/e5215f40-d60b-3e49-abd2-62cc580d6e9d.png","source":"Company pipeline","source_url":"https://meiragtx.com/programs-pipeline/pipeline/"}],"status":"ACTIVE"},{"name":"AAV8-AIPL1","source_info":[{"normalized_source_id":"df564163e18b49cfb6dbe49169e22f2d","source":"FDA","source_url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=622217"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["c3f6a1a689ea9f0b7f6e85244139be25"],"mechanism_action_id":["767381b1dc9c4d86b67b895270150eb0"],"target_id":["6f130674e1684f219f6a6275f58f0380"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["b1f6cf17890646048c7b20e028f5fc3c","bc788896b8dd449983931a3c10b06507","2ef2f7065d1e476d839aaa6ce50d522d"],"active_org_master_entity_id":["c3f6a1a689ea9f0b7f6e85244139be25","2f55b324e0e20f9411ed3667550d0ba7","cd91deb5f8b1428f5aab46fbe1f6152c"],"research_disease":["b1f6cf17890646048c7b20e028f5fc3c"],"non_research_disease":["bc788896b8dd449983931a3c10b06507","2ef2f7065d1e476d839aaa6ce50d522d"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1738368000000}}],"disease_phase":[{"disease_id":"b1f6cf17890646048c7b20e028f5fc3c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bc788896b8dd449983931a3c10b06507","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"2ef2f7065d1e476d839aaa6ce50d522d","highest_phase_before_ter_global":"8666aad5477e4272b56b94ca1183781d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["2f55b324e0e20f9411ed3667550d0ba7","c3f6a1a689ea9f0b7f6e85244139be25"],"if_speculate":0,"data_source":10}
+{"drug_id":"01ce4075743a493baa6b35f3714e2155","docid":51420,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"8ac6bc4127ad4b47aa436a9b497007dc","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":599529600000,"rnk":26,"target_extend_id":"450cd6ab529c38d4b0ad05aaff0d5fd7","created_ts":"2021-10-08T14:48:18.000Z","updated_ts":"2026-02-24T11:03:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Antihemophilic Factor(Baxalta, Inc.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Antihemophilic factor (USP)","source_info":[{"code":"D02958","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Bioclate (Armour), Recombinate","source_info":[{"code":"BLA103375","normalized_source_id":"f3bd4fd130ec4588971e9008b5010e32","source":"FDA_CBER"}],"status":"ACTIVE"}],"trade_name":[{"name":"Recombinate","status":"ACTIVE"}],"kegg_id":["D02958"],"drug_type":["4d2dcd3fc8b644db955f8cccefca280b"],"originator_org_master_entity_id":["5f37443814e905dbfb0117df404c3aea"],"mechanism_action_id":["979b395f8c612b269b4c98663691de9d","56f56431e88707dc608712608ad0cf88","7bf0ac7ba72ab886ac91b423c45a84fe"],"target_id":["3f888f3938b34a4ca124145b3fa1e229"],"atc_code":["bdb9980ac29148589210c8ef6f77ceef"],"disease_id":["07d4cf59dafc4a35840dbf53e136394a"],"active_org_master_entity_id":["832756352f02f17433dfb065466df2c2","4099573c333dcbc48d8f398aee392060"],"first_approved_country":["cf11da47-6a9f-3948-9d29-8a824f805638"],"first_approved_indication":["07d4cf59dafc4a35840dbf53e136394a"],"research_disease":["07d4cf59dafc4a35840dbf53e136394a"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","cf11da47-6a9f-3948-9d29-8a824f805638"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":723945600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":599529600000}}],"disease_phase":[{"disease_id":"07d4cf59dafc4a35840dbf53e136394a","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"049b4fb21e5041499fa847da088c7c14","docid":1732196,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":26,"target_extend_id":"1ad33aaeecba3d8490842b130de51cf6","has_leading_org_involved":1,"created_ts":"2025-11-14T07:04:16.000Z","updated_ts":"2026-04-18T21:07:01.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"PRT12396","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://investors.preludetx.com/news-releases/news-release-details/prelude-therapeutics-presents-data-2025-ash-annual-meeting-its"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"JAK2V617F JH2 inhibitor(Prelude Therapeutics)","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investors.preludetx.com/news-releases/news-release-details/prelude-therapeutics-announces-exclusive-option-agreement-incyte"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["629b8ef53f0be2a209feb7a6131194e0"],"mechanism_action_id":["5319d0b9180f0b12957d61cde7932a27"],"target_id":["471b7ac440a64d3cbf2d5d01f274f7b5"],"disease_id":["18595e2fb8ec4e41bafa9b28a01b3c2b","bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868"],"active_org_master_entity_id":["629b8ef53f0be2a209feb7a6131194e0"],"research_disease":["18595e2fb8ec4e41bafa9b28a01b3c2b","bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1775001600000}}],"disease_phase":[{"disease_id":"18595e2fb8ec4e41bafa9b28a01b3c2b","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"bb2d2cb31a9b4c9687a2fc8194b7ddbb","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f9411c5705084810ac5fffbb524c86c9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"1c62320dcc394fea8c8ac97b04ccf868","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["0e9d7fb3214303cf4a6cb424c5df10a4","629b8ef53f0be2a209feb7a6131194e0"],"if_speculate":0,"data_source":10}
+{"drug_id":"2a89b22dcfdc4461879cad7dbb2b8977","docid":1733533,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-17T05:36:41.000Z","updated_ts":"2026-03-17T06:34:15.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"[64Cu]-RYM2","source_info":[{"code":"NCT07473102","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07473102"}],"status":"ACTIVE"}],"dev_code":[{"name":"Cu-64-RYM2","source_info":[{"code":"NCT07473102","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07473102"}],"status":"ACTIVE"},{"name":"[64Cu]-RYM2","source_info":[{"code":"NCT07473102","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07473102"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["c247f0fb72b5c027c69606995996a9d1"],"disease_id":["24b9742ce4724b1ba3d7410f3cdd735e"],"active_org_master_entity_id":["c247f0fb72b5c027c69606995996a9d1"],"research_disease":["24b9742ce4724b1ba3d7410f3cdd735e"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1762128000000}}],"disease_phase":[{"disease_id":"24b9742ce4724b1ba3d7410f3cdd735e","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"455fa05807374a4297b33d9451bce186","docid":66324,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":4,"target_extend_id":"eabec2d88b5d3878b8148ff0e852fe3f","created_ts":"2021-10-08T14:41:53.000Z","updated_ts":"2026-03-25T00:42:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"泰利奇拜单抗","source_info":[{"code":"CXSS2500091","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Telikibart","source_info":[{"attachment_path":"data/phs_source_info/041e/cc72/891a/d65a/96906211-bced-3fb8-adcb-da3e8567a8ea.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5da3/9337/4c0f/3634/dc28537d-c0f1-3b9f-82ae-0e14a627e0e9.png","source":"Company pipeline","source_url":"http://www.genrixbio.com/#/science?classId=class1"}],"status":"ACTIVE"}],"dev_code":[{"name":"GR-1802","status":"ACTIVE"},{"name":"GR1802","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MjM5NzQ4MTg2MQ==&mid=2650407683&idx=4&sn=8e4a9ac6468f0bf2cc003bb2cb941778"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["575cf201cc223eac2f65ac65cddb2931"],"mechanism_action_id":["8e46e6d7cb5ef25ed25572cd326c56ec"],"target_id":["9055fd3b7cd6459f9dbb0f84bab4c9aa"],"disease_id":["07ca4cbd5bbe460590b9f3982fa38ec1","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","286ea42cd2f94d18b9f0876bf2c531ac","323fd3aac06145689cb8e1b4fd0a3bc2","666ca45028ad4ccc9383172f2715c649"],"active_org_master_entity_id":["b616983e88821e3a0d8c202958457443"],"research_disease":["07ca4cbd5bbe460590b9f3982fa38ec1","36e0c025abee4597a1af4c2a7cd79896","2b417b8a2edf4cbca4229886a3460547","286ea42cd2f94d18b9f0876bf2c531ac","323fd3aac06145689cb8e1b4fd0a3bc2","666ca45028ad4ccc9383172f2715c649"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1772064000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1757548800000}}],"disease_phase":[{"disease_id":"07ca4cbd5bbe460590b9f3982fa38ec1","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"36e0c025abee4597a1af4c2a7cd79896","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"286ea42cd2f94d18b9f0876bf2c531ac","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"323fd3aac06145689cb8e1b4fd0a3bc2","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"666ca45028ad4ccc9383172f2715c649","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2b417b8a2edf4cbca4229886a3460547","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"35e518d17b384cd1bd2a3e4e276c675e","docid":9005,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":6,"target_extend_id":"103207366d6e3996b6fce2e606cc3996","created_ts":"2021-12-29T11:38:02.000Z","updated_ts":"2026-03-07T21:09:08.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"库莱韦单抗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247532563&idx=4&sn=f16e7828f2b7853e37e0189c8d91ca63"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.ofweek.com/biotech/a656714010667"}],"status":"ACTIVE"},{"lang":"EN","name":"RB-0026","status":"ACTIVE"}],"dev_code":[{"name":"RB 0026","status":"ACTIVE"},{"name":"RB-0026","status":"ACTIVE"},{"name":"RB0026","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["8df3d40342c9cd157cbf0f7406c7f48c"],"mechanism_action_id":["0ebcf1d3c900942ea26ee8d79dfabac7"],"target_id":["77f82229727143e383387cbf39f934fe"],"special_review":["23d3523b7ece48ddacaddac53a66949d"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["8df3d40342c9cd157cbf0f7406c7f48c"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1771027200000}}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"3eef702f9ed747b98372452f4a10b8a0","docid":198,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":38,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2021-10-08T14:47:18.000Z","updated_ts":"2026-04-18T21:07:53.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"艾本那肽","status":"ACTIVE"},{"lang":"EN","name":"Albenatide","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PC-DAC:Exendin-4","status":"ACTIVE"},{"lang":"EN","name":"PCDAC","status":"ACTIVE"},{"lang":"CN","name":"阿贝那肽","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.toutiao.com/article/7565716167622378020/"}],"status":"ACTIVE"}],"dev_code":[{"name":"CJC-1134","status":"ACTIVE"},{"name":"CJC-1134-PC","status":"ACTIVE"},{"name":"CJC1134-PC","status":"ACTIVE"}],"trade_name":[{"name":"PC-DAC","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["32711208f23cd2f8524cb1049779f574"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"disease_id":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["d1c74efab04ed3dadec4e81090cd8560"],"research_disease":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814"],"inactive_org_master_entity_id":["32711208f23cd2f8524cb1049779f574"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1714003200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1500422400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1500422400000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"deal_related_org":["6ce2fd183d3b2dc6b7ecdf158da969d0","32711208f23cd2f8524cb1049779f574"],"if_speculate":0,"data_source":10}
+{"drug_id":"03edb51f7acd479babb89b0b71e79e84","docid":58001,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":49,"target_extend_id":"b1391bc834803f0faabbb5cc05fb37d9","created_ts":"2021-10-08T14:38:44.000Z","updated_ts":"2026-04-04T21:08:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"MDR-1339","status":"ACTIVE"}],"dev_code":[{"name":"DBT-1339","status":"ACTIVE"},{"name":"MDR 1339","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["dd51f73bf73dbd2636b86e6d44d2c231"],"mechanism_action_id":["d4e1560de4a5234590d7e480973bc215"],"target_id":["5ff9d5388b7c4c0a9abf556c9d8659d6"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0"],"active_org_master_entity_id":["2aee56658bc6d4a6eb96ed14b60a6bd7","dd51f73bf73dbd2636b86e6d44d2c231"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"c9e8fce7eb6b4bbd9cc66dc356017aab","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"075eba02dfb34758a9e49575eb8ccd0a","docid":33085,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","linker_id":"b6b2199ed4544f5ea43c3c1dd1adbaf7","payload_id":"fc638b29231e48a194136b167639cc28","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":14,"target_extend_id":"b2c6fb7e717f388e88349de4e1b73cd7","created_ts":"2023-01-18T02:20:23.000Z","updated_ts":"2025-08-16T21:10:25.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"FZ-AD004","source_info":[{"code":"CXSL2300047","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"FZ-AD004抗体偶联剂","source_info":[{"code":"CXSL2300047","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"FZ AD004","status":"ACTIVE"},{"name":"FZ-AD004","status":"ACTIVE"},{"name":"FZAD004","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["bc492086582ce63431e5d448dca205e7"],"mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99","9f012a6b83d88bf152ee30b3d01fa3df"],"target_id":["6acffb63799b4ba3bc85a4c59fcb05d7","d8cdb9ce63174077a9ef868b39bf3421"],"adc_reference":[{"normalized_source_id":"a6adf37f41bb43a3ad9355f080dd5d68","source":"PRNewswire","source_url":"http://www.fd-zj.com/DesktopModules/HT/chinese/News/202301191009044133.aspx?LS=1"}],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["bc492086582ce63431e5d448dca205e7"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686528000000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"moiety_target_extend_id":"ff10f99a311c31f39503da07f9503192","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["9f012a6b83d88bf152ee30b3d01fa3df"],"moiety_target_id":["d8cdb9ce63174077a9ef868b39bf3421"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"0ee48e522b4044fd8bcf95331f90a010","docid":4991,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Pyridoxal_phosphate","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":-192844800000,"rnk":1,"target_extend_id":"badd97eeb5b730919f655688da979c20","created_ts":"2021-10-08T14:47:09.000Z","updated_ts":"2026-04-02T12:54:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"磷酸吡哆醛水合物","status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal Phosphate Hydrate","source_info":[{"code":"21400AMZ00058","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ピリドキサールリン酸エステル水和物","source_info":[{"code":"21400AMZ00058","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Avastrem","status":"ACTIVE"},{"lang":"EN","name":"Cardoxal","status":"ACTIVE"},{"lang":"EN","name":"Codecarboxylase","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"PLP","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal 5'-phosphate","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal 5-monophosphoric acid ester","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal 5-phosphate","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal P","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal phosphate","status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal phosphate anhydrous","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal phosphate hydrate (JP17)","source_info":[{"code":"D00006","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal phosphate monohydrate","source_info":[{"code":"D00006","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal-5P","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Pyridoxal-P","source_info":[{"code":"DB00114","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Tardoxal","status":"ACTIVE"}],"dev_code":[{"name":"CG-A3H","source_info":[{"code":"21400AMZ00058","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/431010_3134003F1388_2_02"}],"status":"ACTIVE"},{"name":"MC-1","status":"ACTIVE"}],"trade_name":[{"name":"Hipyridoxin","source_info":[{"code":"D00006","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"PYDOXAL","source_info":[{"code":"21400AMZ00058","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/431010_3134003F1388_2_02"}],"status":"ACTIVE"},{"name":"ピドキサール","source_info":[{"code":"21400AMZ00058","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/431010_3134003F1388_2_02"}],"status":"ACTIVE"}],"generic_name":[{"name":"Pyridoxal","source_info":[{"code":"F06SGE49M6","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/9e793b80-da77-4029-9c81-722feab9a7f4"}],"status":"ACTIVE"}],"drugbank_id":["DB00114"],"kegg_id":["D00006"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7fae70b2836eab361b47161d77949376"],"mechanism_action_id":["5c43943b47c9165ebe08b60b28e3f8f2"],"target_id":["fa534bf1d2bf41db8d43cb3c65a545ce"],"atc_code":["234975636c7e480aaea33ddbbae0d1ff"],"special_review":["425d71b560a7499087c4f5a36692741c","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["b6d9b6220d004f50bf3fd6fa85b05466","e517c0a11d4e4e1e9df19358c3f1f258","bf821ba3fb194a38a5b2f804bcf68c44","74d974da49ba407195b38595a0aff704","281fcf1b07ee4c13b0297e4ad1a9c106","a41c00c1f16c4b71b41c0ce5a391998b","9b344530ac6c4a109108474a64182933","25b3fc7b1db549809168688ecd3e33ac","ec4d59ce792b465d8e55e7e52840c626","999eb9ef2a744f79b224b568f82b4bc6"],"active_org_master_entity_id":["a9267d4ee22e0fdff8f876ca9c416d6c","b68c8095fd24aaea6a32494a24954a2d","7fae70b2836eab361b47161d77949376"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["b6d9b6220d004f50bf3fd6fa85b05466"],"research_disease":["b6d9b6220d004f50bf3fd6fa85b05466","e517c0a11d4e4e1e9df19358c3f1f258"],"non_research_disease":["bf821ba3fb194a38a5b2f804bcf68c44","74d974da49ba407195b38595a0aff704","281fcf1b07ee4c13b0297e4ad1a9c106","a41c00c1f16c4b71b41c0ce5a391998b","9b344530ac6c4a109108474a64182933","25b3fc7b1db549809168688ecd3e33ac","ec4d59ce792b465d8e55e7e52840c626","999eb9ef2a744f79b224b568f82b4bc6"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-151286400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-192844800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1700697600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1708041600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1550188800000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1550188800000}}],"disease_phase":[{"disease_id":"e517c0a11d4e4e1e9df19358c3f1f258","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"a41c00c1f16c4b71b41c0ce5a391998b","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b6d9b6220d004f50bf3fd6fa85b05466","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"25b3fc7b1db549809168688ecd3e33ac","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"9b344530ac6c4a109108474a64182933","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"999eb9ef2a744f79b224b568f82b4bc6","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"06d36b3b2df141b09bc92a56b610ec79","docid":19744,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"0393f83eb20634aeb69dd65d9da9e310","created_ts":"2022-05-30T12:14:31.000Z","updated_ts":"2026-02-25T21:08:17.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"BIM2b","status":"ACTIVE"}],"dev_code":[{"name":"BIM2B","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8146e29b57f735e57079c9b3b5ce7389"],"mechanism_action_id":["94a1aaff097eb98cfd32e10ff852c276"],"target_id":["5c40ab1e71934b79825fe1cda40d0297"],"disease_id":["913534b87d4543e28eeb8a7215bb8ef4"],"active_org_master_entity_id":["8146e29b57f735e57079c9b3b5ce7389","bca706f9d9bdd009f14324f578016954"],"research_disease":["913534b87d4543e28eeb8a7215bb8ef4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1730419200000}}],"disease_phase":[{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0037b10f3d9340f389b0192c25f75224","docid":17994,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":3,"target_extend_id":"b35fae006e1e3f05a3c4318bbe6c2395","created_ts":"2021-10-08T14:41:12.000Z","updated_ts":"2026-04-20T05:59:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"Elraglusib","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://pubmed.ncbi.nlm.nih.gov/36104795/"}],"status":"ACTIVE"}],"dev_code":[{"name":"9 ING 41","status":"ACTIVE"},{"name":"9-ING-41","status":"ACTIVE"}],"drugbank_id":["DB16047"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8421b0604b1f631d9c7e4f976c3ba488"],"mechanism_action_id":["03c807372d824555b1f9eb57e8037b30"],"target_id":["f2a1a3151cfc443d8720a32f48923b4a"],"special_review":["425d71b560a7499087c4f5a36692741c","043a131d85994801b3617e822e7f87b3"],"disease_id":["7e87f9c6dcd841edb4d0f250b6bee3d9","a311ae2187914c2bbad45810b91f9414","6a962a4341364bbe9959b413849567de","f3816b286d3e447a8ba07beb0e9e1fd0","837bfdb460c547aab1df98ef12508003","bfef803db2774e9184b673498fab2365","fbc5f0802bd549c4abb243168014b938","6570754a6f0b43b78a9926c7bfd00519","8b46f5a2ac544e30ab179a9fa444f884","892e0b3107fc47caba8107d91242697d","f319fa27684c4cdeb6ce59d897217718","d7a26da8f1ff43559e34fe72da812c56","7665e5683a1a443a8f3d3b946d4c9ca2","05554578204541148a5482ad5df4a600","114966a80e4d4ce5a6885c9e09dc08d5","e2fd9bda4aeb4a7b9fa53a2560126d24","5822abc7ac09433bba89ca2349b2dec7","024deb39dbdb42eea0863db300b15242","27c81d33df044a648187f81864221799","3ac5604c4dde49c29b561648d0c0543c","755abeee587145398fee777a94c27445","c7fe8aa844d24e85ba32a990ea28ded3","c1cc2528f29940fc95fd6bc37eb982d4","913534b87d4543e28eeb8a7215bb8ef4","a1ddbb69fd3e46b6980bd4e1f1e64a45","c429db71d4a441d9823a909208d8f08e","a4f7254e36da425087293790eb964551","56e4dcc14b9345298b4715f74c691a18","0ac1b42005084b779f1efce8fbc7236b","598372309fac44dfa9afd74266b0d581","33679852d82540b6b4fa86d88a52dd68","b710ed37a11246c387b08efbe0196b55","527089e16c00490ba34b3a7b518ea526","200844d5d73740deb3c3c825469da915","73fd82d969b1457a85183ca272200cb7","3b4526a3143044edb2c5ae1e0ce8b692","c349d56721634602bd73c8f36c3b496a","7d7534fb1c944f4a969a7518563aad39","bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868","3e6da1e4a8c447e09f7154d933fbccf5","fa82d1705c3a457e82f815cb62db8102","7032985f6c0b414f9993b7072c105fb4","665cab297e0d4a0494e8bccc8bbe4f7d"],"active_org_master_entity_id":["ed4709abe5514910df90ac28b93205fc","8421b0604b1f631d9c7e4f976c3ba488","8d37c263ae1923a40721ec4599990441","30d8c010d54e4c8feffc57abc8c24fed","ce1783471a7add837e1062d85249c974","62871a1eccbe3bf1b5673b4367ea8838","b58e098a24c5ca10481d2c3b0fd96438","f68b0798aa32f5bdaf17a674fc64b4c1"],"research_disease":["7e87f9c6dcd841edb4d0f250b6bee3d9","a311ae2187914c2bbad45810b91f9414","6a962a4341364bbe9959b413849567de","f3816b286d3e447a8ba07beb0e9e1fd0","837bfdb460c547aab1df98ef12508003","bfef803db2774e9184b673498fab2365","fbc5f0802bd549c4abb243168014b938","6570754a6f0b43b78a9926c7bfd00519","8b46f5a2ac544e30ab179a9fa444f884","892e0b3107fc47caba8107d91242697d","f319fa27684c4cdeb6ce59d897217718","d7a26da8f1ff43559e34fe72da812c56","7665e5683a1a443a8f3d3b946d4c9ca2","05554578204541148a5482ad5df4a600","114966a80e4d4ce5a6885c9e09dc08d5","e2fd9bda4aeb4a7b9fa53a2560126d24","5822abc7ac09433bba89ca2349b2dec7","024deb39dbdb42eea0863db300b15242","27c81d33df044a648187f81864221799","3ac5604c4dde49c29b561648d0c0543c","755abeee587145398fee777a94c27445","c7fe8aa844d24e85ba32a990ea28ded3","c1cc2528f29940fc95fd6bc37eb982d4","913534b87d4543e28eeb8a7215bb8ef4"],"non_research_disease":["a1ddbb69fd3e46b6980bd4e1f1e64a45","c429db71d4a441d9823a909208d8f08e","a4f7254e36da425087293790eb964551","56e4dcc14b9345298b4715f74c691a18","0ac1b42005084b779f1efce8fbc7236b","598372309fac44dfa9afd74266b0d581","33679852d82540b6b4fa86d88a52dd68","b710ed37a11246c387b08efbe0196b55","527089e16c00490ba34b3a7b518ea526","200844d5d73740deb3c3c825469da915","73fd82d969b1457a85183ca272200cb7","3b4526a3143044edb2c5ae1e0ce8b692","c349d56721634602bd73c8f36c3b496a","7d7534fb1c944f4a969a7518563aad39","bb2d2cb31a9b4c9687a2fc8194b7ddbb","f9411c5705084810ac5fffbb524c86c9","1c62320dcc394fea8c8ac97b04ccf868","3e6da1e4a8c447e09f7154d933fbccf5","fa82d1705c3a457e82f815cb62db8102","7032985f6c0b414f9993b7072c105fb4","665cab297e0d4a0494e8bccc8bbe4f7d"],"inactive_org_master_entity_id":["0e9d7fb3214303cf4a6cb424c5df10a4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","20f1c6915ff140519285386c54883aae","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1748563200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1647820800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1631577600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1546560000000}}],"disease_phase":[{"disease_id":"755abeee587145398fee777a94c27445","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5822abc7ac09433bba89ca2349b2dec7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"27c81d33df044a648187f81864221799","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"bb2d2cb31a9b4c9687a2fc8194b7ddbb","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"bfef803db2774e9184b673498fab2365","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3e6da1e4a8c447e09f7154d933fbccf5","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"73fd82d969b1457a85183ca272200cb7","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"56e4dcc14b9345298b4715f74c691a18","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c349d56721634602bd73c8f36c3b496a","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"892e0b3107fc47caba8107d91242697d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7e87f9c6dcd841edb4d0f250b6bee3d9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0ac1b42005084b779f1efce8fbc7236b","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"b710ed37a11246c387b08efbe0196b55","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"8b46f5a2ac544e30ab179a9fa444f884","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6a962a4341364bbe9959b413849567de","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"200844d5d73740deb3c3c825469da915","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f9411c5705084810ac5fffbb524c86c9","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1c62320dcc394fea8c8ac97b04ccf868","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"837bfdb460c547aab1df98ef12508003","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"024deb39dbdb42eea0863db300b15242","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"a1ddbb69fd3e46b6980bd4e1f1e64a45","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"fa82d1705c3a457e82f815cb62db8102","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"665cab297e0d4a0494e8bccc8bbe4f7d","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"3ac5604c4dde49c29b561648d0c0543c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"114966a80e4d4ce5a6885c9e09dc08d5","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3b4526a3143044edb2c5ae1e0ce8b692","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f3816b286d3e447a8ba07beb0e9e1fd0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"527089e16c00490ba34b3a7b518ea526","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"fbc5f0802bd549c4abb243168014b938","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7d7534fb1c944f4a969a7518563aad39","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"598372309fac44dfa9afd74266b0d581","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c429db71d4a441d9823a909208d8f08e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"33679852d82540b6b4fa86d88a52dd68","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"7032985f6c0b414f9993b7072c105fb4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["30d8c010d54e4c8feffc57abc8c24fed","ed4709abe5514910df90ac28b93205fc"],"if_speculate":0,"data_source":10}
+{"drug_id":"01c5c26fb74547fc82947da239ebff7a","docid":7215,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-07-19T11:54:30.000Z","updated_ts":"2024-10-30T10:22:50.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"sunying","drug_name":[{"lang":"CN","name":"葫芦巴提取物","source_info":[{"normalized_source_id":"e327c7fe232e4b3ba172121614cef0ba","source":"MANUAL"}],"status":"ACTIVE"},{"lang":"EN","name":"Fenugreek Extract","source_info":[{"code":"NCT05232279","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05232279"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Testofen","source_info":[{"code":"NCT05232279","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05232279"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["1a3021fccb3349150ab57f886d053e3b"],"disease_id":["0dfc10e5c81e42869cd8f7479a1b5021","f21b246b05574261844954d981c3ba89","3c109db8472244f2910db4cb25ecd9d4"],"active_org_master_entity_id":["1a3021fccb3349150ab57f886d053e3b"],"research_disease":["0dfc10e5c81e42869cd8f7479a1b5021","f21b246b05574261844954d981c3ba89","3c109db8472244f2910db4cb25ecd9d4"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1698192000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1650326400000}}],"disease_phase":[{"disease_id":"f21b246b05574261844954d981c3ba89","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"0dfc10e5c81e42869cd8f7479a1b5021","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3c109db8472244f2910db4cb25ecd9d4","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"071ddbd638c3465dbc20dddeb5cbf49b","docid":37868,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1718668800000,"rnk":11,"target_extend_id":"12da1094622c367d8409b3fb561d144a","created_ts":"2021-10-08T14:45:11.000Z","updated_ts":"2026-04-18T21:16:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","first_approved_date_cn":1718668800000,"drug_name":[{"lang":"CN","name":"戈利昔替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/fiB4E-xYEsg0BTikxhKx_g"}],"status":"ACTIVE"},{"lang":"EN","name":"Golidocitinib","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.dizalpharma.com/innovation/P&S"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Golidocitnib","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/dizal-announces-new-data-from-the-phase-i-ii-study-of-golidocitnib-in-refractory-or-relapsed-peripheral-t-cell-lymphoma-selected-for-oral-presentation-at-2022-eha-annual-meeting/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AZD-4205","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/golidocitinib"}],"status":"ACTIVE"},{"name":"DZD 4205","status":"ACTIVE"},{"name":"DZD-4205","status":"ACTIVE"},{"name":"DZD4205","status":"ACTIVE"},{"name":"NC-0322","status":"ACTIVE"}],"trade_name":[{"name":"高瑞哲","source_info":[{"code":"CTR20240028","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=240e3b70b84042269c6b436efc79cfb3"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2bc4277f6cbb60b2f9f65d9cbbc658f3","6e7a2de70d46daa0cef8586ca22ae506"],"mechanism_action_id":["5f5e0563a81f2d5d04703799942dff44"],"target_id":["75baf324563b4c8ab7eaac21da3a9fb8"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["1cfde61efce54a8c9b92dd7b60c30995","2536e79ced34450fbb09de73061cf096","e918886725594b31980380b66df9b8e5","7f06bb1d5bd44ad6aedf53928dbdaf93","ab880bb6e3bc46538769c0c12c849c20","05ae12d567784b85a5c1ca54b2063ee2","4d4cee82fa5c46f19de528f4a8423f62","b8ec886990c246ec89921f3f13e01bf4"],"active_org_master_entity_id":["2bc4277f6cbb60b2f9f65d9cbbc658f3","100dc04c70203464e041c1731583d74f"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["1cfde61efce54a8c9b92dd7b60c30995"],"research_disease":["1cfde61efce54a8c9b92dd7b60c30995","2536e79ced34450fbb09de73061cf096","e918886725594b31980380b66df9b8e5","7f06bb1d5bd44ad6aedf53928dbdaf93","ab880bb6e3bc46538769c0c12c849c20","05ae12d567784b85a5c1ca54b2063ee2"],"non_research_disease":["4d4cee82fa5c46f19de528f4a8423f62","b8ec886990c246ec89921f3f13e01bf4"],"inactive_org_master_entity_id":["6e7a2de70d46daa0cef8586ca22ae506"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","948c9548c2ed46b5865b8693f7f96604","234aad67e4bc46b3906543b77e393606"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1718668800000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1714953600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1714953600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1771632000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1728518400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1771632000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1641686400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1771632000000}}],"disease_phase":[{"disease_id":"2536e79ced34450fbb09de73061cf096","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1cfde61efce54a8c9b92dd7b60c30995","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e918886725594b31980380b66df9b8e5","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b8ec886990c246ec89921f3f13e01bf4","highest_phase_before_ter_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"ab880bb6e3bc46538769c0c12c849c20","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4d4cee82fa5c46f19de528f4a8423f62","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7f06bb1d5bd44ad6aedf53928dbdaf93","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0882fc96d3214fa981a5f161ea0fd38f","docid":6113,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":3,"target_extend_id":"f7778933748c360dbd94f61f8041eb87","created_ts":"2021-12-15T05:21:26.000Z","updated_ts":"2026-04-02T23:28:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"瑞普泊肽","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/VGV77BtVF9QOdOo3wzPoYg"}],"status":"ACTIVE"},{"lang":"EN","name":"Ribupatide","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/VGV77BtVF9QOdOo3wzPoYg"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"利鲁帕肽","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg3OTE3NjA4Nw==&mid=2247623842&idx=2&sn=0641457cd4f04c57a3cd745fa464a065"}],"status":"ACTIVE"},{"lang":"CN","name":"瑞波肽","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg3OTE3NjA4Nw==&mid=2247623033&idx=1&sn=caa546c1142aee85630e226132823413"}],"status":"ACTIVE"}],"dev_code":[{"name":"HRS 9531","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"HRS-9531","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"HRS9531","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"KAI 9531","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/business/kailera-launches-with-400m-to-advance-china-developed-obesity-assets"}],"status":"ACTIVE"},{"name":"KAI-9531","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/business/kailera-launches-with-400m-to-advance-china-developed-obesity-assets"}],"status":"ACTIVE"},{"name":"KAI9531","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/business/kailera-launches-with-400m-to-advance-china-developed-obesity-assets"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["d5537e91192011e3e2bddea1e600f4d6"],"mechanism_action_id":["47b4c1651fa2bfb01b1d26d0a0d27a6f","888b99dda6a62ef2551937c34e253e9c"],"target_id":["a87e2f1913564a9aa418d6a6a8e1a799","c385dcba5fea4e97bf02bc256757613a"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814","8ae7b8895639407b906410d1b46cf4d7","74d974da49ba407195b38595a0aff704","3c3b96bc6e6a431f97684569dba71421","c2c96e5bbe6949eda9849bc07a6b4d60","1064a78afa214911ac4baa36dbf570a4","27013926797d4bc4bf088e4104530e7d","bb895a9780a94318973390e3df4eb213","9922422b86804d79a88005958e17ec8e","d48fb44f1cc045aebb9dcec31eaedfc6"],"active_org_master_entity_id":["d5537e91192011e3e2bddea1e600f4d6","f05511dd6ff17a90ba4bf65aac070817"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814","8ae7b8895639407b906410d1b46cf4d7","74d974da49ba407195b38595a0aff704","3c3b96bc6e6a431f97684569dba71421","c2c96e5bbe6949eda9849bc07a6b4d60","1064a78afa214911ac4baa36dbf570a4","27013926797d4bc4bf088e4104530e7d","bb895a9780a94318973390e3df4eb213","9922422b86804d79a88005958e17ec8e","d48fb44f1cc045aebb9dcec31eaedfc6"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","54e2cf3dc3294445b4a27b990b0ba274","b3fbcd71f916470d88c3c590793fe4f3","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1756771200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1768176000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1766016000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"1064a78afa214911ac4baa36dbf570a4","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9922422b86804d79a88005958e17ec8e","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"8ae7b8895639407b906410d1b46cf4d7","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"3c3b96bc6e6a431f97684569dba71421","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"c2c96e5bbe6949eda9849bc07a6b4d60","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"d48fb44f1cc045aebb9dcec31eaedfc6","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"bb895a9780a94318973390e3df4eb213","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"deal_related_org":["8cf7f3af90ad45cdeb2a74b6e73b6ebf","f05511dd6ff17a90ba4bf65aac070817"],"if_speculate":0,"data_source":10}
+{"drug_id":"0817c2691d284603964570f570027203","docid":49418,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-11-24T11:28:39.000Z","updated_ts":"2025-02-25T10:32:33.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Ga-68 Galmydar","source_info":[{"code":"NCT05625490","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05625490"}],"status":"ACTIVE"}],"dev_code":[{"name":"IND-157468","source_info":[{"code":"NCT05280782","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05280782"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"disease_id":["bf821ba3fb194a38a5b2f804bcf68c44"],"active_org_master_entity_id":["c247f0fb72b5c027c69606995996a9d1"],"research_disease":["bf821ba3fb194a38a5b2f804bcf68c44"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641340800000}}],"disease_phase":[{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03558cc250944a41b2a3c3765e60eb04","docid":62192,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":148,"target_extend_id":"8213c47538943d6abbd8a82878581fef","created_ts":"2021-10-08T14:37:11.000Z","updated_ts":"2026-04-18T21:08:44.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"T-1201","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["eeab49793ba1b2dc4636557041dfa860"],"mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"],"target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["eeab49793ba1b2dc4636557041dfa860"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1624492800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"068e46cf9e4642f0a50bc3393192ce55","docid":15182,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":27,"target_extend_id":"11c51d63bf6232f2b1501030416ca4eb","created_ts":"2022-07-12T10:31:02.000Z","updated_ts":"2026-03-23T21:05:21.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"STC007","source_info":[{"code":"CXHL2200494","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"STC007","source_info":[{"code":"CXHL2200494","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["af77803cd3574c9b2b8e7dd16c4efbb4"],"mechanism_action_id":["b140e0c0f4e3e3d0cfc35c8ed236cefc"],"target_id":["f90cd704355648eb9f42d7fbc9e032bf"],"disease_id":["b306cb1f7ab74a5ab146c5148a8212e3","e05d3f1bc6e8430e8a7dc7171ae02206","bb895a9780a94318973390e3df4eb213"],"active_org_master_entity_id":["af77803cd3574c9b2b8e7dd16c4efbb4"],"research_disease":["b306cb1f7ab74a5ab146c5148a8212e3","e05d3f1bc6e8430e8a7dc7171ae02206"],"non_research_disease":["bb895a9780a94318973390e3df4eb213"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1741046400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1730073600000}}],"disease_phase":[{"disease_id":"e05d3f1bc6e8430e8a7dc7171ae02206","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"bb895a9780a94318973390e3df4eb213","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"b306cb1f7ab74a5ab146c5148a8212e3","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["41c37d4aa2bccb5479b9cdb911e8126e","af77803cd3574c9b2b8e7dd16c4efbb4","ed3e0ff2af22d8a52d27222c1dedb43f"],"if_speculate":0,"data_source":10}
+{"drug_id":"08d6ec94116848f58ba3c68006d1c1ef","docid":33874,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"linker_id":"968df743b15b4c43831be9902e98e054","payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":12,"target_extend_id":"8883b390d2973eb18fb92c73fdf6bc47","created_ts":"2023-02-02T03:13:49.000Z","updated_ts":"2026-04-02T11:20:18.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"[177Lu]Lu-DPI-4452","source_info":[{"code":"NCT05706129","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05706129"},{"attachment_path":"data/phs_source_info/4adf/00bf/ef35/7d3d/bc041761-7963-3685-9829-83dad93a8d8a.png","attachment_type":"image/png","code":"3B Pharmaceuticals-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/314e/855a/865b/355a/41cf5c3c-9adf-3b2a-8423-90aee2ee6f7a.png","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"}],"dev_code":[{"name":"3B-301","status":"ACTIVE"},{"name":"Debio 0228","source_info":[{"normalized_source_id":"42d89394e1d7470596de758366ae816a","source":"PipelineReview","source_url":"https://pipelinereview.com/itm-obtains-exclusive-worldwide-license-from-debiopharm-for-ca-ix-targeted-peptide-based-radiopharmaceutical-programs-targeting-solid-tumors/"},{"attachment_path":"data/phs_source_info/4adf/00bf/ef35/7d3d/bc041761-7963-3685-9829-83dad93a8d8a.png","attachment_type":"image/png","code":"3B Pharmaceuticals-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/314e/855a/865b/355a/41cf5c3c-9adf-3b2a-8423-90aee2ee6f7a.png","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"},{"name":"ITM-91","source_info":[{"normalized_source_id":"42d89394e1d7470596de758366ae816a","source":"PipelineReview","source_url":"https://pipelinereview.com/itm-obtains-exclusive-worldwide-license-from-debiopharm-for-ca-ix-targeted-peptide-based-radiopharmaceutical-programs-targeting-solid-tumors/"},{"attachment_path":"data/phs_source_info/4adf/00bf/ef35/7d3d/bc041761-7963-3685-9829-83dad93a8d8a.png","attachment_type":"image/png","code":"3B Pharmaceuticals-202508","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/314e/855a/865b/355a/41cf5c3c-9adf-3b2a-8423-90aee2ee6f7a.png","source":"Company pipeline","source_url":"https://3b-pharma.com/targeted-radiotherapy/pipeline/pipeline-chart/"}],"status":"ACTIVE"}],"drug_type":["926e8e25a2b04d29864ed28dca6c57b7","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["bed7bd30b54c478f2b2b489619315bff"],"mechanism_action_id":["7ca797205e2f371cfefd80edcf0371f4"],"target_id":["c62e3c8c1fe0410b937a66058b4df96e"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","11cacc262bfc41adbd6259325efbcfec","8c0eafe0f91148099c2aaf56b71ad355","949c20c9e52549008773244a4230da7d","78cb173a4de34f07befac28de907e7bf","c7fe8aa844d24e85ba32a990ea28ded3","3428d019f74042c9b04557aaa3f597e2","f92e4ba771d04f27a1f4daae363b676a","6cca6f9743004e3e8c5cc6d18f36812d","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["e1b49c6db6775df734af8e4abbf19f23","73a71a4b938dfe77120f34aae93b1774","bed7bd30b54c478f2b2b489619315bff"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","11cacc262bfc41adbd6259325efbcfec","8c0eafe0f91148099c2aaf56b71ad355","949c20c9e52549008773244a4230da7d","78cb173a4de34f07befac28de907e7bf","c7fe8aa844d24e85ba32a990ea28ded3","3428d019f74042c9b04557aaa3f597e2","f92e4ba771d04f27a1f4daae363b676a","6cca6f9743004e3e8c5cc6d18f36812d","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1678752000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1678752000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7"},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"6cca6f9743004e3e8c5cc6d18f36812d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8c0eafe0f91148099c2aaf56b71ad355","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"11cacc262bfc41adbd6259325efbcfec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3428d019f74042c9b04557aaa3f597e2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["73a71a4b938dfe77120f34aae93b1774","bed7bd30b54c478f2b2b489619315bff","e1b49c6db6775df734af8e4abbf19f23"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"8883b390d2973eb18fb92c73fdf6bc47","moiety_mechanism_action_id":["7ca797205e2f371cfefd80edcf0371f4"],"moiety_target_id":["c62e3c8c1fe0410b937a66058b4df96e"]}
+{"drug_id":"341fe995166f476b832e4b12cbf9b616","docid":56165,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-03-04T02:46:01.000Z","updated_ts":"2026-03-23T22:40:09.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"REGEND007","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://www.regend.cn/kejiyanfa_cpgx.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Generic Airway Basal Layer Stem Cells(Regend Therapeutics)","source_info":[{"code":"NCT07355868","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07355868"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["89a91a625b85517b2f94971736c109ab"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["486c4f5995ae4425a9c98a48d22c84c8","e9b27c71d3024fd6ab7dc1dfc304f54d","c9f585d1ec3e46b89bb7599c77c8a391","ae1104e7f11d4b7ca4a48e00672b82b6","b910f946457644f28630580432a34e3f"],"active_org_master_entity_id":["89a91a625b85517b2f94971736c109ab"],"research_disease":["486c4f5995ae4425a9c98a48d22c84c8","e9b27c71d3024fd6ab7dc1dfc304f54d","c9f585d1ec3e46b89bb7599c77c8a391","ae1104e7f11d4b7ca4a48e00672b82b6","b910f946457644f28630580432a34e3f"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1773878400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1771113600000}}],"disease_phase":[{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e9b27c71d3024fd6ab7dc1dfc304f54d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c9f585d1ec3e46b89bb7599c77c8a391","highest_phase_cn":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_global":"3da2ce3ce8b0443fb0b2d335be3e591a"},{"disease_id":"b910f946457644f28630580432a34e3f","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"ae1104e7f11d4b7ca4a48e00672b82b6","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0244381981dc4eab9729d3906474270d","docid":261921,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-06-03T05:09:11.000Z","updated_ts":"2025-06-18T07:30:13.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"PF-07872411","source_info":[{"code":"NCT05831124","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05831124"}],"status":"ACTIVE"}],"dev_code":[{"name":"PF-07872411","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["862e74fcd5744d1a914d10fe1dd67b70"],"active_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"research_disease":["862e74fcd5744d1a914d10fe1dd67b70"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1681862400000}}],"disease_phase":[{"disease_id":"862e74fcd5744d1a914d10fe1dd67b70","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"065bc031ce3f4fe08135245078432639","docid":10133,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"e2eeff87633e325e9b70c6bf11921c2a","created_ts":"2022-11-15T05:17:39.000Z","updated_ts":"2026-04-04T21:11:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"BAY-2965501","source_info":[{"code":"NCT05614102","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05614102"}],"status":"ACTIVE"}],"dev_code":[{"name":"BAY 2965501","source_info":[{"code":"2023_926Offringa R, Olesch C, Cichon F, et al. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 2023; 11: doi: 10.1136/jitc-2023-SITC2023.0926","normalized_source_id":"d6bf27e3495948d2a4d1ca87d5b5ba56","source":"SITC","source_url":"https://jitc.bmj.com/content/11/Suppl_1/A1029"},{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diacylglycerol-kinase-zeta-inhibitor-bay2965501"}],"status":"ACTIVE"},{"name":"BAY2965501","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diacylglycerol-kinase-zeta-inhibitor-bay2965501"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d94923980905512f8eac870e9ac6f983"],"mechanism_action_id":["7cf6b3ecf0ae44ff9c859750dd21791e"],"target_id":["c6869a843f2b4bf1aaf63dfeaed0d5f9"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["d94923980905512f8eac870e9ac6f983","bfb00f16ed4994b2b3b71b6f81263611","293345f767c6ce4b4def6a59f32f2b9f"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1667520000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1698883200000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"3da2ce3ce8b0443fb0b2d335be3e591a","highest_phase_global":"3da2ce3ce8b0443fb0b2d335be3e591a"}],"data_source":10}
+{"drug_id":"0403fc76b1024469a8f89255b358a6d0","docid":18599,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-03-02T05:30:44.000Z","updated_ts":"2026-04-06T22:26:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"MM-402","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"R(-)-MDMA","status":"ACTIVE"},{"lang":"EN","name":"Rectus-3,4 methylenedioxymethamphetamine","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates"}],"status":"ACTIVE"}],"dev_code":[{"name":"DT402","source_info":[{"normalized_source_id":"d69160e8845242f2b24e913dcb1e8b85","source":"FiercePharma","source_url":"https://www.fiercepharma.com/marketing/definium-defines-mental-health-applications-lsd-new-awareness-campaign"},{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://definiumtx.com/#pipeline"},{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/press-releases/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates"}],"status":"ACTIVE"},{"name":"MM-402","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["49e4b85e5fafe4bf90fa0ba6555101c8"],"disease_id":["94f13bf88b344e3d9da1438266fa7d58"],"active_org_master_entity_id":["d15a0b69e5904f08c5a968e3fa8fbcc8"],"research_disease":["94f13bf88b344e3d9da1438266fa7d58"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1764720000000}}],"disease_phase":[{"disease_id":"94f13bf88b344e3d9da1438266fa7d58","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"04b7e2d148c04ffc8a3ec540eb24ce90","docid":62195,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2021-10-08T14:44:23.000Z","updated_ts":"2024-10-30T10:20:46.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Grass and birch allergen immunotherapy(Karolinska Institutet)","status":"ACTIVE"}],"drug_type":["de1ecb4751c24f4e9f0fd82235204c60"],"originator_org_master_entity_id":["7d6ad649cc5003ec4ddafc87552d0930"],"disease_id":["00894c5beba2467fa4489e0fa39ddffa"],"active_org_master_entity_id":["7d6ad649cc5003ec4ddafc87552d0930"],"research_disease":["00894c5beba2467fa4489e0fa39ddffa"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"disease_phase":[{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0bf0f43b07da42ce8e5d0a109e7fae45","docid":1761153,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":11,"target_extend_id":"f75ffe05575135998fcdf436d98c50c5","created_ts":"2025-09-17T06:02:03.000Z","updated_ts":"2026-01-29T00:04:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"CS-121","source_info":[{"code":"NCT07176923","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07176923"}],"status":"ACTIVE"}],"dev_code":[{"name":"CS-121","status":"ACTIVE"}],"drug_type":["fda21b9dd9eb45af976dd3ae054d6852"],"originator_org_master_entity_id":["d414afe45c6ef21a8e69d352bb7971c3"],"mechanism_action_id":["7aec930c25852d93bcf4dcf95c0adfcf"],"target_id":["cf16255057a04894a4cd033835112d14"],"disease_id":["6badb41fd9754ecb9b0bed5ea3fff7f7"],"active_org_master_entity_id":["d414afe45c6ef21a8e69d352bb7971c3"],"research_disease":["6badb41fd9754ecb9b0bed5ea3fff7f7"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1769385600000}}],"disease_phase":[{"disease_id":"6badb41fd9754ecb9b0bed5ea3fff7f7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"05c440de20aa48fc955573e4a2bf5f1c","docid":78483,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":16,"target_extend_id":"7573733732c338e09ce09ea5268af92f","created_ts":"2021-10-08T14:49:43.000Z","updated_ts":"2026-04-11T21:05:55.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Ficonalkib","source_info":[{"code":"CTR20232620","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=423876eab1e84c61bb09afa9b089e43d"}],"status":"ACTIVE"}],"dev_code":[{"name":"CT-3505","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ficonalkib"}],"status":"ACTIVE"},{"name":"SY-3505","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ficonalkib"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["0c96ff51adcc862041ed035a36655e73"],"mechanism_action_id":["de265787c9dd3ed3edcddc315b771582"],"target_id":["4cd6a90334f943f3b3302fa176ee44dc"],"disease_id":["9cd57576a455445eaa1432d06bc89b3f","a0304a462da04e7cb03e3f2c5625544e","404d5df8f5bc4c91ae6d4d84db20b66a"],"active_org_master_entity_id":["0c96ff51adcc862041ed035a36655e73"],"research_disease":["9cd57576a455445eaa1432d06bc89b3f","a0304a462da04e7cb03e3f2c5625544e","404d5df8f5bc4c91ae6d4d84db20b66a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1711065600000}}],"disease_phase":[{"disease_id":"404d5df8f5bc4c91ae6d4d84db20b66a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9cd57576a455445eaa1432d06bc89b3f","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"585c1fcdc6534d1a807bc9eb690ce5db","docid":62862,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2023-08-02T07:16:06.000Z","updated_ts":"2025-11-25T10:20:09.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"IN-B00008","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.inno-n.com/eng/rnd/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"IN B00008","status":"ACTIVE"},{"name":"INB00008","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["cbd775ebf63985aaf784615205f805fa"],"disease_id":["1713121f9e9b412d9495f3a785ec61c4"],"active_org_master_entity_id":["cbd775ebf63985aaf784615205f805fa"],"research_disease":["1713121f9e9b412d9495f3a785ec61c4"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"1713121f9e9b412d9495f3a785ec61c4","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"03fe6668e8554c879d8aad556bd58904","docid":61837,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":2,"target_extend_id":"c779ac55e17d38f9a36cc11eba06847b","created_ts":"2021-10-08T14:48:20.000Z","updated_ts":"2025-08-16T21:12:21.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"xinghaiyan2@patsnap.com","drug_name":[{"lang":"EN","name":"Synapsinae","source_info":[{"attachment_path":"data/phs_source_info/83f9/d681/f685/2416/f94d0702-b727-345b-a1b8-bc1af7a6b8b3.jpg","attachment_type":"image/jpeg","code":"SyneuRx-20240923","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/6f82/ab91/10d3/073d/ca54940e-82af-3150-880e-7bbfddce021f.jpg","source":"Company pipeline","source_url":"https://www.syneurx.com/research/#pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"SNG 12","status":"ACTIVE"},{"name":"SNG-12","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d9a28cdd61e4f7facb80b19a904c72f3"],"mechanism_action_id":["f87efe91dfde1d7dceee9263e113e719"],"target_id":["e7905ca082124076b3593df0f3364569"],"disease_id":["2dbed7595ff04b8fae04724f91081116","eea9370cafba4d45aebc3053483aa966"],"active_org_master_entity_id":["d9a28cdd61e4f7facb80b19a904c72f3"],"research_disease":["2dbed7595ff04b8fae04724f91081116","eea9370cafba4d45aebc3053483aa966"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"eea9370cafba4d45aebc3053483aa966","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"04db1f5f725347b699b3ecdcdff99812","docid":68997,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-12-10T12:55:25.000Z","updated_ts":"2026-02-24T18:19:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"四价重组人乳头瘤病毒（6/11/16/18型）疫苗（汉逊酵母）(上海博唯生物科技)","status":"ACTIVE"},{"lang":"EN","name":"Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df","b24e8825fd1d42d1b8832824599ee903"],"originator_org_master_entity_id":["f33a229f67141375405c1a3888df5961"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["86c9dec6885345009f177cb20378fa62","420cc9f14d774e59b4aba167c2777174","c01c2d66bac2413fb67862ce2b2627a6","b42488c9ce3245988e4e93caf2b95590","8e04d2b322b04e38848288e4877f3536","c3142e44fe6044f7a224237816f8eddd","402f598324d54b7399130af6a3b31465","442fc43733074fdaa348ea741ee7d8e4","9e4edd345552442d9a584a897169ac44","eb66daaa12c6416ea299a175f10a1937"],"active_org_master_entity_id":["f33a229f67141375405c1a3888df5961"],"research_disease":["86c9dec6885345009f177cb20378fa62","420cc9f14d774e59b4aba167c2777174","c01c2d66bac2413fb67862ce2b2627a6","b42488c9ce3245988e4e93caf2b95590","8e04d2b322b04e38848288e4877f3536","c3142e44fe6044f7a224237816f8eddd","402f598324d54b7399130af6a3b31465"],"non_research_disease":["442fc43733074fdaa348ea741ee7d8e4","9e4edd345552442d9a584a897169ac44","eb66daaa12c6416ea299a175f10a1937"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1652486400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1631664000000}}],"disease_phase":[{"disease_id":"8e04d2b322b04e38848288e4877f3536","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"442fc43733074fdaa348ea741ee7d8e4","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"420cc9f14d774e59b4aba167c2777174","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c3142e44fe6044f7a224237816f8eddd","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"eb66daaa12c6416ea299a175f10a1937","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"c01c2d66bac2413fb67862ce2b2627a6","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"86c9dec6885345009f177cb20378fa62","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9e4edd345552442d9a584a897169ac44","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"a5183ad464de4fe9bb9a3583425ae4a2","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"402f598324d54b7399130af6a3b31465","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0860abcd754c416d86e95cd2eac077da","docid":55978,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":2,"target_extend_id":"d35e658e01a83da59a16fc173b5fbada","created_ts":"2022-05-31T01:46:00.000Z","updated_ts":"2025-04-29T00:19:00.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"IMB-071703","source_info":[{"code":"CXSL2200235","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"IMB 071703","status":"ACTIVE"},{"name":"IMB071703","status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["5c3334b89bd8d79f49730fdd38b90f10"],"mechanism_action_id":["9d3fe67727026f98efc484ed71bd4fe2","7a2ec2045e500396ec3c948b4a62addb"],"target_id":["08d84b9625394e2a9b3aa5dfccd85ffb","dc0d7e6885484248b9b33823d4135ded"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["5c3334b89bd8d79f49730fdd38b90f10"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1677196800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1708560000000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"data_source":10}
+{"drug_id":"19c1a94df9e84607b95177484f160acd","docid":79140,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":109,"target_extend_id":"2127d2d1ce6736a8be550cf37f0c1c63","created_ts":"2022-12-02T03:04:34.000Z","updated_ts":"2026-04-18T21:07:30.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Sc610 cells(Sun Yat-Sen Memorial Hospital)","source_info":[{"code":"NCT05633589","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05633589"}],"status":"ACTIVE"}],"dev_code":[{"name":"Sc 610","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-gene-modified-pd-1-positive-t-lymphocytes-sc610"}],"status":"ACTIVE"},{"name":"Sc-610","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-gene-modified-pd-1-positive-t-lymphocytes-sc610"}],"status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"originator_org_master_entity_id":["71d71b05e3a71f2758dc77d60eb70f38"],"mechanism_action_id":["4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["8bd6e60a4549486a8d690e66701eb676"],"active_org_master_entity_id":["71d71b05e3a71f2758dc77d60eb70f38"],"research_disease":["8bd6e60a4549486a8d690e66701eb676"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"8bd6e60a4549486a8d690e66701eb676","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"11c3eb2060a5443cad7bdab4a80b1b9b","docid":25955,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1372291200000,"rnk":3,"target_extend_id":"0af8a806695c3915aa8a183ba81eaf8e","has_leading_org_involved":1,"created_ts":"2021-12-10T12:54:47.000Z","updated_ts":"2026-02-25T21:05:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Autologous cultured chondrocytes (Vericel)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Articel","status":"ACTIVE"},{"lang":"EN","name":"Autologous cultured chondrocytes on porcine collagen membrane","status":"ACTIVE"},{"lang":"EN","name":"Matrix-applied-characterised-autologous-cultured-chondrocytes","status":"ACTIVE"},{"lang":"EN","name":"Matrix-induced autologous chondrocyte implant","status":"ACTIVE"}],"trade_name":[{"name":"MACI","source_info":[{"code":"BLA125603","country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125603"}],"status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["ce142c7f5edc33f2e4133e21493a5ffe"],"mechanism_action_id":["a469495a07584dda6dfc197b2fc2c681"],"target_id":["3113fa804db9475fb14f6ffd0eab4dd6"],"disease_id":["ad4b81ffd60b45ce984076faa88b8853","a0a4a68cb14e44b7a1a5c23f194ed63b","e714ac15944c42e7934bc97274142489"],"active_org_master_entity_id":["8f61814de2be7c3010d788376d57cb9c"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["e714ac15944c42e7934bc97274142489"],"research_disease":["ad4b81ffd60b45ce984076faa88b8853","a0a4a68cb14e44b7a1a5c23f194ed63b"],"non_research_disease":["e714ac15944c42e7934bc97274142489"],"inactive_org_master_entity_id":["8a5865926cf14896c527033c90f8dc1e"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1481587200000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"}],"disease_phase":[{"disease_id":"a0a4a68cb14e44b7a1a5c23f194ed63b","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e714ac15944c42e7934bc97274142489","highest_phase_global":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"disease_id":"ad4b81ffd60b45ce984076faa88b8853","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["25839e21e95e65463e11008f6aadaa85","8f61814de2be7c3010d788376d57cb9c","bf85af687373969355a25d2aacd31bfb"],"data_source":10}
+{"drug_id":"220fa6014ce2413ba40e4fda723f2fb5","docid":26,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":13,"target_extend_id":"691fc762e2073b378921c51497cb44e7","created_ts":"2021-12-30T10:02:06.000Z","updated_ts":"2026-01-30T00:38:20.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"乌司奴单抗生物类似药（石药集团）","status":"ACTIVE"},{"lang":"EN","name":"Ustekinumab biosimilar (CSPC Jushi)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Ustekinumab Biosimilar (CSPC Megalith Biopharmaceutial Co., Ltd.)","status":"ACTIVE"},{"lang":"CN","name":"乌司奴单抗生物类似药（CSPC Megalith Biopharmaceutial Co., Ltd.）","status":"ACTIVE"}],"dev_code":[{"name":"SYSA-1902","status":"ACTIVE"},{"name":"SYSA1902","source_info":[{"code":"CTR20230236","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=0ed55b4f389e4f7d9ec6cfb6ddf6c558"}],"status":"ACTIVE"}],"generic_name":[{"name":"Ustekinumab","status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"mechanism_action_id":["8e50d690768a4da2833f4f3dac43056b"],"target_id":["36265960096d4e9fbc536c49f13cd690"],"atc_code":["c5c58dbd85bd402fa4ba7faa42ee4f7c"],"disease_id":["d281a3b362a740d8aeb63e2a10102671","be685463e8e640119dff51e5125e6d0f"],"active_org_master_entity_id":["5cf5fedddb15b3ca0a531d9b789f0286","3ac675fea3e4dfd3dbb1c1dfe219f2a7"],"research_disease":["d281a3b362a740d8aeb63e2a10102671","be685463e8e640119dff51e5125e6d0f"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1732579200000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"be685463e8e640119dff51e5125e6d0f","highest_phase_cn":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"}],"original_drug_id":["79644a1860f84ad787850e4b40d4f71a"],"data_source":10}
+{"drug_id":"026566c6db114b70a7aaadc9abc0f1f9","docid":75807,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":3,"target_extend_id":"250dc4db314c310ca2ff31c7932c91b5","created_ts":"2022-09-02T10:35:54.000Z","updated_ts":"2025-08-16T21:11:10.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SR-8541A","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ENPP1 inhibitor (Translational Genomics Research Institute)","status":"ACTIVE"},{"lang":"EN","name":"STING agonist (Translational Genomics Research Institute)","status":"ACTIVE"}],"dev_code":[{"name":"SR 8541A","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/enpp1-inhibitor-sr-8541a"}],"status":"ACTIVE"},{"name":"SR-8541A","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/enpp1-inhibitor-sr-8541a"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8d72e1cda42064c59302a207c9dcfc14"],"mechanism_action_id":["38c1d632fb014e54813f00006d46354c"],"target_id":["1c8e5a05d2e7415ca0a7a67c4d8c5581"],"disease_id":["58fbfbf692184307a72a2a4f72a657f2","0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"active_org_master_entity_id":["f4302fdcdd91880c07e4e3b1d9270a3e","8d72e1cda42064c59302a207c9dcfc14"],"research_disease":["58fbfbf692184307a72a2a4f72a657f2","0464f5493b0444e9875a0584df17cbf0","62eaee6d9ee44410b8aca59dfc7408e9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1732060800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1697068800000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"58fbfbf692184307a72a2a4f72a657f2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"094fe6bee0f14b61925bdbe132dd2eb2","docid":69335,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":7,"target_extend_id":"165ce47c985e3e60ada002232755c9a0","created_ts":"2023-08-02T08:12:16.000Z","updated_ts":"2026-04-10T14:26:09.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"GTA-182","source_info":[{"attachment_path":"data/phs_source_info/0914/e74c/5eee/ca11/e65ae450-3517-3e54-8331-703094eaba9e.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/4f80/3fcb/a7d3/de63/0bf27729-55be-357d-b611-094b4456d385.png","source":"Company pipeline","source_url":"https://www.apeiron-bio.com/pipeline"},{"code":"CN 113234079 B","normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent"}],"status":"ACTIVE"}],"dev_code":[{"name":"GTA 182","status":"ACTIVE"},{"name":"GTA182","source_info":[{"code":"2025_4229","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/6238"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["98c0d00625eb401cc75257f0c2597252"],"mechanism_action_id":["e6a4767a5dd3493eb7bc349b98a471d1"],"target_id":["7a68e99130134dbc9048af6318b6a4c9"],"disease_id":["78cb173a4de34f07befac28de907e7bf","3beea980d93a4cc0abc864e27514601c","38165dea7b4840888d2d9fe98ca81a94","0464f5493b0444e9875a0584df17cbf0","2518a9726c1a4dd5972ee22f5e4ee159","6c9886cb25eb45faba70292cee1f5518","2bb755a3f43f49dea60661c5f99712a3"],"active_org_master_entity_id":["98c0d00625eb401cc75257f0c2597252"],"research_disease":["78cb173a4de34f07befac28de907e7bf","3beea980d93a4cc0abc864e27514601c","38165dea7b4840888d2d9fe98ca81a94","0464f5493b0444e9875a0584df17cbf0","2518a9726c1a4dd5972ee22f5e4ee159","6c9886cb25eb45faba70292cee1f5518","2bb755a3f43f49dea60661c5f99712a3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1773792000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1762128000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1731974400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1730246400000}}],"disease_phase":[{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2518a9726c1a4dd5972ee22f5e4ee159","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2bb755a3f43f49dea60661c5f99712a3","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"38165dea7b4840888d2d9fe98ca81a94","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6c9886cb25eb45faba70292cee1f5518","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00dd993bc0c6459b992c08361a42a577","docid":69959,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2023-07-14T02:03:51.000Z","updated_ts":"2026-02-14T13:38:09.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"CN","name":"重组人源抗狂犬病病毒单克隆抗体（兰州生物制品研究所）","status":"ACTIVE"},{"lang":"EN","name":"Recombinant human anti-rabies virus monoclonal antibody (Lanzhou Institute of Biological Products)","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["15aba8d18c91dfdc4f7d3f461f8f2838"],"disease_id":["26bdc387cad64dc985f00855d64a3d2d"],"active_org_master_entity_id":["15aba8d18c91dfdc4f7d3f461f8f2838"],"research_disease":["26bdc387cad64dc985f00855d64a3d2d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1769731200000}}],"disease_phase":[{"disease_id":"26bdc387cad64dc985f00855d64a3d2d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0da5a564708997a2e7136bcd822e784b","docid":232104,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":10,"target_extend_id":"f925d5d339cc3170b7e1448f50b4f1d7","created_ts":"2024-07-08T09:59:07.000Z","updated_ts":"2026-04-04T21:05:33.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CD7-CART01","status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["04bcd4ad162e8168d633cd8da18101db"],"mechanism_action_id":["bc3ae3d2a63347f8a25d3186b2a852f0"],"target_id":["b893e5b66e334131a95a3d8e69a969e3"],"disease_id":["33a9d37dd10f424289324134d84d0bbb","4dfdd8ad3a924d7b9e9b33b1ec53c5fc"],"active_org_master_entity_id":["04bcd4ad162e8168d633cd8da18101db"],"research_disease":["33a9d37dd10f424289324134d84d0bbb","4dfdd8ad3a924d7b9e9b33b1ec53c5fc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1713657600000}}],"disease_phase":[{"disease_id":"4dfdd8ad3a924d7b9e9b33b1ec53c5fc","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"33a9d37dd10f424289324134d84d0bbb","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"434442cb6a59451e95334d134d8975d5","docid":1673854,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-02T09:20:39.000Z","updated_ts":"2026-03-02T10:00:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"VGN-Ex05e","source_info":[{"code":"NCT07433517","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07433517"}],"status":"ACTIVE"}],"dev_code":[{"name":"VGN-Ex05e","source_info":[{"code":"NCT07433517","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07433517"}],"status":"ACTIVE"}],"drug_type":["e7c4f0f5c2e64bfea5ee341c7aa1012c"],"originator_org_master_entity_id":["af4429dd673d612c5963f08f96133637"],"disease_id":["94f13bf88b344e3d9da1438266fa7d58","e82aaf48fe7f4e95b63f7b023c920405"],"active_org_master_entity_id":["af4429dd673d612c5963f08f96133637"],"research_disease":["94f13bf88b344e3d9da1438266fa7d58","e82aaf48fe7f4e95b63f7b023c920405"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"94f13bf88b344e3d9da1438266fa7d58","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"e82aaf48fe7f4e95b63f7b023c920405","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03de7151f9be4b309e4893fad3b76bec","docid":65824,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":4,"target_extend_id":"2a539d69b35f3328a444b1cedd88fa19","created_ts":"2021-10-08T14:48:05.000Z","updated_ts":"2024-12-31T00:19:58.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Xoma-3E","status":"ACTIVE"}],"dev_code":[{"name":"NTM 1633","status":"ACTIVE"},{"name":"NTM-1633","status":"ACTIVE"},{"name":"XOMA 3E","status":"ACTIVE"}],"drug_type":["543364a7f55e4f1ca88a741b4a863fc6"],"originator_org_master_entity_id":["69d4bb1505b9a71343002b7d5e6d0f79"],"mechanism_action_id":["ae888f36d70fc1de5705c68b12aa8c38"],"target_id":["d625af0dbdf74900b8a25b1a99da06e4"],"disease_id":["07339dca528c4e648959bf8c2181bb1a"],"active_org_master_entity_id":["011f129c6f2e51080f9ea3df2b71fdf0","69d4bb1505b9a71343002b7d5e6d0f79"],"research_disease":["07339dca528c4e648959bf8c2181bb1a"],"inactive_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1623283200000}}],"disease_phase":[{"disease_id":"07339dca528c4e648959bf8c2181bb1a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["3603d6be852bea04e9d7f2d8f105efb7","69d4bb1505b9a71343002b7d5e6d0f79"],"data_source":10}
+{"drug_id":"049ec85eef804620b5ca172fef8f49fe","docid":52767,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":82,"target_extend_id":"16cba34da95434449d3ade031d382dac","created_ts":"2021-11-30T08:57:22.000Z","updated_ts":"2026-04-04T21:10:40.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"HCW-9302","status":"ACTIVE"}],"dev_code":[{"name":"HCW 9302","status":"ACTIVE"},{"name":"HCW-9302","status":"ACTIVE"},{"name":"HCW9302","source_info":[{"normalized_source_id":"ad23b626-363d-49d0-98f5-70ce57b05f3e","source":"J Immunol","source_url":"http://dx.doi.org/10.4049/jimmunol.204.supp.159.19"}],"status":"ACTIVE"}],"drug_type":["bbbb2e86da504b9d95a00c703880d9fb"],"originator_org_master_entity_id":["55622ccf76e0e032999512b15d666e33"],"mechanism_action_id":["63bd319daa73cda6486ed79345c24583"],"target_id":["6ec0f112e7f24e8eb09ee10490362648"],"disease_id":["061a5c6c24164fadb7fa15fc1d303e75","3f89be495cbf4f1889fb8d6018fd4e76","53f31b7756664bb9b3f7139f7aa9014e","27013926797d4bc4bf088e4104530e7d"],"active_org_master_entity_id":["55622ccf76e0e032999512b15d666e33"],"research_disease":["061a5c6c24164fadb7fa15fc1d303e75","3f89be495cbf4f1889fb8d6018fd4e76","53f31b7756664bb9b3f7139f7aa9014e","27013926797d4bc4bf088e4104530e7d"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75","76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1755302400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"061a5c6c24164fadb7fa15fc1d303e75","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"53f31b7756664bb9b3f7139f7aa9014e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"3f89be495cbf4f1889fb8d6018fd4e76","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"27013926797d4bc4bf088e4104530e7d","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"4ebc5aba09f54c31a1f2abc8dca4231d","highest_phase_before_ter_global":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"deal_related_org":["4b9e59e75aa31a23a9d9ffd98382ffc3","55622ccf76e0e032999512b15d666e33","e04e8291df8aba7bf5ff87f94e6c2add"],"data_source":10}
+{"drug_id":"1538b12be22a42d3b719f5761606c221","docid":41601,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-02-24T06:23:34.000Z","updated_ts":"2024-12-27T00:24:09.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"iPSC-derived RPE(National Eye Institute)","source_info":[{"code":"NCT04339764","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04339764"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Atuologous iPSC-derived RPE","source_info":[{"code":"NCT04339764","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04339764"}],"status":"ACTIVE"}],"drug_type":["b6c764e33db1468bb5c605488cfe00ca"],"originator_org_master_entity_id":["8d45b0506f2aa9dbe3ed7e64f514579c"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["164ba9b819474bcd9c0f89bbf21a934c","de73670e475f43288d92726966cc5962"],"active_org_master_entity_id":["8d45b0506f2aa9dbe3ed7e64f514579c"],"research_disease":["164ba9b819474bcd9c0f89bbf21a934c","de73670e475f43288d92726966cc5962"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1600819200000}}],"disease_phase":[{"disease_id":"164ba9b819474bcd9c0f89bbf21a934c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"de73670e475f43288d92726966cc5962","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"47955ddb7663479688dbea07aa7aa4be","docid":43489,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":38,"target_extend_id":"3362869d276b3fb5b0c78cbf436bfbcb","created_ts":"2021-12-06T10:58:34.000Z","updated_ts":"2026-04-18T21:08:54.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"admin@patsnap.com","drug_name":[{"lang":"CN","name":"司美格鲁肽生物类似药（丽珠集团）","status":"ACTIVE"},{"lang":"EN","name":"Semaglutide biosimilar (Livzon Group)","status":"ACTIVE"}],"generic_name":[{"name":"Semaglutide","status":"ACTIVE"}],"drug_type":["6718bf09d6024f4db4f309a4cc791cf6","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["b303694e3b85b6bb3a6407469e608d02"],"mechanism_action_id":["888b99dda6a62ef2551937c34e253e9c"],"target_id":["c385dcba5fea4e97bf02bc256757613a"],"atc_code":["679079a6331a49aaa6b192c7455e8e0e"],"disease_id":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814","54e2cf3dc3294445b4a27b990b0ba274"],"active_org_master_entity_id":["b303694e3b85b6bb3a6407469e608d02"],"research_disease":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814","54e2cf3dc3294445b4a27b990b0ba274"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1718236800000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["c7a2671dc0574f19bc42d557eca3906f"],"data_source":10}
+{"drug_id":"0382aaf4af994e3ababeee24cacfeab5","docid":64326,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"6e5ad586bf7644cc8dc40f0c33efb033","wiki_link":"https://en.wikipedia.org/wiki/Trafermin","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":986342400000,"rnk":9,"target_extend_id":"3d14c5828f75392dbc4a755cbd061ec3","created_ts":"2021-10-08T14:49:13.000Z","updated_ts":"2026-04-02T17:04:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"曲弗明","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"EN","name":"Trafermin","status":"ACTIVE"},{"lang":"JP","name":"トラフェルミン（遺伝子組換え）","source_info":[{"code":"30100AMX00244000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/620095_1329713X1025_1_03"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Fiblast Spray","status":"ACTIVE"},{"lang":"EN","name":"REGROTH Dental Kit","status":"ACTIVE"},{"lang":"EN","name":"RH-BFGF","status":"ACTIVE"},{"lang":"EN","name":"bFGF","source_info":[{"code":"22800AMX00684000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"},{"code":"22800AMX00685000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"dev_code":[{"name":"CAB 2001","status":"ACTIVE"},{"name":"CAB-2001","status":"ACTIVE"},{"name":"FGF-2","source_info":[{"code":"22800AMX00684000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_2790823U1026_1_07"},{"code":"22800AMX00685000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_2790823U1026_1_07"}],"status":"ACTIVE"},{"name":"KCB-1","status":"ACTIVE"},{"name":"KCB-1B","status":"ACTIVE"},{"name":"KCB-1D","source_info":[{"code":"22800AMX00684000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_2790823U1026_1_07"},{"code":"22800AMX00685000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_2790823U1026_1_07"}],"status":"ACTIVE"},{"name":"NPC-18","source_info":[{"code":"JPRN-jRCT2051230028","normalized_source_id":"168189ddd20e453c95d5d26e09406ad6","source":"WHO-ICTRP","source_url":"https://jrct.niph.go.jp/latest-detail/jRCT2051230028"}],"status":"ACTIVE"}],"trade_name":[{"name":"Fiblast","source_info":[{"code":"21300AMZ00387","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_2699710R1028_1_12"}],"status":"ACTIVE"},{"name":"Regroth","source_info":[{"code":"22800AMX00684","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"Retympa","source_info":[{"code":"30100AMX00244000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/620095_1329713X1025_1_03"}],"status":"ACTIVE"},{"name":"フィブラスト","source_info":[{"code":"21300AMZ00387","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_2699710R1028_1_12"}],"status":"ACTIVE"},{"name":"リグロス","source_info":[{"code":"22800AMX00684","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"リティンパ","source_info":[{"code":"30100AMX00244000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/620095_1329713X1025_1_03"}],"status":"ACTIVE"}],"generic_name":[{"name":"Trafermin","status":"ACTIVE"}],"drugbank_id":["DB06244"],"kegg_id":["D03362"],"drug_type":["c5ab6f92102a4f99a1f8fdc6e24a7f66"],"originator_org_master_entity_id":["e207b806161c4848076fdc3c1891e3dd"],"mechanism_action_id":["b8fddaae01f4bf6f3b5210e7f66c2e49"],"target_id":["9b673462043e40e0afda4ead7cc855b2"],"atc_code":["ff3c2d66a4014693a20783b3d463742f"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["dbf9ae384fb04aa7b4e772d8f66b7d5f","2e66d84237ff4cc783539c366380924d","1a951a454f2f489bafeddedea85edbce","573b45841b7747c3ac129fe3baa18cad","98145e9ef20d4d78b17e43ec1769aefe","c5a9c2f01d9448f4b611fec2d4f6117e","f85a2cb2a69a4eaa98b4dfe297b6b294"],"active_org_master_entity_id":["e207b806161c4848076fdc3c1891e3dd","371f40dfe2917a0feb1762f1e574636c"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["1a951a454f2f489bafeddedea85edbce","573b45841b7747c3ac129fe3baa18cad"],"research_disease":["dbf9ae384fb04aa7b4e772d8f66b7d5f","2e66d84237ff4cc783539c366380924d","1a951a454f2f489bafeddedea85edbce","573b45841b7747c3ac129fe3baa18cad"],"non_research_disease":["98145e9ef20d4d78b17e43ec1769aefe","c5a9c2f01d9448f4b611fec2d4f6117e","f85a2cb2a69a4eaa98b4dfe297b6b294"],"inactive_org_master_entity_id":["a01957c8c353d9aa6ab48f2d910ca3e6"],"therapeutic_area":["20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"approval_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1475020800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986342400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1422748800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1422748800000}},{"country":"6d64b019-4f80-31e9-b248-297aa588c950","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1422748800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1425168000000}}],"disease_phase":[{"disease_id":"dbf9ae384fb04aa7b4e772d8f66b7d5f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c5a9c2f01d9448f4b611fec2d4f6117e","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1a951a454f2f489bafeddedea85edbce","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"98145e9ef20d4d78b17e43ec1769aefe","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f85a2cb2a69a4eaa98b4dfe297b6b294","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"573b45841b7747c3ac129fe3baa18cad","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2e66d84237ff4cc783539c366380924d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0384c448ca874f16a2781b7719990de3","docid":66924,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Dronedarone","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1246406400000,"rnk":1,"target_extend_id":"7d6c316191d53ea8a85b54a7148add3e","created_ts":"2021-10-08T14:48:40.000Z","updated_ts":"2026-04-03T09:15:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","first_approved_date_cn":1571788800000,"drug_name":[{"lang":"CN","name":"盐酸决奈达隆","status":"ACTIVE"},{"lang":"EN","name":"Dronedarone Hydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DRONEDARONE","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"},{"code":"DB04855","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Drondarone","status":"ACTIVE"},{"lang":"EN","name":"Dronedarone hydrochloride (USP)","source_info":[{"code":"D03914","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Multag","status":"ACTIVE"},{"lang":"EN","name":"N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide","source_info":[{"code":"DB04855","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide","source_info":[{"code":"DB04855","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"}],"dev_code":[{"name":"SB-33589","status":"ACTIVE"},{"name":"SR 33589","status":"ACTIVE"},{"name":"SR 33589B","status":"ACTIVE"},{"name":"SR-33589","status":"ACTIVE"},{"name":"SR-33589B","status":"ACTIVE"},{"name":"SR-33598B","source_info":[{"code":"FA36DV299Q","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/f5a535e4-d3c0-45db-b952-aaa54e490100"}],"status":"ACTIVE"},{"name":"SR33598B","source_info":[{"code":"FA36DV299Q","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/f5a535e4-d3c0-45db-b952-aaa54e490100"}],"status":"ACTIVE"}],"trade_name":[{"name":"Multaq","source_info":[{"code":"D03914","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"达新宁","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzAwOTA5MTAzNA==&mid=2651649056&idx=1&sn=84116d6fbb0074879c7c7189b6a00433"}],"status":"ACTIVE"},{"name":"迈达龙","status":"ACTIVE"}],"generic_name":[{"name":"dronedarone","source_info":[{"code":"JQZ1L091Y2","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/b7f782c0-58d3-4ef3-822b-c304eccd871c"}],"status":"ACTIVE"}],"drugbank_id":["DB04855"],"kegg_id":["D03914"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb"],"mechanism_action_id":["67a135c0bf22b5d5c17b2c9084c4284c","16db863605db4eb1b7dcd473e57784d9","fcb08ce46b3ea7ecac71f190250ec6c2","d598b397735eed3368862c100009222e"],"target_id":["a7d10e219edc42718496bb48ed0cc0e9","46f633fb763a4168bf70d222f0e9f220","421aefac71954bea96721f1e429b0d82","dc3e36bb0e204db6b9a558e2710cbae0"],"atc_code":["05a2f9097df54725bec225136646eaa6"],"disease_id":["8b6313831fec4232989e58adca240a3e","174bdfbe11a24794820a1e23997beded","ae092fa59f4d44edaf59ffe23d0a44c3","c8e43d2b48ec49dba16418bc190a3eec"],"active_org_master_entity_id":["54a5f90ed2e95b2035b38ac7bacadf57","bdb31a0ef372c1dafce734bc1c79601f","bd012a014e6d91a45f230bd7d9317f10","ff9484799cb987ac369f354b33a9720f"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["8b6313831fec4232989e58adca240a3e","174bdfbe11a24794820a1e23997beded"],"research_disease":["8b6313831fec4232989e58adca240a3e","174bdfbe11a24794820a1e23997beded","ae092fa59f4d44edaf59ffe23d0a44c3"],"non_research_disease":["c8e43d2b48ec49dba16418bc190a3eec"],"inactive_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1246406400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1639958400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1571788800000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1259107200000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1259107200000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1259107200000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1259107200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1266192000000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1266192000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1266192000000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1266192000000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1266192000000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1351209600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1364688000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1122768000000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"6531106d-1be6-30a6-afa2-c328c682fce0","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1285891200000}},{"country":"6531106d-1be6-30a6-afa2-c328c682fce0","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"adb25fa7-78e4-3d7e-8e7c-4a15ccdd7096","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1285891200000}},{"country":"adb25fa7-78e4-3d7e-8e7c-4a15ccdd7096","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1285891200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1267401600000}}],"disease_phase":[{"disease_id":"174bdfbe11a24794820a1e23997beded","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"8b6313831fec4232989e58adca240a3e","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"074decf10ef744c4bd85264c80de72db","docid":71085,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"a98156ae78c348ecbeed960cd54d5a99","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":5,"target_extend_id":"9c24f6736ce53634994a61bd33c7146a","created_ts":"2021-11-30T08:59:02.000Z","updated_ts":"2026-03-17T00:55:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Debio-1124","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Lutetium-177 minigastrin analogue","status":"ACTIVE"},{"lang":"EN","name":"[177Lu] labelled-minigastrin-analogue","status":"ACTIVE"}],"dev_code":[{"name":"DEBIO 1124","status":"ACTIVE"},{"name":"DEBIO1124","status":"ACTIVE"},{"name":"PPF11N","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.debiopharm.com/drug-development/press-releases/paul-scherrer-institute-regains-license-from-debiopharm-for-the-development-of-tageted-radiopharmaceutical-debio-1124/"}],"status":"ACTIVE"}],"drug_type":["4f6af72be17b47249d6de8c3febef8ab","ce50f8e07075468e8121131d776cd45c"],"originator_org_master_entity_id":["5aa3483c78331dc92da50b706117ba3c"],"mechanism_action_id":["7374daa319bebdfb551fb0ba17e0f617"],"target_id":["c348b86e21c44539ab088568ef7f1f68"],"disease_id":["bcd0ccde4c014a4787337185d6d930f1","b695f1eaa38c40c6b6f62cffb6fbbbe6","2bda170e46844ace8b6488a1651f5972","3690234157ab4ecb90ddc8a777ae4185","8d29f554f371431c9b5b80f5befdf965"],"active_org_master_entity_id":["5aa3483c78331dc92da50b706117ba3c"],"research_disease":["bcd0ccde4c014a4787337185d6d930f1","b695f1eaa38c40c6b6f62cffb6fbbbe6","2bda170e46844ace8b6488a1651f5972","3690234157ab4ecb90ddc8a777ae4185"],"non_research_disease":["8d29f554f371431c9b5b80f5befdf965"],"inactive_org_master_entity_id":["bed7bd30b54c478f2b2b489619315bff"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1427846400000}}],"disease_phase":[{"disease_id":"b695f1eaa38c40c6b6f62cffb6fbbbe6","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"bcd0ccde4c014a4787337185d6d930f1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3690234157ab4ecb90ddc8a777ae4185","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2bda170e46844ace8b6488a1651f5972","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"2b478dc272674a5ebb1b770439151927","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["5aa3483c78331dc92da50b706117ba3c","bed7bd30b54c478f2b2b489619315bff"],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"9c24f6736ce53634994a61bd33c7146a","moiety_mechanism_action_id":["7374daa319bebdfb551fb0ba17e0f617"],"moiety_target_id":["c348b86e21c44539ab088568ef7f1f68"]}
+{"drug_id":"04d84b1eb9a0459caa732a282640a6a1","docid":68647,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"e3f7e8ced8c63503968914d4c0b36e01","created_ts":"2021-10-08T14:41:52.000Z","updated_ts":"2025-02-27T00:16:20.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"M-201","status":"ACTIVE"}],"dev_code":[{"name":"M 201-A","status":"ACTIVE"},{"name":"M-201-A","status":"ACTIVE"},{"name":"M201-A hydrochloride","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["44d415dc92d492076e6f746a2c66db19"],"mechanism_action_id":["84f1cd149efb908d24c8a09cf6bb99a2","9750f311edea02fb48da3bd07ad12489","446cf46f0b065858dc9d47caaf3b46f9"],"target_id":["78e742fd973d43f4b2da4b0a43bebaa3","71aba94737164737bb7e26eb2a719595","c5e328164ab14fa4aa8cc0714b3aac1b"],"disease_id":["c8e43d2b48ec49dba16418bc190a3eec","8b6313831fec4232989e58adca240a3e"],"active_org_master_entity_id":["44d415dc92d492076e6f746a2c66db19"],"research_disease":["c8e43d2b48ec49dba16418bc190a3eec"],"non_research_disease":["8b6313831fec4232989e58adca240a3e"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8b6313831fec4232989e58adca240a3e","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["44d415dc92d492076e6f746a2c66db19","61b144ee62b493adaa60a24d799ed4d3"],"data_source":10}
+{"drug_id":"1a67c06c1da74f8a853e755e1b8ea9cb","docid":59838,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-09-30T06:24:00.000Z","updated_ts":"2024-11-07T16:38:24.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"ALZN002","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/alzamend-neuro-submits-ind-application-for-phase-i-iia-trial-for-an-immunotherapy-alzn002-to-treat-mild-to-moderate-dementia-of-the-alzheimer-s-type/"}],"status":"ACTIVE"}],"dev_code":[{"name":"AL-002(Alzamend Neuro, Inc.)","status":"ACTIVE"},{"name":"ALZN 002","status":"ACTIVE"},{"name":"ALZN-002","status":"ACTIVE"},{"name":"ALZN002","status":"ACTIVE"},{"name":"CAO-22W","status":"ACTIVE"},{"name":"E22-W42","status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["5a27b5cdf90e43a4ee517bc4da36405b"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0"],"active_org_master_entity_id":["5a27b5cdf90e43a4ee517bc4da36405b"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1672185600000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["0023d039f2ae0e60f8492eb3abe7b823","5a27b5cdf90e43a4ee517bc4da36405b","be821640d7370091974e4a6997f1d187"],"data_source":10}
+{"drug_id":"04e5b27c6ea04f228c2e006052322499","docid":230600,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"null_target_reason":"NOT_AVAILABLE","global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-05-08T05:49:02.000Z","updated_ts":"2024-11-07T20:13:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"fangdongbing","drug_name":[{"lang":"CN","name":"丙二醇/聚乙二醇400/甘油","status":"ACTIVE"},{"lang":"EN","name":"Propylene glycol/Polyethylene glycol 400/Glycerin","source_info":[{"code":"NCT06375343","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06375343"}],"status":"ACTIVE"}],"dev_code":[{"name":"PRO-240","source_info":[{"code":"NCT06375343","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06375343"}],"status":"ACTIVE"}],"related_component":["18323a319fb34f91b832272a2c7e8995","b31f955af07043d3958b993a65a6f685"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5cb082bd4dedb57d3fcd858fff7f6c42"],"disease_id":["3271242b681840bcbd5ad0e4baee0770"],"active_org_master_entity_id":["5cb082bd4dedb57d3fcd858fff7f6c42"],"research_disease":["3271242b681840bcbd5ad0e4baee0770"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"disease_phase":[{"disease_id":"3271242b681840bcbd5ad0e4baee0770","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"11542d9daed745c3ae30b8690ed470a2","docid":79772,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":14,"target_extend_id":"cb08ad70f6053dde8ff74674e5530e98","created_ts":"2023-08-31T06:25:18.000Z","updated_ts":"2026-02-07T21:08:59.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"QH104","source_info":[{"code":"NCT06018363","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06018363"},{"attachment_path":"data/phs_source_info/142b/b801/1e17/f686/142bb8011e17f686.png","attachment_type":"image/png","code":"Qinghui Liannuo-202506","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/9a23/0ca8/56e4/c344/9a230ca856e4c344.png","source":"Company pipeline","source_url":"http://www.unicetbio.com/?list=8"},{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"http://www.unicetbio.com/?list=21"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogenic B7H3 CAR-γδT cell(Dushu Lake Hospital)","source_info":[{"code":"NCT06018363","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06018363"}],"status":"ACTIVE"}],"dev_code":[{"name":"QH 104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-anti-b7-h3-car-gamma-delta-t-cells-qh104"}],"status":"ACTIVE"},{"name":"QH-104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-anti-b7-h3-car-gamma-delta-t-cells-qh104"}],"status":"ACTIVE"}],"drug_type":["8cda7e9356a7439ea27ce1a899143e5c"],"originator_org_master_entity_id":["c5dec1a7e71b5c0636a834ad6b2811d5","e0b36221379c434bd3614d3acc73b3e6"],"mechanism_action_id":["1253d086644f4034a91c30422bb266f2","dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["1728e61d30a543eda454c47f2bf1a73a"],"disease_id":["05554578204541148a5482ad5df4a600","4c38270255bc4052a1a6d17475bdc51d","ff2bfb165bee41d6a0d28f32755d0c5e","8f43e38cdd4e4794945b3ede3d6eaa4a"],"active_org_master_entity_id":["e0b36221379c434bd3614d3acc73b3e6","c5dec1a7e71b5c0636a834ad6b2811d5"],"research_disease":["05554578204541148a5482ad5df4a600","4c38270255bc4052a1a6d17475bdc51d","ff2bfb165bee41d6a0d28f32755d0c5e","8f43e38cdd4e4794945b3ede3d6eaa4a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1685577600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1747440000000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ff2bfb165bee41d6a0d28f32755d0c5e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8f43e38cdd4e4794945b3ede3d6eaa4a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1c68a2eaeec941da815b2e585527078b","docid":43628,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"be7301ad69c235488d84ec652372ab9f","created_ts":"2021-10-08T14:49:28.000Z","updated_ts":"2026-03-31T10:04:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"MRX-2843","source_info":[{"code":"2026_1576","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/21436/presentation/4272"}],"status":"ACTIVE"}],"dev_code":[{"name":"MRX 2843","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flt3-mertk-inhibitor-mrx-2843"},{"code":"2025_3488","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/8421"}],"status":"ACTIVE"},{"name":"UNC-2025","status":"ACTIVE"},{"name":"UNC-2371","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9cd351868c1bfe10b743e051ffa2755c"],"mechanism_action_id":["c2f03f15b586e3feebd4738fdeb65f7e","42bff6897e7b912141d2d30072d93d8f","3f43bc28ee500bb1a95f4338d16ab902"],"target_id":["1a0c8a1018a84b97a7b8fb6075ab76a5","2ec11e5c292848d5b07cf6e132871a11","5f0bbe6b72e644f79ea9278d067992dc"],"disease_id":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197","07994e875a7f44dc9af7f9bf3f6989e5","1d78cca79eae4632bc4464c90a574f83","e2251a2774ee4eff8723a33fc035d809","0464f5493b0444e9875a0584df17cbf0","6570754a6f0b43b78a9926c7bfd00519","8df1ce96a8fd4a66ba6dc13760c20282","f048bf0822254413a3ea354eced08eec","f92e4ba771d04f27a1f4daae363b676a","5653d5f4ddd64666970104ebb522a937"],"active_org_master_entity_id":["3edad7bc4bb308f3fa898f652885bf33","9cd351868c1bfe10b743e051ffa2755c","379be598ecf5beae8bbddfb658b003bb","01cf90643eb804939286afdaceb28c1e","324277bfb523b120fce15e9919d1de44"],"research_disease":["a4afc28011454f2ca2f48f95f242a04f","5e8defce0a8e4f8bbdf853ea20a56197","07994e875a7f44dc9af7f9bf3f6989e5","1d78cca79eae4632bc4464c90a574f83","e2251a2774ee4eff8723a33fc035d809","0464f5493b0444e9875a0584df17cbf0","6570754a6f0b43b78a9926c7bfd00519","8df1ce96a8fd4a66ba6dc13760c20282","f048bf0822254413a3ea354eced08eec","f92e4ba771d04f27a1f4daae363b676a","5653d5f4ddd64666970104ebb522a937"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1625097600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1648771200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1526947200000}}],"disease_phase":[{"disease_id":"5e8defce0a8e4f8bbdf853ea20a56197","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"5653d5f4ddd64666970104ebb522a937","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8df1ce96a8fd4a66ba6dc13760c20282","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"a4afc28011454f2ca2f48f95f242a04f","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e2251a2774ee4eff8723a33fc035d809","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["9cd351868c1bfe10b743e051ffa2755c","379be598ecf5beae8bbddfb658b003bb"],"data_source":10}
+{"drug_id":"04bfe3d0a257407caafebbf6dd7660ae","docid":43443,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"4365bc8433e23d64bbb930a1858dba22","created_ts":"2021-10-08T14:49:07.000Z","updated_ts":"2026-04-02T14:08:06.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"IRL-201805","status":"ACTIVE"}],"dev_code":[{"name":"1805","status":"ACTIVE"},{"name":"IRL 201805","status":"ACTIVE"},{"name":"IRL201805","status":"ACTIVE"},{"name":"‘1805","status":"ACTIVE"}],"drug_type":["0d7cf87172e4421ba4ea3f72fcd799d0"],"originator_org_master_entity_id":["172af9f79f1a8c9b02939dec0f3bd4a8","52de765990e106637c2436263e7572cb"],"mechanism_action_id":["17338876bd7149458c4f0698b89af4ca","fe764d661c377fdfb08de03e222a139f","a30504b84e062940a9ec00f77c5f47be"],"target_id":["818c578805ef4aac826f0f0ef71f3675","2a9a8ce9bb804bfd95a46d8e4f8bcb1f"],"disease_id":["02cfd8ea6ff54f9581d513b8521b7b37","6be96778ed424f8d91de00ab82364114","b0e4872424534e56a029081282ee45b2","509a094ddb78441eaeeeae867832dfad","05ae12d567784b85a5c1ca54b2063ee2"],"active_org_master_entity_id":["2249e2aeb582e32aa0a897c11f1cf7b9","52de765990e106637c2436263e7572cb","6c64aadd4fd0a5e5aae321fbb53423db"],"research_disease":["02cfd8ea6ff54f9581d513b8521b7b37","6be96778ed424f8d91de00ab82364114","b0e4872424534e56a029081282ee45b2","509a094ddb78441eaeeeae867832dfad","05ae12d567784b85a5c1ca54b2063ee2"],"inactive_org_master_entity_id":["172af9f79f1a8c9b02939dec0f3bd4a8"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff"}],"disease_phase":[{"disease_id":"02cfd8ea6ff54f9581d513b8521b7b37","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b0e4872424534e56a029081282ee45b2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"509a094ddb78441eaeeeae867832dfad","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"1b5d135b1aa7494faa11052ac8cfb4eb","docid":23757,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"73560325274c3e7598fc5e95df064372","has_leading_org_involved":1,"created_ts":"2021-11-30T08:55:28.000Z","updated_ts":"2026-04-16T22:14:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"GC-012F","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://cn.gracellbio.com/pipeline/index.html"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"BCMA-Antigen X bispecific CAR-T cells","status":"ACTIVE"},{"lang":"EN","name":"BCMA/CD19 dual-targeting CAR-T therapy","source_info":[{"code":"NCT04182581","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04182581"}],"status":"ACTIVE"}],"dev_code":[{"name":"AZD0120","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/article/releases/calquence-acalabrutinib-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percent-vs-standard-of-care-in-patients-with-untreated-mantle-cell-lymphoma-in-echo-phase-iii-trial/"}],"status":"ACTIVE"},{"name":"GC 012","status":"ACTIVE"},{"name":"GC 012F","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-bispecific-bcma-cd19-targeted-car-t-cells-gc012f"}],"status":"ACTIVE"},{"name":"GC012F","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-bispecific-bcma-cd19-targeted-car-t-cells-gc012f"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["5a7018e422390386c17cc3fcb4caa136"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9","2ac451946966904ac6da0d54008cdd9a"],"target_id":["aea9fa6f45bb4e48859be4110f70547b","5eb1fc5283d34305934a031af530f448"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["bf27abf8e60a4af4a578cedc875e80b9","b333bb7c6f974ac8893e67082c824ea0","0c8a0603507542faac6b5ef3e27c6728","c5e1987e283c495aaab2a8d309c6085e","e10523d5d50e41f6841de149d8b794b7","7cd0fcf1c5c243b9b3944405ec4855b5","dba0a7e65b51408ca401deb8364bce94","6be96778ed424f8d91de00ab82364114","51236dbf55d24268aa6d31d9be131f6f","e437a345ba44462b930187c312f380d5","f3433922efe24dfaada77415e3e66ea0","7b34c4c341a74b9984deff61be03c587","fb5dc95cfdfa47f1b5cdb7021a3e77cf","b6d26728646940ed97a62cf24af18ca2","4c9d46b2b7794d128b14d8689f4c357d","56842bd5a0fb4199bc0d99ae22798bdc","beee0b8864754fe4accea8266ec49940","d6d30dfb1c604b55a56b0f79fa245d23"],"active_org_master_entity_id":["5a7018e422390386c17cc3fcb4caa136","6e7a2de70d46daa0cef8586ca22ae506","38716acfc0018167235bc86c0f96ddb2","0f6b1f5704b311d37dcff81b4b3b4fe3","546dcbe5264fccade9cdd29b5d6c8449"],"research_disease":["bf27abf8e60a4af4a578cedc875e80b9","b333bb7c6f974ac8893e67082c824ea0","0c8a0603507542faac6b5ef3e27c6728","c5e1987e283c495aaab2a8d309c6085e","e10523d5d50e41f6841de149d8b794b7","7cd0fcf1c5c243b9b3944405ec4855b5","dba0a7e65b51408ca401deb8364bce94","6be96778ed424f8d91de00ab82364114","51236dbf55d24268aa6d31d9be131f6f","e437a345ba44462b930187c312f380d5","f3433922efe24dfaada77415e3e66ea0","7b34c4c341a74b9984deff61be03c587","fb5dc95cfdfa47f1b5cdb7021a3e77cf","b6d26728646940ed97a62cf24af18ca2","4c9d46b2b7794d128b14d8689f4c357d"],"non_research_disease":["56842bd5a0fb4199bc0d99ae22798bdc","beee0b8864754fe4accea8266ec49940","d6d30dfb1c604b55a56b0f79fa245d23"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1771804800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1723680000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1703548800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1701907200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1624838400000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"56842bd5a0fb4199bc0d99ae22798bdc","highest_phase_before_ter_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"51236dbf55d24268aa6d31d9be131f6f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b333bb7c6f974ac8893e67082c824ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"dba0a7e65b51408ca401deb8364bce94","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"beee0b8864754fe4accea8266ec49940","highest_phase_before_ter_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_before_ter_global":"91ac63db1def4da58e890aec574fe7f4","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7b34c4c341a74b9984deff61be03c587","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e437a345ba44462b930187c312f380d5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f3433922efe24dfaada77415e3e66ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"d6d30dfb1c604b55a56b0f79fa245d23","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4c9d46b2b7794d128b14d8689f4c357d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"b6d26728646940ed97a62cf24af18ca2","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"c5e1987e283c495aaab2a8d309c6085e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"fb5dc95cfdfa47f1b5cdb7021a3e77cf","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"deal_related_org":["5a7018e422390386c17cc3fcb4caa136","6e7a2de70d46daa0cef8586ca22ae506"],"data_source":10}
+{"drug_id":"0361952db958473ab4cece2f451fb503","docid":9134,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Ufenamate","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":402796800000,"rnk":6,"target_extend_id":"20f5fae230343973bd274556c14e65c3","created_ts":"2021-10-08T14:49:52.000Z","updated_ts":"2025-07-31T00:31:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"乌芬那酯","status":"ACTIVE"},{"lang":"EN","name":"Ufenamate","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"lang":"JP","name":"ウフェナマート","source_info":[{"code":"22100AMX01331","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"2-[[3-（三氟甲基）苯基]氨基]苯甲酸丁酯","status":"ACTIVE"},{"lang":"EN","name":"Buty Flufenzmatum","status":"ACTIVE"},{"lang":"EN","name":"Flufenamic acid butyl ester","source_info":[{"code":"D01823","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Ufenamate (JAN/INN)","source_info":[{"code":"D01823","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"CN","name":"氟芬那酸丁酯","status":"ACTIVE"}],"dev_code":[{"name":"HF-264","status":"ACTIVE"}],"trade_name":[{"name":"Combec","source_info":[{"code":"D01823","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"22000AMX02195","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400315_2649727M1040_1_06"}],"status":"ACTIVE"},{"name":"Epiamart S","status":"ACTIVE"},{"name":"Fenazol","source_info":[{"code":"22100AMX01331","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/671450_2649727M1059_3_02"}],"status":"ACTIVE"},{"name":"Fenazole","status":"ACTIVE"},{"name":"コンベック","source_info":[{"code":"22000AMX02195","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/400315_2649727M1040_1_06"}],"status":"ACTIVE"},{"name":"フエナゾール","source_info":[{"code":"22100AMX01331","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/671450_2649727M1059_3_02"}],"status":"ACTIVE"},{"name":"布特","status":"ACTIVE"}],"generic_name":[{"name":"Ufenamate","source_info":[{"code":"D01823","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"kegg_id":["D01823"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8d17cd4d0627c440f278dbcfd8449bb3"],"mechanism_action_id":["a59b2212d1cca741c2d703c3a3ee85ff","6ea83f15b431cf57d758448596d2b0d6"],"target_id":["354b42c493cd41faa61293701c8b176e","271815d56d4440f3b425e4bd5f1dff38"],"atc_code":["f979e872a1c44a1d94d296677bd5f2ab"],"disease_id":["7797ec4549074f4a9a421c156f803a26","58d12f29a80b4a999c6f20193b2effd9","466de00c6f5e468aa2c4f996e784a933","511604c2a0314187a859a68fe99bd4f1","b5068ce40bb1403ab9a02fa97954ebb1","3b1efd66997741189935bf20cfe9774f","b5c9fb6553a943fab9520c9a00b19fd7","02b9f9b0f3464ccbb37429d10f9aea36","d6d2753e6cbb4d7e8d5a68864c145fa4"],"active_org_master_entity_id":["de929f9b203a5fc5c6f302c6ddba2ed5","8d17cd4d0627c440f278dbcfd8449bb3","2ebb33c065b40fbdf9995b46b4ab841d"],"first_approved_country":["676de5ba-893a-36bb-8683-c93306aaf769"],"first_approved_indication":["b5068ce40bb1403ab9a02fa97954ebb1","3b1efd66997741189935bf20cfe9774f","b5c9fb6553a943fab9520c9a00b19fd7","02b9f9b0f3464ccbb37429d10f9aea36","d6d2753e6cbb4d7e8d5a68864c145fa4"],"research_disease":["7797ec4549074f4a9a421c156f803a26","58d12f29a80b4a999c6f20193b2effd9","466de00c6f5e468aa2c4f996e784a933","511604c2a0314187a859a68fe99bd4f1","b5068ce40bb1403ab9a02fa97954ebb1","3b1efd66997741189935bf20cfe9774f","b5c9fb6553a943fab9520c9a00b19fd7","02b9f9b0f3464ccbb37429d10f9aea36","d6d2753e6cbb4d7e8d5a68864c145fa4"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":412905600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":402796800000}}],"disease_phase":[{"disease_id":"02b9f9b0f3464ccbb37429d10f9aea36","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"58d12f29a80b4a999c6f20193b2effd9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d6d2753e6cbb4d7e8d5a68864c145fa4","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b5c9fb6553a943fab9520c9a00b19fd7","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7797ec4549074f4a9a421c156f803a26","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"511604c2a0314187a859a68fe99bd4f1","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"466de00c6f5e468aa2c4f996e784a933","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"3b1efd66997741189935bf20cfe9774f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"b5068ce40bb1403ab9a02fa97954ebb1","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0424a18c35334645ac58d0d07a5ef296","docid":65497,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":101,"target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","created_ts":"2022-06-24T07:41:29.000Z","updated_ts":"2026-04-11T21:06:52.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"JJH-201601","status":"ACTIVE"}],"dev_code":[{"name":"JJH 201601","status":"ACTIVE"},{"name":"JJH-201601","status":"ACTIVE"},{"name":"JJH201601","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9","f9b1093fafc547caabf90e26cef22a1f"],"originator_org_master_entity_id":["5454ec71a29359a7e1b2f1d2868cab78"],"mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"],"target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"disease_id":["9fa7237b86bc4bdba73c3b23e8d84e24","f04e110974bf45b58dd4d2eabcd2c6c1","15839db0de0947ddb9e4c280884a3895","78cb173a4de34f07befac28de907e7bf","83c00fea95ab443a997c1e3818bea37e","836b24a738274167bd3ddf060e18d099"],"active_org_master_entity_id":["5454ec71a29359a7e1b2f1d2868cab78"],"research_disease":["9fa7237b86bc4bdba73c3b23e8d84e24","f04e110974bf45b58dd4d2eabcd2c6c1","15839db0de0947ddb9e4c280884a3895","78cb173a4de34f07befac28de907e7bf","83c00fea95ab443a997c1e3818bea37e","836b24a738274167bd3ddf060e18d099"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1729468800000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"836b24a738274167bd3ddf060e18d099","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"78cb173a4de34f07befac28de907e7bf","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"83c00fea95ab443a997c1e3818bea37e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f04e110974bf45b58dd4d2eabcd2c6c1","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"9fa7237b86bc4bdba73c3b23e8d84e24","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"09dee6da4a8b4f2789f930b5613f7da2","docid":1311083,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"ea8c4fae42643e5199f75b203a61e019","created_ts":"2025-05-12T08:44:06.000Z","updated_ts":"2026-04-04T21:04:59.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Kesonotide","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://filamon.com/our-pipeline/kesonotide/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["f73f263c601c3c78b7493d1f94f2cb64"],"mechanism_action_id":["1bb9ef0bf6623d198dcae3a918b4e84c"],"target_id":["9ab1711ca95d41f5994b35536b26a159"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","05554578204541148a5482ad5df4a600","e2fd9bda4aeb4a7b9fa53a2560126d24","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","c50c74488b3b427b9a7b4260d76fa188"],"active_org_master_entity_id":["f73f263c601c3c78b7493d1f94f2cb64"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","05554578204541148a5482ad5df4a600","e2fd9bda4aeb4a7b9fa53a2560126d24","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","e50aad3dea474cf487e53bd91d5d7c45","c50c74488b3b427b9a7b4260d76fa188"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1762473600000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c50c74488b3b427b9a7b4260d76fa188","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"639ddcd1afa04ed694167e8da7d176d8","docid":73474,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-07-05T08:28:33.000Z","updated_ts":"2024-11-10T00:22:12.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"13价肺炎球菌多糖结合疫苗(艾美卫信生物)","source_info":[{"code":"CXSL2000215","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Zhejiang Vacin Biomedicine)","source_info":[{"code":"CXSL2000215","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PCV13(AIM Vaccine)","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","b24e8825fd1d42d1b8832824599ee903","eb728b38dfb842778019260a7dd09801"],"originator_org_master_entity_id":["e1fa95876bf826eb756c28d03e88aff2"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["862e74fcd5744d1a914d10fe1dd67b70"],"active_org_master_entity_id":["9ded838c4a0dfd4ec55be92ff643b020"],"research_disease":["862e74fcd5744d1a914d10fe1dd67b70"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1730332800000}}],"disease_phase":[{"disease_id":"862e74fcd5744d1a914d10fe1dd67b70","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"005175079a40445b9b22f2b7d9753442","docid":26099,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":-524620800000,"rnk":85,"target_extend_id":"30ed854af12137b3869be714792ad19d","created_ts":"2021-10-08T14:43:53.000Z","updated_ts":"2025-04-05T21:08:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Penicillin G Benzathine/Penicillin G Procaine","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"trade_name":[{"name":"Bicillin C-R","status":"ACTIVE"}],"related_component":["39508300ed864e72b356d6946c9ce007","4c88850439c7466882bb4300670e365a"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"mechanism_action_id":["96af81a44ae49944712b75894f39682f"],"target_id":["20c015d11407415a83ad7902f6d712a5"],"atc_code":["cb6ca8f6d93848a39ecaa4113e8b1adf"],"disease_id":["9a802adb6e94433f8f4eb9be678991b8"],"active_org_master_entity_id":["b8eb75ec39a1d297642cd976e9df144d"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["9a802adb6e94433f8f4eb9be678991b8"],"research_disease":["9a802adb6e94433f8f4eb9be678991b8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":-524620800000}}],"disease_phase":[{"disease_id":"9a802adb6e94433f8f4eb9be678991b8","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"18c62439803d49ac94fdcc9ad5f6cb5b","docid":8989,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":77,"target_extend_id":"e87ff0d2c5223cb0b10f60b549c22441","created_ts":"2021-10-08T14:47:27.000Z","updated_ts":"2026-04-17T22:00:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ILB-2109","source_info":[{"code":"CTR20220392","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=8b80d60527d54a18ace90e07c6522626"}],"status":"ACTIVE"}],"dev_code":[{"name":"ILB 2109","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenosine-a2a-receptor-antagonist-ilb2109"}],"status":"ACTIVE"},{"name":"ILB2109","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenosine-a2a-receptor-antagonist-ilb2109"}],"status":"ACTIVE"},{"name":"WTS-001","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6048109ece9c37a9debab23d23bd51f0"],"mechanism_action_id":["50c5bc150c0d69dfb682c96956000c3f"],"target_id":["08758366ffb64169a43e89145be7fd2b"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","0464f5493b0444e9875a0584df17cbf0","c76f89bb672a4c5db000735eb7f8c6e6","87a9454771a64f2191224b6b7684254a","c1cc2528f29940fc95fd6bc37eb982d4","6b80eb2530e64952b99d1b50407fab55","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","1d6d6b0086ff422ca00418c0e8b0e940","f92e4ba771d04f27a1f4daae363b676a","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["d2cbb5fb32bcd6cfd6173f00a493ee33","6048109ece9c37a9debab23d23bd51f0"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9","0464f5493b0444e9875a0584df17cbf0","c76f89bb672a4c5db000735eb7f8c6e6","87a9454771a64f2191224b6b7684254a","c1cc2528f29940fc95fd6bc37eb982d4","6b80eb2530e64952b99d1b50407fab55","3beea980d93a4cc0abc864e27514601c","c297238c41b2488abe3de6546b105a4e","1d6d6b0086ff422ca00418c0e8b0e940","f92e4ba771d04f27a1f4daae363b676a","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461","5b1dfc2ca8564662860187aef864467d","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"b2ca28b01c34419db0365bad2f8dd09e"}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"c76f89bb672a4c5db000735eb7f8c6e6","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6b80eb2530e64952b99d1b50407fab55","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"deal_related_org":["d2cbb5fb32bcd6cfd6173f00a493ee33","d99b2dacc5fdb5855fecb0118ca0a6a5"],"data_source":10}
+{"drug_id":"400cff71fcda48c4894db24fe4e42a79","docid":1760626,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":387,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2025-08-20T09:03:48.000Z","updated_ts":"2026-04-18T21:06:02.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Allogeneic Anti-CD19 CAR-T(Zhongshan Hospital Fudan University)","source_info":[{"code":"NCT07129642","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07129642"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["bac396e0cead72bfde96d498a8958e29"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["0e1af5cdca874d34b9b87a793d65d466"],"active_org_master_entity_id":["bac396e0cead72bfde96d498a8958e29"],"research_disease":["0e1af5cdca874d34b9b87a793d65d466"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1754784000000}}],"disease_phase":[{"disease_id":"0e1af5cdca874d34b9b87a793d65d466","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00e7fdb14eaa4a80a09ed306c45bf529","docid":20689,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2022-11-21T02:50:54.000Z","updated_ts":"2026-04-03T09:27:15.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"B4T2-001","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://bio4t2.com/"}],"status":"ACTIVE"}],"dev_code":[{"name":"B4T2 001","status":"ACTIVE"},{"name":"B4T2001","status":"ACTIVE"},{"name":"B4t2 001","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-car-t-cells-b4t2-001"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["36392be23425031740f5bdecec73469f"],"mechanism_action_id":["dfe37d566f9caa8f0037337e91887158","0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2","f98fd32baa8447119bb87f84093b925c","3beea980d93a4cc0abc864e27514601c","ae092fa59f4d44edaf59ffe23d0a44c3","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["20d5eec44b266c6b9c49330897b3b40a"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2","f98fd32baa8447119bb87f84093b925c","3beea980d93a4cc0abc864e27514601c","ae092fa59f4d44edaf59ffe23d0a44c3","0464f5493b0444e9875a0584df17cbf0"],"inactive_org_master_entity_id":["36392be23425031740f5bdecec73469f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1696118400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1663113600000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0ae5ee15ad484d6bb1a559102105b5a4","docid":41755,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2021-10-08T14:50:35.000Z","updated_ts":"2025-04-17T07:28:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"EN","name":"BOOST cells(Karolinska Institutet)","status":"ACTIVE"}],"drug_type":["a13258eede9446d0b1a919a20e84bc3b"],"originator_org_master_entity_id":["7d6ad649cc5003ec4ddafc87552d0930"],"disease_id":["b18aaff5a4494dd0a0495922f5a3b30c"],"active_org_master_entity_id":["7d6ad649cc5003ec4ddafc87552d0930"],"research_disease":["b18aaff5a4494dd0a0495922f5a3b30c"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1565568000000}}],"disease_phase":[{"disease_id":"b18aaff5a4494dd0a0495922f5a3b30c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"11202d24e1174c28bcdf6b2960082ae5","docid":1671486,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"d2f715ecb1d434b7974041a8a46ffdcf","created_ts":"2025-09-28T03:06:44.000Z","updated_ts":"2025-12-05T00:30:49.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NG2 and DLL3 CAR-T Cells(Shenzhen Geno-Immune Medical Institute)","source_info":[{"code":"NCT07193966","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07193966"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["26ed2ba5c537881390984f7bc0aefa34"],"mechanism_action_id":["441dc16cbcf04eb0988cf073a3220b48","a59e6c478b6565d0dee823b116867677"],"target_id":["065b028911344da3998f481884610103","2207f013c4204775b1b1c7974c275747"],"disease_id":["c1cc2528f29940fc95fd6bc37eb982d4"],"active_org_master_entity_id":["26ed2ba5c537881390984f7bc0aefa34"],"research_disease":["c1cc2528f29940fc95fd6bc37eb982d4"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756684800000}}],"disease_phase":[{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"458cc852cd674d7680702dc93ab9c395","docid":55870,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:43.000Z","updated_ts":"2025-04-08T09:24:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"elF4E (eFFECTOR Therapeutics)","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a84d92b9845b92079feb06bf4e9fa1d2"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["a84d92b9845b92079feb06bf4e9fa1d2"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1648080000000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"085c24a5c1334595b20303147055dbeb","docid":24560,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","express_system":"ac14778662b7448588663c26ce84cd9e","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","first_approved_date":1716768000000,"rnk":55,"target_extend_id":"146bb3f428153314a68f4fd49a2b7e98","created_ts":"2021-10-08T14:42:29.000Z","updated_ts":"2026-04-10T02:14:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"贝伐珠单抗生物类似药(Outlook Therapeutics)","status":"ACTIVE"},{"lang":"EN","name":"Bevacizumab biosimilar(Outlook Therapeutics)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bevacizumab Biosimilar (Outlook Therapeutics, Inc.)","status":"ACTIVE"},{"lang":"EN","name":"Bevacizumab gamma(Outlook Therapeutics)","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/7119683"}],"status":"ACTIVE"},{"lang":"EN","name":"Bevacizumab-vikg(Outlook Therapeutics)","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.globenewswire.com/NewsRoom/ReleaseNg/7119683"}],"status":"ACTIVE"},{"lang":"CN","name":"贝伐珠单抗生物类似药（Outlook Therapeutics, Inc.）","status":"ACTIVE"},{"lang":"CN","name":"重组人源化抗血管内皮生长因子 (VEGF)单抗 (上海华奥泰生物)","status":"ACTIVE"}],"dev_code":[{"name":"HOT-1010","status":"ACTIVE"},{"name":"JS 501","status":"ACTIVE"},{"name":"ONS-1045","status":"ACTIVE"},{"name":"ONS-5010","status":"ACTIVE"}],"trade_name":[{"name":"Lytenava","status":"ACTIVE"}],"generic_name":[{"name":"bevacizumab","source_info":[{"code":"EMEA/H/C/005723","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava"}],"status":"ACTIVE"}],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["645996268b96e6ba48c156701c0be45a"],"mechanism_action_id":["6b6c2b10657446ed45e401214272b244","0e6dd837ac200d6d4b69e55395b22762"],"target_id":["934f7ab958ca4daf85f5eb42393a0b28"],"atc_code":["e81b6f358235428196e6703ad4dac799"],"disease_id":["b3613eb77a5d4795ac1a12db34d284ba","7bb5556c886343f4a9ec230aacf8706e","08ceae895e4c4d929d71bb1f60574f29","66a1b66e616749eda0c9c89651d60764","949c20c9e52549008773244a4230da7d","163d1c51c1bc4f3fa2a72853d1c99f94","03bd23316cb54eecbbc4f53311087042","7665e5683a1a443a8f3d3b946d4c9ca2","c1cc2528f29940fc95fd6bc37eb982d4","f6678ca4757d4b46843d6dfd2739e2a1","3beea980d93a4cc0abc864e27514601c","b066b599013c44fc8f97812941d0f5aa","c7fe8aa844d24e85ba32a990ea28ded3","2477c68e093d4b818b11333ee1a5ee02","92b029557bee4d3db493a33792fda33a","e35ce4e9b7a846d49e600ce7ac4a7fd6","3760c3b51d764c7085b94f0b767b4c59"],"active_org_master_entity_id":["645996268b96e6ba48c156701c0be45a","6d8c77d8ef57c426b969ecf3691f96f1","4b5343e0cf7d4fb190086931bde323cd","1184509c6caf5289c06d345f6b0125f5","bf81c82aaa11b488432e97dd885a1525"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["b3613eb77a5d4795ac1a12db34d284ba"],"research_disease":["b3613eb77a5d4795ac1a12db34d284ba","7bb5556c886343f4a9ec230aacf8706e","08ceae895e4c4d929d71bb1f60574f29","66a1b66e616749eda0c9c89651d60764","949c20c9e52549008773244a4230da7d","163d1c51c1bc4f3fa2a72853d1c99f94","03bd23316cb54eecbbc4f53311087042","7665e5683a1a443a8f3d3b946d4c9ca2","c1cc2528f29940fc95fd6bc37eb982d4","f6678ca4757d4b46843d6dfd2739e2a1","3beea980d93a4cc0abc864e27514601c","b066b599013c44fc8f97812941d0f5aa","c7fe8aa844d24e85ba32a990ea28ded3","2477c68e093d4b818b11333ee1a5ee02","92b029557bee4d3db493a33792fda33a","e35ce4e9b7a846d49e600ce7ac4a7fd6"],"non_research_disease":["3760c3b51d764c7085b94f0b767b4c59"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","fce2b462d4fa493eb9d82513b9007011","62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","672807de-6d33-3706-a350-c97e6ed7735e","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716854400000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716768000000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1720396800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716854400000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716768000000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716854400000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716768000000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716854400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1716768000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1648684800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1615852800000}}],"disease_phase":[{"disease_id":"03bd23316cb54eecbbc4f53311087042","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b066b599013c44fc8f97812941d0f5aa","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3760c3b51d764c7085b94f0b767b4c59","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"7bb5556c886343f4a9ec230aacf8706e","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2477c68e093d4b818b11333ee1a5ee02","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"92b029557bee4d3db493a33792fda33a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f6678ca4757d4b46843d6dfd2739e2a1","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"94437cab300944a58b3ea8134dea1482","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"08ceae895e4c4d929d71bb1f60574f29","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"949c20c9e52549008773244a4230da7d","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"b3613eb77a5d4795ac1a12db34d284ba","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"163d1c51c1bc4f3fa2a72853d1c99f94","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"66a1b66e616749eda0c9c89651d60764","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"original_drug_id":["fcb8a931669b42458f3daad684b7c1b6"],"deal_related_org":["0c23a4f5ea5415291ba7b2dd2c52282e","2c2da1aa39e842c53cb884b6dfedbd0e","4b5343e0cf7d4fb190086931bde323cd","645996268b96e6ba48c156701c0be45a","6d8c77d8ef57c426b969ecf3691f96f1","bdcc6c2f8bb253813c5ab20596dd395c"],"if_speculate":0,"data_source":10}
+{"drug_id":"173edbb444ba425c808c028a7b42a16c","docid":1910081,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2026-01-28T06:44:23.000Z","updated_ts":"2026-01-28T21:18:09.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"ON-01","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU5NjcwMzQ3Ng==&mid=2247521936&idx=2&sn=023185410c59fd93bf73bd9c0d526c3d"},{"code":"41527280","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/41527280/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ON-01","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU5NjcwMzQ3Ng==&mid=2247521936&idx=2&sn=023185410c59fd93bf73bd9c0d526c3d"},{"code":"41527280","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/41527280/"}],"status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["9f9b047ed50f661cf3cae0542bfd35c0"],"disease_id":["4c38270255bc4052a1a6d17475bdc51d"],"active_org_master_entity_id":["9f9b047ed50f661cf3cae0542bfd35c0"],"research_disease":["4c38270255bc4052a1a6d17475bdc51d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1538352000000}}],"disease_phase":[{"disease_id":"4c38270255bc4052a1a6d17475bdc51d","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"013c516cf39b40e2ac0270f505c7c73d","docid":25332,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:37:26.000Z","updated_ts":"2025-03-28T00:16:37.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"苯唑嗪","status":"ACTIVE"},{"lang":"EN","name":"Phenzolzine","status":"ACTIVE"}],"dev_code":[{"name":"Q-808","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3a63c32d0f6ea100ac69bdca6d9bb810"],"disease_id":["5a66b9249fae4d97afa13193f05749b9"],"active_org_master_entity_id":["3a63c32d0f6ea100ac69bdca6d9bb810"],"research_disease":["5a66b9249fae4d97afa13193f05749b9"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1621468800000}}],"disease_phase":[{"disease_id":"5a66b9249fae4d97afa13193f05749b9","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0977c53b1686478ba796a8304ebb8e7b","docid":1114,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"cf0dad6c335237eeb5eb7beea8386bed","created_ts":"2021-10-08T14:50:10.000Z","updated_ts":"2026-04-03T09:04:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"MB-108","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"C134","source_info":[{"attachment_path":"data/phs_source_info/aacr/6bf4/cb7d/4a44/e683/3c49bf1a-6bf4-3b7d-8a44-e683940479a7.html","attachment_type":"HTML","code":"2024_6654","normalized_source_id":"8806d6ca778544e497f77fce5165778f","preview_attachment_path":"data/phs_source_info/aacr/6bf4/cb7d/4a44/e683/3c49bf1a-6bf4-3b7d-8a44-e683940479a7.html","source":"AACR","source_url":"https://aacrjournals.org/cancerres/article/84/6_Supplement/6654/735185/Abstract-6654-Oncolytic-virotherapy-targeting-high"}],"status":"ACTIVE"},{"lang":"EN","name":"Chimeric Oncolytic Herpes Simplex Virus","status":"ACTIVE"},{"lang":"EN","name":"chimeric oHSV","status":"ACTIVE"}],"dev_code":[{"name":"C 134","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oncolytic-hsv-1-c134"}],"status":"ACTIVE"},{"name":"C-134","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oncolytic-hsv-1-c134"}],"status":"ACTIVE"},{"name":"IRS-1 HSV C134","status":"ACTIVE"},{"name":"IRS-1 HSV-C-134","status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["9f588615919b79714978d8adb24063c6"],"mechanism_action_id":["fad477528be246dab31726479a09ed16","c47ff1e6fb7a4d2db4c1075b2acfcbac","d14c2ee8f93b7874768556f06ceeb8cf"],"target_id":["2691f9d6452a4846a0dacafd95caccc6","4f002d6bebb54561b40143b0af30fad5"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["05554578204541148a5482ad5df4a600","26f8e5d4ef1a40298528d522757fe252","8f43e38cdd4e4794945b3ede3d6eaa4a","913534b87d4543e28eeb8a7215bb8ef4","db0eb9ef2c3a46458ab1640232a6730f"],"active_org_master_entity_id":["438610c1eb38a017224349e54414e69f","38d455ae46701de1355c85611b8d90d5","9f588615919b79714978d8adb24063c6"],"research_disease":["05554578204541148a5482ad5df4a600","26f8e5d4ef1a40298528d522757fe252","8f43e38cdd4e4794945b3ede3d6eaa4a","913534b87d4543e28eeb8a7215bb8ef4"],"non_research_disease":["db0eb9ef2c3a46458ab1640232a6730f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1569196800000}}],"disease_phase":[{"disease_id":"05554578204541148a5482ad5df4a600","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"26f8e5d4ef1a40298528d522757fe252","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"db0eb9ef2c3a46458ab1640232a6730f","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8f43e38cdd4e4794945b3ede3d6eaa4a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"2fcda2e154924e1085af090d7b6aa114","docid":2000,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-09-27T12:39:19.000Z","updated_ts":"2025-06-04T00:18:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"HDV  (Diasome Pharmaceuticals)","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["436a890067602de2a71d461629a9c7e2"],"disease_id":["1dec6017bd924aff8aeae6e7d4a3f874","74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["436a890067602de2a71d461629a9c7e2"],"research_disease":["1dec6017bd924aff8aeae6e7d4a3f874","74d974da49ba407195b38595a0aff704"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1649808000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"51dfcd440df04bde86c26108b5a897b2","docid":59409,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-02-22T08:45:37.000Z","updated_ts":"2026-02-24T13:20:36.000Z","data_status":"ACTIVE","created_by":"wangyufu","updated_by":"sunying","drug_name":[{"lang":"EN","name":"Human umbilical cord mesenchymal stem cells(Shandong Qilu Stem Cells)","source_info":[{"code":"NCT03529136","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03529136"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["a30ed9e0388c051326c823ff5aef5813"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["0824db6086454b1da3cbff7750028bb9","54a77f56d72c4ac6a0eb840f4518e3a0","7cb6983b4169498e89b08fd725a22b46","e938f07eba7148ecadbaa56ae7904072","1a95630392584c7892bec2dc9888cbfc","216b0dcc86a34619bad44c996e80b7b8"],"active_org_master_entity_id":["a30ed9e0388c051326c823ff5aef5813"],"research_disease":["0824db6086454b1da3cbff7750028bb9","54a77f56d72c4ac6a0eb840f4518e3a0","7cb6983b4169498e89b08fd725a22b46","e938f07eba7148ecadbaa56ae7904072","1a95630392584c7892bec2dc9888cbfc"],"non_research_disease":["216b0dcc86a34619bad44c996e80b7b8"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"e938f07eba7148ecadbaa56ae7904072","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"216b0dcc86a34619bad44c996e80b7b8","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0824db6086454b1da3cbff7750028bb9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"1a95630392584c7892bec2dc9888cbfc","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"}],"data_source":10}
+{"drug_id":"02f051e843e1484a81e8c8e967e3af16","docid":13374,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","rnk":2,"target_extend_id":"b3d269b8ea523508b5a681311f29bb57","created_ts":"2021-10-08T14:44:08.000Z","updated_ts":"2024-10-30T10:22:17.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"牛磺酸/氨基己酸/天门冬氨酸/马来酸氯苯那敏","status":"ACTIVE"},{"lang":"EN","name":"Taurine/Aminocaproic Acid/Aspartic Acid/Chlorphenamine Maleate","status":"ACTIVE"}],"related_component":["2d0df98dec674f2793ed527dcc8e1730","442da6a916fd41f6967031fe9ab91fa3","4a33429b32924b679288f9db3025fab4","87d64ecd010549f28cc498342eb1251e"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["d0c8106bb4622df47351b10c7473b784","d8178186ee5ed5f46213a275a4487b47"],"target_id":["638ee1b240b74160b4456cc7857d6fa1","bb2bec296d4043259ed39473e64938fb"],"disease_id":["d87b828805344058888243d7dc618051"],"research_disease":["d87b828805344058888243d7dc618051"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"d87b828805344058888243d7dc618051","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"002e04e6da0341e09fa2e7323abcd5f4","docid":67226,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:43.000Z","updated_ts":"2026-02-24T22:42:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","drug_name":[{"lang":"CN","name":"跌打损伤软膏","status":"ACTIVE"},{"lang":"EN","name":"Traumatic Injury Ointment","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["748cd774e5434241aa073f17e0ed0e0b","997f9e39577a47139ccf356716bdc80d"],"active_org_master_entity_id":["777f4be1da8e8524cfe8ade27709ccd7","d1975c8e62aa0bec3692ff1417c95b82"],"research_disease":["748cd774e5434241aa073f17e0ed0e0b","997f9e39577a47139ccf356716bdc80d"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1598486400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1596499200000}}],"disease_phase":[{"disease_id":"748cd774e5434241aa073f17e0ed0e0b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"997f9e39577a47139ccf356716bdc80d","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"0dc29bdc9285428294e903dd50304f1b","docid":233998,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","antibody_type":"52998785b9a04f81b0cc96f0262a4a53","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":3,"target_extend_id":"4030989df680388dab8a8c247ed9e315","created_ts":"2024-10-24T07:21:42.000Z","updated_ts":"2026-04-13T21:46:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"MHB009C","source_info":[{"code":"2025_351","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/3202"}],"status":"ACTIVE"}],"dev_code":[{"name":"MHB009C","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["ef04c4c6c863d4ac50ad38da5a81f6bd"],"mechanism_action_id":["c01315be957c8c1777af535043d03f2c","cf1cf8ea0f9b80ee88876a3324ceac99"],"target_id":["68b3fb94145f42f5aa6ed0cf8577aee6","6acffb63799b4ba3bc85a4c59fcb05d7"],"dar":{"avg_value":4.0,"value_type":"AVERAGE"},"adc_reference":[{"code":"2025_351","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/3202"}],"disease_id":["0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["ef04c4c6c863d4ac50ad38da5a81f6bd"],"research_disease":["0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1773705600000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"3af7cb28451d3972b4d5c15d13bf3211","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["c01315be957c8c1777af535043d03f2c"],"moiety_target_id":["68b3fb94145f42f5aa6ed0cf8577aee6"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"055fa0313f4d43c6b96e1bc2c46f366b","docid":4987,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Vericiguat","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1611014400000,"rnk":2,"target_extend_id":"6de3e020a9f1398394dfbb20ac7b0fd7","has_leading_org_involved":1,"created_ts":"2021-10-08T14:45:31.000Z","updated_ts":"2026-04-03T09:09:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","first_approved_date_cn":1652832000000,"drug_name":[{"lang":"CN","name":"维立西呱","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Vericiguat","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"ベルイシグアト","source_info":[{"code":"30300AMX00275000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"维利西呱","status":"ACTIVE"}],"dev_code":[{"name":"BAY 102","status":"ACTIVE"},{"name":"BAY 1021189","status":"ACTIVE"},{"name":"BAY-102","status":"ACTIVE"},{"name":"BAY-1021189","source_info":[{"code":"30300AMX00275000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/630004_2190042F1021_1_03"}],"status":"ACTIVE"},{"name":"MK-1242","source_info":[{"code":"30300AMX00275000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/630004_2190042F1021_1_03"}],"status":"ACTIVE"}],"trade_name":[{"name":"Gantra","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.drreddys.com/cms/cms/sites/default/files/2024-04/Press%20Release_Bayer%20and%20Dr.%20Reddy%E2%80%99s%20sign%20a%20marketing%20and%20distribution%20agreement%20for%20second%20brand%20of%20Vericiguat%E2%84%A2%20in%20India.pdf"}],"status":"ACTIVE"},{"name":"Verquvo","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"name":"ベリキューボ","source_info":[{"code":"30300AMX00275000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/630004_2190042F1021_1_03"}],"status":"ACTIVE"},{"name":"唯可同","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzg2OTY4MTEzMA==&mid=2247544119&idx=5&sn=ff4dfa1cf6aa153445edc599d269bd9a"}],"status":"ACTIVE"},{"name":"베르쿠보정","source_info":[{"code":"202107708","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202107708aupdateTs2024-05-25%2015:51:49.0b"}],"status":"ACTIVE"}],"generic_name":[{"name":"vericiguat","source_info":[{"code":"EMEA/H/C/005319","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo"}],"status":"ACTIVE"}],"drugbank_id":["DB15456"],"kegg_id":["D11051"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["d94923980905512f8eac870e9ac6f983"],"mechanism_action_id":["7eb803ae10167128308e22fcd3fc6465"],"target_id":["2e7023e49fa24e88bdf77d5185f8b02e"],"atc_code":["a8f63fe7786b46a5af36d746ab26eeff"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","ca2f2c7dacec450e8a45e2b7f4b74d05","9eb8777c62af4712932b360e6ef3e454"],"disease_id":["c978e6fcc5124517a590344200645b42","c2c96e5bbe6949eda9849bc07a6b4d60","c8e43d2b48ec49dba16418bc190a3eec","a7573d72f2624c84b43127b55120aa0e","66e27e4b656d4c049385668b63ef5c36","be922e278f6948eda61e18b44570856c","0b0518478846465ea474b3c234b98e59","f319fa27684c4cdeb6ce59d897217718","95bf96dfb9894c2687df8f1a6c362b1a","2630d9f6e36341179636d8d22c2ddcd3","f98fd32baa8447119bb87f84093b925c","809470728caf4ac5a9a37f03951b6ae0","f21b246b05574261844954d981c3ba89","7562fe935c444ef486bfebb59f9a33c1","705c2113d90c4f2093f08a991662d37d","a41c00c1f16c4b71b41c0ce5a391998b","87c79e05a7634b239fd28b248ff31eae","4ff6109484ac468abaa8cd310548014e","1064a78afa214911ac4baa36dbf570a4"],"active_org_master_entity_id":["462096edf3de7b2de5a70c8fa9b70fa3","ed2726cd02738de869e61ad610dd6df6","6632a5800bfb389a90c6b15df46d2020","d94923980905512f8eac870e9ac6f983","a9a57513a3ad2be16442d74edcad1fa1","96c0ce87c67baca0bc61b56cea79c08a","038f17469c1153d3ba4939c6f416f0bc"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["c8e43d2b48ec49dba16418bc190a3eec","a7573d72f2624c84b43127b55120aa0e"],"research_disease":["c978e6fcc5124517a590344200645b42","c2c96e5bbe6949eda9849bc07a6b4d60","c8e43d2b48ec49dba16418bc190a3eec","a7573d72f2624c84b43127b55120aa0e","66e27e4b656d4c049385668b63ef5c36","be922e278f6948eda61e18b44570856c","0b0518478846465ea474b3c234b98e59","f319fa27684c4cdeb6ce59d897217718","95bf96dfb9894c2687df8f1a6c362b1a","2630d9f6e36341179636d8d22c2ddcd3","f98fd32baa8447119bb87f84093b925c","809470728caf4ac5a9a37f03951b6ae0","f21b246b05574261844954d981c3ba89","7562fe935c444ef486bfebb59f9a33c1","705c2113d90c4f2093f08a991662d37d","a41c00c1f16c4b71b41c0ce5a391998b","87c79e05a7634b239fd28b248ff31eae"],"non_research_disease":["4ff6109484ac468abaa8cd310548014e","1064a78afa214911ac4baa36dbf570a4"],"inactive_org_master_entity_id":["7a958978fbe701077085efe3bbfac22e"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","67034410be134e2bbb5b0930595b5e75","62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","52d1b118-b540-37ba-9cb2-f5aff686bb10","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1611014400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1652832000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1624406400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1682640000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1636934400000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1638230400000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"67170f77-4ab6-36f2-ab5e-fdff07ac024b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719964800000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"836a1060-0eaa-3033-98b7-58188e9748f5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"8050a7c3-e4ca-32bf-9f3f-e1598c447eb3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1651190400000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1502841600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719964800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719964800000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"9b340ca1-caed-3b00-9811-af8d46feb729","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719964800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1651190400000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1502841600000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"027bd29d-069d-3fdf-aa1a-be891fbaae92","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1635811200000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1472774400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"6d64b019-4f80-31e9-b248-297aa588c950","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"bb8e17b2-4cde-32c4-ab29-ead3a5a5ed1e","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1685491200000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1635897600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1630454400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1630454400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1505433600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1496880000000}},{"country":"2112a05f-55a8-36a9-b77e-ce71a16c4e24","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1614211200000}},{"country":"db572997-4981-336a-8a7e-99006b6612e2","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1630454400000}},{"country":"c2da2aca-0b0b-3198-aaf9-d35fe9c83766","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1630454400000}}],"disease_phase":[{"disease_id":"a41c00c1f16c4b71b41c0ce5a391998b","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c978e6fcc5124517a590344200645b42","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_before_ter_cn":"78c45f1d523646808032edcff807ca59","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"705c2113d90c4f2093f08a991662d37d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"be922e278f6948eda61e18b44570856c","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c2c96e5bbe6949eda9849bc07a6b4d60","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"0b0518478846465ea474b3c234b98e59","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7562fe935c444ef486bfebb59f9a33c1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"66e27e4b656d4c049385668b63ef5c36","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"2630d9f6e36341179636d8d22c2ddcd3","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"95bf96dfb9894c2687df8f1a6c362b1a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"1064a78afa214911ac4baa36dbf570a4","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"f21b246b05574261844954d981c3ba89","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"809470728caf4ac5a9a37f03951b6ae0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"a7573d72f2624c84b43127b55120aa0e","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"87c79e05a7634b239fd28b248ff31eae","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"4ff6109484ac468abaa8cd310548014e","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["0d854e9b4bc4ec17b3eeb3c991800bf1","50118a9f3b7df025657a0e7315e11f7f","6a8c172f1efc649035845f94c31a9c1e","7a958978fbe701077085efe3bbfac22e","ca28f37b82155ad0f26ac1807aa8c0eb","d94923980905512f8eac870e9ac6f983"],"data_source":10}
+{"drug_id":"0fbc8282f6ff4758b4748d4097d96a85","docid":52916,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"e01950ca12b83266a53294cc8bf1edeb","created_ts":"2021-11-30T08:57:22.000Z","updated_ts":"2025-11-12T21:12:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"LX-2020","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"ARVC PKP2 - LEXEO Therapeutics","status":"ACTIVE"},{"lang":"EN","name":"PKP2-gene therapy (LEXEO Therapeutics)","status":"ACTIVE"}],"dev_code":[{"name":"LX 2020","status":"ACTIVE"},{"name":"LX-2020","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["046c680d5c692bccafcf624083f1442d"],"mechanism_action_id":["9c1a4e2aa5154f9c8bb7c74cacc42569","d9627d77b8d00d879e22e88877e54736"],"target_id":["289de9f3dbfc4e1cb34fb0ccfb75c115"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["05d9a851d49e477da59cd9c45128369f"],"active_org_master_entity_id":["721ff2be352170b2eb26a72e3c763659"],"research_disease":["05d9a851d49e477da59cd9c45128369f"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1709164800000}}],"disease_phase":[{"disease_id":"05d9a851d49e477da59cd9c45128369f","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"20f66d6fef2c440d94df5b3efe0f60ae","docid":1702793,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":76,"target_extend_id":"b5924958701432a38eda77a75da2c165","created_ts":"2026-02-28T08:11:57.000Z","updated_ts":"2026-04-18T21:04:17.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Claudin18.2-Targeted Activated DC(Frontiergate Biopharm)","source_info":[{"code":"NCT07416240","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07416240"}],"status":"ACTIVE"}],"drug_type":["86adaf0bdaf94d2b8f3be02d66efb264"],"originator_org_master_entity_id":["5b4b20a63d413c8bc2707f908abffedb"],"mechanism_action_id":["bce8f785f2f2498aa6d659d4e4450291"],"target_id":["45f4868607f34cd5aa6d23ec518f90ac"],"disease_id":["ae092fa59f4d44edaf59ffe23d0a44c3"],"active_org_master_entity_id":["5b4b20a63d413c8bc2707f908abffedb"],"research_disease":["ae092fa59f4d44edaf59ffe23d0a44c3"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1771372800000}}],"disease_phase":[{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00721045e07a42f4a0ca6d347e41b241","docid":46784,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1041379200000,"created_ts":"2023-02-07T05:34:24.000Z","updated_ts":"2024-10-30T10:22:38.000Z","data_status":"ACTIVE","created_by":"yanglili","updated_by":"yanglili","first_approved_date_cn":1041379200000,"drug_name":[{"lang":"CN","name":"狂犬病人免疫球蛋白 (卫光生物)","source_info":[{"code":"国药准字S20033032","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Human Rabies Immunoglobulin (Weiguang Biological)","source_info":[{"code":"国药准字S20033032","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"drug_type":["0d7cf87172e4421ba4ea3f72fcd799d0"],"originator_org_master_entity_id":["cfdb180508e8a7b70c36866d8024465c"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["26bdc387cad64dc985f00855d64a3d2d"],"active_org_master_entity_id":["cfdb180508e8a7b70c36866d8024465c"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["26bdc387cad64dc985f00855d64a3d2d"],"research_disease":["26bdc387cad64dc985f00855d64a3d2d"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1041379200000}}],"disease_phase":[{"disease_id":"26bdc387cad64dc985f00855d64a3d2d","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0265f5f529db45b985cc1f334ba4f75d","docid":53090,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Cilostazol","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":820454400000,"rnk":1,"target_extend_id":"2da586ba2b7a335c8d6da96c94a48e72","has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:26.000Z","updated_ts":"2026-02-24T23:37:51.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":820454400000,"drug_name":[{"lang":"CN","name":"西洛他唑","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Cilostazol","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"},{"lang":"JP","name":"シロスタゾール","source_info":[{"code":"22100AMX02276","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Cilostazol (JP17/USP/INN)","source_info":[{"code":"D01896","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-758936","source_info":[{"code":"N7Z3546B","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/decc48cf-eaf9-4e0f-b9cb-6945806ce09c"}],"status":"ACTIVE"},{"name":"OPC-13013","status":"ACTIVE"},{"name":"OPC-21","status":"ACTIVE"}],"trade_name":[{"name":"Cebralat","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://www.libbs.com.br/nossos-produtos/doenca-vascular-cebralat/"}],"status":"ACTIVE"},{"name":"Pletaal","source_info":[{"code":"21900AMX00602","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/180078_3399002B1026_1_14"}],"status":"ACTIVE"},{"name":"Pletal","source_info":[{"code":"D01896","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"プレタール","source_info":[{"code":"21900AMX00602","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"},{"name":"培达","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"希络","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"希若宁","source_info":[{"code":"CTR20222194","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=081aa992c9d4461891ee579bd7458d8e"}],"status":"ACTIVE"},{"name":"斯特里普","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"name":"邦平","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Cilostazol","source_info":[{"code":"D01896","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB01166"],"kegg_id":["D01896"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bc6241e8a42dd6dff1fe2a92249cdb9d"],"mechanism_action_id":["c487fd3b4d987c05ece32d0e0652544b"],"target_id":["c322a3c1a11a49bdb7625fd0ebbc5d37"],"atc_code":["592af08173a44b6687401f9192a296d0"],"disease_id":["6cf8ff4207bd4f75a9c7ce66676516a0","58fd49f71a3f4a3483307fbc643c9725","e8ac16f06bf54fc9983b790cb4d0f904","e79cc331e912409da00bd00f9165c573","19d54e0602104a638bf33de97a916259","d013284d3b1d4cbea68f92745289853e","0b0518478846465ea474b3c234b98e59","face563bd2b1464cab2738c350a503d7"],"active_org_master_entity_id":["d1182283543c7182888bb0ae60963c88","2527002ad9e576eee8d9751191939314","2d053d9c7f97b70286577320d994fcb7","e04fbf3cf0a0af2bc6856c70d527f8b7"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["19d54e0602104a638bf33de97a916259"],"research_disease":["6cf8ff4207bd4f75a9c7ce66676516a0","58fd49f71a3f4a3483307fbc643c9725","e8ac16f06bf54fc9983b790cb4d0f904","e79cc331e912409da00bd00f9165c573","19d54e0602104a638bf33de97a916259","d013284d3b1d4cbea68f92745289853e"],"non_research_disease":["0b0518478846465ea474b3c234b98e59","face563bd2b1464cab2738c350a503d7"],"inactive_org_master_entity_id":["74fa1285cbf79384185afe468e63184d","345185b4388f283a2a73589cbb4ae44e","0d77d7f1c1db170410f76377130836a1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","234aad67e4bc46b3906543b77e393606"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","676de5ba-893a-36bb-8683-c93306aaf769","bb1d5b11-d9f8-31c4-872c-65a9fad8d193"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":820454400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1173916800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1023235200000}},{"country":"9c6ae9d7-5179-3787-9a19-a8a795c52fdf","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1744156800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_ts":1657756800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1585440000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1514678400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1433116800000}}],"disease_phase":[{"disease_id":"19d54e0602104a638bf33de97a916259","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e8ac16f06bf54fc9983b790cb4d0f904","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d013284d3b1d4cbea68f92745289853e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"face563bd2b1464cab2738c350a503d7","highest_phase_before_ter_global":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e79cc331e912409da00bd00f9165c573","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6cf8ff4207bd4f75a9c7ce66676516a0","highest_phase_before_ter_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"58fd49f71a3f4a3483307fbc643c9725","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"0b0518478846465ea474b3c234b98e59","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["cce07f69ef93d4fc1fb183b996c66f70","e04fbf3cf0a0af2bc6856c70d527f8b7"],"if_speculate":0,"data_source":10}
+{"drug_id":"03382b1ebc4b4530818f75f988d0632b","docid":69481,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":15,"target_extend_id":"ec523ed1911b38449e5e49c96722e772","has_leading_org_involved":1,"created_ts":"2021-10-08T14:49:09.000Z","updated_ts":"2026-04-04T21:11:08.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"PRX-005","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/prothena-reports-topline-phase-1-single-ascending-dose-study-results-of-prx005-a-novel-anti-mtbr-tau-antibody-for-the-potential-treatment-of-alzheimer-s-disease/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-MTBR-Tau","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibbs-Anti-MTBR-Tau-Targeting-Antibody-BMS-986446-Granted-Fast-Track-Designation-by-U-S--FDA-for-the-Treatment-of-Alzheimers-Disease/default.aspx"}],"status":"ACTIVE"}],"dev_code":[{"name":"BMS-986446","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/prothena-reports-third-quarter-2023-financial-results-and-business-highlights/"}],"status":"ACTIVE"},{"name":"PRX005","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["f92188cae567d8f15ec735fec1a614e3"],"mechanism_action_id":["45acfafb2b85ca164024bc9dcab65278"],"target_id":["47175928e7fb46619920e090090bf410"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["54a77f56d72c4ac6a0eb840f4518e3a0"],"active_org_master_entity_id":["dea970434c1183ebd6632e77bd1e19c0","f92188cae567d8f15ec735fec1a614e3"],"research_disease":["54a77f56d72c4ac6a0eb840f4518e3a0"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff"},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}},{"country":"8bbeaa0a-4a43-3f6d-b4c1-7d93af67a5d9","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1710892800000}}],"disease_phase":[{"disease_id":"54a77f56d72c4ac6a0eb840f4518e3a0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["dea970434c1183ebd6632e77bd1e19c0","f92188cae567d8f15ec735fec1a614e3"],"if_speculate":0,"data_source":10}
+{"drug_id":"02c16a73ac5e478a8f1ca34d1f693e25","docid":75322,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":7,"target_extend_id":"001906a0f2043c9a839c2299f6ace620","created_ts":"2021-10-08T14:49:24.000Z","updated_ts":"2026-01-10T21:10:59.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yuanjing","drug_name":[{"lang":"EN","name":"Xemilofiban Hydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Xemilofiban","status":"ACTIVE"},{"lang":"EN","name":"Xemilofiban hydrochloride (USAN)","source_info":[{"code":"D06335","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"lang":"EN","name":"Xemlofiban","status":"ACTIVE"}],"dev_code":[{"name":"CS-551","status":"ACTIVE"},{"name":"SC 54684","status":"ACTIVE"},{"name":"SC 54684A","status":"ACTIVE"},{"name":"SC-5468 4 Hydrochloride","status":"ACTIVE"},{"name":"SC-54684","status":"ACTIVE"},{"name":"SC-54684A","status":"ACTIVE"},{"name":"SC-54684A (HCl)","status":"ACTIVE"}],"generic_name":[{"name":"Xemilofiban","source_info":[{"code":"P614JI3IYK","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/842a15a5-9a3d-404b-acf7-b89268207c63"}],"status":"ACTIVE"}],"kegg_id":["D06335"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf"],"mechanism_action_id":["2daa58380cb94a4618bf4ac620d0e172"],"target_id":["b48720368c7c4a118b966262284fb5ab"],"disease_id":["22713e1eb6cb47209a13c9def522a6f7","22d4d689fe8b43b88ec66a65d7575106"],"active_org_master_entity_id":["e1664a4def09f2a7ae5d255b0eba84f4"],"research_disease":["22713e1eb6cb47209a13c9def522a6f7","22d4d689fe8b43b88ec66a65d7575106"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}}],"disease_phase":[{"disease_id":"22d4d689fe8b43b88ec66a65d7575106","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"22713e1eb6cb47209a13c9def522a6f7","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"00503888b4414b19a33368cd12298fb2","docid":37550,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":1,"target_extend_id":"d5a95b91776b35f29a8984fef1f54dde","created_ts":"2021-10-08T14:48:27.000Z","updated_ts":"2025-12-10T00:36:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"QR-12000","source_info":[{"attachment_path":"data/phs_source_info/b10e/ff8a/a007/4bd3/90413cb2-73de-3221-a3ab-6307ff1f4c37.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/b4b3/0afa/b03b/129a/d961c12d-77de-335b-903d-61d36ff00a36.png","source":"Company pipeline","source_url":"https://www.createrna.com/research-and-development/pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"QR 12000","status":"ACTIVE"},{"name":"QR12000","status":"ACTIVE"}],"related_component":["77e5d72aea59453fabf88f5770b32c00","7967ccdb7a2b4d2481011f2cb88adf28"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["017a77ba457fbd0a0a70c3d83cf9bfd5"],"mechanism_action_id":["e5c17d65ee183c5649ea2df5b6c0ef5c","42131b8e401a4e6b91b0360dceb3417b"],"target_id":["92f6abd82d2145bf965235013aab4fe3","ae1798d1eee6420690642fbab8803b3b"],"disease_id":["74d974da49ba407195b38595a0aff704","f8f9347202e043bab0e0d627ce10e767","c8e43d2b48ec49dba16418bc190a3eec"],"active_org_master_entity_id":["017a77ba457fbd0a0a70c3d83cf9bfd5"],"research_disease":["74d974da49ba407195b38595a0aff704","f8f9347202e043bab0e0d627ce10e767","c8e43d2b48ec49dba16418bc190a3eec"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1761091200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1734307200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f8f9347202e043bab0e0d627ce10e767","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"01881a3b6e5145a680503d6f238f0115","docid":70909,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":17,"target_extend_id":"130787d66d9530b6b04956fe96348a7a","created_ts":"2021-10-08T14:50:40.000Z","updated_ts":"2026-04-04T21:10:46.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","drug_name":[{"lang":"EN","name":"VTX-1463","status":"ACTIVE"}],"dev_code":[{"name":"VTX 1463","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["a323e21460a7069435cb5d3ea2c7b4bd"],"mechanism_action_id":["54ca34745a293f102954fce61ac1c97d"],"target_id":["bfd9ae9131904838b0a638f3917632f2"],"disease_id":["00894c5beba2467fa4489e0fa39ddffa"],"active_org_master_entity_id":["a323e21460a7069435cb5d3ea2c7b4bd"],"research_disease":["00894c5beba2467fa4489e0fa39ddffa"],"inactive_org_master_entity_id":["8eca2b1e039c19dfb9a0bf168b2f667c"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"00894c5beba2467fa4489e0fa39ddffa","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"05d166e6a3494ff78b266786aaf098ee","docid":1341531,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2025-06-04T06:36:27.000Z","updated_ts":"2025-06-04T06:38:12.000Z","data_status":"ACTIVE","created_by":"zhangmumu@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"EN","name":"D759","source_info":[{"code":"NCT05928637","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05928637"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ca28f37b82155ad0f26ac1807aa8c0eb"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["ca28f37b82155ad0f26ac1807aa8c0eb"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1688947200000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0ba28b9904444bd6949be420b06fb86a","docid":950076,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":9,"target_extend_id":"73fd722415e83c2eac0a43a495b860bf","created_ts":"2025-02-20T08:24:44.000Z","updated_ts":"2026-03-14T21:13:20.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences)","source_info":[{"code":"NCT06834529","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06834529"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["11b6c047eed48d28e4c2ddd378a02551"],"mechanism_action_id":["a663e30a2dcb766c1583e40cad7adc51","4c9c02bbdfaac0c794d51e268155fc51"],"target_id":["5eb1fc5283d34305934a031af530f448","d02b07e15b354447b8f22cb9e5c1d369"],"disease_id":["12f91588fe8e4d68acc2a480ba3264d1","0e0dca4dd7f1499a8f65f4fdfcf09954"],"active_org_master_entity_id":["11b6c047eed48d28e4c2ddd378a02551"],"research_disease":["12f91588fe8e4d68acc2a480ba3264d1","0e0dca4dd7f1499a8f65f4fdfcf09954"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1737331200000}}],"disease_phase":[{"disease_id":"12f91588fe8e4d68acc2a480ba3264d1","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1c4b3a79c52240c9b1a9b35b31895133","docid":1730784,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-08-25T05:50:10.000Z","updated_ts":"2025-08-29T07:40:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"HeXell-2020","source_info":[{"code":"NCT07137104","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07137104"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogenic umbilical cord mesenchymal stem cells(HeXun Biosciences)","source_info":[{"code":"NCT07137104","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07137104"}],"status":"ACTIVE"}],"dev_code":[{"name":"HeXell-2020","source_info":[{"code":"NCT07137104","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07137104"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["bd59eeb47a4d73ab50eff819cbb2fbcf"],"disease_id":["8cec41d5bdc544fd806b1578bb7ba435","43b9edccf86846f28da9774ba3236a69"],"active_org_master_entity_id":["bd59eeb47a4d73ab50eff819cbb2fbcf"],"research_disease":["8cec41d5bdc544fd806b1578bb7ba435","43b9edccf86846f28da9774ba3236a69"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"8cec41d5bdc544fd806b1578bb7ba435","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"43b9edccf86846f28da9774ba3236a69","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1cd9a91129134f0f968e8504aba88e55","docid":470874,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"7e56873573b33e3a87fff3e7555ff554","created_ts":"2024-11-26T05:53:22.000Z","updated_ts":"2024-12-26T00:21:59.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"APRIL-BAFF-Bicephali CAR-T cells(Yake Biotechnology)","source_info":[{"code":"NCT06132711","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06132711"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["5edd03a1adce5c0433c488db5986627f","44d0db467a8bd156c38b21243115cbd3"],"target_id":["da9d27a8b3264af3bb7244794a04bb60","e3d49d3759444b51833ce689778fb83c"],"disease_id":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"research_disease":["bf27abf8e60a4af4a578cedc875e80b9","e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1699574400000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"063706f6d63342e98f2db6ebf3cba8c0","docid":23248,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"express_system":"ac14778662b7448588663c26ce84cd9e","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":6,"target_extend_id":"9fac3dfc2cae38f6b0e87b6caf1ac0e1","created_ts":"2022-04-24T06:03:13.000Z","updated_ts":"2026-04-11T21:09:10.000Z","data_status":"ACTIVE","created_by":"qiejingwei","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Navenibart","source_info":[{"code":"LM-72","normalized_source_id":"47c8048a73f94d3b9c626eb4f8a6d7e4","source":"USAN","source_url":"https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fnavenibart.pdf"}],"status":"ACTIVE"}],"dev_code":[{"name":"QLS-215","status":"ACTIVE"},{"name":"STAR 0215","status":"ACTIVE"},{"name":"STAR-0215","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["30f9da6e1c95559527f402b3e1d18db1"],"mechanism_action_id":["16ae63da1c233ed22453d4af335abebf"],"target_id":["c74c091f03224f6097e9cbbdd7ebc6a4"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["a9209de5d36c4de6a98a475011e56b7b","6e0b19fb626347a18144a6f986035dfc"],"active_org_master_entity_id":["4b650433dbde737b2e8becdc2fe97866"],"research_disease":["a9209de5d36c4de6a98a475011e56b7b","6e0b19fb626347a18144a6f986035dfc"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"0293809f-cf7e-3684-b4d2-1fffdaedbb52","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}}],"disease_phase":[{"disease_id":"a9209de5d36c4de6a98a475011e56b7b","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6e0b19fb626347a18144a6f986035dfc","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"deal_related_org":["277f1eb1b653e3f8294cf05faadd6bd5","4b650433dbde737b2e8becdc2fe97866","e207b806161c4848076fdc3c1891e3dd"],"data_source":10}
+{"drug_id":"35bd259e91f14a7e8aabfd773196623b","docid":41457,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/WS-12","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","first_approved_date":1748390400000,"rnk":10,"target_extend_id":"1f797b736a8c3659b83b2c9d2332cc4a","created_ts":"2021-10-08T14:43:47.000Z","updated_ts":"2026-04-16T13:38:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"Acoltremon","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.cn/WS-12.html"},{"code":"NDA217370","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217370"}],"status":"ACTIVE"}],"dev_code":[{"name":"AR 15512","status":"ACTIVE"},{"name":"AR-15512","status":"ACTIVE"},{"name":"AR15512","status":"ACTIVE"},{"name":"AVX-012","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.cn/WS-12.html"}],"status":"ACTIVE"},{"name":"FEMA NO. 4681","source_info":[{"code":"1L7BVT4Z4Z","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/587cdf0c-d044-4604-8b2e-c1e8c8b13bd0"}],"status":"ACTIVE"},{"name":"OT-211","source_info":[{"code":"CTR20260953","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=eb5bcc7689a64534a2fb90702aaa751c"}],"status":"ACTIVE"},{"name":"WS-12","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medchemexpress.cn/WS-12.html"}],"status":"ACTIVE"}],"trade_name":[{"name":"TRYPTYR","source_info":[{"code":"NDA217370","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217370"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7f6c4ebc85d75019eab56bef9e67e652"],"mechanism_action_id":["c783ac34cd0a86080e3a864a73f13a42"],"target_id":["c0e573b49b554b5395c0dd767d2eaf42"],"disease_id":["3271242b681840bcbd5ad0e4baee0770","87a544b4d9354d1487fdd70ed48a779b"],"active_org_master_entity_id":["7f6c4ebc85d75019eab56bef9e67e652","cd6f8ec1c8952de95a9eb13a11c97828","1617fcee5f412dbd1084dc7c364ab29a","aca10265f636fabb0df416d60f7ab024"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["3271242b681840bcbd5ad0e4baee0770"],"research_disease":["3271242b681840bcbd5ad0e4baee0770","87a544b4d9354d1487fdd70ed48a779b"],"inactive_org_master_entity_id":["571b4432d259ed63603ae77c96b17a7a"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1748390400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1769904000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1774569600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1538352000000}}],"disease_phase":[{"disease_id":"87a544b4d9354d1487fdd70ed48a779b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"3271242b681840bcbd5ad0e4baee0770","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["30bac8c35de48f37008560937882886c","5c9d4ddc86a4f5ac97f69432350dc101","adbb9c4401e62794a72d066c26542199","e3fd9245f4dd8b310aaf0ccead33f1b2"],"if_speculate":0,"data_source":10}
+{"drug_id":"44013f7b7da6415e84b1786edccd83c7","docid":45381,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2022-01-05T08:43:40.000Z","updated_ts":"2025-09-12T18:52:09.000Z","data_status":"ACTIVE","created_by":"limingna@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"CN","name":"爱可仑赛","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/p3JM9qJ-1o32CrgyPLi7Sw"}],"status":"ACTIVE"},{"lang":"EN","name":"Expanded Activated Lymphocyte(Immunotech Biopharm)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"EAL","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://1901225107.pool4-site.make.yun300.cn/productsyt2.html"}],"status":"ACTIVE"},{"lang":"EN","name":"expanded activated lymphocyte(Immunotech Biopharm)","status":"ACTIVE"},{"lang":"CN","name":"扩增活化的淋巴细胞（永泰生物）","source_info":[{"normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml"}],"status":"ACTIVE"}],"drug_type":["ba6d649a46b94099864b1173223c2737"],"originator_org_master_entity_id":["6cdb54c72553d9e03d7b28aa894cd72d"],"mechanism_action_id":["a30504b84e062940a9ec00f77c5f47be"],"special_review":["23d3523b7ece48ddacaddac53a66949d","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["15839db0de0947ddb9e4c280884a3895","74beb7d22d474e58b3a8589b108c4957","7665e5683a1a443a8f3d3b946d4c9ca2","0a885de5b4054c2b98d478f91f3e3418","e2fd9bda4aeb4a7b9fa53a2560126d24","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["6cdb54c72553d9e03d7b28aa894cd72d"],"research_disease":["15839db0de0947ddb9e4c280884a3895","74beb7d22d474e58b3a8589b108c4957","7665e5683a1a443a8f3d3b946d4c9ca2","0a885de5b4054c2b98d478f91f3e3418","e2fd9bda4aeb4a7b9fa53a2560126d24","ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1741219200000}}],"disease_phase":[{"disease_id":"15839db0de0947ddb9e4c280884a3895","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"74beb7d22d474e58b3a8589b108c4957","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"deal_related_org":["6cdb54c72553d9e03d7b28aa894cd72d","f6e6c58fe950d38c841cc9e0ed51b996"],"if_speculate":0,"data_source":10}
+{"drug_id":"06783a484ac74956b293c461725e7d08","docid":1611883,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2025-10-09T05:42:40.000Z","updated_ts":"2025-10-09T07:58:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Autologous dendritic cells(National Taiwan University Hospital)","source_info":[{"code":"NCT07202611","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07202611"}],"status":"ACTIVE"}],"drug_type":["86adaf0bdaf94d2b8f3be02d66efb264"],"originator_org_master_entity_id":["95436cb1e8ead43eb60dc8cacee6d04b"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["95436cb1e8ead43eb60dc8cacee6d04b"],"research_disease":["3beea980d93a4cc0abc864e27514601c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1669939200000}}],"disease_phase":[{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0d641f5bea96447790b494208b354fc5","docid":79001,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2022-04-28T12:55:53.000Z","updated_ts":"2025-01-29T21:20:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"nDC vaccination(Dutch National Health Care Institute)","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["e0262faff4c95c5eb682c6be717c7f05"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["8da4804a5bd24352b7d568a7da54c6dc"],"active_org_master_entity_id":["8f25d16685e8c1ca4ecf816dc77e734d"],"research_disease":["8da4804a5bd24352b7d568a7da54c6dc"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1475280000000}}],"disease_phase":[{"disease_id":"8da4804a5bd24352b7d568a7da54c6dc","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"2efb03c861bd40e4bc5b25202cff1a15","docid":231427,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":50,"target_extend_id":"e2b2160581553002818ef8c2ab06de2c","created_ts":"2024-06-07T06:36:56.000Z","updated_ts":"2026-04-11T21:08:01.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"68Ga-AAZTA-093","source_info":[{"code":"NCT06437496","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06437496"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"68Ga-AAZTA-NI-093","source_info":[{"code":"NCT06612580","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06612580"}],"status":"ACTIVE"}],"dev_code":[{"name":"68Ga-AAZTA-093","status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549","926e8e25a2b04d29864ed28dca6c57b7"],"originator_org_master_entity_id":["cb5cdd75f5584091aaa06a33cc336bbc"],"mechanism_action_id":["0389578921da93a1bb6dd14e83f31524"],"target_id":["b7c5c1575f6d4048978a5b5da2159878"],"disease_id":["31a4a651f7744562b44cedbe4a0f942f"],"active_org_master_entity_id":["cb5cdd75f5584091aaa06a33cc336bbc"],"research_disease":["31a4a651f7744562b44cedbe4a0f942f"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1711929600000}}],"disease_phase":[{"disease_id":"31a4a651f7744562b44cedbe4a0f942f","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10,"moiety_target_extend_id":"e2b2160581553002818ef8c2ab06de2c","moiety_mechanism_action_id":["0389578921da93a1bb6dd14e83f31524"],"moiety_target_id":["b7c5c1575f6d4048978a5b5da2159878"]}
+{"drug_id":"073122fdff8b43359390605080ddc2b4","docid":59831,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":4,"target_extend_id":"8067433534a3367b9a695620aabdedb0","created_ts":"2023-02-27T01:40:30.000Z","updated_ts":"2025-11-10T10:55:18.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wangya","drug_name":[{"lang":"EN","name":"HRS-1893","source_info":[{"code":"CXHL2300249","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"BHB-1893","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247580606&idx=4&sn=351681bcebe904b0f1df5ccd13fa65c3"}],"status":"ACTIVE"},{"name":"HRS 1893","status":"ACTIVE"},{"name":"HRS-1893","status":"ACTIVE"},{"name":"HRS1893","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6b1d50252b2e2ea1d72ca591aeb6bca3"],"mechanism_action_id":["69978718a9190e55f17665c52e269f72"],"target_id":["dfdf02e3b0f14d6d9898bb76de83375a"],"disease_id":["6b68fbb0fff64af0b6f9265260b975ad","1064a78afa214911ac4baa36dbf570a4","10f74c2b08eb4735becdbee4a502f648","64ae2b2dbe3e479d825374f14171d0f7"],"active_org_master_entity_id":["6b1d50252b2e2ea1d72ca591aeb6bca3","07bf37752956a04d79674662aad82a57"],"research_disease":["6b68fbb0fff64af0b6f9265260b975ad","1064a78afa214911ac4baa36dbf570a4","10f74c2b08eb4735becdbee4a502f648","64ae2b2dbe3e479d825374f14171d0f7"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1754870400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1750809600000}}],"disease_phase":[{"disease_id":"64ae2b2dbe3e479d825374f14171d0f7","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"1064a78afa214911ac4baa36dbf570a4","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"10f74c2b08eb4735becdbee4a502f648","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"6b68fbb0fff64af0b6f9265260b975ad","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["8cf7f3af90ad45cdeb2a74b6e73b6ebf","b9246f608e5c84db9c15f0e2508e71ee"],"if_speculate":0,"data_source":10}
+{"drug_id":"310edce446362c5fc6b570916b789756","docid":113529,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":102,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2024-06-04T07:48:02.000Z","updated_ts":"2026-04-11T21:07:00.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"Anti-BCMA CAR-T (The Affiliated Hospital of Xuzhou Medical University)","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["733aa34d293853ff604a5d96f056e511"],"mechanism_action_id":["be117d5c44b6d9383994d7542138ebd9"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["7cd0fcf1c5c243b9b3944405ec4855b5","e10523d5d50e41f6841de149d8b794b7"],"active_org_master_entity_id":["733aa34d293853ff604a5d96f056e511"],"research_disease":["7cd0fcf1c5c243b9b3944405ec4855b5","e10523d5d50e41f6841de149d8b794b7"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1554076800000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"1fb2ac556ef74e39a7c47068da908a30","docid":205119,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":5,"target_extend_id":"57abfbaaad6238a88054da1445b94f46","created_ts":"2024-12-17T07:58:01.000Z","updated_ts":"2026-03-21T00:12:15.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"奥博雷通","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzU4MDkxODMxNg==&mid=2247677353&idx=3&sn=6db1320e5c3487ff83e3796f33bcaddb"}],"status":"ACTIVE"},{"lang":"EN","name":"Oveporexton","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.medkoo.com/products/59763"}],"status":"ACTIVE"}],"dev_code":[{"name":"TAK 861","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://www.nature.com/articles/s41598-024-70594-1"}],"status":"ACTIVE"},{"name":"TAK-861","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://www.nature.com/articles/s41598-024-70594-1"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["3213232cf3774bc734def2420b679bb6"],"mechanism_action_id":["e07c8b8c7cf9f3295b7de120d8a651f0"],"target_id":["2f6f2a1619a14ea4b2701297caf45751"],"special_review":["23d3523b7ece48ddacaddac53a66949d","043a131d85994801b3617e822e7f87b3","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["0e06043f6ae5497b833a726151e32b48","5e3541677d4341319d1aa02cfca4968b","43a23f101e694f9b82b834471d1e64c1","8bae1a8f63e0473088d3c5dc3646851b"],"active_org_master_entity_id":["26146ba7ca0c0a8c2d1b40e9040672c5","3213232cf3774bc734def2420b679bb6"],"research_disease":["0e06043f6ae5497b833a726151e32b48","5e3541677d4341319d1aa02cfca4968b","43a23f101e694f9b82b834471d1e64c1","8bae1a8f63e0473088d3c5dc3646851b"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1770681600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1768521600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1719878400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1728345600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1680566400000}}],"disease_phase":[{"disease_id":"0e06043f6ae5497b833a726151e32b48","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"43a23f101e694f9b82b834471d1e64c1","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"8bae1a8f63e0473088d3c5dc3646851b","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"5e3541677d4341319d1aa02cfca4968b","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"if_speculate":0,"data_source":10}
+{"drug_id":"02813d366cd541a7be022836e72792b4","docid":70272,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Levosimendan","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":986860800000,"rnk":2,"target_extend_id":"2da586ba2b7a335c8d6da96c94a48e72","created_ts":"2021-10-08T14:47:55.000Z","updated_ts":"2026-04-03T09:15:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1272499200000,"drug_name":[{"lang":"CN","name":"左西孟旦","status":"ACTIVE"},{"lang":"EN","name":"Levosimendan","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Daxim","status":"ACTIVE"},{"lang":"EN","name":"Levosimendan (USAN/INN)","source_info":[{"code":"D04720","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-759644","source_info":[{"code":"C6T4514L4E","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ac4a445b-2be0-4692-92a8-0c652dbc3e51"}],"status":"ACTIVE"},{"name":"ODM 109","status":"ACTIVE"},{"name":"ODM-109","status":"ACTIVE"},{"name":"OR-1259","status":"ACTIVE"},{"name":"TNX-101","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/tenax-granted-notice-of-allowance-for-u-s-patent-application-covering-use-of-iv-levosimendan-in-pulmonary-hypertension-with-heart-failure-and-preserved-ejection-fraction-ph-hfpef-/"}],"status":"ACTIVE"},{"name":"TNX-103","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/tenax-therapeutics-announces-8-million-pipe-offering-priced-at-the-market-under-nasdaq-rules/"}],"status":"ACTIVE"},{"name":"TNX102","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/tenax-therapeutics-announces-8-million-pipe-offering-priced-at-the-market-under-nasdaq-rules/"}],"status":"ACTIVE"}],"trade_name":[{"name":"Simdax","source_info":[{"code":"D04720","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"悦文","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"generic_name":[{"name":"Levosimendan","source_info":[{"code":"D04720","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB00922"],"kegg_id":["D04720"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["7af884bf49857de9c1d45ea0fe60d687"],"mechanism_action_id":["c487fd3b4d987c05ece32d0e0652544b"],"target_id":["c322a3c1a11a49bdb7625fd0ebbc5d37"],"atc_code":["8a1e14920f78442a8dd2f3b7379d5b54"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["c8e43d2b48ec49dba16418bc190a3eec","564b79f51f3d452f8d1c8e405fe1369c","8ab4572efc344edbad36869731b2bc25","1064a78afa214911ac4baa36dbf570a4","be922e278f6948eda61e18b44570856c","1623a269e26647fda7ecbee5c6923076","67084f74e7874250b472840a5057f573","07e16848760b4be0a3ef260a64786fb9","738546bac89e4895b89af01545f1b054","c2c96e5bbe6949eda9849bc07a6b4d60","bf821ba3fb194a38a5b2f804bcf68c44","96f7f72926d1415288e1da967512a1ee","1e4770d154fa4930948c6d1f4a535eb7","d70beddae6cb408cb826ee8763fa0509","299e91fc2f234bbb9e0156c4f43ad970","66e27e4b656d4c049385668b63ef5c36","9eb7e956c17a46e49c27736a5e9ecfe6","6c3b7009430c4b8387b1b26e17ec4beb","22d4d689fe8b43b88ec66a65d7575106","40a5d9cd655a42ff8373c49062997fdb","323717f7753b4ce6a5561d105a7531cf","a7573d72f2624c84b43127b55120aa0e","a3ae5c00e57b4783af3b916adebb2516","e0c1f75fecd1419ba10f8327d8204140"],"active_org_master_entity_id":["6c75c6b3215a184ee42e6f93f768070e","7af884bf49857de9c1d45ea0fe60d687","0360c44555311966fb6769377a73bf1e","dfe99ed1c70c135d59ffe62895fbbe0c","0bb6804a2738b17bb305b0d80ce08460"],"first_approved_country":["6efc9b0c-3cae-3f31-997d-ad35651f6e74","a6141259-8d80-3db1-be8f-e435a49f1ae4","dc266be9-66b5-3c85-af35-ef210568f738","e56545a6-17ff-3d65-812b-7485498ba644","a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","3d57c904-23bf-3ee0-9924-83496c75b8ee","1b05c4d2-8156-3854-9898-c71e0077e3c6","665d1d12-3d14-3e05-8459-014864489671","deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","b4fc8d4a-92f1-3c80-93c0-29733d8c38b6"],"first_approved_indication":["564b79f51f3d452f8d1c8e405fe1369c"],"research_disease":["c8e43d2b48ec49dba16418bc190a3eec","564b79f51f3d452f8d1c8e405fe1369c","8ab4572efc344edbad36869731b2bc25","1064a78afa214911ac4baa36dbf570a4","be922e278f6948eda61e18b44570856c","1623a269e26647fda7ecbee5c6923076","67084f74e7874250b472840a5057f573","07e16848760b4be0a3ef260a64786fb9"],"non_research_disease":["738546bac89e4895b89af01545f1b054","c2c96e5bbe6949eda9849bc07a6b4d60","bf821ba3fb194a38a5b2f804bcf68c44","96f7f72926d1415288e1da967512a1ee","1e4770d154fa4930948c6d1f4a535eb7","d70beddae6cb408cb826ee8763fa0509","299e91fc2f234bbb9e0156c4f43ad970","66e27e4b656d4c049385668b63ef5c36","9eb7e956c17a46e49c27736a5e9ecfe6","6c3b7009430c4b8387b1b26e17ec4beb","22d4d689fe8b43b88ec66a65d7575106","40a5d9cd655a42ff8373c49062997fdb","323717f7753b4ce6a5561d105a7531cf","a7573d72f2624c84b43127b55120aa0e","a3ae5c00e57b4783af3b916adebb2516","e0c1f75fecd1419ba10f8327d8204140"],"inactive_org_master_entity_id":["73cf2b8f828a3201a51e8a789e03d869","f8408a10b0cfd7df709428a92dd0a1b1"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","948c9548c2ed46b5865b8693f7f96604","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe","a7be8424-b451-3746-9341-a1a254537551","6efc9b0c-3cae-3f31-997d-ad35651f6e74","a6141259-8d80-3db1-be8f-e435a49f1ae4","dc266be9-66b5-3c85-af35-ef210568f738","e56545a6-17ff-3d65-812b-7485498ba644","a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","3d57c904-23bf-3ee0-9924-83496c75b8ee","1b05c4d2-8156-3854-9898-c71e0077e3c6","665d1d12-3d14-3e05-8459-014864489671","deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","b4fc8d4a-92f1-3c80-93c0-29733d8c38b6"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1597190400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1272499200000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1027123200000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"a6141259-8d80-3db1-be8f-e435a49f1ae4","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"deb2b5a6-031d-3817-9b8a-3a08ef9f5aa2","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":986860800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704844800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1704844800000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1772496000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1678320000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1678320000000}},{"country":"b7fd90b0-e7ac-3861-bfdb-762da5fc20be","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1678320000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1678320000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1164931200000}}],"disease_phase":[{"disease_id":"07e16848760b4be0a3ef260a64786fb9","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8ab4572efc344edbad36869731b2bc25","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"96f7f72926d1415288e1da967512a1ee","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"a3ae5c00e57b4783af3b916adebb2516","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"be922e278f6948eda61e18b44570856c","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c2c96e5bbe6949eda9849bc07a6b4d60","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"299e91fc2f234bbb9e0156c4f43ad970","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1e4770d154fa4930948c6d1f4a535eb7","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"66e27e4b656d4c049385668b63ef5c36","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"6c3b7009430c4b8387b1b26e17ec4beb","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"564b79f51f3d452f8d1c8e405fe1369c","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d70beddae6cb408cb826ee8763fa0509","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1064a78afa214911ac4baa36dbf570a4","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"323717f7753b4ce6a5561d105a7531cf","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"22d4d689fe8b43b88ec66a65d7575106","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"1623a269e26647fda7ecbee5c6923076","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"9eb7e956c17a46e49c27736a5e9ecfe6","highest_phase_before_ter_global":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"67084f74e7874250b472840a5057f573","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e0c1f75fecd1419ba10f8327d8204140","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a7573d72f2624c84b43127b55120aa0e","highest_phase_before_ter_global":"9f31233bceb94d9796d3f3556f17ab13","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"40a5d9cd655a42ff8373c49062997fdb","highest_phase_before_ter_global":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"deal_related_org":["8afae3daf43cdcff23d36cccbdfa4c0b","c1e3f6ac0bb4cdea849308693d548e1a","7af884bf49857de9c1d45ea0fe60d687","6c75c6b3215a184ee42e6f93f768070e"],"data_source":10}
+{"drug_id":"07765945f97742e3a585ce3ed1e39e94","docid":1643804,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"1f5e74dbf4423bf9b88720a91ad43abc","created_ts":"2026-01-19T07:12:45.000Z","updated_ts":"2026-01-24T21:12:03.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"EF-M2","status":"ACTIVE"}],"dev_code":[{"name":"EF-M2","status":"ACTIVE"}],"drug_type":["3b73c4ecbe95459da252b83f9b630015"],"originator_org_master_entity_id":["ff11dc6b51b79a97f18475635e9493dc"],"mechanism_action_id":["4dc4c585004541fb879c122c8e87a1f0"],"target_id":["fb50115069c74b4d8fb8e63e57a716cb"],"disease_id":["6be96778ed424f8d91de00ab82364114"],"active_org_master_entity_id":["ff11dc6b51b79a97f18475635e9493dc"],"research_disease":["6be96778ed424f8d91de00ab82364114"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1748908800000}}],"disease_phase":[{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"095f17f460b242f6846db66f1af25230","docid":268198,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","linker_id":"b6b2199ed4544f5ea43c3c1dd1adbaf7","payload_id":"2afd40bdaee84ea986803ab007493096","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"3a2ab0df56b33a59ab565ae942fc33c9","created_ts":"2024-11-12T11:30:46.000Z","updated_ts":"2025-07-31T00:31:12.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"IBI3014","source_info":[{"code":"2025_344","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/3199"}],"status":"ACTIVE"}],"dev_code":[{"name":"IBI3014","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["d02547e21eb6b82077817e61a1a426fb"],"mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2","cf1cf8ea0f9b80ee88876a3324ceac99","9f012a6b83d88bf152ee30b3d01fa3df"],"target_id":["06c7ab146b884a3aa890cfd1a4a0e168","6acffb63799b4ba3bc85a4c59fcb05d7","d8cdb9ce63174077a9ef868b39bf3421"],"adc_reference":[{"code":"2025_344","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/3199"}],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["d02547e21eb6b82077817e61a1a426fb"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1744329600000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"if_speculate":0,"data_source":10,"target_moiety_type":["9a847883d786485489d0ee1d75ae90ba"],"moiety_target_extend_id":"60a6fe5601f8318ca32c5d762c9f93e8","payload_target_extend_id":"8213c47538943d6abbd8a82878581fef","moiety_mechanism_action_id":["5f2b5842256779f2516d3dc21cf298e2","9f012a6b83d88bf152ee30b3d01fa3df"],"moiety_target_id":["06c7ab146b884a3aa890cfd1a4a0e168","d8cdb9ce63174077a9ef868b39bf3421"],"payload_target_id":["6acffb63799b4ba3bc85a4c59fcb05d7"],"payload_mechanism_action_id":["cf1cf8ea0f9b80ee88876a3324ceac99"]}
+{"drug_id":"265c37f97edf4eefab4decc1d23d632a","docid":1611892,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-10-09T06:45:08.000Z","updated_ts":"2025-10-09T07:18:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"NPDR-01","source_info":[{"code":"NCT07198815","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07198815"}],"status":"ACTIVE"}],"dev_code":[{"name":"NPDR-01","source_info":[{"code":"NCT07198815","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07198815"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5b80036db361876ea3f3d1674191bec0"],"disease_id":["e8abceedac774b0d9b0e0e5914aceb10","f880f61785b940cd9ed1bb3212b5c1ce"],"active_org_master_entity_id":["5b80036db361876ea3f3d1674191bec0"],"research_disease":["e8abceedac774b0d9b0e0e5914aceb10","f880f61785b940cd9ed1bb3212b5c1ce"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"disease_phase":[{"disease_id":"e8abceedac774b0d9b0e0e5914aceb10","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f880f61785b940cd9ed1bb3212b5c1ce","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4618c30eaf4940f0a5570f6a09c99a25","docid":1610941,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-08-19T07:48:53.000Z","updated_ts":"2025-08-19T08:02:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Allogeneic γδ T Cells(Hematology Hospital of Chinese Academy of Medical Sciences)","source_info":[{"code":"NCT07126782","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07126782"}],"status":"ACTIVE"}],"drug_type":["82d9b474ba434d6ca4e0a6740a55ac23"],"originator_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"mechanism_action_id":["0f645f87bd7a67c4e2f1daff28d19421"],"disease_id":["7cb6983b4169498e89b08fd725a22b46"],"active_org_master_entity_id":["d0bb13f3cee74cfb0af07e4b69bb76dd"],"research_disease":["7cb6983b4169498e89b08fd725a22b46"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1752969600000}}],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0a4ac44a3a564c48b5ed55e0e7f44e60","docid":269019,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-01-22T05:42:36.000Z","updated_ts":"2025-09-16T05:46:09.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"JKN2306","status":"ACTIVE"}],"dev_code":[{"name":"JKN2306","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["384037642fad2eb1b085146aa601f666"],"disease_id":["f09b7cfbc8314c54a5a207e8f88a2b4c"],"active_org_master_entity_id":["384037642fad2eb1b085146aa601f666"],"research_disease":["f09b7cfbc8314c54a5a207e8f88a2b4c"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1756857600000}}],"disease_phase":[{"disease_id":"f09b7cfbc8314c54a5a207e8f88a2b4c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0ce171e5663448f5bd8c02a0c8242c67","docid":40166,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1714003200000,"rnk":1,"target_extend_id":"aebed6da7b83310ba4b7025bfdcfa8b8","created_ts":"2022-07-06T05:36:07.000Z","updated_ts":"2026-02-12T07:10:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"wangya","drug_name":[{"lang":"EN","name":"Seniprutug","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://www.researchgate.net/publication/378749445_Effectiveness_and_safety_of_BCD180_anti-TRBV9_T-lymphocytes_monoclonal_antibody_in_patients_with_active_radiographic_axial_spondyloarthritis_36-week_results_of_double-blind_randomized_placebo-controll"},{"code":"WHOINN List 129","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_5&download=true"}],"status":"ACTIVE"}],"dev_code":[{"name":"BCD 180","source_info":[{"code":"NCT05407779","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05407779"}],"status":"ACTIVE"},{"name":"BCD-180","source_info":[{"code":"NCT05407779","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05407779"}],"status":"ACTIVE"},{"name":"BCD180","source_info":[{"code":"NCT05407779","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05407779"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["d3a57466e6d758e197b357a64eb4df4f"],"mechanism_action_id":["5440acbb81e642689ae5937755f114ef"],"target_id":["caa94c05a9ab4842a2924cb874654543"],"disease_id":["8da973b225c24afbba255413635fb240","973559487cc743bf8e735686bcabcd06"],"active_org_master_entity_id":["d3a57466e6d758e197b357a64eb4df4f"],"first_approved_country":["9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312"],"first_approved_indication":["8da973b225c24afbba255413635fb240"],"research_disease":["8da973b225c24afbba255413635fb240","973559487cc743bf8e735686bcabcd06"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"approval_country":["9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312"],"research_country":[{"country":"9b148c0c-8ce5-32a0-bab7-f7fa6c1cb312","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1714003200000}},{"country":"e92cf5a5-43e5-3d54-a14b-272415437a2d","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1703462400000}}],"disease_phase":[{"disease_id":"973559487cc743bf8e735686bcabcd06","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"02e4afc9b9b84babb8f7301685636a54","docid":17866,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","created_ts":"2022-02-28T05:05:57.000Z","updated_ts":"2026-02-24T19:47:42.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"心可舒","status":"ACTIVE"},{"lang":"EN","name":"XinKeShu","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"disease_id":["8cec41d5bdc544fd806b1578bb7ba435","412d1b7c01804fe39174a3d438a0abbf","bf821ba3fb194a38a5b2f804bcf68c44","5afbb03451e242f0a07d14c05b62d4eb","281fcf1b07ee4c13b0297e4ad1a9c106"],"research_disease":["8cec41d5bdc544fd806b1578bb7ba435","412d1b7c01804fe39174a3d438a0abbf","bf821ba3fb194a38a5b2f804bcf68c44","5afbb03451e242f0a07d14c05b62d4eb","281fcf1b07ee4c13b0297e4ad1a9c106"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe"}],"disease_phase":[{"disease_id":"8cec41d5bdc544fd806b1578bb7ba435","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"412d1b7c01804fe39174a3d438a0abbf","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"bf821ba3fb194a38a5b2f804bcf68c44","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"5afbb03451e242f0a07d14c05b62d4eb","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"281fcf1b07ee4c13b0297e4ad1a9c106","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"002ef8ab09d54de29afb43e5cb208f66","docid":83220,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":25,"target_extend_id":"0af8a806695c3915aa8a183ba81eaf8e","created_ts":"2024-01-05T09:07:48.000Z","updated_ts":"2026-01-31T21:13:09.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"VS-041","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/vasa-therapeutics-announces-closing-of-seed-financing-to-advance-novel-therapies-for-diseases-of-cardiovascular-aging-302024988.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"VS 041","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/vasa-therapeutics-announces-closing-of-seed-financing-to-advance-novel-therapies-for-diseases-of-cardiovascular-aging-302024988.html"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["bd22742d85a67b6d00fb6431682d51cf"],"mechanism_action_id":["bf484e2737097dbbe051213cffa568b2"],"target_id":["3113fa804db9475fb14f6ffd0eab4dd6"],"disease_id":["1064a78afa214911ac4baa36dbf570a4"],"active_org_master_entity_id":["bd22742d85a67b6d00fb6431682d51cf"],"research_disease":["1064a78afa214911ac4baa36dbf570a4"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1762214400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1725321600000}}],"disease_phase":[{"disease_id":"1064a78afa214911ac4baa36dbf570a4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"3436001cb2b1427ea7454bf79fb048f0","docid":22661,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-09-27T12:39:28.000Z","updated_ts":"2024-11-09T00:14:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ONTC-K216","status":"ACTIVE"}],"dev_code":[{"name":"ONTC-K216","status":"ACTIVE"}],"drug_type":["58846334b4a6496b83493429578a4faa"],"originator_org_master_entity_id":["a7a391de01d931960b36499d7ddc0d03"],"disease_id":["a4f7254e36da425087293790eb964551","0e0dca4dd7f1499a8f65f4fdfcf09954","e50aad3dea474cf487e53bd91d5d7c45"],"active_org_master_entity_id":["a7a391de01d931960b36499d7ddc0d03"],"research_disease":["a4f7254e36da425087293790eb964551","0e0dca4dd7f1499a8f65f4fdfcf09954","e50aad3dea474cf487e53bd91d5d7c45"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1647216000000}}],"disease_phase":[{"disease_id":"e50aad3dea474cf487e53bd91d5d7c45","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a4f7254e36da425087293790eb964551","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"49165b7760844f1faed22820c4d698e1","docid":69831,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":91,"target_extend_id":"27484dc2d43338fd8ff008f88abc23e7","has_leading_org_involved":1,"created_ts":"2021-10-08T14:50:36.000Z","updated_ts":"2026-04-18T21:08:14.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"维普地司他","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650031091&idx=1&sn=14a555e133657efcaa2fc7ed9db34bdc"}],"status":"ACTIVE"},{"lang":"EN","name":"Vepdegestrant","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnewswire.com/news-releases/arvinas-and-quantum-leap-healthcare-announce-clinical-study-to-evaluate-vepdegestrant-arv-471-in-i-spy-2-endocrine-optimization-platform-eop-clinical-trial-301812955.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"ARV 471","status":"ACTIVE"},{"name":"ARV-471","status":"ACTIVE"},{"name":"ARV471","status":"ACTIVE"},{"name":"PF 07850327","status":"ACTIVE"},{"name":"PF-07850327","source_info":[{"code":"JXHL2200233","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"PF07850327","status":"ACTIVE"}],"drug_type":["8288584a840d4f6e9374cc5e9256a4ce"],"originator_org_master_entity_id":["38a2bbec0111da34f6f333a6329311b2"],"mechanism_action_id":["2d73e3e77c5c5ff66fcaf891bde2bb84"],"target_id":["eb553b25d950464798e93c7e998425d2"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","c3c948340a7d40f3b7437081f5e8cb4e"],"disease_id":["b785b1cc5ead4eb3b241d380750d496d","3bf6031206e848cd94f767cd1db43ea0","4035a94ea2d240d7a52aa75633974381","b382bc2a56644776b45dc6084224df3b","de23eb7576d244d4bd3d2263c15d4b85","f98fd32baa8447119bb87f84093b925c","7ef9e2b3cfbf4b3d8966344968de1f01","0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653"],"active_org_master_entity_id":["9597e75ba30c9958d4331f586407d7cf","3400eab4e24ecf42a08fe60b0f0d239a","38a2bbec0111da34f6f333a6329311b2","3581be276590bbca656d780b27806779"],"research_disease":["b785b1cc5ead4eb3b241d380750d496d","3bf6031206e848cd94f767cd1db43ea0","4035a94ea2d240d7a52aa75633974381","b382bc2a56644776b45dc6084224df3b","de23eb7576d244d4bd3d2263c15d4b85","f98fd32baa8447119bb87f84093b925c","7ef9e2b3cfbf4b3d8966344968de1f01","0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1749168000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"a8dbb56e-1021-3ca2-8720-a5c1ca5a6aab","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1691539200000}},{"country":"2db206be-90da-3fc0-8a37-72d9a2fc2b03","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1677801600000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1743638400000}}],"disease_phase":[{"disease_id":"b785b1cc5ead4eb3b241d380750d496d","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"7ef9e2b3cfbf4b3d8966344968de1f01","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"4035a94ea2d240d7a52aa75633974381","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b382bc2a56644776b45dc6084224df3b","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"de23eb7576d244d4bd3d2263c15d4b85","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["9597e75ba30c9958d4331f586407d7cf","38a2bbec0111da34f6f333a6329311b2"],"if_speculate":0,"data_source":10}
+{"drug_id":"0035add8daef4acebecc882cf12a4ac9","docid":440496,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-11-25T09:57:41.000Z","updated_ts":"2026-02-25T00:22:15.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"CN","name":"吸附无细胞百（三组分）白破b型流感嗜血杆菌（结合）-ACYW135群脑膜炎球菌（结合）联合疫苗","status":"ACTIVE"},{"lang":"EN","name":"Combined vaccine(CanSino)","source_info":[{"code":"CXSL2400797","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Absorbed acellular pertussis(three-component), diphtheria, tetanus, Haemophilus influenzae type b (combined)-ACYW135 group meningococcal (combined) combined vaccine","status":"ACTIVE"},{"lang":"CN","name":"DTcP-Hib-MCV4联合疫苗","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=Mzk0ODIxMzU4Mw==&mid=2247530982&idx=4&sn=3c5d039ddc0645aeaa90e0c615d49bf5"}],"status":"ACTIVE"}],"drug_type":["5f5b59262b674cb0a560ddb6aa68bb4f","8f91996d778a4b93aebea69ade081b9f","eb728b38dfb842778019260a7dd09801"],"originator_org_master_entity_id":["e9879b9929b30556ea87baf86ad6c3d3"],"disease_id":["90a4f0aa8f4745188895e0cf401c3cac","34fcc2e14284424e8069bdbbaa3a782c","08b527ea4af04680bbb0a81698cc5ccc","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"active_org_master_entity_id":["e9879b9929b30556ea87baf86ad6c3d3"],"research_disease":["90a4f0aa8f4745188895e0cf401c3cac","34fcc2e14284424e8069bdbbaa3a782c","08b527ea4af04680bbb0a81698cc5ccc","e255185bd59e4c2cbef67fd98444d16f","8f73c0a533f24a49aeae602d1ca70eb7"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1766102400000}}],"disease_phase":[{"disease_id":"90a4f0aa8f4745188895e0cf401c3cac","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"34fcc2e14284424e8069bdbbaa3a782c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8f73c0a533f24a49aeae602d1ca70eb7","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"e255185bd59e4c2cbef67fd98444d16f","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"08b527ea4af04680bbb0a81698cc5ccc","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"00ace29fed364d50b64cace453296b21","docid":1311184,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":19,"target_extend_id":"3a6b630e26753f5fbddf5c02262ecf73","created_ts":"2025-05-16T05:57:01.000Z","updated_ts":"2026-04-14T21:04:21.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"kongfengfeng","drug_name":[{"lang":"EN","name":"TQC3302","status":"ACTIVE"}],"dev_code":[{"name":"TQC3302","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["12435d7219e3736b19bcf1723bde56a6"],"mechanism_action_id":["931504f23ea44715a9ea324a47e0238d","d5c558daba719aadf8062b1bdbac2bd8"],"target_id":["32ac24079a8f47b18069eb35a1f9120d","449193bba3cd46bcad89d76a54d13d06"],"disease_id":["486c4f5995ae4425a9c98a48d22c84c8"],"active_org_master_entity_id":["662d46871bd6f6dc727ddefab40c2a06"],"research_disease":["486c4f5995ae4425a9c98a48d22c84c8"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1764028800000}}],"disease_phase":[{"disease_id":"486c4f5995ae4425a9c98a48d22c84c8","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0698c21a94884917aa24514156036f85","docid":26105,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","payload_id":"1c638a20aa7643b7a261c7bacb40d30a","specific_site":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"1476e466c3e63c30925f392a52f117d4","created_ts":"2022-11-17T05:36:51.000Z","updated_ts":"2026-02-25T00:11:57.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"BB-1709","source_info":[{"code":"CXSL2200580","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"2025_2243","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/8442"}],"status":"ACTIVE"}],"dev_code":[{"name":"BB 1709","status":"ACTIVE"},{"name":"BB-1709","status":"ACTIVE"},{"name":"BB1709","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["7e7714f820bda15820a7e476fc7bbf8c"],"mechanism_action_id":["386175739e781385056f9adccabac2e2","138f7edea9d70a30233e854b342a1eca"],"target_id":["15c6a4929a0c469194a5f637b112cc20","d9461748c4c54a0b84cbad2ae3fce7d5"],"adc_reference":[{"code":"2025_2243","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/8442"}],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5","15cb523e0fbd4617a6a129ad2336eb9a","bcf1e88b4cf44b2aae544df37a3fa411","7665e5683a1a443a8f3d3b946d4c9ca2","913534b87d4543e28eeb8a7215bb8ef4","06547f1d0758469d863d6a799b8e2e6b","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["7e7714f820bda15820a7e476fc7bbf8c","ea2fd45b4f9dbebdc5bd8dc4e2e07eab"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5","15cb523e0fbd4617a6a129ad2336eb9a","bcf1e88b4cf44b2aae544df37a3fa411","7665e5683a1a443a8f3d3b946d4c9ca2","913534b87d4543e28eeb8a7215bb8ef4","06547f1d0758469d863d6a799b8e2e6b","ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1698624000000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1696118400000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"06547f1d0758469d863d6a799b8e2e6b","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"bcf1e88b4cf44b2aae544df37a3fa411","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"b2ca28b01c34419db0365bad2f8dd09e","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"663756cd6b1039b79358d498b37069ae","payload_target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","moiety_mechanism_action_id":["386175739e781385056f9adccabac2e2"],"moiety_target_id":["15c6a4929a0c469194a5f637b112cc20"],"payload_target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"payload_mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"]}
+{"drug_id":"08a0b8241bed47a28f1652f84392a340","docid":113484,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":2,"target_extend_id":"30c29b16394737c3a65e74a8ad9cd913","created_ts":"2024-06-03T07:15:39.000Z","updated_ts":"2026-03-17T00:55:21.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"KK-8123","source_info":[{"attachment_path":"data/phs_source_info/2bdb/52ce/663e/f79e/4c7bb848-dbc8-36f9-80c7-e2d7abf15653.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/104c/b8b3/57ba/4b72/27b49089-7669-3a0f-b8ca-0fb05e923439.png","source":"Company pipeline","source_url":"https://www.kyowakirin.co.jp/research_development_production/pipeline/index.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"KK 8123","source_info":[{"attachment_path":"data/phs_source_info/2bdb/52ce/663e/f79e/4c7bb848-dbc8-36f9-80c7-e2d7abf15653.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/104c/b8b3/57ba/4b72/27b49089-7669-3a0f-b8ca-0fb05e923439.png","source":"Company pipeline","source_url":"https://www.kyowakirin.co.jp/research_development_production/pipeline/index.html"}],"status":"ACTIVE"},{"name":"KK8123","source_info":[{"attachment_path":"data/phs_source_info/2bdb/52ce/663e/f79e/4c7bb848-dbc8-36f9-80c7-e2d7abf15653.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/104c/b8b3/57ba/4b72/27b49089-7669-3a0f-b8ca-0fb05e923439.png","source":"Company pipeline","source_url":"https://www.kyowakirin.co.jp/research_development_production/pipeline/index.html"}],"status":"ACTIVE"}],"drug_type":["58846334b4a6496b83493429578a4faa"],"originator_org_master_entity_id":["991b8679b10cfec97390b0b52f7a43d0"],"mechanism_action_id":["b0fb82d5783af07e360cac6c0c167241"],"target_id":["0f046c93ffbd401c92d0161dede4dc88"],"disease_id":["f1ceb69a283e458885431366b4ee064a","6aa6642fa69a45c9a49e5b15076ef94f"],"active_org_master_entity_id":["991b8679b10cfec97390b0b52f7a43d0"],"research_disease":["f1ceb69a283e458885431366b4ee064a","6aa6642fa69a45c9a49e5b15076ef94f"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1728432000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1728432000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1728432000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1728432000000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1717372800000}}],"disease_phase":[{"disease_id":"f1ceb69a283e458885431366b4ee064a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6aa6642fa69a45c9a49e5b15076ef94f","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"32660410273549df9ffdaa4bdcd17ca8","docid":1763501,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2026-03-02T05:51:36.000Z","updated_ts":"2026-03-14T21:02:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"68Ga-BRP-020063","source_info":[{"code":"NCT07439120","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07439120"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["c4856da10e73bdc25680bb543c05936e"],"disease_id":["0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","3428d019f74042c9b04557aaa3f597e2"],"active_org_master_entity_id":["c4856da10e73bdc25680bb543c05936e"],"research_disease":["0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","3428d019f74042c9b04557aaa3f597e2"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"disease_phase":[{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"3428d019f74042c9b04557aaa3f597e2","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"3aea2ee37b964ae3912e14648cfc262f","docid":262144,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"payload_id":"2a066f0d1ba14bed8fd91beba8e7a06b","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-06-20T01:50:26.000Z","updated_ts":"2025-08-26T08:04:39.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"[68Ga] MDM2/MDMX Peptide","source_info":[{"code":"NCT06443762","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06443762"}],"status":"ACTIVE"}],"drug_type":["78e77521ce074022b4e14bc242b86549"],"originator_org_master_entity_id":["7597a5f65e482a0af413c1f07baef875"],"mechanism_action_id":["0749288ce5e4be2dc4dcdf9173d8f6b3"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["7597a5f65e482a0af413c1f07baef875"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1735862400000}}],"disease_phase":[{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"003c0d5940254f9cbdcf5f59cf54603d","docid":68476,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Tolciclate","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","rnk":10,"target_extend_id":"eda85188332533f5ae60e12736954408","created_ts":"2021-10-08T14:45:59.000Z","updated_ts":"2025-01-25T21:10:37.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"托西拉酯","status":"ACTIVE"},{"lang":"EN","name":"Tolciclate","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Tolciclate (JAN/USAN/INN)","source_info":[{"code":"D01384","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"dev_code":[{"name":"K-9147","status":"ACTIVE"},{"name":"KC-9147","status":"ACTIVE"}],"trade_name":[{"name":"Fungifos","status":"ACTIVE"},{"name":"Tolmicen","status":"ACTIVE"}],"generic_name":[{"name":"Tolciclate","source_info":[{"code":"D01384","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"}],"drugbank_id":["DB13360"],"kegg_id":["D01384"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["dabcb7640cda569e47307669cc7b0ad3"],"target_id":["20ac895372074d43874f0566b82cc78b"],"atc_code":["96c040a03796497ead61ddab45a6e902"],"disease_id":["47837684b8504b7abf69127ccc667c06"],"research_disease":["47837684b8504b7abf69127ccc667c06"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"47837684b8504b7abf69127ccc667c06","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"1af3a75bb73c418c8d53324e69b40867","docid":30258,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":7,"target_extend_id":"0e8c070b1927365bab8db36962be902a","created_ts":"2021-10-08T14:50:17.000Z","updated_ts":"2026-04-02T11:19:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"EN","name":"DTX-201","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"AAV-mediated Factor VIII gene therapy","status":"ACTIVE"}],"dev_code":[{"name":"BAY-2599023","status":"ACTIVE"},{"name":"DTX 201","status":"ACTIVE"}],"generic_name":[{"name":"Peboctocogene camaparvovec","source_info":[{"code":"PL124","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN"}],"status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["bd32ed5d49cc563a662a387eac1124be"],"mechanism_action_id":["f528c022040e058237c25862ead7101e","56f56431e88707dc608712608ad0cf88"],"target_id":["a5ce1e0cfc1b48ac8bcff32762c3c446"],"disease_id":["07d4cf59dafc4a35840dbf53e136394a"],"active_org_master_entity_id":["d94923980905512f8eac870e9ac6f983"],"research_disease":["07d4cf59dafc4a35840dbf53e136394a"],"inactive_org_master_entity_id":["54cf68c1f389120dcc82efa0bcd88014","b38b0ee39b29016f1daa2341f90e049d"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1541548800000}},{"country":"a7cb930b-9b67-3639-97cd-dab2ce82da83","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1541548800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1541548800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1541548800000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1541548800000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"country":"912d59cd-f1d3-3551-bae2-1f6f0062258f","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"disease_phase":[{"disease_id":"07d4cf59dafc4a35840dbf53e136394a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"4ce85fe112c74b4fae4b7b1ddd997016","docid":1730657,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":1,"target_extend_id":"2d34042863f93b64b981579702fb33a6","created_ts":"2025-08-13T09:01:23.000Z","updated_ts":"2026-01-27T10:50:09.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Humanized CD70-Targeted CAR-T Cell Incorporating TLR2(Tongji Hospital)","source_info":[{"code":"NCT07113977","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07113977"}],"status":"ACTIVE"}],"drug_type":["e9f267acd397430897163507bc9d735d"],"originator_org_master_entity_id":["38716acfc0018167235bc86c0f96ddb2"],"mechanism_action_id":["e0a0b70f83bc40c2b45d872d0fe4b7d4","cbdd288bfbef433c7b0a2c7d3c4925bb"],"target_id":["79d24e30a7ff40bb806ff36962c750e8","a54c204e786645f1aeab5220aac46e02"],"disease_id":["14143fc9923b41d9950a59ed79f7731a"],"active_org_master_entity_id":["38716acfc0018167235bc86c0f96ddb2"],"research_disease":["14143fc9923b41d9950a59ed79f7731a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"14143fc9923b41d9950a59ed79f7731a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"4d60d80784bc498180503db4496808e7","docid":1880133,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-12-10T10:24:13.000Z","updated_ts":"2026-02-25T06:56:51.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"CN","name":"NK细胞(北京平安普德生物)","source_info":[{"code":"ChiCTR1900021764","normalized_source_id":"2a39e1fb59c446568df2b08f80e3f6f0","source":"ChiCTR","source_url":"https://www.chictr.org.cn/showproj.html?proj=36112"}],"status":"ACTIVE"},{"lang":"EN","name":"NK cells(Beijing Ping'an Pude Biotechnology)","source_info":[{"code":"ChiCTR1900021764","normalized_source_id":"2a39e1fb59c446568df2b08f80e3f6f0","source":"ChiCTR","source_url":"https://www.chictr.org.cn/showproj.html?proj=36112"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["6bced0c66a419ebd62650105a179f653"],"disease_id":["be26bd5a3626417eabc7fde7a7b8b3d9"],"active_org_master_entity_id":["6bced0c66a419ebd62650105a179f653"],"research_disease":["be26bd5a3626417eabc7fde7a7b8b3d9"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1547164800000}}],"disease_phase":[{"disease_id":"be26bd5a3626417eabc7fde7a7b8b3d9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"08b3c494a70543d0a84c937226b37a6e","docid":68651,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:49:07.000Z","updated_ts":"2026-02-25T00:27:00.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN(Papivax Biotech, Inc.)","status":"ACTIVE"}],"dev_code":[{"name":"PVX 2","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/801534"}],"status":"ACTIVE"},{"name":"PVX-2","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/801534"}],"status":"ACTIVE"}],"drug_type":["7a3a1268f4944eeba114699b1c784746","7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["11b05ea5f487f5a434f3fdfde46d1e0a"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["86c9dec6885345009f177cb20378fa62","f9b845222b9b44a4b0b8807177b74961","d2ee0aa5e8a2440585e9a218d193b710","54a5e060a5bd4e05a7b9bc28bad56533"],"active_org_master_entity_id":["5a3bef9be7157c8c61731090e78376d7","11b05ea5f487f5a434f3fdfde46d1e0a"],"research_disease":["86c9dec6885345009f177cb20378fa62","f9b845222b9b44a4b0b8807177b74961","d2ee0aa5e8a2440585e9a218d193b710"],"non_research_disease":["54a5e060a5bd4e05a7b9bc28bad56533"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1697587200000}}],"disease_phase":[{"disease_id":"d2ee0aa5e8a2440585e9a218d193b710","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"54a5e060a5bd4e05a7b9bc28bad56533","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"86c9dec6885345009f177cb20378fa62","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f9b845222b9b44a4b0b8807177b74961","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0376352ed1434efd918590d2c86b4330","docid":45025,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"4ba5258aed7c47dba5f482bdfe259bb7","registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":3,"target_extend_id":"0dd1683f4d093becb02134970d0415a1","created_ts":"2021-10-08T14:42:46.000Z","updated_ts":"2026-04-16T08:20:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"Surzebiclimab","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Humanised IgG1-variant monoclonal antibody against TIM-3","status":"ACTIVE"}],"dev_code":[{"name":"BGB A425","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/surzebiclimab"}],"status":"ACTIVE"},{"name":"BGB-A425","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/surzebiclimab"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["4d16a460eb330b401d69b3103739c2fd"],"mechanism_action_id":["de58f400c11de83497e4b30d1c361dcb"],"target_id":["876f2d06b8634b6ba8c67fcdb9bb7a6b"],"disease_id":["6570754a6f0b43b78a9926c7bfd00519","3beea980d93a4cc0abc864e27514601c","6fe05469e09f4305b7615b2c277382cd"],"active_org_master_entity_id":["4d16a460eb330b401d69b3103739c2fd","4ff225787808941abe548bf6a8cd83eb"],"research_disease":["6570754a6f0b43b78a9926c7bfd00519","3beea980d93a4cc0abc864e27514601c","6fe05469e09f4305b7615b2c277382cd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"114d705b-6e33-3c5f-8b53-50890ffa0aed","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"00d7d9ab-3d75-3fa9-9849-2f715d69f010","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"48025ffd-0936-3c82-a14a-d131d06461f0","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1576713600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1542067200000}}],"disease_phase":[{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"40d4d50c24a341c29f72ff93bee09c53","docid":1249997,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":204,"target_extend_id":"8c9d87c51a6f35639835c9df30cd1564","created_ts":"2025-03-25T07:56:02.000Z","updated_ts":"2026-04-18T21:04:15.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"BiTE-EV","source_info":[{"code":"NCT06890494","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06890494"}],"status":"ACTIVE"}],"dev_code":[{"name":"BiTE-EV","source_info":[{"code":"NCT06890494","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06890494"}],"status":"ACTIVE"}],"drug_type":["6e43c7fb400c4fda8d8693f12241cc09"],"originator_org_master_entity_id":["5a1e5cbb0de12fd41dff50a5d99f9508"],"mechanism_action_id":["59e827e69bbc5091c37f33d9798f8c02"],"target_id":["fe50c9b7f38746beb4bfd1ae9fa6fd1b"],"disease_id":["c45e529e87834fd582bfd557c409028d"],"active_org_master_entity_id":["5a1e5cbb0de12fd41dff50a5d99f9508"],"research_disease":["c45e529e87834fd582bfd557c409028d"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1737158400000}}],"disease_phase":[{"disease_id":"c45e529e87834fd582bfd557c409028d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"03a5687fb0984f169e5aa47eb2e2c04c","docid":9493,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"e6438687ed214800bb98742ebbeb70a1","created_ts":"2022-06-15T06:22:29.000Z","updated_ts":"2025-05-15T19:56:57.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"SY-201","status":"ACTIVE"}],"dev_code":[{"name":"SY 201","status":"ACTIVE"},{"name":"SY-201","status":"ACTIVE"},{"name":"SY201","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["06d18e2c8fdaec21960c199bf17b42bf"],"disease_id":["3271242b681840bcbd5ad0e4baee0770"],"active_org_master_entity_id":["d4b145a5354ec022bfbde783f8cb5f69","06d18e2c8fdaec21960c199bf17b42bf"],"research_disease":["3271242b681840bcbd5ad0e4baee0770"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1658707200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1666137600000}}],"disease_phase":[{"disease_id":"3271242b681840bcbd5ad0e4baee0770","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"08f0d2c1e0d4453f9048c8ec1bcf9848","docid":6281,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","rnk":4,"target_extend_id":"d28e9a9705463206b1cc1355c91b84a7","created_ts":"2021-10-08T14:50:40.000Z","updated_ts":"2026-02-07T00:36:36.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Caficrestat","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/applied-therapeutics-reports-second-quarter-2023-financial-results/"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"DNAJP1","status":"ACTIVE"},{"lang":"EN","name":"dnaJ peptide","status":"ACTIVE"}],"dev_code":[{"name":"AT-001","source_info":[{"code":"2020_1080-P","normalized_source_id":"bbfdbc5a21b7404786b7338922bbbc1c","source":"ADA","source_url":"https://diabetesjournals.org/diabetes/article/69/Supplement_1/1080-P/60850/1080-P-Addressing-the-Safety-Challenges-of-Aldose"}],"status":"ACTIVE"},{"name":"AT-001(Applied Therapeutics)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.biospace.com/article/releases/applied-therapeutics-reports-second-quarter-2023-financial-results/"}],"status":"ACTIVE"},{"name":"AT001(Applied Therapeutics)","status":"ACTIVE"}],"drugbank_id":["DB15121"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["2ccaea76c0ac01d9cab919d9eef9a314"],"mechanism_action_id":["9d4cb87c917ba171d12b9e9272f075f1"],"target_id":["570e68036eb64d9fbad53996e1ddb107"],"disease_id":["326277c586904a7cb346cea06228f6fe","c8e43d2b48ec49dba16418bc190a3eec","6559fc2117eb4da5bfb0e421044902b8"],"active_org_master_entity_id":["2ccaea76c0ac01d9cab919d9eef9a314"],"research_disease":["326277c586904a7cb346cea06228f6fe","c8e43d2b48ec49dba16418bc190a3eec","6559fc2117eb4da5bfb0e421044902b8"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274","c8df5dce70fd4e0cb3320058ddb95461","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1568937600000}}],"disease_phase":[{"disease_id":"326277c586904a7cb346cea06228f6fe","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c8e43d2b48ec49dba16418bc190a3eec","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"6559fc2117eb4da5bfb0e421044902b8","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["27691575a0fe5b3219a34943d30d8c5d","2ccaea76c0ac01d9cab919d9eef9a314"],"data_source":10}
+{"drug_id":"02a63f544e1145afb3cab1052f20d06f","docid":52425,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"fc29f45629e83061b7f7e8ba13e0442e","created_ts":"2022-06-24T07:41:02.000Z","updated_ts":"2026-02-24T19:28:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MKP-10241","status":"ACTIVE"}],"dev_code":[{"name":"MKP-10241","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["34a2b6b985ad248e4dbe55416748fec6"],"mechanism_action_id":["dae49d7b4ae1acee99c29c4cd2cc5aad"],"target_id":["b4b209ac8a7341189848500477d9b108"],"disease_id":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814","5f9b48cc2f9b482b960830e9d2d84fe3"],"active_org_master_entity_id":["34a2b6b985ad248e4dbe55416748fec6"],"research_disease":["74d974da49ba407195b38595a0aff704","05ee0bc5347a4677a95179fcdcc2b814","5f9b48cc2f9b482b960830e9d2d84fe3"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1754956800000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1632096000000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"5f9b48cc2f9b482b960830e9d2d84fe3","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"data_source":10}
+{"drug_id":"10a3b55c2c214496950e50cf83a15764","docid":1641538,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-08-29T06:59:16.000Z","updated_ts":"2025-08-29T07:36:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Oncolytic virus(Mianyang Central Hospital)","source_info":[{"code":"NCT07145047","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07145047"}],"status":"ACTIVE"}],"drug_type":["9f49b619f70a4d3ca6420b40e6e43b0b"],"originator_org_master_entity_id":["10c13d318b1cc91f5d78ea3fc731d841"],"disease_id":["fc0780b4f42b41d0a3dbbc522d0724dd"],"active_org_master_entity_id":["10c13d318b1cc91f5d78ea3fc731d841"],"research_disease":["fc0780b4f42b41d0a3dbbc522d0724dd"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1698883200000}}],"disease_phase":[{"disease_id":"fc0780b4f42b41d0a3dbbc522d0724dd","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"018bf1913a89461bb4ccea430c793b90","docid":36274,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:34.000Z","updated_ts":"2025-08-21T00:21:29.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"LAUR-301","status":"ACTIVE"}],"dev_code":[{"name":"LAUR-301","status":"ACTIVE"}],"drug_type":["ff9477ffcb8346d59008ad9f2027fd57"],"originator_org_master_entity_id":["7af8ca3eb47deeb543a7e399931c544e"],"disease_id":["738546bac89e4895b89af01545f1b054"],"active_org_master_entity_id":["7af8ca3eb47deeb543a7e399931c544e"],"research_disease":["738546bac89e4895b89af01545f1b054"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1650240000000}}],"disease_phase":[{"disease_id":"738546bac89e4895b89af01545f1b054","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"03eef01d24da482eb348d33de3a5f2d1","docid":7387,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"b9db7f2839d83145bdc8ad720251bfd1","created_ts":"2021-10-08T14:42:12.000Z","updated_ts":"2026-02-24T16:19:48.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"透明质酸/氟尿嘧啶","status":"ACTIVE"},{"lang":"EN","name":"Hyaluronic acid/Fluorouracil","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"HA-5-fluorouracil","status":"ACTIVE"},{"lang":"EN","name":"Hyaluronan acid-5-fluorouracil complex","status":"ACTIVE"},{"lang":"EN","name":"Hyaluronic acid-5-fluorouracil complex","status":"ACTIVE"}],"dev_code":[{"name":"HA-5FU","status":"ACTIVE"}],"trade_name":[{"name":"HyFIVE","status":"ACTIVE"}],"related_component":["acb180ab9ed14a1c813303c96efb1f79","c977e47aa52d494c9c869e9999347807"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9449ccebc717d597eaf0601aad2e1ebf"],"mechanism_action_id":["b31d4f12f395c5e01e0a95894647d841","c2b0909d5ec4f04f4d218553536d81a7"],"target_id":["18690e7233e94f648419371447a2c183","7794e53ee5cb4daeb3d692d42bfb9566"],"disease_id":["7665e5683a1a443a8f3d3b946d4c9ca2"],"active_org_master_entity_id":["4b183294306e5005790ac62a79b15ab2","9449ccebc717d597eaf0601aad2e1ebf"],"research_disease":["7665e5683a1a443a8f3d3b946d4c9ca2"],"inactive_org_master_entity_id":["a6199b158d7fdd71b8a4f05d59841c15"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1515024000000}}],"disease_phase":[{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"08808abc15b54958953b637f349793d3","docid":269031,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2025-01-22T06:39:06.000Z","updated_ts":"2026-04-08T06:31:33.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"异体人再生胰岛","status":"ACTIVE"},{"lang":"EN","name":"E-islet 01","status":"ACTIVE"}],"dev_code":[{"name":"E-islet 01","status":"ACTIVE"}],"drug_type":["66885963f5e941ab98eea63d94c81fd9"],"originator_org_master_entity_id":["b3b2da36096589d4e9cd72165db9a814"],"disease_id":["79d0927ec2f84e79a7fcccb69a7ef9fd","1dec6017bd924aff8aeae6e7d4a3f874"],"active_org_master_entity_id":["b3b2da36096589d4e9cd72165db9a814"],"research_disease":["79d0927ec2f84e79a7fcccb69a7ef9fd","1dec6017bd924aff8aeae6e7d4a3f874"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1754870400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1754006400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1768521600000}}],"disease_phase":[{"disease_id":"1dec6017bd924aff8aeae6e7d4a3f874","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"79d0927ec2f84e79a7fcccb69a7ef9fd","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"10a0e81027e64c6d9698b3152533e23f","docid":9643,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2023-02-23T10:45:21.000Z","updated_ts":"2026-01-10T03:32:27.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"wangya","drug_name":[{"lang":"CN","name":"人脐带间充质干细胞（天士力医药）","status":"ACTIVE"},{"lang":"EN","name":"Human cord derived MSC cell (Tasly Pharmaceutical)","source_info":[{"code":"CXSL2300152","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"B2278","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=Mzk0MzEzNjg4NQ==&mid=2247490941&idx=1&sn=f42941d12469c9249681e68c174737f8"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["1303e7e203d6cccc8f5b09664d4eafe2"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["c2c96e5bbe6949eda9849bc07a6b4d60","844fd18e67cf44a9bc6ee9d7fde7574c"],"active_org_master_entity_id":["1303e7e203d6cccc8f5b09664d4eafe2"],"research_disease":["c2c96e5bbe6949eda9849bc07a6b4d60","844fd18e67cf44a9bc6ee9d7fde7574c"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1766707200000}}],"disease_phase":[{"disease_id":"844fd18e67cf44a9bc6ee9d7fde7574c","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c2c96e5bbe6949eda9849bc07a6b4d60","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"1a662fcb8ba544d9b57eaa3aaa6597ac","docid":38027,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":37,"target_extend_id":"810617e55d723c57b4583e28f109c868","created_ts":"2021-12-15T05:21:27.000Z","updated_ts":"2026-04-04T21:09:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"泰泽苏拜单抗","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"http://www.immuneonco.com/science/pdtpipeline/34.html#SPPDetails"}],"status":"ACTIVE"},{"lang":"EN","name":"Tazlestobart","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"http://cn.immuneonco.com/science/pdtpipeline/34.html#SPPDetails"}],"status":"ACTIVE"}],"dev_code":[{"name":"AXN 27M","source_info":[{"attachment_path":"data/phs_source_info/0c4e/dcf3/e6d3/b35f/0c4edcf3e6d3b35f.jpg","attachment_type":"image/jpeg","code":"Instil-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/4561/e921/e1e9/3a34/4561e921e1e93a34.jpg","source":"Company pipeline","source_url":"https://instilbio.com/pipeline/"}],"status":"ACTIVE"},{"name":"AXN-27M","source_info":[{"attachment_path":"data/phs_source_info/0c4e/dcf3/e6d3/b35f/0c4edcf3e6d3b35f.jpg","attachment_type":"image/jpeg","code":"Instil-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/4561/e921/e1e9/3a34/4561e921e1e93a34.jpg","source":"Company pipeline","source_url":"https://instilbio.com/pipeline/"}],"status":"ACTIVE"},{"name":"AXN27M","source_info":[{"attachment_path":"data/phs_source_info/0c4e/dcf3/e6d3/b35f/0c4edcf3e6d3b35f.jpg","attachment_type":"image/jpeg","code":"Instil-202503","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/4561/e921/e1e9/3a34/4561e921e1e93a34.jpg","source":"Company pipeline","source_url":"https://instilbio.com/pipeline/"}],"status":"ACTIVE"},{"name":"IMM 27M","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"IMM-27M","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"IMM27M","source_info":[{"code":"CXHL2101533","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"name":"SYN-27M","source_info":[{"normalized_source_id":"fdf31f49b90640ea9fc09453c7711824","source":"Corporate Publications","source_url":"https://basic.10jqka.com.cn/ajax/usaph/pubDetail/247d08394f4d3dfe_translation"}],"status":"ACTIVE"},{"name":"SYN27M","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["79a11bcf1eacb6dc40da6bd997cc1eb9"],"mechanism_action_id":["702fa47e9a71b31550c38470d2204ce9","569d7324d3bdd73cc1b9e225fdfc8d5f"],"target_id":["664d9478c81b4059b32f286b5047416c"],"disease_id":["11c9483b13174c4686fd04f48dc66b92","7fb8ceff333b48e8adea2c0803494a48","0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","7665e5683a1a443a8f3d3b946d4c9ca2","87a9454771a64f2191224b6b7684254a","c1cc2528f29940fc95fd6bc37eb982d4","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","c7fe8aa844d24e85ba32a990ea28ded3","8d29f554f371431c9b5b80f5befdf965","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["79a11bcf1eacb6dc40da6bd997cc1eb9","8d7e45cec3de4f792b7b56cdc1525820"],"research_disease":["11c9483b13174c4686fd04f48dc66b92","7fb8ceff333b48e8adea2c0803494a48","0464f5493b0444e9875a0584df17cbf0","6c9c5be211cb4d72a28205c49a16d653","7665e5683a1a443a8f3d3b946d4c9ca2","87a9454771a64f2191224b6b7684254a","c1cc2528f29940fc95fd6bc37eb982d4","c297238c41b2488abe3de6546b105a4e","ae092fa59f4d44edaf59ffe23d0a44c3","c7fe8aa844d24e85ba32a990ea28ded3","8d29f554f371431c9b5b80f5befdf965","6fe05469e09f4305b7615b2c277382cd","f92e4ba771d04f27a1f4daae363b676a","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1753142400000}}],"disease_phase":[{"disease_id":"11c9483b13174c4686fd04f48dc66b92","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"8d29f554f371431c9b5b80f5befdf965","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ae092fa59f4d44edaf59ffe23d0a44c3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c7fe8aa844d24e85ba32a990ea28ded3","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7fb8ceff333b48e8adea2c0803494a48","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["3c8043bdf8a8f257be1dda38813b74fe","79a11bcf1eacb6dc40da6bd997cc1eb9","8d7e45cec3de4f792b7b56cdc1525820"],"if_speculate":0,"data_source":10}
+{"drug_id":"0ebad289aac54fe5acae030620899652","docid":1700255,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2025-07-23T10:01:36.000Z","updated_ts":"2025-07-23T11:04:12.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"TamavaqTM NeoVaccine(Biogenea Pharmaceuticals)","source_info":[{"code":"NCT07077616","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07077616"}],"status":"ACTIVE"}],"drug_type":["7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["f2fd32254fd1896760fbabfe39e4f329"],"disease_id":["0a885de5b4054c2b98d478f91f3e3418"],"active_org_master_entity_id":["f2fd32254fd1896760fbabfe39e4f329"],"research_disease":["0a885de5b4054c2b98d478f91f3e3418"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1751328000000}}],"disease_phase":[{"disease_id":"0a885de5b4054c2b98d478f91f3e3418","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"41f39378396f4020800d5712decf0ac2","docid":1279975,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":2,"target_extend_id":"646378572145348bb840077820c4a797","created_ts":"2025-03-24T02:12:16.000Z","updated_ts":"2025-05-28T10:54:09.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"CD83-positve human umbilical cord mesenchymal stem cells(Daping Hospital)","source_info":[{"code":"NCT06882811","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06882811"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CD83-positve MSC(Daping Hospital)","source_info":[{"code":"NCT06882811","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06882811"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["bcecb106d6d1921b08e5ab0ca083383b"],"mechanism_action_id":["6de734caf64f4dadbd4801e1d0a348fd"],"target_id":["97482715f2ff493e9b328042bb6d825e"],"disease_id":["7cf66a4af7ac4b51b888c59d7e30a2c4"],"active_org_master_entity_id":["bcecb106d6d1921b08e5ab0ca083383b"],"research_disease":["7cf66a4af7ac4b51b888c59d7e30a2c4"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1747872000000}}],"disease_phase":[{"disease_id":"7cf66a4af7ac4b51b888c59d7e30a2c4","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"if_speculate":0,"data_source":10}
+{"drug_id":"17895b52f6784d3da6ef62136108feac","docid":1643462,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"d08ce314c98e4f7fb9b4af6d2b443bc4","is_pathway":1,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","created_ts":"2025-12-17T05:20:22.000Z","updated_ts":"2025-12-17T05:22:12.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"CN","name":"流感病毒裂解疫苗（民海生物）","status":"ACTIVE"},{"lang":"EN","name":"Influenza Vaccine(Inactivated, split)(Beijing Minhai)","status":"ACTIVE"}],"drug_type":["00458ff770344a2b962324da6b29d16f","8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["1c2414a4bb7240c190cbeaafe12c0648"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"atc_code":["6bccb55cc5bf4f7d8d554d1d7107cda8"],"disease_id":["2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["c07eb244da5082a671fd4397254bb14e"],"research_disease":["2a8a3f6ab7ec4061858144283e7ce0ca"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1758672000000}}],"disease_phase":[{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0988c1535002497b9ea66b41289f4aab","docid":54207,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"8f2cfdd1633c35998c413c470457415d","created_ts":"2021-10-08T14:48:05.000Z","updated_ts":"2026-02-24T16:45:33.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wangyufu","drug_name":[{"lang":"CN","name":"安基奥仑赛","status":"ACTIVE"},{"lang":"EN","name":"Anbalcabtagene autoleucel","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anbal-cel","status":"ACTIVE"},{"lang":"EN","name":"Anti-CD19 CAR-T therapy - Curocell","status":"ACTIVE"}],"dev_code":[{"name":"CRC 01","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anbalcabtagene-autoleucel"}],"status":"ACTIVE"},{"name":"CRC-01","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anbalcabtagene-autoleucel"}],"status":"ACTIVE"},{"name":"CRC01","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anbalcabtagene-autoleucel"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["74a25e9b26a1311d73259a7c3e15b567"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a","4dd338b149b3ecd0ee860e1fb379b44f","054e8d3f5e89d1ba5bc975d4614a6141","d9627d77b8d00d879e22e88877e54736","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["5eb1fc5283d34305934a031af530f448","9786d32e3d244a688ec6a60d2fe1b10b","369b0d8bda6c4e7e9bfa08bbabd60f0d"],"disease_id":["0e0dca4dd7f1499a8f65f4fdfcf09954","8cb614b11c9342c4a95baba4d699177d","cd4227aef4c54f77ad3046625b9987dc","0c8a0603507542faac6b5ef3e27c6728","e89afc6a432744b1a88281329dc46d91","a622cec9c1e34e88a3c46c3b7fa00884","c17d3b80f53e409c930fc2d37ed244ec"],"active_org_master_entity_id":["74a25e9b26a1311d73259a7c3e15b567","a06f58477a2ed19c6fa0e04e34968814"],"research_disease":["0e0dca4dd7f1499a8f65f4fdfcf09954","8cb614b11c9342c4a95baba4d699177d","cd4227aef4c54f77ad3046625b9987dc","0c8a0603507542faac6b5ef3e27c6728","e89afc6a432744b1a88281329dc46d91","a622cec9c1e34e88a3c46c3b7fa00884","c17d3b80f53e409c930fc2d37ed244ec"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1762905600000}}],"disease_phase":[{"disease_id":"a622cec9c1e34e88a3c46c3b7fa00884","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"8cb614b11c9342c4a95baba4d699177d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"cd4227aef4c54f77ad3046625b9987dc","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e89afc6a432744b1a88281329dc46d91","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"c17d3b80f53e409c930fc2d37ed244ec","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0c8a0603507542faac6b5ef3e27c6728","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"09618567f2e94499ba9060364cf05fd3","docid":67837,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":16,"target_extend_id":"6b8ac8f9502b31a6b8d1b591abe4a174","created_ts":"2023-06-12T05:42:49.000Z","updated_ts":"2026-04-19T00:30:09.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Turenkibart","source_info":[{"code":"NCT05894707","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05894707"},{"code":"pl131","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN","source_url":"https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl131.pdf?sfvrsn=ba04dc1b_5&download=true"},{"code":"CN114286827B","normalized_source_id":"e8b9d4e5a1b040ef8ec077af2bac85dd","source":"Patent","source_url":"https://synapse.zhihuiya.com/patent/6380cd39-23b2-47ef-a0ff-701772cc6c3d"}],"status":"ACTIVE"}],"dev_code":[{"name":"SCT650C","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["75fd61a30802f9048e7d1d25b614b764"],"mechanism_action_id":["529b9d60826a4c1a5765e42277efc255"],"target_id":["9b99b0dfb49c480fae5688010b373f83"],"disease_id":["d281a3b362a740d8aeb63e2a10102671","7a92f69cdbd343dea8043ec3c078dbc0","6be96778ed424f8d91de00ab82364114","4712857948a346d3afcae1e72a543e4c","8da973b225c24afbba255413635fb240","1f54367dda3b44f590bf2e196f85ff93"],"active_org_master_entity_id":["75fd61a30802f9048e7d1d25b614b764","ec2861a7b6ea38a5daef664b97e69916"],"research_disease":["d281a3b362a740d8aeb63e2a10102671","7a92f69cdbd343dea8043ec3c078dbc0","6be96778ed424f8d91de00ab82364114","4712857948a346d3afcae1e72a543e4c","8da973b225c24afbba255413635fb240","1f54367dda3b44f590bf2e196f85ff93"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","63ed6e7cb91a42928300df21dd9d3ac1","9a802adb6e94433f8f4eb9be678991b8","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764201600000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1719792000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1716768000000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1685577600000}}],"disease_phase":[{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"1f54367dda3b44f590bf2e196f85ff93","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6be96778ed424f8d91de00ab82364114","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"8da973b225c24afbba255413635fb240","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"4712857948a346d3afcae1e72a543e4c","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"7a92f69cdbd343dea8043ec3c078dbc0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"2fd57b8c9f2949c7a02b314933730ff8","docid":115836,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","rnk":152,"target_extend_id":"e49efee164e537c2a4ba9cec109e0adb","created_ts":"2024-10-24T08:39:58.000Z","updated_ts":"2026-04-11T21:04:56.000Z","data_status":"ACTIVE","created_by":"zhangzhengzheng@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)","source_info":[{"code":"NCT04194931","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04194931"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Autologous BCMA CAR-T cell(The First Affiliated Hospital of Nanchang University)","source_info":[{"code":"NCT04194931","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04194931"}],"status":"ACTIVE"}],"dev_code":[{"name":"CG-105-12","source_info":[{"code":"NCT06999031","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06999031"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["f66f92729a5a1e6536bd45eff0483296"],"mechanism_action_id":["05c361c13a65003a2be6fed62b2276a1"],"target_id":["aea9fa6f45bb4e48859be4110f70547b"],"disease_id":["e10523d5d50e41f6841de149d8b794b7","bf27abf8e60a4af4a578cedc875e80b9"],"active_org_master_entity_id":["bfdd81c4feba34b6c8136e7d4798b2b1"],"research_disease":["e10523d5d50e41f6841de149d8b794b7"],"non_research_disease":["bf27abf8e60a4af4a578cedc875e80b9"],"inactive_org_master_entity_id":["f66f92729a5a1e6536bd45eff0483296"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1725494400000}}],"disease_phase":[{"disease_id":"e10523d5d50e41f6841de149d8b794b7","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"bf27abf8e60a4af4a578cedc875e80b9","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2bfbaae39a6c4b8f870ad59e3654deea","docid":8836,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2021-12-10T12:54:30.000Z","updated_ts":"2024-11-08T12:46:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"huangxingyu","drug_name":[{"lang":"EN","name":"ZKGZ-005","status":"ACTIVE"}],"dev_code":[{"name":"ZKGZ 005","status":"ACTIVE"},{"name":"ZKGZ005","status":"ACTIVE"}],"drug_type":["06bc75afc2f44364a9663730fa37c37a"],"originator_org_master_entity_id":["5806922764071ed82a9c6e6283111271"],"disease_id":["2e52db813eb94143a5488cb1b73f87b5"],"active_org_master_entity_id":["9a998e8040d286c07ca6bec440f12fc8"],"research_disease":["2e52db813eb94143a5488cb1b73f87b5"],"therapeutic_area":["63ed6e7cb91a42928300df21dd9d3ac1"],"disease_phase":[{"disease_id":"2e52db813eb94143a5488cb1b73f87b5","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"081a4c9d18314534bf4546e0cbce16a3","docid":440544,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2024-12-04T02:39:50.000Z","updated_ts":"2026-01-06T05:57:03.000Z","data_status":"ACTIVE","created_by":"xinghaiyan2@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"ENV-308","source_info":[{"attachment_path":"data/phs_source_info/e7d4/c143/f512/0442/e7d4c143f5120442.png","attachment_type":"image/png","code":"Enveda-202512","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/37a1/8a61/a404/edff/37a18a61a404edff.png","source":"Company pipeline","source_url":"https://enveda.com/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ENV308","source_info":[{"attachment_path":"data/phs_source_info/8b87/bc98/4459/a5d2/5a5da381-7fb1-3f96-a58b-26d2e3531f39.jpg","attachment_type":"image/jpeg","code":"Enveda-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/b045/d5f9/5d23/5a98/daab16ff-4455-3a28-9f29-2e286f3c7962.jpg","source":"Company pipeline","source_url":"https://enveda.com/pipeline/"}],"status":"ACTIVE"},{"name":"ESN-O","source_info":[{"attachment_path":"data/phs_source_info/8b87/bc98/4459/a5d2/5a5da381-7fb1-3f96-a58b-26d2e3531f39.jpg","attachment_type":"image/jpeg","code":"Enveda-202412","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/b045/d5f9/5d23/5a98/daab16ff-4455-3a28-9f29-2e286f3c7962.jpg","source":"Company pipeline","source_url":"https://enveda.com/pipeline/"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["05895534f8102d71cb72bc126837cdb9"],"disease_id":["05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["05895534f8102d71cb72bc126837cdb9"],"research_disease":["05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"2cce3795dd60468c9eab7288559c0ad2","docid":815,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","rnk":39,"target_extend_id":"c1ac453247713a2aad9d306341865992","created_ts":"2022-06-24T02:53:31.000Z","updated_ts":"2026-04-11T21:06:44.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Anti-CD19 CART cell therapy (YaKe Biotechnology)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Anti-CD19 chimeric antigen receptor T cell therapy - Yake Biotechnology","status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["65adf3c1dca5ffe3f67583f2a393cb1d"],"mechanism_action_id":["2ac451946966904ac6da0d54008cdd9a","0f645f87bd7a67c4e2f1daff28d19421"],"target_id":["5eb1fc5283d34305934a031af530f448"],"disease_id":["399e275f8a1540159276f95612ad43b6","0e0dca4dd7f1499a8f65f4fdfcf09954","00e8490d2faa487b9b82530708f78d21","1d9cb4fabfc74fc49d342c14c9ff3b1a","7593fb8265c54bdc9ccfb7bc788785dc","c45e529e87834fd582bfd557c409028d","321c439bbe614dc2afd13cb803a48cec","1d78cca79eae4632bc4464c90a574f83","d7a26da8f1ff43559e34fe72da812c56","a425e59e374549b7bd0f75605eba80c8","7efab03e4b4847ebacf875d1285d615e","36609fa8bece4207b887d409854a3271"],"active_org_master_entity_id":["90163e2d1d85519e993176af80281cd8","65adf3c1dca5ffe3f67583f2a393cb1d"],"research_disease":["399e275f8a1540159276f95612ad43b6","0e0dca4dd7f1499a8f65f4fdfcf09954","00e8490d2faa487b9b82530708f78d21","1d9cb4fabfc74fc49d342c14c9ff3b1a","7593fb8265c54bdc9ccfb7bc788785dc","c45e529e87834fd582bfd557c409028d","321c439bbe614dc2afd13cb803a48cec","1d78cca79eae4632bc4464c90a574f83","d7a26da8f1ff43559e34fe72da812c56","a425e59e374549b7bd0f75605eba80c8"],"non_research_disease":["7efab03e4b4847ebacf875d1285d615e","36609fa8bece4207b887d409854a3271"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","76732dd51f2842799e6843eef80820ea","5b1dfc2ca8564662860187aef864467d","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","fce2b462d4fa493eb9d82513b9007011","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1764460800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1606953600000}}],"disease_phase":[{"disease_id":"7593fb8265c54bdc9ccfb7bc788785dc","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"00e8490d2faa487b9b82530708f78d21","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"399e275f8a1540159276f95612ad43b6","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"d7a26da8f1ff43559e34fe72da812c56","highest_phase_before_ter_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"1d78cca79eae4632bc4464c90a574f83","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"7efab03e4b4847ebacf875d1285d615e","highest_phase_before_ter_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_before_ter_global":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"c45e529e87834fd582bfd557c409028d","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"36609fa8bece4207b887d409854a3271","highest_phase_before_ter_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"0e0dca4dd7f1499a8f65f4fdfcf09954","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"321c439bbe614dc2afd13cb803a48cec","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"a425e59e374549b7bd0f75605eba80c8","highest_phase_global":"055a60cf40bb4b4eb69c41b492c45a03"},{"disease_id":"1d9cb4fabfc74fc49d342c14c9ff3b1a","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"00bad63eb9df49efa64beab7525e77d5","docid":71386,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1420070400000,"rnk":7,"target_extend_id":"bd3af5370e35377b8e8a7900fb50456e","created_ts":"2021-10-08T14:39:33.000Z","updated_ts":"2025-11-26T05:25:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"重组人血小板生成素生物类似药(Biolotus Biotech Ltda.)","status":"ACTIVE"},{"lang":"EN","name":"Recombinant human thrombopoietin biosimilar(Biolotus Biotech Ltda.)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Recombinant human thrombopoietin","status":"ACTIVE"},{"lang":"EN","name":"TPO","status":"ACTIVE"},{"lang":"EN","name":"ZYPOTIN-TPO","status":"ACTIVE"},{"lang":"EN","name":"rhTPO","status":"ACTIVE"}],"drugbank_id":["DB16364"],"drug_type":["9f2e2934e5b2477e916cdbedf928934b","be1042327c9746ba938a106be15c8b0b"],"originator_org_master_entity_id":["755f14f1c1b2e5bafa1688ef90adbf0b"],"mechanism_action_id":["4fcadafd505e2dd7760a740c1f68d520"],"target_id":["29924b0ca79a48c6ab78f090e6aa5ae4"],"atc_code":["31d8e37caf8c4415baedb063d41ac96a"],"disease_id":["e5f253250473456d96564776882bd28f"],"active_org_master_entity_id":["755f14f1c1b2e5bafa1688ef90adbf0b"],"first_approved_country":["bb1d5b11-d9f8-31c4-872c-65a9fad8d193"],"first_approved_indication":["e5f253250473456d96564776882bd28f"],"research_disease":["e5f253250473456d96564776882bd28f"],"therapeutic_area":["5b1dfc2ca8564662860187aef864467d"],"approval_country":["bb1d5b11-d9f8-31c4-872c-65a9fad8d193"],"research_country":[{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1420070400000}}],"disease_phase":[{"disease_id":"e5f253250473456d96564776882bd28f","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["c15eaddcf43a4a22979d0a37ce4d32a3"],"data_source":10}
+{"drug_id":"069c054f93a04ff693cc44cf6e191c00","docid":11811,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e6438687ed214800bb98742ebbeb70a1","created_ts":"2023-03-14T06:00:10.000Z","updated_ts":"2026-01-15T03:10:09.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"JCXH-108","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.immorna.com/cn/pipeline.html"}],"status":"ACTIVE"}],"alias":[{"lang":"CN","name":"RSV mRNA疫苗","source_info":[{"code":"CXSL2500920","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"dev_code":[{"name":"JCXH 108","status":"ACTIVE"},{"name":"JCXH108","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","e24259c0e9fe439b8b8fb5985182a517"],"originator_org_master_entity_id":["7786712171524c6d779f4ae2e33057b2"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["7786712171524c6d779f4ae2e33057b2"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1727222400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1768262400000}}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10}
+{"drug_id":"080c7452f56a48d78f909a712d6a4e26","docid":33086,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","has_leading_org_involved":1,"created_ts":"2023-03-02T05:30:48.000Z","updated_ts":"2025-09-23T08:31:03.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"PRX-019","status":"ACTIVE"}],"dev_code":[{"name":"BMS-986495","source_info":[{"attachment_path":"data/phs_source_info/dd8d/d2b4/febe/2d3b/dd8dd2b4febe2d3b.png","attachment_type":"image/png","code":"Bristol Myers-202509","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/4d60/01b6/e8da/d636/4d6001b6e8dad636.png","source":"Company pipeline","source_url":"https://www.bms.com/researchers-and-partners/in-the-pipeline.html"}],"status":"ACTIVE"},{"name":"BMS986495","source_info":[{"attachment_path":"data/phs_source_info/dd8d/d2b4/febe/2d3b/dd8dd2b4febe2d3b.png","attachment_type":"image/png","code":"Bristol Myers-202509","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/4d60/01b6/e8da/d636/4d6001b6e8dad636.png","source":"Company pipeline","source_url":"https://www.bms.com/researchers-and-partners/in-the-pipeline.html"}],"status":"ACTIVE"},{"name":"PRX019","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["f92188cae567d8f15ec735fec1a614e3"],"disease_id":["53f31b7756664bb9b3f7139f7aa9014e"],"active_org_master_entity_id":["f92188cae567d8f15ec735fec1a614e3","dea970434c1183ebd6632e77bd1e19c0","0b4f6c56f11bba250cd08ae052c24c0a"],"research_disease":["53f31b7756664bb9b3f7139f7aa9014e"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1731024000000}}],"disease_phase":[{"disease_id":"53f31b7756664bb9b3f7139f7aa9014e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["dea970434c1183ebd6632e77bd1e19c0","f92188cae567d8f15ec735fec1a614e3"],"if_speculate":0,"data_source":10}
+{"drug_id":"0826acdaa31c473480a705191150f6f5","docid":39001,"is_nme":1,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1626393600000,"rnk":2,"target_extend_id":"430eb4c1247f3584863138d3f7e48851","has_leading_org_involved":1,"created_ts":"2021-10-08T14:47:54.000Z","updated_ts":"2026-04-16T09:44:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","first_approved_date_cn":1690848000000,"drug_name":[{"lang":"CN","name":"甲磺酸贝舒地尔","source_info":[{"code":"国药准字HJ20230095","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9NDc4OWFjMzMwNTBiYWIzOWE1YWY4NzI0YjM5ZGRjZTcmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4NjY1NzExODAw"}],"status":"ACTIVE"},{"lang":"EN","name":"Belumosudil Mesilate","source_info":[{"code":"30600AMX00126000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780009_39990E8F1026_1_02"}],"status":"ACTIVE"},{"lang":"JP","name":"ベルモスジルメシル酸塩","source_info":[{"code":"30600AMX00126000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780009_39990E8F1026_1_02#HDR_DateOfPreparationOrRevision"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Belumosudil Mesylate","source_info":[{"code":"fg-182","normalized_source_id":"47c8048a73f94d3b9c626eb4f8a6d7e4","source":"USAN","source_url":"https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fbelumosudil-mesylate-.pdf"}],"status":"ACTIVE"},{"lang":"CN","name":"贝舒地尔","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.cn-healthcare.com/articlewm/20211129/content-1290006.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"BN-101","status":"ACTIVE"},{"name":"KD-025","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/belumosudil"}],"status":"ACTIVE"},{"name":"KD-025 MESYLATE","source_info":[{"code":"6MX7XE1MU","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/70964abe-bdff-42a7-b5cd-7d613e443b14"}],"status":"ACTIVE"},{"name":"KD025","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/belumosudil"}],"status":"ACTIVE"},{"name":"ME3208","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://www.meiji.com/global/pharmaceuticals/pipeline.html"}],"status":"ACTIVE"},{"name":"SAR445761/ KD025","source_info":[{"code":"NCT06616415","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06616415"}],"status":"ACTIVE"},{"name":"SLX-2119","status":"ACTIVE"}],"trade_name":[{"name":"Rezurock","source_info":[{"normalized_source_id":"4313dbdea4844940816740b801d08999","source":"DBPC"},{"code":"30600AMX00126000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780009_39990E8F1026_1_02"}],"status":"ACTIVE"},{"name":"レズロック","source_info":[{"code":"30600AMX00126000","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780009_39990E8F1026_1_02"}],"status":"ACTIVE"},{"name":"乐舒克","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mitsui-global.com/zh-hans/%e7%83%a8%e8%be%89%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e4%b9%90%e8%88%92%e5%85%8b%ef%bc%88%e7%94%b2%e7%a3%ba%e9%85%b8%e8%b4%9d%e8%88%92%e5%9c%b0%e5%b0%94%e7%89%87%ef%bc%89%e6%ad%a3%e5%bc%8f/"}],"status":"ACTIVE"},{"name":"易来克","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.prnasia.com/story/431117-1.shtml"}],"status":"ACTIVE"},{"name":"레주록정","source_info":[{"code":"202402080","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202402080aupdateTs2024-08-29%2009:22:06.318318b"}],"status":"ACTIVE"}],"generic_name":[{"name":"Belumosudil","source_info":[{"code":"D11815","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"},{"code":"10.1002/cpdd.1082","normalized_source_id":"3a35cdb7-0f33-4417-a43d-5456963ef5a1","source":"Clin Pharmacol Drug Dev","source_url":"http://dx.doi.org/10.1002/cpdd.1082"},{"code":"35230741","normalized_source_id":"e7f29b256e9c46c19d4acbc643430038","source":"Pubmed","source_url":"https://pubmed.ncbi.nlm.nih.gov/35230741/"}],"status":"ACTIVE"},{"name":"Belumosudil (USAN)","source_info":[{"code":"D11815","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"RHOLISTIQ","source_info":[{"normalized_source_id":"d960dac41dfe49609b6b380987cae0d9","source":"TGA","source_url":"https://www.tga.gov.au/resources/prescription-medicines-registrations/rholistiq-kadmon-oceania-pty-ltd"}],"status":"ACTIVE"}],"kegg_id":["D11815","D11816"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ae2dce62ef4b2d34337f85285a582c08"],"mechanism_action_id":["97072b01b17387968831c972ba816ef8","81fb2f81b0e61e88953777c5dc1f69f1"],"target_id":["9cf84e9054ab4027adc29a6e0fbdd712","34a1f6f94fd54d5f9f522c493a4cc703"],"special_review":["23d3523b7ece48ddacaddac53a66949d","6501abeba2b6400ca8c822d8b2bff598","c3c948340a7d40f3b7437081f5e8cb4e","043a131d85994801b3617e822e7f87b3"],"disease_id":["f29fb34df54145209e94a0f36fc22eb2","e4a2fddde49f4fcab2ba689d9cfa9ce3","47385e430db349dba0005f75f623ba3e","81c09231decf46c7a3cf819e3a4fa91d","7cd0fcf1c5c243b9b3944405ec4855b5","4f7fc625fc8545498f761c38239d6264","1f54367dda3b44f590bf2e196f85ff93","a4553a07d41b47b3aa96442a0f718303","a129f757d3124c448c547ab7ad5d2882","e9b27c71d3024fd6ab7dc1dfc304f54d","d281a3b362a740d8aeb63e2a10102671","e97fd2618ec34b9b965b2ac71a0ee4b5","d3a8e491a4c84426a7d31d10c8e166f3"],"active_org_master_entity_id":["bf85af687373969355a25d2aacd31bfb","ae2dce62ef4b2d34337f85285a582c08","ff75289b565dca0aad78bb6ee4dcaf4a","510286335d2b7829aa997e40a3832148","98e9327c55abf6c8432ac3710796aebb","cbbf76a88531a784ba707dcae4df57ac","bdb31a0ef372c1dafce734bc1c79601f","f621e341bf34b81bd0f932ddf4ed6d0e","82d8ef8e6586a8371efe37274e78441b","3f07904b2420d0dde827c23d0f253d8b"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["f29fb34df54145209e94a0f36fc22eb2"],"research_disease":["f29fb34df54145209e94a0f36fc22eb2","e4a2fddde49f4fcab2ba689d9cfa9ce3","47385e430db349dba0005f75f623ba3e","81c09231decf46c7a3cf819e3a4fa91d","7cd0fcf1c5c243b9b3944405ec4855b5","4f7fc625fc8545498f761c38239d6264"],"non_research_disease":["1f54367dda3b44f590bf2e196f85ff93","a4553a07d41b47b3aa96442a0f718303","a129f757d3124c448c547ab7ad5d2882","e9b27c71d3024fd6ab7dc1dfc304f54d","d281a3b362a740d8aeb63e2a10102671","e97fd2618ec34b9b965b2ac71a0ee4b5","d3a8e491a4c84426a7d31d10c8e166f3"],"inactive_org_master_entity_id":["a7517808379f8c206c0546b8652c80ad","3dd26183aece84ced3e03edf690d9ea8","53f5e821d42d3249c1e30c21fd4b749f","4f9d8cd214c239fa5e16543fa63d0141"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604","62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","cf11da47-6a9f-3948-9d29-8a824f805638","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","52d1b118-b540-37ba-9cb2-f5aff686bb10","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1626393600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1690848000000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1774310400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1711411200000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1647993600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1636675200000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1774310400000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1724889600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1774310400000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1774310400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"6efc9b0c-3cae-3f31-997d-ad35651f6e74","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"f90b616d-f10d-35fb-b13d-b2f114ecf4c2","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"ee96fb71-2762-3fed-a869-ba2761ce8cc3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}},{"country":"184959bf-87b7-3479-827e-d53d6c70ebd4","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"95c67304-766d-3248-a52e-759791c1118b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1696896000000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1705968000000}}],"disease_phase":[{"disease_id":"47385e430db349dba0005f75f623ba3e","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e4a2fddde49f4fcab2ba689d9cfa9ce3","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"e9b27c71d3024fd6ab7dc1dfc304f54d","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"1f54367dda3b44f590bf2e196f85ff93","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"a129f757d3124c448c547ab7ad5d2882","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"e97fd2618ec34b9b965b2ac71a0ee4b5","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"76732dd51f2842799e6843eef80820ea","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"4f7fc625fc8545498f761c38239d6264","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"d281a3b362a740d8aeb63e2a10102671","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d3a8e491a4c84426a7d31d10c8e166f3","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"f29fb34df54145209e94a0f36fc22eb2","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7cd0fcf1c5c243b9b3944405ec4855b5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"a4553a07d41b47b3aa96442a0f718303","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"81c09231decf46c7a3cf819e3a4fa91d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"deal_related_org":["103dd76821dff99f8f89b37876dead20","2a83a39dad54a871cdac3c87989fa964","510286335d2b7829aa997e40a3832148","82d8ef8e6586a8371efe37274e78441b","a7517808379f8c206c0546b8652c80ad","ae2dce62ef4b2d34337f85285a582c08","bf85af687373969355a25d2aacd31bfb"],"if_speculate":0,"data_source":10}
+{"drug_id":"09ddb353475e48babf7da0ff4e039300","docid":1670651,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","created_ts":"2025-08-11T07:22:42.000Z","updated_ts":"2025-12-01T00:29:33.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Inhaled liposomal ciprofloxacin(Savara/Grifols)","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.businesswire.com/news/home/20200402005492/en/Savara-Obtains-Global-Rights-to-Develop-and-Commercialize-Apulmiq"}],"status":"ACTIVE"}],"trade_name":[{"name":"Apulmiq","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.businesswire.com/news/home/20200402005492/en/Savara-Obtains-Global-Rights-to-Develop-and-Commercialize-Apulmiq"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["06c2e3dcbde90e86d87995feb862cbe2"],"disease_id":["a349575c028e4157a6c775f5260484e1"],"active_org_master_entity_id":["06c2e3dcbde90e86d87995feb862cbe2","95a8adb4046070ad668c2b78cda3576c"],"research_disease":["a349575c028e4157a6c775f5260484e1"],"therapeutic_area":["948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba"}],"disease_phase":[{"disease_id":"a349575c028e4157a6c775f5260484e1","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["06c2e3dcbde90e86d87995feb862cbe2","95a8adb4046070ad668c2b78cda3576c"],"if_speculate":0,"data_source":10}
+{"drug_id":"0ea2d81a9c624d5da83718d70d52655d","docid":32931,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:32.000Z","updated_ts":"2024-12-26T00:21:45.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Triolimus","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4602b48b0ca6d4e05fd961945d63d4e9"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","56e4dcc14b9345298b4715f74c691a18","3beea980d93a4cc0abc864e27514601c"],"active_org_master_entity_id":["4602b48b0ca6d4e05fd961945d63d4e9"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","56e4dcc14b9345298b4715f74c691a18","3beea980d93a4cc0abc864e27514601c"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641168000000}}],"disease_phase":[{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"56e4dcc14b9345298b4715f74c691a18","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"1ee08991804b45bc9afa8d2d83e591d7","docid":231380,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2024-06-06T07:05:25.000Z","updated_ts":"2025-01-03T00:20:02.000Z","data_status":"ACTIVE","created_by":"yangjinhua@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"MYJ-1633","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"}],"dev_code":[{"name":"MYJ 1633","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"},{"name":"MYJ1633","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"},{"name":"MYJ1633-BCS","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"},{"name":"MYJ1633-SCSa","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"},{"name":"MYJ1633-SCSs","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"},{"name":"MYJ1633-TNBC","source_info":[{"attachment_path":"data/phs_source_info/cd7d/405b/6519/831c/c0e83c60-1082-3841-9e6c-ec277372585d.jpeg","attachment_type":"image/jpeg","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/1201/1679/a96b/8e1b/a19745db-543a-3241-b84f-89dc5c74b647.jpeg","source":"Company pipeline","source_url":"https://www.immunisbio.com/pages/tech-pipeline"}],"status":"ACTIVE"}],"drug_type":["0e608b50dc8b43bda2a8ca9b9033f1a0"],"originator_org_master_entity_id":["9509c8eff4b1d494f542ff7692f9b9bc"],"disease_id":["62eaee6d9ee44410b8aca59dfc7408e9","ab7c198e47834770a36ab3282d331531","01684be75345494899a4d8410bef348b","f8ade5ce0e364264af82a379ab65f6a2","f92e4ba771d04f27a1f4daae363b676a"],"active_org_master_entity_id":["9509c8eff4b1d494f542ff7692f9b9bc"],"research_disease":["62eaee6d9ee44410b8aca59dfc7408e9","ab7c198e47834770a36ab3282d331531","01684be75345494899a4d8410bef348b","f8ade5ce0e364264af82a379ab65f6a2","f92e4ba771d04f27a1f4daae363b676a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"78c45f1d523646808032edcff807ca59"}],"disease_phase":[{"disease_id":"62eaee6d9ee44410b8aca59dfc7408e9","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"f92e4ba771d04f27a1f4daae363b676a","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"},{"disease_id":"f8ade5ce0e364264af82a379ab65f6a2","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"01684be75345494899a4d8410bef348b","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"04aa2660b6f14baa9b04b44800841091","docid":140200,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":196,"target_extend_id":"2127d2d1ce6736a8be550cf37f0c1c63","created_ts":"2024-03-27T10:43:40.000Z","updated_ts":"2026-04-11T21:04:13.000Z","data_status":"ACTIVE","created_by":"yangjingyi@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"P-1801","source_info":[{"attachment_path":"data/phs_source_info/41bf/b1d5/6dd6/0199/896c469a-6dc1-3dc4-9bed-ce096e4f525c.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/6fdd/4681/b1e3/de51/8758b2a5-eca7-30e2-b8be-4501b85271b3.png","source":"Company pipeline","source_url":"https://us.pharmaessentia.com/focus-mpn/pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"P 1801","status":"ACTIVE"},{"name":"P1801","status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90"],"originator_org_master_entity_id":["dbc66d4ac180831ea7489b33c04ad67c"],"mechanism_action_id":["4dd338b149b3ecd0ee860e1fb379b44f"],"target_id":["9786d32e3d244a688ec6a60d2fe1b10b"],"disease_id":["15cb523e0fbd4617a6a129ad2336eb9a"],"active_org_master_entity_id":["dbc66d4ac180831ea7489b33c04ad67c"],"research_disease":["15cb523e0fbd4617a6a129ad2336eb9a"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1745193600000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"03cace1cade44fe58840460e52056318","docid":67230,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1038614400000,"created_ts":"2022-02-28T05:06:26.000Z","updated_ts":"2026-02-24T23:01:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","first_approved_date_cn":1038614400000,"drug_name":[{"lang":"CN","name":"喜炎平","status":"ACTIVE"},{"lang":"EN","name":"XiYanPing","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["75a97ac3ca3a26f6eb720d524f5a018d"],"disease_id":["3ff780f1137a464ab0a977fd9228b405","8fd7f2b21bff4eacac47e40d6801aa39","aa274a7144984376a7e57b5889e8a980","d284e38757884726a060b0320ebc2e29","717a9bf79e584830859595b8dbe9d433","8cc945b5023646d7974076a2a6ceb7ff","2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["75a97ac3ca3a26f6eb720d524f5a018d","4b78e479d174003f2a8646fecd848ded"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["3ff780f1137a464ab0a977fd9228b405","8fd7f2b21bff4eacac47e40d6801aa39","aa274a7144984376a7e57b5889e8a980","d284e38757884726a060b0320ebc2e29"],"research_disease":["3ff780f1137a464ab0a977fd9228b405","8fd7f2b21bff4eacac47e40d6801aa39","aa274a7144984376a7e57b5889e8a980","d284e38757884726a060b0320ebc2e29","717a9bf79e584830859595b8dbe9d433"],"non_research_disease":["8cc945b5023646d7974076a2a6ceb7ff","2a8a3f6ab7ec4061858144283e7ce0ca"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606","20f1c6915ff140519285386c54883aae","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1038614400000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"3ff780f1137a464ab0a977fd9228b405","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8cc945b5023646d7974076a2a6ceb7ff","highest_phase_before_ter_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_before_ter_global":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"},{"disease_id":"d284e38757884726a060b0320ebc2e29","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"aa274a7144984376a7e57b5889e8a980","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8fd7f2b21bff4eacac47e40d6801aa39","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_before_ter_cn":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_before_ter_global":"055a60cf40bb4b4eb69c41b492c45a03","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"03748d1ccbf2421195bbe43704fd0fce","docid":2923,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Pentobarbital","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":-1262304000000,"rnk":20,"target_extend_id":"725956a9c78d30f4949ca10e07814d8e","created_ts":"2021-10-08T14:47:38.000Z","updated_ts":"2025-12-21T21:16:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"liuhui4","first_approved_date_cn":788918400000,"drug_name":[{"lang":"CN","name":"戊巴比妥钠","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Pentobarbital Sodium","status":"ACTIVE"},{"lang":"JP","name":"ペントバルビタール","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"PENTOBARBITAL","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"dev_code":[{"name":"NSC-28708","source_info":[{"code":"I47448IR","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ee0a31f9-e4c2-4e58-9de9-6451065334a5"}],"status":"ACTIVE"}],"trade_name":[{"name":"Nembutal","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"generic_name":[{"name":"pentobarbital","source_info":[{"code":"I4744080IR","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/ee0a31f9-e4c2-4e58-9de9-6451065334a5"}],"status":"ACTIVE"}],"drugbank_id":["DB00312"],"kegg_id":["D00500"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["c86fa16989b253f3b62115c4c3685062"],"target_id":["504f33d0958c4c128ee629fdca31a63d"],"atc_code":["4bed232bc9eb446b870996504a38649a"],"disease_id":["6ce0ad7b690f47158f3f2ce2756f2193","dca26135a3174a70b3094a4751d59f5f","8bcfe5328ebd4fd0bddab7146a2c2c5f"],"active_org_master_entity_id":["028207d1b2c05825d45b1d473b145981"],"first_approved_indication":["8bcfe5328ebd4fd0bddab7146a2c2c5f"],"research_disease":["6ce0ad7b690f47158f3f2ce2756f2193","dca26135a3174a70b3094a4751d59f5f","8bcfe5328ebd4fd0bddab7146a2c2c5f"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe"},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":788918400000}}],"disease_phase":[{"disease_id":"dca26135a3174a70b3094a4751d59f5f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"8bcfe5328ebd4fd0bddab7146a2c2c5f","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"6ce0ad7b690f47158f3f2ce2756f2193","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"deal_related_org":["77f69e6bbdc2cf992f97479b466f2ff3","d8d2a4f175e6414a35831b9b24daa719"],"data_source":10}
+{"drug_id":"0734a85488b445e79d51f34383179a42","docid":9,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-12-10T12:54:27.000Z","updated_ts":"2025-05-15T14:10:54.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"重组诺如病毒双价（GI.1/GII.4）疫苗（汉逊酵母）(国药中生生物技术研究院有限公司)","source_info":[{"code":"CTR20192432","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=534cf8a43e334734be9adbdc9533ff14"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bivalent recombinant Norovirus vaccine","status":"ACTIVE"},{"lang":"EN","name":"Norovirus Bivalent (GI.1 / GII.4) Vaccine National Vaccine and Serum Institute","status":"ACTIVE"},{"lang":"CN","name":"双价重组诺如病毒疫苗","status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f","b24e8825fd1d42d1b8832824599ee903","e1aca0be003744f0afbfb1a90c7bc8ac"],"originator_org_master_entity_id":["3acccd37bee9fe026692e19380147740"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["817cb0f00ca34e19acd1bf3458c395dc"],"active_org_master_entity_id":["3acccd37bee9fe026692e19380147740","15aba8d18c91dfdc4f7d3f461f8f2838","5628e31b2bc29e70b526f9994ce6e2f5"],"research_disease":["817cb0f00ca34e19acd1bf3458c395dc"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1685059200000}}],"disease_phase":[{"disease_id":"817cb0f00ca34e19acd1bf3458c395dc","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"2ede05f0a5224424a3d2c66e77180e73","docid":110487,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2024-02-19T10:05:18.000Z","updated_ts":"2025-12-05T00:30:47.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"CMV-specific HIV-CAR T Cells(City of Hope National Medical Center)","source_info":[{"code":"NCT06252402","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06252402"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CMV/HIV CAR T Cell Therapy","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://helocyte.com/fortress-biotech-subsidiary-helocyte-announces-option-agreement-with-city-of-hope-for-exclusive-worldwide-rights-to-use-a-novel-bispecific-cmv-hiv-car-t-cell-therapy-optionally-in-combination-with-tr/"}],"status":"ACTIVE"},{"lang":"EN","name":"CMV/HIV-CAR T Cells","source_info":[{"code":"NCT06252402","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06252402"}],"status":"ACTIVE"},{"lang":"EN","name":"Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells","source_info":[{"code":"NCT06252402","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT06252402"}],"status":"ACTIVE"}],"drug_type":["2fbfdb3e92d942c48cbb0adb79f23526"],"originator_org_master_entity_id":["cc168bd6b3777890022201b4f755e4ed"],"disease_id":["ae8e6f653866483981475b969413b581","acfaaa0373944ffd89b0a2ace0d8c564"],"active_org_master_entity_id":["cc168bd6b3777890022201b4f755e4ed","051a0e3d36c795ccd387a2b16b77878d"],"research_disease":["ae8e6f653866483981475b969413b581","acfaaa0373944ffd89b0a2ace0d8c564"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1734566400000}}],"disease_phase":[{"disease_id":"ae8e6f653866483981475b969413b581","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"acfaaa0373944ffd89b0a2ace0d8c564","highest_phase_global":"b2ca28b01c34419db0365bad2f8dd09e"}],"if_speculate":0,"data_source":10}
+{"drug_id":"01c941a61a8c4cdb9a971bf8a305bc49","docid":1610960,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1647907200000,"rnk":1,"target_extend_id":"20397b38921133218101283dd4912826","created_ts":"2025-08-26T01:59:37.000Z","updated_ts":"2025-08-30T21:16:09.000Z","data_status":"ACTIVE","created_by":"shimeihua@patsnap.com","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"CN","name":"盐酸双环胺/盐酸罂粟碱","status":"ACTIVE"},{"lang":"EN","name":"Dicyclomine Hydrochloride/Papaverine Hydrochloride","source_info":[{"code":"202201131","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202201131aupdateTs2025-08-08%2008:39:24.5422b"}],"status":"ACTIVE"}],"trade_name":[{"name":"Cloverine","source_info":[{"code":"202201131","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202201131aupdateTs2025-08-08%2008:39:24.5422b"}],"status":"ACTIVE"},{"name":"클로베린정","source_info":[{"code":"202201131","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source":"MFDS","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202201131aupdateTs2025-08-08%2008:39:24.5422b"}],"status":"ACTIVE"}],"related_component":["1534edeaa1be4b1e9f4ba3f03640e774","711fa9c439bc4c9a96797769c7f2ba7c"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["4894ac8891fffa73d3db06fc63e01e3d"],"mechanism_action_id":["82116d319140e99fc7204bb46f3102e9","931504f23ea44715a9ea324a47e0238d"],"target_id":["93fb16a1c5df4915a157aba160a9ae7a","449193bba3cd46bcad89d76a54d13d06"],"disease_id":["d8f393bc51824d189ee7c8a124a2d464","48d491c8e2d04af5b54fa54d82d7f4ae","299f6a130b8342c89ba7d35a1775a8bc","44552112fc244a9a8bbf4c3f5e1865d9","ef2e3362836a45cc9087983d1860e0b1"],"active_org_master_entity_id":["4894ac8891fffa73d3db06fc63e01e3d"],"first_approved_country":["52d1b118-b540-37ba-9cb2-f5aff686bb10"],"first_approved_indication":["d8f393bc51824d189ee7c8a124a2d464","48d491c8e2d04af5b54fa54d82d7f4ae","299f6a130b8342c89ba7d35a1775a8bc","44552112fc244a9a8bbf4c3f5e1865d9","ef2e3362836a45cc9087983d1860e0b1"],"research_disease":["d8f393bc51824d189ee7c8a124a2d464","48d491c8e2d04af5b54fa54d82d7f4ae","299f6a130b8342c89ba7d35a1775a8bc","44552112fc244a9a8bbf4c3f5e1865d9","ef2e3362836a45cc9087983d1860e0b1"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c354b2ea74d349da99bef8388390c7d8","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75"],"approval_country":["52d1b118-b540-37ba-9cb2-f5aff686bb10"],"research_country":[{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1647907200000}}],"disease_phase":[{"disease_id":"d8f393bc51824d189ee7c8a124a2d464","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"48d491c8e2d04af5b54fa54d82d7f4ae","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"299f6a130b8342c89ba7d35a1775a8bc","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"44552112fc244a9a8bbf4c3f5e1865d9","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"ef2e3362836a45cc9087983d1860e0b1","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0253944380504fd198c8d1c6f159c508","docid":65206,"is_nme":0,"is_first_in_class":1,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"ac14778662b7448588663c26ce84cd9e","wiki_link":"https://en.wikipedia.org/wiki/Alpha-galactosidase","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":996796800000,"rnk":1,"target_extend_id":"5893b9a569f73655b027d7a5d89cbf04","created_ts":"2021-10-08T14:49:22.000Z","updated_ts":"2026-04-02T21:20:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","first_approved_date_cn":1576627200000,"drug_name":[{"lang":"CN","name":"阿加糖酶β","source_info":[{"normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Agalsidase Beta","source_info":[{"normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Agalsidase Beta (Genetical Recombination)","source_info":[{"normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"},{"code":"DB00103","normalized_source_id":"6bfddbfde33b4a4781436fc73d7bc9ab","source":"DRUGBANK"}],"status":"ACTIVE"},{"lang":"EN","name":"Recombinant human α-galactosidase A","status":"ACTIVE"},{"lang":"JP","name":"遺伝子組換え型ヒトα-ガラクトシダーゼ","source_info":[{"code":"21600AMY00008","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA"}],"status":"ACTIVE"}],"dev_code":[{"name":"GZ-419828","status":"ACTIVE"},{"name":"JC0599","status":"ACTIVE"}],"trade_name":[{"name":"Fabrazyme","source_info":[{"code":"21600AMY00008","normalized_source_id":"b5713ff9ea774e908282b147d30973d7","source":"PMDA","source_url":"https://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_3959409D1029_2_07"}],"status":"ACTIVE"},{"name":"파브라자임주","source_info":[{"code":"201302494","normalized_source_id":"6f08ac4a5ca144f8b59de74187e41886","source_url":"https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=201302494aupdateTs2024-06-30%2020:20:12.0b"}],"status":"ACTIVE"}],"generic_name":[{"name":"agalsidase beta","source_info":[{"code":"EMEA/H/C/000370","normalized_source_id":"c550fafe5544447091b21ca6c19f70f2","source":"EMA","source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/fabrazyme"}],"status":"ACTIVE"}],"drugbank_id":["DB00103"],"kegg_id":["D03228"],"drug_type":["c6f7aa5028654d4d8ac6153f9b53e8a2"],"originator_org_master_entity_id":["bbc5fe68369d38a0223445bb4a014033"],"mechanism_action_id":["1ecc4aee626a49c2b04a238a42591dcb"],"target_id":["d632a9fb3a844a1cafa273f3ae9aa46f"],"atc_code":["c836ec7ac9ce4f2fb345136b378faea5"],"special_review":["cf246d061d3f4483a6479f9df8faadda","23d3523b7ece48ddacaddac53a66949d","df5e83eb171a4eb095fcab2f1470348d","043a131d85994801b3617e822e7f87b3"],"disease_id":["c030b4369d7b41c2953386b363b99f6e","7b34c4c341a74b9984deff61be03c587"],"active_org_master_entity_id":["bbc5fe68369d38a0223445bb4a014033","cbbf76a88531a784ba707dcae4df57ac","bf85af687373969355a25d2aacd31bfb","9b6e960192021f2925c1f02f0b53caa9","dc180c752e2e318177fc5db76c4e0933"],"first_approved_country":["9a18968a-f130-3a00-80b6-8b9e2eec4838","3d57c904-23bf-3ee0-9924-83496c75b8ee","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"first_approved_indication":["c030b4369d7b41c2953386b363b99f6e"],"research_disease":["c030b4369d7b41c2953386b363b99f6e"],"non_research_disease":["7b34c4c341a74b9984deff61be03c587"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be","5a365096-b2a6-31cb-acdf-1de1f5ab3abe","9a18968a-f130-3a00-80b6-8b9e2eec4838","676de5ba-893a-36bb-8683-c93306aaf769","ecc919b1-c2b7-3740-bfa7-7cda77176d07","3d57c904-23bf-3ee0-9924-83496c75b8ee","52d1b118-b540-37ba-9cb2-f5aff686bb10","e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","665d1d12-3d14-3e05-8459-014864489671"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1051142400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1576627200000}},{"country":"9a18968a-f130-3a00-80b6-8b9e2eec4838","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":996796800000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1075334400000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1022716800000}},{"country":"3d57c904-23bf-3ee0-9924-83496c75b8ee","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":996796800000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1359417600000}},{"country":"e0cd4ddd-6722-341f-bdc4-b3df494a7d1b","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":996796800000}},{"country":"665d1d12-3d14-3e05-8459-014864489671","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":996796800000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1496188800000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1496188800000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1496188800000}}],"disease_phase":[{"disease_id":"c030b4369d7b41c2953386b363b99f6e","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"7b34c4c341a74b9984deff61be03c587","highest_phase_before_ter_global":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"034f80744539143c7e9fe364c3b98650","docid":25334,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":1,"target_extend_id":"855693b13a1e3d308e8d31289c2e690c","created_ts":"2023-05-19T07:33:23.000Z","updated_ts":"2025-06-19T08:50:09.000Z","data_status":"ACTIVE","created_by":"sunying","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"BA-1302","status":"ACTIVE"}],"dev_code":[{"name":"BA 1302","status":"ACTIVE"},{"name":"BA1302","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["6c1c05d7b168bb2f8eea060cbbe68021"],"mechanism_action_id":["85bf75d458207b603213381f8fdfd8a1"],"target_id":["7416a3fe886846fbb9ee86cd2a540b41"],"special_review":["043a131d85994801b3617e822e7f87b3"],"disease_id":["3bf6031206e848cd94f767cd1db43ea0","a0304a462da04e7cb03e3f2c5625544e","0464f5493b0444e9875a0584df17cbf0","a311ae2187914c2bbad45810b91f9414","024deb39dbdb42eea0863db300b15242","7665e5683a1a443a8f3d3b946d4c9ca2","07994e875a7f44dc9af7f9bf3f6989e5"],"active_org_master_entity_id":["6c1c05d7b168bb2f8eea060cbbe68021"],"research_disease":["3bf6031206e848cd94f767cd1db43ea0","a0304a462da04e7cb03e3f2c5625544e","0464f5493b0444e9875a0584df17cbf0","a311ae2187914c2bbad45810b91f9414","024deb39dbdb42eea0863db300b15242","7665e5683a1a443a8f3d3b946d4c9ca2","07994e875a7f44dc9af7f9bf3f6989e5"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1726012800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1750118400000}}],"disease_phase":[{"disease_id":"024deb39dbdb42eea0863db300b15242","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"7665e5683a1a443a8f3d3b946d4c9ca2","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a0304a462da04e7cb03e3f2c5625544e","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"a311ae2187914c2bbad45810b91f9414","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"if_speculate":0,"data_source":10,"moiety_target_extend_id":"855693b13a1e3d308e8d31289c2e690c","moiety_mechanism_action_id":["85bf75d458207b603213381f8fdfd8a1"],"moiety_target_id":["7416a3fe886846fbb9ee86cd2a540b41"]}
+{"drug_id":"11588faa530d4589ab635cb3d06792d5","docid":45199,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":6,"target_extend_id":"cc685ba2b6343a6a9d11899e137bb447","created_ts":"2021-10-08T14:45:11.000Z","updated_ts":"2026-04-20T13:40:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"wanghuimin","drug_name":[{"lang":"CN","name":"安瑞替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==&mid=2247577523&idx=1&sn=354f2511118380404655109f8c6d38e4"}],"status":"ACTIVE"},{"lang":"EN","name":"VC-004","status":"ACTIVE"}],"alias":[{"lang":"CN","name":"安瑞曲替尼","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"http://mp.weixin.qq.com/s?__biz=MzA4MDU3NDgxNA==&mid=2651341089&idx=3&sn=3e74815947ff2edad6925b8c98a324f0"}],"status":"ACTIVE"}],"dev_code":[{"name":"VC 004","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trk-inhibitor-vc004"}],"status":"ACTIVE"},{"name":"VC004","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trk-inhibitor-vc004"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["29068b5541719b6de1b72eb946c71edc"],"mechanism_action_id":["739e931decb0519141a9f7955a78d25c"],"target_id":["0721ba0ab1774bd982aa96e2cb1f400f"],"special_review":["23d3523b7ece48ddacaddac53a66949d"],"disease_id":["b2b7ad6adc804def8f33cf2e6fab4b82","15cb523e0fbd4617a6a129ad2336eb9a","941ef5bdf9fa49b3b8054dd755019209","913534b87d4543e28eeb8a7215bb8ef4","6c9c5be211cb4d72a28205c49a16d653","299d13086d40436593c92394d168e298","1d6d6b0086ff422ca00418c0e8b0e940","2b478dc272674a5ebb1b770439151927","99e0da7f19d241408a5fe39ac6f18456","0f968d49014449fb8cbcb8426c4b4f68","e10e6a48f3ea4ee2b2eee51942ed4ef0"],"active_org_master_entity_id":["29068b5541719b6de1b72eb946c71edc","6be511cca5b41e1ab8c0bdb2bf9e0292"],"research_disease":["b2b7ad6adc804def8f33cf2e6fab4b82","15cb523e0fbd4617a6a129ad2336eb9a","941ef5bdf9fa49b3b8054dd755019209","913534b87d4543e28eeb8a7215bb8ef4","6c9c5be211cb4d72a28205c49a16d653","299d13086d40436593c92394d168e298","1d6d6b0086ff422ca00418c0e8b0e940","2b478dc272674a5ebb1b770439151927","99e0da7f19d241408a5fe39ac6f18456","0f968d49014449fb8cbcb8426c4b4f68","e10e6a48f3ea4ee2b2eee51942ed4ef0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","20f1c6915ff140519285386c54883aae","67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1751587200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6438687ed214800bb98742ebbeb70a1","dev_status_time":{"time_trust_code":7,"time_ts":1729123200000}}],"disease_phase":[{"disease_id":"15cb523e0fbd4617a6a129ad2336eb9a","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"99e0da7f19d241408a5fe39ac6f18456","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"0f968d49014449fb8cbcb8426c4b4f68","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"e10e6a48f3ea4ee2b2eee51942ed4ef0","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"913534b87d4543e28eeb8a7215bb8ef4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b2b7ad6adc804def8f33cf2e6fab4b82","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"},{"disease_id":"1d6d6b0086ff422ca00418c0e8b0e940","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"2b478dc272674a5ebb1b770439151927","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"941ef5bdf9fa49b3b8054dd755019209","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"299d13086d40436593c92394d168e298","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"005934e4a0f248c693727ad610d61abe","docid":56125,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:43.000Z","updated_ts":"2024-11-06T12:11:12.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"youjia@patsnap.com","drug_name":[{"lang":"EN","name":"JNS-110","status":"ACTIVE"}],"dev_code":[{"name":"JNS-110","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["9c605151bfb92087006694ab1176cc4c"],"disease_id":["7c6adeed2c67494b9197876df5548508"],"active_org_master_entity_id":["9c605151bfb92087006694ab1176cc4c"],"research_disease":["7c6adeed2c67494b9197876df5548508"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1641772800000}}],"disease_phase":[{"disease_id":"7c6adeed2c67494b9197876df5548508","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"01b2e21c8417479bba6f84d38e7f4c41","docid":27044,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"5c19b1310e523f0e8a241e6fe3f7b1c2","created_ts":"2022-10-12T06:12:20.000Z","updated_ts":"2026-04-11T21:05:47.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"SYH-2043","source_info":[{"code":"CXHL2200782","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"code":"CXHL2200781","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"},{"attachment_path":"data/phs_source_info/f179/d841/7fc2/d726/df877127-2713-3ef4-8028-b728d9d4d617.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/05ae/9baa/2033/7b40/01bdfbed-614a-3012-81a4-0f6ef21d896d.png","source":"Company pipeline","source_url":"https://www.e-cspc.com/development/index.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"CPO-166","source_info":[{"attachment_path":"data/phs_source_info/1282/29b8/b12a/10e1/42a89dd1-5a75-3f7a-80e0-a7831e531536.png","attachment_type":"image/png","code":"Conjupro-202501","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/9507/ed9d/7ec2/7142/04d93071-68b5-38cd-8903-dcd66ccde7e4.png","source":"Company pipeline","source_url":"https://conjuprobio.com/products/"}],"status":"ACTIVE"},{"name":"CPO166","source_info":[{"attachment_path":"data/phs_source_info/1282/29b8/b12a/10e1/42a89dd1-5a75-3f7a-80e0-a7831e531536.png","attachment_type":"image/png","code":"Conjupro-202501","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/9507/ed9d/7ec2/7142/04d93071-68b5-38cd-8903-dcd66ccde7e4.png","source":"Company pipeline","source_url":"https://conjuprobio.com/products/"}],"status":"ACTIVE"},{"name":"SYH 2043","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk2-4-6-inhibitor-syh2043"}],"status":"ACTIVE"},{"name":"SYH2043","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk2-4-6-inhibitor-syh2043"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ff9484799cb987ac369f354b33a9720f"],"mechanism_action_id":["91fdc697ef49f0f8d4efbbea2e348631","35627e4eec1e3431be33b96b6f77dd56","24787486e57de6b1428a1229ed3a7840"],"target_id":["d3686d3f02004bc6b3a42b115d73fec5","1c9a8e0192c1473cb0155b1d3196ee34","f29254fec6614d4d8396deec87a95f36"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","6570754a6f0b43b78a9926c7bfd00519","f98fd32baa8447119bb87f84093b925c","3bf6031206e848cd94f767cd1db43ea0"],"active_org_master_entity_id":["f6f07c9a95f0a155cbcc38f7fab146c2","5cf5fedddb15b3ca0a531d9b789f0286","ff9484799cb987ac369f354b33a9720f"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","6570754a6f0b43b78a9926c7bfd00519","f98fd32baa8447119bb87f84093b925c","3bf6031206e848cd94f767cd1db43ea0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1686700800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1679529600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"disease_phase":[{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f98fd32baa8447119bb87f84093b925c","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3bf6031206e848cd94f767cd1db43ea0","highest_phase_cn":"e6438687ed214800bb98742ebbeb70a1","highest_phase_global":"e6438687ed214800bb98742ebbeb70a1"}],"if_speculate":0,"data_source":10}
+{"drug_id":"04e50474b3b24b4090bb5605574fcd5f","docid":39478,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":6,"target_extend_id":"658e3d9b9dd33cbcae2c45707d285c5c","created_ts":"2023-08-03T10:41:44.000Z","updated_ts":"2025-07-31T00:31:22.000Z","data_status":"ACTIVE","created_by":"wangya","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NN-6020","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.pharmaceutical-technology.com/data-insights/nn-6020-novo-nordisk-alcohol-addiction-likelihood-of-approval/"}],"status":"ACTIVE"}],"dev_code":[{"name":"NN 6020","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.pharmaceutical-technology.com/data-insights/nn-6020-novo-nordisk-alcohol-addiction-likelihood-of-approval/"}],"status":"ACTIVE"}],"drug_type":["f003312d10e84e7991180046b0a18b59"],"originator_org_master_entity_id":["5c1eb05d43334b6d6d7973ee3073b7b4"],"mechanism_action_id":["661ac363d925d1f7dd76cf10702f2010"],"target_id":["dd6798e0fd9b4454be262693928a0eb7"],"disease_id":["cac7bcd5f38b47f195972090c4a78468"],"active_org_master_entity_id":["5c1eb05d43334b6d6d7973ee3073b7b4"],"research_disease":["cac7bcd5f38b47f195972090c4a78468"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"disease_phase":[{"disease_id":"cac7bcd5f38b47f195972090c4a78468","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"genetic_material":"ee8e7b3f7e4e4063807592ff2cacb2f1","data_source":10,"regulation_type":["8d0d11ebf505452e96bd7cb85e27128c"],"delivery_system":["42e15f5307df48c0b79434dc95ae3720"],"paired_region":["3d18f77322ed46e99b3872e7dd628c1d"]}
+{"drug_id":"04cf95ea964049278ee5a8fd96f0551c","docid":40794,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","highest_dev_status_cn":"7b79728539354f189772a4eab9cc9fff","created_ts":"2022-08-03T08:55:38.000Z","updated_ts":"2024-12-27T00:24:02.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"赤母妇炎宁胶囊","status":"ACTIVE"},{"lang":"EN","name":"Chimu Fuyanning Capsule","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["6a809ef304d5d57952fcab8517b3c1ab"],"disease_id":["797de48dbefc4bfdbfec47bf1d30327b"],"active_org_master_entity_id":["6a809ef304d5d57952fcab8517b3c1ab"],"research_disease":["797de48dbefc4bfdbfec47bf1d30327b"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1378944000000}}],"disease_phase":[{"disease_id":"797de48dbefc4bfdbfec47bf1d30327b","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"07d51f6bfe44439e8f4e0336a1c96715","docid":49417,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"9f31233bceb94d9796d3f3556f17ab13","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":1,"target_extend_id":"39f034046eee3ee1a11b201e580726fd","created_ts":"2021-10-08T14:50:22.000Z","updated_ts":"2026-04-09T08:31:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"Tovecimig","source_info":[{"normalized_source_id":"e63f5c1131c74903b6e7acaf172c2026","source":"Company_Website","source_url":"https://investors.compasstherapeutics.com/news-releases/news-release-details/tovecimig-ctx-009-meets-primary-endpoint-ongoing-randomized"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247526479&idx=1&sn=e6374cbce59fede1c8c1d69b42b93faa"}],"status":"ACTIVE"}],"dev_code":[{"name":"ABL-001","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll4-anti-vegf-a-bispecific-antibody-ctx-009"}],"status":"ACTIVE"},{"name":"ABL-001-ABL BIO","status":"ACTIVE"},{"name":"ABL001-ABL BIO","status":"ACTIVE"},{"name":"CTX-009","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll4-anti-vegf-a-bispecific-antibody-ctx-009"},{"code":"2025_7297","normalized_source_id":"8806d6ca778544e497f77fce5165778f","source":"AACR","source_url":"https://www.abstractsonline.com/pp8/#!/20273/presentation/7801"}],"status":"ACTIVE"},{"name":"ES 104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll4-anti-vegf-a-bispecific-antibody-ctx-009"}],"status":"ACTIVE"},{"name":"ES-104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll4-anti-vegf-a-bispecific-antibody-ctx-009"}],"status":"ACTIVE"},{"name":"ES104","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll4-anti-vegf-a-bispecific-antibody-ctx-009"}],"status":"ACTIVE"},{"name":"HD-B001A","source_info":[{"attachment_path":"data/phs_source_info/c93b/3b1b/08c1/4a5f/c93b3b1b08c14a5f.jpg","attachment_type":"image/jpeg","code":"Handok-202505","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/5317/8bb0/9720/5929/53178bb097205929.jpg","source":"Company pipeline","source_url":"https://www.handok.co.kr/en/page/pipeline"}],"status":"ACTIVE"},{"name":"NOV-1501","source_info":[{"code":"NCT03292783","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT03292783"}],"status":"ACTIVE"},{"name":"NOV1501","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source":"NCI","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-dll4-anti-vegf-a-bispecific-antibody-ctx-009"}],"status":"ACTIVE"},{"name":"TR-009","status":"ACTIVE"}],"drug_type":["9a847883d786485489d0ee1d75ae90ba"],"originator_org_master_entity_id":["f57bfbbcdf2372e91619c8860a073648"],"mechanism_action_id":["30b9a0bd8d10613754cd94fad4753e87","6b6c2b10657446ed45e401214272b244"],"target_id":["1c13a0f04e7d4db4b508aeb1f11ba400","934f7ab958ca4daf85f5eb42393a0b28"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05","043a131d85994801b3617e822e7f87b3"],"disease_id":["95a54797602d47399b0c1f7da7566001","0f95a21242434922813936cc4da12f67","e5090e6e73c349b9a671c67b6e0ef6e3","9fa7237b86bc4bdba73c3b23e8d84e24","0b6fc9357c10436293f430d95423c7ea","275ecda875e0460f84aa768ca9b2e5d6","e35ce4e9b7a846d49e600ce7ac4a7fd6","1714ace3a2f941d8921c9dbc77a8ba1d","fc0780b4f42b41d0a3dbbc522d0724dd","fa098591720544fd95a695394a09b52c","03bd23316cb54eecbbc4f53311087042","c297238c41b2488abe3de6546b105a4e","0464f5493b0444e9875a0584df17cbf0","f04e110974bf45b58dd4d2eabcd2c6c1","6c9c5be211cb4d72a28205c49a16d653"],"active_org_master_entity_id":["2a9937d4298503ee2a3c7afa74187445","cf1271e7ec57f508db903d8f1d5197b7","0c48bc43b292c4fe093f87c055228d02","97a56fda0dadc76f85e74af9a3725dff","fa2c98f703ee225e7f3a46e01c27f98f","f57bfbbcdf2372e91619c8860a073648","c43879f007970cfba62ad29a8ee46a4e","c2a5e9830c1f32a2896a7f578b4eb4e7"],"research_disease":["95a54797602d47399b0c1f7da7566001","0f95a21242434922813936cc4da12f67","e5090e6e73c349b9a671c67b6e0ef6e3","9fa7237b86bc4bdba73c3b23e8d84e24","0b6fc9357c10436293f430d95423c7ea","275ecda875e0460f84aa768ca9b2e5d6","e35ce4e9b7a846d49e600ce7ac4a7fd6","1714ace3a2f941d8921c9dbc77a8ba1d","fc0780b4f42b41d0a3dbbc522d0724dd","fa098591720544fd95a695394a09b52c","03bd23316cb54eecbbc4f53311087042","c297238c41b2488abe3de6546b105a4e"],"non_research_disease":["0464f5493b0444e9875a0584df17cbf0","f04e110974bf45b58dd4d2eabcd2c6c1","6c9c5be211cb4d72a28205c49a16d653"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75","042cbe45c973477b957717ded29ef7b6","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"9f31233bceb94d9796d3f3556f17ab13","dev_status_time":{"time_trust_code":7,"time_ts":1673222400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"9f31233bceb94d9796d3f3556f17ab13"},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1651622400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1645747200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1644537600000}}],"disease_phase":[{"disease_id":"03bd23316cb54eecbbc4f53311087042","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"275ecda875e0460f84aa768ca9b2e5d6","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"fa098591720544fd95a695394a09b52c","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"95a54797602d47399b0c1f7da7566001","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"0f95a21242434922813936cc4da12f67","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"1714ace3a2f941d8921c9dbc77a8ba1d","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"e5090e6e73c349b9a671c67b6e0ef6e3","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f04e110974bf45b58dd4d2eabcd2c6c1","highest_phase_before_ter_global":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"},{"disease_id":"fc0780b4f42b41d0a3dbbc522d0724dd","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"0b6fc9357c10436293f430d95423c7ea","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"},{"disease_id":"e35ce4e9b7a846d49e600ce7ac4a7fd6","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"9fa7237b86bc4bdba73c3b23e8d84e24","highest_phase_global":"9f31233bceb94d9796d3f3556f17ab13"}],"deal_related_org":["2a9937d4298503ee2a3c7afa74187445","97a56fda0dadc76f85e74af9a3725dff","b3c998bbcb0d5d034a8dfcdb9f3cae67","c2a5e9830c1f32a2896a7f578b4eb4e7","f57bfbbcdf2372e91619c8860a073648"],"if_speculate":0,"data_source":10}
+{"drug_id":"0ef29ac5988743518fcb831104479e72","docid":51277,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","created_ts":"2022-11-03T09:06:54.000Z","updated_ts":"2026-02-25T01:16:33.000Z","data_status":"ACTIVE","created_by":"zhongxia","updated_by":"limingna","drug_name":[{"lang":"EN","name":"Autologous Mesenchymal Stromal Cells(Karolinska University Hospital)","source_info":[{"code":"NCT04290182","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04290182"}],"status":"ACTIVE"}],"dev_code":[{"name":"MSC-KI-PL-204","source_info":[{"code":"NCT04290182","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04290182"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["16bd2d75a372ad8c47aef79ee7655198"],"mechanism_action_id":["0d7c42efc8ef17d26ddc3c038d201e47"],"disease_id":["18c8c47ce9f84a97811ca9eba13ec5a5","65b0240338c149bbbd5336f6089935b4","3d958eb7647f4866a9d9c7e6e59cbdd3","be5fb0a061a3421c8d2da4149e02549e","ec9cb0720b6b4977a8da1ca9fedd4f58"],"active_org_master_entity_id":["2260bbc2313813f6e2ef6cfd1ffe4e67","16bd2d75a372ad8c47aef79ee7655198"],"research_disease":["18c8c47ce9f84a97811ca9eba13ec5a5","65b0240338c149bbbd5336f6089935b4","3d958eb7647f4866a9d9c7e6e59cbdd3","be5fb0a061a3421c8d2da4149e02549e","ec9cb0720b6b4977a8da1ca9fedd4f58"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","4e8519876cfb47e1a3b07957e869ef32","948c9548c2ed46b5865b8693f7f96604","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1614556800000}}],"disease_phase":[{"disease_id":"be5fb0a061a3421c8d2da4149e02549e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"65b0240338c149bbbd5336f6089935b4","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"18c8c47ce9f84a97811ca9eba13ec5a5","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"3d958eb7647f4866a9d9c7e6e59cbdd3","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ec9cb0720b6b4977a8da1ca9fedd4f58","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"037d0245ba844f95b2541b76057f188a","docid":21640,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":18,"target_extend_id":"c8ba33d656bc38dd96d8e20e1373a45d","created_ts":"2022-04-19T10:34:10.000Z","updated_ts":"2026-03-07T21:10:25.000Z","data_status":"ACTIVE","created_by":"sunying","updated_by":"wangya","drug_name":[{"lang":"EN","name":"ALG-097558","status":"ACTIVE"}],"dev_code":[{"name":"ALG 097558","status":"ACTIVE"},{"name":"ALG097558","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["61dc89ea7fef56ef4737e020b3b87260","6b5d695221e90877ee74b35a6bd049bf"],"mechanism_action_id":["7ad9ba0b58b5315e14168eeeb9684891"],"target_id":["43e7a86fd47941f992552fe35d1c5af7"],"disease_id":["717a9bf79e584830859595b8dbe9d433"],"active_org_master_entity_id":["d4d92a03e5018a19f576119a9c25debd","4ef507e5cd6a2844c42b10fe48393139","6b5d695221e90877ee74b35a6bd049bf"],"research_disease":["717a9bf79e584830859595b8dbe9d433"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1593734400000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1593734400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1747094400000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1736812800000}}],"disease_phase":[{"disease_id":"717a9bf79e584830859595b8dbe9d433","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"1688c4738c3b4d0e918873184e1b096b","docid":66769,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","highest_dev_status_cn":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-07-06T11:51:00.000Z","updated_ts":"2026-01-27T23:06:12.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"sunying","drug_name":[{"lang":"CN","name":"扶正解毒化瘀方","source_info":[{"normalized_source_id":"e327c7fe232e4b3ba172121614cef0ba","source":"MANUAL"}],"status":"ACTIVE"},{"lang":"EN","name":"Fuzheng Jiedu Huayu Principle","source_info":[{"code":"NCT05152498","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05152498"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Fu Zheng Jie Du Hua Yu Principle","source_info":[{"code":"NCT05152498","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT05152498"}],"status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["b8a85278f2c6725ea5cd80000676de56"],"disease_id":["8b107203951e4ae9bfe9667fccbe8df9","74beb7d22d474e58b3a8589b108c4957"],"active_org_master_entity_id":["b8a85278f2c6725ea5cd80000676de56"],"research_disease":["8b107203951e4ae9bfe9667fccbe8df9","74beb7d22d474e58b3a8589b108c4957"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1609459200000}}],"disease_phase":[{"disease_id":"8b107203951e4ae9bfe9667fccbe8df9","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"74beb7d22d474e58b3a8589b108c4957","highest_phase_cn":"91ac63db1def4da58e890aec574fe7f4","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"04705eb169f94a08a360fca5f0fa312a","docid":83229,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","linker_id":"17d59c4fb13647dabcb79824e1f138ac","payload_id":"fe7bd7763925439182e1d16efe58c192","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_dev_status_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":16,"target_extend_id":"4f2c22baf88e313e889f4359834c592a","created_ts":"2024-01-08T05:27:04.000Z","updated_ts":"2026-03-11T00:45:39.000Z","data_status":"ACTIVE","created_by":"youjia@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"NC-18","status":"ACTIVE"}],"dev_code":[{"name":"NC18","status":"ACTIVE"}],"drug_type":["6be383aaee904d2b8321e2d1fdacf8bb"],"originator_org_master_entity_id":["c8c026a9f39a5f6246b4c48fabe8d76b"],"mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151","138f7edea9d70a30233e854b342a1eca"],"target_id":["a3c3158483984ff9922b1b0ba939a068","d9461748c4c54a0b84cbad2ae3fce7d5"],"adc_reference":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://www.163.com/dy/article/IV31QF1U05349C3I.html"}],"disease_id":["3f57dd8d41ef4c68abb3228b7fdac7b6","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["0cb811a6bf46a559624f912be8b3b083","c8c026a9f39a5f6246b4c48fabe8d76b"],"research_disease":["3f57dd8d41ef4c68abb3228b7fdac7b6","0464f5493b0444e9875a0584df17cbf0"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1719273600000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1706659200000}}],"disease_phase":[{"disease_id":"3f57dd8d41ef4c68abb3228b7fdac7b6","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"moiety_target_extend_id":"7b338f40fb243fc79806ffa4e81c4c5a","payload_target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","moiety_mechanism_action_id":["31fadb5b59dc513706fe7b9bf39b9151"],"moiety_target_id":["a3c3158483984ff9922b1b0ba939a068"],"payload_target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"payload_mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"]}
+{"drug_id":"093f95e0cd3345db94d11ad51f789202","docid":10617,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:43:41.000Z","updated_ts":"2024-10-30T10:21:11.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Live attenuated RSV vaccine (Codagenix)","source_info":[{"code":"NCT04919109","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04919109"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"CodaVax-RSV","source_info":[{"code":"NCT04919109","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04919109"}],"status":"ACTIVE"},{"lang":"EN","name":"live attenuated RSV vaccine (Codagenix)","source_info":[{"code":"NCT04919109","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT04919109"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["963fa734d3e94336938268465b8a85f0"],"mechanism_action_id":["16ccfc71f7d7d93489db07c2cb0e4d5c","d14c2ee8f93b7874768556f06ceeb8cf"],"special_review":["ca2f2c7dacec450e8a45e2b7f4b74d05"],"disease_id":["21596fe3eb8541c8b661ee50ba37ec61"],"active_org_master_entity_id":["963fa734d3e94336938268465b8a85f0"],"research_disease":["21596fe3eb8541c8b661ee50ba37ec61"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1679961600000}},{"country":"a7693298-e9f4-3dfb-ad3e-fda6b7e59658","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1679961600000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1685059200000}}],"disease_phase":[{"disease_id":"21596fe3eb8541c8b661ee50ba37ec61","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"0125f72bdde44e3c8c707f3a66bbadac","docid":59029,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"7b79728539354f189772a4eab9cc9fff","rnk":1,"target_extend_id":"f0f70d63b8e038c6913ce84c4a02f7cf","created_ts":"2021-10-08T14:42:00.000Z","updated_ts":"2024-10-30T10:14:41.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"优普色替/二甲基亚砜曲美替尼","status":"ACTIVE"},{"lang":"EN","name":"Uprosertib/Trametinib Dimethyl Sulfoxide","status":"ACTIVE"}],"related_component":["b1f2e0fd3be648f09a896c2e975e2d09","e6902861906e4503b92a260aff28c35a"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["5ab40a53d04875aabb9d32d5cef5e61d"],"mechanism_action_id":["62ea20c4d71266d0c5d6e91d9d056e2b","4a23871d470b5fe590bad3f4fc36add0","c7da4d8f9454ffc8ce22f0c9c3b145bf","7f7646912030b7c1b04b271ca541f370","a2b3a86e5f720e06257c697e06637b57"],"target_id":["ab6344feeead4ae1a30ab8bbf433d86e","23715baafe2d4ccc90c4e1b0d16bbdfc","129a7529d0654031a7919208391fab53","06b2538026464b3d8f8c6814eb1456b2","91dd2182a86f4500835a69c006d5d024"],"disease_id":["7cb6983b4169498e89b08fd725a22b46","87a9454771a64f2191224b6b7684254a","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["5ab40a53d04875aabb9d32d5cef5e61d"],"research_disease":["7cb6983b4169498e89b08fd725a22b46","87a9454771a64f2191224b6b7684254a","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","5b1dfc2ca8564662860187aef864467d","b3fbcd71f916470d88c3c590793fe4f3"],"disease_phase":[{"disease_id":"7cb6983b4169498e89b08fd725a22b46","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"data_source":10}
+{"drug_id":"3d78d68ec42a4dce8ac0c1436c635447","docid":261194,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","rnk":2,"target_extend_id":"68e64fef18f7366b9700847b92f63675","created_ts":"2024-05-16T08:37:53.000Z","updated_ts":"2026-04-02T13:47:30.000Z","data_status":"ACTIVE","created_by":"zhoumeng@patsnap.com","updated_by":"wangya","drug_name":[{"lang":"EN","name":"ACI-15916","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/article/releases/ac-immune-reports-first-quarter-2024-financial-results-and-provides-a-corporate-update/"}],"status":"ACTIVE"}],"dev_code":[{"name":"ACI-15916","source_info":[{"normalized_source_id":"cd334fbbf1624f83816b22c25549d6df","source":"Biospace","source_url":"https://www.biospace.com/article/releases/ac-immune-reports-first-quarter-2024-financial-results-and-provides-a-corporate-update/"}],"status":"ACTIVE"}],"drug_type":["20a3b1b0beb74d9fb8649b0afa104f67"],"originator_org_master_entity_id":["e88ce629f475329fa649d4d512e69c70"],"mechanism_action_id":["d94828c8986040dfba948a173b5d67fc","cc11b317a53f4817ae2e2ea2ef1d3238"],"target_id":["f791c10d7a1f4690aae6966e483a6d87","f24bb8a7752f4a9f80345cdc493a0f86"],"disease_id":["99bd009aa0e84d9599e2428d73786197","e750d2827d3b4217b8c1561c11aa8eab","f1ad50b3010e4721a3ce9b148c940a5a"],"active_org_master_entity_id":["e88ce629f475329fa649d4d512e69c70"],"research_disease":["99bd009aa0e84d9599e2428d73786197","e750d2827d3b4217b8c1561c11aa8eab","f1ad50b3010e4721a3ce9b148c940a5a"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","c8df5dce70fd4e0cb3320058ddb95461","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"b4fc8d4a-92f1-3c80-93c0-29733d8c38b6","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"666d5a51-60da-3482-b804-e6df04651a1e","dev_status":"b2ca28b01c34419db0365bad2f8dd09e","dev_status_time":{"time_trust_code":7,"time_ts":1715558400000}}],"disease_phase":[{"disease_id":"e750d2827d3b4217b8c1561c11aa8eab","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"99bd009aa0e84d9599e2428d73786197","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"},{"disease_id":"f1ad50b3010e4721a3ce9b148c940a5a","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"02bc24c6f8fe436ab89d2cb73822f396","docid":71235,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":631152000000,"created_ts":"2021-10-08T14:47:01.000Z","updated_ts":"2025-10-11T05:36:30.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"fangdongbing","first_approved_date_cn":631152000000,"drug_name":[{"lang":"CN","name":"藻酸双酯钠","status":"ACTIVE"},{"lang":"EN","name":"Polysaccharide sulfate","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Alginic Sodium Diester","source_info":[{"code":"国药准字H20031098","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"},{"lang":"EN","name":"Alginidatum Natricum","source_info":[{"code":"国药准字H21022010","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA","source_url":"https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9ZmZhZmI1YzJkYjE1MzVjODU2YzAyNmZlOWEwZDg2ZjImaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm"}],"status":"ACTIVE"},{"lang":"EN","name":"polysaccharide sulfate","status":"ACTIVE"}],"trade_name":[{"name":"元杰","source_info":[{"code":"国药准字H20031098","normalized_source_id":"3f2dbc379c394cd7b1307649f4a49eae","source":"NMPA"}],"status":"ACTIVE"}],"drug_type":["1b5ad16f8e6946e29ab70ca460d3fe90","f3c03fcf0e9b440a982a470f083158d6"],"originator_org_master_entity_id":["35f6fb4e882bd1e6af315852fd42cbf8"],"disease_id":["d5deeaa810d74b9c857ba1753a67fc31","2f16162be3dd4332b1659532540d92f7","bf990e70cead4515abfacb60aa9d3130"],"active_org_master_entity_id":["35f6fb4e882bd1e6af315852fd42cbf8"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["d5deeaa810d74b9c857ba1753a67fc31","2f16162be3dd4332b1659532540d92f7","bf990e70cead4515abfacb60aa9d3130"],"research_disease":["d5deeaa810d74b9c857ba1753a67fc31","2f16162be3dd4332b1659532540d92f7","bf990e70cead4515abfacb60aa9d3130"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","5b1dfc2ca8564662860187aef864467d","b3fbcd71f916470d88c3c590793fe4f3"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":631152000000}}],"disease_phase":[{"disease_id":"2f16162be3dd4332b1659532540d92f7","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"d5deeaa810d74b9c857ba1753a67fc31","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"bf990e70cead4515abfacb60aa9d3130","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"if_speculate":0,"data_source":10}
+{"drug_id":"154ca1da8ad8456a8b8ff9c93fcb969f","docid":15028,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-12-28T06:06:12.000Z","updated_ts":"2026-03-06T03:54:12.000Z","data_status":"ACTIVE","created_by":"fangdongbing@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"CN","name":"人源TH-SC01细胞(江苏拓弘康恒医药)","source_info":[{"code":"CXSL2200093","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical)","source_info":[{"code":"CXSL2200093","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"MSCs(Jiangsu Topcel-KH Pharmaceutical)","status":"ACTIVE"},{"lang":"EN","name":"Mesenchymal Stem Cells(Jiangsu Topcel-KH Pharmaceutical)","status":"ACTIVE"},{"lang":"EN","name":"Solizmestrocel","source_info":[{"normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/beta/substances/712761f7-accd-915f-9342-4bff27cefd7d"}],"status":"ACTIVE"}],"dev_code":[{"name":"TH-SC01","source_info":[{"code":"CXSL2200093","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"drug_type":["df3b7852578a48df98a90ff323213aed"],"originator_org_master_entity_id":["a6f7ca6b2cf33e5c50de5261bebb0644"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"disease_id":["05ae12d567784b85a5c1ca54b2063ee2","968cde5e2d4d48c0870a73dfff303514","ace72e392f6d48c6a580e565755af115","038fda5360cd4ab388a849cee1f0e4c7","5036f93ecc594712b2064f8b78a7e5c0","c6ef7905197e407f93835e7499b72ff2"],"active_org_master_entity_id":["a6f7ca6b2cf33e5c50de5261bebb0644"],"research_disease":["05ae12d567784b85a5c1ca54b2063ee2","968cde5e2d4d48c0870a73dfff303514","ace72e392f6d48c6a580e565755af115","038fda5360cd4ab388a849cee1f0e4c7","5036f93ecc594712b2064f8b78a7e5c0"],"non_research_disease":["c6ef7905197e407f93835e7499b72ff2"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","234aad67e4bc46b3906543b77e393606","67034410be134e2bbb5b0930595b5e75","54e2cf3dc3294445b4a27b990b0ba274","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1742428800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1737331200000}}],"disease_phase":[{"disease_id":"ace72e392f6d48c6a580e565755af115","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"05ae12d567784b85a5c1ca54b2063ee2","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"038fda5360cd4ab388a849cee1f0e4c7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"5036f93ecc594712b2064f8b78a7e5c0","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"968cde5e2d4d48c0870a73dfff303514","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c6ef7905197e407f93835e7499b72ff2","highest_phase_before_ter_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_cn":"4d95bf5fb0c340fbb38cda626c1c9c60","highest_phase_global":"4d95bf5fb0c340fbb38cda626c1c9c60"}],"data_source":10}
+{"drug_id":"01c57adde9e6408793fcebdce33ee564","docid":59207,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","created_ts":"2021-12-09T05:35:33.000Z","updated_ts":"2025-12-23T13:42:09.000Z","data_status":"ACTIVE","created_by":"wangyufu@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"阴道用乳杆菌二联活菌 (浙江欣力菲生物)","source_info":[{"code":"CXSL2101094","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Lactobacillus double live bacteria for vagina(Zhejiang Xinlifei)","status":"ACTIVE"}],"dev_code":[{"name":"XLF 055","status":"ACTIVE"},{"name":"XLF-055","status":"ACTIVE"},{"name":"XLF055","source_info":[{"code":"CTR20222591","normalized_source_id":"1b9e8b92be3044208aae581b41dfb235","source":"CTR","source_url":"http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=d109df1cdf434ea0a14ed4aceb15f057"}],"status":"ACTIVE"}],"drug_type":["8f930c8db8eb4a2fa9bec8350384ba05"],"originator_org_master_entity_id":["b8a5f7a1b02e86ad0b8d69a989e8ea65"],"mechanism_action_id":["55dfe0316462a82e77a38e66c0520ec4","1a41a587feb28542b3050eb67b912259"],"disease_id":["34a4665d7a5c4c6eba92ec840f130d64"],"active_org_master_entity_id":["b8a5f7a1b02e86ad0b8d69a989e8ea65"],"research_disease":["34a4665d7a5c4c6eba92ec840f130d64"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1766448000000}}],"disease_phase":[{"disease_id":"34a4665d7a5c4c6eba92ec840f130d64","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"data_source":10}
+{"drug_id":"0788c1f5ac66417a9d7784d995a78840","docid":1733213,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":12,"target_extend_id":"6b0b4fe3d338392bbba45720a094e581","created_ts":"2026-02-02T10:41:58.000Z","updated_ts":"2026-04-02T12:00:15.000Z","data_status":"ACTIVE","created_by":"yuanjing","updated_by":"yuanjing","drug_name":[{"lang":"EN","name":"Elegrobart","source_info":[{"attachment_path":"data/phs_source_info/d430/9fa3/08af/8ddf/d4309fa308af8ddf.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3379/218f/f6fc/c0e5/3379218ff6fcc0e5.png","source":"Company pipeline","source_url":"https://www.viridiantherapeutics.com/pipeline/ted-programs/subcutaneous-program/"},{"code":"PL132","normalized_source_id":"652379c95cb2441fb8c51b77f96d117b","source":"WHOINN"}],"status":"ACTIVE"}],"dev_code":[{"name":"VRDN-003","source_info":[{"attachment_path":"data/phs_source_info/d430/9fa3/08af/8ddf/d4309fa308af8ddf.png","attachment_type":"image/png","normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","preview_attachment_path":"data/phs_source_info/3379/218f/f6fc/c0e5/3379218ff6fcc0e5.png","source":"Company pipeline","source_url":"https://www.viridiantherapeutics.com/pipeline/ted-programs/subcutaneous-program/"},{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Prepares-for-Transformational-2026/default.aspx"}],"status":"ACTIVE"},{"name":"ZL-1109","source_info":[{"code":"NCT07211776","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07211776"}],"status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["dd757f293fa1dab3d7dfe1cacb7417b2"],"mechanism_action_id":["10f44d78c3144d5346d0b9ebea2ac131"],"target_id":["13800a50d8f04c5c8cf73efc150d572e"],"disease_id":["200cadf5855b4a1e962c82fc373a49d5"],"active_org_master_entity_id":["dd757f293fa1dab3d7dfe1cacb7417b2","f88e18e0aea84e6ec8c5a23ee04bd722"],"research_disease":["200cadf5855b4a1e962c82fc373a49d5"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","c354b2ea74d349da99bef8388390c7d8","c8df5dce70fd4e0cb3320058ddb95461","fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1724716800000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1764892800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1738540800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1738540800000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1738540800000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1738540800000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1738540800000}},{"country":"4ac42935-7005-3e0d-a0e9-698b15e3986b","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1738540800000}}],"disease_phase":[{"disease_id":"200cadf5855b4a1e962c82fc373a49d5","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"}],"deal_related_org":["dd757f293fa1dab3d7dfe1cacb7417b2","f88e18e0aea84e6ec8c5a23ee04bd722"],"if_speculate":0,"data_source":10}
+{"drug_id":"036c346e3eb94a519138ff9dc46f73e2","docid":63307,"is_nme":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","highest_dev_status_cn":"efd6215835394b07b046125e3175d3fe","first_approved_date":1551139200000,"created_ts":"2022-08-03T08:55:42.000Z","updated_ts":"2024-10-30T10:20:40.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"sunying","first_approved_date_cn":1551139200000,"drug_name":[{"lang":"CN","name":"化滞柔肝颗粒","status":"ACTIVE"},{"lang":"EN","name":"Huazhi Rougan Granules","status":"ACTIVE"}],"drug_type":["679157c100db499cb44a3d862eba6211"],"originator_org_master_entity_id":["4626b1641ed3af8ed82891f4a73301fe"],"disease_id":["e8a478bebb37412c908e089d8925a176"],"active_org_master_entity_id":["4626b1641ed3af8ed82891f4a73301fe"],"first_approved_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"first_approved_indication":["e8a478bebb37412c908e089d8925a176"],"research_disease":["e8a478bebb37412c908e089d8925a176"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"approval_country":["5a365096-b2a6-31cb-acdf-1de1f5ab3abe"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1551139200000}}],"disease_phase":[{"disease_id":"e8a478bebb37412c908e089d8925a176","highest_phase_cn":"efd6215835394b07b046125e3175d3fe","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"0335f2e3323c42a58c5d8b0b45a7fc38","docid":8668,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","created_ts":"2021-10-08T14:38:38.000Z","updated_ts":"2025-05-15T16:13:42.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Methyl-GBB oral(Grindeks AS)","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ef9fcd4e023e16f0931f8fcff1a3185c"],"disease_id":["54e2cf3dc3294445b4a27b990b0ba274"],"active_org_master_entity_id":["0e11cc6b691f11e534b1d723ae2200b7","ef9fcd4e023e16f0931f8fcff1a3185c"],"research_disease":["54e2cf3dc3294445b4a27b990b0ba274"],"therapeutic_area":["54e2cf3dc3294445b4a27b990b0ba274"],"disease_phase":[{"disease_id":"54e2cf3dc3294445b4a27b990b0ba274","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"09ac6363ef9640439478991185574512","docid":58703,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"24e880ca34164447985071b78dbf6ba2","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":7,"target_extend_id":"0e8c070b1927365bab8db36962be902a","created_ts":"2023-04-11T02:31:03.000Z","updated_ts":"2026-03-14T21:13:35.000Z","data_status":"ACTIVE","created_by":"huangxingyu","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"ZS-802","source_info":[{"code":"CXSL2300243","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Factor VIII-ZS802","status":"ACTIVE"},{"lang":"CN","name":"凝血因子Ⅷ-ZS802","status":"ACTIVE"}],"dev_code":[{"name":"ZS 802","status":"ACTIVE"},{"name":"ZS802","status":"ACTIVE"}],"drug_type":["b51433cd1da74a149827b44701498192"],"originator_org_master_entity_id":["f75840f48b4bc49d54fb2747a97d23f0"],"mechanism_action_id":["6ae143ef22e98d53d86bb30af0196035"],"target_id":["a5ce1e0cfc1b48ac8bcff32762c3c446"],"disease_id":["07d4cf59dafc4a35840dbf53e136394a"],"active_org_master_entity_id":["f75840f48b4bc49d54fb2747a97d23f0"],"research_disease":["07d4cf59dafc4a35840dbf53e136394a"],"therapeutic_area":["c354b2ea74d349da99bef8388390c7d8","5b1dfc2ca8564662860187aef864467d","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1694649600000}}],"disease_phase":[{"disease_id":"07d4cf59dafc4a35840dbf53e136394a","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"data_source":10}
+{"drug_id":"2bafc26097e54926a43913c3498a7d86","docid":79310,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2022-06-20T06:07:01.000Z","updated_ts":"2024-12-06T00:21:09.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"己二酸苯丙胺/硫酸苯丙胺/己二酸右安非他明/硫酸右安非他明","status":"ACTIVE"},{"lang":"EN","name":"Amphetamine Adipate/Amphetamine Sulfate/Dextroamphetamine Adipate/Dextroamphetamine Sulfate","source_info":[{"code":"083563","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083563"}],"status":"ACTIVE"}],"trade_name":[{"name":"Delcobese","source_info":[{"code":"083563","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083563"}],"status":"ACTIVE"}],"related_component":["2eae734cf7564a23968db5bcbe044c1f","4cb035a9b807439180ede3af45791ec9","e30717d982264a90a7b2f5775f6017d3"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["6b350368a8e6b23b9fb49b9d7ac27f82"],"disease_id":["04dae429301a42e8964272475870785b"],"active_org_master_entity_id":["0d77d7f1c1db170410f76377130836a1"],"research_disease":["04dae429301a42e8964272475870785b"],"inactive_org_master_entity_id":["6b350368a8e6b23b9fb49b9d7ac27f82"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1711929600000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e6a367db1b4a4819bcc16b76dd26d5f3"}],"disease_phase":[{"disease_id":"04dae429301a42e8964272475870785b","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"006cc22ce7ed4a06be402e69bf197644","docid":54683,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"biological_drug_source":"73e5ce1889d1434980e5b831bdb80c76","express_system":"1a9ea1307f82439f86318fa381543664","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1104537600000,"rnk":68,"target_extend_id":"bf62bd8dffad3c5dab58859fa4ebb785","created_ts":"2021-10-08T14:49:25.000Z","updated_ts":"2026-03-17T00:55:15.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"干扰素α-2a生物类似药(Rhein-Minapharm)","status":"ACTIVE"},{"lang":"EN","name":"Interferon alpha-2a biosimilar(Rhein-Minapharm)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Hansenula-derived interferon alpha-2a (Rhein-Minapharm)","status":"ACTIVE"},{"lang":"EN","name":"IFN-alpha-2a biosimilar (Rhein-Minapharm)","status":"ACTIVE"},{"lang":"EN","name":"Interferon alfa-2a biosimilar (Rhein-Minapharm)","status":"ACTIVE"},{"lang":"EN","name":"Interferon alpha-2a biosimilar (Rhein-Minapharm)","status":"ACTIVE"},{"lang":"EN","name":"Reiferon","status":"ACTIVE"}],"generic_name":[{"name":"interferon alfa-2a","status":"ACTIVE"}],"drug_type":["57c42dc16879482eb4ac47835d127eca","9f2e2934e5b2477e916cdbedf928934b"],"originator_org_master_entity_id":["92e39b63e5af882f6ed4912e214e4758"],"mechanism_action_id":["29dce79255d3796ed0748359d54c87bf","a30504b84e062940a9ec00f77c5f47be","d05876caed645eadb8a2c315d512516f"],"target_id":["5d3fe45508034425ab92f769d3fafdb0"],"atc_code":["dcfa2605cf5c429ca184798c3905cafb"],"disease_id":["5f0765227409473d803995e585313374"],"active_org_master_entity_id":["92e39b63e5af882f6ed4912e214e4758"],"first_approved_country":["9c6ae9d7-5179-3787-9a19-a8a795c52fdf"],"first_approved_indication":["5f0765227409473d803995e585313374"],"research_disease":["5f0765227409473d803995e585313374"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","234aad67e4bc46b3906543b77e393606"],"approval_country":["9c6ae9d7-5179-3787-9a19-a8a795c52fdf"],"research_country":[{"country":"9c6ae9d7-5179-3787-9a19-a8a795c52fdf","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1104537600000}}],"disease_phase":[{"disease_id":"5f0765227409473d803995e585313374","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"original_drug_id":["a84bbd114c9d4cdfb2cc97c9c6f12af5"],"data_source":10}
+{"drug_id":"017e700113614f5b94972bcc9d77e113","docid":29136,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","created_ts":"2022-04-29T06:10:27.000Z","updated_ts":"2026-04-02T14:10:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"kongfengfeng","drug_name":[{"lang":"EN","name":"Influenza vaccine(GSK)","source_info":[{"normalized_source_id":"f47efe2cbd0441bdb071fc24e8714d3e","source":"Literature","source_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538610/"}],"status":"ACTIVE"}],"trade_name":[{"name":"ALPHA-RIX-TETRA","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.mesvaccins.net/web/vaccines/563-alpha-rix-tetra#vaccin_composition"}],"status":"ACTIVE"},{"name":"Alfarix","source_info":[{"normalized_source_id":"6ede8d4125e04e5f89f14e1cc3428f82","source":"WEB","source_url":"https://www.mesvaccins.net/web/vaccines/563-alpha-rix-tetra#vaccin_composition"}],"status":"ACTIVE"}],"drug_type":["8f91996d778a4b93aebea69ade081b9f"],"originator_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["2a8a3f6ab7ec4061858144283e7ce0ca"],"active_org_master_entity_id":["9b027bb089fcaa2c937327ac652321dd"],"research_disease":["2a8a3f6ab7ec4061858144283e7ce0ca"],"inactive_org_master_entity_id":["265d713140d1497cd9d29e9107887af8"],"therapeutic_area":["9a802adb6e94433f8f4eb9be678991b8","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["61238041-bc83-3404-a7b4-d7d38443f6b5","acd16cc5-b737-343f-9ffb-3966b2a3fd41"],"research_country":[{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"efd6215835394b07b046125e3175d3fe"},{"country":"acd16cc5-b737-343f-9ffb-3966b2a3fd41","dev_status":"efd6215835394b07b046125e3175d3fe"},{"country":"bf2107a8-40c7-303a-b4d5-7c28d3903f02","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1296172800000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1229472000000}},{"country":"e56545a6-17ff-3d65-812b-7485498ba644","dev_status":"4d95bf5fb0c340fbb38cda626c1c9c60","dev_status_time":{"time_trust_code":7,"time_ts":1229558400000}}],"disease_phase":[{"disease_id":"2a8a3f6ab7ec4061858144283e7ce0ca","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"004612c55ed04ec3bc416aecf75a4bfa","docid":77194,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"registered_classification_cn":"4d29afa3da4e4cf1981d76ea3dcf5f3f","is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","highest_dev_status_cn":"192e487c57e24234b7562b7eafaeb8b7","rnk":109,"target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","created_ts":"2022-02-11T10:26:16.000Z","updated_ts":"2026-04-11T21:06:33.000Z","data_status":"ACTIVE","created_by":"maliman","updated_by":"shimeihua@patsnap.com","drug_name":[{"lang":"CN","name":"莱古杉醇","source_info":[{"code":"CXHL2200087","normalized_source_id":"b7b271757e8b49b084f46bf8f4f8e40d","source":"CDE","source_url":"https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"}],"status":"ACTIVE"},{"lang":"EN","name":"Legutaxel","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://affinity.net.cn/pipeline.html"}],"status":"ACTIVE"}],"dev_code":[{"name":"QHL-236","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"http://affinity.net.cn/pipeline.html"}],"status":"ACTIVE"}],"drug_type":["71bc3ec61acf4095b17a748da29068ef"],"originator_org_master_entity_id":["1f1b70574d80fd18275c0e3ab789557b"],"mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"],"target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"disease_id":["ee2ede109de84cfda49bc999601085b4","0464f5493b0444e9875a0584df17cbf0","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["1f1b70574d80fd18275c0e3ab789557b"],"research_disease":["ee2ede109de84cfda49bc999601085b4","0464f5493b0444e9875a0584df17cbf0","ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1774310400000}}],"disease_phase":[{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ee2ede109de84cfda49bc999601085b4","highest_phase_cn":"192e487c57e24234b7562b7eafaeb8b7","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_cn":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10,"payload_target_extend_id":"90cc0c6fee9536e7b65f8e3f2d962507","payload_target_id":["d9461748c4c54a0b84cbad2ae3fce7d5"],"payload_mechanism_action_id":["138f7edea9d70a30233e854b342a1eca"]}
+{"drug_id":"3cb21f3abab042b2a67999836f67da84","docid":6634,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":8,"target_extend_id":"058ec3693c9b3c04a2c7fe4ed5480c13","created_ts":"2022-04-01T01:49:37.000Z","updated_ts":"2024-12-27T00:24:40.000Z","data_status":"ACTIVE","created_by":"wanghuimin","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"多洛替格韦/拉米夫定/替诺福韦-阿拉芬酰胺","status":"ACTIVE"},{"lang":"EN","name":"Dolutegravir/Lamivudine/Tenofovir Alafenamide","source_info":[{"code":"NDA212527","normalized_source_id":"713ce6480d33457e84ba18159638cafb","source":"FDA_CDER","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212527"}],"status":"ACTIVE"}],"related_component":["16ec23aad0ae407d8aa2eb4fbc590f1c","b5d71611cdba43bea51422cd079f6e52","d5936f60f3454d5891925aed588c5a94"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["8c2f664a9f3fb97016666e3b4741e0a8"],"mechanism_action_id":["b3b480bddc09907e4bc9ceff91440644","2d77c4c1eb97b801cfa550ff71f74f22"],"target_id":["8525101e957c4de99dbd9064c3748628","992d7e466ac3426690fbcfee24888448"],"disease_id":["ae8e6f653866483981475b969413b581"],"active_org_master_entity_id":["8c2f664a9f3fb97016666e3b4741e0a8"],"research_disease":["ae8e6f653866483981475b969413b581"],"therapeutic_area":["76732dd51f2842799e6843eef80820ea","9a802adb6e94433f8f4eb9be678991b8","b3fbcd71f916470d88c3c590793fe4f3"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"78c45f1d523646808032edcff807ca59"}],"disease_phase":[{"disease_id":"ae8e6f653866483981475b969413b581","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"62e3128924694e8ebae999b09ac7a416","docid":63717,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","rnk":86,"target_extend_id":"878d9901835b3b9ba3658fd66609ca79","created_ts":"2022-11-06T07:14:40.000Z","updated_ts":"2026-03-07T21:10:39.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"RH-Insulin (Sunshine Lake)","status":"ACTIVE"}],"drug_type":["aa5356cb42dd499fba9f47c4477ae115"],"originator_org_master_entity_id":["eb98b8e94cfb5db5afd777edd77b44fa"],"mechanism_action_id":["89d008170060809747026a21ea6a221c"],"target_id":["e2c363f6524147f882b3236e9a9966b6"],"disease_id":["0d05187284b446c5803cce38a3e53ebf"],"active_org_master_entity_id":["eb98b8e94cfb5db5afd777edd77b44fa"],"research_disease":["0d05187284b446c5803cce38a3e53ebf"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"disease_phase":[{"disease_id":"0d05187284b446c5803cce38a3e53ebf","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"0281d2009ad64d399fd6d773d319ad15","docid":68326,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"wiki_link":"https://en.wikipedia.org/wiki/Melperone","is_pathway":0,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","rnk":58,"target_extend_id":"8b0874f8c59739a09f03ccb9375771df","created_ts":"2021-10-08T14:37:52.000Z","updated_ts":"2026-02-28T21:10:20.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"yanglili","drug_name":[{"lang":"CN","name":"盐酸美哌隆","status":"ACTIVE"},{"lang":"EN","name":"Melperone Hydrochloride","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Bunil","status":"ACTIVE"},{"lang":"EN","name":"Melperon","status":"ACTIVE"},{"lang":"EN","name":"Melperone","status":"ACTIVE"},{"lang":"EN","name":"Methylperon","status":"ACTIVE"},{"lang":"EN","name":"Methylperone","status":"ACTIVE"},{"lang":"EN","name":"Metylperon","status":"ACTIVE"},{"lang":"EN","name":"Metylperone","status":"ACTIVE"}],"dev_code":[{"name":"FG-5111","status":"ACTIVE"}],"trade_name":[{"name":"Buronil","source_info":[{"code":"D08172","normalized_source_id":"a07dbc9f94144f609a25c9d343a2ec5b","source":"KEGG"}],"status":"ACTIVE"},{"name":"Eunerpan","status":"ACTIVE"},{"name":"Harmosin","status":"ACTIVE"},{"name":"Melneurin","status":"ACTIVE"},{"name":"Melpax","status":"ACTIVE"}],"generic_name":[{"name":"melperone","source_info":[{"code":"J8WA3K39B7","normalized_source_id":"a69257a1f6e645e29d7e433ddc094e1d","source":"GSRS","source_url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/a2ef4d17-aa9c-4787-99ee-e7efb2e1c717"}],"status":"ACTIVE"}],"drugbank_id":["DB09224"],"kegg_id":["D08172"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"mechanism_action_id":["1f3788f2a405b9eacebf8e943509af03"],"target_id":["af7f43fe15e340f5871239caaa09cc01"],"atc_code":["4362947a9ead4a1fbe6d6e5d3a5f37c1"],"disease_id":["ec4d59ce792b465d8e55e7e52840c626"],"research_disease":["ec4d59ce792b465d8e55e7e52840c626"],"therapeutic_area":["042cbe45c973477b957717ded29ef7b6"],"disease_phase":[{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_global":"efd6215835394b07b046125e3175d3fe"}],"data_source":10}
+{"drug_id":"08ee2f42bdbd4605a18dfd7eab891efb","docid":12579,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":68,"target_extend_id":"c37e9d6add8f35fbbf2b3f5ac6000990","created_ts":"2021-10-08T14:45:22.000Z","updated_ts":"2026-04-04T21:04:27.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"SL-901","source_info":[{"normalized_source_id":"cf0e26a9d83243f2a3855089fd5c4870","source":"Company pipeline","source_url":"https://stemline.com/product-pipeline/"}],"status":"ACTIVE"}],"dev_code":[{"name":"SL 901","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["cce07f69ef93d4fc1fb183b996c66f70"],"mechanism_action_id":["71813800256e40af81905223c130a950"],"target_id":["abff4ac6cd3849379da3d9453cb35eb3"],"disease_id":["07994e875a7f44dc9af7f9bf3f6989e5","e2fd9bda4aeb4a7b9fa53a2560126d24","0464f5493b0444e9875a0584df17cbf0"],"active_org_master_entity_id":["cce07f69ef93d4fc1fb183b996c66f70","fb36ad697ed5ea5a6a5889090d841fc5"],"research_disease":["07994e875a7f44dc9af7f9bf3f6989e5","e2fd9bda4aeb4a7b9fa53a2560126d24"],"non_research_disease":["0464f5493b0444e9875a0584df17cbf0"],"inactive_org_master_entity_id":["7704ebdd052f9b5dcac820a34124bdcb"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1643500800000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"a5183ad464de4fe9bb9a3583425ae4a2","dev_status_time":{"time_trust_code":7,"time_ts":1736380800000}}],"disease_phase":[{"disease_id":"e2fd9bda4aeb4a7b9fa53a2560126d24","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"07994e875a7f44dc9af7f9bf3f6989e5","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"0464f5493b0444e9875a0584df17cbf0","highest_phase_before_ter_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d","highest_phase_global":"a5183ad464de4fe9bb9a3583425ae4a2"}],"data_source":10}
+{"drug_id":"11e2d0de2db748f5a42d48fca827c71b","docid":30107,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"f835774c48404593b64ef05369eb8eba","highest_dev_status_cn":"f835774c48404593b64ef05369eb8eba","rnk":5,"target_extend_id":"f7778933748c360dbd94f61f8041eb87","created_ts":"2021-10-08T14:50:22.000Z","updated_ts":"2026-04-15T07:32:24.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"zhangzhengzheng@patsnap.com","drug_name":[{"lang":"EN","name":"Brenipatide","source_info":[{"code":"NCT07219966","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07219966"}],"status":"ACTIVE"}],"alias":[{"lang":"EN","name":"LY-3537031","status":"ACTIVE"}],"dev_code":[{"name":"LY-3537031","status":"ACTIVE"}],"drug_type":["58f172e4a4794372b08b2dda980530de"],"originator_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"mechanism_action_id":["47b4c1651fa2bfb01b1d26d0a0d27a6f","888b99dda6a62ef2551937c34e253e9c"],"target_id":["a87e2f1913564a9aa418d6a6a8e1a799","c385dcba5fea4e97bf02bc256757613a"],"disease_id":["2dbed7595ff04b8fae04724f91081116","f1c3e5bf53414ba481ce6c6876b7b6f2","cac7bcd5f38b47f195972090c4a78468","27dbebece4ff4babbc6faa1162d8f26c","ec4d59ce792b465d8e55e7e52840c626","cb7217deff414b12aa26916c246295de","666ca45028ad4ccc9383172f2715c649","daab2465015849b1841c496bf22afd40","c7d5cce64ed44f1cb761da3ae4f9a631","15fe4881cb88431eb9d44b018619d7b0","05ee0bc5347a4677a95179fcdcc2b814"],"active_org_master_entity_id":["2f55b324e0e20f9411ed3667550d0ba7"],"research_disease":["2dbed7595ff04b8fae04724f91081116","f1c3e5bf53414ba481ce6c6876b7b6f2","cac7bcd5f38b47f195972090c4a78468","27dbebece4ff4babbc6faa1162d8f26c","ec4d59ce792b465d8e55e7e52840c626","cb7217deff414b12aa26916c246295de","666ca45028ad4ccc9383172f2715c649","daab2465015849b1841c496bf22afd40","c7d5cce64ed44f1cb761da3ae4f9a631","15fe4881cb88431eb9d44b018619d7b0","05ee0bc5347a4677a95179fcdcc2b814"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75","c8df5dce70fd4e0cb3320058ddb95461","76732dd51f2842799e6843eef80820ea","042cbe45c973477b957717ded29ef7b6","948c9548c2ed46b5865b8693f7f96604"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"672807de-6d33-3706-a350-c97e6ed7735e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"ecc919b1-c2b7-3740-bfa7-7cda77176d07","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"a7be8424-b451-3746-9341-a1a254537551","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"61238041-bc83-3404-a7b4-d7d38443f6b5","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"bb1d5b11-d9f8-31c4-872c-65a9fad8d193","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"0e7802a9-bad3-33a3-98ae-ff755c717809","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"dc266be9-66b5-3c85-af35-ef210568f738","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"a9ac313e-6b2c-39ce-b83b-3ec5bf1760ff","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"52d1b118-b540-37ba-9cb2-f5aff686bb10","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"15d3c741-f4c4-35d8-9273-339b5972916e","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1770595200000}},{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"f835774c48404593b64ef05369eb8eba","dev_status_time":{"time_trust_code":7,"time_ts":1760486400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1770681600000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1763942400000}},{"country":"2f753928-f426-3cc1-9ea6-8c25f6a4d330","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1761091200000}},{"country":"d75944da-2a69-3c58-82a0-c8138ec47d50","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1761091200000}},{"country":"bf460c70-eac8-3426-baa3-7e6c72bc0889","dev_status":"7b79728539354f189772a4eab9cc9fff","dev_status_time":{"time_trust_code":7,"time_ts":1761091200000}}],"disease_phase":[{"disease_id":"cac7bcd5f38b47f195972090c4a78468","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"cb7217deff414b12aa26916c246295de","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"15fe4881cb88431eb9d44b018619d7b0","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"2dbed7595ff04b8fae04724f91081116","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"27dbebece4ff4babbc6faa1162d8f26c","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"daab2465015849b1841c496bf22afd40","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"f1c3e5bf53414ba481ce6c6876b7b6f2","highest_phase_cn":"f835774c48404593b64ef05369eb8eba","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"c7d5cce64ed44f1cb761da3ae4f9a631","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"ec4d59ce792b465d8e55e7e52840c626","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"05ee0bc5347a4677a95179fcdcc2b814","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"666ca45028ad4ccc9383172f2715c649","highest_phase_cn":"7b79728539354f189772a4eab9cc9fff","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"}],"if_speculate":0,"data_source":10}
+{"drug_id":"48b20685e4d04b609b87cd849814eb2e","docid":23783,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-09-27T12:39:29.000Z","updated_ts":"2024-11-09T18:26:18.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"TRX-105","status":"ACTIVE"}],"dev_code":[{"name":"TRX-105","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["ac2063e42408c52194a52abf4f5c29f4"],"disease_id":["bf349ed31a0d442799396adf4e8488ae"],"active_org_master_entity_id":["ac2063e42408c52194a52abf4f5c29f4"],"research_disease":["bf349ed31a0d442799396adf4e8488ae"],"therapeutic_area":["234aad67e4bc46b3906543b77e393606"],"research_country":[{"country":"ad1d5207-9af6-3187-b43c-e734b719e82c","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1650153600000}}],"disease_phase":[{"disease_id":"bf349ed31a0d442799396adf4e8488ae","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"578c7cf089ab4c859fdfa6411742f63d","docid":21867,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"UNDEFINED","is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","created_ts":"2023-03-02T05:30:45.000Z","updated_ts":"2025-09-05T00:24:13.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"PH011","status":"ACTIVE"}],"dev_code":[{"name":"PH011","status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["26114f97d3bdb5c69e24aa3c80804902"],"disease_id":["fb9e9ab9c73a456b9ece2227bf2392b8"],"active_org_master_entity_id":["26114f97d3bdb5c69e24aa3c80804902"],"research_disease":["fb9e9ab9c73a456b9ece2227bf2392b8"],"therapeutic_area":["fce2b462d4fa493eb9d82513b9007011"],"research_country":[{"country":"1b05c4d2-8156-3854-9898-c71e0077e3c6","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1665532800000}}],"disease_phase":[{"disease_id":"fb9e9ab9c73a456b9ece2227bf2392b8","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}
+{"drug_id":"01b00b23f957405ca4b37792562810ba","docid":61508,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","rnk":3,"target_extend_id":"9b0f36043ac83feab9c56e02c56bc658","has_leading_org_involved":1,"created_ts":"2021-10-08T14:48:40.000Z","updated_ts":"2026-03-28T21:09:50.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"DS-1055","status":"ACTIVE"}],"dev_code":[{"name":"DS 1055A","status":"ACTIVE"},{"name":"DS 1055a","source_info":[{"normalized_source_id":"e3d139db7d7f437db0b0294c25afb68a","source_url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-garp-monoclonal-antibody-ds-1055a"}],"status":"ACTIVE"},{"name":"DS-1055A","status":"ACTIVE"}],"drug_type":["c38eb408d6b842f487d6a27484156633"],"originator_org_master_entity_id":["7867fd8c5c8fb5b43b912d4a03a9b148","a386cdb3b202d480ca4f6c125586164d"],"mechanism_action_id":["075066c79a40d20ee979c903c368fb06"],"target_id":["605ee9f5c9554ed1ba8cde4c31670c0d"],"disease_id":["6570754a6f0b43b78a9926c7bfd00519","f7ea24f0370d421480503e720310bf86","c1cc2528f29940fc95fd6bc37eb982d4","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","ab7c198e47834770a36ab3282d331531"],"active_org_master_entity_id":["7867fd8c5c8fb5b43b912d4a03a9b148"],"research_disease":["6570754a6f0b43b78a9926c7bfd00519","f7ea24f0370d421480503e720310bf86","c1cc2528f29940fc95fd6bc37eb982d4","6c9c5be211cb4d72a28205c49a16d653","3beea980d93a4cc0abc864e27514601c","ab7c198e47834770a36ab3282d331531"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1602201600000}},{"country":"676de5ba-893a-36bb-8683-c93306aaf769","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1602201600000}},{"country":"cf11da47-6a9f-3948-9d29-8a824f805638","dev_status":"e2c11c24a7ee4b4e81bbde9eb7127c6d","dev_status_time":{"time_trust_code":7,"time_ts":1602201600000}}],"disease_phase":[{"disease_id":"6c9c5be211cb4d72a28205c49a16d653","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"f7ea24f0370d421480503e720310bf86","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"3beea980d93a4cc0abc864e27514601c","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"c1cc2528f29940fc95fd6bc37eb982d4","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"6570754a6f0b43b78a9926c7bfd00519","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"},{"disease_id":"ab7c198e47834770a36ab3282d331531","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"deal_related_org":["7867fd8c5c8fb5b43b912d4a03a9b148","a386cdb3b202d480ca4f6c125586164d"],"data_source":10}
+{"drug_id":"1d5d0f4483d24a69addc1693a4cbd6a2","docid":1730651,"is_nme":1,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"is_pathway":0,"global_highest_dev_status":"192e487c57e24234b7562b7eafaeb8b7","rnk":13,"target_extend_id":"4c680d73d9303870971c5a14001347e2","created_ts":"2025-08-13T09:01:19.000Z","updated_ts":"2026-01-13T21:08:00.000Z","data_status":"ACTIVE","created_by":"limingna","updated_by":"yanglili","drug_name":[{"lang":"EN","name":"TER-2013","source_info":[{"code":"NCT07109726","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07109726"}],"status":"ACTIVE"}],"dev_code":[{"name":"TER-2013","source_info":[{"code":"NCT07109726","normalized_source_id":"51e8953a6bcb4f318902c6545399a7ae","source":"CTgov","source_url":"https://clinicaltrials.gov/study/NCT07109726"}],"status":"ACTIVE"}],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["38d1abe4aba0716f9b3cc7e9a659f28c"],"mechanism_action_id":["62ea20c4d71266d0c5d6e91d9d056e2b"],"target_id":["ab6344feeead4ae1a30ab8bbf433d86e"],"disease_id":["f319fa27684c4cdeb6ce59d897217718","87a9454771a64f2191224b6b7684254a","74ba301586ab419b9c9accd39cd20782","c297238c41b2488abe3de6546b105a4e","6fe05469e09f4305b7615b2c277382cd","d72da63a46074c3594fc0e08f4f47e62","b42488c9ce3245988e4e93caf2b95590"],"active_org_master_entity_id":["38d1abe4aba0716f9b3cc7e9a659f28c"],"research_disease":["f319fa27684c4cdeb6ce59d897217718","87a9454771a64f2191224b6b7684254a","74ba301586ab419b9c9accd39cd20782","c297238c41b2488abe3de6546b105a4e","6fe05469e09f4305b7615b2c277382cd","d72da63a46074c3594fc0e08f4f47e62","b42488c9ce3245988e4e93caf2b95590"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9","234aad67e4bc46b3906543b77e393606","c8df5dce70fd4e0cb3320058ddb95461","948c9548c2ed46b5865b8693f7f96604","63ed6e7cb91a42928300df21dd9d3ac1","b3fbcd71f916470d88c3c590793fe4f3","67034410be134e2bbb5b0930595b5e75"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"192e487c57e24234b7562b7eafaeb8b7","dev_status_time":{"time_trust_code":7,"time_ts":1758585600000}}],"disease_phase":[{"disease_id":"c297238c41b2488abe3de6546b105a4e","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"87a9454771a64f2191224b6b7684254a","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"6fe05469e09f4305b7615b2c277382cd","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"f319fa27684c4cdeb6ce59d897217718","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"74ba301586ab419b9c9accd39cd20782","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"d72da63a46074c3594fc0e08f4f47e62","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"},{"disease_id":"b42488c9ce3245988e4e93caf2b95590","highest_phase_global":"192e487c57e24234b7562b7eafaeb8b7"}],"if_speculate":0,"data_source":10}
+{"drug_id":"0c1cd7452c694379a8a8f11afe10dfa0","docid":69488,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"efd6215835394b07b046125e3175d3fe","first_approved_date":1732060800000,"created_ts":"2022-03-23T05:46:08.000Z","updated_ts":"2026-02-25T00:14:33.000Z","data_status":"ACTIVE","created_by":"sunying","updated_by":"chenghongyan@patsnap.com","drug_name":[{"lang":"EN","name":"HPC-Cord Blood (StemCyte)","status":"ACTIVE"}],"alias":[{"lang":"EN","name":"Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy(StemCyte)","status":"ACTIVE"},{"lang":"EN","name":"Umbilical cord hematopoietic progenitor cell (StemCyte)","status":"ACTIVE"}],"trade_name":[{"name":"RegeneCyte","source_info":[{"code":"BLA125764","normalized_source_id":"f3bd4fd130ec4588971e9008b5010e32","source":"FDA_CBER","source_url":"https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenecyte"}],"status":"ACTIVE"}],"drug_type":["cceb301a25ec4f3cbc1aff3ae1169416"],"originator_org_master_entity_id":["daaee51eb7fb2e1a707c525772d5775d"],"mechanism_action_id":["dcffdad6c05d58f9ce2c12d757a27686"],"special_review":["ed88b5b02898448483d0dd3ce010cfba"],"disease_id":["cd524b773fc6463a9a080ec578bf9c0d","f21b246b05574261844954d981c3ba89","e2bf071405ab4c4787be311613287430","79be3185012346da907292e157abf99f"],"active_org_master_entity_id":["82f92121401205c55af9c1ceebdc6401","daaee51eb7fb2e1a707c525772d5775d"],"first_approved_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"first_approved_indication":["cd524b773fc6463a9a080ec578bf9c0d"],"research_disease":["cd524b773fc6463a9a080ec578bf9c0d","f21b246b05574261844954d981c3ba89","e2bf071405ab4c4787be311613287430","79be3185012346da907292e157abf99f"],"therapeutic_area":["67034410be134e2bbb5b0930595b5e75","9a802adb6e94433f8f4eb9be678991b8","042cbe45c973477b957717ded29ef7b6","54e2cf3dc3294445b4a27b990b0ba274","948c9548c2ed46b5865b8693f7f96604"],"approval_country":["0dc5d896-7408-3c87-84c0-22e3d9b784be"],"research_country":[{"country":"0dc5d896-7408-3c87-84c0-22e3d9b784be","dev_status":"efd6215835394b07b046125e3175d3fe","dev_status_time":{"time_trust_code":7,"time_ts":1732060800000}}],"disease_phase":[{"disease_id":"f21b246b05574261844954d981c3ba89","highest_phase_global":"f835774c48404593b64ef05369eb8eba"},{"disease_id":"cd524b773fc6463a9a080ec578bf9c0d","highest_phase_global":"efd6215835394b07b046125e3175d3fe"},{"disease_id":"e2bf071405ab4c4787be311613287430","highest_phase_global":"7b79728539354f189772a4eab9cc9fff"},{"disease_id":"79be3185012346da907292e157abf99f","highest_phase_global":"e2c11c24a7ee4b4e81bbde9eb7127c6d"}],"data_source":10}
+{"drug_id":"44aa0fa875ea469ebffd110601310cdf","docid":27559,"is_nme":0,"is_compound_medicine":0,"null_target_reason":"NOT_AVAILABLE","is_pathway":1,"global_highest_dev_status":"91ac63db1def4da58e890aec574fe7f4","created_ts":"2022-04-28T12:55:33.000Z","updated_ts":"2025-05-30T17:36:09.000Z","data_status":"ACTIVE","created_by":"data@patsnap.com","updated_by":"data@patsnap.com","drug_name":[{"lang":"EN","name":"Neoantigen Peptide Vaccine(Instituto de Medicina Regenerativa)","status":"ACTIVE"}],"drug_type":["0946c72f7fd34d50a2f928cc33170a12","7c30e94c8f714d38adf754e17130f9df"],"originator_org_master_entity_id":["22cb9d2d5483ce70f781deadf38747bd"],"mechanism_action_id":["d14c2ee8f93b7874768556f06ceeb8cf"],"disease_id":["f048bf0822254413a3ea354eced08eec"],"active_org_master_entity_id":["22cb9d2d5483ce70f781deadf38747bd"],"research_disease":["f048bf0822254413a3ea354eced08eec"],"therapeutic_area":["62eaee6d9ee44410b8aca59dfc7408e9"],"research_country":[{"country":"07913a83-63e2-3a89-83a4-d16241a04ce3","dev_status":"91ac63db1def4da58e890aec574fe7f4","dev_status_time":{"time_trust_code":7,"time_ts":1597017600000}}],"disease_phase":[{"disease_id":"f048bf0822254413a3ea354eced08eec","highest_phase_global":"91ac63db1def4da58e890aec574fe7f4"}],"data_source":10}
+{"drug_id":"32be9d888a4f444a883877159c5077f4","docid":14714,"is_nme":0,"is_first_in_class":0,"is_qidp":0,"is_compound_medicine":1,"is_pathway":0,"global_highest_dev_status":"78c45f1d523646808032edcff807ca59","highest_dev_status_cn":"78c45f1d523646808032edcff807ca59","rnk":13,"target_extend_id":"4d016fb1cab33f229a1ef722b3460062","created_ts":"2022-05-17T14:08:39.000Z","updated_ts":"2026-03-14T21:14:29.000Z","data_status":"ACTIVE","created_by":"fangdongbing","updated_by":"data@patsnap.com","drug_name":[{"lang":"CN","name":"加格列净/二甲双胍","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/mHUDjocPe_-r2FKuUL7tSA"}],"status":"ACTIVE"},{"lang":"EN","name":"Janagliflozin/Metformin","source_info":[{"normalized_source_id":"0b0db149ab6e4a978c1c4e83498d6d5a","source":"NEWS","source_url":"https://mp.weixin.qq.com/s/mHUDjocPe_-r2FKuUL7tSA"}],"status":"ACTIVE"}],"related_component":["73336b28c2ba4443a6aff49791c321d0","9657cbcc9f4042d5a8f324024c32b7e7"],"drug_type":["1151dbc710f64a85923dc05d4a5a0ba9"],"originator_org_master_entity_id":["1b130caf2b241723ee507706dd2bae56"],"mechanism_action_id":["2f8d928921b506e350c09eb3f2f8ed6d","b33a5535c71348d2824dea81333c6197"],"target_id":["7c6744915bcf435497c2b2e6ae24ae6d","a995e993b483437ab03a1b4f5da488a8"],"disease_id":["74d974da49ba407195b38595a0aff704"],"active_org_master_entity_id":["1b130caf2b241723ee507706dd2bae56"],"research_disease":["74d974da49ba407195b38595a0aff704"],"therapeutic_area":["c8df5dce70fd4e0cb3320058ddb95461"],"research_country":[{"country":"5a365096-b2a6-31cb-acdf-1de1f5ab3abe","dev_status":"78c45f1d523646808032edcff807ca59","dev_status_time":{"time_trust_code":7,"time_ts":1652745600000}}],"disease_phase":[{"disease_id":"74d974da49ba407195b38595a0aff704","highest_phase_cn":"78c45f1d523646808032edcff807ca59","highest_phase_global":"78c45f1d523646808032edcff807ca59"}],"data_source":10}